words,sentence_id,labels
Glucose,0,O
6-phosphate,0,O
dehydrogenase,0,O
variants,0,O
:,0,O
Gd,0,O
(,0,O
+,0,O
),0,O
Alexandra,0,O
associated,0,O
with,0,O
neonatal,0,B-SpecificDisease
jaundice,0,I-SpecificDisease
and,0,O
Gd,0,O
(,0,O
-,0,O
),0,O
Camperdown,0,O
in,0,O
a,0,O
young,0,O
man,0,O
with,0,O
lamellar,0,O
cataracts,0,O
.,0,O
Two,1,O
male,1,O
subjects,1,O
are,1,O
described,1,O
",",1,O
with,1,O
unusual,1,O
clinical,1,O
presentations,1,O
and,1,O
with,1,O
hitherto,1,O
undescribed,1,O
G6PD,1,O
variants,1,O
.,1,O
The,2,O
first,2,O
",",2,O
of,2,O
Italian,2,O
extraction,2,O
",",2,O
suffered,2,O
from,2,O
severe,2,O
neonatal,2,B-SpecificDisease
jaundice,2,I-SpecificDisease
following,2,O
maternal,2,O
ingestion,2,O
of,2,O
fresh,2,O
broad,2,O
beans,2,O
(,2,O
Vicia,2,O
fava,2,O
),2,O
both,2,O
prenatally,2,O
and,2,O
postnatally,2,O
the,2,O
expression,2,O
of,2,O
the,2,O
enzymatic,2,O
defect,2,O
was,2,O
much,2,O
more,2,O
severe,2,O
in,2,O
the,2,O
neonatal,2,O
period,2,O
than,2,O
on,2,O
retesting,2,O
in,2,O
adolescence,2,O
",",2,O
when,2,O
biochemical,2,O
characterization,2,O
showed,2,O
unique,2,O
features,2,O
which,2,O
justify,2,O
designation,2,O
as,2,O
a,2,O
new,2,O
variant,2,O
Gd,2,O
(,2,O
+,2,O
),2,O
Alexandra,2,O
.,2,O
The,3,O
second,3,O
patient,3,O
",",3,O
a,3,O
boy,3,O
of,3,O
Maltese,3,O
extraction,3,O
who,3,O
was,3,O
found,3,O
to,3,O
have,3,O
bilateral,3,O
lamellar,3,O
cataracts,3,O
at,3,O
the,3,O
age,3,O
of,3,O
4,3,O
years,3,O
",",3,O
was,3,O
identified,3,O
as,3,O
G6PD,3,B-SpecificDisease
deficient,3,I-SpecificDisease
only,3,O
as,3,O
a,3,O
result,3,O
of,3,O
a,3,O
survey,3,O
of,3,O
children,3,O
of,3,O
Mediterranean,3,O
origin,3,O
with,3,O
unexplained,3,O
cataract,3,B-Modifier
formation,3,O
;,3,O
he,3,O
has,3,O
approximately,3,O
15,3,O
%,3,O
of,3,O
normal,3,O
enzyme,3,O
activity,3,O
",",3,O
with,3,O
another,3,O
unique,3,O
combination,3,O
of,3,O
biochemical,3,O
characteristics,3,O
which,3,O
has,3,O
led,3,O
to,3,O
its,3,O
designation,3,O
as,3,O
Gd,3,O
(,3,O
-,3,O
),3,O
Camperdown,3,O
.,3,O
Although,4,O
this,4,O
association,4,O
may,4,O
be,4,O
coincidental,4,O
",",4,O
it,4,O
prompts,4,O
further,4,O
attention,4,O
to,4,O
the,4,O
possibility,4,O
that,4,O
under,4,O
certain,4,O
circumstances,4,O
G6PD,4,B-SpecificDisease
deficiency,4,I-SpecificDisease
may,4,O
favor,4,O
cataract,4,B-Modifier
formation,4,O
.,4,O
The,5,O
two,5,O
cases,5,O
illustrate,5,O
the,5,O
value,5,O
of,5,O
characterization,5,O
of,5,O
the,5,O
mutant,5,O
enzyme,5,O
whenever,5,O
unexpected,5,O
clinical,5,O
or,5,O
laboratory,5,O
results,5,O
are,5,O
obtained,5,O
..,5,O
Familial,6,B-SpecificDisease
deficiency,6,I-SpecificDisease
of,6,I-SpecificDisease
the,6,I-SpecificDisease
seventh,6,I-SpecificDisease
component,6,I-SpecificDisease
of,6,I-SpecificDisease
complement,6,I-SpecificDisease
associated,6,O
with,6,O
recurrent,6,O
bacteremic,6,B-DiseaseClass
infections,6,I-DiseaseClass
due,6,I-DiseaseClass
to,6,I-DiseaseClass
Neisseria,6,I-DiseaseClass
.,6,O
The,7,O
serum,7,O
of,7,O
a,7,O
29-year,7,O
old,7,O
woman,7,O
with,7,O
a,7,O
recent,7,O
episode,7,O
of,7,O
disseminated,7,B-SpecificDisease
gonococcal,7,I-SpecificDisease
infection,7,I-SpecificDisease
and,7,O
a,7,O
history,7,O
of,7,O
meningococcal,7,B-SpecificDisease
meningitis,7,I-SpecificDisease
and,7,O
arthritis,7,B-DiseaseClass
as,7,O
a,7,O
child,7,O
was,7,O
found,7,O
to,7,O
lack,7,O
serum,7,O
hemolytic,7,O
complement,7,O
activity,7,O
.,7,O
The,8,O
seventh,8,O
component,8,O
of,8,O
complement,8,O
(,8,O
C7,8,O
),8,O
was,8,O
not,8,O
detected,8,O
by,8,O
functional,8,O
or,8,O
immunochemical,8,O
assays,8,O
",",8,O
whereas,8,O
other,8,O
components,8,O
were,8,O
normal,8,O
by,8,O
hemolytic,8,O
and,8,O
immunochemical,8,O
assessment,8,O
.,8,O
Her,9,O
fresh,9,O
serum,9,O
lacked,9,O
complement-mediated,9,O
bactericidal,9,O
activity,9,O
against,9,O
Neisseria,9,O
gonorrhoeae,9,O
",",9,O
but,9,O
the,9,O
addition,9,O
of,9,O
fresh,9,O
normal,9,O
serum,9,O
or,9,O
purified,9,O
C7,9,O
restored,9,O
bactericidal,9,O
activity,9,O
as,9,O
well,9,O
as,9,O
hemolytic,9,O
activity,9,O
.,9,O
The,10,O
absence,10,B-Modifier
of,10,I-Modifier
functional,10,I-Modifier
C7,10,I-Modifier
activity,10,O
could,10,O
not,10,O
be,10,O
accounted,10,O
for,10,O
on,10,O
the,10,O
basis,10,O
of,10,O
an,10,O
inhibitor,10,O
.,10,O
Opsonization,11,O
and,11,O
generation,11,O
of,11,O
chemotactic,11,O
activity,11,O
functioned,11,O
normally,11,O
.,11,O
Complete,12,B-SpecificDisease
absence,12,I-SpecificDisease
of,12,I-SpecificDisease
C7,12,I-SpecificDisease
was,12,O
also,12,O
found,12,O
in,12,O
one,12,O
sibling,12,O
who,12,O
had,12,O
the,12,O
clinical,12,O
syndrome,12,O
of,12,O
meningococcal,12,B-SpecificDisease
meningitis,12,I-SpecificDisease
and,12,O
arthritis,12,B-DiseaseClass
as,12,O
a,12,O
child,12,O
and,12,O
in,12,O
this,12,O
siblings,12,O
clinically,12,O
well,12,O
eight-year-old,12,O
son,12,O
.,12,O
HLA,13,O
histocompatibility,13,O
typing,13,O
of,13,O
the,13,O
family,13,O
members,13,O
did,13,O
not,13,O
demonstrate,13,O
evidence,13,O
for,13,O
genetic,13,O
linkage,13,O
of,13,O
C7,13,B-SpecificDisease
deficiency,13,I-SpecificDisease
with,13,O
the,13,O
major,13,O
histocompatibility,13,O
loci,13,O
.,13,O
This,14,O
report,14,O
represents,14,O
the,14,O
first,14,O
cases,14,O
of,14,O
C7,14,B-SpecificDisease
deficiency,14,I-SpecificDisease
associated,14,O
with,14,O
infectious,14,O
complications,14,O
and,14,O
suggests,14,O
that,14,O
bactericidal,14,O
activity,14,O
may,14,O
be,14,O
important,14,O
in,14,O
host,14,O
defense,14,O
against,14,O
bacteremic,14,B-SpecificDisease
neisseria,14,I-SpecificDisease
infections,14,I-SpecificDisease
.,14,O
Combined,15,O
genetic,15,O
deficiency,15,O
of,15,O
C6,15,O
and,15,O
C7,15,O
in,15,O
man,15,O
.,15,O
By,16,O
routine,16,O
screening,16,O
of,16,O
sera,16,O
",",16,O
a,16,O
subject,16,O
was,16,O
discovered,16,O
who,16,O
showed,16,O
a,16,O
sub-total,16,O
deficiency,16,O
of,16,O
C6,16,O
and,16,O
C7,16,O
.,16,O
No,17,O
clinical,17,O
disease,17,O
was,17,O
associated,17,O
with,17,O
this,17,O
deficiency,17,O
which,17,O
was,17,O
transmitted,17,O
through,17,O
the,17,O
subjects,17,O
family,17,O
as,17,O
a,17,O
single,17,O
genetic,17,O
characteristic,17,O
",",17,O
the,17,O
C6,17,B-SpecificDisease
deficiency,17,I-SpecificDisease
being,17,O
associated,17,O
with,17,O
a,17,O
silent,17,O
allele,17,O
at,17,O
the,17,O
structural,17,O
locus,17,O
.,17,O
The,18,O
propositus,18,O
was,18,O
found,18,O
to,18,O
have,18,O
low,18,O
quantities,18,O
of,18,O
an,18,O
abnormal,18,O
C6,18,O
which,18,O
was,18,O
both,18,O
antigenically,18,O
deficient,18,O
and,18,O
smaller,18,O
in,18,O
size,18,O
than,18,O
normal,18,O
C6,18,O
(,18,O
110,18,O
",",18,O
000,18,O
daltons,18,O
compared,18,O
with,18,O
140,18,O
",",18,O
000,18,O
daltons,18,O
),18,O
and,18,O
small,18,O
quantities,18,O
of,18,O
apparently,18,O
normal,18,O
C7,18,O
.,18,O
It,19,O
is,19,O
concluded,19,O
that,19,O
the,19,O
most,19,O
likely,19,O
explanation,19,O
for,19,O
this,19,O
defect,19,O
is,19,O
that,19,O
the,19,O
subject,19,O
has,19,O
a,19,O
structural,19,O
mutation,19,O
in,19,O
his,19,O
C6,19,O
gene,19,O
which,19,O
produces,19,O
hyopsynthesis,19,O
not,19,O
only,19,O
of,19,O
C6,19,O
but,19,O
also,19,O
of,19,O
the,19,O
closely,19,O
linked,19,O
gene,19,O
for,19,O
C7,19,O
.,19,O
These,20,O
findings,20,O
suggest,20,O
the,20,O
possibility,20,O
that,20,O
C6,20,O
and,20,O
C7,20,O
may,20,O
function,20,O
as,20,O
a,20,O
single,20,O
genetic,20,O
unit,20,O
and,20,O
that,20,O
the,20,O
primary,20,O
transcript,20,O
copied,20,O
from,20,O
the,20,O
genome,20,O
includes,20,O
information,20,O
for,20,O
both,20,O
proteins,20,O
..,20,O
HLA,21,O
B27,21,O
and,21,O
the,21,O
genetics,21,O
of,21,O
ankylosing,21,B-SpecificDisease
spondylitis,21,I-SpecificDisease
.,21,O
One,22,O
hundred,22,O
and,22,O
twenty-eight,22,O
of,22,O
145,22,O
patients,22,O
with,22,O
ankylosing,22,B-SpecificDisease
spondylitis,22,I-SpecificDisease
(,22,O
AS,22,B-SpecificDisease
),22,O
were,22,O
found,22,O
to,22,O
be,22,O
HLA,22,O
B27,22,O
positive,22,O
.,22,O
Five,23,O
patients,23,O
had,23,O
evidence,23,O
of,23,O
a,23,O
sero-negative,23,O
peripheral,23,B-SpecificDisease
arthritis,23,I-SpecificDisease
resembling,23,O
peripheral,23,B-SpecificDisease
psoriatic,23,I-SpecificDisease
arthritis,23,I-SpecificDisease
and,23,O
3,23,O
of,23,O
these,23,O
were,23,O
B27,23,O
negative,23,O
.,23,O
One,24,O
further,24,O
B27,24,O
negative,24,O
patients,24,O
had,24,O
a,24,O
sister,24,O
with,24,O
ankylosing,24,B-SpecificDisease
spondylitis,24,I-SpecificDisease
and,24,O
ulcerative,24,B-SpecificDisease
colitis,24,I-SpecificDisease
and,24,O
a,24,O
mother,24,O
with,24,O
ulcerative,24,B-SpecificDisease
colitis,24,I-SpecificDisease
.,24,O
There,25,O
was,25,O
evidence,25,O
of,25,O
a,25,O
somewhat,25,O
later,25,O
age,25,O
of,25,O
onset,25,O
of,25,O
symptoms,25,O
in,25,O
B27,25,O
negative,25,O
patients,25,O
.,25,O
These,26,O
findings,26,O
are,26,O
interpreted,26,O
as,26,O
suggesting,26,O
some,26,O
degree,26,O
of,26,O
clinical,26,O
and,26,O
genetic,26,O
heterogeneity,26,O
in,26,O
ankylosing,26,B-SpecificDisease
spondylitis,26,I-SpecificDisease
with,26,O
genes,26,O
for,26,O
psoriasis,26,B-SpecificDisease
and,26,O
inflammatory,26,B-SpecificDisease
bowel,26,I-SpecificDisease
disease,26,I-SpecificDisease
being,26,O
important,26,O
in,26,O
some,26,O
individuals,26,O
",",26,O
particularly,26,O
those,26,O
who,26,O
are,26,O
B27,26,O
negative,26,O
.,26,O
Twenty-five,27,O
first-degree,27,O
relatives,27,O
with,27,O
ankylosing,27,B-SpecificDisease
spondylitis,27,I-SpecificDisease
were,27,O
all,27,O
B27,27,O
positive,27,O
.,27,O
The,28,O
only,28,O
instance,28,O
of,28,O
disassociation,28,O
of,28,O
B27,28,O
and,28,O
spondylitis,28,B-SpecificDisease
in,28,O
a,28,O
family,28,O
was,28,O
where,28,O
the,28,O
proband,28,O
had,28,O
ulcerative,28,B-SpecificDisease
colitis,28,I-SpecificDisease
as,28,O
well,28,O
as,28,O
spondylitis,28,B-SpecificDisease
.,28,O
Of,29,O
13,29,O
B27,29,O
positive,29,O
fathers,29,O
3,29,O
could,29,O
be,29,O
diagnosed,29,O
as,29,O
having,29,O
definite,29,O
ankylosing,29,B-SpecificDisease
spondylitis,29,I-SpecificDisease
(,29,O
23,29,O
%,29,O
),29,O
.,29,O
These,30,O
findings,30,O
are,30,O
thought,30,O
to,30,O
provide,30,O
evidence,30,O
against,30,O
the,30,O
concept,30,O
that,30,O
the,30,O
gene,30,O
for,30,O
ankylosing,30,B-SpecificDisease
spondylitis,30,I-SpecificDisease
is,30,O
not,30,O
B27,30,O
but,30,O
a,30,O
closely,30,O
linked,30,O
gene,30,O
and,30,O
favour,30,O
the,30,O
occurrence,30,O
of,30,O
an,30,O
environmental,30,O
event,30,O
affecting,30,O
approximately,30,O
one-fifth,30,O
of,30,O
B27,30,O
positive,30,O
males,30,O
to,30,O
result,30,O
in,30,O
disease,30,O
..,30,O
Carrier,31,O
detection,31,O
of,31,O
pyruvate,31,B-SpecificDisease
carboxylase,31,I-SpecificDisease
deficiency,31,I-SpecificDisease
in,31,O
fibroblasts,31,O
and,31,O
lymphocytes,31,O
.,31,O
Pyruvate,32,O
carboxylase,32,O
(,32,O
E.,32,O
C.,32,O
6,32,O
.,32,O
4,33,O
.,33,O
1,34,O
.,34,O
1,35,O
),35,O
activity,35,O
was,35,O
determined,35,O
in,35,O
the,35,O
circulating,35,O
peripheral,35,O
lymphocytes,35,O
and,35,O
cultured,35,O
skin,35,O
fibroblasts,35,O
from,35,O
the,35,O
family,35,O
of,35,O
a,35,O
patient,35,O
with,35,O
hepatic,35,O
",",35,O
cerebral,35,O
",",35,O
renal,35,O
cortical,35,O
",",35,O
leukocyte,35,O
",",35,O
and,35,O
fibroblast,35,O
pyruvate,35,B-SpecificDisease
carboxylase,35,I-SpecificDisease
deficiency,35,I-SpecificDisease
(,35,O
PC,35,B-SpecificDisease
Portland,35,I-SpecificDisease
deficiency,35,I-SpecificDisease
),35,O
.,35,O
Lymphocyte,36,O
activities,36,O
were,36,O
mother,36,O
",",36,O
33,36,O
--,36,O
39,36,O
%,36,O
;,36,O
father,36,O
",",36,O
11,36,O
--,36,O
29,36,O
%,36,O
;,36,O
brother,36,O
",",36,O
82,36,O
--,36,O
103,36,O
%,36,O
;,36,O
and,36,O
sister,36,O
",",36,O
38,36,O
--,36,O
48,36,O
%,36,O
of,36,O
the,36,O
lowest,36,O
normal,36,O
.,36,O
Fibroblasts,37,O
from,37,O
the,37,O
patients,37,O
mother,37,O
and,37,O
father,37,O
had,37,O
42,37,O
and,37,O
34,37,O
%,37,O
",",37,O
respectively,37,O
",",37,O
of,37,O
the,37,O
activity,37,O
of,37,O
the,37,O
lowest,37,O
normal,37,O
.,37,O
These,38,O
data,38,O
demonstrate,38,O
that,38,O
the,38,O
disease,38,O
is,38,O
inherited,38,O
in,38,O
an,38,O
autosomal,38,O
recessive,38,O
manner,38,O
and,38,O
that,38,O
lymphocytes,38,O
and,38,O
fibroblasts,38,O
can,38,O
be,38,O
used,38,O
to,38,O
detect,38,O
carriers,38,O
.,38,O
Neither,39,O
pyruvate,39,O
carboxylase,39,O
nor,39,O
mitochondrial,39,O
PEPCK,39,O
activity,39,O
in,39,O
lymphocytes,39,O
was,39,O
increased,39,O
by,39,O
a,39,O
21-hr,39,O
fast,39,O
.,39,O
Prenatal,40,O
diagnosis,40,O
of,40,O
Wolman,40,B-SpecificDisease
disease,40,I-SpecificDisease
.,40,O
Two,41,O
pregnancies,41,O
at,41,O
risk,41,O
for,41,O
Wolman,41,B-SpecificDisease
disease,41,I-SpecificDisease
were,41,O
monitored,41,O
by,41,O
assay,41,O
and,41,O
electrophoresis,41,O
of,41,O
acid,41,O
lipase,41,O
in,41,O
cultured,41,O
amniotic-fluid,41,O
cells,41,O
.,41,O
Cells,42,O
from,42,O
patient,42,O
1,42,O
had,42,O
5,42,O
%,42,O
of,42,O
control,42,O
levels,42,O
of,42,O
acid,42,O
lipase,42,O
",",42,O
using,42,O
14C-triolein,42,O
as,42,O
substrate,42,O
;,42,O
however,42,O
",",42,O
when,42,O
artificial,42,O
substrates,42,O
(,42,O
esters,42,O
of,42,O
4-methylumbelliferone,42,O
and,42,O
p-nitrophenol,42,O
),42,O
were,42,O
used,42,O
to,42,O
measure,42,O
acid,42,O
lipase,42,O
",",42,O
these,42,O
cells,42,O
had,42,O
30,42,O
%,42,O
of,42,O
control,42,O
levels,42,O
.,42,O
Electrophoresis,43,O
of,43,O
cell,43,O
extracts,43,O
revealed,43,O
the,43,O
absence,43,O
of,43,O
the,43,O
A,43,O
form,43,O
of,43,O
acid,43,O
lipase,43,O
",",43,O
consistent,43,O
with,43,O
the,43,O
diagnosis,43,O
of,43,O
Wolman,43,B-SpecificDisease
disease,43,I-SpecificDisease
.,43,O
Analysis,44,O
of,44,O
fetal,44,O
tissues,44,O
following,44,O
prostaglandin,44,O
termination,44,O
of,44,O
this,44,O
pregnancy,44,O
confirmed,44,O
the,44,O
diagnosis,44,O
.,44,O
Assay,45,O
of,45,O
fetal-skin,45,O
fibroblasts,45,O
with,45,O
14C-triolein,45,O
",",45,O
as,45,O
well,45,O
as,45,O
with,45,O
artificial,45,O
substrates,45,O
",",45,O
showed,45,O
marked,45,O
deficiency,45,O
of,45,O
acid,45,O
lipase,45,O
activity,45,O
.,45,O
Electrophoresis,46,O
of,46,O
fetal-tissue,46,O
extracts,46,O
also,46,O
demonstrated,46,O
the,46,O
absence,46,O
of,46,O
the,46,O
A,46,O
form,46,O
of,46,O
acid,46,O
lipase,46,O
.,46,O
Amniotic-fluid,47,O
cells,47,O
from,47,O
patient,47,O
2,47,O
showed,47,O
normal,47,O
levels,47,O
of,47,O
acid,47,O
lipase,47,O
with,47,O
all,47,O
substrates,47,O
tested,47,O
;,47,O
the,47,O
electrophoretic,47,O
pattern,47,O
of,47,O
acid,47,O
lipase,47,O
was,47,O
normal,47,O
.,47,O
The,48,O
results,48,O
suggest,48,O
that,48,O
the,48,O
prenatal,48,O
diagnosis,48,O
of,48,O
Wolman,48,B-SpecificDisease
disease,48,I-SpecificDisease
be,48,O
made,48,O
using,48,O
the,48,O
radioassay,48,O
of,48,O
acid,48,O
lipase,48,O
and/or,48,O
electrophoresis,48,O
..,48,O
Striking,49,O
prevalence,49,O
of,49,O
ankylosing,49,B-SpecificDisease
spondylitis,49,I-SpecificDisease
in,49,O
``,49,O
healthy,49,O
'',49,O
w27,49,O
positive,49,O
males,49,O
and,49,O
females,49,O
.,49,O
Ankylosing,50,B-SpecificDisease
spondylitis,50,I-SpecificDisease
is,50,O
diagnosed,50,O
once,50,O
or,50,O
twice,50,O
in,50,O
each,50,O
1000,50,O
males,50,O
and,50,O
one,50,O
tenth,50,O
as,50,O
frequently,50,O
in,50,O
females,50,O
",",50,O
but,50,O
the,50,O
true,50,O
prevalence,50,O
is,50,O
unknown,50,O
.,50,O
Indentification,51,O
of,51,O
genetic,51,O
marker,51,O
",",51,O
HL-A,51,O
W27,51,O
",",51,O
for,51,O
susceptible,51,O
persons,51,O
has,51,O
provided,51,O
a,51,O
tool,51,O
facilitating,51,O
epidemiologic,51,O
studies,51,O
and,51,O
allowing,51,O
identification,51,O
of,51,O
``,51,O
control,51,O
``,51,O
populations,51,O
without,51,O
the,51,O
marker,51,O
.,51,O
Evaluation,52,O
by,52,O
postal,52,O
questionnaires,52,O
",",52,O
and,52,O
pelvic,52,O
radiography,52,O
of,52,O
78,52,O
HL-A,52,O
27W-positive,52,O
blood,52,O
donors,52,O
selected,52,O
from,52,O
a,52,O
group,52,O
of,52,O
apparently,52,O
healthy,52,O
subjects,52,O
revealed,52,O
14,52,O
who,52,O
satisfied,52,O
the,52,O
criteria,52,O
for,52,O
definite,52,O
ankylosing,52,B-SpecificDisease
spondylitis,52,I-SpecificDisease
.,52,O
The,53,O
prevalence,53,O
was,53,O
similar,53,O
in,53,O
both,53,O
sexes,53,O
.,53,O
One,54,O
hundred,54,O
and,54,O
twenty-six,54,O
W27-negative,54,O
controls,54,O
matched,54,O
for,54,O
race,54,O
",",54,O
sex,54,O
",",54,O
and,54,O
age,54,O
failed,54,O
to,54,O
yield,54,O
a,54,O
single,54,O
case,54,O
.,54,O
For,55,O
a,55,O
person,55,O
of,55,O
either,55,O
sex,55,O
with,55,O
HL-A,55,O
W27,55,O
",",55,O
there,55,O
appears,55,O
to,55,O
be,55,O
about,55,O
a,55,O
20,55,O
per,55,O
cent,55,O
chance,55,O
that,55,O
ankylosing,55,B-SpecificDisease
spondylitis,55,I-SpecificDisease
will,55,O
develop,55,O
",",55,O
suggesting,55,O
a,55,O
prevalence,55,O
of,55,O
10,55,O
to,55,O
15,55,O
per,55,O
thousand,55,O
.,55,O
Hitherto,56,O
accepted,56,O
figures,56,O
may,56,O
underestimate,56,O
the,56,O
frequency,56,O
by,56,O
a,56,O
factor,56,O
of,56,O
10,56,O
to,56,O
20,56,O
..,56,O
Linkage,57,O
of,57,O
gene,57,O
for,57,O
C2,57,B-SpecificDisease
deficiency,57,I-SpecificDisease
and,57,O
the,57,O
major,57,O
histocompatibility,57,O
complex,57,O
MHC,57,O
in,57,O
man,57,O
.,57,O
Family,58,O
study,58,O
of,58,O
a,58,O
further,58,O
case,58,O
.,58,O
Close,59,O
linkage,59,O
between,59,O
HL-A,59,O
and,59,O
C2,59,B-SpecificDisease
deficiency,59,I-SpecificDisease
was,59,O
first,59,O
reported,59,O
by,59,O
FU,59,O
and,59,O
co-workers,59,O
in,59,O
1974,59,O
.,59,O
We,60,O
present,60,O
here,60,O
a,60,O
pedigree,60,O
of,60,O
a,60,O
31-year-old,60,O
C2-deficient,60,B-Modifier
individual,60,O
with,60,O
clinical,60,O
manifestations,60,O
of,60,O
Hodgkins,60,B-SpecificDisease
disease,60,I-SpecificDisease
.,60,O
The,61,O
following,61,O
markers,61,O
were,61,O
tested,61,O
C2,61,O
levels,61,O
",",61,O
factor,61,O
B,61,O
polymorphism,61,O
",",61,O
blood,61,O
groups,61,O
",",61,O
and,61,O
enzyme,61,O
typing,61,O
.,61,O
In,62,O
addition,62,O
to,62,O
close,62,O
linkage,62,O
between,62,O
HL-A,62,O
and,62,O
C2,62,B-SpecificDisease
deficiency,62,I-SpecificDisease
",",62,O
both,62,O
parents,62,O
were,62,O
heterozygous,62,O
for,62,O
Bf,62,O
(,62,O
HL-A,62,O
linked,62,O
",",62,O
electrophoretic,62,O
variation,62,O
of,62,O
B,62,O
),62,O
.,62,O
The,63,O
two,63,O
HL-A,63,O
haplotypes,63,O
closely,63,O
linked,63,O
to,63,O
C2,63,B-SpecificDisease
deficiency,63,I-SpecificDisease
are,63,O
different,63,O
2,63,O
",",63,O
W18,63,O
and,63,O
W24,63,O
",",63,O
W18,63,O
.,63,O
They,64,O
share,64,O
",",64,O
however,64,O
",",64,O
the,64,O
SD2,64,O
antigen,64,O
W18,64,O
and,64,O
the,64,O
LD,64,O
type,64,O
7a,64,O
..,64,O
[,65,O
Genetic,65,O
heterogeneity,65,O
of,65,O
G6PD,65,B-SpecificDisease
deficiency,65,I-SpecificDisease
:,65,O
mutant,65,O
alleles,65,O
of,65,O
G6PD,65,O
in,65,O
the,65,O
Shekii,65,O
district,65,O
of,65,O
Azerbaijan,65,O
],65,O
Examination,65,O
on,65,O
G6PD,65,B-SpecificDisease
deficiency,65,I-SpecificDisease
in,65,O
349,65,O
patients,65,O
of,65,O
Shekii,65,O
district,65,O
hospital,65,O
(,65,O
Azerbaijan,65,O
),65,O
revealed,65,O
16,65,O
hemi-,65,O
",",65,O
4,65,O
homo-,65,O
and,65,O
9,65,O
heterozygotic,65,O
carriers,65,O
of,65,O
the,65,O
defect,65,O
.,65,O
Gd-,66,O
frequency,66,O
",",66,O
calculated,66,O
from,66,O
the,66,O
data,66,O
obtained,66,O
(,66,O
7,66,O
.,66,O
7,67,O
%,67,O
),67,O
",",67,O
may,67,O
be,67,O
compared,67,O
to,67,O
neighbouring,67,O
regions,67,O
frequencies,67,O
(,67,O
6-30,67,O
%,67,O
),67,O
.,67,O
Carriers,68,O
of,68,O
G6PD,68,B-SpecificDisease
deficiency,68,I-SpecificDisease
are,68,O
residents,68,O
of,68,O
11,68,O
villages,68,O
located,68,O
in,68,O
Alasani-Aphtalan,68,O
valley,68,O
",",68,O
highly,68,O
endemic,68,O
with,68,O
malaria,68,B-SpecificDisease
in,68,O
the,68,O
past,68,O
;,68,O
nearly,68,O
all,68,O
marriages,68,O
are,68,O
endogamic,68,O
.,68,O
Physico-chemical,69,O
and,69,O
kinetic,69,O
study,69,O
of,69,O
10,69,O
mutant,69,O
forms,69,O
of,69,O
G6PD,69,O
",",69,O
according,69,O
to,69,O
WHO,69,O
program,69,O
",",69,O
led,69,O
to,69,O
identification,69,O
of,69,O
5,69,O
variants,69,O
of,69,O
the,69,O
II,69,O
class,69,O
(,69,O
Shekii,69,O
",",69,O
Bideiz,69,O
",",69,O
Shirin-Bulakh,69,O
",",69,O
Okhut,69,O
I,69,O
and,69,O
Zakataly,69,O
),69,O
and,69,O
2,69,O
variants,69,O
of,69,O
the,69,O
III,69,O
class,69,O
(,69,O
Okhut,69,O
II,69,O
and,69,O
Martinique-like,69,O
),69,O
.,69,O
Resemblance,70,O
of,70,O
the,70,O
majority,70,O
of,70,O
variants,70,O
in,70,O
electrophoretic,70,O
mobility,70,O
and,70,O
the,70,O
level,70,O
of,70,O
erythrocyte,70,O
enzyme,70,O
activity,70,O
permit,70,O
to,70,O
suggest,70,O
the,70,O
existence,70,O
of,70,O
a,70,O
common,70,O
parental,70,O
mutant,70,O
G6PD,70,O
allele,70,O
distributed,70,O
in,70,O
this,70,O
area,70,O
.,70,O
Linkage,71,O
relationship,71,O
of,71,O
C2,71,B-SpecificDisease
deficiency,71,I-SpecificDisease
",",71,O
HLA,71,O
and,71,O
glyoxalase,71,O
I,71,O
loci,71,O
.,71,O
Immunogenetic,72,O
analysis,72,O
of,72,O
a,72,O
homozygous,72,O
C2-deficient,72,B-Modifier
individual,72,O
and,72,O
family,72,O
members,72,O
demonstrated,72,O
linkage,72,O
of,72,O
HLA-A25,72,O
",",72,O
B18,72,O
and,72,O
C2o,72,O
.,72,O
HLA-D,73,O
typing,73,O
showed,73,O
that,73,O
5,73,O
members,73,O
typed,73,O
with,73,O
homozygous,73,O
Dw2,73,O
typing,73,O
cells,73,O
from,73,O
an,73,O
individual,73,O
with,73,O
C2,73,B-SpecificDisease
deficiency,73,I-SpecificDisease
but,73,O
not,73,O
with,73,O
Dw2,73,O
typing,73,O
cells,73,O
from,73,O
2,73,O
individuals,73,O
with,73,O
normal,73,O
C2,73,O
.,73,O
The,74,O
homozygous,74,O
C2-deficient,74,B-Modifier
propositus,74,O
and,74,O
brother,74,O
were,74,O
HLA-A,74,O
and,74,O
B,74,O
homozygous,74,O
but,74,O
heterozygous,74,O
at,74,O
the,74,O
HLA-D,74,O
and,74,O
glyoxalase,74,O
I,74,O
loci,74,O
.,74,O
Therefore,75,O
",",75,O
in,75,O
this,75,O
family,75,O
",",75,O
the,75,O
C2o,75,O
gene,75,O
is,75,O
linked,75,O
with,75,O
two,75,O
distinct,75,O
haplotypes,75,O
HLA-A25,75,O
",",75,O
B18,75,O
",",75,O
Dw2,75,O
",",75,O
GLO1,75,O
and,75,O
HLA-A25,75,O
",",75,O
B18,75,O
",",75,O
D,75,O
unknown,75,O
",",75,O
GL02,75,O
.,75,O
These,76,O
results,76,O
could,76,O
be,76,O
explained,76,O
by,76,O
an,76,O
ancestral,76,O
recombinant,76,O
event,76,O
",",76,O
which,76,O
occurred,76,O
between,76,O
the,76,O
C2o,76,O
locus,76,O
and,76,O
HLA-D,76,O
locus,76,O
in,76,O
which,76,O
C2o,76,O
segregated,76,O
with,76,O
HLA-B,76,O
.,76,O
This,77,O
would,77,O
suggest,77,O
that,77,O
the,77,O
locus,77,O
for,77,O
the,77,O
C2o,77,O
gene,77,O
maps,77,O
between,77,O
HLA-B,77,O
and,77,O
HLA-D,77,O
on,77,O
the,77,O
sixth,77,O
chromosome,77,O
..,77,O
Adrenoleukodystrophy,78,B-SpecificDisease
and,78,O
adrenomyeloneuropathy,78,B-SpecificDisease
associated,78,O
with,78,O
partial,78,O
adrenal,78,B-DiseaseClass
insufficiency,78,I-DiseaseClass
in,78,O
three,78,O
generations,78,O
of,78,O
a,78,O
kindred,78,O
.,78,O
Four,79,O
cases,79,O
of,79,O
adrenoleukodystrophy,79,B-SpecificDisease
(,79,O
ALD,79,B-SpecificDisease
),79,O
and,79,O
one,79,O
case,79,O
of,79,O
adrenomyeloneuropathy,79,B-SpecificDisease
(,79,O
AMN,79,B-SpecificDisease
),79,O
have,79,O
developed,79,O
in,79,O
a,79,O
kindred,79,O
over,79,O
three,79,O
generations,79,O
demonstrating,79,O
that,79,O
AMN,79,B-SpecificDisease
is,79,O
a,79,O
clinical,79,O
variant,79,O
of,79,O
ALD,79,B-SpecificDisease
.,79,O
Pituitary-adrenal,80,O
function,80,O
studies,80,O
were,80,O
performed,80,O
in,80,O
10,80,O
family,80,O
members,80,O
",",80,O
including,80,O
two,80,O
affected,80,O
males,80,O
and,80,O
four,80,O
females,80,O
identified,80,O
as,80,O
carriers,80,O
of,80,O
ALD/AMN,80,B-SpecificDisease
.,80,O
No,81,O
pituitary-adrenal,81,B-DiseaseClass
abnormality,81,I-DiseaseClass
was,81,O
found,81,O
in,81,O
the,81,O
carriers,81,O
.,81,O
However,82,O
",",82,O
basal,82,O
morning,82,O
plasma,82,O
adrenocorticotropic,82,O
hormone,82,O
(,82,O
ACTH,82,O
),82,O
levels,82,O
were,82,O
markedly,82,O
elevated,82,O
in,82,O
the,82,O
two,82,O
males,82,O
with,82,O
ALD,82,B-SpecificDisease
and,82,O
AMN,82,B-SpecificDisease
",",82,O
despite,82,O
the,82,O
fact,82,O
that,82,O
they,82,O
had,82,O
no,82,O
clinical,82,O
signs,82,O
of,82,O
adrenal,82,B-DiseaseClass
insufficiency,82,I-DiseaseClass
and,82,O
that,82,O
morning,82,O
plasma,82,O
cortisol,82,O
levels,82,O
and,82,O
their,82,O
response,82,O
to,82,O
maximal,82,O
exogenous,82,O
ACTH,82,O
stimulation,82,O
appeared,82,O
to,82,O
be,82,O
normal,82,O
.,82,O
In,83,O
addition,83,O
",",83,O
the,83,O
integrated,83,O
24-hour,83,O
response,83,O
to,83,O
the,83,O
administration,83,O
were,83,O
also,83,O
subnormal,83,O
in,83,O
these,83,O
two,83,O
cases,83,O
.,83,O
Thus,84,O
",",84,O
people,84,O
with,84,O
ALD,84,B-SpecificDisease
and,84,O
AMN,84,B-SpecificDisease
may,84,O
have,84,O
subclinical,84,O
partial,84,O
adrenocrotical,84,B-DiseaseClass
insufficiency,84,I-DiseaseClass
.,84,O
No,85,O
other,85,O
endocrinologic,85,B-DiseaseClass
dysfunction,85,I-DiseaseClass
was,85,O
identified,85,O
..,85,O
Hereditary,86,B-SpecificDisease
C2,86,I-SpecificDisease
deficiency,86,I-SpecificDisease
associated,86,O
with,86,O
common,86,O
variable,86,O
immunodeficiency,86,B-DiseaseClass
.,86,O
Homozygous,87,O
C2,87,B-SpecificDisease
deficiency,87,I-SpecificDisease
in,87,O
a,87,O
19-year-old,87,O
boy,87,O
was,87,O
associated,87,O
with,87,O
variable,87,O
immunodeficiency,87,B-DiseaseClass
manifested,87,O
by,87,O
marked,87,O
hypoimmunoglobulinemia,87,B-DiseaseClass
and,87,O
impaired,87,O
antibody,87,O
responses,87,O
",",87,O
normal,87,O
circulating,87,O
B,87,O
lymphocytes,87,O
",",87,O
and,87,O
subnormal,87,O
T-cell,87,O
functions,87,O
.,87,O
Neither,88,O
antilymphocytic,88,O
autoantibodies,88,O
nor,88,O
chromosomal,88,B-DiseaseClass
abnormalities,88,I-DiseaseClass
were,88,O
found,88,O
.,88,O
Serum,89,O
immunoglobulin,89,O
levels,89,O
were,89,O
within,89,O
normal,89,O
limits,89,O
in,89,O
his,89,O
parents,89,O
and,89,O
brother,89,O
who,89,O
were,89,O
heterozygous,89,O
for,89,O
C2,89,B-SpecificDisease
deficiency,89,I-SpecificDisease
.,89,O
The,90,O
patients,90,O
lymphocytes,90,O
were,90,O
homozygous,90,O
at,90,O
the,90,O
HLA-D,90,O
locus,90,O
but,90,O
expressed,90,O
an,90,O
antigen,90,O
different,90,O
from,90,O
DW2,90,O
..,90,O
Hereditary,91,B-SpecificDisease
deficiency,91,I-SpecificDisease
of,91,I-SpecificDisease
the,91,I-SpecificDisease
third,91,I-SpecificDisease
component,91,I-SpecificDisease
of,91,I-SpecificDisease
complement,91,I-SpecificDisease
in,91,O
a,91,O
child,91,O
with,91,O
fever,91,B-DiseaseClass
",",91,O
skin,91,B-DiseaseClass
rash,91,I-DiseaseClass
",",91,O
and,91,O
arthralgias,91,B-DiseaseClass
:,91,O
response,91,O
to,91,O
transfusion,91,O
of,91,O
whole,91,O
blood,91,O
.,91,O
A,92,O
previously,92,O
well,92,O
34-month-old,92,O
male,92,O
presenting,92,O
with,92,O
fever,92,B-DiseaseClass
",",92,O
skin,92,B-DiseaseClass
rash,92,I-DiseaseClass
",",92,O
and,92,O
arthralgias,92,B-DiseaseClass
was,92,O
found,92,O
to,92,O
lack,92,O
C3,92,O
by,92,O
immunochemical,92,O
(,92,O
undetectable,92,O
),92,O
and,92,O
hemolytic,92,O
(,92,O
1,92,O
%,92,O
normal,92,O
),92,O
assays,92,O
.,92,O
No,93,O
infectious,93,O
agent,93,O
could,93,O
be,93,O
demonstrated,93,O
.,93,O
Protein,94,O
levels,94,O
of,94,O
Clq,94,O
.,94,O
C4,95,O
",",95,O
C5,95,O
",",95,O
properdin,95,O
",",95,O
and,95,O
C3b-INA,95,O
and,95,O
hemolytic,95,O
activities,95,O
of,95,O
complement,95,O
components,95,O
C1,95,O
to,95,O
C9,95,O
except,95,O
C3,95,O
were,95,O
normal,95,O
or,95,O
elevated,95,O
;,95,O
total,95,O
hemolytic,95,O
complement,95,O
activity,95,O
was,95,O
13,95,O
%,95,O
of,95,O
normal,95,O
and,95,O
was,95,O
reconstituted,95,O
by,95,O
purified,95,O
C3,95,O
.,95,O
Properdin,96,O
factor,96,O
B,96,O
was,96,O
702,96,O
(,96,O
normal,96,O
175,96,O
to,96,O
275,96,O
),96,O
mug/ml,96,O
",",96,O
and,96,O
was,96,O
not,96,O
cleaver,96,O
upon,96,O
addition,96,O
of,96,O
zymosan,96,O
or,96,O
cobra,96,O
venom,96,O
factor,96,O
.,96,O
The,97,O
serum,97,O
had,97,O
normal,97,O
immune,97,O
adherence,97,O
activity,97,O
",",97,O
but,97,O
was,97,O
deficient,97,O
in,97,O
ability,97,O
to,97,O
opsonize,97,O
Candida,97,O
albicans,97,O
for,97,O
uptake,97,O
and,97,O
Escherichia,97,O
coli,97,O
for,97,O
killing,97,O
by,97,O
neurophils,97,O
",",97,O
generate,97,O
neutrophil,97,O
chemotactic,97,O
factors,97,O
and,97,O
inhibit,97,O
the,97,O
growth,97,O
of,97,O
E.,97,O
coli,97,O
;,97,O
these,97,O
activities,97,O
were,97,O
restored,97,O
by,97,O
purified,97,O
C3,97,O
.,97,O
A,98,O
transfusion,98,O
of,98,O
320,98,O
ml,98,O
1-hour-old,98,O
normal,98,O
whole,98,O
blood,98,O
on,98,O
the,98,O
fifty-second,98,O
day,98,O
resulted,98,O
in,98,O
transitory,98,O
elevation,98,O
of,98,O
the,98,O
C3,98,O
level,98,O
to,98,O
25,98,O
mg/dl,98,O
with,98,O
a,98,O
fall-off,98,O
(,98,O
approximately,98,O
2,98,O
1/2,98,O
%,98,O
per,98,O
hour,98,O
),98,O
to,98,O
undetectable,98,O
levels,98,O
by,98,O
69,98,O
hours,98,O
;,98,O
it,98,O
was,98,O
followed,98,O
by,98,O
disappearance,98,O
of,98,O
the,98,O
skin,98,B-DiseaseClass
rash,98,I-DiseaseClass
and,98,O
arthralgias,98,B-DiseaseClass
and,98,O
return,98,O
to,98,O
normal,98,O
of,98,O
the,98,O
previously,98,O
elevated,98,O
temperature,98,O
and,98,O
CRP,98,O
levels,98,O
.,98,O
C3,99,O
levels,99,O
in,99,O
family,99,O
members,99,O
(,99,O
seven,99,O
of,99,O
24,99,O
half-normal,99,O
),99,O
",",99,O
lack,99,O
of,99,O
anti-C3,99,O
activity,99,O
",",99,O
normal,99,O
C3b-INA,99,O
levels,99,O
and,99,O
a,99,O
normal,99,O
rate,99,O
of,99,O
catabolism,99,O
of,99,O
transfused,99,O
C3,99,O
indicated,99,O
that,99,O
the,99,O
deficiency,99,O
was,99,O
inherited,99,O
with,99,O
autosomal,99,O
codominance,99,O
and,99,O
involved,99,O
decreased,99,B-DiseaseClass
synthesis,99,I-DiseaseClass
of,99,I-DiseaseClass
C3,99,I-DiseaseClass
.,99,O
Thus,100,O
",",100,O
this,100,O
child,100,O
is,100,O
a,100,O
unique,100,O
individual,100,O
with,100,O
inherited,100,B-SpecificDisease
C3,100,I-SpecificDisease
deficiency,100,I-SpecificDisease
presenting,100,O
with,100,O
absence,100,O
of,100,O
repeated,100,O
infections,100,O
",",100,O
whose,100,O
symptoms,100,O
of,100,O
fever,100,B-DiseaseClass
",",100,O
skin,100,B-DiseaseClass
rash,100,I-DiseaseClass
",",100,O
and,100,O
arthralgia,100,B-DiseaseClass
were,100,O
abated,100,O
by,100,O
whole,100,O
blood,100,O
transfusion,100,O
..,100,O
Hereditary,101,B-SpecificDisease
C7,101,I-SpecificDisease
deficiency,101,I-SpecificDisease
.,101,O
Diagnosis,102,O
and,102,O
HLA,102,O
studies,102,O
in,102,O
a,102,O
French-Canadian,102,O
family,102,O
.,102,O
The,103,O
serum,103,O
of,103,O
a,103,O
44-yr-old,103,O
woman,103,O
of,103,O
French-Canadian,103,O
descent,103,O
having,103,O
a,103,O
B-27,103,O
positive,103,O
ankylosing,103,B-SpecificDisease
spondylitis,103,I-SpecificDisease
was,103,O
deficient,103,B-SpecificDisease
in,103,I-SpecificDisease
the,103,I-SpecificDisease
seventh,103,I-SpecificDisease
component,103,I-SpecificDisease
of,103,I-SpecificDisease
complement,103,I-SpecificDisease
(,103,O
C7,103,O
),103,O
as,103,O
determined,103,O
by,103,O
hemolytic,103,O
and,103,O
immunochemical,103,O
methods,103,O
.,103,O
No,104,O
inhibitor,104,O
against,104,O
C7,104,O
was,104,O
detected,104,O
",",104,O
and,104,O
the,104,O
levels,104,O
of,104,O
all,104,O
other,104,O
complement,104,O
components,104,O
were,104,O
normal,104,O
.,104,O
No,105,O
deficiency,105,O
in,105,O
the,105,O
opsonic,105,O
activity,105,O
of,105,O
the,105,O
serum,105,O
was,105,O
found,105,O
",",105,O
and,105,O
the,105,O
results,105,O
of,105,O
basic,105,O
coagulation,105,O
studies,105,O
of,105,O
the,105,O
plasma,105,O
were,105,O
normal,105,O
.,105,O
On,106,O
investigation,106,O
of,106,O
the,106,O
patients,106,O
family,106,O
",",106,O
two,106,O
sisters,106,O
were,106,O
found,106,O
to,106,O
have,106,O
the,106,O
same,106,O
deficiency,106,O
but,106,O
were,106,O
otherwise,106,O
in,106,O
good,106,O
health,106,O
.,106,O
The,107,O
seven,107,O
other,107,O
siblings,107,O
were,107,O
heterozygous,107,O
for,107,O
C7,107,B-SpecificDisease
deficiency,107,I-SpecificDisease
",",107,O
while,107,O
the,107,O
paternal,107,O
aunt,107,O
had,107,O
a,107,O
normal,107,O
C7,107,O
level,107,O
.,107,O
In,108,O
the,108,O
third,108,O
generation,108,O
",",108,O
six,108,O
children,108,O
of,108,O
the,108,O
three,108,O
homozygous,108,O
sisters,108,O
and,108,O
five,108,O
children,108,O
of,108,O
heterozygotes,108,O
were,108,O
available,108,O
for,108,O
testing,108,O
.,108,O
Studies,109,O
of,109,O
the,109,O
HLA,109,O
antigens,109,O
in,109,O
all,109,O
the,109,O
22,109,O
subjects,109,O
and,109,O
in,109,O
three,109,O
spouses,109,O
indicated,109,O
no,109,O
close,109,O
linkage,109,O
between,109,O
the,109,O
CM,109,B-SpecificDisease
deficienty,109,I-SpecificDisease
and,109,O
the,109,O
HLA,109,O
system,109,O
.,109,O
In,110,O
addition,110,O
",",110,O
the,110,O
simultaneous,110,O
occurrence,110,O
of,110,O
two,110,O
hereditary,110,O
complement,110,O
deficiencies,110,O
(,110,O
C2,110,O
and,110,O
C7,110,O
),110,O
was,110,O
discovered,110,O
in,110,O
one,110,O
family,110,O
of,110,O
this,110,O
remarkable,110,O
kindred,110,O
..,110,O
Genetic,111,O
defect,111,B-SpecificDisease
in,111,I-SpecificDisease
secretion,111,I-SpecificDisease
of,111,I-SpecificDisease
complement,111,I-SpecificDisease
C5,111,I-SpecificDisease
in,111,O
mice,111,O
.,111,O
A,112,O
genetic,112,O
deficiency,112,B-SpecificDisease
of,112,I-SpecificDisease
the,112,I-SpecificDisease
fifth,112,I-SpecificDisease
(,112,I-SpecificDisease
C5,112,I-SpecificDisease
),112,I-SpecificDisease
component,112,I-SpecificDisease
of,112,I-SpecificDisease
complement1-3,112,I-SpecificDisease
",",112,O
a,112,O
serum,112,O
glycoprotein,112,O
of,112,O
molecular,112,O
weight,112,O
(,112,O
MW,112,O
),112,O
220,112,O
",",112,O
000,112,O
(,112,O
ref,112,O
.,112,O
4,113,O
),113,O
",",113,O
has,113,O
been,113,O
found,113,O
in,113,O
39,113,O
%,113,O
of,113,O
inbred,113,O
strains,113,O
of,113,O
mice3,113,O
.,113,O
Sera,114,O
of,114,O
deficient,114,O
mice,114,O
lack,114,O
detectable,114,O
C5,114,O
activity,114,O
and,114,O
protein2,114,O
",",114,O
3,114,O
.,114,O
In,115,O
addition,115,O
deficient,115,O
mice,115,O
produce,115,O
antibody,115,O
to,115,O
mouse,115,O
C5,115,O
when,115,O
injected,115,O
with,115,O
sera,115,O
from,115,O
C5,115,O
sufficient,115,O
(,115,O
normal,115,O
),115,O
strains,115,O
.,115,O
Levy,116,O
et,116,O
al,116,O
.,116,O
5,117,O
showed,117,O
that,117,O
somatic,117,O
cell,117,O
hybrids,117,O
between,117,O
C5,117,O
deficient,117,O
(,117,O
B10,117,O
.,117,O
D2/old,118,O
line,118,O
),118,O
macrophages,118,O
and,118,O
either,118,O
C5,118,O
sufficient,118,O
(,118,O
B10,118,O
.,118,O
D2/new,119,O
line,119,O
),119,O
mouse,119,O
kidney,119,O
or,119,O
chicken,119,O
erythroblasts,119,O
secreted,119,O
haemolytically,119,O
active,119,O
mouse,119,O
C5,119,O
in,119,O
vitro,119,O
.,119,O
Several,120,O
possible,120,O
molecular,120,O
mechanisms,120,O
to,120,O
account,120,O
for,120,O
the,120,O
findings,120,O
were,120,O
considered,120,O
",",120,O
but,120,O
insufficient,120,O
direct,120,O
data,120,O
were,120,O
available,120,O
to,120,O
choose,120,O
among,120,O
them,120,O
.,120,O
We,121,O
recently,121,O
reported,121,O
that,121,O
mouse,121,O
(,121,O
CD,121,O
.,121,O
1,122,O
strain,122,O
),122,O
peritoneal,122,O
cells,122,O
in,122,O
culture,122,O
synthesise,122,O
and,122,O
secrete,122,O
a,122,O
single,122,O
chain,122,O
precursor,122,O
",",122,O
pro-C5,122,O
(,122,O
MW,122,O
approximately,122,O
210,122,O
",",122,O
000,122,O
),122,O
",",122,O
of,122,O
the,122,O
two-chain,122,O
(,122,O
alpha,122,O
chain,122,O
",",122,O
125,122,O
",",122,O
000,122,O
and,122,O
beta,122,O
chain,122,O
83,122,O
",",122,O
000,122,O
MW,122,O
),122,O
C5,122,O
protein6,122,O
.,122,O
Radiolabelled,123,O
precursor,123,O
C5,123,O
was,123,O
contained,123,O
within,123,O
the,123,O
cells,123,O
and,123,O
was,123,O
secreted,123,O
into,123,O
the,123,O
tissue,123,O
culture,123,O
media,123,O
.,123,O
Using,124,O
similar,124,O
methods,124,O
",",124,O
we,124,O
now,124,O
find,124,O
that,124,O
C5,124,B-SpecificDisease
deficiency,124,I-SpecificDisease
in,124,O
each,124,O
of,124,O
five,124,O
different,124,O
mouse,124,O
strains,124,O
(,124,O
AKR,124,O
",",124,O
SWR,124,O
",",124,O
DBA/2J8,124,O
A/HeJ,124,O
and,124,O
B10,124,O
.,124,O
D2/old,125,O
line,125,O
),125,O
is,125,O
due,125,O
to,125,O
a,125,O
failure,125,O
in,125,O
secretion,125,O
of,125,O
C5,125,O
protein,125,O
and,125,O
not,125,O
to,125,O
a,125,O
failure,125,O
in,125,O
biosynthesis,125,O
of,125,O
pro-C5,125,O
Recurrent,126,O
meningococcal,126,B-SpecificDisease
meningitis,126,I-SpecificDisease
with,126,O
absence,126,B-SpecificDisease
of,126,I-SpecificDisease
the,126,I-SpecificDisease
sixth,126,I-SpecificDisease
component,126,I-SpecificDisease
of,126,I-SpecificDisease
complement,126,I-SpecificDisease
:,126,O
an,126,O
evaluation,126,O
of,126,O
underlying,126,O
immunologic,126,O
mechanisms,126,O
.,126,O
A,127,O
51/2-year-old,127,O
black,127,O
girl,127,O
with,127,O
recurrent,127,O
meningococcal,127,B-SpecificDisease
meningitis,127,I-SpecificDisease
and,127,O
absence,127,B-SpecificDisease
of,127,I-SpecificDisease
the,127,I-SpecificDisease
sixth,127,I-SpecificDisease
component,127,I-SpecificDisease
of,127,I-SpecificDisease
complement,127,I-SpecificDisease
(,127,O
C6,127,O
),127,O
is,127,O
reported,127,O
.,127,O
To,128,O
explore,128,O
the,128,O
pathogenesis,128,O
of,128,O
recurrent,128,O
neisserial,128,B-SpecificDisease
infections,128,I-SpecificDisease
in,128,O
C6,128,B-SpecificDisease
deficiency,128,I-SpecificDisease
",",128,O
a,128,O
detailed,128,O
analysis,128,O
of,128,O
her,128,O
immune,128,O
competence,128,O
was,128,O
conducted,128,O
.,128,O
Her,129,O
serum,129,O
had,129,O
normal,129,O
chemotactic,129,O
",",129,O
opsonic,129,O
",",129,O
alternative,129,O
complement,129,O
pathway,129,O
",",129,O
and,129,O
specific,129,O
antibody,129,O
activity,129,O
",",129,O
but,129,O
lacked,129,O
complement-mediated,129,O
bacteriolytic,129,O
activity,129,O
.,129,O
In,130,O
addition,130,O
",",130,O
her,130,O
C6-deficient,130,B-Modifier
serum,130,O
was,130,O
indistinguishable,130,O
from,130,O
normal,130,O
serum,130,O
in,130,O
a,130,O
complement-dependent,130,O
assay,130,O
of,130,O
phagocyte,130,O
bactericidal,130,O
activity,130,O
.,130,O
Absent,131,O
bacteriolysis,131,O
remains,131,O
the,131,O
only,131,O
consistent,131,O
defect,131,O
associated,131,O
with,131,O
recurrent,131,O
neisserial,131,B-SpecificDisease
infections,131,I-SpecificDisease
and,131,O
absence,131,O
of,131,O
one,131,O
of,131,O
the,131,O
late-acting,131,O
complement,131,O
components,131,O
..,131,O
Deficiency,132,B-SpecificDisease
of,132,I-SpecificDisease
the,132,I-SpecificDisease
fifth,132,I-SpecificDisease
component,132,I-SpecificDisease
of,132,I-SpecificDisease
complement,132,I-SpecificDisease
in,132,O
human,132,O
subjects,132,O
.,132,O
Clinical,133,O
",",133,O
genetic,133,O
and,133,O
immunologic,133,O
studies,133,O
in,133,O
a,133,O
large,133,O
kindred,133,O
.,133,O
The,134,O
discovery,134,O
of,134,O
a,134,O
large,134,O
kindred,134,O
with,134,O
a,134,O
heritable,134,O
deficiency,134,B-SpecificDisease
of,134,I-SpecificDisease
the,134,I-SpecificDisease
fifth,134,I-SpecificDisease
component,134,I-SpecificDisease
of,134,I-SpecificDisease
complement,134,I-SpecificDisease
(,134,O
C5,134,O
),134,O
has,134,O
permitted,134,O
the,134,O
accumulation,134,O
of,134,O
new,134,O
clinical,134,O
",",134,O
genetic,134,O
and,134,O
immunologic,134,O
data,134,O
concerning,134,O
the,134,O
role,134,O
of,134,O
C5,134,O
in,134,O
human,134,O
subjects,134,O
.,134,O
The,135,O
proband,135,O
",",135,O
who,135,O
has,135,O
had,135,O
nine,135,O
episodes,135,O
of,135,O
disseminated,135,O
gonococcal,135,B-SpecificDisease
infection,135,I-SpecificDisease
",",135,O
has,135,O
a,135,O
hemolytic,135,O
C5,135,O
level,135,O
of,135,O
approximately,135,O
0,135,O
.,135,O
5,136,O
per,136,O
cent,136,O
of,136,O
normal,136,O
.,136,O
No,137,O
C5,137,O
protein,137,O
was,137,O
detectable,137,O
",",137,O
but,137,O
low,137,O
levels,137,O
of,137,O
functional,137,O
C5,137,O
activity,137,O
could,137,O
be,137,O
found,137,O
using,137,O
a,137,O
sensitive,137,O
bactericidal,137,O
assay,137,O
.,137,O
The,138,O
probands,138,O
twin,138,O
as,138,O
well,138,O
as,138,O
another,138,O
sister,138,O
also,138,O
had,138,O
extremely,138,O
low,138,O
levels,138,O
of,138,O
hemolytic,138,O
C5,138,O
(,138,O
approximately,138,O
0,138,O
.,138,O
5,139,O
per,139,O
cent,139,O
normal,139,O
),139,O
",",139,O
but,139,O
both,139,O
these,139,O
subjects,139,O
have,139,O
been,139,O
healthy,139,O
.,139,O
Hemolytic,140,O
complement,140,O
and,140,O
bacteriolytic,140,O
activity,140,O
could,140,O
be,140,O
restored,140,O
by,140,O
the,140,O
addition,140,O
of,140,O
purified,140,O
C5,140,O
.,140,O
No,141,O
chemotactic,141,O
activity,141,O
for,141,O
polymorphonuclear,141,O
leukocytes,141,O
could,141,O
be,141,O
generated,141,O
in,141,O
the,141,O
C5-deficient,141,B-Modifier
serums,141,O
upon,141,O
activation,141,O
of,141,O
either,141,O
the,141,O
classic,141,O
or,141,O
alternative,141,O
pathways,141,O
",",141,O
again,141,O
demonstrating,141,O
the,141,O
importance,141,O
of,141,O
C5,141,O
in,141,O
human,141,O
subjects,141,O
for,141,O
the,141,O
production,141,O
of,141,O
chemotactic,141,O
factors,141,O
.,141,O
The,142,O
chemotactic,142,O
responsiveness,142,O
of,142,O
the,142,O
patients,142,O
polymorphonuclear,142,O
leukocytes,142,O
and,142,O
monocytes,142,O
to,142,O
preformed,142,O
chemotactic,142,O
factors,142,O
was,142,O
not,142,O
depressed,142,O
.,142,O
Twenty-two,143,O
of,143,O
32,143,O
other,143,O
family,143,O
members,143,O
from,143,O
three,143,O
generations,143,O
had,143,O
depressed,143,O
whole,143,O
hemolytic,143,O
complement,143,O
levels,143,O
.,143,O
In,144,O
19,144,O
of,144,O
30,144,O
family,144,O
members,144,O
",",144,O
levels,144,O
of,144,O
hemolytic,144,O
C5,144,O
ranged,144,O
from,144,O
13,144,O
to,144,O
64,144,O
per,144,O
cent,144,O
of,144,O
normal,144,O
.,144,O
No,145,O
linkage,145,O
for,145,O
C5,145,B-SpecificDisease
deficiency,145,I-SpecificDisease
and,145,O
the,145,O
A,145,O
or,145,O
B,145,O
loci,145,O
of,145,O
the,145,O
major,145,O
histocompatibility,145,O
complex,145,O
could,145,O
be,145,O
found,145,O
.,145,O
These,146,O
data,146,O
suggest,146,O
an,146,O
autosomal,146,O
codominant,146,O
mode,146,O
of,146,O
inheritance,146,O
of,146,O
C5,146,B-SpecificDisease
deficiency,146,I-SpecificDisease
.,146,O
Deficiency,147,B-SpecificDisease
of,147,I-SpecificDisease
C5,147,I-SpecificDisease
is,147,O
compatible,147,O
with,147,O
good,147,O
health,147,O
",",147,O
but,147,O
it,147,O
can,147,O
be,147,O
associated,147,O
with,147,O
repeated,147,O
disseminated,147,O
gonococcal,147,B-SpecificDisease
infection,147,I-SpecificDisease
Incidence,148,O
and,148,O
characteristics,148,O
of,148,O
glucose-6-phosphate,148,O
dehydrogenase,148,O
variants,148,O
in,148,O
Japan,148,O
.,148,O
A,149,O
total,149,O
of,149,O
3000,149,O
men,149,O
living,149,O
in,149,O
Yamaguchi,149,O
were,149,O
screened,149,O
for,149,O
glucose-6-phosphate,149,B-SpecificDisease
dehydrogenase,149,I-SpecificDisease
(,149,I-SpecificDisease
G6PD,149,I-SpecificDisease
),149,I-SpecificDisease
deficiency,149,I-SpecificDisease
using,149,O
Beutlers,149,O
spot,149,O
test,149,O
and,149,O
three,149,O
types,149,O
of,149,O
starch,149,O
gel,149,O
electrophoresis,149,O
.,149,O
These,150,O
electrophoresis,150,O
used,150,O
a,150,O
phosphate,150,O
buffer,150,O
system,150,O
at,150,O
pH,150,O
7,150,O
.,150,O
0,151,O
",",151,O
a,151,O
TRIS-EDTA-borate,151,O
buffer,151,O
system,151,O
at,151,O
pH,151,O
8,151,O
.,151,O
6,152,O
",",152,O
and,152,O
a,152,O
TRIS-hydrochloride,152,O
buffer,152,O
system,152,O
at,152,O
pH,152,O
8,152,O
..,152,O
Fifteen,152,O
G6PD-deficient,152,B-Modifier
variants,152,O
were,152,O
found,152,O
at,152,O
the,152,O
rate,152,O
of,152,O
0,152,O
.,152,O
5,153,O
%,153,O
and,153,O
classified,153,O
into,153,O
four,153,O
groups,153,O
.,153,O
As,154,O
new,154,O
variants,154,O
",",154,O
G6PD,154,O
Konan,154,O
",",154,O
Kamiube,154,O
",",154,O
and,154,O
Kiwa,154,O
were,154,O
identified,154,O
.,154,O
These,155,O
three,155,O
variants,155,O
had,155,O
a,155,O
mild,155,O
to,155,O
moderate,155,O
G6PD,155,B-SpecificDisease
deficiency,155,I-SpecificDisease
and,155,O
were,155,O
not,155,O
associated,155,O
with,155,O
any,155,O
clinical,155,O
signs,155,O
.,155,O
G6PD,156,O
Konan,156,O
had,156,O
fast,156,O
electrophoretic,156,O
mobility,156,O
as,156,O
compared,156,O
with,156,O
normal,156,O
levels,156,O
",",156,O
G6PD,156,O
Kiwa,156,O
had,156,O
slightly,156,O
elevated,156,O
electrophoretic,156,O
mobility,156,O
",",156,O
and,156,O
G6PD,156,O
Kamiube,156,O
had,156,O
normal,156,O
electrophoretic,156,O
mobility,156,O
.,156,O
These,157,O
three,157,O
variants,157,O
had,157,O
normal,157,O
levels,157,O
of,157,O
Km,157,O
G6P,157,O
",",157,O
Km,157,O
NADP,157,O
",",157,O
and,157,O
Ki,157,O
NADPH,157,O
",",157,O
normal,157,O
utilizations,157,O
of,157,O
both,157,O
2-deoxy-G6P,157,O
and,157,O
deamino-NAPD,157,O
",",157,O
normal,157,O
heat,157,O
stability,157,O
",",157,O
and,157,O
a,157,O
normal,157,O
pH,157,O
curve,157,O
.,157,O
The,158,O
other,158,O
variant,158,O
was,158,O
G6PD,158,O
Ube,158,O
",",158,O
which,158,O
we,158,O
had,158,O
previously,158,O
found,158,O
in,158,O
Yamaguchi,158,O
(,158,O
Nakashima,158,O
et,158,O
al.,158,O
",",158,O
1977,158,O
),158,O
.,158,O
One,159,O
boy,159,O
with,159,O
G6PD,159,O
Ube,159,O
was,159,O
Korean,159,O
Utilization,160,O
of,160,O
purines,160,O
by,160,O
an,160,O
HPRT,160,O
variant,160,O
in,160,O
an,160,O
intelligent,160,O
",",160,O
nonmutilative,160,O
patient,160,O
with,160,O
features,160,O
of,160,O
the,160,O
Lesch-Nyhan,160,B-SpecificDisease
syndrome,160,I-SpecificDisease
.,160,O
The,161,O
patient,161,O
",",161,O
H.,161,O
Chr,161,O
.,161,O
B.,162,O
",",162,O
was,162,O
among,162,O
the,162,O
first,162,O
reported,162,O
with,162,O
hyperuricemia,162,B-SpecificDisease
and,162,O
central,162,B-DiseaseClass
nervous,162,I-DiseaseClass
system,162,I-DiseaseClass
symptoms,162,I-DiseaseClass
.,162,O
He,163,O
has,163,O
been,163,O
found,163,O
to,163,O
have,163,O
a,163,O
variant,163,O
of,163,O
hypoxanthine,163,O
guanine,163,O
phosphoribosyl,163,O
transferase,163,O
(,163,O
HPRT,163,O
;,163,O
E.,163,O
C.,163,O
2,163,O
.,163,O
4,164,O
.,164,O
2,165,O
.,165,O
8,166,O
),166,O
distinct,166,O
from,166,O
the,166,O
enzyme,166,O
present,166,O
in,166,O
patients,166,O
with,166,O
the,166,O
Lesch-Nyhan,166,B-SpecificDisease
syndrome,166,I-SpecificDisease
.,166,O
The,167,O
patient,167,O
had,167,O
chroeoathetosis,167,B-SpecificDisease
",",167,O
spasticity,167,B-SpecificDisease
",",167,O
dysarthric,167,B-SpecificDisease
speech,167,I-SpecificDisease
",",167,O
and,167,O
hyperuricemia,167,B-SpecificDisease
.,167,O
However,168,O
",",168,O
his,168,O
intelligence,168,O
was,168,O
normal,168,O
and,168,O
he,168,O
had,168,O
no,168,O
evidence,168,O
of,168,O
self-mutilation,168,O
.,168,O
There,169,O
was,169,O
no,169,O
activity,169,O
of,169,O
HPRT,169,O
in,169,O
the,169,O
lysates,169,O
of,169,O
erythrocytes,169,O
and,169,O
cultured,169,O
fibroblasts,169,O
when,169,O
analyzed,169,O
in,169,O
the,169,O
usual,169,O
manner,169,O
.,169,O
Using,170,O
a,170,O
newly,170,O
developed,170,O
method,170,O
for,170,O
the,170,O
study,170,O
of,170,O
purine,170,O
metabolism,170,O
in,170,O
intact,170,O
cultured,170,O
cells,170,O
",",170,O
this,170,O
patient,170,O
was,170,O
found,170,O
to,170,O
metabolize,170,O
some,170,O
9,170,O
%,170,O
of,170,O
8-14C-hypoxanthine,170,O
",",170,O
and,170,O
90,170,O
%,170,O
of,170,O
the,170,O
isotope,170,O
utilized,170,O
was,170,O
converted,170,O
to,170,O
adenine,170,O
and,170,O
guanine,170,O
nucleotides,170,O
.,170,O
In,171,O
contrast,171,O
",",171,O
cells,171,O
from,171,O
patients,171,O
with,171,O
the,171,O
Lesch-Nyhan,171,B-SpecificDisease
syndrome,171,I-SpecificDisease
were,171,O
virtually,171,O
completely,171,O
unable,171,O
to,171,O
convert,171,O
hypoxanthine,171,O
to,171,O
nucleotides,171,O
.,171,O
The,172,O
patients,172,O
fibroblasts,172,O
were,172,O
even,172,O
more,172,O
efficient,172,O
in,172,O
the,172,O
metabolism,172,O
of,172,O
8-14C-guanine,172,O
",",172,O
which,172,O
was,172,O
utilized,172,O
to,172,O
the,172,O
extent,172,O
of,172,O
27,172,O
%,172,O
",",172,O
over,172,O
80,172,O
%,172,O
of,172,O
which,172,O
was,172,O
converted,172,O
to,172,O
guanine,172,O
and,172,O
adenine,172,O
nucleotides,172,O
.,172,O
The,173,O
growth,173,O
of,173,O
the,173,O
cultured,173,O
fibroblasts,173,O
of,173,O
this,173,O
patient,173,O
was,173,O
intermediate,173,O
in,173,O
media,173,O
containing,173,O
hypoxanthine,173,O
aminopterin,173,O
thymidine,173,O
(,173,O
HAT,173,O
),173,O
",",173,O
whereas,173,O
the,173,O
growth,173,O
of,173,O
Lesch-Nyhan,173,B-Modifier
cells,173,O
was,173,O
inhibited,173,O
and,173,O
normal,173,O
cells,173,O
grew,173,O
normally,173,O
.,173,O
Similarly,174,O
in,174,O
8-azaguanine,174,O
",",174,O
6-thioguanine,174,O
",",174,O
and,174,O
8-azahypoxanthine,174,O
",",174,O
the,174,O
growth,174,O
of,174,O
the,174,O
patients,174,O
cells,174,O
was,174,O
intermediate,174,O
between,174,O
normal,174,O
and,174,O
Lesch-Nyhan,174,B-Modifier
cells,174,O
.,174,O
These,175,O
observations,175,O
provide,175,O
further,175,O
evidence,175,O
for,175,O
genetic,175,O
heterogeneity,175,O
among,175,O
patients,175,O
with,175,O
disorders,175,O
in,175,O
purine,175,O
metabolism,175,O
involving,175,O
the,175,O
HPRT,175,O
gene,175,O
.,175,O
They,176,O
document,176,O
that,176,O
this,176,O
famous,176,O
patient,176,O
did,176,O
not,176,O
have,176,O
the,176,O
Lesch-Nyhan,176,B-SpecificDisease
syndrome,176,I-SpecificDisease
Heterogeneity,177,O
of,177,O
glucose-6-phosphate,177,B-SpecificDisease
dehydrogenase,177,I-SpecificDisease
deficiency,177,I-SpecificDisease
in,177,O
Algeria,177,O
.,177,O
Study,178,O
in,178,O
Northern,178,O
Algeria,178,O
with,178,O
description,178,O
of,178,O
five,178,O
new,178,O
variants,178,O
.,178,O
Glucose-6-phosphate,179,B-SpecificDisease
dehydrogenase,179,I-SpecificDisease
(,179,I-SpecificDisease
G6PD,179,I-SpecificDisease
),179,I-SpecificDisease
deficiency,179,I-SpecificDisease
was,179,O
found,179,O
in,179,O
3,179,O
.,179,O
2,180,O
%,180,O
of,180,O
the,180,O
male,180,O
population,180,O
living,180,O
in,180,O
the,180,O
urban,180,O
area,180,O
of,180,O
Algiers,180,O
.,180,O
The,181,O
deficient,181,O
subjects,181,O
originated,181,O
from,181,O
multiple,181,O
geographic,181,O
regions,181,O
of,181,O
Northern,181,O
Algeria,181,O
",",181,O
with,181,O
prevalence,181,O
of,181,O
individuals,181,O
of,181,O
Berber-Kabyle,181,O
origin,181,O
.,181,O
Red,182,O
blood,182,O
cell,182,O
G6PD,182,O
was,182,O
partially,182,O
purified,182,O
and,182,O
characterized,182,O
in,182,O
deficient,182,O
males,182,O
from,182,O
17,182,O
families,182,O
",",182,O
and,182,O
six,182,O
different,182,O
variants,182,O
were,182,O
found,182,O
.,182,O
Among,183,O
them,183,O
",",183,O
only,183,O
one,183,O
",",183,O
the,183,O
Gd,183,O
(,183,O
-,183,O
),183,O
Kabyle,183,O
variant,183,O
",",183,O
had,183,O
been,183,O
previously,183,O
described,183,O
.,183,O
It,184,O
was,184,O
detected,184,O
in,184,O
nine,184,O
families,184,O
.,184,O
The,185,O
other,185,O
five,185,O
variants,185,O
were,185,O
new,185,O
Gd,185,O
(,185,O
-,185,O
),185,O
Laghouat,185,O
(,185,O
four,185,O
cases,185,O
),185,O
",",185,O
Gd,185,O
(,185,O
-,185,O
),185,O
Blida,185,O
(,185,O
one,185,O
case,185,O
),185,O
",",185,O
Gd,185,O
(,185,O
-,185,O
),185,O
Thenia,185,O
(,185,O
one,185,O
case,185,O
),185,O
",",185,O
Gd,185,O
(,185,O
-,185,O
),185,O
Titteri,185,O
(,185,O
one,185,O
case,185,O
),185,O
",",185,O
and,185,O
Gd,185,O
(,185,O
-,185,O
),185,O
Alger,185,O
(,185,O
two,185,O
brothers,185,O
),185,O
.,185,O
Strikingly,186,O
",",186,O
the,186,O
common,186,O
Mediterranean,186,O
variant,186,O
was,186,O
not,186,O
found,186,O
.,186,O
G6PD,187,B-SpecificDisease
deficiency,187,I-SpecificDisease
is,187,O
heterogeneous,187,O
in,187,O
northern,187,O
Algeria,187,O
where,187,O
autochtonous,187,O
variants,187,O
seem,187,O
to,187,O
prevail,187,O
.,187,O
The,188,O
Kabyle,188,O
variant,188,O
may,188,O
be,188,O
common,188,O
in,188,O
this,188,O
country,188,O
.,188,O
Hereditary,189,B-SpecificDisease
deficiency,189,I-SpecificDisease
of,189,I-SpecificDisease
the,189,I-SpecificDisease
fifth,189,I-SpecificDisease
component,189,I-SpecificDisease
of,189,I-SpecificDisease
complement,189,I-SpecificDisease
in,189,O
man,189,O
.,189,O
II,190,O
.,190,O
Biological,191,O
properties,191,O
of,191,O
C5-deficient,191,B-Modifier
human,191,O
serum,191,O
.,191,O
The,192,O
first,192,O
known,192,O
human,192,O
kindred,192,O
with,192,O
hereditary,192,B-SpecificDisease
deficiency,192,I-SpecificDisease
of,192,I-SpecificDisease
the,192,I-SpecificDisease
fifth,192,I-SpecificDisease
component,192,I-SpecificDisease
of,192,I-SpecificDisease
complement,192,I-SpecificDisease
(,192,O
C5,192,O
),192,O
was,192,O
documented,192,O
in,192,O
the,192,O
accompanying,192,O
report,192,O
.,192,O
This,193,O
study,193,O
examines,193,O
several,193,O
biological,193,O
properties,193,O
of,193,O
C5-deficient,193,B-Modifier
(,193,O
C5D,193,B-Modifier
),193,O
human,193,O
serum,193,O
",",193,O
particularly,193,O
sera,193,O
obtained,193,O
from,193,O
two,193,O
C5D,193,B-Modifier
homozygotes,193,O
.,193,O
The,194,O
proband,194,O
",",194,O
who,194,O
has,194,O
inactive,194,O
systemic,194,B-SpecificDisease
lupus,194,I-SpecificDisease
erythematosus,194,I-SpecificDisease
is,194,O
completely,194,O
lacking,194,O
C5,194,O
",",194,O
while,194,O
her,194,O
healthy,194,O
half-sister,194,O
has,194,O
1-2,194,O
%,194,O
of,194,O
normal,194,O
levels,194,O
.,194,O
Both,195,O
sera,195,O
were,195,O
severely,195,O
impaired,195,O
in,195,O
their,195,O
ability,195,O
to,195,O
generate,195,O
chemotactic,195,O
activity,195,O
for,195,O
normal,195,O
human,195,O
neutrophils,195,O
upon,195,O
incubation,195,O
with,195,O
aggregated,195,O
human,195,O
gamma-globulin,195,O
or,195,O
Escherichia,195,O
coli,195,O
endotoxin,195,O
.,195,O
This,196,O
function,196,O
was,196,O
fully,196,O
restored,196,O
in,196,O
the,196,O
siblings,196,O
serum,196,O
",",196,O
and,196,O
substantially,196,O
improved,196,O
in,196,O
the,196,O
probands,196,O
serum,196,O
",",196,O
by,196,O
addition,196,O
of,196,O
highly,196,O
purified,196,O
human,196,O
C5,196,O
to,196,O
normal,196,O
serum,196,O
concentrations,196,O
.,196,O
Sera,197,O
from,197,O
eight,197,O
family,197,O
members,197,O
who,197,O
were,197,O
apparently,197,O
heterozygous,197,O
for,197,O
C5,197,B-SpecificDisease
deficiency,197,I-SpecificDisease
gave,197,O
normal,197,O
chemotactic,197,O
scores,197,O
.,197,O
The,198,O
ability,198,O
of,198,O
C5D,198,B-Modifier
serum,198,O
to,198,O
opsonize,198,O
Saccharomyces,198,O
cerevisiae,198,O
(,198,O
bakers,198,O
yeast,198,O
),198,O
or,198,O
Candida,198,O
albicans,198,O
for,198,O
ingestion,198,O
by,198,O
normal,198,O
neutrophils,198,O
was,198,O
completely,198,O
normal,198,O
.,198,O
In,199,O
addition,199,O
",",199,O
C5D,199,B-Modifier
serum,199,O
was,199,O
capable,199,O
of,199,O
promoting,199,O
normal,199,O
phagocytosis,199,O
and,199,O
intracellular,199,O
killing,199,O
of,199,O
Staphylococcus,199,O
aureus,199,O
.,199,O
The,200,O
probands,200,O
serum,200,O
was,200,O
incapable,200,O
of,200,O
mediating,200,O
lysis,200,O
of,200,O
erythrocytes,200,O
from,200,O
a,200,O
patient,200,O
with,200,O
paroxysmal,200,B-SpecificDisease
nocturnal,200,I-SpecificDisease
hemoglobinuria,200,I-SpecificDisease
in,200,O
both,200,O
the,200,O
sucrose,200,O
hemolysia,200,O
and,200,O
acid,200,O
hemolysis,200,O
tests,200,O
",",200,O
and,200,O
also,200,O
lacked,200,O
bactericidal,200,O
activity,200,O
against,200,O
sensitized,200,O
or,200,O
unsensitized,200,O
Salmonella,200,O
typhi,200,O
.,200,O
The,201,O
siblings,201,O
serum,201,O
",",201,O
containing,201,O
only,201,O
1-2,201,O
%,201,O
of,201,O
normal,201,O
C5,201,O
",",201,O
effectively,201,O
lysed,201,O
S.,201,O
typhi,201,O
",",201,O
but,201,O
only,201,O
at,201,O
eightfold,201,O
lower,201,O
serum,201,O
dilutions,201,O
as,201,O
compared,201,O
to,201,O
normals,201,O
.,201,O
These,202,O
findings,202,O
underscore,202,O
the,202,O
critical,202,O
role,202,O
of,202,O
C5,202,O
in,202,O
the,202,O
generation,202,O
of,202,O
chemotactic,202,O
activity,202,O
and,202,O
in,202,O
cytolytic,202,O
reactions,202,O
",",202,O
as,202,O
opposed,202,O
to,202,O
a,202,O
nonobligatory,202,O
or,202,O
minimal,202,O
role,202,O
in,202,O
opsonization,202,O
",",202,O
at,202,O
least,202,O
for,202,O
the,202,O
organisms,202,O
under,202,O
study,202,O
..,202,O
Somatic,203,O
rearrangement,203,O
of,203,O
chromosome,203,O
14,203,O
in,203,O
human,203,O
lymphocytes,203,O
.,203,O
Ataxia-telangiectasia,204,B-SpecificDisease
is,204,O
a,204,O
rare,204,O
genetic,204,B-DiseaseClass
disorder,204,I-DiseaseClass
associated,204,O
with,204,O
immune,204,B-DiseaseClass
deficiency,204,I-DiseaseClass
",",204,O
chromosome,204,B-DiseaseClass
instability,204,I-DiseaseClass
",",204,O
and,204,O
a,204,O
predisposition,204,O
to,204,O
lymphoid,204,B-SpecificDisease
malignancy,204,I-SpecificDisease
.,204,O
We,205,O
have,205,O
detected,205,O
chromosomally,205,O
anomalous,205,O
clones,205,O
of,205,O
lymphocytes,205,O
in,205,O
eight,205,O
patients,205,O
with,205,O
this,205,O
disorder,205,O
.,205,O
Chromosome,206,O
banding,206,O
disclosed,206,O
that,206,O
the,206,O
clones,206,O
are,206,O
consistently,206,O
marked,206,O
by,206,O
structural,206,O
rearrangement,206,O
of,206,O
the,206,O
long,206,O
arm,206,O
(,206,O
q,206,O
),206,O
of,206,O
chromosome,206,O
14,206,O
.,206,O
A,207,O
translocation,207,O
involving,207,O
14q,207,O
was,207,O
found,207,O
in,207,O
clones,207,O
obtained,207,O
from,207,O
seven,207,O
of,207,O
the,207,O
eight,207,O
patients,207,O
whereas,207,O
a,207,O
ring,207,O
14,207,O
chromosome,207,O
was,207,O
found,207,O
in,207,O
a,207,O
clone,207,O
obtained,207,O
from,207,O
the,207,O
other,207,O
.,207,O
These,208,O
findings,208,O
as,208,O
well,208,O
as,208,O
data,208,O
obtained,208,O
by,208,O
others,208,O
for,208,O
patients,208,O
with,208,O
ataxia-telangiectasia,208,B-SpecificDisease
suggest,208,O
that,208,O
structural,208,O
rearrangement,208,O
of,208,O
14q,208,O
is,208,O
the,208,O
initial,208,O
chromosomal,208,O
change,208,O
in,208,O
lymphocyte,208,O
clones,208,O
of,208,O
patients,208,O
with,208,O
this,208,O
disorder,208,O
.,208,O
Chromosomes,209,O
of,209,O
lymphocytes,209,O
from,209,O
one,209,O
of,209,O
the,209,O
patients,209,O
were,209,O
studied,209,O
before,209,O
and,209,O
after,209,O
the,209,O
onset,209,O
of,209,O
chronic,209,B-SpecificDisease
lymphocytic,209,I-SpecificDisease
leukemia,209,I-SpecificDisease
.,209,O
Before,210,O
leukemia,210,B-DiseaseClass
was,210,O
diagnosed,210,O
",",210,O
the,210,O
patient,210,O
had,210,O
a,210,O
lymphocyte,210,O
clone,210,O
with,210,O
a,210,O
14q,210,O
translocation,210,O
.,210,O
This,211,O
clone,211,O
appears,211,O
to,211,O
have,211,O
given,211,O
rise,211,O
to,211,O
the,211,O
leukemic,211,B-Modifier
cells,211,O
.,211,O
We,212,O
hypothesize,212,O
that,212,O
structural,212,O
rearrangement,212,O
of,212,O
14q,212,O
is,212,O
directly,212,O
related,212,O
to,212,O
abnormal,212,O
growth,212,O
of,212,O
lymphocytes,212,O
and,212,O
that,212,O
it,212,O
may,212,O
be,212,O
a,212,O
step,212,O
toward,212,O
the,212,O
development,212,O
of,212,O
lymphoid,212,B-SpecificDisease
malignancies,212,I-SpecificDisease
.,212,O
Increasing,213,O
evidence,213,O
",",213,O
provided,213,O
by,213,O
others,213,O
",",213,O
for,213,O
the,213,O
nonrandom,213,O
involvement,213,O
of,213,O
14q,213,O
in,213,O
African-type,213,O
Burkitts,213,B-SpecificDisease
lymphoma,213,I-SpecificDisease
and,213,O
other,213,O
lymphoid,213,B-DiseaseClass
neoplasms,213,I-DiseaseClass
further,213,O
strengthens,213,O
this,213,O
hypothesis,213,O
..,213,O
Analbuminemia,214,B-SpecificDisease
in,214,O
a,214,O
neonate,214,O
.,214,O
A,215,O
small-for-gestational-age,215,O
infant,215,O
",",215,O
found,215,O
to,215,O
have,215,O
analbuminemia,215,B-SpecificDisease
in,215,O
the,215,O
neonatal,215,O
period,215,O
",",215,O
is,215,O
reported,215,O
and,215,O
the,215,O
twelve,215,O
cases,215,O
recorded,215,O
in,215,O
the,215,O
world,215,O
literature,215,O
are,215,O
reviewed,215,O
.,215,O
Patients,216,O
lacking,216,O
this,216,O
serum,216,O
protein,216,O
are,216,O
essentially,216,O
asymptomatic,216,O
",",216,O
apart,216,O
from,216,O
minimal,216,O
ankle,216,B-DiseaseClass
edema,216,I-DiseaseClass
and,216,O
ease,216,B-DiseaseClass
of,216,I-DiseaseClass
fatigue,216,I-DiseaseClass
.,216,O
Apparent,217,O
compensatory,217,O
mechanisms,217,O
which,217,O
come,217,O
into,217,O
play,217,O
when,217,O
serum,217,O
albumin,217,O
is,217,O
low,217,O
include,217,O
prolonged,217,O
half-life,217,O
of,217,O
albumin,217,O
and,217,O
transferrin,217,O
",",217,O
an,217,O
increase,217,O
in,217,O
serum,217,O
globulins,217,O
",",217,O
beta,217,O
lipoprotein,217,O
",",217,O
and,217,O
glycoproteins,217,O
",",217,O
arterial,217,B-DiseaseClass
hypotension,217,I-DiseaseClass
with,217,O
reduced,217,O
capillary,217,O
hydrostatic,217,O
pressure,217,O
",",217,O
and,217,O
the,217,O
ability,217,O
to,217,O
respond,217,O
with,217,O
rapid,217,O
sodium,217,O
and,217,O
chloride,217,O
diuresis,217,O
in,217,O
response,217,O
to,217,O
small,217,O
volume,217,O
changes,217,O
.,217,O
Examination,218,O
of,218,O
plasma,218,O
amino,218,O
acids,218,O
",",218,O
an,218,O
investigation,218,O
not,218,O
previously,218,O
reported,218,O
",",218,O
revealed,218,O
an,218,O
extremely,218,O
low,218,O
plasma,218,O
tryptophan,218,O
level,218,O
",",218,O
a,218,O
finding,218,O
which,218,O
may,218,O
be,218,O
important,218,O
in,218,O
view,218,O
of,218,O
the,218,O
role,218,O
of,218,O
tryptophan,218,O
in,218,O
albumin,218,O
synthesis,218,O
..,218,O
Histidinemia,219,B-SpecificDisease
.,219,O
Classical,220,O
and,220,O
atypical,220,O
form,220,O
in,220,O
siblings,220,O
.,220,O
Two,221,O
brothers,221,O
",",221,O
6,221,O
and,221,O
13,221,O
years,221,O
old,221,O
",",221,O
had,221,O
histidinemia,221,B-SpecificDisease
.,221,O
On,222,O
the,222,O
basis,222,O
of,222,O
clinical,222,O
and,222,O
biochemical,222,O
observations,222,O
",",222,O
the,222,O
younger,222,O
boy,222,O
was,222,O
considered,222,O
to,222,O
have,222,O
a,222,O
classical,222,O
type,222,O
of,222,O
the,222,O
disease,222,O
",",222,O
while,222,O
the,222,O
older,222,O
boy,222,O
had,222,O
an,222,O
atypical,222,O
form,222,O
characterized,222,O
by,222,O
partial,222,O
impairment,222,O
of,222,O
the,222,O
skin,222,O
histidase,222,O
activity,222,O
and,222,O
a,222,O
moderately,222,O
prolonged,222,O
half-life,222,O
of,222,O
blood,222,O
histidine,222,O
.,222,O
The,223,O
mother,223,O
is,223,O
a,223,O
heterozygous,223,O
carrier,223,O
",",223,O
while,223,O
the,223,O
father,223,O
and,223,O
sister,223,O
seem,223,O
to,223,O
be,223,O
normal,223,O
..,223,O
Glucose-6-phosphate,224,O
dehydrogenase,224,O
variants,224,O
from,224,O
Italian,224,O
subjects,224,O
associated,224,O
with,224,O
severe,224,B-SpecificDisease
neonatal,224,I-SpecificDisease
jaundice,224,I-SpecificDisease
.,224,O
Screening,225,O
for,225,O
the,225,O
G6PD,225,B-SpecificDisease
deficiency,225,I-SpecificDisease
was,225,O
carried,225,O
out,225,O
at,225,O
the,225,O
Maternity,225,O
Division,225,O
of,225,O
the,225,O
Galliera,225,O
Hospital,225,O
in,225,O
Genoa,225,O
",",225,O
Italy,225,O
.,225,O
Two,226,O
groups,226,O
of,226,O
subjects,226,O
with,226,O
hyperbilirubinaemia,226,B-DiseaseClass
of,226,O
non-immunological,226,O
origin,226,O
were,226,O
examined,226,O
(,226,O
a,226,O
),226,O
302,226,O
newborn,226,O
babies,226,O
of,226,O
Sardinian,226,O
extraction,226,O
(,226,O
on,226,O
cord,226,O
blood,226,O
),226,O
and,226,O
(,226,O
b,226,O
),226,O
201,226,O
newborn,226,O
babies,226,O
of,226,O
south,226,O
Italian,226,O
ancestry,226,O
(,226,O
on,226,O
peripheral,226,O
blood,226,O
),226,O
.,226,O
Among,227,O
503,227,O
subjects,227,O
",",227,O
43,227,O
showed,227,O
an,227,O
enzyme,227,O
deficiency,227,O
;,227,O
in,227,O
39,227,O
the,227,O
defect,227,O
was,227,O
of,227,O
the,227,O
Mediterranean,227,O
type,227,O
.,227,O
In,228,O
one,228,O
case,228,O
",",228,O
previously,228,O
described,228,O
",",228,O
the,228,O
enzyme,228,O
was,228,O
of,228,O
the,228,O
A-,228,O
type,228,O
.,228,O
In,229,O
the,229,O
remaining,229,O
cases,229,O
three,229,O
different,229,O
variants,229,O
were,229,O
identified,229,O
.,229,O
In,230,O
the,230,O
present,230,O
work,230,O
these,230,O
three,230,O
cases,230,O
",",230,O
each,230,O
with,230,O
severe,230,B-SpecificDisease
neonatal,230,I-SpecificDisease
jaundice,230,I-SpecificDisease
",",230,O
are,230,O
reported,230,O
.,230,O
Their,231,O
parents,231,O
originated,231,O
from,231,O
Calabria,231,O
",",231,O
from,231,O
Sardinia,231,O
and,231,O
from,231,O
Sicily,231,O
.,231,O
The,232,O
abnormal,232,O
enzymes,232,O
are,232,O
respectively,232,O
designated,232,O
as,232,O
GdDcbrousse-like,232,O
",",232,O
GdGallura,232,O
and,232,O
GdAgrigento,232,O
..,232,O
Cytogenetic,233,O
investigations,233,O
in,233,O
families,233,O
with,233,O
ataxia-telangiectasia,233,B-SpecificDisease
.,233,O
Chromosomal,234,O
studies,234,O
were,234,O
performed,234,O
on,234,O
peripheral,234,O
blood,234,O
lymphocytes,234,O
and,234,O
cultured,234,O
skin,234,O
fibroblasts,234,O
from,234,O
five,234,O
Israeli-Moroccan,234,O
families,234,O
with,234,O
ataxia-telangiectasia,234,B-SpecificDisease
.,234,O
A,235,O
total,235,O
of,235,O
24,235,O
individuals,235,O
",",235,O
including,235,O
seven,235,O
propositi,235,O
",",235,O
was,235,O
investigated,235,O
.,235,O
Among,236,O
the,236,O
probands,236,O
",",236,O
significantly,236,O
elevated,236,O
rates,236,O
of,236,O
chromosome,236,O
damage,236,O
were,236,O
observed,236,O
in,236,O
both,236,O
blood,236,O
and,236,O
skin,236,O
.,236,O
Skin,237,O
fibroblasts,237,O
of,237,O
affected,237,O
individuals,237,O
showed,237,O
several,237,O
orders,237,O
of,237,O
magnitude,237,O
more,237,O
chromosome,237,O
breakage,237,O
than,237,O
lymphocytes,237,O
.,237,O
Increased,238,O
rates,238,O
of,238,O
chromosome,238,O
damage,238,O
were,238,O
also,238,O
observed,238,O
in,238,O
the,238,O
fibroblasts,238,O
of,238,O
some,238,O
phenotypically,238,O
normal,238,O
family,238,O
members,238,O
(,238,O
obligate,238,O
heterozygotes,238,O
and,238,O
sibs,238,O
),238,O
when,238,O
compared,238,O
to,238,O
normal,238,O
controls,238,O
.,238,O
An,239,O
apparent,239,O
abnormal,239,O
clone,239,O
of,239,O
cells,239,O
",",239,O
possessing,239,O
a,239,O
large,239,O
acrocentric,239,O
marker,239,O
chromosome,239,O
(,239,O
14q,239,O
+,239,O
),239,O
",",239,O
was,239,O
observed,239,O
in,239,O
varying,239,O
proportions,239,O
among,239,O
cells,239,O
of,239,O
all,239,O
the,239,O
propositi,239,O
(,239,O
2-5,239,O
%,239,O
of,239,O
lymphocytes,239,O
;,239,O
1-9,239,O
%,239,O
of,239,O
fibroblasts,239,O
),239,O
..,239,O
Malignant,240,B-DiseaseClass
neoplasms,240,I-DiseaseClass
in,240,O
the,240,O
families,240,O
of,240,O
patients,240,O
with,240,O
ataxia-telangiectasia,240,B-SpecificDisease
.,240,O
Ataxia-telangiectasia,241,B-SpecificDisease
(,241,O
A-T,241,B-SpecificDisease
),241,O
is,241,O
an,241,O
autosomal,241,B-DiseaseClass
recessive,241,I-DiseaseClass
syndrome,241,I-DiseaseClass
associated,241,O
with,241,O
a,241,O
greatly,241,O
increased,241,O
incidence,241,O
of,241,O
malignant,241,B-DiseaseClass
neoplasms,241,I-DiseaseClass
in,241,O
homozygous,241,O
affected,241,O
individuals,241,O
.,241,O
Heterozygotes,242,O
for,242,O
the,242,O
gene,242,O
for,242,O
A-T,242,B-SpecificDisease
are,242,O
thought,242,O
to,242,O
comprise,242,O
about,242,O
1,242,O
%,242,O
of,242,O
the,242,O
general,242,O
population,242,O
and,242,O
",",242,O
therefore,242,O
",",242,O
it,242,O
is,242,O
important,242,O
to,242,O
know,242,O
whether,242,O
this,242,O
gene,242,O
also,242,O
predisposes,242,O
the,242,O
heterozygous,242,O
carrier,242,O
to,242,O
cancers,242,B-DiseaseClass
.,242,O
Heterozygous,243,O
carriers,243,O
of,243,O
this,243,O
gene,243,O
are,243,O
common,243,O
among,243,O
the,243,O
close,243,O
relatives,243,O
of,243,O
patients,243,O
with,243,O
A-T,243,B-SpecificDisease
",",243,O
although,243,O
individual,243,O
carriers,243,O
can,243,O
not,243,O
be,243,O
identified,243,O
by,243,O
any,243,O
clinical,243,O
criterion,243,O
or,243,O
laboratory,243,O
test,243,O
.,243,O
For,244,O
this,244,O
reason,244,O
",",244,O
we,244,O
compared,244,O
the,244,O
incidence,244,O
of,244,O
death,244,O
from,244,O
malignant,244,B-DiseaseClass
neoplasms,244,I-DiseaseClass
in,244,O
2,244,O
families,244,O
of,244,O
patients,244,O
with,244,O
A-T,244,B-SpecificDisease
to,244,O
that,244,O
expected,244,O
in,244,O
a,244,O
random,244,O
sample,244,O
of,244,O
the,244,O
general,244,O
population,244,O
.,244,O
There,245,O
were,245,O
59,245,O
deaths,245,O
from,245,O
malignant,245,B-DiseaseClass
neoplasms,245,I-DiseaseClass
in,245,O
relatives,245,O
dying,245,O
before,245,O
age,245,O
75,245,O
",",245,O
compared,245,O
to,245,O
42,245,O
.,245,O
6,246,O
expected,246,O
(,246,O
p,246,O
less,246,O
than,246,O
0,246,O
.,246,O
02,247,O
),247,O
.,247,O
For,248,O
A-T,248,B-Modifier
heterozygotes,248,O
younger,248,O
than,248,O
age,248,O
45,248,O
",",248,O
the,248,O
risk,248,O
of,248,O
dying,248,O
from,248,O
a,248,O
malignant,248,B-DiseaseClass
neoplasm,248,I-DiseaseClass
was,248,O
estimated,248,O
to,248,O
be,248,O
greater,248,O
than,248,O
5,248,O
times,248,O
the,248,O
risk,248,O
for,248,O
the,248,O
general,248,O
population,248,O
.,248,O
A-T,249,B-Modifier
heterozygotes,249,O
may,249,O
comprise,249,O
more,249,O
than,249,O
5,249,O
%,249,O
of,249,O
all,249,O
persons,249,O
dying,249,O
from,249,O
a,249,O
cancer,249,B-DiseaseClass
before,249,O
age,249,O
45,249,O
.,249,O
The,250,O
incidence,250,O
of,250,O
ovarian,250,O
",",250,O
gastric,250,O
",",250,O
and,250,O
biliary,250,O
system,250,O
carcinomas,250,O
and,250,O
of,250,O
leukemia,250,B-DiseaseClass
and,250,O
lymphoma,250,B-DiseaseClass
was,250,O
increased,250,O
in,250,O
these,250,O
A-T,250,B-Modifier
families,250,O
.,250,O
Other,251,O
neoplasms,251,B-DiseaseClass
that,251,O
may,251,O
be,251,O
associated,251,O
with,251,O
this,251,O
gene,251,O
in,251,O
heterozygotes,251,O
include,251,O
pancreatic,251,O
",",251,O
basal,251,O
cell,251,O
",",251,O
colonic,251,O
",",251,O
breast,251,O
",",251,O
and,251,O
cervical,251,O
carcinomas,251,O
.,251,O
Analbuminemia,252,B-SpecificDisease
in,252,O
an,252,O
American,252,O
Indian,252,O
girl,252,O
.,252,O
Analbuminemia,253,B-SpecificDisease
was,253,O
fortuitously,253,O
detected,253,O
in,253,O
a,253,O
nonedematous,253,O
12-year-old,253,O
American,253,O
Indian,253,O
girl,253,O
with,253,O
atopic,253,B-SpecificDisease
dermatitis,253,I-SpecificDisease
",",253,O
mild,253,O
bronchial,253,B-SpecificDisease
asthma,253,I-SpecificDisease
",",253,O
a,253,O
mild,253,O
seizure,253,B-SpecificDisease
disorder,253,I-SpecificDisease
",",253,O
and,253,O
hyperlipoproteinemia,253,B-SpecificDisease
with,253,O
a,253,O
corneal,253,B-SpecificDisease
arcus,253,I-SpecificDisease
.,253,O
Immunologic,254,O
methods,254,O
revealed,254,O
trace,254,O
amounts,254,O
(,254,O
17,254,O
mg/100,254,O
ml,254,O
),254,O
of,254,O
apparently,254,O
normal,254,O
serum,254,O
albumin,254,O
.,254,O
The,255,O
patients,255,O
parents,255,O
were,255,O
remotely,255,O
related,255,O
.,255,O
The,256,O
pedigree,256,O
and,256,O
clinical,256,O
findings,256,O
were,256,O
compatible,256,O
with,256,O
autosomal,256,O
recessive,256,O
transmission,256,O
of,256,O
analbuminemia,256,B-SpecificDisease
.,256,O
Heterozygotes,257,O
had,257,O
subnormal,257,O
levels,257,O
of,257,O
serum,257,O
albumin,257,O
.,257,O
The,258,O
Gc-locus,258,O
is,258,O
closely,258,O
linked,258,O
to,258,O
the,258,O
structural,258,O
albumin,258,O
locus,258,O
.,258,O
Gc-protein,259,O
levels,259,O
were,259,O
normal,259,O
in,259,O
the,259,O
patient,259,O
and,259,O
together,259,O
with,259,O
normal,259,O
chromosomal,259,O
banding,259,O
studies,259,O
make,259,O
it,259,O
unlikely,259,O
that,259,O
a,259,O
chromosomal,259,O
deletion,259,O
caused,259,O
analbuminemia,259,B-SpecificDisease
.,259,O
Gc-types,260,O
in,260,O
the,260,O
family,260,O
were,260,O
compatible,260,O
with,260,O
",",260,O
but,260,O
did,260,O
not,260,O
prove,260,O
",",260,O
linkage,260,O
of,260,O
analbuminemia,260,B-SpecificDisease
to,260,O
the,260,O
Gc-locus,260,O
.,260,O
These,261,O
findings,261,O
suggest,261,O
a,261,O
``,261,O
thalassemia,261,B-Modifier
``,261,O
-like,261,O
mutation,261,O
for,261,O
this,261,O
disorder,261,O
..,261,O
Deletion,262,O
of,262,O
the,262,O
KIT,262,O
and,262,O
PDGFRA,262,O
genes,262,O
in,262,O
a,262,O
patient,262,O
with,262,O
piebaldism,262,B-SpecificDisease
.,262,O
We,263,O
have,263,O
previously,263,O
shown,263,O
that,263,O
human,263,O
piebaldism,263,B-SpecificDisease
results,263,O
from,263,O
mutations,263,O
of,263,O
the,263,O
KIT,263,O
gene,263,O
",",263,O
which,263,O
encodes,263,O
the,263,O
receptor,263,O
for,263,O
the,263,O
mast/stem,263,O
cell,263,O
growth,263,O
factor,263,O
and,263,O
is,263,O
located,263,O
in,263,O
chromosome,263,O
segment,263,O
4q12,263,O
.,263,O
Using,264,O
DNA,264,O
of,264,O
a,264,O
patient,264,O
with,264,O
piebaldism,264,B-SpecificDisease
",",264,O
mental,264,B-DiseaseClass
retardation,264,I-DiseaseClass
",",264,O
and,264,O
multiple,264,B-DiseaseClass
congenital,264,I-DiseaseClass
anomalies,264,I-DiseaseClass
associated,264,O
with,264,O
a,264,O
46,264,O
",",264,O
XY,264,O
",",264,O
del,264,O
(,264,O
4,264,O
),264,O
(,264,O
q12q21,264,O
.,264,O
1,265,O
),265,O
karyotype,265,O
",",265,O
we,265,O
carried,265,O
out,265,O
quantitative,265,O
Southern,265,O
blot,265,O
hybridization,265,O
analyses,265,O
of,265,O
the,265,O
KIT,265,O
gene,265,O
and,265,O
the,265,O
adjacent,265,O
PDGFRA,265,O
(,265,O
platelet-derived,265,O
growth,265,O
factor,265,O
receptor,265,O
alpha,265,O
subunit,265,O
),265,O
genes,265,O
.,265,O
The,266,O
patient,266,O
was,266,O
hemizygous,266,O
for,266,O
both,266,O
the,266,O
KIT,266,O
and,266,O
PDGFRA,266,O
genes,266,O
",",266,O
indicating,266,O
that,266,O
both,266,O
of,266,O
these,266,O
genes,266,O
are,266,O
included,266,O
within,266,O
the,266,O
deleted,266,O
region,266,O
.,266,O
Therefore,267,O
",",267,O
deletion,267,O
of,267,O
the,267,O
KIT,267,O
and,267,O
PDGFRA,267,O
genes,267,O
may,267,O
account,267,O
for,267,O
the,267,O
piebald,267,B-Modifier
phenotype,267,O
in,267,O
this,267,O
patient,267,O
.,267,O
A,268,O
germ,268,O
line,268,O
mutation,268,O
within,268,O
the,268,O
coding,268,O
sequence,268,O
for,268,O
the,268,O
putative,268,O
5-phosphoribosyl-1-pyrophosphate,268,O
binding,268,O
site,268,O
of,268,O
hypoxanthine-guanine,268,O
phosphoribosyltransferase,268,O
(,268,O
HPRT,268,O
),268,O
in,268,O
a,268,O
Lesch-Nyhan,268,B-Modifier
patient,268,O
:,268,O
missense,268,O
mutations,268,O
within,268,O
a,268,O
functionally,268,O
important,268,O
region,268,O
probably,268,O
cause,268,O
disease,268,O
.,268,O
Lesch-Nyhan,269,B-SpecificDisease
syndrome,269,I-SpecificDisease
caused,269,O
by,269,O
a,269,O
complete,269,B-SpecificDisease
deficiency,269,I-SpecificDisease
of,269,I-SpecificDisease
hypoxanthine,269,I-SpecificDisease
guanine,269,I-SpecificDisease
phosphoribosyltransferase,269,I-SpecificDisease
(,269,O
HPRT,269,O
),269,O
is,269,O
the,269,O
result,269,O
of,269,O
a,269,O
heterogeneous,269,O
group,269,O
of,269,O
germ,269,O
line,269,O
mutations,269,O
.,269,O
Identification,270,O
of,270,O
each,270,O
mutant,270,O
gene,270,O
provides,270,O
valuable,270,O
information,270,O
as,270,O
to,270,O
the,270,O
type,270,O
of,270,O
mutation,270,O
that,270,O
occurs,270,O
spontaneously,270,O
.,270,O
We,271,O
report,271,O
here,271,O
a,271,O
newly,271,O
identified,271,O
HPRT,271,O
mutation,271,O
in,271,O
a,271,O
Japanese,271,O
patient,271,O
with,271,O
Lesch-Nyhan,271,B-SpecificDisease
syndrome,271,I-SpecificDisease
.,271,O
This,272,O
gene,272,O
",",272,O
designated,272,O
HPRT,272,O
Tokyo,272,O
",",272,O
had,272,O
a,272,O
single,272,O
nucleotide,272,O
change,272,O
from,272,O
G,272,O
to,272,O
A,272,O
",",272,O
as,272,O
identified,272,O
by,272,O
sequencing,272,O
cDNA,272,O
amplified,272,O
by,272,O
the,272,O
polymerase,272,O
chain,272,O
reaction,272,O
.,272,O
Allele,273,O
specific,273,O
oligonucleotide,273,O
hybridization,273,O
analysis,273,O
using,273,O
amplified,273,O
genomic,273,O
DNA,273,O
showed,273,O
that,273,O
the,273,O
mutant,273,O
gene,273,O
was,273,O
transmitted,273,O
from,273,O
the,273,O
maternal,273,O
germ,273,O
line,273,O
.,273,O
This,274,O
mutation,274,O
would,274,O
lead,274,O
to,274,O
an,274,O
amino,274,O
acid,274,O
substitution,274,O
of,274,O
Asp,274,O
for,274,O
Gly,274,O
at,274,O
the,274,O
amino,274,O
acid,274,O
position,274,O
140,274,O
located,274,O
within,274,O
the,274,O
putative,274,O
5-phosphoribosyl-1-pyrophosphate,274,O
(,274,O
PRPP,274,O
),274,O
binding,274,O
region,274,O
.,274,O
Missense,275,O
mutations,275,O
in,275,O
human,275,O
HPRT,275,B-Modifier
deficient,275,I-Modifier
patients,275,O
thus,275,O
far,275,O
reported,275,O
tend,275,O
to,275,O
accumulate,275,O
in,275,O
this,275,O
functionally,275,O
active,275,O
region,275,O
.,275,O
However,276,O
",",276,O
a,276,O
comparison,276,O
of,276,O
the,276,O
data,276,O
suggested,276,O
that,276,O
both,276,O
missense,276,O
and,276,O
synonymous,276,O
mutations,276,O
can,276,O
occur,276,O
at,276,O
any,276,O
coding,276,O
sequence,276,O
of,276,O
the,276,O
human,276,O
germ,276,O
line,276,O
HPRT,276,O
gene,276,O
",",276,O
but,276,O
that,276,O
a,276,O
limited,276,O
percentage,276,O
of,276,O
all,276,O
the,276,O
missense,276,O
mutations,276,O
cause,276,O
disease,276,O
.,276,O
The,277,O
probability,277,O
that,277,O
a,277,O
mutation,277,O
will,277,O
cause,277,O
disease,277,O
tends,277,O
to,277,O
be,277,O
higher,277,O
when,277,O
the,277,O
missense,277,O
mutation,277,O
is,277,O
within,277,O
a,277,O
functionally,277,O
important,277,O
sequence,277,O
..,277,O
Characterisation,278,O
of,278,O
a,278,O
new,278,O
rare,278,O
fragile,278,O
site,278,O
easily,278,O
confused,278,O
with,278,O
the,278,O
fragile,278,B-SpecificDisease
X,278,I-SpecificDisease
.,278,O
A,279,O
new,279,O
fragile,279,O
site,279,O
(,279,O
FRAXE,279,O
),279,O
in,279,O
Xq28,279,O
is,279,O
described,279,O
.,279,O
It,280,O
appears,280,O
to,280,O
be,280,O
a,280,O
typical,280,O
folate,280,O
sensitive,280,O
fragile,280,O
site,280,O
.,280,O
The,281,O
fragile,281,O
site,281,O
is,281,O
not,281,O
associated,281,O
with,281,O
mental,281,B-DiseaseClass
retardation,281,I-DiseaseClass
",",281,O
it,281,O
does,281,O
not,281,O
give,281,O
abnormal,281,O
results,281,O
when,281,O
subjected,281,O
to,281,O
Southern,281,O
analysis,281,O
with,281,O
probe,281,O
pfxa3,281,O
which,281,O
detects,281,O
the,281,O
unstable,281,O
DNA,281,O
sequence,281,O
characteristic,281,O
of,281,O
fragile,281,B-SpecificDisease
X,281,I-SpecificDisease
syndrome,281,I-SpecificDisease
.,281,O
In,282,O
situ,282,O
hybridization,282,O
mapping,282,O
locates,282,O
the,282,O
fragile,282,O
site,282,O
between,282,O
150,282,O
kb,282,O
and,282,O
600,282,O
kb,282,O
distal,282,O
to,282,O
FRAXA,282,O
.,282,O
The,283,O
distinction,283,O
between,283,O
the,283,O
two,283,O
fragile,283,O
sites,283,O
is,283,O
important,283,O
clinically,283,O
since,283,O
cytogenetic,283,O
detection,283,O
of,283,O
FRAXE,283,O
",",283,O
without,283,O
molecular,283,O
analysis,283,O
",",283,O
could,283,O
result,283,O
in,283,O
misdiagnosis,283,O
of,283,O
fragile,283,B-SpecificDisease
X,283,I-SpecificDisease
syndrome,283,I-SpecificDisease
..,283,O
The,284,O
Norrie,284,B-Modifier
disease,284,I-Modifier
gene,284,O
maps,284,O
to,284,O
a,284,O
150,284,O
kb,284,O
region,284,O
on,284,O
chromosome,284,O
Xp11.3,284,O
.,284,O
Norrie,285,B-SpecificDisease
disease,285,I-SpecificDisease
is,285,O
a,285,O
human,285,O
X-linked,285,B-DiseaseClass
recessive,285,I-DiseaseClass
disorder,285,I-DiseaseClass
of,285,O
unknown,285,O
etiology,285,O
characterized,285,O
by,285,O
congenital,285,B-SpecificDisease
blindness,285,I-SpecificDisease
",",285,O
sensory,285,B-SpecificDisease
neural,285,I-SpecificDisease
deafness,285,I-SpecificDisease
and,285,O
mental,285,B-DiseaseClass
retardation,285,I-DiseaseClass
.,285,O
This,286,O
disease,286,O
gene,286,O
was,286,O
previously,286,O
linked,286,O
to,286,O
the,286,O
DXS7,286,O
(,286,O
L1,286,O
.,286,O
28,287,O
),287,O
locus,287,O
and,287,O
the,287,O
MAO,287,O
genes,287,O
in,287,O
band,287,O
Xp11,287,O
.,287,O
3,288,O
3,288,O
.,288,O
We,289,O
report,289,O
here,289,O
fine,289,O
physical,289,O
mapping,289,O
of,289,O
the,289,O
obligate,289,O
region,289,O
containing,289,O
the,289,O
Norrie,289,B-Modifier
disease,289,I-Modifier
gene,289,O
(,289,O
NDP,289,O
),289,O
defined,289,O
by,289,O
a,289,O
recombination,289,O
and,289,O
by,289,O
the,289,O
smallest,289,O
submicroscopic,289,O
chromosomal,289,O
deletion,289,O
associated,289,O
with,289,O
Norrie,289,B-SpecificDisease
disease,289,I-SpecificDisease
identified,289,O
to,289,O
date,289,O
.,289,O
Analysis,290,O
",",290,O
using,290,O
in,290,O
addition,290,O
two,290,O
overlapping,290,O
YAC,290,O
clones,290,O
from,290,O
this,290,O
region,290,O
",",290,O
allowed,290,O
orientation,290,O
of,290,O
the,290,O
MAOA,290,O
and,290,O
MAOB,290,O
genes,290,O
in,290,O
a,290,O
5-3-3-5,290,O
configuration,290,O
.,290,O
A,291,O
recombination,291,O
event,291,O
between,291,O
a,291,O
(,291,O
GT,291,O
),291,O
n,291,O
polymorphism,291,O
in,291,O
intron,291,O
2,291,O
of,291,O
the,291,O
MAOB,291,O
gene,291,O
and,291,O
the,291,O
NDP,291,O
locus,291,O
",",291,O
in,291,O
a,291,O
family,291,O
previously,291,O
reported,291,O
to,291,O
have,291,O
a,291,O
recombination,291,O
between,291,O
DXS7,291,O
and,291,O
NDP,291,O
",",291,O
delineates,291,O
a,291,O
flanking,291,O
marker,291,O
telomeric,291,O
to,291,O
this,291,O
disease,291,O
gene,291,O
.,291,O
An,292,O
anonymous,292,O
DNA,292,O
probe,292,O
",",292,O
dc12,292,O
",",292,O
present,292,O
in,292,O
one,292,O
of,292,O
the,292,O
YACs,292,O
and,292,O
in,292,O
a,292,O
patient,292,O
with,292,O
a,292,O
submicroscopic,292,O
deletion,292,O
which,292,O
includes,292,O
MAOA,292,O
and,292,O
MAOB,292,O
but,292,O
not,292,O
L1,292,O
.,292,O
28,293,O
",",293,O
serves,293,O
as,293,O
a,293,O
flanking,293,O
marker,293,O
centromeric,293,O
to,293,O
the,293,O
disease,293,O
gene,293,O
.,293,O
An,294,O
Alu-PCR,294,O
fragment,294,O
from,294,O
the,294,O
right,294,O
arm,294,O
of,294,O
the,294,O
MAO,294,O
YAC,294,O
(,294,O
YMAO,294,O
.,294,O
AluR,295,O
),295,O
is,295,O
not,295,O
deleted,295,O
in,295,O
this,295,O
patient,295,O
and,295,O
also,295,O
delineates,295,O
the,295,O
centromeric,295,O
extent,295,O
of,295,O
the,295,O
obligate,295,O
disease,295,O
region,295,O
.,295,O
The,296,O
apparent,296,O
order,296,O
of,296,O
these,296,O
loci,296,O
is,296,O
telomere,296,O
.,296,O
DXS7-MAOA-MAOB-NDP-dc12-YMAO,297,O
DXS7-MAOA-MAOB-NDP-dc12-YMAO,297,O
.,297,O
AluR,298,O
.,298,O
centromere,299,O
.,299,O
Together,300,O
these,300,O
data,300,O
define,300,O
the,300,O
obligate,300,O
region,300,O
containing,300,O
the,300,O
NDP,300,O
gene,300,O
to,300,O
a,300,O
chromosomal,300,O
segment,300,O
less,300,O
than,300,O
150,300,O
kb,300,O
.,300,O
Molecular,301,O
basis,301,O
of,301,O
phenylketonuria,301,B-SpecificDisease
and,301,O
related,301,O
hyperphenylalaninemias,301,B-DiseaseClass
:,301,O
mutations,301,O
and,301,O
polymorphisms,301,O
in,301,O
the,301,O
human,301,O
phenylalanine,301,O
hydroxylase,301,O
gene,301,O
.,301,O
Mutations,302,O
in,302,O
the,302,O
human,302,O
phenylalanine,302,O
hydroxylase,302,O
gene,302,O
producing,302,O
phenylketonuria,302,B-SpecificDisease
or,302,O
hyperphenylalaninemia,302,B-DiseaseClass
have,302,O
now,302,O
been,302,O
identified,302,O
in,302,O
many,302,O
patients,302,O
from,302,O
various,302,O
ethnic,302,O
groups,302,O
.,302,O
These,303,O
mutations,303,O
all,303,O
exhibit,303,O
a,303,O
high,303,O
degree,303,O
of,303,O
association,303,O
with,303,O
specific,303,O
restriction,303,O
fragment-length,303,O
polymorphism,303,O
haplotypes,303,O
at,303,O
the,303,O
PAH,303,O
locus,303,O
.,303,O
About,304,O
50,304,O
of,304,O
these,304,O
mutations,304,O
are,304,O
single-base,304,O
substitutions,304,O
",",304,O
including,304,O
six,304,O
nonsense,304,O
mutations,304,O
and,304,O
eight,304,O
splicing,304,O
mutations,304,O
",",304,O
with,304,O
the,304,O
remainder,304,O
being,304,O
missense,304,O
mutations,304,O
.,304,O
One,305,O
splicing,305,O
mutation,305,O
results,305,O
in,305,O
a,305,O
3,305,O
amino,305,O
acid,305,O
in-frame,305,O
insertion,305,O
.,305,O
Two,306,O
or,306,O
3,306,O
large,306,O
deletions,306,O
",",306,O
2,306,O
single,306,O
codon,306,O
deletions,306,O
",",306,O
and,306,O
2,306,O
single,306,O
base,306,O
deletions,306,O
have,306,O
been,306,O
found,306,O
.,306,O
Twelve,307,O
of,307,O
the,307,O
missense,307,O
mutations,307,O
apparently,307,O
result,307,O
from,307,O
the,307,O
methylation,307,O
and,307,O
subsequent,307,O
deamination,307,O
of,307,O
highly,307,O
mutagenic,307,O
CpG,307,O
dinucleotides,307,O
.,307,O
Recurrent,308,O
mutation,308,O
has,308,O
been,308,O
observed,308,O
at,308,O
several,308,O
of,308,O
these,308,O
sites,308,O
",",308,O
producing,308,O
associations,308,O
with,308,O
different,308,O
haplotypes,308,O
in,308,O
different,308,O
populations,308,O
.,308,O
About,309,O
half,309,O
of,309,O
all,309,O
missense,309,O
mutations,309,O
have,309,O
been,309,O
examined,309,O
by,309,O
in,309,O
vitro,309,O
expression,309,O
analysis,309,O
",",309,O
and,309,O
a,309,O
significant,309,O
correlation,309,O
has,309,O
been,309,O
observed,309,O
between,309,O
residual,309,O
PAH,309,O
activity,309,O
and,309,O
disease,309,O
phenotype,309,O
.,309,O
Since,310,O
continuing,310,O
advances,310,O
in,310,O
molecular,310,O
methodologies,310,O
have,310,O
dramatically,310,O
accelerated,310,O
the,310,O
rate,310,O
in,310,O
which,310,O
new,310,O
mutations,310,O
are,310,O
being,310,O
identified,310,O
and,310,O
characterized,310,O
",",310,O
this,310,O
register,310,O
of,310,O
mutations,310,O
will,310,O
be,310,O
updated,310,O
periodically,310,O
..,310,O
A,311,O
glycine250,311,O
--,311,O
>,311,O
aspartate,311,O
substitution,311,O
in,311,O
the,311,O
alpha-subunit,311,O
of,311,O
hexosaminidase,311,O
A,311,O
causes,311,O
juvenile-onset,311,O
Tay-Sachs,311,B-SpecificDisease
disease,311,I-SpecificDisease
in,311,O
a,311,O
Lebanese-Canadian,311,O
family,311,O
.,311,O
The,312,O
mutation,312,O
causing,312,O
juvenile,312,O
Tay-Sachs,312,B-SpecificDisease
disease,312,I-SpecificDisease
(,312,O
TSD,312,B-SpecificDisease
),312,O
in,312,O
two,312,O
sibs,312,O
of,312,O
Lebanese-Maronite,312,O
origin,312,O
is,312,O
described,312,O
.,312,O
An,313,O
mRNA-containing,313,O
extract,313,O
of,313,O
cultured,313,O
fibroblasts,313,O
obtained,313,O
from,313,O
one,313,O
of,313,O
the,313,O
probands,313,O
was,313,O
used,313,O
as,313,O
a,313,O
template,313,O
to,313,O
amplify,313,O
the,313,O
coding,313,O
sequence,313,O
of,313,O
the,313,O
hexosaminidase,313,O
A,313,O
(,313,O
Hex,313,O
A,313,O
),313,O
alpha-subunit,313,O
.,313,O
Sequencing,314,O
of,314,O
amplified,314,O
cDNA,314,O
fragments,314,O
revealed,314,O
a,314,O
single,314,O
alteration,314,O
",",314,O
guanine,314,O
to,314,O
adenine,314,O
at,314,O
nt,314,O
749,314,O
creating,314,O
a,314,O
G250D,314,O
mutation,314,O
.,314,O
The,315,O
mutation,315,O
introduces,315,O
a,315,O
new,315,O
recognition,315,O
site,315,O
for,315,O
the,315,O
restriction,315,O
enzyme,315,O
Eco,315,O
RV,315,O
",",315,O
permitting,315,O
identification,315,O
of,315,O
heterozygotes,315,O
for,315,O
this,315,O
allele,315,O
following,315,O
PCR,315,O
amplification,315,O
and,315,O
Eco,315,O
RV,315,O
digestion,315,O
of,315,O
exon,315,O
7,315,O
sequences,315,O
from,315,O
genomic,315,O
DNA,315,O
templates,315,O
.,315,O
In,316,O
order,316,O
to,316,O
test,316,O
the,316,O
effect,316,O
of,316,O
this,316,O
substitution,316,O
",",316,O
an,316,O
in,316,O
vitro,316,O
mutagenized,316,O
cDNA,316,O
construct,316,O
was,316,O
introduced,316,O
into,316,O
a,316,O
mammalian,316,O
expression,316,O
vector,316,O
and,316,O
transfected,316,O
into,316,O
monkey,316,O
Cos-1,316,O
cells,316,O
separately,316,O
or,316,O
along,316,O
with,316,O
a,316,O
beta-cDNA,316,O
expression,316,O
vector,316,O
.,316,O
When,317,O
the,317,O
mutant,317,O
alpha-cDNA,317,O
was,317,O
the,317,O
only,317,O
gene,317,O
introduced,317,O
into,317,O
COS,317,O
cells,317,O
no,317,O
enzymatic,317,O
activity,317,O
above,317,O
endogenous,317,O
COS,317,O
cell,317,O
activity,317,O
was,317,O
detected,317,O
.,317,O
Cotransfection,318,O
of,318,O
normal,318,O
alpha-cDNA,318,O
and,318,O
beta-cDNA,318,O
followed,318,O
by,318,O
immunoprecipitation,318,O
of,318,O
human,318,O
Hex,318,O
A,318,O
resulted,318,O
in,318,O
20-fold,318,O
increase,318,O
in,318,O
the,318,O
ratio,318,O
between,318,O
positive,318,O
and,318,O
negative,318,O
(,318,O
mock,318,O
transfection,318,O
),318,O
control,318,O
values,318,O
.,318,O
This,319,O
allowed,319,O
the,319,O
detection,319,O
of,319,O
some,319,O
residual,319,O
activity,319,O
(,319,O
12,319,O
%,319,O
of,319,O
the,319,O
positive,319,O
control,319,O
),319,O
when,319,O
the,319,O
mutant,319,O
alpha-cDNA,319,O
replaced,319,O
its,319,O
wild-type,319,O
counterpart,319,O
.,319,O
The,320,O
predicted,320,O
protein,320,O
environment,320,O
in,320,O
which,320,O
the,320,O
mutation,320,O
occurs,320,O
is,320,O
compared,320,O
to,320,O
that,320,O
of,320,O
the,320,O
adult-onset,320,O
Tay-Sachs,320,B-Modifier
disease,320,I-Modifier
mutation,320,O
caused,320,O
by,320,O
a,320,O
Gly269,320,O
--,320,O
>,320,O
Ser,320,O
substitution,320,O
in,320,O
exon,320,O
7,320,O
.,320,O
(,321,O
ABSTRACT,321,O
TRUNCATED,321,O
AT,321,O
250,321,O
WORDS,321,O
),321,O
.,321,O
Novel,322,O
Tay-Sachs,322,B-Modifier
disease,322,I-Modifier
mutations,322,O
from,322,O
China,322,O
.,322,O
We,323,O
describe,323,O
three,323,O
HEXA,323,O
mutations,323,O
associated,323,O
with,323,O
infantile,323,O
Tay-Sachs,323,B-SpecificDisease
disease,323,I-SpecificDisease
(,323,O
TSD,323,B-SpecificDisease
),323,O
in,323,O
three,323,O
unrelated,323,O
nonconsanguineous,323,O
Chinese,323,O
families,323,O
.,323,O
Novel,324,O
mutations,324,O
were,324,O
found,324,O
in,324,O
two,324,O
of,324,O
these,324,O
families,324,O
.,324,O
The,325,O
third,325,O
is,325,O
a,325,O
previously,325,O
reported,325,O
mutation,325,O
(,325,O
G,325,O
--,325,O
>,325,O
A,325,O
transition,325,O
at,325,O
nt,325,O
1444,325,O
),325,O
(,325,O
Nakano,325,O
et,325,O
al.,325,O
",",325,O
1988,325,O
),325,O
.,325,O
Direct,326,O
sequencing,326,O
of,326,O
PCR,326,O
products,326,O
identified,326,O
a,326,O
novel,326,O
insertion,326,O
of,326,O
an,326,O
A,326,O
after,326,O
nt,326,O
547,326,O
in,326,O
family,326,O
1,326,O
.,326,O
This,327,O
change,327,O
generates,327,O
an,327,O
early,327,O
termination,327,O
codon,327,O
6,327,O
bp,327,O
downstream,327,O
from,327,O
the,327,O
insertion,327,O
site,327,O
.,327,O
Allele-specific,328,O
oligonucleotide,328,O
hybridization,328,O
confirmed,328,O
homozygosity,328,O
in,328,O
the,328,O
proband,328,O
.,328,O
Single,329,O
strand,329,O
conformational,329,O
polymorphism,329,O
analysis,329,O
and,329,O
direct,329,O
sequencing,329,O
of,329,O
amplified,329,O
exon,329,O
13,329,O
revealed,329,O
a,329,O
T,329,O
--,329,O
>,329,O
C,329,O
transition,329,O
at,329,O
nt,329,O
1453,329,O
with,329,O
the,329,O
corresponding,329,O
amino,329,O
acid,329,O
substitution,329,O
W485R,329,O
in,329,O
the,329,O
second,329,O
family,329,O
.,329,O
This,330,O
mutation,330,O
creates,330,O
an,330,O
Fnu4HI,330,O
restriction,330,O
site,330,O
.,330,O
The,331,O
proband,331,O
is,331,O
homozygous,331,O
for,331,O
this,331,O
allele,331,O
.,331,O
When,332,O
the,332,O
site-specific,332,O
mutagenized,332,O
alpha,332,O
cDNA,332,O
carrying,332,O
the,332,O
T,332,O
--,332,O
>,332,O
C,332,O
transition,332,O
at,332,O
nt,332,O
1453,332,O
was,332,O
expressed,332,O
in,332,O
COS,332,O
1,332,O
cells,332,O
hexosaminidase,332,O
S,332,O
activity,332,O
was,332,O
not,332,O
detectable,332,O
above,332,O
background,332,O
.,332,O
A,333,O
G,333,O
--,333,O
>,333,O
A,333,O
transition,333,O
at,333,O
nt,333,O
1444,333,O
(,333,O
exon,333,O
13,333,O
),333,O
corresponding,333,O
to,333,O
the,333,O
E482K,333,O
substitution,333,O
was,333,O
found,333,O
in,333,O
the,333,O
third,333,O
family,333,O
.,333,O
This,334,O
mutation,334,O
occurs,334,O
at,334,O
a,334,O
CpG,334,O
dinucleotide,334,O
.,334,O
It,335,O
has,335,O
been,335,O
reported,335,O
in,335,O
an,335,O
Italian,335,O
TSD,335,B-Modifier
proband,335,O
and,335,O
causes,335,O
defective,335,O
intracellular,335,O
transport,335,O
of,335,O
the,335,O
alpha-subunit,335,O
from,335,O
the,335,O
rough,335,O
endoplasmic,335,O
reticulum,335,O
to,335,O
the,335,O
Golgi,335,O
apparatus,335,O
.,335,O
Two,336,O
missense,336,O
mutations,336,O
causing,336,O
mild,336,O
hyperphenylalaninemia,336,B-DiseaseClass
associated,336,O
with,336,O
DNA,336,O
haplotype,336,O
12,336,O
.,336,O
The,337,O
genetic,337,B-DiseaseClass
defects,337,I-DiseaseClass
responsible,337,O
for,337,O
most,337,O
phenylketonuria,337,B-SpecificDisease
(,337,O
PKU,337,B-SpecificDisease
),337,O
and,337,O
hyperphenylalaninemia,337,B-DiseaseClass
(,337,O
HPA,337,B-DiseaseClass
),337,O
cases,337,O
are,337,O
located,337,O
in,337,O
the,337,O
phenylalanine,337,O
hydroxylase,337,O
(,337,O
PAH,337,O
),337,O
gene,337,O
.,337,O
Approximately,338,O
50-60,338,O
mutations,338,O
have,338,O
been,338,O
reported,338,O
in,338,O
Caucasians,338,O
and,338,O
are,338,O
reflected,338,O
in,338,O
a,338,O
wide,338,O
range,338,O
of,338,O
clinical,338,O
severities,338,O
.,338,O
Most,339,O
mutations,339,O
are,339,O
linked,339,O
to,339,O
specific,339,O
haplotypes,339,O
",",339,O
as,339,O
defined,339,O
by,339,O
eight,339,O
polymorphic,339,O
restriction,339,O
sites,339,O
in,339,O
the,339,O
PAH,339,O
gene,339,O
.,339,O
We,340,O
hypothesized,340,O
that,340,O
there,340,O
is,340,O
at,340,O
least,340,O
one,340,O
mild,340,O
mutation,340,O
linked,340,O
to,340,O
haplotype,340,O
12,340,O
in,340,O
the,340,O
Swedish,340,O
PKU/HPA,340,B-Modifier
population,340,O
",",340,O
since,340,O
7,340,O
of,340,O
8,340,O
patients,340,O
carrying,340,O
haplotype,340,O
12,340,O
had,340,O
mild,340,O
HPA,340,B-DiseaseClass
.,340,O
Sequence,341,O
analysis,341,O
revealed,341,O
a,341,O
C-to-G,341,O
transversion,341,O
at,341,O
the,341,O
second,341,O
base,341,O
of,341,O
codon,341,O
322,341,O
",",341,O
resulting,341,O
in,341,O
a,341,O
substitution,341,O
of,341,O
glycine,341,O
for,341,O
alanine,341,O
",",341,O
in,341,O
four,341,O
mutant,341,O
haplotype,341,O
12,341,O
genes,341,O
",",341,O
and,341,O
a,341,O
G-to-A,341,O
transition,341,O
at,341,O
the,341,O
second,341,O
base,341,O
of,341,O
codon,341,O
408,341,O
",",341,O
resulting,341,O
in,341,O
a,341,O
substitution,341,O
of,341,O
glutamine,341,O
for,341,O
arginine,341,O
",",341,O
in,341,O
another,341,O
three,341,O
mutant,341,O
haplotype,341,O
12,341,O
genes,341,O
.,341,O
These,342,O
mutations,342,O
segregated,342,O
with,342,O
mutant,342,O
haplotype,342,O
12,342,O
alleles,342,O
in,342,O
nuclear,342,O
families,342,O
but,342,O
were,342,O
not,342,O
present,342,O
on,342,O
normal,342,O
or,342,O
other,342,O
mutant,342,O
alleles,342,O
.,342,O
Both,343,O
mutations,343,O
were,343,O
tested,343,O
in,343,O
a,343,O
eukaryotic,343,O
expression,343,O
system,343,O
in,343,O
which,343,O
enzyme,343,O
activities,343,O
of,343,O
different,343,O
mutant,343,O
PAH,343,O
enzymes,343,O
reflect,343,O
the,343,O
relative,343,O
severities,343,O
of,343,O
the,343,O
mutations,343,O
",",343,O
although,343,O
these,343,O
in,343,O
vitro,343,O
activities,343,O
can,343,O
not,343,O
be,343,O
translated,343,O
directly,343,O
into,343,O
in,343,O
vivo,343,O
hepatic,343,O
activities,343,O
.,343,O
The,344,O
A322G,344,O
mutant,344,O
PAH,344,O
had,344,O
about,344,O
75,344,O
%,344,O
and,344,O
the,344,O
R408Q,344,O
mutant,344,O
PAH,344,O
about,344,O
55,344,O
%,344,O
of,344,O
the,344,O
wild-type,344,O
PAH,344,O
enzyme,344,O
activity,344,O
.,344,O
These,345,O
in,345,O
vitro,345,O
activities,345,O
are,345,O
the,345,O
highest,345,O
reported,345,O
for,345,O
mutant,345,O
PAH,345,O
enzymes,345,O
produced,345,O
in,345,O
the,345,O
same,345,O
expression,345,O
system,345,O
.,345,O
(,346,O
ABSTRACT,346,O
TRUNCATED,346,O
AT,346,O
250,346,O
WORDS,346,O
),346,O
.,346,O
In,347,O
vitro,347,O
and,347,O
in,347,O
vivo,347,O
correlations,347,O
for,347,O
I65T,347,O
and,347,O
M1V,347,O
mutations,347,O
at,347,O
the,347,O
phenylalanine,347,O
hydroxylase,347,O
locus,347,O
.,347,O
Mutations,348,O
at,348,O
the,348,O
phenylalanine,348,O
hydroxylase,348,O
(,348,O
PAH,348,O
),348,O
locus,348,O
are,348,O
the,348,O
major,348,O
cause,348,O
of,348,O
hyperphenylalaninemia,348,B-DiseaseClass
.,348,O
We,349,O
have,349,O
previously,349,O
described,349,O
four,349,O
mutations,349,O
(,349,O
M1V,349,O
",",349,O
IVS12nt1,349,O
",",349,O
R408W,349,O
",",349,O
and,349,O
S349P,349,O
),349,O
at,349,O
the,349,O
PAH,349,O
locus,349,O
in,349,O
French,349,O
Canadians,349,O
with,349,O
ancestry,349,O
in,349,O
eastern,349,O
Quebec,349,O
.,349,O
Here,350,O
we,350,O
report,350,O
(,350,O
1,350,O
),350,O
identification,350,O
of,350,O
another,350,O
mutation,350,O
",",350,O
on,350,O
a,350,O
haplotype,350,O
9,350,O
chromosome,350,O
",",350,O
which,350,O
converts,350,O
codon,350,O
65,350,O
from,350,O
isoleucine,350,O
(,350,O
ATT,350,O
),350,O
to,350,O
threonine,350,O
(,350,O
ACT,350,O
),350,O
",",350,O
(,350,O
2,350,O
),350,O
expression,350,O
analysis,350,O
of,350,O
the,350,O
I65T,350,O
mutation,350,O
in,350,O
COS,350,O
cells,350,O
demonstrating,350,O
75,350,O
%,350,O
loss,350,O
of,350,O
both,350,O
immunoreactive,350,O
protein,350,O
and,350,O
enzyme,350,O
activity,350,O
",",350,O
and,350,O
(,350,O
3,350,O
),350,O
expression,350,O
analysis,350,O
of,350,O
the,350,O
most,350,O
prevalent,350,O
PKU,350,B-Modifier
allele,350,O
(,350,O
M1V,350,O
),350,O
in,350,O
eastern,350,O
Quebec,350,O
",",350,O
showing,350,O
nondetectable,350,O
levels,350,O
of,350,O
PAH,350,O
protein,350,O
and,350,O
activity,350,O
",",350,O
a,350,O
finding,350,O
compatible,350,O
with,350,O
a,350,O
mutation,350,O
in,350,O
the,350,O
translation,350,O
initiation,350,O
codon,350,O
.,350,O
Homozygosity,351,O
for,351,O
M1V,351,O
and,351,O
codominant,351,O
inheritance,351,O
of,351,O
I65T/R408W,351,O
were,351,O
both,351,O
associated,351,O
with,351,O
classical,351,B-SpecificDisease
phenylketonuria,351,I-SpecificDisease
..,351,O
Molecular,352,O
basis,352,O
of,352,O
hexosaminidase,352,B-SpecificDisease
A,352,I-SpecificDisease
deficiency,352,I-SpecificDisease
and,352,O
pseudodeficiency,352,O
in,352,O
the,352,O
Berks,352,O
County,352,O
Pennsylvania,352,O
Dutch,352,O
.,352,O
Following,353,O
the,353,O
birth,353,O
of,353,O
two,353,O
infants,353,O
with,353,O
Tay-Sachs,353,B-SpecificDisease
disease,353,I-SpecificDisease
(,353,O
TSD,353,B-SpecificDisease
),353,O
",",353,O
a,353,O
non-Jewish,353,O
",",353,O
Pennsylvania,353,O
Dutch,353,O
kindred,353,O
was,353,O
screened,353,O
for,353,O
TSD,353,B-Modifier
carriers,353,O
using,353,O
the,353,O
biochemical,353,O
assay,353,O
.,353,O
A,354,O
high,354,O
frequency,354,O
of,354,O
individuals,354,O
who,354,O
appeared,354,O
to,354,O
be,354,O
TSD,354,B-Modifier
heterozygotes,354,O
was,354,O
detected,354,O
(,354,O
Kelly,354,O
et,354,O
al.,354,O
",",354,O
1975,354,O
),354,O
.,354,O
Clinical,355,O
and,355,O
biochemical,355,O
evidence,355,O
suggested,355,O
that,355,O
the,355,O
increased,355,O
carrier,355,O
frequency,355,O
was,355,O
due,355,O
to,355,O
at,355,O
least,355,O
two,355,O
altered,355,O
alleles,355,O
for,355,O
the,355,O
hexosaminidase,355,O
A,355,O
alpha-subunit,355,O
.,355,O
We,356,O
now,356,O
report,356,O
two,356,O
mutant,356,O
alleles,356,O
in,356,O
this,356,O
Pennsylvania,356,O
Dutch,356,O
kindred,356,O
",",356,O
and,356,O
one,356,O
polymorphism,356,O
.,356,O
One,357,O
allele,357,O
",",357,O
reported,357,O
originally,357,O
in,357,O
a,357,O
French,357,O
TSD,357,B-Modifier
patient,357,O
(,357,O
Akli,357,O
et,357,O
al.,357,O
",",357,O
1991,357,O
),357,O
",",357,O
is,357,O
a,357,O
GT,357,O
--,357,O
>,357,O
AT,357,O
transition,357,O
at,357,O
the,357,O
donor,357,O
splice-site,357,O
of,357,O
intron,357,O
9,357,O
.,357,O
The,358,O
second,358,O
",",358,O
a,358,O
C,358,O
--,358,O
>,358,O
T,358,O
transition,358,O
at,358,O
nucleotide,358,O
739,358,O
(,358,O
Arg247Trp,358,O
),358,O
",",358,O
has,358,O
been,358,O
shown,358,O
by,358,O
Triggs-Raine,358,O
et,358,O
al,358,O
.,358,O
(,359,O
1992,359,O
),359,O
to,359,O
be,359,O
a,359,O
clinically,359,O
benign,359,O
``,359,O
pseudodeficient,359,O
``,359,O
allele,359,O
associated,359,O
with,359,O
reduced,359,O
enzyme,359,O
activity,359,O
against,359,O
artificial,359,O
substrate,359,O
.,359,O
Finally,360,O
",",360,O
a,360,O
polymorphism,360,O
[,360,O
G,360,O
--,360,O
>,360,O
A,360,O
(,360,O
759,360,O
),360,O
],360,O
",",360,O
which,360,O
leaves,360,O
valine,360,O
at,360,O
codon,360,O
253,360,O
unchanged,360,O
",",360,O
is,360,O
described,360,O
.,360,O
A,361,O
mutation,361,O
common,361,O
in,361,O
non-Jewish,361,O
Tay-Sachs,361,B-SpecificDisease
disease,361,I-SpecificDisease
:,361,O
frequency,361,O
and,361,O
RNA,361,O
studies,361,O
.,361,O
Tay-Sachs,362,B-SpecificDisease
disease,362,I-SpecificDisease
(,362,O
TSD,362,B-SpecificDisease
),362,O
is,362,O
an,362,O
autosomal,362,B-DiseaseClass
recessive,362,I-DiseaseClass
genetic,362,I-DiseaseClass
disorder,362,I-DiseaseClass
resulting,362,O
from,362,O
mutation,362,O
of,362,O
the,362,O
HEXA,362,O
gene,362,O
encoding,362,O
the,362,O
alpha-subunit,362,O
of,362,O
the,362,O
lysosomal,362,O
enzyme,362,O
",",362,O
beta-N-acetylhexosaminidase,362,O
A,362,O
(,362,O
Hex,362,O
A,362,O
),362,O
.,362,O
We,363,O
have,363,O
discovered,363,O
that,363,O
a,363,O
Tay-Sachs,363,B-Modifier
mutation,363,O
",",363,O
IVS-9,363,O
+,363,O
1,363,O
G,363,O
--,363,O
>,363,O
A,363,O
",",363,O
first,363,O
detected,363,O
by,363,O
Akli,363,O
et,363,O
al,363,O
.,363,O
(,364,O
Genomics,364,O
11,364,O
124-134,364,O
",",364,O
1991,364,O
),364,O
",",364,O
is,364,O
a,364,O
common,364,O
disease,364,O
allele,364,O
in,364,O
non-Jewish,364,O
Caucasians,364,O
(,364,O
10/58,364,O
alleles,364,O
examined,364,O
),364,O
.,364,O
A,365,O
PCR-based,365,O
diagnostic,365,O
test,365,O
",",365,O
which,365,O
detects,365,O
an,365,O
NlaIII,365,O
site,365,O
generated,365,O
by,365,O
the,365,O
mutation,365,O
",",365,O
revealed,365,O
a,365,O
frequency,365,O
among,365,O
enzyme-defined,365,O
carriers,365,O
of,365,O
9/64,365,O
(,365,O
14,365,O
%,365,O
),365,O
.,365,O
Most,366,O
of,366,O
those,366,O
carrying,366,O
the,366,O
allele,366,O
trace,366,O
their,366,O
origins,366,O
to,366,O
the,366,O
United,366,O
Kingdom,366,O
",",366,O
Ireland,366,O
",",366,O
or,366,O
Western,366,O
Europe,366,O
.,366,O
It,367,O
was,367,O
not,367,O
identified,367,O
among,367,O
12,367,O
Black,367,O
American,367,O
TSD,367,B-Modifier
alleles,367,O
or,367,O
in,367,O
any,367,O
of,367,O
18,367,O
Ashkenazi,367,O
Jewish,367,O
",",367,O
enzyme-defined,367,O
carriers,367,O
who,367,O
did,367,O
not,367,O
carry,367,O
any,367,O
of,367,O
the,367,O
mutations,367,O
common,367,O
to,367,O
this,367,O
population,367,O
.,367,O
No,368,O
normally,368,O
spliced,368,O
RNA,368,O
was,368,O
detected,368,O
in,368,O
PCR,368,O
products,368,O
generated,368,O
from,368,O
reverse,368,O
transcription,368,O
of,368,O
RNA,368,O
carrying,368,O
the,368,O
IVS-9,368,O
mutation,368,O
.,368,O
Instead,369,O
",",369,O
the,369,O
low,369,O
levels,369,O
of,369,O
mRNA,369,O
from,369,O
this,369,O
allele,369,O
were,369,O
comprised,369,O
of,369,O
aberrant,369,O
species,369,O
resulting,369,O
from,369,O
the,369,O
use,369,O
of,369,O
either,369,O
of,369,O
two,369,O
cryptic,369,O
donor,369,O
sites,369,O
",",369,O
one,369,O
truncating,369,O
exon,369,O
9,369,O
and,369,O
the,369,O
other,369,O
within,369,O
IVS-9,369,O
",",369,O
spliced,369,O
to,369,O
exon,369,O
10,369,O
.,369,O
Numerous,370,O
additional,370,O
splice,370,O
products,370,O
were,370,O
detected,370,O
",",370,O
most,370,O
involving,370,O
skipping,370,O
of,370,O
one,370,O
or,370,O
more,370,O
surrounding,370,O
exons,370,O
.,370,O
Together,371,O
with,371,O
a,371,O
recently,371,O
identified,371,O
allele,371,O
responsible,371,O
for,371,O
Hex,371,O
A,371,O
pseudodeficiency,371,O
(,371,O
Triggs-Raine,371,O
et,371,O
al,371,O
.,371,O
Am,372,O
J,372,O
Hum,372,O
Genet,372,O
",",372,O
1992,372,O
),372,O
",",372,O
these,372,O
two,372,O
alleles,372,O
accounted,372,O
for,372,O
almost,372,O
50,372,O
%,372,O
(,372,O
29/64,372,O
),372,O
of,372,O
TSD,372,B-Modifier
or,372,O
carrier,372,O
alleles,372,O
ascertained,372,O
by,372,O
enzyme,372,O
screening,372,O
tests,372,O
in,372,O
non-Jewish,372,O
Caucasians,372,O
..,372,O
Aberrant,373,O
splicing,373,O
of,373,O
the,373,O
CHM,373,B-Modifier
gene,373,O
is,373,O
a,373,O
significant,373,O
cause,373,O
of,373,O
choroideremia,373,B-SpecificDisease
.,373,O
Choroideremia,374,B-SpecificDisease
(,374,O
CHM,374,B-SpecificDisease
),374,O
is,374,O
an,374,O
X-linked,374,B-DiseaseClass
progressive,374,I-DiseaseClass
degeneration,374,I-DiseaseClass
of,374,I-DiseaseClass
the,374,I-DiseaseClass
choroid,374,I-DiseaseClass
and,374,I-DiseaseClass
retina,374,I-DiseaseClass
.,374,O
12,375,O
%,375,O
of,375,O
unrelated,375,O
male,375,O
patients,375,O
carry,375,O
deletions,375,O
of,375,O
the,375,O
partially,375,O
cloned,375,O
CHM,375,B-Modifier
gene,375,O
.,375,O
In,376,O
Finland,376,O
",",376,O
there,376,O
are,376,O
more,376,O
than,376,O
120,376,O
living,376,O
CHM,376,B-Modifier
patients,376,O
belonging,376,O
to,376,O
eight,376,O
apparently,376,O
unrelated,376,O
pedigrees,376,O
.,376,O
Molecular,377,O
deletions,377,O
involving,377,O
the,377,O
CHM,377,B-Modifier
gene,377,O
have,377,O
been,377,O
detected,377,O
in,377,O
three,377,O
families,377,O
.,377,O
We,378,O
have,378,O
screened,378,O
the,378,O
remaining,378,O
five,378,O
families,378,O
for,378,O
point,378,O
mutations,378,O
.,378,O
In,379,O
one,379,O
large,379,O
family,379,O
a,379,O
single,379,O
nucleotide,379,O
(,379,O
T,379,O
),379,O
insertion,379,O
into,379,O
the,379,O
donor,379,O
splice,379,O
site,379,O
of,379,O
exon,379,O
C,379,O
leads,379,O
to,379,O
two,379,O
aberrantly,379,O
spliced,379,O
mRNAs,379,O
both,379,O
producing,379,O
a,379,O
premature,379,O
stop,379,O
codon,379,O
.,379,O
The,380,O
mutation,380,O
can,380,O
be,380,O
assayed,380,O
easily,380,O
by,380,O
amplification,380,O
and,380,O
digestion,380,O
with,380,O
Msel,380,O
.,380,O
Our,381,O
findings,381,O
provide,381,O
additional,381,O
evidence,381,O
for,381,O
the,381,O
pathogenetic,381,O
role,381,O
of,381,O
CHM,381,B-Modifier
mutations,381,O
and,381,O
provide,381,O
a,381,O
diagnostic,381,O
tool,381,O
for,381,O
one,381,O
fifth,381,O
of,381,O
the,381,O
worlds,381,O
known,381,O
CHM,381,B-Modifier
patients,381,O
..,381,O
Germline,382,O
intronic,382,O
and,382,O
exonic,382,O
mutations,382,O
in,382,O
the,382,O
Wilms,382,B-Modifier
',382,I-Modifier
tumour,382,I-Modifier
gene,382,O
(,382,O
WT1,382,O
),382,O
affecting,382,O
urogenital,382,O
development,382,O
.,382,O
Denys-Drash,383,B-SpecificDisease
syndrome,383,I-SpecificDisease
is,383,O
a,383,O
rare,383,O
human,383,O
developmental,383,B-DiseaseClass
disorder,383,I-DiseaseClass
affecting,383,O
the,383,O
urogenital,383,O
system,383,O
and,383,O
leading,383,O
to,383,O
renal,383,B-DiseaseClass
failure,383,I-DiseaseClass
",",383,O
intersex,383,B-DiseaseClass
disorders,383,I-DiseaseClass
and,383,O
Wilms,383,B-SpecificDisease
tumour,383,I-SpecificDisease
.,383,O
In,384,O
this,384,O
report,384,O
",",384,O
four,384,O
individuals,384,O
with,384,O
this,384,O
syndrome,384,O
are,384,O
described,384,O
carrying,384,O
germline,384,O
point,384,O
mutations,384,O
in,384,O
the,384,O
Wilms,384,B-Modifier
tumour,384,I-Modifier
suppressor,384,O
gene,384,O
",",384,O
WT1,384,O
.,384,O
Three,385,O
of,385,O
these,385,O
mutations,385,O
were,385,O
in,385,O
the,385,O
zinc,385,O
finger,385,O
domains,385,O
of,385,O
WT1,385,O
.,385,O
The,386,O
fourth,386,O
occurred,386,O
within,386,O
intron,386,O
9,386,O
",",386,O
preventing,386,O
splicing,386,O
at,386,O
one,386,O
of,386,O
the,386,O
alternatively,386,O
chosen,386,O
splice,386,O
donor,386,O
sites,386,O
of,386,O
exon,386,O
9,386,O
when,386,O
assayed,386,O
in,386,O
vitro,386,O
.,386,O
These,387,O
results,387,O
provide,387,O
genetic,387,O
evidence,387,O
for,387,O
distinct,387,O
functional,387,O
roles,387,O
of,387,O
the,387,O
WT1,387,O
isoforms,387,O
in,387,O
urogenital,387,O
development,387,O
..,387,O
Characterization,388,O
of,388,O
the,388,O
myotonic,388,B-Modifier
dystrophy,388,I-Modifier
region,388,O
predicts,388,O
multiple,388,O
protein,388,O
isoform-encoding,388,O
mRNAs,388,O
.,388,O
The,389,O
mutation,389,O
underlying,389,O
myotonic,389,B-SpecificDisease
dystrophy,389,I-SpecificDisease
(,389,O
DM,389,B-SpecificDisease
),389,O
has,389,O
been,389,O
identified,389,O
as,389,O
an,389,O
expansion,389,O
of,389,O
a,389,O
polymorphic,389,O
CTG-repeat,389,O
in,389,O
a,389,O
gene,389,O
encoding,389,O
protein,389,O
kinase,389,O
activity,389,O
.,389,O
Brain,390,O
and,390,O
heart,390,O
transcripts,390,O
of,390,O
the,390,O
DM-kinase,390,O
(,390,O
DMR-B15,390,O
),390,O
gene,390,O
are,390,O
subject,390,O
to,390,O
alternative,390,O
RNA,390,O
splicing,390,O
in,390,O
both,390,O
human,390,O
and,390,O
mouse,390,O
.,390,O
The,391,O
unstable,391,O
[,391,O
CTG,391,O
],391,O
5-30,391,O
motif,391,O
is,391,O
found,391,O
uniquely,391,O
in,391,O
humans,391,O
",",391,O
although,391,O
the,391,O
flanking,391,O
nucleotides,391,O
are,391,O
also,391,O
present,391,O
in,391,O
mouse,391,O
.,391,O
Characterization,392,O
of,392,O
the,392,O
DM,392,B-Modifier
region,392,O
of,392,O
both,392,O
species,392,O
reveals,392,O
another,392,O
active,392,O
gene,392,O
(,392,O
DMR-N9,392,O
),392,O
in,392,O
close,392,O
proximity,392,O
to,392,O
the,392,O
kinase,392,O
gene,392,O
.,392,O
DMR-N9,393,O
transcripts,393,O
",",393,O
mainly,393,O
expressed,393,O
in,393,O
brain,393,O
and,393,O
testis,393,O
",",393,O
possess,393,O
a,393,O
single,393,O
",",393,O
large,393,O
open,393,O
reading,393,O
frame,393,O
",",393,O
but,393,O
the,393,O
function,393,O
of,393,O
its,393,O
protein,393,O
product,393,O
is,393,O
unknown,393,O
.,393,O
Clinical,394,O
manifestation,394,O
of,394,O
DM,394,B-SpecificDisease
may,394,O
be,394,O
caused,394,O
by,394,O
the,394,O
expanded,394,O
CTG-repeat,394,O
compromising,394,O
the,394,O
(,394,O
alternative,394,O
),394,O
expression,394,O
of,394,O
DM-kinase,394,O
or,394,O
DMR-N9,394,O
proteins,394,O
..,394,O
Fragile,395,B-SpecificDisease
X,395,I-SpecificDisease
syndrome,395,I-SpecificDisease
without,395,O
CCG,395,O
amplification,395,O
has,395,O
an,395,O
FMR1,395,O
deletion,395,O
.,395,O
We,396,O
describe,396,O
a,396,O
patient,396,O
with,396,O
typical,396,O
clinical,396,O
features,396,O
of,396,O
the,396,O
fragile,396,B-SpecificDisease
X,396,I-SpecificDisease
syndrome,396,I-SpecificDisease
",",396,O
but,396,O
without,396,O
cytogenetic,396,O
expression,396,O
of,396,O
the,396,O
fragile,396,B-SpecificDisease
X,396,I-SpecificDisease
or,396,O
an,396,O
amplified,396,O
CCG,396,O
trinucleotide,396,O
repeat,396,O
fragment,396,O
.,396,O
The,397,O
patient,397,O
has,397,O
a,397,O
previously,397,O
uncharacterized,397,O
submicroscopic,397,O
deletion,397,O
encompassing,397,O
the,397,O
CCG,397,O
repeat,397,O
",",397,O
the,397,O
entire,397,O
FMR1,397,O
gene,397,O
and,397,O
about,397,O
2,397,O
.,397,O
5,398,O
megabases,398,O
of,398,O
flanking,398,O
sequences,398,O
.,398,O
This,399,O
finding,399,O
confirms,399,O
that,399,O
the,399,O
fragile,399,B-Modifier
X,399,I-Modifier
phenotype,399,O
can,399,O
exist,399,O
",",399,O
without,399,O
amplification,399,O
of,399,O
the,399,O
CCG,399,O
repeat,399,O
or,399,O
cytogenetic,399,O
expression,399,O
of,399,O
the,399,O
fragile,399,B-SpecificDisease
X,399,I-SpecificDisease
",",399,O
and,399,O
that,399,O
fragile,399,B-SpecificDisease
X,399,I-SpecificDisease
syndrome,399,I-SpecificDisease
is,399,O
a,399,O
genetically,399,O
homogeneous,399,O
disorder,399,O
involving,399,O
FMR1,399,O
.,399,O
We,400,O
also,400,O
found,400,O
random,400,O
X-inactivation,400,O
in,400,O
the,400,O
mother,400,O
of,400,O
the,400,O
patient,400,O
who,400,O
was,400,O
shown,400,O
to,400,O
be,400,O
a,400,O
carrier,400,O
of,400,O
this,400,O
deletion,400,O
.,400,O
Cloning,401,O
of,401,O
the,401,O
Huntington,401,B-Modifier
disease,401,I-Modifier
region,401,O
in,401,O
yeast,401,O
artificial,401,O
chromosomes,401,O
.,401,O
The,402,O
gene,402,O
responsible,402,O
for,402,O
Huntington,402,B-SpecificDisease
disease,402,I-SpecificDisease
has,402,O
been,402,O
localized,402,O
to,402,O
a,402,O
2,402,O
.,402,O
5,403,O
million,403,O
base,403,O
pair,403,O
(,403,O
Mb,403,O
),403,O
region,403,O
between,403,O
the,403,O
loci,403,O
D4S10,403,O
and,403,O
D4S168,403,O
on,403,O
the,403,O
short,403,O
arm,403,O
of,403,O
chromosome,403,O
4,403,O
.,403,O
As,404,O
part,404,O
of,404,O
a,404,O
strategy,404,O
to,404,O
clone,404,O
the,404,O
HD,404,B-Modifier
gene,404,O
on,404,O
the,404,O
basis,404,O
of,404,O
its,404,O
chromosomal,404,O
location,404,O
",",404,O
we,404,O
isolated,404,O
genomic,404,O
DNA,404,O
from,404,O
the,404,O
HD,404,B-Modifier
region,404,O
as,404,O
a,404,O
set,404,O
of,404,O
overlapping,404,O
yeast,404,O
artificial,404,O
chromosome,404,O
(,404,O
YAC,404,O
),404,O
clones,404,O
.,404,O
Twenty-eight,405,O
YAC,405,O
clones,405,O
were,405,O
identified,405,O
by,405,O
screening,405,O
human,405,O
YAC,405,O
libraries,405,O
with,405,O
twelve,405,O
PCR-based,405,O
sequence-tagged,405,O
sites,405,O
(,405,O
STSs,405,O
),405,O
from,405,O
the,405,O
region,405,O
.,405,O
We,406,O
assembled,406,O
the,406,O
YAC,406,O
clones,406,O
into,406,O
overlapping,406,O
sets,406,O
by,406,O
hybridizing,406,O
them,406,O
to,406,O
a,406,O
large,406,O
number,406,O
of,406,O
DNA,406,O
probes,406,O
from,406,O
the,406,O
HD,406,B-Modifier
region,406,O
",",406,O
including,406,O
the,406,O
STSs,406,O
.,406,O
In,407,O
addition,407,O
",",407,O
we,407,O
isolated,407,O
the,407,O
ends,407,O
of,407,O
the,407,O
human,407,O
DNA,407,O
inserts,407,O
of,407,O
most,407,O
of,407,O
the,407,O
YAC,407,O
clones,407,O
to,407,O
assist,407,O
in,407,O
the,407,O
construction,407,O
of,407,O
the,407,O
contig,407,O
.,407,O
Although,408,O
almost,408,O
half,408,O
of,408,O
the,408,O
YACs,408,O
appear,408,O
to,408,O
contain,408,O
chimeric,408,O
inserts,408,O
and,408,O
several,408,O
contain,408,O
internal,408,O
deletions,408,O
or,408,O
other,408,O
rearrangements,408,O
",",408,O
we,408,O
were,408,O
able,408,O
to,408,O
obtain,408,O
over,408,O
2,408,O
.,408,O
2,409,O
Mb,409,O
of,409,O
the,409,O
HD,409,B-Modifier
region,409,O
in,409,O
YACs,409,O
",",409,O
including,409,O
one,409,O
continuous,409,O
segment,409,O
of,409,O
2,409,O
.,409,O
0,410,O
Mb,410,O
covering,410,O
the,410,O
region,410,O
that,410,O
most,410,O
likely,410,O
contains,410,O
the,410,O
HD,410,B-Modifier
gene,410,O
.,410,O
Ten,411,O
of,411,O
the,411,O
twenty,411,O
eight,411,O
YAC,411,O
clones,411,O
comprise,411,O
a,411,O
minimal,411,O
set,411,O
spanning,411,O
the,411,O
2,411,O
.,411,O
2,412,O
Mb,412,O
.,412,O
These,413,O
clones,413,O
provide,413,O
reagents,413,O
for,413,O
the,413,O
complete,413,O
characterization,413,O
of,413,O
this,413,O
region,413,O
of,413,O
the,413,O
genome,413,O
and,413,O
for,413,O
the,413,O
eventual,413,O
isolation,413,O
of,413,O
the,413,O
HD,413,B-Modifier
gene,413,O
.,413,O
Characterization,414,O
of,414,O
a,414,O
YAC,414,O
containing,414,O
part,414,O
or,414,O
all,414,O
of,414,O
the,414,O
Norrie,414,B-Modifier
disease,414,I-Modifier
locus,414,O
.,414,O
It,415,O
has,415,O
been,415,O
shown,415,O
from,415,O
pulsed-field,415,O
gel,415,O
electrophoresis,415,O
(,415,O
PFGE,415,O
),415,O
that,415,O
the,415,O
monoamine,415,O
oxidase,415,O
genes,415,O
A,415,O
and,415,O
B,415,O
(,415,O
MAOA,415,O
&,415,O
MAOB,415,O
),415,O
and,415,O
DXS7,415,O
loci,415,O
are,415,O
physically,415,O
very,415,O
close,415,O
.,415,O
We,416,O
have,416,O
therefore,416,O
extended,416,O
studies,416,O
on,416,O
their,416,O
relationship,416,O
through,416,O
the,416,O
characterisation,416,O
of,416,O
a,416,O
650,416,O
kb,416,O
YAC,416,O
isolated,416,O
using,416,O
L1,416,O
.,416,O
28,417,O
(,417,O
recognising,417,O
the,417,O
DXS7,417,O
locus,417,O
),417,O
as,417,O
a,417,O
probe,417,O
.,417,O
Restriction,418,O
mapping,418,O
of,418,O
the,418,O
YAC,418,O
indicates,418,O
that,418,O
it,418,O
contains,418,O
both,418,O
MAOA,418,O
and,418,O
MAOB,418,O
genes,418,O
in,418,O
addition,418,O
to,418,O
the,418,O
DXS7,418,O
locus,418,O
.,418,O
The,419,O
map,419,O
derived,419,O
from,419,O
the,419,O
YL1,419,O
.,419,O
28-YAC,420,O
is,420,O
compatible,420,O
both,420,O
with,420,O
the,420,O
map,420,O
from,420,O
an,420,O
independently,420,O
derived,420,O
YAC,420,O
carrying,420,O
MAOA,420,O
and,420,O
B,420,O
genes,420,O
and,420,O
with,420,O
the,420,O
long,420,O
range,420,O
genomic,420,O
map,420,O
for,420,O
the,420,O
region,420,O
.,420,O
A,421,O
series,421,O
of,421,O
subclones,421,O
prepared,421,O
from,421,O
a,421,O
phage,421,O
library,421,O
(,421,O
lambda,421,O
DASH,421,O
II,421,O
),421,O
of,421,O
the,421,O
YAC,421,O
have,421,O
been,421,O
characterised,421,O
and,421,O
have,421,O
been,421,O
employed,421,O
to,421,O
determine,421,O
the,421,O
end,421,O
point,421,O
of,421,O
the,421,O
deletion,421,O
of,421,O
a,421,O
Norrie,421,B-Modifier
disease,421,I-Modifier
(,421,O
NDP,421,B-Modifier
),421,O
patient,421,O
who,421,O
has,421,O
been,421,O
shown,421,O
to,421,O
lack,421,O
both,421,O
DXS7,421,O
and,421,O
MAO,421,O
coding,421,O
sequences,421,O
.,421,O
The,422,O
pattern,422,O
of,422,O
retention,422,O
of,422,O
subclones,422,O
in,422,O
the,422,O
deletion,422,O
patient,422,O
place,422,O
the,422,O
end,422,O
point,422,O
of,422,O
the,422,O
deletion,422,O
within,422,O
30-130,422,O
kb,422,O
of,422,O
the,422,O
proximal,422,O
end,422,O
of,422,O
the,422,O
YAC,422,O
.,422,O
By,423,O
combining,423,O
the,423,O
data,423,O
with,423,O
established,423,O
recombination,423,O
analysis,423,O
",",423,O
we,423,O
provide,423,O
evidence,423,O
that,423,O
all,423,O
or,423,O
part,423,O
of,423,O
the,423,O
NDP,423,O
lies,423,O
in,423,O
the,423,O
interval,423,O
of,423,O
approximately,423,O
250kb,423,O
within,423,O
the,423,O
YAC,423,O
.,423,O
Both,424,O
mutations,424,O
in,424,O
G6PD,424,O
A-,424,O
are,424,O
necessary,424,O
to,424,O
produce,424,O
the,424,O
G6PD,424,B-Modifier
deficient,424,I-Modifier
phenotype,424,O
.,424,O
The,425,O
high,425,O
prevalence,425,O
of,425,O
glucose,425,B-SpecificDisease
6-phosphate,425,I-SpecificDisease
dehydrogenase,425,I-SpecificDisease
(,425,I-SpecificDisease
G6PD,425,I-SpecificDisease
),425,I-SpecificDisease
deficiency,425,I-SpecificDisease
in,425,O
African,425,O
populations,425,O
is,425,O
due,425,O
almost,425,O
entirely,425,O
to,425,O
the,425,O
enzyme,425,O
variant,425,O
A-,425,O
",",425,O
which,425,O
differs,425,O
from,425,O
the,425,O
wild-type,425,O
G6PD,425,O
B,425,O
by,425,O
two,425,O
amino,425,O
acid,425,O
replacements,425,O
",",425,O
68,425,O
Val,425,O
--,425,O
>,425,O
Met,425,O
and,425,O
126,425,O
Asn,425,O
--,425,O
>,425,O
Asp,425,O
.,425,O
The,426,O
non-deficient,426,O
polymorphic,426,O
variant,426,O
G6PD,426,O
A,426,O
contains,426,O
only,426,O
the,426,O
mutation,426,O
126,426,O
Asn,426,O
--,426,O
>,426,O
Asp,426,O
.,426,O
The,427,O
frequencies,427,O
of,427,O
the,427,O
G6PD,427,O
A,427,O
and,427,O
of,427,O
the,427,O
G6PD,427,O
A-,427,O
genes,427,O
in,427,O
parts,427,O
of,427,O
Africa,427,O
are,427,O
both,427,O
about,427,O
0,427,O
.,427,O
2,428,O
.,428,O
The,429,O
68,429,O
Val,429,O
--,429,O
>,429,O
Met,429,O
mutation,429,O
has,429,O
not,429,O
been,429,O
found,429,O
in,429,O
a,429,O
B,429,O
background,429,O
.,429,O
This,430,O
could,430,O
be,430,O
because,430,O
the,430,O
68,430,O
Val,430,O
--,430,O
>,430,O
Met,430,O
mutation,430,O
happened,430,O
to,430,O
arise,430,O
in,430,O
an,430,O
A,430,O
gene,430,O
in,430,O
the,430,O
first,430,O
instance,430,O
",",430,O
or,430,O
because,430,O
the,430,O
68,430,O
Val,430,O
--,430,O
>,430,O
Met,430,O
mutation,430,O
alone,430,O
is,430,O
not,430,O
sufficient,430,O
to,430,O
cause,430,O
G6PD,430,B-SpecificDisease
deficiency,430,I-SpecificDisease
.,430,O
We,431,O
have,431,O
approached,431,O
this,431,O
question,431,O
by,431,O
producing,431,O
G6PD,431,O
B,431,O
",",431,O
A,431,O
",",431,O
A-,431,O
",",431,O
and,431,O
G6PD,431,O
68,431,O
Val,431,O
--,431,O
>,431,O
Met,431,O
in,431,O
a,431,O
bacterial,431,O
expression,431,O
system,431,O
and,431,O
analysing,431,O
their,431,O
biochemical,431,O
properties,431,O
.,431,O
With,432,O
each,432,O
single,432,O
mutation,432,O
we,432,O
found,432,O
a,432,O
slight,432,O
decrease,432,O
in,432,O
both,432,O
the,432,O
specific,432,O
activity,432,O
and,432,O
the,432,O
yield,432,O
of,432,O
enzyme,432,O
when,432,O
compared,432,O
to,432,O
G6PD,432,O
B,432,O
.,432,O
When,433,O
both,433,O
mutations,433,O
were,433,O
introduced,433,O
together,433,O
",",433,O
there,433,O
was,433,O
a,433,O
roughly,433,O
additive,433,O
effect,433,O
on,433,O
specific,433,O
activity,433,O
",",433,O
but,433,O
a,433,O
much,433,O
more,433,O
drastic,433,O
effect,433,O
on,433,O
enzyme,433,O
yield,433,O
(,433,O
4,433,O
%,433,O
of,433,O
normal,433,O
),433,O
.,433,O
This,434,O
synergistic,434,O
effect,434,O
was,434,O
also,434,O
demonstrated,434,O
on,434,O
thermal,434,O
stability,434,O
",",434,O
especially,434,O
at,434,O
low,434,O
NADP,434,O
concentrations,434,O
.,434,O
Comparable,435,O
results,435,O
were,435,O
produced,435,O
when,435,O
the,435,O
replacement,435,O
119,435,O
Gln,435,O
--,435,O
>,435,O
Glu,435,O
was,435,O
studied,435,O
instead,435,O
of,435,O
126,435,O
Asn,435,O
--,435,O
>,435,O
Asp,435,O
.,435,O
We,436,O
infer,436,O
that,436,O
the,436,O
coexistence,436,O
of,436,O
the,436,O
two,436,O
mutations,436,O
is,436,O
responsible,436,O
for,436,O
enzyme,436,B-SpecificDisease
deficiency,436,I-SpecificDisease
in,436,I-SpecificDisease
G6PD,436,I-SpecificDisease
A-,436,O
because,436,O
they,436,O
act,436,O
synergistically,436,O
in,436,O
causing,436,O
instability,436,O
of,436,O
the,436,O
enzyme,436,O
.,436,O
Small,437,O
nuclear,437,O
ribonucleoprotein,437,O
polypeptide,437,O
N,437,O
(,437,O
SNRPN,437,O
),437,O
",",437,O
an,437,O
expressed,437,O
gene,437,O
in,437,O
the,437,O
Prader-Willi,437,B-Modifier
syndrome,437,I-Modifier
critical,437,O
region,437,O
.,437,O
Prader-Willi,438,B-SpecificDisease
syndrome,438,I-SpecificDisease
(,438,O
PWS,438,B-SpecificDisease
),438,O
is,438,O
associated,438,O
with,438,O
paternally,438,O
derived,438,O
chromosomal,438,O
deletions,438,O
in,438,O
region,438,O
15q11-13,438,O
or,438,O
with,438,O
maternal,438,B-SpecificDisease
disomy,438,I-SpecificDisease
for,438,I-SpecificDisease
chromosome,438,I-SpecificDisease
15,438,I-SpecificDisease
.,438,O
Therefore,439,O
",",439,O
loss,439,O
of,439,O
the,439,O
expressed,439,O
paternal,439,O
alleles,439,O
of,439,O
maternally,439,O
imprinted,439,O
genes,439,O
must,439,O
be,439,O
responsible,439,O
for,439,O
the,439,O
PWS,439,B-Modifier
phenotype,439,O
.,439,O
We,440,O
have,440,O
mapped,440,O
the,440,O
gene,440,O
encoding,440,O
the,440,O
small,440,O
nuclear,440,O
RNA,440,O
associated,440,O
polypeptide,440,O
SmN,440,O
(,440,O
SNRPN,440,O
),440,O
to,440,O
human,440,O
chromosome,440,O
15q12,440,O
and,440,O
a,440,O
processed,440,O
pseudogene,440,O
SNRPNP1,440,O
to,440,O
chromosome,440,O
region,440,O
6pter-p21,440,O
.,440,O
Furthermore,441,O
",",441,O
SNRPN,441,O
was,441,O
mapped,441,O
to,441,O
the,441,O
minimal,441,O
deletion,441,O
interval,441,O
that,441,O
is,441,O
critical,441,O
for,441,O
PWS,441,B-SpecificDisease
.,441,O
The,442,O
fact,442,O
that,442,O
the,442,O
mouse,442,O
Snrpn,442,O
gene,442,O
is,442,O
maternally,442,O
imprinted,442,O
in,442,O
brain,442,O
suggests,442,O
that,442,O
loss,442,O
of,442,O
the,442,O
paternally,442,O
derived,442,O
SNRPN,442,O
allele,442,O
may,442,O
be,442,O
involved,442,O
in,442,O
the,442,O
PWS,442,B-Modifier
phenotype,442,O
..,442,O
The,443,O
presence,443,O
of,443,O
two,443,O
different,443,O
infantile,443,O
Tay-Sachs,443,B-Modifier
disease,443,I-Modifier
mutations,443,O
in,443,O
a,443,O
Cajun,443,O
population,443,O
.,443,O
A,444,O
study,444,O
was,444,O
undertaken,444,O
to,444,O
characterize,444,O
the,444,O
mutation,444,O
(,444,O
s,444,O
),444,O
responsible,444,O
for,444,O
Tay-Sachs,444,B-SpecificDisease
disease,444,I-SpecificDisease
(,444,O
TSD,444,B-SpecificDisease
),444,O
in,444,O
a,444,O
Cajun,444,O
population,444,O
in,444,O
southwest,444,O
Louisiana,444,O
and,444,O
to,444,O
identify,444,O
the,444,O
origins,444,O
of,444,O
these,444,O
mutations,444,O
.,444,O
Eleven,445,O
of,445,O
12,445,O
infantile,445,O
TSD,445,B-Modifier
alleles,445,O
examined,445,O
in,445,O
six,445,O
families,445,O
had,445,O
the,445,O
beta-hexosaminidase,445,O
A,445,O
(,445,O
Hex,445,O
A,445,O
),445,O
alpha-subunit,445,O
exon,445,O
11,445,O
insertion,445,O
mutation,445,O
that,445,O
is,445,O
present,445,O
in,445,O
approximately,445,O
70,445,O
%,445,O
of,445,O
Ashkenazi,445,O
Jewish,445,O
TSD,445,B-Modifier
heterozygotes,445,O
.,445,O
The,446,O
mutation,446,O
in,446,O
the,446,O
remaining,446,O
allele,446,O
was,446,O
a,446,O
single-base,446,O
transition,446,O
in,446,O
the,446,O
donor,446,O
splice,446,O
site,446,O
of,446,O
the,446,O
alpha-subunit,446,O
intron,446,O
9,446,O
.,446,O
To,447,O
determine,447,O
the,447,O
origins,447,O
of,447,O
these,447,O
two,447,O
mutations,447,O
in,447,O
the,447,O
Cajun,447,O
population,447,O
",",447,O
the,447,O
TSD,447,B-Modifier
carrier,447,O
status,447,O
was,447,O
enzymatically,447,O
determined,447,O
for,447,O
90,447,O
members,447,O
of,447,O
four,447,O
of,447,O
the,447,O
six,447,O
families,447,O
",",447,O
and,447,O
extensive,447,O
pedigrees,447,O
were,447,O
constructed,447,O
for,447,O
all,447,O
carriers,447,O
.,447,O
A,448,O
single,448,O
ancestral,448,O
couple,448,O
from,448,O
France,448,O
was,448,O
found,448,O
to,448,O
be,448,O
common,448,O
to,448,O
most,448,O
of,448,O
the,448,O
carriers,448,O
of,448,O
the,448,O
exon,448,O
11,448,O
insertion,448,O
.,448,O
Pedigree,449,O
data,449,O
suggest,449,O
that,449,O
this,449,O
mutation,449,O
has,449,O
been,449,O
in,449,O
the,449,O
Cajun,449,O
population,449,O
since,449,O
its,449,O
founding,449,O
over,449,O
2,449,O
centuries,449,O
ago,449,O
and,449,O
that,449,O
it,449,O
may,449,O
be,449,O
widely,449,O
distributed,449,O
within,449,O
the,449,O
population,449,O
.,449,O
In,450,O
contrast,450,O
",",450,O
the,450,O
intron,450,O
9,450,O
mutation,450,O
apparently,450,O
was,450,O
introduced,450,O
within,450,O
the,450,O
last,450,O
century,450,O
and,450,O
probably,450,O
is,450,O
limited,450,O
to,450,O
a,450,O
few,450,O
Louisiana,450,O
families,450,O
..,450,O
Mutations,451,O
in,451,O
the,451,O
candidate,451,O
gene,451,O
for,451,O
Norrie,451,B-SpecificDisease
disease,451,I-SpecificDisease
.,451,O
Recently,452,O
",",452,O
we,452,O
and,452,O
others,452,O
have,452,O
isolated,452,O
a,452,O
candidate,452,O
gene,452,O
for,452,O
X,452,B-SpecificDisease
linked,452,I-SpecificDisease
Norrie,452,I-SpecificDisease
disease,452,I-SpecificDisease
(,452,O
ND,452,B-SpecificDisease
),452,O
which,452,O
was,452,O
found,452,O
to,452,O
be,452,O
deleted,452,O
or,452,O
disrupted,452,O
in,452,O
several,452,O
patients,452,O
.,452,O
As,453,O
a,453,O
prerequisite,453,O
for,453,O
the,453,O
identification,453,O
of,453,O
point,453,O
mutations,453,O
in,453,O
the,453,O
ND,453,B-Modifier
gene,453,O
we,453,O
have,453,O
established,453,O
the,453,O
exon-intron,453,O
structure,453,O
of,453,O
this,453,O
gene,453,O
.,453,O
In,454,O
17,454,O
unrelated,454,O
patients,454,O
and,454,O
15,454,O
controls,454,O
",",454,O
PCR,454,O
products,454,O
derived,454,O
from,454,O
the,454,O
promoter,454,O
region,454,O
",",454,O
exons,454,O
1,454,O
and,454,O
2,454,O
as,454,O
well,454,O
as,454,O
the,454,O
coding,454,O
part,454,O
of,454,O
exon,454,O
3,454,O
were,454,O
analysed,454,O
with,454,O
the,454,O
single,454,O
strand,454,O
conformation,454,O
polymorphism,454,O
(,454,O
SSCP,454,O
),454,O
technique,454,O
.,454,O
In,455,O
12,455,O
patients,455,O
altered,455,O
PCR,455,O
fragments,455,O
were,455,O
detected,455,O
which,455,O
were,455,O
studied,455,O
in,455,O
detail,455,O
by,455,O
direct,455,O
sequencing,455,O
.,455,O
Eleven,456,O
different,456,O
mutations,456,O
were,456,O
found,456,O
",",456,O
and,456,O
all,456,O
but,456,O
one,456,O
are,456,O
likely,456,O
to,456,O
give,456,O
rise,456,O
to,456,O
significant,456,O
structural,456,O
changes,456,O
in,456,O
the,456,O
predicted,456,O
protein,456,O
.,456,O
These,457,O
findings,457,O
",",457,O
and,457,O
the,457,O
absence,457,O
of,457,O
functionally,457,O
relevant,457,O
base,457,O
changes,457,O
in,457,O
healthy,457,O
controls,457,O
",",457,O
emphasize,457,O
the,457,O
causal,457,O
role,457,O
of,457,O
this,457,O
candidate,457,O
gene,457,O
in,457,O
Norrie,457,B-SpecificDisease
disease,457,I-SpecificDisease
and,457,O
pave,457,O
the,457,O
way,457,O
for,457,O
reliable,457,O
diagnosis,457,O
and,457,O
carrier,457,O
detection,457,O
..,457,O
Detection,458,O
of,458,O
a,458,O
nonsense,458,O
mutation,458,O
in,458,O
the,458,O
dystrophin,458,O
gene,458,O
by,458,O
multiple,458,O
SSCP,458,O
.,458,O
A,459,O
combination,459,O
of,459,O
multiplex,459,O
PCR,459,O
with,459,O
the,459,O
single,459,O
strand,459,O
conformation,459,O
polymorphism,459,O
(,459,O
SSCP,459,O
),459,O
technique,459,O
was,459,O
employed,459,O
to,459,O
screen,459,O
for,459,O
point,459,O
mutations,459,O
in,459,O
the,459,O
human,459,O
dystrophin,459,O
gene,459,O
.,459,O
Co-amplification,460,O
of,460,O
11,460,O
exons,460,O
from,460,O
genomic,460,O
DNA,460,O
of,460,O
Duchenne,460,O
and,460,O
Becker,460,O
muscular,460,O
dystrophy,460,O
(,460,O
DMD/BMD,460,B-Modifier
),460,O
patients,460,O
with,460,O
no,460,O
deletion,460,O
or,460,O
duplication,460,O
was,460,O
performed,460,O
and,460,O
the,460,O
samples,460,O
subjected,460,O
to,460,O
multiple,460,O
SSCP,460,O
analysis,460,O
.,460,O
We,461,O
report,461,O
the,461,O
case,461,O
of,461,O
a,461,O
nonsense,461,O
mutation,461,O
in,461,O
a,461,O
Duchenne,461,B-Modifier
patient,461,O
identified,461,O
by,461,O
this,461,O
approach,461,O
.,461,O
The,462,O
mutation,462,O
introduces,462,O
a,462,O
termination,462,O
codon,462,O
within,462,O
exon,462,O
8,462,O
of,462,O
the,462,O
dystrophin,462,O
gene,462,O
.,462,O
It,463,O
is,463,O
predicted,463,O
to,463,O
cause,463,O
a,463,O
very,463,O
premature,463,O
translational,463,O
termination,463,O
accounting,463,O
for,463,O
the,463,O
severe,463,O
phenotype,463,O
observed,463,O
.,463,O
The,464,O
patient,464,O
inherited,464,O
this,464,O
mutation,464,O
from,464,O
his,464,O
mother,464,O
.,464,O
In,465,O
addition,465,O
the,465,O
analysis,465,O
revealed,465,O
5,465,O
polymorphisms,465,O
useful,465,O
for,465,O
internal,465,O
control,465,O
..,465,O
Proliferation-related,466,O
expression,466,O
of,466,O
p19/nm23,466,O
nucleoside,466,O
diphosphate,466,O
kinase,466,O
.,466,O
High,467,O
level,467,O
expression,467,O
of,467,O
the,467,O
nm23-H1,467,O
gene,467,O
",",467,O
which,467,O
encodes,467,O
for,467,O
a,467,O
nucleoside,467,O
diphosphate,467,O
kinase,467,O
",",467,O
has,467,O
been,467,O
found,467,O
to,467,O
correlate,467,O
with,467,O
diminished,467,O
metastasis,467,O
in,467,O
some,467,O
tumors,467,B-DiseaseClass
but,467,O
not,467,O
in,467,O
others,467,O
.,467,O
We,468,O
have,468,O
previously,468,O
identified,468,O
the,468,O
protein,468,O
product,468,O
of,468,O
the,468,O
nm23-H1,468,O
gene,468,O
in,468,O
two-dimensional,468,O
electrophoretic,468,O
gels,468,O
and,468,O
have,468,O
designated,468,O
it,468,O
p19/nm23,468,O
.,468,O
In,469,O
neuroblastoma,469,B-SpecificDisease
",",469,O
higher,469,O
levels,469,O
of,469,O
p19/nm23,469,O
",",469,O
which,469,O
are,469,O
associated,469,O
with,469,O
amplification,469,O
of,469,O
the,469,O
N-myc,469,O
oncogene,469,O
",",469,O
large,469,O
tumor,469,B-Modifier
mass,469,O
",",469,O
and,469,O
metastasis,469,O
",",469,O
were,469,O
observed,469,O
in,469,O
advanced,469,O
stage,469,O
tumors,469,B-DiseaseClass
compared,469,O
with,469,O
limited,469,O
stage,469,O
disease,469,O
.,469,O
Because,470,O
of,470,O
the,470,O
variable,470,O
expression,470,O
of,470,O
nm23-H1,470,O
in,470,O
different,470,O
tumors,470,B-DiseaseClass
",",470,O
we,470,O
have,470,O
investigated,470,O
the,470,O
relationship,470,O
between,470,O
amounts,470,O
of,470,O
the,470,O
protein,470,O
and,470,O
cell,470,O
proliferation,470,O
.,470,O
The,471,O
levels,471,O
of,471,O
p19/nm23,471,O
were,471,O
compared,471,O
between,471,O
resting,471,O
and,471,O
mitotically,471,O
stimulated,471,O
normal,471,O
human,471,O
PBLs,471,O
and,471,O
in,471,O
leukemia,471,B-Modifier
cells,471,O
.,471,O
The,472,O
amount,472,O
of,472,O
p19/nm23,472,O
increased,472,O
in,472,O
normal,472,O
lymphocytes,472,O
in,472,O
response,472,O
to,472,O
mitotic,472,O
stimulation,472,O
and,472,O
paralleled,472,O
the,472,O
increase,472,O
in,472,O
DNA,472,O
synthesis,472,O
.,472,O
In,473,O
leukemia,473,B-Modifier
cells,473,O
obtained,473,O
from,473,O
patients,473,O
with,473,O
different,473,O
subtypes,473,O
of,473,O
acute,473,B-SpecificDisease
leukemia,473,I-SpecificDisease
",",473,O
p19/nm23,473,O
levels,473,O
were,473,O
also,473,O
increased,473,O
relative,473,O
to,473,O
resting,473,O
normal,473,O
lymphocytes,473,O
.,473,O
Treatment,474,O
of,474,O
mitotically,474,O
stimulated,474,O
lymphocytes,474,O
with,474,O
cyclosporin,474,O
",",474,O
which,474,O
inhibits,474,O
proliferation,474,O
",",474,O
blocked,474,O
the,474,O
increase,474,O
in,474,O
p19/nm23,474,O
;,474,O
treatment,474,O
of,474,O
the,474,O
leukemia,474,B-Modifier
cell,474,O
line,474,O
HL-60,474,O
with,474,O
dimethylsulfoxide,474,O
",",474,O
which,474,O
induces,474,O
terminal,474,O
differentiation,474,O
",",474,O
resulted,474,O
in,474,O
diminished,474,O
levels,474,O
of,474,O
p19/nm23,474,O
.,474,O
Our,475,O
data,475,O
therefore,475,O
provide,475,O
evidence,475,O
that,475,O
nm23-H1,475,O
expression,475,O
is,475,O
related,475,O
to,475,O
cell,475,O
proliferative,475,O
activity,475,O
..,475,O
An,476,O
intrachromosomal,476,O
insertion,476,O
causing,476,O
5q22,476,O
deletion,476,O
and,476,O
familial,476,B-SpecificDisease
adenomatous,476,I-SpecificDisease
polyposis,476,I-SpecificDisease
coli,476,I-SpecificDisease
in,476,O
two,476,O
generations,476,O
.,476,O
We,477,O
report,477,O
familial,477,B-SpecificDisease
adenomatous,477,I-SpecificDisease
polyposis,477,I-SpecificDisease
coli,477,I-SpecificDisease
(,477,O
FAPC,477,B-SpecificDisease
),477,O
with,477,O
epidermoid,477,B-SpecificDisease
cysts,477,I-SpecificDisease
",",477,O
osteomata,477,B-SpecificDisease
",",477,O
and,477,O
areas,477,O
of,477,O
congenital,477,B-SpecificDisease
hypertrophy,477,I-SpecificDisease
of,477,I-SpecificDisease
the,477,I-SpecificDisease
retinal,477,I-SpecificDisease
pigment,477,I-SpecificDisease
epithelium,477,I-SpecificDisease
(,477,O
CHRPEs,477,B-SpecificDisease
),477,O
in,477,O
a,477,O
male,477,O
patient,477,O
and,477,O
his,477,O
maternal,477,O
aunt,477,O
",",477,O
both,477,O
of,477,O
whom,477,O
suffered,477,O
a,477,O
mild,477,O
to,477,O
moderate,477,O
degree,477,O
of,477,O
mental,477,B-DiseaseClass
handicap,477,I-DiseaseClass
.,477,O
Both,478,O
had,478,O
an,478,O
interstitial,478,O
deletion,478,O
of,478,O
the,478,O
long,478,O
arm,478,O
of,478,O
chromosome,478,O
5,478,O
(,478,O
del,478,O
(,478,O
5,478,O
),478,O
(,478,O
q22q23,478,O
.,478,O
2,479,O
),479,O
),479,O
.,479,O
Two,480,O
other,480,O
normal,480,O
family,480,O
members,480,O
had,480,O
the,480,O
underlying,480,O
direct,480,O
insertion,480,O
of,480,O
chromosome,480,O
5,480,O
(,480,O
dir,480,O
ins,480,O
(,480,O
5,480,O
),480,O
(,480,O
q31,480,O
.,480,O
3q22q23,481,O
3q22q23,481,O
.,481,O
2,482,O
),482,O
),482,O
.,482,O
Molecular,483,O
genetic,483,O
and,483,O
fluorescent,483,O
hybridisation,483,O
studies,483,O
have,483,O
shown,483,O
that,483,O
loci,483,O
D5S37,483,O
and,483,O
D5S98,483,O
are,483,O
outside,483,O
the,483,O
deletion,483,O
whereas,483,O
loci,483,O
detected,483,O
by,483,O
probes,483,O
EF5,483,O
.,483,O
44,484,O
and,484,O
YN5,484,O
.,484,O
48,485,O
are,485,O
lost,485,O
.,485,O
As,486,O
expected,486,O
",",486,O
the,486,O
molecular,486,O
analyses,486,O
indicate,486,O
loss,486,O
of,486,O
one,486,O
allele,486,O
at,486,O
the,486,O
MCC,486,O
and,486,O
APC,486,B-Modifier
loci,486,O
.,486,O
The,487,O
APC,487,B-Modifier
gene,487,O
is,487,O
located,487,O
within,487,O
band,487,O
5q22,487,O
.,487,O
Familial,488,O
direct,488,O
insertions,488,O
should,488,O
be,488,O
considered,488,O
as,488,O
a,488,O
cause,488,O
of,488,O
recurrent,488,O
microdeletion,488,O
syndromes,488,O
.,488,O
Chromosome,489,O
mapping,489,O
of,489,O
the,489,O
rod,489,O
photoreceptor,489,O
cGMP,489,O
phosphodiesterase,489,O
beta-subunit,489,O
gene,489,O
in,489,O
mouse,489,O
and,489,O
human,489,O
:,489,O
tight,489,O
linkage,489,O
to,489,O
the,489,O
Huntington,489,B-Modifier
disease,489,I-Modifier
region,489,O
(,489,O
4p16.3,489,O
),489,O
.,489,O
The,490,O
retinal,490,B-Modifier
degeneration,490,I-Modifier
mouse,490,O
(,490,O
gene,490,O
symbol,490,O
",",490,O
rd,490,O
),490,O
is,490,O
an,490,O
animal,490,O
model,490,O
for,490,O
certain,490,O
forms,490,O
of,490,O
human,490,O
hereditary,490,B-DiseaseClass
retinopathies,490,I-DiseaseClass
.,490,O
Recent,491,O
findings,491,O
of,491,O
a,491,O
nonsense,491,O
mutation,491,O
in,491,O
the,491,O
rd,491,O
mouse,491,O
PDE,491,O
beta-subunit,491,O
gene,491,O
(,491,O
Pdeb,491,O
),491,O
prompted,491,O
us,491,O
to,491,O
investigate,491,O
the,491,O
chromosome,491,O
locations,491,O
of,491,O
the,491,O
mouse,491,O
and,491,O
human,491,O
genes,491,O
.,491,O
We,492,O
have,492,O
utilized,492,O
backcross,492,O
analysis,492,O
in,492,O
mice,492,O
to,492,O
verify,492,O
and,492,O
define,492,O
more,492,O
precisely,492,O
the,492,O
location,492,O
of,492,O
the,492,O
Pdeb,492,O
locus,492,O
6,492,O
.,492,O
1,493,O
+/-,493,O
2,493,O
.,493,O
3,494,O
cM,494,O
distal,494,O
of,494,O
Mgsa,494,O
on,494,O
mouse,494,O
chromosome,494,O
5,494,O
.,494,O
We,495,O
have,495,O
determined,495,O
that,495,O
the,495,O
human,495,O
gene,495,O
(,495,O
PDEB,495,O
),495,O
maps,495,O
to,495,O
4p16,495,O
.,495,O
3,496,O
",",496,O
very,496,O
close,496,O
to,496,O
the,496,O
Huntington,496,B-Modifier
disease,496,I-Modifier
(,496,O
HD,496,B-Modifier
),496,O
region,496,O
.,496,O
Analysis,497,O
of,497,O
the,497,O
comparative,497,O
map,497,O
for,497,O
mice,497,O
and,497,O
humans,497,O
shows,497,O
that,497,O
the,497,O
mouse,497,O
homologue,497,O
of,497,O
the,497,O
HD,497,B-Modifier
gene,497,O
will,497,O
reside,497,O
on,497,O
chromosome,497,O
5,497,O
.,497,O
Linkage,498,O
of,498,O
the,498,O
mouse,498,O
Pdeb,498,O
locus,498,O
with,498,O
other,498,O
homologues,498,O
in,498,O
the,498,O
human,498,O
4p16,498,O
.,498,O
3,499,O
region,499,O
is,499,O
maintained,499,O
but,499,O
gene,499,O
order,499,O
is,499,O
not,499,O
",",499,O
suggesting,499,O
at,499,O
least,499,O
three,499,O
possible,499,O
sites,499,O
for,499,O
the,499,O
corresponding,499,O
mouse,499,O
HD,499,B-Modifier
gene,499,O
.,499,O
Coincident,500,O
Kaposi,500,B-SpecificDisease
sarcoma,500,I-SpecificDisease
and,500,O
T-cell,500,B-SpecificDisease
lymphoma,500,I-SpecificDisease
in,500,O
a,500,O
patient,500,O
with,500,O
the,500,O
Wiskott-Aldrich,500,B-SpecificDisease
syndrome,500,I-SpecificDisease
.,500,O
A,501,O
24,501,O
year,501,O
old,501,O
male,501,O
with,501,O
a,501,O
history,501,O
of,501,O
eczema,501,B-DiseaseClass
",",501,O
recurrent,501,O
mild,501,O
infections,501,O
",",501,O
and,501,O
thrombocytopenia,501,B-SpecificDisease
consistent,501,O
with,501,O
the,501,O
Wiskott-Aldrich,501,B-SpecificDisease
syndrome,501,I-SpecificDisease
(,501,O
WAS,501,B-SpecificDisease
),501,O
presented,501,O
with,501,O
a,501,O
mediastinal,501,O
mass,501,O
",",501,O
generalized,501,O
lymphadenopathy,501,B-SpecificDisease
",",501,O
splenomegaly,501,B-SpecificDisease
",",501,O
and,501,O
severe,501,O
thrombocytopenia,501,B-SpecificDisease
.,501,O
Studies,502,O
of,502,O
immune,502,O
function,502,O
including,502,O
immunoglobulin,502,O
levels,502,O
and,502,O
T-cell,502,O
subsets,502,O
were,502,O
normal,502,O
.,502,O
Furthermore,503,O
",",503,O
his,503,O
T,503,O
lymphocytes,503,O
proliferated,503,O
normally,503,O
in,503,O
response,503,O
to,503,O
phytohemagglutinin,503,O
",",503,O
concanavalin,503,O
A,503,O
",",503,O
and,503,O
the,503,O
combination,503,O
of,503,O
neuraminidase/galactose,503,O
oxidase,503,O
.,503,O
However,504,O
",",504,O
their,504,O
proliferative,504,O
responses,504,O
to,504,O
anti-CD43,504,O
antibody,504,O
and,504,O
periodate,504,O
were,504,O
diminished,504,O
",",504,O
consistent,504,O
with,504,O
the,504,O
clinical,504,O
diagnosis,504,O
of,504,O
WAS,504,B-SpecificDisease
.,504,O
An,505,O
initial,505,O
inguinal,505,O
lymph,505,O
node,505,O
biopsy,505,O
surprisingly,505,O
revealed,505,O
Kaposi,505,B-SpecificDisease
sarcoma,505,I-SpecificDisease
.,505,O
However,506,O
",",506,O
following,506,O
splenectomy,506,O
to,506,O
increase,506,O
the,506,O
platelet,506,O
count,506,O
",",506,O
biopsy,506,O
of,506,O
the,506,O
mediastinal,506,O
mass,506,O
revealed,506,O
T-cell,506,B-SpecificDisease
large,506,I-SpecificDisease
cell,506,I-SpecificDisease
lymphoma,506,I-SpecificDisease
.,506,O
Studies,507,O
of,507,O
biopsied,507,O
tissue,507,O
for,507,O
the,507,O
presence,507,O
of,507,O
Epstein-Barr,507,B-SpecificDisease
virus,507,I-SpecificDisease
and,507,O
cytomegalovirus,507,B-SpecificDisease
were,507,O
negative,507,O
",",507,O
as,507,O
were,507,O
studies,507,O
of,507,O
blood,507,O
",",507,O
including,507,O
the,507,O
polymerase,507,O
chain,507,O
reaction,507,O
",",507,O
for,507,O
the,507,O
presence,507,O
of,507,O
the,507,O
human,507,B-SpecificDisease
immunodeficiency,507,I-SpecificDisease
virus,507,I-SpecificDisease
(,507,O
HIV,507,B-SpecificDisease
),507,O
.,507,O
This,508,O
is,508,O
the,508,O
first,508,O
report,508,O
of,508,O
Kaposi,508,B-SpecificDisease
sarcoma,508,I-SpecificDisease
arising,508,O
in,508,O
a,508,O
patient,508,O
with,508,O
a,508,O
congenital,508,B-DiseaseClass
immunodeficiency,508,I-DiseaseClass
syndrome,508,I-DiseaseClass
.,508,O
Although,509,O
Kaposi,509,B-SpecificDisease
sarcoma,509,I-SpecificDisease
can,509,O
arise,509,O
in,509,O
the,509,O
face,509,O
of,509,O
the,509,O
severe,509,O
immunosuppression,509,O
that,509,O
follows,509,O
allograft,509,O
transplantation,509,O
and,509,O
in,509,O
patients,509,O
infected,509,O
with,509,O
HIV,509,B-SpecificDisease
",",509,O
we,509,O
postulate,509,O
that,509,O
longevity,509,O
in,509,O
the,509,O
face,509,O
of,509,O
mild,509,O
immunosuppression,509,O
was,509,O
the,509,O
major,509,O
factor,509,O
in,509,O
the,509,O
development,509,O
of,509,O
Kaposi,509,B-SpecificDisease
sarcoma,509,I-SpecificDisease
in,509,O
this,509,O
patient,509,O
..,509,O
The,510,O
APC,510,B-Modifier
gene,510,O
",",510,O
responsible,510,O
for,510,O
familial,510,B-SpecificDisease
adenomatous,510,I-SpecificDisease
polyposis,510,I-SpecificDisease
",",510,O
is,510,O
mutated,510,O
in,510,O
human,510,O
gastric,510,B-SpecificDisease
cancer,510,I-SpecificDisease
.,510,O
Although,511,O
gastric,511,B-SpecificDisease
cancer,511,I-SpecificDisease
is,511,O
the,511,O
most,511,O
common,511,O
cancer,511,B-DiseaseClass
in,511,O
the,511,O
world,511,O
",",511,O
genetic,511,O
changes,511,O
during,511,O
its,511,O
carcinogenesis,511,O
are,511,O
not,511,O
well,511,O
understood,511,O
.,511,O
Since,512,O
some,512,O
gastric,512,B-SpecificDisease
cancers,512,I-SpecificDisease
are,512,O
considered,512,O
to,512,O
originate,512,O
from,512,O
the,512,O
intestinal,512,O
metaplasia,512,O
",",512,O
it,512,O
is,512,O
likely,512,O
that,512,O
the,512,O
adenomatous,512,B-Modifier
polyposis,512,I-Modifier
coli,512,I-Modifier
(,512,O
APC,512,B-Modifier
),512,O
gene,512,O
",",512,O
the,512,O
mutation,512,O
of,512,O
which,512,O
causes,512,O
adenomatous,512,B-SpecificDisease
polyps,512,I-SpecificDisease
in,512,I-SpecificDisease
the,512,I-SpecificDisease
colon,512,I-SpecificDisease
",",512,O
is,512,O
associated,512,O
with,512,O
carcinogenesis,512,O
of,512,O
gastric,512,B-SpecificDisease
cancer,512,I-SpecificDisease
.,512,O
Based,513,O
on,513,O
this,513,O
idea,513,O
",",513,O
DNAs,513,O
isolated,513,O
from,513,O
gastric,513,B-SpecificDisease
cancers,513,I-SpecificDisease
were,513,O
examined,513,O
by,513,O
means,513,O
of,513,O
a,513,O
RNase,513,O
protection,513,O
analysis,513,O
coupled,513,O
with,513,O
polymerase,513,O
chain,513,O
reaction,513,O
followed,513,O
by,513,O
sequencing,513,O
of,513,O
the,513,O
polymerase,513,O
chain,513,O
reaction,513,O
products,513,O
.,513,O
By,514,O
screening,514,O
nearly,514,O
one-half,514,O
of,514,O
the,514,O
coding,514,O
region,514,O
of,514,O
the,514,O
APC,514,B-Modifier
gene,514,O
in,514,O
44,514,O
tumors,514,B-DiseaseClass
",",514,O
somatic,514,O
mutations,514,O
were,514,O
detected,514,O
in,514,O
three,514,O
tumors,514,B-DiseaseClass
a,514,O
missense,514,O
mutation,514,O
",",514,O
a,514,O
nonsense,514,O
mutation,514,O
",",514,O
and,514,O
a,514,O
5-base,514,O
pair,514,O
deletion,514,O
resulting,514,O
in,514,O
a,514,O
frame,514,O
shift,514,O
which,514,O
causes,514,O
truncation,514,O
of,514,O
the,514,O
gene,514,O
product,514,O
.,514,O
These,515,O
results,515,O
suggest,515,O
that,515,O
the,515,O
mutation,515,O
of,515,O
the,515,O
APC,515,B-Modifier
gene,515,O
also,515,O
plays,515,O
an,515,O
important,515,O
role,515,O
during,515,O
the,515,O
carcinogenesis,515,O
of,515,O
at,515,O
least,515,O
some,515,O
gastric,515,B-SpecificDisease
cancers,515,I-SpecificDisease
..,515,O
A,516,O
71-kilodalton,516,O
protein,516,O
is,516,O
a,516,O
major,516,O
product,516,O
of,516,O
the,516,O
Duchenne,516,B-Modifier
muscular,516,I-Modifier
dystrophy,516,I-Modifier
gene,516,O
in,516,O
brain,516,O
and,516,O
other,516,O
nonmuscle,516,O
tissues,516,O
.,516,O
The,517,O
known,517,O
Duchenne,517,B-Modifier
muscular,517,I-Modifier
dystrophy,517,I-Modifier
(,517,O
DMD,517,B-Modifier
),517,O
gene,517,O
products,517,O
",",517,O
the,517,O
muscle-,517,O
and,517,O
brain-type,517,O
dystrophin,517,O
isoforms,517,O
",",517,O
are,517,O
427-kDa,517,O
proteins,517,O
translated,517,O
from,517,O
14-kilobase,517,O
(,517,O
kb,517,O
),517,O
mRNAs,517,O
.,517,O
Recently,518,O
we,518,O
described,518,O
a,518,O
6,518,O
.,518,O
5-kb,519,O
mRNA,519,O
that,519,O
also,519,O
is,519,O
transcribed,519,O
from,519,O
the,519,O
DMD,519,B-Modifier
gene,519,O
.,519,O
Cloning,520,O
and,520,O
in,520,O
vitro,520,O
transcription,520,O
and,520,O
translation,520,O
of,520,O
the,520,O
entire,520,O
coding,520,O
region,520,O
show,520,O
that,520,O
the,520,O
6,520,O
.,520,O
5-kb,521,O
mRNA,521,O
encodes,521,O
a,521,O
70,521,O
.,521,O
8-kDa,522,O
protein,522,O
that,522,O
is,522,O
a,522,O
major,522,O
product,522,O
of,522,O
the,522,O
DMD,522,B-Modifier
gene,522,O
.,522,O
It,523,O
contains,523,O
the,523,O
C-terminal,523,O
and,523,O
the,523,O
cysteine-rich,523,O
domains,523,O
of,523,O
dystrophin,523,O
",",523,O
seven,523,O
additional,523,O
amino,523,O
acids,523,O
at,523,O
the,523,O
N,523,O
terminus,523,O
",",523,O
and,523,O
some,523,O
modifications,523,O
formed,523,O
by,523,O
alternative,523,O
splicing,523,O
in,523,O
the,523,O
C-terminal,523,O
domain,523,O
.,523,O
It,524,O
lacks,524,O
the,524,O
entire,524,O
large,524,O
domain,524,O
of,524,O
spectrin-like,524,O
repeats,524,O
and,524,O
the,524,O
actin-binding,524,O
N-terminal,524,O
domain,524,O
of,524,O
dystrophin,524,O
.,524,O
This,525,O
protein,525,O
is,525,O
the,525,O
major,525,O
DMD,525,B-Modifier
gene,525,O
product,525,O
in,525,O
brain,525,O
and,525,O
other,525,O
nonmuscle,525,O
tissues,525,O
but,525,O
is,525,O
undetectable,525,O
in,525,O
skeletal,525,O
muscle,525,O
extracts,525,O
.,525,O
Correlation,526,O
between,526,O
the,526,O
location,526,O
of,526,O
germ-line,526,O
mutations,526,O
in,526,O
the,526,O
APC,526,B-Modifier
gene,526,O
and,526,O
the,526,O
number,526,O
of,526,O
colorectal,526,B-SpecificDisease
polyps,526,I-SpecificDisease
in,526,O
familial,526,B-Modifier
adenomatous,526,I-Modifier
polyposis,526,I-Modifier
patients,526,O
.,526,O
Recently,527,O
we,527,O
have,527,O
isolated,527,O
the,527,O
adenomatous,527,B-Modifier
polyposis,527,I-Modifier
coli,527,I-Modifier
(,527,O
APC,527,B-Modifier
),527,O
gene,527,O
which,527,O
causes,527,O
familial,527,B-SpecificDisease
adenomatous,527,I-SpecificDisease
polyposis,527,I-SpecificDisease
(,527,O
FAP,527,B-SpecificDisease
),527,O
",",527,O
and,527,O
its,527,O
germ-line,527,O
mutations,527,O
in,527,O
a,527,O
substantial,527,O
number,527,O
of,527,O
FAP,527,B-Modifier
patients,527,O
have,527,O
been,527,O
identified,527,O
.,527,O
On,528,O
the,528,O
basis,528,O
of,528,O
this,528,O
information,528,O
",",528,O
we,528,O
compared,528,O
the,528,O
location,528,O
of,528,O
germ-line,528,O
mutations,528,O
in,528,O
the,528,O
APC,528,B-Modifier
gene,528,O
in,528,O
22,528,O
unrelated,528,O
patients,528,O
(,528,O
12,528,O
of,528,O
whom,528,O
have,528,O
been,528,O
reported,528,O
previously,528,O
),528,O
with,528,O
the,528,O
number,528,O
of,528,O
colorectal,528,B-SpecificDisease
polyps,528,I-SpecificDisease
developed,528,O
in,528,O
FAP,528,B-Modifier
patients,528,O
;,528,O
17,528,O
were,528,O
sparse,528,O
types,528,O
and,528,O
five,528,O
were,528,O
profuse,528,O
types,528,O
.,528,O
All,529,O
but,529,O
one,529,O
of,529,O
the,529,O
mutations,529,O
were,529,O
considered,529,O
to,529,O
cause,529,O
truncation,529,O
of,529,O
the,529,O
gene,529,O
product,529,O
by,529,O
frame-shift,529,O
due,529,O
to,529,O
deletion,529,O
(,529,O
14,529,O
cases,529,O
),529,O
or,529,O
nonsense,529,O
mutation,529,O
(,529,O
seven,529,O
cases,529,O
),529,O
.,529,O
The,530,O
location,530,O
of,530,O
the,530,O
germ-line,530,O
mutations,530,O
seems,530,O
to,530,O
correlate,530,O
with,530,O
the,530,O
two,530,O
clinical,530,O
types,530,O
;,530,O
germ-line,530,O
mutations,530,O
in,530,O
five,530,O
FAP,530,B-Modifier
patients,530,O
with,530,O
profuse,530,O
polyps,530,B-DiseaseClass
were,530,O
observed,530,O
between,530,O
codon,530,O
1250,530,O
and,530,O
codon,530,O
1464,530,O
",",530,O
whereas,530,O
mutations,530,O
in,530,O
17,530,O
FAP,530,B-Modifier
patients,530,O
with,530,O
fewer,530,O
polyps,530,B-DiseaseClass
were,530,O
observed,530,O
in,530,O
the,530,O
other,530,O
regions,530,O
of,530,O
the,530,O
APC,530,B-Modifier
gene,530,O
.,530,O
The,531,O
result,531,O
suggests,531,O
that,531,O
the,531,O
number,531,O
of,531,O
colorectal,531,B-SpecificDisease
polyps,531,I-SpecificDisease
in,531,O
FAP,531,B-Modifier
patients,531,O
may,531,O
be,531,O
associated,531,O
with,531,O
a,531,O
difference,531,O
in,531,O
the,531,O
stability,531,O
or,531,O
biological,531,O
function,531,O
of,531,O
the,531,O
truncated,531,O
APC,531,B-Modifier
protein,531,O
..,531,O
Identification,532,O
and,532,O
rapid,532,O
detection,532,O
of,532,O
three,532,O
Tay-Sachs,532,B-Modifier
mutations,532,O
in,532,O
the,532,O
Moroccan,532,O
Jewish,532,O
population,532,O
.,532,O
Infantile,533,O
Tay-Sachs,533,B-SpecificDisease
disease,533,I-SpecificDisease
(,533,O
TSD,533,B-SpecificDisease
),533,O
is,533,O
caused,533,O
by,533,O
mutations,533,O
in,533,O
the,533,O
HEXA,533,O
gene,533,O
that,533,O
result,533,O
in,533,O
the,533,O
complete,533,O
absence,533,O
of,533,O
beta-hexosaminidase,533,O
A,533,O
activity,533,O
.,533,O
It,534,O
is,534,O
well,534,O
known,534,O
that,534,O
an,534,O
elevated,534,O
frequency,534,O
of,534,O
TSD,534,B-Modifier
mutations,534,O
exists,534,O
among,534,O
Ashkenazi,534,O
Jews,534,O
.,534,O
More,535,O
recently,535,O
it,535,O
has,535,O
become,535,O
apparent,535,O
that,535,O
elevated,535,O
carrier,535,O
frequencies,535,O
for,535,O
TSD,535,B-SpecificDisease
also,535,O
occur,535,O
in,535,O
several,535,O
other,535,O
ethnic,535,O
groups,535,O
",",535,O
including,535,O
Moroccan,535,O
Jews,535,O
",",535,O
a,535,O
subgroup,535,O
of,535,O
Sephardic,535,O
Jews,535,O
.,535,O
Elsewhere,536,O
we,536,O
reported,536,O
an,536,O
in-frame,536,O
deletion,536,O
of,536,O
one,536,O
of,536,O
the,536,O
two,536,O
adjacent,536,O
phenylalanine,536,O
codons,536,O
at,536,O
position,536,O
304,536,O
or,536,O
305,536,O
(,536,O
delta,536,O
F304/305,536,O
),536,O
in,536,O
one,536,O
HEXA,536,O
allele,536,O
of,536,O
a,536,O
Moroccan,536,O
Jewish,536,O
TSD,536,B-Modifier
patient,536,O
and,536,O
in,536,O
three,536,O
obligate,536,O
carriers,536,O
from,536,O
six,536,O
unrelated,536,O
Moroccan,536,O
Jewish,536,O
families,536,O
.,536,O
We,537,O
have,537,O
now,537,O
identified,537,O
two,537,O
additional,537,O
mutations,537,O
within,537,O
exon,537,O
5,537,O
of,537,O
the,537,O
HEXA,537,O
gene,537,O
that,537,O
account,537,O
for,537,O
the,537,O
remaining,537,O
TSD,537,B-Modifier
alleles,537,O
in,537,O
the,537,O
patient,537,O
and,537,O
carriers,537,O
.,537,O
One,538,O
of,538,O
the,538,O
mutations,538,O
is,538,O
a,538,O
novel,538,O
C-to-G,538,O
transversion,538,O
",",538,O
resulting,538,O
in,538,O
a,538,O
replacement,538,O
of,538,O
Tyr180,538,O
by,538,O
a,538,O
stop,538,O
codon,538,O
.,538,O
The,539,O
other,539,O
mutation,539,O
is,539,O
a,539,O
G-to-A,539,O
transition,539,O
resulting,539,O
in,539,O
an,539,O
Arg170-to-Gln,539,O
substitution,539,O
.,539,O
This,540,O
mutation,540,O
is,540,O
at,540,O
a,540,O
CpG,540,O
site,540,O
in,540,O
a,540,O
Japanese,540,O
infant,540,O
with,540,O
Tay-Sachs,540,B-SpecificDisease
disease,540,I-SpecificDisease
and,540,O
was,540,O
described,540,O
elsewhere,540,O
.,540,O
Analysis,541,O
of,541,O
nine,541,O
obligate,541,O
carriers,541,O
from,541,O
seven,541,O
unrelated,541,O
families,541,O
showed,541,O
that,541,O
four,541,O
harbor,541,O
the,541,O
delta,541,O
F304/305,541,O
mutation,541,O
",",541,O
two,541,O
the,541,O
Arg170,541,O
--,541,O
--,541,O
Gln,541,O
mutation,541,O
",",541,O
and,541,O
one,541,O
the,541,O
Tyr180,541,O
--,541,O
--,541,O
Stop,541,O
mutation,541,O
.,541,O
We,542,O
also,542,O
have,542,O
developed,542,O
rapid,542,O
",",542,O
nonradioactive,542,O
assays,542,O
for,542,O
the,542,O
detection,542,O
of,542,O
each,542,O
mutation,542,O
",",542,O
which,542,O
should,542,O
be,542,O
helpful,542,O
for,542,O
carrier,542,O
screening,542,O
..,542,O
Molecular,543,O
characterization,543,O
of,543,O
glucose-6-phosphate,543,B-SpecificDisease
dehydrogenase,543,I-SpecificDisease
(,543,I-SpecificDisease
G6PD,543,I-SpecificDisease
),543,I-SpecificDisease
deficiency,543,I-SpecificDisease
by,543,O
natural,543,O
and,543,O
amplification,543,O
created,543,O
restriction,543,O
sites,543,O
:,543,O
five,543,O
mutations,543,O
account,543,O
for,543,O
most,543,O
G6PD,543,B-SpecificDisease
deficiency,543,I-SpecificDisease
cases,543,O
in,543,O
Taiwan,543,O
.,543,O
We,544,O
have,544,O
developed,544,O
a,544,O
rapid,544,O
and,544,O
simple,544,O
method,544,O
to,544,O
diagnose,544,O
the,544,O
molecular,544,O
defects,544,O
of,544,O
glucose-6-phosphate,544,B-SpecificDisease
dehydrogenase,544,I-SpecificDisease
(,544,I-SpecificDisease
G6PD,544,I-SpecificDisease
),544,I-SpecificDisease
deficiency,544,I-SpecificDisease
in,544,O
Chinese,544,O
in,544,O
Taiwan,544,O
.,544,O
This,545,O
method,545,O
involves,545,O
the,545,O
selective,545,O
amplification,545,O
of,545,O
a,545,O
DNA,545,O
fragment,545,O
from,545,O
human,545,O
G6PD,545,O
gene,545,O
with,545,O
specific,545,O
oligonucleotide,545,O
primers,545,O
followed,545,O
by,545,O
digestion,545,O
with,545,O
restriction,545,O
enzymes,545,O
that,545,O
recognize,545,O
artificially,545,O
created,545,O
or,545,O
naturally,545,O
occurring,545,O
restriction,545,O
sites,545,O
.,545,O
Ninety-four,546,O
Chinese,546,O
males,546,O
with,546,O
G6PD,546,B-SpecificDisease
deficiency,546,I-SpecificDisease
were,546,O
studied,546,O
.,546,O
The,547,O
results,547,O
show,547,O
that,547,O
50,547,O
%,547,O
(,547,O
47,547,O
of,547,O
94,547,O
),547,O
were,547,O
G,547,O
to,547,O
T,547,O
mutation,547,O
at,547,O
nucleotide,547,O
(,547,O
nt,547,O
),547,O
1376,547,O
",",547,O
21,547,O
.,547,O
3,548,O
%,548,O
(,548,O
20,548,O
of,548,O
94,548,O
),548,O
were,548,O
G,548,O
to,548,O
A,548,O
mutation,548,O
at,548,O
nt,548,O
1388,548,O
",",548,O
7,548,O
.,548,O
4,549,O
%,549,O
(,549,O
7,549,O
of,549,O
94,549,O
),549,O
were,549,O
A,549,O
to,549,O
G,549,O
mutation,549,O
at,549,O
nt,549,O
493,549,O
",",549,O
7,549,O
.,549,O
4,550,O
%,550,O
(,550,O
7,550,O
of,550,O
94,550,O
),550,O
were,550,O
A,550,O
to,550,O
G,550,O
mutation,550,O
at,550,O
nt,550,O
95,550,O
",",550,O
4,550,O
.,550,O
2,551,O
%,551,O
(,551,O
4,551,O
of,551,O
94,551,O
),551,O
were,551,O
C,551,O
to,551,O
T,551,O
mutation,551,O
at,551,O
nt,551,O
1024,551,O
",",551,O
1,551,O
.,551,O
1,552,O
%,552,O
(,552,O
1,552,O
of,552,O
94,552,O
),552,O
was,552,O
G,552,O
to,552,O
T,552,O
mutation,552,O
at,552,O
nt,552,O
392,552,O
",",552,O
and,552,O
1,552,O
.,552,O
1,553,O
%,553,O
(,553,O
1,553,O
of,553,O
94,553,O
),553,O
was,553,O
G,553,O
to,553,O
A,553,O
mutation,553,O
at,553,O
nt,553,O
487,553,O
.,553,O
These,554,O
results,554,O
show,554,O
that,554,O
the,554,O
former,554,O
five,554,O
mutations,554,O
account,554,O
for,554,O
more,554,O
than,554,O
90,554,O
%,554,O
of,554,O
G6PD,554,B-SpecificDisease
deficiency,554,I-SpecificDisease
cases,554,O
in,554,O
Taiwan,554,O
.,554,O
Aside,555,O
from,555,O
showing,555,O
that,555,O
G,555,O
to,555,O
T,555,O
change,555,O
at,555,O
nt,555,O
1376,555,O
is,555,O
the,555,O
most,555,O
common,555,O
mutation,555,O
",",555,O
our,555,O
research,555,O
indicates,555,O
that,555,O
nt,555,O
493,555,O
mutation,555,O
is,555,O
a,555,O
frequent,555,O
mutation,555,O
among,555,O
Chinese,555,O
in,555,O
Taiwan,555,O
.,555,O
We,556,O
compared,556,O
G6PD,556,O
activity,556,O
among,556,O
different,556,O
mutations,556,O
",",556,O
without,556,O
discovering,556,O
significant,556,O
differences,556,O
between,556,O
them,556,O
.,556,O
Eight,557,O
novel,557,O
inactivating,557,O
germ,557,O
line,557,O
mutations,557,O
at,557,O
the,557,O
APC,557,B-Modifier
gene,557,O
identified,557,O
by,557,O
denaturing,557,O
gradient,557,O
gel,557,O
electrophoresis,557,O
.,557,O
Familial,558,B-SpecificDisease
adenomatous,558,I-SpecificDisease
polyposis,558,I-SpecificDisease
(,558,O
FAP,558,B-SpecificDisease
),558,O
is,558,O
a,558,O
dominantly,558,O
inherited,558,O
condition,558,O
predisposing,558,O
to,558,O
colorectal,558,B-SpecificDisease
cancer,558,I-SpecificDisease
.,558,O
The,559,O
recent,559,O
isolation,559,O
of,559,O
the,559,O
responsible,559,O
gene,559,O
(,559,O
adenomatous,559,B-SpecificDisease
polyposis,559,I-SpecificDisease
coli,559,I-SpecificDisease
or,559,O
APC,559,B-SpecificDisease
),559,O
has,559,O
facilitated,559,O
the,559,O
search,559,O
for,559,O
germ,559,O
line,559,O
mutations,559,O
in,559,O
affected,559,O
individuals,559,O
.,559,O
Previous,560,O
authors,560,O
have,560,O
used,560,O
the,560,O
RNase,560,O
protection,560,O
assay,560,O
and,560,O
the,560,O
single-strand,560,O
conformation,560,O
polymorphisms,560,O
procedure,560,O
to,560,O
screen,560,O
for,560,O
mutations,560,O
.,560,O
In,561,O
this,561,O
study,561,O
we,561,O
used,561,O
denaturing,561,O
gradient,561,O
gel,561,O
electrophoresis,561,O
(,561,O
DGGE,561,O
),561,O
.,561,O
DGGE,562,O
analysis,562,O
of,562,O
10,562,O
APC,562,B-Modifier
exons,562,O
(,562,O
4,562,O
",",562,O
5,562,O
",",562,O
7,562,O
",",562,O
8,562,O
",",562,O
9,562,O
",",562,O
10,562,O
",",562,O
12,562,O
",",562,O
13,562,O
",",562,O
14,562,O
",",562,O
and,562,O
part,562,O
of,562,O
15,562,O
),562,O
in,562,O
33,562,O
unrelated,562,O
Dutch,562,O
FAP,562,B-Modifier
patients,562,O
has,562,O
led,562,O
to,562,O
the,562,O
identification,562,O
of,562,O
eight,562,O
novel,562,O
germ,562,O
line,562,O
mutations,562,O
resulting,562,O
in,562,O
stop,562,O
codons,562,O
or,562,O
frameshifts,562,O
.,562,O
The,563,O
results,563,O
reported,563,O
here,563,O
indicate,563,O
that,563,O
(,563,O
1,563,O
),563,O
familial,563,B-SpecificDisease
adenomatous,563,I-SpecificDisease
polyposis,563,I-SpecificDisease
is,563,O
caused,563,O
by,563,O
an,563,O
extremely,563,O
heterogeneous,563,O
spectrum,563,O
of,563,O
point,563,O
mutations,563,O
;,563,O
(,563,O
2,563,O
),563,O
all,563,O
the,563,O
mutations,563,O
found,563,O
in,563,O
this,563,O
study,563,O
are,563,O
chain,563,O
terminating,563,O
;,563,O
and,563,O
(,563,O
3,563,O
),563,O
DGGE,563,O
represents,563,O
a,563,O
rapid,563,O
and,563,O
sensitive,563,O
technique,563,O
for,563,O
the,563,O
detection,563,O
of,563,O
mutations,563,O
in,563,O
the,563,O
unusually,563,O
large,563,O
APC,563,B-Modifier
gene,563,O
.,563,O
An,564,O
extension,564,O
of,564,O
the,564,O
DGGE,564,O
analysis,564,O
to,564,O
the,564,O
entire,564,O
coding,564,O
region,564,O
in,564,O
a,564,O
sufficient,564,O
number,564,O
of,564,O
clinically,564,O
well-characterized,564,O
",",564,O
unrelated,564,O
patients,564,O
will,564,O
facilitate,564,O
the,564,O
establishment,564,O
of,564,O
genotype-phenotype,564,O
correlations,564,O
.,564,O
On,565,O
the,565,O
other,565,O
hand,565,O
",",565,O
the,565,O
occurrence,565,O
of,565,O
an,565,O
extremely,565,O
heterogeneous,565,O
spectrum,565,O
of,565,O
mutations,565,O
spread,565,O
throughout,565,O
the,565,O
entire,565,O
length,565,O
of,565,O
the,565,O
large,565,O
APC,565,B-Modifier
gene,565,O
among,565,O
the,565,O
FAP,565,B-Modifier
patients,565,O
indicates,565,O
that,565,O
this,565,O
approach,565,O
may,565,O
not,565,O
be,565,O
useful,565,O
as,565,O
a,565,O
rapid,565,O
presymptomatic,565,O
diagnostic,565,O
procedure,565,O
in,565,O
a,565,O
routine,565,O
laboratory,565,O
.,565,O
Nevertheless,566,O
",",566,O
the,566,O
above,566,O
DGGE,566,O
approach,566,O
has,566,O
incidentally,566,O
led,566,O
to,566,O
the,566,O
identification,566,O
of,566,O
a,566,O
common,566,O
polymorphism,566,O
in,566,O
exon,566,O
13,566,O
.,566,O
Such,567,O
intragenic,567,O
polymorphisms,567,O
offer,567,O
a,567,O
practical,567,O
approach,567,O
to,567,O
a,567,O
more,567,O
rapid,567,O
procedure,567,O
for,567,O
presymptomatic,567,O
diagnosis,567,O
of,567,O
FAP,567,B-SpecificDisease
by,567,O
linkage,567,O
analysis,567,O
in,567,O
informative,567,O
families,567,O
..,567,O
Yeast,568,O
artificial,568,O
chromosomes,568,O
for,568,O
the,568,O
molecular,568,O
analysis,568,O
of,568,O
the,568,O
familial,568,B-Modifier
polyposis,568,I-Modifier
APC,568,I-Modifier
gene,568,O
region,568,O
.,568,O
Two,569,O
yeast,569,O
artificial,569,O
chromosomes,569,O
(,569,O
YACs,569,O
),569,O
spanning,569,O
a,569,O
total,569,O
distance,569,O
of,569,O
1,569,O
.,569,O
1,570,O
megabase,570,O
pairs,570,O
of,570,O
DNA,570,O
around,570,O
the,570,O
MCC,570,O
(,570,O
for,570,O
mutated,570,O
in,570,O
colorectal,570,B-SpecificDisease
carcinoma,570,I-SpecificDisease
),570,O
and,570,O
APC,570,B-Modifier
(,570,O
for,570,O
adenomatous,570,B-Modifier
polyposis,570,I-Modifier
coli,570,I-Modifier
),570,O
genes,570,O
at,570,O
5q21,570,O
have,570,O
been,570,O
isolated,570,O
and,570,O
characterized,570,O
.,570,O
Starting,571,O
from,571,O
the,571,O
MCC,571,O
gene,571,O
",",571,O
a,571,O
strategy,571,O
was,571,O
undertaken,571,O
to,571,O
identify,571,O
constitutional,571,O
submicroscopic,571,O
deletions,571,O
in,571,O
familial,571,B-Modifier
adenomatous,571,I-Modifier
polyposis,571,I-Modifier
patients,571,O
that,571,O
might,571,O
considerably,571,O
narrow,571,O
down,571,O
the,571,O
position,571,O
of,571,O
the,571,O
APC,571,B-Modifier
gene,571,O
.,571,O
To,572,O
this,572,O
end,572,O
",",572,O
YACs,572,O
identified,572,O
by,572,O
the,572,O
MCC,572,O
gene,572,O
were,572,O
screened,572,O
across,572,O
a,572,O
chromosome,572,O
5-specific,572,O
cosmid,572,O
library,572,O
to,572,O
provide,572,O
a,572,O
source,572,O
of,572,O
DNA,572,O
probes,572,O
for,572,O
genomic,572,O
scanning,572,O
.,572,O
The,573,O
cosmids,573,O
isolated,573,O
from,573,O
these,573,O
experiments,573,O
were,573,O
used,573,O
to,573,O
screen,573,O
a,573,O
panel,573,O
of,573,O
somatic,573,O
cell,573,O
hybrids,573,O
containing,573,O
chromosome,573,O
5,573,O
segregated,573,O
from,573,O
patients,573,O
suspected,573,O
to,573,O
carry,573,O
putative,573,O
interstitial,573,O
deletions,573,O
.,573,O
This,574,O
screening,574,O
approach,574,O
led,574,O
to,574,O
the,574,O
confirmation,574,O
of,574,O
a,574,O
small,574,O
heterozygous,574,O
deletion,574,O
in,574,O
a,574,O
polyposis,574,B-Modifier
patient,574,O
that,574,O
overlaps,574,O
one,574,O
of,574,O
the,574,O
two,574,O
isolated,574,O
YACs,574,O
.,574,O
This,575,O
YAC,575,O
has,575,O
been,575,O
shown,575,O
to,575,O
contain,575,O
the,575,O
entire,575,O
APC,575,B-Modifier
gene,575,O
",",575,O
in,575,O
addition,575,O
to,575,O
a,575,O
significant,575,O
portion,575,O
of,575,O
DNA,575,O
flanking,575,O
the,575,O
5,575,O
end,575,O
of,575,O
the,575,O
gene,575,O
",",575,O
and,575,O
should,575,O
therefore,575,O
prove,575,O
a,575,O
valuable,575,O
resource,575,O
for,575,O
functional,575,O
studies,575,O
by,575,O
transfer,575,O
to,575,O
colorectal,575,B-Modifier
tumor-derived,575,O
cell,575,O
lines,575,O
.,575,O
Inherited,576,O
WT1,576,O
mutation,576,O
in,576,O
Denys-Drash,576,B-SpecificDisease
syndrome,576,I-SpecificDisease
.,576,O
Patients,577,O
with,577,O
the,577,O
Denys-Drash,577,B-SpecificDisease
syndrome,577,I-SpecificDisease
(,577,O
Wilms,577,B-SpecificDisease
tumor,577,I-SpecificDisease
",",577,O
genital,577,B-DiseaseClass
anomalies,577,I-DiseaseClass
",",577,O
and,577,O
nephropathy,577,B-SpecificDisease
),577,O
have,577,O
been,577,O
demonstrated,577,O
to,577,O
carry,577,O
de,577,O
novo,577,O
constitutional,577,O
mutations,577,O
in,577,O
WT1,577,O
",",577,O
the,577,O
Wilms,577,B-Modifier
tumor,577,I-Modifier
gene,577,O
at,577,O
chromosome,577,O
11p13,577,O
.,577,O
We,578,O
report,578,O
three,578,O
new,578,O
cases,578,O
",",578,O
two,578,O
carrying,578,O
a,578,O
previously,578,O
described,578,O
WT1,578,O
exon,578,O
9,578,O
mutation,578,O
and,578,O
one,578,O
with,578,O
a,578,O
novel,578,O
WT1,578,O
exon,578,O
8,578,O
mutation,578,O
.,578,O
However,579,O
",",579,O
unlike,579,O
patients,579,O
in,579,O
previous,579,O
reports,579,O
",",579,O
one,579,O
of,579,O
our,579,O
three,579,O
patients,579,O
inherited,579,O
the,579,O
affected,579,O
allele,579,O
from,579,O
his,579,O
phenotypically,579,O
unaffected,579,O
father,579,O
.,579,O
This,580,O
observation,580,O
indicates,580,O
that,580,O
the,580,O
WT1,580,O
exon,580,O
9,580,O
mutation,580,O
affecting,580,O
394Arg,580,O
demonstrated,580,O
in,580,O
over,580,O
one-half,580,O
of,580,O
the,580,O
patients,580,O
with,580,O
the,580,O
Denys-Drash,580,B-SpecificDisease
syndrome,580,I-SpecificDisease
may,580,O
exhibit,580,O
incomplete,580,O
penetrance,580,O
.,580,O
Consequently,581,O
",",581,O
familial,581,O
studies,581,O
in,581,O
patients,581,O
affected,581,O
by,581,O
this,581,O
syndrome,581,O
are,581,O
recommended,581,O
..,581,O
Submicroscopic,582,O
deletions,582,O
at,582,O
the,582,O
WAGR,582,B-Modifier
locus,582,O
",",582,O
revealed,582,O
by,582,O
nonradioactive,582,O
in,582,O
situ,582,O
hybridization,582,O
.,582,O
Fluorescence,583,O
in,583,O
situ,583,O
hybridization,583,O
(,583,O
FISH,583,O
),583,O
with,583,O
biotin-labeled,583,O
probes,583,O
mapping,583,O
to,583,O
11p13,583,O
has,583,O
been,583,O
used,583,O
for,583,O
the,583,O
molecular,583,O
analysis,583,O
of,583,O
deletions,583,O
of,583,O
the,583,O
WAGR,583,B-Modifier
(,583,O
Wilms,583,B-Modifier
tumor,583,I-Modifier
",",583,O
aniridia,583,B-Modifier
",",583,O
genitourinary,583,B-Modifier
abnormalities,583,I-Modifier
",",583,O
and,583,O
mental,583,B-Modifier
retardation,583,I-Modifier
),583,O
locus,583,O
.,583,O
We,584,O
have,584,O
detected,584,O
a,584,O
submicroscopic,584,O
11p13,584,O
deletion,584,O
in,584,O
a,584,O
child,584,O
with,584,O
inherited,584,O
aniridia,584,B-SpecificDisease
who,584,O
subsequently,584,O
presented,584,O
with,584,O
Wilms,584,B-SpecificDisease
tumor,584,I-SpecificDisease
in,584,O
a,584,O
horseshoe,584,O
kidney,584,O
",",584,O
only,584,O
revealed,584,O
at,584,O
surgery,584,O
.,584,O
The,585,O
mother,585,O
",",585,O
who,585,O
has,585,O
aniridia,585,B-SpecificDisease
",",585,O
was,585,O
also,585,O
found,585,O
to,585,O
carry,585,O
a,585,O
deletion,585,O
including,585,O
both,585,O
the,585,O
aniridia,585,B-Modifier
candidate,585,O
gene,585,O
(,585,O
AN2,585,O
),585,O
and,585,O
the,585,O
Wilms,585,B-Modifier
tumor,585,I-Modifier
predisposition,585,O
gene,585,O
(,585,O
WT1,585,O
),585,O
.,585,O
This,586,O
is,586,O
therefore,586,O
a,586,O
rare,586,O
case,586,O
of,586,O
an,586,O
inherited,586,O
WAGR,586,B-Modifier
deletion,586,O
.,586,O
Wilms,587,B-SpecificDisease
tumor,587,I-SpecificDisease
has,587,O
so,587,O
far,587,O
only,587,O
been,587,O
associated,587,O
with,587,O
sporadic,587,O
de,587,O
novo,587,O
aniridia,587,B-Modifier
cases,587,O
.,587,O
We,588,O
have,588,O
shown,588,O
that,588,O
a,588,O
cosmid,588,O
probe,588,O
for,588,O
a,588,O
candidate,588,O
aniridia,588,B-Modifier
gene,588,O
",",588,O
homologous,588,O
to,588,O
the,588,O
mouse,588,O
Pax-6,588,O
gene,588,O
",",588,O
is,588,O
deleted,588,O
in,588,O
cell,588,O
lines,588,O
from,588,O
aniridia,588,B-Modifier
patients,588,O
with,588,O
previously,588,O
characterized,588,O
deletions,588,O
at,588,O
11p13,588,O
",",588,O
while,588,O
another,588,O
cosmid,588,O
marker,588,O
mapping,588,O
between,588,O
two,588,O
aniridia-associated,588,B-Modifier
translocation,588,O
breakpoints,588,O
(,588,O
and,588,O
hence,588,O
a,588,O
second,588,O
candidate,588,O
marker,588,O
),588,O
is,588,O
present,588,O
on,588,O
both,588,O
chromosomes,588,O
.,588,O
These,589,O
results,589,O
support,589,O
the,589,O
Pax-6,589,O
homologue,589,O
as,589,O
a,589,O
strong,589,O
candidate,589,O
for,589,O
the,589,O
AN2,589,O
gene,589,O
.,589,O
FISH,590,O
with,590,O
cosmid,590,O
probes,590,O
has,590,O
proved,590,O
to,590,O
be,590,O
a,590,O
fast,590,O
and,590,O
reliable,590,O
technique,590,O
for,590,O
the,590,O
molecular,590,O
analysis,590,O
of,590,O
deletions,590,O
.,590,O
It,591,O
can,591,O
be,591,O
used,591,O
with,591,O
limited,591,O
amounts,591,O
of,591,O
material,591,O
and,591,O
has,591,O
strong,591,O
potential,591,O
for,591,O
clinical,591,O
applications,591,O
..,591,O
Screening,592,O
for,592,O
germ-line,592,O
mutations,592,O
in,592,O
familial,592,B-Modifier
adenomatous,592,I-Modifier
polyposis,592,I-Modifier
patients,592,O
:,592,O
61,592,O
new,592,O
patients,592,O
and,592,O
a,592,O
summary,592,O
of,592,O
150,592,O
unrelated,592,O
patients,592,O
.,592,O
We,593,O
report,593,O
here,593,O
the,593,O
result,593,O
of,593,O
a,593,O
screening,593,O
for,593,O
germ-line,593,O
mutations,593,O
in,593,O
the,593,O
adenomatous,593,B-Modifier
polyposis,593,I-Modifier
coli,593,I-Modifier
(,593,O
APC,593,B-Modifier
),593,O
gene,593,O
in,593,O
61,593,O
new,593,O
familial,593,B-Modifier
adenomatous,593,I-Modifier
polyposis,593,I-Modifier
(,593,O
FAP,593,B-Modifier
),593,O
patients,593,O
as,593,O
well,593,O
as,593,O
a,593,O
summary,593,O
of,593,O
the,593,O
results,593,O
of,593,O
150,593,O
patients,593,O
.,593,O
Examination,594,O
of,594,O
the,594,O
entire,594,O
coding,594,O
region,594,O
of,594,O
the,594,O
APC,594,B-Modifier
gene,594,O
",",594,O
based,594,O
on,594,O
a,594,O
ribonuclease,594,O
protection,594,O
assay,594,O
coupled,594,O
with,594,O
the,594,O
polymerase,594,O
chain,594,O
reaction,594,O
(,594,O
PCR,594,O
),594,O
",",594,O
disclosed,594,O
mutations,594,O
that,594,O
were,594,O
considered,594,O
to,594,O
cause,594,O
significant,594,O
defects,594,O
in,594,O
the,594,O
APC,594,B-Modifier
product,594,O
in,594,O
97,594,O
of,594,O
150,594,O
unrelated,594,O
FAP,594,B-Modifier
patients,594,O
.,594,O
Our,595,O
findings,595,O
revealed,595,O
the,595,O
following,595,O
characteristics,595,O
of,595,O
the,595,O
germ-line,595,O
mutations,595,O
of,595,O
APC,595,O
1,595,O
),595,O
the,595,O
great,595,O
majority,595,O
of,595,O
the,595,O
mutations,595,O
were,595,O
found,595,O
to,595,O
truncate,595,O
the,595,O
APC,595,B-Modifier
product,595,O
;,595,O
2,595,O
),595,O
almost,595,O
all,595,O
of,595,O
the,595,O
mutations,595,O
were,595,O
located,595,O
within,595,O
the,595,O
first,595,O
half,595,O
of,595,O
the,595,O
coding,595,O
region,595,O
;,595,O
3,595,O
),595,O
no,595,O
correlation,595,O
was,595,O
observed,595,O
between,595,O
the,595,O
locations,595,O
of,595,O
germ-line,595,O
mutations,595,O
and,595,O
extracolonic,595,O
manifestations,595,O
in,595,O
FAP,595,B-Modifier
patients,595,O
;,595,O
4,595,O
),595,O
more,595,O
than,595,O
80,595,O
%,595,O
of,595,O
base,595,O
substitutions,595,O
in,595,O
the,595,O
APC,595,B-Modifier
gene,595,O
were,595,O
from,595,O
cytosine,595,O
to,595,O
other,595,O
nucleotides,595,O
",",595,O
nearly,595,O
one-third,595,O
of,595,O
which,595,O
occurred,595,O
at,595,O
the,595,O
GpG,595,O
site,595,O
.,595,O
Our,596,O
results,596,O
provide,596,O
information,596,O
helpful,596,O
to,596,O
an,596,O
understanding,596,O
of,596,O
the,596,O
APC,596,B-Modifier
gene,596,O
and,596,O
will,596,O
also,596,O
contribute,596,O
to,596,O
presymptomatic,596,O
diagnosis,596,O
of,596,O
members,596,O
in,596,O
FAP,596,B-Modifier
families,596,O
..,596,O
Somatic,597,O
mutations,597,O
of,597,O
the,597,O
APC,597,B-Modifier
gene,597,O
in,597,O
colorectal,597,B-DiseaseClass
tumors,597,I-DiseaseClass
:,597,O
mutation,597,O
cluster,597,O
region,597,O
in,597,O
the,597,O
APC,597,B-Modifier
gene,597,O
.,597,O
We,598,O
examined,598,O
somatic,598,O
mutations,598,O
of,598,O
the,598,O
adenomatous,598,B-Modifier
polyposis,598,I-Modifier
coli,598,I-Modifier
(,598,O
APC,598,B-Modifier
),598,O
gene,598,O
in,598,O
63,598,O
colorectal,598,B-DiseaseClass
tumors,598,I-DiseaseClass
(,598,O
16,598,O
adenomas,598,B-DiseaseClass
and,598,O
47,598,O
carcinomas,598,B-DiseaseClass
),598,O
developed,598,O
in,598,O
familial,598,B-Modifier
adenomatous,598,I-Modifier
polyposis,598,I-Modifier
(,598,O
FAP,598,B-Modifier
),598,O
and,598,O
non-FAP,598,O
patients,598,O
.,598,O
In,599,O
addition,599,O
to,599,O
loss,599,O
of,599,O
heterozygosity,599,O
(,599,O
LOH,599,O
),599,O
at,599,O
the,599,O
APC,599,B-Modifier
locus,599,O
in,599,O
30,599,O
tumors,599,B-DiseaseClass
",",599,O
43,599,O
other,599,O
somatic,599,O
mutations,599,O
were,599,O
detected,599,O
.,599,O
Twenty-one,600,O
of,600,O
them,600,O
were,600,O
point,600,O
mutations,600,O
;,600,O
16,600,O
nonsense,600,O
and,600,O
two,600,O
missense,600,O
mutations,600,O
",",600,O
and,600,O
three,600,O
occurred,600,O
in,600,O
introns,600,O
at,600,O
the,600,O
splicing,600,O
site,600,O
.,600,O
Twenty-two,601,O
tumors,601,B-DiseaseClass
had,601,O
frameshift,601,O
mutations,601,O
due,601,O
to,601,O
deletion,601,O
or,601,O
insertion,601,O
;,601,O
nineteen,601,O
of,601,O
them,601,O
were,601,O
deletions,601,O
of,601,O
one,601,O
to,601,O
31,601,O
bp,601,O
and,601,O
three,601,O
were,601,O
a,601,O
1-bp,601,O
insertion,601,O
.,601,O
One,602,O
tumor,602,B-DiseaseClass
had,602,O
a,602,O
1-bp,602,O
deletion,602,O
in,602,O
an,602,O
intron,602,O
near,602,O
the,602,O
splicing,602,O
site,602,O
.,602,O
Hence,603,O
",",603,O
41,603,O
(,603,O
95,603,O
%,603,O
),603,O
of,603,O
43,603,O
mutations,603,O
resulted,603,O
in,603,O
truncation,603,O
of,603,O
the,603,O
APC,603,B-Modifier
protein,603,O
.,603,O
Over,604,O
60,604,O
%,604,O
of,604,O
the,604,O
somatic,604,O
mutations,604,O
in,604,O
the,604,O
APC,604,B-Modifier
gene,604,O
were,604,O
clustered,604,O
within,604,O
a,604,O
small,604,O
region,604,O
of,604,O
exon,604,O
15,604,O
",",604,O
designated,604,O
as,604,O
MCR,604,O
(,604,O
mutation,604,O
cluster,604,O
region,604,O
),604,O
",",604,O
which,604,O
accounted,604,O
for,604,O
less,604,O
than,604,O
10,604,O
%,604,O
of,604,O
the,604,O
coding,604,O
region,604,O
.,604,O
Combining,605,O
these,605,O
data,605,O
and,605,O
the,605,O
results,605,O
of,605,O
LOH,605,O
",",605,O
more,605,O
than,605,O
80,605,O
%,605,O
of,605,O
tumors,605,B-DiseaseClass
(,605,O
14,605,O
adenomas,605,B-DiseaseClass
and,605,O
39,605,O
carcinomas,605,B-DiseaseClass
),605,O
had,605,O
at,605,O
least,605,O
one,605,O
mutation,605,O
in,605,O
the,605,O
APC,605,B-Modifier
gene,605,O
",",605,O
of,605,O
which,605,O
more,605,O
than,605,O
60,605,O
%,605,O
(,605,O
9,605,O
adenomas,605,B-DiseaseClass
and,605,O
23,605,O
carcinomas,605,B-DiseaseClass
),605,O
had,605,O
two,605,O
mutations,605,O
.,605,O
These,606,O
results,606,O
strongly,606,O
suggest,606,O
that,606,O
somatic,606,O
mutations,606,O
of,606,O
the,606,O
APC,606,B-Modifier
gene,606,O
are,606,O
associated,606,O
with,606,O
development,606,O
of,606,O
a,606,O
great,606,O
majority,606,O
of,606,O
colorectal,606,B-DiseaseClass
tumors,606,I-DiseaseClass
..,606,O
Constitutional,607,O
mutations,607,O
in,607,O
the,607,O
WT1,607,O
gene,607,O
in,607,O
patients,607,O
with,607,O
Denys-Drash,607,B-SpecificDisease
syndrome,607,I-SpecificDisease
.,607,O
The,608,O
Denys-Drash,608,B-SpecificDisease
syndrome,608,I-SpecificDisease
is,608,O
characterised,608,O
by,608,O
a,608,O
typical,608,O
nephropathy,608,B-DiseaseClass
",",608,O
genital,608,B-DiseaseClass
abnormalities,608,I-DiseaseClass
and,608,O
also,608,O
predisposes,608,O
to,608,O
the,608,O
development,608,O
of,608,O
Wilms,608,B-SpecificDisease
tumor,608,I-SpecificDisease
.,608,O
These,609,O
patients,609,O
eventually,609,O
go,609,O
into,609,O
end,609,O
stage,609,O
renal,609,B-SpecificDisease
failure,609,I-SpecificDisease
.,609,O
A,610,O
candidate,610,O
Wilms,610,B-Modifier
tumor,610,I-Modifier
gene,610,O
",",610,O
WT1,610,O
",",610,O
from,610,O
the,610,O
11p13,610,O
chromosome,610,O
region,610,O
has,610,O
recently,610,O
been,610,O
cloned,610,O
.,610,O
We,611,O
have,611,O
analysed,611,O
the,611,O
DNA,611,O
sequence,611,O
in,611,O
constitutional,611,O
cells,611,O
from,611,O
eight,611,O
patients,611,O
and,611,O
have,611,O
shown,611,O
heterozygous,611,O
mutations,611,O
in,611,O
six,611,O
of,611,O
them,611,O
.,611,O
Four,612,O
of,612,O
the,612,O
mutations,612,O
were,612,O
in,612,O
exon,612,O
9,612,O
",",612,O
all,612,O
resulting,612,O
in,612,O
missense,612,O
mutations,612,O
.,612,O
Three,613,O
were,613,O
at,613,O
nucleotide,613,O
position,613,O
1180,613,O
resulting,613,O
in,613,O
an,613,O
arg,613,O
>,613,O
trp,613,O
amino,613,O
acid,613,O
change,613,O
.,613,O
The,614,O
other,614,O
was,614,O
at,614,O
position,614,O
1186,614,O
converting,614,O
an,614,O
asp,614,O
>,614,O
asn,614,O
in,614,O
the,614,O
predicted,614,O
resultant,614,O
protein,614,O
.,614,O
One,615,O
patient,615,O
had,615,O
a,615,O
missense,615,O
mutation,615,O
in,615,O
exon,615,O
8,615,O
",",615,O
converting,615,O
an,615,O
arg,615,O
>,615,O
his,615,O
.,615,O
A,616,O
single,616,O
base,616,O
pair,616,O
insertion,616,O
at,616,O
nucleotide,616,O
position,616,O
821,616,O
in,616,O
exon,616,O
6,616,O
resulted,616,O
in,616,O
the,616,O
generation,616,O
of,616,O
a,616,O
premature,616,O
stop,616,O
codon,616,O
in,616,O
the,616,O
last,616,O
patient,616,O
.,616,O
We,617,O
were,617,O
unable,617,O
to,617,O
find,617,O
a,617,O
mutation,617,O
in,617,O
one,617,O
patient,617,O
despite,617,O
complete,617,O
sequencing,617,O
of,617,O
the,617,O
genomic,617,O
sequence,617,O
of,617,O
the,617,O
gene,617,O
.,617,O
The,618,O
last,618,O
patient,618,O
carried,618,O
a,618,O
constitutional,618,O
deletion,618,O
of,618,O
the,618,O
11p13,618,O
region,618,O
and,618,O
no,618,O
additional,618,O
mutation,618,O
was,618,O
found,618,O
.,618,O
There,619,O
was,619,O
no,619,O
obvious,619,O
correlation,619,O
between,619,O
the,619,O
type,619,O
of,619,O
mutation,619,O
and,619,O
phenotypic,619,O
expression,619,O
.,619,O
These,620,O
results,620,O
further,620,O
demonstrate,620,O
that,620,O
the,620,O
WT1,620,O
gene,620,O
is,620,O
important,620,O
in,620,O
both,620,O
the,620,O
development,620,O
of,620,O
the,620,O
kidney,620,O
and,620,O
the,620,O
genito-urinary,620,O
system,620,O
..,620,O
Linkage,621,O
disequilibrium,621,O
mapping,621,O
in,621,O
isolated,621,O
founder,621,O
populations,621,O
:,621,O
diastrophic,621,B-SpecificDisease
dysplasia,621,I-SpecificDisease
in,621,O
Finland,621,O
.,621,O
Linkage,622,O
disequilibrium,622,O
mapping,622,O
in,622,O
isolated,622,O
populations,622,O
provides,622,O
a,622,O
powerful,622,O
tool,622,O
for,622,O
fine,622,O
structure,622,O
localization,622,O
of,622,O
disease,622,O
genes,622,O
.,622,O
Here,623,O
",",623,O
Luria,623,O
and,623,O
Delbrucks,623,O
classical,623,O
methods,623,O
for,623,O
analysing,623,O
bacterial,623,O
cultures,623,O
are,623,O
adapted,623,O
to,623,O
the,623,O
study,623,O
of,623,O
human,623,O
isolated,623,O
founder,623,O
populations,623,O
in,623,O
order,623,O
to,623,O
estimate,623,O
(,623,O
i,623,O
),623,O
the,623,O
recombination,623,O
fraction,623,O
between,623,O
a,623,O
disease,623,O
locus,623,O
and,623,O
a,623,O
marker,623,O
;,623,O
(,623,O
ii,623,O
),623,O
the,623,O
expected,623,O
degree,623,O
of,623,O
allelic,623,O
homogeneity,623,O
in,623,O
a,623,O
population,623,O
;,623,O
and,623,O
(,623,O
iii,623,O
),623,O
the,623,O
mutation,623,O
rate,623,O
of,623,O
marker,623,O
loci,623,O
.,623,O
Using,624,O
these,624,O
methods,624,O
",",624,O
we,624,O
report,624,O
striking,624,O
linkage,624,O
disequilibrium,624,O
for,624,O
diastrophic,624,B-SpecificDisease
dysplasia,624,I-SpecificDisease
(,624,O
DTD,624,B-SpecificDisease
),624,O
in,624,O
Finland,624,O
indicating,624,O
that,624,O
the,624,O
DTD,624,B-Modifier
gene,624,O
should,624,O
lie,624,O
within,624,O
0,624,O
.,624,O
06,625,O
centimorgans,625,O
(,625,O
or,625,O
about,625,O
60,625,O
kilobases,625,O
),625,O
of,625,O
the,625,O
CSF1R,625,O
gene,625,O
.,625,O
Predictions,626,O
about,626,O
allelic,626,O
homogeneity,626,O
in,626,O
Finland,626,O
and,626,O
mutation,626,O
rates,626,O
in,626,O
simple,626,O
sequence,626,O
repeats,626,O
are,626,O
confirmed,626,O
by,626,O
independent,626,O
observations,626,O
.,626,O
The,627,O
Wiskott-Aldrich,627,B-SpecificDisease
syndrome,627,I-SpecificDisease
:,627,O
refinement,627,O
of,627,O
the,627,O
localization,627,O
on,627,O
Xp,627,O
and,627,O
identification,627,O
of,627,O
another,627,O
closely,627,O
linked,627,O
marker,627,O
locus,627,O
",",627,O
OATL1,627,O
.,627,O
The,628,O
Wiskott-Aldrich,628,B-SpecificDisease
syndrome,628,I-SpecificDisease
(,628,O
WAS,628,B-SpecificDisease
),628,O
has,628,O
previously,628,O
been,628,O
mapped,628,O
to,628,O
the,628,O
proximal,628,O
short,628,O
arm,628,O
of,628,O
the,628,O
X,628,O
chromosome,628,O
between,628,O
the,628,O
DXS14,628,O
and,628,O
DXS7,628,O
loci,628,O
.,628,O
In,629,O
this,629,O
study,629,O
",",629,O
further,629,O
segregation,629,O
analysis,629,O
has,629,O
been,629,O
performed,629,O
using,629,O
a,629,O
newly,629,O
identified,629,O
WAS,629,B-Modifier
family,629,O
as,629,O
well,629,O
as,629,O
an,629,O
additional,629,O
marker,629,O
probe,629,O
",",629,O
HOATL1,629,O
.,629,O
The,630,O
results,630,O
indicate,630,O
close,630,O
linkage,630,O
between,630,O
the,630,O
WAS,630,B-SpecificDisease
and,630,O
OATL1,630,O
loci,630,O
(,630,O
Z,630,O
=,630,O
6,630,O
.,630,O
08,631,O
at,631,O
theta,631,O
=,631,O
0,631,O
.,631,O
00,632,O
),632,O
and,632,O
localize,632,O
the,632,O
TIMP,632,O
",",632,O
OATL1,632,O
",",632,O
DXS255,632,O
",",632,O
and,632,O
WAS,632,B-Modifier
loci,632,O
distal,632,O
to,632,O
DXS146,632,O
and,632,O
the,632,O
OATL1,632,O
and,632,O
WAS,632,B-Modifier
loci,632,O
proximal,632,O
to,632,O
TIMP,632,O
.,632,O
These,633,O
linkage,633,O
data,633,O
narrow,633,O
the,633,O
boundaries,633,O
within,633,O
which,633,O
the,633,O
WAS,633,B-Modifier
locus,633,O
maps,633,O
to,633,O
the,633,O
chromosomal,633,O
region,633,O
bracketed,633,O
by,633,O
TIMP,633,O
and,633,O
DXS146,633,O
and,633,O
support,633,O
the,633,O
loci,633,O
order,633,O
Xpter-DXS7-TIMP-,633,O
(,633,O
OATL1,633,O
",",633,O
WAS,633,O
",",633,O
DXS255,633,O
),633,O
-DXS146,633,O
.,633,O
Detection,634,O
of,634,O
an,634,O
unstable,634,O
fragment,634,O
of,634,O
DNA,634,O
specific,634,O
to,634,O
individuals,634,O
with,634,O
myotonic,634,B-SpecificDisease
dystrophy,634,I-SpecificDisease
.,634,O
Myotonic,635,B-SpecificDisease
dystrophy,635,I-SpecificDisease
(,635,O
DM,635,B-SpecificDisease
),635,O
is,635,O
the,635,O
most,635,O
common,635,O
form,635,O
of,635,O
adult,635,O
muscular,635,B-SpecificDisease
dystrophy,635,I-SpecificDisease
",",635,O
with,635,O
a,635,O
prevalence,635,O
of,635,O
2-14,635,O
per,635,O
100,635,O
",",635,O
000,635,O
individuals,635,O
.,635,O
The,636,O
disease,636,O
is,636,O
characterized,636,O
by,636,O
progressive,636,O
muscle,636,B-DiseaseClass
weakness,636,I-DiseaseClass
and,636,O
sustained,636,B-DiseaseClass
muscle,636,I-DiseaseClass
contraction,636,I-DiseaseClass
",",636,O
often,636,O
with,636,O
a,636,O
wide,636,O
range,636,O
of,636,O
accompanying,636,O
symptoms,636,O
.,636,O
The,637,O
age,637,O
at,637,O
onset,637,O
and,637,O
severity,637,O
of,637,O
the,637,O
disease,637,O
show,637,O
extreme,637,O
variation,637,O
",",637,O
both,637,O
within,637,O
and,637,O
between,637,O
families,637,O
.,637,O
Despite,638,O
its,638,O
clinical,638,O
variability,638,O
",",638,O
this,638,O
dominant,638,O
condition,638,O
segregates,638,O
as,638,O
a,638,O
single,638,O
locus,638,O
at,638,O
chromosome,638,O
19q13,638,O
.,638,O
3,639,O
in,639,O
every,639,O
population,639,O
studied,639,O
.,639,O
It,640,O
is,640,O
flanked,640,O
by,640,O
the,640,O
tightly,640,O
linked,640,O
genetic,640,O
markers,640,O
ERCC1,640,O
proximally,640,O
and,640,O
D19S51,640,O
distally,640,O
;,640,O
these,640,O
define,640,O
the,640,O
DM,640,B-Modifier
critical,640,O
region,640,O
.,640,O
We,641,O
report,641,O
the,641,O
isolation,641,O
of,641,O
an,641,O
expressed,641,O
sequence,641,O
from,641,O
this,641,O
region,641,O
which,641,O
detects,641,O
a,641,O
DNA,641,O
fragment,641,O
that,641,O
is,641,O
larger,641,O
in,641,O
affected,641,O
individuals,641,O
than,641,O
in,641,O
normal,641,O
siblings,641,O
or,641,O
unaffected,641,O
controls,641,O
.,641,O
The,642,O
size,642,O
of,642,O
this,642,O
fragment,642,O
varies,642,O
between,642,O
affected,642,O
siblings,642,O
",",642,O
and,642,O
increases,642,O
in,642,O
size,642,O
through,642,O
generations,642,O
in,642,O
parallel,642,O
with,642,O
increasing,642,O
severity,642,O
of,642,O
the,642,O
disease,642,O
.,642,O
We,643,O
postulate,643,O
that,643,O
this,643,O
unstable,643,O
DNA,643,O
sequence,643,O
is,643,O
the,643,O
molecular,643,O
feature,643,O
that,643,O
underlies,643,O
DM,643,B-SpecificDisease
.,643,O
Common,644,O
sequence,644,O
motifs,644,O
at,644,O
the,644,O
rearrangement,644,O
sites,644,O
of,644,O
a,644,O
constitutional,644,O
X/autosome,644,O
translocation,644,O
and,644,O
associated,644,O
deletion,644,O
.,644,O
Reciprocal,645,O
chromosome,645,O
translocations,645,O
are,645,O
common,645,O
de,645,O
novo,645,O
rearrangements,645,O
that,645,O
occur,645,O
randomly,645,O
throughout,645,O
the,645,O
human,645,O
genome,645,O
.,645,O
To,646,O
learn,646,O
about,646,O
causative,646,O
mechanisms,646,O
",",646,O
we,646,O
have,646,O
cloned,646,O
and,646,O
sequenced,646,O
the,646,O
breakpoints,646,O
of,646,O
a,646,O
cytologically,646,O
balanced,646,O
constitutional,646,O
reciprocal,646,O
translocation,646,O
",",646,O
t,646,O
(,646,O
X,646,O
;,646,O
4,646,O
),646,O
(,646,O
p21,646,O
.,646,O
2,647,O
;,647,O
q31,647,O
.,647,O
22,648,O
),648,O
",",648,O
present,648,O
in,648,O
a,648,O
girl,648,O
with,648,O
Duchenne,648,B-SpecificDisease
muscular,648,I-SpecificDisease
dystrophy,648,I-SpecificDisease
(,648,O
DMD,648,B-SpecificDisease
),648,O
.,648,O
Physical,649,O
mapping,649,O
of,649,O
the,649,O
derivative,649,O
chromosomes,649,O
",",649,O
after,649,O
their,649,O
separation,649,O
in,649,O
somatic,649,O
cell,649,O
hybrids,649,O
",",649,O
reveals,649,O
that,649,O
the,649,O
translocation,649,O
disrupts,649,O
the,649,O
DMD,649,B-Modifier
gene,649,O
in,649,O
Xp21,649,O
within,649,O
the,649,O
18-kb,649,O
intron,649,O
16,649,O
.,649,O
Restriction,650,O
mapping,650,O
and,650,O
sequencing,650,O
of,650,O
clones,650,O
that,650,O
span,650,O
both,650,O
translocation,650,O
breakpoints,650,O
as,650,O
well,650,O
as,650,O
the,650,O
corresponding,650,O
normal,650,O
regions,650,O
indicate,650,O
the,650,O
loss,650,O
of,650,O
approximately,650,O
5,650,O
kb,650,O
in,650,O
the,650,O
formation,650,O
of,650,O
the,650,O
derivative,650,O
X,650,O
chromosome,650,O
",",650,O
with,650,O
4-6,650,O
bp,650,O
deleted,650,O
from,650,O
chromosome,650,O
4,650,O
.,650,O
RFLP,651,O
and,651,O
Southern,651,O
analyses,651,O
indicate,651,O
that,651,O
the,651,O
de,651,O
novo,651,O
translocation,651,O
is,651,O
a,651,O
paternal,651,O
origin,651,O
and,651,O
that,651,O
the,651,O
fathers,651,O
X,651,O
chromosome,651,O
contains,651,O
the,651,O
DNA,651,O
that,651,O
is,651,O
deleted,651,O
in,651,O
the,651,O
derivative,651,O
X,651,O
.,651,O
Most,652,O
likely,652,O
",",652,O
deletion,652,O
and,652,O
translation,652,O
arose,652,O
simultaneously,652,O
from,652,O
a,652,O
complex,652,O
rearrangement,652,O
event,652,O
that,652,O
involves,652,O
three,652,O
chromosomal,652,O
breakpoints,652,O
.,652,O
Short,653,O
regions,653,O
of,653,O
sequence,653,O
homology,653,O
were,653,O
present,653,O
at,653,O
the,653,O
three,653,O
sites,653,O
.,653,O
A,654,O
5-bp,654,O
sequence,654,O
",",654,O
GGAAT,654,O
",",654,O
found,654,O
exactly,654,O
at,654,O
the,654,O
translocation,654,O
breakpoints,654,O
on,654,O
both,654,O
normal,654,O
chromosomes,654,O
X,654,O
and,654,O
4,654,O
",",654,O
has,654,O
been,654,O
preserved,654,O
only,654,O
on,654,O
the,654,O
der,654,O
(,654,O
4,654,O
),654,O
chromosome,654,O
.,654,O
It,655,O
is,655,O
likely,655,O
that,655,O
the,655,O
X-derived,655,O
sequence,655,O
GGAATCA,655,O
has,655,O
been,655,O
lost,655,O
in,655,O
the,655,O
formation,655,O
of,655,O
the,655,O
der,655,O
(,655,O
X,655,O
),655,O
chromosome,655,O
",",655,O
as,655,O
it,655,O
matches,655,O
an,655,O
inverted,655,O
GAATCA,655,O
sequence,655,O
present,655,O
on,655,O
the,655,O
opposite,655,O
strand,655,O
exactly,655,O
at,655,O
the,655,O
other,655,O
end,655,O
of,655,O
the,655,O
deleted,655,O
5-kb,655,O
fragment,655,O
.,655,O
A,656,O
genetic,656,O
etiology,656,O
for,656,O
DiGeorge,656,B-SpecificDisease
syndrome,656,I-SpecificDisease
:,656,O
consistent,656,O
deletions,656,O
and,656,O
microdeletions,656,O
of,656,O
22q11,656,O
.,656,O
DiGeorge,657,B-SpecificDisease
syndrome,657,I-SpecificDisease
(,657,O
DGS,657,B-SpecificDisease
),657,O
",",657,O
a,657,O
developmental,657,O
field,657,O
defect,657,O
of,657,O
the,657,O
third,657,O
and,657,O
fourth,657,O
pharyngeal,657,O
pouches,657,O
",",657,O
is,657,O
characterized,657,O
by,657,O
aplasia,657,O
or,657,O
hypoplasia,657,O
of,657,O
the,657,O
thymus,657,O
and,657,O
parathyroid,657,O
glands,657,O
and,657,O
by,657,O
conotruncal,657,B-SpecificDisease
cardiac,657,I-SpecificDisease
malformations,657,I-SpecificDisease
.,657,O
Cytogenetic,658,O
studies,658,O
support,658,O
the,658,O
presence,658,O
of,658,O
a,658,O
DGS,658,B-Modifier
critical,658,O
region,658,O
in,658,O
band,658,O
22q11,658,O
.,658,O
In,659,O
the,659,O
present,659,O
study,659,O
",",659,O
we,659,O
report,659,O
the,659,O
results,659,O
of,659,O
clinical,659,O
",",659,O
cytogenetic,659,O
",",659,O
and,659,O
molecular,659,O
studies,659,O
of,659,O
14,659,O
patients,659,O
with,659,O
DGS,659,B-SpecificDisease
.,659,O
Chromosome,660,O
analysis,660,O
",",660,O
utilizing,660,O
high-resolution,660,O
banding,660,O
techniques,660,O
",",660,O
detected,660,O
interstitial,660,O
deletions,660,O
in,660,O
five,660,O
probands,660,O
and,660,O
was,660,O
inconclusive,660,O
for,660,O
a,660,O
deletion,660,O
in,660,O
three,660,O
probands,660,O
.,660,O
The,661,O
remaining,661,O
six,661,O
patients,661,O
had,661,O
normal,661,O
karyotypes,661,O
.,661,O
In,662,O
contrast,662,O
",",662,O
molecular,662,O
analysis,662,O
detected,662,O
DNA,662,O
deletions,662,O
in,662,O
all,662,O
14,662,O
probands,662,O
.,662,O
Two,663,O
of,663,O
10,663,O
loci,663,O
tested,663,O
",",663,O
D22S75,663,O
and,663,O
D22S259,663,O
",",663,O
are,663,O
deleted,663,O
in,663,O
all,663,O
14,663,O
patients,663,O
.,663,O
A,664,O
third,664,O
locus,664,O
",",664,O
D22S66,664,O
",",664,O
is,664,O
deleted,664,O
in,664,O
the,664,O
eight,664,O
DGS,664,B-Modifier
probands,664,O
tested,664,O
.,664,O
Physical,665,O
mapping,665,O
using,665,O
somatic,665,O
cell,665,O
hybrids,665,O
places,665,O
D22S66,665,O
between,665,O
D22S75,665,O
and,665,O
D22S259,665,O
",",665,O
suggesting,665,O
that,665,O
it,665,O
should,665,O
be,665,O
deleted,665,O
in,665,O
the,665,O
remaining,665,O
six,665,O
cases,665,O
.,665,O
Parent-of-origin,666,O
studies,666,O
were,666,O
performed,666,O
in,666,O
five,666,O
families,666,O
.,666,O
Four,667,O
probands,667,O
failed,667,O
to,667,O
inherit,667,O
a,667,O
maternal,667,O
allele,667,O
",",667,O
and,667,O
one,667,O
failed,667,O
to,667,O
inherit,667,O
a,667,O
paternal,667,O
allele,667,O
.,667,O
On,668,O
the,668,O
basis,668,O
of,668,O
these,668,O
families,668,O
",",668,O
and,668,O
of,668,O
six,668,O
maternally,668,O
and,668,O
five,668,O
paternally,668,O
derived,668,O
unbalanced-translocation,668,O
DGS,668,B-Modifier
probands,668,O
in,668,O
the,668,O
literature,668,O
",",668,O
parent,668,O
of,668,O
origin,668,O
or,668,O
imprinting,668,O
does,668,O
not,668,O
appear,668,O
to,668,O
play,668,O
an,668,O
important,668,O
role,668,O
in,668,O
the,668,O
pathogenesis,668,O
of,668,O
DGS,668,B-SpecificDisease
.,668,O
Deletion,669,O
of,669,O
the,669,O
same,669,O
three,669,O
loci,669,O
in,669,O
all,669,O
14,669,O
DGS,669,B-Modifier
probands,669,O
begins,669,O
to,669,O
delineate,669,O
the,669,O
region,669,O
of,669,O
chromosome,669,O
22,669,O
critical,669,O
for,669,O
DGS,669,B-SpecificDisease
and,669,O
confirms,669,O
the,669,O
hypothesis,669,O
that,669,O
submicroscopic,669,O
deletions,669,O
of,669,O
22q11,669,O
are,669,O
etiologic,669,O
in,669,O
the,669,O
vast,669,O
majority,669,O
of,669,O
cases,669,O
..,669,O
Loss,670,O
of,670,O
normal,670,O
allele,670,O
of,670,O
the,670,O
APC,670,B-Modifier
gene,670,O
in,670,O
an,670,O
adrenocortical,670,B-SpecificDisease
carcinoma,670,I-SpecificDisease
from,670,O
a,670,O
patient,670,O
with,670,O
familial,670,B-SpecificDisease
adenomatous,670,I-SpecificDisease
polyposis,670,I-SpecificDisease
.,670,O
Endocrine,671,B-DiseaseClass
neoplasms,671,I-DiseaseClass
have,671,O
been,671,O
reported,671,O
occasionally,671,O
in,671,O
patients,671,O
with,671,O
familial,671,B-SpecificDisease
adenomatous,671,I-SpecificDisease
polyposis,671,I-SpecificDisease
(,671,O
FAP,671,B-SpecificDisease
),671,O
.,671,O
An,672,O
adrenocorotical,672,B-SpecificDisease
carcinoma,672,I-SpecificDisease
was,672,O
studied,672,O
in,672,O
a,672,O
patient,672,O
with,672,O
a,672,O
family,672,O
history,672,O
of,672,O
FAP,672,B-SpecificDisease
.,672,O
Loss,673,O
of,673,O
heterozygosity,673,O
(,673,O
LOH,673,O
),673,O
in,673,O
the,673,O
region,673,O
close,673,O
to,673,O
the,673,O
adenomatous,673,B-Modifier
polyposis,673,I-Modifier
coli,673,I-Modifier
(,673,O
APC,673,B-Modifier
),673,O
gene,673,O
was,673,O
detected,673,O
in,673,O
this,673,O
carcinoma,673,B-DiseaseClass
",",673,O
and,673,O
evidence,673,O
was,673,O
obtained,673,O
that,673,O
there,673,O
was,673,O
a,673,O
loss,673,O
of,673,O
the,673,O
normal,673,O
allele,673,O
of,673,O
the,673,O
APC,673,B-Modifier
gene,673,O
.,673,O
This,674,O
is,674,O
the,674,O
first,674,O
demonstration,674,O
of,674,O
LOH,674,O
at,674,O
the,674,O
APC,674,B-Modifier
locus,674,O
in,674,O
adrenocortical,674,B-SpecificDisease
tumors,674,I-SpecificDisease
.,674,O
The,675,O
present,675,O
results,675,O
and,675,O
our,675,O
previous,675,O
data,675,O
on,675,O
LOH,675,O
in,675,O
a,675,O
recurring,675,O
desmoid,675,B-SpecificDisease
tumor,675,I-SpecificDisease
suggest,675,O
that,675,O
the,675,O
heterozygous,675,O
mutant/wild-type,675,O
condition,675,O
of,675,O
the,675,O
APC,675,B-Modifier
gene,675,O
may,675,O
give,675,O
rise,675,O
to,675,O
benign,675,B-DiseaseClass
tumors,675,I-DiseaseClass
",",675,O
and,675,O
that,675,O
functional,675,O
loss,675,O
of,675,O
this,675,O
gene,675,O
leads,675,O
to,675,O
development,675,O
of,675,O
tumors,675,B-DiseaseClass
not,675,O
only,675,O
in,675,O
the,675,O
colon,675,O
but,675,O
also,675,O
in,675,O
other,675,O
various,675,O
parts,675,O
of,675,O
the,675,O
body,675,O
in,675,O
FAP,675,B-Modifier
patients,675,O
..,675,O
Oncogenic,676,O
point,676,O
mutations,676,O
in,676,O
exon,676,O
20,676,O
of,676,O
the,676,O
RB1,676,O
gene,676,O
in,676,O
families,676,O
showing,676,O
incomplete,676,O
penetrance,676,O
and,676,O
mild,676,O
expression,676,O
of,676,O
the,676,O
retinoblastoma,676,B-Modifier
phenotype,676,O
.,676,O
The,677,O
retinoblastoma-predisposition,677,B-Modifier
gene,677,O
",",677,O
RB1,677,O
",",677,O
segregates,677,O
as,677,O
an,677,O
autosomal,677,O
dominant,677,O
trait,677,O
with,677,O
high,677,O
(,677,O
90,677,O
%,677,O
),677,O
penetrance,677,O
.,677,O
Certain,678,O
families,678,O
",",678,O
however,678,O
",",678,O
show,678,O
an,678,O
unusual,678,O
low-penetrance,678,O
phenotype,678,O
with,678,O
many,678,O
individuals,678,O
being,678,O
unaffected,678,O
",",678,O
unilaterally,678,O
affected,678,O
",",678,O
or,678,O
with,678,O
evidence,678,O
of,678,O
spontaneously,678,O
regressed,678,O
tumors,678,B-DiseaseClass
.,678,O
We,679,O
have,679,O
used,679,O
single-strand,679,O
conformation,679,O
polymorphism,679,O
analysis,679,O
and,679,O
PCR,679,O
sequencing,679,O
to,679,O
study,679,O
two,679,O
such,679,O
families,679,O
.,679,O
Mutations,680,O
were,680,O
found,680,O
in,680,O
exon,680,O
20,680,O
of,680,O
RB1,680,O
in,680,O
both,680,O
cases,680,O
.,680,O
In,681,O
one,681,O
family,681,O
a,681,O
C,681,O
--,681,O
--,681,O
T,681,O
transition,681,O
in,681,O
codon,681,O
661,681,O
converts,681,O
an,681,O
arginine,681,O
(,681,O
CGG,681,O
),681,O
to,681,O
a,681,O
tryptophan,681,O
(,681,O
TGG,681,O
),681,O
codon,681,O
.,681,O
In,682,O
this,682,O
family,682,O
",",682,O
incomplete,682,O
penetrance,682,O
and,682,O
mild,682,O
phenotypic,682,O
expression,682,O
were,682,O
observed,682,O
in,682,O
virtually,682,O
all,682,O
patients,682,O
",",682,O
possibly,682,O
indicating,682,O
that,682,O
single,682,O
amino,682,O
acid,682,O
changes,682,O
may,682,O
modify,682,O
protein,682,O
structure/function,682,O
such,682,O
that,682,O
tumorigenesis,682,O
is,682,O
not,682,O
inevitable,682,O
.,682,O
In,683,O
the,683,O
second,683,O
family,683,O
the,683,O
mutation,683,O
in,683,O
codon,683,O
675,683,O
is,683,O
a,683,O
G,683,O
--,683,O
--,683,O
T,683,O
transversion,683,O
that,683,O
converts,683,O
a,683,O
glutamine,683,O
(,683,O
GAA,683,O
),683,O
to,683,O
a,683,O
stop,683,O
(,683,O
TAA,683,O
),683,O
codon,683,O
.,683,O
However,684,O
",",684,O
this,684,O
mutation,684,O
also,684,O
occurs,684,O
near,684,O
a,684,O
potential,684,O
cryptic,684,O
splice,684,O
acceptor,684,O
site,684,O
",",684,O
raising,684,O
the,684,O
possibility,684,O
of,684,O
alternative,684,O
splicing,684,O
resulting,684,O
in,684,O
a,684,O
less,684,O
severely,684,O
disrupted,684,O
protein,684,O
..,684,O
Late-onset,685,O
metachromatic,685,B-SpecificDisease
leukodystrophy,685,I-SpecificDisease
:,685,O
molecular,685,O
pathology,685,O
in,685,O
two,685,O
siblings,685,O
.,685,O
We,686,O
report,686,O
on,686,O
a,686,O
new,686,O
allele,686,O
at,686,O
the,686,O
arylsulfatase,686,O
A,686,O
(,686,O
ARSA,686,O
),686,O
locus,686,O
causing,686,O
late-onset,686,O
metachromatic,686,B-SpecificDisease
leukodystrophy,686,I-SpecificDisease
(,686,O
MLD,686,B-SpecificDisease
),686,O
.,686,O
In,687,O
that,687,O
allele,687,O
arginine84,687,O
",",687,O
a,687,O
residue,687,O
that,687,O
is,687,O
highly,687,O
conserved,687,O
in,687,O
the,687,O
arylsulfatase,687,O
gene,687,O
family,687,O
",",687,O
is,687,O
replaced,687,O
by,687,O
glutamine,687,O
.,687,O
In,688,O
contrast,688,O
to,688,O
alleles,688,O
that,688,O
cause,688,O
early-onset,688,O
MLD,688,B-SpecificDisease
",",688,O
the,688,O
arginine84,688,O
to,688,O
glutamine,688,O
substitution,688,O
is,688,O
associated,688,O
with,688,O
some,688,O
residual,688,O
ARSA,688,O
activity,688,O
.,688,O
A,689,O
comparison,689,O
of,689,O
genotypes,689,O
",",689,O
ARSA,689,O
activities,689,O
",",689,O
and,689,O
clinical,689,O
data,689,O
on,689,O
4,689,O
individuals,689,O
carrying,689,O
the,689,O
allele,689,O
of,689,O
81,689,O
patients,689,O
with,689,O
MLD,689,B-Modifier
examined,689,O
",",689,O
further,689,O
validates,689,O
the,689,O
concept,689,O
that,689,O
different,689,O
degrees,689,O
of,689,O
residual,689,O
ARSA,689,O
activity,689,O
are,689,O
the,689,O
basis,689,O
of,689,O
phenotypical,689,O
variation,689,O
in,689,O
MLD,689,B-SpecificDisease
..,689,O
Trisomy,690,B-SpecificDisease
15,690,I-SpecificDisease
with,690,O
loss,690,O
of,690,O
the,690,O
paternal,690,O
15,690,O
as,690,O
a,690,O
cause,690,O
of,690,O
Prader-Willi,690,B-SpecificDisease
syndrome,690,I-SpecificDisease
due,690,O
to,690,O
maternal,690,B-SpecificDisease
disomy,690,I-SpecificDisease
.,690,O
Uniparental,691,B-SpecificDisease
disomy,691,I-SpecificDisease
has,691,O
recently,691,O
been,691,O
recognized,691,O
to,691,O
cause,691,O
human,691,O
disorders,691,O
",",691,O
including,691,O
Prader-Willi,691,B-SpecificDisease
syndrome,691,I-SpecificDisease
(,691,O
PWS,691,B-SpecificDisease
),691,O
.,691,O
We,692,O
describe,692,O
a,692,O
particularly,692,O
instructive,692,O
case,692,O
which,692,O
raises,692,O
important,692,O
issues,692,O
concerning,692,O
the,692,O
mechanisms,692,O
producing,692,O
uniparental,692,B-SpecificDisease
disomy,692,I-SpecificDisease
and,692,O
whose,692,O
evaluation,692,O
provides,692,O
evidence,692,O
that,692,O
trisomy,692,O
may,692,O
precede,692,O
uniparental,692,B-SpecificDisease
disomy,692,I-SpecificDisease
in,692,O
a,692,O
fetus,692,O
.,692,O
Chorionic,693,O
villus,693,O
sampling,693,O
performed,693,O
for,693,O
advanced,693,O
maternal,693,O
age,693,O
revealed,693,O
trisomy,693,B-SpecificDisease
15,693,I-SpecificDisease
in,693,O
all,693,O
direct,693,O
and,693,O
cultured,693,O
cells,693,O
",",693,O
though,693,O
the,693,O
fetus,693,O
appeared,693,O
normal,693,O
.,693,O
Chromosome,694,O
analysis,694,O
of,694,O
amniocytes,694,O
obtained,694,O
at,694,O
15,694,O
wk,694,O
was,694,O
normal,694,O
in,694,O
over,694,O
100,694,O
cells,694,O
studied,694,O
.,694,O
The,695,O
child,695,O
was,695,O
hypotonic,695,B-SpecificDisease
at,695,O
birth,695,O
",",695,O
and,695,O
high-resolution,695,O
banding,695,O
failed,695,O
to,695,O
reveal,695,O
the,695,O
deletion,695,O
of,695,O
15q11-13,695,O
",",695,O
a,695,O
deletion,695,O
which,695,O
is,695,O
found,695,O
in,695,O
50,695,O
%,695,O
-70,695,O
%,695,O
of,695,O
patients,695,O
with,695,O
PWS,695,B-SpecificDisease
.,695,O
Over,696,O
time,696,O
",",696,O
typical,696,O
features,696,O
of,696,O
PWS,696,B-SpecificDisease
developed,696,O
.,696,O
Molecular,697,O
genetic,697,O
analysis,697,O
using,697,O
probes,697,O
for,697,O
chromosome,697,O
15,697,O
revealed,697,O
maternal,697,O
disomy,697,O
.,697,O
Maternal,698,O
nondisjunction,698,O
with,698,O
fertilization,698,O
of,698,O
a,698,O
disomic,698,O
egg,698,O
by,698,O
a,698,O
normal,698,O
sperm,698,O
",",698,O
followed,698,O
by,698,O
loss,698,O
of,698,O
the,698,O
paternal,698,O
15,698,O
",",698,O
is,698,O
a,698,O
likely,698,O
cause,698,O
of,698,O
confined,698,O
placental,698,O
mosaicism,698,O
and,698,O
uniparental,698,B-SpecificDisease
disomy,698,I-SpecificDisease
in,698,O
this,698,O
case,698,O
of,698,O
PWS,698,B-SpecificDisease
",",698,O
and,698,O
advanced,698,O
maternal,698,O
age,698,O
may,698,O
be,698,O
a,698,O
predisposing,698,O
factor,698,O
..,698,O
Genetic,699,O
heterogeneity,699,O
in,699,O
X-linked,699,B-SpecificDisease
amelogenesis,699,I-SpecificDisease
imperfecta,699,I-SpecificDisease
.,699,O
The,700,O
AMELX,700,O
gene,700,O
located,700,O
at,700,O
Xp22,700,O
.,700,O
1-p22,701,O
.,701,O
3,702,O
encodes,702,O
for,702,O
the,702,O
enamel,702,O
protein,702,O
amelogenin,702,O
and,702,O
has,702,O
been,702,O
implicated,702,O
as,702,O
the,702,O
gene,702,O
responsible,702,O
for,702,O
the,702,O
inherited,702,B-DiseaseClass
dental,702,I-DiseaseClass
abnormality,702,I-DiseaseClass
X-linked,702,B-SpecificDisease
amelogenesis,702,I-SpecificDisease
imperfecta,702,I-SpecificDisease
(,702,O
XAI,702,B-SpecificDisease
),702,O
.,702,O
Three,703,O
families,703,O
with,703,O
XAI,703,B-SpecificDisease
have,703,O
been,703,O
investigated,703,O
using,703,O
polymorphic,703,O
DNA,703,O
markers,703,O
flanking,703,O
the,703,O
position,703,O
of,703,O
AMELX,703,O
.,703,O
Using,704,O
two-point,704,O
linkage,704,O
analysis,704,O
",",704,O
linkage,704,O
was,704,O
established,704,O
between,704,O
XAI,704,B-SpecificDisease
and,704,O
several,704,O
of,704,O
these,704,O
markers,704,O
in,704,O
two,704,O
families,704,O
",",704,O
with,704,O
a,704,O
combined,704,O
lod,704,O
score,704,O
of,704,O
6,704,O
.,704,O
05,705,O
for,705,O
DXS16,705,O
at,705,O
theta,705,O
=,705,O
0,705,O
.,705,O
04,706,O
04,706,O
.,706,O
This,707,O
supports,707,O
the,707,O
involvement,707,O
of,707,O
AMELX,707,O
",",707,O
located,707,O
close,707,O
to,707,O
DXS16,707,O
",",707,O
in,707,O
the,707,O
XAI,707,B-SpecificDisease
disease,707,I-SpecificDisease
process,707,O
(,707,O
AIH1,707,O
),707,O
in,707,O
those,707,O
families,707,O
.,707,O
Using,708,O
multipoint,708,O
linkage,708,O
analysis,708,O
",",708,O
the,708,O
combined,708,O
maximum,708,O
lod,708,O
score,708,O
for,708,O
these,708,O
two,708,O
families,708,O
was,708,O
7,708,O
.,708,O
30,709,O
for,709,O
a,709,O
location,709,O
of,709,O
AIH1,709,O
at,709,O
2,709,O
cM,709,O
distal,709,O
to,709,O
DXS16,709,O
.,709,O
The,710,O
support,710,O
interval,710,O
around,710,O
this,710,O
location,710,O
extended,710,O
about,710,O
8,710,O
cM,710,O
proximal,710,O
to,710,O
DXS92,710,O
",",710,O
and,710,O
the,710,O
AIH1,710,O
location,710,O
could,710,O
not,710,O
be,710,O
precisely,710,O
defined,710,O
by,710,O
multipoint,710,O
mapping,710,O
.,710,O
Study,711,O
of,711,O
recombination,711,O
events,711,O
indicated,711,O
that,711,O
AIH1,711,O
lies,711,O
in,711,O
the,711,O
interval,711,O
between,711,O
DXS143,711,O
and,711,O
DXS85,711,O
.,711,O
There,712,O
was,712,O
significant,712,O
evidence,712,O
against,712,O
linkage,712,O
to,712,O
this,712,O
region,712,O
in,712,O
the,712,O
third,712,O
family,712,O
",",712,O
indicating,712,O
locus,712,O
heterogeneity,712,O
in,712,O
XAI,712,B-SpecificDisease
.,712,O
Further,713,O
analysis,713,O
with,713,O
markers,713,O
on,713,O
the,713,O
long,713,O
arm,713,O
of,713,O
the,713,O
X,713,O
chromosome,713,O
showed,713,O
evidence,713,O
of,713,O
linkage,713,O
to,713,O
DXS144E,713,O
and,713,O
F9,713,O
with,713,O
no,713,O
recombination,713,O
with,713,O
either,713,O
of,713,O
these,713,O
markers,713,O
.,713,O
Two-point,714,O
analysis,714,O
gave,714,O
a,714,O
peak,714,O
lod,714,O
score,714,O
at,714,O
DXS144E,714,O
with,714,O
a,714,O
maximum,714,O
lod,714,O
score,714,O
of,714,O
2,714,O
.,714,O
83,715,O
at,715,O
theta,715,O
=,715,O
0,715,O
",",715,O
with,715,O
a,715,O
peak,715,O
lod,715,O
score,715,O
in,715,O
multipoint,715,O
linkage,715,O
analysis,715,O
of,715,O
2,715,O
.,715,O
84,716,O
at,716,O
theta,716,O
=,716,O
0,716,O
.,716,O
The,717,O
support,717,O
interval,717,O
extended,717,O
9,717,O
cM,717,O
proximal,717,O
to,717,O
DXS144E,717,O
and,717,O
14,717,O
cM,717,O
distal,717,O
to,717,O
F9,717,O
.,717,O
(,718,O
ABSTRACT,718,O
TRUNCATED,718,O
AT,718,O
250,718,O
WORDS,718,O
),718,O
.,718,O
Multiple,719,O
origins,719,O
for,719,O
phenylketonuria,719,B-SpecificDisease
in,719,O
Europe,719,O
.,719,O
Phenylketonuria,720,B-SpecificDisease
(,720,O
PKU,720,B-SpecificDisease
),720,O
",",720,O
a,720,O
disorder,720,B-DiseaseClass
of,720,I-DiseaseClass
amino,720,I-DiseaseClass
acid,720,I-DiseaseClass
metabolism,720,I-DiseaseClass
prevalent,720,O
among,720,O
Caucasians,720,O
and,720,O
other,720,O
ethnic,720,O
groups,720,O
",",720,O
is,720,O
caused,720,O
primarily,720,O
by,720,O
a,720,O
deficiency,720,B-SpecificDisease
of,720,I-SpecificDisease
the,720,I-SpecificDisease
hepatic,720,I-SpecificDisease
enzyme,720,I-SpecificDisease
phenylalanine,720,I-SpecificDisease
hydroxylase,720,I-SpecificDisease
(,720,O
PAH,720,O
),720,O
.,720,O
PKU,721,B-SpecificDisease
is,721,O
a,721,O
highly,721,O
heterogeneous,721,O
disorder,721,O
",",721,O
with,721,O
more,721,O
than,721,O
60,721,O
molecular,721,O
lesions,721,O
identified,721,O
in,721,O
the,721,O
PAH,721,O
gene,721,O
.,721,O
The,722,O
haplotype,722,O
associations,722,O
",",722,O
relative,722,O
frequencies,722,O
",",722,O
and,722,O
distributions,722,O
of,722,O
five,722,O
prevalent,722,O
PAH,722,O
mutations,722,O
(,722,O
R158Q,722,O
",",722,O
R261Q,722,O
",",722,O
IVS10nt546,722,O
",",722,O
R408W,722,O
",",722,O
and,722,O
IVS12n1,722,O
),722,O
were,722,O
established,722,O
in,722,O
a,722,O
comprehensive,722,O
European,722,O
sample,722,O
population,722,O
and,722,O
subsequently,722,O
were,722,O
examined,722,O
to,722,O
determine,722,O
the,722,O
potential,722,O
roles,722,O
of,722,O
several,722,O
genetic,722,O
mechanisms,722,O
in,722,O
explaining,722,O
the,722,O
present,722,O
distribution,722,O
of,722,O
the,722,O
major,722,O
PKU,722,B-Modifier
alleles,722,O
.,722,O
Each,723,O
of,723,O
these,723,O
five,723,O
mutations,723,O
was,723,O
strongly,723,O
associated,723,O
with,723,O
only,723,O
one,723,O
of,723,O
the,723,O
more,723,O
than,723,O
70,723,O
chromosomal,723,O
haplotypes,723,O
defined,723,O
by,723,O
eight,723,O
RFLPs,723,O
in,723,O
or,723,O
near,723,O
the,723,O
PAH,723,O
gene,723,O
.,723,O
These,724,O
findings,724,O
suggest,724,O
that,724,O
each,724,O
of,724,O
these,724,O
mutations,724,O
arose,724,O
through,724,O
a,724,O
single,724,O
founding,724,O
event,724,O
that,724,O
occurred,724,O
within,724,O
time,724,O
periods,724,O
ranging,724,O
from,724,O
several,724,O
hundred,724,O
to,724,O
several,724,O
thousand,724,O
years,724,O
ago,724,O
.,724,O
From,725,O
the,725,O
significant,725,O
differences,725,O
observed,725,O
in,725,O
the,725,O
relative,725,O
frequencies,725,O
and,725,O
distributions,725,O
of,725,O
these,725,O
five,725,O
alleles,725,O
throughout,725,O
Europe,725,O
",",725,O
four,725,O
of,725,O
these,725,O
putative,725,O
founding,725,O
events,725,O
could,725,O
be,725,O
localized,725,O
to,725,O
specific,725,O
ethnic,725,O
subgroups,725,O
.,725,O
Together,726,O
",",726,O
these,726,O
data,726,O
suggest,726,O
that,726,O
there,726,O
were,726,O
multiple,726,O
",",726,O
geographically,726,O
and,726,O
ethnically,726,O
distinct,726,O
origins,726,O
for,726,O
PKU,726,B-SpecificDisease
within,726,O
the,726,O
European,726,O
population,726,O
..,726,O
Complement,727,B-SpecificDisease
factor,727,I-SpecificDisease
2,727,I-SpecificDisease
deficiency,727,I-SpecificDisease
:,727,O
a,727,O
clinical,727,O
and,727,O
serological,727,O
family,727,O
study,727,O
.,727,O
Inherited,728,B-DiseaseClass
complement,728,I-DiseaseClass
deficiencies,728,I-DiseaseClass
are,728,O
associated,728,O
with,728,O
a,728,O
variety,728,O
of,728,O
connective,728,O
tissue,728,O
diseases,728,O
.,728,O
A,729,O
family,729,O
with,729,O
inherited,729,B-SpecificDisease
deficiency,729,I-SpecificDisease
of,729,I-SpecificDisease
complement,729,I-SpecificDisease
factor,729,I-SpecificDisease
2,729,I-SpecificDisease
(,729,O
C2,729,O
),729,O
is,729,O
described,729,O
in,729,O
which,729,O
two,729,O
family,729,O
members,729,O
with,729,O
homozygous,729,O
C2,729,B-SpecificDisease
deficiency,729,I-SpecificDisease
developed,729,O
cutaneous,729,B-SpecificDisease
vasculitis,729,I-SpecificDisease
and,729,O
sicca,729,B-SpecificDisease
syndrome,729,I-SpecificDisease
.,729,O
The,730,O
other,730,O
family,730,O
members,730,O
had,730,O
heterozygous,730,O
C2,730,B-SpecificDisease
deficiency,730,I-SpecificDisease
and,730,O
each,730,O
member,730,O
had,730,O
the,730,O
HLA-A25,730,O
",",730,O
B18,730,O
",",730,O
DR2,730,O
(,730,O
w15,730,O
),730,O
haplotype,730,O
.,730,O
The,731,O
mother,731,O
had,731,O
seropositive,731,B-SpecificDisease
rheumatoid,731,I-SpecificDisease
arthritis,731,I-SpecificDisease
.,731,O
Further,732,O
studies,732,O
showed,732,O
the,732,O
presence,732,O
of,732,O
cryoglobulins,732,O
",",732,O
antibodies,732,O
against,732,O
endothelial,732,O
cells,732,O
",",732,O
and,732,O
anticardiolipin,732,O
antibodies,732,O
..,732,O
New,733,O
variant,733,O
in,733,O
exon,733,O
3,733,O
of,733,O
the,733,O
proteolipid,733,O
protein,733,O
(,733,O
PLP,733,O
),733,O
gene,733,O
in,733,O
a,733,O
family,733,O
with,733,O
Pelizaeus-Merzbacher,733,B-SpecificDisease
disease,733,I-SpecificDisease
.,733,O
A,734,O
C,734,O
--,734,O
greater,734,O
than,734,O
G,734,O
transversion,734,O
has,734,O
been,734,O
found,734,O
in,734,O
exon,734,O
3,734,O
of,734,O
the,734,O
PLP,734,O
gene,734,O
of,734,O
affected,734,O
males,734,O
and,734,O
their,734,O
mother,734,O
in,734,O
a,734,O
single,734,O
sibship,734,O
with,734,O
Pelizaeus-merzbacher,734,B-SpecificDisease
disease,734,I-SpecificDisease
(,734,O
PMD,734,B-SpecificDisease
),734,O
.,734,O
The,735,O
transversion,735,O
should,735,O
not,735,O
result,735,O
in,735,O
an,735,O
amino,735,O
acid,735,O
change,735,O
in,735,O
the,735,O
protein,735,O
but,735,O
it,735,O
does,735,O
result,735,O
in,735,O
the,735,O
loss,735,O
of,735,O
a,735,O
HaeIII,735,O
restriction,735,O
endonuclease,735,O
cleavage,735,O
site,735,O
.,735,O
It,736,O
is,736,O
concordant,736,O
with,736,O
the,736,O
disease,736,O
in,736,O
this,736,O
family,736,O
.,736,O
One-hundred-ten,737,O
unrelated,737,O
X,737,O
chromosomes,737,O
are,737,O
negative,737,O
for,737,O
this,737,O
mutation,737,O
.,737,O
No,738,O
other,738,O
sequence,738,O
defect,738,O
was,738,O
found,738,O
in,738,O
the,738,O
PLP,738,O
exons,738,O
of,738,O
the,738,O
affected,738,O
males,738,O
.,738,O
The,739,O
cause,739,O
of,739,O
disease,739,O
in,739,O
this,739,O
family,739,O
remains,739,O
unknown,739,O
",",739,O
but,739,O
the,739,O
association,739,O
between,739,O
this,739,O
rare,739,O
mutation,739,O
and,739,O
PMD,739,B-SpecificDisease
is,739,O
intriguing,739,O
.,739,O
The,740,O
mutation,740,O
can,740,O
serve,740,O
as,740,O
a,740,O
marker,740,O
for,740,O
following,740,O
segregation,740,O
of,740,O
the,740,O
PLP,740,O
gene,740,O
..,740,O
Uncoupling,741,O
of,741,O
hypomyelination,741,B-SpecificDisease
and,741,O
glial,741,B-SpecificDisease
cell,741,I-SpecificDisease
death,741,I-SpecificDisease
by,741,O
a,741,O
mutation,741,O
in,741,O
the,741,O
proteolipid,741,O
protein,741,O
gene,741,O
.,741,O
Proteolipid,742,O
protein,742,O
(,742,O
PLP,742,O
;,742,O
M,742,O
(,742,O
r,742,O
),742,O
30,742,O
",",742,O
000,742,O
),742,O
is,742,O
a,742,O
highly,742,O
conserved,742,O
major,742,O
polytopic,742,O
membrane,742,O
protein,742,O
in,742,O
myelin,742,O
but,742,O
its,742,O
cellular,742,O
function,742,O
remains,742,O
obscure,742,O
.,742,O
Neurological,743,O
mutant,743,O
mice,743,O
can,743,O
often,743,O
provide,743,O
model,743,O
systems,743,O
for,743,O
human,743,O
genetic,743,B-DiseaseClass
disorders,743,I-DiseaseClass
.,743,O
Mutations,744,O
of,744,O
the,744,O
X-chromosome-linked,744,O
PLP,744,O
gene,744,O
are,744,O
lethal,744,O
",",744,O
identified,744,O
first,744,O
in,744,O
the,744,O
jimpy,744,O
mouse,744,O
and,744,O
subsequently,744,O
in,744,O
patients,744,O
with,744,O
Pelizaeus-Merzbacher,744,B-SpecificDisease
disease,744,I-SpecificDisease
.,744,O
The,745,O
unexplained,745,O
phenotype,745,O
of,745,O
these,745,O
mutations,745,O
includes,745,O
degeneration,745,B-CompositeMention
and,745,I-CompositeMention
premature,745,I-CompositeMention
cell,745,I-CompositeMention
death,745,I-CompositeMention
of,745,I-CompositeMention
oligodendrocytes,745,I-CompositeMention
with,745,O
associated,745,O
hypomyelination,745,B-SpecificDisease
.,745,O
Here,746,O
we,746,O
show,746,O
that,746,O
a,746,O
new,746,O
mouse,746,O
mutant,746,O
rumpshaker,746,O
is,746,O
defined,746,O
by,746,O
the,746,O
amino-acid,746,O
substitution,746,O
Ile-to-Thr,746,O
at,746,O
residue,746,O
186,746,O
in,746,O
a,746,O
membrane-embedded,746,O
domain,746,O
of,746,O
PLP,746,O
.,746,O
Surprisingly,747,O
",",747,O
rumpshaker,747,O
mice,747,O
",",747,O
although,747,O
myelin-deficient,747,B-SpecificDisease
",",747,O
have,747,O
normal,747,O
longevity,747,O
and,747,O
a,747,O
full,747,O
complement,747,O
of,747,O
morphologically,747,O
normal,747,O
oligodendrocytes,747,O
.,747,O
Hypomyelination,748,B-SpecificDisease
can,748,O
thus,748,O
be,748,O
genetically,748,O
separated,748,O
from,748,O
the,748,O
PLP-dependent,748,O
oligodendrocyte,748,B-SpecificDisease
degeneration,748,I-SpecificDisease
.,748,O
We,749,O
suggest,749,O
that,749,O
PLP,749,O
has,749,O
a,749,O
vital,749,O
function,749,O
in,749,O
glial,749,O
cell,749,O
development,749,O
",",749,O
distinct,749,O
from,749,O
its,749,O
later,749,O
role,749,O
in,749,O
myelin,749,O
assembly,749,O
",",749,O
and,749,O
that,749,O
this,749,O
dichotomy,749,O
of,749,O
action,749,O
may,749,O
explain,749,O
the,749,O
clinical,749,O
spectrum,749,O
of,749,O
Pelizaeus-Merzbacher,749,B-SpecificDisease
disease,749,I-SpecificDisease
..,749,O
A,750,O
pseudodeficiency,750,O
allele,750,O
common,750,O
in,750,O
non-Jewish,750,O
Tay-Sachs,750,B-Modifier
carriers,750,O
:,750,O
implications,750,O
for,750,O
carrier,750,O
screening,750,O
.,750,O
Deficiency,751,B-SpecificDisease
of,751,I-SpecificDisease
beta-hexosaminidase,751,I-SpecificDisease
A,751,I-SpecificDisease
(,751,O
Hex,751,O
A,751,O
),751,O
activity,751,O
typically,751,O
results,751,O
in,751,O
Tay-Sachs,751,B-SpecificDisease
disease,751,I-SpecificDisease
.,751,O
However,752,O
",",752,O
healthy,752,O
subjects,752,O
found,752,O
to,752,O
be,752,O
deficient,752,B-SpecificDisease
in,752,I-SpecificDisease
Hex,752,I-SpecificDisease
A,752,I-SpecificDisease
activity,752,O
(,752,O
i.,752,O
e.,752,O
",",752,O
pseudodeficient,752,O
),752,O
by,752,O
means,752,O
of,752,O
in,752,O
vitro,752,O
biochemical,752,O
tests,752,O
have,752,O
been,752,O
described,752,O
.,752,O
We,753,O
analyzed,753,O
the,753,O
HEXA,753,O
gene,753,O
of,753,O
one,753,O
pseudodeficient,753,O
subject,753,O
and,753,O
identified,753,O
both,753,O
a,753,O
C739-to-T,753,O
substitution,753,O
that,753,O
changes,753,O
Arg247,753,O
--,753,O
--,753,O
Trp,753,O
on,753,O
one,753,O
allele,753,O
and,753,O
a,753,O
previously,753,O
identified,753,O
Tay-Sachs,753,B-Modifier
disease,753,I-Modifier
mutation,753,O
on,753,O
the,753,O
second,753,O
allele,753,O
.,753,O
Six,754,O
additional,754,O
pseudodeficient,754,O
subjects,754,O
were,754,O
found,754,O
to,754,O
have,754,O
the,754,O
C739-to-T,754,O
mutation,754,O
.,754,O
This,755,O
allele,755,O
accounted,755,O
for,755,O
32,755,O
%,755,O
(,755,O
20/62,755,O
),755,O
of,755,O
non-Jewish,755,O
enzyme-defined,755,O
Tay-Sachs,755,B-Modifier
disease,755,I-Modifier
carriers,755,O
but,755,O
for,755,O
none,755,O
of,755,O
36,755,O
Jewish,755,O
enzyme-defined,755,O
carriers,755,O
who,755,O
did,755,O
not,755,O
have,755,O
one,755,O
of,755,O
three,755,O
known,755,O
mutations,755,O
common,755,O
to,755,O
this,755,O
group,755,O
.,755,O
The,756,O
C739-to-T,756,O
allele,756,O
",",756,O
together,756,O
with,756,O
a,756,O
``,756,O
true,756,O
``,756,O
Tay-Sachs,756,B-Modifier
disease,756,I-Modifier
allele,756,O
",",756,O
causes,756,O
Hex,756,O
A,756,O
pseudodeficiency,756,O
.,756,O
Given,757,O
both,757,O
the,757,O
large,757,O
proportion,757,O
of,757,O
non-Jewish,757,O
carriers,757,O
with,757,O
this,757,O
allele,757,O
and,757,O
that,757,O
standard,757,O
biochemical,757,O
screening,757,O
can,757,O
not,757,O
differentiate,757,O
between,757,O
heterozygotes,757,O
for,757,O
the,757,O
C739-to-T,757,O
mutations,757,O
and,757,O
Tay-Sachs,757,B-Modifier
disease,757,I-Modifier
carriers,757,O
",",757,O
DNA,757,O
testing,757,O
for,757,O
this,757,O
mutation,757,O
in,757,O
at-risk,757,O
couples,757,O
is,757,O
essential,757,O
.,757,O
Pelizaeus-Merzbacher,758,B-SpecificDisease
disease,758,I-SpecificDisease
:,758,O
detection,758,O
of,758,O
mutations,758,O
Thr181,758,O
--,758,O
--,758,O
Pro,758,O
and,758,O
Leu223,758,O
--,758,O
--,758,O
Pro,758,O
in,758,O
the,758,O
proteolipid,758,O
protein,758,O
gene,758,O
",",758,O
and,758,O
prenatal,758,O
diagnosis,758,O
.,758,O
A,759,O
family,759,O
with,759,O
an,759,O
apparent,759,O
history,759,O
of,759,O
X-linked,759,O
Pelizaeus-Merzbacher,759,B-SpecificDisease
disease,759,I-SpecificDisease
presented,759,O
for,759,O
genetic,759,O
counseling,759,O
",",759,O
requesting,759,O
carrier,759,O
detection,759,O
and,759,O
prenatal,759,O
diagnosis,759,O
.,759,O
RFLP,760,O
analysis,760,O
using,760,O
the,760,O
proteolipid,760,O
protein,760,O
(,760,O
PLP,760,O
),760,O
gene,760,O
probe,760,O
was,760,O
uninformative,760,O
in,760,O
this,760,O
family,760,O
.,760,O
A,761,O
prenatal,761,O
diagnosis,761,O
on,761,O
a,761,O
chorionic,761,O
villus,761,O
sample,761,O
(,761,O
CVS,761,O
),761,O
was,761,O
carried,761,O
out,761,O
using,761,O
single-strand,761,O
conformation,761,O
polymorphism,761,O
(,761,O
SSCP,761,O
),761,O
analysis,761,O
of,761,O
a,761,O
variant,761,O
in,761,O
exon,761,O
4,761,O
of,761,O
the,761,O
PLP,761,O
gene,761,O
.,761,O
The,762,O
fetus,762,O
was,762,O
predicted,762,O
to,762,O
be,762,O
unaffected,762,O
.,762,O
Sequencing,763,O
of,763,O
the,763,O
exon,763,O
from,763,O
the,763,O
CVS,763,O
",",763,O
the,763,O
predicted-carrier,763,O
mother,763,O
",",763,O
and,763,O
the,763,O
obligate-carrier,763,O
grandmother,763,O
revealed,763,O
an,763,O
A-to-C,763,O
change,763,O
at,763,O
nucleotide,763,O
541,763,O
in,763,O
the,763,O
two,763,O
women,763,O
but,763,O
not,763,O
in,763,O
the,763,O
fetus,763,O
.,763,O
As,764,O
this,764,O
change,764,O
results,764,O
in,764,O
a,764,O
Thr-to-Pro,764,O
change,764,O
at,764,O
amino,764,O
acid,764,O
181,764,O
in,764,O
a,764,O
region,764,O
of,764,O
the,764,O
gene,764,O
predicted,764,O
to,764,O
be,764,O
part,764,O
of,764,O
a,764,O
transmembrane,764,O
segment,764,O
",",764,O
it,764,O
was,764,O
concluded,764,O
that,764,O
this,764,O
was,764,O
the,764,O
mutation,764,O
causing,764,O
the,764,O
disease,764,O
in,764,O
this,764,O
family,764,O
.,764,O
In,765,O
addition,765,O
",",765,O
in,765,O
a,765,O
second,765,O
family,765,O
",",765,O
an,765,O
exon,765,O
5,765,O
variant,765,O
band,765,O
pattern,765,O
on,765,O
SSCP,765,O
analysis,765,O
was,765,O
shown,765,O
by,765,O
sequencing,765,O
to,765,O
be,765,O
due,765,O
to,765,O
a,765,O
T-to-C,765,O
change,765,O
at,765,O
nucleotide,765,O
668,765,O
.,765,O
This,766,O
results,766,O
in,766,O
a,766,O
Leu-to-Pro,766,O
change,766,O
in,766,O
a,766,O
carrier,766,O
mother,766,O
and,766,O
in,766,O
her,766,O
two,766,O
affected,766,O
sons,766,O
.,766,O
These,767,O
results,767,O
provide,767,O
further,767,O
examples,767,O
of,767,O
mutations,767,O
in,767,O
PLP,767,O
that,767,O
cause,767,O
Pelizaeus-Merzbacher,767,B-SpecificDisease
disease,767,I-SpecificDisease
and,767,O
illustrate,767,O
the,767,O
value,767,O
of,767,O
SSCP,767,O
in,767,O
genetic,767,O
analysis,767,O
..,767,O
von,768,B-SpecificDisease
Willebrand,768,I-SpecificDisease
disease,768,I-SpecificDisease
type,768,I-SpecificDisease
B,768,I-SpecificDisease
:,768,O
a,768,O
missense,768,O
mutation,768,O
selectively,768,O
abolishes,768,O
ristocetin-induced,768,O
von,768,B-Modifier
Willebrand,768,I-Modifier
factor,768,O
binding,768,O
to,768,O
platelet,768,O
glycoprotein,768,O
Ib,768,O
.,768,O
von,769,B-Modifier
Willebrand,769,I-Modifier
factor,769,O
(,769,O
vWF,769,O
),769,O
is,769,O
a,769,O
multimeric,769,O
glycoprotein,769,O
that,769,O
mediates,769,O
the,769,O
adhesion,769,O
of,769,O
platelets,769,O
to,769,O
the,769,O
subendothelium,769,O
by,769,O
binding,769,O
to,769,O
platelet,769,O
glycoprotein,769,O
Ib,769,O
.,769,O
For,770,O
human,770,O
vWF,770,O
",",770,O
this,770,O
interaction,770,O
can,770,O
be,770,O
induced,770,O
in,770,O
vitro,770,O
by,770,O
the,770,O
antibiotic,770,O
ristocetin,770,O
or,770,O
the,770,O
snake,770,O
venom,770,O
protein,770,O
botrocetin,770,O
.,770,O
A,771,O
missense,771,O
mutation,771,O
",",771,O
Gly-561,771,O
--,771,O
>,771,O
Ser,771,O
",",771,O
was,771,O
identified,771,O
within,771,O
the,771,O
proposed,771,O
glycoprotein,771,O
Ib,771,O
binding,771,O
domain,771,O
of,771,O
vWF,771,O
in,771,O
the,771,O
proband,771,O
with,771,O
von,771,B-SpecificDisease
Willebrand,771,I-SpecificDisease
disease,771,I-SpecificDisease
type,771,I-SpecificDisease
B,771,I-SpecificDisease
",",771,O
a,771,O
unique,771,O
variant,771,O
characterized,771,O
by,771,O
no,771,O
ristocetin-induced,771,O
",",771,O
but,771,O
normal,771,O
botrocetin-induced,771,O
",",771,O
binding,771,O
to,771,O
glycoprotein,771,O
Ib,771,O
.,771,O
The,772,O
corresponding,772,O
mutant,772,O
recombinant,772,O
protein,772,O
",",772,O
rvWF,772,O
(,772,O
G561S,772,O
),772,O
",",772,O
formed,772,O
normal,772,O
multimers,772,O
and,772,O
exhibited,772,O
the,772,O
same,772,O
functional,772,O
defect,772,O
as,772,O
the,772,O
patients,772,O
plasma,772,O
vWF,772,O
",",772,O
confirming,772,O
that,772,O
this,772,O
mutation,772,O
causes,772,O
von,772,B-SpecificDisease
Willebrand,772,I-SpecificDisease
disease,772,I-SpecificDisease
type,772,I-SpecificDisease
B,772,I-SpecificDisease
.,772,O
These,773,O
data,773,O
show,773,O
that,773,O
botrocetin,773,O
and,773,O
ristocetin,773,O
cofactor,773,O
activities,773,O
of,773,O
vWF,773,O
can,773,O
be,773,O
dissociated,773,O
by,773,O
a,773,O
point,773,O
mutation,773,O
and,773,O
confirm,773,O
that,773,O
these,773,O
mediators,773,O
promote,773,O
vWF,773,O
binding,773,O
to,773,O
platelets,773,O
by,773,O
different,773,O
mechanisms,773,O
.,773,O
The,774,O
normal,774,O
botrocetin-induced,774,O
binding,774,O
and,774,O
the,774,O
defective,774,O
ristocetin-induced,774,O
binding,774,O
of,774,O
rvWF,774,O
(,774,O
G561S,774,O
),774,O
suggest,774,O
that,774,O
the,774,O
primary,774,O
defect,774,O
in,774,O
von,774,B-SpecificDisease
Willebrand,774,I-SpecificDisease
disease,774,I-SpecificDisease
type,774,I-SpecificDisease
B,774,I-SpecificDisease
may,774,O
be,774,O
a,774,O
failure,774,O
of,774,O
normal,774,O
allosteric,774,O
regulation,774,O
of,774,O
the,774,O
glycoprotein,774,O
Ib,774,O
binding,774,O
function,774,O
of,774,O
vWF,774,O
..,774,O
Typical,775,O
and,775,O
partial,775,O
cat,775,O
eye,775,O
syndrome,775,O
:,775,O
identification,775,O
of,775,O
the,775,O
marker,775,O
chromosome,775,O
by,775,O
FISH,775,O
.,775,O
Three,776,O
children,776,O
are,776,O
reported,776,O
with,776,O
typical,776,O
cat,776,O
eye,776,O
syndrome,776,O
(,776,O
CES,776,O
),776,O
and,776,O
three,776,O
more,776,O
children,776,O
with,776,O
partial,776,O
CES,776,O
because,776,O
of,776,O
absence,776,O
of,776,O
coloboma,776,O
",",776,O
in,776,O
which,776,O
the,776,O
supernumerary,776,O
marker,776,O
chromosome,776,O
was,776,O
studied,776,O
by,776,O
FISH,776,O
.,776,O
Using,777,O
a,777,O
genomic,777,O
library,777,O
",",777,O
and,777,O
also,777,O
a,777,O
centromeric,777,O
and,777,O
particularly,777,O
a,777,O
cosmid,777,O
probe,777,O
of,777,O
22q11,777,O
",",777,O
partial,777,O
tetrasomy,777,B-DiseaseClass
was,777,O
shown,777,O
in,777,O
all,777,O
cases,777,O
..,777,O
Craniofrontonasal,778,B-SpecificDisease
dysplasia,778,I-SpecificDisease
.,778,O
We,779,O
report,779,O
on,779,O
nine,779,O
patients,779,O
with,779,O
craniofrontonasal,779,B-SpecificDisease
dysplasia,779,I-SpecificDisease
(,779,O
CFND,779,B-SpecificDisease
),779,O
.,779,O
Seven,780,O
classical,780,O
cases,780,O
had,780,O
facial,780,O
features,780,O
suggestive,780,O
of,780,O
frontonasal,780,B-SpecificDisease
dysplasia,780,I-SpecificDisease
and,780,O
coronal,780,B-SpecificDisease
craniosynostosis,780,I-SpecificDisease
.,780,O
Extracranial,781,B-DiseaseClass
abnormalities,781,I-DiseaseClass
such,781,O
as,781,O
brittle,781,B-SpecificDisease
nails,781,I-SpecificDisease
with,781,I-SpecificDisease
prominent,781,I-SpecificDisease
longitudinal,781,I-SpecificDisease
grooves,781,I-SpecificDisease
or,781,O
syndactyly,781,B-CompositeMention
of,781,I-CompositeMention
fingers,781,I-CompositeMention
and,781,I-CompositeMention
toes,781,I-CompositeMention
were,781,O
observed,781,O
in,781,O
individual,781,O
patients,781,O
.,781,O
In,782,O
two,782,O
families,782,O
the,782,O
father,782,O
of,782,O
classical,782,O
cases,782,O
showed,782,O
a,782,O
milder,782,O
pattern,782,O
of,782,O
abnormalities,782,O
",",782,O
consistent,782,O
with,782,O
the,782,O
diagnosis,782,O
.,782,O
We,783,O
present,783,O
a,783,O
2-,783,O
to,783,O
13-year,783,O
follow-up,783,O
on,783,O
our,783,O
patients,783,O
.,783,O
Hypotonia,784,B-SpecificDisease
and,784,O
laxity,784,B-SpecificDisease
of,784,I-SpecificDisease
joints,784,I-SpecificDisease
are,784,O
common,784,O
and,784,O
may,784,O
necessitate,784,O
supportive,784,O
measures,784,O
.,784,O
Mild,785,O
developmental,785,B-DiseaseClass
delay,785,I-DiseaseClass
was,785,O
noted,785,O
in,785,O
three,785,O
out,785,O
of,785,O
six,785,O
classical,785,O
cases,785,O
studied,785,O
in,785,O
detail,785,O
.,785,O
Unlike,786,O
almost,786,O
all,786,O
other,786,O
X-linked,786,B-DiseaseClass
disorders,786,I-DiseaseClass
",",786,O
clinical,786,O
expression,786,O
in,786,O
CFND,786,B-SpecificDisease
is,786,O
generally,786,O
much,786,O
more,786,O
severe,786,O
in,786,O
females,786,O
than,786,O
in,786,O
males,786,O
.,786,O
In,787,O
contrast,787,O
to,787,O
previous,787,O
reports,787,O
of,787,O
this,787,O
condition,787,O
",",787,O
one,787,O
of,787,O
our,787,O
severely,787,O
affected,787,O
cases,787,O
is,787,O
a,787,O
male,787,O
..,787,O
The,788,O
intron,788,O
7,788,O
donor,788,O
splice,788,O
site,788,O
transition,788,O
:,788,O
a,788,O
second,788,O
Tay-Sachs,788,B-Modifier
disease,788,I-Modifier
mutation,788,O
in,788,O
French,788,O
Canada,788,O
.,788,O
Mutations,789,O
at,789,O
the,789,O
hexosaminidase,789,O
A,789,O
(,789,O
HEXA,789,O
),789,O
gene,789,O
which,789,O
cause,789,O
Tay-Sachs,789,B-SpecificDisease
disease,789,I-SpecificDisease
(,789,O
TSD,789,B-SpecificDisease
),789,O
have,789,O
elevated,789,O
frequency,789,O
in,789,O
the,789,O
Ashkenazi,789,O
Jewish,789,O
and,789,O
French-Canadian,789,O
populations,789,O
.,789,O
We,790,O
report,790,O
a,790,O
novel,790,O
TSD,790,B-Modifier
allele,790,O
in,790,O
the,790,O
French-Canadian,790,O
population,790,O
associated,790,O
with,790,O
the,790,O
infantile,790,O
form,790,O
of,790,O
the,790,O
disease,790,O
.,790,O
The,791,O
mutation,791,O
",",791,O
a,791,O
G,791,O
--,791,O
>,791,O
A,791,O
transition,791,O
at,791,O
the,791,O
+,791,O
1,791,O
position,791,O
of,791,O
intron,791,O
7,791,O
",",791,O
abolishes,791,O
the,791,O
donor,791,O
splice,791,O
site,791,O
.,791,O
Cultured,792,O
human,792,O
fibroblasts,792,O
from,792,O
a,792,O
compound,792,O
heterozygote,792,O
for,792,O
this,792,O
transition,792,O
(,792,O
and,792,O
for,792,O
a,792,O
deletion,792,O
mutation,792,O
),792,O
produce,792,O
no,792,O
detectable,792,O
HEXA,792,O
mRNA,792,O
.,792,O
The,793,O
intron,793,O
7,793,O
+,793,O
1,793,O
mutation,793,O
occurs,793,O
in,793,O
the,793,O
base,793,O
adjacent,793,O
to,793,O
the,793,O
site,793,O
of,793,O
the,793,O
adult-onset,793,O
TSD,793,B-Modifier
mutation,793,O
(,793,O
G805A,793,O
),793,O
.,793,O
In,794,O
both,794,O
mutations,794,O
a,794,O
restriction,794,O
site,794,O
for,794,O
the,794,O
endonuclease,794,O
EcoRII,794,O
is,794,O
abolished,794,O
.,794,O
Unambiguous,795,O
diagnosis,795,O
",",795,O
therefore,795,O
",",795,O
requires,795,O
allele-specific,795,O
oligonucleotide,795,O
hybridization,795,O
to,795,O
distinguish,795,O
between,795,O
these,795,O
two,795,O
mutant,795,O
alleles,795,O
.,795,O
The,796,O
intron,796,O
7,796,O
+,796,O
1,796,O
mutation,796,O
has,796,O
been,796,O
detected,796,O
in,796,O
three,796,O
unrelated,796,O
families,796,O
.,796,O
Obligate,797,O
heterozygotes,797,O
for,797,O
the,797,O
intron,797,O
7,797,O
+,797,O
1,797,O
mutation,797,O
were,797,O
born,797,O
in,797,O
the,797,O
Saguenay-Lac-St-Jean,797,O
region,797,O
of,797,O
Quebec,797,O
.,797,O
The,798,O
most,798,O
recent,798,O
ancestors,798,O
common,798,O
to,798,O
obligate,798,O
carriers,798,O
of,798,O
this,798,O
mutation,798,O
were,798,O
from,798,O
the,798,O
Charlevoix,798,O
region,798,O
of,798,O
the,798,O
province,798,O
of,798,O
Quebec,798,O
.,798,O
This,799,O
mutation,799,O
thus,799,O
has,799,O
a,799,O
different,799,O
geographic,799,O
centre,799,O
of,799,O
diffusion,799,O
and,799,O
is,799,O
probably,799,O
less,799,O
common,799,O
than,799,O
the,799,O
exon,799,O
1,799,O
deletion,799,O
TSD,799,B-Modifier
mutation,799,O
in,799,O
French,799,O
Canadians,799,O
.,799,O
Neither,800,O
mutation,800,O
has,800,O
been,800,O
detected,800,O
in,800,O
France,800,O
",",800,O
the,800,O
ancestral,800,O
homeland,800,O
of,800,O
French,800,O
Canada,800,O
..,800,O
Assignment,801,O
of,801,O
the,801,O
aspartylglucosaminidase,801,O
gene,801,O
(,801,O
AGA,801,O
),801,O
to,801,O
4q33,801,O
--,801,O
--,801,O
q35,801,O
based,801,O
on,801,O
decreased,801,O
activity,801,O
in,801,O
a,801,O
girl,801,O
with,801,O
a,801,O
46,801,O
",",801,O
XX,801,O
",",801,O
del,801,O
(,801,O
4,801,O
),801,O
(,801,O
q33,801,O
),801,O
karyotype,801,O
.,801,O
Aspartylglucosaminuria,802,B-SpecificDisease
(,802,O
AGU,802,B-SpecificDisease
),802,O
is,802,O
a,802,O
recessive,802,O
autosomally,802,O
inherited,802,O
lysosomal,802,B-DiseaseClass
storage,802,I-DiseaseClass
disorder,802,I-DiseaseClass
due,802,O
to,802,O
deficiency,802,B-SpecificDisease
of,802,I-SpecificDisease
the,802,I-SpecificDisease
enzyme,802,I-SpecificDisease
aspartylglucosaminidase,802,I-SpecificDisease
(,802,O
AGA,802,O
),802,O
.,802,O
The,803,O
structural,803,O
gene,803,O
for,803,O
this,803,O
human,803,O
enzyme,803,O
(,803,O
AGA,803,O
),803,O
has,803,O
been,803,O
assigned,803,O
to,803,O
the,803,O
region,803,O
4q21,803,O
--,803,O
--,803,O
qter,803,O
.,803,O
We,804,O
determined,804,O
the,804,O
AGA,804,O
activity,804,O
in,804,O
cultured,804,O
fibroblasts,804,O
of,804,O
a,804,O
girl,804,O
with,804,O
a,804,O
46,804,O
",",804,O
XX,804,O
",",804,O
del,804,O
(,804,O
4,804,O
),804,O
(,804,O
q33,804,O
),804,O
karyotype,804,O
.,804,O
The,805,O
results,805,O
indicate,805,O
that,805,O
the,805,O
girl,805,O
is,805,O
a,805,O
hemizygote,805,O
for,805,O
AGA,805,O
",",805,O
permitting,805,O
the,805,O
assignment,805,O
of,805,O
human,805,O
AGA,805,O
to,805,O
the,805,O
region,805,O
4q33,805,O
--,805,O
--,805,O
qter,805,O
..,805,O
Resolution,806,O
of,806,O
the,806,O
two,806,O
loci,806,O
for,806,O
autosomal,806,O
dominant,806,O
aniridia,806,B-SpecificDisease
",",806,O
AN1,806,O
and,806,O
AN2,806,O
",",806,O
to,806,O
a,806,O
single,806,O
locus,806,O
on,806,O
chromosome,806,O
11p13,806,O
.,806,O
Two,807,O
distinct,807,O
loci,807,O
have,807,O
been,807,O
proposed,807,O
for,807,O
aniridia,807,B-SpecificDisease
;,807,O
AN1,807,O
for,807,O
autosomal,807,O
dominant,807,O
aniridia,807,B-SpecificDisease
on,807,O
chromosome,807,O
2p,807,O
and,807,O
AN2,807,O
for,807,O
the,807,O
aniridia,807,B-SpecificDisease
in,807,O
the,807,O
WAGR,807,B-SpecificDisease
contiguous,807,I-SpecificDisease
gene,807,I-SpecificDisease
syndrome,807,I-SpecificDisease
on,807,O
chromosome,807,O
11p13,807,O
.,807,O
In,808,O
this,808,O
report,808,O
",",808,O
the,808,O
kindred,808,O
segregating,808,O
for,808,O
autosomal,808,O
dominant,808,O
aniridia,808,B-SpecificDisease
",",808,O
which,808,O
suggested,808,O
linkage,808,O
to,808,O
acid,808,O
phosphatase-1,808,O
(,808,O
ACP1,808,O
),808,O
and,808,O
led,808,O
to,808,O
the,808,O
assignment,808,O
of,808,O
the,808,O
AN1,808,O
locus,808,O
on,808,O
chromosome,808,O
2p,808,O
",",808,O
has,808,O
been,808,O
updated,808,O
and,808,O
expanded,808,O
.,808,O
Linkage,809,O
analysis,809,O
between,809,O
the,809,O
aniridia,809,B-SpecificDisease
phenotype,809,O
and,809,O
ACP1,809,O
does,809,O
not,809,O
support,809,O
the,809,O
original,809,O
linkage,809,O
results,809,O
",",809,O
excluding,809,O
linkage,809,O
up,809,O
to,809,O
theta,809,O
=,809,O
0,809,O
.,809,O
17,810,O
with,810,O
Z,810,O
=,810,O
-2,810,O
.,810,O
Tests,811,O
for,811,O
linkage,811,O
to,811,O
other,811,O
chromosome,811,O
2p,811,O
markers,811,O
.,811,O
APOB,812,O
",",812,O
D2S71,812,O
",",812,O
D2S5,812,O
",",812,O
and,812,O
D2S1,812,O
",",812,O
also,812,O
excluded,812,O
linkage,812,O
to,812,O
aniridia,812,B-SpecificDisease
.,812,O
Markers,813,O
that,813,O
have,813,O
been,813,O
isolated,813,O
from,813,O
the,813,O
chromosome,813,O
11p13,813,O
region,813,O
were,813,O
then,813,O
analyzed,813,O
in,813,O
this,813,O
aniridia,813,B-Modifier
family,813,O
.,813,O
Two,814,O
RFLPs,814,O
at,814,O
the,814,O
D11S323,814,O
locus,814,O
give,814,O
significant,814,O
evidence,814,O
for,814,O
linkage,814,O
.,814,O
The,815,O
PvuII,815,O
polymorphism,815,O
detected,815,O
by,815,O
probe,815,O
p5S1,815,O
.,815,O
6,816,O
detects,816,O
no,816,O
recombinants,816,O
",",816,O
with,816,O
a,816,O
maximum,816,O
lod,816,O
score,816,O
of,816,O
Z,816,O
=,816,O
6,816,O
.,816,O
97,817,O
at,817,O
theta,817,O
=,817,O
0,817,O
.,817,O
00,818,O
00,818,O
.,818,O
The,819,O
HaeIII,819,O
polymorphism,819,O
detected,819,O
by,819,O
the,819,O
probe,819,O
p5BE1,819,O
.,819,O
2,820,O
gives,820,O
a,820,O
maximum,820,O
lod,820,O
score,820,O
of,820,O
Z,820,O
=,820,O
2,820,O
.,820,O
57,821,O
at,821,O
theta,821,O
=,821,O
0,821,O
.,821,O
00,822,O
00,822,O
.,822,O
Locus,823,O
D11S325,823,O
gives,823,O
a,823,O
lod,823,O
score,823,O
of,823,O
Z,823,O
=,823,O
1,823,O
.,823,O
53,824,O
at,824,O
theta,824,O
=,824,O
0,824,O
.,824,O
00,825,O
00,825,O
.,825,O
These,826,O
data,826,O
suggest,826,O
that,826,O
a,826,O
locus,826,O
for,826,O
aniridia,826,B-SpecificDisease
(,826,O
AN1,826,O
),826,O
on,826,O
chromosome,826,O
2p,826,O
has,826,O
been,826,O
misassigned,826,O
and,826,O
that,826,O
this,826,O
autosomal,826,O
dominant,826,O
aniridia,826,B-Modifier
family,826,O
is,826,O
segregating,826,O
for,826,O
an,826,O
aniridia,826,B-Modifier
mutation,826,O
linked,826,O
to,826,O
markers,826,O
in,826,O
the,826,O
11p13,826,O
region,826,O
.,826,O
Fatal,827,O
pyoderma,827,B-SpecificDisease
gangrenosum,827,I-SpecificDisease
in,827,O
association,827,O
with,827,O
C7,827,B-SpecificDisease
deficiency,827,I-SpecificDisease
.,827,O
Although,828,O
pyoderma,828,B-SpecificDisease
gangrenosum,828,I-SpecificDisease
(,828,O
PG,828,B-SpecificDisease
),828,O
is,828,O
often,828,O
associated,828,O
with,828,O
systemic,828,B-DiseaseClass
diseases,828,I-DiseaseClass
",",828,O
it,828,O
has,828,O
not,828,O
been,828,O
reported,828,O
in,828,O
association,828,O
with,828,O
congenital,828,B-DiseaseClass
complement,828,I-DiseaseClass
deficiencies,828,I-DiseaseClass
.,828,O
We,829,O
describe,829,O
an,829,O
aggressive,829,O
and,829,O
ultimately,829,O
fatal,829,O
case,829,O
of,829,O
PG,829,B-SpecificDisease
in,829,O
a,829,O
patient,829,O
with,829,O
a,829,O
congenital,829,O
C7,829,B-SpecificDisease
deficiency,829,I-SpecificDisease
.,829,O
Deficiencies,830,B-SpecificDisease
of,830,I-SpecificDisease
C7,830,I-SpecificDisease
can,830,O
be,830,O
associated,830,O
with,830,O
decreased,830,O
neutrophil,830,O
chemotaxis,830,O
",",830,O
phagocytosis,830,O
",",830,O
and,830,O
opsonization,830,O
",",830,O
similar,830,O
to,830,O
the,830,O
immunologic,830,B-DiseaseClass
abnormalities,830,I-DiseaseClass
described,830,O
in,830,O
patients,830,O
with,830,O
PG,830,B-SpecificDisease
.,830,O
Our,831,O
patients,831,O
decreased,831,O
complement,831,O
level,831,O
",",831,O
if,831,O
not,831,O
directly,831,O
related,831,O
to,831,O
the,831,O
development,831,O
of,831,O
PG,831,B-SpecificDisease
",",831,O
may,831,O
have,831,O
contributed,831,O
to,831,O
the,831,O
aggressive,831,O
nature,831,O
of,831,O
her,831,O
disease,831,O
..,831,O
Diverse,832,O
point,832,O
mutations,832,O
result,832,O
in,832,O
glucose-6-phosphate,832,O
dehydrogenase,832,O
(,832,O
G6PD,832,O
),832,O
polymorphism,832,O
in,832,O
Taiwan,832,O
.,832,O
Glucose-6-PHOSPHATE,833,O
dehydrogenase,833,O
(,833,O
G6PD,833,O
;,833,O
EC,833,O
1.1,833,O
.,833,O
1,834,O
.,834,O
49,835,O
),835,O
deficiency,835,O
is,835,O
the,835,O
most,835,O
common,835,O
human,835,O
enzymopathy,835,B-DiseaseClass
",",835,O
affecting,835,O
more,835,O
than,835,O
200,835,O
million,835,O
people,835,O
worldwide,835,O
.,835,O
Although,836,O
greater,836,O
than,836,O
400,836,O
variants,836,O
have,836,O
been,836,O
described,836,O
based,836,O
on,836,O
clinical,836,O
and,836,O
biochemical,836,O
criteria,836,O
",",836,O
little,836,O
is,836,O
known,836,O
about,836,O
the,836,O
molecular,836,O
basis,836,O
of,836,O
these,836,O
G6PD,836,B-SpecificDisease
deficiencies,836,I-SpecificDisease
.,836,O
Recently,837,O
",",837,O
the,837,O
gene,837,O
that,837,O
encodes,837,O
human,837,O
G6PD,837,O
has,837,O
been,837,O
cloned,837,O
and,837,O
sequenced,837,O
",",837,O
which,837,O
enables,837,O
us,837,O
to,837,O
examine,837,O
directly,837,O
the,837,O
heterogeneity,837,O
of,837,O
G6PD,837,O
at,837,O
the,837,O
DNA,837,O
level,837,O
.,837,O
During,838,O
the,838,O
past,838,O
10,838,O
years,838,O
",",838,O
we,838,O
examined,838,O
the,838,O
G6PD,838,O
activity,838,O
in,838,O
21,838,O
",",838,O
271,838,O
newborn,838,O
Chinese,838,O
infants,838,O
(,838,O
11,838,O
",",838,O
400,838,O
males,838,O
and,838,O
9,838,O
",",838,O
871,838,O
females,838,O
),838,O
and,838,O
identified,838,O
314,838,O
(,838,O
2,838,O
.,838,O
8,839,O
%,839,O
),839,O
males,839,O
and,839,O
246,839,O
(,839,O
2,839,O
.,839,O
5,840,O
%,840,O
),840,O
females,840,O
having,840,O
low,840,O
G6PD,840,O
activity,840,O
.,840,O
The,841,O
G6PD,841,O
gene,841,O
from,841,O
10,841,O
randomly,841,O
selected,841,O
affected,841,O
individuals,841,O
and,841,O
their,841,O
relatives,841,O
was,841,O
polymerase,841,O
chain,841,O
reaction,841,O
(,841,O
PCR,841,O
),841,O
amplified,841,O
",",841,O
subcloned,841,O
",",841,O
and,841,O
sequenced,841,O
.,841,O
Our,842,O
results,842,O
indicate,842,O
that,842,O
at,842,O
least,842,O
four,842,O
types,842,O
of,842,O
mutation,842,O
are,842,O
responsible,842,O
for,842,O
the,842,O
G6PD,842,O
polymorphism,842,O
in,842,O
Taiwan,842,O
.,842,O
The,843,O
first,843,O
type,843,O
of,843,O
mutation,843,O
(,843,O
487,843,O
G,843,O
--,843,O
--,843,O
A,843,O
),843,O
was,843,O
found,843,O
in,843,O
an,843,O
affected,843,O
Chinese,843,O
with,843,O
a,843,O
G,843,O
to,843,O
A,843,O
change,843,O
at,843,O
nucleotide,843,O
487,843,O
",",843,O
which,843,O
results,843,O
in,843,O
a,843,O
(,843,O
163,843,O
),843,O
Gly,843,O
to,843,O
Ser,843,O
substitution,843,O
.,843,O
The,844,O
second,844,O
type,844,O
of,844,O
mutation,844,O
(,844,O
493,844,O
A,844,O
--,844,O
--,844,O
G,844,O
),844,O
is,844,O
a,844,O
novel,844,O
mutation,844,O
that,844,O
has,844,O
not,844,O
been,844,O
reported,844,O
in,844,O
any,844,O
other,844,O
ethnic,844,O
group,844,O
and,844,O
was,844,O
identified,844,O
in,844,O
two,844,O
affected,844,O
Chinese,844,O
.,844,O
This,845,O
mutation,845,O
causes,845,O
an,845,O
A,845,O
to,845,O
G,845,O
change,845,O
at,845,O
nucleotide,845,O
position,845,O
493,845,O
",",845,O
producing,845,O
an,845,O
(,845,O
165,845,O
),845,O
Asn,845,O
to,845,O
Asp,845,O
substitution,845,O
.,845,O
Interestingly,846,O
",",846,O
the,846,O
487,846,O
G,846,O
--,846,O
--,846,O
A,846,O
and,846,O
493,846,O
A,846,O
--,846,O
--,846,O
G,846,O
mutations,846,O
create,846,O
Alu,846,O
I,846,O
and,846,O
Ava,846,O
II,846,O
recognition,846,O
sites,846,O
",",846,O
respectively,846,O
",",846,O
which,846,O
enabled,846,O
us,846,O
to,846,O
rapidly,846,O
detect,846,O
these,846,O
two,846,O
mutations,846,O
by,846,O
PCR/restriction,846,O
enzyme,846,O
(,846,O
RE,846,O
),846,O
digestion,846,O
method,846,O
.,846,O
The,847,O
third,847,O
mutation,847,O
(,847,O
1376,847,O
G,847,O
--,847,O
--,847,O
T,847,O
),847,O
was,847,O
found,847,O
in,847,O
four,847,O
affected,847,O
Chinese,847,O
.,847,O
This,848,O
mutation,848,O
causes,848,O
a,848,O
G,848,O
to,848,O
T,848,O
change,848,O
at,848,O
nucleotide,848,O
position,848,O
1376,848,O
that,848,O
results,848,O
in,848,O
an,848,O
(,848,O
459,848,O
),848,O
Arg,848,O
to,848,O
Leu,848,O
substitution,848,O
.,848,O
The,849,O
1376,849,O
G,849,O
--,849,O
--,849,O
T,849,O
mutation,849,O
seems,849,O
to,849,O
be,849,O
the,849,O
dominant,849,O
allele,849,O
that,849,O
causes,849,O
G6PD,849,B-SpecificDisease
deficiency,849,I-SpecificDisease
in,849,O
Taiwan,849,O
.,849,O
Finally,850,O
",",850,O
two,850,O
affected,850,O
Chinese,850,O
were,850,O
identified,850,O
as,850,O
having,850,O
the,850,O
fourth,850,O
mutation,850,O
(,850,O
1388,850,O
G,850,O
--,850,O
--,850,O
A,850,O
),850,O
.,850,O
This,851,O
mutation,851,O
causes,851,O
a,851,O
G,851,O
to,851,O
A,851,O
change,851,O
at,851,O
nucleotide,851,O
1388,851,O
that,851,O
produces,851,O
an,851,O
(,851,O
463,851,O
),851,O
Arg,851,O
to,851,O
His,851,O
substitution,851,O
.,851,O
Our,852,O
studies,852,O
provide,852,O
the,852,O
direct,852,O
proof,852,O
of,852,O
the,852,O
genetic,852,O
heterogeneity,852,O
of,852,O
G6PD,852,B-SpecificDisease
deficiency,852,I-SpecificDisease
in,852,O
the,852,O
Chinese,852,O
populations,852,O
of,852,O
Taiwan,852,O
and,852,O
the,852,O
PCR/RE,852,O
digestion,852,O
method,852,O
is,852,O
suitable,852,O
for,852,O
simultaneous,852,O
detection,852,O
of,852,O
the,852,O
487,852,O
G,852,O
--,852,O
--,852,O
A,852,O
and,852,O
493,852,O
A,852,O
--,852,O
--,852,O
G,852,O
mutations,852,O
.,852,O
An,853,O
error,853,O
in,853,O
dystrophin,853,O
mRNA,853,O
processing,853,O
in,853,O
golden,853,B-SpecificDisease
retriever,853,I-SpecificDisease
muscular,853,I-SpecificDisease
dystrophy,853,I-SpecificDisease
",",853,O
an,853,O
animal,853,O
homologue,853,O
of,853,O
Duchenne,853,B-SpecificDisease
muscular,853,I-SpecificDisease
dystrophy,853,I-SpecificDisease
.,853,O
Golden,854,B-SpecificDisease
retriever,854,I-SpecificDisease
muscular,854,I-SpecificDisease
dystrophy,854,I-SpecificDisease
(,854,O
GRMD,854,B-SpecificDisease
),854,O
is,854,O
a,854,O
spontaneous,854,O
",",854,O
X-linked,854,O
",",854,O
progressively,854,O
fatal,854,O
disease,854,O
of,854,O
dogs,854,O
and,854,O
is,854,O
also,854,O
a,854,O
homologue,854,O
of,854,O
Duchenne,854,B-SpecificDisease
muscular,854,I-SpecificDisease
dystrophy,854,I-SpecificDisease
(,854,O
DMD,854,B-SpecificDisease
),854,O
.,854,O
Two-thirds,855,O
of,855,O
DMD,855,B-Modifier
patients,855,O
carry,855,O
detectable,855,O
deletions,855,O
in,855,O
their,855,O
dystrophin,855,O
gene,855,O
.,855,O
The,856,O
defect,856,O
underlying,856,O
the,856,O
remaining,856,O
one-third,856,O
of,856,O
DMD,856,B-Modifier
patients,856,O
is,856,O
undetermined,856,O
.,856,O
Analysis,857,O
of,857,O
the,857,O
canine,857,O
dystrophin,857,O
gene,857,O
in,857,O
normal,857,O
and,857,O
GRMD,857,B-Modifier
dogs,857,O
has,857,O
failed,857,O
to,857,O
demonstrate,857,O
any,857,O
detectable,857,O
loss,857,O
of,857,O
exons,857,O
.,857,O
Here,858,O
",",858,O
we,858,O
have,858,O
demonstrated,858,O
a,858,O
RNA,858,O
processing,858,O
error,858,O
in,858,O
GRMD,858,B-SpecificDisease
that,858,O
results,858,O
from,858,O
a,858,O
single,858,O
base,858,O
change,858,O
in,858,O
the,858,O
3,858,O
consensus,858,O
splice,858,O
site,858,O
of,858,O
intron,858,O
6,858,O
.,858,O
The,859,O
seventh,859,O
exon,859,O
is,859,O
then,859,O
skipped,859,O
",",859,O
which,859,O
predicts,859,O
a,859,O
termination,859,O
of,859,O
the,859,O
dystrophin,859,O
reading,859,O
frame,859,O
within,859,O
its,859,O
N-terminal,859,O
domain,859,O
in,859,O
exon,859,O
8,859,O
.,859,O
This,860,O
is,860,O
the,860,O
first,860,O
example,860,O
of,860,O
dystrophin,860,B-SpecificDisease
deficiency,860,I-SpecificDisease
caused,860,O
by,860,O
a,860,O
splice-site,860,O
mutation,860,O
..,860,O
Type,861,B-SpecificDisease
I,861,I-SpecificDisease
human,861,I-SpecificDisease
complement,861,I-SpecificDisease
C2,861,I-SpecificDisease
deficiency,861,I-SpecificDisease
.,861,O
A,862,O
28-base,862,O
pair,862,O
gene,862,O
deletion,862,O
causes,862,O
skipping,862,O
of,862,O
exon,862,O
6,862,O
during,862,O
RNA,862,O
splicing,862,O
.,862,O
Two,863,O
variants,863,O
of,863,O
a,863,O
genetic,863,O
deficiency,863,B-SpecificDisease
of,863,I-SpecificDisease
complement,863,I-SpecificDisease
protein,863,I-SpecificDisease
C2,863,I-SpecificDisease
(,863,O
C2D,863,O
),863,O
have,863,O
been,863,O
previously,863,O
identified,863,O
.,863,O
No,864,O
C2,864,O
protein,864,O
translation,864,O
is,864,O
detected,864,O
in,864,O
type,864,O
I,864,O
deficiency,864,O
",",864,O
while,864,O
type,864,O
II,864,O
deficiency,864,O
is,864,O
characterized,864,O
by,864,O
a,864,O
selective,864,O
block,864,O
in,864,O
C2,864,O
secretion,864,O
.,864,O
Type,865,B-SpecificDisease
I,865,I-SpecificDisease
C2,865,I-SpecificDisease
deficiency,865,I-SpecificDisease
was,865,O
described,865,O
in,865,O
a,865,O
family,865,O
in,865,O
which,865,O
the,865,O
C2,865,O
null,865,O
allele,865,O
(,865,O
C2Q0,865,O
),865,O
is,865,O
associated,865,O
with,865,O
the,865,O
major,865,O
histocompatibility,865,O
haplotype/complotype,865,O
HLA-A25,865,O
",",865,O
B18,865,O
",",865,O
C2Q0,865,O
",",865,O
BfS,865,O
",",865,O
C4A4,865,O
",",865,O
C4B2,865,O
",",865,O
Drw2,865,O
;,865,O
this,865,O
extended,865,O
haplotype,865,O
occurs,865,O
in,865,O
over,865,O
90,865,O
%,865,O
of,865,O
C2-deficient,865,B-Modifier
individuals,865,O
(,865,O
common,865,O
complotype/haplotype,865,O
),865,O
.,865,O
To,866,O
determine,866,O
the,866,O
molecular,866,O
basis,866,O
of,866,O
type,866,B-SpecificDisease
I,866,I-SpecificDisease
C2,866,I-SpecificDisease
deficiency,866,I-SpecificDisease
",",866,O
the,866,O
C2,866,O
gene,866,O
and,866,O
cDNA,866,O
were,866,O
characterized,866,O
from,866,O
a,866,O
homozygous,866,O
type,866,B-Modifier
I,866,I-Modifier
C2-deficient,866,I-Modifier
individual,866,O
with,866,O
the,866,O
common,866,O
associated,866,O
haplotype/complotype,866,O
.,866,O
We,867,O
found,867,O
a,867,O
28-base,867,O
pair,867,O
deletion,867,O
in,867,O
the,867,O
type,867,O
I,867,O
C2Q0,867,O
gene,867,O
",",867,O
beginning,867,O
9,867,O
base,867,O
pairs,867,O
upstream,867,O
of,867,O
the,867,O
3-end,867,O
of,867,O
exon,867,O
6,867,O
",",867,O
that,867,O
generates,867,O
a,867,O
C2,867,O
transcript,867,O
with,867,O
a,867,O
complete,867,O
deletion,867,O
of,867,O
exon,867,O
6,867,O
(,867,O
134,867,O
base,867,O
pair,867,O
),867,O
and,867,O
a,867,O
premature,867,O
termination,867,O
codon,867,O
.,867,O
In,868,O
studies,868,O
of,868,O
eight,868,O
kindred,868,O
",",868,O
the,868,O
28-base,868,O
pair,868,O
deletion,868,O
was,868,O
observed,868,O
in,868,O
all,868,O
C2Q0,868,O
alleles,868,O
associated,868,O
with,868,O
the,868,O
common,868,O
type,868,O
I,868,O
deficient,868,O
complotype/haplotype,868,O
;,868,O
this,868,O
deletion,868,O
was,868,O
not,868,O
present,868,O
in,868,O
normal,868,O
C2,868,O
nor,868,O
in,868,O
type,868,B-Modifier
II,868,I-Modifier
C2-deficient,868,I-Modifier
genes,868,O
.,868,O
These,869,O
data,869,O
demonstrate,869,O
that,869,O
1,869,O
),869,O
type,869,B-SpecificDisease
I,869,I-SpecificDisease
human,869,I-SpecificDisease
complement,869,I-SpecificDisease
C2,869,I-SpecificDisease
deficiency,869,I-SpecificDisease
is,869,O
caused,869,O
by,869,O
a,869,O
28-base,869,O
pair,869,O
genomic,869,O
deletion,869,O
that,869,O
causes,869,O
skipping,869,O
of,869,O
exon,869,O
6,869,O
during,869,O
RNA,869,O
splicing,869,O
",",869,O
resulting,869,O
in,869,O
generation,869,O
of,869,O
a,869,O
premature,869,O
termination,869,O
codon,869,O
",",869,O
2,869,O
),869,O
the,869,O
28-base,869,O
pair,869,O
deletion,869,O
in,869,O
the,869,O
type,869,O
I,869,O
C2Q0,869,O
gene,869,O
is,869,O
strongly,869,O
associated,869,O
with,869,O
the,869,O
HLA,869,O
haplotype/complotype,869,O
A25,869,O
",",869,O
B18,869,O
",",869,O
C2Q0,869,O
",",869,O
BfS,869,O
",",869,O
C4A4,869,O
",",869,O
C4B2,869,O
",",869,O
Drw2,869,O
",",869,O
suggesting,869,O
that,869,O
all,869,O
C2-deficient,869,B-Modifier
individuals,869,O
with,869,O
this,869,O
haplotype/complotype,869,O
will,869,O
harbor,869,O
the,869,O
28-base,869,O
pair,869,O
C2,869,O
gene,869,O
deletion,869,O
",",869,O
and,869,O
3,869,O
),869,O
type,869,B-SpecificDisease
II,869,I-SpecificDisease
C2,869,I-SpecificDisease
deficiency,869,I-SpecificDisease
is,869,O
caused,869,O
by,869,O
a,869,O
different,869,O
",",869,O
as,869,O
yet,869,O
uncharacterized,869,O
",",869,O
molecular,869,O
genetic,869,B-DiseaseClass
defect,869,I-DiseaseClass
..,869,O
Molecular,870,O
characterization,870,O
of,870,O
two,870,O
galactosemia,870,B-Modifier
mutations,870,O
and,870,O
one,870,O
polymorphism,870,O
:,870,O
implications,870,O
for,870,O
structure-function,870,O
analysis,870,O
of,870,O
human,870,O
galactose-1-phosphate,870,O
uridyltransferase,870,O
.,870,O
We,871,O
report,871,O
here,871,O
the,871,O
molecular,871,O
characterization,871,O
of,871,O
two,871,O
galactosemia,871,B-Modifier
mutations,871,O
",",871,O
L74P,871,O
and,871,O
F171S,871,O
",",871,O
and,871,O
one,871,O
polymorphism,871,O
",",871,O
S135L,871,O
",",871,O
in,871,O
human,871,O
galactose-1-phosphate,871,O
uridyltransferase,871,O
(,871,O
GALT,871,O
),871,O
.,871,O
Both,872,O
galactosemia,872,B-Modifier
mutations,872,O
result,872,O
in,872,O
reduced,872,O
enzymatic,872,O
activity,872,O
when,872,O
reconstructed,872,O
in,872,O
the,872,O
cDNA,872,O
and,872,O
overexpressed,872,O
.,872,O
The,873,O
polymorphism,873,O
",",873,O
in,873,O
contrast,873,O
",",873,O
has,873,O
near,873,O
normal,873,O
activity,873,O
.,873,O
Both,874,O
mutations,874,O
affect,874,O
evolutionarily,874,O
conserved,874,O
residues,874,O
",",874,O
suggesting,874,O
that,874,O
they,874,O
are,874,O
functionally,874,O
important,874,O
",",874,O
while,874,O
the,874,O
polymorphism,874,O
occurs,874,O
in,874,O
a,874,O
nonconserved,874,O
domain,874,O
which,874,O
is,874,O
presumably,874,O
not,874,O
critical,874,O
for,874,O
enzymatic,874,O
function,874,O
.,874,O
The,875,O
F171S,875,O
mutation,875,O
is,875,O
close,875,O
to,875,O
the,875,O
putative,875,O
active-site,875,O
nucleophile,875,O
.,875,O
Our,876,O
data,876,O
further,876,O
support,876,O
the,876,O
notion,876,O
of,876,O
molecular,876,O
heterogeneity,876,O
of,876,O
galactosemia,876,B-SpecificDisease
and,876,O
suggest,876,O
that,876,O
galactosemia,876,B-Modifier
mutations,876,O
and,876,O
GALT,876,O
polymorphisms,876,O
may,876,O
be,876,O
useful,876,O
tools,876,O
in,876,O
highlighting,876,O
different,876,O
functional,876,O
domains,876,O
in,876,O
human,876,O
GALT,876,O
..,876,O
Germline,877,O
mutations,877,O
in,877,O
the,877,O
Wilms,877,B-Modifier
',877,I-Modifier
tumor,877,I-Modifier
suppressor,877,O
gene,877,O
are,877,O
associated,877,O
with,877,O
abnormal,877,O
urogenital,877,O
development,877,O
in,877,O
Denys-Drash,877,B-SpecificDisease
syndrome,877,I-SpecificDisease
.,877,O
Denys-Drash,878,B-SpecificDisease
syndrome,878,I-SpecificDisease
is,878,O
a,878,O
rare,878,O
human,878,O
condition,878,O
in,878,O
which,878,O
severe,878,O
urogenital,878,B-DiseaseClass
aberrations,878,I-DiseaseClass
result,878,O
in,878,O
renal,878,B-SpecificDisease
failure,878,I-SpecificDisease
",",878,O
pseudohermaphroditism,878,B-SpecificDisease
",",878,O
and,878,O
Wilms,878,B-SpecificDisease
tumor,878,I-SpecificDisease
(,878,O
nephroblastoma,878,B-SpecificDisease
),878,O
.,878,O
To,879,O
investigate,879,O
its,879,O
possible,879,O
role,879,O
",",879,O
we,879,O
have,879,O
analyzed,879,O
the,879,O
coding,879,O
exons,879,O
of,879,O
the,879,O
Wilms,879,B-Modifier
tumor,879,I-Modifier
suppressor,879,O
gene,879,O
(,879,O
WT1,879,O
),879,O
for,879,O
germline,879,O
mutations,879,O
.,879,O
In,880,O
ten,880,O
independent,880,O
cases,880,O
of,880,O
Denys-Drash,880,B-SpecificDisease
syndrome,880,I-SpecificDisease
",",880,O
point,880,O
mutations,880,O
in,880,O
the,880,O
zinc,880,O
finger,880,O
domains,880,O
of,880,O
one,880,O
WT1,880,O
gene,880,O
copy,880,O
were,880,O
found,880,O
.,880,O
Nine,881,O
of,881,O
these,881,O
mutations,881,O
are,881,O
found,881,O
within,881,O
exon,881,O
9,881,O
(,881,O
zinc,881,O
finger,881,O
III,881,O
),881,O
;,881,O
the,881,O
remaining,881,O
mutation,881,O
is,881,O
in,881,O
exon,881,O
8,881,O
(,881,O
zinc,881,O
finger,881,O
II,881,O
),881,O
.,881,O
These,882,O
mutations,882,O
directly,882,O
affect,882,O
DNA,882,O
sequence,882,O
recognition,882,O
.,882,O
In,883,O
two,883,O
families,883,O
analyzed,883,O
",",883,O
the,883,O
mutations,883,O
were,883,O
shown,883,O
to,883,O
arise,883,O
de,883,O
novo,883,O
.,883,O
Wilms,884,B-SpecificDisease
tumors,884,I-SpecificDisease
from,884,O
three,884,O
individuals,884,O
and,884,O
one,884,O
juvenile,884,O
granulosa,884,O
cell,884,O
tumor,884,B-DiseaseClass
demonstrate,884,O
reduction,884,O
to,884,O
homozygosity,884,O
for,884,O
the,884,O
mutated,884,O
WT1,884,O
allele,884,O
.,884,O
Our,885,O
results,885,O
provide,885,O
evidence,885,O
of,885,O
a,885,O
direct,885,O
role,885,O
for,885,O
WT1,885,O
in,885,O
Denys-Drash,885,B-SpecificDisease
syndrome,885,I-SpecificDisease
and,885,O
thus,885,O
urogenital,885,O
system,885,O
development,885,O
..,885,O
Linkage,886,O
analysis,886,O
in,886,O
X-linked,886,B-SpecificDisease
adrenoleukodystrophy,886,I-SpecificDisease
and,886,O
application,886,O
in,886,O
post-,886,O
and,886,O
prenatal,886,O
diagnosis,886,O
.,886,O
We,887,O
have,887,O
performed,887,O
linkage,887,O
analysis,887,O
with,887,O
the,887,O
DNA,887,O
markers,887,O
DXS52,887,O
and,887,O
the,887,O
clotting,887,O
factor,887,O
VIII,887,O
gene,887,O
(,887,O
F8C,887,O
),887,O
",",887,O
in,887,O
several,887,O
large,887,O
families,887,O
with,887,O
X-linked,887,B-SpecificDisease
adrenoleukodystrophy,887,I-SpecificDisease
(,887,O
ALD,887,B-SpecificDisease
),887,O
.,887,O
The,888,O
tight,888,O
linkage,888,O
to,888,O
DXS52,888,O
could,888,O
be,888,O
extended,888,O
giving,888,O
a,888,O
maximal,888,O
LOD,888,O
score,888,O
of,888,O
22,888,O
.,888,O
5,889,O
at,889,O
1,889,O
cM,889,O
.,889,O
F8C,890,O
was,890,O
also,890,O
tightly,890,O
linked,890,O
to,890,O
ALD,890,B-SpecificDisease
with,890,O
a,890,O
maximal,890,O
LOD,890,O
score,890,O
of,890,O
7,890,O
.,890,O
8,891,O
without,891,O
recombination,891,O
.,891,O
Multipoint,892,O
linkage,892,O
analysis,892,O
with,892,O
the,892,O
markers,892,O
DXS304,892,O
",",892,O
DXS52,892,O
",",892,O
and,892,O
F8C,892,O
indicated,892,O
that,892,O
both,892,O
the,892,O
gene,892,O
for,892,O
ALD,892,B-SpecificDisease
and,892,O
for,892,O
F8C,892,O
are,892,O
distal,892,O
to,892,O
DXS52,892,O
.,892,O
In,893,O
four,893,O
patients,893,O
with,893,O
ALD,893,B-SpecificDisease
",",893,O
no,893,O
major,893,O
structural,893,O
rearrangement,893,O
in,893,O
the,893,O
Xqter,893,O
region,893,O
was,893,O
observed,893,O
;,893,O
in,893,O
particular,893,O
",",893,O
there,893,O
were,893,O
no,893,O
abnormalities,893,B-DiseaseClass
in,893,I-DiseaseClass
the,893,I-DiseaseClass
vision,893,I-DiseaseClass
blindness,893,I-DiseaseClass
genes,893,I-DiseaseClass
.,893,O
DNA,894,O
analysis,894,O
appeared,894,O
to,894,O
be,894,O
of,894,O
use,894,O
in,894,O
determination,894,O
of,894,O
the,894,O
carrier,894,O
status,894,O
of,894,O
females,894,O
at,894,O
risk,894,O
",",894,O
for,894,O
the,894,O
determination,894,O
of,894,O
the,894,O
origin,894,O
of,894,O
the,894,O
mutation,894,O
in,894,O
a,894,O
particular,894,O
family,894,O
",",894,O
and,894,O
for,894,O
prenatal,894,O
diagnosis,894,O
.,894,O
Two,895,O
distinct,895,O
mutations,895,O
at,895,O
a,895,O
single,895,O
BamHI,895,O
site,895,O
in,895,O
phenylketonuria,895,B-SpecificDisease
.,895,O
Classical,896,B-SpecificDisease
phenylketonuria,896,I-SpecificDisease
is,896,O
an,896,O
autosomal,896,B-DiseaseClass
recessive,896,I-DiseaseClass
disease,896,I-DiseaseClass
caused,896,O
by,896,O
a,896,O
deficiency,896,B-SpecificDisease
of,896,I-SpecificDisease
hepatic,896,I-SpecificDisease
phenylalanine,896,I-SpecificDisease
hydroxylase,896,I-SpecificDisease
(,896,O
PAH,896,O
),896,O
.,896,O
The,897,O
abolition,897,O
of,897,O
an,897,O
invariant,897,O
BamHI,897,O
site,897,O
located,897,O
in,897,O
the,897,O
coding,897,O
sequence,897,O
of,897,O
the,897,O
PAH,897,O
gene,897,O
(,897,O
exon,897,O
7,897,O
),897,O
led,897,O
to,897,O
the,897,O
recognition,897,O
of,897,O
two,897,O
new,897,O
point,897,O
mutations,897,O
at,897,O
codon,897,O
272,897,O
and,897,O
273,897,O
(,897,O
272gly,897,O
--,897,O
--,897,O
stop,897,O
and,897,O
273ser,897,O
--,897,O
--,897,O
phe,897,O
",",897,O
respectively,897,O
),897,O
.,897,O
Both,898,O
mutations,898,O
were,898,O
detected,898,O
in,898,O
north,898,O
eastern,898,O
France,898,O
or,898,O
Belgium,898,O
and,898,O
occurred,898,O
on,898,O
the,898,O
background,898,O
of,898,O
RFLP,898,O
haplotype,898,O
7,898,O
alleles,898,O
.,898,O
The,899,O
present,899,O
study,899,O
supports,899,O
the,899,O
view,899,O
that,899,O
the,899,O
clinical,899,O
heterogeneity,899,O
in,899,O
PKU,899,B-SpecificDisease
is,899,O
accounted,899,O
for,899,O
by,899,O
the,899,O
large,899,O
variety,899,O
of,899,O
mutant,899,O
genotypes,899,O
associated,899,O
with,899,O
PAH,899,B-SpecificDisease
deficiencies,899,I-SpecificDisease
..,899,O
A,900,O
detailed,900,O
multipoint,900,O
map,900,O
of,900,O
human,900,O
chromosome,900,O
4,900,O
provides,900,O
evidence,900,O
for,900,O
linkage,900,O
heterogeneity,900,O
and,900,O
position-specific,900,O
recombination,900,O
rates,900,O
.,900,O
Utilizing,901,O
the,901,O
CEPH,901,O
reference,901,O
panel,901,O
and,901,O
genotypic,901,O
data,901,O
for,901,O
53,901,O
markers,901,O
",",901,O
we,901,O
have,901,O
constructed,901,O
a,901,O
20-locus,901,O
multipoint,901,O
genetic,901,O
map,901,O
of,901,O
human,901,O
chromosome,901,O
4,901,O
.,901,O
New,902,O
RFLPs,902,O
are,902,O
reported,902,O
for,902,O
four,902,O
loci,902,O
.,902,O
The,903,O
map,903,O
integrates,903,O
a,903,O
high-resolution,903,O
genetic,903,O
map,903,O
of,903,O
4p16,903,O
into,903,O
a,903,O
continuous,903,O
map,903,O
extending,903,O
to,903,O
4q31,903,O
and,903,O
an,903,O
unlinked,903,O
cluster,903,O
of,903,O
three,903,O
loci,903,O
at,903,O
4q35,903,O
.,903,O
The,904,O
20,904,O
linked,904,O
markers,904,O
form,904,O
a,904,O
continuous,904,O
linkage,904,O
group,904,O
of,904,O
152,904,O
cM,904,O
in,904,O
males,904,O
and,904,O
202,904,O
cM,904,O
in,904,O
females,904,O
.,904,O
Likely,905,O
genetic,905,O
locations,905,O
are,905,O
provided,905,O
for,905,O
25,905,O
polymorphic,905,O
anonymous,905,O
sequences,905,O
and,905,O
28,905,O
gene-specific,905,O
RFLPs,905,O
.,905,O
The,906,O
map,906,O
was,906,O
constructed,906,O
employing,906,O
the,906,O
LINKAGE,906,O
and,906,O
CRIMAP,906,O
computational,906,O
methodologies,906,O
to,906,O
build,906,O
the,906,O
multipoint,906,O
map,906,O
via,906,O
a,906,O
stepwise,906,O
algorithm,906,O
.,906,O
A,907,O
detailed,907,O
10-point,907,O
map,907,O
of,907,O
the,907,O
4p16,907,O
region,907,O
constructed,907,O
from,907,O
the,907,O
CEPH,907,O
panel,907,O
provides,907,O
evidence,907,O
for,907,O
heterogeneity,907,O
in,907,O
the,907,O
linkage,907,O
maps,907,O
constructed,907,O
from,907,O
families,907,O
segregating,907,O
for,907,O
Huntington,907,B-SpecificDisease
disease,907,I-SpecificDisease
(,907,O
HD,907,B-SpecificDisease
),907,O
.,907,O
It,908,O
additionally,908,O
provides,908,O
evidence,908,O
for,908,O
position-specific,908,O
recombination,908,O
frequencies,908,O
in,908,O
the,908,O
telomeric,908,O
region,908,O
of,908,O
4p,908,O
..,908,O
Carrier,909,O
detection,909,O
and,909,O
prenatal,909,O
diagnosis,909,O
of,909,O
Pelizaeus-Merzbacher,909,B-SpecificDisease
disease,909,I-SpecificDisease
using,909,O
a,909,O
combination,909,O
of,909,O
anonymous,909,O
DNA,909,O
polymorphisms,909,O
and,909,O
the,909,O
proteolipid,909,O
protein,909,O
(,909,O
PLP,909,O
),909,O
gene,909,O
cDNA,909,O
.,909,O
We,910,O
report,910,O
carrier,910,O
identification,910,O
and,910,O
a,910,O
prenatal,910,O
diagnosis,910,O
using,910,O
DNA,910,O
polymorphisms,910,O
in,910,O
2,910,O
families,910,O
with,910,O
X-linked,910,B-SpecificDisease
Pelizaeus-Merzbacher,910,I-SpecificDisease
disease,910,I-SpecificDisease
(,910,O
PMD,910,B-SpecificDisease
),910,O
.,910,O
In,911,O
both,911,O
families,911,O
",",911,O
the,911,O
proteolipid,911,O
protein,911,O
(,911,O
PLP,911,O
),911,O
gene,911,O
in,911,O
the,911,O
single,911,O
affected,911,O
male,911,O
could,911,O
be,911,O
traced,911,O
back,911,O
to,911,O
his,911,O
unaffected,911,O
maternal,911,O
grandfather,911,O
.,911,O
Therefore,912,O
",",912,O
each,912,O
family,912,O
contains,912,O
a,912,O
new,912,O
mutation,912,O
.,912,O
In,913,O
the,913,O
case,913,O
of,913,O
the,913,O
prenatal,913,O
diagnosis,913,O
",",913,O
the,913,O
fetus,913,O
was,913,O
shown,913,O
by,913,O
cytogenetic,913,O
analysis,913,O
to,913,O
be,913,O
a,913,O
female,913,O
",",913,O
who,913,O
we,913,O
predict,913,O
will,913,O
be,913,O
a,913,O
noncarrier,913,O
of,913,O
PMD,913,B-SpecificDisease
based,913,O
on,913,O
her,913,O
genotype,913,O
with,913,O
the,913,O
PLP,913,O
intragenic,913,O
polymorphism,913,O
..,913,O
Identification,914,O
of,914,O
deletion,914,O
mutations,914,O
and,914,O
three,914,O
new,914,O
genes,914,O
at,914,O
the,914,O
familial,914,B-Modifier
polyposis,914,I-Modifier
locus,914,O
.,914,O
Small,915,O
(,915,O
100-260,915,O
kb,915,O
),915,O
",",915,O
nested,915,O
deletions,915,O
were,915,O
characterized,915,O
in,915,O
DNA,915,O
from,915,O
two,915,O
unrelated,915,O
patients,915,O
with,915,O
familial,915,B-SpecificDisease
adenomatous,915,I-SpecificDisease
polyposis,915,I-SpecificDisease
coli,915,I-SpecificDisease
(,915,O
APC,915,B-SpecificDisease
),915,O
.,915,O
Three,916,O
candidate,916,O
genes,916,O
located,916,O
within,916,O
the,916,O
deleted,916,O
region,916,O
were,916,O
ascertained,916,O
and,916,O
a,916,O
previous,916,O
candidate,916,O
gene,916,O
",",916,O
MCC,916,O
",",916,O
was,916,O
shown,916,O
to,916,O
be,916,O
located,916,O
outside,916,O
the,916,O
deleted,916,O
region,916,O
.,916,O
One,917,O
of,917,O
the,917,O
new,917,O
genes,917,O
contained,917,O
sequence,917,O
identical,917,O
to,917,O
SRP19,917,O
",",917,O
the,917,O
gene,917,O
coding,917,O
for,917,O
the,917,O
19,917,O
kd,917,O
component,917,O
of,917,O
the,917,O
ribosomal,917,O
signal,917,O
recognition,917,O
particle,917,O
.,917,O
The,918,O
second,918,O
",",918,O
provisionally,918,O
designated,918,O
DP1,918,O
(,918,O
deleted,918,O
in,918,O
polyposis,918,O
1,918,O
),918,O
",",918,O
was,918,O
found,918,O
to,918,O
be,918,O
transcribed,918,O
in,918,O
the,918,O
same,918,O
orientation,918,O
as,918,O
MCC,918,O
.,918,O
Two,919,O
other,919,O
cDNAs,919,O
",",919,O
DP2,919,O
and,919,O
DP3,919,O
",",919,O
were,919,O
found,919,O
to,919,O
overlap,919,O
",",919,O
forming,919,O
a,919,O
single,919,O
gene,919,O
",",919,O
DP2,919,O
.,919,O
5,920,O
",",920,O
that,920,O
is,920,O
transcribed,920,O
in,920,O
the,920,O
same,920,O
orientation,920,O
as,920,O
SRP19,920,O
.,920,O
Exclusion,921,O
of,921,O
linkage,921,O
between,921,O
familial,921,B-SpecificDisease
Mediterranean,921,I-SpecificDisease
fever,921,I-SpecificDisease
and,921,O
the,921,O
human,921,O
serum,921,O
amyloid,921,O
A,921,O
(,921,O
SAA,921,O
),921,O
gene,921,O
cluster,921,O
.,921,O
We,922,O
studied,922,O
the,922,O
relationship,922,O
between,922,O
the,922,O
autosomal,922,O
recessive,922,O
trait,922,O
familial,922,B-SpecificDisease
Mediterranean,922,I-SpecificDisease
fever,922,I-SpecificDisease
(,922,O
FMF,922,B-SpecificDisease
),922,O
and,922,O
the,922,O
serum,922,O
amyloid,922,O
A,922,O
(,922,O
SAA,922,O
),922,O
genes,922,O
by,922,O
comparing,922,O
alleles,922,O
of,922,O
a,922,O
highly,922,O
polymorphic,922,O
dinucleotide,922,O
repeat,922,O
and,922,O
a,922,O
conventional,922,O
restriction,922,O
fragment,922,O
length,922,O
polymorphism,922,O
(,922,O
RFLP,922,O
),922,O
in,922,O
the,922,O
SAA,922,O
gene,922,O
cluster,922,O
in,922,O
Israeli,922,O
FMF,922,B-Modifier
kindreds,922,O
.,922,O
By,923,O
haplotype,923,O
analysis,923,O
",",923,O
our,923,O
data,923,O
indicate,923,O
a,923,O
minimum,923,O
crossover,923,O
frequency,923,O
of,923,O
22,923,O
%,923,O
between,923,O
the,923,O
SAA,923,O
gene,923,O
marker,923,O
and,923,O
FMF,923,B-SpecificDisease
.,923,O
By,924,O
conventional,924,O
linkage,924,O
analysis,924,O
this,924,O
eliminates,924,O
a,924,O
minimum,924,O
of,924,O
10,924,O
.,924,O
4,925,O
cM,925,O
including,925,O
and,925,O
surrounding,925,O
the,925,O
SAA,925,O
gene,925,O
cluster,925,O
as,925,O
the,925,O
site,925,O
of,925,O
the,925,O
FMF,925,B-Modifier
mutation,925,O
although,925,O
SAA,925,O
proteins,925,O
are,925,O
prominent,925,O
physiologic,925,O
markers,925,O
of,925,O
the,925,O
acute,925,O
attacks,925,O
.,925,O
PRAD1,926,O
",",926,O
a,926,O
candidate,926,O
BCL1,926,O
oncogene,926,O
:,926,O
mapping,926,O
and,926,O
expression,926,O
in,926,O
centrocytic,926,B-DiseaseClass
lymphoma,926,I-DiseaseClass
.,926,O
Rearrangement,927,O
of,927,O
the,927,O
BCL1,927,O
(,927,O
B-cell,927,O
lymphoma,927,O
1,927,O
),927,O
region,927,O
on,927,O
chromosome,927,O
11q13,927,O
appears,927,O
to,927,O
be,927,O
highly,927,O
characteristic,927,O
of,927,O
centrocytic,927,B-DiseaseClass
lymphoma,927,I-DiseaseClass
and,927,O
also,927,O
is,927,O
found,927,O
infrequently,927,O
in,927,O
other,927,O
B-cell,927,B-SpecificDisease
neoplasms,927,I-SpecificDisease
.,927,O
Rearrangement,928,O
is,928,O
thought,928,O
to,928,O
deregulate,928,O
a,928,O
nearby,928,O
protooncogene,928,O
",",928,O
but,928,O
transcribed,928,O
sequences,928,O
in,928,O
the,928,O
immediate,928,O
vicinity,928,O
of,928,O
BCL1,928,O
breakpoints,928,O
had,928,O
not,928,O
been,928,O
identified,928,O
.,928,O
PRAD1,929,O
",",929,O
previously,929,O
designated,929,O
D11S287E,929,O
",",929,O
was,929,O
identified,929,O
on,929,O
11q13,929,O
as,929,O
a,929,O
chromosomal,929,O
breakpoint,929,O
region,929,O
rearranged,929,O
with,929,O
the,929,O
parathyroid,929,O
hormone,929,O
gene,929,O
in,929,O
a,929,O
subset,929,O
of,929,O
parathyroid,929,B-DiseaseClass
adenomas,929,I-DiseaseClass
;,929,O
this,929,O
highly,929,O
conserved,929,O
putative,929,O
oncogene,929,O
",",929,O
which,929,O
encodes,929,O
a,929,O
novel,929,O
cyclin,929,O
",",929,O
has,929,O
been,929,O
linked,929,O
to,929,O
BCL1,929,O
and,929,O
implicated,929,O
also,929,O
in,929,O
subsets,929,O
of,929,O
breast,929,O
and,929,O
squamous,929,O
cell,929,O
neoplasms,929,O
with,929,O
11q13,929,O
amplification,929,O
.,929,O
We,930,O
report,930,O
pulsed-field,930,O
gel,930,O
electrophoresis,930,O
data,930,O
showing,930,O
BCL1,930,O
and,930,O
PRAD1,930,O
to,930,O
be,930,O
no,930,O
more,930,O
than,930,O
130,930,O
kilobases,930,O
apart,930,O
.,930,O
PRAD1,931,O
mRNA,931,O
is,931,O
abundantly,931,O
expressed,931,O
in,931,O
seven,931,O
of,931,O
seven,931,O
centrocytic,931,B-DiseaseClass
lymphomas,931,I-DiseaseClass
(,931,O
Kiel,931,O
classification,931,O
),931,O
",",931,O
in,931,O
contrast,931,O
to,931,O
13,931,O
closely,931,O
related,931,O
but,931,O
noncentrocytic,931,B-DiseaseClass
lymphomas,931,I-DiseaseClass
.,931,O
Three,932,O
of,932,O
the,932,O
seven,932,O
centrocytic,932,B-DiseaseClass
lymphomas,932,I-DiseaseClass
had,932,O
detectable,932,O
BCL1,932,O
DNA,932,O
rearrangement,932,O
.,932,O
Also,933,O
",",933,O
two,933,O
unusual,933,O
cases,933,O
of,933,O
CLL,933,O
with,933,O
BCL1,933,O
rearrangement,933,O
overexpressed,933,O
PRAD1,933,O
",",933,O
in,933,O
contrast,933,O
to,933,O
five,933,O
CLL,933,O
controls,933,O
.,933,O
Thus,934,O
",",934,O
PRAD1,934,O
is,934,O
an,934,O
excellent,934,O
candidate,934,O
``,934,O
BCL1,934,O
oncogene.,934,O
``,934,O
Its,935,O
overexpression,935,O
may,935,O
be,935,O
a,935,O
key,935,O
consequence,935,O
of,935,O
rearrangement,935,O
of,935,O
the,935,O
BCL1,935,O
vicinity,935,O
in,935,O
B-cell,935,B-SpecificDisease
neoplasms,935,I-SpecificDisease
and,935,O
a,935,O
unifying,935,O
pathogenetic,935,O
feature,935,O
in,935,O
centrocytic,935,B-DiseaseClass
lymphoma,935,I-DiseaseClass
.,935,O
Two,936,O
new,936,O
arylsulfatase,936,O
A,936,O
(,936,O
ARSA,936,O
),936,O
mutations,936,O
in,936,O
a,936,O
juvenile,936,O
metachromatic,936,B-Modifier
leukodystrophy,936,I-Modifier
(,936,O
MLD,936,B-Modifier
),936,O
patient,936,O
.,936,O
Fragments,937,O
of,937,O
the,937,O
arylsulfatase,937,O
A,937,O
(,937,O
ARSA,937,O
),937,O
gene,937,O
from,937,O
a,937,O
patient,937,O
with,937,O
juvenile-onset,937,O
metachromatic,937,B-SpecificDisease
leukodystrophy,937,I-SpecificDisease
(,937,O
MLD,937,B-SpecificDisease
),937,O
were,937,O
amplified,937,O
by,937,O
PCR,937,O
and,937,O
ligated,937,O
into,937,O
MP13,937,O
cloning,937,O
vectors,937,O
.,937,O
Clones,938,O
hybridizing,938,O
with,938,O
cDNA,938,O
for,938,O
human,938,O
ARSA,938,O
were,938,O
selected,938,O
",",938,O
examined,938,O
for,938,O
appropriate,938,O
size,938,O
inserts,938,O
",",938,O
and,938,O
used,938,O
to,938,O
prepare,938,O
single-stranded,938,O
phage,938,O
DNA,938,O
.,938,O
Examination,939,O
of,939,O
the,939,O
entire,939,O
coding,939,O
and,939,O
most,939,O
of,939,O
the,939,O
intronic,939,O
sequence,939,O
revealed,939,O
two,939,O
putative,939,O
disease-related,939,O
mutations,939,O
.,939,O
One,940,O
",",940,O
a,940,O
point,940,O
mutation,940,O
in,940,O
exon,940,O
3,940,O
",",940,O
resulted,940,O
in,940,O
the,940,O
substitution,940,O
of,940,O
isoleucine,940,O
by,940,O
serine,940,O
.,940,O
Introduction,941,O
of,941,O
this,941,O
alteration,941,O
into,941,O
the,941,O
normal,941,O
ARSA,941,O
cDNA,941,O
sequence,941,O
resulted,941,O
in,941,O
a,941,O
substantial,941,O
decrease,941,O
in,941,O
ARSA,941,O
activity,941,O
on,941,O
transient,941,O
expression,941,O
in,941,O
cultured,941,O
baby,941,O
hamster,941,O
kidney,941,O
cells,941,O
.,941,O
About,942,O
5,942,O
%,942,O
of,942,O
the,942,O
control,942,O
expression,942,O
was,942,O
observed,942,O
",",942,O
suggesting,942,O
a,942,O
small,942,O
residual,942,O
activity,942,O
in,942,O
the,942,O
mutated,942,O
ARSA,942,O
.,942,O
The,943,O
second,943,O
mutation,943,O
",",943,O
a,943,O
G-to-A,943,O
transition,943,O
",",943,O
occurred,943,O
in,943,O
the,943,O
other,943,O
allele,943,O
and,943,O
resulted,943,O
in,943,O
an,943,O
altered,943,O
splice-recognition,943,O
sequence,943,O
between,943,O
exon,943,O
7,943,O
and,943,O
the,943,O
following,943,O
intron,943,O
.,943,O
The,944,O
mutation,944,O
also,944,O
resulted,944,O
in,944,O
the,944,O
loss,944,O
of,944,O
a,944,O
restriction,944,O
site,944,O
.,944,O
Apparently,945,O
normal,945,O
levels,945,O
of,945,O
mRNA,945,O
were,945,O
generated,945,O
from,945,O
this,945,O
allele,945,O
",",945,O
but,945,O
no,945,O
ARSA,945,O
activity,945,O
or,945,O
immuno-cross-reactive,945,O
material,945,O
could,945,O
be,945,O
detected,945,O
.,945,O
A,946,O
collection,946,O
of,946,O
DNA,946,O
samples,946,O
from,946,O
known,946,O
or,946,O
suspected,946,O
MLD,946,B-Modifier
patients,946,O
",",946,O
members,946,O
of,946,O
their,946,O
families,946,O
",",946,O
and,946,O
normal,946,O
controls,946,O
was,946,O
screened,946,O
for,946,O
these,946,O
mutations,946,O
.,946,O
Four,947,O
additional,947,O
individuals,947,O
carrying,947,O
each,947,O
of,947,O
the,947,O
mutations,947,O
were,947,O
found,947,O
among,947,O
the,947,O
nearly,947,O
100,947,O
MLD,947,B-Modifier
patients,947,O
in,947,O
the,947,O
sample,947,O
.,947,O
Gene,948,O
segregation,948,O
in,948,O
the,948,O
original,948,O
patients,948,O
family,948,O
was,948,O
consistent,948,O
with,948,O
available,948,O
clinical,948,O
and,948,O
biochemical,948,O
data,948,O
.,948,O
No,949,O
individuals,949,O
homozygous,949,O
for,949,O
either,949,O
of,949,O
these,949,O
two,949,O
mutations,949,O
were,949,O
identified,949,O
.,949,O
However,950,O
",",950,O
combinations,950,O
with,950,O
other,950,O
MLD,950,B-Modifier
mutations,950,O
suggest,950,O
that,950,O
the,950,O
point,950,O
mutation,950,O
in,950,O
exon,950,O
3,950,O
does,950,O
result,950,O
in,950,O
some,950,O
residual,950,O
enzyme,950,O
activity,950,O
and,950,O
is,950,O
associated,950,O
with,950,O
late-onset,950,O
forms,950,O
of,950,O
the,950,O
disease,950,O
.,950,O
The,951,O
splice-site,951,O
mutation,951,O
following,951,O
exon,951,O
7,951,O
produces,951,O
late-infantile,951,O
MLD,951,B-SpecificDisease
when,951,O
combined,951,O
with,951,O
other,951,O
enzyme-null,951,O
mutations,951,O
",",951,O
implying,951,O
that,951,O
it,951,O
is,951,O
completely,951,O
silent,951,O
enzymatically,951,O
..,951,O
Analysis,952,O
of,952,O
X-chromosome,952,O
inactivation,952,O
and,952,O
presumptive,952,O
expression,952,O
of,952,O
the,952,O
Wiskott-Aldrich,952,B-Modifier
syndrome,952,I-Modifier
(,952,O
WAS,952,B-Modifier
),952,O
gene,952,O
in,952,O
hematopoietic,952,O
cell,952,O
lineages,952,O
of,952,O
a,952,O
thrombocytopenic,952,O
carrier,952,O
female,952,O
of,952,O
WAS,952,B-SpecificDisease
.,952,O
We,953,O
report,953,O
on,953,O
a,953,O
thrombocytopenic,953,B-Modifier
female,953,O
belonging,953,O
to,953,O
a,953,O
pedigree,953,O
with,953,O
the,953,O
Wiskott-Aldrich,953,B-SpecificDisease
syndrome,953,I-SpecificDisease
(,953,O
WAS,953,B-SpecificDisease
),953,O
.,953,O
Restriction,954,O
fragment,954,O
length,954,O
polymorphism,954,O
(,954,O
RFLP,954,O
),954,O
analysis,954,O
with,954,O
probe,954,O
M27,954,O
beta,954,O
",",954,O
closely,954,O
linked,954,O
to,954,O
the,954,O
WAS,954,B-Modifier
gene,954,O
",",954,O
demonstrated,954,O
that,954,O
she,954,O
is,954,O
a,954,O
carrier,954,O
of,954,O
WAS,954,B-SpecificDisease
.,954,O
Both,955,O
small-sized,955,O
and,955,O
normal-sized,955,O
platelets,955,O
were,955,O
present,955,O
",",955,O
suggesting,955,O
that,955,O
",",955,O
unlike,955,O
the,955,O
vast,955,O
majority,955,O
of,955,O
WAS,955,B-Modifier
carriers,955,O
",",955,O
she,955,O
does,955,O
not,955,O
manifest,955,O
nonrandom,955,O
X-chromosome,955,O
inactivation,955,O
in,955,O
the,955,O
thrombopoietic,955,O
cell,955,O
lineage,955,O
.,955,O
Study,956,O
of,956,O
X-chromosome,956,O
inactivation,956,O
by,956,O
means,956,O
of,956,O
RFLP,956,O
and,956,O
methylation,956,O
analysis,956,O
demonstrated,956,O
that,956,O
the,956,O
pattern,956,O
of,956,O
X-chromosome,956,O
inactivation,956,O
was,956,O
nonrandom,956,O
in,956,O
T,956,O
lymphocytes,956,O
",",956,O
but,956,O
random,956,O
in,956,O
granulocytes,956,O
.,956,O
While,957,O
this,957,O
is,957,O
the,957,O
first,957,O
complete,957,O
report,957,O
on,957,O
the,957,O
occurrence,957,O
of,957,O
thrombocytopenia,957,B-SpecificDisease
in,957,O
a,957,O
carrier,957,O
female,957,O
of,957,O
WAS,957,B-SpecificDisease
as,957,O
the,957,O
result,957,O
of,957,O
atypical,957,O
lyonization,957,O
",",957,O
it,957,O
also,957,O
suggests,957,O
that,957,O
expression,957,O
of,957,O
the,957,O
WAS,957,B-Modifier
gene,957,O
occurs,957,O
at,957,O
(,957,O
or,957,O
extends,957,O
up,957,O
to,957,O
),957,O
a,957,O
later,957,O
stage,957,O
than,957,O
the,957,O
multipotent,957,O
stem,957,O
cell,957,O
along,957,O
the,957,O
hematopoietic,957,O
differentiation,957,O
pathway,957,O
..,957,O
A,958,O
new,958,O
mutation,958,O
in,958,O
the,958,O
proteolipid,958,O
protein,958,O
(,958,O
PLP,958,O
),958,O
gene,958,O
in,958,O
a,958,O
German,958,O
family,958,O
with,958,O
Pelizaeus-Merzbacher,958,B-SpecificDisease
disease,958,I-SpecificDisease
.,958,O
A,959,O
C-to-T,959,O
transition,959,O
in,959,O
exon,959,O
4,959,O
of,959,O
the,959,O
PLP,959,O
gene,959,O
was,959,O
found,959,O
in,959,O
2,959,O
affected,959,O
males,959,O
and,959,O
two,959,O
obligate,959,O
carriers,959,O
in,959,O
a,959,O
German,959,O
family,959,O
with,959,O
Pelizaeus-Merzbacher,959,B-SpecificDisease
disease,959,I-SpecificDisease
.,959,O
The,960,O
mutation,960,O
",",960,O
which,960,O
causes,960,O
loss,960,O
of,960,O
an,960,O
HphI,960,O
site,960,O
and,960,O
changes,960,O
amino,960,O
acid,960,O
155,960,O
from,960,O
threonine,960,O
to,960,O
isoleucine,960,O
",",960,O
was,960,O
absent,960,O
from,960,O
108,960,O
normal,960,O
chromosomes,960,O
.,960,O
There,961,O
are,961,O
5,961,O
concordances,961,O
and,961,O
1,961,O
discrepancy,961,O
between,961,O
these,961,O
results,961,O
and,961,O
those,961,O
obtained,961,O
by,961,O
magnetic,961,O
resonance,961,O
imaging,961,O
in,961,O
this,961,O
family,961,O
..,961,O
A,962,O
3-base,962,O
pair,962,O
in-frame,962,O
deletion,962,O
of,962,O
the,962,O
phenylalanine,962,O
hydroxylase,962,O
gene,962,O
results,962,O
in,962,O
a,962,O
kinetic,962,O
variant,962,O
of,962,O
phenylketonuria,962,B-SpecificDisease
.,962,O
Phenylketonuria,963,B-SpecificDisease
(,963,O
PKU,963,B-SpecificDisease
),963,O
is,963,O
an,963,O
autosomal,963,B-DiseaseClass
recessive,963,I-DiseaseClass
disease,963,I-DiseaseClass
due,963,O
to,963,O
deficiency,963,B-SpecificDisease
of,963,I-SpecificDisease
a,963,I-SpecificDisease
hepatic,963,I-SpecificDisease
enzyme,963,I-SpecificDisease
",",963,I-SpecificDisease
phenylalanine,963,I-SpecificDisease
hydroxylase,963,I-SpecificDisease
(,963,O
PAH,963,O
),963,O
.,963,O
The,964,O
absence,964,O
of,964,O
PAH,964,O
activity,964,O
results,964,O
in,964,O
typical,964,O
PKU,964,B-SpecificDisease
while,964,O
persistence,964,O
of,964,O
a,964,O
residual,964,O
enzyme,964,O
activity,964,O
gives,964,O
rise,964,O
to,964,O
variant,964,O
forms,964,O
of,964,O
the,964,O
disease,964,O
.,964,O
We,965,O
report,965,O
here,965,O
a,965,O
3-base,965,O
pair,965,O
in-frame,965,O
deletion,965,O
of,965,O
the,965,O
PAH,965,O
gene,965,O
(,965,O
delta,965,O
194,965,O
),965,O
in,965,O
a,965,O
mild,965,O
variant,965,O
",",965,O
with,965,O
markedly,965,O
reduced,965,O
affinity,965,O
of,965,O
the,965,O
enzyme,965,O
for,965,O
phenylalanine,965,O
(,965,O
Km,965,O
=,965,O
160,965,O
nM,965,O
),965,O
",",965,O
and,965,O
we,965,O
provide,965,O
functional,965,O
evidence,965,O
for,965,O
responsibility,965,O
of,965,O
the,965,O
deletion,965,O
in,965,O
the,965,O
mutant,965,O
phenotype,965,O
.,965,O
Since,966,O
the,966,O
deletion,966,O
was,966,O
located,966,O
in,966,O
the,966,O
third,966,O
exon,966,O
of,966,O
the,966,O
gene,966,O
",",966,O
which,966,O
presents,966,O
no,966,O
homology,966,O
with,966,O
other,966,O
hydroxylases,966,O
",",966,O
we,966,O
suggest,966,O
that,966,O
exon,966,O
3,966,O
is,966,O
involved,966,O
in,966,O
the,966,O
specificity,966,O
of,966,O
the,966,O
enzyme,966,O
for,966,O
phenylalanine,966,O
.,966,O
Finally,967,O
",",967,O
since,967,O
none,967,O
of,967,O
the,967,O
98,967,O
PKU,967,B-Modifier
patients,967,O
tested,967,O
were,967,O
found,967,O
to,967,O
carry,967,O
this,967,O
particular,967,O
deletion,967,O
",",967,O
our,967,O
study,967,O
suggests,967,O
that,967,O
this,967,O
molecular,967,O
event,967,O
probably,967,O
occurred,967,O
recently,967,O
on,967,O
the,967,O
background,967,O
of,967,O
a,967,O
haplotype,967,O
2,967,O
gene,967,O
in,967,O
Portugal,967,O
..,967,O
Mutation,968,O
of,968,O
the,968,O
KIT,968,O
(,968,O
mast/stem,968,O
cell,968,O
growth,968,O
factor,968,O
receptor,968,O
),968,O
protooncogene,968,O
in,968,O
human,968,O
piebaldism,968,B-SpecificDisease
.,968,O
Piebaldism,969,B-SpecificDisease
is,969,O
an,969,O
autosomal,969,B-DiseaseClass
dominant,969,I-DiseaseClass
genetic,969,I-DiseaseClass
disorder,969,I-DiseaseClass
characterized,969,O
by,969,O
cogenital,969,O
patches,969,O
of,969,O
skin,969,O
and,969,O
hair,969,O
from,969,O
which,969,O
melanocytes,969,O
are,969,O
completely,969,O
absent,969,O
.,969,O
A,970,O
similar,970,O
disorder,970,O
of,970,O
mouse,970,O
",",970,O
dominant,970,O
white,970,O
spotting,970,O
(,970,O
W,970,O
),970,O
",",970,O
results,970,O
from,970,O
mutations,970,O
of,970,O
the,970,O
c-Kit,970,O
protooncogene,970,O
",",970,O
which,970,O
encodes,970,O
and,970,O
receptor,970,O
for,970,O
mast/stem,970,O
cell,970,O
growth,970,O
factor,970,O
.,970,O
We,971,O
identified,971,O
a,971,O
KIT,971,O
gene,971,O
mutation,971,O
in,971,O
a,971,O
proband,971,O
with,971,O
classic,971,O
autosomal,971,O
dominant,971,O
piebaldism,971,B-SpecificDisease
.,971,O
This,972,O
mutation,972,O
results,972,O
in,972,O
a,972,O
Gly,972,O
--,972,O
--,972,O
Arg,972,O
substitution,972,O
at,972,O
codon,972,O
664,972,O
",",972,O
within,972,O
the,972,O
tyrosine,972,O
kinase,972,O
domain,972,O
.,972,O
This,973,O
substitution,973,O
was,973,O
not,973,O
seen,973,O
in,973,O
any,973,O
normal,973,O
individuals,973,O
and,973,O
was,973,O
completely,973,O
linked,973,O
to,973,O
the,973,O
piebald,973,B-Modifier
phenotype,973,O
in,973,O
the,973,O
probands,973,O
family,973,O
.,973,O
Piebaldism,974,B-SpecificDisease
in,974,O
this,974,O
family,974,O
thus,974,O
appears,974,O
to,974,O
be,974,O
the,974,O
human,974,O
homologue,974,O
to,974,O
dominant,974,O
white,974,O
spotting,974,O
(,974,O
W,974,O
),974,O
of,974,O
the,974,O
mouse,974,O
..,974,O
Genetic,975,O
analysis,975,O
of,975,O
a,975,O
Japanese,975,O
family,975,O
with,975,O
normotriglyceridemic,975,B-SpecificDisease
abetalipoproteinemia,975,I-SpecificDisease
indicates,975,O
a,975,O
lack,975,O
of,975,O
linkage,975,O
to,975,O
the,975,O
apolipoprotein,975,O
B,975,O
gene,975,O
.,975,O
Normotriglyceridemic,976,B-SpecificDisease
abetalipoproteinemia,976,I-SpecificDisease
is,976,O
a,976,O
rare,976,O
familial,976,B-DiseaseClass
disorder,976,I-DiseaseClass
characterized,976,O
by,976,O
an,976,O
isolated,976,O
deficiency,976,B-SpecificDisease
of,976,I-SpecificDisease
apoB-100,976,I-SpecificDisease
.,976,O
We,977,O
have,977,O
previously,977,O
reported,977,O
a,977,O
patient,977,O
with,977,O
this,977,O
disease,977,O
",",977,O
who,977,O
had,977,O
normal,977,O
apoB-48,977,O
but,977,O
no,977,O
apoB-100,977,O
.,977,O
To,978,O
elucidate,978,O
the,978,O
genetic,978,B-DiseaseClass
abnormalities,978,I-DiseaseClass
in,978,O
this,978,O
family,978,O
",",978,O
we,978,O
studied,978,O
the,978,O
linkage,978,O
of,978,O
apoB,978,O
gene,978,O
using,978,O
three,978,O
genetic,978,O
markers,978,O
.,978,O
The,979,O
proband,979,O
and,979,O
her,979,O
affected,979,O
brother,979,O
showed,979,O
completely,979,O
different,979,O
apoB,979,O
gene,979,O
alleles,979,O
",",979,O
suggesting,979,O
that,979,O
the,979,O
apoB,979,O
gene,979,O
itself,979,O
is,979,O
not,979,O
related,979,O
to,979,O
this,979,O
disorder,979,O
in,979,O
this,979,O
family,979,O
.,979,O
By,980,O
contrast,980,O
",",980,O
an,980,O
American,980,O
case,980,O
had,980,O
a,980,O
point,980,O
substitution,980,O
in,980,O
the,980,O
apoB,980,O
gene,980,O
generating,980,O
an,980,O
in-frame,980,O
stop,980,O
codon,980,O
.,980,O
These,981,O
results,981,O
indicate,981,O
that,981,O
this,981,O
disorder,981,O
can,981,O
be,981,O
caused,981,O
by,981,O
defect,981,O
(,981,O
s,981,O
),981,O
of,981,O
either,981,O
an,981,O
apoB,981,O
gene,981,O
or,981,O
other,981,O
genes,981,O
..,981,O
Localisation,982,O
of,982,O
the,982,O
gene,982,O
for,982,O
Norrie,982,B-SpecificDisease
disease,982,I-SpecificDisease
to,982,O
between,982,O
DXS7,982,O
and,982,O
DXS426,982,O
on,982,O
Xp,982,O
.,982,O
A,983,O
highly,983,O
informative,983,O
microsatellite,983,O
marker,983,O
",",983,O
DXS426,983,O
",",983,O
which,983,O
maps,983,O
proximal,983,O
to,983,O
DXS7,983,O
in,983,O
the,983,O
interval,983,O
Xp11,983,O
.,983,O
4-Xp11,984,O
4-Xp11,984,O
.,984,O
23,985,O
",",985,O
has,985,O
been,985,O
used,985,O
to,985,O
refine,985,O
further,985,O
the,985,O
localisation,985,O
of,985,O
the,985,O
gene,985,O
for,985,O
Norrie,985,B-SpecificDisease
disease,985,I-SpecificDisease
(,985,O
NDP,985,B-SpecificDisease
),985,O
.,985,O
The,986,O
results,986,O
from,986,O
a,986,O
multiply,986,O
informative,986,O
crossover,986,O
localize,986,O
the,986,O
NDP,986,B-Modifier
gene,986,O
proximal,986,O
to,986,O
DXS7,986,O
.,986,O
In,987,O
conjunction,987,O
with,987,O
information,987,O
from,987,O
2,987,O
NDP,987,B-Modifier
patients,987,O
who,987,O
have,987,O
a,987,O
deletion,987,O
for,987,O
DXS7,987,O
but,987,O
not,987,O
for,987,O
DSX426,987,O
",",987,O
our,987,O
data,987,O
indicate,987,O
that,987,O
the,987,O
NDP,987,B-Modifier
gene,987,O
lies,987,O
between,987,O
DXS7,987,O
and,987,O
DXS426,987,O
on,987,O
proximal,987,O
Xp,987,O
.,987,O
Aberrant,988,O
splicing,988,O
of,988,O
phenylalanine,988,O
hydroxylase,988,O
mRNA,988,O
:,988,O
the,988,O
major,988,O
cause,988,O
for,988,O
phenylketonuria,988,B-SpecificDisease
in,988,O
parts,988,O
of,988,O
southern,988,O
Europe,988,O
.,988,O
We,989,O
report,989,O
a,989,O
mutation,989,O
within,989,O
the,989,O
phenylalanine,989,O
hydroxylase,989,O
(,989,O
PAH,989,O
),989,O
gene,989,O
that,989,O
causes,989,O
aberrant,989,O
splicing,989,O
of,989,O
the,989,O
mRNA,989,O
and,989,O
that,989,O
is,989,O
in,989,O
tight,989,O
association,989,O
with,989,O
chromosomal,989,O
haplotypes,989,O
6,989,O
",",989,O
10,989,O
",",989,O
and,989,O
36,989,O
.,989,O
Because,990,O
of,990,O
the,990,O
high,990,O
frequency,990,O
of,990,O
these,990,O
particular,990,O
haplotypes,990,O
in,990,O
Bulgaria,990,O
",",990,O
Italy,990,O
",",990,O
and,990,O
Turkey,990,O
",",990,O
it,990,O
appears,990,O
to,990,O
be,990,O
one,990,O
of,990,O
the,990,O
more,990,O
frequent,990,O
defects,990,O
in,990,O
the,990,O
PAH,990,O
gene,990,O
causing,990,O
classical,990,O
phenylketonuria,990,B-SpecificDisease
in,990,O
this,990,O
part,990,O
of,990,O
Europe,990,O
.,990,O
The,991,O
mutation,991,O
is,991,O
a,991,O
G,991,O
to,991,O
A,991,O
transition,991,O
at,991,O
position,991,O
546,991,O
in,991,O
intron,991,O
10,991,O
of,991,O
the,991,O
PAH,991,O
gene,991,O
",",991,O
11,991,O
bp,991,O
upstream,991,O
from,991,O
the,991,O
intron,991,O
10/exon,991,O
11,991,O
boundary,991,O
.,991,O
It,992,O
activates,992,O
a,992,O
cryptic,992,O
splice,992,O
site,992,O
and,992,O
results,992,O
in,992,O
an,992,O
in-frame,992,O
insertion,992,O
of,992,O
9,992,O
nucleotides,992,O
between,992,O
exon,992,O
10,992,O
and,992,O
exon,992,O
11,992,O
of,992,O
the,992,O
processed,992,O
mRNA,992,O
.,992,O
Normal,993,O
amounts,993,O
of,993,O
liver,993,O
PAH,993,O
protein,993,O
are,993,O
present,993,O
in,993,O
homozygous,993,O
patients,993,O
",",993,O
but,993,O
no,993,O
catalytic,993,O
activity,993,O
can,993,O
be,993,O
detected,993,O
.,993,O
This,994,O
loss,994,O
of,994,O
enzyme,994,O
activity,994,O
is,994,O
probably,994,O
caused,994,O
by,994,O
conformational,994,O
changes,994,O
resulting,994,O
from,994,O
the,994,O
insertion,994,O
of,994,O
three,994,O
additional,994,O
amino,994,O
acids,994,O
(,994,O
Gly-Leu-Gln,994,O
),994,O
between,994,O
the,994,O
normal,994,O
sequences,994,O
encoded,994,O
by,994,O
exon,994,O
10,994,O
and,994,O
exon,994,O
11,994,O
..,994,O
Gardner,995,B-SpecificDisease
syndrome,995,I-SpecificDisease
in,995,O
a,995,O
boy,995,O
with,995,O
interstitial,995,O
deletion,995,O
of,995,O
the,995,O
long,995,O
arm,995,O
of,995,O
chromosome,995,O
5,995,O
.,995,O
We,996,O
described,996,O
a,996,O
15-year-old,996,O
boy,996,O
with,996,O
Gardner,996,B-SpecificDisease
syndrome,996,I-SpecificDisease
(,996,O
GS,996,B-SpecificDisease
),996,O
",",996,O
mental,996,B-DiseaseClass
retardation,996,I-DiseaseClass
",",996,O
and,996,O
craniofacial,996,B-DiseaseClass
abnormalities,996,I-DiseaseClass
.,996,O
High-resolution,997,O
banding,997,O
analysis,997,O
showed,997,O
an,997,O
interstitial,997,O
deletion,997,O
of,997,O
the,997,O
long,997,O
arm,997,O
of,997,O
chromosome,997,O
5,997,O
(,997,O
q22,997,O
.,997,O
1,998,O
--,998,O
--,998,O
q31,998,O
1,998,O
--,998,O
--,998,O
q31,998,O
.,998,O
1,999,O
),999,O
.,999,O
The,1000,O
breakpoints,1000,O
in,1000,O
the,1000,O
present,1000,O
case,1000,O
and,1000,O
in,1000,O
3,1000,O
previously,1000,O
reported,1000,O
5q-,1000,O
patients,1000,O
with,1000,O
adenomatous,1000,B-SpecificDisease
polyposis,1000,I-SpecificDisease
coli,1000,I-SpecificDisease
suggest,1000,O
that,1000,O
the,1000,O
gene,1000,O
responsible,1000,O
for,1000,O
GS/or,1000,B-SpecificDisease
familial,1000,B-SpecificDisease
polyposis,1000,I-SpecificDisease
coli,1000,I-SpecificDisease
(,1000,O
FPC,1000,B-SpecificDisease
),1000,O
is,1000,O
in,1000,O
the,1000,O
5q22,1000,O
region,1000,O
",",1000,O
a,1000,O
result,1000,O
consistent,1000,O
with,1000,O
the,1000,O
findings,1000,O
of,1000,O
linkage,1000,O
studies,1000,O
Huntington,1001,B-SpecificDisease
disease,1001,I-SpecificDisease
and,1001,O
childhood-onset,1001,O
Tourette,1001,B-SpecificDisease
syndrome,1001,I-SpecificDisease
.,1001,O
A,1002,O
40-year-old,1002,O
man,1002,O
with,1002,O
childhood-onset,1002,O
Tourette,1002,B-SpecificDisease
syndrome,1002,I-SpecificDisease
(,1002,O
TS,1002,B-SpecificDisease
),1002,O
developed,1002,O
Huntington,1002,B-SpecificDisease
disease,1002,I-SpecificDisease
(,1002,O
HD,1002,B-SpecificDisease
),1002,O
.,1002,O
We,1003,O
believe,1003,O
this,1003,O
to,1003,O
be,1003,O
the,1003,O
first,1003,O
reported,1003,O
case,1003,O
of,1003,O
childhood-onset,1003,O
TS,1003,B-SpecificDisease
with,1003,O
adult,1003,O
onset,1003,O
HD,1003,B-SpecificDisease
.,1003,O
Discovery,1004,O
of,1004,O
other,1004,O
cases,1004,O
with,1004,O
both,1004,O
disorders,1004,O
may,1004,O
provide,1004,O
clues,1004,O
to,1004,O
the,1004,O
pathophysiology,1004,O
of,1004,O
both,1004,O
conditions,1004,O
..,1004,O
Sequence,1005,O
of,1005,O
DNA,1005,O
flanking,1005,O
the,1005,O
exons,1005,O
of,1005,O
the,1005,O
HEXA,1005,O
gene,1005,O
",",1005,O
and,1005,O
identification,1005,O
of,1005,O
mutations,1005,O
in,1005,O
Tay-Sachs,1005,B-SpecificDisease
disease,1005,I-SpecificDisease
.,1005,O
The,1006,O
rapid,1006,O
identification,1006,O
of,1006,O
mutations,1006,O
causing,1006,O
Tay-Sachs,1006,B-SpecificDisease
disease,1006,I-SpecificDisease
requires,1006,O
the,1006,O
capacity,1006,O
to,1006,O
readily,1006,O
screen,1006,O
the,1006,O
regions,1006,O
of,1006,O
the,1006,O
HEXA,1006,O
gene,1006,O
most,1006,O
likely,1006,O
to,1006,O
be,1006,O
affected,1006,O
by,1006,O
mutation,1006,O
.,1006,O
We,1007,O
have,1007,O
sequenced,1007,O
the,1007,O
portions,1007,O
of,1007,O
the,1007,O
introns,1007,O
flanking,1007,O
each,1007,O
of,1007,O
the,1007,O
14,1007,O
HEXA,1007,O
exons,1007,O
in,1007,O
order,1007,O
to,1007,O
specify,1007,O
oligonucleotide,1007,O
primers,1007,O
for,1007,O
the,1007,O
PCR-dependent,1007,O
amplification,1007,O
of,1007,O
each,1007,O
exon,1007,O
and,1007,O
splice-junction,1007,O
sequence,1007,O
.,1007,O
The,1008,O
amplified,1008,O
products,1008,O
were,1008,O
analyzed,1008,O
",",1008,O
by,1008,O
electrophoresis,1008,O
in,1008,O
nondenaturing,1008,O
polyacrylamide,1008,O
gels,1008,O
",",1008,O
for,1008,O
the,1008,O
presence,1008,O
of,1008,O
either,1008,O
heteroduplexes,1008,O
",",1008,O
derived,1008,O
from,1008,O
the,1008,O
annealing,1008,O
of,1008,O
normal,1008,O
and,1008,O
mutant,1008,O
DNA,1008,O
strands,1008,O
",",1008,O
or,1008,O
single-strand,1008,O
conformational,1008,O
polymorphisms,1008,O
(,1008,O
SSCP,1008,O
),1008,O
",",1008,O
derived,1008,O
from,1008,O
the,1008,O
renaturation,1008,O
of,1008,O
single-stranded,1008,O
DNA,1008,O
.,1008,O
Five,1009,O
novel,1009,O
mutations,1009,O
from,1009,O
Tay-Sachs,1009,B-Modifier
disease,1009,I-Modifier
patients,1009,O
were,1009,O
detected,1009,O
a,1009,O
5-bp,1009,O
deletion,1009,O
of,1009,O
TCTCC,1009,O
in,1009,O
IVS-9,1009,O
;,1009,O
a,1009,O
2-bp,1009,O
deletion,1009,O
of,1009,O
TG,1009,O
in,1009,O
exon,1009,O
5,1009,O
;,1009,O
G78,1009,O
to,1009,O
A,1009,O
",",1009,O
giving,1009,O
a,1009,O
stop,1009,O
codon,1009,O
in,1009,O
exon,1009,O
1,1009,O
;,1009,O
G533,1009,O
to,1009,O
T,1009,O
in,1009,O
exon,1009,O
5,1009,O
",",1009,O
producing,1009,O
the,1009,O
third,1009,O
amino,1009,O
acid,1009,O
substitution,1009,O
detected,1009,O
at,1009,O
this,1009,O
site,1009,O
;,1009,O
and,1009,O
G,1009,O
to,1009,O
C,1009,O
at,1009,O
position,1009,O
1,1009,O
of,1009,O
IVS-2,1009,O
",",1009,O
expected,1009,O
to,1009,O
produce,1009,O
abnormal,1009,O
splicing,1009,O
.,1009,O
In,1010,O
addition,1010,O
",",1010,O
two,1010,O
mutations,1010,O
",",1010,O
(,1010,O
G1496,1010,O
to,1010,O
A,1010,O
in,1010,O
exon,1010,O
13,1010,O
and,1010,O
a,1010,O
4-bp,1010,O
insertion,1010,O
in,1010,O
exon,1010,O
11,1010,O
),1010,O
that,1010,O
have,1010,O
previously,1010,O
been,1010,O
reported,1010,O
were,1010,O
identified,1010,O
..,1010,O
Molecular,1011,O
characterization,1011,O
of,1011,O
two,1011,O
galactosemia,1011,B-Modifier
mutations,1011,O
:,1011,O
correlation,1011,O
of,1011,O
mutations,1011,O
with,1011,O
highly,1011,O
conserved,1011,O
domains,1011,O
in,1011,O
galactose-1-phosphate,1011,O
uridyl,1011,O
transferase,1011,O
.,1011,O
Galactosemia,1012,B-SpecificDisease
is,1012,O
an,1012,O
autosomal,1012,B-DiseaseClass
recessive,1012,I-DiseaseClass
disorder,1012,I-DiseaseClass
of,1012,I-DiseaseClass
human,1012,I-DiseaseClass
galactose,1012,I-DiseaseClass
metabolism,1012,I-DiseaseClass
caused,1012,O
by,1012,O
deficiency,1012,B-SpecificDisease
of,1012,I-SpecificDisease
the,1012,I-SpecificDisease
enzyme,1012,I-SpecificDisease
galactose-1-phosphate,1012,I-SpecificDisease
uridyl,1012,I-SpecificDisease
transferase,1012,I-SpecificDisease
(,1012,O
GALT,1012,O
),1012,O
.,1012,O
The,1013,O
molecular,1013,O
basis,1013,O
of,1013,O
this,1013,O
disorder,1013,O
is,1013,O
at,1013,O
present,1013,O
not,1013,O
well,1013,O
understood,1013,O
.,1013,O
We,1014,O
report,1014,O
here,1014,O
two,1014,O
missense,1014,O
mutations,1014,O
which,1014,O
result,1014,O
in,1014,O
low,1014,O
or,1014,O
undetectable,1014,O
enzymatic,1014,O
activity,1014,O
.,1014,O
First,1015,O
",",1015,O
we,1015,O
identified,1015,O
at,1015,O
nucleotide,1015,O
591,1015,O
a,1015,O
transition,1015,O
which,1015,O
substitutes,1015,O
glutamine,1015,O
188,1015,O
by,1015,O
arginine,1015,O
.,1015,O
The,1016,O
mutated,1016,O
glutamine,1016,O
is,1016,O
not,1016,O
only,1016,O
highly,1016,O
conserved,1016,O
in,1016,O
evolution,1016,O
(,1016,O
conserved,1016,O
also,1016,O
in,1016,O
Escherichia,1016,O
coli,1016,O
and,1016,O
Saccharomyces,1016,O
cerevisiae,1016,O
),1016,O
",",1016,O
but,1016,O
is,1016,O
also,1016,O
two,1016,O
amino,1016,O
acid,1016,O
residues,1016,O
downstream,1016,O
from,1016,O
the,1016,O
active,1016,O
site,1016,O
histidine-proline-histidine,1016,O
triad,1016,O
and,1016,O
results,1016,O
in,1016,O
about,1016,O
10,1016,O
%,1016,O
of,1016,O
normal,1016,O
enzymatic,1016,O
activity,1016,O
.,1016,O
The,1017,O
arginine,1017,O
188,1017,O
mutation,1017,O
is,1017,O
the,1017,O
most,1017,O
common,1017,O
galactosemia,1017,B-Modifier
mutation,1017,O
characterized,1017,O
to,1017,O
date,1017,O
.,1017,O
It,1018,O
accounts,1018,O
for,1018,O
one-fourth,1018,O
of,1018,O
the,1018,O
galactosemia,1018,B-Modifier
alleles,1018,O
studied,1018,O
.,1018,O
Second,1019,O
",",1019,O
we,1019,O
report,1019,O
the,1019,O
substitution,1019,O
of,1019,O
arginine,1019,O
333,1019,O
by,1019,O
tryptophan,1019,O
",",1019,O
caused,1019,O
by,1019,O
a,1019,O
transition,1019,O
at,1019,O
nucleotide,1019,O
1025,1019,O
.,1019,O
The,1020,O
area,1020,O
surrounding,1020,O
this,1020,O
missense,1020,O
mutation,1020,O
is,1020,O
the,1020,O
most,1020,O
highly,1020,O
conserved,1020,O
domain,1020,O
in,1020,O
the,1020,O
homologous,1020,O
enzymes,1020,O
from,1020,O
E.,1020,O
coli,1020,O
",",1020,O
yeast,1020,O
",",1020,O
and,1020,O
humans,1020,O
",",1020,O
and,1020,O
this,1020,O
mutation,1020,O
results,1020,O
in,1020,O
undetectable,1020,O
enzymatic,1020,O
activity,1020,O
",",1020,O
suggesting,1020,O
that,1020,O
this,1020,O
is,1020,O
a,1020,O
severe,1020,O
mutation,1020,O
.,1020,O
This,1021,O
second,1021,O
mutation,1021,O
appears,1021,O
to,1021,O
be,1021,O
rare,1021,O
",",1021,O
since,1021,O
it,1021,O
was,1021,O
found,1021,O
only,1021,O
in,1021,O
the,1021,O
patient,1021,O
we,1021,O
sequenced,1021,O
.,1021,O
Our,1022,O
data,1022,O
provide,1022,O
further,1022,O
evidence,1022,O
for,1022,O
the,1022,O
heterogeneity,1022,O
of,1022,O
galactosemia,1022,B-SpecificDisease
at,1022,O
the,1022,O
molecular,1022,O
level,1022,O
",",1022,O
heterogeneity,1022,O
which,1022,O
might,1022,O
be,1022,O
related,1022,O
to,1022,O
the,1022,O
variable,1022,O
clinical,1022,O
outcome,1022,O
observed,1022,O
in,1022,O
this,1022,O
disorder,1022,O
..,1022,O
Hypoxanthine-guanine,1023,B-SpecificDisease
phosphoribosyltransferase,1023,I-SpecificDisease
deficiency,1023,I-SpecificDisease
:,1023,O
analysis,1023,O
of,1023,O
HPRT,1023,O
mutations,1023,O
by,1023,O
direct,1023,O
sequencing,1023,O
and,1023,O
allele-specific,1023,O
amplification,1023,O
.,1023,O
The,1024,O
Lesch-Nyhan,1024,B-SpecificDisease
syndrome,1024,I-SpecificDisease
is,1024,O
a,1024,O
severe,1024,O
X,1024,B-DiseaseClass
chromosome-linked,1024,I-DiseaseClass
human,1024,I-DiseaseClass
disease,1024,I-DiseaseClass
caused,1024,O
by,1024,O
a,1024,O
virtual,1024,O
absence,1024,B-SpecificDisease
of,1024,I-SpecificDisease
hypoxanthine-guanine,1024,I-SpecificDisease
phosphoribosyltransferase,1024,I-SpecificDisease
(,1024,I-SpecificDisease
HPRT,1024,I-SpecificDisease
),1024,I-SpecificDisease
activity,1024,I-SpecificDisease
.,1024,O
A,1025,O
partial,1025,O
deficiency,1025,O
in,1025,O
the,1025,O
activity,1025,O
of,1025,O
this,1025,O
enzyme,1025,O
can,1025,O
result,1025,O
in,1025,O
gouty,1025,B-SpecificDisease
arthritis,1025,I-SpecificDisease
.,1025,O
To,1026,O
determine,1026,O
the,1026,O
genetic,1026,O
basis,1026,O
for,1026,O
reduction,1026,O
or,1026,O
loss,1026,O
of,1026,O
enzyme,1026,O
activity,1026,O
",",1026,O
we,1026,O
have,1026,O
amplified,1026,O
and,1026,O
sequenced,1026,O
the,1026,O
coding,1026,O
region,1026,O
of,1026,O
HPRT,1026,O
cDNA,1026,O
from,1026,O
four,1026,O
patients,1026,O
one,1026,O
with,1026,O
Lesch-Nyhan,1026,B-SpecificDisease
syndrome,1026,I-SpecificDisease
(,1026,O
HPRTPerth,1026,O
),1026,O
and,1026,O
three,1026,O
with,1026,O
partial,1026,B-DiseaseClass
deficiencies,1026,I-DiseaseClass
of,1026,I-DiseaseClass
HPRT,1026,I-DiseaseClass
activity,1026,I-DiseaseClass
",",1026,O
which,1026,O
have,1026,O
been,1026,O
designated,1026,O
HPRTUrangan,1026,O
",",1026,O
HPRTSwan,1026,O
and,1026,O
HPRTToowong,1026,O
.,1026,O
In,1027,O
all,1027,O
four,1027,O
patients,1027,O
",",1027,O
the,1027,O
only,1027,O
mutation,1027,O
identified,1027,O
was,1027,O
a,1027,O
single,1027,O
base,1027,O
substitution,1027,O
in,1027,O
exons,1027,O
2,1027,O
or,1027,O
3,1027,O
of,1027,O
the,1027,O
coding,1027,O
region,1027,O
",",1027,O
which,1027,O
in,1027,O
each,1027,O
case,1027,O
predicts,1027,O
a,1027,O
single,1027,O
amino,1027,O
acid,1027,O
substitution,1027,O
in,1027,O
the,1027,O
translated,1027,O
protein,1027,O
.,1027,O
Each,1028,O
base,1028,O
change,1028,O
was,1028,O
confirmed,1028,O
by,1028,O
allele-specific,1028,O
amplification,1028,O
of,1028,O
the,1028,O
patients,1028,O
genomic,1028,O
DNA,1028,O
.,1028,O
It,1029,O
is,1029,O
interesting,1029,O
to,1029,O
note,1029,O
that,1029,O
the,1029,O
mutation,1029,O
found,1029,O
for,1029,O
HPRTPerth,1029,O
is,1029,O
identical,1029,O
to,1029,O
that,1029,O
reported,1029,O
for,1029,O
HPRTFlint,1029,O
.,1029,O
It,1030,O
appears,1030,O
that,1030,O
the,1030,O
two,1030,O
mutations,1030,O
are,1030,O
de,1030,O
novo,1030,O
events,1030,O
..,1030,O
Molecular,1031,O
and,1031,O
metabolic,1031,O
basis,1031,O
for,1031,O
the,1031,O
metabolic,1031,B-DiseaseClass
disorder,1031,I-DiseaseClass
normotriglyceridemic,1031,B-SpecificDisease
abetalipoproteinemia,1031,I-SpecificDisease
.,1031,O
We,1032,O
have,1032,O
previously,1032,O
described,1032,O
a,1032,O
disorder,1032,O
",",1032,O
normotriglyceridemic,1032,B-SpecificDisease
abetalipoproteinemia,1032,I-SpecificDisease
",",1032,O
that,1032,O
is,1032,O
characterized,1032,O
by,1032,O
the,1032,O
virtual,1032,O
absence,1032,O
of,1032,O
plasma,1032,O
low,1032,O
density,1032,O
lipoproteins,1032,O
and,1032,O
complete,1032,O
absence,1032,O
of,1032,O
apoB-100,1032,O
",",1032,O
but,1032,O
with,1032,O
apparently,1032,O
normal,1032,O
secretion,1032,O
of,1032,O
triglyceride-rich,1032,O
lipoproteins,1032,O
containing,1032,O
apoB-48,1032,O
.,1032,O
The,1033,O
patients,1033,O
plasma,1033,O
lipoproteins,1033,O
were,1033,O
shown,1033,O
on,1033,O
polyacrylamide,1033,O
gels,1033,O
and,1033,O
by,1033,O
antibody,1033,O
mapping,1033,O
to,1033,O
have,1033,O
a,1033,O
new,1033,O
truncated,1033,O
apoB,1033,O
variant,1033,O
",",1033,O
apoB-50,1033,O
",",1033,O
circulating,1033,O
along,1033,O
with,1033,O
her,1033,O
apoB-48,1033,O
.,1033,O
We,1034,O
have,1034,O
found,1034,O
this,1034,O
individual,1034,O
to,1034,O
be,1034,O
homozygous,1034,O
for,1034,O
a,1034,O
single,1034,O
C-to-T,1034,O
nucleotide,1034,O
substitution,1034,O
at,1034,O
apoB,1034,O
codon,1034,O
2252,1034,O
",",1034,O
which,1034,O
produces,1034,O
a,1034,O
premature,1034,O
in-frame,1034,O
stop,1034,O
codon,1034,O
.,1034,O
Thus,1035,O
",",1035,O
this,1035,O
is,1035,O
a,1035,O
rare,1035,O
example,1035,O
of,1035,O
homozygous,1035,B-SpecificDisease
hypobetalipoproteinemia,1035,I-SpecificDisease
.,1035,O
Electron,1036,O
photomicrographs,1036,O
revealed,1036,O
that,1036,O
the,1036,O
diameters,1036,O
of,1036,O
particles,1036,O
in,1036,O
the,1036,O
d,1036,O
less,1036,O
than,1036,O
1,1036,O
.,1036,O
006,1037,O
g/ml,1037,O
lipoprotein,1037,O
fraction,1037,O
",",1037,O
in,1037,O
both,1037,O
the,1037,O
postprandial,1037,O
and,1037,O
postabsorptive,1037,O
state,1037,O
",",1037,O
are,1037,O
bimodally,1037,O
distributed,1037,O
.,1037,O
The,1038,O
molar,1038,O
ratio,1038,O
of,1038,O
apoE,1038,O
to,1038,O
apoB,1038,O
in,1038,O
these,1038,O
particles,1038,O
is,1038,O
3,1038,O
.,1038,O
5,1039,O
1,1039,O
",",1039,O
similar,1039,O
to,1039,O
normal,1039,O
VLDL,1039,O
.,1039,O
The,1040,O
plasma,1040,O
LDL,1040,O
interval,1040,O
contains,1040,O
both,1040,O
spherical,1040,O
and,1040,O
cuboidal,1040,O
particles,1040,O
.,1040,O
Autologous,1041,O
reinfusion,1041,O
of,1041,O
labeled,1041,O
d,1041,O
less,1041,O
than,1041,O
1,1041,O
.,1041,O
006,1042,O
g/ml,1042,O
lipoproteins,1042,O
showed,1042,O
exponential,1042,O
disappearance,1042,O
from,1042,O
plasma,1042,O
",",1042,O
with,1042,O
an,1042,O
apparent,1042,O
half-removal,1042,O
time,1042,O
of,1042,O
50,1042,O
min,1042,O
",",1042,O
somewhat,1042,O
slower,1042,O
than,1042,O
for,1042,O
normal,1042,O
chylomicrons,1042,O
but,1042,O
within,1042,O
the,1042,O
normal,1042,O
range,1042,O
for,1042,O
VLDL,1042,O
.,1042,O
The,1043,O
calculated,1043,O
production,1043,O
rate,1043,O
for,1043,O
apoB,1043,O
was,1043,O
within,1043,O
the,1043,O
normal,1043,O
range,1043,O
in,1043,O
this,1043,O
subject,1043,O
.,1043,O
A,1044,O
single,1044,O
origin,1044,O
of,1044,O
phenylketonuria,1044,B-SpecificDisease
in,1044,O
Yemenite,1044,O
Jews,1044,O
.,1044,O
Phenylketonuria,1045,B-SpecificDisease
(,1045,O
PKU,1045,B-SpecificDisease
),1045,O
is,1045,O
a,1045,O
metabolic,1045,B-DiseaseClass
disease,1045,I-DiseaseClass
caused,1045,O
by,1045,O
recessive,1045,O
mutations,1045,O
of,1045,O
the,1045,O
gene,1045,O
encoding,1045,O
the,1045,O
hepatic,1045,O
enzyme,1045,O
phenylalanine,1045,O
hydroxylase,1045,O
(,1045,O
PAH,1045,O
),1045,O
.,1045,O
The,1046,O
incidence,1046,O
of,1046,O
PKU,1046,B-SpecificDisease
varies,1046,O
widely,1046,O
across,1046,O
different,1046,O
geographic,1046,O
areas,1046,O
",",1046,O
and,1046,O
is,1046,O
highest,1046,O
(,1046,O
about,1046,O
1,1046,O
in,1046,O
5,1046,O
",",1046,O
000,1046,O
live,1046,O
births,1046,O
),1046,O
in,1046,O
Ireland,1046,O
and,1046,O
western,1046,O
Scotland,1046,O
",",1046,O
and,1046,O
among,1046,O
Yemenite,1046,O
Jews,1046,O
.,1046,O
A,1047,O
limited,1047,O
number,1047,O
of,1047,O
point,1047,O
mutations,1047,O
account,1047,O
for,1047,O
most,1047,O
of,1047,O
the,1047,O
PKU,1047,B-Modifier
cases,1047,O
in,1047,O
the,1047,O
European,1047,O
population,1047,O
.,1047,O
Here,1048,O
we,1048,O
report,1048,O
that,1048,O
a,1048,O
single,1048,O
molecular,1048,O
defect,1048,O
--,1048,O
a,1048,O
deletion,1048,O
spanning,1048,O
the,1048,O
third,1048,O
exon,1048,O
of,1048,O
the,1048,O
PAH,1048,O
gene,1048,O
--,1048,O
is,1048,O
responsible,1048,O
for,1048,O
all,1048,O
the,1048,O
PKU,1048,B-Modifier
cases,1048,O
among,1048,O
the,1048,O
Yemenite,1048,O
Jews,1048,O
.,1048,O
Examination,1049,O
of,1049,O
a,1049,O
random,1049,O
sample,1049,O
of,1049,O
Yemenite,1049,O
Jews,1049,O
using,1049,O
a,1049,O
molecular,1049,O
probe,1049,O
that,1049,O
detects,1049,O
the,1049,O
carriers,1049,O
of,1049,O
this,1049,O
deletion,1049,O
indicated,1049,O
a,1049,O
high,1049,O
frequency,1049,O
of,1049,O
the,1049,O
defective,1049,O
gene,1049,O
in,1049,O
this,1049,O
community,1049,O
.,1049,O
Although,1050,O
the,1050,O
deleted,1050,O
PAH,1050,O
gene,1050,O
was,1050,O
traced,1050,O
to,1050,O
25,1050,O
different,1050,O
locations,1050,O
throughout,1050,O
Yemen,1050,O
",",1050,O
family,1050,O
histories,1050,O
and,1050,O
official,1050,O
documents,1050,O
of,1050,O
the,1050,O
Yemenite,1050,O
Jewish,1050,O
community,1050,O
showed,1050,O
that,1050,O
the,1050,O
common,1050,O
ancestor,1050,O
of,1050,O
all,1050,O
the,1050,O
carriers,1050,O
of,1050,O
this,1050,O
genetic,1050,B-DiseaseClass
defect,1050,I-DiseaseClass
lived,1050,O
in,1050,O
Sana,1050,O
",",1050,O
the,1050,O
capital,1050,O
of,1050,O
Yemen,1050,O
",",1050,O
before,1050,O
the,1050,O
eighteenth,1050,O
century,1050,O
..,1050,O
Linkage,1051,O
of,1051,O
aspartylglucosaminuria,1051,B-SpecificDisease
(,1051,O
AGU,1051,B-SpecificDisease
),1051,O
to,1051,O
marker,1051,O
loci,1051,O
on,1051,O
the,1051,O
long,1051,O
arm,1051,O
of,1051,O
chromosome,1051,O
4,1051,O
.,1051,O
Aspartylglucosaminuria,1052,B-SpecificDisease
(,1052,O
AGU,1052,B-SpecificDisease
),1052,O
is,1052,O
caused,1052,O
by,1052,O
deficient,1052,O
activity,1052,O
of,1052,O
the,1052,O
enzyme,1052,O
aspartylglucosaminidase,1052,O
(,1052,O
AGA,1052,O
),1052,O
.,1052,O
The,1053,O
structural,1053,O
gene,1053,O
for,1053,O
AGA,1053,O
has,1053,O
been,1053,O
assigned,1053,O
to,1053,O
the,1053,O
region,1053,O
4q21-qter,1053,O
of,1053,O
chromosome,1053,O
4,1053,O
.,1053,O
We,1054,O
have,1054,O
studied,1054,O
the,1054,O
map,1054,O
position,1054,O
of,1054,O
the,1054,O
AGU,1054,O
locus,1054,O
in,1054,O
relation,1054,O
to,1054,O
other,1054,O
marker,1054,O
loci,1054,O
on,1054,O
the,1054,O
long,1054,O
arm,1054,O
of,1054,O
chromosome,1054,O
4,1054,O
using,1054,O
linkage,1054,O
analyses,1054,O
.,1054,O
Restriction,1055,O
fragment,1055,O
length,1055,O
polymorphism,1055,O
alleles,1055,O
for,1055,O
the,1055,O
ADH2,1055,O
",",1055,O
ADH3,1055,O
",",1055,O
EGF,1055,O
",",1055,O
FG,1055,O
alpha,1055,O
and,1055,O
FG,1055,O
beta,1055,O
loci,1055,O
and,1055,O
blood,1055,O
group,1055,O
antigens,1055,O
for,1055,O
the,1055,O
MNS,1055,O
locus,1055,O
were,1055,O
determined,1055,O
in,1055,O
a,1055,O
panel,1055,O
of,1055,O
12,1055,O
Finnish,1055,O
AGU,1055,B-Modifier
families,1055,O
.,1055,O
The,1056,O
heterozygous,1056,O
family,1056,O
members,1056,O
were,1056,O
identified,1056,O
by,1056,O
reduced,1056,O
activity,1056,O
of,1056,O
AGA,1056,O
in,1056,O
lymphocytes,1056,O
.,1056,O
Linkage,1057,O
studies,1057,O
were,1057,O
performed,1057,O
using,1057,O
both,1057,O
pairwise,1057,O
and,1057,O
multipoint,1057,O
analyses,1057,O
.,1057,O
Loose,1058,O
linkage,1058,O
of,1058,O
the,1058,O
AGU,1058,B-Modifier
locus,1058,O
to,1058,O
the,1058,O
FG,1058,O
and,1058,O
MNS,1058,O
loci,1058,O
was,1058,O
observed,1058,O
(,1058,O
z,1058,O
=,1058,O
1,1058,O
.,1058,O
16,1059,O
",",1059,O
z,1059,O
=,1059,O
1,1059,O
.,1059,O
39,1060,O
",",1060,O
respectively,1060,O
),1060,O
.,1060,O
Multipoint,1061,O
analysis,1061,O
to,1061,O
the,1061,O
fixed,1061,O
map,1061,O
[,1061,O
ADH-,1061,O
(,1061,O
0,1061,O
.,1061,O
03,1062,O
),1062,O
-EGF-,1062,O
(,1062,O
0,1062,O
.,1062,O
35,1063,O
),1063,O
-FG-,1063,O
(,1063,O
0,1063,O
.,1063,O
11,1064,O
),1064,O
-MNS,1064,O
],1064,O
suggests,1064,O
that,1064,O
the,1064,O
location,1064,O
of,1064,O
the,1064,O
AGU,1064,O
locus,1064,O
is,1064,O
0,1064,O
.,1064,O
05-0,1065,O
.,1065,O
30,1066,O
recombination,1066,O
units,1066,O
distal,1066,O
to,1066,O
MNS,1066,O
(,1066,O
z,1066,O
=,1066,O
3,1066,O
.,1066,O
03,1067,O
),1067,O
.,1067,O
The,1068,O
order,1068,O
cen-ADH-EGF-FG-MNS-AGU,1068,O
is,1068,O
35,1068,O
times,1068,O
more,1068,O
likely,1068,O
than,1068,O
the,1068,O
next,1068,O
best,1068,O
order,1068,O
cen-ADH-EGF-AGU-FG-MNS,1068,O
.,1068,O
Linkage,1069,O
relationships,1069,O
of,1069,O
the,1069,O
apolipoprotein,1069,O
C1,1069,O
gene,1069,O
and,1069,O
a,1069,O
cytochrome,1069,O
P450,1069,O
gene,1069,O
(,1069,O
CYP2A,1069,O
),1069,O
to,1069,O
myotonic,1069,B-SpecificDisease
dystrophy,1069,I-SpecificDisease
.,1069,O
We,1070,O
have,1070,O
studied,1070,O
the,1070,O
genetic,1070,O
linkage,1070,O
of,1070,O
two,1070,O
markers,1070,O
",",1070,O
the,1070,O
apolipoprotein,1070,O
C1,1070,O
(,1070,O
APOC1,1070,O
),1070,O
gene,1070,O
and,1070,O
a,1070,O
cytochrome,1070,O
P450,1070,O
(,1070,O
CYP2A,1070,O
),1070,O
gene,1070,O
",",1070,O
in,1070,O
relation,1070,O
to,1070,O
the,1070,O
gene,1070,O
for,1070,O
myotonic,1070,B-SpecificDisease
dystrophy,1070,I-SpecificDisease
(,1070,O
DM,1070,B-SpecificDisease
),1070,O
.,1070,O
A,1071,O
peak,1071,O
lod,1071,O
score,1071,O
of,1071,O
9,1071,O
.,1071,O
29,1072,O
at,1072,O
2,1072,O
cM,1072,O
was,1072,O
observed,1072,O
for,1072,O
APOC1-DM,1072,O
",",1072,O
with,1072,O
a,1072,O
lod,1072,O
score,1072,O
of,1072,O
8,1072,O
.,1072,O
55,1073,O
at,1073,O
4,1073,O
cM,1073,O
for,1073,O
CYP2A-DM,1073,O
.,1073,O
These,1074,O
two,1074,O
markers,1074,O
also,1074,O
show,1074,O
close,1074,O
linkage,1074,O
to,1074,O
each,1074,O
other,1074,O
(,1074,O
theta,1074,O
max,1074,O
=,1074,O
0,1074,O
.,1074,O
05,1075,O
",",1075,O
Zmax,1075,O
=,1075,O
9,1075,O
.,1075,O
09,1076,O
),1076,O
.,1076,O
From,1077,O
examination,1077,O
of,1077,O
the,1077,O
genotypes,1077,O
of,1077,O
the,1077,O
recombinant,1077,O
individuals,1077,O
",",1077,O
CYP2A,1077,O
appears,1077,O
to,1077,O
map,1077,O
proximal,1077,O
to,1077,O
DM,1077,O
because,1077,O
in,1077,O
one,1077,O
recombinant,1077,O
individual,1077,O
CYP2A,1077,O
",",1077,O
APOC2,1077,O
and,1077,O
CKMM,1077,O
had,1077,O
all,1077,O
recombined,1077,O
with,1077,O
DM,1077,O
.,1077,O
Evidence,1078,O
from,1078,O
another,1078,O
CYP2A-DM,1078,O
recombinant,1078,O
individual,1078,O
places,1078,O
CYP2A,1078,O
proximal,1078,O
to,1078,O
APOC2,1078,O
and,1078,O
CKMM,1078,O
.,1078,O
Localisation,1079,O
of,1079,O
CYP2A,1079,O
on,1079,O
a,1079,O
panel,1079,O
of,1079,O
somatic,1079,O
cell,1079,O
hybrids,1079,O
also,1079,O
suggests,1079,O
that,1079,O
it,1079,O
is,1079,O
proximal,1079,O
to,1079,O
DM,1079,O
and,1079,O
APOC2/C1/E,1079,O
gene,1079,O
cluster,1079,O
.,1079,O
Genetic,1080,O
linkage,1080,O
map,1080,O
of,1080,O
six,1080,O
polymorphic,1080,O
DNA,1080,O
markers,1080,O
around,1080,O
the,1080,O
gene,1080,O
for,1080,O
familial,1080,B-SpecificDisease
adenomatous,1080,I-SpecificDisease
polyposis,1080,I-SpecificDisease
on,1080,O
chromosome,1080,O
5,1080,O
.,1080,O
A,1081,O
genetic,1081,O
linkage,1081,O
map,1081,O
of,1081,O
six,1081,O
polymorphic,1081,O
DNA,1081,O
markers,1081,O
close,1081,O
to,1081,O
the,1081,O
gene,1081,O
(,1081,O
APC,1081,O
),1081,O
for,1081,O
familial,1081,B-SpecificDisease
adenomatous,1081,I-SpecificDisease
polyposis,1081,I-SpecificDisease
(,1081,O
FAP,1081,B-SpecificDisease
),1081,O
on,1081,O
chromosome,1081,O
5q,1081,O
is,1081,O
reported,1081,O
.,1081,O
One,1082,O
hundred,1082,O
fifty-five,1082,O
typed,1082,O
members,1082,O
of,1082,O
nine,1082,O
FAP,1082,B-Modifier
kindred,1082,O
provided,1082,O
more,1082,O
than,1082,O
90,1082,O
meioses,1082,O
for,1082,O
linkage,1082,O
analysis,1082,O
.,1082,O
A,1083,O
number,1083,O
of,1083,O
crucial,1083,O
recombination,1083,O
events,1083,O
have,1083,O
been,1083,O
identified,1083,O
which,1083,O
are,1083,O
informative,1083,O
at,1083,O
three,1083,O
or,1083,O
more,1083,O
loci,1083,O
",",1083,O
allowing,1083,O
confident,1083,O
ordering,1083,O
of,1083,O
parts,1083,O
of,1083,O
the,1083,O
map,1083,O
.,1083,O
There,1084,O
was,1084,O
no,1084,O
evidence,1084,O
of,1084,O
genetic,1084,O
heterogeneity,1084,O
",",1084,O
with,1084,O
all,1084,O
families,1084,O
showing,1084,O
linkage,1084,O
of,1084,O
at,1084,O
least,1084,O
one,1084,O
chromosome,1084,O
5,1084,O
marker,1084,O
to,1084,O
the,1084,O
gene,1084,O
.,1084,O
Recombination,1085,O
data,1085,O
and,1085,O
two-point,1085,O
linkage,1085,O
analysis,1085,O
support,1085,O
a,1085,O
locus,1085,O
order,1085,O
of,1085,O
centromere-pi,1085,O
227-C11P11-ECB27-L5,1085,O
.,1085,O
62-APC-EF5,1086,O
62-APC-EF5,1086,O
.,1086,O
44-YN5,1087,O
44-YN5,1087,O
.,1087,O
48-telomer,1088,O
e,1088,O
",",1088,O
although,1088,O
EF5,1088,O
.,1088,O
44,1089,O
could,1089,O
lie,1089,O
in,1089,O
the,1089,O
interval,1089,O
L5,1089,O
.,1089,O
62-APC,1090,O
or,1090,O
ECB27-L5,1090,O
.,1090,O
62,1091,O
.,1091,O
No,1092,O
recombinants,1092,O
were,1092,O
identified,1092,O
between,1092,O
APC,1092,O
and,1092,O
either,1092,O
EF5,1092,O
.,1092,O
44,1093,O
or,1093,O
YN5,1093,O
.,1093,O
48,1094,O
",",1094,O
but,1094,O
published,1094,O
deletion,1094,O
mapping,1094,O
in,1094,O
colorectal,1094,B-SpecificDisease
carcinomas,1094,I-SpecificDisease
and,1094,O
linkage,1094,O
analysis,1094,O
in,1094,O
FAP,1094,B-SpecificDisease
suggest,1094,O
that,1094,O
YN5,1094,O
.,1094,O
48,1095,O
is,1095,O
1-3,1095,O
cM,1095,O
from,1095,O
APC,1095,O
.,1095,O
The,1096,O
present,1096,O
study,1096,O
suggests,1096,O
that,1096,O
YN5,1096,O
.,1096,O
48,1097,O
and,1097,O
L5,1097,O
.,1097,O
62,1098,O
delineate,1098,O
a,1098,O
small,1098,O
region,1098,O
of,1098,O
chromosome,1098,O
5,1098,O
within,1098,O
which,1098,O
the,1098,O
EF5,1098,O
.,1098,O
44,1099,O
locus,1099,O
lies,1099,O
very,1099,O
close,1099,O
to,1099,O
the,1099,O
APC,1099,B-Modifier
gene,1099,O
.,1099,O
These,1100,O
data,1100,O
not,1100,O
only,1100,O
allow,1100,O
use,1100,O
of,1100,O
flanking,1100,O
markers,1100,O
for,1100,O
presymptomatic,1100,O
diagnosis,1100,O
of,1100,O
FAP,1100,B-SpecificDisease
but,1100,O
also,1100,O
provide,1100,O
a,1100,O
high-density,1100,O
map,1100,O
of,1100,O
the,1100,O
region,1100,O
for,1100,O
isolation,1100,O
of,1100,O
the,1100,O
APC,1100,B-Modifier
gene,1100,O
itself,1100,O
and,1100,O
for,1100,O
further,1100,O
assessment,1100,O
of,1100,O
the,1100,O
role,1100,O
of,1100,O
chromosome,1100,O
5,1100,O
deletions,1100,O
in,1100,O
the,1100,O
biology,1100,O
of,1100,O
sporadic,1100,O
colorectal,1100,B-SpecificDisease
cancer,1100,I-SpecificDisease
.,1100,O
Serum,1101,O
amyloid,1101,O
A,1101,O
and,1101,O
P,1101,O
protein,1101,O
genes,1101,O
in,1101,O
familial,1101,B-SpecificDisease
Mediterranean,1101,I-SpecificDisease
fever,1101,I-SpecificDisease
.,1101,O
Two,1102,O
recent,1102,O
studies,1102,O
have,1102,O
suggested,1102,O
the,1102,O
involvement,1102,O
of,1102,O
serum,1102,O
amyloid,1102,O
A,1102,O
(,1102,O
SAA,1102,O
),1102,O
and,1102,O
P,1102,O
(,1102,O
APCS,1102,O
),1102,O
genes,1102,O
in,1102,O
familial,1102,B-SpecificDisease
Mediterranean,1102,I-SpecificDisease
fever,1102,I-SpecificDisease
(,1102,O
MEF,1102,B-SpecificDisease
),1102,O
.,1102,O
To,1103,O
test,1103,O
the,1103,O
role,1103,O
of,1103,O
SAA,1103,O
and,1103,O
APCS,1103,O
in,1103,O
MEF,1103,B-SpecificDisease
and,1103,O
MEF-amyloidosis,1103,O
",",1103,O
we,1103,O
studied,1103,O
17,1103,O
informative,1103,O
families,1103,O
(,1103,O
15,1103,O
Armenians,1103,O
",",1103,O
2,1103,O
non-Ashkenazi,1103,O
Jews,1103,O
),1103,O
and,1103,O
8,1103,O
MEF,1103,B-Modifier
patients,1103,O
with,1103,O
amyloidosis,1103,B-DiseaseClass
using,1103,O
a,1103,O
candidate,1103,O
gene,1103,O
approach,1103,O
.,1103,O
No,1104,O
evidence,1104,O
for,1104,O
any,1104,O
MEF-associated,1104,B-Modifier
polymorphism,1104,O
was,1104,O
found,1104,O
in,1104,O
any,1104,O
of,1104,O
the,1104,O
41,1104,O
Armenian,1104,O
and,1104,O
Jewish,1104,O
MEF,1104,B-Modifier
patients,1104,O
tested,1104,O
.,1104,O
Our,1105,O
family,1105,O
studies,1105,O
allowed,1105,O
us,1105,O
to,1105,O
rule,1105,O
out,1105,O
tight,1105,O
linkage,1105,O
between,1105,O
SAA,1105,O
and,1105,O
MEF,1105,B-SpecificDisease
(,1105,O
lod,1105,O
score,1105,O
=,1105,O
-2,1105,O
.,1105,O
16,1106,O
",",1106,O
theta,1106,O
less,1106,O
than,1106,O
or,1106,O
equal,1106,O
to,1106,O
0,1106,O
.,1106,O
06,1107,O
),1107,O
.,1107,O
For,1108,O
APCS,1108,O
we,1108,O
found,1108,O
that,1108,O
the,1108,O
allele,1108,O
frequency,1108,O
in,1108,O
the,1108,O
MEF-amyloidosis,1108,O
patients,1108,O
was,1108,O
similar,1108,O
to,1108,O
that,1108,O
in,1108,O
18,1108,O
unrelated,1108,O
MEF,1108,B-Modifier
patients,1108,O
without,1108,O
amyloidosis,1108,B-DiseaseClass
and,1108,O
their,1108,O
33,1108,O
healthy,1108,O
parents,1108,O
.,1108,O
Some,1109,O
Mexican,1109,O
glucose-6-phosphate,1109,O
dehydrogenase,1109,O
variants,1109,O
revisited,1109,O
.,1109,O
Glucose-6-phosphate,1110,B-SpecificDisease
dehydrogenase,1110,I-SpecificDisease
(,1110,I-SpecificDisease
G6PD,1110,I-SpecificDisease
),1110,I-SpecificDisease
deficiency,1110,I-SpecificDisease
appears,1110,O
to,1110,O
be,1110,O
fairly,1110,O
common,1110,O
in,1110,O
Mexico,1110,O
.,1110,O
We,1111,O
have,1111,O
now,1111,O
examined,1111,O
the,1111,O
DNA,1111,O
of,1111,O
three,1111,O
previously,1111,O
reported,1111,O
electrophoretically,1111,O
fast,1111,O
Mexican,1111,O
G6PD,1111,O
variants,1111,O
",",1111,O
-G6PD,1111,O
Distrito,1111,O
Federal,1111,O
",",1111,O
G6PD,1111,O
Tepic,1111,O
",",1111,O
and,1111,O
G6PD,1111,O
Castilla,1111,O
.,1111,O
All,1112,O
three,1112,O
of,1112,O
these,1112,O
variants,1112,O
",",1112,O
believed,1112,O
on,1112,O
the,1112,O
basis,1112,O
of,1112,O
biochemical,1112,O
characterization,1112,O
and,1112,O
population,1112,O
origin,1112,O
to,1112,O
be,1112,O
unique,1112,O
",",1112,O
have,1112,O
the,1112,O
G,1112,O
--,1112,O
--,1112,O
A,1112,O
transition,1112,O
at,1112,O
nucleotide,1112,O
202,1112,O
and,1112,O
the,1112,O
A,1112,O
--,1112,O
--,1112,O
G,1112,O
transition,1112,O
at,1112,O
nucleotide,1112,O
376,1112,O
",",1112,O
mutations,1112,O
that,1112,O
we,1112,O
now,1112,O
recognize,1112,O
to,1112,O
be,1112,O
characteristic,1112,O
of,1112,O
G6PD,1112,O
A-,1112,O
.,1112,O
Two,1113,O
other,1113,O
Mexican,1113,O
males,1113,O
with,1113,O
G6PD,1113,B-SpecificDisease
deficiency,1113,I-SpecificDisease
were,1113,O
found,1113,O
to,1113,O
have,1113,O
the,1113,O
same,1113,O
mutation,1113,O
.,1113,O
All,1114,O
five,1114,O
have,1114,O
the,1114,O
(,1114,O
NlaIII/FokI/PvuII/PstI,1114,O
),1114,O
haplotype,1114,O
characteristic,1114,O
of,1114,O
G6PD,1114,O
A,1114,O
-in,1114,O
Africa,1114,O
.,1114,O
Since,1115,O
the,1115,O
PvuII,1115,O
+,1115,O
genotype,1115,O
seems,1115,O
to,1115,O
be,1115,O
rare,1115,O
in,1115,O
Europe,1115,O
",",1115,O
we,1115,O
conclude,1115,O
that,1115,O
all,1115,O
of,1115,O
these,1115,O
G6PD,1115,O
A,1115,O
-,1115,O
genes,1115,O
had,1115,O
their,1115,O
ancient,1115,O
origin,1115,O
in,1115,O
Africa,1115,O
",",1115,O
although,1115,O
in,1115,O
many,1115,O
of,1115,O
the,1115,O
Mexican,1115,O
patients,1115,O
with,1115,O
G6PD,1115,O
A,1115,O
-202A/376G,1115,O
the,1115,O
gene,1115,O
may,1115,O
have,1115,O
been,1115,O
imported,1115,O
more,1115,O
recently,1115,O
from,1115,O
Spain,1115,O
",",1115,O
where,1115,O
this,1115,O
variant,1115,O
",",1115,O
formerly,1115,O
known,1115,O
as,1115,O
G6PD,1115,O
Betica,1115,O
",",1115,O
is,1115,O
also,1115,O
prevalent,1115,O
..,1115,O
Hereditary,1116,O
deficiency,1116,B-SpecificDisease
of,1116,I-SpecificDisease
C5,1116,I-SpecificDisease
in,1116,O
association,1116,O
with,1116,O
discoid,1116,B-SpecificDisease
lupus,1116,I-SpecificDisease
erythematosus,1116,I-SpecificDisease
.,1116,O
A,1117,O
29-year-old,1117,O
woman,1117,O
with,1117,O
discoid,1117,B-SpecificDisease
lupus,1117,I-SpecificDisease
erythematosus,1117,I-SpecificDisease
had,1117,O
undetectable,1117,O
classic,1117,O
pathway,1117,O
complement,1117,O
activity,1117,O
.,1117,O
Hypocomplementemia,1118,B-DiseaseClass
was,1118,O
due,1118,O
to,1118,O
selective,1118,O
deficiency,1118,B-SpecificDisease
of,1118,I-SpecificDisease
C5,1118,I-SpecificDisease
.,1118,O
One,1119,O
of,1119,O
her,1119,O
children,1119,O
was,1119,O
also,1119,O
deficient,1119,O
.,1119,O
To,1120,O
our,1120,O
knowledge,1120,O
this,1120,O
is,1120,O
the,1120,O
first,1120,O
documented,1120,O
case,1120,O
of,1120,O
an,1120,O
association,1120,O
between,1120,O
discoid,1120,B-SpecificDisease
lupus,1120,I-SpecificDisease
erythematosus,1120,I-SpecificDisease
and,1120,O
C5,1120,B-SpecificDisease
deficiency,1120,I-SpecificDisease
..,1120,O
Founder,1121,O
effect,1121,O
of,1121,O
a,1121,O
prevalent,1121,O
phenylketonuria,1121,B-Modifier
mutation,1121,O
in,1121,O
the,1121,O
Oriental,1121,O
population,1121,O
.,1121,O
A,1122,O
missense,1122,O
mutation,1122,O
has,1122,O
been,1122,O
identified,1122,O
in,1122,O
the,1122,O
human,1122,O
phenylalanine,1122,O
hydroxylase,1122,O
[,1122,O
PAH,1122,O
;,1122,O
phenylalanine,1122,O
4-monooxygenase,1122,O
;,1122,O
L-phenylalanine,1122,O
",",1122,O
tetrahydrobiopterin,1122,O
oxygen,1122,O
oxidoreductase,1122,O
(,1122,O
4-hydroxylating,1122,O
),1122,O
",",1122,O
EC,1122,O
1,1122,O
.,1122,O
14,1123,O
.,1123,O
16,1124,O
.,1124,O
1,1125,O
],1125,O
gene,1125,O
in,1125,O
a,1125,O
Chinese,1125,O
patient,1125,O
with,1125,O
classic,1125,O
phenylketonuria,1125,B-SpecificDisease
(,1125,O
PKU,1125,B-SpecificDisease
),1125,O
.,1125,O
A,1126,O
G-to-C,1126,O
transition,1126,O
at,1126,O
the,1126,O
second,1126,O
base,1126,O
of,1126,O
codon,1126,O
413,1126,O
in,1126,O
exon,1126,O
12,1126,O
of,1126,O
the,1126,O
gene,1126,O
results,1126,O
in,1126,O
the,1126,O
substitution,1126,O
of,1126,O
Pro413,1126,O
for,1126,O
Arg413,1126,O
in,1126,O
the,1126,O
mutant,1126,O
protein,1126,O
.,1126,O
This,1127,O
mutation,1127,O
(,1127,O
R413P,1127,O
),1127,O
results,1127,O
in,1127,O
negligible,1127,O
enzymatic,1127,O
activity,1127,O
when,1127,O
expressed,1127,O
in,1127,O
heterologous,1127,O
mammalian,1127,O
cells,1127,O
and,1127,O
is,1127,O
compatible,1127,O
with,1127,O
a,1127,O
classic,1127,O
PKU,1127,B-Modifier
phenotype,1127,O
in,1127,O
the,1127,O
patient,1127,O
.,1127,O
Population,1128,O
genetic,1128,O
studies,1128,O
reveal,1128,O
that,1128,O
this,1128,O
mutation,1128,O
is,1128,O
tightly,1128,O
linked,1128,O
to,1128,O
restriction,1128,O
fragment,1128,O
length,1128,O
polymorphism,1128,O
haplotype,1128,O
4,1128,O
",",1128,O
which,1128,O
is,1128,O
the,1128,O
predominant,1128,O
haplotype,1128,O
of,1128,O
the,1128,O
PAH,1128,O
locus,1128,O
in,1128,O
the,1128,O
Oriental,1128,O
population,1128,O
.,1128,O
It,1129,O
accounts,1129,O
for,1129,O
13,1129,O
.,1129,O
8,1130,O
%,1130,O
of,1130,O
northern,1130,O
Chinese,1130,O
and,1130,O
27,1130,O
%,1130,O
of,1130,O
Japanese,1130,O
PKU,1130,B-Modifier
alleles,1130,O
",",1130,O
but,1130,O
it,1130,O
is,1130,O
rare,1130,O
in,1130,O
southern,1130,O
Chinese,1130,O
(,1130,O
2,1130,O
.,1130,O
2,1131,O
%,1131,O
),1131,O
and,1131,O
is,1131,O
absent,1131,O
in,1131,O
the,1131,O
Caucasian,1131,O
population,1131,O
.,1131,O
The,1132,O
data,1132,O
demonstrate,1132,O
unambiguously,1132,O
that,1132,O
the,1132,O
mutation,1132,O
occurred,1132,O
after,1132,O
racial,1132,O
divergence,1132,O
of,1132,O
Orientals,1132,O
and,1132,O
Caucasians,1132,O
and,1132,O
suggest,1132,O
that,1132,O
the,1132,O
allele,1132,O
has,1132,O
spread,1132,O
throughout,1132,O
the,1132,O
Orient,1132,O
by,1132,O
a,1132,O
founder,1132,O
effect,1132,O
.,1132,O
Previous,1133,O
protein,1133,O
polymorphism,1133,O
studies,1133,O
in,1133,O
eastern,1133,O
Asia,1133,O
have,1133,O
led,1133,O
to,1133,O
the,1133,O
hypothesis,1133,O
that,1133,O
``,1133,O
northern,1133,O
Mongoloids,1133,O
``,1133,O
represented,1133,O
a,1133,O
founding,1133,O
population,1133,O
in,1133,O
Asia,1133,O
.,1133,O
Our,1134,O
results,1134,O
are,1134,O
compatible,1134,O
with,1134,O
this,1134,O
hypothesis,1134,O
in,1134,O
that,1134,O
the,1134,O
PKU,1134,B-Modifier
mutation,1134,O
might,1134,O
have,1134,O
occurred,1134,O
in,1134,O
northern,1134,O
Mongoloids,1134,O
and,1134,O
subsequently,1134,O
spread,1134,O
to,1134,O
the,1134,O
Chinese,1134,O
and,1134,O
Japanese,1134,O
populations,1134,O
.,1134,O
Glucose/galactose,1135,B-SpecificDisease
malabsorption,1135,I-SpecificDisease
caused,1135,O
by,1135,O
a,1135,O
defect,1135,O
in,1135,O
the,1135,O
Na+/glucose,1135,O
cotransporter,1135,O
.,1135,O
Glucose/galactose,1136,B-SpecificDisease
malabsorption,1136,I-SpecificDisease
(,1136,O
GGM,1136,B-SpecificDisease
),1136,O
is,1136,O
an,1136,O
autosomal,1136,B-DiseaseClass
recessive,1136,I-DiseaseClass
disease,1136,I-DiseaseClass
manifesting,1136,O
within,1136,O
the,1136,O
first,1136,O
weeks,1136,O
of,1136,O
life,1136,O
and,1136,O
characterized,1136,O
by,1136,O
a,1136,O
selective,1136,O
failure,1136,O
to,1136,O
absorb,1136,O
dietary,1136,O
glucose,1136,O
and,1136,O
galactose,1136,O
from,1136,O
the,1136,O
intestine,1136,O
.,1136,O
The,1137,O
consequent,1137,O
severe,1137,O
diarrhoea,1137,B-SpecificDisease
and,1137,O
dehydration,1137,B-SpecificDisease
are,1137,O
usually,1137,O
fatal,1137,O
unless,1137,O
these,1137,O
sugars,1137,O
are,1137,O
eliminated,1137,O
from,1137,O
the,1137,O
diet,1137,O
.,1137,O
Intestinal,1138,O
biopsies,1138,O
of,1138,O
GGM,1138,B-Modifier
patients,1138,O
have,1138,O
revealed,1138,O
a,1138,O
specific,1138,O
defect,1138,O
in,1138,O
Na,1138,O
(,1138,O
+,1138,O
),1138,O
-dependent,1138,O
absorption,1138,O
of,1138,O
glucose,1138,O
in,1138,O
the,1138,O
brush,1138,O
border,1138,O
.,1138,O
Normal,1139,O
glucose,1139,O
absorption,1139,O
is,1139,O
mediated,1139,O
by,1139,O
the,1139,O
Na,1139,O
+/glucose,1139,O
cotransporter,1139,O
in,1139,O
the,1139,O
brush,1139,O
border,1139,O
membrane,1139,O
of,1139,O
the,1139,O
intestinal,1139,O
epithelium,1139,O
.,1139,O
Cellular,1140,O
influx,1140,O
is,1140,O
driven,1140,O
by,1140,O
the,1140,O
transmembrane,1140,O
Na,1140,O
+,1140,O
electrochemical,1140,O
potential,1140,O
gradient,1140,O
;,1140,O
thereafter,1140,O
the,1140,O
sugar,1140,O
moves,1140,O
to,1140,O
the,1140,O
blood,1140,O
across,1140,O
the,1140,O
basolateral,1140,O
membrane,1140,O
via,1140,O
the,1140,O
facilitated,1140,O
glucose,1140,O
carrier,1140,O
.,1140,O
We,1141,O
have,1141,O
previously,1141,O
cloned,1141,O
and,1141,O
sequenced,1141,O
a,1141,O
Na,1141,O
+/glucose,1141,O
cotransporter,1141,O
from,1141,O
normal,1141,O
human,1141,O
ileum,1141,O
and,1141,O
shown,1141,O
that,1141,O
this,1141,O
gene,1141,O
",",1141,O
SGLT1,1141,O
",",1141,O
resides,1141,O
on,1141,O
the,1141,O
distal,1141,O
q,1141,O
arm,1141,O
of,1141,O
chromosome,1141,O
22,1141,O
.,1141,O
We,1142,O
have,1142,O
now,1142,O
amplified,1142,O
SGLT1,1142,O
complementary,1142,O
DNA,1142,O
and,1142,O
genomic,1142,O
DNA,1142,O
from,1142,O
members,1142,O
of,1142,O
a,1142,O
family,1142,O
affected,1142,O
with,1142,O
GGM,1142,B-SpecificDisease
by,1142,O
the,1142,O
polymerase,1142,O
chain,1142,O
reaction,1142,O
.,1142,O
Sequence,1143,O
analysis,1143,O
of,1143,O
the,1143,O
amplified,1143,O
products,1143,O
has,1143,O
revealed,1143,O
a,1143,O
single,1143,O
missense,1143,O
mutation,1143,O
in,1143,O
SGLT1,1143,O
which,1143,O
cosegregates,1143,O
with,1143,O
the,1143,O
GGM,1143,B-Modifier
phenotype,1143,O
and,1143,O
results,1143,O
in,1143,O
a,1143,O
complete,1143,O
loss,1143,O
of,1143,O
Na,1143,O
(,1143,O
+,1143,O
),1143,O
-dependent,1143,O
glucose,1143,O
transport,1143,O
in,1143,O
Xenopus,1143,O
oocytes,1143,O
injected,1143,O
with,1143,O
this,1143,O
complementary,1143,O
RNA,1143,O
..,1143,O
A,1144,O
de,1144,O
novo,1144,O
unbalanced,1144,O
reciprocal,1144,O
translocation,1144,O
identified,1144,O
as,1144,O
paternal,1144,O
in,1144,O
origin,1144,O
in,1144,O
the,1144,O
Prader-Willi,1144,B-SpecificDisease
syndrome,1144,I-SpecificDisease
.,1144,O
Interstitial,1145,O
cytogenetic,1145,O
deletions,1145,O
involving,1145,O
the,1145,O
paternally,1145,O
derived,1145,O
chromosome,1145,O
15q11-13,1145,O
have,1145,O
been,1145,O
described,1145,O
in,1145,O
patients,1145,O
with,1145,O
the,1145,O
Prader-Willi,1145,B-SpecificDisease
syndrome,1145,I-SpecificDisease
(,1145,O
PWS,1145,B-SpecificDisease
),1145,O
.,1145,O
We,1146,O
report,1146,O
a,1146,O
child,1146,O
with,1146,O
PWS,1146,B-SpecificDisease
and,1146,O
a,1146,O
de,1146,O
novo,1146,O
unbalanced,1146,O
karyotype,1146,O
-45,1146,O
",",1146,O
XY,1146,O
",",1146,O
-9,1146,O
",",1146,O
-15,1146,O
",",1146,O
+,1146,O
der,1146,O
(,1146,O
9,1146,O
),1146,O
t,1146,O
(,1146,O
9,1146,O
;,1146,O
15,1146,O
),1146,O
(,1146,O
q34,1146,O
;,1146,O
q13,1146,O
),1146,O
.,1146,O
Molecular,1147,O
studies,1147,O
with,1147,O
the,1147,O
DNA,1147,O
probe,1147,O
pML34,1147,O
confirmed,1147,O
that,1147,O
only,1147,O
a,1147,O
single,1147,O
Prader,1147,B-Modifier
Willi,1147,I-Modifier
critical,1147,O
region,1147,O
(,1147,O
PWCR,1147,O
15q11,1147,O
.,1147,O
2-q12,1148,O
),1148,O
copy,1148,O
was,1148,O
present,1148,O
.,1148,O
Hybridisation,1149,O
of,1149,O
patient,1149,O
and,1149,O
parental,1149,O
DNA,1149,O
with,1149,O
the,1149,O
multi-allelic,1149,O
probe,1149,O
CMW1,1149,O
",",1149,O
which,1149,O
maps,1149,O
to,1149,O
pter-15q13,1149,O
",",1149,O
showed,1149,O
that,1149,O
the,1149,O
chromosome,1149,O
involved,1149,O
in,1149,O
the,1149,O
translocation,1149,O
was,1149,O
paternal,1149,O
in,1149,O
origin,1149,O
.,1149,O
This,1150,O
is,1150,O
the,1150,O
first,1150,O
example,1150,O
of,1150,O
a,1150,O
paternally-derived,1150,O
PWCR,1150,O
allele,1150,O
loss,1150,O
caused,1150,O
by,1150,O
an,1150,O
unbalanced,1150,O
translocation,1150,O
that,1150,O
has,1150,O
arisen,1150,O
de,1150,O
novo,1150,O
.,1150,O
Localisation,1151,O
of,1151,O
the,1151,O
myotonic,1151,B-Modifier
dystrophy,1151,I-Modifier
locus,1151,O
to,1151,O
19q13.2-19q13.3,1151,O
and,1151,O
its,1151,O
relationship,1151,O
to,1151,O
twelve,1151,O
polymorphic,1151,O
loci,1151,O
on,1151,O
19q,1151,O
.,1151,O
The,1152,O
order,1152,O
of,1152,O
fourteen,1152,O
polymorphic,1152,O
markers,1152,O
localised,1152,O
to,1152,O
the,1152,O
long,1152,O
arm,1152,O
of,1152,O
human,1152,O
chromosome,1152,O
19,1152,O
has,1152,O
been,1152,O
established,1152,O
by,1152,O
multipoint,1152,O
mapping,1152,O
in,1152,O
a,1152,O
set,1152,O
of,1152,O
40,1152,O
CEPH,1152,O
(,1152,O
Centre,1152,O
dEtude,1152,O
de,1152,O
Polymorphisme,1152,O
Humain,1152,O
",",1152,O
Paris,1152,O
),1152,O
reference,1152,O
families,1152,O
.,1152,O
We,1153,O
report,1153,O
here,1153,O
the,1153,O
linkage,1153,O
relationship,1153,O
of,1153,O
the,1153,O
myotonic,1153,B-Modifier
dystrophy,1153,I-Modifier
(,1153,O
DM,1153,B-Modifier
),1153,O
locus,1153,O
to,1153,O
twelve,1153,O
of,1153,O
these,1153,O
markers,1153,O
as,1153,O
studied,1153,O
in,1153,O
45,1153,O
families,1153,O
with,1153,O
DM,1153,B-SpecificDisease
.,1153,O
The,1154,O
resulting,1154,O
genetic,1154,O
map,1154,O
is,1154,O
supported,1154,O
by,1154,O
the,1154,O
localisation,1154,O
of,1154,O
the,1154,O
DNA,1154,O
markers,1154,O
in,1154,O
a,1154,O
panel,1154,O
of,1154,O
somatic,1154,O
cell,1154,O
hybrids,1154,O
.,1154,O
Ten,1155,O
of,1155,O
the,1155,O
twelve,1155,O
markers,1155,O
have,1155,O
been,1155,O
shown,1155,O
to,1155,O
be,1155,O
proximal,1155,O
to,1155,O
the,1155,O
DM,1155,B-Modifier
gene,1155,O
and,1155,O
two,1155,O
",",1155,O
PRKCG,1155,O
and,1155,O
D19S22,1155,O
",",1155,O
distal,1155,O
but,1155,O
at,1155,O
distances,1155,O
of,1155,O
approximately,1155,O
25,1155,O
cM,1155,O
and,1155,O
15,1155,O
cM,1155,O
",",1155,O
respectively,1155,O
.,1155,O
The,1156,O
closest,1156,O
proximal,1156,O
markers,1156,O
are,1156,O
APOC2,1156,O
(,1156,O
apolipoprotein,1156,O
C-II,1156,O
),1156,O
and,1156,O
CKM,1156,O
(,1156,O
creatine,1156,O
kinase,1156,O
",",1156,O
muscle,1156,O
),1156,O
approximately,1156,O
3,1156,O
cM,1156,O
and,1156,O
2,1156,O
cM,1156,O
from,1156,O
the,1156,O
DM,1156,B-Modifier
gene,1156,O
respectively,1156,O
",",1156,O
in,1156,O
the,1156,O
order,1156,O
APOC2-CKM-DM,1156,O
.,1156,O
The,1157,O
distance,1157,O
between,1157,O
APOC2,1157,O
",",1157,O
CKM,1157,O
and,1157,O
DM,1157,B-SpecificDisease
(,1157,O
of,1157,O
the,1157,O
order,1157,O
of,1157,O
2,1157,O
million,1157,O
base,1157,O
pairs,1157,O
),1157,O
and,1157,O
their,1157,O
known,1157,O
orientation,1157,O
should,1157,O
permit,1157,O
directional,1157,O
chromosome,1157,O
walking,1157,O
and,1157,O
jumping,1157,O
.,1157,O
The,1158,O
data,1158,O
presented,1158,O
here,1158,O
should,1158,O
enable,1158,O
us,1158,O
to,1158,O
determine,1158,O
whether,1158,O
or,1158,O
not,1158,O
new,1158,O
markers,1158,O
are,1158,O
distal,1158,O
to,1158,O
APOC2/CKM,1158,O
and,1158,O
thus,1158,O
potentially,1158,O
flank,1158,O
the,1158,O
DM,1158,B-Modifier
gene,1158,O
..,1158,O
Localization,1159,O
of,1159,O
histidase,1159,O
to,1159,O
human,1159,O
chromosome,1159,O
region,1159,O
12q22,1159,O
--,1159,O
--,1159,O
q24.1,1159,O
and,1159,O
mouse,1159,O
chromosome,1159,O
region,1159,O
10C2,1159,O
--,1159,O
--,1159,O
D1,1159,O
.,1159,O
The,1160,O
human,1160,O
gene,1160,O
for,1160,O
histidase,1160,O
(,1160,O
histidine,1160,O
ammonia-lyase,1160,O
;,1160,O
HAL,1160,O
),1160,O
",",1160,O
the,1160,O
enzyme,1160,O
deficient,1160,O
in,1160,O
histidinemia,1160,B-SpecificDisease
",",1160,O
was,1160,O
assigned,1160,O
to,1160,O
human,1160,O
chromosome,1160,O
12,1160,O
by,1160,O
Southern,1160,O
blot,1160,O
analysis,1160,O
of,1160,O
human,1160,O
X,1160,O
mouse,1160,O
somatic,1160,O
cell,1160,O
hybrid,1160,O
DNA,1160,O
.,1160,O
The,1161,O
gene,1161,O
was,1161,O
sublocalized,1161,O
to,1161,O
region,1161,O
12q22,1161,O
--,1161,O
--,1161,O
q24,1161,O
.,1161,O
1,1162,O
by,1162,O
in,1162,O
situ,1162,O
hybridization,1162,O
",",1162,O
using,1162,O
a,1162,O
human,1162,O
histidase,1162,O
cDNA,1162,O
.,1162,O
The,1163,O
homologous,1163,O
locus,1163,O
in,1163,O
the,1163,O
mouse,1163,O
(,1163,O
Hal,1163,O
),1163,O
was,1163,O
mapped,1163,O
to,1163,O
region,1163,O
10C2,1163,O
--,1163,O
--,1163,O
D1,1163,O
by,1163,O
in,1163,O
situ,1163,O
hybridization,1163,O
",",1163,O
using,1163,O
a,1163,O
cell,1163,O
line,1163,O
from,1163,O
a,1163,O
mouse,1163,O
homozygous,1163,O
for,1163,O
a,1163,O
1,1163,O
.,1163,O
10,1164,O
Robertsonian,1164,O
translocation,1164,O
.,1164,O
These,1165,O
assignments,1165,O
extend,1165,O
the,1165,O
conserved,1165,O
syntenic,1165,O
region,1165,O
between,1165,O
human,1165,O
chromosome,1165,O
12,1165,O
and,1165,O
mouse,1165,O
chromosome,1165,O
10,1165,O
that,1165,O
includes,1165,O
the,1165,O
genes,1165,O
for,1165,O
phenylalanine,1165,O
hydroxylase,1165,O
",",1165,O
gamma,1165,O
interferon,1165,O
",",1165,O
peptidase,1165,O
",",1165,O
and,1165,O
citrate,1165,O
synthase,1165,O
.,1165,O
The,1166,O
localization,1166,O
of,1166,O
histidase,1166,O
to,1166,O
mouse,1166,O
chromosome,1166,O
10,1166,O
suggests,1166,O
that,1166,O
the,1166,O
histidase,1166,O
regulatory,1166,O
locus,1166,O
(,1166,O
Hsd,1166,O
),1166,O
and,1166,O
the,1166,O
histidinemia,1166,O
mutation,1166,O
(,1166,O
his,1166,O
),1166,O
",",1166,O
which,1166,O
are,1166,O
both,1166,O
known,1166,O
to,1166,O
be,1166,O
on,1166,O
chromosome,1166,O
10,1166,O
",",1166,O
may,1166,O
be,1166,O
alleles,1166,O
of,1166,O
the,1166,O
histidase,1166,O
structural,1166,O
gene,1166,O
locus,1166,O
.,1166,O
Determination,1167,O
of,1167,O
the,1167,O
mutations,1167,O
responsible,1167,O
for,1167,O
the,1167,O
Lesch-Nyhan,1167,B-SpecificDisease
syndrome,1167,I-SpecificDisease
in,1167,O
17,1167,O
subjects,1167,O
.,1167,O
Hypoxanthine,1168,O
--,1168,O
guanine,1168,O
phosphoribosyltransferase,1168,O
(,1168,O
HPRT,1168,O
),1168,O
is,1168,O
a,1168,O
purine,1168,O
salvage,1168,O
enzyme,1168,O
that,1168,O
catalyzes,1168,O
the,1168,O
conversion,1168,O
of,1168,O
hypoxanthine,1168,O
to,1168,O
inosine,1168,O
monophosphate,1168,O
and,1168,O
guanine,1168,O
to,1168,O
guanosine,1168,O
monophosphate,1168,O
.,1168,O
Previous,1169,O
studies,1169,O
of,1169,O
mutant,1169,O
HPRT,1169,O
proteins,1169,O
analyzed,1169,O
at,1169,O
the,1169,O
molecular,1169,O
level,1169,O
have,1169,O
shown,1169,O
a,1169,O
significant,1169,O
heterogeneity,1169,O
.,1169,O
This,1170,O
investigation,1170,O
further,1170,O
verifies,1170,O
this,1170,O
heterogeneity,1170,O
and,1170,O
identifies,1170,O
insertions,1170,O
",",1170,O
deletions,1170,O
",",1170,O
and,1170,O
point,1170,O
mutations,1170,O
.,1170,O
The,1171,O
direct,1171,O
sequencing,1171,O
of,1171,O
the,1171,O
polymerase,1171,O
chain,1171,O
reaction-amplified,1171,O
product,1171,O
of,1171,O
reverse-transcribed,1171,O
HPRT,1171,O
mRNA,1171,O
enabled,1171,O
the,1171,O
rapid,1171,O
identification,1171,O
of,1171,O
the,1171,O
mutations,1171,O
found,1171,O
in,1171,O
17,1171,O
previously,1171,O
uncharacterized,1171,O
cell,1171,O
lines,1171,O
derived,1171,O
from,1171,O
patients,1171,O
with,1171,O
the,1171,O
Lesch-Nyhan,1171,B-SpecificDisease
syndrome,1171,I-SpecificDisease
..,1171,O
Linkage,1172,O
of,1172,O
DNA,1172,O
markers,1172,O
at,1172,O
Xq28,1172,O
to,1172,O
adrenoleukodystrophy,1172,B-SpecificDisease
and,1172,O
adrenomyeloneuropathy,1172,B-SpecificDisease
present,1172,O
within,1172,O
the,1172,O
same,1172,O
family,1172,O
.,1172,O
We,1173,O
present,1173,O
a,1173,O
large,1173,O
kindred,1173,O
that,1173,O
contained,1173,O
patients,1173,O
with,1173,O
either,1173,O
adrenoleukodystrophy,1173,B-SpecificDisease
(,1173,O
ALD,1173,B-SpecificDisease
),1173,O
or,1173,O
adrenomyeloneuropathy,1173,B-SpecificDisease
(,1173,O
AMN,1173,B-SpecificDisease
),1173,O
.,1173,O
The,1174,O
pedigree,1174,O
clearly,1174,O
supported,1174,O
the,1174,O
X-linked,1174,O
mode,1174,O
of,1174,O
inheritance,1174,O
of,1174,O
the,1174,O
nonneonatal,1174,O
form,1174,O
of,1174,O
ALD/AMN,1174,B-SpecificDisease
.,1174,O
Analysis,1175,O
with,1175,O
DNA,1175,O
markers,1175,O
at,1175,O
Xq28,1175,O
suggested,1175,O
segregation,1175,O
of,1175,O
both,1175,O
ALD,1175,B-SpecificDisease
and,1175,O
AMN,1175,B-SpecificDisease
with,1175,O
an,1175,O
identical,1175,O
haplotype,1175,O
.,1175,O
This,1176,O
indicated,1176,O
that,1176,O
nonneonatal,1176,O
ALD,1176,B-SpecificDisease
and,1176,O
AMN,1176,B-SpecificDisease
are,1176,O
caused,1176,O
by,1176,O
a,1176,O
mutation,1176,O
in,1176,O
the,1176,O
same,1176,O
gene,1176,O
at,1176,O
Xq28,1176,O
.,1176,O
It,1177,O
showed,1177,O
",",1177,O
furthermore,1177,O
",",1177,O
that,1177,O
phenotypic,1177,O
differences,1177,O
between,1177,O
ALD,1177,B-SpecificDisease
and,1177,O
AMN,1177,B-SpecificDisease
are,1177,O
not,1177,O
necessarily,1177,O
the,1177,O
consequence,1177,O
of,1177,O
allelic,1177,O
heterogeneity,1177,O
due,1177,O
to,1177,O
different,1177,O
mutations,1177,O
within,1177,O
the,1177,O
same,1177,O
gene,1177,O
.,1177,O
The,1178,O
maximal,1178,O
lod,1178,O
score,1178,O
for,1178,O
linkage,1178,O
of,1178,O
the,1178,O
ALD/AMN,1178,B-Modifier
gene,1178,O
and,1178,O
the,1178,O
multiallelic,1178,O
anonymous,1178,O
DNA,1178,O
marker,1178,O
at,1178,O
DXS52,1178,O
was,1178,O
3,1178,O
.,1178,O
0,1179,O
at,1179,O
a,1179,O
recombination,1179,O
fraction,1179,O
of,1179,O
0,1179,O
.,1179,O
00,1180,O
.,1180,O
This,1181,O
made,1181,O
a,1181,O
prenatal,1181,O
or,1181,O
presymptomatic,1181,O
diagnosis,1181,O
and,1181,O
heterozygote,1181,O
detection,1181,O
by,1181,O
DNA,1181,O
analysis,1181,O
with,1181,O
this,1181,O
marker,1181,O
reliable,1181,O
.,1181,O
Skewed,1182,O
X,1182,O
inactivation,1182,O
in,1182,O
a,1182,O
female,1182,O
MZ,1182,O
twin,1182,O
results,1182,O
in,1182,O
Duchenne,1182,B-SpecificDisease
muscular,1182,I-SpecificDisease
dystrophy,1182,I-SpecificDisease
.,1182,O
One,1183,O
of,1183,O
female,1183,O
MZ,1183,O
twins,1183,O
presented,1183,O
with,1183,O
muscular,1183,B-DiseaseClass
dystrophy,1183,I-DiseaseClass
.,1183,O
Physical,1184,O
examination,1184,O
",",1184,O
creatine,1184,O
phosphokinase,1184,O
levels,1184,O
",",1184,O
and,1184,O
muscle,1184,O
biopsy,1184,O
were,1184,O
consistent,1184,O
with,1184,O
Duchenne,1184,B-SpecificDisease
muscular,1184,I-SpecificDisease
dystrophy,1184,I-SpecificDisease
(,1184,O
DMD,1184,B-SpecificDisease
),1184,O
.,1184,O
However,1185,O
",",1185,O
because,1185,O
of,1185,O
her,1185,O
sex,1185,O
she,1185,O
was,1185,O
diagnosed,1185,O
as,1185,O
having,1185,O
limb-girdle,1185,B-SpecificDisease
muscular,1185,I-SpecificDisease
dystrophy,1185,I-SpecificDisease
.,1185,O
With,1186,O
cDNA,1186,O
probes,1186,O
to,1186,O
the,1186,O
DMD,1186,B-Modifier
gene,1186,O
",",1186,O
a,1186,O
gene,1186,O
deletion,1186,O
was,1186,O
detected,1186,O
in,1186,O
the,1186,O
twins,1186,O
and,1186,O
their,1186,O
mother,1186,O
.,1186,O
The,1187,O
de,1187,O
novo,1187,O
mutation,1187,O
which,1187,O
arose,1187,O
in,1187,O
the,1187,O
mother,1187,O
was,1187,O
shown,1187,O
by,1187,O
novel,1187,O
junction,1187,O
fragments,1187,O
generated,1187,O
by,1187,O
HindIII,1187,O
",",1187,O
PstI,1187,O
",",1187,O
or,1187,O
TaqI,1187,O
when,1187,O
probed,1187,O
with,1187,O
cDNA8,1187,O
.,1187,O
Additional,1188,O
evidence,1188,O
of,1188,O
a,1188,O
large,1188,O
gene,1188,O
deletion,1188,O
was,1188,O
given,1188,O
by,1188,O
novel,1188,O
SfiI,1188,O
junction,1188,O
fragments,1188,O
detected,1188,O
by,1188,O
probes,1188,O
p20,1188,O
",",1188,O
J-Bir,1188,O
",",1188,O
and,1188,O
J-66,1188,O
on,1188,O
pulsed-field,1188,O
gel,1188,O
electrophoresis,1188,O
(,1188,O
PFGE,1188,O
),1188,O
.,1188,O
Immunoblot,1189,O
analysis,1189,O
of,1189,O
muscle,1189,O
from,1189,O
the,1189,O
affected,1189,O
twin,1189,O
showed,1189,O
dystrophin,1189,O
of,1189,O
normal,1189,O
size,1189,O
but,1189,O
of,1189,O
reduced,1189,O
amount,1189,O
.,1189,O
Immunofluorescent,1190,O
visualization,1190,O
of,1190,O
dystrophin,1190,O
revealed,1190,O
foci,1190,O
of,1190,O
dystrophin-positive,1190,O
fibers,1190,O
adjacent,1190,O
to,1190,O
foci,1190,O
of,1190,O
dystrophin-negative,1190,O
fibers,1190,O
.,1190,O
These,1191,O
data,1191,O
indicate,1191,O
that,1191,O
the,1191,O
affected,1191,O
twin,1191,O
is,1191,O
a,1191,O
manifesting,1191,O
carrier,1191,O
of,1191,O
an,1191,O
abnormal,1191,O
DMD,1191,B-Modifier
gene,1191,O
",",1191,O
her,1191,O
myopathy,1191,B-DiseaseClass
being,1191,O
a,1191,O
direct,1191,O
result,1191,O
of,1191,O
underexpression,1191,O
of,1191,O
dystrophin,1191,O
.,1191,O
Cytogenetic,1192,O
analysis,1192,O
revealed,1192,O
normal,1192,O
karyotypes,1192,O
",",1192,O
eliminating,1192,O
the,1192,O
possibility,1192,O
of,1192,O
a,1192,O
translocation,1192,O
affecting,1192,O
DMD,1192,B-Modifier
gene,1192,O
function,1192,O
.,1192,O
Both,1193,O
linkage,1193,O
analysis,1193,O
and,1193,O
DNA,1193,O
fingerprint,1193,O
analysis,1193,O
revealed,1193,O
that,1193,O
each,1193,O
twin,1193,O
has,1193,O
two,1193,O
different,1193,O
X,1193,O
chromosomes,1193,O
",",1193,O
eliminating,1193,O
the,1193,O
possibility,1193,O
of,1193,O
uniparental,1193,B-SpecificDisease
disomy,1193,I-SpecificDisease
as,1193,O
a,1193,O
mechanism,1193,O
for,1193,O
DMD,1193,B-Modifier
expression,1193,O
.,1193,O
On,1194,O
the,1194,O
basis,1194,O
of,1194,O
methylation,1194,O
differences,1194,O
of,1194,O
the,1194,O
paternal,1194,O
and,1194,O
maternal,1194,O
X,1194,O
chromosomes,1194,O
in,1194,O
these,1194,O
MZ,1194,O
twins,1194,O
",",1194,O
we,1194,O
propose,1194,O
uneven,1194,O
lyonization,1194,O
(,1194,O
X,1194,O
chromosome,1194,O
inactivation,1194,O
),1194,O
as,1194,O
the,1194,O
underlying,1194,O
mechanism,1194,O
for,1194,O
disease,1194,O
expression,1194,O
in,1194,O
the,1194,O
affected,1194,O
female,1194,O
..,1194,O
Regional,1195,O
localisation,1195,O
of,1195,O
the,1195,O
Friedreich,1195,B-Modifier
ataxia,1195,I-Modifier
locus,1195,O
to,1195,O
human,1195,O
chromosome,1195,O
9q13,1195,O
--,1195,O
--,1195,O
q21.1,1195,O
.,1195,O
We,1196,O
have,1196,O
previously,1196,O
assigned,1196,O
the,1196,O
Friedreich,1196,B-Modifier
ataxia,1196,I-Modifier
locus,1196,O
(,1196,O
FRDA,1196,O
),1196,O
to,1196,O
chromosome,1196,O
9,1196,O
;,1196,O
the,1196,O
current,1196,O
maximal,1196,O
lod,1196,O
score,1196,O
between,1196,O
FRDA,1196,O
and,1196,O
MCT112,1196,O
(,1196,O
D9S15,1196,O
),1196,O
is,1196,O
greater,1196,O
than,1196,O
50,1196,O
at,1196,O
a,1196,O
recombination,1196,O
fraction,1196,O
of,1196,O
theta,1196,O
=,1196,O
0,1196,O
.,1196,O
The,1197,O
physical,1197,O
assignment,1197,O
of,1197,O
the,1197,O
locus,1197,O
defined,1197,O
by,1197,O
MCT112,1197,O
",",1197,O
and,1197,O
hence,1197,O
FRDA,1197,O
",",1197,O
has,1197,O
not,1197,O
been,1197,O
determined,1197,O
",",1197,O
although,1197,O
linkage,1197,O
analysis,1197,O
of,1197,O
MCT112,1197,O
with,1197,O
other,1197,O
chromosome,1197,O
9,1197,O
markers,1197,O
inferred,1197,O
a,1197,O
location,1197,O
close,1197,O
to,1197,O
the,1197,O
centromere,1197,O
.,1197,O
We,1198,O
have,1198,O
used,1198,O
in,1198,O
situ,1198,O
hybridisation,1198,O
with,1198,O
MCT112,1198,O
",",1198,O
a,1198,O
corresponding,1198,O
cosmid,1198,O
MJ1,1198,O
",",1198,O
and,1198,O
DR47,1198,O
(,1198,O
D9S5,1198,O
),1198,O
",",1198,O
coupled,1198,O
with,1198,O
mapping,1198,O
studies,1198,O
on,1198,O
hybrid,1198,O
cell,1198,O
panels,1198,O
",",1198,O
to,1198,O
define,1198,O
more,1198,O
precisely,1198,O
the,1198,O
location,1198,O
of,1198,O
the,1198,O
disease,1198,O
locus,1198,O
.,1198,O
The,1199,O
in,1199,O
situ,1199,O
location,1199,O
of,1199,O
all,1199,O
three,1199,O
probes,1199,O
is,1199,O
9q13,1199,O
--,1199,O
--,1199,O
q21,1199,O
.,1199,O
1,1200,O
",",1200,O
distal,1200,O
to,1200,O
the,1200,O
variable,1200,O
heterochromatin,1200,O
region,1200,O
.,1200,O
Physical,1201,O
assignment,1201,O
of,1201,O
FRDA,1201,O
will,1201,O
allow,1201,O
us,1201,O
to,1201,O
identify,1201,O
hybrid,1201,O
cell,1201,O
lines,1201,O
containing,1201,O
the,1201,O
mutated,1201,O
gene,1201,O
.,1201,O
Increased,1202,O
high-density,1202,O
lipoprotein,1202,O
levels,1202,O
caused,1202,O
by,1202,O
a,1202,O
common,1202,O
cholesteryl-ester,1202,O
transfer,1202,O
protein,1202,O
gene,1202,O
mutation,1202,O
.,1202,O
BACKGROUND,1203,O
AND,1203,O
METHODS,1203,O
.,1203,O
The,1204,O
plasma,1204,O
cholesteryl-ester,1204,O
transfer,1204,O
protein,1204,O
(,1204,O
CETP,1204,O
),1204,O
catalyzes,1204,O
the,1204,O
transfer,1204,O
of,1204,O
cholesteryl,1204,O
esters,1204,O
from,1204,O
high-density,1204,O
lipoprotein,1204,O
(,1204,O
HDL,1204,O
),1204,O
to,1204,O
other,1204,O
lipoproteins,1204,O
.,1204,O
We,1205,O
recently,1205,O
described,1205,O
a,1205,O
Japanese,1205,O
family,1205,O
with,1205,O
increased,1205,O
HDL,1205,O
levels,1205,O
and,1205,O
CETP,1205,B-SpecificDisease
deficiency,1205,I-SpecificDisease
due,1205,O
to,1205,O
a,1205,O
splicing,1205,O
defect,1205,O
of,1205,O
the,1205,O
CETP,1205,O
gene,1205,O
.,1205,O
To,1206,O
assess,1206,O
the,1206,O
frequency,1206,O
and,1206,O
phenotype,1206,O
of,1206,O
this,1206,O
condition,1206,O
",",1206,O
we,1206,O
screened,1206,O
11,1206,O
additional,1206,O
families,1206,O
with,1206,O
high,1206,O
HDL,1206,O
levels,1206,O
by,1206,O
means,1206,O
of,1206,O
a,1206,O
radioimmunoassay,1206,O
for,1206,O
CETP,1206,O
and,1206,O
DNA,1206,O
analysis,1206,O
.,1206,O
RESULTS,1207,O
.,1207,O
We,1208,O
found,1208,O
the,1208,O
same,1208,O
CETP,1208,O
gene,1208,O
mutation,1208,O
in,1208,O
four,1208,O
families,1208,O
from,1208,O
three,1208,O
different,1208,O
regions,1208,O
of,1208,O
Japan,1208,O
.,1208,O
Analysis,1209,O
of,1209,O
restriction-fragment-length,1209,O
polymorphisms,1209,O
of,1209,O
the,1209,O
mutant,1209,O
CETP,1209,O
allele,1209,O
showed,1209,O
that,1209,O
all,1209,O
probands,1209,O
were,1209,O
homozygous,1209,O
for,1209,O
the,1209,O
identical,1209,O
haplotype,1209,O
.,1209,O
Family,1210,O
members,1210,O
homozygous,1210,O
for,1210,O
CETP,1210,B-SpecificDisease
deficiency,1210,I-SpecificDisease
(,1210,O
n,1210,O
=,1210,O
10,1210,O
),1210,O
had,1210,O
moderate,1210,O
hypercholesterolemia,1210,B-SpecificDisease
(,1210,O
mean,1210,O
total,1210,O
cholesterol,1210,O
level,1210,O
[,1210,O
+/-,1210,O
SD,1210,O
],1210,O
",",1210,O
7,1210,O
.,1210,O
01,1211,O
+/-,1211,O
0,1211,O
.,1211,O
83,1212,O
mmol,1212,O
per,1212,O
liter,1212,O
),1212,O
",",1212,O
markedly,1212,O
increased,1212,O
levels,1212,O
of,1212,O
HDL,1212,O
cholesterol,1212,O
(,1212,O
4,1212,O
.,1212,O
24,1213,O
+/-,1213,O
1,1213,O
.,1213,O
01,1214,O
mmol,1214,O
per,1214,O
liter,1214,O
),1214,O
and,1214,O
apolipoprotein,1214,O
A-I,1214,O
",",1214,O
and,1214,O
decreased,1214,O
levels,1214,O
of,1214,O
low-density,1214,O
lipoprotein,1214,O
cholesterol,1214,O
(,1214,O
1,1214,O
.,1214,O
99,1215,O
+/-,1215,O
0,1215,O
.,1215,O
80,1216,O
mmol,1216,O
per,1216,O
liter,1216,O
),1216,O
and,1216,O
apolipoprotein,1216,O
B,1216,O
.,1216,O
Members,1217,O
heterozygous,1217,O
for,1217,O
the,1217,O
deficiency,1217,O
(,1217,O
n,1217,O
=,1217,O
20,1217,O
),1217,O
",",1217,O
whose,1217,O
CETP,1217,O
levels,1217,O
were,1217,O
in,1217,O
the,1217,O
lower,1217,O
part,1217,O
of,1217,O
the,1217,O
normal,1217,O
range,1217,O
",",1217,O
had,1217,O
moderately,1217,O
increased,1217,O
levels,1217,O
of,1217,O
HDL,1217,O
cholesterol,1217,O
and,1217,O
apolipoprotein,1217,O
A-I,1217,O
and,1217,O
an,1217,O
increased,1217,O
ratio,1217,O
of,1217,O
HDL,1217,O
subclass,1217,O
2,1217,O
to,1217,O
HDL,1217,O
subclass,1217,O
3,1217,O
",",1217,O
as,1217,O
compared,1217,O
with,1217,O
unaffected,1217,O
family,1217,O
members,1217,O
(,1217,O
1,1217,O
.,1217,O
5,1218,O
+/-,1218,O
0,1218,O
.,1218,O
8,1219,O
vs.,1219,O
0,1219,O
.,1219,O
7,1220,O
+/-,1220,O
0,1220,O
.,1220,O
4,1221,O
),1221,O
.,1221,O
CETP,1222,B-SpecificDisease
deficiency,1222,I-SpecificDisease
was,1222,O
not,1222,O
found,1222,O
in,1222,O
six,1222,O
unrelated,1222,O
subjects,1222,O
with,1222,O
elevated,1222,O
HDL,1222,O
cholesterol,1222,O
levels,1222,O
who,1222,O
were,1222,O
from,1222,O
different,1222,O
parts,1222,O
of,1222,O
the,1222,O
United,1222,O
States,1222,O
.,1222,O
CONCLUSIONS,1223,O
.,1223,O
CETP,1224,B-SpecificDisease
deficiency,1224,I-SpecificDisease
appears,1224,O
to,1224,O
be,1224,O
a,1224,O
frequent,1224,O
cause,1224,O
of,1224,O
increased,1224,O
HDL,1224,O
levels,1224,O
in,1224,O
the,1224,O
population,1224,O
of,1224,O
Japan,1224,O
",",1224,O
possibly,1224,O
because,1224,O
of,1224,O
a,1224,O
founder,1224,O
effect,1224,O
.,1224,O
The,1225,O
results,1225,O
that,1225,O
we,1225,O
observed,1225,O
in,1225,O
heterozygotes,1225,O
suggest,1225,O
that,1225,O
CETP,1225,O
normally,1225,O
plays,1225,O
a,1225,O
part,1225,O
in,1225,O
the,1225,O
regulation,1225,O
of,1225,O
levels,1225,O
of,1225,O
HDL,1225,O
subclass,1225,O
2,1225,O
.,1225,O
There,1226,O
was,1226,O
no,1226,O
evidence,1226,O
of,1226,O
premature,1226,B-SpecificDisease
atherosclerosis,1226,I-SpecificDisease
in,1226,O
the,1226,O
families,1226,O
with,1226,O
CETP,1226,B-SpecificDisease
deficiency,1226,I-SpecificDisease
.,1226,O
In,1227,O
fact,1227,O
",",1227,O
the,1227,O
lipoprotein,1227,O
profile,1227,O
of,1227,O
persons,1227,O
with,1227,O
CETP,1227,B-SpecificDisease
deficiency,1227,I-SpecificDisease
is,1227,O
potentially,1227,O
antiatherogenic,1227,O
and,1227,O
may,1227,O
be,1227,O
associated,1227,O
with,1227,O
an,1227,O
increased,1227,O
life,1227,O
span,1227,O
.,1227,O
Further,1228,O
mapping,1228,O
of,1228,O
an,1228,O
ataxia-telangiectasia,1228,B-Modifier
locus,1228,O
to,1228,O
the,1228,O
chromosome,1228,O
11q23,1228,O
region,1228,O
.,1228,O
We,1229,O
recently,1229,O
mapped,1229,O
the,1229,O
gene,1229,O
for,1229,O
ataxia-telangiectasia,1229,B-Modifier
group,1229,O
A,1229,O
(,1229,O
ATA,1229,O
),1229,O
to,1229,O
chromosome,1229,O
11q22-23,1229,O
by,1229,O
linkage,1229,O
analysis,1229,O
",",1229,O
using,1229,O
the,1229,O
genetic,1229,O
markers,1229,O
THY1,1229,O
and,1229,O
pYNB3,1229,O
.,1229,O
12,1230,O
(,1230,O
D11S144,1230,O
),1230,O
.,1230,O
The,1231,O
most,1231,O
likely,1231,O
order,1231,O
was,1231,O
cent-AT-S144-THY1,1231,O
.,1231,O
The,1232,O
present,1232,O
paper,1232,O
describes,1232,O
further,1232,O
mapping,1232,O
of,1232,O
the,1232,O
AT,1232,B-Modifier
locus,1232,O
by,1232,O
means,1232,O
of,1232,O
a,1232,O
panel,1232,O
of,1232,O
10,1232,O
markers,1232,O
that,1232,O
span,1232,O
approximately,1232,O
60,1232,O
cM,1232,O
in,1232,O
the,1232,O
11q22-23,1232,O
region,1232,O
centered,1232,O
around,1232,O
S144,1232,O
and,1232,O
THY1,1232,O
.,1232,O
Location,1233,O
scores,1233,O
indicate,1233,O
that,1233,O
three,1233,O
contiguous,1233,O
subsegments,1233,O
within,1233,O
the,1233,O
[,1233,O
S144-THY1,1233,O
],1233,O
segment,1233,O
",",1233,O
as,1233,O
well,1233,O
as,1233,O
three,1233,O
contiguous,1233,O
segments,1233,O
telomeric,1233,O
to,1233,O
THY1,1233,O
",",1233,O
are,1233,O
each,1233,O
unlikely,1233,O
to,1233,O
contain,1233,O
the,1233,O
AT,1233,B-Modifier
locus,1233,O
",",1233,O
while,1233,O
the,1233,O
more,1233,O
centromeric,1233,O
[,1233,O
STMY-S144,1233,O
],1233,O
segment,1233,O
is,1233,O
most,1233,O
likely,1233,O
to,1233,O
contain,1233,O
the,1233,O
AT,1233,B-Modifier
locus,1233,O
.,1233,O
These,1234,O
data,1234,O
",",1234,O
together,1234,O
with,1234,O
recent,1234,O
refinements,1234,O
in,1234,O
the,1234,O
linkage,1234,O
and,1234,O
physical,1234,O
maps,1234,O
of,1234,O
11q22-23,1234,O
",",1234,O
place,1234,O
the,1234,O
AT,1234,B-Modifier
locus,1234,O
at,1234,O
11q23,1234,O
.,1234,O
Recurrent,1235,O
meningitis,1235,B-SpecificDisease
in,1235,O
a,1235,O
patient,1235,O
with,1235,O
congenital,1235,B-SpecificDisease
deficiency,1235,I-SpecificDisease
of,1235,I-SpecificDisease
the,1235,I-SpecificDisease
C9,1235,I-SpecificDisease
component,1235,I-SpecificDisease
of,1235,I-SpecificDisease
complement,1235,I-SpecificDisease
.,1235,O
First,1236,O
case,1236,O
of,1236,O
C9,1236,B-SpecificDisease
deficiency,1236,I-SpecificDisease
in,1236,O
Europe,1236,O
.,1236,O
We,1237,O
describe,1237,O
the,1237,O
first,1237,O
cases,1237,O
",",1237,O
to,1237,O
our,1237,O
knowledge,1237,O
",",1237,O
of,1237,O
C9,1237,B-SpecificDisease
deficiency,1237,I-SpecificDisease
in,1237,O
Europe,1237,O
that,1237,O
were,1237,O
detected,1237,O
in,1237,O
a,1237,O
Swiss,1237,O
family,1237,O
",",1237,O
of,1237,O
which,1237,O
two,1237,O
members,1237,O
--,1237,O
one,1237,O
with,1237,O
a,1237,O
complete,1237,O
deficiency,1237,O
and,1237,O
the,1237,O
other,1237,O
with,1237,O
approximately,1237,O
half-normal,1237,O
C9,1237,O
levels,1237,O
--,1237,O
experienced,1237,O
bacterial,1237,B-SpecificDisease
meningitis,1237,I-SpecificDisease
.,1237,O
The,1238,O
index,1238,O
patient,1238,O
",",1238,O
a,1238,O
56-year-old,1238,O
white,1238,O
man,1238,O
with,1238,O
a,1238,O
history,1238,O
of,1238,O
purulent,1238,B-SpecificDisease
meningitis,1238,I-SpecificDisease
at,1238,O
the,1238,O
age,1238,O
of,1238,O
23,1238,O
years,1238,O
",",1238,O
presented,1238,O
with,1238,O
an,1238,O
acute,1238,B-SpecificDisease
meningococcal,1238,I-SpecificDisease
meningitis,1238,I-SpecificDisease
.,1238,O
No,1239,O
impairment,1239,B-DiseaseClass
of,1239,I-DiseaseClass
cellular,1239,I-DiseaseClass
immunity,1239,I-DiseaseClass
or,1239,O
immunoglobulin,1239,B-SpecificDisease
deficiency,1239,I-SpecificDisease
could,1239,O
be,1239,O
found,1239,O
.,1239,O
Complement,1240,O
assays,1240,O
showed,1240,O
a,1240,O
complete,1240,B-SpecificDisease
deficiency,1240,I-SpecificDisease
of,1240,I-SpecificDisease
the,1240,I-SpecificDisease
C9,1240,I-SpecificDisease
component,1240,I-SpecificDisease
",",1240,O
while,1240,O
the,1240,O
other,1240,O
individual,1240,O
component,1240,O
levels,1240,O
were,1240,O
normal,1240,O
and,1240,O
the,1240,O
hemolytic,1240,O
activity,1240,O
(,1240,O
measured,1240,O
using,1240,O
the,1240,O
CH50,1240,O
assay,1240,O
),1240,O
was,1240,O
only,1240,O
slightly,1240,O
reduced,1240,O
.,1240,O
A,1241,O
family,1241,O
study,1241,O
revealed,1241,O
complete,1241,B-SpecificDisease
C9,1241,I-SpecificDisease
deficiency,1241,I-SpecificDisease
in,1241,O
the,1241,O
patients,1241,O
healthy,1241,O
brother,1241,O
and,1241,O
half-normal,1241,O
C9,1241,O
concentrations,1241,O
in,1241,O
his,1241,O
sister,1241,O
",",1241,O
his,1241,O
son,1241,O
(,1241,O
who,1241,O
also,1241,O
had,1241,O
experienced,1241,O
an,1241,O
episode,1241,O
of,1241,O
bacterial,1241,B-SpecificDisease
meningitis,1241,I-SpecificDisease
),1241,O
",",1241,O
and,1241,O
his,1241,O
niece,1241,O
",",1241,O
consistent,1241,O
with,1241,O
an,1241,O
inherited,1241,O
C9,1241,B-SpecificDisease
deficiency,1241,I-SpecificDisease
.,1241,O
This,1242,O
first,1242,O
case,1242,O
of,1242,O
recurrent,1242,B-SpecificDisease
meningitis,1242,I-SpecificDisease
in,1242,O
a,1242,O
white,1242,O
patient,1242,O
with,1242,O
complete,1242,B-SpecificDisease
C9,1242,I-SpecificDisease
deficiency,1242,I-SpecificDisease
suggests,1242,O
that,1242,O
this,1242,O
complement,1242,B-DiseaseClass
defect,1242,I-DiseaseClass
may,1242,O
also,1242,O
be,1242,O
a,1242,O
risk,1242,O
factor,1242,O
for,1242,O
bacterial,1242,B-DiseaseClass
",",1242,I-DiseaseClass
especially,1242,I-DiseaseClass
neisserial,1242,I-DiseaseClass
",",1242,I-DiseaseClass
infections,1242,I-DiseaseClass
..,1242,O
Detection,1243,O
of,1243,O
98,1243,O
%,1243,O
of,1243,O
DMD/BMD,1243,B-Modifier
gene,1243,O
deletions,1243,O
by,1243,O
polymerase,1243,O
chain,1243,O
reaction,1243,O
.,1243,O
We,1244,O
describe,1244,O
oligonucleotide,1244,O
primer,1244,O
sequences,1244,O
that,1244,O
can,1244,O
be,1244,O
used,1244,O
to,1244,O
amplify,1244,O
eight,1244,O
exons,1244,O
plus,1244,O
the,1244,O
muscle,1244,O
promoter,1244,O
of,1244,O
the,1244,O
dystrophin,1244,O
gene,1244,O
in,1244,O
a,1244,O
single,1244,O
multiplex,1244,O
polymerase,1244,O
chain,1244,O
reaction,1244,O
(,1244,O
PCR,1244,O
),1244,O
.,1244,O
When,1245,O
used,1245,O
in,1245,O
conjunction,1245,O
with,1245,O
an,1245,O
existing,1245,O
primer,1245,O
set,1245,O
",",1245,O
these,1245,O
two,1245,O
multiplex,1245,O
reactions,1245,O
detect,1245,O
about,1245,O
98,1245,O
%,1245,O
of,1245,O
deletions,1245,O
in,1245,O
patients,1245,O
with,1245,O
Duchenne,1245,O
or,1245,O
Becker,1245,O
muscular,1245,O
dystrophy,1245,O
(,1245,O
DMD,1245,B-SpecificDisease
",",1245,O
BMD,1245,B-SpecificDisease
),1245,O
.,1245,O
Furthermore,1246,O
",",1246,O
these,1246,O
primers,1246,O
amplify,1246,O
most,1246,O
of,1246,O
the,1246,O
exons,1246,O
in,1246,O
the,1246,O
deletion,1246,O
prone,1246,O
``,1246,O
hot,1246,O
spot,1246,O
``,1246,O
region,1246,O
around,1246,O
exons,1246,O
44,1246,O
to,1246,O
53,1246,O
",",1246,O
allowing,1246,O
determination,1246,O
of,1246,O
deletion,1246,O
endpoints,1246,O
and,1246,O
prediction,1246,O
of,1246,O
mutational,1246,O
effects,1246,O
on,1246,O
the,1246,O
translational,1246,O
reading,1246,O
frame,1246,O
.,1246,O
Thus,1247,O
",",1247,O
use,1247,O
of,1247,O
these,1247,O
PCR-based,1247,O
assays,1247,O
will,1247,O
allow,1247,O
deletion,1247,O
detection,1247,O
and,1247,O
prenatal,1247,O
diagnosis,1247,O
for,1247,O
most,1247,O
DMD/BMD,1247,B-Modifier
patients,1247,O
in,1247,O
a,1247,O
fraction,1247,O
of,1247,O
the,1247,O
time,1247,O
required,1247,O
for,1247,O
Southern,1247,O
blot,1247,O
analysis,1247,O
..,1247,O
Genetic,1248,O
heterogeneity,1248,O
at,1248,O
the,1248,O
glucose-6-phosphate,1248,O
dehydrogenase,1248,O
locus,1248,O
in,1248,O
southern,1248,O
Italy,1248,O
:,1248,O
a,1248,O
study,1248,O
on,1248,O
a,1248,O
population,1248,O
from,1248,O
the,1248,O
Matera,1248,O
district,1248,O
.,1248,O
Glucose-6-phosphate,1249,O
dehydrogenase,1249,O
(,1249,O
G6PD,1249,O
),1249,O
has,1249,O
been,1249,O
analyzed,1249,O
by,1249,O
gel,1249,O
electrophoresis,1249,O
and,1249,O
by,1249,O
quantitative,1249,O
assay,1249,O
in,1249,O
an,1249,O
unselected,1249,O
sample,1249,O
of,1249,O
1524,1249,O
schoolboys,1249,O
from,1249,O
the,1249,O
province,1249,O
of,1249,O
Matera,1249,O
(,1249,O
Lucania,1249,O
),1249,O
in,1249,O
southern,1249,O
Italy,1249,O
.,1249,O
We,1250,O
have,1250,O
identified,1250,O
43,1250,O
subjects,1250,O
with,1250,O
a,1250,O
G6PD,1250,O
variant,1250,O
.,1250,O
Of,1251,O
these,1251,O
",",1251,O
31,1251,O
had,1251,O
severe,1251,O
G6PD,1251,B-SpecificDisease
deficiency,1251,I-SpecificDisease
",",1251,O
nine,1251,O
had,1251,O
mild,1251,O
to,1251,O
moderate,1251,O
deficiency,1251,O
",",1251,O
and,1251,O
three,1251,O
had,1251,O
a,1251,O
non-deficient,1251,O
electrophoretic,1251,O
variant,1251,O
.,1251,O
The,1252,O
overall,1252,O
rate,1252,O
of,1252,O
G6PD,1252,B-SpecificDisease
deficiency,1252,I-SpecificDisease
was,1252,O
2,1252,O
.,1252,O
6,1253,O
%,1253,O
.,1253,O
The,1254,O
frequency,1254,O
of,1254,O
G6PD,1254,B-SpecificDisease
deficiency,1254,I-SpecificDisease
",",1254,O
ranging,1254,O
from,1254,O
7,1254,O
.,1254,O
2,1255,O
%,1255,O
on,1255,O
the,1255,O
Ionian,1255,O
Coast,1255,O
to,1255,O
zero,1255,O
on,1255,O
the,1255,O
eastern,1255,O
side,1255,O
of,1255,O
the,1255,O
Lucanian,1255,O
Apennines,1255,O
",",1255,O
appears,1255,O
to,1255,O
be,1255,O
inversely,1255,O
related,1255,O
to,1255,O
the,1255,O
distance,1255,O
of,1255,O
each,1255,O
town,1255,O
examined,1255,O
from,1255,O
the,1255,O
Ionian,1255,O
Coast,1255,O
",",1255,O
suggesting,1255,O
that,1255,O
this,1255,O
geographic,1255,O
distribution,1255,O
may,1255,O
reflect,1255,O
",",1255,O
at,1255,O
least,1255,O
in,1255,O
part,1255,O
",",1255,O
gene,1255,O
flow,1255,O
from,1255,O
Greek,1255,O
settlers,1255,O
.,1255,O
Biochemical,1256,O
characterization,1256,O
has,1256,O
shown,1256,O
that,1256,O
most,1256,O
of,1256,O
the,1256,O
G6PD,1256,B-SpecificDisease
deficiency,1256,I-SpecificDisease
in,1256,O
this,1256,O
population,1256,O
is,1256,O
accounted,1256,O
for,1256,O
by,1256,O
G6PD,1256,O
Mediterranean,1256,O
.,1256,O
In,1257,O
addition,1257,O
",",1257,O
we,1257,O
have,1257,O
found,1257,O
several,1257,O
examples,1257,O
of,1257,O
two,1257,O
other,1257,O
known,1257,O
polymorphic,1257,O
variants,1257,O
(,1257,O
G6PD,1257,O
Cagliari,1257,O
and,1257,O
G6PD,1257,O
A-,1257,O
),1257,O
;,1257,O
three,1257,O
new,1257,O
polymorphic,1257,O
variants,1257,O
",",1257,O
G6PD,1257,O
Metaponto,1257,O
(,1257,O
class,1257,O
III,1257,O
),1257,O
",",1257,O
G6PD,1257,O
Montalbano,1257,O
(,1257,O
class,1257,O
III,1257,O
),1257,O
",",1257,O
and,1257,O
G6PD,1257,O
Pisticci,1257,O
(,1257,O
class,1257,O
IV,1257,O
),1257,O
;,1257,O
and,1257,O
two,1257,O
sporadic,1257,O
variants,1257,O
",",1257,O
G6PD,1257,O
Tursi,1257,O
(,1257,O
class,1257,O
III,1257,O
),1257,O
and,1257,O
G6PD,1257,O
Ferrandina,1257,O
(,1257,O
class,1257,O
II,1257,O
),1257,O
.,1257,O
These,1258,O
data,1258,O
provide,1258,O
further,1258,O
evidence,1258,O
for,1258,O
the,1258,O
marked,1258,O
genetic,1258,O
heterogeneity,1258,O
of,1258,O
G6PD,1258,B-SpecificDisease
deficiency,1258,I-SpecificDisease
within,1258,O
a,1258,O
relatively,1258,O
narrow,1258,O
geographic,1258,O
area,1258,O
and,1258,O
they,1258,O
prove,1258,O
the,1258,O
presence,1258,O
in,1258,O
the,1258,O
Italian,1258,O
peninsula,1258,O
of,1258,O
a,1258,O
gene,1258,O
(,1258,O
GdA-,1258,O
),1258,O
regarded,1258,O
as,1258,O
characteristically,1258,O
African,1258,O
.,1258,O
Deficiency,1259,B-SpecificDisease
of,1259,I-SpecificDisease
the,1259,I-SpecificDisease
murine,1259,I-SpecificDisease
fifth,1259,I-SpecificDisease
complement,1259,I-SpecificDisease
component,1259,I-SpecificDisease
(,1259,I-SpecificDisease
C5,1259,I-SpecificDisease
),1259,I-SpecificDisease
.,1259,O
A,1260,O
2-base,1260,O
pair,1260,O
gene,1260,O
deletion,1260,O
in,1260,O
a,1260,O
5'-exon,1260,O
.,1260,O
To,1261,O
ascertain,1261,O
the,1261,O
molecular,1261,O
mechanism,1261,O
that,1261,O
causes,1261,O
murine,1261,O
C5,1261,B-SpecificDisease
deficiency,1261,I-SpecificDisease
",",1261,O
genomic,1261,O
and,1261,O
cDNA,1261,O
libraries,1261,O
were,1261,O
constructed,1261,O
from,1261,O
mouse,1261,O
liver,1261,O
DNA,1261,O
and,1261,O
mRNA,1261,O
employing,1261,O
the,1261,O
congenic,1261,O
strains,1261,O
B10,1261,O
.,1261,O
D2/nSnJ,1262,O
and,1262,O
B10,1262,O
.,1262,O
D2/oSnJ,1263,O
that,1263,O
are,1263,O
sufficient,1263,O
and,1263,O
deficient,1263,B-SpecificDisease
for,1263,I-SpecificDisease
C5,1263,I-SpecificDisease
",",1263,O
respectively,1263,O
.,1263,O
Genomic,1264,O
fragments,1264,O
were,1264,O
isolated,1264,O
which,1264,O
correspond,1264,O
to,1264,O
PvuII,1264,O
and,1264,O
HindIII,1264,O
restriction,1264,O
fragment,1264,O
length,1264,O
polymorphisms,1264,O
associated,1264,O
with,1264,O
C5,1264,B-SpecificDisease
deficiency,1264,I-SpecificDisease
.,1264,O
Sequence,1265,O
analyses,1265,O
demonstrated,1265,O
that,1265,O
each,1265,O
of,1265,O
these,1265,O
polymorphisms,1265,O
resulted,1265,O
from,1265,O
single,1265,O
base,1265,O
pair,1265,O
substitutions,1265,O
and,1265,O
that,1265,O
neither,1265,O
substitution,1265,O
would,1265,O
probably,1265,O
cause,1265,O
or,1265,O
contribute,1265,O
to,1265,O
the,1265,O
C5,1265,B-SpecificDisease
deficiency,1265,I-SpecificDisease
.,1265,O
Sequence,1266,O
analyses,1266,O
of,1266,O
C5,1266,O
sufficient,1266,O
and,1266,O
deficient,1266,O
cDNAs,1266,O
revealed,1266,O
a,1266,O
2,1266,O
base-pair,1266,O
deletion,1266,O
in,1266,O
the,1266,O
deficient,1266,O
cDNAs,1266,O
.,1266,O
The,1267,O
``,1267,O
TA,1267,O
``,1267,O
deletion,1267,O
was,1267,O
located,1267,O
near,1267,O
the,1267,O
5,1267,O
end,1267,O
of,1267,O
the,1267,O
cDNA,1267,O
.,1267,O
This,1268,O
deletion,1268,O
shifts,1268,O
the,1268,O
reading,1268,O
frame,1268,O
of,1268,O
the,1268,O
C5,1268,O
mRNA,1268,O
so,1268,O
that,1268,O
the,1268,O
termination,1268,O
codon,1268,O
UGA,1268,O
is,1268,O
present,1268,O
4,1268,O
base,1268,O
pairs,1268,O
downstream,1268,O
from,1268,O
the,1268,O
deletion,1268,O
.,1268,O
Genomic,1269,O
DNA,1269,O
was,1269,O
amplified,1269,O
and,1269,O
sequenced,1269,O
corresponding,1269,O
to,1269,O
the,1269,O
area,1269,O
surrounding,1269,O
the,1269,O
2-base,1269,O
pair,1269,O
deletion,1269,O
.,1269,O
Six,1270,O
C5-deficient,1270,B-Modifier
strains,1270,O
",",1270,O
A/HeJ,1270,O
",",1270,O
AKR/J,1270,O
",",1270,O
DBA/2J,1270,O
",",1270,O
NZB/B1NJ,1270,O
",",1270,O
SWR/J,1270,O
",",1270,O
and,1270,O
B10,1270,O
.,1270,O
D2/oSnJ,1271,O
",",1271,O
and,1271,O
four,1271,O
C5-sufficient,1271,O
strains,1271,O
",",1271,O
Balb/CJ,1271,O
",",1271,O
C57Bl/6J,1271,O
",",1271,O
DBA/1J,1271,O
",",1271,O
and,1271,O
B10,1271,O
.,1271,O
D2/nSnJ,1272,O
",",1272,O
were,1272,O
analyzed,1272,O
.,1272,O
The,1273,O
sequencing,1273,O
data,1273,O
revealed,1273,O
that,1273,O
the,1273,O
2,1273,O
base,1273,O
pairs,1273,O
were,1273,O
deleted,1273,O
from,1273,O
the,1273,O
C5,1273,O
gene,1273,O
of,1273,O
each,1273,O
deficient,1273,O
mouse,1273,O
tested,1273,O
but,1273,O
not,1273,O
from,1273,O
the,1273,O
C5,1273,O
gene,1273,O
of,1273,O
any,1273,O
sufficient,1273,O
mouse,1273,O
.,1273,O
These,1274,O
data,1274,O
demonstrate,1274,O
that,1274,O
1,1274,O
),1274,O
there,1274,O
is,1274,O
an,1274,O
identical,1274,O
2-base,1274,O
pair,1274,O
deletion,1274,O
in,1274,O
an,1274,O
exon,1274,O
of,1274,O
the,1274,O
C5,1274,O
gene,1274,O
in,1274,O
several,1274,O
different,1274,O
C5-deficient,1274,B-Modifier
mouse,1274,O
strains,1274,O
;,1274,O
2,1274,O
),1274,O
the,1274,O
mRNA,1274,O
transcribed,1274,O
from,1274,O
the,1274,O
C5D,1274,O
gene,1274,O
retains,1274,O
this,1274,O
deletion,1274,O
;,1274,O
and,1274,O
3,1274,O
),1274,O
this,1274,O
mutation,1274,O
should,1274,O
result,1274,O
in,1274,O
C5,1274,B-SpecificDisease
protein,1274,I-SpecificDisease
deficiency,1274,I-SpecificDisease
.,1274,O
Molecular,1275,O
genetics,1275,O
of,1275,O
PKU,1275,B-SpecificDisease
in,1275,O
eastern,1275,O
Europe,1275,O
:,1275,O
a,1275,O
nonsense,1275,O
mutation,1275,O
associated,1275,O
with,1275,O
haplotype,1275,O
4,1275,O
of,1275,O
the,1275,O
phenylalanine,1275,O
hydroxylase,1275,O
gene,1275,O
.,1275,O
Phenylketonuria,1276,B-SpecificDisease
(,1276,O
PKU,1276,B-SpecificDisease
),1276,O
is,1276,O
a,1276,O
genetic,1276,B-DiseaseClass
disorder,1276,I-DiseaseClass
secondary,1276,O
to,1276,O
a,1276,O
deficiency,1276,B-SpecificDisease
of,1276,I-SpecificDisease
hepatic,1276,I-SpecificDisease
phenylalanine,1276,I-SpecificDisease
hydroxylase,1276,I-SpecificDisease
(,1276,O
PAH,1276,O
),1276,O
.,1276,O
Several,1277,O
mutations,1277,O
in,1277,O
the,1277,O
PAH,1277,O
gene,1277,O
have,1277,O
recently,1277,O
been,1277,O
reported,1277,O
",",1277,O
and,1277,O
linkage,1277,O
disequilibrium,1277,O
was,1277,O
observed,1277,O
between,1277,O
RFLP,1277,O
haplotypes,1277,O
and,1277,O
specific,1277,O
mutations,1277,O
.,1277,O
A,1278,O
new,1278,O
molecular,1278,B-DiseaseClass
lesion,1278,I-DiseaseClass
has,1278,O
been,1278,O
identified,1278,O
in,1278,O
exon,1278,O
7,1278,O
of,1278,O
the,1278,O
PAH,1278,O
gene,1278,O
in,1278,O
a,1278,O
Hungarian,1278,O
PKU,1278,B-Modifier
patient,1278,O
by,1278,O
direct,1278,O
sequencing,1278,O
of,1278,O
PCR-amplified,1278,O
DNA,1278,O
.,1278,O
The,1279,O
C-to-T,1279,O
transition,1279,O
causes,1279,O
the,1279,O
substitution,1279,O
of,1279,O
Arg243,1279,O
to,1279,O
a,1279,O
termination,1279,O
codon,1279,O
",",1279,O
and,1279,O
the,1279,O
mutant,1279,O
allele,1279,O
is,1279,O
associated,1279,O
with,1279,O
haplotype,1279,O
4,1279,O
of,1279,O
the,1279,O
PAH,1279,O
gene,1279,O
.,1279,O
The,1280,O
mutation,1280,O
is,1280,O
present,1280,O
in,1280,O
two,1280,O
of,1280,O
nine,1280,O
mutant,1280,O
haplotype,1280,O
4,1280,O
alleles,1280,O
among,1280,O
Eastern,1280,O
Europeans,1280,O
and,1280,O
is,1280,O
not,1280,O
present,1280,O
among,1280,O
Western,1280,O
Europeans,1280,O
and,1280,O
Asians,1280,O
.,1280,O
The,1281,O
rarity,1281,O
of,1281,O
this,1281,O
mutant,1281,O
allele,1281,O
and,1281,O
its,1281,O
restricted,1281,O
geographic,1281,O
distribution,1281,O
suggest,1281,O
that,1281,O
the,1281,O
mutational,1281,O
event,1281,O
occurred,1281,O
recently,1281,O
on,1281,O
a,1281,O
normal,1281,O
haplotype,1281,O
4,1281,O
background,1281,O
in,1281,O
Eastern,1281,O
Europe,1281,O
..,1281,O
The,1282,O
red-green,1282,O
visual,1282,O
pigment,1282,O
gene,1282,O
region,1282,O
in,1282,O
adrenoleukodystrophy,1282,B-SpecificDisease
.,1282,O
Although,1283,O
recent,1283,O
data,1283,O
established,1283,O
that,1283,O
a,1283,O
specific,1283,O
very-long-chain,1283,O
fatty,1283,O
acyl-CoA,1283,O
synthetase,1283,O
is,1283,O
defective,1283,O
in,1283,O
X-linked,1283,B-SpecificDisease
adrenoleukodystrophy,1283,I-SpecificDisease
(,1283,O
ALD,1283,B-SpecificDisease
),1283,O
",",1283,O
the,1283,O
ALD,1283,B-Modifier
gene,1283,O
is,1283,O
still,1283,O
unidentified,1283,O
.,1283,O
The,1284,O
ALD,1284,B-Modifier
locus,1284,O
has,1284,O
been,1284,O
mapped,1284,O
to,1284,O
Xq28,1284,O
",",1284,O
like,1284,O
the,1284,O
red,1284,O
and,1284,O
green,1284,O
color,1284,O
pigment,1284,O
genes,1284,O
.,1284,O
Abnormal,1285,B-DiseaseClass
color,1285,I-DiseaseClass
vision,1285,I-DiseaseClass
has,1285,O
been,1285,O
observed,1285,O
in,1285,O
12,1285,O
of,1285,O
27,1285,O
patients,1285,O
with,1285,O
adrenomyeloneuropathy,1285,B-SpecificDisease
(,1285,O
AMN,1285,B-SpecificDisease
),1285,O
",",1285,O
a,1285,O
milder,1285,O
form,1285,O
of,1285,O
ALD,1285,B-SpecificDisease
.,1285,O
Furthermore,1286,O
",",1286,O
rearrangements,1286,O
of,1286,O
the,1286,O
color,1286,O
vision,1286,O
gene,1286,O
cluster,1286,O
were,1286,O
found,1286,O
in,1286,O
four,1286,O
of,1286,O
eight,1286,O
ALD,1286,B-Modifier
kindreds,1286,O
.,1286,O
This,1287,O
led,1287,O
us,1287,O
to,1287,O
propose,1287,O
that,1287,O
a,1287,O
single,1287,O
DNA,1287,O
rearrangement,1287,O
could,1287,O
underlie,1287,O
both,1287,O
ALD,1287,B-SpecificDisease
and,1287,O
abnormal,1287,B-SpecificDisease
color,1287,I-SpecificDisease
vision,1287,I-SpecificDisease
in,1287,O
these,1287,O
patients,1287,O
.,1287,O
Study,1288,O
of,1288,O
34,1288,O
French,1288,O
ALD,1288,B-Modifier
patients,1288,O
failed,1288,O
to,1288,O
reveal,1288,O
a,1288,O
higher,1288,O
than,1288,O
expected,1288,O
frequency,1288,O
of,1288,O
green/red,1288,O
visual,1288,O
pigment,1288,O
rearrangements,1288,O
3,1288,O
to,1288,O
the,1288,O
red/green,1288,O
color,1288,O
vision,1288,O
gene,1288,O
complex,1288,O
.,1288,O
The,1289,O
previous,1289,O
report,1289,O
of,1289,O
such,1289,O
rearrangements,1289,O
was,1289,O
based,1289,O
on,1289,O
small,1289,O
numbers,1289,O
and,1289,O
lack,1289,O
of,1289,O
knowledge,1289,O
that,1289,O
the,1289,O
frequency,1289,O
of,1289,O
``,1289,O
abnormal,1289,O
``,1289,O
color,1289,O
vision,1289,O
arrays,1289,O
on,1289,O
molecular,1289,O
analysis,1289,O
was,1289,O
twice,1289,O
as,1289,O
high,1289,O
as,1289,O
expected,1289,O
on,1289,O
the,1289,O
basis,1289,O
of,1289,O
the,1289,O
frequency,1289,O
of,1289,O
phenotypic,1289,B-SpecificDisease
color,1289,I-SpecificDisease
vision,1289,I-SpecificDisease
defects,1289,I-SpecificDisease
.,1289,O
The,1290,O
red/green,1290,O
color,1290,O
pigment,1290,O
(,1290,O
R/GCP,1290,O
),1290,O
region,1290,O
was,1290,O
studied,1290,O
by,1290,O
pulsed-field,1290,O
gel,1290,O
electrophoresis,1290,O
in,1290,O
14,1290,O
of,1290,O
these,1290,O
patients,1290,O
",",1290,O
and,1290,O
we,1290,O
did,1290,O
not,1290,O
find,1290,O
any,1290,O
fragment,1290,O
size,1290,O
difference,1290,O
between,1290,O
the,1290,O
patients,1290,O
and,1290,O
normal,1290,O
individuals,1290,O
who,1290,O
have,1290,O
the,1290,O
same,1290,O
number,1290,O
of,1290,O
pigment,1290,O
genes,1290,O
.,1290,O
The,1291,O
R/GCP,1291,O
region,1291,O
was,1291,O
also,1291,O
analyzed,1291,O
in,1291,O
29,1291,O
French,1291,O
and,1291,O
seven,1291,O
North,1291,O
American,1291,O
ALD,1291,B-Modifier
patients,1291,O
by,1291,O
using,1291,O
six,1291,O
genomic,1291,O
DNA,1291,O
probes,1291,O
",",1291,O
isolated,1291,O
from,1291,O
a,1291,O
cosmid,1291,O
walk,1291,O
",",1291,O
that,1291,O
flank,1291,O
the,1291,O
color,1291,O
vision,1291,O
genes,1291,O
.,1291,O
No,1292,O
deletions,1292,O
were,1292,O
found,1292,O
with,1292,O
probes,1292,O
that,1292,O
lie,1292,O
3,1292,O
of,1292,O
the,1292,O
green,1292,O
pigment,1292,O
genes,1292,O
.,1292,O
One,1293,O
of,1293,O
the,1293,O
eight,1293,O
previously,1293,O
reported,1293,O
ALD,1293,B-Modifier
individuals,1293,O
has,1293,O
a,1293,O
long,1293,O
deletion,1293,O
5,1293,O
of,1293,O
the,1293,O
red,1293,O
pigment,1293,O
gene,1293,O
",",1293,O
a,1293,O
deletion,1293,O
causing,1293,O
blue,1293,O
cone,1293,O
monochromacy,1293,O
.,1293,O
This,1294,O
finding,1294,O
and,1294,O
the,1294,O
previous,1294,O
findings,1294,O
of,1294,O
a,1294,O
45,1294,O
%,1294,O
frequency,1294,O
of,1294,O
phenotypic,1294,O
color,1294,O
vision,1294,O
defects,1294,O
in,1294,O
patients,1294,O
with,1294,O
AMN,1294,B-SpecificDisease
may,1294,O
suggest,1294,O
that,1294,O
the,1294,O
ALD/AMN,1294,B-Modifier
gene,1294,O
lies,1294,O
5,1294,O
to,1294,O
the,1294,O
red,1294,O
pigment,1294,O
gene,1294,O
and,1294,O
that,1294,O
the,1294,O
frequent,1294,O
phenotypic,1294,O
color,1294,B-DiseaseClass
vision,1294,I-DiseaseClass
anomalies,1294,I-DiseaseClass
owe,1294,O
their,1294,O
origin,1294,O
to,1294,O
deleted,1294,O
DNA,1294,O
that,1294,O
includes,1294,O
regulatory,1294,O
genes,1294,O
for,1294,O
color,1294,O
vision,1294,O
.,1294,O
It,1295,O
is,1295,O
possible,1295,O
",",1295,O
however,1295,O
",",1295,O
that,1295,O
phenotypic,1295,O
color,1295,B-DiseaseClass
vision,1295,I-DiseaseClass
anomalies,1295,I-DiseaseClass
in,1295,O
AMN,1295,B-SpecificDisease
may,1295,O
be,1295,O
phenocopies,1295,O
secondary,1295,O
to,1295,O
retinal,1295,O
or,1295,O
neural,1295,O
involvement,1295,O
by,1295,O
the,1295,O
disease,1295,O
.,1295,O
The,1296,O
single,1296,O
case,1296,O
of,1296,O
blue,1296,O
cone,1296,O
monochromacy,1296,O
may,1296,O
therefore,1296,O
be,1296,O
a,1296,O
fortuitous,1296,O
coincidence,1296,O
of,1296,O
two,1296,O
diseases,1296,O
..,1296,O
Paroxysmal,1297,B-SpecificDisease
nocturnal,1297,I-SpecificDisease
haemoglobinuria,1297,I-SpecificDisease
with,1297,O
coexisting,1297,O
deficiency,1297,B-SpecificDisease
of,1297,I-SpecificDisease
the,1297,I-SpecificDisease
ninth,1297,I-SpecificDisease
component,1297,I-SpecificDisease
of,1297,I-SpecificDisease
complement,1297,I-SpecificDisease
:,1297,O
lack,1297,O
of,1297,O
massive,1297,O
haemolytic,1297,B-SpecificDisease
attack,1297,I-SpecificDisease
.,1297,O
A,1298,O
47-year-old,1298,O
woman,1298,O
with,1298,O
paroxysmal,1298,B-SpecificDisease
nocturnal,1298,I-SpecificDisease
haemoglobinuria,1298,I-SpecificDisease
(,1298,O
PNH,1298,B-SpecificDisease
),1298,O
was,1298,O
found,1298,O
to,1298,O
have,1298,O
an,1298,O
inherited,1298,B-SpecificDisease
deficiency,1298,I-SpecificDisease
in,1298,I-SpecificDisease
the,1298,I-SpecificDisease
ninth,1298,I-SpecificDisease
complement,1298,I-SpecificDisease
component,1298,I-SpecificDisease
(,1298,O
C9,1298,O
),1298,O
.,1298,O
In,1299,O
complement-sensitivity,1299,O
lysis,1299,O
tests,1299,O
",",1299,O
80,1299,O
%,1299,O
of,1299,O
her,1299,O
erythrocytes,1299,O
were,1299,O
markedly,1299,O
complement-sensitive,1299,O
(,1299,O
PNH-III,1299,O
),1299,O
.,1299,O
Laser,1300,O
cytofluorimetry,1300,O
with,1300,O
a,1300,O
monoclonal,1300,O
antibody,1300,O
against,1300,O
decay-accelerating,1300,O
factor,1300,O
(,1300,O
DAF,1300,O
),1300,O
revealed,1300,O
that,1300,O
95,1300,O
%,1300,O
of,1300,O
her,1300,O
erythrocytes,1300,O
were,1300,O
DAF-negative,1300,O
.,1300,O
Surprisingly,1301,O
",",1301,O
she,1301,O
has,1301,O
suffered,1301,O
only,1301,O
mild,1301,O
haemolysis,1301,B-SpecificDisease
and,1301,O
has,1301,O
never,1301,O
experienced,1301,O
massive,1301,O
spontaneous,1301,O
haemolysis,1301,B-SpecificDisease
.,1301,O
Gross,1302,O
haemoglobinuria,1302,B-SpecificDisease
and,1302,O
jaundice,1302,B-SpecificDisease
occurred,1302,O
only,1302,O
after,1302,O
receiving,1302,O
postoperative,1302,O
transfusion,1302,O
of,1302,O
whole,1302,O
blood,1302,O
.,1302,O
In,1303,O
her,1303,O
serum,1303,O
",",1303,O
C9,1303,O
was,1303,O
not,1303,O
detectable,1303,O
either,1303,O
by,1303,O
immunological,1303,O
or,1303,O
by,1303,O
functional,1303,O
assays,1303,O
.,1303,O
Both,1304,O
the,1304,O
Ham,1304,O
test,1304,O
and,1304,O
the,1304,O
sugar,1304,O
water,1304,O
test,1304,O
using,1304,O
normal,1304,O
human,1304,O
serum,1304,O
or,1304,O
plasma,1304,O
yielded,1304,O
marked,1304,O
haemolysis,1304,O
of,1304,O
the,1304,O
patients,1304,O
erythrocytes,1304,O
.,1304,O
When,1305,O
the,1305,O
patients,1305,O
serum,1305,O
or,1305,O
plasma,1305,O
was,1305,O
used,1305,O
",",1305,O
only,1305,O
a,1305,O
trace,1305,O
of,1305,O
lysis,1305,O
was,1305,O
detected,1305,O
.,1305,O
Addition,1306,O
of,1306,O
purified,1306,O
human,1306,O
C9,1306,O
to,1306,O
her,1306,O
plasma,1306,O
fully,1306,O
restored,1306,O
haemolysis,1306,O
.,1306,O
These,1307,O
observations,1307,O
indicated,1307,O
that,1307,O
C9,1307,O
may,1307,O
play,1307,O
a,1307,O
critical,1307,O
role,1307,O
in,1307,O
haemolytic,1307,B-DiseaseClass
attacks,1307,I-DiseaseClass
in,1307,O
patients,1307,O
with,1307,O
PNH,1307,B-SpecificDisease
and,1307,O
that,1307,O
characteristic,1307,O
haemolysis,1307,B-SpecificDisease
in,1307,O
PNH,1307,B-SpecificDisease
may,1307,O
be,1307,O
tempered,1307,O
by,1307,O
coexisting,1307,O
C9,1307,B-SpecificDisease
deficiency,1307,I-SpecificDisease
..,1307,O
Duplicational,1308,O
mutation,1308,O
at,1308,O
the,1308,O
Duchenne,1308,B-Modifier
muscular,1308,I-Modifier
dystrophy,1308,I-Modifier
locus,1308,O
:,1308,O
its,1308,O
frequency,1308,O
",",1308,O
distribution,1308,O
",",1308,O
origin,1308,O
",",1308,O
and,1308,O
phenotypegenotype,1308,O
correlation,1308,O
.,1308,O
Partial,1309,O
gene,1309,O
deletion,1309,O
is,1309,O
the,1309,O
major,1309,O
cause,1309,O
of,1309,O
mutation,1309,O
leading,1309,O
to,1309,O
Duchenne,1309,B-SpecificDisease
muscular,1309,I-SpecificDisease
dystrophy,1309,I-SpecificDisease
(,1309,O
DMD,1309,B-SpecificDisease
),1309,O
and,1309,O
Becker,1309,B-SpecificDisease
muscular,1309,I-SpecificDisease
dystrophy,1309,I-SpecificDisease
(,1309,O
BMD,1309,B-SpecificDisease
),1309,O
.,1309,O
Partial,1310,O
gene,1310,O
duplication,1310,O
has,1310,O
also,1310,O
been,1310,O
recognized,1310,O
in,1310,O
a,1310,O
few,1310,O
cases,1310,O
.,1310,O
We,1311,O
have,1311,O
conducted,1311,O
a,1311,O
survey,1311,O
for,1311,O
duplication,1311,O
in,1311,O
72,1311,O
unrelated,1311,O
nondeletion,1311,O
patients,1311,O
",",1311,O
analyzed,1311,O
by,1311,O
Southern,1311,O
blot,1311,O
hybridization,1311,O
with,1311,O
clones,1311,O
representing,1311,O
the,1311,O
entire,1311,O
DMD,1311,B-Modifier
cDNA,1311,O
.,1311,O
With,1312,O
careful,1312,O
quantitative,1312,O
analysis,1312,O
of,1312,O
hybridization,1312,O
band,1312,O
intensity,1312,O
",",1312,O
10,1312,O
cases,1312,O
were,1312,O
found,1312,O
to,1312,O
carry,1312,O
a,1312,O
duplication,1312,O
of,1312,O
part,1312,O
of,1312,O
the,1312,O
gene,1312,O
",",1312,O
a,1312,O
frequency,1312,O
of,1312,O
14,1312,O
%,1312,O
for,1312,O
nondeletion,1312,O
cases,1312,O
(,1312,O
10/72,1312,O
),1312,O
",",1312,O
or,1312,O
6,1312,O
%,1312,O
for,1312,O
all,1312,O
cases,1312,O
(,1312,O
10/181,1312,O
),1312,O
.,1312,O
The,1313,O
extent,1313,O
of,1313,O
these,1313,O
duplications,1313,O
has,1313,O
been,1313,O
characterized,1313,O
according,1313,O
to,1313,O
the,1313,O
published,1313,O
exon-containing,1313,O
HindIII,1313,O
fragment,1313,O
map,1313,O
",",1313,O
and,1313,O
in,1313,O
six,1313,O
of,1313,O
the,1313,O
10,1313,O
duplications,1313,O
a,1313,O
novel,1313,O
restriction,1313,O
fragment,1313,O
that,1313,O
spanned,1313,O
the,1313,O
duplication,1313,O
junction,1313,O
was,1313,O
detected,1313,O
.,1313,O
The,1314,O
resulting,1314,O
translational,1314,O
reading,1314,O
frame,1314,O
of,1314,O
mRNA,1314,O
has,1314,O
been,1314,O
predicted,1314,O
for,1314,O
nine,1314,O
duplications,1314,O
.,1314,O
A,1315,O
shift,1315,O
of,1315,O
the,1315,O
reading,1315,O
frame,1315,O
was,1315,O
predicted,1315,O
in,1315,O
four,1315,O
of,1315,O
the,1315,O
six,1315,O
DMD,1315,B-Modifier
cases,1315,O
and,1315,O
in,1315,O
one,1315,O
of,1315,O
the,1315,O
two,1315,O
intermediate,1315,O
cases,1315,O
",",1315,O
while,1315,O
the,1315,O
reading,1315,O
frame,1315,O
remained,1315,O
uninterrupted,1315,O
in,1315,O
both,1315,O
BMD,1315,B-Modifier
cases,1315,O
.,1315,O
RFLP,1316,O
and,1316,O
quantitative,1316,O
Southern,1316,O
blot,1316,O
analyses,1316,O
revealed,1316,O
a,1316,O
grandpaternal,1316,O
origin,1316,O
of,1316,O
duplication,1316,O
in,1316,O
four,1316,O
families,1316,O
and,1316,O
grandmaternal,1316,O
origin,1316,O
in,1316,O
one,1316,O
family,1316,O
.,1316,O
In,1317,O
all,1317,O
five,1317,O
families,1317,O
",",1317,O
the,1317,O
duplication,1317,O
was,1317,O
found,1317,O
to,1317,O
originate,1317,O
from,1317,O
a,1317,O
single,1317,O
X,1317,O
chromosome,1317,O
.,1317,O
Unequal,1318,O
sister-chromatid,1318,O
exchange,1318,O
is,1318,O
proposed,1318,O
to,1318,O
be,1318,O
the,1318,O
mechanism,1318,O
for,1318,O
the,1318,O
formation,1318,O
of,1318,O
these,1318,O
duplications,1318,O
..,1318,O
Statistical,1319,O
analysis,1319,O
of,1319,O
the,1319,O
two,1319,O
stage,1319,O
mutation,1319,O
model,1319,O
in,1319,O
von,1319,B-SpecificDisease
Hippel-Lindau,1319,I-SpecificDisease
disease,1319,I-SpecificDisease
",",1319,O
and,1319,O
in,1319,O
sporadic,1319,B-SpecificDisease
cerebellar,1319,I-SpecificDisease
haemangioblastoma,1319,I-SpecificDisease
and,1319,O
renal,1319,B-SpecificDisease
cell,1319,I-SpecificDisease
carcinoma,1319,I-SpecificDisease
.,1319,O
Analysis,1320,O
of,1320,O
the,1320,O
age,1320,O
incidence,1320,O
curves,1320,O
for,1320,O
unilateral,1320,B-CompositeMention
and,1320,I-CompositeMention
bilateral,1320,I-CompositeMention
retinoblastoma,1320,I-CompositeMention
led,1320,O
Knudson,1320,O
to,1320,O
propose,1320,O
that,1320,O
hereditary,1320,B-DiseaseClass
tumours,1320,I-DiseaseClass
may,1320,O
arise,1320,O
by,1320,O
a,1320,O
single,1320,O
event,1320,O
and,1320,O
sporadic,1320,B-DiseaseClass
tumours,1320,I-DiseaseClass
by,1320,O
a,1320,O
two,1320,O
stage,1320,O
mutation,1320,O
process,1320,O
.,1320,O
It,1321,O
has,1321,O
been,1321,O
suggested,1321,O
recently,1321,O
that,1321,O
sporadic,1321,B-SpecificDisease
renal,1321,I-SpecificDisease
cell,1321,I-SpecificDisease
carcinoma,1321,I-SpecificDisease
may,1321,O
arise,1321,O
from,1321,O
a,1321,O
two,1321,O
stage,1321,O
mutation,1321,O
process,1321,O
.,1321,O
We,1322,O
analysed,1322,O
the,1322,O
age,1322,O
incidence,1322,O
curves,1322,O
for,1322,O
symptomatic,1322,O
renal,1322,B-SpecificDisease
cell,1322,I-SpecificDisease
carcinoma,1322,I-SpecificDisease
(,1322,O
n,1322,O
=,1322,O
26,1322,O
),1322,O
and,1322,O
cerebellar,1322,B-SpecificDisease
haemangioblastoma,1322,I-SpecificDisease
(,1322,O
n,1322,O
=,1322,O
68,1322,O
),1322,O
in,1322,O
109,1322,O
patients,1322,O
with,1322,O
von,1322,B-SpecificDisease
Hippel-Lindau,1322,I-SpecificDisease
(,1322,I-SpecificDisease
VHL,1322,I-SpecificDisease
),1322,I-SpecificDisease
disease,1322,I-SpecificDisease
",",1322,O
and,1322,O
compared,1322,O
them,1322,O
to,1322,O
104,1322,O
patients,1322,O
with,1322,O
sporadic,1322,B-SpecificDisease
renal,1322,I-SpecificDisease
cell,1322,I-SpecificDisease
carcinoma,1322,I-SpecificDisease
and,1322,O
43,1322,O
patients,1322,O
with,1322,O
sporadic,1322,B-SpecificDisease
cerebellar,1322,I-SpecificDisease
haemangioblastoma,1322,I-SpecificDisease
.,1322,O
The,1323,O
age,1323,O
incidence,1323,O
curves,1323,O
for,1323,O
renal,1323,B-SpecificDisease
cell,1323,I-SpecificDisease
carcinoma,1323,I-SpecificDisease
and,1323,O
cerebellar,1323,B-SpecificDisease
haemangioblastoma,1323,I-SpecificDisease
in,1323,O
VHL,1323,B-SpecificDisease
disease,1323,I-SpecificDisease
were,1323,O
compatible,1323,O
with,1323,O
a,1323,O
single,1323,O
mutation,1323,O
model,1323,O
",",1323,O
whereas,1323,O
the,1323,O
age,1323,O
incidence,1323,O
curves,1323,O
for,1323,O
sporadic,1323,B-SpecificDisease
renal,1323,I-SpecificDisease
cell,1323,I-SpecificDisease
carcinoma,1323,I-SpecificDisease
and,1323,O
cerebellar,1323,B-SpecificDisease
haemangioblastoma,1323,I-SpecificDisease
suggested,1323,O
a,1323,O
two,1323,O
stage,1323,O
mutation,1323,O
process,1323,O
.,1323,O
These,1324,O
data,1324,O
are,1324,O
compatible,1324,O
with,1324,O
the,1324,O
VHL,1324,B-Modifier
gene,1324,O
functioning,1324,O
as,1324,O
a,1324,O
recessive,1324,O
tumour,1324,B-Modifier
suppressor,1324,O
gene,1324,O
.,1324,O
Sporadic,1325,B-SpecificDisease
cerebellar,1325,I-SpecificDisease
haemangioblastoma,1325,I-SpecificDisease
and,1325,O
some,1325,O
renal,1325,B-SpecificDisease
cell,1325,I-SpecificDisease
carcinoma,1325,I-SpecificDisease
may,1325,O
arise,1325,O
from,1325,O
somatic,1325,O
mutations,1325,O
inactivating,1325,O
both,1325,O
alleles,1325,O
at,1325,O
the,1325,O
VHL,1325,B-Modifier
locus,1325,O
..,1325,O
Screening,1326,O
for,1326,O
carriers,1326,O
of,1326,O
Tay-Sachs,1326,B-SpecificDisease
disease,1326,I-SpecificDisease
among,1326,O
Ashkenazi,1326,O
Jews,1326,O
.,1326,O
A,1327,O
comparison,1327,O
of,1327,O
DNA-based,1327,O
and,1327,O
enzyme-based,1327,O
tests,1327,O
.,1327,O
BACKGROUND,1328,O
AND,1328,O
METHODS,1328,O
.,1328,O
The,1329,O
prevention,1329,O
of,1329,O
Tay-Sachs,1329,B-SpecificDisease
disease,1329,I-SpecificDisease
(,1329,O
GM2,1329,B-SpecificDisease
gangliosidosis,1329,I-SpecificDisease
",",1329,I-SpecificDisease
type,1329,I-SpecificDisease
1,1329,I-SpecificDisease
),1329,O
depends,1329,O
on,1329,O
the,1329,O
identification,1329,O
of,1329,O
carriers,1329,O
of,1329,O
the,1329,O
gene,1329,O
for,1329,O
this,1329,O
autosomal,1329,B-DiseaseClass
recessive,1329,I-DiseaseClass
disorder,1329,I-DiseaseClass
.,1329,O
We,1330,O
compared,1330,O
the,1330,O
enzyme-based,1330,O
test,1330,O
widely,1330,O
used,1330,O
in,1330,O
screening,1330,O
for,1330,O
Tay-Sachs,1330,B-SpecificDisease
disease,1330,I-SpecificDisease
with,1330,O
a,1330,O
test,1330,O
based,1330,O
on,1330,O
analysis,1330,O
of,1330,O
DNA,1330,O
.,1330,O
We,1331,O
developed,1331,O
methods,1331,O
to,1331,O
detect,1331,O
the,1331,O
three,1331,O
mutations,1331,O
in,1331,O
the,1331,O
HEXA,1331,O
gene,1331,O
that,1331,O
occur,1331,O
with,1331,O
high,1331,O
frequency,1331,O
among,1331,O
Ashkenazi,1331,O
Jews,1331,O
two,1331,O
mutations,1331,O
cause,1331,O
infantile,1331,O
Tay-Sachs,1331,B-SpecificDisease
disease,1331,I-SpecificDisease
",",1331,O
and,1331,O
the,1331,O
third,1331,O
causes,1331,O
the,1331,O
adult-onset,1331,O
form,1331,O
of,1331,O
the,1331,O
disease,1331,O
.,1331,O
DNA,1332,O
segments,1332,O
containing,1332,O
these,1332,O
mutation,1332,O
sites,1332,O
were,1332,O
amplified,1332,O
with,1332,O
the,1332,O
polymerase,1332,O
chain,1332,O
reaction,1332,O
and,1332,O
analyzed,1332,O
for,1332,O
the,1332,O
presence,1332,O
of,1332,O
the,1332,O
mutations,1332,O
.,1332,O
RESULTS,1333,O
.,1333,O
Among,1334,O
62,1334,O
Ashkenazi,1334,O
obligate,1334,O
carriers,1334,O
of,1334,O
Tay-Sachs,1334,B-SpecificDisease
disease,1334,I-SpecificDisease
",",1334,O
the,1334,O
three,1334,O
specific,1334,O
mutations,1334,O
accounted,1334,O
for,1334,O
all,1334,O
but,1334,O
one,1334,O
of,1334,O
the,1334,O
mutant,1334,O
alleles,1334,O
(,1334,O
98,1334,O
percent,1334,O
),1334,O
.,1334,O
In,1335,O
216,1335,O
Ashkenazi,1335,O
carriers,1335,O
identified,1335,O
by,1335,O
the,1335,O
enzyme,1335,O
test,1335,O
",",1335,O
DNA,1335,O
analysis,1335,O
showed,1335,O
that,1335,O
177,1335,O
(,1335,O
82,1335,O
percent,1335,O
),1335,O
had,1335,O
one,1335,O
of,1335,O
the,1335,O
identified,1335,O
mutations,1335,O
.,1335,O
Of,1336,O
the,1336,O
177,1336,O
",",1336,O
79,1336,O
percent,1336,O
had,1336,O
the,1336,O
exon,1336,O
11,1336,O
insertion,1336,O
mutation,1336,O
",",1336,O
18,1336,O
percent,1336,O
had,1336,O
the,1336,O
intron,1336,O
12,1336,O
splice-junction,1336,O
mutation,1336,O
",",1336,O
and,1336,O
3,1336,O
percent,1336,O
had,1336,O
the,1336,O
less,1336,O
severe,1336,O
exon,1336,O
7,1336,O
mutation,1336,O
associated,1336,O
with,1336,O
adult-onset,1336,O
disease,1336,O
.,1336,O
The,1337,O
results,1337,O
of,1337,O
the,1337,O
enzyme,1337,O
tests,1337,O
in,1337,O
the,1337,O
39,1337,O
subjects,1337,O
(,1337,O
18,1337,O
percent,1337,O
),1337,O
who,1337,O
were,1337,O
defined,1337,O
as,1337,O
carriers,1337,O
but,1337,O
in,1337,O
whom,1337,O
DNA,1337,O
analysis,1337,O
did,1337,O
not,1337,O
identify,1337,O
a,1337,O
mutant,1337,O
allele,1337,O
were,1337,O
probably,1337,O
false,1337,O
positive,1337,O
(,1337,O
although,1337,O
there,1337,O
remains,1337,O
some,1337,O
possibility,1337,O
of,1337,O
unidentified,1337,O
mutations,1337,O
),1337,O
.,1337,O
In,1338,O
addition,1338,O
",",1338,O
of,1338,O
152,1338,O
persons,1338,O
defined,1338,O
as,1338,O
noncarriers,1338,O
by,1338,O
the,1338,O
enzyme-based,1338,O
test,1338,O
",",1338,O
1,1338,O
was,1338,O
identified,1338,O
as,1338,O
a,1338,O
carrier,1338,O
by,1338,O
DNA,1338,O
analysis,1338,O
(,1338,O
i.,1338,O
e,1338,O
e.,1338,O
",",1338,O
a,1338,O
false,1338,O
negative,1338,O
enzyme-test,1338,O
result,1338,O
),1338,O
.,1338,O
CONCLUSIONS,1339,O
.,1339,O
The,1340,O
increased,1340,O
specificity,1340,O
and,1340,O
predictive,1340,O
value,1340,O
of,1340,O
the,1340,O
DNA-based,1340,O
test,1340,O
make,1340,O
it,1340,O
a,1340,O
useful,1340,O
adjunct,1340,O
to,1340,O
the,1340,O
diagnostic,1340,O
tests,1340,O
currently,1340,O
used,1340,O
to,1340,O
screen,1340,O
for,1340,O
carriers,1340,O
of,1340,O
Tay-Sachs,1340,B-SpecificDisease
disease,1340,I-SpecificDisease
.,1340,O
Total,1341,B-SpecificDisease
deficiency,1341,I-SpecificDisease
of,1341,I-SpecificDisease
plasma,1341,I-SpecificDisease
cholesteryl,1341,I-SpecificDisease
ester,1341,I-SpecificDisease
transfer,1341,I-SpecificDisease
protein,1341,I-SpecificDisease
in,1341,O
subjects,1341,O
homozygous,1341,O
and,1341,O
heterozygous,1341,O
for,1341,O
the,1341,O
intron,1341,O
14,1341,O
splicing,1341,O
defect,1341,O
.,1341,O
The,1342,O
molecular,1342,O
basis,1342,O
of,1342,O
cholesteryl,1342,B-SpecificDisease
ester,1342,I-SpecificDisease
transfer,1342,I-SpecificDisease
protein,1342,I-SpecificDisease
(,1342,I-SpecificDisease
CETP,1342,I-SpecificDisease
),1342,I-SpecificDisease
deficiency,1342,I-SpecificDisease
was,1342,O
investigated,1342,O
in,1342,O
4,1342,O
unrelated,1342,O
CETP-deficient,1342,B-Modifier
families,1342,O
.,1342,O
The,1343,O
high,1343,O
density,1343,O
lipoprotein-cholesterol,1343,O
levels,1343,O
of,1343,O
the,1343,O
probands,1343,O
exceeded,1343,O
150,1343,O
mg/dl,1343,O
.,1343,O
The,1344,O
plasma,1344,O
of,1344,O
the,1344,O
probands,1344,O
was,1344,O
totally,1344,O
deficient,1344,O
in,1344,O
CETP,1344,O
activity,1344,O
and,1344,O
mass,1344,O
.,1344,O
The,1345,O
genomic,1345,O
DNA,1345,O
of,1345,O
the,1345,O
patients,1345,O
was,1345,O
amplified,1345,O
by,1345,O
polymerase,1345,O
chain,1345,O
reaction,1345,O
",",1345,O
using,1345,O
two,1345,O
oligonucleotide,1345,O
primers,1345,O
located,1345,O
in,1345,O
the,1345,O
intron,1345,O
12,1345,O
and,1345,O
14,1345,O
of,1345,O
the,1345,O
CETP,1345,O
gene,1345,O
",",1345,O
and,1345,O
the,1345,O
amplified,1345,O
products,1345,O
were,1345,O
directly,1345,O
sequenced,1345,O
.,1345,O
Two,1346,O
patients,1346,O
were,1346,O
homozygous,1346,O
for,1346,O
a,1346,O
G-to-A,1346,O
change,1346,O
at,1346,O
the,1346,O
5-splice,1346,O
donor,1346,O
site,1346,O
of,1346,O
the,1346,O
intron,1346,O
14,1346,O
.,1346,O
The,1347,O
G-to-A,1347,O
change,1347,O
would,1347,O
cause,1347,O
impaired,1347,O
splicing,1347,O
of,1347,O
pre-messenger,1347,O
RNA,1347,O
.,1347,O
The,1348,O
other,1348,O
two,1348,O
probands,1348,O
were,1348,O
heterozygous,1348,O
for,1348,O
the,1348,O
mutation,1348,O
",",1348,O
but,1348,O
totally,1348,O
lacked,1348,O
CETP,1348,O
.,1348,O
Their,1349,O
lipoprotein,1349,O
patterns,1349,O
were,1349,O
also,1349,O
similar,1349,O
to,1349,O
those,1349,O
of,1349,O
the,1349,O
two,1349,O
homozygotes,1349,O
.,1349,O
Thus,1350,O
",",1350,O
other,1350,O
genetic,1350,B-DiseaseClass
defects,1350,I-DiseaseClass
or,1350,O
metabolic,1350,O
factors,1350,O
influencing,1350,O
CETP,1350,O
expression,1350,O
are,1350,O
implicated,1350,O
.,1350,O
The,1351,O
data,1351,O
suggest,1351,O
that,1351,O
the,1351,O
G-to-A,1351,O
mutation,1351,O
may,1351,O
be,1351,O
common,1351,O
in,1351,O
human,1351,O
plasma,1351,O
CETP,1351,B-SpecificDisease
deficiency,1351,I-SpecificDisease
.,1351,O
Furthermore,1352,O
",",1352,O
there,1352,O
could,1352,O
be,1352,O
compound,1352,O
heterozygotes,1352,O
who,1352,O
totally,1352,O
lack,1352,O
plasma,1352,O
CETP,1352,O
and,1352,O
have,1352,O
lipoprotein,1352,O
profiles,1352,O
similar,1352,O
to,1352,O
those,1352,O
of,1352,O
homozygotes,1352,O
..,1352,O
Molecular,1353,O
genetics,1353,O
of,1353,O
the,1353,O
glucose-6-phosphate,1353,O
dehydrogenase,1353,O
(,1353,O
G6PD,1353,O
),1353,O
Mediterranean,1353,O
variant,1353,O
and,1353,O
description,1353,O
of,1353,O
a,1353,O
new,1353,O
G6PD,1353,O
mutant,1353,O
",",1353,O
G6PD,1353,O
Andalus1361A,1353,O
.,1353,O
Glucose-6-phosphate,1354,O
dehydrogenase,1354,O
(,1354,O
G6PD,1354,O
;,1354,O
E.,1354,O
C.,1354,O
1,1354,O
.,1354,O
1,1355,O
.,1355,O
1,1356,O
.,1356,O
49,1357,O
),1357,O
deficiency,1357,O
is,1357,O
the,1357,O
most,1357,O
common,1357,O
human,1357,O
enzymopathy,1357,B-DiseaseClass
;,1357,O
more,1357,O
than,1357,O
300,1357,O
different,1357,O
biochemical,1357,O
variants,1357,O
of,1357,O
the,1357,O
enzyme,1357,O
have,1357,O
been,1357,O
described,1357,O
.,1357,O
In,1358,O
many,1358,O
parts,1358,O
of,1358,O
the,1358,O
world,1358,O
the,1358,O
Mediterranean,1358,O
type,1358,O
of,1358,O
G6PD,1358,B-SpecificDisease
deficiency,1358,I-SpecificDisease
is,1358,O
prevalent,1358,O
.,1358,O
However,1359,O
",",1359,O
G6PD,1359,O
Mediterranean,1359,O
has,1359,O
come,1359,O
to,1359,O
be,1359,O
regarded,1359,O
as,1359,O
a,1359,O
generic,1359,O
term,1359,O
applied,1359,O
to,1359,O
similar,1359,O
G6PD,1359,O
mutations,1359,O
thought,1359,O
",",1359,O
however,1359,O
",",1359,O
to,1359,O
represent,1359,O
a,1359,O
somewhat,1359,O
heterogeneous,1359,O
group,1359,O
.,1359,O
A,1360,O
C,1360,O
--,1360,O
--,1360,O
T,1360,O
mutation,1360,O
at,1360,O
nucleotide,1360,O
563,1360,O
of,1360,O
G6PD,1360,O
Mediterranean,1360,O
has,1360,O
been,1360,O
identified,1360,O
by,1360,O
Vulliamy,1360,O
et,1360,O
al.,1360,O
",",1360,O
and,1360,O
the,1360,O
same,1360,O
mutation,1360,O
has,1360,O
been,1360,O
found,1360,O
by,1360,O
De,1360,O
Vita,1360,O
et,1360,O
al,1360,O
.,1360,O
in,1361,O
G6PD,1361,O
Mediterranean,1361,O
",",1361,O
G6PD,1361,O
Sassari,1361,O
",",1361,O
and,1361,O
G6PD,1361,O
Cagliari,1361,O
.,1361,O
The,1362,O
latter,1362,O
subjects,1362,O
had,1362,O
an,1362,O
additional,1362,O
mutation,1362,O
",",1362,O
at,1362,O
nucleotide,1362,O
1311,1362,O
",",1362,O
that,1362,O
did,1362,O
not,1362,O
produce,1362,O
a,1362,O
coding,1362,O
change,1362,O
.,1362,O
We,1363,O
have,1363,O
examined,1363,O
genomic,1363,O
DNA,1363,O
of,1363,O
five,1363,O
patients,1363,O
--,1363,O
four,1363,O
of,1363,O
Spanish,1363,O
origin,1363,O
and,1363,O
one,1363,O
of,1363,O
Jewish,1363,O
origin,1363,O
--,1363,O
having,1363,O
enzymatically,1363,O
documented,1363,O
G6PD,1363,O
Mediterranean,1363,O
.,1363,O
All,1364,O
had,1364,O
both,1364,O
the,1364,O
mutation,1364,O
at,1364,O
nucleotide,1364,O
563,1364,O
and,1364,O
that,1364,O
at,1364,O
nucleotide,1364,O
1311,1364,O
.,1364,O
A,1365,O
sixth,1365,O
sample,1365,O
",",1365,O
resembling,1365,O
G6PD,1365,O
Mediterranean,1365,O
kinetically,1365,O
but,1365,O
with,1365,O
a,1365,O
slightly,1365,O
rapid,1365,O
electrophoretic,1365,O
mobility,1365,O
",",1365,O
was,1365,O
designated,1365,O
G6PD,1365,O
Andalus,1365,O
and,1365,O
was,1365,O
found,1365,O
to,1365,O
have,1365,O
a,1365,O
different,1365,O
mutation,1365,O
",",1365,O
a,1365,O
G,1365,O
--,1365,O
--,1365,O
A,1365,O
transition,1365,O
at,1365,O
nucleotide,1365,O
1361,1365,O
",",1365,O
producing,1365,O
an,1365,O
arginine-to-histidine,1365,O
substitution,1365,O
.,1365,O
These,1366,O
studies,1366,O
suggest,1366,O
that,1366,O
G6PD,1366,O
Mediterranean,1366,O
is,1366,O
",",1366,O
after,1366,O
all,1366,O
",",1366,O
relatively,1366,O
homogeneous,1366,O
.,1366,O
A,1367,O
normal,1367,O
male,1367,O
with,1367,O
an,1367,O
inherited,1367,O
deletion,1367,O
of,1367,O
one,1367,O
exon,1367,O
within,1367,O
the,1367,O
DMD,1367,B-Modifier
gene,1367,O
.,1367,O
We,1368,O
describe,1368,O
two,1368,O
brothers,1368,O
with,1368,O
identical,1368,O
inherited,1368,O
deletions,1368,O
of,1368,O
one,1368,O
single,1368,O
exon,1368,O
within,1368,O
the,1368,O
middle,1368,O
of,1368,O
the,1368,O
DMD,1368,B-Modifier
gene,1368,O
;,1368,O
one,1368,O
brother,1368,O
has,1368,O
Becker,1368,B-SpecificDisease
muscular,1368,I-SpecificDisease
dystrophy,1368,I-SpecificDisease
diagnosed,1368,O
at,1368,O
11,1368,O
years,1368,O
of,1368,O
age,1368,O
",",1368,O
whereas,1368,O
the,1368,O
older,1368,O
brother,1368,O
is,1368,O
normal,1368,O
at,1368,O
18,1368,O
.,1368,O
These,1369,O
results,1369,O
have,1369,O
implications,1369,O
for,1369,O
genetic,1369,O
counselling,1369,O
and,1369,O
prenatal,1369,O
diagnosis,1369,O
in,1369,O
families,1369,O
with,1369,O
Becker,1369,B-SpecificDisease
muscular,1369,I-SpecificDisease
dystrophy,1369,I-SpecificDisease
..,1369,O
Duchenne,1370,B-Modifier
muscular,1370,I-Modifier
dystrophy,1370,I-Modifier
gene,1370,O
expression,1370,O
in,1370,O
normal,1370,O
and,1370,O
diseased,1370,O
human,1370,O
muscle,1370,O
.,1370,O
A,1371,O
probe,1371,O
for,1371,O
the,1371,O
5,1371,O
end,1371,O
of,1371,O
the,1371,O
Duchenne,1371,B-Modifier
muscular,1371,I-Modifier
dystrophy,1371,I-Modifier
(,1371,O
DMD,1371,B-Modifier
),1371,O
gene,1371,O
was,1371,O
used,1371,O
to,1371,O
study,1371,O
expression,1371,O
of,1371,O
the,1371,O
gene,1371,O
in,1371,O
normal,1371,O
human,1371,O
muscle,1371,O
",",1371,O
myogenic,1371,O
cell,1371,O
cultures,1371,O
",",1371,O
and,1371,O
muscle,1371,O
from,1371,O
patients,1371,O
with,1371,O
DMD,1371,B-SpecificDisease
.,1371,O
Expression,1372,O
was,1372,O
found,1372,O
in,1372,O
RNA,1372,O
from,1372,O
normal,1372,O
fetal,1372,O
muscle,1372,O
",",1372,O
adult,1372,O
cardiac,1372,O
and,1372,O
skeletal,1372,O
muscle,1372,O
",",1372,O
and,1372,O
cultured,1372,O
muscle,1372,O
after,1372,O
myoblast,1372,O
fusion,1372,O
.,1372,O
In,1373,O
DMD,1373,B-Modifier
muscle,1373,O
",",1373,O
expression,1373,O
of,1373,O
this,1373,O
portion,1373,O
of,1373,O
the,1373,O
gene,1373,O
was,1373,O
also,1373,O
revealed,1373,O
by,1373,O
in,1373,O
situ,1373,O
RNA,1373,O
hybridization,1373,O
",",1373,O
particularly,1373,O
in,1373,O
regenerating,1373,O
muscle,1373,O
fibers,1373,O
..,1373,O
Molecular,1374,O
and,1374,O
phenotypic,1374,O
analysis,1374,O
of,1374,O
patients,1374,O
with,1374,O
deletions,1374,O
within,1374,O
the,1374,O
deletion-rich,1374,O
region,1374,O
of,1374,O
the,1374,O
Duchenne,1374,B-Modifier
muscular,1374,I-Modifier
dystrophy,1374,I-Modifier
(,1374,O
DMD,1374,B-Modifier
),1374,O
gene,1374,O
.,1374,O
Eighty,1375,O
unrelated,1375,O
individuals,1375,O
with,1375,O
Duchenne,1375,B-SpecificDisease
muscular,1375,I-SpecificDisease
dystrophy,1375,I-SpecificDisease
(,1375,O
DMD,1375,B-SpecificDisease
),1375,O
or,1375,O
Becker,1375,B-SpecificDisease
muscular,1375,I-SpecificDisease
dystrophy,1375,I-SpecificDisease
(,1375,O
BMD,1375,B-SpecificDisease
),1375,O
were,1375,O
found,1375,O
to,1375,O
have,1375,O
deletions,1375,O
in,1375,O
the,1375,O
major,1375,O
deletion-rich,1375,O
region,1375,O
of,1375,O
the,1375,O
DMD,1375,B-Modifier
locus,1375,O
.,1375,O
This,1376,O
region,1376,O
includes,1376,O
the,1376,O
last,1376,O
five,1376,O
exons,1376,O
detected,1376,O
by,1376,O
cDNA5b-7,1376,O
",",1376,O
all,1376,O
exons,1376,O
detected,1376,O
by,1376,O
cDNA8,1376,O
",",1376,O
and,1376,O
the,1376,O
first,1376,O
two,1376,O
exons,1376,O
detected,1376,O
by,1376,O
cDNA9,1376,O
.,1376,O
These,1377,O
80,1377,O
individuals,1377,O
account,1377,O
for,1377,O
approximately,1377,O
75,1377,O
%,1377,O
of,1377,O
109,1377,O
deletions,1377,O
of,1377,O
the,1377,O
gene,1377,O
",",1377,O
detected,1377,O
among,1377,O
181,1377,O
patients,1377,O
analyzed,1377,O
with,1377,O
the,1377,O
entire,1377,O
dystrophin,1377,O
cDNA,1377,O
.,1377,O
Endpoints,1378,O
for,1378,O
many,1378,O
of,1378,O
these,1378,O
deletions,1378,O
were,1378,O
further,1378,O
characterized,1378,O
using,1378,O
two,1378,O
genomic,1378,O
probes,1378,O
",",1378,O
p20,1378,O
(,1378,O
DXS269,1378,O
;,1378,O
Wapenaar,1378,O
et,1378,O
al,1378,O
.,1378,O
),1378,O
and,1379,O
GMGX11,1379,O
(,1379,O
DXS239,1379,O
;,1379,O
present,1379,O
paper,1379,O
),1379,O
.,1379,O
Clinical,1380,O
findings,1380,O
are,1380,O
presented,1380,O
for,1380,O
all,1380,O
80,1380,O
patients,1380,O
allowing,1380,O
a,1380,O
correlation,1380,O
of,1380,O
phenotypic,1380,O
severity,1380,O
with,1380,O
the,1380,O
genotype,1380,O
.,1380,O
Thirty-eight,1381,O
independent,1381,O
patients,1381,O
were,1381,O
old,1381,O
enough,1381,O
to,1381,O
be,1381,O
classified,1381,O
as,1381,O
DMD,1381,B-SpecificDisease
",",1381,O
BMD,1381,B-SpecificDisease
",",1381,O
or,1381,O
intermediate,1381,O
phenotype,1381,O
and,1381,O
had,1381,O
deletions,1381,O
of,1381,O
exons,1381,O
with,1381,O
sequenced,1381,O
intron/exon,1381,O
boundaries,1381,O
.,1381,O
Of,1382,O
these,1382,O
",",1382,O
eight,1382,O
BMD,1382,B-Modifier
patients,1382,O
and,1382,O
one,1382,O
intermediate,1382,O
patient,1382,O
had,1382,O
gene,1382,O
deletions,1382,O
predicted,1382,O
to,1382,O
leave,1382,O
the,1382,O
reading,1382,O
frame,1382,O
intact,1382,O
",",1382,O
while,1382,O
21,1382,O
DMD,1382,B-Modifier
patients,1382,O
",",1382,O
7,1382,O
intermediate,1382,O
patients,1382,O
",",1382,O
and,1382,O
1,1382,O
BMD,1382,B-Modifier
patient,1382,O
had,1382,O
gene,1382,O
deletions,1382,O
predicted,1382,O
to,1382,O
disrupt,1382,O
the,1382,O
reading,1382,O
frame,1382,O
.,1382,O
Thus,1383,O
",",1383,O
with,1383,O
two,1383,O
exceptions,1383,O
",",1383,O
frameshift,1383,O
deletions,1383,O
of,1383,O
the,1383,O
gene,1383,O
resulted,1383,O
in,1383,O
more,1383,O
severe,1383,O
phenotype,1383,O
than,1383,O
did,1383,O
in-frame,1383,O
deletions,1383,O
.,1383,O
This,1384,O
is,1384,O
in,1384,O
agreement,1384,O
with,1384,O
recent,1384,O
findings,1384,O
by,1384,O
Baumbach,1384,O
et,1384,O
al,1384,O
.,1384,O
and,1385,O
Koenig,1385,O
et,1385,O
al,1385,O
.,1385,O
but,1386,O
is,1386,O
in,1386,O
contrast,1386,O
to,1386,O
findings,1386,O
",",1386,O
by,1386,O
Malhotra,1386,O
et,1386,O
al,1386,O
.,1386,O
at,1387,O
the,1387,O
5,1387,O
',1387,O
end,1387,O
of,1387,O
the,1387,O
gene,1387,O
.,1387,O
Cloning,1388,O
of,1388,O
breakpoints,1388,O
of,1388,O
a,1388,O
chromosome,1388,O
translocation,1388,O
identifies,1388,O
the,1388,O
AN2,1388,O
locus,1388,O
.,1388,O
Chromosome,1389,O
translocations,1389,O
involving,1389,O
11p13,1389,O
have,1389,O
been,1389,O
associated,1389,O
with,1389,O
familial,1389,B-SpecificDisease
aniridia,1389,I-SpecificDisease
in,1389,O
two,1389,O
kindreds,1389,O
highlighting,1389,O
the,1389,O
chromosomal,1389,O
localization,1389,O
of,1389,O
the,1389,O
AN2,1389,O
locus,1389,O
.,1389,O
This,1390,O
locus,1390,O
is,1390,O
also,1390,O
part,1390,O
of,1390,O
the,1390,O
WAGR,1390,B-Modifier
complex,1390,O
(,1390,O
Wilms,1390,B-SpecificDisease
tumor,1390,I-SpecificDisease
",",1390,O
aniridia,1390,B-SpecificDisease
",",1390,O
genitourinary,1390,B-DiseaseClass
abnormalities,1390,I-DiseaseClass
",",1390,O
and,1390,O
mental,1390,B-DiseaseClass
retardation,1390,I-DiseaseClass
),1390,O
.,1390,O
In,1391,O
one,1391,O
kindred,1391,O
",",1391,O
the,1391,O
translocation,1391,O
is,1391,O
associated,1391,O
with,1391,O
a,1391,O
deletion,1391,O
",",1391,O
and,1391,O
probes,1391,O
for,1391,O
this,1391,O
region,1391,O
were,1391,O
used,1391,O
to,1391,O
identify,1391,O
and,1391,O
clone,1391,O
the,1391,O
breakpoints,1391,O
of,1391,O
the,1391,O
translocation,1391,O
in,1391,O
the,1391,O
second,1391,O
kindred,1391,O
.,1391,O
Comparison,1392,O
of,1392,O
phage,1392,O
restriction,1392,O
maps,1392,O
exclude,1392,O
the,1392,O
presence,1392,O
of,1392,O
any,1392,O
sizable,1392,O
deletion,1392,O
in,1392,O
this,1392,O
case,1392,O
.,1392,O
Sequences,1393,O
at,1393,O
the,1393,O
chromosome,1393,O
11,1393,O
breakpoint,1393,O
are,1393,O
conserved,1393,O
in,1393,O
multiple,1393,O
species,1393,O
",",1393,O
suggesting,1393,O
that,1393,O
the,1393,O
translocation,1393,O
falls,1393,O
within,1393,O
the,1393,O
AN2,1393,O
gene,1393,O
..,1393,O
Linkage,1394,O
analysis,1394,O
of,1394,O
the,1394,O
apolipoprotein,1394,O
C2,1394,O
gene,1394,O
and,1394,O
myotonic,1394,B-SpecificDisease
dystrophy,1394,I-SpecificDisease
on,1394,O
human,1394,O
chromosome,1394,O
19,1394,O
reveals,1394,O
linkage,1394,O
disequilibrium,1394,O
in,1394,O
a,1394,O
French-Canadian,1394,O
population,1394,O
.,1394,O
The,1395,O
gene,1395,O
for,1395,O
human,1395,O
apolipoprotein,1395,O
C2,1395,O
(,1395,O
APOC2,1395,O
),1395,O
",",1395,O
situated,1395,O
on,1395,O
the,1395,O
proximal,1395,O
long,1395,O
arm,1395,O
of,1395,O
chromosome,1395,O
19,1395,O
",",1395,O
is,1395,O
closely,1395,O
linked,1395,O
to,1395,O
the,1395,O
gene,1395,O
for,1395,O
the,1395,O
most,1395,O
common,1395,O
form,1395,O
of,1395,O
adult,1395,O
muscular,1395,B-DiseaseClass
dystrophy,1395,I-DiseaseClass
",",1395,O
myotonic,1395,B-SpecificDisease
dystrophy,1395,I-SpecificDisease
(,1395,O
DM,1395,B-SpecificDisease
),1395,O
.,1395,O
Six,1396,O
APOC2,1396,O
RFLPs,1396,O
(,1396,O
TaqI,1396,O
",",1396,O
BglI,1396,O
",",1396,O
BanI,1396,O
",",1396,O
BamHI,1396,O
",",1396,O
NcoI,1396,O
",",1396,O
and,1396,O
AvaII,1396,O
),1396,O
have,1396,O
been,1396,O
identified,1396,O
to,1396,O
date,1396,O
.,1396,O
We,1397,O
have,1397,O
conducted,1397,O
a,1397,O
comprehensive,1397,O
DM,1397,B-Modifier
linkage,1397,O
study,1397,O
utilizing,1397,O
all,1397,O
six,1397,O
RFLPs,1397,O
and,1397,O
involving,1397,O
50,1397,O
families,1397,O
and,1397,O
372,1397,O
individuals,1397,O
.,1397,O
The,1398,O
most,1398,O
informative,1398,O
RFLPs,1398,O
are,1398,O
",",1398,O
in,1398,O
descending,1398,O
order,1398,O
",",1398,O
NcoI,1398,O
(,1398,O
lod,1398,O
=,1398,O
6,1398,O
.,1398,O
64,1399,O
",",1399,O
theta,1399,O
=,1399,O
0,1399,O
.,1399,O
05,1400,O
),1400,O
",",1400,O
BglI,1400,O
(,1400,O
lod,1400,O
=,1400,O
6,1400,O
.,1400,O
12,1401,O
",",1401,O
theta,1401,O
=,1401,O
0,1401,O
.,1401,O
05,1402,O
),1402,O
",",1402,O
AvaII,1402,O
(,1402,O
lod,1402,O
=,1402,O
6,1402,O
.,1402,O
02,1403,O
",",1403,O
theta,1403,O
=,1403,O
0,1403,O
.,1403,O
03,1404,O
),1404,O
",",1404,O
BanI,1404,O
(,1404,O
lod,1404,O
=,1404,O
5,1404,O
.,1404,O
76,1405,O
",",1405,O
theta,1405,O
=,1405,O
0,1405,O
.,1405,O
04,1406,O
),1406,O
",",1406,O
TaqI,1406,O
(,1406,O
lod,1406,O
=,1406,O
4,1406,O
.,1406,O
29,1407,O
",",1407,O
theta,1407,O
=,1407,O
0,1407,O
.,1407,O
06,1408,O
),1408,O
",",1408,O
and,1408,O
BamHI,1408,O
(,1408,O
lod,1408,O
=,1408,O
1,1408,O
.,1408,O
75,1409,O
",",1409,O
theta,1409,O
=,1409,O
0,1409,O
.,1409,O
01,1410,O
),1410,O
.,1410,O
A,1411,O
substantial,1411,O
increase,1411,O
in,1411,O
the,1411,O
lod,1411,O
scores,1411,O
over,1411,O
those,1411,O
seen,1411,O
with,1411,O
the,1411,O
individual,1411,O
RFLPs,1411,O
was,1411,O
obtained,1411,O
when,1411,O
the,1411,O
linkage,1411,O
of,1411,O
the,1411,O
entire,1411,O
APOC2,1411,O
haplotype,1411,O
(,1411,O
composed,1411,O
of,1411,O
the,1411,O
six,1411,O
RFLPs,1411,O
),1411,O
was,1411,O
studied,1411,O
(,1411,O
lod,1411,O
=,1411,O
17,1411,O
.,1411,O
87,1412,O
",",1412,O
theta,1412,O
=,1412,O
0,1412,O
.,1412,O
04,1413,O
),1413,O
.,1413,O
We,1414,O
have,1414,O
observed,1414,O
significant,1414,O
inter-APOC2,1414,O
RFLP,1414,O
linkage,1414,O
disequilibrium,1414,O
.,1414,O
Consequently,1415,O
",",1415,O
the,1415,O
three,1415,O
most,1415,O
informative,1415,O
RFLPs,1415,O
have,1415,O
been,1415,O
found,1415,O
to,1415,O
be,1415,O
BanI,1415,O
",",1415,O
TaqI,1415,O
",",1415,O
and,1415,O
either,1415,O
BglI,1415,O
",",1415,O
AvaII,1415,O
",",1415,O
or,1415,O
NcoI,1415,O
polymorphisms,1415,O
.,1415,O
We,1416,O
also,1416,O
demonstrate,1416,O
linkage,1416,O
disequilibrium,1416,O
between,1416,O
DM,1416,O
and,1416,O
APOC2,1416,O
in,1416,O
our,1416,O
French-Canadian,1416,O
population,1416,O
(,1416,O
standardized,1416,O
disequilibrium,1416,O
constant,1416,O
phi,1416,O
=,1416,O
.,1416,O
22,1417,O
",",1417,O
chi,1417,O
2,1417,O
=,1417,O
5,1417,O
.,1417,O
12,1418,O
",",1418,O
df,1418,O
=,1418,O
1,1418,O
",",1418,O
P,1418,O
less,1418,O
than,1418,O
0,1418,O
.,1418,O
04,1419,O
),1419,O
.,1419,O
This,1420,O
represents,1420,O
the,1420,O
first,1420,O
evidence,1420,O
of,1420,O
linkage,1420,O
disequilibrium,1420,O
between,1420,O
APOC2,1420,O
and,1420,O
the,1420,O
DM,1420,B-Modifier
locus,1420,O
.,1420,O
Phenylalanine,1421,O
hydroxylase,1421,O
gene,1421,O
haplotypes,1421,O
in,1421,O
Polynesians,1421,O
:,1421,O
evolutionary,1421,O
origins,1421,O
and,1421,O
absence,1421,O
of,1421,O
alleles,1421,O
associated,1421,O
with,1421,O
severe,1421,O
phenylketonuria,1421,B-SpecificDisease
.,1421,O
A,1422,O
total,1422,O
of,1422,O
630,1422,O
haplotypes,1422,O
for,1422,O
the,1422,O
phenylalanine,1422,O
hydroxylase,1422,O
(,1422,O
PAH,1422,O
),1422,O
gene,1422,O
locus,1422,O
were,1422,O
established,1422,O
in,1422,O
five,1422,O
groups,1422,O
of,1422,O
Polynesians,1422,O
comprising,1422,O
Samoans,1422,O
",",1422,O
Tongans,1422,O
",",1422,O
Cook,1422,O
Islanders,1422,O
",",1422,O
Maori,1422,O
",",1422,O
and,1422,O
Niueans,1422,O
.,1422,O
Considerable,1423,O
genetic,1423,O
continuity,1423,O
was,1423,O
demonstrated,1423,O
between,1423,O
these,1423,O
widely,1423,O
dispersed,1423,O
populations,1423,O
",",1423,O
since,1423,O
three,1423,O
common,1423,O
haplotypes,1423,O
(,1423,O
4,1423,O
",",1423,O
1,1423,O
",",1423,O
and,1423,O
7,1423,O
),1423,O
constituted,1423,O
over,1423,O
95,1423,O
%,1423,O
of,1423,O
alleles,1423,O
.,1423,O
A,1424,O
control,1424,O
group,1424,O
of,1424,O
individuals,1424,O
from,1424,O
Southeast,1424,O
Asia,1424,O
shared,1424,O
the,1424,O
same,1424,O
major,1424,O
haplotypes,1424,O
",",1424,O
4,1424,O
",",1424,O
1,1424,O
",",1424,O
and,1424,O
7,1424,O
",",1424,O
with,1424,O
Polynesians,1424,O
.,1424,O
These,1425,O
data,1425,O
provide,1425,O
further,1425,O
support,1425,O
for,1425,O
the,1425,O
theories,1425,O
of,1425,O
genetic,1425,O
homogeneity,1425,O
and,1425,O
of,1425,O
Asian,1425,O
affinities,1425,O
of,1425,O
the,1425,O
Polynesian,1425,O
precursor,1425,O
populations,1425,O
.,1425,O
The,1426,O
absence,1426,O
of,1426,O
severe,1426,O
phenylketonuria,1426,B-SpecificDisease
(,1426,O
PKU,1426,B-SpecificDisease
),1426,O
in,1426,O
both,1426,O
Polynesians,1426,O
and,1426,O
Southeast,1426,O
Asians,1426,O
is,1426,O
consistent,1426,O
with,1426,O
the,1426,O
lack,1426,O
of,1426,O
PAH,1426,O
haplotypes,1426,O
2,1426,O
and,1426,O
3,1426,O
",",1426,O
on,1426,O
which,1426,O
the,1426,O
severe,1426,O
PKU,1426,B-Modifier
mutants,1426,O
have,1426,O
arisen,1426,O
among,1426,O
Caucasians,1426,O
..,1426,O
Preferential,1427,O
germline,1427,O
mutation,1427,O
of,1427,O
the,1427,O
paternal,1427,O
allele,1427,O
in,1427,O
retinoblastoma,1427,B-SpecificDisease
.,1427,O
The,1428,O
event,1428,O
triggering,1428,O
malignant,1428,O
proliferation,1428,O
in,1428,O
70,1428,O
%,1428,O
of,1428,O
retinoblastoma,1428,B-SpecificDisease
tumours,1428,I-SpecificDisease
is,1428,O
loss,1428,O
of,1428,O
heterozygosity,1428,O
for,1428,O
chromosome,1428,O
13q14,1428,O
",",1428,O
whereby,1428,O
the,1428,O
normal,1428,O
retinoblastoma,1428,B-Modifier
gene,1428,O
(,1428,O
RB1,1428,O
),1428,O
allele,1428,O
is,1428,O
lost,1428,O
and,1428,O
an,1428,O
already,1428,O
mutated,1428,O
RB1,1428,O
allele,1428,O
remains,1428,O
in,1428,O
the,1428,O
tumour,1428,B-DiseaseClass
.,1428,O
The,1429,O
first,1429,O
allele,1429,O
suffers,1429,O
a,1429,O
mutational,1429,O
event,1429,O
--,1429,O
deletion,1429,O
",",1429,O
duplication,1429,O
or,1429,O
point,1429,O
mutation,1429,O
(,1429,O
manuscript,1429,O
in,1429,O
preparation,1429,O
),1429,O
--,1429,O
either,1429,O
in,1429,O
the,1429,O
germ,1429,O
line,1429,O
(,1429,O
all,1429,O
bilateral,1429,O
patients,1429,O
),1429,O
or,1429,O
in,1429,O
a,1429,O
somatic,1429,O
retinal,1429,O
cell,1429,O
(,1429,O
most,1429,O
unilateral,1429,O
patients,1429,O
),1429,O
.,1429,O
Most,1430,O
bilateral,1430,O
patients,1430,O
have,1430,O
no,1430,O
family,1430,O
history,1430,O
of,1430,O
retinoblastoma,1430,B-SpecificDisease
and,1430,O
are,1430,O
presumed,1430,O
to,1430,O
have,1430,O
new,1430,O
germline,1430,O
mutations,1430,O
which,1430,O
arose,1430,O
in,1430,O
the,1430,O
egg,1430,O
",",1430,O
sperm,1430,O
or,1430,O
early,1430,O
embryo,1430,O
.,1430,O
We,1431,O
have,1431,O
determined,1431,O
the,1431,O
parental,1431,O
origin,1431,O
of,1431,O
the,1431,O
retained,1431,O
allele,1431,O
in,1431,O
nine,1431,O
retinoblastoma,1431,B-SpecificDisease
tumours,1431,I-SpecificDisease
from,1431,O
eight,1431,O
unrelated,1431,O
non-familial,1431,O
cases,1431,O
by,1431,O
using,1431,O
RB1-linked,1431,O
genetic,1431,O
markers,1431,O
.,1431,O
Six,1432,O
tumours,1432,B-DiseaseClass
retained,1432,O
the,1432,O
paternal,1432,O
allele,1432,O
and,1432,O
three,1432,O
retained,1432,O
the,1432,O
maternal,1432,O
allele,1432,O
.,1432,O
Of,1433,O
the,1433,O
three,1433,O
unilateral,1433,B-DiseaseClass
tumours,1433,I-DiseaseClass
",",1433,O
only,1433,O
one,1433,O
retained,1433,O
the,1433,O
paternal,1433,O
RB1,1433,O
allele,1433,O
.,1433,O
Thus,1434,O
",",1434,O
there,1434,O
is,1434,O
no,1434,O
evidence,1434,O
that,1434,O
the,1434,O
paternal,1434,O
RB1,1434,O
allele,1434,O
is,1434,O
preferentially,1434,O
retained,1434,O
in,1434,O
retinoblastoma,1434,B-SpecificDisease
",",1434,O
as,1434,O
has,1434,O
been,1434,O
suggested,1434,O
to,1434,O
be,1434,O
the,1434,O
case,1434,O
in,1434,O
osteosarcoma,1434,B-SpecificDisease
.,1434,O
By,1435,O
contrast,1435,O
",",1435,O
tumours,1435,B-DiseaseClass
from,1435,O
four,1435,O
of,1435,O
the,1435,O
five,1435,O
bilateral,1435,O
patients,1435,O
retained,1435,O
the,1435,O
paternal,1435,O
RB1,1435,O
allele,1435,O
.,1435,O
This,1436,O
suggests,1436,O
either,1436,O
that,1436,O
new,1436,O
germline,1436,O
RB1,1436,O
mutations,1436,O
arise,1436,O
more,1436,O
frequently,1436,O
during,1436,O
spermatogenesis,1436,O
than,1436,O
during,1436,O
oogenesis,1436,O
",",1436,O
or,1436,O
that,1436,O
imprinting,1436,O
in,1436,O
the,1436,O
early,1436,O
embryo,1436,O
affects,1436,O
chromosomal,1436,O
susceptibility,1436,O
to,1436,O
mutation,1436,O
..,1436,O
Haplotype,1437,O
analysis,1437,O
of,1437,O
the,1437,O
phenylalanine,1437,O
hydroxylase,1437,O
gene,1437,O
in,1437,O
Turkish,1437,O
phenylketonuria,1437,B-Modifier
families,1437,O
.,1437,O
We,1438,O
have,1438,O
estimated,1438,O
the,1438,O
haplotype,1438,O
distribution,1438,O
of,1438,O
mutant,1438,O
and,1438,O
normal,1438,O
phenylalanine,1438,O
hydroxylase,1438,O
(,1438,O
PAH,1438,O
),1438,O
alleles,1438,O
for,1438,O
17,1438,O
Turkish,1438,O
phenylketonuria,1438,B-Modifier
(,1438,O
PKU,1438,B-Modifier
),1438,O
families,1438,O
20,1438,O
normal,1438,O
and,1438,O
27,1438,O
mutated,1438,O
PAH,1438,O
alleles,1438,O
could,1438,O
be,1438,O
identified,1438,O
.,1438,O
Of,1439,O
the,1439,O
latter,1439,O
",",1439,O
the,1439,O
most,1439,O
prevalent,1439,O
were,1439,O
associated,1439,O
with,1439,O
haplotype,1439,O
6,1439,O
(,1439,O
29,1439,O
.,1439,O
6,1440,O
%,1440,O
),1440,O
",",1440,O
1,1440,O
(,1440,O
18,1440,O
.,1440,O
5,1441,O
%,1441,O
),1441,O
and,1441,O
36,1441,O
(,1441,O
11,1441,O
.,1441,O
1,1442,O
%,1442,O
),1442,O
",",1442,O
while,1442,O
the,1442,O
normal,1442,O
alleles,1442,O
were,1442,O
preferentially,1442,O
associated,1442,O
with,1442,O
haplotype,1442,O
1,1442,O
(,1442,O
20,1442,O
%,1442,O
),1442,O
.,1442,O
Of,1443,O
the,1443,O
19,1443,O
different,1443,O
haplotypes,1443,O
observed,1443,O
",",1443,O
5,1443,O
have,1443,O
not,1443,O
been,1443,O
described,1443,O
previously,1443,O
.,1443,O
The,1444,O
haplotype,1444,O
distribution,1444,O
differed,1444,O
significantly,1444,O
from,1444,O
that,1444,O
of,1444,O
the,1444,O
Northern,1444,O
European,1444,O
population,1444,O
.,1444,O
Two,1445,O
of,1445,O
the,1445,O
eight,1445,O
polymorphic,1445,O
sites,1445,O
were,1445,O
in,1445,O
association,1445,O
with,1445,O
PKU,1445,B-SpecificDisease
.,1445,O
No,1446,O
deletions,1446,O
of,1446,O
exon,1446,O
sequences,1446,O
were,1446,O
found,1446,O
in,1446,O
the,1446,O
families,1446,O
analysed,1446,O
.,1446,O
Huntington,1447,B-SpecificDisease
disease,1447,I-SpecificDisease
:,1447,O
no,1447,O
evidence,1447,O
for,1447,O
locus,1447,O
heterogeneity,1447,O
.,1447,O
A,1448,O
total,1448,O
of,1448,O
63,1448,O
families,1448,O
with,1448,O
Huntington,1448,B-SpecificDisease
disease,1448,I-SpecificDisease
(,1448,O
HD,1448,B-SpecificDisease
),1448,O
were,1448,O
examined,1448,O
for,1448,O
linkage,1448,O
between,1448,O
HD,1448,B-SpecificDisease
and,1448,O
G8,1448,O
(,1448,O
D4S10,1448,O
),1448,O
.,1448,O
The,1449,O
families,1449,O
included,1449,O
57,1449,O
Caucasian,1449,O
",",1449,O
four,1449,O
Black,1449,O
American,1449,O
",",1449,O
and,1449,O
two,1449,O
Japanese,1449,O
.,1449,O
The,1450,O
combined,1450,O
maximum,1450,O
lod,1450,O
score,1450,O
was,1450,O
87,1450,O
.,1450,O
69,1451,O
at,1451,O
theta,1451,O
=,1451,O
0,1451,O
.,1451,O
04,1452,O
(,1452,O
99,1452,O
%,1452,O
confidence,1452,O
interval,1452,O
0,1452,O
.,1452,O
018-0,1453,O
.,1453,O
071,1454,O
),1454,O
.,1454,O
The,1455,O
maximum,1455,O
frequency,1455,O
of,1455,O
recombination,1455,O
was,1455,O
0,1455,O
.,1455,O
03,1456,O
in,1456,O
males,1456,O
and,1456,O
0,1456,O
.,1456,O
05,1457,O
in,1457,O
females,1457,O
.,1457,O
Fifty-seven,1458,O
families,1458,O
gave,1458,O
positive,1458,O
lod,1458,O
scores,1458,O
;,1458,O
five,1458,O
small,1458,O
families,1458,O
gave,1458,O
mildly,1458,O
negative,1458,O
lod,1458,O
scores,1458,O
.,1458,O
The,1459,O
maximum,1459,O
likelihood,1459,O
estimate,1459,O
of,1459,O
alpha,1459,O
",",1459,O
the,1459,O
proportion,1459,O
of,1459,O
linked,1459,O
loci,1459,O
",",1459,O
was,1459,O
1,1459,O
.,1459,O
0,1460,O
with,1460,O
a,1460,O
lower,1460,O
99,1460,O
%,1460,O
confidence,1460,O
interval,1460,O
of,1460,O
0,1460,O
.,1460,O
88,1461,O
.,1461,O
These,1462,O
data,1462,O
suggest,1462,O
that,1462,O
there,1462,O
is,1462,O
only,1462,O
one,1462,O
HD,1462,B-Modifier
locus,1462,O
",",1462,O
although,1462,O
a,1462,O
second,1462,O
rare,1462,O
locus,1462,O
can,1462,O
not,1462,O
be,1462,O
ruled,1462,O
out,1462,O
.,1462,O
Haplotype,1463,O
and,1463,O
multipoint,1463,O
linkage,1463,O
analysis,1463,O
in,1463,O
Finnish,1463,O
choroideremia,1463,B-Modifier
families,1463,O
.,1463,O
Multipoint,1464,O
linkage,1464,O
analysis,1464,O
of,1464,O
choroideremia,1464,B-SpecificDisease
(,1464,O
TCD,1464,B-SpecificDisease
),1464,O
and,1464,O
seven,1464,O
X,1464,O
chromosomal,1464,O
restriction,1464,O
fragment,1464,O
length,1464,O
polymorphisms,1464,O
(,1464,O
RFLPs,1464,O
),1464,O
was,1464,O
carried,1464,O
out,1464,O
in,1464,O
18,1464,O
Finnish,1464,O
TCD,1464,B-Modifier
families,1464,O
.,1464,O
The,1465,O
data,1465,O
place,1465,O
TCD,1465,B-SpecificDisease
distal,1465,O
to,1465,O
PGK,1465,O
and,1465,O
DXS72,1465,O
",",1465,O
very,1465,O
close,1465,O
to,1465,O
DXYS1,1465,O
and,1465,O
DXYS5,1465,O
(,1465,O
Zmax,1465,O
=,1465,O
24,1465,O
at,1465,O
theta,1465,O
=,1465,O
0,1465,O
),1465,O
and,1465,O
proximal,1465,O
to,1465,O
DXYS4,1465,O
and,1465,O
DXYS12,1465,O
.,1465,O
This,1466,O
agrees,1466,O
with,1466,O
the,1466,O
data,1466,O
obtained,1466,O
from,1466,O
other,1466,O
linkage,1466,O
studies,1466,O
and,1466,O
from,1466,O
physical,1466,O
mapping,1466,O
.,1466,O
All,1467,O
the,1467,O
TCD,1467,B-Modifier
males,1467,O
and,1467,O
carrier,1467,O
females,1467,O
studied,1467,O
have,1467,O
the,1467,O
same,1467,O
DXYS1,1467,O
allele,1467,O
in,1467,O
coupling,1467,O
with,1467,O
TCD,1467,B-SpecificDisease
.,1467,O
In,1468,O
Northeastern,1468,O
Finland,1468,O
",",1468,O
66/69,1468,O
chromosomes,1468,O
carrying,1468,O
TCD,1468,B-SpecificDisease
had,1468,O
the,1468,O
same,1468,O
haplotype,1468,O
at,1468,O
loci,1468,O
DXS72,1468,O
",",1468,O
DXYS1,1468,O
",",1468,O
DXYS4,1468,O
",",1468,O
and,1468,O
DXYS12,1468,O
.,1468,O
The,1469,O
same,1469,O
haplotype,1469,O
is,1469,O
seen,1469,O
in,1469,O
only,1469,O
15/99,1469,O
chromosomes,1469,O
not,1469,O
carrying,1469,O
TCD,1469,B-SpecificDisease
.,1469,O
Moreover,1470,O
",",1470,O
in,1470,O
71/104,1470,O
non-TCD,1470,O
chromosomes,1470,O
",",1470,O
the,1470,O
haplotype,1470,O
at,1470,O
six,1470,O
marker,1470,O
loci,1470,O
is,1470,O
different,1470,O
from,1470,O
those,1470,O
seen,1470,O
in,1470,O
any,1470,O
of,1470,O
the,1470,O
76,1470,O
TCD,1470,B-Modifier
chromosomes,1470,O
.,1470,O
This,1471,O
supports,1471,O
the,1471,O
previously,1471,O
described,1471,O
hypothesis,1471,O
that,1471,O
the,1471,O
large,1471,O
Northern,1471,O
Finnish,1471,O
choroideremia,1471,B-Modifier
pedigrees,1471,O
",",1471,O
comprising,1471,O
a,1471,O
total,1471,O
of,1471,O
over,1471,O
80,1471,O
living,1471,O
patients,1471,O
representing,1471,O
more,1471,O
than,1471,O
a,1471,O
fifth,1471,O
of,1471,O
all,1471,O
TCD,1471,B-Modifier
patients,1471,O
described,1471,O
worldwide,1471,O
",",1471,O
carry,1471,O
the,1471,O
same,1471,O
mutation,1471,O
.,1471,O
These,1472,O
linkage,1472,O
and,1472,O
haplotype,1472,O
data,1472,O
provide,1472,O
improved,1472,O
opportunities,1472,O
for,1472,O
prenatal,1472,O
diagnosis,1472,O
based,1472,O
on,1472,O
RFLP,1472,O
studies,1472,O
..,1472,O
Autosomal,1473,O
dominant,1473,O
aniridia,1473,B-SpecificDisease
linked,1473,O
to,1473,O
the,1473,O
chromosome,1473,O
11p13,1473,O
markers,1473,O
catalase,1473,O
and,1473,O
D11S151,1473,O
in,1473,O
a,1473,O
large,1473,O
Dutch,1473,O
family,1473,O
.,1473,O
In,1474,O
a,1474,O
large,1474,O
pedigree,1474,O
with,1474,O
autosomal,1474,O
dominant,1474,O
aniridia,1474,B-SpecificDisease
",",1474,O
we,1474,O
found,1474,O
close,1474,O
linkage,1474,O
between,1474,O
the,1474,O
aniridia,1474,B-Modifier
locus,1474,O
AN2,1474,O
and,1474,O
the,1474,O
markers,1474,O
catalase,1474,O
(,1474,O
CAT,1474,O
),1474,O
(,1474,O
zeta,1474,O
=,1474,O
7,1474,O
.,1474,O
27,1475,O
at,1475,O
theta,1475,O
=,1475,O
0,1475,O
.,1475,O
00,1476,O
),1476,O
and,1476,O
D11S151,1476,O
(,1476,O
zeta,1476,O
=,1476,O
3,1476,O
.,1476,O
86,1477,O
at,1477,O
theta,1477,O
=,1477,O
0,1477,O
.,1477,O
10,1478,O
),1478,O
flanking,1478,O
the,1478,O
AN2,1478,O
locus,1478,O
on,1478,O
11p13,1478,O
.,1478,O
Positive,1479,O
lod,1479,O
scores,1479,O
were,1479,O
also,1479,O
obtained,1479,O
for,1479,O
the,1479,O
11p13,1479,O
--,1479,O
--,1479,O
11p14,1479,O
markers,1479,O
D11S16,1479,O
and,1479,O
FSHB,1479,O
with,1479,O
the,1479,O
linkage,1479,O
group,1479,O
CAT/AN2/D11S151,1479,O
.,1479,O
We,1480,O
conclude,1480,O
that,1480,O
the,1480,O
autosomal,1480,O
dominant,1480,O
aniridia,1480,B-SpecificDisease
in,1480,O
this,1480,O
family,1480,O
is,1480,O
due,1480,O
to,1480,O
a,1480,O
mutation,1480,O
at,1480,O
the,1480,O
AN2,1480,O
locus,1480,O
on,1480,O
11p13,1480,O
.,1480,O
We,1481,O
have,1481,O
excluded,1481,O
linkage,1481,O
(,1481,O
zeta,1481,O
less,1481,O
than,1481,O
-2,1481,O
at,1481,O
theta,1481,O
less,1481,O
than,1481,O
0,1481,O
.,1481,O
18,1482,O
),1482,O
between,1482,O
the,1482,O
aniridia,1482,B-SpecificDisease
and,1482,O
the,1482,O
chromosome,1482,O
2p25,1482,O
marker,1482,O
D2S1,1482,O
(,1482,O
linked,1482,O
to,1482,O
ACP1,1482,O
),1482,O
.,1482,O
Recombination,1483,O
events,1483,O
that,1483,O
locate,1483,O
myotonic,1483,B-SpecificDisease
dystrophy,1483,I-SpecificDisease
distal,1483,O
to,1483,O
APOC2,1483,O
on,1483,O
19q,1483,O
.,1483,O
We,1484,O
previously,1484,O
reported,1484,O
a,1484,O
recombination,1484,O
in,1484,O
an,1484,O
individual,1484,O
with,1484,O
myotonic,1484,B-SpecificDisease
dystrophy,1484,I-SpecificDisease
(,1484,O
DM,1484,B-SpecificDisease
),1484,O
which,1484,O
placed,1484,O
the,1484,O
markers,1484,O
D19S19,1484,O
and,1484,O
APOC2,1484,O
on,1484,O
the,1484,O
same,1484,O
side,1484,O
of,1484,O
the,1484,O
DM,1484,B-Modifier
locus,1484,O
.,1484,O
Haplotyping,1485,O
of,1485,O
this,1485,O
family,1485,O
with,1485,O
more,1485,O
recently,1485,O
characterized,1485,O
probes,1485,O
which,1485,O
are,1485,O
either,1485,O
tightly,1485,O
linked,1485,O
to,1485,O
DM,1485,B-SpecificDisease
or,1485,O
distal,1485,O
to,1485,O
the,1485,O
linkage,1485,O
group,1485,O
at,1485,O
q13,1485,O
.,1485,O
2,1486,O
shows,1486,O
that,1486,O
the,1486,O
DM,1486,B-Modifier
locus,1486,O
is,1486,O
distal,1486,O
to,1486,O
APOC2,1486,O
.,1486,O
This,1487,O
is,1487,O
confirmed,1487,O
by,1487,O
other,1487,O
recombinants,1487,O
where,1487,O
DM,1487,B-SpecificDisease
segregates,1487,O
with,1487,O
distal,1487,O
probes,1487,O
.,1487,O
Additional,1488,O
marker,1488,O
to,1488,O
marker,1488,O
recombinations,1488,O
in,1488,O
unaffected,1488,O
individuals,1488,O
are,1488,O
reported,1488,O
and,1488,O
support,1488,O
the,1488,O
order,1488,O
and,1488,O
orientation,1488,O
of,1488,O
the,1488,O
DM,1488,B-Modifier
linkage,1488,O
group,1488,O
as,1488,O
pter-,1488,O
(,1488,O
INSR,1488,O
",",1488,O
LDLR,1488,O
",",1488,O
S9,1488,O
),1488,O
-,1488,O
(,1488,O
S19,1488,O
",",1488,O
BCL3,1488,O
",",1488,O
APOC2,1488,O
),1488,O
-,1488,O
(,1488,O
CKMM,1488,O
",",1488,O
DM,1488,O
),1488,O
-,1488,O
(,1488,O
S22,1488,O
",",1488,O
+,1488,O
+,1488,O
+,1488,O
PRKCG,1488,O
),1488,O
-qter,1488,O
.,1488,O
The,1489,O
data,1489,O
presented,1489,O
here,1489,O
can,1489,O
not,1489,O
determine,1489,O
whether,1489,O
DM,1489,B-SpecificDisease
is,1489,O
proximal,1489,O
or,1489,O
distal,1489,O
to,1489,O
CKMM,1489,O
.,1489,O
The,1490,O
consequences,1490,O
of,1490,O
this,1490,O
probe,1490,O
order,1490,O
for,1490,O
antenatal,1490,O
diagnosis,1490,O
and,1490,O
future,1490,O
research,1490,O
aiming,1490,O
to,1490,O
isolate,1490,O
the,1490,O
gene,1490,O
which,1490,O
is,1490,O
affected,1490,O
in,1490,O
DM,1490,B-SpecificDisease
are,1490,O
discussed,1490,O
.,1490,O
Mutations,1491,O
in,1491,O
the,1491,O
RB1,1491,O
gene,1491,O
and,1491,O
their,1491,O
effects,1491,O
on,1491,O
transcription,1491,O
.,1491,O
Inactivation,1492,O
of,1492,O
both,1492,O
alleles,1492,O
of,1492,O
the,1492,O
RB1,1492,O
gene,1492,O
during,1492,O
normal,1492,O
retinal,1492,O
development,1492,O
initiates,1492,O
the,1492,O
formation,1492,O
of,1492,O
a,1492,O
retinoblastoma,1492,B-SpecificDisease
(,1492,I-SpecificDisease
RB,1492,I-SpecificDisease
),1492,I-SpecificDisease
tumor,1492,I-SpecificDisease
.,1492,O
To,1493,O
identify,1493,O
the,1493,O
mutations,1493,O
which,1493,O
inactivate,1493,O
RB1,1493,O
",",1493,O
21,1493,O
RB,1493,B-SpecificDisease
tumors,1493,I-SpecificDisease
isolated,1493,O
from,1493,O
19,1493,O
patients,1493,O
were,1493,O
analyzed,1493,O
with,1493,O
the,1493,O
polymerase,1493,O
chain,1493,O
reaction,1493,O
or,1493,O
an,1493,O
RNase,1493,O
protection,1493,O
assay,1493,O
or,1493,O
both,1493,O
.,1493,O
Mutations,1494,O
were,1494,O
identified,1494,O
in,1494,O
13,1494,O
of,1494,O
21,1494,O
RB,1494,B-SpecificDisease
tumors,1494,I-SpecificDisease
;,1494,O
in,1494,O
8,1494,O
tumors,1494,B-DiseaseClass
",",1494,O
the,1494,O
precise,1494,O
errors,1494,O
in,1494,O
nucleotide,1494,O
sequence,1494,O
were,1494,O
characterized,1494,O
.,1494,O
Each,1495,O
of,1495,O
four,1495,O
germ,1495,O
line,1495,O
mutations,1495,O
involved,1495,O
a,1495,O
small,1495,O
deletion,1495,O
or,1495,O
duplication,1495,O
",",1495,O
while,1495,O
three,1495,O
somatic,1495,O
mutations,1495,O
were,1495,O
point,1495,O
mutations,1495,O
leading,1495,O
to,1495,O
splice,1495,O
alterations,1495,O
and,1495,O
loss,1495,O
of,1495,O
an,1495,O
exon,1495,O
from,1495,O
the,1495,O
mature,1495,O
RB1,1495,O
mRNA,1495,O
.,1495,O
We,1496,O
were,1496,O
unable,1496,O
to,1496,O
detect,1496,O
expression,1496,O
of,1496,O
the,1496,O
mutant,1496,O
allele,1496,O
in,1496,O
lymphoblasts,1496,O
of,1496,O
three,1496,O
bilaterally,1496,O
affected,1496,O
patients,1496,O
",",1496,O
although,1496,O
the,1496,O
mutation,1496,O
was,1496,O
present,1496,O
in,1496,O
the,1496,O
genomic,1496,O
DNA,1496,O
and,1496,O
transcripts,1496,O
containing,1496,O
the,1496,O
mutations,1496,O
were,1496,O
obvious,1496,O
in,1496,O
the,1496,O
RB,1496,B-SpecificDisease
tumors,1496,I-SpecificDisease
in,1496,O
the,1496,O
absence,1496,O
of,1496,O
a,1496,O
normal,1496,O
RB1,1496,O
allele,1496,O
.,1496,O
The,1497,O
variations,1497,O
in,1497,O
the,1497,O
level,1497,O
of,1497,O
expression,1497,O
of,1497,O
mutant,1497,O
transcripts,1497,O
suggest,1497,O
deregulation,1497,O
of,1497,O
RB1,1497,O
transcription,1497,O
in,1497,O
the,1497,O
absence,1497,O
of,1497,O
a,1497,O
functional,1497,O
RB1,1497,O
gene,1497,O
product,1497,O
..,1497,O
Partial,1498,O
deletion,1498,O
8q,1498,O
without,1498,O
Langer-Giedion,1498,B-SpecificDisease
syndrome,1498,I-SpecificDisease
:,1498,O
a,1498,O
recognisable,1498,O
syndrome,1498,O
.,1498,O
We,1499,O
report,1499,O
two,1499,O
de,1499,O
novo,1499,O
cases,1499,O
of,1499,O
del,1499,O
(,1499,O
8,1499,O
),1499,O
(,1499,O
pter,1499,O
--,1499,O
--,1499,O
q24,1499,O
.,1499,O
1,1500,O
),1500,O
with,1500,O
breakpoints,1500,O
involving,1500,O
the,1500,O
distal,1500,O
part,1500,O
of,1500,O
band,1500,O
8q24,1500,O
.,1500,O
1,1501,O
1,1501,O
.,1501,O
The,1502,O
clinical,1502,O
features,1502,O
were,1502,O
similar,1502,O
and,1502,O
there,1502,O
were,1502,O
no,1502,O
obvious,1502,O
stigmata,1502,O
of,1502,O
Langer-Giedion,1502,B-SpecificDisease
syndrome,1502,I-SpecificDisease
(,1502,O
LGS,1502,B-SpecificDisease
),1502,O
.,1502,O
There,1503,O
are,1503,O
three,1503,O
other,1503,O
cases,1503,O
reported,1503,O
with,1503,O
a,1503,O
deletion,1503,O
of,1503,O
chromosome,1503,O
8,1503,O
at,1503,O
approximately,1503,O
the,1503,O
same,1503,O
breakpoint,1503,O
",",1503,O
one,1503,O
without,1503,O
LGS,1503,B-SpecificDisease
and,1503,O
some,1503,O
similarities,1503,O
to,1503,O
our,1503,O
cases,1503,O
",",1503,O
the,1503,O
other,1503,O
two,1503,O
with,1503,O
LGS,1503,B-SpecificDisease
.,1503,O
Our,1504,O
findings,1504,O
would,1504,O
support,1504,O
the,1504,O
observation,1504,O
that,1504,O
the,1504,O
critical,1504,O
segment,1504,O
for,1504,O
the,1504,O
assignment,1504,O
of,1504,O
LGS,1504,B-SpecificDisease
is,1504,O
proximal,1504,O
to,1504,O
or,1504,O
involves,1504,O
the,1504,O
proximal,1504,O
part,1504,O
of,1504,O
8q24,1504,O
.,1504,O
1,1505,O
",",1505,O
but,1505,O
a,1505,O
review,1505,O
of,1505,O
published,1505,O
reports,1505,O
suggests,1505,O
that,1505,O
the,1505,O
aetiology,1505,O
of,1505,O
LGS,1505,B-SpecificDisease
may,1505,O
be,1505,O
a,1505,O
more,1505,O
complex,1505,O
issue,1505,O
Myotonic,1506,B-SpecificDisease
dystrophy,1506,I-SpecificDisease
is,1506,O
closely,1506,O
linked,1506,O
to,1506,O
the,1506,O
gene,1506,O
for,1506,O
muscle-type,1506,O
creatine,1506,O
kinase,1506,O
(,1506,O
CKMM,1506,O
),1506,O
.,1506,O
We,1507,O
have,1507,O
studied,1507,O
genetic,1507,O
linkage,1507,O
between,1507,O
the,1507,O
gene,1507,O
for,1507,O
creatine,1507,O
kinase,1507,O
muscle,1507,O
type,1507,O
(,1507,O
CKMM,1507,O
),1507,O
and,1507,O
the,1507,O
gene,1507,O
for,1507,O
myotonic,1507,B-SpecificDisease
dystrophy,1507,I-SpecificDisease
(,1507,O
DM,1507,B-SpecificDisease
),1507,O
.,1507,O
In,1508,O
a,1508,O
panel,1508,O
of,1508,O
65,1508,O
myotonic,1508,B-Modifier
dystrophy,1508,I-Modifier
families,1508,O
from,1508,O
Canada,1508,O
and,1508,O
the,1508,O
Netherlands,1508,O
",",1508,O
a,1508,O
maximum,1508,O
lod,1508,O
score,1508,O
(,1508,O
Zmax,1508,O
),1508,O
of,1508,O
22,1508,O
.,1508,O
8,1509,O
at,1509,O
a,1509,O
recombination,1509,O
frequency,1509,O
(,1509,O
theta,1509,O
),1509,O
of,1509,O
0,1509,O
.,1509,O
03,1510,O
was,1510,O
obtained,1510,O
.,1510,O
Tight,1511,O
linkage,1511,O
was,1511,O
also,1511,O
demonstrated,1511,O
for,1511,O
CKMM,1511,O
and,1511,O
the,1511,O
gene,1511,O
for,1511,O
apolipoprotein,1511,O
C2,1511,O
(,1511,O
ApoC2,1511,O
),1511,O
.,1511,O
This,1512,O
establishes,1512,O
CKMM,1512,O
as,1512,O
a,1512,O
useful,1512,O
marker,1512,O
for,1512,O
myotonic,1512,B-SpecificDisease
dystrophy,1512,I-SpecificDisease
Color,1513,B-DiseaseClass
vision,1513,I-DiseaseClass
defects,1513,I-DiseaseClass
in,1513,O
adrenomyeloneuropathy,1513,B-SpecificDisease
.,1513,O
The,1514,O
relationship,1514,O
between,1514,O
abnormal,1514,B-DiseaseClass
color,1514,I-DiseaseClass
vision,1514,I-DiseaseClass
and,1514,O
adrenomyeloneuropathy,1514,B-SpecificDisease
(,1514,O
AMN,1514,B-SpecificDisease
),1514,O
was,1514,O
investigated,1514,O
in,1514,O
27,1514,O
AMN,1514,B-Modifier
patients,1514,O
and,1514,O
31,1514,O
age-matched,1514,O
controls,1514,O
by,1514,O
using,1514,O
the,1514,O
Farnsworth-Munsell,1514,O
100,1514,O
Hue,1514,O
test,1514,O
.,1514,O
Twelve,1515,O
(,1515,O
44,1515,O
%,1515,O
),1515,O
of,1515,O
27,1515,O
patients,1515,O
showed,1515,O
test,1515,O
scores,1515,O
significantly,1515,O
above,1515,O
normal,1515,O
.,1515,O
The,1516,O
axes,1516,O
of,1516,O
bipolarity,1516,O
determined,1516,O
by,1516,O
the,1516,O
testing,1516,O
differed,1516,O
widely,1516,O
between,1516,O
the,1516,O
patients,1516,O
with,1516,O
abnormal,1516,O
scores,1516,O
",",1516,O
compatible,1516,O
with,1516,O
the,1516,O
notion,1516,O
that,1516,O
different,1516,O
alterations,1516,O
in,1516,O
visual,1516,O
pigment,1516,O
genes,1516,O
occur,1516,O
in,1516,O
different,1516,O
AMN,1516,B-Modifier
kindreds,1516,O
.,1516,O
These,1517,O
observations,1517,O
confirm,1517,O
our,1517,O
earlier,1517,O
impression,1517,O
that,1517,O
the,1517,O
frequency,1517,O
of,1517,O
abnormal,1517,B-DiseaseClass
color,1517,I-DiseaseClass
vision,1517,I-DiseaseClass
is,1517,O
increased,1517,O
in,1517,O
these,1517,O
kindreds,1517,O
",",1517,O
and,1517,O
it,1517,O
supports,1517,O
our,1517,O
contentions,1517,O
that,1517,O
(,1517,O
1,1517,O
),1517,O
AMN,1517,B-SpecificDisease
(,1517,O
and,1517,O
its,1517,O
companion,1517,O
",",1517,O
adrenoleukodystrophy,1517,B-DiseaseClass
),1517,O
are,1517,O
very,1517,O
closely,1517,O
linked,1517,O
to,1517,O
the,1517,O
visual,1517,O
pigment,1517,O
loci,1517,O
at,1517,O
Xq28,1517,O
and,1517,O
(,1517,O
2,1517,O
),1517,O
this,1517,O
proximity,1517,O
might,1517,O
provide,1517,O
the,1517,O
opportunity,1517,O
to,1517,O
observe,1517,O
contiguous,1517,B-DiseaseClass
gene,1517,I-DiseaseClass
defects,1517,I-DiseaseClass
..,1517,O
Molecular,1518,O
analysis,1518,O
of,1518,O
a,1518,O
female,1518,O
Lesch-Nyhan,1518,B-Modifier
patient,1518,O
.,1518,O
We,1519,O
report,1519,O
the,1519,O
identification,1519,O
of,1519,O
a,1519,O
female,1519,O
patient,1519,O
with,1519,O
the,1519,O
X-linked,1519,O
recessive,1519,O
Lesch-Nyhan,1519,B-SpecificDisease
syndrome,1519,I-SpecificDisease
(,1519,O
hypoxanthine,1519,B-SpecificDisease
phosphoribosyltransferase,1519,I-SpecificDisease
[,1519,I-SpecificDisease
HPRT,1519,I-SpecificDisease
],1519,I-SpecificDisease
deficiency,1519,I-SpecificDisease
),1519,O
.,1519,O
Cytogenetic,1520,O
and,1520,O
carrier,1520,O
studies,1520,O
revealed,1520,O
structurally,1520,O
normal,1520,O
chromosomes,1520,O
for,1520,O
this,1520,O
patient,1520,O
and,1520,O
her,1520,O
parents,1520,O
and,1520,O
demonstrated,1520,O
that,1520,O
this,1520,O
mutation,1520,O
arose,1520,O
through,1520,O
a,1520,O
de,1520,O
novo,1520,O
gametic,1520,O
event,1520,O
.,1520,O
Comparison,1521,O
of,1521,O
this,1521,O
patients,1521,O
DNA,1521,O
with,1521,O
the,1521,O
DNA,1521,O
of,1521,O
her,1521,O
parents,1521,O
revealed,1521,O
that,1521,O
a,1521,O
microdeletion,1521,O
",",1521,O
which,1521,O
occurred,1521,O
within,1521,O
a,1521,O
maternal,1521,O
gamete,1521,O
and,1521,O
involved,1521,O
the,1521,O
entire,1521,O
HPRT,1521,O
gene,1521,O
",",1521,O
was,1521,O
partially,1521,O
responsible,1521,O
for,1521,O
the,1521,O
disease,1521,O
in,1521,O
this,1521,O
patient,1521,O
.,1521,O
Somatic,1522,O
cell,1522,O
hybrids,1522,O
",",1522,O
generated,1522,O
to,1522,O
separate,1522,O
maternal,1522,O
and,1522,O
paternal,1522,O
X,1522,O
chromosomes,1522,O
",",1522,O
showed,1522,O
that,1522,O
expression,1522,O
of,1522,O
two,1522,O
additional,1522,O
X-linked,1522,O
enzymes,1522,O
",",1522,O
phosphoglycerate,1522,O
kinase,1522,O
and,1522,O
glucose-6-phosphate,1522,O
dehydrogenase,1522,O
",",1522,O
were,1522,O
expressed,1522,O
only,1522,O
in,1522,O
cells,1522,O
that,1522,O
contained,1522,O
the,1522,O
maternal,1522,O
X,1522,O
chromosome,1522,O
",",1522,O
suggesting,1522,O
the,1522,O
presence,1522,O
of,1522,O
a,1522,O
functionally,1522,O
inactive,1522,O
paternal,1522,O
X,1522,O
chromosome,1522,O
.,1522,O
Furthermore,1523,O
",",1523,O
comparison,1523,O
of,1523,O
methylation,1523,O
patterns,1523,O
within,1523,O
a,1523,O
region,1523,O
of,1523,O
the,1523,O
HPRT,1523,O
gene,1523,O
known,1523,O
to,1523,O
be,1523,O
important,1523,O
in,1523,O
gene,1523,O
regulation,1523,O
revealed,1523,O
differences,1523,O
between,1523,O
DNA,1523,O
from,1523,O
the,1523,O
father,1523,O
and,1523,O
the,1523,O
patient,1523,O
",",1523,O
in,1523,O
keeping,1523,O
with,1523,O
an,1523,O
active,1523,O
HPRT,1523,O
locus,1523,O
in,1523,O
the,1523,O
father,1523,O
and,1523,O
an,1523,O
inactive,1523,O
HPRT,1523,O
locus,1523,O
in,1523,O
the,1523,O
patient,1523,O
.,1523,O
Together,1524,O
these,1524,O
data,1524,O
indicate,1524,O
that,1524,O
nonrandom,1524,O
inactivation,1524,O
of,1524,O
the,1524,O
cytogenetically,1524,O
normal,1524,O
paternal,1524,O
X,1524,O
chromosome,1524,O
and,1524,O
a,1524,O
microdeletion,1524,O
of,1524,O
the,1524,O
HPRT,1524,O
gene,1524,O
on,1524,O
an,1524,O
active,1524,O
maternal,1524,O
X,1524,O
chromosome,1524,O
were,1524,O
responsible,1524,O
for,1524,O
the,1524,O
absence,1524,O
of,1524,O
HPRT,1524,O
in,1524,O
this,1524,O
patient,1524,O
..,1524,O
Pelizaeus-Merzbacher,1525,B-SpecificDisease
disease,1525,I-SpecificDisease
:,1525,O
an,1525,O
X-linked,1525,B-DiseaseClass
neurologic,1525,I-DiseaseClass
disorder,1525,I-DiseaseClass
of,1525,I-DiseaseClass
myelin,1525,I-DiseaseClass
metabolism,1525,I-DiseaseClass
with,1525,O
a,1525,O
novel,1525,O
mutation,1525,O
in,1525,O
the,1525,O
gene,1525,O
encoding,1525,O
proteolipid,1525,O
protein,1525,O
.,1525,O
The,1526,O
nosology,1526,O
of,1526,O
the,1526,O
inborn,1526,B-DiseaseClass
errors,1526,I-DiseaseClass
of,1526,I-DiseaseClass
myelin,1526,I-DiseaseClass
metabolism,1526,I-DiseaseClass
has,1526,O
been,1526,O
stymied,1526,O
by,1526,O
the,1526,O
lack,1526,O
of,1526,O
molecular,1526,O
genetic,1526,O
analysis,1526,O
.,1526,O
Historically,1527,O
",",1527,O
Pelizaeus-Merzbacher,1527,B-SpecificDisease
disease,1527,I-SpecificDisease
has,1527,O
encompassed,1527,O
a,1527,O
host,1527,O
of,1527,O
neurologic,1527,B-DiseaseClass
disorders,1527,I-DiseaseClass
that,1527,O
present,1527,O
with,1527,O
a,1527,O
deficit,1527,B-DiseaseClass
of,1527,I-DiseaseClass
myelin,1527,I-DiseaseClass
",",1527,O
the,1527,O
membrane,1527,O
elaborated,1527,O
by,1527,O
glial,1527,O
cells,1527,O
that,1527,O
encircles,1527,O
and,1527,O
successively,1527,O
enwraps,1527,O
axons,1527,O
.,1527,O
We,1528,O
describe,1528,O
here,1528,O
a,1528,O
Pelizaeus-Merzbacher,1528,B-Modifier
pedigree,1528,O
of,1528,O
the,1528,O
classical,1528,O
type,1528,O
",",1528,O
with,1528,O
X-linked,1528,O
inheritance,1528,O
",",1528,O
a,1528,O
typical,1528,O
clinical,1528,O
progression,1528,O
",",1528,O
and,1528,O
a,1528,O
pathologic,1528,O
loss,1528,O
of,1528,O
myelinating,1528,O
cells,1528,O
and,1528,O
myelin,1528,O
in,1528,O
the,1528,O
central,1528,O
nervous,1528,O
system,1528,O
.,1528,O
To,1529,O
discriminate,1529,O
variants,1529,O
of,1529,O
Pelizaeus-Merzbacher,1529,B-SpecificDisease
disease,1529,I-SpecificDisease
",",1529,O
a,1529,O
set,1529,O
of,1529,O
oligonucleotide,1529,O
primers,1529,O
was,1529,O
constructed,1529,O
to,1529,O
polymerase-chain-reaction,1529,O
(,1529,O
PCR,1529,O
),1529,O
amplify,1529,O
and,1529,O
sequence,1529,O
the,1529,O
gene,1529,O
encoding,1529,O
proteolipid,1529,O
protein,1529,O
(,1529,O
PLP,1529,O
),1529,O
",",1529,O
a,1529,O
structural,1529,O
protein,1529,O
that,1529,O
comprises,1529,O
half,1529,O
of,1529,O
the,1529,O
protein,1529,O
of,1529,O
the,1529,O
myelin,1529,O
sheath,1529,O
.,1529,O
The,1530,O
PLP,1530,O
gene,1530,O
in,1530,O
one,1530,O
of,1530,O
two,1530,O
affected,1530,O
males,1530,O
and,1530,O
the,1530,O
carrier,1530,O
mother,1530,O
of,1530,O
this,1530,O
family,1530,O
exhibited,1530,O
a,1530,O
single,1530,O
base,1530,O
difference,1530,O
in,1530,O
the,1530,O
more,1530,O
than,1530,O
2,1530,O
kb,1530,O
of,1530,O
the,1530,O
PLP,1530,O
gene,1530,O
sequenced,1530,O
",",1530,O
a,1530,O
C,1530,O
--,1530,O
--,1530,O
T,1530,O
transition,1530,O
that,1530,O
would,1530,O
create,1530,O
a,1530,O
serine,1530,O
substitution,1530,O
for,1530,O
proline,1530,O
at,1530,O
the,1530,O
carboxy,1530,O
end,1530,O
of,1530,O
the,1530,O
protein,1530,O
.,1530,O
Our,1531,O
results,1531,O
delineate,1531,O
the,1531,O
clinical,1531,O
features,1531,O
of,1531,O
Pelizaeus-Merzbacher,1531,B-SpecificDisease
disease,1531,I-SpecificDisease
",",1531,O
define,1531,O
the,1531,O
possible,1531,O
molecular,1531,O
pathology,1531,O
of,1531,O
this,1531,O
dysmyelinating,1531,B-DiseaseClass
disorder,1531,I-DiseaseClass
",",1531,O
and,1531,O
address,1531,O
the,1531,O
molecular,1531,O
classification,1531,O
of,1531,O
inborn,1531,B-DiseaseClass
errors,1531,I-DiseaseClass
of,1531,I-DiseaseClass
myelin,1531,I-DiseaseClass
metabolism,1531,I-DiseaseClass
.,1531,O
Patients,1532,O
with,1532,O
the,1532,O
classical,1532,O
form,1532,O
(,1532,O
type,1532,O
I,1532,O
),1532,O
and,1532,O
the,1532,O
more,1532,O
severely,1532,O
affected,1532,O
",",1532,O
connatal,1532,O
variant,1532,O
of,1532,O
Pelizaeus-Merzbacher,1532,B-SpecificDisease
disease,1532,I-SpecificDisease
(,1532,I-SpecificDisease
type,1532,I-SpecificDisease
II,1532,I-SpecificDisease
),1532,I-SpecificDisease
would,1532,O
be,1532,O
predicted,1532,O
to,1532,O
display,1532,O
mutation,1532,O
at,1532,O
the,1532,O
PLP,1532,O
locus,1532,O
.,1532,O
The,1533,O
other,1533,O
variants,1533,O
(,1533,O
types,1533,O
III-VI,1533,O
),1533,O
",",1533,O
which,1533,O
have,1533,O
sometimes,1533,O
been,1533,O
categorized,1533,O
as,1533,O
Pelizaeus-Merzbacher,1533,B-SpecificDisease
disease,1533,I-SpecificDisease
",",1533,O
may,1533,O
represent,1533,O
mutations,1533,O
in,1533,O
genes,1533,O
encoding,1533,O
other,1533,O
structural,1533,O
myelin,1533,O
proteins,1533,O
or,1533,O
proteins,1533,O
critical,1533,O
to,1533,O
myelination,1533,O
..,1533,O
Molecular,1534,O
basis,1534,O
of,1534,O
human,1534,O
von,1534,B-SpecificDisease
Willebrand,1534,I-SpecificDisease
disease,1534,I-SpecificDisease
:,1534,O
analysis,1534,O
of,1534,O
platelet,1534,O
von,1534,B-Modifier
Willebrand,1534,I-Modifier
factor,1534,O
mRNA,1534,O
.,1534,O
von,1535,B-SpecificDisease
Willebrand,1535,I-SpecificDisease
disease,1535,I-SpecificDisease
(,1535,O
vWD,1535,B-SpecificDisease
),1535,O
",",1535,O
the,1535,O
most,1535,O
common,1535,O
inherited,1535,B-DiseaseClass
bleeding,1535,I-DiseaseClass
disorder,1535,I-DiseaseClass
in,1535,O
humans,1535,O
",",1535,O
can,1535,O
result,1535,O
from,1535,O
either,1535,O
a,1535,O
quantitative,1535,O
or,1535,O
a,1535,O
qualitative,1535,O
defect,1535,O
in,1535,O
the,1535,O
adhesive,1535,O
glycoprotein,1535,O
",",1535,O
von,1535,B-Modifier
Willebrand,1535,I-Modifier
factor,1535,O
(,1535,O
vWF,1535,O
),1535,O
.,1535,O
Molecular,1536,O
studies,1536,O
of,1536,O
vWD,1536,B-SpecificDisease
have,1536,O
been,1536,O
limited,1536,O
by,1536,O
the,1536,O
large,1536,O
size,1536,O
of,1536,O
the,1536,O
vWF,1536,O
gene,1536,O
and,1536,O
difficulty,1536,O
in,1536,O
obtaining,1536,O
the,1536,O
vWF,1536,O
mRNA,1536,O
from,1536,O
patients,1536,O
.,1536,O
By,1537,O
use,1537,O
of,1537,O
an,1537,O
adaptation,1537,O
of,1537,O
the,1537,O
polymerase,1537,O
chain,1537,O
reaction,1537,O
",",1537,O
vWF,1537,O
mRNA,1537,O
was,1537,O
amplified,1537,O
and,1537,O
sequenced,1537,O
from,1537,O
peripheral,1537,O
blood,1537,O
platelets,1537,O
.,1537,O
A,1538,O
silent,1538,O
vWF,1538,O
allele,1538,O
was,1538,O
identified,1538,O
",",1538,O
resulting,1538,O
from,1538,O
a,1538,O
cis,1538,O
defect,1538,O
in,1538,O
vWF,1538,O
mRNA,1538,O
transcription,1538,O
or,1538,O
processing,1538,O
.,1538,O
In,1539,O
two,1539,O
type,1539,B-Modifier
IIA,1539,I-Modifier
vWD,1539,I-Modifier
patients,1539,O
",",1539,O
two,1539,O
different,1539,O
but,1539,O
adjacent,1539,O
missense,1539,O
mutations,1539,O
were,1539,O
identified,1539,O
",",1539,O
the,1539,O
locations,1539,O
of,1539,O
which,1539,O
may,1539,O
identify,1539,O
an,1539,O
important,1539,O
vWF,1539,O
functional,1539,O
domain,1539,O
.,1539,O
Expression,1540,O
in,1540,O
heterologous,1540,O
cells,1540,O
of,1540,O
recombinant,1540,O
vWF,1540,O
containing,1540,O
one,1540,O
of,1540,O
these,1540,O
latter,1540,O
mutations,1540,O
reproduced,1540,O
the,1540,O
characteristic,1540,O
structural,1540,O
abnormality,1540,O
seen,1540,O
in,1540,O
type,1540,B-Modifier
IIA,1540,I-Modifier
vWD,1540,I-Modifier
plasma,1540,O
..,1540,O
Familial,1541,B-SpecificDisease
deficiency,1541,I-SpecificDisease
of,1541,I-SpecificDisease
the,1541,I-SpecificDisease
seventh,1541,I-SpecificDisease
component,1541,I-SpecificDisease
of,1541,I-SpecificDisease
complement,1541,I-SpecificDisease
associated,1541,O
with,1541,O
recurrent,1541,O
meningococcal,1541,B-SpecificDisease
infections,1541,I-SpecificDisease
.,1541,O
We,1542,O
describe,1542,O
an,1542,O
11-year-old,1542,O
girl,1542,O
suffering,1542,O
from,1542,O
recurrent,1542,B-SpecificDisease
meningitis,1542,I-SpecificDisease
with,1542,O
a,1542,O
complete,1542,O
absence,1542,B-SpecificDisease
of,1542,I-SpecificDisease
the,1542,I-SpecificDisease
seventh,1542,I-SpecificDisease
component,1542,I-SpecificDisease
of,1542,I-SpecificDisease
complement,1542,O
(,1542,O
C7,1542,O
),1542,O
.,1542,O
Diagnosis,1543,O
was,1543,O
established,1543,O
by,1543,O
haemolytic,1543,O
titration,1543,O
and,1543,O
western,1543,O
blotting,1543,O
.,1543,O
The,1544,O
patients,1544,O
serum,1544,O
lacked,1544,O
the,1544,O
85,1544,O
kDa,1544,O
C7,1544,O
chain,1544,O
.,1544,O
Haemolytic,1545,O
activity,1545,O
of,1545,O
serum,1545,O
was,1545,O
reconstituted,1545,O
with,1545,O
either,1545,O
pooled,1545,O
normal,1545,O
human,1545,O
serum,1545,O
or,1545,O
with,1545,O
purified,1545,O
C7,1545,O
.,1545,O
The,1546,O
relatives,1546,O
(,1546,O
parents,1546,O
and,1546,O
one,1546,O
sister,1546,O
),1546,O
had,1546,O
half-normal,1546,O
levels,1546,O
of,1546,O
both,1546,O
immunochemically,1546,O
and,1546,O
functionally,1546,O
determined,1546,O
C7,1546,O
",",1546,O
indicating,1546,O
a,1546,O
heterozygous,1546,O
state,1546,O
for,1546,O
C7,1546,B-SpecificDisease
deficiency,1546,I-SpecificDisease
..,1546,O
Translocation,1547,O
t,1547,O
(,1547,O
5,1547,O
;,1547,O
11,1547,O
),1547,O
(,1547,O
q13.1,1547,O
;,1547,O
p13,1547,O
),1547,O
associated,1547,O
with,1547,O
familial,1547,O
isolated,1547,B-SpecificDisease
aniridia,1547,I-SpecificDisease
.,1547,O
A,1548,O
father,1548,O
and,1548,O
daughter,1548,O
with,1548,O
isolated,1548,B-SpecificDisease
aniridia,1548,I-SpecificDisease
were,1548,O
observed,1548,O
to,1548,O
have,1548,O
an,1548,O
apparently,1548,O
balanced,1548,O
",",1548,O
reciprocal,1548,O
translocation,1548,O
involving,1548,O
chromosomes,1548,O
5,1548,O
and,1548,O
11,1548,O
[,1548,O
t,1548,O
(,1548,O
5,1548,O
;,1548,O
11,1548,O
),1548,O
(,1548,O
q13,1548,O
.,1548,O
1,1549,O
;,1549,O
p13,1549,O
),1549,O
],1549,O
.,1549,O
No,1550,O
other,1550,O
clinical,1550,O
characteristics,1550,O
often,1550,O
associated,1550,O
with,1550,O
the,1550,O
deletion,1550,O
of,1550,O
11p13,1550,O
were,1550,O
observed,1550,O
in,1550,O
this,1550,O
family,1550,O
.,1550,O
This,1551,O
finding,1551,O
",",1551,O
in,1551,O
association,1551,O
with,1551,O
3,1551,O
other,1551,O
instances,1551,O
of,1551,O
single,1551,O
breaks,1551,O
at,1551,O
11p13,1551,O
and,1551,O
aniridia,1551,B-SpecificDisease
",",1551,O
supports,1551,O
the,1551,O
assignment,1551,O
of,1551,O
AN2,1551,O
to,1551,O
11p13,1551,O
.,1551,O
Homozygous,1552,B-SpecificDisease
hypobetalipoproteinemia,1552,I-SpecificDisease
:,1552,O
a,1552,O
disease,1552,O
distinct,1552,O
from,1552,O
abetalipoproproteinemia,1552,B-SpecificDisease
at,1552,O
the,1552,O
molecular,1552,O
level,1552,O
.,1552,O
apoB,1553,O
DNA,1553,O
",",1553,O
RNA,1553,O
",",1553,O
and,1553,O
protein,1553,O
from,1553,O
two,1553,O
patients,1553,O
with,1553,O
homozygous,1553,B-SpecificDisease
hypobetalipoproteinemia,1553,I-SpecificDisease
(,1553,O
HBL,1553,B-SpecificDisease
),1553,O
were,1553,O
evaluated,1553,O
and,1553,O
compared,1553,O
with,1553,O
normal,1553,O
individuals,1553,O
.,1553,O
Southern,1554,O
blot,1554,O
analysis,1554,O
with,1554,O
10,1554,O
different,1554,O
cDNA,1554,O
probes,1554,O
revealed,1554,O
a,1554,O
normal,1554,O
gene,1554,O
without,1554,O
major,1554,O
insertions,1554,O
",",1554,O
deletions,1554,O
",",1554,O
or,1554,O
rearrangements,1554,O
.,1554,O
Northern,1555,O
and,1555,O
slot,1555,O
blot,1555,O
analyses,1555,O
of,1555,O
total,1555,O
liver,1555,O
mRNA,1555,O
from,1555,O
HBL,1555,B-Modifier
patients,1555,O
documented,1555,O
a,1555,O
normal,1555,O
size,1555,O
apoB,1555,O
mRNA,1555,O
that,1555,O
was,1555,O
present,1555,O
in,1555,O
greatly,1555,O
reduced,1555,O
quantities,1555,O
.,1555,O
ApoB,1556,O
protein,1556,O
was,1556,O
detected,1556,O
within,1556,O
HBL,1556,B-Modifier
hepatocytes,1556,O
utilizing,1556,O
immunohistochemical,1556,O
techniques,1556,O
;,1556,O
however,1556,O
",",1556,O
it,1556,O
was,1556,O
markedly,1556,O
reduced,1556,O
in,1556,O
quantity,1556,O
when,1556,O
compared,1556,O
with,1556,O
control,1556,O
samples,1556,O
.,1556,O
No,1557,O
apoB,1557,O
was,1557,O
detectable,1557,O
in,1557,O
the,1557,O
plasma,1557,O
of,1557,O
HBL,1557,B-Modifier
individuals,1557,O
with,1557,O
an,1557,O
ELISA,1557,O
assay,1557,O
.,1557,O
These,1558,O
data,1558,O
are,1558,O
most,1558,O
consistent,1558,O
with,1558,O
a,1558,O
mutation,1558,O
in,1558,O
the,1558,O
coding,1558,O
portion,1558,O
of,1558,O
the,1558,O
apoB,1558,O
gene,1558,O
in,1558,O
HBL,1558,B-Modifier
patients,1558,O
",",1558,O
leading,1558,O
to,1558,O
an,1558,O
abnormal,1558,O
apoB,1558,O
protein,1558,O
and,1558,O
apoB,1558,O
mRNA,1558,O
instability,1558,O
.,1558,O
These,1559,O
results,1559,O
are,1559,O
distinct,1559,O
from,1559,O
those,1559,O
previously,1559,O
noted,1559,O
in,1559,O
abetalipoproteinemia,1559,B-SpecificDisease
",",1559,O
which,1559,O
was,1559,O
characterized,1559,O
by,1559,O
an,1559,O
elevated,1559,O
level,1559,O
of,1559,O
hepatic,1559,O
apoB,1559,O
mRNA,1559,O
and,1559,O
accumulation,1559,O
of,1559,O
intracellular,1559,O
hepatic,1559,O
apoB,1559,O
protein,1559,O
..,1559,O
Spontaneous,1560,O
reversion,1560,O
of,1560,O
novel,1560,O
Lesch-Nyhan,1560,B-Modifier
mutation,1560,O
by,1560,O
HPRT,1560,O
gene,1560,O
rearrangement,1560,O
.,1560,O
Molecular,1561,O
analysis,1561,O
of,1561,O
an,1561,O
unusual,1561,O
patient,1561,O
with,1561,O
the,1561,O
Lesch-Nyhan,1561,B-SpecificDisease
syndrome,1561,I-SpecificDisease
has,1561,O
suggested,1561,O
that,1561,O
the,1561,O
mutation,1561,O
is,1561,O
due,1561,O
to,1561,O
a,1561,O
partial,1561,O
HPRT,1561,O
gene,1561,O
duplication,1561,O
.,1561,O
We,1562,O
now,1562,O
report,1562,O
the,1562,O
cloning,1562,O
and,1562,O
sequencing,1562,O
of,1562,O
the,1562,O
mutant,1562,O
HPRT,1562,O
cDNA,1562,O
which,1562,O
shows,1562,O
the,1562,O
precise,1562,O
duplication,1562,O
of,1562,O
exons,1562,O
2,1562,O
and,1562,O
3,1562,O
.,1562,O
This,1563,O
mutation,1563,O
is,1563,O
the,1563,O
result,1563,O
of,1563,O
an,1563,O
internal,1563,O
duplication,1563,O
of,1563,O
16-20,1563,O
kilobases,1563,O
of,1563,O
the,1563,O
gene,1563,O
.,1563,O
The,1564,O
structure,1564,O
of,1564,O
the,1564,O
mutant,1564,O
gene,1564,O
suggests,1564,O
that,1564,O
the,1564,O
duplication,1564,O
was,1564,O
not,1564,O
generated,1564,O
by,1564,O
a,1564,O
single,1564,O
unequal,1564,O
crossing-over,1564,O
event,1564,O
between,1564,O
two,1564,O
normal,1564,O
HPRT,1564,O
alleles,1564,O
.,1564,O
Growth,1565,O
of,1565,O
Epstein-Barr,1565,B-Modifier
virus-transformed,1565,O
lymphoblasts,1565,O
from,1565,O
this,1565,O
patient,1565,O
in,1565,O
selective,1565,O
medium,1565,O
has,1565,O
permitted,1565,O
isolation,1565,O
of,1565,O
spontaneous,1565,O
HPRT,1565,O
+,1565,O
revertants,1565,O
of,1565,O
this,1565,O
mutation,1565,O
.,1565,O
The,1566,O
reversion,1566,O
event,1566,O
involves,1566,O
a,1566,O
second,1566,O
major,1566,O
HPRT,1566,O
gene,1566,O
rearrangement,1566,O
where,1566,O
most,1566,O
or,1566,O
all,1566,O
of,1566,O
the,1566,O
duplicated,1566,O
portion,1566,O
of,1566,O
the,1566,O
mutant,1566,O
gene,1566,O
is,1566,O
deleted,1566,O
.,1566,O
The,1567,O
original,1567,O
mutation,1567,O
therefore,1567,O
has,1567,O
the,1567,O
potential,1567,O
for,1567,O
spontaneous,1567,O
somatic,1567,O
reversion,1567,O
.,1567,O
This,1568,O
may,1568,O
explain,1568,O
the,1568,O
relatively,1568,O
mild,1568,O
symptoms,1568,O
of,1568,O
the,1568,O
Lesch-Nyhan,1568,B-SpecificDisease
syndrome,1568,I-SpecificDisease
exhibited,1568,O
by,1568,O
this,1568,O
patient,1568,O
..,1568,O
Complex,1569,B-SpecificDisease
glycerol,1569,I-SpecificDisease
kinase,1569,I-SpecificDisease
deficiency,1569,I-SpecificDisease
:,1569,O
molecular-genetic,1569,O
",",1569,O
cytogenetic,1569,O
",",1569,O
and,1569,O
clinical,1569,O
studies,1569,O
of,1569,O
five,1569,O
Japanese,1569,O
patients,1569,O
.,1569,O
Five,1570,O
male,1570,O
Japanese,1570,O
patients,1570,O
with,1570,O
complex,1570,B-SpecificDisease
glycerol,1570,I-SpecificDisease
kinase,1570,I-SpecificDisease
deficiency,1570,I-SpecificDisease
(,1570,O
CGKD,1570,B-SpecificDisease
),1570,O
and,1570,O
their,1570,O
relatives,1570,O
were,1570,O
studied,1570,O
clinically,1570,O
",",1570,O
cytogenetically,1570,O
",",1570,O
and,1570,O
molecular-genetically,1570,O
.,1570,O
All,1571,O
patients,1571,O
had,1571,O
muscular,1571,B-DiseaseClass
dystrophy,1571,I-DiseaseClass
or,1571,O
muscle,1571,B-DiseaseClass
weakness,1571,I-DiseaseClass
",",1571,O
mental,1571,B-DiseaseClass
retardation,1571,I-DiseaseClass
",",1571,O
congenital,1571,B-SpecificDisease
adrenal,1571,I-SpecificDisease
hypoplasia,1571,I-SpecificDisease
",",1571,O
and,1571,O
glycerol,1571,B-DiseaseClass
kinase,1571,I-DiseaseClass
deficiency,1571,I-DiseaseClass
.,1571,O
High-resolution,1572,O
GTG-banded,1572,O
chromosomes,1572,O
showed,1572,O
a,1572,O
microdeletion,1572,O
in,1572,O
the,1572,O
Xp21,1572,O
region,1572,O
in,1572,O
all,1572,O
four,1572,O
patients,1572,O
examined,1572,O
and,1572,O
in,1572,O
all,1572,O
five,1572,O
mothers,1572,O
.,1572,O
Southern,1573,O
hybridizations,1573,O
",",1573,O
after,1573,O
digestions,1573,O
by,1573,O
restriction,1573,O
endonucleases,1573,O
",",1573,O
with,1573,O
various,1573,O
cloned,1573,O
DNAs,1573,O
(,1573,O
D2,1573,O
",",1573,O
99-6,1573,O
",",1573,O
B24,1573,O
",",1573,O
C7,1573,O
",",1573,O
L1-4,1573,O
",",1573,O
cDMD13-14,1573,O
",",1573,O
J66-HI,1573,O
",",1573,O
P20,1573,O
",",1573,O
J-Bir,1573,O
",",1573,O
ERT87-30,1573,O
",",1573,O
ERT87-15,1573,O
",",1573,O
ERT87-8,1573,O
",",1573,O
ERT87-1,1573,O
",",1573,O
XJ-1,1573,O
.,1573,O
1,1574,O
",",1574,O
754,1574,O
",",1574,O
cx5,1574,O
.,1574,O
7,1575,O
",",1575,O
and,1575,O
OTC-1,1575,O
),1575,O
that,1575,O
are,1575,O
located,1575,O
around,1575,O
Xp21,1575,O
also,1575,O
showed,1575,O
a,1575,O
deletion,1575,O
in,1575,O
the,1575,O
genome,1575,O
of,1575,O
all,1575,O
patients,1575,O
and,1575,O
mothers,1575,O
.,1575,O
Although,1576,O
the,1576,O
deletion,1576,O
differed,1576,O
in,1576,O
size,1576,O
among,1576,O
patients,1576,O
",",1576,O
a,1576,O
segment,1576,O
commonly,1576,O
absent,1576,O
was,1576,O
located,1576,O
between,1576,O
the,1576,O
genomic,1576,O
sequences,1576,O
corresponding,1576,O
to,1576,O
L1-4,1576,O
and,1576,O
cDMD13-14,1576,O
.,1576,O
This,1577,O
finding,1577,O
indicated,1577,O
that,1577,O
the,1577,O
gene,1577,O
coding,1577,O
for,1577,O
glycerol,1577,O
kinase,1577,O
(,1577,O
GK,1577,O
),1577,O
is,1577,O
located,1577,O
within,1577,O
this,1577,O
segment,1577,O
.,1577,O
A,1578,O
comparison,1578,O
of,1578,O
the,1578,O
clinical,1578,O
manifestations,1578,O
of,1578,O
the,1578,O
present,1578,O
five,1578,O
patients,1578,O
and,1578,O
reported,1578,O
CGKD,1578,B-Modifier
or,1578,O
Duchenne,1578,B-Modifier
muscular,1578,I-Modifier
dystrophy,1578,I-Modifier
(,1578,O
DMD,1578,B-Modifier
),1578,O
patients,1578,O
with,1578,O
DNA,1578,O
deletion,1578,O
suggests,1578,O
the,1578,O
existence,1578,O
of,1578,O
a,1578,O
certain,1578,O
gene,1578,O
responsible,1578,O
for,1578,O
gonadotropin,1578,B-SpecificDisease
deficiency,1578,I-SpecificDisease
(,1578,O
GTD,1578,B-SpecificDisease
),1578,O
.,1578,O
The,1579,O
result,1579,O
of,1579,O
the,1579,O
present,1579,O
study,1579,O
and,1579,O
results,1579,O
of,1579,O
previous,1579,O
studies,1579,O
suggest,1579,O
that,1579,O
genes,1579,O
for,1579,O
ornithine,1579,O
transcarbamylase,1579,O
(,1579,O
OTC,1579,O
),1579,O
",",1579,O
DMD,1579,B-SpecificDisease
",",1579,O
and,1579,O
GK,1579,O
and,1579,O
putative,1579,O
genes,1579,O
responsible,1579,O
for,1579,O
congenital,1579,B-SpecificDisease
adrenal,1579,I-SpecificDisease
hypoplasia,1579,I-SpecificDisease
(,1579,O
AHC,1579,B-SpecificDisease
),1579,O
and,1579,O
GTD,1579,B-SpecificDisease
are,1579,O
arranged,1579,O
from,1579,O
telomere,1579,O
to,1579,O
centromere,1579,O
as,1579,O
pter,1579,O
--,1579,O
GTD,1579,O
--,1579,O
AHC,1579,O
--,1579,O
GK,1579,O
--,1579,O
DMD,1579,O
--,1579,O
OTC,1579,O
--,1579,O
cen,1579,O
Genetically,1580,O
determined,1580,O
low,1580,O
C4,1580,O
:,1580,O
a,1580,O
predisposing,1580,O
factor,1580,O
to,1580,O
autoimmune,1580,B-SpecificDisease
chronic,1580,I-SpecificDisease
active,1580,I-SpecificDisease
hepatitis,1580,I-SpecificDisease
.,1580,O
Of,1581,O
26,1581,O
patients,1581,O
with,1581,O
autoimmune,1581,B-SpecificDisease
chronic,1581,I-SpecificDisease
active,1581,I-SpecificDisease
hepatitis,1581,I-SpecificDisease
(,1581,O
CAH,1581,B-SpecificDisease
),1581,O
starting,1581,O
in,1581,O
childhood,1581,O
18,1581,O
(,1581,O
69,1581,O
%,1581,O
),1581,O
had,1581,O
low,1581,O
C4,1581,O
and,1581,O
5,1581,O
(,1581,O
19,1581,O
%,1581,O
),1581,O
had,1581,O
low,1581,O
C3,1581,O
serum,1581,O
levels,1581,O
.,1581,O
Impaired,1582,O
hepatic,1582,O
synthesis,1582,O
and,1582,O
immune-consumption,1582,O
were,1582,O
unlikely,1582,O
since,1582,O
transferrin,1582,O
levels,1582,O
were,1582,O
normal,1582,O
in,1582,O
all,1582,O
patients,1582,O
",",1582,O
albumin,1582,O
levels,1582,O
were,1582,O
persistently,1582,O
low,1582,O
in,1582,O
only,1582,O
3,1582,O
",",1582,O
and,1582,O
only,1582,O
3,1582,O
had,1582,O
raised,1582,O
levels,1582,O
of,1582,O
activation,1582,O
fragment,1582,O
C3d,1582,O
.,1582,O
C4d,1583,O
was,1583,O
normal,1583,O
in,1583,O
all,1583,O
patients,1583,O
studied,1583,O
.,1583,O
In,1584,O
the,1584,O
families,1584,O
of,1584,O
12,1584,O
probands,1584,O
with,1584,O
low,1584,O
C4,1584,O
",",1584,O
7,1584,O
parents,1584,O
had,1584,O
low,1584,O
C4,1584,O
and,1584,O
2,1584,O
had,1584,O
levels,1584,O
which,1584,O
were,1584,O
at,1584,O
the,1584,O
lower,1584,O
limit,1584,O
of,1584,O
normal,1584,O
.,1584,O
5,1585,O
of,1585,O
10,1585,O
siblings,1585,O
from,1585,O
5,1585,O
families,1585,O
had,1585,O
low,1585,O
C4,1585,O
.,1585,O
These,1586,O
results,1586,O
suggest,1586,O
that,1586,O
low,1586,O
C4,1586,O
levels,1586,O
in,1586,O
CAH,1586,B-SpecificDisease
are,1586,O
genetically,1586,O
determined,1586,O
.,1586,O
C4,1587,O
phenotyping,1587,O
in,1587,O
20,1587,O
patients,1587,O
and,1587,O
in,1587,O
26,1587,O
parents,1587,O
showed,1587,O
that,1587,O
90,1587,O
%,1587,O
and,1587,O
81,1587,O
%,1587,O
",",1587,O
respectively,1587,O
",",1587,O
had,1587,O
null,1587,O
allotypes,1587,O
at,1587,O
either,1587,O
the,1587,O
C4A,1587,O
or,1587,O
C4B,1587,O
locus,1587,O
compared,1587,O
with,1587,O
59,1587,O
%,1587,O
in,1587,O
controls,1587,O
",",1587,O
indicating,1587,O
that,1587,O
defective,1587,O
expression,1587,O
of,1587,O
structural,1587,O
genes,1587,O
may,1587,O
contribute,1587,O
to,1587,O
the,1587,O
observed,1587,O
C4,1587,B-SpecificDisease
deficiency,1587,I-SpecificDisease
..,1587,O
An,1588,O
amino-acid,1588,O
substitution,1588,O
involved,1588,O
in,1588,O
phenylketonuria,1588,B-SpecificDisease
is,1588,O
in,1588,O
linkage,1588,O
disequilibrium,1588,O
with,1588,O
DNA,1588,O
haplotype,1588,O
2,1588,O
.,1588,O
Phenylketonuria,1589,B-SpecificDisease
(,1589,O
PKU,1589,B-SpecificDisease
),1589,O
is,1589,O
an,1589,O
autosomal,1589,B-DiseaseClass
recessive,1589,I-DiseaseClass
human,1589,I-DiseaseClass
genetic,1589,I-DiseaseClass
disorder,1589,I-DiseaseClass
caused,1589,O
by,1589,O
a,1589,O
deficiency,1589,B-SpecificDisease
of,1589,I-SpecificDisease
hepatic,1589,I-SpecificDisease
phenylalanine,1589,I-SpecificDisease
hydroxylase,1589,I-SpecificDisease
(,1589,O
PAH,1589,O
",",1589,O
phenylalanine,1589,O
4-monooxygenase,1589,O
",",1589,O
EC,1589,O
1,1589,O
.,1589,O
14,1590,O
.,1590,O
16,1591,O
.,1591,O
1,1592,O
),1592,O
.,1592,O
PKU,1593,B-SpecificDisease
is,1593,O
a,1593,O
common,1593,O
inborn,1593,B-DiseaseClass
error,1593,I-DiseaseClass
of,1593,I-DiseaseClass
amino-acid,1593,I-DiseaseClass
metabolism,1593,I-DiseaseClass
in,1593,O
caucasian,1593,O
populations,1593,O
and,1593,O
approximately,1593,O
1,1593,O
in,1593,O
50,1593,O
individuals,1593,O
are,1593,O
carriers,1593,O
of,1593,O
a,1593,O
PKU,1593,B-Modifier
allele,1593,O
.,1593,O
To,1594,O
define,1594,O
the,1594,O
molecular,1594,O
basis,1594,O
of,1594,O
PKU,1594,B-SpecificDisease
",",1594,O
we,1594,O
characterized,1594,O
twelve,1594,O
restriction,1594,O
fragment-length,1594,O
polymorphism,1594,O
(,1594,O
RFLP,1594,O
),1594,O
haplotypes,1594,O
of,1594,O
the,1594,O
PAH,1594,O
locus,1594,O
in,1594,O
the,1594,O
northern,1594,O
European,1594,O
population,1594,O
and,1594,O
observed,1594,O
that,1594,O
90,1594,O
%,1594,O
of,1594,O
the,1594,O
PKU,1594,B-Modifier
alleles,1594,O
in,1594,O
this,1594,O
population,1594,O
are,1594,O
confined,1594,O
to,1594,O
four,1594,O
common,1594,O
RFLP,1594,O
haplotypes,1594,O
.,1594,O
We,1595,O
have,1595,O
recently,1595,O
reported,1595,O
a,1595,O
splicing,1595,O
mutation,1595,O
in,1595,O
the,1595,O
PAH,1595,O
gene,1595,O
that,1595,O
is,1595,O
associated,1595,O
with,1595,O
RFLP,1595,O
haplotype,1595,O
3,1595,O
which,1595,O
is,1595,O
present,1595,O
at,1595,O
about,1595,O
40,1595,O
%,1595,O
of,1595,O
mutant,1595,O
alleles,1595,O
.,1595,O
We,1596,O
now,1596,O
report,1596,O
the,1596,O
molecular,1596,B-DiseaseClass
lesion,1596,I-DiseaseClass
associated,1596,O
with,1596,O
the,1596,O
RFLP,1596,O
haplotype,1596,O
2,1596,O
mutant,1596,O
allele,1596,O
.,1596,O
This,1597,O
defect,1597,O
is,1597,O
caused,1597,O
by,1597,O
a,1597,O
C-to-T,1597,O
transition,1597,O
in,1597,O
exon,1597,O
12,1597,O
resulting,1597,O
in,1597,O
an,1597,O
amino-acid,1597,O
substitution,1597,O
(,1597,O
Arg,1597,O
to,1597,O
Trp,1597,O
),1597,O
at,1597,O
residue,1597,O
408,1597,O
of,1597,O
PAH,1597,O
.,1597,O
Direct,1598,O
hybridization,1598,O
analysis,1598,O
of,1598,O
the,1598,O
point,1598,O
mutation,1598,O
using,1598,O
a,1598,O
specific,1598,O
oligonucleotide,1598,O
probe,1598,O
demonstrated,1598,O
that,1598,O
this,1598,O
mutation,1598,O
is,1598,O
also,1598,O
in,1598,O
linkage,1598,O
disequilibrium,1598,O
with,1598,O
RFLP,1598,O
haplotype,1598,O
2,1598,O
alleles,1598,O
that,1598,O
make,1598,O
up,1598,O
about,1598,O
20,1598,O
%,1598,O
of,1598,O
mutant,1598,O
PAH,1598,O
genes,1598,O
Choroideremia,1599,B-SpecificDisease
:,1599,O
close,1599,O
linkage,1599,O
to,1599,O
DXYS1,1599,O
and,1599,O
DXYS12,1599,O
demonstrated,1599,O
by,1599,O
segregation,1599,O
analysis,1599,O
and,1599,O
historical-genealogical,1599,O
evidence,1599,O
.,1599,O
Linkage,1600,O
studies,1600,O
using,1600,O
restriction,1600,O
fragment,1600,O
length,1600,O
polymorphisms,1600,O
were,1600,O
conducted,1600,O
in,1600,O
the,1600,O
X-linked,1600,B-DiseaseClass
disorder,1600,I-DiseaseClass
",",1600,O
choroideremia,1600,B-SpecificDisease
",",1600,O
designated,1600,O
TCD,1600,B-SpecificDisease
for,1600,O
Progressive,1600,B-SpecificDisease
Tapeto-Choroidal,1600,I-SpecificDisease
Dystrophy,1600,I-SpecificDisease
.,1600,O
Previously,1601,O
demonstrated,1601,O
close,1601,O
linkage,1601,O
with,1601,O
locus,1601,O
DXYS1,1601,O
was,1601,O
confirmed,1601,O
(,1601,O
lod,1601,O
11,1601,O
.,1601,O
44,1602,O
at,1602,O
0,1602,O
recombination,1602,O
distance,1602,O
),1602,O
.,1602,O
In,1603,O
addition,1603,O
",",1603,O
locus,1603,O
DXYS12,1603,O
was,1603,O
found,1603,O
to,1603,O
be,1603,O
closely,1603,O
linked,1603,O
with,1603,O
TCD,1603,B-SpecificDisease
(,1603,O
lod,1603,O
3,1603,O
.,1603,O
31,1604,O
at,1604,O
0,1604,O
recombination,1604,O
distance,1604,O
),1604,O
.,1604,O
The,1605,O
disease,1605,O
mainly,1605,O
occurs,1605,O
in,1605,O
three,1605,O
large,1605,O
kindreds,1605,O
in,1605,O
remote,1605,O
Northern,1605,O
Finland,1605,O
.,1605,O
While,1606,O
formal,1606,O
genealogical,1606,O
proof,1606,O
is,1606,O
lacking,1606,O
",",1606,O
all,1606,O
presently,1606,O
living,1606,O
(,1606,O
more,1606,O
than,1606,O
80,1606,O
affected,1606,O
males,1606,O
and,1606,O
120,1606,O
carrier,1606,O
females,1606,O
),1606,O
probably,1606,O
originate,1606,O
from,1606,O
a,1606,O
common,1606,O
founder,1606,O
couple,1606,O
born,1606,O
in,1606,O
1644,1606,O
and,1606,O
1646,1606,O
",",1606,O
twelve,1606,O
generations,1606,O
ago,1606,O
.,1606,O
All,1607,O
36,1607,O
patients,1607,O
and,1607,O
48,1607,O
carriers,1607,O
tested,1607,O
from,1607,O
the,1607,O
three,1607,O
kindreds,1607,O
had,1607,O
the,1607,O
same,1607,O
haplotype,1607,O
(,1607,O
TCD/DXYS1,1607,B-SpecificDisease
",",1607,O
11kb/DXYS12,1607,O
",",1607,O
1,1607,O
.,1607,O
6kb,1608,O
),1608,O
.,1608,O
Given,1609,O
that,1609,O
at,1609,O
least,1609,O
105,1609,O
female,1609,O
meioses,1609,O
transmitting,1609,O
TCD,1609,B-SpecificDisease
have,1609,O
occurred,1609,O
since,1609,O
1650,1609,O
in,1609,O
these,1609,O
kindreds,1609,O
",",1609,O
extremely,1609,O
close,1609,O
linkage,1609,O
between,1609,O
TCD,1609,B-SpecificDisease
",",1609,O
DXYS1,1609,O
and,1609,O
DXYS12,1609,O
is,1609,O
suggested,1609,O
.,1609,O
The,1610,O
above,1610,O
haplotype,1610,O
is,1610,O
a,1610,O
very,1610,O
useful,1610,O
diagnostic,1610,O
tool,1610,O
in,1610,O
these,1610,O
TCD,1610,B-Modifier
families,1610,O
.,1610,O
We,1611,O
suggest,1611,O
that,1611,O
our,1611,O
historical-genealogical,1611,O
approach,1611,O
to,1611,O
linkage,1611,O
analysis,1611,O
may,1611,O
be,1611,O
possible,1611,O
elsewhere,1611,O
in,1611,O
similar,1611,O
isolated,1611,O
populations,1611,O
Von,1612,B-SpecificDisease
Hippel-Lindau,1612,I-SpecificDisease
disease,1612,I-SpecificDisease
maps,1612,O
to,1612,O
the,1612,O
region,1612,O
of,1612,O
chromosome,1612,O
3,1612,O
associated,1612,O
with,1612,O
renal,1612,B-SpecificDisease
cell,1612,I-SpecificDisease
carcinoma,1612,I-SpecificDisease
.,1612,O
Von,1613,B-SpecificDisease
Hippel-Lindau,1613,I-SpecificDisease
disease,1613,I-SpecificDisease
(,1613,O
VHL,1613,B-SpecificDisease
),1613,O
is,1613,O
an,1613,O
autosomal,1613,B-DiseaseClass
dominant,1613,I-DiseaseClass
disorder,1613,I-DiseaseClass
with,1613,O
inherited,1613,O
susceptibility,1613,O
to,1613,O
various,1613,O
forms,1613,O
of,1613,O
cancer,1613,B-DiseaseClass
",",1613,O
including,1613,O
hemangioblastomas,1613,B-SpecificDisease
of,1613,O
the,1613,O
central,1613,O
nervous,1613,O
system,1613,O
",",1613,O
phaeochromocytomas,1613,B-SpecificDisease
",",1613,O
pancreatic,1613,B-SpecificDisease
malignancies,1613,I-SpecificDisease
",",1613,O
and,1613,O
renal,1613,B-SpecificDisease
cell,1613,I-SpecificDisease
carcinomas,1613,I-SpecificDisease
.,1613,O
Renal,1614,B-SpecificDisease
cell,1614,I-SpecificDisease
carcinomas,1614,I-SpecificDisease
constitute,1614,O
a,1614,O
particularly,1614,O
frequent,1614,O
cause,1614,O
of,1614,O
death,1614,O
in,1614,O
this,1614,O
disorder,1614,O
",",1614,O
occurring,1614,O
as,1614,O
bilateral,1614,B-CompositeMention
and,1614,I-CompositeMention
multifocal,1614,I-CompositeMention
tumours,1614,I-CompositeMention
",",1614,O
and,1614,O
presenting,1614,O
at,1614,O
an,1614,O
earlier,1614,O
age,1614,O
than,1614,O
in,1614,O
sporadic,1614,O
",",1614,O
non-familial,1614,O
cases,1614,O
of,1614,O
this,1614,O
tumour,1614,B-Modifier
type,1614,O
.,1614,O
We,1615,O
report,1615,O
here,1615,O
that,1615,O
the,1615,O
VHL,1615,B-Modifier
gene,1615,O
is,1615,O
linked,1615,O
to,1615,O
the,1615,O
locus,1615,O
encoding,1615,O
the,1615,O
human,1615,O
homologoue,1615,O
of,1615,O
the,1615,O
RAF1,1615,O
oncogene,1615,O
",",1615,O
which,1615,O
maps,1615,O
to,1615,O
chromosome,1615,O
3p25,1615,O
(,1615,O
ref,1615,O
.,1615,O
4,1616,O
),1616,O
.,1616,O
Crossovers,1617,O
with,1617,O
the,1617,O
VHL,1617,B-Modifier
locus,1617,O
suggest,1617,O
that,1617,O
the,1617,O
defect,1617,O
responsible,1617,O
for,1617,O
the,1617,O
VHL,1617,B-Modifier
phenotype,1617,O
is,1617,O
not,1617,O
a,1617,O
mutation,1617,O
in,1617,O
the,1617,O
RAF1,1617,O
gene,1617,O
itself,1617,O
.,1617,O
An,1618,O
alternative,1618,O
or,1618,O
prior,1618,O
event,1618,O
to,1618,O
oncogene,1618,O
activation,1618,O
in,1618,O
tumour,1618,B-Modifier
formation,1618,O
may,1618,O
be,1618,O
the,1618,O
inactivation,1618,O
of,1618,O
a,1618,O
putative,1618,O
tumour,1618,B-Modifier
suppressor,1618,O
which,1618,O
can,1618,O
be,1618,O
associated,1618,O
with,1618,O
both,1618,O
the,1618,O
inherited,1618,B-CompositeMention
and,1618,I-CompositeMention
sporadic,1618,I-CompositeMention
forms,1618,I-CompositeMention
of,1618,I-CompositeMention
the,1618,I-CompositeMention
cancer,1618,I-CompositeMention
.,1618,O
Sporadic,1619,B-SpecificDisease
renal,1619,I-SpecificDisease
cell,1619,I-SpecificDisease
carcinomas,1619,I-SpecificDisease
have,1619,O
previously,1619,O
been,1619,O
associated,1619,O
with,1619,O
the,1619,O
loss,1619,O
of,1619,O
regions,1619,O
on,1619,O
chromosome,1619,O
3p,1619,O
(,1619,O
refs,1619,O
5,1619,O
",",1619,O
6,1619,O
),1619,O
.,1619,O
Consequently,1620,O
",",1620,O
sporadic,1620,O
and,1620,O
VHL-associated,1620,O
forms,1620,O
of,1620,O
renal,1620,B-SpecificDisease
cell,1620,I-SpecificDisease
carcinoma,1620,I-SpecificDisease
might,1620,O
both,1620,O
result,1620,O
from,1620,O
alterations,1620,O
causing,1620,O
loss,1620,O
of,1620,O
function,1620,O
of,1620,O
the,1620,O
same,1620,O
tumour,1620,B-Modifier
suppressor,1620,O
gene,1620,O
on,1620,O
this,1620,O
chromosome,1620,O
..,1620,O
Tightly,1621,O
linked,1621,O
flanking,1621,O
markers,1621,O
for,1621,O
the,1621,O
Lowe,1621,B-SpecificDisease
oculocerebrorenal,1621,I-SpecificDisease
syndrome,1621,I-SpecificDisease
",",1621,O
with,1621,O
application,1621,O
to,1621,O
carrier,1621,O
assessment,1621,O
.,1621,O
The,1622,O
Lowe,1622,B-SpecificDisease
oculocerebrorenal,1622,I-SpecificDisease
syndrome,1622,I-SpecificDisease
(,1622,O
OCRL,1622,B-SpecificDisease
),1622,O
is,1622,O
characterized,1622,O
by,1622,O
congenital,1622,O
cataract,1622,B-SpecificDisease
",",1622,O
mental,1622,B-DiseaseClass
retardation,1622,I-DiseaseClass
",",1622,O
and,1622,O
defective,1622,B-DiseaseClass
renal,1622,I-DiseaseClass
tubular,1622,I-DiseaseClass
function,1622,I-DiseaseClass
.,1622,O
A,1623,O
map,1623,O
assignment,1623,O
of,1623,O
OCRL,1623,B-SpecificDisease
to,1623,O
Xq24-q26,1623,O
has,1623,O
been,1623,O
made,1623,O
previously,1623,O
by,1623,O
linkage,1623,O
analysis,1623,O
with,1623,O
DXS42,1623,O
at,1623,O
Xq24-q26,1623,O
(,1623,O
theta,1623,O
=,1623,O
0,1623,O
",",1623,O
z,1623,O
=,1623,O
5,1623,O
.,1623,O
09,1624,O
),1624,O
and,1624,O
with,1624,O
DXS10,1624,O
at,1624,O
Xq26,1624,O
(,1624,O
theta,1624,O
=,1624,O
0,1624,O
",",1624,O
z,1624,O
=,1624,O
6,1624,O
.,1624,O
45,1625,O
),1625,O
.,1625,O
Two,1626,O
additional,1626,O
families,1626,O
were,1626,O
studied,1626,O
and,1626,O
three,1626,O
additional,1626,O
polymorphisms,1626,O
were,1626,O
identified,1626,O
at,1626,O
DXS42,1626,O
by,1626,O
using,1626,O
a,1626,O
35-kb,1626,O
sequence,1626,O
isolated,1626,O
with,1626,O
the,1626,O
probe,1626,O
detecting,1626,O
the,1626,O
original,1626,O
polymorphism,1626,O
at,1626,O
DXS42,1626,O
.,1626,O
With,1627,O
additional,1627,O
OCRL,1627,B-Modifier
families,1627,O
made,1627,O
informative,1627,O
for,1627,O
DXS42,1627,O
",",1627,O
theta,1627,O
remained,1627,O
0,1627,O
with,1627,O
z,1627,O
=,1627,O
6,1627,O
.,1627,O
63,1628,O
;,1628,O
and,1628,O
for,1628,O
DXS10,1628,O
theta,1628,O
=,1628,O
0,1628,O
.,1628,O
03,1629,O
and,1629,O
z,1629,O
=,1629,O
7,1629,O
.,1629,O
07,1630,O
.,1630,O
Evidence,1631,O
for,1631,O
placing,1631,O
OCRL,1631,O
at,1631,O
Xq25,1631,O
also,1631,O
comes,1631,O
from,1631,O
a,1631,O
female,1631,O
with,1631,O
Lowe,1631,B-SpecificDisease
syndrome,1631,I-SpecificDisease
and,1631,O
an,1631,O
X,1631,O
;,1631,O
3,1631,O
translocation,1631,O
.,1631,O
We,1632,O
have,1632,O
used,1632,O
the,1632,O
Xq25,1632,O
breakpoint,1632,O
in,1632,O
this,1632,O
patient,1632,O
to,1632,O
determine,1632,O
the,1632,O
position,1632,O
of,1632,O
OCRL,1632,O
relative,1632,O
to,1632,O
the,1632,O
two,1632,O
linked,1632,O
markers,1632,O
.,1632,O
Each,1633,O
derivative,1633,O
chromosome,1633,O
was,1633,O
isolated,1633,O
away,1633,O
from,1633,O
its,1633,O
normal,1633,O
counterpart,1633,O
in,1633,O
somatic,1633,O
cell,1633,O
hybrids,1633,O
.,1633,O
DXS42,1634,O
was,1634,O
mapped,1634,O
to,1634,O
the,1634,O
derivative,1634,O
chromosome,1634,O
X,1634,O
containing,1634,O
Xpterq25,1634,O
",",1634,O
and,1634,O
DXS10,1634,O
was,1634,O
mapped,1634,O
to,1634,O
the,1634,O
derivative,1634,O
chromosome,1634,O
3,1634,O
containing,1634,O
Xq25-qter,1634,O
.,1634,O
The,1635,O
markers,1635,O
DXS10,1635,O
and,1635,O
DXS42,1635,O
therefore,1635,O
show,1635,O
tight,1635,O
linkage,1635,O
with,1635,O
OCRL,1635,B-SpecificDisease
in,1635,O
six,1635,O
families,1635,O
and,1635,O
flank,1635,O
the,1635,O
Xq25,1635,O
breakpoint,1635,O
in,1635,O
a,1635,O
female,1635,O
patient,1635,O
with,1635,O
an,1635,O
X,1635,O
;,1635,O
3,1635,O
translocation,1635,O
.,1635,O
Linkage,1636,O
analysis,1636,O
with,1636,O
flanking,1636,O
markers,1636,O
was,1636,O
used,1636,O
to,1636,O
assess,1636,O
OCRL,1636,B-Modifier
carrier,1636,O
status,1636,O
in,1636,O
women,1636,O
at,1636,O
risk,1636,O
.,1636,O
Results,1637,O
",",1637,O
when,1637,O
compared,1637,O
with,1637,O
carrier,1637,O
determination,1637,O
by,1637,O
ophthalmologic,1637,O
examination,1637,O
",",1637,O
indicated,1637,O
that,1637,O
the,1637,O
slit-lamp,1637,O
exam,1637,O
can,1637,O
be,1637,O
a,1637,O
sensitive,1637,O
and,1637,O
specific,1637,O
method,1637,O
of,1637,O
carrier,1637,O
determination,1637,O
in,1637,O
many,1637,O
cases,1637,O
Identification,1638,O
of,1638,O
a,1638,O
single,1638,O
nucleotide,1638,O
change,1638,O
in,1638,O
the,1638,O
hypoxanthine-guanine,1638,O
phosphoribosyltransferase,1638,O
gene,1638,O
(,1638,O
HPRTYale,1638,O
),1638,O
responsible,1638,O
for,1638,O
Lesch-Nyhan,1638,B-SpecificDisease
syndrome,1638,I-SpecificDisease
.,1638,O
Complete,1639,O
deficiency,1639,B-SpecificDisease
of,1639,I-SpecificDisease
hypoxanthine-guanine,1639,I-SpecificDisease
phosphoribosyltransferase,1639,I-SpecificDisease
(,1639,O
HPRT,1639,O
),1639,O
causes,1639,O
the,1639,O
Lesch-Nyhan,1639,B-SpecificDisease
syndrome,1639,I-SpecificDisease
.,1639,O
Previous,1640,O
characterization,1640,O
of,1640,O
a,1640,O
mutant,1640,O
form,1640,O
of,1640,O
HPRT,1640,O
",",1640,O
HPRTYale,1640,O
",",1640,O
from,1640,O
a,1640,O
subject,1640,O
with,1640,O
the,1640,O
Lesch-Nyhan,1640,B-SpecificDisease
syndrome,1640,I-SpecificDisease
revealed,1640,O
normal,1640,O
mRNA,1640,O
and,1640,O
protein,1640,O
concentrations,1640,O
",",1640,O
no,1640,O
residual,1640,O
catalytic,1640,O
activity,1640,O
",",1640,O
and,1640,O
cathodal,1640,O
migration,1640,O
upon,1640,O
PAGE,1640,O
.,1640,O
We,1641,O
have,1641,O
cloned,1641,O
and,1641,O
sequenced,1641,O
HPRTYale,1641,O
cDNA,1641,O
.,1641,O
The,1642,O
nucleotide,1642,O
sequence,1642,O
of,1642,O
full-length,1642,O
HPRTYale,1642,O
cDNA,1642,O
revealed,1642,O
a,1642,O
single,1642,O
nucleotide,1642,O
substitution,1642,O
compared,1642,O
with,1642,O
normal,1642,O
HPRT,1642,O
cDNA,1642,O
G,1642,O
--,1642,O
--,1642,O
C,1642,O
at,1642,O
nucleotide,1642,O
position,1642,O
211,1642,O
.,1642,O
This,1643,O
transversion,1643,O
predicts,1643,O
substitution,1643,O
of,1643,O
arginine,1643,O
for,1643,O
glycine,1643,O
at,1643,O
amino,1643,O
acid,1643,O
position,1643,O
71,1643,O
",",1643,O
explaining,1643,O
the,1643,O
cathodal,1643,O
migration,1643,O
of,1643,O
HPRTYale,1643,O
.,1643,O
Chou-Fasman,1644,O
secondary,1644,O
structure,1644,O
analysis,1644,O
predicts,1644,O
a,1644,O
change,1644,O
in,1644,O
the,1644,O
probability,1644,O
of,1644,O
beta-turn,1644,O
formation,1644,O
in,1644,O
the,1644,O
region,1644,O
containing,1644,O
the,1644,O
mutation,1644,O
.,1644,O
Inclusion,1645,O
of,1645,O
the,1645,O
bulky,1645,O
arginine,1645,O
side,1645,O
chain,1645,O
in,1645,O
place,1645,O
of,1645,O
glycine,1645,O
probably,1645,O
disrupts,1645,O
protein,1645,O
folding,1645,O
as,1645,O
well,1645,O
.,1645,O
Cloning,1646,O
mutant,1646,O
forms,1646,O
of,1646,O
cDNA,1646,O
allows,1646,O
identification,1646,O
of,1646,O
specific,1646,O
mutations,1646,O
",",1646,O
provides,1646,O
insight,1646,O
into,1646,O
mutational,1646,O
mechanisms,1646,O
",",1646,O
and,1646,O
facilitates,1646,O
structure-function,1646,O
analysis,1646,O
of,1646,O
mutant,1646,O
proteins,1646,O
..,1646,O
Two,1647,O
point,1647,O
mutations,1647,O
are,1647,O
responsible,1647,O
for,1647,O
G6PD,1647,O
polymorphism,1647,O
in,1647,O
Sardinia,1647,O
.,1647,O
The,1648,O
human,1648,O
X-linked,1648,O
gene,1648,O
encoding,1648,O
glucose,1648,O
6-phosphate,1648,O
dehydrogenase,1648,O
(,1648,O
G6PD,1648,O
),1648,O
is,1648,O
highly,1648,O
polymorphic,1648,O
;,1648,O
more,1648,O
than,1648,O
300,1648,O
G6PD,1648,O
variants,1648,O
have,1648,O
been,1648,O
identified,1648,O
.,1648,O
G6PD,1649,B-SpecificDisease
deficiency,1649,I-SpecificDisease
in,1649,O
different,1649,O
geographical,1649,O
areas,1649,O
appears,1649,O
to,1649,O
have,1649,O
arisen,1649,O
through,1649,O
independent,1649,O
mutational,1649,O
events,1649,O
",",1649,O
but,1649,O
within,1649,O
the,1649,O
same,1649,O
population,1649,O
it,1649,O
may,1649,O
also,1649,O
be,1649,O
heterogeneous,1649,O
.,1649,O
One,1650,O
example,1650,O
is,1650,O
the,1650,O
island,1650,O
of,1650,O
Sardinia,1650,O
",",1650,O
where,1650,O
careful,1650,O
clinical,1650,O
and,1650,O
biochemical,1650,O
studies,1650,O
have,1650,O
identified,1650,O
four,1650,O
different,1650,O
G6PD,1650,O
variants,1650,O
.,1650,O
We,1651,O
cloned,1651,O
and,1651,O
sequenced,1651,O
the,1651,O
four,1651,O
G6PD,1651,O
variants,1651,O
from,1651,O
Sardinia,1651,O
and,1651,O
found,1651,O
that,1651,O
only,1651,O
two,1651,O
mutations,1651,O
are,1651,O
responsible,1651,O
for,1651,O
G6PD,1651,B-SpecificDisease
deficiency,1651,I-SpecificDisease
in,1651,O
this,1651,O
area,1651,O
one,1651,O
mutation,1651,O
is,1651,O
the,1651,O
cause,1651,O
of,1651,O
the,1651,O
G6PD,1651,B-SpecificDisease
Seattle-like,1651,I-SpecificDisease
phenotype,1651,I-SpecificDisease
",",1651,O
a,1651,O
milder,1651,O
form,1651,O
of,1651,O
G6PD,1651,B-SpecificDisease
deficiency,1651,I-SpecificDisease
;,1651,O
the,1651,O
other,1651,O
mutation,1651,O
is,1651,O
responsible,1651,O
for,1651,O
all,1651,O
forms,1651,O
of,1651,O
very,1651,O
severe,1651,O
G6PD,1651,B-SpecificDisease
deficiency,1651,I-SpecificDisease
in,1651,O
Sardinia,1651,O
and,1651,O
",",1651,O
possibly,1651,O
",",1651,O
in,1651,O
the,1651,O
Mediterranean,1651,O
..,1651,O
Chronic,1652,B-SpecificDisease
nonspherocytic,1652,I-SpecificDisease
hemolytic,1652,I-SpecificDisease
anemia,1652,I-SpecificDisease
(,1652,O
CNSHA,1652,B-SpecificDisease
),1652,O
and,1652,O
glucose,1652,B-SpecificDisease
6,1652,I-SpecificDisease
phosphate,1652,I-SpecificDisease
dehydrogenase,1652,I-SpecificDisease
(,1652,I-SpecificDisease
G6PD,1652,I-SpecificDisease
),1652,I-SpecificDisease
deficiency,1652,I-SpecificDisease
in,1652,O
a,1652,O
patient,1652,O
with,1652,O
familial,1652,B-SpecificDisease
amyloidotic,1652,I-SpecificDisease
polyneuropathy,1652,I-SpecificDisease
(,1652,O
FAP,1652,B-SpecificDisease
),1652,O
.,1652,O
Molecular,1653,O
study,1653,O
of,1653,O
a,1653,O
new,1653,O
variant,1653,O
(,1653,O
G6PD,1653,O
Clinic,1653,O
),1653,O
with,1653,O
markedly,1653,O
acidic,1653,O
pH,1653,O
optimum,1653,O
.,1653,O
A,1654,O
new,1654,O
glucose-6-phosphate,1654,O
dehydrogenase,1654,O
(,1654,O
G6PD,1654,O
),1654,O
variant,1654,O
with,1654,O
severe,1654,O
erythrocytic,1654,B-SpecificDisease
G6PD,1654,I-SpecificDisease
deficiency,1654,I-SpecificDisease
and,1654,O
a,1654,O
unique,1654,O
pH,1654,O
optimum,1654,O
is,1654,O
described,1654,O
in,1654,O
a,1654,O
young,1654,O
patient,1654,O
with,1654,O
chronic,1654,B-SpecificDisease
nonspherocytic,1654,I-SpecificDisease
hemolytic,1654,I-SpecificDisease
anemia,1654,I-SpecificDisease
(,1654,O
CNSHA,1654,B-SpecificDisease
),1654,O
and,1654,O
familial,1654,B-SpecificDisease
amyloidotic,1654,I-SpecificDisease
polyneuropathy,1654,I-SpecificDisease
(,1654,O
FAP,1654,B-SpecificDisease
),1654,O
.,1654,O
Chronic,1655,B-SpecificDisease
hemolysis,1655,I-SpecificDisease
was,1655,O
present,1655,O
in,1655,O
the,1655,O
absence,1655,O
of,1655,O
infections,1655,O
",",1655,O
oxidant,1655,O
drugs,1655,O
or,1655,O
ingestion,1655,O
of,1655,O
faba,1655,O
beans,1655,O
.,1655,O
Residual,1656,O
enzyme,1656,O
activity,1656,O
was,1656,O
about,1656,O
2,1656,O
.,1656,O
6,1657,O
%,1657,O
and,1657,O
63,1657,O
%,1657,O
of,1657,O
normal,1657,O
activity,1657,O
in,1657,O
erythrocytes,1657,O
and,1657,O
leucocytes,1657,O
",",1657,O
respectively,1657,O
.,1657,O
A,1658,O
molecular,1658,O
study,1658,O
using,1658,O
standard,1658,O
methods,1658,O
showed,1658,O
G6PD,1658,O
in,1658,O
the,1658,O
patient,1658,O
to,1658,O
have,1658,O
normal,1658,O
electrophoretic,1658,O
mobility,1658,O
(,1658,O
at,1658,O
pH,1658,O
7,1658,O
.,1658,O
0,1659,O
",",1659,O
8,1659,O
.,1659,O
0,1660,O
and,1660,O
8,1660,O
.,1660,O
8,1661,O
),1661,O
",",1661,O
normal,1661,O
apparent,1661,O
affinity,1661,O
for,1661,O
substrates,1661,O
(,1661,O
Km,1661,O
",",1661,O
G6P,1661,O
and,1661,O
NADP,1661,O
),1661,O
and,1661,O
a,1661,O
slightly,1661,O
abnormal,1661,O
utilization,1661,O
of,1661,O
substrate,1661,O
analogues,1661,O
(,1661,O
decreased,1661,O
deamino-NADP,1661,O
and,1661,O
increased,1661,O
2-deoxyglucose-6-phosphate,1661,O
utilization,1661,O
),1661,O
.,1661,O
Heat,1662,O
stability,1662,O
was,1662,O
found,1662,O
to,1662,O
be,1662,O
markedly,1662,O
decreased,1662,O
(,1662,O
8,1662,O
%,1662,O
of,1662,O
residual,1662,O
activity,1662,O
after,1662,O
20,1662,O
min,1662,O
of,1662,O
incubation,1662,O
at,1662,O
46,1662,O
degrees,1662,O
C,1662,O
),1662,O
and,1662,O
a,1662,O
particular,1662,O
characteristic,1662,O
of,1662,O
this,1662,O
enzyme,1662,O
was,1662,O
a,1662,O
biphasic,1662,O
pH,1662,O
curve,1662,O
with,1662,O
a,1662,O
greatly,1662,O
increased,1662,O
activity,1662,O
at,1662,O
low,1662,O
pH,1662,O
.,1662,O
Although,1663,O
molecular,1663,O
characteristics,1663,O
of,1663,O
this,1663,O
variant,1663,O
closely,1663,O
resemble,1663,O
those,1663,O
of,1663,O
G6PD,1663,O
Bangkok,1663,O
and,1663,O
G6PD,1663,O
Duarte,1663,O
",",1663,O
it,1663,O
can,1663,O
be,1663,O
distinguished,1663,O
from,1663,O
these,1663,O
and,1663,O
all,1663,O
other,1663,O
previously,1663,O
reported,1663,O
variants,1663,O
by,1663,O
virtue,1663,O
of,1663,O
its,1663,O
unusual,1663,O
pH,1663,O
curve,1663,O
.,1663,O
Therefore,1664,O
the,1664,O
present,1664,O
variant,1664,O
has,1664,O
been,1664,O
designated,1664,O
G6PD,1664,O
Clinic,1664,O
to,1664,O
distinguish,1664,O
it,1664,O
from,1664,O
other,1664,O
G6PD,1664,O
variants,1664,O
previously,1664,O
described,1664,O
Molecular,1665,O
detection,1665,O
of,1665,O
chromosomal,1665,O
translocations,1665,O
that,1665,O
disrupt,1665,O
the,1665,O
putative,1665,O
retinoblastoma,1665,B-Modifier
susceptibility,1665,O
locus,1665,O
.,1665,O
A,1666,O
candidate,1666,O
DNA,1666,O
sequence,1666,O
with,1666,O
many,1666,O
of,1666,O
the,1666,O
properties,1666,O
predicted,1666,O
for,1666,O
the,1666,O
retinoblastoma,1666,B-Modifier
susceptibility,1666,O
(,1666,O
RB1,1666,O
),1666,O
locus,1666,O
has,1666,O
been,1666,O
cloned,1666,O
(,1666,O
S.,1666,O
H.,1666,O
Friend,1666,O
",",1666,O
R.,1666,O
Bernards,1666,O
",",1666,O
S.,1666,O
Rogelj,1666,O
",",1666,O
R.,1666,O
A.,1666,O
Weinberg,1666,O
",",1666,O
J.,1666,O
M.,1666,O
Rapaport,1666,O
",",1666,O
D.,1666,O
M.,1666,O
Albert,1666,O
",",1666,O
and,1666,O
T.,1666,O
P.,1666,O
Dryja,1666,O
",",1666,O
Nature,1666,O
[,1666,O
London,1666,O
],1666,O
323,1666,O
643-645,1666,O
",",1666,O
1986,1666,O
),1666,O
.,1666,O
The,1667,O
large,1667,O
size,1667,O
of,1667,O
this,1667,O
gene,1667,O
(,1667,O
ca,1667,O
.,1667,O
200,1668,O
kilobases,1668,O
[,1668,O
kb,1668,O
],1668,O
),1668,O
and,1668,O
its,1668,O
multiple,1668,O
dispersed,1668,O
exons,1668,O
(,1668,O
Wiggs,1668,O
et,1668,O
al.,1668,O
",",1668,O
N.,1668,O
Engl,1668,O
.,1668,O
J.,1669,O
Med,1669,O
.,1669,O
318,1670,O
151-157,1670,O
",",1670,O
1988,1670,O
),1670,O
complicate,1670,O
molecular,1670,O
screening,1670,O
strategies,1670,O
important,1670,O
in,1670,O
prenatal,1670,O
and,1670,O
presymptomatic,1670,O
diagnosis,1670,O
and,1670,O
in,1670,O
carrier,1670,O
detection,1670,O
.,1670,O
Here,1671,O
we,1671,O
used,1671,O
field,1671,O
inversion,1671,O
gel,1671,O
electrophoresis,1671,O
(,1671,O
FIGE,1671,O
),1671,O
to,1671,O
construct,1671,O
a,1671,O
restriction,1671,O
map,1671,O
of,1671,O
approximately,1671,O
1,1671,O
",",1671,O
000,1671,O
kb,1671,O
of,1671,O
DNA,1671,O
surrounding,1671,O
the,1671,O
RB1,1671,O
locus,1671,O
and,1671,O
to,1671,O
detect,1671,O
the,1671,O
translocation,1671,O
breakpoints,1671,O
in,1671,O
three,1671,O
retinoblastoma,1671,B-Modifier
patients,1671,O
.,1671,O
DNA,1672,O
probes,1672,O
from,1672,O
either,1672,O
the,1672,O
5,1672,O
or,1672,O
3,1672,O
end,1672,O
of,1672,O
the,1672,O
gene,1672,O
were,1672,O
used,1672,O
to,1672,O
detect,1672,O
a,1672,O
250-kb,1672,O
EagI,1672,O
restriction,1672,O
fragment,1672,O
in,1672,O
DNA,1672,O
from,1672,O
unaffected,1672,O
individuals,1672,O
.,1672,O
Both,1673,O
probes,1673,O
identified,1673,O
an,1673,O
additional,1673,O
hybridizing,1673,O
fragment,1673,O
in,1673,O
the,1673,O
DNA,1673,O
from,1673,O
each,1673,O
patient,1673,O
",",1673,O
permitting,1673,O
the,1673,O
breakpoints,1673,O
in,1673,O
all,1673,O
three,1673,O
to,1673,O
be,1673,O
mapped,1673,O
within,1673,O
the,1673,O
cloned,1673,O
RB1,1673,O
gene,1673,O
.,1673,O
Analysis,1674,O
of,1674,O
the,1674,O
breakpoint,1674,O
in,1674,O
one,1674,O
translocation,1674,O
cell,1674,O
line,1674,O
allowed,1674,O
the,1674,O
RB1,1674,O
gene,1674,O
to,1674,O
be,1674,O
oriented,1674,O
with,1674,O
its,1674,O
5,1674,O
end,1674,O
toward,1674,O
the,1674,O
centromere,1674,O
.,1674,O
The,1675,O
5,1675,O
end,1675,O
of,1675,O
the,1675,O
gene,1675,O
also,1675,O
appeared,1675,O
to,1675,O
be,1675,O
associated,1675,O
with,1675,O
a,1675,O
clustering,1675,O
of,1675,O
sites,1675,O
for,1675,O
several,1675,O
infrequently,1675,O
cleaving,1675,O
restriction,1675,O
enzymes,1675,O
",",1675,O
indicating,1675,O
the,1675,O
presence,1675,O
of,1675,O
an,1675,O
HpaII,1675,O
tiny,1675,O
fragment,1675,O
island,1675,O
.,1675,O
The,1676,O
detection,1676,O
and,1676,O
mapping,1676,O
of,1676,O
the,1676,O
translocation,1676,O
breakpoints,1676,O
of,1676,O
all,1676,O
three,1676,O
retinoblastoma,1676,B-Modifier
patients,1676,O
to,1676,O
within,1676,O
the,1676,O
putative,1676,O
RB1,1676,O
gene,1676,O
substantiated,1676,O
the,1676,O
authenticity,1676,O
of,1676,O
this,1676,O
candidate,1676,O
sequence,1676,O
and,1676,O
demonstrated,1676,O
the,1676,O
utility,1676,O
of,1676,O
FIGE,1676,O
in,1676,O
detecting,1676,O
chromosomal,1676,O
rearrangements,1676,O
affecting,1676,O
this,1676,O
locus,1676,O
.,1676,O
Inherited,1677,O
C3,1677,B-SpecificDisease
deficiency,1677,I-SpecificDisease
with,1677,O
recurrent,1677,O
infections,1677,O
and,1677,O
glomerulonephritis,1677,B-SpecificDisease
.,1677,O
A,1678,O
10-year-old,1678,O
Laotian,1678,O
boy,1678,O
had,1678,O
homozygous,1678,O
deficiency,1678,B-SpecificDisease
of,1678,I-SpecificDisease
the,1678,I-SpecificDisease
third,1678,I-SpecificDisease
component,1678,I-SpecificDisease
of,1678,I-SpecificDisease
complement,1678,I-SpecificDisease
and,1678,O
recurrent,1678,O
bacterial,1678,B-DiseaseClass
infections,1678,I-DiseaseClass
beginning,1678,O
at,1678,O
age,1678,O
5,1678,O
months,1678,O
.,1678,O
Cellular,1679,O
and,1679,O
humoral,1679,O
immunity,1679,O
were,1679,O
normal,1679,O
",",1679,O
as,1679,O
were,1679,O
polymorphonuclear,1679,O
leukocyte,1679,O
chemotaxis,1679,O
and,1679,O
bactericidal,1679,O
activities,1679,O
.,1679,O
Serum,1680,O
complement-mediated,1680,O
hemolytic,1680,O
",",1680,O
chemotactic,1680,O
",",1680,O
and,1680,O
opsonic,1680,O
activities,1680,O
were,1680,O
deficient,1680,O
.,1680,O
In,1681,O
vitro,1681,O
addition,1681,O
of,1681,O
purified,1681,O
C3,1681,O
to,1681,O
patient,1681,O
serum,1681,O
restored,1681,O
hemolytic,1681,O
complement,1681,O
to,1681,O
normal,1681,O
levels,1681,O
",",1681,O
and,1681,O
plasma,1681,O
infusion,1681,O
during,1681,O
each,1681,O
of,1681,O
four,1681,O
episodes,1681,O
of,1681,O
pneumonia,1681,B-SpecificDisease
significantly,1681,O
enhanced,1681,O
serum,1681,O
opsonic,1681,O
activity,1681,O
for,1681,O
as,1681,O
long,1681,O
as,1681,O
36,1681,O
hours,1681,O
.,1681,O
A,1682,O
renal,1682,O
biopsy,1682,O
specimen,1682,O
revealed,1682,O
mesangiopathic,1682,B-SpecificDisease
glomerulonephritis,1682,I-SpecificDisease
",",1682,O
although,1682,O
significant,1682,O
levels,1682,O
of,1682,O
circulating,1682,O
IgG,1682,O
immune,1682,O
complexes,1682,O
were,1682,O
not,1682,O
detected,1682,O
.,1682,O
These,1683,O
findings,1683,O
further,1683,O
support,1683,O
the,1683,O
association,1683,O
of,1683,O
C3,1683,B-SpecificDisease
deficiency,1683,I-SpecificDisease
with,1683,O
immune-complex,1683,B-DiseaseClass
disease,1683,I-DiseaseClass
and,1683,O
suggest,1683,O
that,1683,O
plasma,1683,O
infusion,1683,O
may,1683,O
be,1683,O
an,1683,O
adjunct,1683,O
to,1683,O
antibiotic,1683,O
therapy,1683,O
in,1683,O
the,1683,O
management,1683,O
of,1683,O
severe,1683,O
pyogenic,1683,B-DiseaseClass
infections,1683,I-DiseaseClass
in,1683,O
patients,1683,O
with,1683,O
C3,1683,B-SpecificDisease
deficiency,1683,I-SpecificDisease
..,1683,O
DNA,1684,O
restriction,1684,O
fragments,1684,O
associated,1684,O
with,1684,O
alpha,1684,O
1-antitrypsin,1684,O
indicate,1684,O
a,1684,O
single,1684,O
origin,1684,O
for,1684,O
deficiency,1684,O
allele,1684,O
PI,1684,O
Z,1684,O
.,1684,O
The,1685,O
alpha,1685,O
1-protease,1685,O
inhibitor,1685,O
",",1685,O
or,1685,O
alpha-antitrypsin,1685,O
(,1685,O
AAT,1685,O
),1685,O
",",1685,O
a,1685,O
major,1685,O
plasma,1685,O
inhibitor,1685,O
of,1685,O
leukocyte,1685,O
elastase,1685,O
and,1685,O
bacterial,1685,O
proteases,1685,O
",",1685,O
is,1685,O
encoded,1685,O
at,1685,O
the,1685,O
PI,1685,O
locus,1685,O
on,1685,O
chromosome,1685,O
14,1685,O
(,1685,O
14q24,1685,O
.,1685,O
3-q32,1686,O
.,1686,O
1,1687,O
),1687,O
.,1687,O
A,1688,O
deficiency,1688,B-SpecificDisease
of,1688,I-SpecificDisease
AAT,1688,I-SpecificDisease
in,1688,O
individuals,1688,O
homozygous,1688,O
for,1688,O
the,1688,O
PI,1688,O
Z,1688,O
allele,1688,O
occurs,1688,O
in,1688,O
about,1688,O
1,1688,O
in,1688,O
2,1688,O
",",1688,O
000-8,1688,O
",",1688,O
000,1688,O
caucasians,1688,O
and,1688,O
is,1688,O
associated,1688,O
with,1688,O
an,1688,O
increased,1688,O
risk,1688,O
of,1688,O
early,1688,O
adult,1688,O
onset,1688,O
emphysema,1688,B-DiseaseClass
and,1688,O
liver,1688,B-DiseaseClass
disease,1688,I-DiseaseClass
in,1688,O
childhood,1688,O
.,1688,O
We,1689,O
have,1689,O
now,1689,O
used,1689,O
DNA,1689,O
polymorphisms,1689,O
associated,1689,O
with,1689,O
the,1689,O
AAT,1689,O
gene,1689,O
to,1689,O
investigate,1689,O
the,1689,O
origin,1689,O
of,1689,O
the,1689,O
PI,1689,O
Z,1689,O
allele,1689,O
.,1689,O
Using,1690,O
two,1690,O
genomic,1690,O
probes,1690,O
extending,1690,O
into,1690,O
the,1690,O
5,1690,O
and,1690,O
3,1690,O
flanking,1690,O
regions,1690,O
",",1690,O
respectively,1690,O
",",1690,O
we,1690,O
have,1690,O
identified,1690,O
eight,1690,O
polymorphic,1690,O
restriction,1690,O
sites,1690,O
.,1690,O
Extensive,1691,O
linkage,1691,O
disequilibrium,1691,O
occurs,1691,O
throughout,1691,O
the,1691,O
probed,1691,O
region,1691,O
with,1691,O
the,1691,O
PI,1691,O
Z,1691,O
allele,1691,O
",",1691,O
but,1691,O
not,1691,O
with,1691,O
normal,1691,O
PI,1691,O
M,1691,O
alleles,1691,O
.,1691,O
The,1692,O
Z,1692,O
allele,1692,O
occurs,1692,O
mainly,1692,O
with,1692,O
one,1692,O
haplotype,1692,O
",",1692,O
indicating,1692,O
a,1692,O
single,1692,O
",",1692,O
relatively,1692,O
recent,1692,O
",",1692,O
origin,1692,O
in,1692,O
caucasians,1692,O
Segregation,1693,O
analysis,1693,O
of,1693,O
a,1693,O
marker,1693,O
localised,1693,O
Xp21.2-Xp21.3,1693,O
in,1693,O
Duchenne,1693,O
and,1693,O
Becker,1693,O
muscular,1693,O
dystrophy,1693,O
families,1693,O
.,1693,O
A,1694,O
DNA,1694,O
marker,1694,O
C7,1694,O
",",1694,O
localised,1694,O
Xp21,1694,O
.,1694,O
1-Xp21,1695,O
.,1695,O
3,1696,O
",",1696,O
has,1696,O
been,1696,O
studied,1696,O
in,1696,O
kindreds,1696,O
segregating,1696,O
for,1696,O
Duchenne,1696,B-SpecificDisease
muscular,1696,I-SpecificDisease
dystrophy,1696,I-SpecificDisease
(,1696,O
DMD,1696,B-SpecificDisease
),1696,O
and,1696,O
Becker,1696,B-SpecificDisease
muscular,1696,I-SpecificDisease
dystrophy,1696,I-SpecificDisease
(,1696,O
BMD,1696,B-SpecificDisease
),1696,O
.,1696,O
In,1697,O
DMD,1697,B-Modifier
families,1697,O
four,1697,O
crossovers,1697,O
were,1697,O
observed,1697,O
in,1697,O
38,1697,O
informative,1697,O
meioses,1697,O
between,1697,O
C7,1697,O
and,1697,O
the,1697,O
DMD,1697,B-Modifier
locus,1697,O
(,1697,O
theta,1697,O
=,1697,O
0,1697,O
.,1697,O
12,1698,O
",",1698,O
z,1698,O
max,1698,O
=,1698,O
+,1698,O
2,1698,O
.,1698,O
72,1699,O
),1699,O
.,1699,O
In,1700,O
BMD,1700,B-Modifier
families,1700,O
no,1700,O
recombinants,1700,O
were,1700,O
observed,1700,O
in,1700,O
the,1700,O
16,1700,O
informative,1700,O
meioses,1700,O
studied,1700,O
.,1700,O
These,1701,O
data,1701,O
are,1701,O
consistent,1701,O
with,1701,O
the,1701,O
localisation,1701,O
of,1701,O
the,1701,O
mutations,1701,O
in,1701,O
these,1701,O
disorders,1701,O
being,1701,O
in,1701,O
the,1701,O
same,1701,O
region,1701,O
of,1701,O
Xp21,1701,O
.,1701,O
Studies,1702,O
in,1702,O
families,1702,O
also,1702,O
segregating,1702,O
for,1702,O
the,1702,O
DNA,1702,O
marker,1702,O
754,1702,O
support,1702,O
the,1702,O
previously,1702,O
reported,1702,O
physical,1702,O
order,1702,O
of,1702,O
these,1702,O
loci,1702,O
as,1702,O
X,1702,O
centromere-754-DMD-BMD-C7-X,1702,O
telomere,1702,O
.,1702,O
A,1703,O
recombination,1703,O
fraction,1703,O
of,1703,O
0,1703,O
.,1703,O
11,1704,O
(,1704,O
z,1704,O
max,1704,O
=,1704,O
+,1704,O
5,1704,O
.,1704,O
58,1705,O
),1705,O
was,1705,O
found,1705,O
between,1705,O
DMD-754,1705,O
by,1705,O
combining,1705,O
our,1705,O
previously,1705,O
published,1705,O
data,1705,O
with,1705,O
the,1705,O
data,1705,O
presented,1705,O
here,1705,O
.,1705,O
C7,1706,O
and,1706,O
754,1706,O
thus,1706,O
provide,1706,O
good,1706,O
bridging,1706,O
markers,1706,O
for,1706,O
the,1706,O
diagnosis,1706,O
of,1706,O
DMD,1706,B-SpecificDisease
and,1706,O
BMD,1706,B-SpecificDisease
Isolation,1707,O
of,1707,O
molecular,1707,O
probes,1707,O
associated,1707,O
with,1707,O
the,1707,O
chromosome,1707,O
15,1707,O
instability,1707,O
in,1707,O
the,1707,O
Prader-Willi,1707,B-SpecificDisease
syndrome,1707,I-SpecificDisease
.,1707,O
Flow,1708,O
cytometry,1708,O
and,1708,O
recombinant,1708,O
DNA,1708,O
techniques,1708,O
have,1708,O
been,1708,O
used,1708,O
to,1708,O
obtain,1708,O
reagents,1708,O
for,1708,O
a,1708,O
molecular,1708,O
analysis,1708,O
of,1708,O
the,1708,O
Prader-Willi,1708,B-SpecificDisease
syndrome,1708,I-SpecificDisease
(,1708,O
PWS,1708,B-SpecificDisease
),1708,O
.,1708,O
HindIII,1709,O
total-digest,1709,O
libraries,1709,O
were,1709,O
prepared,1709,O
in,1709,O
lambda,1709,O
phage,1709,O
Charon,1709,O
21A,1709,O
from,1709,O
flow-sorted,1709,O
inverted,1709,O
duplicated,1709,O
no,1709,O
.,1709,O
15,1710,O
human,1710,O
chromosomes,1710,O
and,1710,O
propagated,1710,O
on,1710,O
recombination-proficient,1710,O
(,1710,O
LE392,1710,O
),1710,O
and,1710,O
recBC-,1710,O
",",1710,O
sbcB-,1710,O
(,1710,O
DB1257,1710,O
),1710,O
bacteria,1710,O
.,1710,O
Twelve,1711,O
distinct,1711,O
chromosome,1711,O
15-specific,1711,O
probes,1711,O
have,1711,O
been,1711,O
isolated,1711,O
.,1711,O
Eight,1712,O
localized,1712,O
to,1712,O
the,1712,O
region,1712,O
15q11,1712,O
--,1712,O
--,1712,O
13,1712,O
.,1712,O
Four,1713,O
of,1713,O
these,1713,O
eight,1713,O
sublocalized,1713,O
to,1713,O
band,1713,O
15q11,1713,O
.,1713,O
2,1714,O
and,1714,O
are,1714,O
shown,1714,O
to,1714,O
be,1714,O
deleted,1714,O
in,1714,O
DNA,1714,O
of,1714,O
one,1714,O
of,1714,O
two,1714,O
patients,1714,O
examined,1714,O
with,1714,O
the,1714,O
PWS,1714,B-SpecificDisease
.,1714,O
Heteroduplex,1715,O
analysis,1715,O
of,1715,O
two,1715,O
of,1715,O
these,1715,O
clones,1715,O
",",1715,O
which,1715,O
grew,1715,O
on,1715,O
DB1257,1715,O
but,1715,O
not,1715,O
on,1715,O
LE392,1715,O
",",1715,O
revealed,1715,O
stem-loop,1715,O
structures,1715,O
in,1715,O
the,1715,O
inserts,1715,O
",",1715,O
indicative,1715,O
of,1715,O
inverted,1715,O
",",1715,O
repeated,1715,O
DNA,1715,O
elements,1715,O
.,1715,O
Such,1716,O
DNA,1716,O
repeats,1716,O
might,1716,O
account,1716,O
for,1716,O
some,1716,O
of,1716,O
the,1716,O
cloning,1716,O
instability,1716,O
of,1716,O
DNA,1716,O
segments,1716,O
from,1716,O
proximal,1716,O
15q,1716,O
.,1716,O
Analysis,1717,O
of,1717,O
the,1717,O
genetic,1717,O
and,1717,O
physical,1717,O
instability,1717,O
associated,1717,O
with,1717,O
the,1717,O
repeated,1717,O
sequences,1717,O
we,1717,O
have,1717,O
isolated,1717,O
from,1717,O
band,1717,O
15q11,1717,O
.,1717,O
2,1718,O
may,1718,O
elucidate,1718,O
the,1718,O
molecular,1718,O
basis,1718,O
for,1718,O
the,1718,O
instability,1718,O
of,1718,O
this,1718,O
chromosomal,1718,O
region,1718,O
in,1718,O
patients,1718,O
with,1718,O
the,1718,O
PWS,1718,B-SpecificDisease
or,1718,O
other,1718,O
diseases,1718,O
associated,1718,O
with,1718,O
chromosomal,1718,B-DiseaseClass
abnormalities,1718,I-DiseaseClass
in,1718,O
the,1718,O
proximal,1718,O
long,1718,O
arm,1718,O
of,1718,O
human,1718,O
chromosome,1718,O
15,1718,O
Analysis,1719,O
of,1719,O
deletions,1719,O
in,1719,O
DNA,1719,O
from,1719,O
patients,1719,O
with,1719,O
Becker,1719,O
and,1719,O
Duchenne,1719,O
muscular,1719,O
dystrophy,1719,O
.,1719,O
Duchenne,1720,B-SpecificDisease
muscular,1720,I-SpecificDisease
dystrophy,1720,I-SpecificDisease
(,1720,O
DMD,1720,B-SpecificDisease
),1720,O
is,1720,O
an,1720,O
X-linked,1720,B-DiseaseClass
recessive,1720,I-DiseaseClass
genetic,1720,I-DiseaseClass
disorder,1720,I-DiseaseClass
for,1720,O
which,1720,O
the,1720,O
biochemical,1720,O
defect,1720,O
is,1720,O
as,1720,O
yet,1720,O
unknown,1720,O
.,1720,O
Recently,1721,O
",",1721,O
two,1721,O
cloned,1721,O
segments,1721,O
of,1721,O
human,1721,O
X-chromosome,1721,O
DNA,1721,O
have,1721,O
been,1721,O
described,1721,O
which,1721,O
detect,1721,O
structural,1721,O
alterations,1721,O
within,1721,O
or,1721,O
near,1721,O
the,1721,O
genetic,1721,O
locus,1721,O
responsible,1721,O
for,1721,O
the,1721,O
disorder,1721,O
.,1721,O
Both,1722,O
of,1722,O
these,1722,O
cloned,1722,O
segments,1722,O
were,1722,O
described,1722,O
as,1722,O
tightly,1722,O
linked,1722,O
to,1722,O
the,1722,O
locus,1722,O
and,1722,O
were,1722,O
capable,1722,O
of,1722,O
detecting,1722,O
deletions,1722,O
in,1722,O
the,1722,O
DNA,1722,O
of,1722,O
boys,1722,O
affected,1722,O
with,1722,O
DMD,1722,B-SpecificDisease
.,1722,O
In,1723,O
an,1723,O
attempt,1723,O
to,1723,O
determine,1723,O
more,1723,O
precisely,1723,O
the,1723,O
occurrence,1723,O
of,1723,O
these,1723,O
deletions,1723,O
within,1723,O
a,1723,O
large,1723,O
population,1723,O
of,1723,O
DMD,1723,B-Modifier
patients,1723,O
and,1723,O
the,1723,O
accuracy,1723,O
of,1723,O
one,1723,O
of,1723,O
the,1723,O
segments,1723,O
",",1723,O
DXS164,1723,O
(,1723,O
pERT87,1723,O
),1723,O
",",1723,O
in,1723,O
determining,1723,O
the,1723,O
inheritance,1723,O
of,1723,O
the,1723,O
DMD,1723,B-Modifier
X,1723,O
chromosome,1723,O
",",1723,O
the,1723,O
subclones,1723,O
1,1723,O
",",1723,O
8,1723,O
and,1723,O
15,1723,O
were,1723,O
made,1723,O
available,1723,O
to,1723,O
many,1723,O
investigators,1723,O
throughout,1723,O
the,1723,O
world,1723,O
.,1723,O
Here,1724,O
we,1724,O
describe,1724,O
the,1724,O
combined,1724,O
results,1724,O
of,1724,O
more,1724,O
than,1724,O
20,1724,O
research,1724,O
laboratories,1724,O
with,1724,O
respect,1724,O
to,1724,O
the,1724,O
occurrence,1724,O
of,1724,O
deletions,1724,O
at,1724,O
the,1724,O
DXS164,1724,O
locus,1724,O
in,1724,O
DNA,1724,O
samples,1724,O
isolated,1724,O
from,1724,O
patients,1724,O
with,1724,O
DMD,1724,B-SpecificDisease
and,1724,O
Becker,1724,B-SpecificDisease
muscular,1724,I-SpecificDisease
dystrophy,1724,I-SpecificDisease
(,1724,O
BMD,1724,B-SpecificDisease
),1724,O
.,1724,O
The,1725,O
results,1725,O
indicate,1725,O
that,1725,O
the,1725,O
DXS164,1725,O
locus,1725,O
apparently,1725,O
recombines,1725,O
with,1725,O
DMD,1725,B-SpecificDisease
5,1725,O
%,1725,O
of,1725,O
the,1725,O
time,1725,O
",",1725,O
but,1725,O
is,1725,O
probably,1725,O
located,1725,O
between,1725,O
independent,1725,O
sites,1725,O
of,1725,O
mutation,1725,O
which,1725,O
yield,1725,O
DMD,1725,B-SpecificDisease
.,1725,O
The,1726,O
breakpoints,1726,O
of,1726,O
some,1726,O
deletions,1726,O
are,1726,O
delineated,1726,O
within,1726,O
the,1726,O
DXS164,1726,O
locus,1726,O
",",1726,O
and,1726,O
it,1726,O
is,1726,O
evident,1726,O
that,1726,O
the,1726,O
deletions,1726,O
at,1726,O
the,1726,O
DMD,1726,B-Modifier
locus,1726,O
are,1726,O
frequent,1726,O
and,1726,O
extremely,1726,O
large,1726,O
..,1726,O
A,1727,O
potential,1727,O
animal,1727,O
model,1727,O
for,1727,O
Lesch-Nyhan,1727,B-SpecificDisease
syndrome,1727,I-SpecificDisease
through,1727,O
introduction,1727,O
of,1727,O
HPRT,1727,O
mutations,1727,O
into,1727,O
mice,1727,O
.,1727,O
The,1728,O
human,1728,O
Lesch-Nyhan,1728,B-SpecificDisease
syndrome,1728,I-SpecificDisease
is,1728,O
a,1728,O
rare,1728,O
neurological,1728,O
and,1728,O
behavioural,1728,O
disorder,1728,O
",",1728,O
affecting,1728,O
only,1728,O
males,1728,O
",",1728,O
which,1728,O
is,1728,O
caused,1728,O
by,1728,O
an,1728,O
inherited,1728,B-DiseaseClass
deficiency,1728,I-DiseaseClass
in,1728,O
the,1728,O
level,1728,O
of,1728,O
activity,1728,O
of,1728,O
the,1728,O
purine,1728,O
salvage,1728,O
enzyme,1728,O
hypoxanthine-guanosine,1728,O
phosphoribosyl,1728,O
transferase,1728,O
(,1728,O
HPRT,1728,O
),1728,O
.,1728,O
How,1729,O
the,1729,O
resulting,1729,O
alterations,1729,O
in,1729,O
purine,1729,O
metabolism,1729,O
lead,1729,O
to,1729,O
the,1729,O
severe,1729,O
symptoms,1729,O
characteristic,1729,O
of,1729,O
Lesch-Nyhan,1729,B-Modifier
patients,1729,O
is,1729,O
still,1729,O
not,1729,O
understood,1729,O
.,1729,O
No,1730,O
mutations,1730,O
at,1730,O
the,1730,O
Hprt,1730,O
locus,1730,O
leading,1730,O
to,1730,O
loss,1730,O
of,1730,O
activity,1730,O
have,1730,O
been,1730,O
described,1730,O
in,1730,O
laboratory,1730,O
animals,1730,O
.,1730,O
To,1731,O
derive,1731,O
an,1731,O
animal,1731,O
model,1731,O
for,1731,O
the,1731,O
Lesch-Nyhan,1731,B-SpecificDisease
syndrome,1731,I-SpecificDisease
",",1731,O
we,1731,O
have,1731,O
used,1731,O
cultured,1731,O
mouse,1731,O
embryonic,1731,O
stem,1731,O
cells,1731,O
",",1731,O
mutagenized,1731,O
by,1731,O
retroviral,1731,O
insertion,1731,O
and,1731,O
selected,1731,O
for,1731,O
loss,1731,O
of,1731,O
HPRT,1731,O
activity,1731,O
",",1731,O
to,1731,O
construct,1731,O
chimaeric,1731,O
mice,1731,O
.,1731,O
Two,1732,O
clonal,1732,O
lines,1732,O
carrying,1732,O
different,1732,O
mutant,1732,O
Hprt,1732,O
alleles,1732,O
have,1732,O
given,1732,O
rise,1732,O
to,1732,O
germ,1732,O
cells,1732,O
in,1732,O
chimaeras,1732,O
",",1732,O
allowing,1732,O
the,1732,O
derivation,1732,O
of,1732,O
strains,1732,O
of,1732,O
mutant,1732,O
mice,1732,O
having,1732,O
the,1732,O
same,1732,O
biochemical,1732,O
defect,1732,O
as,1732,O
Lesch-Nyhan,1732,B-Modifier
patients,1732,O
.,1732,O
Male,1733,O
mice,1733,O
carrying,1733,O
the,1733,O
mutant,1733,O
alleles,1733,O
are,1733,O
viable,1733,O
and,1733,O
analysis,1733,O
of,1733,O
their,1733,O
cells,1733,O
shows,1733,O
a,1733,O
total,1733,O
lack,1733,O
of,1733,O
HPRT,1733,O
activity,1733,O
..,1733,O
Re-evaluation,1734,O
of,1734,O
the,1734,O
sublocalization,1734,O
of,1734,O
esterase,1734,O
D,1734,O
and,1734,O
its,1734,O
relation,1734,O
to,1734,O
the,1734,O
retinoblastoma,1734,B-Modifier
locus,1734,O
by,1734,O
in,1734,O
situ,1734,O
hybridization,1734,O
.,1734,O
In,1735,O
situ,1735,O
hybridization,1735,O
of,1735,O
a,1735,O
cDNA,1735,O
probe,1735,O
for,1735,O
the,1735,O
esterase,1735,O
D,1735,O
gene,1735,O
(,1735,O
ESD,1735,O
),1735,O
was,1735,O
carried,1735,O
out,1735,O
on,1735,O
human,1735,O
chromosomes,1735,O
.,1735,O
The,1736,O
probe,1736,O
hybridized,1736,O
most,1736,O
strongly,1736,O
to,1736,O
13q14,1736,O
.,1736,O
2,1737,O
and,1737,O
13q14,1737,O
.,1737,O
3,1738,O
.,1738,O
This,1739,O
observation,1739,O
raises,1739,O
doubts,1739,O
concerning,1739,O
the,1739,O
most,1739,O
recently,1739,O
published,1739,O
assignment,1739,O
of,1739,O
ESD,1739,O
to,1739,O
13q14,1739,O
.,1739,O
1,1740,O
.,1740,O
A,1741,O
deletion,1741,O
in,1741,O
an,1741,O
individual,1741,O
with,1741,O
retinoblastoma,1741,B-SpecificDisease
was,1741,O
reported,1741,O
to,1741,O
separate,1741,O
the,1741,O
closely,1741,O
linked,1741,O
ESD,1741,O
and,1741,O
retinoblastoma,1741,B-Modifier
(,1741,O
RB1,1741,O
),1741,O
loci,1741,O
",",1741,O
placing,1741,O
ESD,1741,O
proximal,1741,O
to,1741,O
RB1,1741,O
.,1741,O
Quantitative,1742,O
in,1742,O
situ,1742,O
hybridization,1742,O
studies,1742,O
of,1742,O
this,1742,O
deletion,1742,O
do,1742,O
not,1742,O
confirm,1742,O
this,1742,O
interpretation,1742,O
.,1742,O
Rather,1743,O
",",1743,O
they,1743,O
suggest,1743,O
that,1743,O
ESD,1743,O
is,1743,O
missing,1743,O
from,1743,O
the,1743,O
deleted,1743,O
chromosome,1743,O
13,1743,O
and,1743,O
duplicated,1743,O
on,1743,O
the,1743,O
normal,1743,O
homolog,1743,O
.,1743,O
From,1744,O
these,1744,O
findings,1744,O
",",1744,O
we,1744,O
conclude,1744,O
that,1744,O
the,1744,O
deletion,1744,O
in,1744,O
this,1744,O
individual,1744,O
can,1744,O
not,1744,O
be,1744,O
used,1744,O
to,1744,O
determine,1744,O
the,1744,O
orientation,1744,O
nor,1744,O
the,1744,O
sublocalization,1744,O
of,1744,O
ESD,1744,O
and,1744,O
RB1,1744,O
within,1744,O
the,1744,O
13q14,1744,O
region,1744,O
.,1744,O
Mild,1745,O
and,1745,O
severe,1745,O
muscular,1745,B-DiseaseClass
dystrophy,1745,I-DiseaseClass
associated,1745,O
with,1745,O
deletions,1745,O
in,1745,O
Xp21,1745,O
of,1745,O
the,1745,O
human,1745,O
X,1745,O
chromosome,1745,O
.,1745,O
We,1746,O
have,1746,O
analysed,1746,O
over,1746,O
300,1746,O
patients,1746,O
suffering,1746,O
from,1746,O
Duchenne,1746,O
or,1746,O
Becker,1746,O
muscular,1746,O
dystrophy,1746,O
(,1746,O
DMD,1746,B-SpecificDisease
or,1746,O
BMD,1746,B-SpecificDisease
),1746,O
.,1746,O
Deletions,1747,O
have,1747,O
been,1747,O
characterised,1747,O
which,1747,O
encompass,1747,O
either,1747,O
the,1747,O
pERT87,1747,O
(,1747,O
DXS164,1747,O
),1747,O
locus,1747,O
only,1747,O
",",1747,O
the,1747,O
XJ1,1747,O
.,1747,O
1,1748,O
(,1748,O
DXS206,1748,O
),1748,O
and,1748,O
HIP25,1748,O
loci,1748,O
only,1748,O
",",1748,O
or,1748,O
all,1748,O
three,1748,O
loci,1748,O
.,1748,O
These,1749,O
loci,1749,O
have,1749,O
been,1749,O
shown,1749,O
to,1749,O
lie,1749,O
within,1749,O
the,1749,O
DMD,1749,B-Modifier
region,1749,O
covering,1749,O
several,1749,O
hundred,1749,O
kilobases,1749,O
(,1749,O
kb,1749,O
),1749,O
of,1749,O
DNA,1749,O
.,1749,O
One,1750,O
mildly,1750,O
affected,1750,O
BMD,1750,B-Modifier
patient,1750,O
possesses,1750,O
a,1750,O
deletion,1750,O
of,1750,O
at,1750,O
least,1750,O
110,1750,O
kb,1750,O
including,1750,O
exons,1750,O
of,1750,O
the,1750,O
DMD,1750,B-Modifier
gene,1750,O
.,1750,O
Other,1751,O
patients,1751,O
with,1751,O
similar,1751,O
exon,1751,O
deletions,1751,O
",",1751,O
or,1751,O
smaller,1751,O
deletions,1751,O
",",1751,O
show,1751,O
the,1751,O
more,1751,O
severe,1751,O
phenotype,1751,O
typical,1751,O
of,1751,O
DMD,1751,B-SpecificDisease
.,1751,O
We,1752,O
conclude,1752,O
from,1752,O
these,1752,O
studies,1752,O
that,1752,O
the,1752,O
severity,1752,O
of,1752,O
the,1752,O
clinical,1752,O
phenotype,1752,O
can,1752,O
not,1752,O
be,1752,O
explained,1752,O
on,1752,O
the,1752,O
basis,1752,O
of,1752,O
the,1752,O
size,1752,O
of,1752,O
the,1752,O
deletion,1752,O
.,1752,O
We,1753,O
discuss,1753,O
this,1753,O
in,1753,O
the,1753,O
context,1753,O
of,1753,O
candidate,1753,O
gene,1753,O
sequences,1753,O
.,1753,O
Patterns,1754,O
of,1754,O
exon,1754,O
deletions,1754,O
in,1754,O
Duchenne,1754,O
and,1754,O
Becker,1754,O
muscular,1754,O
dystrophy,1754,O
.,1754,O
A,1755,O
panel,1755,O
of,1755,O
patients,1755,O
with,1755,O
Duchenne,1755,O
and,1755,O
Becker,1755,O
muscular,1755,O
dystrophy,1755,O
(,1755,O
DMD,1755,B-SpecificDisease
and,1755,O
BMD,1755,B-SpecificDisease
),1755,O
has,1755,O
been,1755,O
screened,1755,O
with,1755,O
the,1755,O
cDNA,1755,O
probes,1755,O
Cf56a,1755,O
and,1755,O
Cf23a,1755,O
",",1755,O
which,1755,O
detect,1755,O
exons,1755,O
in,1755,O
the,1755,O
central,1755,O
part,1755,O
of,1755,O
the,1755,O
DMD,1755,B-Modifier
gene,1755,O
.,1755,O
One,1756,O
or,1756,O
more,1756,O
exons,1756,O
were,1756,O
deleted,1756,O
in,1756,O
60,1756,O
%,1756,O
of,1756,O
patients,1756,O
.,1756,O
The,1757,O
deletions,1757,O
were,1757,O
mapped,1757,O
and,1757,O
prove,1757,O
to,1757,O
be,1757,O
heterogeneous,1757,O
in,1757,O
size,1757,O
and,1757,O
extent,1757,O
",",1757,O
particularly,1757,O
in,1757,O
DMD,1757,B-SpecificDisease
.,1757,O
Deletions,1758,O
specific,1758,O
to,1758,O
DMD,1758,B-SpecificDisease
and,1758,O
to,1758,O
BMD,1758,B-SpecificDisease
are,1758,O
described,1758,O
.,1758,O
Half,1759,O
of,1759,O
all,1759,O
BMD,1759,B-Modifier
patients,1759,O
have,1759,O
a,1759,O
deletion,1759,O
of,1759,O
one,1759,O
particular,1759,O
small,1759,O
group,1759,O
of,1759,O
exons,1759,O
;,1759,O
smaller,1759,O
deletions,1759,O
within,1759,O
this,1759,O
same,1759,O
group,1759,O
produce,1759,O
the,1759,O
more,1759,O
severe,1759,O
DMD,1759,B-SpecificDisease
..,1759,O
Glucose-6-phosphate,1760,O
dehydrogenase,1760,O
variants,1760,O
and,1760,O
their,1760,O
frequency,1760,O
in,1760,O
Guangdong,1760,O
",",1760,O
China,1760,O
.,1760,O
Erythrocyte,1761,O
glucose-6-phosphate,1761,O
dehydrogenase,1761,O
(,1761,O
G6PD,1761,O
),1761,O
was,1761,O
characterized,1761,O
in,1761,O
blood,1761,O
samples,1761,O
obtained,1761,O
from,1761,O
97,1761,O
randomly,1761,O
selected,1761,O
males,1761,O
with,1761,O
enzyme,1761,B-DiseaseClass
deficiency,1761,I-DiseaseClass
from,1761,O
various,1761,O
regions,1761,O
of,1761,O
Guangdong,1761,O
Province,1761,O
",",1761,O
China,1761,O
.,1761,O
Nine,1762,O
new,1762,O
variants,1762,O
(,1762,O
Gd,1762,O
Kaiping,1762,O
",",1762,O
Gd,1762,O
Boluo,1762,O
",",1762,O
Gd,1762,O
Huiyang,1762,O
",",1762,O
Gd,1762,O
Gaomin,1762,O
",",1762,O
Gd,1762,O
Qing-Baijiang,1762,O
",",1762,O
Gd,1762,O
Gaozhou,1762,O
",",1762,O
Gd,1762,O
Huazhou,1762,O
",",1762,O
Gd,1762,O
Nanhai,1762,O
",",1762,O
and,1762,O
Gd,1762,O
Guangzhou,1762,O
),1762,O
were,1762,O
identified,1762,O
.,1762,O
Of,1763,O
the,1763,O
31,1763,O
variants,1763,O
found,1763,O
in,1763,O
this,1763,O
province,1763,O
",",1763,O
Gd,1763,O
Kaiping,1763,O
",",1763,O
Gd,1763,O
Taiwan-Hakka,1763,O
",",1763,O
Gd,1763,O
Haad,1763,O
Yai,1763,O
",",1763,O
Gd,1763,O
Haad,1763,O
Yai-like,1763,O
and,1763,O
Gd,1763,O
Huiyang,1763,O
occurred,1763,O
most,1763,O
frequently,1763,O
.,1763,O
The,1764,O
frequency,1764,O
of,1764,O
each,1764,O
variant,1764,O
was,1764,O
calculated,1764,O
.,1764,O
The,1765,O
results,1765,O
demonstrated,1765,O
that,1765,O
the,1765,O
genetic,1765,O
heterogeneity,1765,O
of,1765,O
G6PD,1765,B-SpecificDisease
deficiency,1765,I-SpecificDisease
was,1765,O
high,1765,O
in,1765,O
this,1765,O
area,1765,O
..,1765,O
Homozygous,1766,O
and,1766,O
heterozygous,1766,O
deletions,1766,O
of,1766,O
the,1766,O
von,1766,B-Modifier
Willebrand,1766,I-Modifier
factor,1766,O
gene,1766,O
in,1766,O
patients,1766,O
and,1766,O
carriers,1766,O
of,1766,O
severe,1766,B-SpecificDisease
von,1766,I-SpecificDisease
Willebrand,1766,I-SpecificDisease
disease,1766,I-SpecificDisease
.,1766,O
Severe,1767,B-SpecificDisease
von,1767,I-SpecificDisease
Willebrand,1767,I-SpecificDisease
disease,1767,I-SpecificDisease
is,1767,O
characterized,1767,O
by,1767,O
undetectable,1767,O
or,1767,O
trace,1767,O
quantities,1767,O
of,1767,O
von,1767,B-Modifier
Willebrand,1767,I-Modifier
factor,1767,O
in,1767,O
plasma,1767,O
and,1767,O
tissue,1767,O
stores,1767,O
.,1767,O
We,1768,O
have,1768,O
studied,1768,O
the,1768,O
genomic,1768,O
DNA,1768,O
of,1768,O
10,1768,O
affected,1768,O
individuals,1768,O
from,1768,O
six,1768,O
families,1768,O
with,1768,O
this,1768,O
disorder,1768,O
using,1768,O
probes,1768,O
from,1768,O
the,1768,O
5,1768,O
and,1768,O
3,1768,O
ends,1768,O
of,1768,O
the,1768,O
vWF,1768,O
cDNA,1768,O
and,1768,O
with,1768,O
a,1768,O
probe,1768,O
extending,1768,O
from,1768,O
the,1768,O
5,1768,O
end,1768,O
into,1768,O
the,1768,O
central,1768,O
region,1768,O
.,1768,O
Southern,1769,O
blots,1769,O
of,1769,O
restriction,1769,O
endonuclease,1769,O
digests,1769,O
and,1769,O
gene,1769,O
dosage,1769,O
analysis,1769,O
measurements,1769,O
carried,1769,O
out,1769,O
with,1769,O
quantitative,1769,O
slot,1769,O
blots,1769,O
of,1769,O
undigested,1769,O
genomic,1769,O
DNA,1769,O
separated,1769,O
these,1769,O
patients,1769,O
into,1769,O
three,1769,O
groups,1769,O
.,1769,O
The,1770,O
first,1770,O
group,1770,O
consisted,1770,O
of,1770,O
a,1770,O
family,1770,O
with,1770,O
complete,1770,O
homozygous,1770,O
deletions,1770,O
of,1770,O
the,1770,O
vWF,1770,O
gene,1770,O
in,1770,O
the,1770,O
four,1770,O
probands,1770,O
.,1770,O
Gene,1771,O
dosage,1771,O
analysis,1771,O
was,1771,O
consistent,1771,O
with,1771,O
heterozygous,1771,O
deletions,1771,O
in,1771,O
both,1771,O
of,1771,O
the,1771,O
asymptomatic,1771,O
parents,1771,O
and,1771,O
four,1771,O
asymptomatic,1771,O
siblings,1771,O
of,1771,O
this,1771,O
kindred,1771,O
(,1771,O
P,1771,O
less,1771,O
than,1771,O
0,1771,O
.,1771,O
01,1772,O
),1772,O
.,1772,O
The,1773,O
second,1773,O
group,1773,O
was,1773,O
comprised,1773,O
of,1773,O
a,1773,O
family,1773,O
in,1773,O
which,1773,O
there,1773,O
was,1773,O
a,1773,O
complete,1773,O
heterozygous,1773,O
deletion,1773,O
of,1773,O
the,1773,O
vWF,1773,O
gene,1773,O
in,1773,O
the,1773,O
proband,1773,O
and,1773,O
one,1773,O
asymptomatic,1773,O
parent,1773,O
",",1773,O
suggesting,1773,O
that,1773,O
a,1773,O
different,1773,O
type,1773,O
of,1773,O
genetic,1773,B-DiseaseClass
abnormality,1773,I-DiseaseClass
was,1773,O
inherited,1773,O
from,1773,O
the,1773,O
other,1773,O
parent,1773,O
.,1773,O
Thus,1774,O
",",1774,O
the,1774,O
patient,1774,O
appeared,1774,O
to,1774,O
be,1774,O
doubly,1774,O
heterozygous,1774,O
for,1774,O
interacting,1774,O
genetic,1774,B-DiseaseClass
abnormalities,1774,I-DiseaseClass
affecting,1774,O
vWF,1774,O
expression,1774,O
.,1774,O
In,1775,O
the,1775,O
third,1775,O
group,1775,O
",",1775,O
no,1775,O
gene,1775,O
deletions,1775,O
could,1775,O
be,1775,O
detected,1775,O
.,1775,O
Alloantibodies,1776,O
developed,1776,O
only,1776,O
in,1776,O
the,1776,O
kindred,1776,O
with,1776,O
homozygous,1776,O
deletions,1776,O
.,1776,O
These,1777,O
techniques,1777,O
should,1777,O
prove,1777,O
useful,1777,O
in,1777,O
identifying,1777,O
carriers,1777,O
of,1777,O
severe,1777,B-SpecificDisease
von,1777,I-SpecificDisease
Willebrand,1777,I-SpecificDisease
disease,1777,I-SpecificDisease
and,1777,O
also,1777,O
in,1777,O
defining,1777,O
patients,1777,O
predictably,1777,O
at,1777,O
risk,1777,O
of,1777,O
developing,1777,O
alloantibodies,1777,O
to,1777,O
vWF,1777,O
.,1777,O
Sjogren-Larsson,1778,B-SpecificDisease
syndrome,1778,I-SpecificDisease
.,1778,O
Impaired,1779,O
fatty,1779,O
alcohol,1779,O
oxidation,1779,O
in,1779,O
cultured,1779,O
fibroblasts,1779,O
due,1779,O
to,1779,O
deficient,1779,O
fatty,1779,O
alcohol,1779,O
:,1779,O
nicotinamide,1779,O
adenine,1779,O
dinucleotide,1779,O
oxidoreductase,1779,O
activity,1779,O
.,1779,O
Lipid,1780,O
metabolism,1780,O
was,1780,O
studied,1780,O
in,1780,O
cultured,1780,O
skin,1780,O
fibroblasts,1780,O
from,1780,O
patients,1780,O
with,1780,O
the,1780,O
inherited,1780,B-DiseaseClass
disorder,1780,I-DiseaseClass
",",1780,O
Sjogren-Larsson,1780,B-SpecificDisease
syndrome,1780,I-SpecificDisease
(,1780,O
SLS,1780,B-SpecificDisease
),1780,O
.,1780,O
Intact,1781,O
SLS,1781,B-Modifier
fibroblasts,1781,O
incubated,1781,O
in,1781,O
the,1781,O
presence,1781,O
of,1781,O
[,1781,O
1-14C,1781,O
],1781,O
palmitate,1781,O
accumulated,1781,O
more,1781,O
radioactive,1781,O
hexadecanol,1781,O
than,1781,O
did,1781,O
normal,1781,O
cells,1781,O
",",1781,O
whereas,1781,O
incorporation,1781,O
of,1781,O
radioactivity,1781,O
into,1781,O
other,1781,O
cellular,1781,O
lipids,1781,O
was,1781,O
unaltered,1781,O
.,1781,O
The,1782,O
hexadecanol,1782,O
content,1782,O
of,1782,O
SLS,1782,B-Modifier
fibroblasts,1782,O
was,1782,O
abnormally,1782,O
elevated,1782,O
.,1782,O
Hexadecanol,1783,O
accumulation,1783,O
was,1783,O
not,1783,O
due,1783,O
to,1783,O
increased,1783,O
fatty,1783,O
alcohol,1783,O
synthesis,1783,O
nor,1783,O
its,1783,O
deficient,1783,O
utilization,1783,O
for,1783,O
glycerol,1783,O
ether,1783,O
synthesis,1783,O
.,1783,O
The,1784,O
half-life,1784,O
of,1784,O
intracellular,1784,O
hexadecanol,1784,O
loaded,1784,O
into,1784,O
SLS,1784,B-Modifier
fibroblasts,1784,O
was,1784,O
increased,1784,O
(,1784,O
70,1784,O
min,1784,O
),1784,O
compared,1784,O
with,1784,O
normal,1784,O
(,1784,O
15,1784,O
min,1784,O
),1784,O
",",1784,O
and,1784,O
intact,1784,O
SLS,1784,B-Modifier
fibroblasts,1784,O
showed,1784,O
impaired,1784,O
oxidation,1784,O
of,1784,O
[,1784,O
14C,1784,O
],1784,O
-hexadecanol,1784,O
to,1784,O
fatty,1784,O
acid,1784,O
.,1784,O
Fatty,1785,O
alcohol,1785,O
NAD,1785,O
+,1785,O
oxidoreductase,1785,O
",",1785,O
the,1785,O
enzyme,1785,O
catalyzing,1785,O
this,1785,O
reaction,1785,O
",",1785,O
was,1785,O
deficient,1785,O
in,1785,O
SLS,1785,B-Modifier
fibroblasts,1785,O
.,1785,O
Mean,1786,O
total,1786,O
activity,1786,O
in,1786,O
SLS,1786,B-Modifier
fibroblasts,1786,O
(,1786,O
n,1786,O
=,1786,O
5,1786,O
),1786,O
was,1786,O
13,1786,O
%,1786,O
of,1786,O
that,1786,O
in,1786,O
normal,1786,O
fibroblasts,1786,O
",",1786,O
and,1786,O
palmitoyl,1786,O
CoA-inhibitable,1786,O
activity,1786,O
was,1786,O
1,1786,O
%,1786,O
of,1786,O
normal,1786,O
.,1786,O
Fibroblasts,1787,O
from,1787,O
two,1787,O
obligate,1787,O
SLS,1787,B-Modifier
heterozygotes,1787,O
had,1787,O
enzyme,1787,O
activities,1787,O
intermediate,1787,O
between,1787,O
that,1787,O
in,1787,O
normal,1787,O
fibroblasts,1787,O
and,1787,O
individuals,1787,O
with,1787,O
SLS,1787,B-SpecificDisease
.,1787,O
These,1788,O
results,1788,O
suggest,1788,O
that,1788,O
the,1788,O
primary,1788,O
defect,1788,O
in,1788,O
SLS,1788,B-SpecificDisease
is,1788,O
deficiency,1788,B-SpecificDisease
of,1788,I-SpecificDisease
fatty,1788,I-SpecificDisease
alcohol,1788,I-SpecificDisease
NAD,1788,I-SpecificDisease
+,1788,I-SpecificDisease
oxidoreductase,1788,I-SpecificDisease
.,1788,O
SLS,1789,B-SpecificDisease
represents,1789,O
the,1789,O
first,1789,O
inherited,1789,B-DiseaseClass
disorder,1789,I-DiseaseClass
in,1789,O
man,1789,O
associated,1789,O
with,1789,O
an,1789,O
isolated,1789,O
abnormality,1789,B-DiseaseClass
in,1789,I-DiseaseClass
fatty,1789,I-DiseaseClass
alcohol,1789,I-DiseaseClass
metabolism,1789,I-DiseaseClass
..,1789,O
Germinal,1790,O
mosaicism,1790,O
in,1790,O
Duchenne,1790,B-SpecificDisease
muscular,1790,I-SpecificDisease
dystrophy,1790,I-SpecificDisease
.,1790,O
We,1791,O
have,1791,O
identified,1791,O
a,1791,O
Duchenne,1791,B-Modifier
muscular,1791,I-Modifier
dystrophy,1791,I-Modifier
(,1791,O
DMD,1791,B-Modifier
),1791,O
pedigree,1791,O
where,1791,O
the,1791,O
disease,1791,O
is,1791,O
associated,1791,O
with,1791,O
a,1791,O
molecular,1791,O
deletion,1791,O
within,1791,O
the,1791,O
DMD,1791,B-Modifier
locus,1791,O
.,1791,O
We,1792,O
have,1792,O
examined,1792,O
the,1792,O
meiotic,1792,O
segregation,1792,O
products,1792,O
of,1792,O
the,1792,O
common,1792,O
female,1792,O
ancestor,1792,O
using,1792,O
marker,1792,O
restriction,1792,O
fragment,1792,O
length,1792,O
polymorphisms,1792,O
(,1792,O
RFLPs,1792,O
),1792,O
detected,1792,O
by,1792,O
probes,1792,O
that,1792,O
lie,1792,O
within,1792,O
this,1792,O
deletion,1792,O
.,1792,O
These,1793,O
studies,1793,O
show,1793,O
that,1793,O
this,1793,O
female,1793,O
has,1793,O
transmitted,1793,O
three,1793,O
distinct,1793,O
types,1793,O
of,1793,O
X,1793,O
chromosome,1793,O
to,1793,O
her,1793,O
offspring,1793,O
.,1793,O
This,1794,O
observation,1794,O
may,1794,O
be,1794,O
explained,1794,O
by,1794,O
postulating,1794,O
that,1794,O
the,1794,O
mutation,1794,O
arose,1794,O
as,1794,O
a,1794,O
postzygotic,1794,O
deletion,1794,O
within,1794,O
this,1794,O
common,1794,O
ancestor,1794,O
",",1794,O
who,1794,O
was,1794,O
consequently,1794,O
germinally,1794,O
mosaic,1794,O
..,1794,O
Nebulin,1795,O
seen,1795,O
in,1795,O
DMD,1795,B-Modifier
males,1795,O
including,1795,O
one,1795,O
patient,1795,O
with,1795,O
a,1795,O
large,1795,O
DNA,1795,O
deletion,1795,O
encompassing,1795,O
the,1795,O
DMD,1795,B-Modifier
gene,1795,O
.,1795,O
The,1796,O
presence,1796,O
of,1796,O
nebulin,1796,O
in,1796,O
a,1796,O
muscle,1796,O
specimen,1796,O
from,1796,O
a,1796,O
patient,1796,O
with,1796,O
Duchenne,1796,B-SpecificDisease
muscular,1796,I-SpecificDisease
dystrophy,1796,I-SpecificDisease
(,1796,O
DMD,1796,B-SpecificDisease
),1796,O
due,1796,O
to,1796,O
a,1796,O
large,1796,O
deletion,1796,O
precludes,1796,O
the,1796,O
possibility,1796,O
that,1796,O
this,1796,O
protein,1796,O
is,1796,O
the,1796,O
DMD,1796,B-Modifier
gene,1796,O
product,1796,O
..,1796,O
Expression,1797,O
of,1797,O
the,1797,O
murine,1797,O
Duchenne,1797,B-Modifier
muscular,1797,I-Modifier
dystrophy,1797,I-Modifier
gene,1797,O
in,1797,O
muscle,1797,O
and,1797,O
brain,1797,O
.,1797,O
Complementary,1798,O
DNA,1798,O
clones,1798,O
were,1798,O
isolated,1798,O
that,1798,O
represent,1798,O
the,1798,O
5,1798,O
terminal,1798,O
2,1798,O
.,1798,O
5,1799,O
kilobases,1799,O
of,1799,O
the,1799,O
murine,1799,O
Duchenne,1799,B-Modifier
muscular,1799,I-Modifier
dystrophy,1799,I-Modifier
(,1799,O
Dmd,1799,O
),1799,O
messenger,1799,O
RNA,1799,O
(,1799,O
mRNA,1799,O
),1799,O
.,1799,O
Mouse,1800,O
Dmd,1800,O
mRNA,1800,O
was,1800,O
detectable,1800,O
in,1800,O
skeletal,1800,O
and,1800,O
cardiac,1800,O
muscle,1800,O
and,1800,O
at,1800,O
a,1800,O
level,1800,O
approximately,1800,O
90,1800,O
percent,1800,O
lower,1800,O
in,1800,O
brain,1800,O
.,1800,O
Dmd,1801,O
mRNA,1801,O
is,1801,O
also,1801,O
present,1801,O
",",1801,O
but,1801,O
at,1801,O
much,1801,O
lower,1801,O
than,1801,O
normal,1801,O
levels,1801,O
",",1801,O
in,1801,O
both,1801,O
the,1801,O
muscle,1801,O
and,1801,O
brain,1801,O
of,1801,O
three,1801,O
different,1801,O
strains,1801,O
of,1801,O
dystrophic,1801,B-Modifier
mdx,1801,O
mice,1801,O
.,1801,O
The,1802,O
identification,1802,O
of,1802,O
Dmd,1802,O
mRNA,1802,O
in,1802,O
brain,1802,O
raises,1802,O
the,1802,O
possibility,1802,O
of,1802,O
a,1802,O
relation,1802,O
between,1802,O
human,1802,O
Duchenne,1802,B-SpecificDisease
muscular,1802,I-SpecificDisease
dystrophy,1802,I-SpecificDisease
(,1802,O
DMD,1802,B-SpecificDisease
),1802,O
gene,1802,O
expression,1802,O
and,1802,O
the,1802,O
mental,1802,B-DiseaseClass
retardation,1802,I-DiseaseClass
found,1802,O
in,1802,O
some,1802,O
DMD,1802,B-Modifier
males,1802,O
.,1802,O
These,1803,O
results,1803,O
also,1803,O
provide,1803,O
evidence,1803,O
that,1803,O
the,1803,O
mdx,1803,O
mutations,1803,O
are,1803,O
allelic,1803,O
variants,1803,O
of,1803,O
mouse,1803,O
Dmd,1803,O
gene,1803,O
mutations,1803,O
.,1803,O
Glucose,1804,B-SpecificDisease
6-phosphate,1804,I-SpecificDisease
dehydrogenase,1804,I-SpecificDisease
deficiency,1804,I-SpecificDisease
and,1804,O
incidence,1804,O
of,1804,O
hematologic,1804,B-DiseaseClass
malignancy,1804,I-DiseaseClass
.,1804,O
We,1805,O
have,1805,O
evaluated,1805,O
the,1805,O
hypothesis,1805,O
of,1805,O
a,1805,O
negative,1805,O
association,1805,O
between,1805,O
glucose,1805,B-SpecificDisease
6-phosphate,1805,I-SpecificDisease
dehydrogenase,1805,I-SpecificDisease
(,1805,I-SpecificDisease
G6PD,1805,I-SpecificDisease
),1805,I-SpecificDisease
deficiency,1805,I-SpecificDisease
and,1805,O
cancer,1805,B-DiseaseClass
in,1805,O
a,1805,O
cohort,1805,O
of,1805,O
481,1805,O
Sardinian,1805,O
males,1805,O
with,1805,O
hematological,1805,B-DiseaseClass
malignancies,1805,I-DiseaseClass
.,1805,O
The,1806,O
frequency,1806,O
of,1806,O
G6PD,1806,B-SpecificDisease
deficiency,1806,I-SpecificDisease
in,1806,O
the,1806,O
patients,1806,O
was,1806,O
not,1806,O
different,1806,O
from,1806,O
the,1806,O
incidence,1806,O
in,1806,O
a,1806,O
group,1806,O
of,1806,O
16,1806,O
",",1806,O
219,1806,O
controls,1806,O
.,1806,O
The,1807,O
same,1807,O
conclusion,1807,O
resulted,1807,O
from,1807,O
the,1807,O
comparison,1807,O
of,1807,O
the,1807,O
frequency,1807,O
of,1807,O
expression,1807,O
of,1807,O
the,1807,O
GdB,1807,O
gene,1807,O
in,1807,O
23,1807,O
heterozygous,1807,O
women,1807,O
having,1807,O
a,1807,O
clonal,1807,O
hematologic,1807,B-DiseaseClass
disease,1807,I-DiseaseClass
and,1807,O
a,1807,O
control,1807,O
group,1807,O
of,1807,O
37,1807,O
healthy,1807,O
heterozygotes,1807,O
.,1807,O
Therefore,1808,O
at,1808,O
present,1808,O
there,1808,O
is,1808,O
no,1808,O
evidence,1808,O
that,1808,O
G6PD,1808,B-SpecificDisease
deficiency,1808,I-SpecificDisease
has,1808,O
a,1808,O
protective,1808,O
effect,1808,O
against,1808,O
development,1808,O
of,1808,O
hematologic,1808,B-DiseaseClass
neoplasms,1808,I-DiseaseClass
..,1808,O
Hepatoblastoma,1809,B-SpecificDisease
",",1809,O
pigmented,1809,B-DiseaseClass
ocular,1809,I-DiseaseClass
fundus,1809,I-DiseaseClass
lesions,1809,I-DiseaseClass
and,1809,O
jaw,1809,B-DiseaseClass
lesions,1809,I-DiseaseClass
in,1809,O
Gardner,1809,B-SpecificDisease
syndrome,1809,I-SpecificDisease
.,1809,O
Hepatoblastoma,1810,B-SpecificDisease
is,1810,O
a,1810,O
rare,1810,O
neoplasm,1810,B-DiseaseClass
of,1810,O
infants,1810,O
and,1810,O
children,1810,O
only,1810,O
recently,1810,O
documented,1810,O
in,1810,O
association,1810,O
with,1810,O
hereditary,1810,B-SpecificDisease
adenomatous,1810,I-SpecificDisease
polyposis,1810,I-SpecificDisease
of,1810,I-SpecificDisease
the,1810,I-SpecificDisease
colon,1810,I-SpecificDisease
[,1810,O
Kingston,1810,O
et,1810,O
al.,1810,O
",",1810,O
1983,1810,O
],1810,O
.,1810,O
We,1811,O
report,1811,O
four,1811,O
children,1811,O
with,1811,O
hepatoblastoma,1811,B-SpecificDisease
from,1811,O
four,1811,O
unrelated,1811,O
families,1811,O
with,1811,O
Gardner,1811,B-SpecificDisease
syndrome,1811,I-SpecificDisease
(,1811,O
GS,1811,B-SpecificDisease
),1811,O
.,1811,O
One,1812,O
child,1812,O
",",1812,O
now,1812,O
19,1812,O
years,1812,O
old,1812,O
",",1812,O
survived,1812,O
after,1812,O
a,1812,O
resection,1812,O
of,1812,O
a,1812,O
hepatoblastoma,1812,B-SpecificDisease
in,1812,O
infancy,1812,O
and,1812,O
recently,1812,O
was,1812,O
found,1812,O
to,1812,O
have,1812,O
GS,1812,B-SpecificDisease
.,1812,O
He,1813,O
has,1813,O
an,1813,O
associated,1813,O
odontoma,1813,B-SpecificDisease
and,1813,O
pigmented,1813,B-DiseaseClass
ocular,1813,I-DiseaseClass
fundus,1813,I-DiseaseClass
lesions,1813,I-DiseaseClass
",",1813,O
both,1813,O
of,1813,O
which,1813,O
have,1813,O
been,1813,O
shown,1813,O
to,1813,O
be,1813,O
clinical,1813,O
markers,1813,O
of,1813,O
GS,1813,B-SpecificDisease
.,1813,O
Many,1814,O
individuals,1814,O
in,1814,O
these,1814,O
four,1814,O
GS,1814,B-Modifier
families,1814,O
",",1814,O
both,1814,O
affected,1814,O
and,1814,O
at,1814,O
risk,1814,O
",",1814,O
have,1814,O
osteomatous,1814,B-DiseaseClass
jaw,1814,I-DiseaseClass
lesions,1814,I-DiseaseClass
and,1814,O
pigmented,1814,B-DiseaseClass
ocular,1814,I-DiseaseClass
fundus,1814,I-DiseaseClass
lesions,1814,I-DiseaseClass
.,1814,O
A,1815,O
search,1815,O
for,1815,O
colonic,1815,B-DiseaseClass
polyps,1815,I-DiseaseClass
should,1815,O
be,1815,O
made,1815,O
in,1815,O
families,1815,O
of,1815,O
infants,1815,O
and,1815,O
children,1815,O
with,1815,O
hepatoblastoma,1815,B-SpecificDisease
.,1815,O
If,1816,O
the,1816,O
child,1816,O
survives,1816,O
",",1816,O
he,1816,O
or,1816,O
she,1816,O
should,1816,O
be,1816,O
monitored,1816,O
for,1816,O
the,1816,O
later,1816,O
appearance,1816,O
of,1816,O
colonic,1816,B-DiseaseClass
polyps,1816,I-DiseaseClass
.,1816,O
The,1817,O
finding,1817,O
of,1817,O
jaw,1817,B-DiseaseClass
lesions,1817,I-DiseaseClass
and/or,1817,O
pigmented,1817,B-DiseaseClass
ocular,1817,I-DiseaseClass
fundus,1817,I-DiseaseClass
lesions,1817,I-DiseaseClass
in,1817,O
relatives,1817,O
at,1817,O
risk,1817,O
are,1817,O
indications,1817,O
of,1817,O
the,1817,O
possible,1817,O
presence,1817,O
of,1817,O
the,1817,O
GS,1817,B-Modifier
gene,1817,O
.,1817,O
Identification,1818,O
of,1818,O
an,1818,O
altered,1818,O
splice,1818,O
site,1818,O
in,1818,O
Ashkenazi,1818,O
Tay-Sachs,1818,B-SpecificDisease
disease,1818,I-SpecificDisease
.,1818,O
Tay-Sachs,1819,B-SpecificDisease
disease,1819,I-SpecificDisease
is,1819,O
an,1819,O
autosomal,1819,B-DiseaseClass
recessive,1819,I-DiseaseClass
genetic,1819,I-DiseaseClass
disorder,1819,I-DiseaseClass
resulting,1819,O
from,1819,O
mutation,1819,O
of,1819,O
the,1819,O
HEXA,1819,O
gene,1819,O
encoding,1819,O
the,1819,O
alpha-subunit,1819,O
of,1819,O
the,1819,O
lysosomal,1819,O
enzyme,1819,O
",",1819,O
beta-N-acetylhexosaminidase,1819,O
A,1819,O
(,1819,O
ref,1819,O
.,1819,O
1,1820,O
),1820,O
.,1820,O
A,1821,O
relatively,1821,O
high,1821,O
frequency,1821,O
of,1821,O
carriers,1821,O
(,1821,O
1/27,1821,O
),1821,O
of,1821,O
a,1821,O
lethal,1821,O
",",1821,O
infantile,1821,O
form,1821,O
of,1821,O
the,1821,O
disease,1821,O
is,1821,O
found,1821,O
in,1821,O
the,1821,O
Ashkenazi,1821,O
Jewish,1821,O
population,1821,O
",",1821,O
but,1821,O
it,1821,O
is,1821,O
not,1821,O
yet,1821,O
evident,1821,O
whether,1821,O
this,1821,O
has,1821,O
resulted,1821,O
from,1821,O
a,1821,O
founder,1821,O
effect,1821,O
and,1821,O
random,1821,O
genetic,1821,O
drift,1821,O
or,1821,O
from,1821,O
a,1821,O
selective,1821,O
advantage,1821,O
of,1821,O
heterozygotes,1821,O
.,1821,O
We,1822,O
have,1822,O
identified,1822,O
a,1822,O
single-base,1822,O
mutation,1822,O
in,1822,O
a,1822,O
cloned,1822,O
fragment,1822,O
of,1822,O
the,1822,O
HEXA,1822,O
gene,1822,O
from,1822,O
an,1822,O
Ashkenazi,1822,O
Jewish,1822,O
patient,1822,O
.,1822,O
This,1823,O
change,1823,O
",",1823,O
the,1823,O
substitution,1823,O
of,1823,O
a,1823,O
C,1823,O
for,1823,O
G,1823,O
in,1823,O
the,1823,O
first,1823,O
nucleotide,1823,O
of,1823,O
intron,1823,O
12,1823,O
is,1823,O
expected,1823,O
to,1823,O
result,1823,O
in,1823,O
defective,1823,O
splicing,1823,O
of,1823,O
the,1823,O
messenger,1823,O
RNA,1823,O
.,1823,O
A,1824,O
test,1824,O
for,1824,O
the,1824,O
mutant,1824,O
allele,1824,O
based,1824,O
on,1824,O
amplification,1824,O
of,1824,O
DNA,1824,O
by,1824,O
the,1824,O
polymerase,1824,O
chain,1824,O
rection,1824,O
and,1824,O
cleavage,1824,O
of,1824,O
a,1824,O
DdeI,1824,O
restriction,1824,O
site,1824,O
generated,1824,O
by,1824,O
the,1824,O
mutation,1824,O
revealed,1824,O
that,1824,O
this,1824,O
case,1824,O
and,1824,O
two,1824,O
other,1824,O
cases,1824,O
of,1824,O
the,1824,O
Ashkenazi,1824,O
",",1824,O
infantile,1824,O
form,1824,O
of,1824,O
Tay-Sachs,1824,B-SpecificDisease
disease,1824,I-SpecificDisease
are,1824,O
heterozygous,1824,O
for,1824,O
two,1824,O
different,1824,O
mutations,1824,O
.,1824,O
The,1825,O
occurrence,1825,O
of,1825,O
multiple,1825,O
mutant,1825,O
alleles,1825,O
warrants,1825,O
further,1825,O
examination,1825,O
of,1825,O
the,1825,O
selective,1825,O
advantage,1825,O
hypothesis,1825,O
..,1825,O
X-linked,1826,B-SpecificDisease
glucose-6-phosphate,1826,I-SpecificDisease
dehydrogenase,1826,I-SpecificDisease
deficiency,1826,I-SpecificDisease
in,1826,O
Mus,1826,O
musculus,1826,O
.,1826,O
A,1827,O
mouse,1827,O
with,1827,O
X-linked,1827,B-SpecificDisease
glucose-6-phosphate,1827,I-SpecificDisease
dehydrogenase,1827,I-SpecificDisease
(,1827,I-SpecificDisease
G6PD,1827,I-SpecificDisease
),1827,I-SpecificDisease
deficiency,1827,I-SpecificDisease
has,1827,O
been,1827,O
recovered,1827,O
in,1827,O
offspring,1827,O
of,1827,O
1-ethyl-1-nitrosourea-treated,1827,O
male,1827,O
mice,1827,O
.,1827,O
The,1828,O
activity,1828,O
alteration,1828,O
was,1828,O
detected,1828,O
in,1828,O
blood,1828,O
but,1828,O
can,1828,O
also,1828,O
be,1828,O
observed,1828,O
in,1828,O
other,1828,O
tissue,1828,O
extracts,1828,O
.,1828,O
Hemizygous,1829,O
",",1829,O
heterozygous,1829,O
",",1829,O
and,1829,O
homozygous,1829,O
mutants,1829,O
have,1829,O
",",1829,O
respectively,1829,O
",",1829,O
about,1829,O
15,1829,O
",",1829,O
60,1829,O
",",1829,O
and,1829,O
15,1829,O
%,1829,O
G6PD,1829,O
remaining,1829,O
activity,1829,O
in,1829,O
the,1829,O
blood,1829,O
as,1829,O
compared,1829,O
to,1829,O
the,1829,O
wild,1829,O
type,1829,O
.,1829,O
Erythrocyte,1830,O
indices,1830,O
did,1830,O
not,1830,O
show,1830,O
differences,1830,O
between,1830,O
mutants,1830,O
and,1830,O
wild,1830,O
types,1830,O
.,1830,O
The,1831,O
mutation,1831,O
does,1831,O
not,1831,O
affect,1831,O
the,1831,O
electrophoretic,1831,O
migration,1831,O
",",1831,O
the,1831,O
isoelectric,1831,O
point,1831,O
",",1831,O
or,1831,O
the,1831,O
thermal,1831,O
stability,1831,O
.,1831,O
Kinetic,1832,O
properties,1832,O
",",1832,O
such,1832,O
as,1832,O
the,1832,O
Km,1832,O
for,1832,O
glucose-6-phosphate,1832,O
or,1832,O
for,1832,O
NADP,1832,O
and,1832,O
the,1832,O
relative,1832,O
utilization,1832,O
of,1832,O
substrate,1832,O
analogues,1832,O
",",1832,O
showed,1832,O
no,1832,O
differences,1832,O
between,1832,O
wild,1832,O
types,1832,O
and,1832,O
mutants,1832,O
with,1832,O
the,1832,O
exception,1832,O
of,1832,O
the,1832,O
relative,1832,O
utilization,1832,O
of,1832,O
deamino-NADP,1832,O
which,1832,O
was,1832,O
significantly,1832,O
lower,1832,O
in,1832,O
mutants,1832,O
.,1832,O
This,1833,O
is,1833,O
presently,1833,O
the,1833,O
only,1833,O
animal,1833,O
model,1833,O
for,1833,O
X-linked,1833,B-SpecificDisease
G6PD,1833,I-SpecificDisease
deficiency,1833,I-SpecificDisease
in,1833,O
humans,1833,O
..,1833,O
Diverse,1834,O
point,1834,O
mutations,1834,O
in,1834,O
the,1834,O
human,1834,O
glucose-6-phosphate,1834,O
dehydrogenase,1834,O
gene,1834,O
cause,1834,O
enzyme,1834,B-DiseaseClass
deficiency,1834,I-DiseaseClass
and,1834,O
mild,1834,O
or,1834,O
severe,1834,O
hemolytic,1834,B-SpecificDisease
anemia,1834,I-SpecificDisease
.,1834,O
Glucose-6-phosphate,1835,O
dehydrogenase,1835,O
(,1835,O
G6PD,1835,O
;,1835,O
EC,1835,O
1,1835,O
.,1835,O
1,1836,O
.,1836,O
1,1837,O
.,1837,O
49,1838,O
),1838,O
deficiency,1838,O
is,1838,O
a,1838,O
common,1838,O
genetic,1838,B-DiseaseClass
abnormality,1838,I-DiseaseClass
affecting,1838,O
an,1838,O
estimated,1838,O
400,1838,O
million,1838,O
people,1838,O
worldwide,1838,O
.,1838,O
Clinical,1839,O
and,1839,O
biochemical,1839,O
analyses,1839,O
have,1839,O
identified,1839,O
many,1839,O
variants,1839,O
exhibiting,1839,O
a,1839,O
range,1839,O
of,1839,O
phenotypes,1839,O
",",1839,O
which,1839,O
have,1839,O
been,1839,O
well,1839,O
characterized,1839,O
from,1839,O
the,1839,O
hematological,1839,O
point,1839,O
of,1839,O
view,1839,O
.,1839,O
However,1840,O
",",1840,O
until,1840,O
now,1840,O
",",1840,O
their,1840,O
precise,1840,O
molecular,1840,O
basis,1840,O
has,1840,O
remained,1840,O
unknown,1840,O
.,1840,O
We,1841,O
have,1841,O
cloned,1841,O
and,1841,O
sequenced,1841,O
seven,1841,O
mutant,1841,O
G6PD,1841,O
alleles,1841,O
.,1841,O
In,1842,O
the,1842,O
nondeficient,1842,O
polymorphic,1842,O
African,1842,O
variant,1842,O
G6PD,1842,O
A,1842,O
we,1842,O
have,1842,O
found,1842,O
a,1842,O
single,1842,O
point,1842,O
mutation,1842,O
.,1842,O
The,1843,O
other,1843,O
six,1843,O
mutants,1843,O
investigated,1843,O
were,1843,O
all,1843,O
associated,1843,O
with,1843,O
enzyme,1843,B-DiseaseClass
deficiency,1843,I-DiseaseClass
.,1843,O
In,1844,O
one,1844,O
of,1844,O
the,1844,O
commonest,1844,O
",",1844,O
G6PD,1844,O
Mediterranean,1844,O
",",1844,O
which,1844,O
is,1844,O
associated,1844,O
with,1844,O
favism,1844,B-DiseaseClass
among,1844,O
other,1844,O
clinical,1844,O
manifestations,1844,O
",",1844,O
a,1844,O
single,1844,O
amino,1844,O
acid,1844,O
replacement,1844,O
was,1844,O
found,1844,O
(,1844,O
serine,1844,O
--,1844,O
--,1844,O
phenylalanine,1844,O
),1844,O
it,1844,O
must,1844,O
be,1844,O
responsible,1844,O
for,1844,O
the,1844,O
decreased,1844,O
stability,1844,O
and,1844,O
the,1844,O
reduced,1844,O
catalytic,1844,O
efficiency,1844,O
of,1844,O
this,1844,O
enzyme,1844,O
.,1844,O
Single,1845,O
point,1845,O
mutations,1845,O
were,1845,O
also,1845,O
found,1845,O
in,1845,O
G6PD,1845,O
Metaponto,1845,O
(,1845,O
Southern,1845,O
Italy,1845,O
),1845,O
and,1845,O
in,1845,O
G6PD,1845,O
Ilesha,1845,O
(,1845,O
Nigeria,1845,O
),1845,O
",",1845,O
which,1845,O
are,1845,O
asymptomatic,1845,O
",",1845,O
and,1845,O
in,1845,O
G6PD,1845,O
Chatham,1845,O
",",1845,O
which,1845,O
was,1845,O
observed,1845,O
in,1845,O
an,1845,O
Indian,1845,O
boy,1845,O
with,1845,O
neonatal,1845,B-DiseaseClass
jaundice,1845,I-DiseaseClass
.,1845,O
In,1846,O
G6PD,1846,O
``,1846,O
Matera,1846,O
",",1846,O
``,1846,O
which,1846,O
is,1846,O
now,1846,O
known,1846,O
to,1846,O
be,1846,O
the,1846,O
same,1846,O
as,1846,O
G6PD,1846,O
A-,1846,O
",",1846,O
two,1846,O
separate,1846,O
point,1846,O
mutations,1846,O
were,1846,O
found,1846,O
",",1846,O
one,1846,O
of,1846,O
which,1846,O
is,1846,O
the,1846,O
same,1846,O
as,1846,O
in,1846,O
G6PD,1846,O
A,1846,O
.,1846,O
In,1847,O
G6PD,1847,O
Santiago,1847,O
",",1847,O
a,1847,O
de,1847,O
novo,1847,O
mutation,1847,O
(,1847,O
glycine,1847,O
--,1847,O
--,1847,O
arginine,1847,O
),1847,O
is,1847,O
associated,1847,O
with,1847,O
severe,1847,O
chronic,1847,O
hemolytic,1847,B-SpecificDisease
anemia,1847,I-SpecificDisease
.,1847,O
The,1848,O
mutations,1848,O
observed,1848,O
show,1848,O
a,1848,O
striking,1848,O
predominance,1848,O
of,1848,O
C,1848,O
--,1848,O
--,1848,O
T,1848,O
transitions,1848,O
",",1848,O
with,1848,O
CG,1848,O
doublets,1848,O
involved,1848,O
in,1848,O
four,1848,O
of,1848,O
seven,1848,O
cases,1848,O
.,1848,O
Thus,1849,O
",",1849,O
diverse,1849,O
point,1849,O
mutations,1849,O
may,1849,O
account,1849,O
largely,1849,O
for,1849,O
the,1849,O
phenotypic,1849,O
heterogeneity,1849,O
of,1849,O
G6PD,1849,B-SpecificDisease
deficiency,1849,I-SpecificDisease
.,1849,O
Tight,1850,O
linkage,1850,O
between,1850,O
myotonic,1850,B-Modifier
dystrophy,1850,I-Modifier
and,1850,O
apolipoprotein,1850,O
E,1850,O
genes,1850,O
revealed,1850,O
with,1850,O
allele-specific,1850,O
oligonucleotides,1850,O
.,1850,O
In,1851,O
16,1851,O
families,1851,O
with,1851,O
myotonic,1851,B-SpecificDisease
dystrophy,1851,I-SpecificDisease
(,1851,O
DM,1851,B-SpecificDisease
),1851,O
a,1851,O
novel,1851,O
approach,1851,O
based,1851,O
on,1851,O
use,1851,O
of,1851,O
allele-specific,1851,O
oligonucleotides,1851,O
has,1851,O
been,1851,O
employed,1851,O
to,1851,O
study,1851,O
the,1851,O
linkage,1851,O
relationship,1851,O
between,1851,O
the,1851,O
apolipoprotein,1851,O
E,1851,O
(,1851,O
APOE,1851,O
),1851,O
gene,1851,O
and,1851,O
DM,1851,B-SpecificDisease
.,1851,O
Synthetic,1852,O
oligonucleotides,1852,O
",",1852,O
designed,1852,O
to,1852,O
discriminate,1852,O
between,1852,O
APOE,1852,O
alleles,1852,O
epsilon,1852,O
3,1852,O
and,1852,O
epsilon,1852,O
4,1852,O
",",1852,O
enabled,1852,O
us,1852,O
to,1852,O
distinguish,1852,O
heterozygous,1852,O
carriers,1852,O
in,1852,O
a,1852,O
hybridization,1852,O
assay,1852,O
.,1852,O
In,1853,O
a,1853,O
subset,1853,O
of,1853,O
families,1853,O
",",1853,O
the,1853,O
relevant,1853,O
segment,1853,O
of,1853,O
the,1853,O
APOE,1853,O
gene,1853,O
was,1853,O
enzymatically,1853,O
amplified,1853,O
to,1853,O
increase,1853,O
the,1853,O
sensitivity,1853,O
of,1853,O
the,1853,O
method,1853,O
.,1853,O
For,1854,O
DM,1854,O
and,1854,O
APOE,1854,O
",",1854,O
a,1854,O
maximum,1854,O
lod,1854,O
score,1854,O
(,1854,O
zmax,1854,O
of,1854,O
7,1854,O
.,1854,O
47,1855,O
was,1855,O
obtained,1855,O
at,1855,O
a,1855,O
recombination,1855,O
frequency,1855,O
(,1855,O
theta,1855,O
),1855,O
of,1855,O
0,1855,O
.,1855,O
047,1856,O
(,1856,O
male,1856,O
theta,1856,O
=,1856,O
female,1856,O
theta,1856,O
),1856,O
.,1856,O
No,1857,O
recombination,1857,O
(,1857,O
maximum,1857,O
lod,1857,O
score,1857,O
of,1857,O
5,1857,O
.,1857,O
61,1858,O
at,1858,O
theta,1858,O
=,1858,O
0,1858,O
.,1858,O
0,1859,O
),1859,O
was,1859,O
found,1859,O
between,1859,O
APOE,1859,O
and,1859,O
the,1859,O
apolipoprotein,1859,O
CII,1859,O
(,1859,O
APOC2,1859,O
),1859,O
gene,1859,O
.,1859,O
These,1860,O
results,1860,O
suggest,1860,O
that,1860,O
",",1860,O
in,1860,O
addition,1860,O
to,1860,O
APOC2,1860,O
",",1860,O
APOE,1860,O
is,1860,O
a,1860,O
useful,1860,O
marker,1860,O
for,1860,O
presymptomatic,1860,O
DM,1860,B-Modifier
diagnosis,1860,O
.,1860,O
Regional,1861,O
localization,1861,O
of,1861,O
polymorphic,1861,O
DNA,1861,O
loci,1861,O
on,1861,O
the,1861,O
proximal,1861,O
long,1861,O
arm,1861,O
of,1861,O
the,1861,O
X,1861,O
chromosome,1861,O
using,1861,O
deletions,1861,O
associated,1861,O
with,1861,O
choroideremia,1861,B-SpecificDisease
.,1861,O
In,1862,O
two,1862,O
unrelated,1862,O
families,1862,O
",",1862,O
males,1862,O
have,1862,O
been,1862,O
identified,1862,O
who,1862,O
suffer,1862,O
from,1862,O
choroideremia,1862,B-SpecificDisease
and,1862,O
at,1862,O
the,1862,O
same,1862,O
time,1862,O
have,1862,O
an,1862,O
interstitial,1862,O
deletion,1862,O
on,1862,O
the,1862,O
proximal,1862,O
long,1862,O
arm,1862,O
of,1862,O
the,1862,O
X,1862,O
chromosome,1862,O
.,1862,O
By,1863,O
high-resolution,1863,O
banding,1863,O
we,1863,O
have,1863,O
characterized,1863,O
the,1863,O
deletion,1863,O
chromosomes,1863,O
as,1863,O
del,1863,O
(,1863,O
X,1863,O
),1863,O
(,1863,O
q21,1863,O
.,1863,O
1-q21,1864,O
1-q21,1864,O
.,1864,O
33,1865,O
),1865,O
and,1865,O
del,1865,O
(,1865,O
X,1865,O
),1865,O
(,1865,O
q21,1865,O
.,1865,O
2-q21,1866,O
2-q21,1866,O
.,1866,O
31,1867,O
),1867,O
respectively,1867,O
.,1867,O
By,1868,O
Southern,1868,O
blot,1868,O
analysis,1868,O
we,1868,O
have,1868,O
mapped,1868,O
ten,1868,O
different,1868,O
polymorphic,1868,O
DNA,1868,O
loci,1868,O
relative,1868,O
to,1868,O
the,1868,O
position,1868,O
of,1868,O
the,1868,O
deletion,1868,O
and,1868,O
the,1868,O
choroideremia,1868,B-Modifier
locus,1868,O
TCD,1868,O
.,1868,O
One,1869,O
probe,1869,O
",",1869,O
p31,1869,O
",",1869,O
was,1869,O
shown,1869,O
to,1869,O
cover,1869,O
one,1869,O
of,1869,O
the,1869,O
breakpoints,1869,O
of,1869,O
the,1869,O
smallest,1869,O
deletion,1869,O
.,1869,O
The,1870,O
following,1870,O
order,1870,O
of,1870,O
the,1870,O
loci,1870,O
was,1870,O
suggested,1870,O
by,1870,O
deletion,1870,O
mapping,1870,O
cen-DXS106-DXS72-TCD-,1870,O
(,1870,O
DXYS1/DXYS23/DXYS5,1870,O
),1870,O
-,1870,O
DXYS2-,1870,O
(,1870,O
DXYS12/DXS3,1870,O
),1870,O
-,1870,O
(,1870,O
DXS17/DXS101,1870,O
),1870,O
-,1870,O
Xqter,1870,O
.,1870,O
Retroviral-mediated,1871,O
gene,1871,O
transfer,1871,O
of,1871,O
human,1871,O
phenylalanine,1871,O
hydroxylase,1871,O
into,1871,O
NIH,1871,O
3T3,1871,O
and,1871,O
hepatoma,1871,B-Modifier
cells,1871,O
.,1871,O
Phenylketonuria,1872,B-SpecificDisease
(,1872,O
PKU,1872,B-SpecificDisease
),1872,O
is,1872,O
caused,1872,O
by,1872,O
deficiency,1872,B-SpecificDisease
of,1872,I-SpecificDisease
the,1872,I-SpecificDisease
hepatic,1872,I-SpecificDisease
enzyme,1872,I-SpecificDisease
phenylalanine,1872,I-SpecificDisease
hydroxylase,1872,I-SpecificDisease
(,1872,O
PAH,1872,O
),1872,O
.,1872,O
A,1873,O
full-length,1873,O
human,1873,O
PAH,1873,O
cDNA,1873,O
sequence,1873,O
has,1873,O
been,1873,O
inserted,1873,O
into,1873,O
pzip-neoSV,1873,O
(,1873,O
X,1873,O
),1873,O
",",1873,O
which,1873,O
is,1873,O
a,1873,O
retroviral,1873,O
vector,1873,O
containing,1873,O
the,1873,O
bacterial,1873,O
neo,1873,O
gene,1873,O
.,1873,O
The,1874,O
recombinant,1874,O
has,1874,O
been,1874,O
transfected,1874,O
into,1874,O
psi,1874,O
2,1874,O
cells,1874,O
",",1874,O
which,1874,O
provide,1874,O
synthesis,1874,O
of,1874,O
the,1874,O
retroviral,1874,O
capsid,1874,O
.,1874,O
Recombinant,1875,O
virus,1875,O
was,1875,O
detected,1875,O
in,1875,O
the,1875,O
culture,1875,O
medium,1875,O
of,1875,O
the,1875,O
transfected,1875,O
psi,1875,O
2,1875,O
cells,1875,O
",",1875,O
which,1875,O
is,1875,O
capable,1875,O
of,1875,O
transmitting,1875,O
the,1875,O
human,1875,O
PAH,1875,O
gene,1875,O
into,1875,O
mouse,1875,O
NIH,1875,O
3T3,1875,O
cells,1875,O
by,1875,O
infection,1875,O
leading,1875,O
to,1875,O
stable,1875,O
incorporation,1875,O
of,1875,O
the,1875,O
recombinant,1875,O
provirus,1875,O
.,1875,O
Infected,1876,O
cells,1876,O
express,1876,O
PAH,1876,O
mRNA,1876,O
",",1876,O
immunoreactive,1876,O
PAH,1876,O
protein,1876,O
",",1876,O
and,1876,O
exhibit,1876,O
pterin-dependent,1876,O
phenylalanine,1876,O
hydroxylase,1876,O
activity,1876,O
.,1876,O
The,1877,O
recombinant,1877,O
virus,1877,O
is,1877,O
also,1877,O
capable,1877,O
of,1877,O
infecting,1877,O
a,1877,O
mouse,1877,O
hepatoma,1877,B-Modifier
cell,1877,O
line,1877,O
that,1877,O
does,1877,O
not,1877,O
normally,1877,O
synthesize,1877,O
PAH,1877,O
.,1877,O
PAH,1878,O
activity,1878,O
is,1878,O
present,1878,O
in,1878,O
the,1878,O
cellular,1878,O
extracts,1878,O
and,1878,O
the,1878,O
entire,1878,O
hydroxylation,1878,O
system,1878,O
is,1878,O
reconstituted,1878,O
in,1878,O
the,1878,O
hepatoma,1878,B-Modifier
cells,1878,O
infected,1878,O
with,1878,O
the,1878,O
recombinant,1878,O
viruses,1878,O
.,1878,O
Thus,1879,O
",",1879,O
recombinant,1879,O
viruses,1879,O
containing,1879,O
human,1879,O
PAH,1879,O
cDNA,1879,O
provide,1879,O
a,1879,O
means,1879,O
for,1879,O
introducing,1879,O
functional,1879,O
PAH,1879,O
into,1879,O
mammalian,1879,O
cells,1879,O
of,1879,O
hepatic,1879,O
origin,1879,O
and,1879,O
can,1879,O
potentially,1879,O
be,1879,O
introduced,1879,O
into,1879,O
whole,1879,O
animals,1879,O
as,1879,O
a,1879,O
model,1879,O
for,1879,O
somatic,1879,O
gene,1879,O
therapy,1879,O
for,1879,O
PKU,1879,B-SpecificDisease
..,1879,O
Estimation,1880,O
of,1880,O
the,1880,O
male,1880,O
to,1880,O
female,1880,O
ratio,1880,O
of,1880,O
mutation,1880,O
rates,1880,O
from,1880,O
the,1880,O
segregation,1880,O
of,1880,O
X-chromosomal,1880,O
DNA,1880,O
haplotypes,1880,O
in,1880,O
Duchenne,1880,B-Modifier
muscular,1880,I-Modifier
dystrophy,1880,I-Modifier
families,1880,O
.,1880,O
A,1881,O
novel,1881,O
procedure,1881,O
is,1881,O
presented,1881,O
to,1881,O
estimate,1881,O
the,1881,O
ratio,1881,O
of,1881,O
male,1881,O
to,1881,O
female,1881,O
mutation,1881,O
rates,1881,O
for,1881,O
Duchenne,1881,B-SpecificDisease
muscular,1881,I-SpecificDisease
dystrophy,1881,I-SpecificDisease
(,1881,O
DMD,1881,B-SpecificDisease
),1881,O
.,1881,O
X-specific,1882,O
restriction,1882,O
fragment,1882,O
length,1882,O
polymorphisms,1882,O
are,1882,O
used,1882,O
to,1882,O
establish,1882,O
DNA,1882,O
haplotypes,1882,O
in,1882,O
three-generation,1882,O
DMD,1882,B-Modifier
families,1882,O
.,1882,O
From,1883,O
the,1883,O
proportion,1883,O
of,1883,O
DMD,1883,B-Modifier
patients,1883,O
who,1883,O
have,1883,O
inherited,1883,O
their,1883,O
maternal,1883,O
grandfathers,1883,O
X,1883,O
chromosome,1883,O
",",1883,O
the,1883,O
ratio,1883,O
of,1883,O
mutation,1883,O
rates,1883,O
can,1883,O
be,1883,O
calculated,1883,O
.,1883,O
In,1884,O
contrast,1884,O
to,1884,O
classical,1884,O
methods,1884,O
",",1884,O
the,1884,O
proposed,1884,O
procedure,1884,O
is,1884,O
not,1884,O
restricted,1884,O
to,1884,O
sporadic,1884,O
or,1884,O
familiar,1884,O
cases,1884,O
nor,1884,O
is,1884,O
any,1884,O
information,1884,O
on,1884,O
the,1884,O
carrier,1884,O
status,1884,O
of,1884,O
female,1884,O
relatives,1884,O
required,1884,O
..,1884,O
Deletions,1885,O
of,1885,O
a,1885,O
DNA,1885,O
sequence,1885,O
in,1885,O
retinoblastomas,1885,B-SpecificDisease
and,1885,O
mesenchymal,1885,B-DiseaseClass
tumors,1885,I-DiseaseClass
:,1885,O
organization,1885,O
of,1885,O
the,1885,O
sequence,1885,O
and,1885,O
its,1885,O
encoded,1885,O
protein,1885,O
.,1885,O
Retinoblastoma,1886,B-SpecificDisease
is,1886,O
a,1886,O
childhood,1886,B-DiseaseClass
tumor,1886,I-DiseaseClass
that,1886,O
can,1886,O
arise,1886,O
because,1886,O
of,1886,O
mutant,1886,O
alleles,1886,O
acquired,1886,O
as,1886,O
somatic,1886,O
or,1886,O
germinal,1886,O
mutations,1886,O
.,1886,O
The,1887,O
mutant,1887,O
allele,1887,O
can,1887,O
be,1887,O
carried,1887,O
in,1887,O
the,1887,O
germ,1887,O
line,1887,O
.,1887,O
The,1888,O
mutations,1888,O
creating,1888,O
these,1888,O
alleles,1888,O
act,1888,O
by,1888,O
inactivating,1888,O
copies,1888,O
of,1888,O
a,1888,O
recessive,1888,O
oncogene,1888,O
located,1888,O
within,1888,O
band,1888,O
q14,1888,O
of,1888,O
chromosome,1888,O
13,1888,O
and,1888,O
termed,1888,O
the,1888,O
RB1,1888,O
locus,1888,O
.,1888,O
We,1889,O
have,1889,O
reported,1889,O
isolation,1889,O
of,1889,O
a,1889,O
cDNA,1889,O
fragment,1889,O
that,1889,O
recognizes,1889,O
chromosomal,1889,O
sequences,1889,O
possessing,1889,O
many,1889,O
of,1889,O
the,1889,O
attributes,1889,O
of,1889,O
the,1889,O
retinoblastoma,1889,B-Modifier
gene,1889,O
associated,1889,O
with,1889,O
the,1889,O
RB1,1889,O
locus,1889,O
.,1889,O
We,1890,O
now,1890,O
report,1890,O
that,1890,O
this,1890,O
segment,1890,O
is,1890,O
additionally,1890,O
the,1890,O
target,1890,O
of,1890,O
somatic,1890,O
mutations,1890,O
in,1890,O
mesenchymal,1890,B-DiseaseClass
tumors,1890,I-DiseaseClass
among,1890,O
patients,1890,O
having,1890,O
no,1890,O
apparent,1890,O
predisposition,1890,O
to,1890,O
retinoblastoma,1890,B-SpecificDisease
and,1890,O
no,1890,O
previous,1890,O
evidence,1890,O
of,1890,O
retinoblastoma,1890,B-SpecificDisease
.,1890,O
These,1891,O
tumors,1891,B-DiseaseClass
provide,1891,O
additional,1891,O
evidence,1891,O
that,1891,O
the,1891,O
cloned,1891,O
sequences,1891,O
are,1891,O
representative,1891,O
of,1891,O
a,1891,O
gene,1891,O
that,1891,O
is,1891,O
a,1891,O
frequent,1891,O
target,1891,O
of,1891,O
inactivation,1891,O
during,1891,O
tumorigenesis,1891,O
.,1891,O
Sequence,1892,O
analysis,1892,O
of,1892,O
this,1892,O
cDNA,1892,O
provides,1892,O
little,1892,O
insight,1892,O
into,1892,O
its,1892,O
normal,1892,O
functional,1892,O
role,1892,O
..,1892,O
Treatment,1893,O
of,1893,O
Duchenne,1893,B-SpecificDisease
muscular,1893,I-SpecificDisease
dystrophy,1893,I-SpecificDisease
with,1893,O
growth,1893,O
hormone,1893,O
inhibitors,1893,O
.,1893,O
A,1894,O
controlled,1894,O
",",1894,O
double-blind,1894,O
therapeutic,1894,O
trial,1894,O
with,1894,O
the,1894,O
drug,1894,O
mazindol,1894,O
",",1894,O
a,1894,O
growth,1894,O
hormone,1894,O
inhibitor,1894,O
",",1894,O
was,1894,O
performed,1894,O
in,1894,O
a,1894,O
pair,1894,O
of,1894,O
7,1894,O
1/2,1894,O
year-old,1894,O
monozygotic,1894,O
twins,1894,O
",",1894,O
with,1894,O
Duchenne,1894,B-SpecificDisease
muscular,1894,I-SpecificDisease
dystrophy,1894,I-SpecificDisease
(,1894,O
DMD,1894,B-SpecificDisease
),1894,O
.,1894,O
The,1895,O
rationale,1895,O
for,1895,O
this,1895,O
trial,1895,O
was,1895,O
based,1895,O
on,1895,O
a,1895,O
patient,1895,O
(,1895,O
reported,1895,O
previously,1895,O
),1895,O
affected,1895,O
simultaneously,1895,O
with,1895,O
DMD,1895,B-SpecificDisease
and,1895,O
growth,1895,B-SpecificDisease
hormone,1895,I-SpecificDisease
(,1895,I-SpecificDisease
GH,1895,I-SpecificDisease
),1895,I-SpecificDisease
deficiency,1895,I-SpecificDisease
",",1895,O
who,1895,O
is,1895,O
showing,1895,O
a,1895,O
benign,1895,O
course,1895,O
of,1895,O
the,1895,O
dystrophic,1895,B-DiseaseClass
process,1895,I-DiseaseClass
and,1895,O
is,1895,O
still,1895,O
walking,1895,O
at,1895,O
18,1895,O
years,1895,O
.,1895,O
One,1896,O
of,1896,O
the,1896,O
twins,1896,O
received,1896,O
2,1896,O
mg,1896,O
of,1896,O
mazindol,1896,O
daily,1896,O
",",1896,O
while,1896,O
the,1896,O
other,1896,O
received,1896,O
a,1896,O
placebo,1896,O
.,1896,O
The,1897,O
assessment,1897,O
",",1897,O
repeated,1897,O
every,1897,O
2,1897,O
months,1897,O
",",1897,O
included,1897,O
weight,1897,O
and,1897,O
height,1897,O
measurements,1897,O
",",1897,O
functional,1897,O
and,1897,O
motor,1897,O
ability,1897,O
tests,1897,O
",",1897,O
ergometry,1897,O
and,1897,O
determinations,1897,O
of,1897,O
serum,1897,O
enzymes,1897,O
and,1897,O
GH,1897,O
levels,1897,O
.,1897,O
After,1898,O
one,1898,O
year,1898,O
of,1898,O
trial,1898,O
the,1898,O
code,1898,O
was,1898,O
broken,1898,O
and,1898,O
it,1898,O
was,1898,O
seen,1898,O
that,1898,O
the,1898,O
twin,1898,O
under,1898,O
placebo,1898,O
treatment,1898,O
was,1898,O
strikingly,1898,O
worse,1898,O
than,1898,O
his,1898,O
brother,1898,O
",",1898,O
the,1898,O
progression,1898,O
of,1898,O
whose,1898,O
condition,1898,O
was,1898,O
practically,1898,O
arrested,1898,O
.,1898,O
These,1899,O
results,1899,O
strongly,1899,O
suggest,1899,O
that,1899,O
treatment,1899,O
with,1899,O
a,1899,O
GH,1899,O
inhibitor,1899,O
is,1899,O
beneficial,1899,O
for,1899,O
DMD,1899,B-Modifier
patients,1899,O
..,1899,O
Identification,1900,O
and,1900,O
localization,1900,O
of,1900,O
mutations,1900,O
at,1900,O
the,1900,O
Lesch-Nyhan,1900,B-Modifier
locus,1900,O
by,1900,O
ribonuclease,1900,O
A,1900,O
cleavage,1900,O
.,1900,O
Many,1901,O
mutations,1901,O
leading,1901,O
to,1901,O
human,1901,O
disease,1901,O
are,1901,O
the,1901,O
result,1901,O
of,1901,O
single,1901,O
DNA,1901,O
base,1901,O
pair,1901,O
changes,1901,O
that,1901,O
can,1901,O
not,1901,O
be,1901,O
identified,1901,O
by,1901,O
Southern,1901,O
analysis,1901,O
.,1901,O
This,1902,O
has,1902,O
prompted,1902,O
the,1902,O
development,1902,O
of,1902,O
alternative,1902,O
assays,1902,O
for,1902,O
point,1902,O
mutation,1902,O
detection,1902,O
.,1902,O
The,1903,O
recently,1903,O
described,1903,O
ribonuclease,1903,O
A,1903,O
cleavage,1903,O
procedure,1903,O
",",1903,O
with,1903,O
a,1903,O
polyuridylic,1903,O
acid-paper,1903,O
affinity,1903,O
chromatography,1903,O
step,1903,O
",",1903,O
has,1903,O
been,1903,O
used,1903,O
to,1903,O
identify,1903,O
the,1903,O
mutational,1903,O
lesions,1903,O
in,1903,O
the,1903,O
hypoxanthine,1903,O
phosphoribosyltransferase,1903,O
(,1903,O
HPRT,1903,O
),1903,O
messenger,1903,O
RNAs,1903,O
of,1903,O
patients,1903,O
with,1903,O
Lesch-Nyhan,1903,B-SpecificDisease
syndrome,1903,I-SpecificDisease
.,1903,O
Distinctive,1904,O
ribonuclease,1904,O
A,1904,O
cleavage,1904,O
patterns,1904,O
were,1904,O
identified,1904,O
in,1904,O
messenger,1904,O
RNA,1904,O
from,1904,O
5,1904,O
of,1904,O
14,1904,O
Lesch-Nyhan,1904,B-Modifier
patients,1904,O
who,1904,O
were,1904,O
chosen,1904,O
because,1904,O
no,1904,O
HPRT,1904,O
Southern,1904,O
or,1904,O
Northern,1904,O
blotting,1904,O
pattern,1904,O
changes,1904,O
had,1904,O
been,1904,O
found,1904,O
.,1904,O
This,1905,O
approach,1905,O
now,1905,O
allows,1905,O
HPRT,1905,O
mutation,1905,O
detection,1905,O
in,1905,O
50,1905,O
percent,1905,O
of,1905,O
the,1905,O
cases,1905,O
of,1905,O
Lesch-Nyhan,1905,B-SpecificDisease
syndrome,1905,I-SpecificDisease
.,1905,O
The,1906,O
polyuridylic,1906,O
acid-paper,1906,O
affinity,1906,O
procedure,1906,O
provides,1906,O
a,1906,O
general,1906,O
method,1906,O
for,1906,O
analysis,1906,O
of,1906,O
low,1906,O
abundance,1906,O
messenger,1906,O
RNAs,1906,O
..,1906,O
Two,1907,O
new,1907,O
variants,1907,O
of,1907,O
glucose-6-phosphate,1907,O
dehydrogenase,1907,O
associated,1907,O
with,1907,O
hereditary,1907,B-SpecificDisease
non-spherocytic,1907,I-SpecificDisease
hemolytic,1907,I-SpecificDisease
anemia,1907,I-SpecificDisease
:,1907,O
G6PD,1907,O
Wayne,1907,O
and,1907,O
G6PD,1907,O
Huron,1907,O
.,1907,O
Two,1908,O
new,1908,O
deficient,1908,O
variants,1908,O
of,1908,O
glucose-6-phosphate,1908,O
dehydrogenase,1908,O
(,1908,O
G6PD,1908,O
),1908,O
causing,1908,O
hereditary,1908,B-SpecificDisease
nonspherocytic,1908,I-SpecificDisease
hemolytic,1908,I-SpecificDisease
anemia,1908,I-SpecificDisease
(,1908,O
HNSHA,1908,B-SpecificDisease
),1908,O
are,1908,O
described,1908,O
.,1908,O
Both,1909,O
of,1909,O
these,1909,O
are,1909,O
unique,1909,O
and,1909,O
they,1909,O
have,1909,O
been,1909,O
named,1909,O
G6PD,1909,O
Wayne,1909,O
and,1909,O
G6PD,1909,O
Huron,1909,O
.,1909,O
Patients,1910,O
with,1910,O
G6PD,1910,O
Wayne,1910,O
underwent,1910,O
splenectomy,1910,O
and,1910,O
no,1910,O
objective,1910,O
improvement,1910,O
was,1910,O
noted,1910,O
.,1910,O
The,1911,O
patients,1911,O
with,1911,O
G6PD,1911,O
Huron,1911,O
were,1911,O
under,1911,O
medical,1911,O
observation,1911,O
for,1911,O
a,1911,O
considerable,1911,O
period,1911,O
of,1911,O
time,1911,O
without,1911,O
the,1911,O
diagnosis,1911,O
of,1911,O
G6PD,1911,B-SpecificDisease
deficiency,1911,I-SpecificDisease
being,1911,O
entertained,1911,O
because,1911,O
the,1911,O
family,1911,O
was,1911,O
of,1911,O
Northern,1911,O
European,1911,O
origin,1911,O
.,1911,O
Since,1912,O
sporadic,1912,O
variants,1912,O
of,1912,O
G6PD,1912,O
causing,1912,O
HNSHA,1912,B-SpecificDisease
show,1912,O
no,1912,O
special,1912,O
racial,1912,O
predilection,1912,O
",",1912,O
the,1912,O
diagnosis,1912,O
of,1912,O
G6PD,1912,B-SpecificDisease
deficiency,1912,I-SpecificDisease
should,1912,O
always,1912,O
be,1912,O
considered,1912,O
in,1912,O
patients,1912,O
with,1912,O
this,1912,O
syndrome,1912,O
..,1912,O
Sialophorin,1913,O
",",1913,O
a,1913,O
surface,1913,O
sialoglycoprotein,1913,O
defective,1913,O
in,1913,O
the,1913,O
Wiskott-Aldrich,1913,B-SpecificDisease
syndrome,1913,I-SpecificDisease
",",1913,O
is,1913,O
involved,1913,O
in,1913,O
human,1913,O
T,1913,O
lymphocyte,1913,O
proliferation,1913,O
.,1913,O
The,1914,O
mAb,1914,O
L10,1914,O
was,1914,O
used,1914,O
to,1914,O
determine,1914,O
the,1914,O
distribution,1914,O
and,1914,O
the,1914,O
function,1914,O
of,1914,O
sialophorin,1914,O
",",1914,O
the,1914,O
heavily,1914,O
glycosylated,1914,O
surface,1914,O
molecule,1914,O
that,1914,O
is,1914,O
deficient/defective,1914,O
in,1914,O
lymphocytes,1914,O
of,1914,O
patients,1914,O
with,1914,O
the,1914,O
X-linked,1914,B-SpecificDisease
immunodeficiency,1914,I-SpecificDisease
Wiskott-Aldrich,1914,I-SpecificDisease
syndrome,1914,I-SpecificDisease
.,1914,O
Dual-parameter,1915,O
FACS,1915,O
analysis,1915,O
indicated,1915,O
that,1915,O
sialophorin,1915,O
is,1915,O
expressed,1915,O
on,1915,O
CD4,1915,O
+,1915,O
and,1915,O
CD8,1915,O
+,1915,O
lymphocytes,1915,O
",",1915,O
on,1915,O
a,1915,O
subpopulation,1915,O
of,1915,O
peripheral,1915,O
blood,1915,O
B,1915,O
lymphocytes,1915,O
",",1915,O
on,1915,O
all,1915,O
thymocytes,1915,O
",",1915,O
and,1915,O
on,1915,O
a,1915,O
subpopulation,1915,O
of,1915,O
bone,1915,O
marrow,1915,O
cells,1915,O
.,1915,O
Functional,1916,O
studies,1916,O
demonstrated,1916,O
that,1916,O
L10,1916,O
mAb,1916,O
stimulates,1916,O
the,1916,O
proliferation,1916,O
of,1916,O
peripheral,1916,O
blood,1916,O
T,1916,O
lymphocytes,1916,O
as,1916,O
measured,1916,O
by,1916,O
stimulation,1916,O
of,1916,O
[,1916,O
3H,1916,O
],1916,O
thymidine,1916,O
incorporation,1916,O
.,1916,O
The,1917,O
time,1917,O
course,1917,O
and,1917,O
magnitude,1917,O
of,1917,O
increased,1917,O
[,1917,O
3H,1917,O
],1917,O
thymidine,1917,O
incorporation,1917,O
by,1917,O
T,1917,O
lymphocytes,1917,O
in,1917,O
response,1917,O
to,1917,O
L10,1917,O
mAb,1917,O
paralleled,1917,O
that,1917,O
induced,1917,O
by,1917,O
anti-CD3,1917,O
mAb,1917,O
.,1917,O
Effective,1918,O
stimulation,1918,O
was,1918,O
dependent,1918,O
on,1918,O
the,1918,O
presence,1918,O
of,1918,O
monocytes,1918,O
and,1918,O
the,1918,O
Fc,1918,O
portion,1918,O
of,1918,O
L10,1918,O
mAb,1918,O
.,1918,O
Stimulation,1919,O
of,1919,O
lymphocytes,1919,O
by,1919,O
L10,1919,O
",",1919,O
like,1919,O
stimulation,1919,O
by,1919,O
anti-CD3,1919,O
mAb,1919,O
",",1919,O
involves,1919,O
increased,1919,O
expression,1919,O
of,1919,O
4F2,1919,O
",",1919,O
HLA-DR,1919,O
",",1919,O
and,1919,O
IL-2-R,1919,O
.,1919,O
These,1920,O
observations,1920,O
suggest,1920,O
that,1920,O
sialophorin,1920,O
functions,1920,O
in,1920,O
T,1920,O
cell,1920,O
activation,1920,O
..,1920,O
Hypopigmentation,1921,B-DiseaseClass
in,1921,O
the,1921,O
Prader-Willi,1921,B-SpecificDisease
syndrome,1921,I-SpecificDisease
.,1921,O
Cutaneous,1922,B-CompositeMention
and,1922,I-CompositeMention
ocular,1922,I-CompositeMention
pigmentation,1922,I-CompositeMention
were,1922,O
evaluated,1922,O
in,1922,O
29,1922,O
individuals,1922,O
with,1922,O
the,1922,O
Prader-Willi,1922,B-SpecificDisease
syndrome,1922,I-SpecificDisease
(,1922,O
PWS,1922,B-SpecificDisease
),1922,O
.,1922,O
Criteria,1923,O
for,1923,O
hypopigmentation,1923,B-DiseaseClass
included,1923,O
the,1923,O
presence,1923,O
of,1923,O
type,1923,O
I,1923,O
or,1923,O
II,1923,O
skin,1923,O
",",1923,O
the,1923,O
lightest,1923,O
skin,1923,O
type,1923,O
in,1923,O
the,1923,O
family,1923,O
by,1923,O
history,1923,O
",",1923,O
and,1923,O
iris,1923,O
translucency,1923,O
on,1923,O
globe,1923,O
transillumination,1923,O
.,1923,O
On,1924,O
the,1924,O
basis,1924,O
of,1924,O
these,1924,O
criteria,1924,O
",",1924,O
48,1924,O
%,1924,O
of,1924,O
the,1924,O
PWS,1924,B-Modifier
individuals,1924,O
were,1924,O
hypopigmented,1924,B-Modifier
.,1924,O
The,1925,O
presence,1925,O
of,1925,O
hypopigmentation,1925,B-DiseaseClass
correlated,1925,O
with,1925,O
a,1925,O
small,1925,O
interstitial,1925,O
deletion,1925,O
on,1925,O
the,1925,O
proximal,1925,O
long,1925,O
arm,1925,O
of,1925,O
chromosome,1925,O
15,1925,O
;,1925,O
however,1925,O
",",1925,O
this,1925,O
deletion,1925,O
was,1925,O
also,1925,O
found,1925,O
in,1925,O
individuals,1925,O
who,1925,O
did,1925,O
not,1925,O
meet,1925,O
the,1925,O
full,1925,O
criteria,1925,O
for,1925,O
hypopigmentation,1925,B-DiseaseClass
.,1925,O
Hairbulb,1926,O
tyrosinase,1926,O
activity,1926,O
and,1926,O
glutathione,1926,O
content,1926,O
",",1926,O
as,1926,O
well,1926,O
as,1926,O
urine,1926,O
cysteinyldopa,1926,O
excretion,1926,O
",",1926,O
were,1926,O
low,1926,O
in,1926,O
PWS,1926,B-Modifier
individuals,1926,O
with,1926,O
and,1926,O
without,1926,O
hypopigmentation,1926,B-DiseaseClass
and,1926,O
did,1926,O
not,1926,O
separate,1926,O
these,1926,O
two,1926,O
groups,1926,O
.,1926,O
We,1927,O
conclude,1927,O
that,1927,O
hypopigmentation,1927,B-DiseaseClass
is,1927,O
found,1927,O
in,1927,O
a,1927,O
significant,1927,O
proportion,1927,O
of,1927,O
individuals,1927,O
with,1927,O
PWS,1927,B-SpecificDisease
and,1927,O
that,1927,O
the,1927,O
hypopigmentation,1927,B-DiseaseClass
may,1927,O
be,1927,O
associated,1927,O
with,1927,O
a,1927,O
deletion,1927,O
of,1927,O
the,1927,O
long,1927,O
arm,1927,O
of,1927,O
chromosome,1927,O
15,1927,O
.,1927,O
The,1928,O
mechanism,1928,O
for,1928,O
the,1928,O
hypopigmentation,1928,B-DiseaseClass
is,1928,O
unknown,1928,O
..,1928,O
Phenotype,1929,O
heterogeneity,1929,O
among,1929,O
hemizygotes,1929,O
in,1929,O
a,1929,O
family,1929,O
biochemically,1929,O
screened,1929,O
for,1929,O
adrenoleukodystrophy,1929,B-SpecificDisease
.,1929,O
We,1930,O
report,1930,O
on,1930,O
two,1930,O
clinically,1930,O
",",1930,O
neurologically,1930,O
normal,1930,O
relatives,1930,O
of,1930,O
a,1930,O
boy,1930,O
affected,1930,O
by,1930,O
adrenoleukodystrophy,1930,B-SpecificDisease
(,1930,O
ALD,1930,B-SpecificDisease
),1930,O
;,1930,O
they,1930,O
were,1930,O
found,1930,O
repeatedly,1930,O
to,1930,O
have,1930,O
the,1930,O
biochemical,1930,O
defect,1930,O
of,1930,O
an,1930,O
ALD,1930,B-Modifier
hemizygote,1930,O
.,1930,O
The,1931,O
assay,1931,O
consisted,1931,O
in,1931,O
the,1931,O
determination,1931,O
of,1931,O
very-long-chain,1931,O
fatty,1931,O
acids,1931,O
in,1931,O
lyophilized,1931,O
and,1931,O
reconstituted,1931,O
plasma,1931,O
.,1931,O
While,1932,O
no,1932,O
evidence,1932,O
of,1932,O
neurologic,1932,B-DiseaseClass
disease,1932,I-DiseaseClass
(,1932,O
leukodystrophy,1932,B-SpecificDisease
or,1932,O
myeloneuropathy,1932,B-SpecificDisease
),1932,O
was,1932,O
present,1932,O
in,1932,O
these,1932,O
hemizygotes,1932,O
",",1932,O
adrenocortical,1932,B-DiseaseClass
insufficiency,1932,I-DiseaseClass
provoking,1932,O
compensatory,1932,O
high,1932,O
ACTH,1932,O
release,1932,O
was,1932,O
found,1932,O
in,1932,O
both,1932,O
.,1932,O
These,1933,O
findings,1933,O
should,1933,O
be,1933,O
taken,1933,O
into,1933,O
consideration,1933,O
when,1933,O
counseling,1933,O
families,1933,O
in,1933,O
which,1933,O
cases,1933,O
with,1933,O
clinically,1933,O
expressed,1933,O
ALD,1933,B-SpecificDisease
are,1933,O
represented,1933,O
in,1933,O
several,1933,O
generations,1933,O
..,1933,O
The,1934,O
mapping,1934,O
of,1934,O
a,1934,O
cDNA,1934,O
from,1934,O
the,1934,O
human,1934,O
X-linked,1934,B-Modifier
Duchenne,1934,I-Modifier
muscular,1934,I-Modifier
dystrophy,1934,I-Modifier
gene,1934,O
to,1934,O
the,1934,O
mouse,1934,O
X,1934,O
chromosome,1934,O
.,1934,O
The,1935,O
recent,1935,O
discovery,1935,O
of,1935,O
sequences,1935,O
at,1935,O
the,1935,O
site,1935,O
of,1935,O
the,1935,O
Duchenne,1935,B-Modifier
muscular,1935,I-Modifier
dystrophy,1935,I-Modifier
(,1935,O
DMD,1935,B-Modifier
),1935,O
gene,1935,O
in,1935,O
humans,1935,O
has,1935,O
opened,1935,O
up,1935,O
the,1935,O
possibility,1935,O
of,1935,O
a,1935,O
detailed,1935,O
molecular,1935,O
analysis,1935,O
of,1935,O
the,1935,O
genes,1935,O
in,1935,O
humans,1935,O
and,1935,O
in,1935,O
related,1935,O
mammalian,1935,O
species,1935,O
.,1935,O
Until,1936,O
relatively,1936,O
recently,1936,O
",",1936,O
there,1936,O
was,1936,O
no,1936,O
obvious,1936,O
mouse,1936,O
model,1936,O
of,1936,O
this,1936,O
genetic,1936,B-DiseaseClass
disease,1936,I-DiseaseClass
for,1936,O
the,1936,O
development,1936,O
of,1936,O
therapeutic,1936,O
strategies,1936,O
.,1936,O
The,1937,O
identification,1937,O
of,1937,O
a,1937,O
mouse,1937,O
X-linked,1937,O
mutant,1937,O
showing,1937,O
muscular,1937,B-SpecificDisease
dystrophy,1937,I-SpecificDisease
",",1937,O
mdx,1937,O
",",1937,O
has,1937,O
provided,1937,O
a,1937,O
candidate,1937,O
mouse,1937,O
genetic,1937,O
homologue,1937,O
to,1937,O
the,1937,O
DMD,1937,B-Modifier
locus,1937,O
;,1937,O
the,1937,O
relatively,1937,O
mild,1937,O
pathological,1937,O
features,1937,O
of,1937,O
mdx,1937,O
suggest,1937,O
it,1937,O
may,1937,O
have,1937,O
more,1937,O
in,1937,O
common,1937,O
with,1937,O
mutations,1937,O
of,1937,O
the,1937,O
Becker,1937,B-Modifier
muscular,1937,I-Modifier
dystrophy,1937,I-Modifier
type,1937,O
at,1937,O
the,1937,O
same,1937,O
human,1937,O
locus,1937,O
",",1937,O
however,1937,O
.,1937,O
But,1938,O
the,1938,O
close,1938,O
genetic,1938,O
linkage,1938,O
of,1938,O
mdx,1938,O
to,1938,O
G6PD,1938,O
and,1938,O
Hprt,1938,O
on,1938,O
the,1938,O
mouse,1938,O
X,1938,O
chromosome,1938,O
",",1938,O
coupled,1938,O
with,1938,O
its,1938,O
comparatively,1938,O
mild,1938,O
pathology,1938,O
",",1938,O
have,1938,O
suggested,1938,O
that,1938,O
the,1938,O
mdx,1938,O
mutation,1938,O
may,1938,O
instead,1938,O
correspond,1938,O
to,1938,O
Emery,1938,B-SpecificDisease
Dreifuss,1938,I-SpecificDisease
muscular,1938,I-SpecificDisease
dystrophy,1938,I-SpecificDisease
which,1938,O
itself,1938,O
is,1938,O
closely,1938,O
linked,1938,O
to,1938,O
DNA,1938,O
markers,1938,O
at,1938,O
Xq28-qter,1938,O
in,1938,O
the,1938,O
region,1938,O
of,1938,O
G6PD,1938,O
on,1938,O
the,1938,O
human,1938,O
X,1938,O
chromosome,1938,O
.,1938,O
Using,1939,O
an,1939,O
interspecific,1939,O
mouse,1939,O
domesticus/spretus,1939,O
cross,1939,O
",",1939,O
segregating,1939,O
for,1939,O
a,1939,O
variety,1939,O
of,1939,O
markers,1939,O
on,1939,O
the,1939,O
mouse,1939,O
X,1939,O
chromosome,1939,O
",",1939,O
we,1939,O
have,1939,O
positioned,1939,O
on,1939,O
the,1939,O
mouse,1939,O
X,1939,O
chromosome,1939,O
sequences,1939,O
homologous,1939,O
to,1939,O
a,1939,O
DMD,1939,B-Modifier
cDNA,1939,O
clone,1939,O
.,1939,O
These,1940,O
sequences,1940,O
map,1940,O
provocatively,1940,O
close,1940,O
to,1940,O
the,1940,O
mdx,1940,O
mutation,1940,O
and,1940,O
unexpectedly,1940,O
distant,1940,O
from,1940,O
sparse,1940,O
fur,1940,O
",",1940,O
spf,1940,O
",",1940,O
the,1940,O
mouse,1940,O
homologue,1940,O
of,1940,O
OTC,1940,O
(,1940,O
ornithine,1940,O
transcarbamylase,1940,O
),1940,O
which,1940,O
is,1940,O
closely,1940,O
linked,1940,O
to,1940,O
DMD,1940,B-SpecificDisease
on,1940,O
the,1940,O
human,1940,O
X,1940,O
chromosome,1940,O
..,1940,O
Localization,1941,O
of,1941,O
the,1941,O
region,1941,O
homologous,1941,O
to,1941,O
the,1941,O
Duchenne,1941,B-Modifier
muscular,1941,I-Modifier
dystrophy,1941,I-Modifier
locus,1941,O
on,1941,O
the,1941,O
mouse,1941,O
X,1941,O
chromosome,1941,O
.,1941,O
Recent,1942,O
progress,1942,O
has,1942,O
resulted,1942,O
in,1942,O
part,1942,O
of,1942,O
the,1942,O
gene,1942,O
mutated,1942,O
in,1942,O
Duchenne,1942,O
and,1942,O
the,1942,O
milder,1942,O
Becker,1942,O
muscular,1942,O
dystrophies,1942,O
being,1942,O
cloned,1942,O
and,1942,O
has,1942,O
suggested,1942,O
that,1942,O
the,1942,O
gene,1942,O
itself,1942,O
extends,1942,O
over,1942,O
1,1942,O
",",1942,O
000,1942,O
to,1942,O
2,1942,O
",",1942,O
000,1942,O
kilobases,1942,O
(,1942,O
kb,1942,O
),1942,O
.,1942,O
To,1943,O
study,1943,O
how,1943,O
mutations,1943,O
in,1943,O
this,1943,O
gene,1943,O
affect,1943,O
muscle,1943,O
development,1943,O
and,1943,O
integrity,1943,O
",",1943,O
it,1943,O
would,1943,O
be,1943,O
of,1943,O
interest,1943,O
to,1943,O
have,1943,O
available,1943,O
a,1943,O
mouse,1943,O
model,1943,O
of,1943,O
the,1943,O
human,1943,O
disease,1943,O
.,1943,O
The,1944,O
mouse,1944,O
mdx,1944,O
mutation,1944,O
affects,1944,O
muscle,1944,O
and,1944,O
confers,1944,O
a,1944,O
mild,1944,O
dystrophic,1944,B-SpecificDisease
syndrome,1944,I-SpecificDisease
",",1944,O
but,1944,O
it,1944,O
is,1944,O
not,1944,O
clear,1944,O
whether,1944,O
this,1944,O
mutation,1944,O
is,1944,O
equivalent,1944,O
to,1944,O
Duchenne/Becker,1944,O
muscular,1944,O
dystrophy,1944,O
in,1944,O
man,1944,O
.,1944,O
Here,1945,O
we,1945,O
describe,1945,O
the,1945,O
use,1945,O
of,1945,O
two,1945,O
sequences,1945,O
from,1945,O
the,1945,O
human,1945,O
Duchenne,1945,B-Modifier
muscular,1945,I-Modifier
dystrophy,1945,I-Modifier
(,1945,O
DMD,1945,B-Modifier
),1945,O
gene,1945,O
that,1945,O
cross-hybridize,1945,O
to,1945,O
mouse,1945,O
X-linked,1945,O
sequences,1945,O
to,1945,O
localize,1945,O
the,1945,O
gene,1945,O
homologous,1945,O
to,1945,O
DMD,1945,B-SpecificDisease
in,1945,O
the,1945,O
mouse,1945,O
.,1945,O
Both,1946,O
sequences,1946,O
map,1946,O
to,1946,O
the,1946,O
region,1946,O
of,1946,O
10,1946,O
centimorgan,1946,O
lying,1946,O
between,1946,O
the,1946,O
Tabby,1946,O
(,1946,O
Ta,1946,O
),1946,O
and,1946,O
St14-1,1946,O
(,1946,O
DxPas8,1946,O
),1946,O
loci,1946,O
",",1946,O
close,1946,O
to,1946,O
the,1946,O
phosphorylase,1946,O
b,1946,O
kinase,1946,O
locus,1946,O
(,1946,O
Phk,1946,O
),1946,O
.,1946,O
By,1947,O
analogy,1947,O
with,1947,O
the,1947,O
human,1947,O
X-chromosome,1947,O
",",1947,O
we,1947,O
conclude,1947,O
that,1947,O
the,1947,O
region,1947,O
in,1947,O
the,1947,O
mouse,1947,O
around,1947,O
the,1947,O
G6pd,1947,O
and,1947,O
St14-1,1947,O
loci,1947,O
may,1947,O
contain,1947,O
two,1947,O
genes,1947,O
corresponding,1947,O
to,1947,O
distinct,1947,O
human,1947,O
myopathies,1947,B-DiseaseClass
Emery,1947,B-SpecificDisease
Dreifuss,1947,I-SpecificDisease
muscular,1947,I-SpecificDisease
dystrophy,1947,I-SpecificDisease
which,1947,O
is,1947,O
known,1947,O
to,1947,O
be,1947,O
closely,1947,O
linked,1947,O
to,1947,O
St14-1,1947,O
in,1947,O
man,1947,O
and,1947,O
the,1947,O
DMD,1947,B-Modifier
homologue,1947,O
described,1947,O
here,1947,O
..,1947,O
GT,1948,O
to,1948,O
AT,1948,O
transition,1948,O
at,1948,O
a,1948,O
splice,1948,O
donor,1948,O
site,1948,O
causes,1948,O
skipping,1948,O
of,1948,O
the,1948,O
preceding,1948,O
exon,1948,O
in,1948,O
phenylketonuria,1948,B-SpecificDisease
.,1948,O
Classical,1949,B-SpecificDisease
Phenylketonuria,1949,I-SpecificDisease
(,1949,O
PKU,1949,B-SpecificDisease
),1949,O
is,1949,O
an,1949,O
autosomal,1949,B-DiseaseClass
recessive,1949,I-DiseaseClass
human,1949,I-DiseaseClass
genetic,1949,I-DiseaseClass
disorder,1949,I-DiseaseClass
caused,1949,O
by,1949,O
a,1949,O
deficiency,1949,B-SpecificDisease
of,1949,I-SpecificDisease
hepatic,1949,I-SpecificDisease
phenylalanine,1949,I-SpecificDisease
hydroxylase,1949,I-SpecificDisease
(,1949,O
PAH,1949,O
),1949,O
.,1949,O
We,1950,O
isolated,1950,O
several,1950,O
mutant,1950,O
PAH,1950,O
cDNA,1950,O
clones,1950,O
from,1950,O
a,1950,O
PKU,1950,B-Modifier
carrier,1950,O
individual,1950,O
and,1950,O
showed,1950,O
that,1950,O
they,1950,O
contained,1950,O
an,1950,O
internal,1950,O
116,1950,O
base,1950,O
pair,1950,O
deletion,1950,O
",",1950,O
corresponding,1950,O
precisely,1950,O
to,1950,O
exon,1950,O
12,1950,O
of,1950,O
the,1950,O
human,1950,O
chromosomal,1950,O
PAH,1950,O
gene,1950,O
.,1950,O
The,1951,O
deletion,1951,O
causes,1951,O
the,1951,O
synthesis,1951,O
of,1951,O
a,1951,O
truncated,1951,O
protein,1951,O
lacking,1951,O
the,1951,O
C-terminal,1951,O
52,1951,O
amino,1951,O
acids,1951,O
.,1951,O
Gene,1952,O
transfer,1952,O
and,1952,O
expression,1952,O
studies,1952,O
using,1952,O
the,1952,O
mutant,1952,O
PAH,1952,O
cDNA,1952,O
indicated,1952,O
that,1952,O
the,1952,O
deletion,1952,O
abolishes,1952,O
PAH,1952,O
activity,1952,O
in,1952,O
the,1952,O
cell,1952,O
as,1952,O
a,1952,O
result,1952,O
of,1952,O
protein,1952,O
instability,1952,O
.,1952,O
To,1953,O
determine,1953,O
the,1953,O
molecular,1953,O
basis,1953,O
of,1953,O
the,1953,O
deletion,1953,O
",",1953,O
the,1953,O
mutant,1953,O
chromosomal,1953,O
PAH,1953,O
gene,1953,O
was,1953,O
isolated,1953,O
from,1953,O
this,1953,O
individual,1953,O
and,1953,O
shown,1953,O
to,1953,O
contain,1953,O
a,1953,O
GT,1953,O
--,1953,O
greater,1953,O
than,1953,O
AT,1953,O
substitution,1953,O
at,1953,O
the,1953,O
5,1953,O
splice,1953,O
donor,1953,O
site,1953,O
of,1953,O
intron,1953,O
12,1953,O
.,1953,O
Thus,1954,O
",",1954,O
the,1954,O
consequence,1954,O
of,1954,O
the,1954,O
splice,1954,O
donor,1954,O
site,1954,O
mutation,1954,O
in,1954,O
the,1954,O
human,1954,O
liver,1954,O
is,1954,O
the,1954,O
skipping,1954,O
of,1954,O
the,1954,O
preceding,1954,O
exon,1954,O
during,1954,O
RNA,1954,O
splicing,1954,O
..,1954,O
Conservation,1955,O
of,1955,O
the,1955,O
Duchenne,1955,B-Modifier
muscular,1955,I-Modifier
dystrophy,1955,I-Modifier
gene,1955,O
in,1955,O
mice,1955,O
and,1955,O
humans,1955,O
.,1955,O
A,1956,O
portion,1956,O
of,1956,O
the,1956,O
Duchenne,1956,B-Modifier
muscular,1956,I-Modifier
dystrophy,1956,I-Modifier
(,1956,O
DMD,1956,B-Modifier
),1956,O
gene,1956,O
transcript,1956,O
from,1956,O
human,1956,O
fetal,1956,O
skeletal,1956,O
muscle,1956,O
and,1956,O
mouse,1956,O
adult,1956,O
heart,1956,O
was,1956,O
sequenced,1956,O
",",1956,O
representing,1956,O
approximately,1956,O
25,1956,O
percent,1956,O
of,1956,O
the,1956,O
total,1956,O
",",1956,O
14-kb,1956,O
DMD,1956,B-Modifier
transcript,1956,O
.,1956,O
The,1957,O
nucleic,1957,O
acid,1957,O
and,1957,O
predicted,1957,O
amino,1957,O
acid,1957,O
sequences,1957,O
from,1957,O
the,1957,O
two,1957,O
species,1957,O
are,1957,O
nearly,1957,O
90,1957,O
percent,1957,O
homologous,1957,O
.,1957,O
The,1958,O
amino,1958,O
acid,1958,O
sequence,1958,O
that,1958,O
is,1958,O
predicted,1958,O
from,1958,O
this,1958,O
portion,1958,O
of,1958,O
the,1958,O
DMD,1958,B-Modifier
gene,1958,O
indicates,1958,O
that,1958,O
the,1958,O
protein,1958,O
product,1958,O
might,1958,O
serve,1958,O
a,1958,O
structural,1958,O
role,1958,O
in,1958,O
muscle,1958,O
",",1958,O
but,1958,O
the,1958,O
abundance,1958,O
and,1958,O
tissue,1958,O
distribution,1958,O
of,1958,O
the,1958,O
messenger,1958,O
RNA,1958,O
suggests,1958,O
that,1958,O
the,1958,O
DMD,1958,B-Modifier
protein,1958,O
is,1958,O
not,1958,O
nebulin,1958,O
..,1958,O
Familial,1959,O
Prader-Willi,1959,B-SpecificDisease
syndrome,1959,I-SpecificDisease
with,1959,O
apparently,1959,O
normal,1959,O
chromosomes,1959,O
.,1959,O
We,1960,O
report,1960,O
on,1960,O
4,1960,O
sibs,1960,O
(,1960,O
2F,1960,O
",",1960,O
2M,1960,O
),1960,O
with,1960,O
Prader-Willi,1960,B-SpecificDisease
syndrome,1960,I-SpecificDisease
(,1960,O
PWS,1960,B-SpecificDisease
),1960,O
.,1960,O
Diagnosis,1961,O
was,1961,O
made,1961,O
clinically,1961,O
on,1961,O
the,1961,O
basis,1961,O
of,1961,O
history,1961,O
",",1961,O
behavior,1961,O
",",1961,O
and,1961,O
physical,1961,O
findings,1961,O
in,1961,O
3,1961,O
of,1961,O
the,1961,O
sibs,1961,O
.,1961,O
The,1962,O
other,1962,O
child,1962,O
had,1962,O
died,1962,O
at,1962,O
age,1962,O
10,1962,O
months,1962,O
with,1962,O
a,1962,O
history,1962,O
and,1962,O
clinical,1962,O
findings,1962,O
typical,1962,O
of,1962,O
first,1962,O
phase,1962,O
of,1962,O
PWS,1962,B-SpecificDisease
.,1962,O
Results,1963,O
of,1963,O
chromosome,1963,O
studies,1963,O
on,1963,O
the,1963,O
parents,1963,O
and,1963,O
surviving,1963,O
sibs,1963,O
were,1963,O
normal,1963,O
.,1963,O
The,1964,O
implications,1964,O
of,1964,O
this,1964,O
unusual,1964,O
familial,1964,O
occurrence,1964,O
for,1964,O
our,1964,O
understanding,1964,O
of,1964,O
PWS,1964,B-SpecificDisease
are,1964,O
discussed,1964,O
..,1964,O
Nebulin,1965,O
and,1965,O
titin,1965,O
expression,1965,O
in,1965,O
Duchenne,1965,B-SpecificDisease
muscular,1965,I-SpecificDisease
dystrophy,1965,I-SpecificDisease
appears,1965,O
normal,1965,O
.,1965,O
Monoclonal,1966,O
antibodies,1966,O
which,1966,O
recognize,1966,O
different,1966,O
epitopes,1966,O
on,1966,O
either,1966,O
titin,1966,O
or,1966,O
nebulin,1966,O
show,1966,O
normal,1966,O
staining,1966,O
patterns,1966,O
on,1966,O
frozen,1966,O
sections,1966,O
of,1966,O
three,1966,O
muscle,1966,O
biopsies,1966,O
of,1966,O
Duchenne,1966,B-SpecificDisease
muscular,1966,I-SpecificDisease
dystrophy,1966,I-SpecificDisease
(,1966,O
DMD,1966,B-SpecificDisease
),1966,O
.,1966,O
Gel,1967,O
electrophoresis,1967,O
and,1967,O
immunoblotting,1967,O
performed,1967,O
on,1967,O
two,1967,O
of,1967,O
these,1967,O
muscle,1967,O
biopsies,1967,O
show,1967,O
the,1967,O
normal,1967,O
pattern,1967,O
of,1967,O
titin,1967,O
and,1967,O
nebulin,1967,O
polypeptides,1967,O
.,1967,O
Since,1968,O
the,1968,O
donor,1968,O
of,1968,O
one,1968,O
of,1968,O
these,1968,O
biopsies,1968,O
has,1968,O
a,1968,O
large,1968,O
deletion,1968,O
of,1968,O
the,1968,O
5-region,1968,O
of,1968,O
the,1968,O
DMD,1968,B-Modifier
gene,1968,O
",",1968,O
our,1968,O
results,1968,O
argue,1968,O
against,1968,O
the,1968,O
recent,1968,O
proposal,1968,O
that,1968,O
nebulin,1968,O
is,1968,O
the,1968,O
gene,1968,O
mutated,1968,O
in,1968,O
DMD,1968,B-SpecificDisease
..,1968,O
Heterozygous,1969,B-SpecificDisease
C2,1969,I-SpecificDisease
deficiency,1969,I-SpecificDisease
associated,1969,O
with,1969,O
angioedema,1969,B-SpecificDisease
",",1969,O
myasthenia,1969,B-SpecificDisease
gravis,1969,I-SpecificDisease
",",1969,O
and,1969,O
systemic,1969,B-SpecificDisease
lupus,1969,I-SpecificDisease
erythematosus,1969,I-SpecificDisease
.,1969,O
We,1970,O
describe,1970,O
a,1970,O
patient,1970,O
with,1970,O
myasthenia,1970,B-SpecificDisease
gravis,1970,I-SpecificDisease
",",1970,O
systemic,1970,B-SpecificDisease
lupus,1970,I-SpecificDisease
erythematosus,1970,I-SpecificDisease
",",1970,O
and,1970,O
angioedema,1970,B-SpecificDisease
associated,1970,O
with,1970,O
heterozygous,1970,O
complement,1970,B-SpecificDisease
factor,1970,I-SpecificDisease
2,1970,I-SpecificDisease
(,1970,I-SpecificDisease
C2,1970,I-SpecificDisease
),1970,I-SpecificDisease
deficiency,1970,I-SpecificDisease
.,1970,O
The,1971,O
significance,1971,O
of,1971,O
this,1971,O
association,1971,O
is,1971,O
controversial,1971,O
",",1971,O
though,1971,O
the,1971,O
association,1971,O
of,1971,O
C2,1971,B-SpecificDisease
deficiency,1971,I-SpecificDisease
with,1971,O
certain,1971,O
histocompatibility,1971,O
antigens,1971,O
suggests,1971,O
possible,1971,O
linkage,1971,O
to,1971,O
immune,1971,O
response,1971,O
genes,1971,O
.,1971,O
To,1972,O
our,1972,O
knowledge,1972,O
this,1972,O
is,1972,O
the,1972,O
first,1972,O
report,1972,O
of,1972,O
heterozygous,1972,O
C2,1972,B-SpecificDisease
deficiency,1972,I-SpecificDisease
in,1972,O
association,1972,O
with,1972,O
this,1972,O
combination,1972,O
of,1972,O
autoimmune,1972,B-DiseaseClass
disorders,1972,I-DiseaseClass
",",1972,O
and,1972,O
we,1972,O
discuss,1972,O
the,1972,O
aetiological,1972,O
implications,1972,O
..,1972,O
Genetic,1973,O
analysis,1973,O
of,1973,O
an,1973,O
inherited,1973,O
deficiency,1973,B-SpecificDisease
of,1973,I-SpecificDisease
the,1973,I-SpecificDisease
third,1973,I-SpecificDisease
component,1973,I-SpecificDisease
of,1973,I-SpecificDisease
complement,1973,I-SpecificDisease
in,1973,O
Brittany,1973,O
spaniel,1973,O
dogs,1973,O
.,1973,O
Genetically,1974,O
determined,1974,O
C3,1974,B-SpecificDisease
deficiency,1974,I-SpecificDisease
in,1974,O
Brittany,1974,O
spaniel,1974,O
dogs,1974,O
shares,1974,O
a,1974,O
number,1974,O
of,1974,O
biochemical,1974,O
and,1974,O
clinical,1974,O
characteristics,1974,O
with,1974,O
the,1974,O
human,1974,O
disorder,1974,O
.,1974,O
In,1975,O
humans,1975,O
",",1975,O
the,1975,O
gene,1975,O
for,1975,O
C3,1975,B-SpecificDisease
deficiency,1975,I-SpecificDisease
is,1975,O
a,1975,O
null,1975,O
gene,1975,O
that,1975,O
is,1975,O
allelic,1975,O
to,1975,O
the,1975,O
structural,1975,O
gene,1975,O
for,1975,O
C3,1975,O
and,1975,O
is,1975,O
not,1975,O
linked,1975,O
to,1975,O
the,1975,O
major,1975,O
histocompatibility,1975,O
locus,1975,O
.,1975,O
The,1976,O
current,1976,O
study,1976,O
used,1976,O
allotype,1976,O
analysis,1976,O
of,1976,O
canine,1976,O
C3,1976,O
in,1976,O
order,1976,O
to,1976,O
demonstrate,1976,O
that,1976,O
the,1976,O
gene,1976,O
for,1976,O
C3,1976,B-SpecificDisease
deficiency,1976,I-SpecificDisease
in,1976,O
these,1976,O
dogs,1976,O
is,1976,O
also,1976,O
a,1976,O
null,1976,O
gene,1976,O
allelic,1976,O
to,1976,O
the,1976,O
structural,1976,O
gene,1976,O
for,1976,O
C3,1976,O
.,1976,O
In,1977,O
addition,1977,O
",",1977,O
preliminary,1977,O
pedigree,1977,O
analysis,1977,O
suggests,1977,O
that,1977,O
the,1977,O
gene,1977,O
for,1977,O
canine,1977,O
C3,1977,B-SpecificDisease
deficiency,1977,I-SpecificDisease
is,1977,O
apparently,1977,O
not,1977,O
closely,1977,O
linked,1977,O
to,1977,O
the,1977,O
major,1977,O
histocompatibility,1977,O
complex,1977,O
of,1977,O
the,1977,O
dog,1977,O
.,1977,O
Thus,1978,O
",",1978,O
it,1978,O
appears,1978,O
that,1978,O
C3,1978,B-SpecificDisease
deficiency,1978,I-SpecificDisease
in,1978,O
Brittany,1978,O
spaniel,1978,O
dogs,1978,O
not,1978,O
only,1978,O
shares,1978,O
biochemical,1978,O
and,1978,O
clinical,1978,O
features,1978,O
with,1978,O
C3,1978,B-SpecificDisease
deficiency,1978,I-SpecificDisease
in,1978,O
humans,1978,O
",",1978,O
but,1978,O
also,1978,O
shares,1978,O
some,1978,O
genetic,1978,O
characteristics,1978,O
with,1978,O
the,1978,O
human,1978,O
disorder,1978,O
..,1978,O
Gene,1979,O
transfer,1979,O
and,1979,O
expression,1979,O
of,1979,O
human,1979,O
phenylalanine,1979,O
hydroxylase,1979,O
.,1979,O
Phenylketonuria,1980,B-SpecificDisease
(,1980,O
PKU,1980,B-SpecificDisease
),1980,O
is,1980,O
caused,1980,O
by,1980,O
a,1980,O
genetic,1980,O
deficiency,1980,B-SpecificDisease
of,1980,I-SpecificDisease
the,1980,I-SpecificDisease
enzyme,1980,I-SpecificDisease
phenylalanine,1980,I-SpecificDisease
hydroxylase,1980,I-SpecificDisease
(,1980,O
PAH,1980,O
),1980,O
.,1980,O
A,1981,O
full-length,1981,O
complementary,1981,O
DNA,1981,O
clone,1981,O
of,1981,O
human,1981,O
PAH,1981,O
was,1981,O
inserted,1981,O
into,1981,O
a,1981,O
eukaryotic,1981,O
expression,1981,O
vector,1981,O
and,1981,O
transferred,1981,O
into,1981,O
mouse,1981,O
NIH3T3,1981,O
cells,1981,O
which,1981,O
do,1981,O
not,1981,O
normally,1981,O
express,1981,O
PAH,1981,O
.,1981,O
The,1982,O
transformed,1982,O
mouse,1982,O
cells,1982,O
expressed,1982,O
PAH,1982,O
messenger,1982,O
RNA,1982,O
",",1982,O
immunoreactive,1982,O
protein,1982,O
",",1982,O
and,1982,O
enzymatic,1982,O
activity,1982,O
that,1982,O
are,1982,O
characteristic,1982,O
of,1982,O
the,1982,O
normal,1982,O
human,1982,O
liver,1982,O
products,1982,O
",",1982,O
demonstrating,1982,O
that,1982,O
a,1982,O
single,1982,O
gene,1982,O
contains,1982,O
all,1982,O
of,1982,O
the,1982,O
necessary,1982,O
genetic,1982,O
information,1982,O
to,1982,O
code,1982,O
for,1982,O
functional,1982,O
PAH,1982,O
.,1982,O
These,1983,O
results,1983,O
support,1983,O
the,1983,O
use,1983,O
of,1983,O
the,1983,O
human,1983,O
PAH,1983,O
probe,1983,O
in,1983,O
prenatal,1983,O
diagnosis,1983,O
and,1983,O
detection,1983,O
of,1983,O
carriers,1983,O
",",1983,O
to,1983,O
provide,1983,O
new,1983,O
opportunities,1983,O
for,1983,O
the,1983,O
biochemical,1983,O
characterization,1983,O
of,1983,O
normal,1983,O
and,1983,O
mutant,1983,O
enzymes,1983,O
",",1983,O
and,1983,O
in,1983,O
the,1983,O
investigation,1983,O
of,1983,O
alternative,1983,O
genetic,1983,O
therapies,1983,O
for,1983,O
PKU,1983,B-SpecificDisease
..,1983,O
Regional,1984,O
mapping,1984,O
of,1984,O
the,1984,O
phenylalanine,1984,O
hydroxylase,1984,O
gene,1984,O
and,1984,O
the,1984,O
phenylketonuria,1984,B-Modifier
locus,1984,O
in,1984,O
the,1984,O
human,1984,O
genome,1984,O
.,1984,O
Phenylketonuria,1985,B-SpecificDisease
(,1985,O
PKU,1985,B-SpecificDisease
),1985,O
is,1985,O
an,1985,O
autosomal,1985,B-DiseaseClass
recessive,1985,I-DiseaseClass
disorder,1985,I-DiseaseClass
of,1985,O
amino,1985,O
acid,1985,O
metabolism,1985,O
caused,1985,O
by,1985,O
a,1985,O
deficiency,1985,B-SpecificDisease
of,1985,I-SpecificDisease
the,1985,I-SpecificDisease
hepatic,1985,I-SpecificDisease
enzyme,1985,I-SpecificDisease
phenylalanine,1985,I-SpecificDisease
hydroxylase,1985,I-SpecificDisease
(,1985,O
PAH,1985,O
;,1985,O
phenylalanine,1985,O
4-monooxygenase,1985,O
",",1985,O
EC,1985,O
1,1985,O
.,1985,O
14,1986,O
.,1986,O
16,1987,O
.,1987,O
1,1988,O
),1988,O
.,1988,O
A,1989,O
cDNA,1989,O
clone,1989,O
for,1989,O
human,1989,O
PAH,1989,O
has,1989,O
previously,1989,O
been,1989,O
used,1989,O
to,1989,O
assign,1989,O
the,1989,O
corresponding,1989,O
gene,1989,O
to,1989,O
human,1989,O
chromosome,1989,O
12,1989,O
.,1989,O
To,1990,O
define,1990,O
the,1990,O
regional,1990,O
map,1990,O
position,1990,O
of,1990,O
the,1990,O
disease,1990,O
locus,1990,O
and,1990,O
the,1990,O
PAH,1990,O
gene,1990,O
on,1990,O
human,1990,O
chromosome,1990,O
12,1990,O
",",1990,O
DNA,1990,O
was,1990,O
isolated,1990,O
from,1990,O
human-hamster,1990,O
somatic,1990,O
cell,1990,O
hybrids,1990,O
with,1990,O
various,1990,O
deletions,1990,O
of,1990,O
human,1990,O
chromosome,1990,O
12,1990,O
and,1990,O
was,1990,O
analyzed,1990,O
by,1990,O
Southern,1990,O
blot,1990,O
analysis,1990,O
using,1990,O
the,1990,O
human,1990,O
cDNA,1990,O
PAH,1990,O
clone,1990,O
as,1990,O
a,1990,O
hybridization,1990,O
probe,1990,O
.,1990,O
From,1991,O
these,1991,O
results,1991,O
",",1991,O
together,1991,O
with,1991,O
detailed,1991,O
biochemical,1991,O
and,1991,O
cytogenetic,1991,O
characterization,1991,O
of,1991,O
the,1991,O
hybrid,1991,O
cells,1991,O
",",1991,O
the,1991,O
region,1991,O
on,1991,O
chromosome,1991,O
12,1991,O
containing,1991,O
the,1991,O
human,1991,O
PAH,1991,O
gene,1991,O
has,1991,O
been,1991,O
defined,1991,O
as,1991,O
12q14,1991,O
.,1991,O
3,1992,O
--,1992,O
--,1992,O
qter,1992,O
3,1992,O
--,1992,O
--,1992,O
qter,1992,O
.,1992,O
The,1993,O
PAH,1993,O
map,1993,O
position,1993,O
on,1993,O
chromosome,1993,O
12,1993,O
was,1993,O
further,1993,O
localized,1993,O
by,1993,O
in,1993,O
situ,1993,O
hybridization,1993,O
of,1993,O
125I-labeled,1993,O
human,1993,O
PAH,1993,O
cDNA,1993,O
to,1993,O
chromosomes,1993,O
prepared,1993,O
from,1993,O
a,1993,O
human,1993,O
lymphoblastoid,1993,O
cell,1993,O
line,1993,O
.,1993,O
Results,1994,O
of,1994,O
these,1994,O
experiments,1994,O
demonstrated,1994,O
that,1994,O
the,1994,O
region,1994,O
on,1994,O
chromosome,1994,O
12,1994,O
containing,1994,O
the,1994,O
PAH,1994,O
gene,1994,O
and,1994,O
the,1994,O
PKU,1994,B-Modifier
locus,1994,O
in,1994,O
man,1994,O
is,1994,O
12q22,1994,O
--,1994,O
--,1994,O
12q24,1994,O
.,1994,O
1,1995,O
.,1995,O
These,1996,O
results,1996,O
not,1996,O
only,1996,O
provide,1996,O
a,1996,O
regionalized,1996,O
map,1996,O
position,1996,O
for,1996,O
a,1996,O
major,1996,O
human,1996,O
disease,1996,O
locus,1996,O
but,1996,O
also,1996,O
can,1996,O
serve,1996,O
as,1996,O
a,1996,O
reference,1996,O
point,1996,O
for,1996,O
linkage,1996,O
analysis,1996,O
with,1996,O
other,1996,O
DNA,1996,O
markers,1996,O
on,1996,O
human,1996,O
chromosome,1996,O
12,1996,O
Heterogeneity,1997,O
of,1997,O
type,1997,B-SpecificDisease
I,1997,I-SpecificDisease
von,1997,I-SpecificDisease
Willebrand,1997,I-SpecificDisease
disease,1997,I-SpecificDisease
:,1997,O
evidence,1997,O
for,1997,O
a,1997,O
subgroup,1997,O
with,1997,O
an,1997,O
abnormal,1997,O
von,1997,B-Modifier
Willebrand,1997,I-Modifier
factor,1997,O
.,1997,O
Type,1998,B-SpecificDisease
I,1998,I-SpecificDisease
von,1998,I-SpecificDisease
Willebrand,1998,I-SpecificDisease
disease,1998,I-SpecificDisease
(,1998,O
vWD,1998,B-SpecificDisease
),1998,O
is,1998,O
characterized,1998,O
by,1998,O
equally,1998,O
low,1998,O
plasma,1998,O
concentrations,1998,O
of,1998,O
von,1998,B-Modifier
Willebrand,1998,I-Modifier
factor,1998,O
antigen,1998,O
(,1998,O
vWF,1998,O
Ag,1998,O
),1998,O
and,1998,O
ristocetin,1998,O
cofactor,1998,O
(,1998,O
RiCof,1998,O
),1998,O
and,1998,O
by,1998,O
the,1998,O
presence,1998,O
of,1998,O
all,1998,O
vWF,1998,O
multimers,1998,O
in,1998,O
sodium,1998,O
dodecyl,1998,O
sulfate,1998,O
(,1998,O
SDS,1998,O
),1998,O
-agarose,1998,O
gel,1998,O
electrophoresis,1998,O
.,1998,O
For,1999,O
17,1999,O
patients,1999,O
(,1999,O
13,1999,O
kindreds,1999,O
),1999,O
diagnosed,1999,O
with,1999,O
these,1999,O
criteria,1999,O
",",1999,O
we,1999,O
have,1999,O
studied,1999,O
the,1999,O
platelet,1999,O
contents,1999,O
of,1999,O
vWF,1999,O
Ag,1999,O
and,1999,O
RiCof,1999,O
and,1999,O
the,1999,O
changes,1999,O
of,1999,O
these,1999,O
in,1999,O
plasma,1999,O
after,1999,O
DDAVP,1999,O
infusion,1999,O
.,1999,O
Platelet,2000,O
vWF,2000,O
Ag,2000,O
and,2000,O
RiCof,2000,O
were,2000,O
normal,2000,O
in,2000,O
four,2000,O
kindreds,2000,O
(,2000,O
called,2000,O
``,2000,O
platelet,2000,O
normal,2000,O
``,2000,O
subgroup,2000,O
),2000,O
;,2000,O
following,2000,O
1-deamino-8-D-arginine,2000,O
vasopressin,2000,O
;,2000,O
plasma,2000,O
vWF,2000,O
Ag,2000,O
",",2000,O
RiCof,2000,O
and,2000,O
the,2000,O
bleeding,2000,O
time,2000,O
(,2000,O
BT,2000,O
),2000,O
became,2000,O
normal,2000,O
.,2000,O
In,2001,O
six,2001,O
kindreds,2001,O
",",2001,O
platelet,2001,O
vWF,2001,O
Ag,2001,O
and,2001,O
RiCof,2001,O
were,2001,O
equally,2001,O
low,2001,O
(,2001,O
platelet,2001,O
low,2001,O
),2001,O
;,2001,O
after,2001,O
DDAVP,2001,O
",",2001,O
plasma,2001,O
vWF,2001,O
Ag,2001,O
and,2001,O
RiCof,2001,O
remained,2001,O
low,2001,O
",",2001,O
and,2001,O
the,2001,O
BT,2001,O
was,2001,O
prolonged,2001,O
.,2001,O
In,2002,O
three,2002,O
additional,2002,O
kindreds,2002,O
",",2002,O
platelets,2002,O
contained,2002,O
normal,2002,O
concentrations,2002,O
of,2002,O
vWF,2002,O
Ag,2002,O
",",2002,O
but,2002,O
RiCof,2002,O
was,2002,O
very,2002,O
low,2002,O
(,2002,O
platelet,2002,O
discordant,2002,O
),2002,O
;,2002,O
even,2002,O
though,2002,O
a,2002,O
complete,2002,O
set,2002,O
of,2002,O
multimers,2002,O
was,2002,O
found,2002,O
in,2002,O
plasma,2002,O
and,2002,O
platelets,2002,O
",",2002,O
there,2002,O
was,2002,O
a,2002,O
relatively,2002,O
small,2002,O
amount,2002,O
of,2002,O
large,2002,O
multimers,2002,O
.,2002,O
After,2003,O
DDAVP,2003,O
",",2003,O
plasma,2003,O
vWF,2003,O
Ag,2003,O
became,2003,O
normal,2003,O
",",2003,O
but,2003,O
RiCof,2003,O
remained,2003,O
low,2003,O
and,2003,O
the,2003,O
BT,2003,O
was,2003,O
very,2003,O
prolonged,2003,O
.,2003,O
These,2004,O
findings,2004,O
demonstrated,2004,O
that,2004,O
there,2004,O
can,2004,O
be,2004,O
an,2004,O
abnormal,2004,O
vWF,2004,O
(,2004,O
RiCof,2004,O
less,2004,O
than,2004,O
vWF,2004,O
Ag,2004,O
),2004,O
even,2004,O
in,2004,O
type,2004,B-SpecificDisease
I,2004,I-SpecificDisease
vWD,2004,I-SpecificDisease
",",2004,O
coexisting,2004,O
with,2004,O
a,2004,O
complete,2004,O
set,2004,O
of,2004,O
vWF,2004,O
multimers,2004,O
(,2004,O
platelet,2004,O
discordant,2004,O
),2004,O
;,2004,O
that,2004,O
the,2004,O
abnormal,2004,O
vWF,2004,O
can,2004,O
be,2004,O
shown,2004,O
more,2004,O
clearly,2004,O
in,2004,O
platelets,2004,O
than,2004,O
in,2004,O
plasma,2004,O
or,2004,O
else,2004,O
in,2004,O
plasma,2004,O
after,2004,O
DDAVP,2004,O
infusion,2004,O
;,2004,O
and,2004,O
that,2004,O
DDAVP,2004,O
normalizes,2004,O
the,2004,O
BT,2004,O
only,2004,O
in,2004,O
those,2004,O
patients,2004,O
with,2004,O
normal,2004,O
platelet,2004,O
levels,2004,O
of,2004,O
both,2004,O
vWF,2004,O
Ag,2004,O
and,2004,O
RiCof,2004,O
(,2004,O
platelet,2004,O
normal,2004,O
),2004,O
..,2004,O
Genetic,2005,O
analysis,2005,O
in,2005,O
families,2005,O
with,2005,O
van,2005,B-SpecificDisease
der,2005,I-SpecificDisease
Woude,2005,I-SpecificDisease
syndrome,2005,I-SpecificDisease
.,2005,O
We,2006,O
have,2006,O
brought,2006,O
together,2006,O
information,2006,O
on,2006,O
864,2006,O
affected,2006,O
individuals,2006,O
in,2006,O
164,2006,O
families,2006,O
(,2006,O
including,2006,O
three,2006,O
new,2006,O
pedigrees,2006,O
),2006,O
reported,2006,O
in,2006,O
the,2006,O
137,2006,O
year,2006,O
period,2006,O
since,2006,O
1845,2006,O
when,2006,O
Demarquay,2006,O
first,2006,O
described,2006,O
a,2006,O
family,2006,O
with,2006,O
what,2006,O
was,2006,O
later,2006,O
called,2006,O
van,2006,B-SpecificDisease
der,2006,I-SpecificDisease
Woude,2006,I-SpecificDisease
syndrome,2006,I-SpecificDisease
(,2006,O
VWS,2006,B-SpecificDisease
),2006,O
.,2006,O
Both,2007,O
types,2007,O
of,2007,O
oral,2007,O
cleft,2007,O
",",2007,O
cleft,2007,B-SpecificDisease
palate,2007,I-SpecificDisease
(,2007,O
CP,2007,B-SpecificDisease
),2007,O
and,2007,O
cleft,2007,B-SpecificDisease
lip,2007,I-SpecificDisease
with,2007,O
or,2007,O
without,2007,O
CP,2007,B-SpecificDisease
(,2007,O
CLP,2007,B-SpecificDisease
),2007,O
",",2007,O
segregate,2007,O
in,2007,O
these,2007,O
families,2007,O
together,2007,O
with,2007,O
lower,2007,O
lip,2007,B-SpecificDisease
pits,2007,I-SpecificDisease
or,2007,O
fistulae,2007,B-SpecificDisease
in,2007,O
an,2007,O
autosomal,2007,O
dominant,2007,O
mode,2007,O
with,2007,O
high,2007,O
penetrance,2007,O
estimated,2007,O
to,2007,O
be,2007,O
K,2007,O
=,2007,O
.,2007,O
89,2008,O
and,2008,O
.,2008,O
99,2009,O
by,2009,O
different,2009,O
methods,2009,O
.,2009,O
Cleft,2010,O
types,2010,O
(,2010,O
CLP,2010,B-SpecificDisease
and,2010,O
CP,2010,B-SpecificDisease
),2010,O
occur,2010,O
in,2010,O
VWS,2010,B-SpecificDisease
in,2010,O
the,2010,O
same,2010,O
proportions,2010,O
as,2010,O
in,2010,O
the,2010,O
general,2010,O
non-VWS,2010,O
population,2010,O
",",2010,O
ie,2010,O
",",2010,O
about,2010,O
twice,2010,O
as,2010,O
many,2010,O
cleft-bearing,2010,O
individuals,2010,O
have,2010,O
CLP,2010,B-SpecificDisease
as,2010,O
have,2010,O
CP,2010,B-SpecificDisease
.,2010,O
On,2011,O
the,2011,O
other,2011,O
hand,2011,O
",",2011,O
we,2011,O
do,2011,O
not,2011,O
find,2011,O
the,2011,O
usually,2011,O
observed,2011,O
excess,2011,O
of,2011,O
females,2011,O
with,2011,O
CP,2011,B-SpecificDisease
and,2011,O
excess,2011,O
of,2011,O
males,2011,O
with,2011,O
CLP,2011,B-SpecificDisease
;,2011,O
in,2011,O
VWS,2011,B-SpecificDisease
the,2011,O
sex,2011,O
ratios,2011,O
are,2011,O
more,2011,O
nearly,2011,O
equal,2011,O
.,2011,O
Lip,2012,B-SpecificDisease
pits,2012,I-SpecificDisease
also,2012,O
are,2012,O
equally,2012,O
distributed,2012,O
between,2012,O
the,2012,O
sexes,2012,O
.,2012,O
Affected,2013,O
males,2013,O
and,2013,O
females,2013,O
are,2013,O
equally,2013,O
likely,2013,O
to,2013,O
transmit,2013,O
VWS,2013,B-SpecificDisease
.,2013,O
However,2014,O
",",2014,O
there,2014,O
is,2014,O
an,2014,O
excess,2014,O
of,2014,O
less,2014,O
severely,2014,O
affected,2014,O
individuals,2014,O
among,2014,O
transmitters,2014,O
and,2014,O
a,2014,O
deficiency,2014,O
of,2014,O
more,2014,O
severely,2014,O
affected,2014,O
",",2014,O
brought,2014,O
about,2014,O
by,2014,O
a,2014,O
proband,2014,O
bias,2014,O
and,2014,O
differential,2014,O
fecundity,2014,O
.,2014,O
The,2015,O
expression,2015,O
of,2015,O
VWS,2015,B-SpecificDisease
is,2015,O
significantly,2015,O
modified,2015,O
by,2015,O
the,2015,O
genetic,2015,O
background,2015,O
More,2015,O
extreme,2015,O
phenotypes,2015,O
in,2015,O
parents,2015,O
tend,2015,O
to,2015,O
produce,2015,O
more,2015,O
extreme,2015,O
expression,2015,O
in,2015,O
their,2015,O
children,2015,O
.,2015,O
For,2016,O
a,2016,O
VWS,2016,B-Modifier
gene,2016,O
carrier,2016,O
the,2016,O
relative,2016,O
risk,2016,O
of,2016,O
transmitting,2016,O
a,2016,O
cleft,2016,O
is,2016,O
26,2016,O
.,2016,O
45,2017,O
%,2017,O
;,2017,O
that,2017,O
of,2017,O
transmitting,2017,O
lower,2017,O
lip,2017,B-SpecificDisease
pits,2017,I-SpecificDisease
is,2017,O
23,2017,O
.,2017,O
55,2018,O
%,2018,O
.,2018,O
Three,2019,O
pedigrees,2019,O
of,2019,O
lip,2019,B-SpecificDisease
pits,2019,I-SpecificDisease
in,2019,O
the,2019,O
literature,2019,O
show,2019,O
no,2019,O
clefts,2019,O
among,2019,O
a,2019,O
significant,2019,O
number,2019,O
of,2019,O
affected,2019,O
individuals,2019,O
.,2019,O
Control,2020,O
of,2020,O
gene,2020,O
expression,2020,O
in,2020,O
VWS,2020,B-SpecificDisease
in,2020,O
the,2020,O
three,2020,O
target,2020,O
tissues,2020,O
appears,2020,O
to,2020,O
be,2020,O
independent,2020,O
and,2020,O
separately,2020,O
designated,2020,O
.,2020,O
Mutation,2021,O
rate,2021,O
of,2021,O
the,2021,O
VWS,2021,B-Modifier
gene,2021,O
is,2021,O
calculated,2021,O
to,2021,O
be,2021,O
1,2021,O
.,2021,O
8,2022,O
X,2022,O
10,2022,O
(,2022,O
-5,2022,O
),2022,O
Localisation,2023,O
of,2023,O
the,2023,O
Becker,2023,B-Modifier
muscular,2023,I-Modifier
dystrophy,2023,I-Modifier
gene,2023,O
on,2023,O
the,2023,O
short,2023,O
arm,2023,O
of,2023,O
the,2023,O
X,2023,O
chromosome,2023,O
by,2023,O
linkage,2023,O
to,2023,O
cloned,2023,O
DNA,2023,O
sequences,2023,O
.,2023,O
A,2024,O
linkage,2024,O
study,2024,O
in,2024,O
30,2024,O
Becker,2024,B-SpecificDisease
muscular,2024,I-SpecificDisease
dystrophy,2024,I-SpecificDisease
(,2024,O
BMD,2024,B-SpecificDisease
),2024,O
kindreds,2024,O
using,2024,O
three,2024,O
cloned,2024,O
DNA,2024,O
sequences,2024,O
from,2024,O
the,2024,O
X,2024,O
chromosome,2024,O
which,2024,O
demonstrate,2024,O
restriction,2024,O
fragment,2024,O
length,2024,O
polymorphisms,2024,O
(,2024,O
RFLPs,2024,O
),2024,O
",",2024,O
suggests,2024,O
that,2024,O
the,2024,O
BMD,2024,B-Modifier
gene,2024,O
is,2024,O
located,2024,O
on,2024,O
the,2024,O
short,2024,O
arm,2024,O
of,2024,O
the,2024,O
X,2024,O
chromosome,2024,O
",",2024,O
in,2024,O
the,2024,O
p21,2024,O
region,2024,O
.,2024,O
The,2025,O
genes,2025,O
for,2025,O
Becker,2025,O
and,2025,O
Duchenne,2025,O
dystrophies,2025,O
must,2025,O
therefore,2025,O
be,2025,O
closely,2025,O
linked,2025,O
",",2025,O
if,2025,O
not,2025,O
allelic,2025,O
",",2025,O
and,2025,O
any,2025,O
future,2025,O
DNA,2025,O
probes,2025,O
found,2025,O
to,2025,O
be,2025,O
of,2025,O
practical,2025,O
use,2025,O
in,2025,O
one,2025,O
disorder,2025,O
should,2025,O
be,2025,O
equally,2025,O
applicable,2025,O
to,2025,O
the,2025,O
other,2025,O
.,2025,O
The,2026,O
linkage,2026,O
analysis,2026,O
also,2026,O
provides,2026,O
data,2026,O
on,2026,O
the,2026,O
frequency,2026,O
of,2026,O
recombination,2026,O
along,2026,O
the,2026,O
short,2026,O
arm,2026,O
of,2026,O
the,2026,O
X,2026,O
chromosome,2026,O
",",2026,O
and,2026,O
across,2026,O
the,2026,O
centromeric,2026,O
region,2026,O
..,2026,O
Molecular,2027,O
evidence,2027,O
for,2027,O
new,2027,O
mutation,2027,O
at,2027,O
the,2027,O
hprt,2027,O
locus,2027,O
in,2027,O
Lesch-Nyhan,2027,B-Modifier
patients,2027,O
.,2027,O
Hypoxanthine-guanine,2028,O
phosphoribosyltransferase,2028,O
(,2028,O
HPRT,2028,O
;,2028,O
EC2,2028,O
.,2028,O
4,2029,O
.,2029,O
2,2030,O
.,2030,O
8,2031,O
),2031,O
",",2031,O
which,2031,O
functions,2031,O
in,2031,O
the,2031,O
metabolic,2031,O
salvage,2031,O
of,2031,O
purines,2031,O
",",2031,O
is,2031,O
encoded,2031,O
by,2031,O
an,2031,O
X-linked,2031,O
gene,2031,O
in,2031,O
man,2031,O
.,2031,O
Partial,2032,O
HPRT,2032,B-DiseaseClass
deficiencies,2032,I-DiseaseClass
are,2032,O
associated,2032,O
with,2032,O
gouty,2032,B-SpecificDisease
arthritis,2032,I-SpecificDisease
",",2032,O
while,2032,O
absence,2032,O
of,2032,O
activity,2032,O
results,2032,O
in,2032,O
Lesch-Nyhan,2032,B-SpecificDisease
syndrome,2032,I-SpecificDisease
(,2032,O
L-N,2032,B-SpecificDisease
),2032,O
.,2032,O
L-N,2033,B-Modifier
patients,2033,O
fail,2033,O
to,2033,O
reproduce,2033,O
and,2033,O
the,2033,O
heterozygous,2033,O
state,2033,O
appears,2033,O
to,2033,O
confer,2033,O
no,2033,O
selective,2033,O
advantage,2033,O
.,2033,O
Thus,2034,O
",",2034,O
Haldanes,2034,O
principle,2034,O
predicts,2034,O
that,2034,O
new,2034,O
mutations,2034,O
at,2034,O
the,2034,O
hprt,2034,O
locus,2034,O
must,2034,O
occur,2034,O
frequently,2034,O
in,2034,O
order,2034,O
for,2034,O
L-N,2034,B-SpecificDisease
syndrome,2034,I-SpecificDisease
to,2034,O
be,2034,O
maintained,2034,O
in,2034,O
the,2034,O
population,2034,O
.,2034,O
This,2035,O
constant,2035,O
introduction,2035,O
of,2035,O
new,2035,O
mutations,2035,O
would,2035,O
be,2035,O
expected,2035,O
to,2035,O
result,2035,O
in,2035,O
a,2035,O
heterogeneous,2035,O
collection,2035,O
of,2035,O
genetic,2035,B-DiseaseClass
lesions,2035,I-DiseaseClass
",",2035,O
some,2035,O
of,2035,O
which,2035,O
may,2035,O
be,2035,O
novel,2035,O
.,2035,O
As,2036,O
we,2036,O
report,2036,O
here,2036,O
",",2036,O
the,2036,O
mutations,2036,O
in,2036,O
the,2036,O
hprt,2036,O
gene,2036,O
of,2036,O
seven,2036,O
L-N,2036,B-Modifier
patients,2036,O
",",2036,O
selected,2036,O
from,2036,O
an,2036,O
initial,2036,O
survey,2036,O
of,2036,O
28,2036,O
patients,2036,O
",",2036,O
have,2036,O
been,2036,O
characterized,2036,O
and,2036,O
all,2036,O
were,2036,O
found,2036,O
to,2036,O
be,2036,O
distinctly,2036,O
different,2036,O
",",2036,O
as,2036,O
predicted,2036,O
.,2036,O
The,2037,O
origin,2037,O
of,2037,O
one,2037,O
unusual,2037,O
mutation,2037,O
has,2037,O
been,2037,O
identified,2037,O
by,2037,O
analysis,2037,O
of,2037,O
DNA,2037,O
from,2037,O
four,2037,O
generations,2037,O
of,2037,O
family,2037,O
members,2037,O
.,2037,O
Further,2038,O
molecular,2038,O
analysis,2038,O
of,2038,O
the,2038,O
origin,2038,O
of,2038,O
new,2038,O
mutations,2038,O
at,2038,O
the,2038,O
hprt,2038,O
locus,2038,O
should,2038,O
aid,2038,O
in,2038,O
resolving,2038,O
the,2038,O
issue,2038,O
of,2038,O
an,2038,O
apparent,2038,O
difference,2038,O
in,2038,O
the,2038,O
frequency,2038,O
of,2038,O
hprt,2038,O
mutations,2038,O
in,2038,O
males,2038,O
and,2038,O
females,2038,O
Allelic,2039,O
exclusion,2039,O
of,2039,O
glucose-6-phosphate,2039,O
dehydrogenase,2039,O
in,2039,O
platelets,2039,O
and,2039,O
T,2039,O
lymphocytes,2039,O
from,2039,O
a,2039,O
Wiskott-Aldrich,2039,B-Modifier
syndrome,2039,I-Modifier
carrier,2039,O
.,2039,O
An,2040,O
obligate,2040,O
carrier,2040,O
of,2040,O
the,2040,O
Wiskott-Aldrich,2040,B-SpecificDisease
syndrome,2040,I-SpecificDisease
(,2040,O
WAS,2040,B-SpecificDisease
),2040,O
who,2040,O
was,2040,O
also,2040,O
heterozygous,2040,O
for,2040,O
the,2040,O
A,2040,O
and,2040,O
B,2040,O
types,2040,O
of,2040,O
X-linked,2040,O
glucose-6-phosphate,2040,O
dehydrogenase,2040,O
was,2040,O
found,2040,O
.,2040,O
With,2041,O
her,2041,O
it,2041,O
became,2041,O
possible,2041,O
to,2041,O
determine,2041,O
whether,2041,O
allelic,2041,O
exclusion,2041,O
occurs,2041,O
in,2041,O
particular,2041,O
cell-types,2041,O
of,2041,O
the,2041,O
WAS,2041,B-Modifier
carrier,2041,O
.,2041,O
If,2042,O
so,2042,O
",",2042,O
the,2042,O
remaining,2042,O
cells,2042,O
of,2042,O
a,2042,O
particular,2042,O
cell-type,2042,O
would,2042,O
express,2042,O
only,2042,O
the,2042,O
normal,2042,O
X,2042,O
chromosome,2042,O
and,2042,O
only,2042,O
one,2042,O
glucose-6-phosphate,2042,O
dehydrogenase,2042,O
isoenzyme,2042,O
would,2042,O
be,2042,O
demonstrable,2042,O
.,2042,O
This,2043,O
carrier,2043,O
had,2043,O
only,2043,O
the,2043,O
B,2043,O
isoenzyme,2043,O
of,2043,O
glucose-6-phosphate,2043,O
dehydrogenase,2043,O
in,2043,O
platelets,2043,O
and,2043,O
thymus-derived,2043,O
T,2043,O
lymphocytes,2043,O
",",2043,O
although,2043,O
both,2043,O
isoenzymes,2043,O
A,2043,O
and,2043,O
B,2043,O
were,2043,O
present,2043,O
in,2043,O
erythrocytes,2043,O
and,2043,O
neutrophils,2043,O
.,2043,O
These,2044,O
findings,2044,O
suggest,2044,O
that,2044,O
selection,2044,O
against,2044,O
the,2044,O
WAS,2044,B-Modifier
gene,2044,O
occurs,2044,O
in,2044,O
platelets,2044,O
and,2044,O
thymus-derived,2044,O
T,2044,O
lymphocytes,2044,O
and,2044,O
that,2044,O
the,2044,O
defects,2044,O
associated,2044,O
with,2044,O
WAS,2044,B-SpecificDisease
expressed,2044,O
in,2044,O
these,2044,O
cell-types,2044,O
may,2044,O
be,2044,O
implicated,2044,O
in,2044,O
the,2044,O
genesis,2044,O
of,2044,O
the,2044,O
Wiskott-Aldrich,2044,B-SpecificDisease
syndrome,2044,I-SpecificDisease
..,2044,O
Complement,2045,B-SpecificDisease
deficiency,2045,I-SpecificDisease
and,2045,O
nephritis,2045,B-SpecificDisease
.,2045,O
A,2046,O
report,2046,O
of,2046,O
a,2046,O
family,2046,O
.,2046,O
A,2047,O
family,2047,O
is,2047,O
described,2047,O
in,2047,O
which,2047,O
three,2047,O
children,2047,O
had,2047,O
homozygous,2047,O
deficiency,2047,B-SpecificDisease
of,2047,I-SpecificDisease
C3,2047,I-SpecificDisease
and,2047,O
in,2047,O
which,2047,O
both,2047,O
parents,2047,O
and,2047,O
two,2047,O
other,2047,O
children,2047,O
were,2047,O
heterozygous,2047,O
for,2047,O
the,2047,O
C3,2047,O
null,2047,O
gene,2047,O
.,2047,O
One,2048,O
child,2048,O
with,2048,O
heterozygous,2048,O
C3,2048,B-SpecificDisease
deficiency,2048,I-SpecificDisease
was,2048,O
found,2048,O
to,2048,O
have,2048,O
membranoproliferative,2048,O
glomerulonephritis,2048,B-SpecificDisease
;,2048,O
proteinuria,2048,B-SpecificDisease
and/or,2048,O
microscopical,2048,O
haematuria,2048,B-SpecificDisease
was,2048,O
present,2048,O
in,2048,O
all,2048,O
three,2048,O
homozygous,2048,O
C3-deficient,2048,B-Modifier
children,2048,O
.,2048,O
All,2049,O
children,2049,O
with,2049,O
homozygous,2049,O
or,2049,O
heterozygous,2049,O
C3,2049,B-SpecificDisease
deficiency,2049,I-SpecificDisease
were,2049,O
",",2049,O
to,2049,O
a,2049,O
varying,2049,O
degree,2049,O
",",2049,O
susceptible,2049,O
to,2049,O
infection,2049,O
.,2049,O
The,2050,O
only,2050,O
child,2050,O
of,2050,O
the,2050,O
family,2050,O
with,2050,O
normal,2050,O
complement,2050,O
had,2050,O
no,2050,O
increased,2050,O
risk,2050,O
of,2050,O
infection,2050,O
and,2050,O
no,2050,O
renal,2050,B-DiseaseClass
disease,2050,I-DiseaseClass
.,2050,O
This,2051,O
family,2051,O
study,2051,O
provides,2051,O
further,2051,O
support,2051,O
for,2051,O
the,2051,O
proposal,2051,O
that,2051,O
C3,2051,B-SpecificDisease
deficiency,2051,I-SpecificDisease
predisposes,2051,O
to,2051,O
nephritis,2051,B-SpecificDisease
..,2051,O
Glucose-6-phosphate,2052,B-SpecificDisease
dehydrogenase,2052,I-SpecificDisease
deficiency,2052,I-SpecificDisease
inhibits,2052,O
in,2052,O
vitro,2052,O
growth,2052,O
of,2052,O
Plasmodium,2052,O
falciparum,2052,O
.,2052,O
Glucose-6-phosphate,2053,O
dehydrogenase,2053,O
(,2053,O
G6PD,2053,O
;,2053,O
EC,2053,O
1,2053,O
.,2053,O
1,2054,O
.,2054,O
1,2055,O
.,2055,O
49,2056,O
),2056,O
-deficient,2056,O
red,2056,O
blood,2056,O
cells,2056,O
from,2056,O
male,2056,O
hemizygotes,2056,O
and,2056,O
female,2056,O
heterozygotes,2056,O
from,2056,O
the,2056,O
island,2056,O
of,2056,O
Sardinia,2056,O
were,2056,O
studied,2056,O
for,2056,O
their,2056,O
ability,2056,O
to,2056,O
support,2056,O
growth,2056,O
in,2056,O
vitro,2056,O
of,2056,O
the,2056,O
malaria-causing,2056,B-Modifier
organism,2056,O
Plasmodium,2056,O
falciparum,2056,O
.,2056,O
Parasite,2057,O
growth,2057,O
was,2057,O
approximately,2057,O
one-third,2057,O
of,2057,O
normal,2057,O
in,2057,O
both,2057,O
hemi-,2057,O
and,2057,O
heterozygotes,2057,O
for,2057,O
G6PD,2057,B-SpecificDisease
deficiency,2057,I-SpecificDisease
.,2057,O
In,2058,O
Sardinians,2058,O
with,2058,O
the,2058,O
beta,2058,O
0-thalassemia,2058,O
trait,2058,O
",",2058,O
parasite,2058,O
growth,2058,O
was,2058,O
normal,2058,O
except,2058,O
when,2058,O
G6PD,2058,B-SpecificDisease
deficiency,2058,I-SpecificDisease
occurred,2058,O
together,2058,O
with,2058,O
the,2058,O
thalassemia,2058,B-Modifier
trait,2058,O
.,2058,O
The,2059,O
data,2059,O
support,2059,O
the,2059,O
hypothesis,2059,O
that,2059,O
G6PD,2059,B-SpecificDisease
deficiency,2059,I-SpecificDisease
may,2059,O
confer,2059,O
a,2059,O
selective,2059,O
advantage,2059,O
in,2059,O
a,2059,O
malarious,2059,B-Modifier
area,2059,O
;,2059,O
the,2059,O
female,2059,O
heterozygote,2059,O
may,2059,O
be,2059,O
at,2059,O
a,2059,O
particular,2059,O
advantage,2059,O
because,2059,O
resistance,2059,O
to,2059,O
malaria,2059,B-SpecificDisease
equals,2059,O
that,2059,O
of,2059,O
male,2059,O
hemizygotes,2059,O
",",2059,O
but,2059,O
the,2059,O
risk,2059,O
of,2059,O
fatal,2059,B-SpecificDisease
hemolysis,2059,I-SpecificDisease
may,2059,O
be,2059,O
less,2059,O
.,2059,O
However,2060,O
",",2060,O
more,2060,O
female,2060,O
heterozygotes,2060,O
must,2060,O
be,2060,O
studied,2060,O
to,2060,O
confirm,2060,O
this,2060,O
hypothesis,2060,O
.,2060,O
No,2061,O
protective,2061,O
effect,2061,O
of,2061,O
beta,2061,O
0-thalassemia,2061,O
trait,2061,O
could,2061,O
be,2061,O
demonstrated,2061,O
in,2061,O
vitro,2061,O
.,2061,O
Bone,2062,O
marrow,2062,O
transplant,2062,O
in,2062,O
adrenoleukodystrophy,2062,B-SpecificDisease
.,2062,O
An,2063,O
allogeneic,2063,O
bone,2063,O
marrow,2063,O
transplant,2063,O
(,2063,O
BMT,2063,O
),2063,O
from,2063,O
a,2063,O
normal,2063,O
HLA,2063,O
identical,2063,O
sibling,2063,O
donor,2063,O
was,2063,O
performed,2063,O
in,2063,O
a,2063,O
13-year-old,2063,O
boy,2063,O
with,2063,O
rapidly,2063,O
progressive,2063,O
adrenoleukodystrophy,2063,B-SpecificDisease
(,2063,O
ALD,2063,B-SpecificDisease
),2063,O
.,2063,O
Engraftment,2064,O
and,2064,O
complete,2064,O
hematologic,2064,O
recovery,2064,O
occurred,2064,O
within,2064,O
4,2064,O
weeks,2064,O
",",2064,O
but,2064,O
neurologic,2064,B-DiseaseClass
deterioration,2064,I-DiseaseClass
continued,2064,O
.,2064,O
The,2065,O
patient,2065,O
died,2065,O
of,2065,O
an,2065,O
adenovirus,2065,B-SpecificDisease
infection,2065,I-SpecificDisease
141,2065,O
days,2065,O
after,2065,O
BMT,2065,O
.,2065,O
ALD,2066,B-SpecificDisease
is,2066,O
characterized,2066,O
by,2066,O
abnormally,2066,O
high,2066,O
plasma,2066,O
levels,2066,O
of,2066,O
very,2066,O
long,2066,O
chain,2066,O
fatty,2066,O
acids,2066,O
(,2066,O
VLCFA,2066,O
),2066,O
as,2066,O
a,2066,O
result,2066,O
of,2066,O
impaired,2066,O
capacity,2066,O
to,2066,O
degrade,2066,O
them,2066,O
.,2066,O
Ten,2067,O
days,2067,O
after,2067,O
BMT,2067,O
",",2067,O
the,2067,O
white,2067,O
blood,2067,O
cell,2067,O
VLCFA,2067,O
levels,2067,O
and,2067,O
enzyme,2067,O
activity,2067,O
became,2067,O
normal,2067,O
;,2067,O
after,2067,O
3,2067,O
months,2067,O
",",2067,O
there,2067,O
was,2067,O
progressive,2067,O
reduction,2067,O
of,2067,O
plasma,2067,O
VLCFA,2067,O
to,2067,O
levels,2067,O
only,2067,O
slightly,2067,O
above,2067,O
normal,2067,O
..,2067,O
[,2068,O
Gd-,2068,O
allele,2068,O
distribution,2068,O
patterns,2068,O
in,2068,O
Azerbaijan,2068,O
.,2068,O
III,2069,O
.,2069,O
The,2070,O
identification,2070,O
of,2070,O
mutant,2070,O
forms,2070,O
of,2070,O
glucose-6-phosphate,2070,O
dehydrogenase,2070,O
],2070,O
In,2070,O
28,2070,O
families,2070,O
with,2070,O
G6PD,2070,B-SpecificDisease
deficiency,2070,I-SpecificDisease
living,2070,O
in,2070,O
3,2070,O
settlements,2070,O
of,2070,O
Shekii,2070,O
district,2070,O
of,2070,O
Azerbaijan,2070,O
11,2070,O
G6PD,2070,O
variants,2070,O
of,2070,O
II,2070,O
and,2070,O
III,2070,O
classes,2070,O
differing,2070,O
by,2070,O
kinetic,2070,O
properties,2070,O
were,2070,O
identified,2070,O
according,2070,O
WHO,2070,O
program,2070,O
.,2070,O
9,2071,O
of,2071,O
them,2071,O
are,2071,O
characterized,2071,O
with,2071,O
the,2071,O
same,2071,O
electrophoretic,2071,O
mobility,2071,O
.,2071,O
Comparison,2072,O
of,2072,O
G6PD,2072,O
spectra,2072,O
in,2072,O
two,2072,O
subpopulations,2072,O
and,2072,O
in,2072,O
a,2072,O
mixed,2072,O
group,2072,O
permits,2072,O
to,2072,O
make,2072,O
a,2072,O
conclusion,2072,O
about,2072,O
existence,2072,O
of,2072,O
common,2072,O
and,2072,O
rare,2072,O
G6PD,2072,O
alleles,2072,O
in,2072,O
examined,2072,O
population,2072,O
.,2072,O
They,2073,O
distribute,2073,O
by,2073,O
gene,2073,O
drift,2073,O
supported,2073,O
by,2073,O
natural,2073,O
selection,2073,O
.,2073,O
Among,2074,O
7,2074,O
samples,2074,O
of,2074,O
G6PD,2074,O
with,2074,O
normal,2074,O
and,2074,O
increased,2074,O
activity,2074,O
two,2074,O
new,2074,O
variants,2074,O
of,2074,O
IV,2074,O
class,2074,O
--,2074,O
Nukha,2074,O
and,2074,O
Bash-Kungut,2074,O
--,2074,O
were,2074,O
found,2074,O
..,2074,O
Adrenoleukodystrophy,2075,B-SpecificDisease
:,2075,O
survey,2075,O
of,2075,O
303,2075,O
cases,2075,O
:,2075,O
biochemistry,2075,O
",",2075,O
diagnosis,2075,O
",",2075,O
and,2075,O
therapy,2075,O
.,2075,O
Adrenoleukodystrophy,2076,B-SpecificDisease
(,2076,O
ALD,2076,B-SpecificDisease
),2076,O
is,2076,O
a,2076,O
genetically,2076,O
determined,2076,O
disorder,2076,O
associated,2076,O
with,2076,O
progressive,2076,B-DiseaseClass
central,2076,I-DiseaseClass
demyelination,2076,I-DiseaseClass
and,2076,O
adrenal,2076,B-DiseaseClass
cortical,2076,I-DiseaseClass
insufficiency,2076,I-DiseaseClass
.,2076,O
All,2077,O
affected,2077,O
persons,2077,O
show,2077,O
increased,2077,O
levels,2077,O
of,2077,O
saturated,2077,O
unbranched,2077,O
very-long-chain,2077,O
fatty,2077,O
acids,2077,O
",",2077,O
particularly,2077,O
hexacosanoate,2077,O
(,2077,O
C26,2077,O
0,2077,O
),2077,O
",",2077,O
because,2077,O
of,2077,O
impaired,2077,O
capacity,2077,O
to,2077,O
degrade,2077,O
these,2077,O
acids,2077,O
.,2077,O
This,2078,O
degradation,2078,O
normally,2078,O
takes,2078,O
place,2078,O
in,2078,O
a,2078,O
subcellular,2078,O
organelle,2078,O
called,2078,O
the,2078,O
peroxisome,2078,O
",",2078,O
and,2078,O
ALD,2078,B-SpecificDisease
",",2078,O
together,2078,O
with,2078,O
Zellwegers,2078,B-SpecificDisease
cerebrohepatorenal,2078,I-SpecificDisease
syndrome,2078,I-SpecificDisease
",",2078,O
is,2078,O
now,2078,O
considered,2078,O
to,2078,O
belong,2078,O
to,2078,O
the,2078,O
newly,2078,O
formed,2078,O
category,2078,O
of,2078,O
peroxisomal,2078,B-DiseaseClass
disorders,2078,I-DiseaseClass
.,2078,O
Biochemical,2079,O
assays,2079,O
permit,2079,O
prenatal,2079,O
diagnosis,2079,O
",",2079,O
as,2079,O
well,2079,O
as,2079,O
identification,2079,O
of,2079,O
most,2079,O
heterozygotes,2079,O
.,2079,O
We,2080,O
have,2080,O
identified,2080,O
303,2080,O
patients,2080,O
with,2080,O
ALD,2080,B-SpecificDisease
in,2080,O
217,2080,O
kindreds,2080,O
.,2080,O
These,2081,O
patients,2081,O
show,2081,O
a,2081,O
wide,2081,O
phenotypic,2081,O
variation,2081,O
.,2081,O
Sixty,2082,O
percent,2082,O
of,2082,O
patients,2082,O
had,2082,O
childhood,2082,O
ALD,2082,B-SpecificDisease
and,2082,O
17,2082,O
%,2082,O
adrenomyeloneuropathy,2082,B-SpecificDisease
",",2082,O
both,2082,O
of,2082,O
which,2082,O
are,2082,O
X-linked,2082,O
",",2082,O
with,2082,O
the,2082,O
gene,2082,O
mapped,2082,O
to,2082,O
Xq28,2082,O
.,2082,O
Neonatal,2083,B-SpecificDisease
ALD,2083,I-SpecificDisease
",",2083,O
a,2083,O
distinct,2083,O
entity,2083,O
with,2083,O
autosomal,2083,O
recessive,2083,O
inheritance,2083,O
and,2083,O
points,2083,O
of,2083,O
resemblance,2083,O
to,2083,O
Zellwegers,2083,B-SpecificDisease
syndrome,2083,I-SpecificDisease
",",2083,O
accounted,2083,O
for,2083,O
7,2083,O
%,2083,O
of,2083,O
the,2083,O
cases,2083,O
.,2083,O
Although,2084,O
excess,2084,O
C26,2084,O
0,2084,O
in,2084,O
the,2084,O
brain,2084,O
of,2084,O
patients,2084,O
with,2084,O
ALD,2084,B-SpecificDisease
is,2084,O
partially,2084,O
of,2084,O
dietary,2084,O
origin,2084,O
",",2084,O
dietary,2084,O
C26,2084,O
0,2084,O
restriction,2084,O
did,2084,O
not,2084,O
produce,2084,O
clear,2084,O
benefit,2084,O
.,2084,O
Bone,2085,O
marrow,2085,O
transplant,2085,O
lowered,2085,O
the,2085,O
plasma,2085,O
C26,2085,O
0,2085,O
level,2085,O
but,2085,O
failed,2085,O
to,2085,O
arrest,2085,O
neurological,2085,O
progression,2085,O
..,2085,O
Genetic,2086,O
polymorphism,2086,O
of,2086,O
G6PD,2086,O
in,2086,O
a,2086,O
Bulgarian,2086,O
population,2086,O
.,2086,O
Considerable,2087,O
genetic,2087,O
heterogeneity,2087,O
in,2087,O
G6PD,2087,O
was,2087,O
found,2087,O
in,2087,O
the,2087,O
Bulgarian,2087,O
population-14,2087,O
G6PD,2087,O
variants,2087,O
isolated,2087,O
from,2087,O
117,2087,O
hemizygous,2087,O
carriers,2087,O
of,2087,O
G6PD,2087,B-SpecificDisease
deficiency,2087,I-SpecificDisease
.,2087,O
Of,2088,O
these,2088,O
",",2088,O
G6PD,2088,O
Mediterranean,2088,O
type,2088,O
was,2088,O
a,2088,O
polymorphic,2088,O
variant,2088,O
and,2088,O
G6PD,2088,O
Corinth,2088,O
occurred,2088,O
with,2088,O
high,2088,O
frequency,2088,O
.,2088,O
Two,2089,O
new,2089,O
variants,2089,O
were,2089,O
identified-G6PD,2089,O
Rudosem,2089,O
and,2089,O
G6PD,2089,O
Nedelino,2089,O
.,2089,O
In,2090,O
a,2090,O
selected,2090,O
group,2090,O
of,2090,O
78,2090,O
subjects,2090,O
with,2090,O
clinical,2090,O
manifestations,2090,O
",",2090,O
four,2090,O
variants,2090,O
were,2090,O
established,2090,O
G6PD,2090,O
Mediterranian,2090,O
",",2090,O
G6PD,2090,O
Corinth,2090,O
",",2090,O
G6PD,2090,O
Seattle,2090,O
and,2090,O
G6PD,2090,O
Ohut,2090,O
II,2090,O
..,2090,O
Clinical,2091,O
use,2091,O
of,2091,O
DNA,2091,O
markers,2091,O
linked,2091,O
to,2091,O
the,2091,O
gene,2091,O
for,2091,O
Duchenne,2091,B-SpecificDisease
muscular,2091,I-SpecificDisease
dystrophy,2091,I-SpecificDisease
.,2091,O
Seventy,2092,O
families,2092,O
with,2092,O
Duchenne,2092,B-SpecificDisease
muscular,2092,I-SpecificDisease
dystrophy,2092,I-SpecificDisease
(,2092,O
DMD,2092,B-SpecificDisease
),2092,O
known,2092,O
to,2092,O
the,2092,O
Institute,2092,O
of,2092,O
Child,2092,O
Health,2092,O
fall,2092,O
into,2092,O
three,2092,O
categories,2092,O
with,2092,O
respect,2092,O
to,2092,O
potential,2092,O
linkage,2092,O
analysis,2092,O
with,2092,O
the,2092,O
X,2092,O
chromosome,2092,O
DNA,2092,O
markers,2092,O
RC8,2092,O
and,2092,O
L1,2092,O
.,2092,O
28,2093,O
that,2093,O
bridge,2093,O
the,2093,O
DMD,2093,B-Modifier
gene,2093,O
.,2093,O
Families,2094,O
in,2094,O
which,2094,O
there,2094,O
is,2094,O
at,2094,O
least,2094,O
one,2094,O
obligatory,2094,O
female,2094,O
heterozygote,2094,O
(,2094,O
n,2094,O
=,2094,O
13,2094,O
),2094,O
.,2094,O
Here,2095,O
prediction,2095,O
and,2095,O
exclusion,2095,O
of,2095,O
DMD,2095,B-Modifier
gene,2095,O
transmission,2095,O
may,2095,O
be,2095,O
possible,2095,O
",",2095,O
the,2095,O
accuracy,2095,O
being,2095,O
dependent,2095,O
on,2095,O
the,2095,O
closeness,2095,O
of,2095,O
the,2095,O
linkage,2095,O
of,2095,O
the,2095,O
DNA,2095,O
marker,2095,O
(,2095,O
s,2095,O
),2095,O
to,2095,O
the,2095,O
DMD,2095,B-Modifier
gene,2095,O
;,2095,O
an,2095,O
illustrative,2095,O
case,2095,O
is,2095,O
reported,2095,O
.,2095,O
Families,2096,O
in,2096,O
which,2096,O
there,2096,O
is,2096,O
a,2096,O
single,2096,O
affected,2096,O
boy,2096,O
",",2096,O
who,2096,O
also,2096,O
has,2096,O
one,2096,O
or,2096,O
more,2096,O
healthy,2096,O
brothers,2096,O
(,2096,O
n,2096,O
=,2096,O
26,2096,O
),2096,O
.,2096,O
Given,2097,O
an,2097,O
informative,2097,O
restriction,2097,O
fragment,2097,O
length,2097,O
polymorphism,2097,O
(,2097,O
RFLP,2097,O
),2097,O
",",2097,O
the,2097,O
probability,2097,O
that,2097,O
the,2097,O
boy,2097,O
represents,2097,O
a,2097,O
new,2097,O
mutation,2097,O
can,2097,O
be,2097,O
reassessed,2097,O
;,2097,O
it,2097,O
is,2097,O
also,2097,O
possible,2097,O
to,2097,O
exclude,2097,O
the,2097,O
DMD,2097,B-Modifier
gene,2097,O
in,2097,O
a,2097,O
sister,2097,O
.,2097,O
Families,2098,O
with,2098,O
a,2098,O
single,2098,O
affected,2098,O
boy,2098,O
with,2098,O
no,2098,O
brother,2098,O
(,2098,O
n,2098,O
=,2098,O
30,2098,O
),2098,O
.,2098,O
Here,2099,O
exclusion,2099,O
of,2099,O
the,2099,O
DMD,2099,B-Modifier
gene,2099,O
in,2099,O
a,2099,O
sister,2099,O
may,2099,O
be,2099,O
possible,2099,O
.,2099,O
Only,2100,O
in,2100,O
one,2100,O
family,2100,O
was,2100,O
there,2100,O
no,2100,O
possibility,2100,O
of,2100,O
useful,2100,O
linkage,2100,O
analysis,2100,O
.,2100,O
The,2101,O
linkage,2101,O
analysis,2101,O
required,2101,O
is,2101,O
described,2101,O
",",2101,O
and,2101,O
the,2101,O
need,2101,O
to,2101,O
check,2101,O
DMD,2101,B-Modifier
families,2101,O
for,2101,O
informative,2101,O
RFLPs,2101,O
is,2101,O
stressed,2101,O
.,2101,O
Family,2102,O
studies,2102,O
in,2102,O
Bechterew,2102,B-SpecificDisease
's,2102,I-SpecificDisease
syndrome,2102,I-SpecificDisease
(,2102,O
ankylosing,2102,B-SpecificDisease
spondylitis,2102,I-SpecificDisease
),2102,O
III,2102,O
.,2102,O
Genetics,2103,O
.,2103,O
The,2104,O
results,2104,O
of,2104,O
segregation,2104,O
analyses,2104,O
in,2104,O
75,2104,O
families,2104,O
where,2104,O
the,2104,O
proband,2104,O
had,2104,O
ankylosing,2104,B-SpecificDisease
spondylitis,2104,I-SpecificDisease
",",2104,O
are,2104,O
presented,2104,O
.,2104,O
Of,2105,O
the,2105,O
278,2105,O
adult,2105,O
",",2105,O
living,2105,O
first,2105,O
degree,2105,O
relatives,2105,O
",",2105,O
approximately,2105,O
85,2105,O
%,2105,O
cooperated,2105,O
in,2105,O
the,2105,O
study,2105,O
.,2105,O
Clinical,2106,O
and,2106,O
radiographical,2106,O
examinations,2106,O
were,2106,O
performed,2106,O
and,2106,O
HLA,2106,O
typing,2106,O
was,2106,O
conducted,2106,O
.,2106,O
The,2107,O
results,2107,O
were,2107,O
in,2107,O
agreement,2107,O
with,2107,O
our,2107,O
hypothesis,2107,O
that,2107,O
ankylosing,2107,B-SpecificDisease
spondylitis,2107,I-SpecificDisease
is,2107,O
part,2107,O
of,2107,O
a,2107,O
syndrome,2107,O
where,2107,O
different,2107,O
genetic,2107,O
factors,2107,O
interact,2107,O
.,2107,O
Such,2108,O
known,2108,O
factors,2108,O
are,2108,O
HLA,2108,O
B27,2108,O
associated,2108,O
disease,2108,O
susceptibility,2108,O
",",2108,O
susceptibility,2108,O
to,2108,O
psoriatic,2108,B-SpecificDisease
arthropathy,2108,I-SpecificDisease
and,2108,O
susceptibility,2108,O
to,2108,O
entero-arthropathy,2108,B-SpecificDisease
.,2108,O
Radiographical,2109,O
sacro-iliitis,2109,B-SpecificDisease
was,2109,O
restricted,2109,O
to,2109,O
HLA,2109,O
B27,2109,O
positive,2109,O
relatives,2109,O
",",2109,O
and,2109,O
was,2109,O
more,2109,O
frequently,2109,O
found,2109,O
in,2109,O
relatives,2109,O
to,2109,O
probands,2109,O
with,2109,O
psoriasis,2109,B-SpecificDisease
than,2109,O
in,2109,O
relatives,2109,O
to,2109,O
probands,2109,O
without,2109,O
psoriasis,2109,B-SpecificDisease
.,2109,O
Environmental,2110,O
factors,2110,O
(,2110,O
intestinal,2110,O
bacteria,2110,O
),2110,O
are,2110,O
known,2110,O
to,2110,O
trigger,2110,O
the,2110,O
disease,2110,O
at,2110,O
least,2110,O
in,2110,O
some,2110,O
persons,2110,O
",",2110,O
and,2110,O
we,2110,O
have,2110,O
postulated,2110,O
that,2110,O
all,2110,O
or,2110,O
most,2110,O
of,2110,O
them,2110,O
have,2110,O
the,2110,O
predisposition,2110,O
to,2110,O
develop,2110,O
disease,2110,O
.,2110,O
Thus,2111,O
",",2111,O
the,2111,O
syndrome,2111,O
has,2111,O
a,2111,O
multifactorial,2111,O
etiology,2111,O
.,2111,O
The,2112,O
phenotypic,2112,O
expressions,2112,O
of,2112,O
the,2112,O
different,2112,O
genetic,2112,O
predispositions,2112,O
involved,2112,O
",",2112,O
include,2112,O
sacro-iliitis,2112,B-SpecificDisease
",",2112,O
psoriasis,2112,B-SpecificDisease
",",2112,O
acute,2112,B-SpecificDisease
anterior,2112,I-SpecificDisease
uveitis,2112,I-SpecificDisease
",",2112,O
peripheral,2112,O
arthropathy,2112,B-SpecificDisease
and,2112,O
inflammatory,2112,B-SpecificDisease
bowel,2112,I-SpecificDisease
disease,2112,I-SpecificDisease
.,2112,O
We,2113,O
suggest,2113,O
the,2113,O
descriptive,2113,O
name,2113,O
HEREDITARY,2113,B-SpecificDisease
MULTIFOCAL,2113,I-SpecificDisease
RELAPSING,2113,I-SpecificDisease
INFLAMMATION,2113,I-SpecificDisease
(,2113,O
HEMRI,2113,B-SpecificDisease
),2113,O
for,2113,O
this,2113,O
syndrome,2113,O
.,2113,O
Ankylosing,2114,B-SpecificDisease
spondylitis,2114,I-SpecificDisease
",",2114,O
psoriatic,2114,B-SpecificDisease
arthropathy,2114,I-SpecificDisease
and,2114,O
entero-arthropathy,2114,B-SpecificDisease
may,2114,O
be,2114,O
regarded,2114,O
as,2114,O
clinical,2114,O
sub-types,2114,O
of,2114,O
the,2114,O
syndrome,2114,O
..,2114,O
Prader-Willi,2115,B-SpecificDisease
syndrome,2115,I-SpecificDisease
and,2115,O
chromosome,2115,O
15,2115,O
.,2115,O
A,2116,O
clinical,2116,O
discussion,2116,O
of,2116,O
20,2116,O
cases,2116,O
.,2116,O
A,2117,O
chromosome,2117,B-SpecificDisease
15,2117,I-SpecificDisease
anomaly,2117,I-SpecificDisease
was,2117,O
observed,2117,O
in,2117,O
12,2117,O
of,2117,O
20,2117,O
patients,2117,O
",",2117,O
17,2117,O
of,2117,O
whom,2117,O
were,2117,O
clinically,2117,O
suspected,2117,O
of,2117,O
having,2117,O
Prader-Willi,2117,B-SpecificDisease
syndrome,2117,I-SpecificDisease
(,2117,O
PWS,2117,B-SpecificDisease
),2117,O
.,2117,O
The,2118,O
clinical,2118,O
features,2118,O
of,2118,O
eight,2118,O
cases,2118,O
with,2118,O
15q11-12,2118,O
deletion,2118,O
were,2118,O
very,2118,O
similar,2118,O
to,2118,O
those,2118,O
originally,2118,O
described,2118,O
in,2118,O
PWS,2118,B-SpecificDisease
.,2118,O
On,2119,O
the,2119,O
other,2119,O
hand,2119,O
",",2119,O
the,2119,O
group,2119,O
of,2119,O
normal,2119,O
karyotype,2119,O
patients,2119,O
is,2119,O
heterogeneous,2119,O
",",2119,O
and,2119,O
their,2119,O
features,2119,O
do,2119,O
not,2119,O
strictly,2119,O
correspond,2119,O
to,2119,O
the,2119,O
clinical,2119,O
definition,2119,O
of,2119,O
PWS,2119,B-SpecificDisease
.,2119,O
However,2120,O
",",2120,O
the,2120,O
hypothesis,2120,O
that,2120,O
PWS,2120,B-SpecificDisease
is,2120,O
associated,2120,O
with,2120,O
deletion,2120,O
of,2120,O
15q11-12,2120,O
can,2120,O
neither,2120,O
explain,2120,O
the,2120,O
apparently,2120,O
balanced,2120,O
translocations,2120,O
of,2120,O
chromosome,2120,O
15,2120,O
nor,2120,O
account,2120,O
for,2120,O
the,2120,O
small,2120,O
supernumerary,2120,O
metacentric,2120,O
chromosomes,2120,O
corresponding,2120,O
to,2120,O
an,2120,O
isochromosome,2120,O
15,2120,O
for,2120,O
band,2120,O
15q11,2120,O
observed,2120,O
in,2120,O
some,2120,O
cases,2120,O
..,2120,O
The,2121,O
Tay-Sachs,2121,B-Modifier
disease,2121,I-Modifier
gene,2121,O
in,2121,O
North,2121,O
American,2121,O
Jewish,2121,O
populations,2121,O
:,2121,O
geographic,2121,O
variations,2121,O
and,2121,O
origin,2121,O
.,2121,O
From,2122,O
data,2122,O
collected,2122,O
in,2122,O
a,2122,O
North,2122,O
American,2122,O
Tay-Sachs,2122,B-Modifier
disease,2122,I-Modifier
(,2122,O
TSD,2122,B-Modifier
),2122,O
heterozygote,2122,O
screening,2122,O
program,2122,O
",",2122,O
the,2122,O
TSD,2122,B-Modifier
carrier,2122,O
frequency,2122,O
among,2122,O
46,2122,O
",",2122,O
304,2122,O
Jewish,2122,O
individuals,2122,O
was,2122,O
found,2122,O
to,2122,O
be,2122,O
.,2122,O
0324,2123,O
(,2123,O
1,2123,O
in,2123,O
31,2123,O
individuals,2123,O
),2123,O
.,2123,O
This,2124,O
frequency,2124,O
is,2124,O
consistent,2124,O
with,2124,O
earlier,2124,O
estimates,2124,O
based,2124,O
on,2124,O
TSD,2124,B-Modifier
incidence,2124,O
data,2124,O
.,2124,O
TSD,2125,B-Modifier
carrier,2125,O
frequencies,2125,O
were,2125,O
then,2125,O
examined,2125,O
by,2125,O
single,2125,O
country,2125,O
and,2125,O
single,2125,O
region,2125,O
of,2125,O
origin,2125,O
in,2125,O
28,2125,O
",",2125,O
029,2125,O
Jews,2125,O
within,2125,O
this,2125,O
sample,2125,O
for,2125,O
whom,2125,O
such,2125,O
data,2125,O
were,2125,O
available,2125,O
for,2125,O
analysis,2125,O
.,2125,O
Jews,2126,O
with,2126,O
Polish,2126,O
and/or,2126,O
Russian,2126,O
ancestry,2126,O
constituted,2126,O
88,2126,O
%,2126,O
of,2126,O
this,2126,O
sample,2126,O
and,2126,O
had,2126,O
a,2126,O
TSD,2126,B-Modifier
carrier,2126,O
frequency,2126,O
of,2126,O
.,2126,O
0327,2127,O
.,2127,O
No,2128,O
TSD,2128,B-Modifier
carriers,2128,O
were,2128,O
observed,2128,O
among,2128,O
the,2128,O
166,2128,O
Jews,2128,O
of,2128,O
Near,2128,O
Eastern,2128,O
origins,2128,O
.,2128,O
Relative,2129,O
to,2129,O
Jews,2129,O
of,2129,O
Polish,2129,O
and,2129,O
Russian,2129,O
origins,2129,O
",",2129,O
there,2129,O
was,2129,O
at,2129,O
least,2129,O
a,2129,O
twofold,2129,O
increase,2129,O
in,2129,O
the,2129,O
TSD,2129,B-Modifier
carrier,2129,O
frequency,2129,O
in,2129,O
Jews,2129,O
of,2129,O
Austrian,2129,O
",",2129,O
Hungarian,2129,O
",",2129,O
and,2129,O
Czechoslovakian,2129,O
origins,2129,O
(,2129,O
P,2129,O
less,2129,O
than,2129,O
.,2129,O
005,2130,O
),2130,O
.,2130,O
These,2131,O
findings,2131,O
suggest,2131,O
that,2131,O
the,2131,O
TSD,2131,B-Modifier
gene,2131,O
proliferated,2131,O
among,2131,O
the,2131,O
antecedents,2131,O
of,2131,O
modern,2131,O
Ashkenazi,2131,O
Jewry,2131,O
after,2131,O
the,2131,O
Second,2131,O
Diaspora,2131,O
(,2131,O
70,2131,O
A.,2131,O
D.,2131,O
),2131,O
and,2131,O
before,2131,O
their,2131,O
major,2131,O
migrations,2131,O
to,2131,O
regions,2131,O
of,2131,O
Poland,2131,O
and,2131,O
Russia,2131,O
(,2131,O
before,2131,O
1100,2131,O
A.,2131,O
D.,2131,O
),2131,O
.,2131,O
Human,2132,O
deficiency,2132,B-SpecificDisease
of,2132,I-SpecificDisease
the,2132,I-SpecificDisease
sixth,2132,I-SpecificDisease
component,2132,I-SpecificDisease
of,2132,I-SpecificDisease
complement,2132,I-SpecificDisease
in,2132,O
a,2132,O
patient,2132,O
with,2132,O
meningococcal,2132,B-SpecificDisease
meningitis,2132,I-SpecificDisease
and,2132,O
no,2132,O
haemostasis,2132,B-DiseaseClass
abnormality,2132,I-DiseaseClass
.,2132,O
A,2133,O
case,2133,O
of,2133,O
human,2133,O
complete,2133,O
C6,2133,B-SpecificDisease
deficiency,2133,I-SpecificDisease
is,2133,O
reported,2133,O
.,2133,O
The,2134,O
patient,2134,O
",",2134,O
a,2134,O
31,2134,O
year,2134,O
old,2134,O
white,2134,O
male,2134,O
",",2134,O
was,2134,O
seen,2134,O
on,2134,O
the,2134,O
occasion,2134,O
of,2134,O
an,2134,O
isolated,2134,O
episode,2134,O
of,2134,O
meningococcal,2134,B-SpecificDisease
meningitis,2134,I-SpecificDisease
.,2134,O
Serum,2135,O
complement,2135,O
hemolytic,2135,O
and,2135,O
bactericidal,2135,O
activities,2135,O
were,2135,O
lacking,2135,O
and,2135,O
could,2135,O
be,2135,O
restored,2135,O
to,2135,O
normal,2135,O
by,2135,O
addition,2135,O
of,2135,O
appropriate,2135,O
amounts,2135,O
of,2135,O
purified,2135,O
C6,2135,O
.,2135,O
No,2136,O
hemostatic,2136,B-DiseaseClass
abnormalities,2136,I-DiseaseClass
were,2136,O
observed,2136,O
..,2136,O
Absence,2137,B-SpecificDisease
of,2137,I-SpecificDisease
the,2137,I-SpecificDisease
seventh,2137,I-SpecificDisease
component,2137,I-SpecificDisease
of,2137,I-SpecificDisease
complement,2137,I-SpecificDisease
in,2137,O
a,2137,O
patient,2137,O
with,2137,O
chronic,2137,B-SpecificDisease
meningococcemia,2137,I-SpecificDisease
presenting,2137,O
as,2137,O
vasculitis,2137,B-SpecificDisease
.,2137,O
A,2138,O
previously,2138,O
healthy,2138,O
40-year-old,2138,O
man,2138,O
presenting,2138,O
with,2138,O
fever,2138,B-SpecificDisease
",",2138,O
arthritis,2138,B-SpecificDisease
",",2138,O
and,2138,O
cutaneous,2138,B-SpecificDisease
vasculitis,2138,I-SpecificDisease
was,2138,O
found,2138,O
to,2138,O
have,2138,O
chronic,2138,B-SpecificDisease
meningococcemia,2138,I-SpecificDisease
.,2138,O
Evaluation,2139,O
of,2139,O
his,2139,O
complement,2139,O
system,2139,O
showed,2139,O
an,2139,O
absence,2139,O
of,2139,O
functional,2139,O
and,2139,O
antigenic,2139,O
C7,2139,O
",",2139,O
compatible,2139,O
with,2139,O
a,2139,O
complete,2139,O
deficiency,2139,B-SpecificDisease
of,2139,I-SpecificDisease
the,2139,I-SpecificDisease
seventh,2139,I-SpecificDisease
component,2139,I-SpecificDisease
of,2139,I-SpecificDisease
complement,2139,I-SpecificDisease
.,2139,O
Study,2140,O
of,2140,O
the,2140,O
patients,2140,O
family,2140,O
spanning,2140,O
four,2140,O
generations,2140,O
showed,2140,O
heterozygous,2140,O
deficiency,2140,B-SpecificDisease
of,2140,I-SpecificDisease
C7,2140,I-SpecificDisease
in,2140,O
five,2140,O
members,2140,O
.,2140,O
Chronic,2141,B-SpecificDisease
neisserial,2141,I-SpecificDisease
infection,2141,I-SpecificDisease
can,2141,O
be,2141,O
associated,2141,O
with,2141,O
C7,2141,B-SpecificDisease
deficiency,2141,I-SpecificDisease
and,2141,O
must,2141,O
be,2141,O
distinguished,2141,O
from,2141,O
other,2141,O
causes,2141,O
of,2141,O
cutaneous,2141,B-SpecificDisease
vasculitis,2141,I-SpecificDisease
..,2141,O
Familial,2142,B-SpecificDisease
discoid,2142,I-SpecificDisease
lupus,2142,I-SpecificDisease
erythematosus,2142,I-SpecificDisease
associated,2142,O
with,2142,O
heterozygote,2142,O
C2,2142,B-SpecificDisease
deficiency,2142,I-SpecificDisease
.,2142,O
Two,2143,O
siblings,2143,O
with,2143,O
chronic,2143,B-SpecificDisease
discoid,2143,I-SpecificDisease
lupus,2143,I-SpecificDisease
erythematosus,2143,I-SpecificDisease
and,2143,O
several,2143,O
family,2143,O
members,2143,O
were,2143,O
found,2143,O
with,2143,O
heterozygous,2143,O
C2,2143,B-SpecificDisease
deficiency,2143,I-SpecificDisease
.,2143,O
An,2144,O
association,2144,O
with,2144,O
histocompatibility,2144,O
markers,2144,O
HLA-B18,2144,O
and,2144,O
HLA-Dw2,2144,O
was,2144,O
demonstrated,2144,O
",",2144,O
and,2144,O
the,2144,O
slow,2144,O
allotype,2144,O
of,2144,O
factor,2144,O
B,2144,O
was,2144,O
present,2144,O
.,2144,O
Linkage,2145,O
studies,2145,O
in,2145,O
this,2145,O
family,2145,O
suggested,2145,O
a,2145,O
close,2145,O
linkage,2145,O
between,2145,O
the,2145,O
C2,2145,B-Modifier
deficiency,2145,I-Modifier
gene,2145,O
and,2145,O
genes,2145,O
coding,2145,O
for,2145,O
B18,2145,O
",",2145,O
Dw2,2145,O
",",2145,O
and,2145,O
BfS,2145,O
antigens,2145,O
.,2145,O
One,2146,O
HLA-ACB/DBf,2146,O
recombinant,2146,O
was,2146,O
observed,2146,O
showing,2146,O
closer,2146,O
linkage,2146,O
between,2146,O
HLA-D,2146,O
and,2146,O
Bf,2146,O
than,2146,O
between,2146,O
HLA-B,2146,O
and,2146,O
Bf,2146,O
..,2146,O
Severe-glucose-6-phosphate,2147,B-SpecificDisease
dehydrogenase,2147,I-SpecificDisease
(,2147,I-SpecificDisease
G6PD,2147,I-SpecificDisease
),2147,I-SpecificDisease
deficiency,2147,I-SpecificDisease
associated,2147,O
with,2147,O
chronic,2147,O
hemolytic,2147,B-SpecificDisease
anemia,2147,I-SpecificDisease
",",2147,O
granulocyte,2147,B-DiseaseClass
dysfunction,2147,I-DiseaseClass
",",2147,O
and,2147,O
increased,2147,O
susceptibility,2147,O
to,2147,O
infections,2147,O
:,2147,O
description,2147,O
of,2147,O
a,2147,O
new,2147,O
molecular,2147,O
variant,2147,O
(,2147,O
G6PD,2147,O
Barcelona,2147,O
),2147,O
.,2147,O
Molecular,2148,O
",",2148,O
kinetic,2148,O
",",2148,O
and,2148,O
functional,2148,O
studies,2148,O
were,2148,O
carried,2148,O
out,2148,O
on,2148,O
erythrocytes,2148,O
and,2148,O
leukocytes,2148,O
in,2148,O
a,2148,O
Spanish,2148,O
male,2148,O
with,2148,O
G6PD,2148,B-SpecificDisease
deficiency,2148,I-SpecificDisease
",",2148,O
congenital,2148,B-SpecificDisease
nonspherocytic,2148,I-SpecificDisease
hemolytic,2148,I-SpecificDisease
anemia,2148,I-SpecificDisease
(,2148,O
CNSHA,2148,B-SpecificDisease
),2148,O
",",2148,O
and,2148,O
increased,2148,O
susceptibility,2148,O
to,2148,O
infections,2148,O
.,2148,O
G6PD,2149,O
activity,2149,O
was,2149,O
absent,2149,O
in,2149,O
patients,2149,O
red,2149,O
cells,2149,O
and,2149,O
was,2149,O
about,2149,O
2,2149,O
%,2149,O
of,2149,O
normal,2149,O
in,2149,O
leukocytes,2149,O
.,2149,O
Molecular,2150,O
studies,2150,O
using,2150,O
standard,2150,O
methods,2150,O
(,2150,O
WHO,2150,O
",",2150,O
1967,2150,O
),2150,O
showed,2150,O
G6PD,2150,O
in,2150,O
the,2150,O
patient,2150,O
to,2150,O
have,2150,O
a,2150,O
slightly,2150,O
fast,2150,O
electrophoretic,2150,O
mobility,2150,O
at,2150,O
pH,2150,O
8,2150,O
.,2150,O
0,2151,O
with,2151,O
otherwise,2151,O
normal,2151,O
properties,2151,O
(,2151,O
heat,2151,O
stability,2151,O
at,2151,O
46,2151,O
degrees,2151,O
C,2151,O
",",2151,O
apparent,2151,O
affinity,2151,O
for,2151,O
substrates,2151,O
",",2151,O
optimum,2151,O
pH,2151,O
",",2151,O
and,2151,O
utilization,2151,O
of,2151,O
substrate,2151,O
analogues,2151,O
),2151,O
.,2151,O
Other,2152,O
tests,2152,O
showed,2152,O
the,2152,O
patients,2152,O
granulocytes,2152,O
to,2152,O
engulf,2152,O
latex,2152,O
particles,2152,O
normally,2152,O
",",2152,O
but,2152,O
to,2152,O
have,2152,O
impaired,2152,O
reduction,2152,O
of,2152,O
nitroblue,2152,O
tetrazolium,2152,O
and,2152,O
ferricytochrome-c,2152,O
as,2152,O
well,2152,O
as,2152,O
reduced,2152,O
iodination,2152,O
.,2152,O
Chemotaxis,2153,O
and,2153,O
random,2153,O
migration,2153,O
of,2153,O
the,2153,O
patients,2153,O
granulocytes,2153,O
were,2153,O
normal,2153,O
as,2153,O
were,2153,O
myeloperoxidase,2153,O
",",2153,O
leukocyte,2153,O
alkaline,2153,O
phosphatase,2153,O
(,2153,O
LAP,2153,O
),2153,O
",",2153,O
and,2153,O
ultrastructural,2153,O
features,2153,O
.,2153,O
The,2154,O
molecular,2154,O
characteristics,2154,O
of,2154,O
G6PD,2154,O
in,2154,O
the,2154,O
patient,2154,O
differed,2154,O
from,2154,O
those,2154,O
of,2154,O
all,2154,O
previously,2154,O
reported,2154,O
variants,2154,O
associated,2154,O
with,2154,O
CNSHA,2154,B-SpecificDisease
",",2154,O
so,2154,O
the,2154,O
present,2154,O
variant,2154,O
was,2154,O
provisionally,2154,O
called,2154,O
G6PD,2154,O
Barcelona,2154,O
to,2154,O
distinguish,2154,O
it,2154,O
from,2154,O
other,2154,O
G6PD,2154,O
variants,2154,O
previously,2154,O
described,2154,O
.,2154,O
Possible,2155,O
mechanisms,2155,O
for,2155,O
the,2155,O
severe,2155,O
deficiency,2155,B-SpecificDisease
of,2155,I-SpecificDisease
G6PD,2155,I-SpecificDisease
in,2155,O
erythrocytes,2155,O
and,2155,O
granulocytes,2155,O
was,2155,O
investigated,2155,O
by,2155,O
studies,2155,O
on,2155,O
the,2155,O
immunologic,2155,O
specific,2155,O
activity,2155,O
of,2155,O
the,2155,O
mutant,2155,O
enzyme,2155,O
.,2155,O
Glucose-6-phosphate,2156,B-SpecificDisease
dehydrogenase,2156,I-SpecificDisease
deficiency,2156,I-SpecificDisease
in,2156,O
Papua,2156,O
New,2156,O
Guinea,2156,O
.,2156,O
The,2157,O
description,2157,O
of,2157,O
13,2157,O
new,2157,O
variants,2157,O
.,2157,O
A,2158,O
total,2158,O
of,2158,O
362,2158,O
males,2158,O
from,2158,O
various,2158,O
regions,2158,O
of,2158,O
Papua,2158,O
New,2158,O
Guinea,2158,O
were,2158,O
screened,2158,O
for,2158,O
red,2158,O
cell,2158,O
glucose-6-phosphate,2158,O
dehydrogenase,2158,O
(,2158,O
G6PD,2158,O
),2158,O
activity,2158,O
.,2158,O
Twenty-six,2159,O
G6PD,2159,B-Modifier
deficient,2159,I-Modifier
individuals,2159,O
were,2159,O
identified,2159,O
.,2159,O
Biochemical,2160,O
characterization,2160,O
of,2160,O
G6PD,2160,O
purified,2160,O
from,2160,O
these,2160,O
subjects,2160,O
has,2160,O
revealed,2160,O
13,2160,O
new,2160,O
variants,2160,O
and,2160,O
several,2160,O
copies,2160,O
of,2160,O
previously,2160,O
described,2160,O
forms,2160,O
of,2160,O
G6PD,2160,O
.,2160,O
This,2161,O
study,2161,O
illustrates,2161,O
the,2161,O
extreme,2161,O
heterogeneity,2161,O
of,2161,O
G6PD,2161,B-SpecificDisease
deficiency,2161,I-SpecificDisease
among,2161,O
the,2161,O
people,2161,O
of,2161,O
Papua,2161,O
New,2161,O
Guinea,2161,O
..,2161,O
Heterogeneity,2162,O
of,2162,O
``,2162,O
Mediterranean,2162,O
type,2162,O
'',2162,O
glucose-6-phosphate,2162,B-SpecificDisease
dehydrogenase,2162,I-SpecificDisease
(,2162,I-SpecificDisease
G6PD,2162,I-SpecificDisease
),2162,I-SpecificDisease
deficiency,2162,I-SpecificDisease
in,2162,O
Spain,2162,O
and,2162,O
description,2162,O
of,2162,O
two,2162,O
new,2162,O
variants,2162,O
associated,2162,O
with,2162,O
favism,2162,B-SpecificDisease
.,2162,O
Glucose-6-phosphate,2163,O
dehydrogenase,2163,O
(,2163,O
G6PD,2163,O
),2163,O
;,2163,O
EC,2163,O
1,2163,O
.,2163,O
1,2164,O
.,2164,O
1,2165,O
.,2165,O
49,2166,O
from,2166,O
thirty-six,2166,O
unrelated,2166,O
Spanish,2166,O
males,2166,O
was,2166,O
partially,2166,O
purified,2166,O
from,2166,O
blood,2166,O
",",2166,O
and,2166,O
the,2166,O
variants,2166,O
were,2166,O
characterized,2166,O
biochemically,2166,O
and,2166,O
electrophoretically,2166,O
according,2166,O
to,2166,O
the,2166,O
methods,2166,O
recommended,2166,O
by,2166,O
the,2166,O
world,2166,O
Health,2166,O
Organization,2166,O
.,2166,O
Subjects,2167,O
were,2167,O
from,2167,O
multiple,2167,O
geographic,2167,O
regions,2167,O
within,2167,O
Spain,2167,O
",",2167,O
and,2167,O
all,2167,O
suffered,2167,O
from,2167,O
hemolytic,2167,B-SpecificDisease
anemia,2167,I-SpecificDisease
",",2167,O
either,2167,O
acute,2167,O
(,2167,O
34,2167,O
cases,2167,O
),2167,O
or,2167,O
chronic,2167,O
nonspherocytic,2167,O
(,2167,O
2,2167,O
cases,2167,O
),2167,O
.,2167,O
Almost,2168,O
all,2168,O
the,2168,O
variants,2168,O
studied,2168,O
presented,2168,O
residual,2168,O
erythrocyte,2168,O
G6PD,2168,O
activity,2168,O
ranging,2168,O
from,2168,O
0,2168,O
to,2168,O
10,2168,O
%,2168,O
of,2168,O
normal,2168,O
",",2168,O
and,2168,O
five,2168,O
different,2168,O
mutants,2168,O
were,2168,O
responsible,2168,O
for,2168,O
the,2168,O
deficient,2168,O
phenotype,2168,O
.,2168,O
Three,2169,O
variants,2169,O
were,2169,O
similar,2169,O
to,2169,O
others,2169,O
previously,2169,O
described,2169,O
G6PD,2169,O
Mediterranean,2169,O
(,2169,O
11,2169,O
cases,2169,O
),2169,O
",",2169,O
G6PD,2169,O
Athens-like,2169,O
(,2169,O
3,2169,O
cases,2169,O
),2169,O
",",2169,O
and,2169,O
G6PD,2169,O
Union,2169,O
(,2169,O
2,2169,O
cases,2169,O
),2169,O
.,2169,O
The,2170,O
remaining,2170,O
variants,2170,O
were,2170,O
different,2170,O
from,2170,O
the,2170,O
numerous,2170,O
variants,2170,O
already,2170,O
reported,2170,O
and,2170,O
have,2170,O
been,2170,O
considered,2170,O
as,2170,O
new,2170,O
mutants,2170,O
.,2170,O
Provisionally,2171,O
they,2171,O
are,2171,O
called,2171,O
G6PD,2171,O
Betica,2171,O
(,2171,O
19,2171,O
cases,2171,O
),2171,O
and,2171,O
G6PD,2171,O
Menorca,2171,O
(,2171,O
1,2171,O
case,2171,O
),2171,O
.,2171,O
The,2172,O
present,2172,O
study,2172,O
constitutes,2172,O
the,2172,O
first,2172,O
attempt,2172,O
to,2172,O
characterize,2172,O
the,2172,O
deficient,2172,B-Modifier
G6PD,2172,I-Modifier
variants,2172,O
found,2172,O
in,2172,O
Spain,2172,O
and,2172,O
supplies,2172,O
new,2172,O
data,2172,O
on,2172,O
the,2172,O
relationship,2172,O
between,2172,O
molecular,2172,O
characteristics,2172,O
of,2172,O
deficient,2172,O
variants,2172,O
and,2172,O
their,2172,O
clinical,2172,O
manifestations,2172,O
.,2172,O
The,2173,O
most,2173,O
important,2173,O
findings,2173,O
can,2173,O
be,2173,O
summarized,2173,O
as,2173,O
follows,2173,O
(,2173,O
1,2173,O
),2173,O
The,2173,O
Spanish,2173,O
population,2173,O
is,2173,O
characterized,2173,O
by,2173,O
an,2173,O
important,2173,O
heterogeneity,2173,O
in,2173,O
G6PD,2173,B-SpecificDisease
deficiency,2173,I-SpecificDisease
.,2173,O
(,2174,O
2,2174,O
),2174,O
Although,2174,O
G6PD,2174,O
Mediterranean,2174,O
is,2174,O
very,2174,O
frequent,2174,O
",",2174,O
it,2174,O
presents,2174,O
a,2174,O
relatively,2174,O
high,2174,O
degree,2174,O
of,2174,O
polymorphism,2174,O
.,2174,O
(,2175,O
3,2175,O
),2175,O
Favism,2175,B-SpecificDisease
has,2175,O
been,2175,O
observed,2175,O
associated,2175,O
with,2175,O
all,2175,O
kinds,2175,O
of,2175,O
variants,2175,O
described,2175,O
here,2175,O
.,2175,O
(,2176,O
4,2176,O
),2176,O
G6PD,2176,O
Betica,2176,O
",",2176,O
which,2176,O
is,2176,O
the,2176,O
most,2176,O
frequent,2176,O
variant,2176,O
found,2176,O
in,2176,O
subjects,2176,O
of,2176,O
Southern,2176,O
Spanish,2176,O
origin,2176,O
",",2176,O
has,2176,O
been,2176,O
observed,2176,O
associated,2176,O
with,2176,O
favism,2176,B-SpecificDisease
in,2176,O
all,2176,O
cases,2176,O
except,2176,O
one,2176,O
.,2176,O
A,2177,O
new,2177,O
glucose-6-phosphate,2177,O
dehydrogenase,2177,O
variant,2177,O
(,2177,O
G6PD,2177,O
Nagano,2177,O
),2177,O
associated,2177,O
with,2177,O
congenital,2177,B-SpecificDisease
hemolytic,2177,I-SpecificDisease
anemia,2177,I-SpecificDisease
.,2177,O
A,2178,O
new,2178,O
glucose-6-phosphate,2178,O
dehydrogenase,2178,O
(,2178,O
G6PD,2178,O
),2178,O
variant,2178,O
associated,2178,O
with,2178,O
chronic,2178,B-SpecificDisease
nonspherocytic,2178,I-SpecificDisease
hemolytic,2178,I-SpecificDisease
anemia,2178,I-SpecificDisease
was,2178,O
reported,2178,O
.,2178,O
The,2179,O
patient,2179,O
",",2179,O
a,2179,O
6-year-old,2179,O
Japanese,2179,O
male,2179,O
",",2179,O
was,2179,O
noticed,2179,O
to,2179,O
have,2179,O
hemolytic,2179,B-SpecificDisease
anemia,2179,I-SpecificDisease
soon,2179,O
after,2179,O
birth,2179,O
",",2179,O
and,2179,O
a,2179,O
diagnosis,2179,O
of,2179,O
G6PD,2179,B-SpecificDisease
deficiency,2179,I-SpecificDisease
was,2179,O
made,2179,O
at,2179,O
the,2179,O
age,2179,O
of,2179,O
2,2179,O
.,2179,O
He,2180,O
had,2180,O
episodes,2180,O
of,2180,O
hemolytic,2180,B-DiseaseClass
crisis,2180,I-DiseaseClass
several,2180,O
times,2180,O
after,2180,O
upper,2180,B-SpecificDisease
respiratory,2180,I-SpecificDisease
infection,2180,I-SpecificDisease
.,2180,O
G6PD,2181,O
activity,2181,O
of,2181,O
the,2181,O
patient,2181,O
was,2181,O
5,2181,O
.,2181,O
5,2182,O
%,2182,O
of,2182,O
normal,2182,O
.,2182,O
The,2183,O
enzymatic,2183,O
characteristics,2183,O
were,2183,O
examined,2183,O
when,2183,O
he,2183,O
was,2183,O
5,2183,O
years,2183,O
old,2183,O
",",2183,O
and,2183,O
his,2183,O
G6PD,2183,O
showed,2183,O
faster-than-normal,2183,O
electrophoretic,2183,O
mobility,2183,O
",",2183,O
low,2183,O
Km,2183,O
G6P,2183,O
",",2183,O
high,2183,O
Km,2183,O
NADP,2183,O
",",2183,O
low,2183,O
Ki,2183,O
NADPH,2183,O
",",2183,O
normal,2183,O
utilization,2183,O
of,2183,O
substrate,2183,O
analogues,2183,O
",",2183,O
heat,2183,O
instability,2183,O
",",2183,O
and,2183,O
a,2183,O
normal,2183,O
pH,2183,O
optimum,2183,O
curve,2183,O
.,2183,O
From,2184,O
these,2184,O
results,2184,O
",",2184,O
this,2184,O
was,2184,O
considered,2184,O
to,2184,O
be,2184,O
a,2184,O
new,2184,O
variant,2184,O
and,2184,O
was,2184,O
designated,2184,O
G6PD,2184,O
Nagano,2184,O
.,2184,O
Infection-induced,2185,O
hemolysis,2185,B-SpecificDisease
and,2185,O
chronic,2185,B-SpecificDisease
hemolytic,2185,I-SpecificDisease
anemia,2185,I-SpecificDisease
seem,2185,O
to,2185,O
be,2185,O
due,2185,O
to,2185,O
markedly,2185,O
impaired,2185,O
enzyme,2185,O
activity,2185,O
and,2185,O
thermal,2185,O
instability,2185,O
.,2185,O
Heterozygous,2186,O
C2-deficiency,2186,B-SpecificDisease
and,2186,O
myasthenia,2186,B-SpecificDisease
gravis,2186,I-SpecificDisease
.,2186,O
Complement,2187,B-Modifier
deficiency,2187,I-Modifier
states,2187,O
in,2187,O
myasthenia,2187,B-SpecificDisease
gravis,2187,I-SpecificDisease
(,2187,O
MG,2187,B-SpecificDisease
),2187,O
have,2187,O
not,2187,O
been,2187,O
reported,2187,O
previously,2187,O
.,2187,O
We,2188,O
describe,2188,O
a,2188,O
19-year-old,2188,O
woman,2188,O
with,2188,O
typical,2188,O
MG,2188,B-SpecificDisease
and,2188,O
heterozygous,2188,O
C2,2188,B-SpecificDisease
deficiency,2188,I-SpecificDisease
",",2188,O
along,2188,O
with,2188,O
HLA,2188,O
typing,2188,O
of,2188,O
the,2188,O
patient,2188,O
and,2188,O
her,2188,O
immediate,2188,O
family,2188,O
..,2188,O
Adrenoleukodystrophy,2189,B-SpecificDisease
:,2189,O
increased,2189,O
plasma,2189,O
content,2189,O
of,2189,O
saturated,2189,O
very,2189,O
long,2189,O
chain,2189,O
fatty,2189,O
acids,2189,O
.,2189,O
With,2190,O
a,2190,O
new,2190,O
method,2190,O
we,2190,O
measured,2190,O
the,2190,O
saturated,2190,O
very,2190,O
long,2190,O
chain,2190,O
fatty,2190,O
acids,2190,O
in,2190,O
the,2190,O
plasma,2190,O
of,2190,O
adrenoleukodystrophy,2190,B-Modifier
(,2190,O
ALD,2190,B-Modifier
),2190,O
hemizygotes,2190,O
",",2190,O
ALD,2190,B-Modifier
heterozygotes,2190,O
",",2190,O
and,2190,O
controls,2190,O
.,2190,O
ALD,2191,B-Modifier
hemizygotes,2191,O
showed,2191,O
increased,2191,O
levels,2191,O
of,2191,O
hexacosanoate,2191,O
(,2191,O
C26,2191,O
fatty,2191,O
acid,2191,O
),2191,O
which,2191,O
represented,2191,O
0,2191,O
.,2191,O
081,2192,O
+/-,2192,O
0,2192,O
.,2192,O
0066,2193,O
%,2193,O
(,2193,O
SEM,2193,O
),2193,O
of,2193,O
total,2193,O
fatty,2193,O
acids,2193,O
",",2193,O
compared,2193,O
to,2193,O
0,2193,O
.,2193,O
015,2194,O
+/-,2194,O
0,2194,O
.,2194,O
0032,2195,O
%,2195,O
in,2195,O
the,2195,O
controls,2195,O
.,2195,O
C25,2196,O
",",2196,O
C24,2196,O
",",2196,O
and,2196,O
C23,2196,O
fatty,2196,O
acids,2196,O
were,2196,O
also,2196,O
increased,2196,O
",",2196,O
but,2196,O
the,2196,O
C22,2196,O
and,2196,O
C20,2196,O
fatty,2196,O
acids,2196,O
were,2196,O
normal,2196,O
.,2196,O
C26,2197,O
levels,2197,O
were,2197,O
also,2197,O
increased,2197,O
in,2197,O
most,2197,O
ALD,2197,B-Modifier
heterozygotes,2197,O
",",2197,O
with,2197,O
a,2197,O
mean,2197,O
level,2197,O
0,2197,O
.,2197,O
057,2198,O
+/-,2198,O
0,2198,O
.,2198,O
0063,2199,O
%,2199,O
of,2199,O
total,2199,O
fatty,2199,O
acids,2199,O
.,2199,O
The,2200,O
technique,2200,O
can,2200,O
be,2200,O
used,2200,O
for,2200,O
diagnosis,2200,O
and,2200,O
carrier,2200,O
identification,2200,O
",",2200,O
and,2200,O
in,2200,O
the,2200,O
evaluation,2200,O
of,2200,O
therapy,2200,O
.,2200,O
Abnormal,2201,O
high,2201,O
density,2201,O
lipoproteins,2201,O
in,2201,O
cerebrotendinous,2201,B-SpecificDisease
xanthomatosis,2201,I-SpecificDisease
.,2201,O
The,2202,O
plasma,2202,O
lipoprotein,2202,O
profiles,2202,O
and,2202,O
high,2202,O
density,2202,O
lipoproteins,2202,O
(,2202,O
HDL,2202,O
),2202,O
were,2202,O
characterized,2202,O
in,2202,O
patients,2202,O
with,2202,O
the,2202,O
genetic,2202,B-DiseaseClass
disease,2202,I-DiseaseClass
cerebrotendinous,2202,B-SpecificDisease
xanthomatosis,2202,I-SpecificDisease
(,2202,O
CTX,2202,B-SpecificDisease
),2202,O
.,2202,O
Abnormalities,2203,B-DiseaseClass
in,2203,I-DiseaseClass
the,2203,I-DiseaseClass
HDL,2203,I-DiseaseClass
may,2203,O
contribute,2203,O
to,2203,O
their,2203,O
increased,2203,O
atherogenesis,2203,O
and,2203,O
excessive,2203,O
deposits,2203,O
of,2203,O
tissue,2203,O
sterols,2203,O
in,2203,O
the,2203,O
presence,2203,O
of,2203,O
low,2203,O
or,2203,O
low-normal,2203,O
concentrations,2203,O
of,2203,O
plasma,2203,O
cholesterol,2203,O
(,2203,O
165,2203,O
+/-,2203,O
25,2203,O
mg/dl,2203,O
),2203,O
and,2203,O
low,2203,O
density,2203,O
lipoproteins,2203,O
(,2203,O
LDL,2203,O
),2203,O
.,2203,O
The,2204,O
mean,2204,O
HDL-cholesterol,2204,O
concentration,2204,O
in,2204,O
the,2204,O
CTX,2204,B-Modifier
plasmas,2204,O
was,2204,O
14,2204,O
.,2204,O
5,2205,O
+/-,2205,O
3,2205,O
.,2205,O
2,2206,O
mg/dl,2206,O
",",2206,O
about,2206,O
one-third,2206,O
the,2206,O
normal,2206,O
value,2206,O
.,2206,O
The,2207,O
low,2207,O
HDL-cholesterol,2207,O
reflects,2207,O
a,2207,O
low,2207,O
concentration,2207,O
and,2207,O
an,2207,O
abnormal,2207,O
lipid,2207,O
composition,2207,O
of,2207,O
the,2207,O
plasma,2207,O
HDL,2207,O
.,2207,O
Relative,2208,O
to,2208,O
normal,2208,O
HDL,2208,O
",",2208,O
the,2208,O
cholesteryl,2208,O
esters,2208,O
are,2208,O
low,2208,O
",",2208,O
free,2208,O
cholesterol,2208,O
and,2208,O
phospholipids,2208,O
essentially,2208,O
normal,2208,O
",",2208,O
and,2208,O
triglycerides,2208,O
increased,2208,O
.,2208,O
The,2209,O
ratio,2209,O
of,2209,O
apoprotein,2209,O
(,2209,O
apo,2209,O
),2209,O
to,2209,O
total,2209,O
cholesterol,2209,O
in,2209,O
the,2209,O
HDL,2209,O
of,2209,O
CTX,2209,B-SpecificDisease
was,2209,O
two,2209,O
to,2209,O
three,2209,O
times,2209,O
greater,2209,O
than,2209,O
normal,2209,O
.,2209,O
In,2210,O
the,2210,O
CTX,2210,B-Modifier
HDL,2210,O
",",2210,O
the,2210,O
ratio,2210,O
of,2210,O
apoAI,2210,O
to,2210,O
apoAII,2210,O
was,2210,O
high,2210,O
",",2210,O
the,2210,O
proportion,2210,O
of,2210,O
apoC,2210,O
low,2210,O
",",2210,O
and,2210,O
a,2210,O
normally,2210,O
minor,2210,O
form,2210,O
of,2210,O
apoAI,2210,O
increased,2210,O
relative,2210,O
to,2210,O
other,2210,O
forms,2210,O
.,2210,O
The,2211,O
HDL,2211,O
in,2211,O
electron,2211,O
micrographs,2211,O
appeared,2211,O
normal,2211,O
morphologically,2211,O
and,2211,O
in,2211,O
particle,2211,O
size,2211,O
.,2211,O
The,2212,O
abnormalities,2212,O
in,2212,O
lipoprotein,2212,O
distribution,2212,O
profile,2212,O
and,2212,O
composition,2212,O
of,2212,O
the,2212,O
plasma,2212,O
HDL,2212,O
result,2212,O
from,2212,O
metabolic,2212,O
defects,2212,O
that,2212,O
are,2212,O
not,2212,O
understood,2212,O
but,2212,O
may,2212,O
be,2212,O
linked,2212,O
to,2212,O
the,2212,O
genetic,2212,B-DiseaseClass
defect,2212,I-DiseaseClass
in,2212,O
bile,2212,O
acid,2212,O
synthesis,2212,O
in,2212,O
CTX,2212,B-SpecificDisease
.,2212,O
As,2213,O
a,2213,O
consequence,2213,O
",",2213,O
it,2213,O
is,2213,O
probable,2213,O
that,2213,O
the,2213,O
normal,2213,O
functions,2213,O
of,2213,O
the,2213,O
HDL,2213,O
",",2213,O
possibly,2213,O
including,2213,O
modulation,2213,O
of,2213,O
LDL-cholesterol,2213,O
uptake,2213,O
and,2213,O
the,2213,O
removal,2213,O
of,2213,O
excess,2213,O
cholesterol,2213,O
from,2213,O
peripheral,2213,O
tissues,2213,O
",",2213,O
are,2213,O
perturbed,2213,O
significantly,2213,O
in,2213,O
this,2213,O
disease,2213,O
.,2213,O
Genetics,2214,O
of,2214,O
cerebrotendinous,2214,B-SpecificDisease
xanthomatosis,2214,I-SpecificDisease
(,2214,O
CTX,2214,B-SpecificDisease
),2214,O
:,2214,O
an,2214,O
autosomal,2214,O
recessive,2214,O
trait,2214,O
with,2214,O
high,2214,O
gene,2214,O
frequency,2214,O
in,2214,O
Sephardim,2214,O
of,2214,O
Moroccan,2214,O
origin,2214,O
.,2214,O
We,2215,O
described,2215,O
6,2215,O
patients,2215,O
(,2215,O
from,2215,O
3,2215,O
families,2215,O
),2215,O
affected,2215,O
with,2215,O
cerebrotendinous,2215,B-SpecificDisease
xanthomatosis,2215,I-SpecificDisease
(,2215,O
CTX,2215,B-SpecificDisease
),2215,O
.,2215,O
All,2216,O
are,2216,O
Sephardic,2216,O
Jews,2216,O
of,2216,O
Moroccan,2216,O
extraction,2216,O
.,2216,O
In,2217,O
view,2217,O
of,2217,O
the,2217,O
small,2217,O
number,2217,O
of,2217,O
CTX,2217,B-Modifier
patients,2217,O
diagnosed,2217,O
in,2217,O
the,2217,O
world,2217,O
(,2217,O
a,2217,O
total,2217,O
of,2217,O
50,2217,O
including,2217,O
our,2217,O
6,2217,O
patients,2217,O
),2217,O
",",2217,O
we,2217,O
are,2217,O
probably,2217,O
dealing,2217,O
with,2217,O
an,2217,O
ethnic,2217,O
subgroup,2217,O
with,2217,O
a,2217,O
high,2217,O
CTX,2217,O
gene,2217,O
frequency,2217,O
",",2217,O
which,2217,O
we,2217,O
have,2217,O
estimated,2217,O
to,2217,O
be,2217,O
1/108,2217,O
.,2217,O
Since,2218,O
there,2218,O
are,2218,O
differences,2218,O
in,2218,O
expression,2218,O
in,2218,O
this,2218,O
disease,2218,O
",",2218,O
we,2218,O
recommend,2218,O
cholestanol,2218,O
study,2218,O
in,2218,O
cases,2218,O
of,2218,O
undiagnosed,2218,O
cataract,2218,B-SpecificDisease
or,2218,O
tendinous,2218,B-SpecificDisease
xanthomas,2218,I-SpecificDisease
in,2218,O
childhood,2218,O
or,2218,O
early,2218,O
adolescence,2218,O
.,2218,O
The,2219,O
diagnosis,2219,O
in,2219,O
CTX,2219,B-SpecificDisease
is,2219,O
important,2219,O
not,2219,O
only,2219,O
for,2219,O
genetic,2219,O
counseling,2219,O
",",2219,O
but,2219,O
also,2219,O
in,2219,O
veiw,2219,O
of,2219,O
possible,2219,O
treatment,2219,O
..,2219,O
New,2220,O
genetic,2220,O
variants,2220,O
of,2220,O
glucose,2220,O
6-phosphate,2220,O
dehydrogenase,2220,O
(,2220,O
G6PD,2220,O
),2220,O
in,2220,O
Italy,2220,O
.,2220,O
Six,2221,O
new,2221,O
variants,2221,O
of,2221,O
human,2221,O
erythrocyte,2221,O
G6PD,2221,O
have,2221,O
been,2221,O
characterized,2221,O
.,2221,O
All,2222,O
of,2222,O
them,2222,O
were,2222,O
found,2222,O
in,2222,O
Italian,2222,O
males,2222,O
and,2222,O
all,2222,O
were,2222,O
associated,2222,O
with,2222,O
enzyme,2222,B-DiseaseClass
deficiency,2222,I-DiseaseClass
",",2222,O
but,2222,O
only,2222,O
two,2222,O
with,2222,O
signs,2222,O
of,2222,O
haemolysis,2222,B-SpecificDisease
.,2222,O
These,2223,O
and,2223,O
other,2223,O
variants,2223,O
reported,2223,O
in,2223,O
the,2223,O
literature,2223,O
",",2223,O
which,2223,O
must,2223,O
thus,2223,O
far,2223,O
be,2223,O
regarded,2223,O
as,2223,O
sporadic,2223,O
",",2223,O
are,2223,O
found,2223,O
to,2223,O
map,2223,O
in,2223,O
parts,2223,O
of,2223,O
Italy,2223,O
where,2223,O
common,2223,O
types,2223,O
of,2223,O
G6PD,2223,B-SpecificDisease
deficiency,2223,I-SpecificDisease
are,2223,O
also,2223,O
prevalent,2223,O
..,2223,O
Variants,2224,O
of,2224,O
erythrocyte,2224,O
glucose-6-phosphate,2224,O
dehydrogenase,2224,O
(,2224,O
G6PD,2224,O
),2224,O
in,2224,O
Bulgarian,2224,O
populations,2224,O
.,2224,O
Ten,2225,O
variants,2225,O
of,2225,O
erythrocyte,2225,O
glucose-6-phosphate,2225,O
dehydrogenase,2225,O
were,2225,O
identified,2225,O
in,2225,O
22,2225,O
patients,2225,O
with,2225,O
G6PD,2225,B-SpecificDisease
deficiency,2225,I-SpecificDisease
from,2225,O
three,2225,O
districts,2225,O
of,2225,O
Bulgaria,2225,O
.,2225,O
Corinth-like,2226,O
and,2226,O
Fayoum-like,2226,O
variants,2226,O
were,2226,O
the,2226,O
most,2226,O
frequent,2226,O
;,2226,O
Mediterranean,2226,O
",",2226,O
Ohut,2226,O
II,2226,O
",",2226,O
Kilgore,2226,O
",",2226,O
Boston,2226,O
",",2226,O
Poznan,2226,O
",",2226,O
and,2226,O
Panay,2226,O
variants,2226,O
and,2226,O
two,2226,O
new,2226,O
variants,2226,O
",",2226,O
Petrich,2226,O
and,2226,O
Gotze,2226,O
Delchev,2226,O
",",2226,O
were,2226,O
each,2226,O
found,2226,O
in,2226,O
one,2226,O
or,2226,O
two,2226,O
carriers,2226,O
.,2226,O
No,2227,O
correlation,2227,O
was,2227,O
revealed,2227,O
between,2227,O
clinical,2227,O
and,2227,O
biochemical,2227,O
polymorphism,2227,O
..,2227,O
Nephropathy,2228,B-SpecificDisease
in,2228,O
the,2228,O
Wiskott-Aldrich,2228,B-SpecificDisease
syndrome,2228,I-SpecificDisease
.,2228,O
Nephropathy,2229,B-SpecificDisease
was,2229,O
detected,2229,O
in,2229,O
five,2229,O
of,2229,O
32,2229,O
patients,2229,O
with,2229,O
the,2229,O
Wiskott-Aldrich,2229,B-SpecificDisease
syndrome,2229,I-SpecificDisease
who,2229,O
were,2229,O
participating,2229,O
in,2229,O
a,2229,O
study,2229,O
of,2229,O
transfer,2229,O
factor,2229,O
(,2229,O
TF,2229,O
),2229,O
therapy,2229,O
.,2229,O
In,2230,O
two,2230,O
patients,2230,O
",",2230,O
nephropathy,2230,B-SpecificDisease
was,2230,O
present,2230,O
before,2230,O
TF,2230,O
and,2230,O
did,2230,O
not,2230,O
appear,2230,O
changed,2230,O
by,2230,O
TF,2230,O
therapy,2230,O
.,2230,O
One,2231,O
of,2231,O
these,2231,O
patients,2231,O
subsequently,2231,O
developed,2231,O
progressive,2231,O
renal,2231,B-SpecificDisease
failure,2231,I-SpecificDisease
requiring,2231,O
dialysis,2231,O
beginning,2231,O
5,2231,O
1/2,2231,O
years,2231,O
after,2231,O
TF,2231,O
therapy,2231,O
.,2231,O
In,2232,O
two,2232,O
patients,2232,O
",",2232,O
decreased,2232,O
renal,2232,O
function,2232,O
appeared,2232,O
very,2232,O
soon,2232,O
after,2232,O
the,2232,O
administration,2232,O
of,2232,O
TF,2232,O
.,2232,O
One,2233,O
patient,2233,O
showed,2233,O
gradually,2233,O
decreasing,2233,O
renal,2233,O
function,2233,O
beginning,2233,O
after,2233,O
two,2233,O
years,2233,O
of,2233,O
TF,2233,O
therapy,2233,O
.,2233,O
An,2234,O
additional,2234,O
patient,2234,O
was,2234,O
identified,2234,O
who,2234,O
died,2234,O
with,2234,O
renal,2234,B-SpecificDisease
failure,2234,I-SpecificDisease
without,2234,O
having,2234,O
received,2234,O
TF,2234,O
.,2234,O
The,2235,O
results,2235,O
suggest,2235,O
that,2235,O
renal,2235,B-SpecificDisease
failure,2235,I-SpecificDisease
occurs,2235,O
in,2235,O
the,2235,O
Wiskott-Aldrich,2235,B-SpecificDisease
syndrome,2235,I-SpecificDisease
more,2235,O
frequently,2235,O
than,2235,O
generally,2235,O
recognized,2235,O
and,2235,O
that,2235,O
administration,2235,O
of,2235,O
TF,2235,O
may,2235,O
precipitate,2235,O
or,2235,O
accelerate,2235,O
the,2235,O
renal,2235,B-SpecificDisease
disease,2235,I-SpecificDisease
in,2235,O
patients,2235,O
with,2235,O
this,2235,O
syndrome,2235,O
..,2235,O
Wiskott-Aldrich,2236,B-SpecificDisease
syndrome,2236,I-SpecificDisease
:,2236,O
cellular,2236,O
impairments,2236,O
and,2236,O
their,2236,O
implication,2236,O
for,2236,O
carrier,2236,O
detection,2236,O
.,2236,O
A,2237,O
family,2237,O
in,2237,O
which,2237,O
two,2237,O
male,2237,O
siblings,2237,O
were,2237,O
affected,2237,O
with,2237,O
Wiskott-Aldrich,2237,B-SpecificDisease
syndrome,2237,I-SpecificDisease
(,2237,O
WAS,2237,B-SpecificDisease
),2237,O
was,2237,O
studied,2237,O
using,2237,O
G-6-PD,2237,O
isoenzymes,2237,O
as,2237,O
an,2237,O
X-linked,2237,O
marker,2237,O
in,2237,O
order,2237,O
to,2237,O
investigate,2237,O
the,2237,O
nature,2237,O
of,2237,O
cellular,2237,O
abnormalities,2237,O
.,2237,O
Isolated,2238,O
peripheral,2238,O
blood,2238,O
cell,2238,O
types,2238,O
from,2238,O
the,2238,O
doubly,2238,O
heterozygous,2238,O
mother,2238,O
of,2238,O
the,2238,O
affected,2238,O
males,2238,O
seemingly,2238,O
failed,2238,O
to,2238,O
express,2238,O
the,2238,O
G-6-PD,2238,O
allele,2238,O
in,2238,O
cis,2238,O
position,2238,O
with,2238,O
the,2238,O
WAS,2238,B-Modifier
allele,2238,O
while,2238,O
her,2238,O
cultured,2238,O
skin,2238,O
fibroblasts,2238,O
expressed,2238,O
both,2238,O
G-6-PD,2238,O
alleles,2238,O
.,2238,O
Additionally,2239,O
",",2239,O
a,2239,O
histogram,2239,O
analysis,2239,O
of,2239,O
platelet,2239,O
size,2239,O
revealed,2239,O
a,2239,O
single,2239,O
population,2239,O
of,2239,O
abnormally,2239,O
small,2239,O
platelets,2239,O
in,2239,O
the,2239,O
affected,2239,O
propositus,2239,O
",",2239,O
whereas,2239,O
the,2239,O
heterozygous,2239,O
mother,2239,O
had,2239,O
no,2239,O
appreciable,2239,O
small,2239,O
platelet,2239,O
subpopulation,2239,O
.,2239,O
In,2240,O
vitro,2240,O
culture,2240,O
of,2240,O
hemopoietic,2240,O
progenitor,2240,O
cells,2240,O
of,2240,O
the,2240,O
heterozygous,2240,O
mother,2240,O
showed,2240,O
that,2240,O
the,2240,O
majority,2240,O
of,2240,O
progenitor,2240,O
cells,2240,O
did,2240,O
not,2240,O
express,2240,O
the,2240,O
WAS,2240,B-Modifier
allele,2240,O
.,2240,O
However,2241,O
",",2241,O
a,2241,O
small,2241,O
number,2241,O
of,2241,O
cells,2241,O
expressing,2241,O
the,2241,O
G-6-PD,2241,O
type,2241,O
linked,2241,O
with,2241,O
the,2241,O
WAS,2241,B-Modifier
allele,2241,O
were,2241,O
detected,2241,O
.,2241,O
The,2242,O
proportion,2242,O
of,2242,O
the,2242,O
latter,2242,O
progenitors,2242,O
was,2242,O
significantly,2242,O
higher,2242,O
among,2242,O
more,2242,O
primitive,2242,O
progenitors,2242,O
(,2242,O
those,2242,O
giving,2242,O
rise,2242,O
to,2242,O
later,2242,O
appearing,2242,O
colonies,2242,O
),2242,O
.,2242,O
This,2243,O
observation,2243,O
suggests,2243,O
that,2243,O
selection,2243,O
against,2243,O
cells,2243,O
expressing,2243,O
the,2243,O
Wiskott-Aldrich,2243,B-SpecificDisease
defect,2243,I-SpecificDisease
takes,2243,O
place,2243,O
in,2243,O
the,2243,O
hemopoietic,2243,O
system,2243,O
of,2243,O
the,2243,O
heterozygous,2243,O
female,2243,O
and,2243,O
offers,2243,O
a,2243,O
possible,2243,O
means,2243,O
of,2243,O
carrier,2243,O
detection,2243,O
in,2243,O
some,2243,O
women,2243,O
.,2243,O
Linkage,2244,O
studies,2244,O
in,2244,O
this,2244,O
family,2244,O
revealed,2244,O
one,2244,O
example,2244,O
of,2244,O
probable,2244,O
recombination,2244,O
between,2244,O
the,2244,O
loci,2244,O
for,2244,O
WAS,2244,B-SpecificDisease
and,2244,O
G-6-PD,2244,O
among,2244,O
three,2244,O
informative,2244,O
subjects,2244,O
",",2244,O
suggesting,2244,O
that,2244,O
these,2244,O
two,2244,O
loci,2244,O
may,2244,O
not,2244,O
be,2244,O
closely,2244,O
linked,2244,O
on,2244,O
the,2244,O
X-chromosome,2244,O
..,2244,O
A,2245,O
new,2245,O
CT,2245,O
pattern,2245,O
in,2245,O
adrenoleukodystrophy,2245,B-SpecificDisease
.,2245,O
A,2246,O
new,2246,O
CT,2246,O
pattern,2246,O
was,2246,O
observed,2246,O
in,2246,O
2,2246,O
patients,2246,O
with,2246,O
adrenoleukodystrophy,2246,B-SpecificDisease
(,2246,O
ALD,2246,B-SpecificDisease
),2246,O
.,2246,O
This,2247,O
pattern,2247,O
",",2247,O
which,2247,O
the,2247,O
authors,2247,O
call,2247,O
Type,2247,O
II,2247,O
",",2247,O
is,2247,O
characterized,2247,O
by,2247,O
the,2247,O
absence,2247,O
of,2247,O
posterior,2247,O
periventricular,2247,O
areas,2247,O
of,2247,O
decreased,2247,O
attenuation,2247,O
around,2247,O
the,2247,O
trigone,2247,O
on,2247,O
non-contrast,2247,O
scans,2247,O
after,2247,O
contrast,2247,O
infusion,2247,O
",",2247,O
however,2247,O
",",2247,O
there,2247,O
is,2247,O
striking,2247,O
enhancement,2247,O
of,2247,O
various,2247,O
white-matter,2247,O
structures,2247,O
(,2247,O
tracts,2247,O
or,2247,O
fiber,2247,O
systems,2247,O
),2247,O
such,2247,O
as,2247,O
the,2247,O
internal,2247,O
capsules,2247,O
",",2247,O
corpus,2247,O
callosum,2247,O
",",2247,O
corona,2247,O
radiata,2247,O
",",2247,O
forceps,2247,O
major,2247,O
",",2247,O
and,2247,O
cerebral,2247,O
peduncles,2247,O
.,2247,O
This,2248,O
is,2248,O
different,2248,O
from,2248,O
numerous,2248,O
previous,2248,O
descriptions,2248,O
of,2248,O
the,2248,O
CT,2248,O
pattern,2248,O
in,2248,O
ALD,2248,B-SpecificDisease
.,2248,O
Type,2249,B-SpecificDisease
II,2249,I-SpecificDisease
ALD,2249,I-SpecificDisease
does,2249,O
not,2249,O
appear,2249,O
to,2249,O
have,2249,O
been,2249,O
seen,2249,O
in,2249,O
any,2249,O
other,2249,O
leukoencephalopathy,2249,B-DiseaseClass
and,2249,O
is,2249,O
probably,2249,O
specific,2249,O
for,2249,O
a,2249,O
phenotypic,2249,O
variant,2249,O
or,2249,O
an,2249,O
evolving,2249,O
stage,2249,O
of,2249,O
ALD,2249,B-SpecificDisease
..,2249,O
Further,2250,O
evidence,2250,O
for,2250,O
heterogeneity,2250,O
of,2250,O
glucose-6-phosphate,2250,B-SpecificDisease
dehydrogenase,2250,I-SpecificDisease
deficiency,2250,I-SpecificDisease
in,2250,O
Papua,2250,O
New,2250,O
Guinea,2250,O
.,2250,O
Four,2251,O
new,2251,O
G6PD,2251,O
variants,2251,O
have,2251,O
been,2251,O
characterized,2251,O
in,2251,O
individuals,2251,O
from,2251,O
Papua,2251,O
New,2251,O
Guinea,2251,O
.,2251,O
This,2252,O
study,2252,O
demonstrates,2252,O
that,2252,O
the,2252,O
previously,2252,O
reported,2252,O
Markham,2252,O
variant,2252,O
and,2252,O
the,2252,O
newly,2252,O
characterized,2252,O
Salata,2252,O
variant,2252,O
may,2252,O
be,2252,O
widely,2252,O
distributed,2252,O
in,2252,O
Papua,2252,O
New,2252,O
Guinea,2252,O
.,2252,O
Th,2253,O
data,2253,O
presented,2253,O
here,2253,O
together,2253,O
with,2253,O
those,2253,O
of,2253,O
previously,2253,O
published,2253,O
studies,2253,O
demonstrate,2253,O
a,2253,O
degree,2253,O
of,2253,O
heterogeneity,2253,O
of,2253,O
G6PD,2253,B-SpecificDisease
deficiency,2253,I-SpecificDisease
that,2253,O
is,2253,O
much,2253,O
higher,2253,O
than,2253,O
that,2253,O
in,2253,O
other,2253,O
regions,2253,O
of,2253,O
the,2253,O
world,2253,O
where,2253,O
G6PD,2253,B-SpecificDisease
deficiency,2253,I-SpecificDisease
is,2253,O
common,2253,O
..,2253,O
Increased,2254,O
incidence,2254,O
of,2254,O
cataracts,2254,B-SpecificDisease
in,2254,O
male,2254,O
subjects,2254,O
deficient,2254,B-SpecificDisease
in,2254,I-SpecificDisease
glucose-6-phosphate,2254,I-SpecificDisease
dehydrogenase,2254,I-SpecificDisease
.,2254,O
Glucose-6-phosphate,2255,B-SpecificDisease
dehydrogenase,2255,I-SpecificDisease
(,2255,I-SpecificDisease
G6PD,2255,I-SpecificDisease
),2255,I-SpecificDisease
deficiency,2255,I-SpecificDisease
in,2255,O
RBCs,2255,O
was,2255,O
found,2255,O
significantly,2255,O
more,2255,O
frequently,2255,O
in,2255,O
210,2255,O
male,2255,O
cataractous,2255,B-Modifier
patients,2255,O
than,2255,O
in,2255,O
672,2255,O
control,2255,O
subjects,2255,O
of,2255,O
Sardinian,2255,O
origin,2255,O
.,2255,O
The,2256,O
frequency,2256,O
of,2256,O
the,2256,O
deficiency,2256,O
was,2256,O
increasingly,2256,O
higher,2256,O
in,2256,O
presenile,2256,O
cataracts,2256,B-SpecificDisease
.,2256,O
In,2257,O
the,2257,O
G6PD-deficient,2257,B-Modifier
group,2257,O
",",2257,O
the,2257,O
incidence,2257,O
of,2257,O
cortical,2257,B-CompositeMention
and,2257,I-CompositeMention
total,2257,I-CompositeMention
cataracts,2257,I-CompositeMention
was,2257,O
also,2257,O
increased,2257,O
.,2257,O
It,2258,O
is,2258,O
suggested,2258,O
that,2258,O
decrease,2258,O
of,2258,O
the,2258,O
G6PD,2258,O
activity,2258,O
in,2258,O
the,2258,O
lens,2258,O
",",2258,O
which,2258,O
accompanies,2258,O
its,2258,O
deficiency,2258,O
in,2258,O
the,2258,O
erythrocyte,2258,O
",",2258,O
might,2258,O
play,2258,O
a,2258,O
role,2258,O
in,2258,O
the,2258,O
cataracto-genesis,2258,O
of,2258,O
these,2258,O
patients,2258,O
.,2258,O
Moreover,2259,O
",",2259,O
G6PD,2259,B-SpecificDisease
deficiency,2259,I-SpecificDisease
should,2259,O
be,2259,O
added,2259,O
to,2259,O
other,2259,O
conditions,2259,O
",",2259,O
such,2259,O
as,2259,O
the,2259,O
galactosemic,2259,B-Modifier
states,2259,O
and,2259,O
riboflavin,2259,B-SpecificDisease
deficiency,2259,I-SpecificDisease
",",2259,O
where,2259,O
cataracts,2259,B-SpecificDisease
represent,2259,O
a,2259,O
sensitive,2259,O
indicator,2259,O
of,2259,O
metabolic,2259,B-DiseaseClass
abnormalities,2259,I-DiseaseClass
of,2259,O
the,2259,O
RBC,2259,O
..,2259,O
Molecular,2260,O
basis,2260,O
of,2260,O
human,2260,O
mitochondrial,2260,O
very-long-chain,2260,B-SpecificDisease
acyl-CoA,2260,I-SpecificDisease
dehydrogenase,2260,I-SpecificDisease
deficiency,2260,I-SpecificDisease
causing,2260,O
cardiomyopathy,2260,B-SpecificDisease
and,2260,O
sudden,2260,B-SpecificDisease
death,2260,I-SpecificDisease
in,2260,O
childhood,2260,O
.,2260,O
beta-Oxidation,2261,O
of,2261,O
long-chain,2261,O
fatty,2261,O
acids,2261,O
provides,2261,O
the,2261,O
major,2261,O
source,2261,O
of,2261,O
energy,2261,O
in,2261,O
the,2261,O
heart,2261,O
.,2261,O
Defects,2262,O
in,2262,O
enzymes,2262,O
of,2262,O
the,2262,O
beta-oxidation,2262,O
pathway,2262,O
cause,2262,O
sudden,2262,B-SpecificDisease
",",2262,I-SpecificDisease
unexplained,2262,I-SpecificDisease
death,2262,I-SpecificDisease
in,2262,O
childhood,2262,O
",",2262,O
acute,2262,O
hepatic,2262,B-SpecificDisease
encephalopathy,2262,I-SpecificDisease
or,2262,O
liver,2262,B-SpecificDisease
failure,2262,I-SpecificDisease
",",2262,O
skeletal,2262,B-SpecificDisease
myopathy,2262,I-SpecificDisease
",",2262,O
and,2262,O
cardiomyopathy,2262,B-SpecificDisease
.,2262,O
Very-long-chain,2263,O
acyl-CoA,2263,O
dehydrogenase,2263,O
[,2263,O
VLCAD,2263,O
;,2263,O
very-long-chain-acyl-CoA,2263,O
(,2263,O
acceptor,2263,O
),2263,O
2,2263,O
",",2263,O
3-oxidoreductase,2263,O
",",2263,O
EC,2263,O
1,2263,O
.,2263,O
3,2264,O
3,2264,O
.,2264,O
99,2265,O
99,2265,O
.,2265,O
13,2266,O
],2266,O
catalyzes,2266,O
the,2266,O
first,2266,O
step,2266,O
in,2266,O
beta-oxidation,2266,O
.,2266,O
We,2267,O
have,2267,O
isolated,2267,O
the,2267,O
human,2267,O
VLCAD,2267,O
cDNA,2267,O
and,2267,O
gene,2267,O
and,2267,O
determined,2267,O
the,2267,O
complete,2267,O
nucleotide,2267,O
sequences,2267,O
.,2267,O
Polymerase,2268,O
chain,2268,O
reaction,2268,O
amplification,2268,O
of,2268,O
VLCAD,2268,O
mRNA,2268,O
and,2268,O
genomic,2268,O
exons,2268,O
defined,2268,O
the,2268,O
molecular,2268,O
defects,2268,O
in,2268,O
two,2268,O
patients,2268,O
with,2268,O
VLCAD,2268,B-SpecificDisease
deficiency,2268,I-SpecificDisease
who,2268,O
presented,2268,O
with,2268,O
unexplained,2268,O
cardiac,2268,B-SpecificDisease
arrest,2268,I-SpecificDisease
and,2268,O
cardiomyopathy,2268,B-SpecificDisease
.,2268,O
In,2269,O
one,2269,O
",",2269,O
a,2269,O
homozygous,2269,O
mutation,2269,O
in,2269,O
the,2269,O
consensus,2269,O
dinucleotide,2269,O
of,2269,O
the,2269,O
donor,2269,O
splice,2269,O
site,2269,O
(,2269,O
g,2269,O
+,2269,O
1,2269,O
--,2269,O
>,2269,O
a,2269,O
),2269,O
was,2269,O
associated,2269,O
with,2269,O
universal,2269,O
skipping,2269,O
of,2269,O
the,2269,O
prior,2269,O
exon,2269,O
(,2269,O
exon,2269,O
11,2269,O
),2269,O
.,2269,O
The,2270,O
second,2270,O
patient,2270,O
was,2270,O
a,2270,O
compound,2270,O
heterozygote,2270,O
",",2270,O
with,2270,O
a,2270,O
missense,2270,O
mutation,2270,O
",",2270,O
C1837,2270,O
--,2270,O
>,2270,O
T,2270,O
",",2270,O
changing,2270,O
the,2270,O
arginine,2270,O
at,2270,O
residue,2270,O
613,2270,O
to,2270,O
tryptophan,2270,O
on,2270,O
one,2270,O
allele,2270,O
and,2270,O
a,2270,O
single,2270,O
base,2270,O
deletion,2270,O
at,2270,O
the,2270,O
intron-exon,2270,O
6,2270,O
boundary,2270,O
as,2270,O
the,2270,O
second,2270,O
mutation,2270,O
.,2270,O
This,2271,O
initial,2271,O
delineation,2271,O
of,2271,O
human,2271,O
mutations,2271,O
in,2271,O
VLCAD,2271,O
suggests,2271,O
that,2271,O
VLCAD,2271,B-SpecificDisease
deficiency,2271,I-SpecificDisease
reduces,2271,O
myocardial,2271,O
fatty,2271,O
acid,2271,O
beta-oxidation,2271,O
and,2271,O
energy,2271,O
production,2271,O
and,2271,O
is,2271,O
associated,2271,O
with,2271,O
cardiomyopathy,2271,B-SpecificDisease
and,2271,O
sudden,2271,B-SpecificDisease
death,2271,I-SpecificDisease
in,2271,O
childhood,2271,O
.,2271,O
Aberrant,2272,O
subcellular,2272,O
localization,2272,O
of,2272,O
BRCA1,2272,O
in,2272,O
breast,2272,B-SpecificDisease
cancer,2272,I-SpecificDisease
.,2272,O
The,2273,O
BRCA1,2273,O
gene,2273,O
product,2273,O
was,2273,O
identified,2273,O
as,2273,O
a,2273,O
220-kilodalton,2273,O
nuclear,2273,O
phosphoprotein,2273,O
in,2273,O
normal,2273,O
cells,2273,O
",",2273,O
including,2273,O
breast,2273,O
ductal,2273,O
epithelial,2273,O
cells,2273,O
",",2273,O
and,2273,O
in,2273,O
18,2273,O
of,2273,O
20,2273,O
tumor,2273,B-Modifier
cell,2273,O
lines,2273,O
derived,2273,O
from,2273,O
tissues,2273,O
other,2273,O
than,2273,O
breast,2273,O
and,2273,O
ovary,2273,O
.,2273,O
In,2274,O
16,2274,O
of,2274,O
17,2274,O
breast,2274,O
and,2274,O
ovarian,2274,O
cancer,2274,O
lines,2274,O
and,2274,O
17,2274,O
of,2274,O
17,2274,O
samples,2274,O
of,2274,O
cells,2274,O
obtained,2274,O
from,2274,O
malignant,2274,O
effusions,2274,O
",",2274,O
however,2274,O
",",2274,O
BRCA1,2274,O
localized,2274,O
mainly,2274,O
in,2274,O
cytoplasm,2274,O
.,2274,O
Absence,2275,O
of,2275,O
BRCA1,2275,O
or,2275,O
aberrant,2275,O
subcellular,2275,O
location,2275,O
was,2275,O
also,2275,O
observed,2275,O
to,2275,O
a,2275,O
variable,2275,O
extent,2275,O
in,2275,O
histological,2275,O
sections,2275,O
of,2275,O
many,2275,O
breast,2275,B-Modifier
cancer,2275,I-Modifier
biopsies,2275,O
.,2275,O
These,2276,O
findings,2276,O
suggest,2276,O
that,2276,O
BRCA1,2276,B-DiseaseClass
abnormalities,2276,I-DiseaseClass
may,2276,O
be,2276,O
involved,2276,O
in,2276,O
the,2276,O
pathogenesis,2276,O
of,2276,O
many,2276,O
breast,2276,B-SpecificDisease
cancers,2276,I-SpecificDisease
",",2276,O
sporadic,2276,O
as,2276,O
well,2276,O
as,2276,O
familial,2276,O
..,2276,O
Mapping,2277,O
of,2277,O
the,2277,O
mouse,2277,O
homologue,2277,O
of,2277,O
the,2277,O
Wilson,2277,B-Modifier
disease,2277,I-Modifier
gene,2277,O
to,2277,O
mouse,2277,O
chromosome,2277,O
8,2277,O
.,2277,O
ATP7B,2278,O
",",2278,O
the,2278,O
gene,2278,O
altered,2278,O
in,2278,O
Wilson,2278,B-Modifier
disease,2278,I-Modifier
(,2278,O
WD,2278,B-Modifier
),2278,O
patients,2278,O
",",2278,O
lies,2278,O
in,2278,O
a,2278,O
block,2278,O
of,2278,O
homology,2278,O
shared,2278,O
between,2278,O
human,2278,O
chromosome,2278,O
13q14,2278,O
and,2278,O
the,2278,O
central,2278,O
region,2278,O
of,2278,O
mouse,2278,O
chromosome,2278,O
14,2278,O
.,2278,O
However,2279,O
",",2279,O
we,2279,O
have,2279,O
mapped,2279,O
the,2279,O
murine,2279,O
homologue,2279,O
of,2279,O
ATP7B,2279,O
(,2279,O
Atp7b,2279,O
),2279,O
to,2279,O
mouse,2279,O
chromosome,2279,O
8,2279,O
by,2279,O
somatic,2279,O
cell,2279,O
hybrid,2279,O
analysis,2279,O
.,2279,O
Analysis,2280,O
of,2280,O
80,2280,O
interspecific,2280,O
backcross,2280,O
offspring,2280,O
was,2280,O
used,2280,O
to,2280,O
position,2280,O
Atp7b,2280,O
close,2280,O
to,2280,O
D8Mit3,2280,O
and,2280,O
another,2280,O
ATPase,2280,O
locus,2280,O
",",2280,O
Atp4b,2280,O
",",2280,O
on,2280,O
mouse,2280,O
chromosome,2280,O
8,2280,O
.,2280,O
ATP4B,2281,O
lies,2281,O
in,2281,O
13q34,2281,O
and,2281,O
is,2281,O
separated,2281,O
from,2281,O
ATP7B,2281,O
by,2281,O
several,2281,O
loci,2281,O
whose,2281,O
mouse,2281,O
homologues,2281,O
map,2281,O
to,2281,O
mouse,2281,O
chromosome,2281,O
14,2281,O
.,2281,O
The,2282,O
assignment,2282,O
of,2282,O
Atp7b,2282,O
to,2282,O
mouse,2282,O
chromosome,2282,O
8,2282,O
identifies,2282,O
a,2282,O
previously,2282,O
unrecognized,2282,O
region,2282,O
of,2282,O
homology,2282,O
between,2282,O
this,2282,O
chromosome,2282,O
and,2282,O
human,2282,O
chromosome,2282,O
13,2282,O
.,2282,O
This,2283,O
assignment,2283,O
suggests,2283,O
a,2283,O
possible,2283,O
location,2283,O
for,2283,O
the,2283,O
toxic,2283,O
milk,2283,O
mutation,2283,O
in,2283,O
the,2283,O
mouse,2283,O
",",2283,O
which,2283,O
has,2283,O
been,2283,O
proposed,2283,O
as,2283,O
a,2283,O
homologue,2283,O
of,2283,O
WD,2283,B-SpecificDisease
..,2283,O
Germline,2284,O
mutations,2284,O
of,2284,O
the,2284,O
BRCA1,2284,O
gene,2284,O
in,2284,O
breast,2284,B-Modifier
and,2284,I-Modifier
ovarian,2284,I-Modifier
cancer,2284,I-Modifier
families,2284,O
provide,2284,O
evidence,2284,O
for,2284,O
a,2284,O
genotype-phenotype,2284,O
correlation,2284,O
.,2284,O
Mutations,2285,O
in,2285,O
the,2285,O
BRCA1,2285,O
gene,2285,O
",",2285,O
discovered,2285,O
in,2285,O
1994,2285,O
",",2285,O
are,2285,O
associated,2285,O
with,2285,O
an,2285,O
80-90,2285,O
%,2285,O
lifetime,2285,O
risk,2285,O
of,2285,O
breast,2285,B-SpecificDisease
cancer,2285,I-SpecificDisease
.,2285,O
We,2286,O
have,2286,O
analysed,2286,O
60,2286,O
families,2286,O
with,2286,O
a,2286,O
history,2286,O
of,2286,O
breast,2286,B-CompositeMention
and/or,2286,I-CompositeMention
ovarian,2286,I-CompositeMention
cancer,2286,I-CompositeMention
for,2286,O
germline,2286,O
mutations,2286,O
in,2286,O
BRCA1,2286,O
.,2286,O
Twenty-two,2287,O
different,2287,O
mutations,2287,O
were,2287,O
detected,2287,O
in,2287,O
32,2287,O
families,2287,O
(,2287,O
53,2287,O
%,2287,O
),2287,O
",",2287,O
of,2287,O
which,2287,O
14,2287,O
are,2287,O
previously,2287,O
unreported,2287,O
.,2287,O
We,2288,O
observed,2288,O
a,2288,O
significant,2288,O
correlation,2288,O
between,2288,O
the,2288,O
location,2288,O
of,2288,O
the,2288,O
mutation,2288,O
in,2288,O
the,2288,O
gene,2288,O
and,2288,O
the,2288,O
ratio,2288,O
of,2288,O
breast,2288,O
to,2288,O
ovarian,2288,O
cancer,2288,O
incidence,2288,O
within,2288,O
each,2288,O
family,2288,O
.,2288,O
Our,2289,O
data,2289,O
suggest,2289,O
a,2289,O
transition,2289,O
in,2289,O
risk,2289,O
such,2289,O
that,2289,O
mutations,2289,O
in,2289,O
the,2289,O
3,2289,O
third,2289,O
of,2289,O
the,2289,O
gene,2289,O
are,2289,O
associated,2289,O
with,2289,O
a,2289,O
lower,2289,O
proportion,2289,O
of,2289,O
ovarian,2289,B-SpecificDisease
cancer,2289,I-SpecificDisease
.,2289,O
Haplotype,2290,O
analysis,2290,O
supports,2290,O
previous,2290,O
data,2290,O
which,2290,O
suggest,2290,O
some,2290,O
BRCA1,2290,O
mutation,2290,O
carriers,2290,O
have,2290,O
common,2290,O
ancestors,2290,O
;,2290,O
however,2290,O
",",2290,O
we,2290,O
have,2290,O
found,2290,O
at,2290,O
least,2290,O
two,2290,O
examples,2290,O
where,2290,O
recurrent,2290,O
mutations,2290,O
appear,2290,O
to,2290,O
have,2290,O
arisen,2290,O
independently,2290,O
..,2290,O
Hereditary,2291,O
deficiency,2291,B-SpecificDisease
of,2291,I-SpecificDisease
the,2291,I-SpecificDisease
seventh,2291,I-SpecificDisease
component,2291,I-SpecificDisease
of,2291,I-SpecificDisease
complement,2291,I-SpecificDisease
and,2291,O
recurrent,2291,O
meningococcal,2291,B-SpecificDisease
infection,2291,I-SpecificDisease
:,2291,O
investigations,2291,O
of,2291,O
an,2291,O
Irish,2291,O
family,2291,O
using,2291,O
a,2291,O
novel,2291,O
haemolytic,2291,O
screening,2291,O
assay,2291,O
for,2291,O
complement,2291,O
activity,2291,O
and,2291,O
C7,2291,O
M/N,2291,O
allotyping,2291,O
.,2291,O
Terminal,2292,B-SpecificDisease
complement,2292,I-SpecificDisease
component,2292,I-SpecificDisease
deficiency,2292,I-SpecificDisease
predisposes,2292,O
to,2292,O
meningococcal,2292,B-SpecificDisease
infection,2292,I-SpecificDisease
and,2292,O
is,2292,O
inherited,2292,O
in,2292,O
an,2292,O
autosomal,2292,O
co-dominant,2292,O
manner,2292,O
.,2292,O
An,2293,O
Irish,2293,O
family,2293,O
is,2293,O
described,2293,O
",",2293,O
in,2293,O
which,2293,O
2,2293,O
of,2293,O
3,2293,O
brothers,2293,O
had,2293,O
recurrent,2293,O
meningococcal,2293,B-SpecificDisease
infection,2293,I-SpecificDisease
.,2293,O
A,2294,O
novel,2294,O
screening,2294,O
assay,2294,O
was,2294,O
used,2294,O
to,2294,O
investigate,2294,O
for,2294,O
terminal,2294,B-SpecificDisease
complement,2294,I-SpecificDisease
deficiency,2294,I-SpecificDisease
and,2294,O
the,2294,O
2,2294,O
affected,2294,O
brothers,2294,O
were,2294,O
found,2294,O
to,2294,O
be,2294,O
completely,2294,B-SpecificDisease
deficient,2294,I-SpecificDisease
in,2294,I-SpecificDisease
the,2294,I-SpecificDisease
seventh,2294,I-SpecificDisease
component,2294,I-SpecificDisease
of,2294,I-SpecificDisease
complement,2294,I-SpecificDisease
(,2294,O
C7,2294,O
),2294,O
.,2294,O
Enzyme-linked,2295,O
immunosorbent,2295,O
assay,2295,O
for,2295,O
C7,2295,O
revealed,2295,O
lower,2295,O
than,2295,O
normal,2295,O
levels,2295,O
in,2295,O
the,2295,O
remaining,2295,O
brother,2295,O
and,2295,O
parents,2295,O
.,2295,O
C7,2296,O
M/N,2296,O
protein,2296,O
polymorphism,2296,O
allotyping,2296,O
",",2296,O
used,2296,O
to,2296,O
investigate,2296,O
the,2296,O
segregation,2296,O
of,2296,O
the,2296,O
C7,2296,B-Modifier
deficiency,2296,I-Modifier
genes,2296,O
",",2296,O
showed,2296,O
that,2296,O
the,2296,O
apparently,2296,O
complement,2296,O
sufficient,2296,O
brother,2296,O
was,2296,O
heterozygous,2296,O
C7,2296,B-SpecificDisease
deficient,2296,I-SpecificDisease
and,2296,O
a,2296,O
carrier,2296,O
of,2296,O
one,2296,O
of,2296,O
the,2296,O
deficiency,2296,O
genes,2296,O
.,2296,O
Complement,2297,O
screening,2297,O
should,2297,O
be,2297,O
carried,2297,O
out,2297,O
in,2297,O
any,2297,O
individual,2297,O
suffering,2297,O
recurrent,2297,O
meningococcal,2297,B-SpecificDisease
infection,2297,I-SpecificDisease
or,2297,O
infection,2297,O
with,2297,O
an,2297,O
uncommon,2297,O
meningococcal,2297,B-Modifier
serogroup,2297,O
.,2297,O
Identification,2298,O
of,2298,O
complement,2298,B-Modifier
deficient,2298,I-Modifier
patients,2298,O
allows,2298,O
the,2298,O
implementation,2298,O
of,2298,O
strategies,2298,O
to,2298,O
prevent,2298,O
recurrent,2298,O
infection,2298,O
..,2298,O
Molecular,2299,O
basis,2299,O
of,2299,O
subtotal,2299,B-SpecificDisease
complement,2299,I-SpecificDisease
C6,2299,I-SpecificDisease
deficiency,2299,I-SpecificDisease
.,2299,O
A,2300,O
carboxy-terminally,2300,O
truncated,2300,O
but,2300,O
functionally,2300,O
active,2300,O
C6,2300,O
.,2300,O
Individuals,2301,O
with,2301,O
subtotal,2301,B-SpecificDisease
complement,2301,I-SpecificDisease
C6,2301,I-SpecificDisease
deficiency,2301,I-SpecificDisease
possess,2301,O
a,2301,O
C6,2301,O
molecule,2301,O
that,2301,O
is,2301,O
14,2301,O
%,2301,O
shorter,2301,O
than,2301,O
normal,2301,O
C6,2301,O
and,2301,O
present,2301,O
in,2301,O
low,2301,O
but,2301,O
detectable,2301,O
concentrations,2301,O
(,2301,O
1-2,2301,O
%,2301,O
of,2301,O
the,2301,O
normal,2301,O
mean,2301,O
),2301,O
.,2301,O
We,2302,O
now,2302,O
show,2302,O
that,2302,O
this,2302,O
dysmorphic,2302,O
C6,2302,O
is,2302,O
bactericidally,2302,O
active,2302,O
and,2302,O
lacks,2302,O
an,2302,O
epitope,2302,O
that,2302,O
was,2302,O
mapped,2302,O
to,2302,O
the,2302,O
most,2302,O
carboxy-terminal,2302,O
part,2302,O
of,2302,O
C6,2302,O
using,2302,O
C6,2302,O
cDNA,2302,O
fragments,2302,O
expressed,2302,O
as,2302,O
fusion,2302,O
proteins,2302,O
in,2302,O
the,2302,O
pUEX,2302,O
expression,2302,O
system,2302,O
.,2302,O
We,2303,O
thus,2303,O
predicted,2303,O
that,2303,O
the,2303,O
abnormal,2303,O
C6,2303,O
molecule,2303,O
might,2303,O
be,2303,O
carboxy-terminally,2303,O
truncated,2303,O
and,2303,O
sought,2303,O
a,2303,O
mutation,2303,O
in,2303,O
an,2303,O
area,2303,O
approximately,2303,O
14,2303,O
%,2303,O
from,2303,O
the,2303,O
carboxy-terminal,2303,O
end,2303,O
of,2303,O
the,2303,O
coding,2303,O
sequence,2303,O
.,2303,O
By,2304,O
sequencing,2304,O
PCR-amplified,2304,O
products,2304,O
from,2304,O
this,2304,O
region,2304,O
",",2304,O
we,2304,O
found,2304,O
",",2304,O
in,2304,O
three,2304,O
individuals,2304,O
from,2304,O
two,2304,O
families,2304,O
",",2304,O
a,2304,O
mutation,2304,O
that,2304,O
might,2304,O
plausibly,2304,O
be,2304,O
responsible,2304,O
for,2304,O
the,2304,O
defect,2304,O
.,2304,O
All,2305,O
three,2305,O
have,2305,O
an,2305,O
abnormal,2305,O
5,2305,O
splice,2305,O
donor,2305,O
site,2305,O
of,2305,O
intron,2305,O
15,2305,O
",",2305,O
which,2305,O
would,2305,O
probably,2305,O
prevent,2305,O
splicing,2305,O
.,2305,O
An,2306,O
in-frame,2306,O
stop,2306,O
codon,2306,O
is,2306,O
found,2306,O
17,2306,O
codons,2306,O
downstream,2306,O
from,2306,O
the,2306,O
intron,2306,O
boundary,2306,O
",",2306,O
which,2306,O
would,2306,O
lead,2306,O
to,2306,O
a,2306,O
truncated,2306,O
polypeptide,2306,O
13,2306,O
.,2306,O
5,2307,O
%,2307,O
smaller,2307,O
than,2307,O
normal,2307,O
C6,2307,O
.,2307,O
This,2308,O
result,2308,O
was,2308,O
unexpected,2308,O
",",2308,O
as,2308,O
earlier,2308,O
studies,2308,O
mapped,2308,O
the,2308,O
C5b,2308,O
binding,2308,O
site,2308,O
",",2308,O
or,2308,O
a,2308,O
putative,2308,O
enzymatic,2308,O
region,2308,O
",",2308,O
to,2308,O
this,2308,O
part,2308,O
of,2308,O
C6,2308,O
.,2308,O
Interestingly,2309,O
",",2309,O
all,2309,O
three,2309,O
subjects,2309,O
were,2309,O
probably,2309,O
heterozygous,2309,O
for,2309,O
both,2309,O
subtotal,2309,B-CompositeMention
C6,2309,I-CompositeMention
and,2309,I-CompositeMention
complete,2309,I-CompositeMention
C6,2309,I-CompositeMention
deficiency,2309,I-CompositeMention
.,2309,O
Myotonic,2310,B-SpecificDisease
dystrophy,2310,I-SpecificDisease
:,2310,O
evidence,2310,O
for,2310,O
a,2310,O
possible,2310,O
dominant-negative,2310,O
RNA,2310,O
mutation,2310,O
.,2310,O
The,2311,O
trinucleotide,2311,O
expansion,2311,O
mutation,2311,O
causing,2311,O
myotonic,2311,B-SpecificDisease
dystrophy,2311,I-SpecificDisease
is,2311,O
in,2311,O
the,2311,O
3,2311,O
untranslated,2311,O
region,2311,O
of,2311,O
a,2311,O
protein,2311,O
kinase,2311,O
gene,2311,O
.,2311,O
The,2312,O
molecular,2312,O
mechanisms,2312,O
by,2312,O
which,2312,O
the,2312,O
expanded,2312,O
repeat,2312,O
causes,2312,O
the,2312,O
clinically,2312,O
variable,2312,O
and,2312,O
multisystemic,2312,B-DiseaseClass
disease,2312,I-DiseaseClass
",",2312,O
myotonic,2312,B-SpecificDisease
dystrophy,2312,I-SpecificDisease
",",2312,O
are,2312,O
not,2312,O
understood,2312,O
.,2312,O
It,2313,O
has,2313,O
been,2313,O
particularly,2313,O
difficult,2313,O
to,2313,O
rationalize,2313,O
the,2313,O
dominant,2313,O
inheritance,2313,O
with,2313,O
the,2313,O
fact,2313,O
that,2313,O
the,2313,O
expansion,2313,O
mutation,2313,O
lies,2313,O
outside,2313,O
of,2313,O
the,2313,O
protein-encoding,2313,O
gene,2313,O
elements,2313,O
",",2313,O
and,2313,O
should,2313,O
not,2313,O
be,2313,O
translated,2313,O
into,2313,O
protein,2313,O
.,2313,O
Here,2314,O
we,2314,O
use,2314,O
muscle,2314,O
biopsies,2314,O
from,2314,O
classical,2314,O
adult-onset,2314,O
myotonic,2314,B-Modifier
dystrophy,2314,I-Modifier
patients,2314,O
to,2314,O
study,2314,O
the,2314,O
accumulation,2314,O
of,2314,O
transcripts,2314,O
from,2314,O
both,2314,O
the,2314,O
normal,2314,O
and,2314,O
expanded,2314,O
DM,2314,B-Modifier
kinase,2314,O
genes,2314,O
in,2314,O
patient,2314,O
muscle,2314,O
",",2314,O
and,2314,O
compare,2314,O
the,2314,O
results,2314,O
to,2314,O
normal,2314,O
and,2314,O
myopathic,2314,B-Modifier
controls,2314,O
.,2314,O
We,2315,O
found,2315,O
relatively,2315,O
small,2315,O
decreases,2315,O
of,2315,O
DM,2315,B-Modifier
kinase,2315,O
RNA,2315,O
in,2315,O
the,2315,O
total,2315,O
RNA,2315,O
pool,2315,O
from,2315,O
muscle,2315,O
;,2315,O
however,2315,O
",",2315,O
these,2315,O
reductions,2315,O
were,2315,O
not,2315,O
disease,2315,O
specific,2315,O
.,2315,O
Analysis,2316,O
of,2316,O
poly,2316,O
(,2316,O
A,2316,O
),2316,O
+,2316,O
RNA,2316,O
showed,2316,O
dramatic,2316,O
decreases,2316,O
of,2316,O
both,2316,O
the,2316,O
mutant,2316,O
and,2316,O
normal,2316,O
DM,2316,B-Modifier
kinase,2316,O
RNAs,2316,O
",",2316,O
and,2316,O
these,2316,O
changes,2316,O
were,2316,O
disease-specific,2316,O
.,2316,O
Our,2317,O
findings,2317,O
are,2317,O
consistent,2317,O
with,2317,O
a,2317,O
novel,2317,O
molecular,2317,O
pathogenetic,2317,O
mechanism,2317,O
for,2317,O
myotonic,2317,B-SpecificDisease
dystrophy,2317,I-SpecificDisease
both,2317,O
the,2317,O
normal,2317,O
and,2317,O
expanded,2317,O
DM,2317,B-Modifier
kinase,2317,O
genes,2317,O
are,2317,O
transcribed,2317,O
in,2317,O
patient,2317,O
muscle,2317,O
",",2317,O
but,2317,O
the,2317,O
abnormal,2317,O
expansion-containing,2317,O
RNA,2317,O
has,2317,O
a,2317,O
dominant,2317,O
effect,2317,O
on,2317,O
RNA,2317,O
metabolism,2317,O
by,2317,O
preventing,2317,O
the,2317,O
accumulation,2317,O
of,2317,O
poly,2317,O
(,2317,O
A,2317,O
),2317,O
+,2317,O
RNA,2317,O
.,2317,O
The,2318,O
ability,2318,O
of,2318,O
the,2318,O
expansion,2318,O
mutation,2318,O
to,2318,O
alter,2318,O
accumulation,2318,O
of,2318,O
poly,2318,O
(,2318,O
A,2318,O
),2318,O
+,2318,O
RNA,2318,O
in,2318,O
trans,2318,O
suggests,2318,O
that,2318,O
myotonic,2318,B-SpecificDisease
dystrophy,2318,I-SpecificDisease
may,2318,O
be,2318,O
the,2318,O
first,2318,O
example,2318,O
of,2318,O
a,2318,O
dominant-negative,2318,O
mutation,2318,O
manifested,2318,O
at,2318,O
the,2318,O
RNA,2318,O
level,2318,O
..,2318,O
A,2319,O
strong,2319,O
candidate,2319,O
for,2319,O
the,2319,O
breast,2319,B-Modifier
and,2319,I-Modifier
ovarian,2319,I-Modifier
cancer,2319,I-Modifier
susceptibility,2319,O
gene,2319,O
BRCA1,2319,O
.,2319,O
A,2320,O
strong,2320,O
candidate,2320,O
for,2320,O
the,2320,O
17q-linked,2320,O
BRCA1,2320,O
gene,2320,O
",",2320,O
which,2320,O
influences,2320,O
susceptibility,2320,O
to,2320,O
breast,2320,B-CompositeMention
and,2320,I-CompositeMention
ovarian,2320,I-CompositeMention
cancer,2320,I-CompositeMention
",",2320,O
has,2320,O
been,2320,O
identified,2320,O
by,2320,O
positional,2320,O
cloning,2320,O
methods,2320,O
.,2320,O
Probable,2321,O
predisposing,2321,O
mutations,2321,O
have,2321,O
been,2321,O
detected,2321,O
in,2321,O
five,2321,O
of,2321,O
eight,2321,O
kindreds,2321,O
presumed,2321,O
to,2321,O
segregate,2321,O
BRCA1,2321,O
susceptibility,2321,O
alleles,2321,O
.,2321,O
The,2322,O
mutations,2322,O
include,2322,O
an,2322,O
11-base,2322,O
pair,2322,O
deletion,2322,O
",",2322,O
a,2322,O
1-base,2322,O
pair,2322,O
insertion,2322,O
",",2322,O
a,2322,O
stop,2322,O
codon,2322,O
",",2322,O
a,2322,O
missense,2322,O
substitution,2322,O
",",2322,O
and,2322,O
an,2322,O
inferred,2322,O
regulatory,2322,O
mutation,2322,O
.,2322,O
The,2323,O
BRCA1,2323,O
gene,2323,O
is,2323,O
expressed,2323,O
in,2323,O
numerous,2323,O
tissues,2323,O
",",2323,O
including,2323,O
breast,2323,O
and,2323,O
ovary,2323,O
",",2323,O
and,2323,O
encodes,2323,O
a,2323,O
predicted,2323,O
protein,2323,O
of,2323,O
1863,2323,O
amino,2323,O
acids,2323,O
.,2323,O
This,2324,O
protein,2324,O
contains,2324,O
a,2324,O
zinc,2324,O
finger,2324,O
domain,2324,O
in,2324,O
its,2324,O
amino-terminal,2324,O
region,2324,O
",",2324,O
but,2324,O
is,2324,O
otherwise,2324,O
unrelated,2324,O
to,2324,O
previously,2324,O
described,2324,O
proteins,2324,O
.,2324,O
Identification,2325,O
of,2325,O
BRCA1,2325,O
should,2325,O
facilitate,2325,O
early,2325,O
diagnosis,2325,O
of,2325,O
breast,2325,B-Modifier
and,2325,I-Modifier
ovarian,2325,I-Modifier
cancer,2325,I-Modifier
susceptibility,2325,O
in,2325,O
some,2325,O
individuals,2325,O
as,2325,O
well,2325,O
as,2325,O
a,2325,O
better,2325,O
understanding,2325,O
of,2325,O
breast,2325,B-Modifier
cancer,2325,I-Modifier
biology,2325,O
..,2325,O
Molecular,2326,O
characterization,2326,O
of,2326,O
galactosemia,2326,B-Modifier
(,2326,O
type,2326,O
1,2326,O
),2326,O
mutations,2326,O
in,2326,O
Japanese,2326,O
.,2326,O
We,2327,O
characterized,2327,O
two,2327,O
novel,2327,O
mutations,2327,O
of,2327,O
the,2327,O
galactose-1-phosphate,2327,O
uridyltransferase,2327,O
(,2327,O
GALT,2327,O
),2327,O
gene,2327,O
in,2327,O
two,2327,O
Japanese,2327,O
patients,2327,O
with,2327,O
GALT,2327,B-SpecificDisease
deficiency,2327,I-SpecificDisease
and,2327,O
identified,2327,O
N314D,2327,O
and,2327,O
R333W,2327,O
mutations,2327,O
",",2327,O
previously,2327,O
found,2327,O
in,2327,O
Caucasians,2327,O
.,2327,O
One,2328,O
novel,2328,O
missense,2328,O
mutation,2328,O
was,2328,O
an,2328,O
G-to-A,2328,O
transition,2328,O
in,2328,O
exon,2328,O
8,2328,O
",",2328,O
resulting,2328,O
in,2328,O
the,2328,O
substitution,2328,O
of,2328,O
arginine,2328,O
by,2328,O
histidine,2328,O
at,2328,O
the,2328,O
codon,2328,O
231,2328,O
(,2328,O
R231H,2328,O
),2328,O
.,2328,O
GALT,2329,O
activity,2329,O
of,2329,O
the,2329,O
R231H,2329,O
mutant,2329,O
construct,2329,O
was,2329,O
reduced,2329,O
to,2329,O
15,2329,O
%,2329,O
of,2329,O
normal,2329,O
controls,2329,O
in,2329,O
a,2329,O
COS,2329,O
cell,2329,O
expression,2329,O
system,2329,O
.,2329,O
The,2330,O
other,2330,O
was,2330,O
a,2330,O
splicing,2330,O
mutation,2330,O
",",2330,O
an,2330,O
A-to-G,2330,O
transition,2330,O
at,2330,O
the,2330,O
38th,2330,O
nucleotide,2330,O
in,2330,O
exon,2330,O
3,2330,O
(,2330,O
318A,2330,O
--,2330,O
>,2330,O
G,2330,O
),2330,O
",",2330,O
resulting,2330,O
in,2330,O
a,2330,O
38-bp,2330,O
deletion,2330,O
in,2330,O
the,2330,O
GALT,2330,O
cDNA,2330,O
by,2330,O
activating,2330,O
a,2330,O
cryptic,2330,O
splice,2330,O
acceptor,2330,O
site,2330,O
.,2330,O
In,2331,O
seven,2331,O
Japanese,2331,O
families,2331,O
(,2331,O
14,2331,O
alleles,2331,O
for,2331,O
classic,2331,O
form,2331,O
and,2331,O
one,2331,O
allele,2331,O
for,2331,O
Duarte,2331,O
variant,2331,O
),2331,O
with,2331,O
GALT,2331,B-SpecificDisease
deficiency,2331,I-SpecificDisease
",",2331,O
the,2331,O
R231H,2331,O
and,2331,O
318A,2331,O
--,2331,O
>,2331,O
G,2331,O
mutations,2331,O
were,2331,O
found,2331,O
only,2331,O
on,2331,O
both,2331,O
alleles,2331,O
of,2331,O
the,2331,O
proband,2331,O
.,2331,O
The,2332,O
N314D,2332,O
and,2332,O
R333W,2332,O
mutations,2332,O
were,2332,O
found,2332,O
on,2332,O
one,2332,O
allele,2332,O
each,2332,O
.,2332,O
The,2333,O
Q188R,2333,O
was,2333,O
prevalent,2333,O
in,2333,O
the,2333,O
United,2333,O
States,2333,O
but,2333,O
not,2333,O
in,2333,O
Japanese,2333,O
patients,2333,O
.,2333,O
The,2334,O
N314D,2334,O
mutation,2334,O
was,2334,O
associated,2334,O
with,2334,O
the,2334,O
Duarte,2334,O
variant,2334,O
in,2334,O
Japanese,2334,O
persons,2334,O
",",2334,O
as,2334,O
well,2334,O
as,2334,O
in,2334,O
the,2334,O
United,2334,O
States,2334,O
.,2334,O
We,2335,O
speculate,2335,O
that,2335,O
classic,2335,B-Modifier
galactosemia,2335,I-Modifier
mutations,2335,O
appear,2335,O
to,2335,O
differ,2335,O
between,2335,O
Japanese,2335,O
and,2335,O
Caucasian,2335,O
patients,2335,O
.,2335,O
Our,2336,O
limited,2336,O
data,2336,O
set,2336,O
on,2336,O
galactosemia,2336,B-Modifier
mutations,2336,O
in,2336,O
Japanese,2336,O
suggests,2336,O
that,2336,O
the,2336,O
N314D,2336,O
GALT,2336,O
mutation,2336,O
encoding,2336,O
the,2336,O
Duarte,2336,O
variant,2336,O
arose,2336,O
before,2336,O
Asian,2336,O
and,2336,O
Caucasian,2336,O
people,2336,O
diverged,2336,O
and,2336,O
that,2336,O
classic,2336,B-Modifier
galactosemia,2336,I-Modifier
mutations,2336,O
arose,2336,O
and/or,2336,O
accumulated,2336,O
after,2336,O
the,2336,O
divergence,2336,O
of,2336,O
Asian,2336,O
and,2336,O
Caucasian,2336,O
populations,2336,O
..,2336,O
Three,2337,O
novel,2337,O
aniridia,2337,B-Modifier
mutations,2337,O
in,2337,O
the,2337,O
human,2337,O
PAX6,2337,O
gene,2337,O
.,2337,O
Aniridia,2338,B-SpecificDisease
(,2338,O
iris,2338,B-SpecificDisease
hypoplasia,2338,I-SpecificDisease
),2338,O
is,2338,O
an,2338,O
autosomal,2338,B-DiseaseClass
dominant,2338,I-DiseaseClass
congenital,2338,I-DiseaseClass
disorder,2338,I-DiseaseClass
of,2338,I-DiseaseClass
the,2338,I-DiseaseClass
eye,2338,I-DiseaseClass
.,2338,O
Mutations,2339,O
in,2339,O
the,2339,O
human,2339,O
aniridia,2339,B-Modifier
(,2339,O
PAX6,2339,O
),2339,O
gene,2339,O
have,2339,O
now,2339,O
been,2339,O
identified,2339,O
in,2339,O
many,2339,O
patients,2339,O
from,2339,O
various,2339,O
ethnic,2339,O
groups,2339,O
.,2339,O
In,2340,O
the,2340,O
study,2340,O
reported,2340,O
here,2340,O
we,2340,O
describe,2340,O
PAX6,2340,O
mutations,2340,O
in,2340,O
one,2340,O
sporadic,2340,O
and,2340,O
five,2340,O
familial,2340,O
cases,2340,O
with,2340,O
aniridia,2340,B-SpecificDisease
.,2340,O
Of,2341,O
the,2341,O
four,2341,O
different,2341,O
mutations,2341,O
identified,2341,O
",",2341,O
one,2341,O
was,2341,O
identical,2341,O
to,2341,O
a,2341,O
previously,2341,O
reported,2341,O
mutation,2341,O
(,2341,O
C,2341,O
--,2341,O
>,2341,O
T,2341,O
transition,2341,O
at,2341,O
codon,2341,O
240,2341,O
),2341,O
",",2341,O
and,2341,O
three,2341,O
were,2341,O
novel,2341,O
two,2341,O
in,2341,O
the,2341,O
glycine-rich,2341,O
region,2341,O
and,2341,O
one,2341,O
in,2341,O
the,2341,O
proline/serine/threonine-rich,2341,O
(,2341,O
PST,2341,O
),2341,O
region,2341,O
.,2341,O
One,2342,O
PAX6,2342,O
mutation,2342,O
found,2342,O
in,2342,O
the,2342,O
PST,2342,O
region,2342,O
was,2342,O
associated,2342,O
with,2342,O
cataracts,2342,B-SpecificDisease
in,2342,O
an,2342,O
aniridia,2342,B-Modifier
family,2342,O
.,2342,O
Another,2343,O
splice,2343,O
mutation,2343,O
in,2343,O
the,2343,O
PST,2343,O
domain,2343,O
occurred,2343,O
in,2343,O
an,2343,O
aniridia,2343,B-Modifier
patient,2343,O
with,2343,O
anosmia,2343,B-SpecificDisease
(,2343,O
inability,2343,O
to,2343,O
smell,2343,O
),2343,O
.,2343,O
The,2344,O
six,2344,O
new,2344,O
aniridia,2344,B-Modifier
cases,2344,O
reported,2344,O
here,2344,O
have,2344,O
mutations,2344,O
predicted,2344,O
to,2344,O
generate,2344,O
incomplete,2344,O
PAX6,2344,O
proteins,2344,O
.,2344,O
These,2345,O
results,2345,O
support,2345,O
the,2345,O
theory,2345,O
that,2345,O
human,2345,O
aniridia,2345,B-SpecificDisease
is,2345,O
caused,2345,O
by,2345,O
haploinsufficiency,2345,B-SpecificDisease
of,2345,I-SpecificDisease
PAX6,2345,I-SpecificDisease
..,2345,O
The,2346,O
carrier,2346,O
frequency,2346,O
of,2346,O
the,2346,O
BRCA1,2346,O
185delAG,2346,O
mutation,2346,O
is,2346,O
approximately,2346,O
1,2346,O
percent,2346,O
in,2346,O
Ashkenazi,2346,O
Jewish,2346,O
individuals,2346,O
.,2346,O
Since,2347,O
BRCA1,2347,O
",",2347,O
the,2347,O
first,2347,O
major,2347,O
gene,2347,O
responsible,2347,O
for,2347,O
inherited,2347,B-SpecificDisease
breast,2347,I-SpecificDisease
cancer,2347,I-SpecificDisease
",",2347,O
was,2347,O
cloned,2347,O
",",2347,O
more,2347,O
than,2347,O
50,2347,O
unique,2347,O
mutations,2347,O
have,2347,O
been,2347,O
detected,2347,O
in,2347,O
the,2347,O
germline,2347,O
of,2347,O
individuals,2347,O
with,2347,O
breast,2347,B-CompositeMention
and,2347,I-CompositeMention
ovarian,2347,I-CompositeMention
cancer,2347,I-CompositeMention
.,2347,O
In,2348,O
high-risk,2348,O
pedigrees,2348,O
",",2348,O
female,2348,O
carriers,2348,O
of,2348,O
BRCA1,2348,O
mutations,2348,O
have,2348,O
an,2348,O
80-90,2348,O
%,2348,O
lifetime,2348,O
risk,2348,O
of,2348,O
breast,2348,B-SpecificDisease
cancer,2348,I-SpecificDisease
",",2348,O
and,2348,O
a,2348,O
40-50,2348,O
%,2348,O
risk,2348,O
of,2348,O
ovarian,2348,B-SpecificDisease
cancer,2348,I-SpecificDisease
.,2348,O
However,2349,O
",",2349,O
the,2349,O
mutation,2349,O
stats,2349,O
of,2349,O
individuals,2349,O
unselected,2349,O
for,2349,O
breast,2349,O
or,2349,O
ovarian,2349,O
cancer,2349,O
has,2349,O
not,2349,O
been,2349,O
determined,2349,O
",",2349,O
and,2349,O
it,2349,O
is,2349,O
not,2349,O
known,2349,O
whether,2349,O
mutations,2349,O
in,2349,O
such,2349,O
individuals,2349,O
confer,2349,O
the,2349,O
same,2349,O
risk,2349,O
of,2349,O
cancer,2349,B-DiseaseClass
as,2349,O
in,2349,O
individuals,2349,O
from,2349,O
the,2349,O
high-risk,2349,O
families,2349,O
studied,2349,O
so,2349,O
far,2349,O
.,2349,O
Following,2350,O
the,2350,O
finding,2350,O
of,2350,O
a,2350,O
185delAG,2350,O
frameshift,2350,O
mutation,2350,O
in,2350,O
several,2350,O
Ashkenazi,2350,O
Jewish,2350,O
breast/ovarian,2350,O
families,2350,O
",",2350,O
we,2350,O
have,2350,O
determined,2350,O
the,2350,O
frequency,2350,O
of,2350,O
this,2350,O
mutation,2350,O
in,2350,O
858,2350,O
Ashkenazim,2350,O
seeking,2350,O
genetic,2350,O
testing,2350,O
for,2350,O
conditions,2350,O
unrelated,2350,O
to,2350,O
cancer,2350,B-DiseaseClass
",",2350,O
and,2350,O
in,2350,O
815,2350,O
reference,2350,O
individuals,2350,O
not,2350,O
selected,2350,O
for,2350,O
ethnic,2350,O
origin,2350,O
.,2350,O
We,2351,O
observed,2351,O
the,2351,O
185delAG,2351,O
mutation,2351,O
in,2351,O
0,2351,O
.,2351,O
9,2352,O
%,2352,O
of,2352,O
Ashkenazim,2352,O
(,2352,O
95,2352,O
%,2352,O
confidence,2352,O
limit,2352,O
",",2352,O
0,2352,O
.,2352,O
4-1,2353,O
.,2353,O
8,2354,O
%,2354,O
),2354,O
and,2354,O
in,2354,O
none,2354,O
of,2354,O
the,2354,O
reference,2354,O
samples,2354,O
.,2354,O
Our,2355,O
results,2355,O
suggest,2355,O
that,2355,O
one,2355,O
in,2355,O
a,2355,O
hundred,2355,O
women,2355,O
of,2355,O
Ashkenazi,2355,O
descent,2355,O
may,2355,O
be,2355,O
at,2355,O
especially,2355,O
high,2355,O
risk,2355,O
of,2355,O
developing,2355,O
breast,2355,O
and/or,2355,O
ovarian,2355,O
cancer,2355,O
.,2355,O
Identification,2356,O
and,2356,O
localization,2356,O
of,2356,O
huntingtin,2356,O
in,2356,O
brain,2356,O
and,2356,O
human,2356,O
lymphoblastoid,2356,O
cell,2356,O
lines,2356,O
with,2356,O
anti-fusion,2356,O
protein,2356,O
antibodies,2356,O
.,2356,O
The,2357,O
Huntington,2357,B-Modifier
disease,2357,I-Modifier
(,2357,O
HD,2357,B-Modifier
),2357,O
phenotype,2357,O
is,2357,O
associated,2357,O
with,2357,O
expansion,2357,O
of,2357,O
a,2357,O
trinucleotide,2357,O
repeat,2357,O
in,2357,O
the,2357,O
IT15,2357,O
gene,2357,O
",",2357,O
which,2357,O
is,2357,O
predicted,2357,O
to,2357,O
encode,2357,O
a,2357,O
348-kDa,2357,O
protein,2357,O
named,2357,O
huntington,2357,O
.,2357,O
We,2358,O
used,2358,O
polyclonal,2358,O
and,2358,O
monoclonal,2358,O
anti-fusion,2358,O
protein,2358,O
antibodies,2358,O
to,2358,O
identify,2358,O
native,2358,O
huntingtin,2358,O
in,2358,O
rat,2358,O
",",2358,O
monkey,2358,O
",",2358,O
and,2358,O
human,2358,O
.,2358,O
Western,2359,O
blots,2359,O
revealed,2359,O
a,2359,O
protein,2359,O
with,2359,O
the,2359,O
expected,2359,O
molecular,2359,O
weight,2359,O
which,2359,O
is,2359,O
present,2359,O
in,2359,O
the,2359,O
soluble,2359,O
fraction,2359,O
of,2359,O
rat,2359,O
and,2359,O
monkey,2359,O
brain,2359,O
tissues,2359,O
and,2359,O
lymphoblastoid,2359,O
cells,2359,O
from,2359,O
control,2359,O
cases,2359,O
.,2359,O
In,2360,O
lymphoblastoid,2360,O
cell,2360,O
lines,2360,O
from,2360,O
juvenile-onset,2360,O
heterozygote,2360,O
HD,2360,B-Modifier
cases,2360,O
",",2360,O
both,2360,O
normal,2360,O
and,2360,O
mutant,2360,O
huntingtin,2360,O
are,2360,O
expressed,2360,O
",",2360,O
and,2360,O
increasing,2360,O
repeat,2360,O
expansion,2360,O
leads,2360,O
to,2360,O
lower,2360,O
levels,2360,O
of,2360,O
the,2360,O
mutant,2360,O
protein,2360,O
.,2360,O
Immunocytochemistry,2361,O
indicates,2361,O
that,2361,O
huntingtin,2361,O
is,2361,O
located,2361,O
in,2361,O
neurons,2361,O
throughout,2361,O
the,2361,O
brain,2361,O
",",2361,O
with,2361,O
the,2361,O
highest,2361,O
levels,2361,O
evident,2361,O
in,2361,O
larger,2361,O
neurons,2361,O
.,2361,O
In,2362,O
the,2362,O
human,2362,O
striatum,2362,O
",",2362,O
huntingtin,2362,O
is,2362,O
enriched,2362,O
in,2362,O
a,2362,O
patch-like,2362,O
distribution,2362,O
",",2362,O
potentially,2362,O
corresponding,2362,O
to,2362,O
the,2362,O
first,2362,O
areas,2362,O
affected,2362,O
in,2362,O
HD,2362,B-SpecificDisease
.,2362,O
Subcellular,2363,O
localization,2363,O
of,2363,O
huntingtin,2363,O
is,2363,O
consistent,2363,O
with,2363,O
a,2363,O
cytosolic,2363,O
protein,2363,O
primarily,2363,O
found,2363,O
in,2363,O
somatodendritic,2363,O
regions,2363,O
.,2363,O
Huntingtin,2364,O
appears,2364,O
to,2364,O
particularly,2364,O
associate,2364,O
with,2364,O
microtubules,2364,O
",",2364,O
although,2364,O
some,2364,O
is,2364,O
also,2364,O
associated,2364,O
with,2364,O
synaptic,2364,O
vesicles,2364,O
.,2364,O
On,2365,O
the,2365,O
basis,2365,O
of,2365,O
the,2365,O
localization,2365,O
of,2365,O
huntingtin,2365,O
in,2365,O
association,2365,O
with,2365,O
microtubules,2365,O
",",2365,O
we,2365,O
speculate,2365,O
that,2365,O
the,2365,O
mutation,2365,O
impairs,2365,O
the,2365,O
cytoskeletal,2365,O
anchoring,2365,O
or,2365,O
transport,2365,O
of,2365,O
mitochondria,2365,O
",",2365,O
vesicles,2365,O
",",2365,O
or,2365,O
other,2365,O
organelles,2365,O
or,2365,O
molecules,2365,O
..,2365,O
Marked,2366,O
phenotypic,2366,O
heterogeneity,2366,O
associated,2366,O
with,2366,O
expansion,2366,O
of,2366,O
a,2366,O
CAG,2366,O
repeat,2366,O
sequence,2366,O
at,2366,O
the,2366,O
spinocerebellar,2366,B-Modifier
ataxia,2366,I-Modifier
3/Machado-Joseph,2366,I-Modifier
disease,2366,I-Modifier
locus,2366,O
.,2366,O
The,2367,O
spinocerebellar,2367,B-Modifier
ataxia,2367,I-Modifier
3,2367,I-Modifier
locus,2367,O
(,2367,O
SCA3,2367,B-SpecificDisease
),2367,O
for,2367,O
type,2367,B-SpecificDisease
I,2367,I-SpecificDisease
autosomal,2367,I-SpecificDisease
dominant,2367,I-SpecificDisease
cerebellar,2367,I-SpecificDisease
ataxia,2367,I-SpecificDisease
(,2367,O
ADCA,2367,B-SpecificDisease
type,2367,I-SpecificDisease
I,2367,I-SpecificDisease
),2367,O
",",2367,O
a,2367,O
clinically,2367,O
and,2367,O
genetically,2367,O
heterogeneous,2367,O
group,2367,O
of,2367,O
neurodegenerative,2367,B-DiseaseClass
disorders,2367,I-DiseaseClass
",",2367,O
has,2367,O
been,2367,O
mapped,2367,O
to,2367,O
chromosome,2367,O
14q32,2367,O
.,2367,O
1,2368,O
1,2368,O
.,2368,O
ADCA,2369,B-Modifier
type,2369,I-Modifier
I,2369,I-Modifier
patients,2369,O
from,2369,O
families,2369,O
segregating,2369,O
SCA3,2369,B-SpecificDisease
share,2369,O
clinical,2369,O
features,2369,O
in,2369,O
common,2369,O
with,2369,O
those,2369,O
with,2369,O
Machado-Joseph,2369,B-SpecificDisease
disease,2369,I-SpecificDisease
(,2369,O
MJD,2369,B-SpecificDisease
),2369,O
",",2369,O
the,2369,O
gene,2369,O
of,2369,O
which,2369,O
maps,2369,O
to,2369,O
the,2369,O
same,2369,O
region,2369,O
.,2369,O
We,2370,O
show,2370,O
here,2370,O
that,2370,O
the,2370,O
disease,2370,O
gene,2370,O
segregating,2370,O
in,2370,O
each,2370,O
of,2370,O
three,2370,O
French,2370,O
ADCA,2370,B-Modifier
type,2370,I-Modifier
I,2370,I-Modifier
kindreds,2370,O
and,2370,O
in,2370,O
a,2370,O
French,2370,O
family,2370,O
with,2370,O
neuropathological,2370,O
findings,2370,O
suggesting,2370,O
the,2370,O
ataxochoreic,2370,O
form,2370,O
of,2370,O
dentatorubropallidoluysian,2370,B-SpecificDisease
atrophy,2370,I-SpecificDisease
carries,2370,O
an,2370,O
expanded,2370,O
CAG,2370,O
repeat,2370,O
sequence,2370,O
located,2370,O
at,2370,O
the,2370,O
same,2370,O
locus,2370,O
as,2370,O
that,2370,O
for,2370,O
MJD,2370,B-SpecificDisease
.,2370,O
Analysis,2371,O
of,2371,O
the,2371,O
mutation,2371,O
in,2371,O
these,2371,O
families,2371,O
shows,2371,O
a,2371,O
strong,2371,O
negative,2371,O
correlation,2371,O
between,2371,O
size,2371,O
of,2371,O
the,2371,O
expanded,2371,O
CAG,2371,O
repeat,2371,O
and,2371,O
age,2371,O
at,2371,O
onset,2371,O
of,2371,O
clinical,2371,O
disease,2371,O
.,2371,O
Instability,2372,O
of,2372,O
the,2372,O
expanded,2372,O
triplet,2372,O
repeat,2372,O
was,2372,O
not,2372,O
found,2372,O
to,2372,O
be,2372,O
affected,2372,O
by,2372,O
sex,2372,O
of,2372,O
the,2372,O
parent,2372,O
transmitting,2372,O
the,2372,O
mutation,2372,O
.,2372,O
Evidence,2373,O
was,2373,O
found,2373,O
for,2373,O
somatic,2373,O
and,2373,O
gonadal,2373,O
mosaicism,2373,O
for,2373,O
alleles,2373,O
carrying,2373,O
expanded,2373,O
trinucleotide,2373,O
repeats,2373,O
.,2373,O
Overexpression,2374,O
of,2374,O
DM20,2374,O
messenger,2374,O
RNA,2374,O
in,2374,O
two,2374,O
brothers,2374,O
with,2374,O
Pelizaeus-Merzbacher,2374,B-SpecificDisease
disease,2374,I-SpecificDisease
.,2374,O
Pelizaeus-Merzbacher,2375,B-SpecificDisease
disease,2375,I-SpecificDisease
is,2375,O
a,2375,O
rare,2375,B-DiseaseClass
",",2375,I-DiseaseClass
sex-linked,2375,I-DiseaseClass
recessive,2375,I-DiseaseClass
",",2375,I-DiseaseClass
dysmyelinating,2375,I-DiseaseClass
disease,2375,I-DiseaseClass
of,2375,I-DiseaseClass
the,2375,I-DiseaseClass
central,2375,I-DiseaseClass
nervous,2375,I-DiseaseClass
system,2375,I-DiseaseClass
that,2375,O
has,2375,O
been,2375,O
associated,2375,O
with,2375,O
mutations,2375,O
in,2375,O
the,2375,O
myelin,2375,O
proteolipid,2375,O
protein,2375,O
(,2375,O
PLP,2375,O
),2375,O
gene,2375,O
.,2375,O
Only,2376,O
25,2376,O
%,2376,O
of,2376,O
patients,2376,O
studied,2376,O
with,2376,O
Pelizaeus-Merzbacher,2376,B-SpecificDisease
disease,2376,I-SpecificDisease
have,2376,O
exonic,2376,O
mutations,2376,O
in,2376,O
this,2376,O
gene,2376,O
",",2376,O
the,2376,O
underlying,2376,O
cause,2376,O
of,2376,O
the,2376,O
disease,2376,O
in,2376,O
the,2376,O
remaining,2376,O
patients,2376,O
is,2376,O
unknown,2376,O
.,2376,O
The,2377,O
PLP,2377,O
gene,2377,O
encodes,2377,O
two,2377,O
major,2377,O
alternatively,2377,O
spliced,2377,O
transcripts,2377,O
called,2377,O
PLP,2377,O
and,2377,O
DM20,2377,O
.,2377,O
PLP,2378,O
messenger,2378,O
RNA,2378,O
is,2378,O
specifically,2378,O
expressed,2378,O
in,2378,O
central,2378,O
nervous,2378,O
system,2378,O
tissue,2378,O
",",2378,O
whereas,2378,O
DM20,2378,O
messenger,2378,O
RNA,2378,O
is,2378,O
found,2378,O
in,2378,O
central,2378,O
nervous,2378,O
system,2378,O
",",2378,O
cardiac,2378,O
",",2378,O
and,2378,O
other,2378,O
tissues,2378,O
.,2378,O
We,2379,O
studied,2379,O
cultured,2379,O
skin,2379,O
fibroblasts,2379,O
from,2379,O
2,2379,O
brothers,2379,O
with,2379,O
Pelizaeus-Merzbacher,2379,B-SpecificDisease
disease,2379,I-SpecificDisease
who,2379,O
exhibited,2379,O
no,2379,O
detectable,2379,O
exonic,2379,O
mutation,2379,O
of,2379,O
the,2379,O
PLP,2379,O
gene,2379,O
.,2379,O
Examination,2380,O
of,2380,O
RNA,2380,O
from,2380,O
these,2380,O
cells,2380,O
showed,2380,O
that,2380,O
the,2380,O
level,2380,O
of,2380,O
DM20,2380,O
messenger,2380,O
RNA,2380,O
is,2380,O
elevated,2380,O
sixfold,2380,O
relative,2380,O
to,2380,O
male,2380,O
control,2380,O
skin,2380,O
fibroblasts,2380,O
.,2380,O
An,2381,O
unrelated,2381,O
female,2381,O
carrier,2381,O
",",2381,O
also,2381,O
with,2381,O
no,2381,O
detectable,2381,O
exonic,2381,O
mutation,2381,O
",",2381,O
showed,2381,O
a,2381,O
threefold,2381,O
increase,2381,O
in,2381,O
DM20,2381,O
messenger,2381,O
RNA,2381,O
in,2381,O
cultured,2381,O
skin,2381,O
fibroblasts,2381,O
.,2381,O
Our,2382,O
findings,2382,O
suggest,2382,O
that,2382,O
in,2382,O
some,2382,O
patients,2382,O
",",2382,O
Pelizaeus-Merzbacher,2382,B-SpecificDisease
disease,2382,I-SpecificDisease
is,2382,O
caused,2382,O
by,2382,O
overexpression,2382,O
of,2382,O
PLP,2382,O
gene,2382,O
transcripts,2382,O
",",2382,O
and,2382,O
that,2382,O
in,2382,O
these,2382,O
families,2382,O
a,2382,O
50,2382,O
%,2382,O
increase,2382,O
of,2382,O
DM20,2382,O
messenger,2382,O
RNA,2382,O
in,2382,O
females,2382,O
",",2382,O
relative,2382,O
to,2382,O
the,2382,O
increase,2382,O
in,2382,O
affected,2382,O
males,2382,O
",",2382,O
can,2382,O
identify,2382,O
a,2382,O
female,2382,O
carrier,2382,O
..,2382,O
The,2383,O
Wiskott-Aldrich,2383,B-SpecificDisease
syndrome,2383,I-SpecificDisease
and,2383,O
X-linked,2383,B-SpecificDisease
congenital,2383,I-SpecificDisease
thrombocytopenia,2383,I-SpecificDisease
are,2383,O
caused,2383,O
by,2383,O
mutations,2383,O
of,2383,O
the,2383,O
same,2383,O
gene,2383,O
.,2383,O
The,2384,O
Wiskott-Aldrich,2384,B-SpecificDisease
syndrome,2384,I-SpecificDisease
(,2384,O
WAS,2384,B-SpecificDisease
),2384,O
is,2384,O
an,2384,O
X-linked,2384,B-DiseaseClass
recessive,2384,I-DiseaseClass
disorder,2384,I-DiseaseClass
characterized,2384,O
by,2384,O
thrombocytopenia,2384,B-SpecificDisease
",",2384,O
small,2384,O
platelets,2384,O
",",2384,O
eczema,2384,B-SpecificDisease
",",2384,O
recurrent,2384,O
infections,2384,O
",",2384,O
and,2384,O
immunodeficiency,2384,B-DiseaseClass
.,2384,O
Besides,2385,O
the,2385,O
classic,2385,O
WAS,2385,B-Modifier
phenotype,2385,O
",",2385,O
there,2385,O
is,2385,O
a,2385,O
group,2385,O
of,2385,O
patients,2385,O
with,2385,O
congenital,2385,B-SpecificDisease
X-linked,2385,I-SpecificDisease
thrombocytopenia,2385,I-SpecificDisease
(,2385,O
XLT,2385,B-SpecificDisease
),2385,O
who,2385,O
have,2385,O
small,2385,O
platelets,2385,O
but,2385,O
only,2385,O
transient,2385,O
eczema,2385,B-SpecificDisease
",",2385,O
if,2385,O
any,2385,O
",",2385,O
and,2385,O
minimal,2385,O
immune,2385,B-DiseaseClass
deficiency,2385,I-DiseaseClass
.,2385,O
Because,2386,O
the,2386,O
gene,2386,O
responsible,2386,O
for,2386,O
WAS,2386,B-SpecificDisease
has,2386,O
been,2386,O
sequenced,2386,O
",",2386,O
it,2386,O
was,2386,O
possible,2386,O
to,2386,O
correlate,2386,O
the,2386,O
WAS,2386,B-Modifier
phenotypes,2386,O
with,2386,O
WAS,2386,B-Modifier
gene,2386,O
mutations,2386,O
.,2386,O
Using,2387,O
a,2387,O
fingerprinting,2387,O
screening,2387,O
technique,2387,O
",",2387,O
we,2387,O
determined,2387,O
the,2387,O
approximate,2387,O
location,2387,O
of,2387,O
the,2387,O
mutation,2387,O
in,2387,O
13,2387,O
unrelated,2387,O
WAS,2387,B-Modifier
patients,2387,O
with,2387,O
mild,2387,O
to,2387,O
severe,2387,O
clinical,2387,O
symptoms,2387,O
.,2387,O
Direct,2388,O
sequence,2388,O
analysis,2388,O
of,2388,O
cDNA,2388,O
and,2388,O
genomic,2388,O
DNA,2388,O
obtained,2388,O
from,2388,O
patient-derived,2388,O
cell,2388,O
lines,2388,O
showed,2388,O
12,2388,O
unique,2388,O
mutations,2388,O
distributed,2388,O
throughout,2388,O
the,2388,O
WAS,2388,B-Modifier
gene,2388,O
",",2388,O
including,2388,O
insertions,2388,O
",",2388,O
deletions,2388,O
",",2388,O
and,2388,O
point,2388,O
mutations,2388,O
resulting,2388,O
in,2388,O
amino,2388,O
acid,2388,O
substitutions,2388,O
",",2388,O
termination,2388,O
",",2388,O
exon,2388,O
skipping,2388,O
",",2388,O
or,2388,O
splicing,2388,O
defects,2388,O
.,2388,O
Of,2389,O
4,2389,O
unrelated,2389,O
patients,2389,O
with,2389,O
the,2389,O
XLT,2389,B-Modifier
phenotype,2389,O
",",2389,O
3,2389,O
had,2389,O
missense,2389,O
mutations,2389,O
affecting,2389,O
exon,2389,O
2,2389,O
and,2389,O
1,2389,O
had,2389,O
a,2389,O
splice-site,2389,O
mutation,2389,O
affecting,2389,O
exon,2389,O
9,2389,O
.,2389,O
Patients,2390,O
with,2390,O
classic,2390,O
WAS,2390,B-SpecificDisease
had,2390,O
more,2390,O
complex,2390,O
mutations,2390,O
",",2390,O
resulting,2390,O
in,2390,O
termination,2390,O
codons,2390,O
",",2390,O
frameshift,2390,O
",",2390,O
and,2390,O
early,2390,O
termination,2390,O
.,2390,O
These,2391,O
findings,2391,O
provide,2391,O
direct,2391,O
evidence,2391,O
that,2391,O
XLT,2391,B-SpecificDisease
and,2391,O
WAS,2391,B-SpecificDisease
are,2391,O
caused,2391,O
by,2391,O
mutations,2391,O
of,2391,O
the,2391,O
same,2391,O
gene,2391,O
and,2391,O
suggest,2391,O
that,2391,O
severe,2391,O
clinical,2391,O
phenotypes,2391,O
are,2391,O
associated,2391,O
with,2391,O
complex,2391,O
mutations,2391,O
..,2391,O
Myotonia,2392,B-SpecificDisease
levior,2392,I-SpecificDisease
is,2392,O
a,2392,O
chloride,2392,B-DiseaseClass
channel,2392,I-DiseaseClass
disorder,2392,I-DiseaseClass
.,2392,O
The,2393,O
group,2393,O
of,2393,O
dominant,2393,B-DiseaseClass
non-dystrophic,2393,I-DiseaseClass
myotonias,2393,I-DiseaseClass
",",2393,O
comprising,2393,O
disorders,2393,O
characterized,2393,O
by,2393,O
clinically,2393,O
similar,2393,O
forms,2393,O
of,2393,O
myogenic,2393,O
muscle,2393,O
stiffness,2393,O
",",2393,O
is,2393,O
genetically,2393,O
inhomogeneous,2393,O
.,2393,O
Dominant,2394,B-SpecificDisease
myotonia,2394,I-SpecificDisease
congenita,2394,I-SpecificDisease
(,2394,O
Thomsens,2394,B-SpecificDisease
disease,2394,I-SpecificDisease
),2394,O
is,2394,O
linked,2394,O
to,2394,O
CLCN1,2394,O
",",2394,O
the,2394,O
gene,2394,O
encoding,2394,O
the,2394,O
major,2394,O
muscle,2394,O
chloride,2394,O
channel,2394,O
",",2394,O
localized,2394,O
on,2394,O
chromosome,2394,O
7q35,2394,O
.,2394,O
In,2395,O
contrast,2395,O
",",2395,O
dominant,2395,B-DiseaseClass
myotonias,2395,I-DiseaseClass
sensitive,2395,O
to,2395,O
potassium,2395,O
are,2395,O
caused,2395,O
by,2395,O
point,2395,O
mutations,2395,O
in,2395,O
SCN4A,2395,O
on,2395,O
chromosome,2395,O
17q,2395,O
",",2395,O
the,2395,O
gene,2395,O
for,2395,O
the,2395,O
alpha,2395,O
subunit,2395,O
of,2395,O
the,2395,O
adult,2395,O
skeletal,2395,O
muscle,2395,O
sodium,2395,O
channel,2395,O
.,2395,O
No,2396,O
linkage,2396,O
or,2396,O
molecular,2396,O
genetic,2396,O
data,2396,O
are,2396,O
as,2396,O
yet,2396,O
available,2396,O
on,2396,O
myotonia,2396,B-SpecificDisease
levior,2396,I-SpecificDisease
characterized,2396,O
by,2396,O
milder,2396,O
symptoms,2396,O
and,2396,O
later,2396,O
onset,2396,O
of,2396,O
myotonia,2396,B-DiseaseClass
than,2396,O
in,2396,O
Thomsens,2396,B-SpecificDisease
disease,2396,I-SpecificDisease
",",2396,O
and,2396,O
absence,2396,O
of,2396,O
muscle,2396,B-SpecificDisease
hypertrophy,2396,I-SpecificDisease
.,2396,O
We,2397,O
report,2397,O
a,2397,O
CLCN1,2397,O
Gln-552-Arg,2397,O
substitution,2397,O
for,2397,O
a,2397,O
family,2397,O
with,2397,O
dominant,2397,O
inheritance,2397,O
previously,2397,O
diagnosed,2397,O
to,2397,O
have,2397,O
myotonia,2397,B-SpecificDisease
levior,2397,I-SpecificDisease
.,2397,O
Thus,2398,O
",",2398,O
this,2398,O
disorder,2398,O
appears,2398,O
as,2398,O
a,2398,O
variant,2398,O
of,2398,O
Thomsens,2398,B-SpecificDisease
disease,2398,I-SpecificDisease
due,2398,O
to,2398,O
mutations,2398,O
leading,2398,O
to,2398,O
low,2398,O
clinical,2398,O
expressivity,2398,O
.,2398,O
In,2399,O
addition,2399,O
",",2399,O
we,2399,O
report,2399,O
a,2399,O
novel,2399,O
Ile-290-Met,2399,O
CLCN1,2399,O
mutation,2399,O
for,2399,O
a,2399,O
typical,2399,O
Thomsen,2399,O
pedigree,2399,O
.,2399,O
In,2400,O
another,2400,O
family,2400,O
previously,2400,O
diagnosed,2400,O
as,2400,O
having,2400,O
Thomsens,2400,B-SpecificDisease
disease,2400,I-SpecificDisease
",",2400,O
we,2400,O
unexpectedly,2400,O
found,2400,O
a,2400,O
CLCN1,2400,O
14,2400,O
bp,2400,O
deletion,2400,O
known,2400,O
to,2400,O
cause,2400,O
recessive,2400,B-DiseaseClass
myotonia,2400,I-DiseaseClass
",",2400,O
and,2400,O
a,2400,O
rare,2400,O
Trp-118-Gly,2400,O
polymorphism,2400,O
..,2400,O
Southern,2401,O
analysis,2401,O
reveals,2401,O
a,2401,O
large,2401,O
deletion,2401,O
at,2401,O
the,2401,O
hypoxanthine,2401,O
phosphoribosyltransferase,2401,O
locus,2401,O
in,2401,O
a,2401,O
patient,2401,O
with,2401,O
Lesch-Nyhan,2401,B-SpecificDisease
syndrome,2401,I-SpecificDisease
.,2401,O
Whole,2402,O
genomic,2402,O
hprt,2402,O
clones,2402,O
were,2402,O
used,2402,O
in,2402,O
Southern,2402,O
analysis,2402,O
to,2402,O
screen,2402,O
the,2402,O
integrity,2402,O
of,2402,O
the,2402,O
hprt,2402,O
gene,2402,O
in,2402,O
a,2402,O
family,2402,O
that,2402,O
includes,2402,O
a,2402,O
patient,2402,O
with,2402,O
HPRT,2402,B-SpecificDisease
enzyme,2402,I-SpecificDisease
deficiency,2402,I-SpecificDisease
causal,2402,O
to,2402,O
Lesch-Nyhan,2402,B-SpecificDisease
syndrome,2402,I-SpecificDisease
.,2402,O
A,2403,O
5,2403,O
kb,2403,O
DNA,2403,O
sequence,2403,O
deletion,2403,O
was,2403,O
found,2403,O
to,2403,O
have,2403,O
its,2403,O
endpoints,2403,O
in,2403,O
the,2403,O
first,2403,O
and,2403,O
third,2403,O
introns,2403,O
.,2403,O
The,2404,O
probes,2404,O
identified,2404,O
the,2404,O
carrier,2404,O
status,2404,O
of,2404,O
female,2404,O
family,2404,O
members,2404,O
",",2404,O
aided,2404,O
by,2404,O
an,2404,O
RFLP,2404,O
carried,2404,O
by,2404,O
the,2404,O
mothers,2404,O
normal,2404,O
X-chromosome,2404,O
..,2404,O
Characterisation,2405,O
of,2405,O
molecular,2405,O
defects,2405,O
in,2405,O
X-linked,2405,B-SpecificDisease
amelogenesis,2405,I-SpecificDisease
imperfecta,2405,I-SpecificDisease
(,2405,O
AIH1,2405,O
),2405,O
.,2405,O
Amelogenins,2406,O
are,2406,O
an,2406,O
heterogenous,2406,O
family,2406,O
of,2406,O
proteins,2406,O
produced,2406,O
by,2406,O
ameloblasts,2406,O
of,2406,O
the,2406,O
enamel,2406,O
organ,2406,O
during,2406,O
tooth,2406,O
development,2406,O
.,2406,O
Disturbances,2407,O
of,2407,O
enamel,2407,O
formation,2407,O
occur,2407,O
in,2407,O
amelogenesis,2407,B-DiseaseClass
imperfecta,2407,I-DiseaseClass
",",2407,O
a,2407,O
clinically,2407,O
heterogenous,2407,O
group,2407,O
of,2407,O
inherited,2407,B-DiseaseClass
disorders,2407,I-DiseaseClass
characterised,2407,O
by,2407,O
defective,2407,O
enamel,2407,O
biomineralisation,2407,O
.,2407,O
An,2408,O
amelogenin,2408,O
gene,2408,O
",",2408,O
AMGX,2408,O
",",2408,O
has,2408,O
been,2408,O
mapped,2408,O
to,2408,O
the,2408,O
short,2408,O
of,2408,O
the,2408,O
X,2408,O
chromosome,2408,O
(,2408,O
Xp22,2408,O
.,2408,O
1-p22,2409,O
.,2409,O
3,2410,O
),2410,O
and,2410,O
has,2410,O
been,2410,O
implicated,2410,O
in,2410,O
the,2410,O
molecular,2410,O
pathology,2410,O
of,2410,O
X-linked,2410,B-SpecificDisease
amelogenesis,2410,I-SpecificDisease
imperfecta,2410,I-SpecificDisease
(,2410,O
AIH1,2410,B-SpecificDisease
),2410,O
.,2410,O
We,2411,O
have,2411,O
identified,2411,O
three,2411,O
families,2411,O
exhibiting,2411,O
AIH1,2411,B-SpecificDisease
and,2411,O
screened,2411,O
the,2411,O
AMGX,2411,O
gene,2411,O
for,2411,O
mutations,2411,O
using,2411,O
single-strand,2411,O
conformational,2411,O
polymorphism,2411,O
analysis,2411,O
and,2411,O
DNA,2411,O
sequencing,2411,O
.,2411,O
Three,2412,O
novel,2412,O
mutations,2412,O
were,2412,O
identified,2412,O
a,2412,O
C-T,2412,O
substitution,2412,O
in,2412,O
exon,2412,O
5,2412,O
",",2412,O
and,2412,O
a,2412,O
G-T,2412,O
substitution,2412,O
and,2412,O
single,2412,O
cytosine,2412,O
deletion,2412,O
in,2412,O
exon,2412,O
6,2412,O
",",2412,O
confirming,2412,O
the,2412,O
existence,2412,O
of,2412,O
extensive,2412,O
allelic,2412,O
heterogeneity,2412,O
in,2412,O
this,2412,O
condition,2412,O
.,2412,O
The,2413,O
identification,2413,O
of,2413,O
family-specific,2413,O
mutations,2413,O
will,2413,O
enable,2413,O
early,2413,O
identification,2413,O
of,2413,O
affected,2413,O
individuals,2413,O
and,2413,O
correlation,2413,O
of,2413,O
clinical,2413,O
phenotype,2413,O
with,2413,O
genotype,2413,O
will,2413,O
facilitate,2413,O
an,2413,O
objective,2413,O
system,2413,O
of,2413,O
disease,2413,O
classification,2413,O
.,2413,O
Frequency,2414,O
of,2414,O
exon,2414,O
15,2414,O
missense,2414,O
mutation,2414,O
(,2414,O
442D,2414,O
:,2414,O
G,2414,O
),2414,O
in,2414,O
cholesteryl,2414,O
ester,2414,O
transfer,2414,O
protein,2414,O
gene,2414,O
in,2414,O
hyperalphalipoproteinemic,2414,B-Modifier
Japanese,2414,O
subjects,2414,O
.,2414,O
Cholesteryl,2415,O
ester,2415,O
transfer,2415,O
protein,2415,O
(,2415,O
CETP,2415,O
),2415,O
transfers,2415,O
cholesteryl,2415,O
ester,2415,O
from,2415,O
high,2415,O
density,2415,O
lipoprotein,2415,O
(,2415,O
HDL,2415,O
),2415,O
to,2415,O
apo,2415,O
B-containing,2415,O
lipoproteins,2415,O
.,2415,O
The,2416,O
hyperalphalipoproteinemia,2416,B-SpecificDisease
caused,2416,O
by,2416,O
CETP,2416,B-SpecificDisease
deficiency,2416,I-SpecificDisease
is,2416,O
fairly,2416,O
common,2416,O
in,2416,O
Japan,2416,O
and,2416,O
one,2416,O
of,2416,O
the,2416,O
most,2416,O
common,2416,O
mutations,2416,O
in,2416,O
the,2416,O
CETP,2416,O
gene,2416,O
is,2416,O
the,2416,O
splicing,2416,O
defect,2416,O
of,2416,O
the,2416,O
intron,2416,O
14,2416,O
",",2416,O
the,2416,O
allelic,2416,O
frequency,2416,O
of,2416,O
which,2416,O
has,2416,O
been,2416,O
shown,2416,O
to,2416,O
be,2416,O
0,2416,O
.,2416,O
0049,2417,O
in,2417,O
the,2417,O
Japanese,2417,O
general,2417,O
population,2417,O
.,2417,O
Recently,2418,O
",",2418,O
we,2418,O
have,2418,O
reported,2418,O
a,2418,O
missense,2418,O
mutation,2418,O
in,2418,O
exon,2418,O
15,2418,O
of,2418,O
the,2418,O
CETP,2418,O
gene,2418,O
(,2418,O
442D,2418,O
G,2418,O
),2418,O
",",2418,O
showing,2418,O
a,2418,O
dominant,2418,O
effect,2418,O
on,2418,O
the,2418,O
CETP,2418,O
activity,2418,O
and,2418,O
HDL-cholesterol,2418,O
level,2418,O
.,2418,O
In,2419,O
the,2419,O
current,2419,O
study,2419,O
",",2419,O
we,2419,O
determined,2419,O
the,2419,O
frequency,2419,O
of,2419,O
this,2419,O
new,2419,O
mutation,2419,O
in,2419,O
Japanese,2419,O
hyperalphalipoproteinemic,2419,B-Modifier
(,2419,O
HDL-cholesterol,2419,O
>,2419,O
or,2419,O
=,2419,O
100,2419,O
mg/dl,2419,O
),2419,O
subjects,2419,O
.,2419,O
A,2420,O
rapid,2420,O
and,2420,O
easy,2420,O
screening,2420,O
method,2420,O
for,2420,O
this,2420,O
new,2420,O
mutation,2420,O
was,2420,O
developed,2420,O
using,2420,O
a,2420,O
polymerase,2420,O
chain,2420,O
reaction,2420,O
(,2420,O
PCR,2420,O
),2420,O
-mediated,2420,O
site-directed,2420,O
mutagenesis,2420,O
.,2420,O
Among,2421,O
117,2421,O
Japanese,2421,O
hyperalphalipoproteinemic,2421,B-Modifier
subjects,2421,O
(,2421,O
HDL-cholesterol,2421,O
;,2421,O
116,2421,O
.,2421,O
7,2422,O
+/-,2422,O
16,2422,O
.,2422,O
5,2423,O
mg/dl,2423,O
",",2423,O
mean,2423,O
+/-,2423,O
S.,2423,O
D.,2423,O
),2423,O
without,2423,O
the,2423,O
intron,2423,O
14,2423,O
splice,2423,O
defect,2423,O
",",2423,O
three,2423,O
homozygotes,2423,O
(,2423,O
2,2423,O
.,2423,O
5,2424,O
%,2424,O
),2424,O
and,2424,O
34,2424,O
heterozygotes,2424,O
(,2424,O
29,2424,O
.,2424,O
1,2425,O
%,2425,O
),2425,O
were,2425,O
found,2425,O
to,2425,O
have,2425,O
the,2425,O
442D,2425,O
G,2425,O
mutation,2425,O
.,2425,O
The,2426,O
relative,2426,O
allelic,2426,O
frequency,2426,O
of,2426,O
this,2426,O
mutation,2426,O
was,2426,O
calculated,2426,O
to,2426,O
be,2426,O
0,2426,O
.,2426,O
17,2427,O
.,2427,O
One,2428,O
of,2428,O
the,2428,O
homozygotes,2428,O
for,2428,O
the,2428,O
442D,2428,O
G,2428,O
mutation,2428,O
was,2428,O
the,2428,O
patient,2428,O
previously,2428,O
described,2428,O
by,2428,O
us,2428,O
as,2428,O
having,2428,O
hyperalphalipoproteinemia,2428,B-SpecificDisease
with,2428,O
corneal,2428,B-SpecificDisease
opacity,2428,I-SpecificDisease
and,2428,O
coronary,2428,B-SpecificDisease
heart,2428,I-SpecificDisease
disease,2428,I-SpecificDisease
.,2428,O
This,2429,O
was,2429,O
the,2429,O
first,2429,O
reported,2429,O
subject,2429,O
homozygous,2429,O
for,2429,O
the,2429,O
CETP,2429,B-SpecificDisease
deficiency,2429,I-SpecificDisease
who,2429,O
also,2429,O
demonstrated,2429,O
atherosclerotic,2429,B-DiseaseClass
symptoms,2429,I-DiseaseClass
.,2429,O
In,2430,O
homozygous,2430,O
subjects,2430,O
",",2430,O
CETP,2430,O
activity,2430,O
ranged,2430,O
from,2430,O
37,2430,O
%,2430,O
to,2430,O
62,2430,O
%,2430,O
of,2430,O
the,2430,O
normal,2430,O
value,2430,O
",",2430,O
which,2430,O
was,2430,O
consistent,2430,O
with,2430,O
the,2430,O
results,2430,O
obtained,2430,O
from,2430,O
the,2430,O
transient,2430,O
expression,2430,O
experiment,2430,O
previously,2430,O
reported,2430,O
;,2430,O
however,2430,O
",",2430,O
the,2430,O
specific,2430,O
activity,2430,O
of,2430,O
CETP,2430,O
was,2430,O
not,2430,O
as,2430,O
low,2430,O
as,2430,O
expected,2430,O
.,2430,O
(,2431,O
ABSTRACT,2431,O
TRUNCATED,2431,O
AT,2431,O
250,2431,O
WORDS,2431,O
),2431,O
Mucopolysaccharidosis,2432,B-SpecificDisease
type,2432,I-SpecificDisease
IVA,2432,I-SpecificDisease
:,2432,O
common,2432,O
double,2432,O
deletion,2432,O
in,2432,O
the,2432,O
N-acetylgalactosamine-6-sulfatase,2432,O
gene,2432,O
(,2432,O
GALNS,2432,O
),2432,O
.,2432,O
Mucopolysaccharidosis,2433,B-SpecificDisease
IVA,2433,I-SpecificDisease
(,2433,O
MPS,2433,B-SpecificDisease
IVA,2433,I-SpecificDisease
),2433,O
is,2433,O
an,2433,O
autosomal,2433,B-DiseaseClass
recessive,2433,I-DiseaseClass
disorder,2433,I-DiseaseClass
caused,2433,O
by,2433,O
a,2433,O
deficiency,2433,B-SpecificDisease
in,2433,I-SpecificDisease
N-acetylgalactosamine-6-sulfatase,2433,I-SpecificDisease
(,2433,O
GALNS,2433,O
),2433,O
.,2433,O
We,2434,O
found,2434,O
two,2434,O
separate,2434,O
deletions,2434,O
of,2434,O
nearly,2434,O
8,2434,O
.,2434,O
0,2435,O
and,2435,O
6,2435,O
.,2435,O
0,2436,O
kb,2436,O
in,2436,O
the,2436,O
GALNS,2436,O
gene,2436,O
",",2436,O
including,2436,O
some,2436,O
exons,2436,O
.,2436,O
There,2437,O
are,2437,O
Alu,2437,O
repetitive,2437,O
elements,2437,O
near,2437,O
the,2437,O
breakpoints,2437,O
of,2437,O
the,2437,O
8,2437,O
.,2437,O
0-kb,2438,O
deletion,2438,O
",",2438,O
and,2438,O
this,2438,O
deletion,2438,O
resulted,2438,O
from,2438,O
an,2438,O
Alu-Alu,2438,O
recombination,2438,O
.,2438,O
The,2439,O
other,2439,O
6,2439,O
.,2439,O
0-kb,2440,O
deletion,2440,O
involved,2440,O
illegitimate,2440,O
recombinational,2440,O
events,2440,O
between,2440,O
incomplete,2440,O
short,2440,O
direct,2440,O
repeats,2440,O
of,2440,O
8,2440,O
bp,2440,O
at,2440,O
deletion,2440,O
breakpoints,2440,O
.,2440,O
The,2441,O
same,2441,O
rearrangement,2441,O
has,2441,O
been,2441,O
observed,2441,O
in,2441,O
a,2441,O
heteroallelic,2441,O
state,2441,O
in,2441,O
four,2441,O
unrelated,2441,O
patients,2441,O
.,2441,O
This,2442,O
is,2442,O
the,2442,O
first,2442,O
documentation,2442,O
of,2442,O
a,2442,O
common,2442,O
double,2442,O
deletion,2442,O
a,2442,O
gene,2442,O
that,2442,O
is,2442,O
not,2442,O
a,2442,O
member,2442,O
of,2442,O
a,2442,O
gene,2442,O
cluster,2442,O
.,2442,O
Detection,2443,O
of,2443,O
eight,2443,O
BRCA1,2443,O
mutations,2443,O
in,2443,O
10,2443,O
breast/ovarian,2443,B-Modifier
cancer,2443,I-Modifier
families,2443,O
",",2443,O
including,2443,O
1,2443,O
family,2443,O
with,2443,O
male,2443,B-SpecificDisease
breast,2443,I-SpecificDisease
cancer,2443,I-SpecificDisease
.,2443,O
Genetic,2444,O
epidemiological,2444,O
evidence,2444,O
suggests,2444,O
that,2444,O
mutations,2444,O
in,2444,O
BRCA1,2444,O
may,2444,O
be,2444,O
responsible,2444,O
for,2444,O
approximately,2444,O
one,2444,O
half,2444,O
of,2444,O
early,2444,O
onset,2444,O
familial,2444,B-SpecificDisease
breast,2444,I-SpecificDisease
cancer,2444,I-SpecificDisease
and,2444,O
the,2444,O
majority,2444,O
of,2444,O
familial,2444,B-CompositeMention
breast/ovarian,2444,I-CompositeMention
cancer,2444,I-CompositeMention
.,2444,O
The,2445,O
recent,2445,O
cloning,2445,O
of,2445,O
BRCA1,2445,O
allows,2445,O
for,2445,O
the,2445,O
direct,2445,O
detection,2445,O
of,2445,O
mutations,2445,O
",",2445,O
but,2445,O
the,2445,O
feasibility,2445,O
of,2445,O
presymptomatic,2445,O
screening,2445,O
for,2445,O
cancer,2445,B-Modifier
susceptibility,2445,O
is,2445,O
unknown,2445,O
.,2445,O
We,2446,O
analyzed,2446,O
genomic,2446,O
DNA,2446,O
from,2446,O
one,2446,O
affected,2446,O
individual,2446,O
from,2446,O
each,2446,O
of,2446,O
24,2446,O
families,2446,O
with,2446,O
at,2446,O
least,2446,O
three,2446,O
cases,2446,O
of,2446,O
ovarian,2446,O
or,2446,O
breast,2446,O
cancer,2446,O
",",2446,O
using,2446,O
SSCP,2446,O
assays,2446,O
.,2446,O
Variant,2447,O
SSCP,2447,O
bands,2447,O
were,2447,O
subcloned,2447,O
and,2447,O
sequenced,2447,O
.,2447,O
Allele-specific,2448,O
oligonucleotide,2448,O
hybridization,2448,O
was,2448,O
used,2448,O
to,2448,O
verify,2448,O
sequence,2448,O
changes,2448,O
and,2448,O
to,2448,O
screen,2448,O
DNA,2448,O
from,2448,O
control,2448,O
individuals,2448,O
.,2448,O
Six,2449,O
frameshift,2449,O
and,2449,O
two,2449,O
missense,2449,O
mutations,2449,O
were,2449,O
detected,2449,O
in,2449,O
10,2449,O
different,2449,O
families,2449,O
.,2449,O
A,2450,O
frameshift,2450,O
mutation,2450,O
was,2450,O
detected,2450,O
in,2450,O
a,2450,O
male,2450,O
proband,2450,O
affected,2450,O
with,2450,O
both,2450,O
breast,2450,O
and,2450,O
prostate,2450,O
cancer,2450,O
.,2450,O
A,2451,O
40-bp,2451,O
deletion,2451,O
was,2451,O
detected,2451,O
in,2451,O
a,2451,O
patient,2451,O
who,2451,O
developed,2451,O
intra-abdominal,2451,B-DiseaseClass
carcinomatosis,2451,I-DiseaseClass
1,2451,O
year,2451,O
after,2451,O
prophylactic,2451,O
oophorectomy,2451,O
.,2451,O
Mutations,2452,O
were,2452,O
detected,2452,O
throughout,2452,O
the,2452,O
gene,2452,O
",",2452,O
and,2452,O
only,2452,O
one,2452,O
was,2452,O
detected,2452,O
in,2452,O
more,2452,O
than,2452,O
a,2452,O
single,2452,O
family,2452,O
.,2452,O
These,2453,O
results,2453,O
provide,2453,O
further,2453,O
evidence,2453,O
that,2453,O
inherited,2453,B-CompositeMention
breast,2453,I-CompositeMention
and,2453,I-CompositeMention
ovarian,2453,I-CompositeMention
cancer,2453,I-CompositeMention
can,2453,O
occur,2453,O
as,2453,O
a,2453,O
consequence,2453,O
of,2453,O
a,2453,O
wide,2453,O
array,2453,O
of,2453,O
BRCA1,2453,O
mutations,2453,O
.,2453,O
These,2454,O
results,2454,O
suggests,2454,O
that,2454,O
development,2454,O
of,2454,O
a,2454,O
screening,2454,O
test,2454,O
for,2454,O
BRCA1,2454,O
mutations,2454,O
will,2454,O
be,2454,O
technically,2454,O
challenging,2454,O
.,2454,O
The,2455,O
finding,2455,O
of,2455,O
a,2455,O
mutation,2455,O
in,2455,O
a,2455,O
family,2455,O
with,2455,O
male,2455,B-SpecificDisease
breast,2455,I-SpecificDisease
cancer,2455,I-SpecificDisease
",",2455,O
not,2455,O
previously,2455,O
thought,2455,O
to,2455,O
be,2455,O
related,2455,O
to,2455,O
BRCA1,2455,O
",",2455,O
also,2455,O
illustrates,2455,O
the,2455,O
potential,2455,O
difficulties,2455,O
of,2455,O
genetic,2455,O
counseling,2455,O
for,2455,O
individuals,2455,O
known,2455,O
to,2455,O
carry,2455,O
mutations,2455,O
..,2455,O
Natural,2456,O
selection,2456,O
of,2456,O
hemi-,2456,O
and,2456,O
heterozygotes,2456,O
for,2456,O
G6PD,2456,B-SpecificDisease
deficiency,2456,I-SpecificDisease
in,2456,O
Africa,2456,O
by,2456,O
resistance,2456,O
to,2456,O
severe,2456,O
malaria,2456,B-SpecificDisease
.,2456,O
Glucose-6-phosphate,2457,B-SpecificDisease
dehydrogenase,2457,I-SpecificDisease
(,2457,I-SpecificDisease
G6PD,2457,I-SpecificDisease
),2457,I-SpecificDisease
deficiency,2457,I-SpecificDisease
",",2457,O
the,2457,O
most,2457,O
common,2457,O
enzymopathy,2457,B-DiseaseClass
of,2457,O
humans,2457,O
",",2457,O
affects,2457,O
over,2457,O
400,2457,O
million,2457,O
people,2457,O
.,2457,O
The,2458,O
geographical,2458,O
correlation,2458,O
of,2458,O
its,2458,O
distribution,2458,O
with,2458,O
the,2458,O
historical,2458,O
endemicity,2458,O
of,2458,O
malaria,2458,B-SpecificDisease
suggests,2458,O
that,2458,O
this,2458,O
disorder,2458,O
has,2458,O
risen,2458,O
in,2458,O
frequency,2458,O
through,2458,O
natural,2458,O
selection,2458,O
by,2458,O
malaria,2458,B-SpecificDisease
.,2458,O
However,2459,O
",",2459,O
attempts,2459,O
to,2459,O
confirm,2459,O
that,2459,O
G6PD,2459,B-SpecificDisease
deficiency,2459,I-SpecificDisease
is,2459,O
protective,2459,O
in,2459,O
case-control,2459,O
studies,2459,O
of,2459,O
malaria,2459,B-SpecificDisease
have,2459,O
yielded,2459,O
conflicting,2459,O
results,2459,O
.,2459,O
Hence,2460,O
",",2460,O
for,2460,O
this,2460,O
X-linked,2460,B-DiseaseClass
disorder,2460,I-DiseaseClass
",",2460,O
it,2460,O
is,2460,O
unclear,2460,O
whether,2460,O
both,2460,O
male,2460,O
hemizygotes,2460,O
and,2460,O
female,2460,O
heterozygotes,2460,O
are,2460,O
protected,2460,O
or,2460,O
",",2460,O
as,2460,O
frequently,2460,O
suggested,2460,O
",",2460,O
only,2460,O
females,2460,O
.,2460,O
Furthermore,2461,O
",",2461,O
how,2461,O
much,2461,O
protection,2461,O
may,2461,O
be,2461,O
afforded,2461,O
is,2461,O
unknown,2461,O
.,2461,O
Here,2462,O
we,2462,O
report,2462,O
that,2462,O
",",2462,O
in,2462,O
two,2462,O
large,2462,O
case-control,2462,O
studies,2462,O
of,2462,O
over,2462,O
2,2462,O
",",2462,O
000,2462,O
African,2462,O
children,2462,O
",",2462,O
the,2462,O
common,2462,O
African,2462,O
form,2462,O
of,2462,O
G6PD,2462,B-SpecificDisease
deficiency,2462,I-SpecificDisease
(,2462,O
G6PD,2462,B-SpecificDisease
A-,2462,I-SpecificDisease
),2462,O
is,2462,O
associated,2462,O
with,2462,O
a,2462,O
46-58,2462,O
%,2462,O
reduction,2462,O
in,2462,O
risk,2462,O
of,2462,O
severe,2462,O
malaria,2462,B-SpecificDisease
for,2462,O
both,2462,O
female,2462,O
heterozygotes,2462,O
and,2462,O
male,2462,O
hemizygotes,2462,O
.,2462,O
A,2463,O
mathematical,2463,O
model,2463,O
incorporating,2463,O
the,2463,O
measured,2463,O
selective,2463,O
advantage,2463,O
against,2463,O
malaria,2463,B-SpecificDisease
suggests,2463,O
that,2463,O
a,2463,O
counterbalancing,2463,O
selective,2463,O
disadvantage,2463,O
",",2463,O
associated,2463,O
with,2463,O
this,2463,O
enzyme,2463,B-DiseaseClass
deficiency,2463,I-DiseaseClass
",",2463,O
has,2463,O
retarded,2463,O
its,2463,O
rise,2463,O
in,2463,O
frequency,2463,O
in,2463,O
malaria-endemic,2463,B-Modifier
regions,2463,O
.,2463,O
Although,2464,O
G6PD,2464,B-SpecificDisease
deficiency,2464,I-SpecificDisease
is,2464,O
now,2464,O
regarded,2464,O
as,2464,O
a,2464,O
generally,2464,O
benign,2464,O
disorder,2464,O
",",2464,O
in,2464,O
earlier,2464,O
environmental,2464,O
conditions,2464,O
it,2464,O
could,2464,O
have,2464,O
been,2464,O
significantly,2464,O
disadvantageous,2464,O
..,2464,O
The,2465,O
alveolar,2465,B-Modifier
rhabdomyosarcoma,2465,I-Modifier
PAX3/FKHR,2465,O
fusion,2465,O
protein,2465,O
is,2465,O
a,2465,O
transcriptional,2465,O
activator,2465,O
.,2465,O
Chimeric,2466,O
transcription,2466,O
factors,2466,O
",",2466,O
created,2466,O
by,2466,O
gene,2466,O
fusions,2466,O
as,2466,O
the,2466,O
result,2466,O
of,2466,O
chromosomal,2466,O
translocations,2466,O
",",2466,O
have,2466,O
been,2466,O
implicated,2466,O
in,2466,O
the,2466,O
pathogenesis,2466,O
of,2466,O
several,2466,O
pathologically,2466,O
disparate,2466,O
solid,2466,B-DiseaseClass
tumors,2466,I-DiseaseClass
.,2466,O
The,2467,O
PAX3/FKHR,2467,O
fusion,2467,O
gene,2467,O
",",2467,O
formed,2467,O
by,2467,O
a,2467,O
t,2467,O
(,2467,O
2,2467,O
;,2467,O
13,2467,O
),2467,O
(,2467,O
q35,2467,O
;,2467,O
q14,2467,O
),2467,O
in,2467,O
alveolar,2467,B-SpecificDisease
rhabdomyosarcoma,2467,I-SpecificDisease
",",2467,O
encodes,2467,O
a,2467,O
hybrid,2467,O
protein,2467,O
that,2467,O
contains,2467,O
both,2467,O
PAX3,2467,O
DNA,2467,O
binding,2467,O
domains,2467,O
",",2467,O
the,2467,O
paired,2467,O
box,2467,O
and,2467,O
homeodomain,2467,O
",",2467,O
linked,2467,O
to,2467,O
the,2467,O
bisected,2467,O
DNA,2467,O
binding,2467,O
domain,2467,O
of,2467,O
FKHR,2467,O
",",2467,O
a,2467,O
member,2467,O
of,2467,O
the,2467,O
forkhead,2467,O
family,2467,O
of,2467,O
transcription,2467,O
factors,2467,O
.,2467,O
Here,2468,O
we,2468,O
report,2468,O
that,2468,O
PAX3,2468,O
and,2468,O
PAX3/FKHR,2468,O
display,2468,O
similar,2468,O
",",2468,O
but,2468,O
not,2468,O
identical,2468,O
transactivation,2468,O
activities,2468,O
when,2468,O
tested,2468,O
with,2468,O
model,2468,O
Pax,2468,O
recognition,2468,O
sequences,2468,O
.,2468,O
No,2469,O
functional,2469,O
role,2469,O
could,2469,O
be,2469,O
ascribed,2469,O
solely,2469,O
to,2469,O
the,2469,O
residual,2469,O
FKHR,2469,O
binding,2469,O
domain,2469,O
present,2469,O
in,2469,O
the,2469,O
fusion,2469,O
protein,2469,O
",",2469,O
but,2469,O
FKHR,2469,O
was,2469,O
found,2469,O
to,2469,O
contribute,2469,O
a,2469,O
strong,2469,O
carboxyl,2469,O
terminal,2469,O
activation,2469,O
domain,2469,O
replacing,2469,O
the,2469,O
one,2469,O
located,2469,O
in,2469,O
the,2469,O
unrearranged,2469,O
PAX3,2469,O
gene,2469,O
.,2469,O
We,2470,O
show,2470,O
that,2470,O
the,2470,O
native,2470,O
PAX3/FKHR,2470,O
protein,2470,O
present,2470,O
in,2470,O
tumor,2470,B-Modifier
cells,2470,O
with,2470,O
this,2470,O
translocation,2470,O
has,2470,O
transcriptional,2470,O
characteristics,2470,O
similar,2470,O
to,2470,O
the,2470,O
in,2470,O
vitro,2470,O
expressed,2470,O
protein,2470,O
.,2470,O
The,2471,O
ability,2471,O
of,2471,O
the,2471,O
PAX3/FKHR,2471,O
hybrid,2471,O
protein,2471,O
to,2471,O
bind,2471,O
DNA,2471,O
in,2471,O
a,2471,O
sequence,2471,O
specific,2471,O
manner,2471,O
and,2471,O
to,2471,O
transactivate,2471,O
the,2471,O
expression,2471,O
of,2471,O
artificial,2471,O
reporter,2471,O
genes,2471,O
suggests,2471,O
that,2471,O
its,2471,O
aberrant,2471,O
expression,2471,O
could,2471,O
subvert,2471,O
the,2471,O
transcriptional,2471,O
programs,2471,O
that,2471,O
normally,2471,O
control,2471,O
the,2471,O
growth,2471,O
",",2471,O
differentiation,2471,O
",",2471,O
and,2471,O
survival,2471,O
of,2471,O
primitive,2471,O
myogenic,2471,O
precursors,2471,O
in,2471,O
vivo,2471,O
..,2471,O
A,2472,O
p16INK4a-insensitive,2472,O
CDK4,2472,O
mutant,2472,O
targeted,2472,O
by,2472,O
cytolytic,2472,O
T,2472,O
lymphocytes,2472,O
in,2472,O
a,2472,O
human,2472,O
melanoma,2472,B-SpecificDisease
.,2472,O
A,2473,O
mutated,2473,O
cyclin-dependent,2473,O
kinase,2473,O
4,2473,O
(,2473,O
CDK4,2473,O
),2473,O
was,2473,O
identified,2473,O
as,2473,O
a,2473,O
tumor-specific,2473,B-Modifier
antigen,2473,O
recognized,2473,O
by,2473,O
HLA-A2,2473,O
.,2473,O
1-restricted,2474,O
autologous,2474,O
cytolytic,2474,O
T,2474,O
lymphocytes,2474,O
(,2474,O
CTLs,2474,O
),2474,O
in,2474,O
a,2474,O
human,2474,O
melanoma,2474,B-SpecificDisease
.,2474,O
The,2475,O
mutated,2475,O
CDK4,2475,O
allele,2475,O
was,2475,O
present,2475,O
in,2475,O
autologous,2475,O
cultured,2475,O
melanoma,2475,B-Modifier
cells,2475,O
and,2475,O
metastasis,2475,O
tissue,2475,O
",",2475,O
but,2475,O
not,2475,O
in,2475,O
the,2475,O
patients,2475,O
lymphocytes,2475,O
.,2475,O
The,2476,O
mutation,2476,O
",",2476,O
an,2476,O
arginine-to-cysteine,2476,O
exchange,2476,O
at,2476,O
residue,2476,O
24,2476,O
",",2476,O
was,2476,O
part,2476,O
of,2476,O
the,2476,O
CDK4,2476,O
peptide,2476,O
recognized,2476,O
by,2476,O
CTLs,2476,O
and,2476,O
prevented,2476,O
binding,2476,O
of,2476,O
the,2476,O
CDK4,2476,O
inhibitor,2476,O
p16INK4a,2476,O
",",2476,O
but,2476,O
not,2476,O
of,2476,O
p21,2476,O
or,2476,O
of,2476,O
p27KIP1,2476,O
.,2476,O
The,2477,O
same,2477,O
mutation,2477,O
was,2477,O
found,2477,O
in,2477,O
one,2477,O
additional,2477,O
melanoma,2477,B-SpecificDisease
among,2477,O
28,2477,O
melanomas,2477,B-SpecificDisease
analyzed,2477,O
.,2477,O
These,2478,O
results,2478,O
suggest,2478,O
that,2478,O
mutation,2478,O
of,2478,O
CDK4,2478,O
can,2478,O
create,2478,O
a,2478,O
tumor-specific,2478,B-Modifier
antigen,2478,O
and,2478,O
can,2478,O
disrupt,2478,O
the,2478,O
cell-cycle,2478,O
regulation,2478,O
exerted,2478,O
by,2478,O
the,2478,O
tumor,2478,B-Modifier
suppressor,2478,O
p16INK4a,2478,O
..,2478,O
Rapid,2479,O
detection,2479,O
of,2479,O
BRCA1,2479,O
mutations,2479,O
by,2479,O
the,2479,O
protein,2479,O
truncation,2479,O
test,2479,O
.,2479,O
More,2480,O
than,2480,O
75,2480,O
%,2480,O
of,2480,O
the,2480,O
reported,2480,O
mutations,2480,O
in,2480,O
the,2480,O
hereditary,2480,B-Modifier
breast,2480,I-Modifier
and,2480,I-Modifier
ovarian,2480,I-Modifier
cancer,2480,I-Modifier
gene,2480,O
",",2480,O
BRCA1,2480,O
",",2480,O
result,2480,O
in,2480,O
truncated,2480,O
proteins,2480,O
.,2480,O
We,2481,O
have,2481,O
used,2481,O
the,2481,O
protein,2481,O
truncation,2481,O
test,2481,O
(,2481,O
PTT,2481,O
),2481,O
to,2481,O
screen,2481,O
for,2481,O
mutations,2481,O
in,2481,O
exon,2481,O
11,2481,O
",",2481,O
which,2481,O
encodes,2481,O
61,2481,O
%,2481,O
of,2481,O
BRCA1,2481,O
.,2481,O
In,2482,O
45,2482,O
patients,2482,O
from,2482,O
breast,2482,O
and/or,2482,O
ovarian,2482,O
cancer,2482,O
families,2482,O
we,2482,O
found,2482,O
six,2482,O
novel,2482,O
mutations,2482,O
two,2482,O
single,2482,O
nucleotide,2482,O
insertions,2482,O
",",2482,O
three,2482,O
small,2482,O
deletions,2482,O
(,2482,O
1-5,2482,O
bp,2482,O
),2482,O
and,2482,O
a,2482,O
nonsense,2482,O
mutation,2482,O
identified,2482,O
two,2482,O
unrelated,2482,O
families,2482,O
.,2482,O
Furthermore,2483,O
",",2483,O
we,2483,O
were,2483,O
able,2483,O
to,2483,O
amplify,2483,O
the,2483,O
remaining,2483,O
coding,2483,O
region,2483,O
by,2483,O
RT-PCR,2483,O
using,2483,O
lymphocyte,2483,O
RNA,2483,O
.,2483,O
Combined,2484,O
with,2484,O
PTT,2484,O
",",2484,O
we,2484,O
detected,2484,O
aberrantly,2484,O
spliced,2484,O
products,2484,O
affecting,2484,O
exons,2484,O
5,2484,O
and,2484,O
6,2484,O
in,2484,O
one,2484,O
of,2484,O
two,2484,O
BRCA1-linked,2484,O
families,2484,O
examined,2484,O
.,2484,O
The,2485,O
protein,2485,O
truncation,2485,O
test,2485,O
promises,2485,O
to,2485,O
become,2485,O
a,2485,O
valuable,2485,O
technique,2485,O
in,2485,O
detecting,2485,O
BRCA1,2485,O
mutations,2485,O
..,2485,O
Cloning,2486,O
of,2486,O
human,2486,O
very-long-chain,2486,O
acyl-coenzyme,2486,O
A,2486,O
dehydrogenase,2486,O
and,2486,O
molecular,2486,O
characterization,2486,O
of,2486,O
its,2486,O
deficiency,2486,O
in,2486,O
two,2486,O
patients,2486,O
.,2486,O
Two,2487,O
overlapping,2487,O
cDNA,2487,O
clones,2487,O
(,2487,O
1,2487,O
",",2487,O
991,2487,O
bp,2487,O
and,2487,O
736,2487,O
bp,2487,O
",",2487,O
respectively,2487,O
),2487,O
encoding,2487,O
the,2487,O
precursor,2487,O
of,2487,O
human,2487,O
mitochondrial,2487,O
very-long-chain,2487,O
acyl-coenzyme,2487,O
A,2487,O
dehydrogenase,2487,O
(,2487,O
VLCAD,2487,O
),2487,O
were,2487,O
cloned,2487,O
and,2487,O
sequenced,2487,O
.,2487,O
The,2488,O
cDNA,2488,O
inserts,2488,O
of,2488,O
these,2488,O
clones,2488,O
together,2488,O
encompass,2488,O
a,2488,O
region,2488,O
of,2488,O
2,2488,O
",",2488,O
177,2488,O
bases,2488,O
",",2488,O
encoding,2488,O
the,2488,O
entire,2488,O
protein,2488,O
of,2488,O
655,2488,O
amino,2488,O
acids,2488,O
",",2488,O
including,2488,O
a,2488,O
40-amino,2488,O
acid,2488,O
leader,2488,O
peptide,2488,O
and,2488,O
a,2488,O
615-amino,2488,O
acid,2488,O
mature,2488,O
polypeptide,2488,O
.,2488,O
PCR-amplified,2489,O
VLCAD,2489,O
cDNAs,2489,O
were,2489,O
sequenced,2489,O
in,2489,O
cultured,2489,O
fibroblasts,2489,O
from,2489,O
two,2489,O
VLCAD-deficient,2489,B-Modifier
patients,2489,O
.,2489,O
In,2490,O
both,2490,O
patients,2490,O
",",2490,O
a,2490,O
105-bp,2490,O
deletion,2490,O
encompassing,2490,O
bases,2490,O
1078-1182,2490,O
in,2490,O
VLCAD,2490,O
cDNA,2490,O
was,2490,O
identified,2490,O
.,2490,O
The,2491,O
deletion,2491,O
seems,2491,O
to,2491,O
occur,2491,O
due,2491,O
to,2491,O
exon,2491,O
skipping,2491,O
during,2491,O
processing,2491,O
of,2491,O
VLCAD,2491,O
pre-mRNA,2491,O
.,2491,O
This,2492,O
is,2492,O
the,2492,O
first,2492,O
demonstration,2492,O
of,2492,O
a,2492,O
mutation,2492,O
causing,2492,O
VLCAD,2492,B-SpecificDisease
deficiency,2492,I-SpecificDisease
.,2492,O
Quantitative,2493,O
cDNA,2493,O
expression,2493,O
of,2493,O
normal,2493,O
human,2493,O
VLCAD,2493,O
was,2493,O
performed,2493,O
in,2493,O
the,2493,O
patients,2493,O
fibroblasts,2493,O
",",2493,O
using,2493,O
vaccinia,2493,O
viral,2493,O
system,2493,O
",",2493,O
which,2493,O
demonstrated,2493,O
that,2493,O
the,2493,O
deficiency,2493,B-SpecificDisease
of,2493,I-SpecificDisease
the,2493,I-SpecificDisease
normal,2493,I-SpecificDisease
VLCAD,2493,I-SpecificDisease
protein,2493,I-SpecificDisease
causes,2493,O
impaired,2493,O
long-chain,2493,O
fatty,2493,O
acid,2493,O
beta-oxidation,2493,O
activity,2493,O
in,2493,O
the,2493,O
patients,2493,O
fibroblasts,2493,O
.,2493,O
In,2494,O
patient,2494,O
fibroblasts,2494,O
",",2494,O
raising,2494,O
VLCAD,2494,O
activity,2494,O
to,2494,O
approximately,2494,O
20,2494,O
%,2494,O
of,2494,O
normal,2494,O
control,2494,O
fibroblast,2494,O
activity,2494,O
raised,2494,O
palmitic,2494,O
acid,2494,O
beta-oxidation,2494,O
flux,2494,O
to,2494,O
the,2494,O
level,2494,O
found,2494,O
in,2494,O
control,2494,O
fibroblasts,2494,O
",",2494,O
which,2494,O
may,2494,O
offer,2494,O
important,2494,O
information,2494,O
for,2494,O
the,2494,O
rational,2494,O
design,2494,O
of,2494,O
future,2494,O
somatic,2494,O
gene,2494,O
therapy,2494,O
for,2494,O
VLCAD,2494,B-SpecificDisease
deficiency,2494,I-SpecificDisease
..,2494,O
Brain,2495,B-DiseaseClass
disease,2495,I-DiseaseClass
and,2495,O
molecular,2495,O
analysis,2495,O
in,2495,O
myotonic,2495,B-SpecificDisease
dystrophy,2495,I-SpecificDisease
.,2495,O
Abnormal,2496,O
amplification,2496,O
of,2496,O
a,2496,O
CTG,2496,O
repeat,2496,O
on,2496,O
chromosome,2496,O
19,2496,O
is,2496,O
the,2496,O
molecular,2496,O
basis,2496,O
of,2496,O
myotonic,2496,B-SpecificDisease
dystrophy,2496,I-SpecificDisease
(,2496,O
DM,2496,B-SpecificDisease
),2496,O
.,2496,O
Expansion,2497,O
of,2497,O
the,2497,O
repeat,2497,O
has,2497,O
been,2497,O
correlated,2497,O
with,2497,O
severity,2497,O
of,2497,O
several,2497,O
clinical,2497,O
features,2497,O
of,2497,O
the,2497,O
disease,2497,O
.,2497,O
We,2498,O
performed,2498,O
extensive,2498,O
cognitive,2498,O
testing,2498,O
",",2498,O
cerebral,2498,O
magnetic,2498,O
resonance,2498,O
imaging,2498,O
(,2498,O
MRI,2498,O
),2498,O
and,2498,O
a,2498,O
molecular,2498,O
analysis,2498,O
in,2498,O
28,2498,O
cases,2498,O
of,2498,O
DM,2498,B-SpecificDisease
to,2498,O
determine,2498,O
the,2498,O
relationship,2498,O
between,2498,O
the,2498,O
molecular,2498,O
defect,2498,O
and,2498,O
brain,2498,B-DiseaseClass
disease,2498,I-DiseaseClass
.,2498,O
Performance,2499,O
in,2499,O
two,2499,O
or,2499,O
more,2499,O
cognitive,2499,O
tests,2499,O
was,2499,O
pathological,2499,O
in,2499,O
10,2499,O
cases,2499,O
.,2499,O
Fourteen,2500,O
patients,2500,O
had,2500,O
subcortical,2500,O
white,2500,B-DiseaseClass
matter,2500,I-DiseaseClass
lesions,2500,I-DiseaseClass
on,2500,O
MRI,2500,O
",",2500,O
14,2500,O
had,2500,O
cerebral,2500,B-SpecificDisease
atrophy,2500,I-SpecificDisease
.,2500,O
Amplification,2501,O
of,2501,O
the,2501,O
CTG,2501,O
repeat,2501,O
showed,2501,O
a,2501,O
strong,2501,O
correlation,2501,O
with,2501,O
cognitive,2501,O
test,2501,O
deficits,2501,O
when,2501,O
exceeding,2501,O
a,2501,O
length,2501,O
of,2501,O
over,2501,O
1000,2501,O
trinucleotides,2501,O
.,2501,O
MRI,2502,O
lesions,2502,O
were,2502,O
associated,2502,O
with,2502,O
impaired,2502,O
psychometric,2502,O
performance,2502,O
",",2502,O
but,2502,O
MRI,2502,O
and,2502,O
molecular,2502,O
findings,2502,O
were,2502,O
only,2502,O
weakly,2502,O
related,2502,O
.,2502,O
Disease,2503,O
duration,2503,O
influenced,2503,O
the,2503,O
appearance,2503,O
and,2503,O
amount,2503,O
of,2503,O
white,2503,B-DiseaseClass
matter,2503,I-DiseaseClass
lesions,2503,I-DiseaseClass
on,2503,O
MRI,2503,O
.,2503,O
Quantification,2504,O
of,2504,O
CTG,2504,O
repeat,2504,O
size,2504,O
may,2504,O
allow,2504,O
an,2504,O
early,2504,O
estimate,2504,O
on,2504,O
the,2504,O
probability,2504,O
of,2504,O
brain,2504,O
involvement,2504,O
in,2504,O
DM,2504,B-SpecificDisease
;,2504,O
cognitive,2504,B-DiseaseClass
dysfunction,2504,I-DiseaseClass
is,2504,O
associated,2504,O
with,2504,O
white,2504,B-DiseaseClass
matter,2504,I-DiseaseClass
lesions,2504,I-DiseaseClass
and,2504,O
cerebral,2504,B-SpecificDisease
atrophy,2504,I-SpecificDisease
later,2504,O
on,2504,O
in,2504,O
the,2504,O
course,2504,O
..,2504,O
Mutations,2505,O
in,2505,O
the,2505,O
gene,2505,O
for,2505,O
X-linked,2505,B-SpecificDisease
adrenoleukodystrophy,2505,I-SpecificDisease
in,2505,O
patients,2505,O
with,2505,O
different,2505,O
clinical,2505,O
phenotypes,2505,O
.,2505,O
Recently,2506,O
",",2506,O
the,2506,O
gene,2506,O
for,2506,O
the,2506,O
most,2506,O
common,2506,O
peroxisomal,2506,B-DiseaseClass
disorder,2506,I-DiseaseClass
",",2506,O
X-linked,2506,B-SpecificDisease
adrenoleukodystrophy,2506,I-SpecificDisease
(,2506,O
X-ALD,2506,B-SpecificDisease
),2506,O
",",2506,O
has,2506,O
been,2506,O
described,2506,O
encoding,2506,O
a,2506,O
peroxisomal,2506,O
membrane,2506,O
transporter,2506,O
protein,2506,O
.,2506,O
We,2507,O
analyzed,2507,O
the,2507,O
entire,2507,O
protein-coding,2507,O
sequence,2507,O
of,2507,O
this,2507,O
gene,2507,O
by,2507,O
reverse-transcription,2507,O
PCR,2507,O
",",2507,O
SSCP,2507,O
",",2507,O
and,2507,O
DNA,2507,O
sequencing,2507,O
in,2507,O
five,2507,O
patients,2507,O
with,2507,O
different,2507,O
clinical,2507,O
expression,2507,O
of,2507,O
X-ALD,2507,B-SpecificDisease
and,2507,O
in,2507,O
their,2507,O
female,2507,O
relatives,2507,O
;,2507,O
these,2507,O
clinical,2507,O
expressions,2507,O
were,2507,O
cerebral,2507,O
childhood,2507,O
ALD,2507,B-SpecificDisease
",",2507,O
adrenomyeloneuropathy,2507,B-SpecificDisease
(,2507,O
AMN,2507,B-SpecificDisease
),2507,O
",",2507,O
and,2507,O
``,2507,O
Addison,2507,B-Modifier
disease,2507,I-Modifier
only,2507,I-Modifier
``,2507,O
(,2507,O
ADO,2507,B-Modifier
),2507,O
phenotype,2507,O
.,2507,O
In,2508,O
the,2508,O
three,2508,O
patients,2508,O
exhibiting,2508,O
the,2508,O
classical,2508,O
picture,2508,O
of,2508,O
severe,2508,O
childhood,2508,O
ALD,2508,B-SpecificDisease
we,2508,O
identified,2508,O
in,2508,O
the,2508,O
5,2508,O
portion,2508,O
of,2508,O
the,2508,O
X-ALD,2508,B-Modifier
gene,2508,O
a,2508,O
38-bp,2508,O
deletion,2508,O
that,2508,O
causes,2508,O
a,2508,O
frameshift,2508,O
mutation,2508,O
",",2508,O
a,2508,O
3-bp,2508,O
deletion,2508,O
leading,2508,O
to,2508,O
a,2508,O
deletion,2508,O
of,2508,O
an,2508,O
amino,2508,O
acid,2508,O
in,2508,O
the,2508,O
ATP-binding,2508,O
domain,2508,O
of,2508,O
the,2508,O
ALD,2508,B-Modifier
protein,2508,O
",",2508,O
and,2508,O
a,2508,O
missense,2508,O
mutation,2508,O
.,2508,O
In,2509,O
the,2509,O
patient,2509,O
with,2509,O
the,2509,O
clinical,2509,O
phenotype,2509,O
of,2509,O
AMN,2509,B-SpecificDisease
",",2509,O
a,2509,O
nonsense,2509,O
mutation,2509,O
in,2509,O
codon,2509,O
212,2509,O
",",2509,O
along,2509,O
with,2509,O
a,2509,O
second,2509,O
site,2509,O
mutation,2509,O
at,2509,O
codon,2509,O
178,2509,O
",",2509,O
was,2509,O
observed,2509,O
.,2509,O
Analysis,2510,O
of,2510,O
the,2510,O
patient,2510,O
with,2510,O
the,2510,O
ADO,2510,B-Modifier
phenotype,2510,O
revealed,2510,O
a,2510,O
further,2510,O
missense,2510,O
mutation,2510,O
at,2510,O
a,2510,O
highly,2510,O
conserved,2510,O
position,2510,O
in,2510,O
the,2510,O
ALDP/PMP70,2510,O
comparison,2510,O
.,2510,O
The,2511,O
disruptive,2511,O
nature,2511,O
of,2511,O
two,2511,O
mutations,2511,O
(,2511,O
i.,2511,O
e.,2511,O
",",2511,O
the,2511,O
frameshift,2511,O
and,2511,O
the,2511,O
nonsense,2511,O
mutation,2511,O
),2511,O
in,2511,O
patients,2511,O
with,2511,O
biochemically,2511,O
proved,2511,O
childhood,2511,O
ALD,2511,B-SpecificDisease
and,2511,O
AMN,2511,B-SpecificDisease
further,2511,O
strongly,2511,O
supports,2511,O
the,2511,O
hypothesis,2511,O
that,2511,O
alterations,2511,O
in,2511,O
this,2511,O
gene,2511,O
play,2511,O
a,2511,O
crucial,2511,O
role,2511,O
in,2511,O
the,2511,O
pathogenesis,2511,O
of,2511,O
X-ALD,2511,B-SpecificDisease
.,2511,O
Since,2512,O
the,2512,O
current,2512,O
biochemical,2512,O
techniques,2512,O
for,2512,O
X-ALD,2512,B-Modifier
carrier,2512,O
detection,2512,O
in,2512,O
affected,2512,O
families,2512,O
lack,2512,O
sufficient,2512,O
reliability,2512,O
",",2512,O
our,2512,O
procedure,2512,O
described,2512,O
for,2512,O
systematic,2512,O
mutation,2512,O
scanning,2512,O
is,2512,O
also,2512,O
capable,2512,O
of,2512,O
improving,2512,O
genetic,2512,O
counseling,2512,O
and,2512,O
prenatal,2512,O
diagnosis,2512,O
Duchenne,2513,B-SpecificDisease
muscular,2513,I-SpecificDisease
dystrophy,2513,I-SpecificDisease
and,2513,O
myotonic,2513,B-SpecificDisease
dystrophy,2513,I-SpecificDisease
in,2513,O
the,2513,O
same,2513,O
patient,2513,O
.,2513,O
We,2514,O
report,2514,O
on,2514,O
the,2514,O
first,2514,O
patient,2514,O
identified,2514,O
with,2514,O
myotonic,2514,B-SpecificDisease
dystrophy,2514,I-SpecificDisease
and,2514,O
Duchenne,2514,B-SpecificDisease
muscular,2514,I-SpecificDisease
dystrophy,2514,I-SpecificDisease
(,2514,O
DMD,2514,B-SpecificDisease
),2514,O
.,2514,O
The,2515,O
family,2515,O
of,2515,O
the,2515,O
propositus,2515,O
had,2515,O
a,2515,O
strong,2515,O
history,2515,O
of,2515,O
myotonic,2515,B-SpecificDisease
dystrophy,2515,I-SpecificDisease
",",2515,O
and,2515,O
there,2515,O
was,2515,O
an,2515,O
intrafamilial,2515,O
pathological,2515,O
expansion,2515,O
of,2515,O
the,2515,O
responsible,2515,O
CTG,2515,O
repeat,2515,O
between,2515,O
the,2515,O
mildly,2515,O
affected,2515,O
mother,2515,O
(,2515,O
160,2515,O
repeats,2515,O
;,2515,O
normal,2515,O
27,2515,O
repeats,2515,O
),2515,O
and,2515,O
her,2515,O
more,2515,O
severely,2515,O
affected,2515,O
son,2515,O
(,2515,O
650,2515,O
repeats,2515,O
),2515,O
",",2515,O
and,2515,O
his,2515,O
sister,2515,O
(,2515,O
650,2515,O
repeats,2515,O
),2515,O
.,2515,O
The,2516,O
propositus,2516,O
was,2516,O
an,2516,O
isolated,2516,O
case,2516,O
of,2516,O
Duchenne,2516,B-SpecificDisease
muscular,2516,I-SpecificDisease
dystrophy,2516,I-SpecificDisease
with,2516,O
marked,2516,O
dystrophin,2516,B-SpecificDisease
deficiency,2516,I-SpecificDisease
in,2516,O
muscle,2516,O
biopsy,2516,O
.,2516,O
The,2517,O
patient,2517,O
was,2517,O
still,2517,O
ambulatory,2517,O
post,2517,O
age,2517,O
16,2517,O
.,2517,O
Myotonic,2518,B-SpecificDisease
dystrophy,2518,I-SpecificDisease
could,2518,O
interfere,2518,O
to,2518,O
some,2518,O
extent,2518,O
with,2518,O
the,2518,O
progression,2518,O
of,2518,O
Duchenne,2518,B-SpecificDisease
dystrophy,2518,I-SpecificDisease
.,2518,O
However,2519,O
",",2519,O
other,2519,O
interpretations,2519,O
are,2519,O
possible,2519,O
.,2519,O
Twelve,2520,O
percent,2520,O
of,2520,O
dystrophin,2520,O
revertant,2520,O
fibers,2520,O
as,2520,O
observed,2520,O
by,2520,O
immunohistochemistry,2520,O
could,2520,O
be,2520,O
sufficient,2520,O
to,2520,O
ameliorate,2520,O
typical,2520,O
DMD,2520,B-Modifier
clinical,2520,O
severity,2520,O
",",2520,O
or,2520,O
the,2520,O
patient,2520,O
may,2520,O
present,2520,O
a,2520,O
somatic,2520,O
mosaic,2520,O
.,2520,O
The,2521,O
pathophysiological,2521,O
interactions,2521,O
of,2521,O
these,2521,O
two,2521,O
unlinked,2521,O
disorders,2521,O
are,2521,O
discussed,2521,O
at,2521,O
the,2521,O
clinical,2521,O
and,2521,O
histopathological,2521,O
levels,2521,O
..,2521,O
Age,2522,O
at,2522,O
diagnosis,2522,O
as,2522,O
an,2522,O
indicator,2522,O
of,2522,O
eligibility,2522,O
for,2522,O
BRCA1,2522,O
DNA,2522,O
testing,2522,O
in,2522,O
familial,2522,B-SpecificDisease
breast,2522,I-SpecificDisease
cancer,2522,I-SpecificDisease
.,2522,O
We,2523,O
searched,2523,O
for,2523,O
criteria,2523,O
that,2523,O
could,2523,O
indicate,2523,O
breast,2523,B-Modifier
cancer,2523,I-Modifier
families,2523,O
with,2523,O
a,2523,O
high,2523,O
prior,2523,O
probability,2523,O
of,2523,O
being,2523,O
caused,2523,O
by,2523,O
the,2523,O
breast/ovarian,2523,B-Modifier
cancer,2523,I-Modifier
susceptibility,2523,O
locus,2523,O
BRCA1,2523,O
on,2523,O
chromosome,2523,O
17,2523,O
.,2523,O
To,2524,O
this,2524,O
end,2524,O
",",2524,O
we,2524,O
performed,2524,O
a,2524,O
linkage,2524,O
study,2524,O
with,2524,O
59,2524,O
consecutively,2524,O
collected,2524,O
Dutch,2524,O
breast,2524,B-Modifier
cancer,2524,I-Modifier
families,2524,O
",",2524,O
including,2524,O
16,2524,O
with,2524,O
at,2524,O
least,2524,O
one,2524,O
case,2524,O
of,2524,O
ovarian,2524,B-SpecificDisease
cancer,2524,I-SpecificDisease
.,2524,O
We,2525,O
used,2525,O
an,2525,O
intake,2525,O
cut-off,2525,O
of,2525,O
at,2525,O
least,2525,O
three,2525,O
first-degree,2525,O
relatives,2525,O
with,2525,O
breast,2525,O
and/or,2525,O
ovarian,2525,O
cancer,2525,O
at,2525,O
any,2525,O
age,2525,O
.,2525,O
Significant,2526,O
evidence,2526,O
for,2526,O
linkage,2526,O
was,2526,O
found,2526,O
only,2526,O
among,2526,O
the,2526,O
13,2526,O
breast,2526,B-Modifier
cancer,2526,I-Modifier
families,2526,O
with,2526,O
a,2526,O
mean,2526,O
age,2526,O
at,2526,O
diagnosis,2526,O
of,2526,O
less,2526,O
than,2526,O
45,2526,O
years,2526,O
.,2526,O
An,2527,O
unexpectedly,2527,O
low,2527,O
proportion,2527,O
of,2527,O
the,2527,O
breast-ovarian,2527,B-Modifier
cancer,2527,I-Modifier
families,2527,O
were,2527,O
estimated,2527,O
to,2527,O
be,2527,O
linked,2527,O
to,2527,O
BRCA1,2527,O
",",2527,O
which,2527,O
could,2527,O
be,2527,O
due,2527,O
to,2527,O
a,2527,O
founder,2527,O
effect,2527,O
in,2527,O
the,2527,O
Dutch,2527,O
population,2527,O
.,2527,O
Given,2528,O
the,2528,O
expected,2528,O
logistical,2528,O
problems,2528,O
in,2528,O
clinical,2528,O
management,2528,O
now,2528,O
that,2528,O
BRCA1,2528,O
has,2528,O
been,2528,O
identified,2528,O
",",2528,O
we,2528,O
propose,2528,O
an,2528,O
interim,2528,O
period,2528,O
in,2528,O
which,2528,O
only,2528,O
families,2528,O
with,2528,O
a,2528,O
strong,2528,O
positive,2528,O
family,2528,O
history,2528,O
for,2528,O
early,2528,O
onset,2528,O
breast,2528,O
and/or,2528,O
ovarian,2528,O
cancer,2528,O
will,2528,O
be,2528,O
offered,2528,O
BRCA1,2528,O
mutation,2528,O
testing,2528,O
..,2528,O
Linkage,2529,O
analysis,2529,O
of,2529,O
26,2529,O
Canadian,2529,O
breast,2529,O
and,2529,O
breast-ovarian,2529,O
cancer,2529,O
families,2529,O
.,2529,O
We,2530,O
have,2530,O
examined,2530,O
26,2530,O
Canadian,2530,O
families,2530,O
with,2530,O
hereditary,2530,B-CompositeMention
breast,2530,I-CompositeMention
or,2530,I-CompositeMention
ovarian,2530,I-CompositeMention
cancer,2530,I-CompositeMention
for,2530,O
linkage,2530,O
to,2530,O
markers,2530,O
flanking,2530,O
the,2530,O
BRCA1,2530,O
gene,2530,O
on,2530,O
chromosome,2530,O
17q12-q21,2530,O
.,2530,O
Of,2531,O
the,2531,O
15,2531,O
families,2531,O
that,2531,O
contain,2531,O
cases,2531,O
of,2531,O
ovarian,2531,B-SpecificDisease
cancer,2531,I-SpecificDisease
",",2531,O
94,2531,O
%,2531,O
were,2531,O
estimated,2531,O
to,2531,O
be,2531,O
linked,2531,O
to,2531,O
BRCA1,2531,O
.,2531,O
In,2532,O
contrast,2532,O
",",2532,O
there,2532,O
was,2532,O
no,2532,O
overall,2532,O
evidence,2532,O
of,2532,O
linkage,2532,O
in,2532,O
the,2532,O
group,2532,O
of,2532,O
10,2532,O
families,2532,O
with,2532,O
breast,2532,B-SpecificDisease
cancer,2532,I-SpecificDisease
without,2532,O
ovarian,2532,B-SpecificDisease
cancer,2532,I-SpecificDisease
.,2532,O
A,2533,O
genetic,2533,O
recombinant,2533,O
in,2533,O
a,2533,O
breast-ovarian,2533,B-Modifier
cancer,2533,I-Modifier
family,2533,O
indicates,2533,O
a,2533,O
placement,2533,O
of,2533,O
BRCA1,2533,O
telomeric,2533,O
to,2533,O
D17S776,2533,O
",",2533,O
and,2533,O
helps,2533,O
to,2533,O
define,2533,O
the,2533,O
region,2533,O
of,2533,O
assignment,2533,O
of,2533,O
the,2533,O
cancer,2533,B-Modifier
susceptibility,2533,O
gene,2533,O
.,2533,O
Other,2534,O
cancers,2534,B-DiseaseClass
of,2534,O
interest,2534,O
that,2534,O
appeared,2534,O
in,2534,O
the,2534,O
BRCA1-linked,2534,O
families,2534,O
included,2534,O
primary,2534,B-SpecificDisease
peritoneal,2534,I-SpecificDisease
cancer,2534,I-SpecificDisease
",",2534,O
cancer,2534,B-SpecificDisease
of,2534,I-SpecificDisease
the,2534,I-SpecificDisease
fallopian,2534,I-SpecificDisease
tube,2534,I-SpecificDisease
",",2534,O
and,2534,O
malignant,2534,B-SpecificDisease
melanoma,2534,I-SpecificDisease
..,2534,O
Structural,2535,O
analysis,2535,O
of,2535,O
the,2535,O
5,2535,O
',2535,O
region,2535,O
of,2535,O
mouse,2535,O
and,2535,O
human,2535,O
Huntington,2535,B-Modifier
disease,2535,I-Modifier
genes,2535,O
reveals,2535,O
conservation,2535,O
of,2535,O
putative,2535,O
promoter,2535,O
region,2535,O
and,2535,O
di-,2535,O
and,2535,O
trinucleotide,2535,O
polymorphisms,2535,O
.,2535,O
We,2536,O
have,2536,O
previously,2536,O
cloned,2536,O
and,2536,O
characterized,2536,O
the,2536,O
murine,2536,O
homologue,2536,O
of,2536,O
the,2536,O
Huntington,2536,B-Modifier
disease,2536,I-Modifier
(,2536,O
HD,2536,B-Modifier
),2536,O
gene,2536,O
and,2536,O
shown,2536,O
that,2536,O
it,2536,O
maps,2536,O
to,2536,O
mouse,2536,O
chromosome,2536,O
5,2536,O
within,2536,O
a,2536,O
region,2536,O
of,2536,O
conserved,2536,O
synteny,2536,O
with,2536,O
human,2536,O
chromosome,2536,O
4p16,2536,O
.,2536,O
3,2537,O
3,2537,O
.,2537,O
Here,2538,O
we,2538,O
present,2538,O
a,2538,O
detailed,2538,O
comparison,2538,O
of,2538,O
the,2538,O
sequence,2538,O
of,2538,O
the,2538,O
putative,2538,O
promoter,2538,O
and,2538,O
the,2538,O
organization,2538,O
of,2538,O
the,2538,O
5,2538,O
genomic,2538,O
region,2538,O
of,2538,O
the,2538,O
murine,2538,O
(,2538,O
Hdh,2538,O
),2538,O
and,2538,O
human,2538,O
HD,2538,B-Modifier
genes,2538,O
encompassing,2538,O
the,2538,O
first,2538,O
five,2538,O
exons,2538,O
.,2538,O
We,2539,O
show,2539,O
that,2539,O
in,2539,O
this,2539,O
region,2539,O
these,2539,O
two,2539,O
genes,2539,O
share,2539,O
identical,2539,O
exon,2539,O
boundaries,2539,O
",",2539,O
but,2539,O
have,2539,O
different-size,2539,O
introns,2539,O
.,2539,O
Two,2540,O
dinucleotide,2540,O
(,2540,O
CT,2540,O
),2540,O
and,2540,O
one,2540,O
trinucleotide,2540,O
intronic,2540,O
polymorphism,2540,O
in,2540,O
Hdh,2540,O
and,2540,O
an,2540,O
intronic,2540,O
CA,2540,O
polymorphism,2540,O
in,2540,O
the,2540,O
HD,2540,B-Modifier
gene,2540,O
were,2540,O
identified,2540,O
.,2540,O
Comparison,2541,O
of,2541,O
940-bp,2541,O
sequence,2541,O
5,2541,O
to,2541,O
the,2541,O
putative,2541,O
translation,2541,O
start,2541,O
site,2541,O
reveals,2541,O
a,2541,O
highly,2541,O
conserved,2541,O
region,2541,O
(,2541,O
78,2541,O
.,2541,O
8,2542,O
%,2542,O
nucleotide,2542,O
identity,2542,O
),2542,O
between,2542,O
Hdh,2542,O
and,2542,O
the,2542,O
HD,2542,B-Modifier
gene,2542,O
from,2542,O
nucleotide,2542,O
-56,2542,O
to,2542,O
-206,2542,O
(,2542,O
of,2542,O
Hdh,2542,O
),2542,O
.,2542,O
Neither,2543,O
Hdh,2543,O
nor,2543,O
the,2543,O
HD,2543,B-Modifier
gene,2543,O
have,2543,O
typical,2543,O
TATA,2543,O
or,2543,O
CCAAT,2543,O
elements,2543,O
",",2543,O
but,2543,O
both,2543,O
show,2543,O
one,2543,O
putative,2543,O
AP2,2543,O
binding,2543,O
site,2543,O
and,2543,O
numerous,2543,O
potential,2543,O
Sp1,2543,O
binding,2543,O
sites,2543,O
.,2543,O
The,2544,O
high,2544,O
sequence,2544,O
identity,2544,O
between,2544,O
Hdh,2544,O
and,2544,O
the,2544,O
HD,2544,B-Modifier
gene,2544,O
for,2544,O
approximately,2544,O
200,2544,O
bp,2544,O
5,2544,O
to,2544,O
the,2544,O
putative,2544,O
translation,2544,O
start,2544,O
site,2544,O
indicates,2544,O
that,2544,O
these,2544,O
sequences,2544,O
may,2544,O
play,2544,O
a,2544,O
role,2544,O
in,2544,O
regulating,2544,O
expression,2544,O
of,2544,O
the,2544,O
Huntington,2544,B-Modifier
disease,2544,I-Modifier
gene,2544,O
The,2545,O
protein,2545,O
deficient,2545,O
in,2545,O
Lowe,2545,B-SpecificDisease
syndrome,2545,I-SpecificDisease
is,2545,O
a,2545,O
"phosphatidylinositol-4,5-bisphosphate",2545,O
5-phosphatase,2545,O
.,2545,O
Lowe,2546,B-SpecificDisease
syndrome,2546,I-SpecificDisease
",",2546,O
also,2546,O
known,2546,O
as,2546,O
oculocerebrorenal,2546,B-SpecificDisease
syndrome,2546,I-SpecificDisease
",",2546,O
is,2546,O
caused,2546,O
by,2546,O
mutations,2546,O
in,2546,O
the,2546,O
X,2546,O
chromosome-encoded,2546,O
OCRL,2546,O
gene,2546,O
.,2546,O
The,2547,O
OCRL,2547,O
protein,2547,O
is,2547,O
51,2547,O
%,2547,O
identical,2547,O
to,2547,O
inositol,2547,O
polyphosphate,2547,O
5-phosphatase,2547,O
II,2547,O
(,2547,O
5-phosphatase,2547,O
II,2547,O
),2547,O
from,2547,O
human,2547,O
platelets,2547,O
over,2547,O
a,2547,O
span,2547,O
of,2547,O
744,2547,O
aa,2547,O
",",2547,O
suggesting,2547,O
that,2547,O
OCRL,2547,O
may,2547,O
be,2547,O
a,2547,O
similar,2547,O
enzyme,2547,O
.,2547,O
We,2548,O
engineered,2548,O
a,2548,O
construct,2548,O
of,2548,O
the,2548,O
OCRL,2548,O
cDNA,2548,O
that,2548,O
encodes,2548,O
amino,2548,O
acids,2548,O
homologous,2548,O
to,2548,O
the,2548,O
platelet,2548,O
5-phosphatase,2548,O
for,2548,O
expression,2548,O
in,2548,O
baculovirus-infected,2548,O
Sf9,2548,O
insect,2548,O
cells,2548,O
.,2548,O
This,2549,O
cDNA,2549,O
encodes,2549,O
aa,2549,O
264-968,2549,O
of,2549,O
the,2549,O
OCRL,2549,O
protein,2549,O
.,2549,O
The,2550,O
recombinant,2550,O
protein,2550,O
was,2550,O
found,2550,O
to,2550,O
catalyze,2550,O
the,2550,O
reactions,2550,O
also,2550,O
carried,2550,O
out,2550,O
by,2550,O
platelet,2550,O
5-phosphatase,2550,O
II,2550,O
.,2550,O
Thus,2551,O
OCRL,2551,O
converts,2551,O
inositol,2551,O
1,2551,O
",",2551,O
4,2551,O
",",2551,O
5-trisphosphate,2551,O
to,2551,O
inositol,2551,O
1,2551,O
",",2551,O
4-bisphosphate,2551,O
",",2551,O
and,2551,O
it,2551,O
converts,2551,O
inositol,2551,O
1,2551,O
",",2551,O
3,2551,O
",",2551,O
4,2551,O
",",2551,O
5-tetrakisphosphate,2551,O
to,2551,O
inositol,2551,O
1,2551,O
",",2551,O
3,2551,O
",",2551,O
4-trisphosphate,2551,O
.,2551,O
Most,2552,O
important,2552,O
",",2552,O
the,2552,O
enzyme,2552,O
converts,2552,O
phosphatidylinositol,2552,O
4,2552,O
",",2552,O
5-bisphosphate,2552,O
to,2552,O
phosphatidylinositol,2552,O
4-phosphate,2552,O
.,2552,O
The,2553,O
relative,2553,O
ability,2553,O
of,2553,O
OCRL,2553,O
to,2553,O
catalyze,2553,O
the,2553,O
three,2553,O
reactions,2553,O
is,2553,O
different,2553,O
from,2553,O
that,2553,O
of,2553,O
5-phosphatase,2553,O
II,2553,O
and,2553,O
from,2553,O
that,2553,O
of,2553,O
another,2553,O
5-phosphatase,2553,O
isoenzyme,2553,O
from,2553,O
platelets,2553,O
",",2553,O
5-phosphatase,2553,O
I,2553,O
.,2553,O
The,2554,O
recombinant,2554,O
OCRL,2554,O
protein,2554,O
hydrolyzes,2554,O
the,2554,O
phospholipid,2554,O
substrate,2554,O
10-,2554,O
to,2554,O
30-fold,2554,O
better,2554,O
than,2554,O
5-phosphatase,2554,O
II,2554,O
",",2554,O
and,2554,O
5-phosphatase,2554,O
I,2554,O
does,2554,O
not,2554,O
cleave,2554,O
the,2554,O
lipid,2554,O
at,2554,O
all,2554,O
.,2554,O
We,2555,O
also,2555,O
show,2555,O
that,2555,O
OCRL,2555,O
functions,2555,O
as,2555,O
a,2555,O
phosphatidylinositol,2555,O
4,2555,O
",",2555,O
5-bisphosphate,2555,O
5-phosphatase,2555,O
in,2555,O
OCRL-expressing,2555,O
Sf9,2555,O
cells,2555,O
.,2555,O
These,2556,O
results,2556,O
suggest,2556,O
that,2556,O
OCRL,2556,O
is,2556,O
mainly,2556,O
a,2556,O
lipid,2556,O
phosphatase,2556,O
that,2556,O
may,2556,O
control,2556,O
cellular,2556,O
levels,2556,O
of,2556,O
a,2556,O
critical,2556,O
metabolite,2556,O
",",2556,O
phosphatidylinositol,2556,O
4,2556,O
",",2556,O
5-bisphosphate,2556,O
.,2556,O
Deficiency,2557,O
of,2557,O
this,2557,O
enzyme,2557,O
apparently,2557,O
causes,2557,O
the,2557,O
protean,2557,O
manifestations,2557,O
of,2557,O
Lowe,2557,B-SpecificDisease
syndrome,2557,I-SpecificDisease
..,2557,O
New,2558,O
founder,2558,O
haplotypes,2558,O
at,2558,O
the,2558,O
myotonic,2558,B-Modifier
dystrophy,2558,I-Modifier
locus,2558,O
in,2558,O
southern,2558,O
Africa,2558,O
.,2558,O
The,2559,O
association,2559,O
between,2559,O
normal,2559,O
alleles,2559,O
at,2559,O
the,2559,O
CTG,2559,O
repeat,2559,O
and,2559,O
two,2559,O
nearby,2559,O
polymorphisms,2559,O
in,2559,O
the,2559,O
myotonin,2559,O
protein,2559,O
kinase,2559,O
gene,2559,O
",",2559,O
the,2559,O
Alu,2559,O
insertion/deletion,2559,O
polymorphism,2559,O
and,2559,O
the,2559,O
myotonic,2559,B-Modifier
dystrophy,2559,I-Modifier
kinase,2559,O
(,2559,O
DMK,2559,O
),2559,O
(,2559,O
G/T,2559,O
),2559,O
intron,2559,O
9/HinfI,2559,O
polymorphism,2559,O
",",2559,O
has,2559,O
been,2559,O
analyzed,2559,O
in,2559,O
South,2559,O
African,2559,O
Negroids,2559,O
",",2559,O
a,2559,O
population,2559,O
in,2559,O
which,2559,O
myotonic,2559,B-SpecificDisease
dystrophy,2559,I-SpecificDisease
(,2559,O
DM,2559,B-SpecificDisease
),2559,O
has,2559,O
not,2559,O
been,2559,O
described,2559,O
.,2559,O
South,2560,O
African,2560,O
Negroids,2560,O
have,2560,O
a,2560,O
CTG,2560,O
allelic,2560,O
distribution,2560,O
that,2560,O
is,2560,O
significantly,2560,O
different,2560,O
from,2560,O
that,2560,O
in,2560,O
Caucasoids,2560,O
and,2560,O
Japanese,2560,O
the,2560,O
CTG,2560,O
repeat,2560,O
lengths,2560,O
of,2560,O
>,2560,O
or,2560,O
=,2560,O
19,2560,O
are,2560,O
very,2560,O
rare,2560,O
.,2560,O
The,2561,O
striking,2561,O
linkage,2561,O
disequilibrium,2561,O
between,2561,O
specific,2561,O
alleles,2561,O
at,2561,O
the,2561,O
Alu,2561,O
polymorphism,2561,O
(,2561,O
Alu,2561,O
(,2561,O
ins,2561,O
),2561,O
and,2561,O
Alu,2561,O
(,2561,O
del,2561,O
),2561,O
),2561,O
",",2561,O
the,2561,O
HinfI,2561,O
polymorphism,2561,O
(,2561,O
HinfI-1,2561,O
and,2561,O
HinfI-2,2561,O
),2561,O
",",2561,O
and,2561,O
the,2561,O
CTG,2561,O
repeat,2561,O
polymorphism,2561,O
seen,2561,O
in,2561,O
Caucasoid,2561,O
(,2561,O
Europeans,2561,O
and,2561,O
Canadians,2561,O
),2561,O
populations,2561,O
was,2561,O
also,2561,O
found,2561,O
in,2561,O
the,2561,O
South,2561,O
African,2561,O
Negroid,2561,O
population,2561,O
.,2561,O
Numerous,2562,O
haplotypes,2562,O
",",2562,O
not,2562,O
previously,2562,O
described,2562,O
in,2562,O
Europeans,2562,O
",",2562,O
were,2562,O
",",2562,O
however,2562,O
",",2562,O
found,2562,O
.,2562,O
It,2563,O
thus,2563,O
seems,2563,O
likely,2563,O
that,2563,O
only,2563,O
a,2563,O
small,2563,O
number,2563,O
of,2563,O
these,2563,O
``,2563,O
African,2563,O
``,2563,O
chromosomes,2563,O
were,2563,O
present,2563,O
in,2563,O
the,2563,O
progenitors,2563,O
of,2563,O
all,2563,O
non-African,2563,O
peoples,2563,O
.,2563,O
These,2564,O
data,2564,O
provide,2564,O
support,2564,O
for,2564,O
the,2564,O
``,2564,O
out,2564,O
of,2564,O
Africa,2564,O
``,2564,O
model,2564,O
for,2564,O
the,2564,O
origin,2564,O
of,2564,O
modern,2564,O
humans,2564,O
and,2564,O
suggest,2564,O
that,2564,O
the,2564,O
rare,2564,O
ancestral,2564,O
DM,2564,B-Modifier
mutation,2564,O
event,2564,O
may,2564,O
have,2564,O
occurred,2564,O
after,2564,O
the,2564,O
migration,2564,O
from,2564,O
Africa,2564,O
",",2564,O
hence,2564,O
the,2564,O
absence,2564,O
of,2564,O
DM,2564,B-SpecificDisease
in,2564,O
sub-Saharan,2564,O
Negroid,2564,O
peoples,2564,O
..,2564,O
Discordant,2565,O
clinical,2565,O
outcome,2565,O
in,2565,O
myotonic,2565,B-Modifier
dystrophy,2565,I-Modifier
relatives,2565,O
showing,2565,O
(,2565,O
CTG,2565,O
),2565,O
n,2565,O
>,2565,O
700,2565,O
repeats,2565,O
.,2565,O
A,2566,O
myotonic,2566,B-Modifier
dystrophy,2566,I-Modifier
(,2566,O
DM,2566,B-Modifier
),2566,O
family,2566,O
is,2566,O
described,2566,O
in,2566,O
which,2566,O
discordant,2566,O
DM,2566,B-Modifier
phenotypes,2566,O
were,2566,O
found,2566,O
in,2566,O
the,2566,O
children,2566,O
of,2566,O
two,2566,O
affected,2566,O
sisters,2566,O
with,2566,O
similar,2566,O
CTG,2566,O
expansion,2566,O
and,2566,O
clinical,2566,O
manifestations,2566,O
.,2566,O
In,2567,O
this,2567,O
family,2567,O
",",2567,O
congenital,2567,O
as,2567,O
well,2567,O
as,2567,O
early,2567,O
severe,2567,O
childhood,2567,O
and,2567,O
later,2567,O
childhood,2567,O
onset,2567,O
DM,2567,B-SpecificDisease
coexist,2567,O
.,2567,O
This,2568,O
observation,2568,O
strengthens,2568,O
the,2568,O
limited,2568,O
ability,2568,O
of,2568,O
lymphocytes,2568,O
CTG,2568,O
repeat,2568,O
number,2568,O
analysis,2568,O
in,2568,O
predicting,2568,O
genotype-phenotype,2568,O
correlations,2568,O
in,2568,O
DM,2568,B-Modifier
patients,2568,O
..,2568,O
Purification,2569,O
of,2569,O
human,2569,O
very-long-chain,2569,O
acyl-coenzyme,2569,O
A,2569,O
dehydrogenase,2569,O
and,2569,O
characterization,2569,O
of,2569,O
its,2569,O
deficiency,2569,O
in,2569,O
seven,2569,O
patients,2569,O
.,2569,O
Mitochondrial,2570,O
very-long-chain,2570,O
acyl-coenzyme,2570,O
A,2570,O
dehydrogenase,2570,O
(,2570,O
VLCAD,2570,O
),2570,O
was,2570,O
purified,2570,O
from,2570,O
human,2570,O
liver,2570,O
.,2570,O
The,2571,O
molecular,2571,O
masses,2571,O
of,2571,O
the,2571,O
native,2571,O
enzyme,2571,O
and,2571,O
the,2571,O
subunit,2571,O
were,2571,O
estimated,2571,O
to,2571,O
be,2571,O
154,2571,O
and,2571,O
70,2571,O
kD,2571,O
",",2571,O
respectively,2571,O
.,2571,O
The,2572,O
enzyme,2572,O
was,2572,O
found,2572,O
to,2572,O
catalyze,2572,O
the,2572,O
major,2572,O
part,2572,O
of,2572,O
mitochondrial,2572,O
palmitoylcoenzyme,2572,O
A,2572,O
dehydrogenation,2572,O
in,2572,O
liver,2572,O
",",2572,O
heart,2572,O
",",2572,O
skeletal,2572,O
muscle,2572,O
",",2572,O
and,2572,O
skin,2572,O
fibroblasts,2572,O
(,2572,O
89-97,2572,O
",",2572,O
86-99,2572,O
",",2572,O
96-99,2572,O
",",2572,O
and,2572,O
78-87,2572,O
%,2572,O
",",2572,O
respectively,2572,O
),2572,O
.,2572,O
Skin,2573,O
fibroblasts,2573,O
from,2573,O
26,2573,O
patients,2573,O
suspected,2573,O
of,2573,O
having,2573,O
a,2573,O
disorder,2573,O
of,2573,O
mitochondrial,2573,O
beta-oxidation,2573,O
were,2573,O
analyzed,2573,O
for,2573,O
VLCAD,2573,O
protein,2573,O
using,2573,O
immunoblotting,2573,O
",",2573,O
and,2573,O
7,2573,O
of,2573,O
them,2573,O
contained,2573,O
undetectable,2573,O
or,2573,O
trace,2573,O
levels,2573,O
of,2573,O
the,2573,O
enzyme,2573,O
.,2573,O
The,2574,O
seven,2574,O
deficient,2574,O
fibroblast,2574,O
lines,2574,O
were,2574,O
characterized,2574,O
by,2574,O
measuring,2574,O
acyl-coenzyme,2574,O
A,2574,O
dehydrogenation,2574,O
activities,2574,O
",",2574,O
overall,2574,O
palmitic,2574,O
acid,2574,O
oxidation,2574,O
",",2574,O
and,2574,O
VLCAD,2574,O
protein,2574,O
synthesis,2574,O
using,2574,O
pulse-chase,2574,O
",",2574,O
further,2574,O
confirming,2574,O
the,2574,O
diagnosis,2574,O
of,2574,O
VLCAD,2574,B-SpecificDisease
deficiency,2574,I-SpecificDisease
.,2574,O
These,2575,O
results,2575,O
suggested,2575,O
the,2575,O
heterogenous,2575,O
nature,2575,O
of,2575,O
the,2575,O
mutations,2575,O
causing,2575,O
the,2575,O
deficiency,2575,O
in,2575,O
the,2575,O
seven,2575,O
patients,2575,O
.,2575,O
Clinically,2576,O
",",2576,O
all,2576,O
patients,2576,O
with,2576,O
VLCAD,2576,B-SpecificDisease
deficiency,2576,I-SpecificDisease
exhibited,2576,O
cardiac,2576,B-DiseaseClass
disease,2576,I-DiseaseClass
.,2576,O
At,2577,O
least,2577,O
four,2577,O
of,2577,O
them,2577,O
presented,2577,O
with,2577,O
hypertrophic,2577,B-SpecificDisease
cardiomyopathy,2577,I-SpecificDisease
.,2577,O
This,2578,O
frequency,2578,O
(,2578,O
>,2578,O
57,2578,O
%,2578,O
),2578,O
was,2578,O
much,2578,O
higher,2578,O
than,2578,O
that,2578,O
observed,2578,O
in,2578,O
patients,2578,O
with,2578,O
other,2578,O
disorders,2578,O
of,2578,O
mitochondrial,2578,O
long-chain,2578,O
fatty,2578,O
acid,2578,O
oxidation,2578,O
that,2578,O
may,2578,O
be,2578,O
accompanied,2578,O
by,2578,O
cardiac,2578,B-DiseaseClass
disease,2578,I-DiseaseClass
in,2578,O
infants,2578,O
..,2578,O
Human,2579,O
peroxisomal,2579,O
targeting,2579,O
signal-1,2579,O
receptor,2579,O
restores,2579,O
peroxisomal,2579,O
protein,2579,O
import,2579,O
in,2579,O
cells,2579,O
from,2579,O
patients,2579,O
with,2579,O
fatal,2579,O
peroxisomal,2579,B-DiseaseClass
disorders,2579,I-DiseaseClass
.,2579,O
Two,2580,O
peroxisomal,2580,O
targeting,2580,O
signals,2580,O
",",2580,O
PTS1,2580,O
and,2580,O
PTS2,2580,O
",",2580,O
are,2580,O
involved,2580,O
in,2580,O
the,2580,O
import,2580,O
of,2580,O
proteins,2580,O
into,2580,O
the,2580,O
peroxisome,2580,O
matrix,2580,O
.,2580,O
Human,2581,O
patients,2581,O
with,2581,O
fatal,2581,O
generalized,2581,O
peroxisomal,2581,B-DiseaseClass
deficiency,2581,I-DiseaseClass
disorders,2581,I-DiseaseClass
fall,2581,O
into,2581,O
at,2581,O
least,2581,O
nine,2581,O
genetic,2581,O
complementation,2581,O
groups,2581,O
.,2581,O
Cells,2582,O
from,2582,O
many,2582,O
of,2582,O
these,2582,O
patients,2582,O
are,2582,O
deficient,2582,O
in,2582,O
the,2582,O
import,2582,O
of,2582,O
PTS1-containing,2582,O
proteins,2582,O
",",2582,O
but,2582,O
the,2582,O
causes,2582,O
of,2582,O
the,2582,O
protein-import,2582,O
defect,2582,O
in,2582,O
these,2582,O
patients,2582,O
are,2582,O
unknown,2582,O
.,2582,O
We,2583,O
have,2583,O
cloned,2583,O
and,2583,O
sequenced,2583,O
the,2583,O
human,2583,O
cDNA,2583,O
homologue,2583,O
(,2583,O
PTS1R,2583,O
),2583,O
of,2583,O
the,2583,O
Pichia,2583,O
pastoris,2583,O
PAS8,2583,O
gene,2583,O
",",2583,O
the,2583,O
PTS1,2583,O
receptor,2583,O
(,2583,O
McCollum,2583,O
",",2583,O
D.,2583,O
",",2583,O
E.,2583,O
Monosov,2583,O
",",2583,O
and,2583,O
S.,2583,O
Subramani,2583,O
.,2583,O
1993,2584,O
.,2584,O
J,2585,O
.,2585,O
Cell,2586,O
Biol,2586,O
.,2586,O
121,2587,O
761-774,2587,O
),2587,O
.,2587,O
The,2588,O
PTS1R,2588,O
mRNA,2588,O
is,2588,O
expressed,2588,O
in,2588,O
all,2588,O
human,2588,O
tissues,2588,O
examined,2588,O
.,2588,O
Antibodies,2589,O
to,2589,O
the,2589,O
human,2589,O
PTS1R,2589,O
recognize,2589,O
this,2589,O
protein,2589,O
in,2589,O
human,2589,O
",",2589,O
monkey,2589,O
",",2589,O
rat,2589,O
",",2589,O
and,2589,O
hamster,2589,O
cells,2589,O
.,2589,O
The,2590,O
protein,2590,O
is,2590,O
localized,2590,O
mainly,2590,O
in,2590,O
the,2590,O
cytosol,2590,O
but,2590,O
is,2590,O
also,2590,O
found,2590,O
to,2590,O
be,2590,O
associated,2590,O
with,2590,O
peroxisomes,2590,O
.,2590,O
Part,2591,O
of,2591,O
the,2591,O
peroxisomal,2591,O
PTS1R,2591,O
protein,2591,O
is,2591,O
tightly,2591,O
bound,2591,O
to,2591,O
the,2591,O
peroxisomal,2591,O
membrane,2591,O
.,2591,O
Antibodies,2592,O
to,2592,O
PTS1R,2592,O
inhibit,2592,O
peroxisomal,2592,O
protein-import,2592,O
of,2592,O
PTS1-containing,2592,O
proteins,2592,O
in,2592,O
a,2592,O
permeabilized,2592,O
CHO,2592,O
cell,2592,O
system,2592,O
.,2592,O
In,2593,O
vitro-translated,2593,O
PTS1R,2593,O
protein,2593,O
specifically,2593,O
binds,2593,O
a,2593,O
serine-lysine-leucine-peptide,2593,O
.,2593,O
A,2594,O
PAS8-PTS1R,2594,O
fusion,2594,O
protein,2594,O
complements,2594,O
the,2594,O
P.,2594,O
pastoris,2594,O
pas8,2594,O
mutant,2594,O
.,2594,O
The,2595,O
PTS1R,2595,O
cDNA,2595,O
also,2595,O
complements,2595,O
the,2595,O
PTS1,2595,O
protein-import,2595,O
defect,2595,O
in,2595,O
skin,2595,O
fibroblasts,2595,O
from,2595,O
patients,2595,O
--,2595,O
belonging,2595,O
to,2595,O
complementation,2595,O
group,2595,O
two,2595,O
--,2595,O
diagnosed,2595,O
as,2595,O
having,2595,O
neonatal,2595,B-SpecificDisease
adrenoleukodystrophy,2595,I-SpecificDisease
or,2595,O
Zellweger,2595,B-SpecificDisease
syndrome,2595,I-SpecificDisease
.,2595,O
The,2596,O
PTS1R,2596,O
gene,2596,O
has,2596,O
been,2596,O
localized,2596,O
to,2596,O
a,2596,O
chromosomal,2596,O
location,2596,O
where,2596,O
no,2596,O
other,2596,O
peroxisomal,2596,B-Modifier
disorder,2596,I-Modifier
genes,2596,O
are,2596,O
known,2596,O
to,2596,O
map,2596,O
.,2596,O
Our,2597,O
findings,2597,O
represent,2597,O
the,2597,O
only,2597,O
case,2597,O
in,2597,O
which,2597,O
the,2597,O
molecular,2597,O
basis,2597,O
of,2597,O
the,2597,O
protein-import,2597,B-DiseaseClass
deficiency,2597,I-DiseaseClass
in,2597,O
human,2597,O
peroxisomal,2597,B-DiseaseClass
disorders,2597,I-DiseaseClass
is,2597,O
understood,2597,O
.,2597,O
Spectrum,2598,O
of,2598,O
germline,2598,O
mutations,2598,O
in,2598,O
the,2598,O
RB1,2598,O
gene,2598,O
:,2598,O
a,2598,O
study,2598,O
of,2598,O
232,2598,O
patients,2598,O
with,2598,O
hereditary,2598,B-CompositeMention
and,2598,I-CompositeMention
non,2598,I-CompositeMention
hereditary,2598,I-CompositeMention
retinoblastoma,2598,I-CompositeMention
.,2598,O
Germline,2599,O
mutations,2599,O
in,2599,O
the,2599,O
RB1,2599,O
gene,2599,O
confer,2599,O
hereditary,2599,O
predisposition,2599,O
to,2599,O
retinoblastoma,2599,B-SpecificDisease
.,2599,O
We,2600,O
have,2600,O
performed,2600,O
a,2600,O
mutation,2600,O
survey,2600,O
of,2600,O
the,2600,O
RB1,2600,O
gene,2600,O
in,2600,O
232,2600,O
patients,2600,O
with,2600,O
hereditary,2600,B-CompositeMention
or,2600,I-CompositeMention
non,2600,I-CompositeMention
hereditary,2600,I-CompositeMention
retinoblastoma,2600,I-CompositeMention
.,2600,O
We,2601,O
systematically,2601,O
explored,2601,O
all,2601,O
27,2601,O
exons,2601,O
and,2601,O
flanking,2601,O
sequences,2601,O
as,2601,O
well,2601,O
as,2601,O
the,2601,O
promotor,2601,O
.,2601,O
All,2602,O
types,2602,O
of,2602,O
point,2602,O
mutations,2602,O
are,2602,O
represented,2602,O
and,2602,O
are,2602,O
found,2602,O
unequally,2602,O
distributed,2602,O
along,2602,O
the,2602,O
RB1,2602,O
gene,2602,O
sequence,2602,O
.,2602,O
In,2603,O
the,2603,O
population,2603,O
we,2603,O
studied,2603,O
",",2603,O
exons,2603,O
3,2603,O
",",2603,O
8,2603,O
",",2603,O
18,2603,O
and,2603,O
19,2603,O
are,2603,O
preferentially,2603,O
altered,2603,O
.,2603,O
The,2604,O
range,2604,O
of,2604,O
frequency,2604,O
of,2604,O
detection,2604,O
of,2604,O
germline,2604,O
mutations,2604,O
is,2604,O
about,2604,O
20,2604,O
%,2604,O
",",2604,O
indicating,2604,O
that,2604,O
other,2604,O
mechanisms,2604,O
of,2604,O
inactivation,2604,O
of,2604,O
RB1,2604,O
should,2604,O
be,2604,O
involved,2604,O
.,2604,O
The,2605,O
spectrum,2605,O
of,2605,O
mutations,2605,O
presented,2605,O
here,2605,O
should,2605,O
help,2605,O
to,2605,O
improve,2605,O
the,2605,O
clinical,2605,O
management,2605,O
of,2605,O
retinoblastoma,2605,B-SpecificDisease
and,2605,O
to,2605,O
understand,2605,O
the,2605,O
molecular,2605,O
mechanisms,2605,O
leading,2605,O
to,2605,O
tumorigenesis,2605,O
..,2605,O
Aniridia-associated,2606,B-Modifier
cytogenetic,2606,O
rearrangements,2606,O
suggest,2606,O
that,2606,O
a,2606,O
position,2606,O
effect,2606,O
may,2606,O
cause,2606,O
the,2606,O
mutant,2606,O
phenotype,2606,O
.,2606,O
Current,2607,O
evidence,2607,O
suggests,2607,O
that,2607,O
aniridia,2607,B-SpecificDisease
(,2607,O
absence,2607,B-SpecificDisease
of,2607,I-SpecificDisease
iris,2607,I-SpecificDisease
),2607,O
is,2607,O
caused,2607,O
by,2607,O
loss,2607,O
of,2607,O
function,2607,O
of,2607,O
one,2607,O
copy,2607,O
of,2607,O
the,2607,O
PAX6,2607,O
gene,2607,O
",",2607,O
which,2607,O
maps,2607,O
to,2607,O
11p13,2607,O
.,2607,O
We,2608,O
present,2608,O
the,2608,O
further,2608,O
characterisation,2608,O
of,2608,O
two,2608,O
aniridia,2608,B-Modifier
pedigrees,2608,O
in,2608,O
which,2608,O
the,2608,O
disease,2608,O
segregates,2608,O
with,2608,O
chromosomal,2608,O
rearrangements,2608,O
which,2608,O
involve,2608,O
11p13,2608,O
but,2608,O
do,2608,O
not,2608,O
disrupt,2608,O
the,2608,O
PAX6,2608,O
gene,2608,O
.,2608,O
We,2609,O
have,2609,O
isolated,2609,O
three,2609,O
human,2609,O
YAC,2609,O
clones,2609,O
which,2609,O
encompass,2609,O
the,2609,O
PAX6,2609,O
locus,2609,O
and,2609,O
we,2609,O
have,2609,O
used,2609,O
these,2609,O
to,2609,O
show,2609,O
that,2609,O
in,2609,O
both,2609,O
cases,2609,O
the,2609,O
chromosomal,2609,O
breakpoint,2609,O
is,2609,O
at,2609,O
least,2609,O
85,2609,O
kb,2609,O
distal,2609,O
of,2609,O
the,2609,O
3,2609,O
end,2609,O
of,2609,O
PAX6,2609,O
.,2609,O
In,2610,O
addition,2610,O
",",2610,O
the,2610,O
open,2610,O
reading,2610,O
frame,2610,O
of,2610,O
PAX6,2610,O
is,2610,O
apparently,2610,O
free,2610,O
of,2610,O
mutations,2610,O
.,2610,O
We,2611,O
propose,2611,O
that,2611,O
the,2611,O
PAX6,2611,O
gene,2611,O
on,2611,O
the,2611,O
rearranged,2611,O
chromosome,2611,O
11,2611,O
is,2611,O
in,2611,O
an,2611,O
inappropriate,2611,O
chromatin,2611,O
environment,2611,O
for,2611,O
normal,2611,O
expression,2611,O
and,2611,O
therefore,2611,O
that,2611,O
a,2611,O
position,2611,O
effect,2611,O
is,2611,O
the,2611,O
underlying,2611,O
mechanism,2611,O
of,2611,O
disease,2611,O
in,2611,O
these,2611,O
families,2611,O
..,2611,O
Somatic,2612,O
mutations,2612,O
in,2612,O
the,2612,O
BRCA1,2612,O
gene,2612,O
in,2612,O
sporadic,2612,B-SpecificDisease
ovarian,2612,I-SpecificDisease
tumours,2612,I-SpecificDisease
.,2612,O
The,2613,O
BRCA1,2613,O
gene,2613,O
on,2613,O
chromosome,2613,O
17q21,2613,O
is,2613,O
responsible,2613,O
for,2613,O
an,2613,O
autosomal,2613,B-DiseaseClass
dominant,2613,I-DiseaseClass
syndrome,2613,I-DiseaseClass
of,2613,O
increased,2613,O
susceptibility,2613,O
to,2613,O
breast,2613,B-CompositeMention
and,2613,I-CompositeMention
ovarian,2613,I-CompositeMention
cancer,2613,I-CompositeMention
but,2613,O
no,2613,O
somatic,2613,O
mutations,2613,O
in,2613,O
tumours,2613,B-DiseaseClass
have,2613,O
yet,2613,O
been,2613,O
described,2613,O
.,2613,O
To,2614,O
study,2614,O
the,2614,O
potential,2614,O
role,2614,O
of,2614,O
BRCA1,2614,O
in,2614,O
sporadic,2614,O
carcinogenesis,2614,O
",",2614,O
we,2614,O
analysed,2614,O
the,2614,O
genomic,2614,O
DNA,2614,O
of,2614,O
tumour,2614,B-DiseaseClass
and,2614,O
normal,2614,O
fractions,2614,O
of,2614,O
47,2614,O
ovarian,2614,B-SpecificDisease
cancers,2614,I-SpecificDisease
for,2614,O
mutations,2614,O
in,2614,O
BRCA1,2614,O
using,2614,O
the,2614,O
single-strand,2614,O
conformation,2614,O
polymorphism,2614,O
technique,2614,O
.,2614,O
We,2615,O
now,2615,O
describe,2615,O
somatic,2615,O
mutations,2615,O
in,2615,O
the,2615,O
DNA,2615,O
of,2615,O
four,2615,O
tumours,2615,B-DiseaseClass
which,2615,O
also,2615,O
had,2615,O
loss,2615,O
of,2615,O
heterozygosity,2615,O
(,2615,O
LOH,2615,O
),2615,O
at,2615,O
a,2615,O
BRCA1,2615,O
intragenic,2615,O
marker,2615,O
.,2615,O
Our,2616,O
data,2616,O
support,2616,O
a,2616,O
tumour,2616,B-Modifier
suppressor,2616,O
mechanism,2616,O
for,2616,O
BRCA1,2616,O
;,2616,O
somatic,2616,O
mutations,2616,O
and,2616,O
LOH,2616,O
may,2616,O
result,2616,O
in,2616,O
inactivation,2616,O
of,2616,O
BRCA1,2616,O
in,2616,O
at,2616,O
least,2616,O
a,2616,O
small,2616,O
number,2616,O
of,2616,O
ovarian,2616,B-SpecificDisease
cancers,2616,I-SpecificDisease
..,2616,O
Decreased,2617,O
expression,2617,O
of,2617,O
BRCA1,2617,O
accelerates,2617,O
growth,2617,O
and,2617,O
is,2617,O
often,2617,O
present,2617,O
during,2617,O
sporadic,2617,B-Modifier
breast,2617,I-Modifier
cancer,2617,I-Modifier
progression,2617,O
.,2617,O
We,2618,O
have,2618,O
characterized,2618,O
expression,2618,O
of,2618,O
the,2618,O
familial,2618,B-Modifier
breast,2618,I-Modifier
and,2618,I-Modifier
ovarian,2618,I-Modifier
cancer,2618,I-Modifier
gene,2618,O
",",2618,O
BRCA1,2618,O
",",2618,O
in,2618,O
cases,2618,O
of,2618,O
non-hereditary,2618,B-SpecificDisease
(,2618,I-SpecificDisease
sporadic,2618,I-SpecificDisease
),2618,I-SpecificDisease
breast,2618,I-SpecificDisease
cancer,2618,I-SpecificDisease
and,2618,O
analyzed,2618,O
the,2618,O
effect,2618,O
of,2618,O
antisense,2618,O
inhibition,2618,O
of,2618,O
BRCA1,2618,O
on,2618,O
the,2618,O
proliferative,2618,O
rate,2618,O
of,2618,O
mammary,2618,O
epithelial,2618,O
cells,2618,O
.,2618,O
BRCA1,2619,O
mRNA,2619,O
levels,2619,O
are,2619,O
markedly,2619,O
decreased,2619,O
during,2619,O
the,2619,O
transition,2619,O
from,2619,O
carcinoma,2619,B-DiseaseClass
in,2619,I-DiseaseClass
situ,2619,I-DiseaseClass
to,2619,O
invasive,2619,B-DiseaseClass
cancer,2619,I-DiseaseClass
.,2619,O
Experimental,2620,O
inhibition,2620,O
of,2620,O
BRCA1,2620,O
expression,2620,O
with,2620,O
antisense,2620,O
oligonucleotides,2620,O
produced,2620,O
accelerated,2620,O
growth,2620,O
of,2620,O
normal,2620,O
and,2620,O
malignant,2620,O
mammary,2620,O
cells,2620,O
",",2620,O
but,2620,O
had,2620,O
no,2620,O
effect,2620,O
on,2620,O
non-mammary,2620,O
epithelial,2620,O
cells,2620,O
.,2620,O
These,2621,O
studies,2621,O
suggest,2621,O
that,2621,O
BRCA1,2621,O
may,2621,O
normally,2621,O
serve,2621,O
as,2621,O
a,2621,O
negative,2621,O
regulator,2621,O
of,2621,O
mammary,2621,O
epithelial,2621,O
cell,2621,O
growth,2621,O
whose,2621,O
function,2621,O
is,2621,O
compromised,2621,O
in,2621,O
breast,2621,B-SpecificDisease
cancer,2621,I-SpecificDisease
either,2621,O
by,2621,O
direct,2621,O
mutation,2621,O
or,2621,O
alterations,2621,O
in,2621,O
gene,2621,O
expression,2621,O
..,2621,O
Additional,2622,O
case,2622,O
of,2622,O
female,2622,O
monozygotic,2622,O
twins,2622,O
discordant,2622,O
for,2622,O
the,2622,O
clinical,2622,O
manifestations,2622,O
of,2622,O
Duchenne,2622,B-SpecificDisease
muscular,2622,I-SpecificDisease
dystrophy,2622,I-SpecificDisease
due,2622,O
to,2622,O
opposite,2622,O
X-chromosome,2622,O
inactivation,2622,O
.,2622,O
A,2623,O
pair,2623,O
of,2623,O
female,2623,O
monozygotic,2623,O
(,2623,O
MZ,2623,O
),2623,O
twins,2623,O
",",2623,O
heterozygous,2623,O
carriers,2623,O
for,2623,O
a,2623,O
deletion,2623,O
in,2623,O
the,2623,O
DMD,2623,B-Modifier
gene,2623,O
and,2623,O
discordant,2623,O
for,2623,O
the,2623,O
clinical,2623,O
manifestations,2623,O
of,2623,O
Duchenne,2623,B-SpecificDisease
muscular,2623,I-SpecificDisease
dystrophy,2623,I-SpecificDisease
",",2623,O
were,2623,O
analyzed,2623,O
by,2623,O
molecular,2623,O
studies,2623,O
",",2623,O
in,2623,O
situ,2623,O
hybridization,2623,O
",",2623,O
and,2623,O
methylation,2623,O
pattern,2623,O
of,2623,O
X,2623,O
chromosomes,2623,O
to,2623,O
search,2623,O
for,2623,O
opposite,2623,O
X,2623,O
inactivation,2623,O
as,2623,O
an,2623,O
explanation,2623,O
of,2623,O
their,2623,O
clinical,2623,O
discordance,2623,O
.,2623,O
Results,2624,O
in,2624,O
lymphocytes,2624,O
and,2624,O
skin,2624,O
fibroblast,2624,O
cell,2624,O
lines,2624,O
suggest,2624,O
a,2624,O
partial,2624,O
mirror,2624,O
inactivation,2624,O
with,2624,O
the,2624,O
normal,2624,O
X,2624,O
chromosome,2624,O
preferentially,2624,O
active,2624,O
in,2624,O
the,2624,O
unaffected,2624,O
twin,2624,O
",",2624,O
and,2624,O
the,2624,O
maternal,2624,O
deleted,2624,O
X,2624,O
chromosome,2624,O
preferentially,2624,O
active,2624,O
in,2624,O
the,2624,O
affected,2624,O
twin,2624,O
.,2624,O
A,2625,O
review,2625,O
shows,2625,O
that,2625,O
MZ,2625,O
female,2625,O
twins,2625,O
discordant,2625,O
for,2625,O
X-linked,2625,B-DiseaseClass
diseases,2625,I-DiseaseClass
are,2625,O
not,2625,O
uncommon,2625,O
.,2625,O
Twinning,2626,O
and,2626,O
X,2626,O
inactivation,2626,O
may,2626,O
be,2626,O
interrelated,2626,O
and,2626,O
could,2626,O
explain,2626,O
the,2626,O
female,2626,O
twins,2626,O
discordant,2626,O
for,2626,O
X-linked,2626,O
traits,2626,O
..,2626,O
X-linked,2627,B-SpecificDisease
adrenoleukodystrophy,2627,I-SpecificDisease
(,2627,O
ALD,2627,B-SpecificDisease
),2627,O
:,2627,O
a,2627,O
novel,2627,O
mutation,2627,O
of,2627,O
the,2627,O
ALD,2627,B-Modifier
gene,2627,O
in,2627,O
6,2627,O
members,2627,O
of,2627,O
a,2627,O
family,2627,O
presenting,2627,O
with,2627,O
5,2627,O
different,2627,O
phenotypes,2627,O
.,2627,O
Fragments,2628,O
of,2628,O
the,2628,O
adrenoleukodystrophy,2628,B-Modifier
(,2628,O
ALD,2628,B-Modifier
),2628,O
cDNA,2628,O
from,2628,O
a,2628,O
patient,2628,O
with,2628,O
adolescent,2628,B-SpecificDisease
ALD,2628,I-SpecificDisease
were,2628,O
amplified,2628,O
by,2628,O
polymerase,2628,O
chain,2628,O
reaction,2628,O
and,2628,O
subcloned,2628,O
.,2628,O
Bidirectional,2629,O
sequencing,2629,O
of,2629,O
the,2629,O
entire,2629,O
coding,2629,O
ALD,2629,B-Modifier
gene,2629,O
disclosed,2629,O
a,2629,O
cytosine,2629,O
to,2629,O
guanine,2629,O
transversion,2629,O
at,2629,O
nucleotide,2629,O
1451,2629,O
in,2629,O
exon,2629,O
five,2629,O
",",2629,O
resulting,2629,O
in,2629,O
substitution,2629,O
of,2629,O
proline,2629,O
484,2629,O
by,2629,O
arginine,2629,O
.,2629,O
Five,2630,O
of,2630,O
nine,2630,O
siblings,2630,O
of,2630,O
the,2630,O
patient,2630,O
",",2630,O
comprising,2630,O
two,2630,O
cerebral,2630,B-SpecificDisease
ALD,2630,I-SpecificDisease
",",2630,O
one,2630,O
adrenomyeloneuropathy,2630,B-SpecificDisease
",",2630,O
one,2630,O
Addison,2630,B-SpecificDisease
only,2630,I-SpecificDisease
as,2630,O
well,2630,O
as,2630,O
the,2630,O
symptomatic,2630,O
mother,2630,O
(,2630,O
all,2630,O
accumulating,2630,O
very,2630,O
long,2630,O
chain,2630,O
fatty,2630,O
acids,2630,O
),2630,O
carried,2630,O
this,2630,O
mutation,2630,O
",",2630,O
which,2630,O
was,2630,O
not,2630,O
found,2630,O
in,2630,O
the,2630,O
unaffected,2630,O
persons,2630,O
",",2630,O
in,2630,O
five,2630,O
unrelated,2630,O
ALD,2630,B-Modifier
patients,2630,O
",",2630,O
and,2630,O
in,2630,O
twenty,2630,O
controls,2630,O
.,2630,O
We,2631,O
propose,2631,O
that,2631,O
this,2631,O
missense,2631,O
mutation,2631,O
generated,2631,O
the,2631,O
disease,2631,O
per,2631,O
se,2631,O
as,2631,O
well,2631,O
as,2631,O
the,2631,O
metabolic,2631,O
defect,2631,O
;,2631,O
the,2631,O
different,2631,O
phenotypes,2631,O
",",2631,O
however,2631,O
",",2631,O
must,2631,O
have,2631,O
originated,2631,O
by,2631,O
means,2631,O
of,2631,O
additional,2631,O
pathogenetic,2631,O
factors,2631,O
..,2631,O
Novel,2632,O
mutation,2632,O
at,2632,O
the,2632,O
initiation,2632,O
codon,2632,O
in,2632,O
the,2632,O
Norrie,2632,B-Modifier
disease,2632,I-Modifier
gene,2632,O
in,2632,O
two,2632,O
Japanese,2632,O
families,2632,O
.,2632,O
We,2633,O
have,2633,O
identified,2633,O
a,2633,O
new,2633,O
mutation,2633,O
of,2633,O
Norrie,2633,B-Modifier
disease,2633,I-Modifier
(,2633,O
ND,2633,B-Modifier
),2633,O
gene,2633,O
in,2633,O
two,2633,O
Japanese,2633,O
males,2633,O
from,2633,O
unrelated,2633,O
families,2633,O
;,2633,O
they,2633,O
showed,2633,O
typical,2633,O
ocular,2633,O
features,2633,O
of,2633,O
ND,2633,B-SpecificDisease
but,2633,O
no,2633,O
mental,2633,B-DiseaseClass
retardation,2633,I-DiseaseClass
or,2633,O
hearing,2633,B-DiseaseClass
impairment,2633,I-DiseaseClass
.,2633,O
A,2634,O
mutation,2634,O
was,2634,O
found,2634,O
in,2634,O
both,2634,O
patients,2634,O
at,2634,O
the,2634,O
initiation,2634,O
codon,2634,O
of,2634,O
exon,2634,O
2,2634,O
of,2634,O
the,2634,O
ND,2634,B-Modifier
gene,2634,O
(,2634,O
ATG,2634,O
to,2634,O
GTG,2634,O
),2634,O
",",2634,O
with,2634,O
otherwise,2634,O
normal,2634,O
nucleotide,2634,O
sequences,2634,O
.,2634,O
Their,2635,O
mothers,2635,O
had,2635,O
the,2635,O
normal,2635,O
and,2635,O
mutant,2635,O
types,2635,O
of,2635,O
the,2635,O
gene,2635,O
",",2635,O
which,2635,O
was,2635,O
expected,2635,O
for,2635,O
heterozygotes,2635,O
of,2635,O
the,2635,O
disease,2635,O
.,2635,O
The,2636,O
mutation,2636,O
of,2636,O
the,2636,O
initiation,2636,O
codon,2636,O
would,2636,O
cause,2636,O
the,2636,O
failure,2636,O
of,2636,O
ND,2636,B-Modifier
gene,2636,O
expression,2636,O
or,2636,O
a,2636,O
defect,2636,O
in,2636,O
translation,2636,O
thereby,2636,O
truncating,2636,O
the,2636,O
amino,2636,O
terminus,2636,O
of,2636,O
ND,2636,B-Modifier
protein,2636,O
.,2636,O
In,2637,O
view,2637,O
of,2637,O
the,2637,O
rarity,2637,O
and,2637,O
marked,2637,O
heterogeneity,2637,O
of,2637,O
mutations,2637,O
in,2637,O
the,2637,O
ND,2637,B-Modifier
gene,2637,O
",",2637,O
the,2637,O
present,2637,O
apparently,2637,O
unrelated,2637,O
Japanese,2637,O
families,2637,O
who,2637,O
have,2637,O
lived,2637,O
in,2637,O
the,2637,O
same,2637,O
area,2637,O
for,2637,O
over,2637,O
two,2637,O
centuries,2637,O
presumably,2637,O
share,2637,O
the,2637,O
origin,2637,O
of,2637,O
the,2637,O
mutation,2637,O
..,2637,O
Anticipation,2638,O
resulting,2638,O
in,2638,O
elimination,2638,O
of,2638,O
the,2638,O
myotonic,2638,B-Modifier
dystrophy,2638,I-Modifier
gene,2638,O
:,2638,O
a,2638,O
follow,2638,O
up,2638,O
study,2638,O
of,2638,O
one,2638,O
extended,2638,O
family,2638,O
.,2638,O
We,2639,O
have,2639,O
re-examined,2639,O
an,2639,O
extended,2639,O
myotonic,2639,B-Modifier
dystrophy,2639,I-Modifier
(,2639,O
DM,2639,B-Modifier
),2639,O
family,2639,O
",",2639,O
previously,2639,O
described,2639,O
in,2639,O
1955,2639,O
",",2639,O
in,2639,O
order,2639,O
to,2639,O
study,2639,O
the,2639,O
long,2639,O
term,2639,O
effects,2639,O
of,2639,O
anticipation,2639,O
in,2639,O
DM,2639,B-SpecificDisease
and,2639,O
in,2639,O
particular,2639,O
the,2639,O
implications,2639,O
for,2639,O
families,2639,O
affected,2639,O
by,2639,O
this,2639,O
disease,2639,O
.,2639,O
This,2640,O
follow,2640,O
up,2640,O
study,2640,O
provides,2640,O
data,2640,O
on,2640,O
35,2640,O
gene,2640,O
carriers,2640,O
and,2640,O
46,2640,O
asymptomatic,2640,O
at,2640,O
risk,2640,O
family,2640,O
members,2640,O
in,2640,O
five,2640,O
generations,2640,O
.,2640,O
Clinical,2641,O
anticipation,2641,O
",",2641,O
defined,2641,O
as,2641,O
the,2641,O
cascade,2641,O
of,2641,O
mild,2641,O
",",2641,O
adult,2641,O
",",2641,O
childhood,2641,O
",",2641,O
or,2641,O
congenital,2641,B-DiseaseClass
disease,2641,I-DiseaseClass
in,2641,O
subsequent,2641,O
generations,2641,O
",",2641,O
appeared,2641,O
to,2641,O
be,2641,O
a,2641,O
relentless,2641,O
process,2641,O
",",2641,O
occurring,2641,O
in,2641,O
all,2641,O
affected,2641,O
branches,2641,O
of,2641,O
the,2641,O
family,2641,O
.,2641,O
The,2642,O
cascade,2642,O
was,2642,O
found,2642,O
to,2642,O
proceed,2642,O
asynchronously,2642,O
in,2642,O
the,2642,O
different,2642,O
branches,2642,O
",",2642,O
mainly,2642,O
because,2642,O
of,2642,O
an,2642,O
unequal,2642,O
number,2642,O
of,2642,O
generations,2642,O
with,2642,O
mild,2642,O
disease,2642,O
.,2642,O
The,2643,O
transition,2643,O
from,2643,O
the,2643,O
mild,2643,O
to,2643,O
the,2643,O
adult,2643,O
type,2643,O
was,2643,O
associated,2643,O
with,2643,O
transmission,2643,O
through,2643,O
a,2643,O
male,2643,O
parent,2643,O
.,2643,O
Stable,2644,O
transmission,2644,O
of,2644,O
the,2644,O
asymptomatic/mild,2644,O
phenotype,2644,O
showed,2644,O
a,2644,O
female,2644,O
transmission,2644,O
bias,2644,O
.,2644,O
We,2645,O
further,2645,O
examined,2645,O
the,2645,O
extent,2645,O
and,2645,O
causes,2645,O
of,2645,O
gene,2645,O
loss,2645,O
in,2645,O
this,2645,O
pedigree,2645,O
.,2645,O
Gene,2646,O
loss,2646,O
in,2646,O
the,2646,O
patient,2646,O
group,2646,O
was,2646,O
complete,2646,O
",",2646,O
owing,2646,O
to,2646,O
infertility,2646,B-DiseaseClass
of,2646,O
the,2646,O
male,2646,O
patients,2646,O
with,2646,O
adult,2646,O
onset,2646,O
disease,2646,O
and,2646,O
the,2646,O
fact,2646,O
that,2646,O
mentally,2646,B-DiseaseClass
retarded,2646,I-DiseaseClass
patients,2646,O
did,2646,O
not,2646,O
procreate,2646,O
.,2646,O
Out,2647,O
of,2647,O
the,2647,O
46,2647,O
at,2647,O
risk,2647,O
subjects,2647,O
in,2647,O
the,2647,O
two,2647,O
youngest,2647,O
generations,2647,O
",",2647,O
only,2647,O
one,2647,O
was,2647,O
found,2647,O
to,2647,O
have,2647,O
a,2647,O
full,2647,O
mutation,2647,O
.,2647,O
This,2648,O
is,2648,O
the,2648,O
only,2648,O
subject,2648,O
who,2648,O
may,2648,O
transmit,2648,O
the,2648,O
gene,2648,O
to,2648,O
the,2648,O
sixth,2648,O
generation,2648,O
.,2648,O
No,2649,O
protomutation,2649,O
carriers,2649,O
were,2649,O
found,2649,O
in,2649,O
the,2649,O
fourth,2649,O
and,2649,O
fifth,2649,O
generations,2649,O
.,2649,O
Therefore,2650,O
it,2650,O
is,2650,O
highly,2650,O
probable,2650,O
that,2650,O
the,2650,O
DM,2650,B-Modifier
gene,2650,O
will,2650,O
be,2650,O
eliminated,2650,O
from,2650,O
this,2650,O
pedigree,2650,O
within,2650,O
one,2650,O
generation,2650,O
.,2650,O
The,2651,O
high,2651,O
population,2651,O
frequency,2651,O
of,2651,O
DM,2651,B-SpecificDisease
can,2651,O
at,2651,O
present,2651,O
not,2651,O
be,2651,O
explained,2651,O
by,2651,O
the,2651,O
contribution,2651,O
of,2651,O
asymptomatic,2651,O
cases,2651,O
in,2651,O
the,2651,O
younger,2651,O
generations,2651,O
of,2651,O
known,2651,O
families,2651,O
",",2651,O
but,2651,O
is,2651,O
probably,2651,O
caused,2651,O
by,2651,O
the,2651,O
events,2651,O
in,2651,O
the,2651,O
ancestral,2651,O
generations,2651,O
..,2651,O
The,2652,O
gene,2652,O
for,2652,O
spinal,2652,B-Modifier
cerebellar,2652,I-Modifier
ataxia,2652,I-Modifier
3,2652,O
(,2652,O
SCA3,2652,O
),2652,O
is,2652,O
located,2652,O
in,2652,O
a,2652,O
region,2652,O
of,2652,O
approximately,2652,O
3,2652,O
cM,2652,O
on,2652,O
chromosome,2652,O
14q24.3-q32.2,2652,O
.,2652,O
SCA3,2653,O
",",2653,O
the,2653,O
gene,2653,O
for,2653,O
spinal,2653,B-Modifier
cerebellar,2653,I-Modifier
ataxia,2653,I-Modifier
3,2653,O
",",2653,O
was,2653,O
recently,2653,O
mapped,2653,O
to,2653,O
a,2653,O
15-cM,2653,O
interval,2653,O
between,2653,O
D14S67,2653,O
and,2653,O
D14S81,2653,O
on,2653,O
chromosome,2653,O
14q,2653,O
",",2653,O
by,2653,O
linkage,2653,O
analysis,2653,O
in,2653,O
two,2653,O
families,2653,O
of,2653,O
French,2653,O
ancestry,2653,O
.,2653,O
The,2654,O
SCA3,2654,O
candidate,2654,O
region,2654,O
has,2654,O
now,2654,O
been,2654,O
refined,2654,O
by,2654,O
linkage,2654,O
analysis,2654,O
with,2654,O
four,2654,O
new,2654,O
microsatellite,2654,O
markers,2654,O
(,2654,O
D14S256,2654,O
",",2654,O
D14S291,2654,O
",",2654,O
D14S280,2654,O
",",2654,O
and,2654,O
AFM343vf1,2654,O
),2654,O
in,2654,O
the,2654,O
same,2654,O
two,2654,O
families,2654,O
",",2654,O
in,2654,O
which,2654,O
19,2654,O
additional,2654,O
individuals,2654,O
were,2654,O
genotyped,2654,O
",",2654,O
and,2654,O
in,2654,O
a,2654,O
third,2654,O
French,2654,O
family,2654,O
.,2654,O
Combined,2655,O
two-point,2655,O
linkage,2655,O
analyses,2655,O
show,2655,O
that,2655,O
the,2655,O
new,2655,O
markers,2655,O
",",2655,O
D14S280,2655,O
and,2655,O
AFM343vf1,2655,O
",",2655,O
are,2655,O
tightly,2655,O
linked,2655,O
to,2655,O
the,2655,O
SCA3,2655,O
locus,2655,O
",",2655,O
with,2655,O
maximal,2655,O
lod,2655,O
scores,2655,O
",",2655,O
at,2655,O
recombination,2655,O
fraction,2655,O
",",2655,O
(,2655,O
theta,2655,O
),2655,O
=,2655,O
.,2655,O
00,2656,O
",",2656,O
of,2656,O
7,2656,O
.,2656,O
05,2657,O
and,2657,O
13,2657,O
.,2657,O
70,2658,O
",",2658,O
respectively,2658,O
.,2658,O
Combined,2659,O
multipoint,2659,O
and,2659,O
recombinant,2659,O
haplotype,2659,O
analyses,2659,O
localize,2659,O
the,2659,O
SCA3,2659,O
locus,2659,O
to,2659,O
a,2659,O
3-cM,2659,O
interval,2659,O
flanked,2659,O
by,2659,O
D14S291,2659,O
and,2659,O
D14S81,2659,O
.,2659,O
The,2660,O
same,2660,O
allele,2660,O
for,2660,O
D14S280,2660,O
segregates,2660,O
with,2660,O
the,2660,O
disease,2660,O
locus,2660,O
in,2660,O
the,2660,O
three,2660,O
kindreds,2660,O
.,2660,O
This,2661,O
allele,2661,O
is,2661,O
frequent,2661,O
in,2661,O
the,2661,O
French,2661,O
population,2661,O
",",2661,O
however,2661,O
",",2661,O
and,2661,O
linkage,2661,O
disequilibrium,2661,O
is,2661,O
not,2661,O
clearly,2661,O
established,2661,O
.,2661,O
The,2662,O
SCA3,2662,O
locus,2662,O
remains,2662,O
within,2662,O
the,2662,O
29-cM,2662,O
region,2662,O
on,2662,O
14q24,2662,O
.,2662,O
3-q32,2663,O
.,2663,O
2,2664,O
containing,2664,O
the,2664,O
gene,2664,O
for,2664,O
the,2664,O
Machado-Joseph,2664,B-SpecificDisease
disease,2664,I-SpecificDisease
",",2664,O
which,2664,O
is,2664,O
clinically,2664,O
related,2664,O
to,2664,O
the,2664,O
phenotype,2664,O
determined,2664,O
by,2664,O
SCA3,2664,O
",",2664,O
but,2664,O
it,2664,O
can,2664,O
not,2664,O
yet,2664,O
be,2664,O
concluded,2664,O
that,2664,O
both,2664,O
diseases,2664,O
result,2664,O
from,2664,O
alterations,2664,O
of,2664,O
the,2664,O
same,2664,O
gene,2664,O
An,2665,O
evaluation,2665,O
of,2665,O
genetic,2665,O
heterogeneity,2665,O
in,2665,O
145,2665,O
breast-ovarian,2665,B-Modifier
cancer,2665,I-Modifier
families,2665,O
.,2665,O
Breast,2666,B-Modifier
Cancer,2666,I-Modifier
Linkage,2666,O
Consortium,2666,O
.,2666,O
The,2667,O
breast-ovary,2667,B-SpecificDisease
cancer-family,2667,I-SpecificDisease
syndrome,2667,I-SpecificDisease
is,2667,O
a,2667,O
dominant,2667,O
predisposition,2667,O
to,2667,O
cancer,2667,O
of,2667,O
the,2667,O
breast,2667,O
and,2667,O
ovaries,2667,O
which,2667,O
has,2667,O
been,2667,O
mapped,2667,O
to,2667,O
chromosome,2667,O
region,2667,O
17q12-q21,2667,O
.,2667,O
The,2668,O
majority,2668,O
",",2668,O
but,2668,O
not,2668,O
all,2668,O
",",2668,O
of,2668,O
breast-ovary,2668,B-Modifier
cancer,2668,I-Modifier
families,2668,O
show,2668,O
linkage,2668,O
to,2668,O
this,2668,O
susceptibility,2668,O
locus,2668,O
",",2668,O
designated,2668,O
BRCA1,2668,O
.,2668,O
We,2669,O
report,2669,O
here,2669,O
the,2669,O
results,2669,O
of,2669,O
a,2669,O
linkage,2669,O
analysis,2669,O
of,2669,O
145,2669,O
families,2669,O
with,2669,O
both,2669,O
breast,2669,O
and,2669,O
ovarian,2669,O
cancer,2669,O
.,2669,O
These,2670,O
families,2670,O
contain,2670,O
either,2670,O
a,2670,O
total,2670,O
of,2670,O
three,2670,O
or,2670,O
more,2670,O
cases,2670,O
of,2670,O
early-onset,2670,O
(,2670,O
before,2670,O
age,2670,O
60,2670,O
years,2670,O
),2670,O
breast,2670,B-SpecificDisease
cancer,2670,I-SpecificDisease
or,2670,O
ovarian,2670,B-SpecificDisease
cancer,2670,I-SpecificDisease
.,2670,O
All,2671,O
families,2671,O
contained,2671,O
at,2671,O
least,2671,O
one,2671,O
case,2671,O
of,2671,O
ovarian,2671,B-SpecificDisease
cancer,2671,I-SpecificDisease
.,2671,O
Overall,2672,O
",",2672,O
an,2672,O
estimated,2672,O
76,2672,O
%,2672,O
of,2672,O
the,2672,O
145,2672,O
families,2672,O
are,2672,O
linked,2672,O
to,2672,O
the,2672,O
BRCA1,2672,O
locus,2672,O
.,2672,O
None,2673,O
of,2673,O
the,2673,O
13,2673,O
families,2673,O
with,2673,O
cases,2673,O
of,2673,O
male,2673,B-SpecificDisease
breast,2673,I-SpecificDisease
cancer,2673,I-SpecificDisease
appear,2673,O
to,2673,O
be,2673,O
linked,2673,O
",",2673,O
but,2673,O
it,2673,O
is,2673,O
estimated,2673,O
that,2673,O
92,2673,O
%,2673,O
(,2673,O
95,2673,O
%,2673,O
confidence,2673,O
interval,2673,O
76,2673,O
%,2673,O
-100,2673,O
%,2673,O
),2673,O
of,2673,O
families,2673,O
with,2673,O
no,2673,O
male,2673,B-SpecificDisease
breast,2673,I-SpecificDisease
cancer,2673,I-SpecificDisease
and,2673,O
with,2673,O
two,2673,O
or,2673,O
more,2673,O
ovarian,2673,B-SpecificDisease
cancers,2673,I-SpecificDisease
are,2673,O
linked,2673,O
to,2673,O
BRCA1,2673,O
.,2673,O
These,2674,O
data,2674,O
suggest,2674,O
that,2674,O
the,2674,O
breast-ovarian,2674,B-SpecificDisease
cancer-family,2674,I-SpecificDisease
syndrome,2674,I-SpecificDisease
is,2674,O
genetically,2674,O
heterogeneous,2674,O
.,2674,O
However,2675,O
",",2675,O
the,2675,O
large,2675,O
majority,2675,O
of,2675,O
families,2675,O
with,2675,O
early-onset,2675,O
breast,2675,B-SpecificDisease
cancer,2675,I-SpecificDisease
and,2675,O
with,2675,O
two,2675,O
or,2675,O
more,2675,O
cases,2675,O
of,2675,O
ovarian,2675,B-SpecificDisease
cancer,2675,I-SpecificDisease
are,2675,O
likely,2675,O
to,2675,O
be,2675,O
due,2675,O
to,2675,O
BRCA1,2675,O
mutations,2675,O
..,2675,O
Molecular,2676,O
basis,2676,O
of,2676,O
essential,2676,B-SpecificDisease
fructosuria,2676,I-SpecificDisease
:,2676,O
molecular,2676,O
cloning,2676,O
and,2676,O
mutational,2676,O
analysis,2676,O
of,2676,O
human,2676,O
ketohexokinase,2676,O
(,2676,O
fructokinase,2676,O
),2676,O
.,2676,O
Essential,2677,B-SpecificDisease
fructosuria,2677,I-SpecificDisease
is,2677,O
one,2677,O
of,2677,O
the,2677,O
oldest,2677,O
known,2677,O
inborn,2677,B-DiseaseClass
errors,2677,I-DiseaseClass
of,2677,I-DiseaseClass
metabolism,2677,I-DiseaseClass
.,2677,O
It,2678,O
is,2678,O
a,2678,O
benign,2678,O
condition,2678,O
which,2678,O
is,2678,O
believed,2678,O
to,2678,O
result,2678,O
from,2678,O
deficiency,2678,B-SpecificDisease
of,2678,I-SpecificDisease
hepatic,2678,I-SpecificDisease
fructokinase,2678,I-SpecificDisease
(,2678,O
ketohexokinase,2678,O
",",2678,O
KHK,2678,O
",",2678,O
E.,2678,O
C.,2678,O
2,2678,O
.,2678,O
7,2679,O
.,2679,O
1,2680,O
.,2680,O
3,2681,O
),2681,O
.,2681,O
This,2682,O
enzyme,2682,O
catalyses,2682,O
the,2682,O
first,2682,O
step,2682,O
of,2682,O
metabolism,2682,O
of,2682,O
dietary,2682,O
fructose,2682,O
",",2682,O
conversion,2682,O
of,2682,O
fructose,2682,O
to,2682,O
fructose-1-phosphate,2682,O
.,2682,O
Despite,2683,O
the,2683,O
early,2683,O
recognition,2683,O
of,2683,O
this,2683,O
disorder,2683,O
",",2683,O
the,2683,O
primary,2683,O
structure,2683,O
of,2683,O
human,2683,O
KHK,2683,O
and,2683,O
the,2683,O
molecular,2683,O
basis,2683,O
of,2683,O
essential,2683,B-SpecificDisease
fructosuria,2683,I-SpecificDisease
have,2683,O
not,2683,O
been,2683,O
previously,2683,O
defined,2683,O
.,2683,O
In,2684,O
this,2684,O
report,2684,O
",",2684,O
the,2684,O
isolation,2684,O
and,2684,O
sequencing,2684,O
of,2684,O
full-length,2684,O
cDNA,2684,O
clones,2684,O
encoding,2684,O
human,2684,O
ketohexokinase,2684,O
are,2684,O
described,2684,O
.,2684,O
Alternative,2685,O
mRNA,2685,O
species,2685,O
and,2685,O
alternative,2685,O
KHK,2685,O
isozymes,2685,O
are,2685,O
produced,2685,O
by,2685,O
alternative,2685,O
polyadenylation,2685,O
and,2685,O
splicing,2685,O
of,2685,O
the,2685,O
KHK,2685,O
gene,2685,O
.,2685,O
The,2686,O
KHK,2686,O
proteins,2686,O
show,2686,O
a,2686,O
high,2686,O
level,2686,O
of,2686,O
sequence,2686,O
conservation,2686,O
relative,2686,O
to,2686,O
rat,2686,O
KHK,2686,O
.,2686,O
Direct,2687,O
evidence,2687,O
that,2687,O
mutation,2687,O
of,2687,O
the,2687,O
KHK,2687,O
structural,2687,O
gene,2687,O
is,2687,O
the,2687,O
cause,2687,O
of,2687,O
essential,2687,B-SpecificDisease
fructosuria,2687,I-SpecificDisease
was,2687,O
also,2687,O
obtained,2687,O
.,2687,O
In,2688,O
a,2688,O
well-characterized,2688,O
family,2688,O
",",2688,O
in,2688,O
which,2688,O
three,2688,O
of,2688,O
eight,2688,O
siblings,2688,O
have,2688,O
fructosuria,2688,B-DiseaseClass
",",2688,O
all,2688,O
affected,2688,O
individuals,2688,O
are,2688,O
compound,2688,O
heterozygotes,2688,O
for,2688,O
two,2688,O
mutations,2688,O
Gly40Arg,2688,O
and,2688,O
Ala43Thr,2688,O
.,2688,O
Both,2689,O
mutations,2689,O
result,2689,O
from,2689,O
G,2689,O
--,2689,O
>,2689,O
A,2689,O
transitions,2689,O
",",2689,O
and,2689,O
each,2689,O
alters,2689,O
the,2689,O
same,2689,O
conserved,2689,O
region,2689,O
of,2689,O
the,2689,O
KHK,2689,O
protein,2689,O
.,2689,O
Neither,2690,O
mutation,2690,O
was,2690,O
seen,2690,O
in,2690,O
a,2690,O
sample,2690,O
of,2690,O
52,2690,O
unrelated,2690,O
control,2690,O
individuals,2690,O
.,2690,O
An,2691,O
additional,2691,O
conservative,2691,O
amino,2691,O
acid,2691,O
change,2691,O
(,2691,O
Val49IIe,2691,O
),2691,O
was,2691,O
present,2691,O
on,2691,O
the,2691,O
KHK,2691,O
allele,2691,O
bearing,2691,O
Ala43Thr,2691,O
Homozygous,2692,O
presence,2692,O
of,2692,O
the,2692,O
crossover,2692,O
(,2692,O
fusion,2692,O
gene,2692,O
),2692,O
mutation,2692,O
identified,2692,O
in,2692,O
a,2692,O
type,2692,B-Modifier
II,2692,I-Modifier
Gaucher,2692,I-Modifier
disease,2692,I-Modifier
fetus,2692,O
:,2692,O
is,2692,O
this,2692,O
analogous,2692,O
to,2692,O
the,2692,O
Gaucher,2692,O
knock-out,2692,O
mouse,2692,O
model,2692,O
?,2692,O
Gaucher,2693,B-SpecificDisease
disease,2693,I-SpecificDisease
(,2693,O
GD,2693,B-SpecificDisease
),2693,O
is,2693,O
an,2693,O
inherited,2693,O
deficiency,2693,B-SpecificDisease
of,2693,I-SpecificDisease
beta-glucocerebrosidase,2693,I-SpecificDisease
(,2693,O
EC,2693,O
3,2693,O
.,2693,O
1,2694,O
.,2694,O
2,2695,O
.,2695,O
45,2696,O
",",2696,O
gene,2696,O
symbol,2696,O
GBA,2696,O
),2696,O
.,2696,O
In,2697,O
type,2697,B-SpecificDisease
I,2697,I-SpecificDisease
GD,2697,I-SpecificDisease
",",2697,O
the,2697,O
CNS,2697,O
is,2697,O
not,2697,O
involved,2697,O
(,2697,O
nonneuronopathic,2697,O
),2697,O
",",2697,O
whereas,2697,O
in,2697,O
type,2697,B-SpecificDisease
II,2697,I-SpecificDisease
GD,2697,I-SpecificDisease
(,2697,O
acute,2697,O
neuronopathic,2697,O
),2697,O
CNS,2697,O
involvement,2697,O
is,2697,O
early,2697,O
and,2697,O
rapidly,2697,O
progressive,2697,O
",",2697,O
while,2697,O
in,2697,O
type,2697,B-SpecificDisease
III,2697,I-SpecificDisease
GD,2697,I-SpecificDisease
(,2697,O
subacute,2697,O
neuronopathic,2697,O
),2697,O
CNS,2697,O
involvement,2697,O
occurs,2697,O
later,2697,O
and,2697,O
is,2697,O
slowly,2697,O
progressive,2697,O
.,2697,O
The,2698,O
T6433C,2698,O
(,2698,O
L444P,2698,O
),2698,O
substitution,2698,O
is,2698,O
prevalent,2698,O
in,2698,O
type,2698,B-SpecificDisease
GD,2698,I-SpecificDisease
II,2698,I-SpecificDisease
.,2698,O
It,2699,O
may,2699,O
occur,2699,O
alone,2699,O
as,2699,O
a,2699,O
single,2699,O
base-pair,2699,O
mutation,2699,O
but,2699,O
often,2699,O
is,2699,O
found,2699,O
as,2699,O
part,2699,O
of,2699,O
a,2699,O
complex,2699,O
allele,2699,O
containing,2699,O
additional,2699,O
GBA,2699,O
nucleotide,2699,O
substitutions,2699,O
",",2699,O
G6468C,2699,O
(,2699,O
A456P,2699,O
),2699,O
and,2699,O
G6482C,2699,O
(,2699,O
V460V,2699,O
),2699,O
",",2699,O
without,2699,O
(,2699,O
recNciI,2699,O
),2699,O
or,2699,O
with,2699,O
(,2699,O
recTL,2699,O
),2699,O
G5957C,2699,O
(,2699,O
D409H,2699,O
),2699,O
.,2699,O
This,2700,O
complex,2700,O
allele,2700,O
is,2700,O
presumed,2700,O
to,2700,O
have,2700,O
formed,2700,O
by,2700,O
recombination,2700,O
(,2700,O
crossover,2700,O
",",2700,O
fusion,2700,O
),2700,O
of,2700,O
the,2700,O
structural,2700,O
gene,2700,O
with,2700,O
the,2700,O
pseudogene,2700,O
",",2700,O
which,2700,O
contains,2700,O
the,2700,O
mutated,2700,O
sequences,2700,O
.,2700,O
Two,2701,O
complex,2701,O
alleles,2701,O
have,2701,O
never,2701,O
been,2701,O
demonstrated,2701,O
to,2701,O
coexist,2701,O
in,2701,O
any,2701,O
individual,2701,O
.,2701,O
We,2702,O
devised,2702,O
a,2702,O
selective,2702,O
PCR,2702,O
method,2702,O
for,2702,O
the,2702,O
specific,2702,O
amplification,2702,O
of,2702,O
the,2702,O
normal,2702,O
and/or,2702,O
fusion,2702,O
gene,2702,O
.,2702,O
Using,2703,O
this,2703,O
procedure,2703,O
we,2703,O
demonstrated,2703,O
the,2703,O
fusion,2703,O
gene,2703,O
in,2703,O
homozygous,2703,O
form,2703,O
for,2703,O
the,2703,O
first,2703,O
time,2703,O
",",2703,O
in,2703,O
a,2703,O
Macedonian/Ashkenazi,2703,O
Jewish,2703,O
GD,2703,B-Modifier
type,2703,I-Modifier
II,2703,I-Modifier
fetus,2703,O
.,2703,O
Both,2704,O
parents,2704,O
were,2704,O
carriers,2704,O
of,2704,O
the,2704,O
recombination,2704,O
.,2704,O
This,2705,O
was,2705,O
confirmed,2705,O
by,2705,O
direct,2705,O
sequence,2705,O
analysis,2705,O
.,2705,O
A,2706,O
previous,2706,O
conceptus,2706,O
in,2706,O
this,2706,O
family,2706,O
was,2706,O
stillborn,2706,B-DiseaseClass
at,2706,O
36,2706,O
weeks,2706,O
",",2706,O
with,2706,O
features,2706,O
of,2706,O
severe,2706,O
type,2706,B-SpecificDisease
II,2706,I-SpecificDisease
GD,2706,I-SpecificDisease
.,2706,O
Neonates,2707,O
showing,2707,O
a,2707,O
severe,2707,O
clinical,2707,O
phenotype,2707,O
",",2707,O
analogous,2707,O
to,2707,O
the,2707,O
early,2707,O
neonatal,2707,O
lethal,2707,O
disease,2707,O
occurring,2707,O
in,2707,O
mice,2707,O
homozygous,2707,O
for,2707,O
a,2707,O
null,2707,O
allele,2707,O
produced,2707,O
by,2707,O
targeted,2707,O
disruption,2707,O
of,2707,O
GBA,2707,O
",",2707,O
have,2707,O
been,2707,O
described,2707,O
elsewhere,2707,O
",",2707,O
but,2707,O
the,2707,O
specific,2707,O
mutations,2707,O
in,2707,O
these,2707,O
cases,2707,O
have,2707,O
not,2707,O
yet,2707,O
been,2707,O
characterized,2707,O
.,2707,O
(,2708,O
ABSTRACT,2708,O
TRUNCATED,2708,O
AT,2708,O
250,2708,O
WORDS,2708,O
),2708,O
Late,2709,O
infantile,2709,O
metachromatic,2709,B-SpecificDisease
leukodystrophy,2709,I-SpecificDisease
in,2709,O
Israel,2709,O
.,2709,O
Metachromatic,2710,B-SpecificDisease
Leukodystrophy,2710,I-SpecificDisease
(,2710,O
MLD,2710,B-SpecificDisease
),2710,O
is,2710,O
a,2710,O
neurodegenerative,2710,B-DiseaseClass
disease,2710,I-DiseaseClass
in,2710,O
which,2710,O
the,2710,O
lysosomal,2710,O
enzyme,2710,O
",",2710,O
Aryl,2710,O
sulfatase,2710,O
A,2710,O
(,2710,O
ARSA,2710,O
),2710,O
is,2710,O
deficient,2710,O
.,2710,O
The,2711,O
disease,2711,O
is,2711,O
inherited,2711,O
as,2711,O
an,2711,O
autosomal,2711,O
recessive,2711,O
trait,2711,O
and,2711,O
its,2711,O
frequency,2711,O
is,2711,O
estimated,2711,O
to,2711,O
be,2711,O
1/40,2711,O
",",2711,O
000,2711,O
live,2711,O
births,2711,O
.,2711,O
The,2712,O
gene,2712,O
of,2712,O
ARSA,2712,O
has,2712,O
been,2712,O
cloned,2712,O
and,2712,O
up,2712,O
to,2712,O
now,2712,O
eight,2712,O
mutations,2712,O
causing,2712,O
MLD,2712,B-SpecificDisease
have,2712,O
been,2712,O
reported,2712,O
.,2712,O
Another,2713,O
mutation,2713,O
",",2713,O
PD,2713,O
",",2713,O
leads,2713,O
to,2713,O
the,2713,O
deficiency,2713,O
of,2713,O
the,2713,O
enzyme,2713,O
in,2713,O
vitro,2713,O
(,2713,O
pseudodeficiency,2713,O
),2713,O
without,2713,O
any,2713,O
known,2713,O
clinical,2713,O
effect,2713,O
.,2713,O
The,2714,O
PD,2714,O
mutation,2714,O
is,2714,O
frequent,2714,O
in,2714,O
all,2714,O
populations,2714,O
.,2714,O
In,2715,O
Israel,2715,O
",",2715,O
late,2715,O
infantile,2715,O
MLD,2715,B-SpecificDisease
was,2715,O
found,2715,O
to,2715,O
be,2715,O
very,2715,O
frequent,2715,O
in,2715,O
a,2715,O
small,2715,O
Jewish,2715,O
isolate,2715,O
",",2715,O
the,2715,O
Habbanite,2715,O
Jews,2715,O
(,2715,O
1/75,2715,O
live,2715,O
births,2715,O
),2715,O
.,2715,O
The,2716,O
molecular,2716,O
analysis,2716,O
demonstrated,2716,O
that,2716,O
in,2716,O
the,2716,O
Habbanite,2716,O
population,2716,O
",",2716,O
the,2716,O
mutation,2716,O
occurred,2716,O
on,2716,O
an,2716,O
allele,2716,O
with,2716,O
the,2716,O
PD,2716,O
mutation,2716,O
.,2716,O
The,2717,O
loss,2717,O
of,2717,O
ARSA,2717,O
activity,2717,O
is,2717,O
due,2717,O
to,2717,O
a,2717,O
point,2717,O
mutation,2717,O
C,2717,O
>,2717,O
T,2717,O
leading,2717,O
to,2717,O
a,2717,O
change,2717,O
of,2717,O
proline,2717,O
to,2717,O
leucine,2717,O
.,2717,O
MLD,2718,B-SpecificDisease
is,2718,O
also,2718,O
frequent,2718,O
among,2718,O
Moslem,2718,O
Arabs,2718,O
in,2718,O
Jerusalem,2718,O
.,2718,O
The,2719,O
mutation,2719,O
is,2719,O
a,2719,O
transition,2719,O
G,2719,O
>,2719,O
A,2719,O
destroying,2719,O
the,2719,O
splice,2719,O
donor,2719,O
site,2719,O
of,2719,O
exon,2719,O
2,2719,O
.,2719,O
This,2720,O
mutation,2720,O
has,2720,O
been,2720,O
reported,2720,O
in,2720,O
patients,2720,O
with,2720,O
the,2720,O
late,2720,O
infantile,2720,O
MLD,2720,B-SpecificDisease
from,2720,O
different,2720,O
ethnic,2720,O
groups,2720,O
.,2720,O
The,2721,O
Christian,2721,O
Arabs,2721,O
in,2721,O
Israel,2721,O
also,2721,O
have,2721,O
a,2721,O
high,2721,O
incidence,2721,O
of,2721,O
the,2721,O
disease,2721,O
(,2721,O
1/10,2721,O
",",2721,O
000,2721,O
live,2721,O
births,2721,O
),2721,O
;,2721,O
the,2721,O
mutation,2721,O
in,2721,O
this,2721,O
population,2721,O
is,2721,O
still,2721,O
unknown,2721,O
.,2721,O
Knowledge,2722,O
of,2722,O
the,2722,O
different,2722,O
mutations,2722,O
causing,2722,O
MLD,2722,B-SpecificDisease
in,2722,O
these,2722,O
defined,2722,O
populations,2722,O
will,2722,O
allow,2722,O
a,2722,O
carrier,2722,O
screening,2722,O
program,2722,O
to,2722,O
be,2722,O
carried,2722,O
out,2722,O
and,2722,O
prevent,2722,O
the,2722,O
birth,2722,O
of,2722,O
additional,2722,O
affected,2722,O
children,2722,O
..,2722,O
A,2723,O
single,2723,O
amino,2723,O
acid,2723,O
substitution,2723,O
(,2723,O
G103D,2723,O
),2723,O
in,2723,O
the,2723,O
type,2723,O
II,2723,O
collagen,2723,O
triple,2723,O
helix,2723,O
produces,2723,O
Kniest,2723,B-SpecificDisease
dysplasia,2723,I-SpecificDisease
.,2723,O
Kniest,2724,B-SpecificDisease
dysplasia,2724,I-SpecificDisease
is,2724,O
a,2724,O
moderately,2724,O
severe,2724,O
chondrodysplasia,2724,B-Modifier
phenotype,2724,O
that,2724,O
results,2724,O
from,2724,O
mutations,2724,O
in,2724,O
the,2724,O
gene,2724,O
for,2724,O
type,2724,O
II,2724,O
collagen,2724,O
",",2724,O
COL2A1,2724,O
.,2724,O
Characteristics,2725,O
of,2725,O
the,2725,O
disorder,2725,O
include,2725,O
a,2725,O
short,2725,B-SpecificDisease
trunk,2725,I-SpecificDisease
and,2725,I-SpecificDisease
extremities,2725,I-SpecificDisease
",",2725,O
mid-face,2725,B-DiseaseClass
hypoplasia,2725,I-DiseaseClass
",",2725,O
cleft,2725,B-SpecificDisease
palate,2725,I-SpecificDisease
",",2725,O
myopia,2725,B-DiseaseClass
",",2725,O
retinal,2725,B-SpecificDisease
detachment,2725,I-SpecificDisease
",",2725,O
and,2725,O
hearing,2725,B-DiseaseClass
loss,2725,I-DiseaseClass
.,2725,O
Recently,2726,O
",",2726,O
deletions,2726,O
of,2726,O
all,2726,O
or,2726,O
part,2726,O
of,2726,O
exon,2726,O
12,2726,O
have,2726,O
been,2726,O
identified,2726,O
in,2726,O
individuals,2726,O
with,2726,O
Kniest,2726,B-SpecificDisease
dysplasia,2726,I-SpecificDisease
",",2726,O
suggesting,2726,O
that,2726,O
mutations,2726,O
within,2726,O
this,2726,O
region,2726,O
of,2726,O
the,2726,O
protein,2726,O
may,2726,O
primarily,2726,O
result,2726,O
in,2726,O
the,2726,O
Kniest,2726,B-Modifier
dysplasia,2726,I-Modifier
phenotype,2726,O
.,2726,O
We,2727,O
used,2727,O
SSCP,2727,O
to,2727,O
analyze,2727,O
an,2727,O
amplified,2727,O
genomic,2727,O
DNA,2727,O
fragment,2727,O
containing,2727,O
exon,2727,O
12,2727,O
from,2727,O
seven,2727,O
individuals,2727,O
with,2727,O
Kniest,2727,B-SpecificDisease
dysplasia,2727,I-SpecificDisease
.,2727,O
An,2728,O
abnormality,2728,O
was,2728,O
identified,2728,O
in,2728,O
one,2728,O
patient,2728,O
.,2728,O
DNA,2729,O
sequence,2729,O
analysis,2729,O
demonstrated,2729,O
that,2729,O
the,2729,O
patient,2729,O
was,2729,O
heterozygous,2729,O
for,2729,O
a,2729,O
G,2729,O
to,2729,O
A,2729,O
transition,2729,O
that,2729,O
implied,2729,O
substitution,2729,O
of,2729,O
glycine103,2729,O
of,2729,O
the,2729,O
triple,2729,O
helical,2729,O
domain,2729,O
by,2729,O
aspartate,2729,O
.,2729,O
The,2730,O
mutation,2730,O
was,2730,O
not,2730,O
observed,2730,O
in,2730,O
DNA,2730,O
from,2730,O
either,2730,O
of,2730,O
the,2730,O
clinically,2730,O
unaffected,2730,O
parents,2730,O
of,2730,O
the,2730,O
proband,2730,O
.,2730,O
Protein,2731,O
microsequencing,2731,O
demonstrated,2731,O
expression,2731,O
of,2731,O
the,2731,O
abnormal,2731,O
allele,2731,O
in,2731,O
cartilage,2731,O
.,2731,O
These,2732,O
data,2732,O
demonstrate,2732,O
that,2732,O
point,2732,O
mutations,2732,O
which,2732,O
result,2732,O
in,2732,O
single,2732,O
amino,2732,O
acid,2732,O
substitutions,2732,O
can,2732,O
produce,2732,O
Kniest,2732,B-SpecificDisease
dysplasia,2732,I-SpecificDisease
and,2732,O
further,2732,O
support,2732,O
the,2732,O
hypothesis,2732,O
that,2732,O
alteration,2732,O
of,2732,O
a,2732,O
domain,2732,O
",",2732,O
which,2732,O
includes,2732,O
the,2732,O
region,2732,O
encoded,2732,O
by,2732,O
exon,2732,O
12,2732,O
",",2732,O
in,2732,O
the,2732,O
type,2732,O
II,2732,O
collagen,2732,O
protein,2732,O
leads,2732,O
to,2732,O
this,2732,O
disorder,2732,O
..,2732,O
CAG,2733,O
expansions,2733,O
in,2733,O
a,2733,O
novel,2733,O
gene,2733,O
for,2733,O
Machado-Joseph,2733,B-SpecificDisease
disease,2733,I-SpecificDisease
at,2733,O
chromosome,2733,O
14q32.1,2733,O
.,2733,O
We,2734,O
have,2734,O
identified,2734,O
a,2734,O
novel,2734,O
gene,2734,O
containing,2734,O
CAG,2734,O
repeats,2734,O
and,2734,O
mapped,2734,O
it,2734,O
to,2734,O
chromosome,2734,O
14q32,2734,O
.,2734,O
1,2735,O
",",2735,O
the,2735,O
genetic,2735,O
locus,2735,O
for,2735,O
Machado-Joseph,2735,B-SpecificDisease
disease,2735,I-SpecificDisease
(,2735,O
MJD,2735,B-SpecificDisease
),2735,O
.,2735,O
In,2736,O
normal,2736,O
individuals,2736,O
the,2736,O
gene,2736,O
contains,2736,O
between,2736,O
13,2736,O
and,2736,O
36,2736,O
CAG,2736,O
repeats,2736,O
",",2736,O
whereas,2736,O
most,2736,O
of,2736,O
the,2736,O
clinically,2736,O
diagnosed,2736,O
patients,2736,O
and,2736,O
all,2736,O
of,2736,O
the,2736,O
affected,2736,O
members,2736,O
of,2736,O
a,2736,O
family,2736,O
with,2736,O
the,2736,O
clinical,2736,O
and,2736,O
pathological,2736,O
diagnosis,2736,O
of,2736,O
MJD,2736,B-SpecificDisease
show,2736,O
expansion,2736,O
of,2736,O
the,2736,O
repeat-number,2736,O
(,2736,O
from,2736,O
68-79,2736,O
),2736,O
.,2736,O
Southern,2737,O
blot,2737,O
analyses,2737,O
and,2737,O
genomic,2737,O
cloning,2737,O
demonstrates,2737,O
the,2737,O
existence,2737,O
of,2737,O
related,2737,O
genes,2737,O
.,2737,O
These,2738,O
results,2738,O
raise,2738,O
the,2738,O
possibility,2738,O
that,2738,O
similar,2738,O
abnormalities,2738,O
in,2738,O
related,2738,O
genes,2738,O
may,2738,O
give,2738,O
rise,2738,O
to,2738,O
diseases,2738,O
similar,2738,O
to,2738,O
MJD,2738,B-SpecificDisease
.,2738,O
Mutations,2739,O
in,2739,O
the,2739,O
BRCA1,2739,O
gene,2739,O
in,2739,O
families,2739,O
with,2739,O
early-onset,2739,O
breast,2739,B-CompositeMention
and,2739,I-CompositeMention
ovarian,2739,I-CompositeMention
cancer,2739,I-CompositeMention
.,2739,O
We,2740,O
analysed,2740,O
50,2740,O
probands,2740,O
with,2740,O
a,2740,O
family,2740,O
history,2740,O
of,2740,O
breast,2740,B-CompositeMention
and/or,2740,I-CompositeMention
ovarian,2740,I-CompositeMention
cancer,2740,I-CompositeMention
for,2740,O
germline,2740,O
mutations,2740,O
in,2740,O
the,2740,O
coding,2740,O
region,2740,O
of,2740,O
the,2740,O
BRCA1,2740,O
candidate,2740,O
gene,2740,O
",",2740,O
using,2740,O
single-strand,2740,O
conformation,2740,O
polymorphism,2740,O
(,2740,O
SSCP,2740,O
),2740,O
analysis,2740,O
on,2740,O
PCR-amplified,2740,O
genomic,2740,O
DNA,2740,O
.,2740,O
A,2741,O
total,2741,O
of,2741,O
eight,2741,O
putative,2741,O
disease-causing,2741,O
alterations,2741,O
were,2741,O
identified,2741,O
four,2741,O
of,2741,O
these,2741,O
are,2741,O
frameshifts,2741,O
and,2741,O
two,2741,O
are,2741,O
nonsense,2741,O
mutations,2741,O
.,2741,O
In,2742,O
addition,2742,O
",",2742,O
we,2742,O
found,2742,O
two,2742,O
missense,2742,O
mutations,2742,O
",",2742,O
one,2742,O
of,2742,O
which,2742,O
changes,2742,O
the,2742,O
final,2742,O
cysteine,2742,O
of,2742,O
the,2742,O
BRCA1,2742,O
zinc,2742,O
finger,2742,O
motif,2742,O
to,2742,O
glycine,2742,O
.,2742,O
These,2743,O
data,2743,O
are,2743,O
consistent,2743,O
with,2743,O
a,2743,O
tumour,2743,B-Modifier
suppressor,2743,O
model,2743,O
",",2743,O
and,2743,O
support,2743,O
the,2743,O
notion,2743,O
that,2743,O
this,2743,O
candidate,2743,O
gene,2743,O
is,2743,O
in,2743,O
fact,2743,O
BRCA1,2743,O
.,2743,O
The,2744,O
heterogeneity,2744,O
of,2744,O
mutations,2744,O
",",2744,O
coupled,2744,O
with,2744,O
the,2744,O
large,2744,O
size,2744,O
of,2744,O
the,2744,O
gene,2744,O
",",2744,O
indicates,2744,O
that,2744,O
clinical,2744,O
application,2744,O
of,2744,O
BRCA1,2744,O
mutation,2744,O
testing,2744,O
will,2744,O
be,2744,O
technically,2744,O
challenging,2744,O
..,2744,O
Confirmation,2745,O
of,2745,O
BRCA1,2745,O
by,2745,O
analysis,2745,O
of,2745,O
germline,2745,O
mutations,2745,O
linked,2745,O
to,2745,O
breast,2745,B-CompositeMention
and,2745,I-CompositeMention
ovarian,2745,I-CompositeMention
cancer,2745,I-CompositeMention
in,2745,O
ten,2745,O
families,2745,O
.,2745,O
We,2746,O
provide,2746,O
genetic,2746,O
evidence,2746,O
supporting,2746,O
the,2746,O
identity,2746,O
of,2746,O
the,2746,O
candidate,2746,O
gene,2746,O
for,2746,O
BRCA1,2746,O
through,2746,O
the,2746,O
characterization,2746,O
of,2746,O
germline,2746,O
mutations,2746,O
in,2746,O
63,2746,O
breast,2746,B-Modifier
cancer,2746,I-Modifier
patients,2746,O
and,2746,O
10,2746,O
ovarian,2746,B-Modifier
cancer,2746,I-Modifier
patients,2746,O
in,2746,O
ten,2746,O
families,2746,O
with,2746,O
cancer,2746,B-DiseaseClass
linked,2746,O
to,2746,O
chromosome,2746,O
17q21,2746,O
.,2746,O
Nine,2747,O
different,2747,O
mutations,2747,O
were,2747,O
detected,2747,O
by,2747,O
screening,2747,O
BRCA1,2747,O
DNA,2747,O
and,2747,O
RNA,2747,O
by,2747,O
single-strand,2747,O
conformation,2747,O
polymorphism,2747,O
analysis,2747,O
and,2747,O
direct,2747,O
sequencing,2747,O
.,2747,O
Seven,2748,O
mutations,2748,O
lead,2748,O
to,2748,O
protein,2748,O
truncations,2748,O
at,2748,O
sites,2748,O
throughout,2748,O
the,2748,O
gene,2748,O
.,2748,O
One,2749,O
missense,2749,O
mutation,2749,O
(,2749,O
which,2749,O
occurred,2749,O
independently,2749,O
in,2749,O
two,2749,O
families,2749,O
),2749,O
leads,2749,O
to,2749,O
loss,2749,O
of,2749,O
a,2749,O
cysteine,2749,O
in,2749,O
the,2749,O
zinc,2749,O
binding,2749,O
domain,2749,O
.,2749,O
An,2750,O
intronic,2750,O
single,2750,O
basepair,2750,O
substitution,2750,O
destroys,2750,O
an,2750,O
acceptor,2750,O
site,2750,O
and,2750,O
activates,2750,O
a,2750,O
cryptic,2750,O
splice,2750,O
site,2750,O
",",2750,O
leading,2750,O
to,2750,O
a,2750,O
59,2750,O
basepair,2750,O
insertion,2750,O
and,2750,O
chain,2750,O
termination,2750,O
.,2750,O
The,2751,O
four,2751,O
families,2751,O
with,2751,O
both,2751,O
breast,2751,B-CompositeMention
and,2751,I-CompositeMention
ovarian,2751,I-CompositeMention
cancer,2751,I-CompositeMention
had,2751,O
chain,2751,O
termination,2751,O
mutations,2751,O
in,2751,O
the,2751,O
N-terminal,2751,O
half,2751,O
of,2751,O
the,2751,O
protein,2751,O
..,2751,O
High,2752,O
resolution,2752,O
genetic,2752,O
analysis,2752,O
suggests,2752,O
one,2752,O
ancestral,2752,O
predisposing,2752,O
haplotype,2752,O
for,2752,O
the,2752,O
origin,2752,O
of,2752,O
the,2752,O
myotonic,2752,B-Modifier
dystrophy,2752,I-Modifier
mutation,2752,O
.,2752,O
The,2753,O
mutation,2753,O
causing,2753,O
myotonic,2753,B-SpecificDisease
dystrophy,2753,I-SpecificDisease
(,2753,O
DM,2753,B-SpecificDisease
),2753,O
has,2753,O
been,2753,O
identified,2753,O
as,2753,O
an,2753,O
amplification,2753,O
of,2753,O
an,2753,O
unstable,2753,O
trinucleotide,2753,O
(,2753,O
CTG,2753,O
),2753,O
n,2753,O
repeat,2753,O
in,2753,O
over,2753,O
99,2753,O
%,2753,O
of,2753,O
the,2753,O
global,2753,O
DM,2753,B-Modifier
population,2753,O
.,2753,O
It,2754,O
is,2754,O
in,2754,O
complete,2754,O
linkage,2754,O
disequilibrium,2754,O
with,2754,O
an,2754,O
Alu,2754,O
element,2754,O
polymorphism,2754,O
within,2754,O
the,2754,O
DM,2754,B-Modifier
kinase,2754,O
gene,2754,O
",",2754,O
suggesting,2754,O
that,2754,O
DM,2754,B-SpecificDisease
is,2754,O
a,2754,O
consequence,2754,O
of,2754,O
one,2754,O
or,2754,O
few,2754,O
ancestral,2754,O
mutations,2754,O
.,2754,O
A,2755,O
recent,2755,O
analysis,2755,O
utilizing,2755,O
this,2755,O
polymorphism,2755,O
as,2755,O
well,2755,O
as,2755,O
a,2755,O
flanking,2755,O
dinucleotide,2755,O
marker,2755,O
",",2755,O
suggested,2755,O
that,2755,O
similar,2755,O
to,2755,O
Fragile,2755,B-SpecificDisease
X,2755,I-SpecificDisease
syndrome,2755,I-SpecificDisease
",",2755,O
DM,2755,B-SpecificDisease
exhibited,2755,O
a,2755,O
founder,2755,O
effect,2755,O
(,2755,O
Imbert,2755,O
et,2755,O
al.,2755,O
",",2755,O
1993,2755,O
Nature,2755,O
Genet,2755,O
.,2755,O
4,2756,O
",",2756,O
72-76,2756,O
),2756,O
.,2756,O
In,2757,O
contrast,2757,O
",",2757,O
the,2757,O
low,2757,O
reproductive,2757,O
fitness,2757,O
of,2757,O
individuals,2757,O
with,2757,O
congenital,2757,O
DM,2757,B-SpecificDisease
(,2757,O
the,2757,O
endpoint,2757,O
of,2757,O
genetic,2757,O
anticipation,2757,O
in,2757,O
myotonic,2757,B-SpecificDisease
dystrophy,2757,I-SpecificDisease
),2757,O
suggests,2757,O
a,2757,O
higher,2757,O
rate,2757,O
of,2757,O
new,2757,O
mutations,2757,O
.,2757,O
We,2758,O
present,2758,O
a,2758,O
high,2758,O
resolution,2758,O
genetic,2758,O
analysis,2758,O
of,2758,O
the,2758,O
DM,2758,B-Modifier
locus,2758,O
using,2758,O
PCR,2758,O
based,2758,O
assays,2758,O
of,2758,O
nine,2758,O
polymorphisms,2758,O
",",2758,O
spanning,2758,O
a,2758,O
physical,2758,O
distance,2758,O
of,2758,O
30,2758,O
kb,2758,O
",",2758,O
within,2758,O
and,2758,O
immediately,2758,O
flanking,2758,O
the,2758,O
DM,2758,B-Modifier
kinase,2758,O
gene,2758,O
.,2758,O
The,2759,O
persistent,2759,O
complete,2759,O
allelic,2759,O
association,2759,O
of,2759,O
the,2759,O
DM,2759,B-Modifier
mutation,2759,O
with,2759,O
all,2759,O
these,2759,O
polymorphisms,2759,O
provides,2759,O
further,2759,O
support,2759,O
to,2759,O
previous,2759,O
observations,2759,O
and,2759,O
suggests,2759,O
more,2759,O
strongly,2759,O
that,2759,O
the,2759,O
DM,2759,B-Modifier
mutation,2759,O
occurred,2759,O
on,2759,O
the,2759,O
background,2759,O
of,2759,O
a,2759,O
particular,2759,O
haplotype,2759,O
in,2759,O
which,2759,O
the,2759,O
(,2759,O
CTG,2759,O
),2759,O
n,2759,O
repeat,2759,O
became,2759,O
inherently,2759,O
unstable,2759,O
and,2759,O
therefore,2759,O
predisposed,2759,O
to,2759,O
amplification,2759,O
.,2759,O
Genetic,2760,O
instability,2760,O
in,2760,O
human,2760,O
ovarian,2760,B-Modifier
cancer,2760,I-Modifier
cell,2760,O
lines,2760,O
.,2760,O
We,2761,O
have,2761,O
analyzed,2761,O
the,2761,O
stability,2761,O
of,2761,O
microsatellites,2761,O
in,2761,O
cell,2761,O
lines,2761,O
derived,2761,O
from,2761,O
human,2761,O
ovarian,2761,B-SpecificDisease
cancers,2761,I-SpecificDisease
and,2761,O
found,2761,O
that,2761,O
5,2761,O
out,2761,O
of,2761,O
10,2761,O
of,2761,O
the,2761,O
ovarian,2761,B-Modifier
tumor,2761,I-Modifier
cell,2761,O
lines,2761,O
are,2761,O
genetically,2761,O
unstable,2761,O
at,2761,O
the,2761,O
majority,2761,O
of,2761,O
the,2761,O
loci,2761,O
analyzed,2761,O
.,2761,O
In,2762,O
clones,2762,O
and,2762,O
subclones,2762,O
derived,2762,O
serially,2762,O
from,2762,O
one,2762,O
of,2762,O
these,2762,O
cell,2762,O
lines,2762,O
(,2762,O
2774,2762,O
;,2762,O
serous,2762,B-SpecificDisease
cystadenocarcinoma,2762,I-SpecificDisease
),2762,O
",",2762,O
a,2762,O
very,2762,O
high,2762,O
proportion,2762,O
of,2762,O
microsatellites,2762,O
distributed,2762,O
in,2762,O
many,2762,O
different,2762,O
regions,2762,O
of,2762,O
the,2762,O
genome,2762,O
change,2762,O
their,2762,O
size,2762,O
in,2762,O
a,2762,O
mercurial,2762,O
fashion,2762,O
.,2762,O
We,2763,O
conclude,2763,O
that,2763,O
genomic,2763,O
instability,2763,O
in,2763,O
ovarian,2763,B-SpecificDisease
tumors,2763,I-SpecificDisease
is,2763,O
a,2763,O
dynamic,2763,O
and,2763,O
ongoing,2763,O
process,2763,O
whose,2763,O
high,2763,O
frequency,2763,O
may,2763,O
have,2763,O
been,2763,O
previously,2763,O
underestimated,2763,O
by,2763,O
PCR-based,2763,O
allelotyping,2763,O
of,2763,O
bulk,2763,O
tumor,2763,B-Modifier
tissue,2763,O
.,2763,O
We,2764,O
have,2764,O
identified,2764,O
the,2764,O
source,2764,O
of,2764,O
the,2764,O
genetic,2764,O
instability,2764,O
in,2764,O
one,2764,O
ovarian,2764,B-SpecificDisease
tumor,2764,I-SpecificDisease
as,2764,O
a,2764,O
point,2764,O
mutation,2764,O
(,2764,O
R524P,2764,O
),2764,O
in,2764,O
the,2764,O
human,2764,O
mismatch-repair,2764,O
gene,2764,O
MSH2,2764,O
(,2764,O
Salmonella,2764,O
MutS,2764,O
homologue,2764,O
),2764,O
",",2764,O
which,2764,O
has,2764,O
recently,2764,O
been,2764,O
shown,2764,O
to,2764,O
be,2764,O
involved,2764,O
in,2764,O
hereditary,2764,B-SpecificDisease
nonpolyposis,2764,I-SpecificDisease
colorectal,2764,I-SpecificDisease
cancer,2764,I-SpecificDisease
.,2764,O
Patient,2765,O
2774,2765,O
was,2765,O
a,2765,O
38-year-old,2765,O
heterozygote,2765,O
",",2765,O
and,2765,O
her,2765,O
normal,2765,O
tissue,2765,O
carried,2765,O
both,2765,O
mutant,2765,O
and,2765,O
wild-type,2765,O
alleles,2765,O
of,2765,O
the,2765,O
human,2765,O
MSH2,2765,O
gene,2765,O
.,2765,O
However,2766,O
the,2766,O
wild-type,2766,O
allele,2766,O
was,2766,O
lost,2766,O
at,2766,O
some,2766,O
point,2766,O
early,2766,O
during,2766,O
tumorigenesis,2766,O
so,2766,O
that,2766,O
DNA,2766,O
isolated,2766,O
either,2766,O
from,2766,O
the,2766,O
patients,2766,O
ovarian,2766,B-SpecificDisease
tumor,2766,I-SpecificDisease
or,2766,O
from,2766,O
the,2766,O
2774,2766,O
cell,2766,O
line,2766,O
carries,2766,O
only,2766,O
the,2766,O
mutant,2766,O
allele,2766,O
of,2766,O
the,2766,O
human,2766,O
MSH2,2766,O
gene,2766,O
.,2766,O
The,2767,O
genetic,2767,O
instability,2767,O
observed,2767,O
in,2767,O
the,2767,O
tumor,2767,B-DiseaseClass
and,2767,O
cell,2767,O
line,2767,O
DNA,2767,O
",",2767,O
together,2767,O
with,2767,O
the,2767,O
germ-line,2767,O
mutation,2767,O
in,2767,O
a,2767,O
mismatch-repair,2767,O
gene,2767,O
",",2767,O
suggest,2767,O
that,2767,O
the,2767,O
MSH2,2767,O
gene,2767,O
is,2767,O
involved,2767,O
in,2767,O
the,2767,O
onset,2767,O
and/or,2767,O
progression,2767,O
in,2767,O
a,2767,O
subset,2767,O
of,2767,O
ovarian,2767,B-SpecificDisease
cancer,2767,I-SpecificDisease
..,2767,O
BRCA1,2768,O
mutations,2768,O
in,2768,O
primary,2768,O
breast,2768,O
and,2768,O
ovarian,2768,O
carcinomas,2768,O
.,2768,O
Loss,2769,O
of,2769,O
heterozygosity,2769,O
data,2769,O
from,2769,O
familial,2769,B-DiseaseClass
tumors,2769,I-DiseaseClass
suggest,2769,O
that,2769,O
BRCA1,2769,O
",",2769,O
a,2769,O
gene,2769,O
that,2769,O
confers,2769,O
susceptibility,2769,O
to,2769,O
ovarian,2769,B-CompositeMention
and,2769,I-CompositeMention
early-onset,2769,I-CompositeMention
breast,2769,B-CompositeMention
cancer,2769,I-CompositeMention
",",2769,O
encodes,2769,O
a,2769,O
tumor,2769,B-Modifier
suppressor,2769,O
.,2769,O
The,2770,O
BRCA1,2770,O
region,2770,O
is,2770,O
also,2770,O
subject,2770,O
to,2770,O
allelic,2770,O
loss,2770,O
in,2770,O
sporadic,2770,O
breast,2770,O
and,2770,O
ovarian,2770,O
cancers,2770,O
",",2770,O
an,2770,O
indication,2770,O
that,2770,O
BRCA1,2770,O
mutations,2770,O
may,2770,O
occur,2770,O
somatically,2770,O
in,2770,O
these,2770,O
tumors,2770,B-DiseaseClass
.,2770,O
The,2771,O
BRCA1,2771,O
coding,2771,O
region,2771,O
was,2771,O
examined,2771,O
for,2771,O
mutations,2771,O
in,2771,O
primary,2771,O
breast,2771,O
and,2771,O
ovarian,2771,O
tumors,2771,O
that,2771,O
show,2771,O
allele,2771,O
loss,2771,O
at,2771,O
the,2771,O
BRCA1,2771,O
locus,2771,O
.,2771,O
Mutations,2772,O
were,2772,O
detected,2772,O
in,2772,O
3,2772,O
of,2772,O
32,2772,O
breast,2772,O
and,2772,O
1,2772,O
of,2772,O
12,2772,O
ovarian,2772,B-SpecificDisease
carcinomas,2772,I-SpecificDisease
;,2772,O
all,2772,O
four,2772,O
mutations,2772,O
were,2772,O
germline,2772,O
alterations,2772,O
and,2772,O
occurred,2772,O
in,2772,O
early-onset,2772,O
cancers,2772,B-DiseaseClass
.,2772,O
These,2773,O
results,2773,O
suggest,2773,O
that,2773,O
mutation,2773,O
of,2773,O
BRCA1,2773,O
may,2773,O
not,2773,O
be,2773,O
critical,2773,O
in,2773,O
the,2773,O
development,2773,O
of,2773,O
the,2773,O
majority,2773,O
of,2773,O
breast,2773,O
and,2773,O
ovarian,2773,O
cancers,2773,O
that,2773,O
arise,2773,O
in,2773,O
the,2773,O
absence,2773,O
of,2773,O
a,2773,O
mutant,2773,O
germline,2773,O
allele,2773,O
..,2773,O
PAX6,2774,O
gene,2774,O
dosage,2774,O
effect,2774,O
in,2774,O
a,2774,O
family,2774,O
with,2774,O
congenital,2774,B-SpecificDisease
cataracts,2774,I-SpecificDisease
",",2774,O
aniridia,2774,B-SpecificDisease
",",2774,O
anophthalmia,2774,B-SpecificDisease
and,2774,O
central,2774,B-DiseaseClass
nervous,2774,I-DiseaseClass
system,2774,I-DiseaseClass
defects,2774,I-DiseaseClass
.,2774,O
The,2775,O
human,2775,O
eye,2775,O
malformation,2775,O
aniridia,2775,B-SpecificDisease
results,2775,O
from,2775,O
haploinsufficiency,2775,B-SpecificDisease
of,2775,I-SpecificDisease
PAX6,2775,I-SpecificDisease
",",2775,O
a,2775,O
paired,2775,O
box,2775,O
DNA-binding,2775,O
protein,2775,O
.,2775,O
To,2776,O
study,2776,O
this,2776,O
dosage,2776,O
effect,2776,O
",",2776,O
we,2776,O
characterized,2776,O
two,2776,O
PAX6,2776,O
mutations,2776,O
in,2776,O
a,2776,O
family,2776,O
segregating,2776,O
aniridia,2776,B-SpecificDisease
and,2776,O
a,2776,O
milder,2776,O
syndrome,2776,O
consisting,2776,O
of,2776,O
congenital,2776,B-SpecificDisease
cataracts,2776,I-SpecificDisease
and,2776,O
late,2776,O
onset,2776,O
corneal,2776,B-SpecificDisease
dystrophy,2776,I-SpecificDisease
.,2776,O
The,2777,O
nonsense,2777,O
mutations,2777,O
",",2777,O
at,2777,O
codons,2777,O
103,2777,O
and,2777,O
353,2777,O
",",2777,O
truncate,2777,O
PAX6,2777,O
within,2777,O
the,2777,O
N-terminal,2777,O
paired,2777,O
and,2777,O
C-terminal,2777,O
PST,2777,O
domains,2777,O
",",2777,O
respectively,2777,O
.,2777,O
The,2778,O
wild-type,2778,O
PST,2778,O
domain,2778,O
activates,2778,O
transcription,2778,O
autonomously,2778,O
and,2778,O
the,2778,O
mutant,2778,O
form,2778,O
has,2778,O
partial,2778,O
activity,2778,O
.,2778,O
A,2779,O
compound,2779,O
heterozygote,2779,O
had,2779,O
severe,2779,O
craniofacial,2779,O
and,2779,O
central,2779,O
nervous,2779,O
system,2779,O
defects,2779,O
and,2779,O
no,2779,B-DiseaseClass
eyes,2779,I-DiseaseClass
.,2779,O
The,2780,O
pattern,2780,O
of,2780,O
malformations,2780,O
is,2780,O
similar,2780,O
to,2780,O
that,2780,O
in,2780,O
homozygous,2780,O
Sey,2780,O
mice,2780,O
and,2780,O
suggests,2780,O
a,2780,O
critical,2780,O
role,2780,O
for,2780,O
PAX6,2780,O
in,2780,O
controlling,2780,O
the,2780,O
migration,2780,O
and,2780,O
differentiation,2780,O
of,2780,O
specific,2780,O
neuronal,2780,O
progenitor,2780,O
cells,2780,O
in,2780,O
the,2780,O
brain,2780,O
..,2780,O
A,2781,O
physical,2781,O
map,2781,O
and,2781,O
candidate,2781,O
genes,2781,O
in,2781,O
the,2781,O
BRCA1,2781,O
region,2781,O
on,2781,O
chromosome,2781,O
17q12-21,2781,O
.,2781,O
We,2782,O
have,2782,O
constructed,2782,O
a,2782,O
physical,2782,O
map,2782,O
of,2782,O
a,2782,O
4,2782,O
cM,2782,O
region,2782,O
on,2782,O
chromosome,2782,O
17q12-21,2782,O
that,2782,O
contains,2782,O
the,2782,O
hereditary,2782,B-Modifier
breast,2782,I-Modifier
and,2782,I-Modifier
ovarian,2782,I-Modifier
cancer,2782,I-Modifier
gene,2782,O
BRCA1,2782,O
.,2782,O
The,2783,O
map,2783,O
comprises,2783,O
a,2783,O
contig,2783,O
of,2783,O
137,2783,O
overlapping,2783,O
yeast,2783,O
artificial,2783,O
chromosomes,2783,O
and,2783,O
P1,2783,O
clones,2783,O
",",2783,O
onto,2783,O
which,2783,O
we,2783,O
have,2783,O
placed,2783,O
112,2783,O
PCR,2783,O
markers,2783,O
.,2783,O
We,2784,O
have,2784,O
localized,2784,O
more,2784,O
than,2784,O
20,2784,O
genes,2784,O
on,2784,O
this,2784,O
map,2784,O
",",2784,O
ten,2784,O
of,2784,O
which,2784,O
had,2784,O
not,2784,O
been,2784,O
mapped,2784,O
to,2784,O
the,2784,O
region,2784,O
previously,2784,O
",",2784,O
and,2784,O
have,2784,O
isolated,2784,O
30,2784,O
cDNA,2784,O
clones,2784,O
representing,2784,O
partial,2784,O
sequences,2784,O
of,2784,O
as,2784,O
yet,2784,O
unidentified,2784,O
genes,2784,O
.,2784,O
Two,2785,O
genes,2785,O
that,2785,O
lie,2785,O
within,2785,O
a,2785,O
narrow,2785,O
region,2785,O
defined,2785,O
by,2785,O
meiotic,2785,O
breakpoints,2785,O
in,2785,O
BRCA1,2785,O
patients,2785,O
have,2785,O
been,2785,O
sequenced,2785,O
in,2785,O
breast,2785,B-Modifier
cancer,2785,I-Modifier
patients,2785,O
without,2785,O
revealing,2785,O
any,2785,O
deleterious,2785,O
mutations,2785,O
.,2785,O
These,2786,O
new,2786,O
reagents,2786,O
should,2786,O
facilitate,2786,O
the,2786,O
identification,2786,O
of,2786,O
BRCA1,2786,O
..,2786,O
The,2787,O
LEC,2787,O
rat,2787,O
has,2787,O
a,2787,O
deletion,2787,O
in,2787,O
the,2787,O
copper,2787,O
transporting,2787,O
ATPase,2787,O
gene,2787,O
homologous,2787,O
to,2787,O
the,2787,O
Wilson,2787,B-Modifier
disease,2787,I-Modifier
gene,2787,O
.,2787,O
The,2788,O
Long-Evans,2788,O
Cinnamon,2788,O
(,2788,O
LEC,2788,O
),2788,O
rat,2788,O
shows,2788,O
similarity,2788,O
to,2788,O
Wilson,2788,B-SpecificDisease
disease,2788,I-SpecificDisease
in,2788,O
many,2788,O
clinical,2788,O
and,2788,O
biochemical,2788,O
features,2788,O
.,2788,O
We,2789,O
have,2789,O
cloned,2789,O
cDNAs,2789,O
for,2789,O
the,2789,O
rat,2789,O
gene,2789,O
(,2789,O
Atp7b,2789,O
),2789,O
homologous,2789,O
to,2789,O
the,2789,O
human,2789,O
Wilson,2789,B-Modifier
disease,2789,I-Modifier
gene,2789,O
(,2789,O
ATP7B,2789,O
),2789,O
and,2789,O
have,2789,O
used,2789,O
them,2789,O
to,2789,O
identify,2789,O
a,2789,O
partial,2789,O
deletion,2789,O
in,2789,O
the,2789,O
Atp7b,2789,O
gene,2789,O
in,2789,O
the,2789,O
LEC,2789,O
rat,2789,O
.,2789,O
The,2790,O
deletion,2790,O
removes,2790,O
at,2790,O
least,2790,O
900,2790,O
bp,2790,O
of,2790,O
the,2790,O
coding,2790,O
region,2790,O
at,2790,O
the,2790,O
3,2790,O
end,2790,O
",",2790,O
includes,2790,O
the,2790,O
crucial,2790,O
ATP,2790,O
binding,2790,O
domain,2790,O
and,2790,O
extends,2790,O
downstream,2790,O
of,2790,O
the,2790,O
gene,2790,O
.,2790,O
Our,2791,O
results,2791,O
provide,2791,O
convincing,2791,O
evidence,2791,O
for,2791,O
defining,2791,O
the,2791,O
LEC,2791,O
rat,2791,O
as,2791,O
an,2791,O
animal,2791,O
model,2791,O
for,2791,O
Wilson,2791,B-SpecificDisease
disease,2791,I-SpecificDisease
.,2791,O
This,2792,O
model,2792,O
will,2792,O
be,2792,O
important,2792,O
for,2792,O
studying,2792,O
liver,2792,O
pathophysiology,2792,O
",",2792,O
for,2792,O
developing,2792,O
therapy,2792,O
for,2792,O
Wilson,2792,B-SpecificDisease
disease,2792,I-SpecificDisease
and,2792,O
for,2792,O
studying,2792,O
the,2792,O
pathway,2792,O
of,2792,O
copper,2792,O
transport,2792,O
and,2792,O
its,2792,O
possible,2792,O
interaction,2792,O
with,2792,O
other,2792,O
heavy,2792,O
metals,2792,O
..,2792,O
Genomic,2793,O
organization,2793,O
of,2793,O
the,2793,O
adrenoleukodystrophy,2793,B-Modifier
gene,2793,O
.,2793,O
Adrenoleukodystrophy,2794,B-SpecificDisease
(,2794,O
ALD,2794,B-SpecificDisease
),2794,O
",",2794,O
the,2794,O
most,2794,O
frequent,2794,O
peroxisomal,2794,B-DiseaseClass
disorder,2794,I-DiseaseClass
",",2794,O
is,2794,O
a,2794,O
severe,2794,O
neurodegenerative,2794,B-DiseaseClass
disease,2794,I-DiseaseClass
associated,2794,O
with,2794,O
an,2794,O
impairment,2794,B-DiseaseClass
of,2794,I-DiseaseClass
very,2794,I-DiseaseClass
long,2794,I-DiseaseClass
chain,2794,I-DiseaseClass
fatty,2794,I-DiseaseClass
acids,2794,I-DiseaseClass
beta-oxidation,2794,I-DiseaseClass
.,2794,O
We,2795,O
have,2795,O
recently,2795,O
identified,2795,O
by,2795,O
positional,2795,O
cloning,2795,O
the,2795,O
gene,2795,O
responsible,2795,O
for,2795,O
ALD,2795,B-SpecificDisease
",",2795,O
located,2795,O
in,2795,O
Xq28,2795,O
.,2795,O
It,2796,O
encodes,2796,O
a,2796,O
new,2796,O
member,2796,O
of,2796,O
the,2796,O
``,2796,O
ABC,2796,O
``,2796,O
superfamily,2796,O
of,2796,O
membrane-associated,2796,O
transporters,2796,O
that,2796,O
shows,2796,O
",",2796,O
in,2796,O
particular,2796,O
",",2796,O
significant,2796,O
homology,2796,O
to,2796,O
the,2796,O
70-kDa,2796,O
peroxisomal,2796,O
membrane,2796,O
protein,2796,O
(,2796,O
PMP70,2796,O
),2796,O
.,2796,O
We,2797,O
report,2797,O
here,2797,O
a,2797,O
detailed,2797,O
characterization,2797,O
of,2797,O
the,2797,O
ALD,2797,B-Modifier
gene,2797,O
structure,2797,O
.,2797,O
It,2798,O
extends,2798,O
over,2798,O
21,2798,O
kb,2798,O
and,2798,O
consists,2798,O
of,2798,O
10,2798,O
exons,2798,O
.,2798,O
To,2799,O
facilitate,2799,O
the,2799,O
detection,2799,O
of,2799,O
mutations,2799,O
in,2799,O
ALD,2799,B-Modifier
patients,2799,O
",",2799,O
we,2799,O
have,2799,O
determined,2799,O
the,2799,O
intronic,2799,O
sequences,2799,O
flanking,2799,O
the,2799,O
exons,2799,O
as,2799,O
well,2799,O
as,2799,O
the,2799,O
sequence,2799,O
of,2799,O
the,2799,O
3,2799,O
untranslated,2799,O
region,2799,O
and,2799,O
of,2799,O
the,2799,O
immediate,2799,O
5,2799,O
promoter,2799,O
region,2799,O
.,2799,O
Sequences,2800,O
present,2800,O
in,2800,O
distal,2800,O
exons,2800,O
cross-hybridize,2800,O
strongly,2800,O
to,2800,O
additional,2800,O
sequences,2800,O
in,2800,O
the,2800,O
human,2800,O
genome,2800,O
.,2800,O
The,2801,O
ALD,2801,B-Modifier
gene,2801,O
has,2801,O
been,2801,O
positioned,2801,O
on,2801,O
a,2801,O
pulsed-field,2801,O
map,2801,O
between,2801,O
DXS15,2801,O
and,2801,O
the,2801,O
L1CAM,2801,O
gene,2801,O
",",2801,O
about,2801,O
650,2801,O
kb,2801,O
upstream,2801,O
from,2801,O
the,2801,O
color,2801,O
pigment,2801,O
genes,2801,O
.,2801,O
The,2802,O
frequent,2802,O
occurrence,2802,O
of,2802,O
color,2802,O
vision,2802,O
anomalies,2802,O
observed,2802,O
in,2802,O
patients,2802,O
with,2802,O
adrenomyeloneuropathy,2802,B-SpecificDisease
(,2802,O
the,2802,O
adult,2802,O
onset,2802,O
form,2802,O
of,2802,O
ALD,2802,B-SpecificDisease
),2802,O
thus,2802,O
does,2802,O
not,2802,O
represent,2802,O
a,2802,O
contiguous,2802,B-DiseaseClass
gene,2802,I-DiseaseClass
syndrome,2802,I-DiseaseClass
but,2802,O
a,2802,O
secondary,2802,O
manifestation,2802,O
of,2802,O
ALD,2802,B-SpecificDisease
..,2802,O
The,2803,O
murine,2803,O
homologues,2803,O
of,2803,O
the,2803,O
Huntington,2803,B-Modifier
disease,2803,I-Modifier
gene,2803,O
(,2803,O
Hdh,2803,O
),2803,O
and,2803,O
the,2803,O
alpha-adducin,2803,O
gene,2803,O
(,2803,O
Add1,2803,O
),2803,O
map,2803,O
to,2803,O
mouse,2803,O
chromosome,2803,O
5,2803,O
within,2803,O
a,2803,O
region,2803,O
of,2803,O
conserved,2803,O
synteny,2803,O
with,2803,O
human,2803,O
chromosome,2803,O
4p16.3,2803,O
.,2803,O
Huntington,2804,B-SpecificDisease
disease,2804,I-SpecificDisease
(,2804,O
HD,2804,B-SpecificDisease
),2804,O
is,2804,O
a,2804,O
severe,2804,O
autosomal,2804,B-DiseaseClass
dominant,2804,I-DiseaseClass
neurodegenerative,2804,I-DiseaseClass
disorder,2804,I-DiseaseClass
associated,2804,O
with,2804,O
a,2804,O
novel,2804,O
gene,2804,O
(,2804,O
IT15,2804,O
),2804,O
.,2804,O
Recently,2805,O
",",2805,O
we,2805,O
reported,2805,O
the,2805,O
cloning,2805,O
of,2805,O
Hdh,2805,O
",",2805,O
the,2805,O
murine,2805,O
homologue,2805,O
of,2805,O
IT15,2805,O
.,2805,O
Here,2806,O
",",2806,O
using,2806,O
an,2806,O
interspecific,2806,O
backcross,2806,O
",",2806,O
we,2806,O
have,2806,O
mapped,2806,O
both,2806,O
Hdh,2806,O
and,2806,O
the,2806,O
mouse,2806,O
homologue,2806,O
of,2806,O
human,2806,O
alpha-adducin,2806,O
(,2806,O
Add1,2806,O
),2806,O
",",2806,O
a,2806,O
membrane-associated,2806,O
cytoskeletal,2806,O
protein,2806,O
gene,2806,O
.,2806,O
Both,2807,O
of,2807,O
these,2807,O
genes,2807,O
map,2807,O
in,2807,O
the,2807,O
same,2807,O
position,2807,O
on,2807,O
mouse,2807,O
chromosome,2807,O
5,2807,O
in,2807,O
a,2807,O
region,2807,O
associated,2807,O
with,2807,O
ancestral,2807,O
chromosomal,2807,O
rearrangements,2807,O
and,2807,O
show,2807,O
no,2807,O
recombination,2807,O
with,2807,O
D5H4S43,2807,O
",",2807,O
D5H4S115,2807,O
",",2807,O
and,2807,O
D5H4S62,2807,O
",",2807,O
the,2807,O
murine,2807,O
homologues,2807,O
of,2807,O
D4S43,2807,O
",",2807,O
D4S115,2807,O
",",2807,O
and,2807,O
D4S62,2807,O
",",2807,O
respectively,2807,O
.,2807,O
Further,2808,O
mapping,2808,O
studies,2808,O
of,2808,O
humans,2808,O
",",2808,O
mice,2808,O
",",2808,O
and,2808,O
other,2808,O
mammalian,2808,O
species,2808,O
should,2808,O
reveal,2808,O
the,2808,O
nature,2808,O
of,2808,O
the,2808,O
rearrangements,2808,O
affecting,2808,O
this,2808,O
chromosomal,2808,O
segment,2808,O
during,2808,O
mammalian,2808,O
evolution,2808,O
..,2808,O
Genetic,2809,O
cholesteryl,2809,B-SpecificDisease
ester,2809,I-SpecificDisease
transfer,2809,I-SpecificDisease
protein,2809,I-SpecificDisease
deficiency,2809,I-SpecificDisease
caused,2809,O
by,2809,O
two,2809,O
prevalent,2809,O
mutations,2809,O
as,2809,O
a,2809,O
major,2809,O
determinant,2809,O
of,2809,O
increased,2809,O
levels,2809,O
of,2809,O
high,2809,O
density,2809,O
lipoprotein,2809,O
cholesterol,2809,O
.,2809,O
Genetic,2810,O
determinants,2810,O
of,2810,O
HDL,2810,O
cholesterol,2810,O
(,2810,O
HDL-C,2810,O
),2810,O
levels,2810,O
in,2810,O
the,2810,O
general,2810,O
population,2810,O
are,2810,O
poorly,2810,O
understood,2810,O
.,2810,O
We,2811,O
previously,2811,O
described,2811,O
plasma,2811,O
cholesteryl,2811,B-SpecificDisease
ester,2811,I-SpecificDisease
transfer,2811,I-SpecificDisease
protein,2811,I-SpecificDisease
(,2811,I-SpecificDisease
CETP,2811,I-SpecificDisease
),2811,I-SpecificDisease
deficiency,2811,I-SpecificDisease
due,2811,O
to,2811,O
an,2811,O
intron,2811,O
14,2811,O
G,2811,O
(,2811,O
+,2811,O
1,2811,O
),2811,O
-to-A,2811,O
mutation,2811,O
(,2811,O
Int14,2811,O
A,2811,O
),2811,O
in,2811,O
several,2811,O
families,2811,O
with,2811,O
very,2811,O
high,2811,O
HDL-C,2811,O
levels,2811,O
in,2811,O
Japan,2811,O
.,2811,O
Subjects,2812,O
with,2812,O
HDL-C,2812,O
>,2812,O
or,2812,O
=,2812,O
100,2812,O
mg/dl,2812,O
(,2812,O
n,2812,O
=,2812,O
130,2812,O
),2812,O
were,2812,O
screened,2812,O
by,2812,O
PCR,2812,O
single,2812,O
strand,2812,O
conformational,2812,O
polymorphism,2812,O
analysis,2812,O
of,2812,O
the,2812,O
CETP,2812,O
gene,2812,O
.,2812,O
Two,2813,O
other,2813,O
mutations,2813,O
were,2813,O
identified,2813,O
by,2813,O
DNA,2813,O
sequencing,2813,O
or,2813,O
primer-mediated,2813,O
restriction,2813,O
map,2813,O
modification,2813,O
of,2813,O
PCR,2813,O
products,2813,O
a,2813,O
novel,2813,O
intron,2813,O
14,2813,O
splice,2813,O
donor,2813,O
site,2813,O
mutation,2813,O
caused,2813,O
by,2813,O
a,2813,O
T,2813,O
insertion,2813,O
at,2813,O
position,2813,O
+,2813,O
3,2813,O
from,2813,O
the,2813,O
exon14/intron14,2813,O
boundary,2813,O
(,2813,O
Int14,2813,O
T,2813,O
),2813,O
and,2813,O
a,2813,O
missense,2813,O
mutation,2813,O
(,2813,O
Asp442,2813,O
to,2813,O
Gly,2813,O
),2813,O
within,2813,O
exon,2813,O
15,2813,O
(,2813,O
D442G,2813,O
),2813,O
.,2813,O
The,2814,O
Int14,2814,O
T,2814,O
mutation,2814,O
was,2814,O
only,2814,O
found,2814,O
in,2814,O
one,2814,O
family,2814,O
.,2814,O
However,2815,O
",",2815,O
the,2815,O
D442G,2815,O
and,2815,O
Int14,2815,O
A,2815,O
mutations,2815,O
were,2815,O
highly,2815,O
prevalent,2815,O
in,2815,O
subjects,2815,O
with,2815,O
HDL-C,2815,O
>,2815,O
or,2815,O
=,2815,O
60,2815,O
mg/dl,2815,O
",",2815,O
with,2815,O
combined,2815,O
allele,2815,O
frequencies,2815,O
of,2815,O
9,2815,O
%,2815,O
",",2815,O
12,2815,O
%,2815,O
",",2815,O
21,2815,O
%,2815,O
and,2815,O
43,2815,O
%,2815,O
for,2815,O
HDL-C,2815,O
60-79,2815,O
",",2815,O
80-99,2815,O
",",2815,O
100-119,2815,O
",",2815,O
and,2815,O
>,2815,O
or,2815,O
=,2815,O
120,2815,O
mg/dl,2815,O
",",2815,O
respectively,2815,O
.,2815,O
Furthermore,2816,O
",",2816,O
prevalences,2816,O
of,2816,O
the,2816,O
D442G,2816,O
and,2816,O
Int14,2816,O
A,2816,O
mutations,2816,O
were,2816,O
extremely,2816,O
high,2816,O
in,2816,O
a,2816,O
general,2816,O
sample,2816,O
of,2816,O
Japanese,2816,O
men,2816,O
(,2816,O
n,2816,O
=,2816,O
236,2816,O
),2816,O
",",2816,O
with,2816,O
heterozygote,2816,O
frequencies,2816,O
of,2816,O
7,2816,O
%,2816,O
and,2816,O
2,2816,O
%,2816,O
",",2816,O
respectively,2816,O
.,2816,O
These,2817,O
two,2817,O
mutations,2817,O
accounted,2817,O
for,2817,O
about,2817,O
10,2817,O
%,2817,O
of,2817,O
the,2817,O
total,2817,O
variance,2817,O
of,2817,O
HDL-C,2817,O
in,2817,O
this,2817,O
population,2817,O
.,2817,O
The,2818,O
phenotype,2818,O
in,2818,O
a,2818,O
genetic,2818,O
compound,2818,O
heterozygote,2818,O
(,2818,O
Int14,2818,O
T,2818,O
and,2818,O
Int14,2818,O
A,2818,O
),2818,O
was,2818,O
similar,2818,O
to,2818,O
that,2818,O
of,2818,O
Int14,2818,O
A,2818,O
homozygotes,2818,O
(,2818,O
no,2818,O
detectable,2818,O
CETP,2818,O
and,2818,O
markedly,2818,O
increased,2818,O
HDL-C,2818,O
),2818,O
",",2818,O
indicating,2818,O
that,2818,O
the,2818,O
Int14,2818,O
T,2818,O
produces,2818,O
a,2818,O
null,2818,O
allele,2818,O
.,2818,O
In,2819,O
four,2819,O
D442G,2819,O
homozygotes,2819,O
",",2819,O
mean,2819,O
HDL-C,2819,O
levels,2819,O
(,2819,O
86,2819,O
+/-,2819,O
26,2819,O
mg/dl,2819,O
),2819,O
were,2819,O
lower,2819,O
than,2819,O
in,2819,O
Int14,2819,O
A,2819,O
homozygotes,2819,O
(,2819,O
158,2819,O
+/-,2819,O
35,2819,O
mg/dl,2819,O
),2819,O
",",2819,O
reflecting,2819,O
residual,2819,O
CETP,2819,O
activity,2819,O
in,2819,O
plasma,2819,O
.,2819,O
In,2820,O
47,2820,O
D442G,2820,O
heterozygotes,2820,O
",",2820,O
mean,2820,O
HDL-C,2820,O
levels,2820,O
were,2820,O
91,2820,O
+/-,2820,O
23,2820,O
mg/dl,2820,O
",",2820,O
similar,2820,O
to,2820,O
the,2820,O
level,2820,O
in,2820,O
D442G,2820,O
homozygotes,2820,O
",",2820,O
and,2820,O
significantly,2820,O
greater,2820,O
than,2820,O
mean,2820,O
HDL-C,2820,O
levels,2820,O
in,2820,O
Int14,2820,O
A,2820,O
heterozygotes,2820,O
(,2820,O
69,2820,O
+/-,2820,O
15,2820,O
mg/dl,2820,O
),2820,O
.,2820,O
Thus,2821,O
",",2821,O
the,2821,O
D442G,2821,O
mutation,2821,O
acts,2821,O
differently,2821,O
to,2821,O
the,2821,O
null,2821,O
mutations,2821,O
with,2821,O
weaker,2821,O
effects,2821,O
on,2821,O
HDL,2821,O
in,2821,O
the,2821,O
homozygous,2821,O
state,2821,O
and,2821,O
stronger,2821,O
effects,2821,O
in,2821,O
the,2821,O
heterozygotes,2821,O
",",2821,O
suggesting,2821,O
dominant,2821,O
expression,2821,O
of,2821,O
a,2821,O
partially,2821,O
defective,2821,O
allele,2821,O
.,2821,O
CETP,2822,B-SpecificDisease
deficiency,2822,I-SpecificDisease
",",2822,O
reflecting,2822,O
two,2822,O
prevalent,2822,O
mutations,2822,O
(,2822,O
D442G,2822,O
and,2822,O
Int14,2822,O
A,2822,O
),2822,O
",",2822,O
is,2822,O
the,2822,O
first,2822,O
example,2822,O
of,2822,O
a,2822,O
genetic,2822,B-Modifier
deficiency,2822,I-Modifier
state,2822,O
which,2822,O
is,2822,O
sufficiently,2822,O
common,2822,O
to,2822,O
explain,2822,O
a,2822,O
significant,2822,O
fraction,2822,O
of,2822,O
the,2822,O
variation,2822,O
in,2822,O
HDL-C,2822,O
in,2822,O
the,2822,O
general,2822,O
population,2822,O
..,2822,O
Treatment,2823,O
of,2823,O
cerebrotendinous,2823,B-SpecificDisease
xanthomatosis,2823,I-SpecificDisease
:,2823,O
effects,2823,O
of,2823,O
chenodeoxycholic,2823,O
acid,2823,O
",",2823,O
pravastatin,2823,O
",",2823,O
and,2823,O
combined,2823,O
use,2823,O
.,2823,O
Treatments,2824,O
by,2824,O
oral,2824,O
administration,2824,O
of,2824,O
chenodeoxycholic,2824,O
acid,2824,O
(,2824,O
CDCA,2824,O
),2824,O
alone,2824,O
",",2824,O
3-hydroxy-3-methylglutaryl,2824,O
(,2824,O
HMG,2824,O
),2824,O
CoA,2824,O
reductase,2824,O
inhibitor,2824,O
(,2824,O
pravastatin,2824,O
),2824,O
alone,2824,O
",",2824,O
and,2824,O
combination,2824,O
of,2824,O
the,2824,O
two,2824,O
drugs,2824,O
were,2824,O
attempted,2824,O
for,2824,O
7,2824,O
patients,2824,O
with,2824,O
cerebrotendinous,2824,B-SpecificDisease
xanthomatosis,2824,I-SpecificDisease
(,2824,O
CTX,2824,B-SpecificDisease
),2824,O
.,2824,O
CDCA,2825,O
treatment,2825,O
at,2825,O
a,2825,O
dose,2825,O
of,2825,O
300,2825,O
mg/day,2825,O
reduced,2825,O
serum,2825,O
cholestanol,2825,O
(,2825,O
67,2825,O
.,2825,O
3,2826,O
%,2826,O
reduction,2826,O
),2826,O
",",2826,O
lathosterol,2826,O
(,2826,O
50,2826,O
.,2826,O
8,2827,O
%,2827,O
),2827,O
",",2827,O
campesterol,2827,O
(,2827,O
61,2827,O
.,2827,O
7,2828,O
%,2828,O
),2828,O
and,2828,O
sitosterol,2828,O
(,2828,O
12,2828,O
.,2828,O
7,2829,O
%,2829,O
),2829,O
.,2829,O
However,2830,O
",",2830,O
the,2830,O
sera,2830,O
of,2830,O
the,2830,O
patients,2830,O
changed,2830,O
to,2830,O
be,2830,O
``,2830,O
atherogenic,2830,O
``,2830,O
;,2830,O
total,2830,O
cholesterol,2830,O
",",2830,O
triglyceride,2830,O
and,2830,O
low-density,2830,O
lipoprotein,2830,O
(,2830,O
LDL,2830,O
),2830,O
-cholesterol,2830,O
were,2830,O
increased,2830,O
",",2830,O
while,2830,O
high-density,2830,O
lipoprotein,2830,O
(,2830,O
HDL,2830,O
),2830,O
-cholesterol,2830,O
was,2830,O
decreased,2830,O
.,2830,O
Contrarily,2831,O
",",2831,O
pravastatin,2831,O
at,2831,O
a,2831,O
dose,2831,O
of,2831,O
10,2831,O
mg/day,2831,O
improved,2831,O
the,2831,O
sera,2831,O
of,2831,O
the,2831,O
patients,2831,O
to,2831,O
be,2831,O
markedly,2831,O
``,2831,O
anti-atherogenic,2831,O
``,2831,O
",",2831,O
but,2831,O
the,2831,O
reductions,2831,O
of,2831,O
cholestanol,2831,O
(,2831,O
30,2831,O
.,2831,O
4,2832,O
%,2832,O
),2832,O
",",2832,O
lathosterol,2832,O
(,2832,O
44,2832,O
.,2832,O
0,2833,O
%,2833,O
),2833,O
",",2833,O
campesterol,2833,O
(,2833,O
22,2833,O
.,2833,O
9,2834,O
%,2834,O
),2834,O
and,2834,O
sitosterol,2834,O
(,2834,O
9,2834,O
.,2834,O
6,2835,O
%,2835,O
),2835,O
were,2835,O
inadequate,2835,O
.,2835,O
Combined,2836,O
treatment,2836,O
with,2836,O
CDCA,2836,O
and,2836,O
pravastatin,2836,O
showed,2836,O
good,2836,O
overlapping,2836,O
of,2836,O
the,2836,O
effects,2836,O
of,2836,O
each,2836,O
drug,2836,O
alone,2836,O
.,2836,O
The,2837,O
sera,2837,O
of,2837,O
the,2837,O
patients,2837,O
were,2837,O
apparently,2837,O
more,2837,O
``,2837,O
anti-atherogenic,2837,O
``,2837,O
than,2837,O
those,2837,O
after,2837,O
CDCA,2837,O
treatment,2837,O
.,2837,O
Serum,2838,O
cholestanol,2838,O
concentration,2838,O
was,2838,O
still,2838,O
2,2838,O
.,2838,O
7,2839,O
times,2839,O
higher,2839,O
than,2839,O
in,2839,O
controls,2839,O
",",2839,O
but,2839,O
the,2839,O
serum,2839,O
lathosterol,2839,O
level,2839,O
was,2839,O
within,2839,O
the,2839,O
normal,2839,O
range,2839,O
",",2839,O
indicating,2839,O
that,2839,O
the,2839,O
enhancement,2839,O
of,2839,O
overall,2839,O
cholesterol,2839,O
synthesis,2839,O
in,2839,O
the,2839,O
patients,2839,O
was,2839,O
sufficiently,2839,O
suppressed,2839,O
.,2839,O
Plant,2840,O
sterol,2840,O
levels,2840,O
were,2840,O
also,2840,O
within,2840,O
the,2840,O
normal,2840,O
range,2840,O
.,2840,O
The,2841,O
combination,2841,O
of,2841,O
CDCA,2841,O
and,2841,O
pravastatin,2841,O
was,2841,O
a,2841,O
good,2841,O
treatment,2841,O
for,2841,O
CTX,2841,B-SpecificDisease
",",2841,O
based,2841,O
on,2841,O
the,2841,O
improvement,2841,O
of,2841,O
serum,2841,O
lipoprotein,2841,O
metabolism,2841,O
",",2841,O
the,2841,O
suppression,2841,O
of,2841,O
cholesterol,2841,O
synthesis,2841,O
",",2841,O
and,2841,O
reductions,2841,O
of,2841,O
cholestanol,2841,O
and,2841,O
plant,2841,O
sterol,2841,O
levels,2841,O
.,2841,O
In,2842,O
all,2842,O
of,2842,O
7,2842,O
patients,2842,O
",",2842,O
the,2842,O
progression,2842,O
of,2842,O
disease,2842,O
was,2842,O
arrested,2842,O
",",2842,O
but,2842,O
dramatic,2842,O
effects,2842,O
on,2842,O
clinical,2842,O
manifestations,2842,O
",",2842,O
xanthoma,2842,B-DiseaseClass
",",2842,O
and,2842,O
electrophysiological,2842,O
findings,2842,O
could,2842,O
not,2842,O
be,2842,O
found,2842,O
after,2842,O
the,2842,O
treatment,2842,O
of,2842,O
these,2842,O
drugs,2842,O
Mutation,2843,O
spectrum,2843,O
in,2843,O
the,2843,O
CHM,2843,B-Modifier
gene,2843,O
of,2843,O
Danish,2843,O
and,2843,O
Swedish,2843,O
choroideremia,2843,B-Modifier
patients,2843,O
.,2843,O
The,2844,O
recent,2844,O
isolation,2844,O
of,2844,O
the,2844,O
complete,2844,O
open,2844,O
reading,2844,O
frame,2844,O
of,2844,O
the,2844,O
choroideremia,2844,B-Modifier
(,2844,O
CHM,2844,B-Modifier
),2844,O
gene,2844,O
and,2844,O
the,2844,O
characterization,2844,O
of,2844,O
the,2844,O
exon-intron,2844,O
boundaries,2844,O
has,2844,O
paved,2844,O
the,2844,O
way,2844,O
to,2844,O
mutation,2844,O
detection,2844,O
in,2844,O
patients,2844,O
with,2844,O
classical,2844,O
choroideremia,2844,B-SpecificDisease
.,2844,O
We,2845,O
have,2845,O
performed,2845,O
mutation,2845,O
screening,2845,O
in,2845,O
patients,2845,O
from,2845,O
15,2845,O
Danish,2845,O
and,2845,O
Swedish,2845,O
families,2845,O
by,2845,O
using,2845,O
Southern,2845,O
blot,2845,O
hybridization,2845,O
and,2845,O
the,2845,O
polymerase,2845,O
chain,2845,O
reaction,2845,O
single-strand,2845,O
conformation,2845,O
polymorphism,2845,O
(,2845,O
PCR-SSCP,2845,O
),2845,O
technique,2845,O
.,2845,O
Causative,2846,O
mutations,2846,O
in,2846,O
the,2846,O
CHM,2846,B-Modifier
gene,2846,O
were,2846,O
detected,2846,O
in,2846,O
at,2846,O
least,2846,O
12,2846,O
families,2846,O
",",2846,O
indicating,2846,O
that,2846,O
a,2846,O
substantial,2846,O
part,2846,O
of,2846,O
the,2846,O
mutations,2846,O
can,2846,O
be,2846,O
identified,2846,O
by,2846,O
this,2846,O
approach,2846,O
.,2846,O
In,2847,O
four,2847,O
of,2847,O
these,2847,O
families,2847,O
deletions,2847,O
of,2847,O
different,2847,O
sizes,2847,O
were,2847,O
found,2847,O
.,2847,O
Thus,2848,O
",",2848,O
in,2848,O
one,2848,O
patient,2848,O
",",2848,O
the,2848,O
deletion,2848,O
resulted,2848,O
in,2848,O
the,2848,O
absence,2848,O
of,2848,O
only,2848,O
one,2848,O
exon,2848,O
",",2848,O
while,2848,O
in,2848,O
another,2848,O
the,2848,O
deletion,2848,O
comprised,2848,O
the,2848,O
entire,2848,O
CHM,2848,B-Modifier
gene,2848,O
.,2848,O
Mapping,2849,O
of,2849,O
the,2849,O
deletion,2849,O
endpoints,2849,O
in,2849,O
these,2849,O
four,2849,O
patients,2849,O
and,2849,O
in,2849,O
another,2849,O
11,2849,O
male,2849,O
patients,2849,O
with,2849,O
sizeable,2849,O
deletions,2849,O
enabled,2849,O
us,2849,O
to,2849,O
construct,2849,O
a,2849,O
very,2849,O
detailed,2849,O
map,2849,O
of,2849,O
intervals,2849,O
2,2849,O
and,2849,O
3,2849,O
of,2849,O
Xq21,2849,O
.,2849,O
In,2850,O
the,2850,O
remaining,2850,O
11,2850,O
Danish,2850,O
and,2850,O
Swedish,2850,O
families,2850,O
at,2850,O
least,2850,O
8,2850,O
causative,2850,O
mutations,2850,O
were,2850,O
found,2850,O
by,2850,O
PCR-SSCP,2850,O
analysis,2850,O
and,2850,O
direct,2850,O
sequencing,2850,O
.,2850,O
Interestingly,2851,O
",",2851,O
all,2851,O
CHM,2851,B-Modifier
gene,2851,O
mutations,2851,O
detected,2851,O
thus,2851,O
far,2851,O
in,2851,O
choroideremia,2851,B-Modifier
patients,2851,O
give,2851,O
rise,2851,O
to,2851,O
the,2851,O
introduction,2851,O
of,2851,O
a,2851,O
premature,2851,O
stop,2851,O
codon,2851,O
..,2851,O
Predominance,2852,O
of,2852,O
the,2852,O
adrenomyeloneuropathy,2852,B-Modifier
phenotype,2852,O
of,2852,O
X-linked,2852,B-SpecificDisease
adrenoleukodystrophy,2852,I-SpecificDisease
in,2852,O
The,2852,O
Netherlands,2852,O
:,2852,O
a,2852,O
survey,2852,O
of,2852,O
30,2852,O
kindreds,2852,O
.,2852,O
X-linked,2853,B-SpecificDisease
adrenoleukodystrophy,2853,I-SpecificDisease
(,2853,O
X-ALD,2853,B-SpecificDisease
),2853,O
is,2853,O
an,2853,O
inherited,2853,B-DiseaseClass
disorder,2853,I-DiseaseClass
of,2853,O
peroxisomal,2853,O
beta-oxidation,2853,O
associated,2853,O
with,2853,O
accumulation,2853,O
of,2853,O
saturated,2853,O
very,2853,O
long-chain,2853,O
fatty,2853,O
acids,2853,O
",",2853,O
which,2853,O
results,2853,O
in,2853,O
central,2853,O
and,2853,O
peripheral,2853,O
demyelination,2853,B-DiseaseClass
and,2853,O
in,2853,O
impaired,2853,B-CompositeMention
function,2853,I-CompositeMention
of,2853,I-CompositeMention
adrenal,2853,I-CompositeMention
cortex,2853,I-CompositeMention
and,2853,I-CompositeMention
testes,2853,I-CompositeMention
.,2853,O
The,2854,O
phenotypic,2854,O
expression,2854,O
is,2854,O
highly,2854,O
variable,2854,O
",",2854,O
childhood,2854,B-SpecificDisease
cerebral,2854,I-SpecificDisease
ALD,2854,I-SpecificDisease
(,2854,O
CCALD,2854,B-SpecificDisease
),2854,O
and,2854,O
adrenomyeloneuropathy,2854,B-SpecificDisease
(,2854,O
AMN,2854,B-SpecificDisease
),2854,O
being,2854,O
the,2854,O
main,2854,O
variants,2854,O
.,2854,O
We,2855,O
explored,2855,O
the,2855,O
30,2855,O
Dutch,2855,O
kindreds,2855,O
well,2855,O
known,2855,O
to,2855,O
the,2855,O
Dutch,2855,O
X-ALD/AMN,2855,B-Modifier
Study,2855,O
Group,2855,O
and,2855,O
phenotyped,2855,O
77,2855,O
male,2855,O
patients,2855,O
35,2855,O
(,2855,O
46,2855,O
%,2855,O
),2855,O
had,2855,O
AMN,2855,B-SpecificDisease
and,2855,O
24,2855,O
(,2855,O
31,2855,O
%,2855,O
),2855,O
CCALD,2855,B-SpecificDisease
or,2855,O
adolescent,2855,B-SpecificDisease
cerebral,2855,I-SpecificDisease
ALD,2855,I-SpecificDisease
(,2855,O
AdolCALD,2855,B-SpecificDisease
),2855,O
.,2855,O
These,2856,O
percentages,2856,O
differ,2856,O
significantly,2856,O
from,2856,O
previous,2856,O
reports,2856,O
",",2856,O
in,2856,O
which,2856,O
25,2856,O
to,2856,O
28,2856,O
%,2856,O
of,2856,O
the,2856,O
patients,2856,O
developed,2856,O
AMN,2856,B-SpecificDisease
and,2856,O
53,2856,O
to,2856,O
57,2856,O
%,2856,O
CCALD,2856,B-SpecificDisease
or,2856,O
AdolCALD,2856,B-SpecificDisease
.,2856,O
Our,2857,O
findings,2857,O
indicate,2857,O
that,2857,O
--,2857,O
at,2857,O
least,2857,O
in,2857,O
the,2857,O
Netherlands,2857,O
--,2857,O
AMN,2857,B-SpecificDisease
may,2857,O
be,2857,O
the,2857,O
most,2857,O
frequent,2857,O
phenotype,2857,O
of,2857,O
X-ALD,2857,B-SpecificDisease
..,2857,O
Adrenoleukodystrophy,2858,B-Modifier
gene,2858,O
encodes,2858,O
an,2858,O
80,2858,O
kDa,2858,O
membrane,2858,O
protein,2858,O
.,2858,O
An,2859,O
antibody,2859,O
against,2859,O
the,2859,O
synthetic,2859,O
C-terminal,2859,O
peptides,2859,O
deduced,2859,O
from,2859,O
the,2859,O
cDNA,2859,O
of,2859,O
the,2859,O
gene,2859,O
responsible,2859,O
for,2859,O
X-linked,2859,B-SpecificDisease
adrenoleukodystrophy,2859,I-SpecificDisease
(,2859,O
ALD,2859,B-SpecificDisease
),2859,O
was,2859,O
produced,2859,O
to,2859,O
characterize,2859,O
the,2859,O
product,2859,O
of,2859,O
the,2859,O
ALD,2859,B-Modifier
gene,2859,O
.,2859,O
The,2860,O
antibody,2860,O
reacted,2860,O
with,2860,O
the,2860,O
80,2860,O
kDa,2860,O
band,2860,O
protein,2860,O
in,2860,O
control,2860,O
fibroblasts,2860,O
",",2860,O
while,2860,O
no,2860,O
bands,2860,O
were,2860,O
detected,2860,O
in,2860,O
the,2860,O
fibroblasts,2860,O
from,2860,O
a,2860,O
patient,2860,O
with,2860,O
ALD,2860,B-SpecificDisease
(,2860,O
#,2860,O
163,2860,O
),2860,O
",",2860,O
in,2860,O
which,2860,O
mRNA,2860,O
of,2860,O
the,2860,O
ALD,2860,B-Modifier
gene,2860,O
was,2860,O
undetectable,2860,O
based,2860,O
on,2860,O
Northern,2860,O
blot,2860,O
analysis,2860,O
.,2860,O
The,2861,O
293T,2861,O
cells,2861,O
transfected,2861,O
with,2861,O
the,2861,O
full-coding,2861,O
cDNA,2861,O
inserted,2861,O
in,2861,O
the,2861,O
expression,2861,O
vector,2861,O
produced,2861,O
a,2861,O
new,2861,O
80,2861,O
kDa,2861,O
protein,2861,O
",",2861,O
as,2861,O
detected,2861,O
by,2861,O
Western,2861,O
blot,2861,O
.,2861,O
In,2862,O
an,2862,O
immunocytological,2862,O
study,2862,O
",",2862,O
the,2862,O
staining,2862,O
was,2862,O
in,2862,O
a,2862,O
punctate,2862,O
pattern,2862,O
",",2862,O
in,2862,O
the,2862,O
normal,2862,O
fibroblasts,2862,O
.,2862,O
However,2863,O
",",2863,O
there,2863,O
was,2863,O
no,2863,O
punctate,2863,O
staining,2863,O
in,2863,O
the,2863,O
#,2863,O
163,2863,O
cells,2863,O
.,2863,O
These,2864,O
data,2864,O
thus,2864,O
indicate,2864,O
that,2864,O
the,2864,O
ALD,2864,B-Modifier
gene,2864,O
encodes,2864,O
an,2864,O
80,2864,O
kDa,2864,O
membrane,2864,O
protein,2864,O
..,2864,O
Isolation,2865,O
of,2865,O
the,2865,O
gene,2865,O
for,2865,O
McLeod,2865,B-SpecificDisease
syndrome,2865,I-SpecificDisease
that,2865,O
encodes,2865,O
a,2865,O
novel,2865,O
membrane,2865,O
transport,2865,O
protein,2865,O
.,2865,O
McLeod,2866,B-SpecificDisease
syndrome,2866,I-SpecificDisease
is,2866,O
an,2866,O
X-linked,2866,B-DiseaseClass
multisystem,2866,I-DiseaseClass
disorder,2866,I-DiseaseClass
characterized,2866,O
by,2866,O
abnormalities,2866,O
in,2866,O
the,2866,O
neuromuscular,2866,O
and,2866,O
hematopoietic,2866,O
systems,2866,O
.,2866,O
We,2867,O
have,2867,O
assembled,2867,O
a,2867,O
cosmid,2867,O
contig,2867,O
of,2867,O
360,2867,O
kb,2867,O
that,2867,O
encompasses,2867,O
the,2867,O
McLeod,2867,B-Modifier
gene,2867,O
locus,2867,O
.,2867,O
A,2868,O
50,2868,O
kb,2868,O
deletion,2868,O
was,2868,O
detected,2868,O
by,2868,O
screening,2868,O
DNA,2868,O
from,2868,O
patients,2868,O
with,2868,O
radiolabeled,2868,O
whole,2868,O
cosmids,2868,O
",",2868,O
and,2868,O
two,2868,O
transcription,2868,O
units,2868,O
were,2868,O
identified,2868,O
within,2868,O
this,2868,O
deletion,2868,O
.,2868,O
The,2869,O
mRNA,2869,O
expression,2869,O
pattern,2869,O
of,2869,O
one,2869,O
of,2869,O
them,2869,O
",",2869,O
designated,2869,O
as,2869,O
XK,2869,O
",",2869,O
correlates,2869,O
closely,2869,O
to,2869,O
the,2869,O
McLeod,2869,B-Modifier
phenotype,2869,O
.,2869,O
XK,2870,O
encodes,2870,O
a,2870,O
novel,2870,O
protein,2870,O
with,2870,O
structural,2870,O
characteristics,2870,O
of,2870,O
prokaryotic,2870,O
and,2870,O
eukaryotic,2870,O
membrane,2870,O
transport,2870,O
proteins,2870,O
.,2870,O
Nucleotide,2871,O
sequence,2871,O
analysis,2871,O
of,2871,O
XK,2871,O
from,2871,O
two,2871,O
unrelated,2871,O
McLeod,2871,B-Modifier
patients,2871,O
has,2871,O
identified,2871,O
point,2871,O
mutations,2871,O
at,2871,O
conserved,2871,O
splice,2871,O
donor,2871,O
and,2871,O
acceptor,2871,O
sites,2871,O
.,2871,O
These,2872,O
findings,2872,O
provide,2872,O
direct,2872,O
evidence,2872,O
that,2872,O
XK,2872,O
is,2872,O
responsible,2872,O
for,2872,O
McLeod,2872,B-SpecificDisease
syndrome,2872,I-SpecificDisease
..,2872,O
X-linked,2873,B-SpecificDisease
spastic,2873,I-SpecificDisease
paraplegia,2873,I-SpecificDisease
and,2873,O
Pelizaeus-Merzbacher,2873,B-SpecificDisease
disease,2873,I-SpecificDisease
are,2873,O
allelic,2873,B-DiseaseClass
disorders,2873,I-DiseaseClass
at,2873,O
the,2873,O
proteolipid,2873,O
protein,2873,O
locus,2873,O
.,2873,O
Three,2874,O
forms,2874,O
of,2874,O
X-linked,2874,B-SpecificDisease
spastic,2874,I-SpecificDisease
paraplegia,2874,I-SpecificDisease
(,2874,O
SPG,2874,B-SpecificDisease
),2874,O
have,2874,O
been,2874,O
defined,2874,O
.,2874,O
One,2875,O
locus,2875,O
(,2875,O
SPG,2875,O
1,2875,O
),2875,O
maps,2875,O
to,2875,O
Xq28,2875,O
while,2875,O
two,2875,O
clinically,2875,O
distinct,2875,O
forms,2875,O
map,2875,O
to,2875,O
Xq22,2875,O
(,2875,O
SPG2,2875,O
),2875,O
.,2875,O
A,2876,O
rare,2876,O
X-linked,2876,B-DiseaseClass
dysmyelinating,2876,I-DiseaseClass
disorder,2876,I-DiseaseClass
of,2876,O
the,2876,O
central,2876,O
nervous,2876,O
system,2876,O
",",2876,O
Pelizaeus-Merzbacher,2876,B-SpecificDisease
disease,2876,I-SpecificDisease
(,2876,O
PMD,2876,B-SpecificDisease
),2876,O
",",2876,O
has,2876,O
also,2876,O
been,2876,O
mapped,2876,O
to,2876,O
Xq21-q22,2876,O
",",2876,O
and,2876,O
is,2876,O
caused,2876,O
by,2876,O
mutations,2876,O
in,2876,O
the,2876,O
proteolipid,2876,O
protein,2876,O
gene,2876,O
(,2876,O
PLP,2876,O
),2876,O
which,2876,O
encodes,2876,O
two,2876,O
myelin,2876,O
proteins,2876,O
",",2876,O
PLP,2876,O
and,2876,O
DM20,2876,O
.,2876,O
While,2877,O
narrowing,2877,O
the,2877,O
genetic,2877,O
interval,2877,O
containing,2877,O
SPG2,2877,O
in,2877,O
a,2877,O
large,2877,O
pedigree,2877,O
",",2877,O
we,2877,O
found,2877,O
that,2877,O
PLP,2877,O
was,2877,O
the,2877,O
closest,2877,O
marker,2877,O
to,2877,O
the,2877,O
disease,2877,O
locus,2877,O
",",2877,O
implicating,2877,O
PLP,2877,O
as,2877,O
a,2877,O
possible,2877,O
candidate,2877,O
gene,2877,O
.,2877,O
We,2878,O
have,2878,O
found,2878,O
that,2878,O
a,2878,O
point,2878,O
mutation,2878,O
(,2878,O
His139Tyr,2878,O
),2878,O
in,2878,O
exon,2878,O
3B,2878,O
of,2878,O
an,2878,O
affected,2878,O
male,2878,O
produces,2878,O
a,2878,O
mutant,2878,O
PLP,2878,O
but,2878,O
a,2878,O
normal,2878,O
DM20,2878,O
",",2878,O
and,2878,O
segregates,2878,O
with,2878,O
the,2878,O
disease,2878,O
(,2878,O
Zmax,2878,O
=,2878,O
6,2878,O
.,2878,O
63,2879,O
",",2879,O
theta,2879,O
=,2879,O
0,2879,O
.,2879,O
00,2880,O
),2880,O
.,2880,O
It,2881,O
appears,2881,O
",",2881,O
therefore,2881,O
",",2881,O
that,2881,O
SPG2,2881,O
and,2881,O
PMD,2881,B-SpecificDisease
are,2881,O
allelic,2881,B-DiseaseClass
disorders,2881,I-DiseaseClass
Canavan,2882,B-SpecificDisease
disease,2882,I-SpecificDisease
:,2882,O
mutations,2882,O
among,2882,O
Jewish,2882,O
and,2882,O
non-Jewish,2882,O
patients,2882,O
.,2882,O
Canavan,2883,B-SpecificDisease
disease,2883,I-SpecificDisease
is,2883,O
an,2883,O
autosomal,2883,B-DiseaseClass
recessive,2883,I-DiseaseClass
leukodystrophy,2883,I-DiseaseClass
caused,2883,O
by,2883,O
the,2883,O
deficiency,2883,B-SpecificDisease
of,2883,I-SpecificDisease
aspartoacylase,2883,I-SpecificDisease
(,2883,O
ASPA,2883,O
),2883,O
.,2883,O
Sixty-four,2884,O
probands,2884,O
were,2884,O
analyzed,2884,O
for,2884,O
mutations,2884,O
in,2884,O
the,2884,O
ASPA,2884,O
gene,2884,O
.,2884,O
Three,2885,O
point,2885,O
mutations,2885,O
--,2885,O
693C,2885,O
--,2885,O
>,2885,O
A,2885,O
",",2885,O
854A,2885,O
--,2885,O
>,2885,O
C,2885,O
",",2885,O
and,2885,O
914C,2885,O
--,2885,O
>,2885,O
A,2885,O
--,2885,O
were,2885,O
identified,2885,O
in,2885,O
the,2885,O
coding,2885,O
sequence,2885,O
.,2885,O
The,2886,O
693C,2886,O
--,2886,O
>,2886,O
A,2886,O
and,2886,O
914C,2886,O
--,2886,O
>,2886,O
A,2886,O
base,2886,O
changes,2886,O
",",2886,O
resulting,2886,O
in,2886,O
nonsense,2886,O
tyr231,2886,O
--,2886,O
>,2886,O
ter,2886,O
and,2886,O
missense,2886,O
ala305,2886,O
--,2886,O
>,2886,O
glu,2886,O
mutations,2886,O
",",2886,O
respectively,2886,O
",",2886,O
lead,2886,O
to,2886,O
complete,2886,O
loss,2886,O
of,2886,O
ASPA,2886,O
activity,2886,O
in,2886,O
in,2886,O
vitro,2886,O
expression,2886,O
studies,2886,O
.,2886,O
The,2887,O
854A,2887,O
--,2887,O
>,2887,O
C,2887,O
transversion,2887,O
converted,2887,O
glu,2887,O
to,2887,O
ala,2887,O
in,2887,O
codon,2887,O
285,2887,O
.,2887,O
The,2888,O
glu285,2888,O
--,2888,O
>,2888,O
ala,2888,O
mutant,2888,O
ASPA,2888,O
has,2888,O
2,2888,O
.,2888,O
5,2889,O
%,2889,O
of,2889,O
the,2889,O
activity,2889,O
expressed,2889,O
by,2889,O
the,2889,O
wild-type,2889,O
enzyme,2889,O
.,2889,O
A,2890,O
fourth,2890,O
mutation,2890,O
",",2890,O
433,2890,O
--,2890,O
2,2890,O
(,2890,O
A,2890,O
--,2890,O
>,2890,O
G,2890,O
),2890,O
transition,2890,O
",",2890,O
was,2890,O
identified,2890,O
at,2890,O
the,2890,O
splice-acceptor,2890,O
site,2890,O
in,2890,O
intron,2890,O
2,2890,O
.,2890,O
The,2891,O
splice-site,2891,O
mutation,2891,O
would,2891,O
lead,2891,O
to,2891,O
skipping,2891,O
of,2891,O
exon,2891,O
3,2891,O
",",2891,O
accompanied,2891,O
by,2891,O
a,2891,O
frameshift,2891,O
",",2891,O
and,2891,O
thus,2891,O
would,2891,O
produce,2891,O
aberrant,2891,O
ASPA,2891,O
.,2891,O
Of,2892,O
the,2892,O
128,2892,O
unrelated,2892,O
Canavan,2892,B-Modifier
chromosomes,2892,O
analyzed,2892,O
",",2892,O
88,2892,O
were,2892,O
from,2892,O
probands,2892,O
of,2892,O
Ashkenazi,2892,O
Jewish,2892,O
descent,2892,O
.,2892,O
The,2893,O
glu285,2893,O
--,2893,O
>,2893,O
ala,2893,O
mutation,2893,O
was,2893,O
predominant,2893,O
(,2893,O
82,2893,O
.,2893,O
9,2894,O
%,2894,O
),2894,O
in,2894,O
this,2894,O
population,2894,O
",",2894,O
followed,2894,O
by,2894,O
the,2894,O
tyr231,2894,O
--,2894,O
>,2894,O
ter,2894,O
(,2894,O
14,2894,O
.,2894,O
8,2895,O
%,2895,O
),2895,O
and,2895,O
433,2895,O
--,2895,O
2,2895,O
(,2895,O
A,2895,O
--,2895,O
>,2895,O
G,2895,O
),2895,O
(,2895,O
1,2895,O
.,2895,O
1,2896,O
%,2896,O
),2896,O
mutations,2896,O
.,2896,O
The,2897,O
three,2897,O
mutations,2897,O
account,2897,O
for,2897,O
98,2897,O
.,2897,O
8,2898,O
%,2898,O
of,2898,O
the,2898,O
Canavan,2898,B-Modifier
chromosomes,2898,O
of,2898,O
Ashkenazi,2898,O
Jewish,2898,O
origin,2898,O
.,2898,O
The,2899,O
ala305,2899,O
--,2899,O
>,2899,O
glu,2899,O
mutation,2899,O
was,2899,O
found,2899,O
exclusively,2899,O
in,2899,O
non-Jewish,2899,O
probands,2899,O
of,2899,O
European,2899,O
descent,2899,O
and,2899,O
constituted,2899,O
60,2899,O
%,2899,O
of,2899,O
the,2899,O
40,2899,O
mutant,2899,O
chromosomes,2899,O
.,2899,O
Predominant,2900,O
occurrence,2900,O
of,2900,O
certain,2900,O
mutations,2900,O
among,2900,O
Ashkenazi,2900,O
Jewish,2900,O
and,2900,O
non-Jewish,2900,O
patients,2900,O
with,2900,O
Canavan,2900,B-SpecificDisease
disease,2900,I-SpecificDisease
would,2900,O
suggest,2900,O
a,2900,O
founding-father,2900,O
effect,2900,O
in,2900,O
propagation,2900,O
of,2900,O
these,2900,O
mutant,2900,O
chromosomes,2900,O
Intelligence,2901,O
quotient,2901,O
profile,2901,O
in,2901,O
myotonic,2901,B-SpecificDisease
dystrophy,2901,I-SpecificDisease
",",2901,O
intergenerational,2901,O
deficit,2901,O
",",2901,O
and,2901,O
correlation,2901,O
with,2901,O
CTG,2901,O
amplification,2901,O
.,2901,O
An,2902,O
abbreviated,2902,O
Wechsler,2902,O
Adult,2902,O
Intelligence,2902,O
Scale,2902,O
Revised,2902,O
(,2902,O
WAIS-R,2902,O
),2902,O
was,2902,O
used,2902,O
to,2902,O
assess,2902,O
verbal,2902,O
and,2902,O
arithmetical,2902,O
cognitive,2902,O
performance,2902,O
in,2902,O
55,2902,O
subjects,2902,O
with,2902,O
myotonic,2902,B-SpecificDisease
dystrophy,2902,I-SpecificDisease
(,2902,O
DM,2902,B-SpecificDisease
),2902,O
",",2902,O
covering,2902,O
all,2902,O
grades,2902,O
of,2902,O
disease,2902,O
severity,2902,O
",",2902,O
and,2902,O
31,2902,O
controls,2902,O
at,2902,O
50,2902,O
%,2902,O
risk,2902,O
of,2902,O
inheriting,2902,O
DM,2902,B-SpecificDisease
.,2902,O
Scaled,2903,O
scores,2903,O
from,2903,O
the,2903,O
assessment,2903,O
were,2903,O
converted,2903,O
into,2903,O
an,2903,O
intelligence,2903,O
quotient,2903,O
(,2903,O
IQ,2903,O
),2903,O
estimation,2903,O
on,2903,O
each,2903,O
person,2903,O
.,2903,O
Significant,2904,O
IQ,2904,O
differences,2904,O
were,2904,O
found,2904,O
between,2904,O
(,2904,O
1,2904,O
),2904,O
all,2904,O
55,2904,O
DM,2904,B-Modifier
subjects,2904,O
(,2904,O
mean,2904,O
90,2904,O
.,2904,O
2,2905,O
",",2905,O
SD,2905,O
16,2905,O
.,2905,O
1,2906,O
),2906,O
and,2906,O
31,2906,O
controls,2906,O
(,2906,O
102,2906,O
.,2906,O
6,2907,O
",",2907,O
SD,2907,O
9,2907,O
.,2907,O
4,2908,O
),2908,O
",",2908,O
with,2908,O
no,2908,O
sex,2908,O
differences,2908,O
in,2908,O
either,2908,O
group,2908,O
;,2908,O
(,2908,O
2,2908,O
),2908,O
15,2908,O
affected,2908,O
parents,2908,O
(,2908,O
99,2908,O
.,2908,O
3,2909,O
",",2909,O
SD,2909,O
12,2909,O
.,2909,O
2,2910,O
),2910,O
and,2910,O
their,2910,O
affected,2910,O
children,2910,O
(,2910,O
88,2910,O
.,2910,O
1,2911,O
",",2911,O
SD,2911,O
17,2911,O
.,2911,O
2,2912,O
),2912,O
",",2912,O
where,2912,O
significance,2912,O
was,2912,O
dependent,2912,O
on,2912,O
parental,2912,O
sex,2912,O
being,2912,O
female,2912,O
;,2912,O
and,2912,O
(,2912,O
3,2912,O
),2912,O
15,2912,O
pairs,2912,O
of,2912,O
affected,2912,O
sibs,2912,O
(,2912,O
89,2912,O
.,2912,O
6,2913,O
",",2913,O
SD,2913,O
13,2913,O
.,2913,O
2,2914,O
),2914,O
and,2914,O
their,2914,O
normal,2914,O
sibs,2914,O
(,2914,O
100,2914,O
.,2914,O
2,2915,O
",",2915,O
SD,2915,O
7,2915,O
.,2915,O
6,2916,O
),2916,O
.,2916,O
IQ,2917,O
steadily,2917,O
declined,2917,O
as,2917,O
(,2917,O
1,2917,O
),2917,O
the,2917,O
age,2917,O
of,2917,O
onset,2917,O
of,2917,O
signs,2917,O
and,2917,O
symptoms,2917,O
decreased,2917,O
",",2917,O
and,2917,O
(,2917,O
2,2917,O
),2917,O
the,2917,O
CTG,2917,O
expansion,2917,O
size,2917,O
increased,2917,O
.,2917,O
The,2918,O
correlation,2918,O
appeared,2918,O
to,2918,O
be,2918,O
more,2918,O
linear,2918,O
with,2918,O
age,2918,O
of,2918,O
onset,2918,O
.,2918,O
The,2919,O
correlation,2919,O
of,2919,O
IQ,2919,O
difference,2919,O
and,2919,O
CTG,2919,O
expansion,2919,O
difference,2919,O
in,2919,O
both,2919,O
the,2919,O
DM,2919,B-Modifier
parent-child,2919,O
pairs,2919,O
and,2919,O
normal,2919,O
sib-affected,2919,O
sib,2919,O
pairs,2919,O
was,2919,O
poor,2919,O
",",2919,O
indicating,2919,O
that,2919,O
CTG,2919,O
expansion,2919,O
is,2919,O
not,2919,O
a,2919,O
reliable,2919,O
predictor,2919,O
of,2919,O
IQ,2919,O
either,2919,O
in,2919,O
individual,2919,O
persons,2919,O
or,2919,O
families,2919,O
.,2919,O
Further,2920,O
analysis,2920,O
of,2920,O
cognitive,2920,O
function,2920,O
in,2920,O
DM,2920,B-SpecificDisease
is,2920,O
required,2920,O
to,2920,O
clarify,2920,O
specific,2920,O
deficits,2920,O
characteristic,2920,O
of,2920,O
this,2920,O
patient,2920,O
group,2920,O
Adenomatous,2921,B-SpecificDisease
polyposis,2921,I-SpecificDisease
coli,2921,I-SpecificDisease
and,2921,O
a,2921,O
cytogenetic,2921,O
deletion,2921,O
of,2921,O
chromosome,2921,O
5,2921,O
resulting,2921,O
from,2921,O
a,2921,O
maternal,2921,O
intrachromosomal,2921,O
insertion,2921,O
.,2921,O
We,2922,O
present,2922,O
the,2922,O
clinical,2922,O
and,2922,O
laboratory,2922,O
findings,2922,O
in,2922,O
an,2922,O
institutionalised,2922,O
adult,2922,O
patient,2922,O
originally,2922,O
referred,2922,O
for,2922,O
autism,2922,B-SpecificDisease
.,2922,O
A,2923,O
high,2923,O
risk,2923,O
of,2923,O
colorectal,2923,B-SpecificDisease
cancer,2923,I-SpecificDisease
was,2923,O
predicted,2923,O
when,2923,O
an,2923,O
interstitial,2923,O
deletion,2923,O
of,2923,O
the,2923,O
long,2923,O
arm,2923,O
of,2923,O
chromosome,2923,O
5,2923,O
",",2923,O
del,2923,O
(,2923,O
5,2923,O
),2923,O
(,2923,O
q15q22,2923,O
.,2923,O
3,2924,O
),2924,O
",",2924,O
was,2924,O
detected,2924,O
in,2924,O
her,2924,O
lymphocytes,2924,O
and,2924,O
deletion,2924,O
of,2924,O
the,2924,O
MCC,2924,O
and,2924,O
APC,2924,B-Modifier
genes,2924,O
confirmed,2924,O
by,2924,O
molecular,2924,O
analysis,2924,O
.,2924,O
Adenomatous,2925,B-SpecificDisease
polyposis,2925,I-SpecificDisease
coli,2925,I-SpecificDisease
and,2925,O
carcinoma,2925,B-SpecificDisease
of,2925,I-SpecificDisease
the,2925,I-SpecificDisease
rectum,2925,I-SpecificDisease
were,2925,O
subsequently,2925,O
diagnosed,2925,O
in,2925,O
the,2925,O
patient,2925,O
.,2925,O
She,2926,O
was,2926,O
profoundly,2926,O
mentally,2926,B-Modifier
retarded,2926,I-Modifier
",",2926,O
autistic,2926,B-Modifier
",",2926,O
and,2926,O
had,2926,O
minor,2926,O
dysmorphic,2926,B-SpecificDisease
features,2926,I-SpecificDisease
consistent,2926,O
with,2926,O
those,2926,O
of,2926,O
previous,2926,O
patients,2926,O
with,2926,O
similar,2926,O
deletions,2926,O
.,2926,O
The,2927,O
deletion,2927,O
arose,2927,O
as,2927,O
a,2927,O
result,2927,O
of,2927,O
recombination,2927,O
within,2927,O
the,2927,O
small,2927,O
insertion,2927,O
loop,2927,O
formed,2927,O
at,2927,O
meiosis,2927,O
by,2927,O
the,2927,O
direct,2927,O
insertion,2927,O
(,2927,O
dir,2927,O
ins,2927,O
(,2927,O
5,2927,O
),2927,O
(,2927,O
q22,2927,O
.,2927,O
3q14,2928,O
.,2928,O
2q15,2929,O
),2929,O
),2929,O
found,2929,O
in,2929,O
the,2929,O
patients,2929,O
mother,2929,O
.,2929,O
This,2930,O
family,2930,O
further,2930,O
confirms,2930,O
the,2930,O
cytogenetic,2930,O
mapping,2930,O
of,2930,O
both,2930,O
MCC,2930,O
and,2930,O
APC,2930,B-Modifier
genes,2930,O
to,2930,O
5q22,2930,O
and,2930,O
comparison,2930,O
with,2930,O
other,2930,O
recent,2930,O
cases,2930,O
suggests,2930,O
that,2930,O
both,2930,O
genes,2930,O
and,2930,O
their,2930,O
closely,2930,O
linked,2930,O
markers,2930,O
lie,2930,O
within,2930,O
the,2930,O
5q22,2930,O
.,2930,O
1,2931,O
subband,2931,O
Familial,2932,B-SpecificDisease
male,2932,I-SpecificDisease
breast,2932,I-SpecificDisease
cancer,2932,I-SpecificDisease
is,2932,O
not,2932,O
linked,2932,O
to,2932,O
the,2932,O
BRCA1,2932,O
locus,2932,O
on,2932,O
chromosome,2932,O
17q,2932,O
.,2932,O
Breast,2933,B-SpecificDisease
cancer,2933,I-SpecificDisease
in,2933,O
men,2933,O
is,2933,O
about,2933,O
a,2933,O
hundredfold,2933,O
less,2933,O
common,2933,O
than,2933,O
in,2933,O
women,2933,O
and,2933,O
this,2933,O
has,2933,O
hindered,2933,O
research,2933,O
into,2933,O
its,2933,O
genetic,2933,O
basis,2933,O
.,2933,O
We,2934,O
have,2934,O
examined,2934,O
22,2934,O
families,2934,O
with,2934,O
at,2934,O
least,2934,O
one,2934,O
case,2934,O
of,2934,O
male,2934,B-SpecificDisease
breast,2934,I-SpecificDisease
cancer,2934,I-SpecificDisease
for,2934,O
linkage,2934,O
to,2934,O
the,2934,O
hereditary,2934,B-Modifier
breast,2934,I-Modifier
and,2934,I-Modifier
ovarian,2934,I-Modifier
cancer,2934,I-Modifier
locus,2934,O
",",2934,O
BRCA1,2934,O
",",2934,O
on,2934,O
chromosome,2934,O
17q,2934,O
.,2934,O
We,2935,O
found,2935,O
strong,2935,O
evidence,2935,O
against,2935,O
linkage,2935,O
to,2935,O
BRCA1,2935,O
(,2935,O
lod,2935,O
score-16,2935,O
.,2935,O
63,2936,O
),2936,O
and,2936,O
the,2936,O
best,2936,O
estimate,2936,O
of,2936,O
the,2936,O
proportion,2936,O
of,2936,O
linked,2936,O
families,2936,O
was,2936,O
0,2936,O
%,2936,O
(,2936,O
95,2936,O
%,2936,O
CI,2936,O
0-18,2936,O
%,2936,O
),2936,O
.,2936,O
Our,2937,O
results,2937,O
indicate,2937,O
that,2937,O
there,2937,O
is,2937,O
a,2937,O
gene,2937,O
(,2937,O
s,2937,O
),2937,O
other,2937,O
than,2937,O
BRCA1,2937,O
which,2937,O
predisposes,2937,O
to,2937,O
early-onset,2937,O
breast,2937,B-SpecificDisease
cancer,2937,I-SpecificDisease
in,2937,O
women,2937,O
and,2937,O
which,2937,O
confers,2937,O
a,2937,O
higher,2937,O
risk,2937,O
of,2937,O
male,2937,B-SpecificDisease
breast,2937,I-SpecificDisease
cancer,2937,I-SpecificDisease
.,2937,O
Identification,2938,O
of,2938,O
additional,2938,O
pedigrees,2938,O
that,2938,O
include,2938,O
cases,2938,O
of,2938,O
male,2938,B-SpecificDisease
breast,2938,I-SpecificDisease
cancer,2938,I-SpecificDisease
may,2938,O
therefore,2938,O
facilitate,2938,O
the,2938,O
mapping,2938,O
and,2938,O
isolation,2938,O
of,2938,O
this,2938,O
gene,2938,O
.,2938,O
The,2939,O
EWS,2939,O
gene,2939,O
",",2939,O
involved,2939,O
in,2939,O
Ewing,2939,B-DiseaseClass
family,2939,I-DiseaseClass
of,2939,I-DiseaseClass
tumors,2939,I-DiseaseClass
",",2939,O
malignant,2939,B-DiseaseClass
melanoma,2939,I-DiseaseClass
of,2939,I-DiseaseClass
soft,2939,I-DiseaseClass
parts,2939,I-DiseaseClass
and,2939,O
desmoplastic,2939,B-SpecificDisease
small,2939,I-SpecificDisease
round,2939,I-SpecificDisease
cell,2939,I-SpecificDisease
tumors,2939,I-SpecificDisease
",",2939,O
codes,2939,O
for,2939,O
an,2939,O
RNA,2939,O
binding,2939,O
protein,2939,O
with,2939,O
novel,2939,O
regulatory,2939,O
domains,2939,O
.,2939,O
The,2940,O
EWS,2940,O
gene,2940,O
",",2940,O
which,2940,O
maps,2940,O
to,2940,O
band,2940,O
q12,2940,O
of,2940,O
human,2940,O
chromosome,2940,O
22,2940,O
",",2940,O
is,2940,O
involved,2940,O
in,2940,O
a,2940,O
wide,2940,O
variety,2940,O
of,2940,O
human,2940,O
solid,2940,B-DiseaseClass
tumors,2940,I-DiseaseClass
including,2940,O
Ewing,2940,B-SpecificDisease
sarcoma,2940,I-SpecificDisease
",",2940,O
related,2940,O
primitive,2940,O
neuroectodermal,2940,B-DiseaseClass
tumors,2940,I-DiseaseClass
",",2940,O
malignant,2940,B-DiseaseClass
melanoma,2940,I-DiseaseClass
of,2940,I-DiseaseClass
soft,2940,I-DiseaseClass
parts,2940,I-DiseaseClass
and,2940,O
desmoplastic,2940,B-DiseaseClass
small,2940,I-DiseaseClass
round,2940,I-DiseaseClass
cell,2940,I-DiseaseClass
tumors,2940,I-DiseaseClass
.,2940,O
In,2941,O
these,2941,O
tumors,2941,B-DiseaseClass
",",2941,O
the,2941,O
EWS,2941,O
is,2941,O
fused,2941,O
to,2941,O
genes,2941,O
encoding,2941,O
transcriptional,2941,O
activators/repressors,2941,O
",",2941,O
like,2941,O
Fli-1,2941,O
or,2941,O
erg,2941,O
or,2941,O
ATF,2941,O
1,2941,O
or,2941,O
wt1,2941,O
.,2941,O
To,2942,O
better,2942,O
understand,2942,O
the,2942,O
function,2942,O
of,2942,O
the,2942,O
EWS,2942,O
protein,2942,O
",",2942,O
we,2942,O
cloned,2942,O
the,2942,O
EWS,2942,O
cDNA,2942,O
.,2942,O
Sequence,2943,O
analysis,2943,O
of,2943,O
this,2943,O
cDNA,2943,O
revealed,2943,O
differential,2943,O
splicing,2943,O
involving,2943,O
two,2943,O
exons,2943,O
encoding,2943,O
72,2943,O
amino,2943,O
acids,2943,O
.,2943,O
Both,2944,O
alternatively,2944,O
spliced,2944,O
transcripts,2944,O
",",2944,O
EWS,2944,O
and,2944,O
EWS-b,2944,O
",",2944,O
are,2944,O
expressed,2944,O
in,2944,O
a,2944,O
variety,2944,O
of,2944,O
cells,2944,O
.,2944,O
Because,2945,O
EWS,2945,O
proteins,2945,O
contain,2945,O
putative,2945,O
conserved,2945,O
RNA,2945,O
binding,2945,O
motifs,2945,O
",",2945,O
we,2945,O
studied,2945,O
the,2945,O
RNA,2945,O
binding,2945,O
properties,2945,O
of,2945,O
the,2945,O
EWS,2945,O
protein,2945,O
.,2945,O
The,2946,O
EWS-b,2946,O
protein,2946,O
binds,2946,O
to,2946,O
RNA,2946,O
in,2946,O
vitro,2946,O
and,2946,O
",",2946,O
specifically,2946,O
",",2946,O
to,2946,O
poly,2946,O
G,2946,O
and,2946,O
poly,2946,O
U,2946,O
.,2946,O
The,2947,O
RNA,2947,O
binding,2947,O
activity,2947,O
was,2947,O
localized,2947,O
to,2947,O
the,2947,O
carboxy,2947,O
terminal,2947,O
86,2947,O
amino,2947,O
acids,2947,O
",",2947,O
which,2947,O
constitute,2947,O
RGG,2947,O
box,2947,O
.,2947,O
Thus,2948,O
the,2948,O
amino,2948,O
terminal,2948,O
domain,2948,O
of,2948,O
EWS,2948,O
(,2948,O
NTD-EWS,2948,O
),2948,O
",",2948,O
which,2948,O
is,2948,O
involved,2948,O
in,2948,O
chromosome,2948,O
translocation,2948,O
may,2948,O
regulate,2948,O
the,2948,O
specificity,2948,O
of,2948,O
RNA,2948,O
binding,2948,O
activity,2948,O
of,2948,O
EWS,2948,O
.,2948,O
An,2949,O
EWS-erg,2949,O
chimeric,2949,O
protein,2949,O
",",2949,O
which,2949,O
is,2949,O
found,2949,O
in,2949,O
Ewings,2949,B-Modifier
sarcoma,2949,I-Modifier
cells,2949,O
",",2949,O
functions,2949,O
as,2949,O
a,2949,O
transcriptional,2949,O
activator,2949,O
.,2949,O
Mutational,2950,O
analysis,2950,O
of,2950,O
EWS-erg,2950,O
chimeric,2950,O
protein,2950,O
revealed,2950,O
that,2950,O
NTD-EWS,2950,O
functions,2950,O
as,2950,O
a,2950,O
regulatory,2950,O
domain,2950,O
for,2950,O
the,2950,O
transcriptional,2950,O
activation,2950,O
properties,2950,O
of,2950,O
EWS-erg,2950,O
chimeric,2950,O
protein,2950,O
..,2950,O
Canavan,2951,B-SpecificDisease
disease,2951,I-SpecificDisease
:,2951,O
genomic,2951,O
organization,2951,O
and,2951,O
localization,2951,O
of,2951,O
human,2951,O
ASPA,2951,O
to,2951,O
17p13-ter,2951,O
and,2951,O
conservation,2951,O
of,2951,O
the,2951,O
ASPA,2951,O
gene,2951,O
during,2951,O
evolution,2951,O
.,2951,O
Canavan,2952,B-SpecificDisease
disease,2952,I-SpecificDisease
",",2952,O
or,2952,O
spongy,2952,B-SpecificDisease
degeneration,2952,I-SpecificDisease
of,2952,I-SpecificDisease
the,2952,I-SpecificDisease
brain,2952,I-SpecificDisease
",",2952,O
is,2952,O
a,2952,O
severe,2952,O
leukodystrophy,2952,B-SpecificDisease
caused,2952,O
by,2952,O
the,2952,O
deficiency,2952,B-SpecificDisease
of,2952,I-SpecificDisease
aspartoacylase,2952,I-SpecificDisease
(,2952,O
ASPA,2952,O
),2952,O
.,2952,O
Recently,2953,O
",",2953,O
a,2953,O
missense,2953,O
mutation,2953,O
was,2953,O
identified,2953,O
in,2953,O
human,2953,O
ASPA,2953,O
coding,2953,O
sequence,2953,O
from,2953,O
patients,2953,O
with,2953,O
Canavan,2953,B-SpecificDisease
disease,2953,I-SpecificDisease
.,2953,O
The,2954,O
human,2954,O
ASPA,2954,O
gene,2954,O
has,2954,O
been,2954,O
cloned,2954,O
and,2954,O
found,2954,O
to,2954,O
span,2954,O
29,2954,O
kb,2954,O
of,2954,O
the,2954,O
genome,2954,O
.,2954,O
Human,2955,O
aspartoacylase,2955,O
is,2955,O
coded,2955,O
by,2955,O
six,2955,O
exons,2955,O
intervened,2955,O
by,2955,O
five,2955,O
introns,2955,O
.,2955,O
The,2956,O
exons,2956,O
vary,2956,O
from,2956,O
94,2956,O
(,2956,O
exon,2956,O
III,2956,O
),2956,O
to,2956,O
514,2956,O
(,2956,O
exon,2956,O
VI,2956,O
),2956,O
bases,2956,O
.,2956,O
The,2957,O
exon/intron,2957,O
splice,2957,O
junction,2957,O
sites,2957,O
follow,2957,O
the,2957,O
gt/ag,2957,O
consensus,2957,O
sequence,2957,O
rule,2957,O
.,2957,O
Southern,2958,O
blot,2958,O
analysis,2958,O
of,2958,O
genomic,2958,O
DNA,2958,O
from,2958,O
human/mouse,2958,O
somatic,2958,O
cell,2958,O
hybrid,2958,O
cell,2958,O
lines,2958,O
localized,2958,O
ASPA,2958,O
to,2958,O
human,2958,O
chromosome,2958,O
17,2958,O
.,2958,O
The,2959,O
human,2959,O
ASPA,2959,O
locus,2959,O
was,2959,O
further,2959,O
mapped,2959,O
in,2959,O
the,2959,O
17p13-ter,2959,O
region,2959,O
by,2959,O
fluorescence,2959,O
in,2959,O
situ,2959,O
hybridization,2959,O
.,2959,O
The,2960,O
bovine,2960,O
aspa,2960,O
gene,2960,O
has,2960,O
also,2960,O
been,2960,O
cloned,2960,O
",",2960,O
and,2960,O
its,2960,O
exon/intron,2960,O
organization,2960,O
is,2960,O
identical,2960,O
to,2960,O
that,2960,O
of,2960,O
the,2960,O
human,2960,O
gene,2960,O
.,2960,O
The,2961,O
500-base,2961,O
sequence,2961,O
upstream,2961,O
of,2961,O
the,2961,O
initiator,2961,O
ATG,2961,O
codon,2961,O
in,2961,O
the,2961,O
human,2961,O
gene,2961,O
and,2961,O
that,2961,O
in,2961,O
the,2961,O
bovine,2961,O
gene,2961,O
are,2961,O
77,2961,O
%,2961,O
identical,2961,O
.,2961,O
Human,2962,O
ASPA,2962,O
coding,2962,O
sequences,2962,O
cross-hybridize,2962,O
with,2962,O
genomic,2962,O
DNA,2962,O
from,2962,O
yeast,2962,O
",",2962,O
chicken,2962,O
",",2962,O
rabbit,2962,O
",",2962,O
cow,2962,O
",",2962,O
dog,2962,O
",",2962,O
mouse,2962,O
",",2962,O
rat,2962,O
",",2962,O
and,2962,O
monkey,2962,O
.,2962,O
The,2963,O
specificity,2963,O
of,2963,O
cross-species,2963,O
hybridization,2963,O
of,2963,O
coding,2963,O
sequences,2963,O
suggests,2963,O
that,2963,O
aspartoacylase,2963,O
has,2963,O
been,2963,O
conserved,2963,O
during,2963,O
evolution,2963,O
.,2963,O
It,2964,O
should,2964,O
now,2964,O
be,2964,O
possible,2964,O
to,2964,O
identify,2964,O
mutations,2964,O
in,2964,O
the,2964,O
noncoding,2964,O
genomic,2964,O
sequences,2964,O
that,2964,O
lead,2964,O
to,2964,O
Canavan,2964,B-SpecificDisease
disease,2964,I-SpecificDisease
and,2964,O
to,2964,O
study,2964,O
the,2964,O
regulation,2964,O
of,2964,O
ASPA,2964,O
..,2964,O
Myotonic,2965,B-SpecificDisease
dystrophy,2965,I-SpecificDisease
:,2965,O
size-,2965,O
and,2965,O
sex-dependent,2965,O
dynamics,2965,O
of,2965,O
CTG,2965,O
meiotic,2965,O
instability,2965,O
",",2965,O
and,2965,O
somatic,2965,O
mosaicism,2965,O
.,2965,O
Myotonic,2966,B-SpecificDisease
dystrophy,2966,I-SpecificDisease
(,2966,O
DM,2966,B-SpecificDisease
),2966,O
is,2966,O
a,2966,O
progressive,2966,O
neuromuscular,2966,B-DiseaseClass
disorder,2966,I-DiseaseClass
which,2966,O
results,2966,O
from,2966,O
elongations,2966,O
of,2966,O
an,2966,O
unstable,2966,O
(,2966,O
CTG,2966,O
),2966,O
n,2966,O
repeat,2966,O
",",2966,O
located,2966,O
in,2966,O
the,2966,O
3,2966,O
untranslated,2966,O
region,2966,O
of,2966,O
the,2966,O
DM,2966,B-Modifier
gene,2966,O
.,2966,O
A,2967,O
correlation,2967,O
has,2967,O
been,2967,O
demonstrated,2967,O
between,2967,O
the,2967,O
increase,2967,O
in,2967,O
the,2967,O
repeat,2967,O
number,2967,O
of,2967,O
this,2967,O
sequence,2967,O
and,2967,O
the,2967,O
severity,2967,O
of,2967,O
the,2967,O
disease,2967,O
.,2967,O
However,2968,O
",",2968,O
the,2968,O
clinical,2968,O
status,2968,O
of,2968,O
patients,2968,O
can,2968,O
not,2968,O
be,2968,O
unambiguously,2968,O
ascertained,2968,O
solely,2968,O
on,2968,O
the,2968,O
basis,2968,O
of,2968,O
the,2968,O
number,2968,O
of,2968,O
CTG,2968,O
repeats,2968,O
.,2968,O
Moreover,2969,O
",",2969,O
the,2969,O
exclusive,2969,O
maternal,2969,O
inheritance,2969,O
of,2969,O
the,2969,O
congenital,2969,O
form,2969,O
remains,2969,O
unexplained,2969,O
.,2969,O
Our,2970,O
observation,2970,O
of,2970,O
differently,2970,O
sized,2970,O
repeats,2970,O
in,2970,O
various,2970,O
DM,2970,B-Modifier
tissues,2970,O
from,2970,O
the,2970,O
same,2970,O
individual,2970,O
may,2970,O
explain,2970,O
why,2970,O
the,2970,O
size,2970,O
of,2970,O
the,2970,O
mutation,2970,O
observed,2970,O
in,2970,O
lymphocytes,2970,O
does,2970,O
not,2970,O
necessarily,2970,O
correlate,2970,O
with,2970,O
the,2970,O
severity,2970,O
and,2970,O
nature,2970,O
of,2970,O
symptoms,2970,O
.,2970,O
Through,2971,O
a,2971,O
molecular,2971,O
and,2971,O
genetic,2971,O
study,2971,O
of,2971,O
142,2971,O
families,2971,O
including,2971,O
418,2971,O
DM,2971,B-Modifier
patients,2971,O
",",2971,O
we,2971,O
have,2971,O
investigated,2971,O
the,2971,O
dynamics,2971,O
of,2971,O
the,2971,O
CTG,2971,O
repeat,2971,O
meiotic,2971,O
instability,2971,O
.,2971,O
A,2972,O
positive,2972,O
correlation,2972,O
between,2972,O
the,2972,O
size,2972,O
of,2972,O
the,2972,O
repeat,2972,O
and,2972,O
the,2972,O
intergenerational,2972,O
enlargement,2972,O
was,2972,O
observed,2972,O
similarly,2972,O
through,2972,O
male,2972,O
and,2972,O
female,2972,O
meioses,2972,O
for,2972,O
<,2972,O
or,2972,O
=,2972,O
0,2972,O
.,2972,O
5-kb,2973,O
CTG,2973,O
sequences,2973,O
.,2973,O
Beyond,2974,O
0,2974,O
.,2974,O
5,2975,O
kb,2975,O
",",2975,O
the,2975,O
intergenerational,2975,O
variation,2975,O
was,2975,O
more,2975,O
important,2975,O
through,2975,O
female,2975,O
meioses,2975,O
",",2975,O
whereas,2975,O
a,2975,O
tendency,2975,O
to,2975,O
compression,2975,O
was,2975,O
observed,2975,O
almost,2975,O
exclusively,2975,O
in,2975,O
male,2975,O
meioses,2975,O
",",2975,O
for,2975,O
>,2975,O
or,2975,O
=,2975,O
1,2975,O
.,2975,O
5-kb,2976,O
fragments,2976,O
.,2976,O
This,2977,O
implies,2977,O
a,2977,O
size-,2977,O
and,2977,O
sex-dependent,2977,O
meiotic,2977,O
instability,2977,O
.,2977,O
Moreover,2978,O
",",2978,O
segregation,2978,O
analysis,2978,O
supports,2978,O
the,2978,O
hypothesis,2978,O
of,2978,O
a,2978,O
maternal,2978,O
as,2978,O
well,2978,O
as,2978,O
a,2978,O
familial,2978,O
predisposition,2978,O
for,2978,O
the,2978,O
occurrence,2978,O
of,2978,O
the,2978,O
congenital,2978,O
form,2978,O
.,2978,O
Finally,2979,O
",",2979,O
this,2979,O
analysis,2979,O
reveals,2979,O
a,2979,O
significant,2979,O
excess,2979,O
of,2979,O
transmitting,2979,O
grandfathers,2979,O
partially,2979,O
accounted,2979,O
for,2979,O
by,2979,O
increased,2979,O
fertility,2979,O
in,2979,O
affected,2979,O
males,2979,O
Illegitimate,2980,O
transcription,2980,O
of,2980,O
the,2980,O
phenylalanine,2980,O
hydroxylase,2980,O
gene,2980,O
in,2980,O
lymphocytes,2980,O
for,2980,O
identification,2980,O
of,2980,O
mutations,2980,O
in,2980,O
phenylketonuria,2980,B-SpecificDisease
.,2980,O
Taking,2981,O
advantage,2981,O
of,2981,O
the,2981,O
illegitimate,2981,O
transcription,2981,O
of,2981,O
the,2981,O
phenylalanine,2981,O
hydroxylase,2981,O
(,2981,O
PAH,2981,O
),2981,O
gene,2981,O
",",2981,O
we,2981,O
have,2981,O
been,2981,O
able,2981,O
to,2981,O
analyse,2981,O
the,2981,O
PAH,2981,O
cDNA,2981,O
sequence,2981,O
of,2981,O
hyperphenylalaninemic,2981,B-Modifier
children,2981,O
in,2981,O
circulating,2981,O
lymphocytes,2981,O
.,2981,O
Using,2982,O
this,2982,O
approach,2982,O
",",2982,O
we,2982,O
have,2982,O
also,2982,O
identified,2982,O
3,2982,O
novel,2982,O
mutations,2982,O
in,2982,O
cDNA,2982,O
from,2982,O
liver,2982,O
and,2982,O
lymphocytes,2982,O
of,2982,O
two,2982,O
patients,2982,O
.,2982,O
One,2983,O
mutation,2983,O
",",2983,O
detected,2983,O
by,2983,O
the,2983,O
abnormal,2983,O
pattern,2983,O
of,2983,O
migration,2983,O
of,2983,O
an,2983,O
amplified,2983,O
fragment,2983,O
",",2983,O
is,2983,O
a,2983,O
C,2983,O
to,2983,O
T,2983,O
transition,2983,O
in,2983,O
the,2983,O
splice,2983,O
acceptor,2983,O
site,2983,O
of,2983,O
intron,2983,O
10,2983,O
",",2983,O
which,2983,O
resulted,2983,O
in,2983,O
the,2983,O
skipping,2983,O
of,2983,O
exon,2983,O
11,2983,O
with,2983,O
the,2983,O
premature,2983,O
termination,2983,O
of,2983,O
RNA,2983,O
translation,2983,O
downstream,2983,O
from,2983,O
exon,2983,O
12,2983,O
(,2983,O
-3,2983,O
IVS10,2983,O
),2983,O
.,2983,O
The,2984,O
other,2984,O
two,2984,O
mutations,2984,O
are,2984,O
missense,2984,O
mutations,2984,O
in,2984,O
exons,2984,O
10,2984,O
and,2984,O
11,2984,O
(,2984,O
respectively,2984,O
",",2984,O
L333F,2984,O
and,2984,O
E390G,2984,O
),2984,O
.,2984,O
The,2985,O
present,2985,O
study,2985,O
supports,2985,O
the,2985,O
view,2985,O
that,2985,O
circulating,2985,O
lymphocytes,2985,O
give,2985,O
easy,2985,O
access,2985,O
to,2985,O
PAH,2985,O
gene,2985,O
transcripts,2985,O
whose,2985,O
nucleotide,2985,O
sequence,2985,O
is,2985,O
identical,2985,O
to,2985,O
that,2985,O
reported,2985,O
in,2985,O
liver,2985,O
and,2985,O
therefore,2985,O
represent,2985,O
a,2985,O
useful,2985,O
tool,2985,O
for,2985,O
molecular,2985,O
genetic,2985,O
studies,2985,O
in,2985,O
phenylketonuria,2985,B-SpecificDisease
..,2985,O
High,2986,O
residual,2986,O
arylsulfatase,2986,O
A,2986,O
(,2986,O
ARSA,2986,O
),2986,O
activity,2986,O
in,2986,O
a,2986,O
patient,2986,O
with,2986,O
late-infantile,2986,B-SpecificDisease
metachromatic,2986,I-SpecificDisease
leukodystrophy,2986,I-SpecificDisease
.,2986,O
We,2987,O
identified,2987,O
a,2987,O
patient,2987,O
suffering,2987,O
from,2987,O
late-infantile,2987,B-SpecificDisease
metachromatic,2987,I-SpecificDisease
leukodystrophy,2987,I-SpecificDisease
(,2987,O
MLD,2987,B-SpecificDisease
),2987,O
who,2987,O
has,2987,O
a,2987,O
residual,2987,O
arylsulfatase,2987,O
A,2987,O
(,2987,O
ARSA,2987,O
),2987,O
activity,2987,O
of,2987,O
about,2987,O
10,2987,O
%,2987,O
.,2987,O
Fibroblasts,2988,O
of,2988,O
the,2988,O
patient,2988,O
show,2988,O
significant,2988,O
sulfatide,2988,O
degradation,2988,O
activity,2988,O
exceeding,2988,O
that,2988,O
of,2988,O
adult,2988,B-Modifier
MLD,2988,I-Modifier
patients,2988,O
.,2988,O
Analysis,2989,O
of,2989,O
the,2989,O
ARSA,2989,O
gene,2989,O
in,2989,O
this,2989,O
patient,2989,O
revealed,2989,O
heterozygosity,2989,O
for,2989,O
two,2989,O
new,2989,O
mutant,2989,O
alleles,2989,O
in,2989,O
one,2989,O
allele,2989,O
",",2989,O
deletion,2989,O
of,2989,O
C,2989,O
447,2989,O
in,2989,O
exon,2989,O
2,2989,O
leads,2989,O
to,2989,O
a,2989,O
frameshift,2989,O
and,2989,O
to,2989,O
a,2989,O
premature,2989,O
stop,2989,O
codon,2989,O
at,2989,O
amino,2989,O
acid,2989,O
position,2989,O
105,2989,O
;,2989,O
in,2989,O
the,2989,O
second,2989,O
allele,2989,O
",",2989,O
a,2989,O
G,2989,O
--,2989,O
>,2989,O
A,2989,O
transition,2989,O
in,2989,O
exon,2989,O
5,2989,O
causes,2989,O
a,2989,O
Gly309,2989,O
--,2989,O
>,2989,O
Ser,2989,O
substitution,2989,O
.,2989,O
Transient,2990,O
expression,2990,O
of,2990,O
the,2990,O
mutant,2990,O
Ser309-ARSA,2990,O
resulted,2990,O
in,2990,O
only,2990,O
13,2990,O
%,2990,O
enzyme,2990,O
activity,2990,O
of,2990,O
that,2990,O
observed,2990,O
in,2990,O
cells,2990,O
expressing,2990,O
normal,2990,O
ARSA,2990,O
.,2990,O
The,2991,O
mutant,2991,O
ARSA,2991,O
is,2991,O
correctly,2991,O
targeted,2991,O
to,2991,O
the,2991,O
lysosomes,2991,O
but,2991,O
is,2991,O
unstable,2991,O
.,2991,O
These,2992,O
findings,2992,O
are,2992,O
in,2992,O
contrast,2992,O
to,2992,O
previous,2992,O
results,2992,O
showing,2992,O
that,2992,O
the,2992,O
late-infantile,2992,B-SpecificDisease
type,2992,I-SpecificDisease
of,2992,I-SpecificDisease
MLD,2992,I-SpecificDisease
is,2992,O
always,2992,O
associated,2992,O
with,2992,O
the,2992,O
complete,2992,O
absence,2992,O
of,2992,O
ARSA,2992,O
activity,2992,O
.,2992,O
The,2993,O
expression,2993,O
of,2993,O
the,2993,O
mutant,2993,O
ARSA,2993,O
protein,2993,O
may,2993,O
be,2993,O
influenced,2993,O
by,2993,O
particular,2993,O
features,2993,O
of,2993,O
oligodendrocytes,2993,O
",",2993,O
such,2993,O
that,2993,O
the,2993,O
level,2993,O
of,2993,O
mutant,2993,O
enzyme,2993,O
is,2993,O
lower,2993,O
in,2993,O
these,2993,O
cells,2993,O
than,2993,O
in,2993,O
others,2993,O
..,2993,O
An,2994,O
arylsulfatase,2994,O
A,2994,O
(,2994,O
ARSA,2994,O
),2994,O
missense,2994,O
mutation,2994,O
(,2994,O
T274M,2994,O
),2994,O
causing,2994,O
late-infantile,2994,B-SpecificDisease
metachromatic,2994,I-SpecificDisease
leukodystrophy,2994,I-SpecificDisease
.,2994,O
Metachromatic,2995,B-SpecificDisease
leukodystrophy,2995,I-SpecificDisease
(,2995,O
MLD,2995,B-SpecificDisease
),2995,O
is,2995,O
an,2995,O
autosomal,2995,B-DiseaseClass
recessive,2995,I-DiseaseClass
lysosomal,2995,I-DiseaseClass
storage,2995,I-DiseaseClass
disorder,2995,I-DiseaseClass
caused,2995,O
by,2995,O
a,2995,O
deficiency,2995,B-SpecificDisease
of,2995,I-SpecificDisease
arylsulfatase,2995,I-SpecificDisease
A,2995,I-SpecificDisease
(,2995,O
ARSA,2995,O
;,2995,O
EC,2995,O
3,2995,O
.,2995,O
1,2996,O
.,2996,O
6,2997,O
.,2997,O
8,2998,O
),2998,O
.,2998,O
The,2999,O
8,2999,O
ARSA,2999,O
exons,2999,O
and,2999,O
adjacent,2999,O
intron,2999,O
boundaries,2999,O
from,2999,O
a,2999,O
patient,2999,O
with,2999,O
late-infantile,2999,B-SpecificDisease
metachromatic,2999,I-SpecificDisease
leukodystrophy,2999,I-SpecificDisease
were,2999,O
polymerase,2999,O
chain,2999,O
reaction,2999,O
(,2999,O
PCR,2999,O
),2999,O
amplified,2999,O
in,2999,O
seven,2999,O
discrete,2999,O
reactions,2999,O
.,2999,O
Amplified,3000,O
ARSA,3000,O
exons,3000,O
were,3000,O
analysed,3000,O
for,3000,O
the,3000,O
presence,3000,O
of,3000,O
sequence,3000,O
alterations,3000,O
by,3000,O
single-strand,3000,O
conformation,3000,O
polymorphism,3000,O
analysis,3000,O
",",3000,O
followed,3000,O
by,3000,O
direct,3000,O
sequencing,3000,O
of,3000,O
PCR,3000,O
products,3000,O
.,3000,O
The,3001,O
patient,3001,O
was,3001,O
found,3001,O
to,3001,O
be,3001,O
homozygous,3001,O
for,3001,O
a,3001,O
C,3001,O
--,3001,O
>,3001,O
T,3001,O
transition,3001,O
in,3001,O
exon,3001,O
IV,3001,O
that,3001,O
results,3001,O
in,3001,O
the,3001,O
substitution,3001,O
of,3001,O
a,3001,O
highly,3001,O
conserved,3001,O
threonine,3001,O
residue,3001,O
at,3001,O
amino,3001,O
acid,3001,O
274,3001,O
with,3001,O
a,3001,O
methionine,3001,O
(,3001,O
T274M,3001,O
),3001,O
.,3001,O
Analysis,3002,O
of,3002,O
a,3002,O
further,3002,O
29,3002,O
MLD,3002,B-Modifier
patients,3002,O
revealed,3002,O
the,3002,O
presence,3002,O
of,3002,O
five,3002,O
additional,3002,O
homozygotes,3002,O
for,3002,O
T274M,3002,O
.,3002,O
All,3003,O
6,3003,O
T274M,3003,O
homozygotes,3003,O
(,3003,O
representing,3003,O
four,3003,O
families,3003,O
),3003,O
were,3003,O
of,3003,O
Lebanese,3003,O
descent,3003,O
",",3003,O
and,3003,O
all,3003,O
were,3003,O
known,3003,O
to,3003,O
be,3003,O
the,3003,O
result,3003,O
of,3003,O
consanguineous,3003,O
marriages,3003,O
.,3003,O
The,3004,O
altered,3004,O
amino,3004,O
acid,3004,O
is,3004,O
rigidly,3004,O
conserved,3004,O
among,3004,O
10,3004,O
sulfatases,3004,O
from,3004,O
Escherichia,3004,O
coli,3004,O
to,3004,O
humans,3004,O
;,3004,O
therefore,3004,O
",",3004,O
it,3004,O
is,3004,O
most,3004,O
likely,3004,O
that,3004,O
the,3004,O
resultant,3004,O
mutant,3004,O
protein,3004,O
will,3004,O
have,3004,O
little,3004,O
or,3004,O
no,3004,O
enzyme,3004,O
activity,3004,O
.,3004,O
This,3005,O
is,3005,O
consistent,3005,O
with,3005,O
the,3005,O
very,3005,O
low,3005,O
ARSA,3005,O
activity,3005,O
measured,3005,O
in,3005,O
these,3005,O
patients,3005,O
and,3005,O
their,3005,O
uniformly,3005,O
severe,3005,O
clinical,3005,O
presentation,3005,O
Mutations,3006,O
in,3006,O
the,3006,O
PAX6,3006,O
gene,3006,O
in,3006,O
patients,3006,O
with,3006,O
hereditary,3006,O
aniridia,3006,B-SpecificDisease
.,3006,O
The,3007,O
14,3007,O
exons,3007,O
of,3007,O
the,3007,O
PAX6,3007,O
gene,3007,O
have,3007,O
been,3007,O
analysed,3007,O
exon-by-exon,3007,O
using,3007,O
SSCP,3007,O
in,3007,O
6,3007,O
aniridia,3007,B-Modifier
families,3007,O
.,3007,O
In,3008,O
each,3008,O
family,3008,O
band,3008,O
shifts,3008,O
were,3008,O
observed,3008,O
on,3008,O
the,3008,O
SSCP,3008,O
gels,3008,O
for,3008,O
only,3008,O
one,3008,O
exon,3008,O
and,3008,O
direct,3008,O
PCR-sequencing,3008,O
revealed,3008,O
mutations,3008,O
in,3008,O
each,3008,O
case,3008,O
.,3008,O
Two,3009,O
mutations,3009,O
involved,3009,O
C,3009,O
--,3009,O
>,3009,O
T,3009,O
transitions,3009,O
in,3009,O
CGAarg,3009,O
codons,3009,O
in,3009,O
exons,3009,O
9,3009,O
and,3009,O
11,3009,O
.,3009,O
Another,3010,O
C,3010,O
--,3010,O
>,3010,O
T,3010,O
transition,3010,O
converted,3010,O
a,3010,O
CAG-glutamine,3010,O
to,3010,O
a,3010,O
TAG-stop,3010,O
in,3010,O
exon,3010,O
7,3010,O
.,3010,O
Small,3011,O
insertions,3011,O
created,3011,O
frameshifts,3011,O
which,3011,O
produced,3011,O
downstream,3011,O
stop,3011,O
codons,3011,O
in,3011,O
another,3011,O
two,3011,O
patients,3011,O
and,3011,O
an,3011,O
A,3011,O
--,3011,O
>,3011,O
T,3011,O
mutation,3011,O
disrupted,3011,O
the,3011,O
splice,3011,O
donor,3011,O
site,3011,O
of,3011,O
exon,3011,O
5,3011,O
in,3011,O
the,3011,O
remaining,3011,O
family,3011,O
.,3011,O
Thus,3012,O
",",3012,O
complete,3012,O
inactivation,3012,O
of,3012,O
the,3012,O
PAX6,3012,O
gene,3012,O
is,3012,O
predicted,3012,O
in,3012,O
all,3012,O
cases,3012,O
.,3012,O
Analysis,3013,O
of,3013,O
other,3013,O
affected,3013,O
members,3013,O
of,3013,O
the,3013,O
families,3013,O
showed,3013,O
that,3013,O
",",3013,O
in,3013,O
each,3013,O
case,3013,O
",",3013,O
all,3013,O
affected,3013,O
individuals,3013,O
carried,3013,O
the,3013,O
same,3013,O
family-specific,3013,O
mutation,3013,O
.,3013,O
One,3014,O
polymorphism,3014,O
was,3014,O
found,3014,O
in,3014,O
exon,3014,O
7,3014,O
.,3014,O
This,3015,O
data,3015,O
strongly,3015,O
supports,3015,O
the,3015,O
candidature,3015,O
of,3015,O
PAX6,3015,O
as,3015,O
the,3015,O
gene,3015,O
responsible,3015,O
for,3015,O
hereditary,3015,O
aniridia,3015,B-SpecificDisease
..,3015,O
Three,3016,O
novel,3016,O
mutations,3016,O
in,3016,O
five,3016,O
unrelated,3016,O
subjects,3016,O
with,3016,O
hereditary,3016,O
protein,3016,B-SpecificDisease
S,3016,I-SpecificDisease
deficiency,3016,I-SpecificDisease
type,3016,I-SpecificDisease
I,3016,I-SpecificDisease
.,3016,O
A,3017,O
panel,3017,O
of,3017,O
eight,3017,O
unrelated,3017,O
subjects,3017,O
with,3017,O
inherited,3017,O
type,3017,B-SpecificDisease
I,3017,I-SpecificDisease
protein,3017,I-SpecificDisease
S,3017,I-SpecificDisease
deficiency,3017,I-SpecificDisease
was,3017,O
screened,3017,O
for,3017,O
mutations,3017,O
in,3017,O
the,3017,O
PROS1,3017,O
gene,3017,O
.,3017,O
In,3018,O
five,3018,O
subjects,3018,O
an,3018,O
abnormality,3018,O
was,3018,O
found,3018,O
but,3018,O
mutations,3018,O
were,3018,O
not,3018,O
detected,3018,O
in,3018,O
the,3018,O
remaining,3018,O
three,3018,O
subjects,3018,O
.,3018,O
Two,3019,O
subjects,3019,O
shared,3019,O
a,3019,O
G,3019,O
--,3019,O
>,3019,O
A,3019,O
transition,3019,O
at,3019,O
position,3019,O
+,3019,O
5,3019,O
of,3019,O
the,3019,O
donor,3019,O
splice,3019,O
site,3019,O
consensus,3019,O
sequence,3019,O
of,3019,O
intron,3019,O
10,3019,O
.,3019,O
Also,3020,O
in,3020,O
two,3020,O
subjects,3020,O
an,3020,O
A,3020,O
--,3020,O
>,3020,O
T,3020,O
transversion,3020,O
was,3020,O
detected,3020,O
in,3020,O
the,3020,O
stopcodon,3020,O
of,3020,O
the,3020,O
PROS1,3020,O
gene,3020,O
;,3020,O
this,3020,O
transversion,3020,O
predicts,3020,O
a,3020,O
protein,3020,O
S,3020,O
molecule,3020,O
that,3020,O
is,3020,O
extended,3020,O
by,3020,O
14,3020,O
amino,3020,O
acids,3020,O
.,3020,O
The,3021,O
fifth,3021,O
subject,3021,O
was,3021,O
found,3021,O
to,3021,O
possess,3021,O
two,3021,O
sequence,3021,O
abnormalities,3021,O
.,3021,O
One,3022,O
allele,3022,O
carried,3022,O
a,3022,O
G,3022,O
--,3022,O
>,3022,O
A,3022,O
transition,3022,O
near,3022,O
the,3022,O
donor,3022,O
splice,3022,O
junction,3022,O
of,3022,O
intron,3022,O
2,3022,O
",",3022,O
but,3022,O
this,3022,O
abnormality,3022,O
is,3022,O
probably,3022,O
neutral,3022,O
",",3022,O
since,3022,O
it,3022,O
was,3022,O
inherited,3022,O
from,3022,O
the,3022,O
parent,3022,O
with,3022,O
normal,3022,O
protein,3022,O
S,3022,O
antigen,3022,O
levels,3022,O
.,3022,O
In,3023,O
the,3023,O
other,3023,O
allele,3023,O
a,3023,O
single,3023,O
T,3023,O
insertion,3023,O
in,3023,O
codon,3023,O
-25,3023,O
was,3023,O
found,3023,O
.,3023,O
Analysis,3024,O
of,3024,O
platelet,3024,O
RNA,3024,O
showed,3024,O
that,3024,O
only,3024,O
the,3024,O
mRNA,3024,O
with,3024,O
the,3024,O
A,3024,O
--,3024,O
>,3024,O
T,3024,O
mutation,3024,O
in,3024,O
the,3024,O
stopcodon,3024,O
is,3024,O
present,3024,O
in,3024,O
amounts,3024,O
comparable,3024,O
to,3024,O
wildtype,3024,O
RNA,3024,O
.,3024,O
mRNA,3025,O
from,3025,O
the,3025,O
alleles,3025,O
with,3025,O
the,3025,O
other,3025,O
two,3025,O
mutations,3025,O
was,3025,O
either,3025,O
undetectable,3025,O
or,3025,O
present,3025,O
in,3025,O
greatly,3025,O
reduced,3025,O
amounts,3025,O
.,3025,O
The,3026,O
latter,3026,O
indicates,3026,O
that,3026,O
a,3026,O
mRNA,3026,O
based,3026,O
approach,3026,O
is,3026,O
not,3026,O
feasible,3026,O
for,3026,O
the,3026,O
genetic,3026,O
analysis,3026,O
of,3026,O
protein,3026,B-SpecificDisease
S,3026,I-SpecificDisease
deficiency,3026,I-SpecificDisease
type,3026,I-SpecificDisease
I,3026,I-SpecificDisease
..,3026,O
Characteristics,3027,O
of,3027,O
intergenerational,3027,O
contractions,3027,O
of,3027,O
the,3027,O
CTG,3027,O
repeat,3027,O
in,3027,O
myotonic,3027,B-SpecificDisease
dystrophy,3027,I-SpecificDisease
.,3027,O
In,3028,O
myotonic,3028,B-SpecificDisease
dystrophy,3028,I-SpecificDisease
(,3028,O
DM,3028,B-SpecificDisease
),3028,O
",",3028,O
the,3028,O
size,3028,O
of,3028,O
a,3028,O
CTG,3028,O
repeat,3028,O
in,3028,O
the,3028,O
DM,3028,B-Modifier
kinase,3028,O
gene,3028,O
generally,3028,O
increases,3028,O
in,3028,O
successive,3028,O
generations,3028,O
with,3028,O
clinical,3028,O
evidence,3028,O
of,3028,O
anticipation,3028,O
.,3028,O
However,3029,O
",",3029,O
there,3029,O
have,3029,O
also,3029,O
been,3029,O
cases,3029,O
with,3029,O
an,3029,O
intergenerational,3029,O
contraction,3029,O
of,3029,O
the,3029,O
repeat,3029,O
.,3029,O
We,3030,O
examined,3030,O
1,3030,O
",",3030,O
489,3030,O
DM,3030,B-Modifier
parent-offspring,3030,O
pairs,3030,O
",",3030,O
of,3030,O
which,3030,O
95,3030,O
(,3030,O
6,3030,O
.,3030,O
4,3031,O
%,3031,O
),3031,O
showed,3031,O
such,3031,O
contractions,3031,O
in,3031,O
peripheral,3031,O
blood,3031,O
leukocytes,3031,O
(,3031,O
PBL,3031,O
),3031,O
.,3031,O
In,3032,O
56,3032,O
of,3032,O
the,3032,O
95,3032,O
pairs,3032,O
",",3032,O
clinical,3032,O
data,3032,O
allowed,3032,O
an,3032,O
analysis,3032,O
of,3032,O
their,3032,O
anticipation,3032,O
status,3032,O
.,3032,O
It,3033,O
is,3033,O
surprising,3033,O
that,3033,O
anticipation,3033,O
occurred,3033,O
in,3033,O
27,3033,O
(,3033,O
48,3033,O
%,3033,O
),3033,O
of,3033,O
these,3033,O
56,3033,O
pairs,3033,O
",",3033,O
while,3033,O
none,3033,O
clearly,3033,O
showed,3033,O
a,3033,O
later,3033,O
onset,3033,O
of,3033,O
DM,3033,B-SpecificDisease
in,3033,O
the,3033,O
symptomatic,3033,O
offspring,3033,O
.,3033,O
The,3034,O
contraction,3034,O
occurred,3034,O
in,3034,O
76,3034,O
(,3034,O
10,3034,O
%,3034,O
),3034,O
of,3034,O
753,3034,O
paternal,3034,O
transmissions,3034,O
and,3034,O
in,3034,O
19,3034,O
(,3034,O
3,3034,O
%,3034,O
),3034,O
of,3034,O
736,3034,O
maternal,3034,O
transmissions,3034,O
.,3034,O
Anticipation,3035,O
was,3035,O
observed,3035,O
more,3035,O
frequently,3035,O
in,3035,O
maternal,3035,O
(,3035,O
85,3035,O
%,3035,O
),3035,O
than,3035,O
in,3035,O
paternal,3035,O
(,3035,O
37,3035,O
%,3035,O
),3035,O
transmissions,3035,O
(,3035,O
P,3035,O
<,3035,O
.,3035,O
001,3036,O
),3036,O
.,3036,O
The,3037,O
parental,3037,O
repeat,3037,O
size,3037,O
correlated,3037,O
with,3037,O
the,3037,O
size,3037,O
of,3037,O
intergenerational,3037,O
contraction,3037,O
(,3037,O
r2,3037,O
=,3037,O
.,3037,O
50,3038,O
",",3038,O
P,3038,O
<,3038,O
<,3038,O
.,3038,O
001,3039,O
),3039,O
",",3039,O
and,3039,O
the,3039,O
slope,3039,O
of,3039,O
linear,3039,O
regression,3039,O
was,3039,O
steeper,3039,O
in,3039,O
paternal,3039,O
(,3039,O
-,3039,O
.,3039,O
62,3040,O
),3040,O
than,3040,O
in,3040,O
maternal,3040,O
(,3040,O
-,3040,O
.,3040,O
30,3041,O
),3041,O
transmissions,3041,O
(,3041,O
P,3041,O
<,3041,O
<,3041,O
.,3041,O
001,3042,O
),3042,O
.,3042,O
Sixteen,3043,O
DM,3043,B-Modifier
parents,3043,O
had,3043,O
multiple,3043,O
DM,3043,B-Modifier
offspring,3043,O
with,3043,O
the,3043,O
CTG,3043,O
repeat,3043,O
contractions,3043,O
.,3043,O
This,3044,O
frequency,3044,O
was,3044,O
higher,3044,O
than,3044,O
the,3044,O
frequency,3044,O
expected,3044,O
from,3044,O
the,3044,O
probability,3044,O
of,3044,O
the,3044,O
repeat,3044,O
contractions,3044,O
(,3044,O
6,3044,O
.,3044,O
4,3045,O
%,3045,O
),3045,O
and,3045,O
the,3045,O
size,3045,O
of,3045,O
DM,3045,B-Modifier
sib,3045,O
population,3045,O
(,3045,O
1,3045,O
.,3045,O
54,3046,O
DM,3046,B-Modifier
offspring,3046,O
per,3046,O
DM,3046,B-Modifier
parent,3046,O
",",3046,O
in,3046,O
968,3046,O
DM,3046,B-Modifier
parents,3046,O
),3046,O
.,3046,O
We,3047,O
conclude,3047,O
that,3047,O
(,3047,O
1,3047,O
),3047,O
intergenerational,3047,O
contractions,3047,O
of,3047,O
the,3047,O
CTG,3047,O
repeat,3047,O
in,3047,O
leukocyte,3047,O
DNA,3047,O
frequently,3047,O
accompanies,3047,O
apparent,3047,O
anticipation,3047,O
",",3047,O
especially,3047,O
when,3047,O
DM,3047,B-SpecificDisease
is,3047,O
maternally,3047,O
transmitted,3047,O
",",3047,O
and,3047,O
(,3047,O
2,3047,O
),3047,O
the,3047,O
paternal,3047,O
origin,3047,O
of,3047,O
the,3047,O
repeat,3047,O
and,3047,O
the,3047,O
presence,3047,O
of,3047,O
the,3047,O
repeat,3047,O
contraction,3047,O
in,3047,O
a,3047,O
sibling,3047,O
increase,3047,O
the,3047,O
probability,3047,O
of,3047,O
the,3047,O
CTG,3047,O
repeat,3047,O
contraction,3047,O
Gonosomal,3048,O
mosaicism,3048,O
in,3048,O
myotonic,3048,B-Modifier
dystrophy,3048,I-Modifier
patients,3048,O
:,3048,O
involvement,3048,O
of,3048,O
mitotic,3048,O
events,3048,O
in,3048,O
(,3048,O
CTG,3048,O
),3048,O
n,3048,O
repeat,3048,O
variation,3048,O
and,3048,O
selection,3048,O
against,3048,O
extreme,3048,O
expansion,3048,O
in,3048,O
sperm,3048,O
.,3048,O
Myotonic,3049,B-SpecificDisease
dystrophy,3049,I-SpecificDisease
(,3049,O
DM,3049,B-SpecificDisease
),3049,O
is,3049,O
caused,3049,O
by,3049,O
abnormal,3049,O
expansion,3049,O
of,3049,O
a,3049,O
polymorphic,3049,O
(,3049,O
CTG,3049,O
),3049,O
n,3049,O
repeat,3049,O
",",3049,O
located,3049,O
in,3049,O
the,3049,O
DM,3049,B-Modifier
protein,3049,O
kinase,3049,O
gene,3049,O
.,3049,O
We,3050,O
determined,3050,O
the,3050,O
(,3050,O
CTG,3050,O
),3050,O
n,3050,O
repeat,3050,O
lengths,3050,O
in,3050,O
a,3050,O
broad,3050,O
range,3050,O
of,3050,O
tissue,3050,O
DNAs,3050,O
from,3050,O
patients,3050,O
with,3050,O
mild,3050,O
",",3050,O
classical,3050,O
",",3050,O
or,3050,O
congenital,3050,O
manifestation,3050,O
of,3050,O
DM,3050,B-Modifier
.,3050,O
Differences,3051,O
in,3051,O
the,3051,O
repeat,3051,O
length,3051,O
were,3051,O
seen,3051,O
in,3051,O
somatic,3051,O
tissues,3051,O
from,3051,O
single,3051,O
DM,3051,B-Modifier
individuals,3051,O
and,3051,O
twins,3051,O
.,3051,O
Repeats,3052,O
appeared,3052,O
to,3052,O
expand,3052,O
to,3052,O
a,3052,O
similar,3052,O
extent,3052,O
in,3052,O
tissues,3052,O
originating,3052,O
from,3052,O
the,3052,O
same,3052,O
embryonal,3052,O
origin,3052,O
.,3052,O
In,3053,O
most,3053,O
male,3053,O
patients,3053,O
carrying,3053,O
intermediate-,3053,O
or,3053,O
small-sized,3053,O
expansions,3053,O
in,3053,O
blood,3053,O
",",3053,O
the,3053,O
repeat,3053,O
lengths,3053,O
covered,3053,O
a,3053,O
markedly,3053,O
wider,3053,O
range,3053,O
in,3053,O
sperm,3053,O
.,3053,O
In,3054,O
contrast,3054,O
",",3054,O
male,3054,O
patients,3054,O
with,3054,O
large,3054,O
allele,3054,O
expansions,3054,O
in,3054,O
blood,3054,O
(,3054,O
>,3054,O
700,3054,O
CTGs,3054,O
),3054,O
had,3054,O
similar,3054,O
or,3054,O
smaller,3054,O
repeats,3054,O
in,3054,O
sperm,3054,O
",",3054,O
when,3054,O
detectable,3054,O
.,3054,O
Sperm,3055,O
alleles,3055,O
with,3055,O
>,3055,O
1,3055,O
",",3055,O
000,3055,O
CTGs,3055,O
were,3055,O
not,3055,O
seen,3055,O
.,3055,O
We,3056,O
conclude,3056,O
that,3056,O
DM,3056,B-Modifier
patients,3056,O
can,3056,O
be,3056,O
considered,3056,O
gonosomal,3056,O
mosaics,3056,O
",",3056,O
i.,3056,O
e,3056,O
e.,3056,O
",",3056,O
combined,3056,O
somatic,3056,O
and,3056,O
germ-line,3056,O
tissue,3056,O
mosaics,3056,O
.,3056,O
Most,3057,O
remarkably,3057,O
",",3057,O
we,3057,O
observed,3057,O
multiple,3057,O
cases,3057,O
where,3057,O
the,3057,O
length,3057,O
distributions,3057,O
of,3057,O
intermediate-,3057,O
or,3057,O
small-sized,3057,O
alleles,3057,O
in,3057,O
fathers,3057,O
sperm,3057,O
were,3057,O
significantly,3057,O
different,3057,O
from,3057,O
that,3057,O
in,3057,O
their,3057,O
offsprings,3057,O
blood,3057,O
.,3057,O
Our,3058,O
combined,3058,O
findings,3058,O
indicate,3058,O
that,3058,O
intergenerational,3058,O
length,3058,O
changes,3058,O
in,3058,O
the,3058,O
unstable,3058,O
CTG,3058,O
repeat,3058,O
are,3058,O
most,3058,O
likely,3058,O
to,3058,O
occur,3058,O
during,3058,O
early,3058,O
embryonic,3058,O
mitotic,3058,O
divisions,3058,O
in,3058,O
both,3058,O
somatic,3058,O
and,3058,O
germ-line,3058,O
tissue,3058,O
formation,3058,O
.,3058,O
Both,3059,O
the,3059,O
initial,3059,O
CTG,3059,O
length,3059,O
",",3059,O
the,3059,O
overall,3059,O
number,3059,O
of,3059,O
cell,3059,O
divisions,3059,O
involved,3059,O
in,3059,O
tissue,3059,O
formation,3059,O
",",3059,O
and,3059,O
perhaps,3059,O
a,3059,O
specific,3059,O
selection,3059,O
process,3059,O
in,3059,O
spermatogenesis,3059,O
may,3059,O
influence,3059,O
the,3059,O
dynamics,3059,O
of,3059,O
this,3059,O
process,3059,O
.,3059,O
A,3060,O
model,3060,O
explaining,3060,O
mitotic,3060,O
instability,3060,O
and,3060,O
sex-dependent,3060,O
segregation,3060,O
phenomena,3060,O
in,3060,O
DM,3060,B-Modifier
manifestation,3060,O
is,3060,O
discussed,3060,O
Regionally,3061,O
clustered,3061,O
APC,3061,B-Modifier
mutations,3061,O
are,3061,O
associated,3061,O
with,3061,O
a,3061,O
severe,3061,O
phenotype,3061,O
and,3061,O
occur,3061,O
at,3061,O
a,3061,O
high,3061,O
frequency,3061,O
in,3061,O
new,3061,O
mutation,3061,O
cases,3061,O
of,3061,O
adenomatous,3061,B-SpecificDisease
polyposis,3061,I-SpecificDisease
coli,3061,I-SpecificDisease
.,3061,O
Germline,3062,O
mutation,3062,O
in,3062,O
APC,3062,O
at,3062,O
5q21-22,3062,O
results,3062,O
in,3062,O
the,3062,O
dominantly,3062,O
inherited,3062,O
syndrome,3062,O
adenomatous,3062,B-SpecificDisease
polyposis,3062,I-SpecificDisease
coli,3062,I-SpecificDisease
(,3062,O
APC,3062,B-SpecificDisease
),3062,O
.,3062,O
Somatic,3063,O
mutation,3063,O
in,3063,O
this,3063,O
gene,3063,O
is,3063,O
an,3063,O
early,3063,O
event,3063,O
in,3063,O
colorectal,3063,O
tumourigenesis,3063,O
.,3063,O
Both,3064,O
types,3064,O
of,3064,O
mutation,3064,O
are,3064,O
concentrated,3064,O
in,3064,O
the,3064,O
5,3064,O
half,3064,O
of,3064,O
exon,3064,O
15,3064,O
.,3064,O
We,3065,O
have,3065,O
used,3065,O
single,3065,O
strand,3065,O
conformational,3065,O
polymorphism,3065,O
(,3065,O
SSCP,3065,O
),3065,O
and,3065,O
heteroduplex,3065,O
analysis,3065,O
to,3065,O
screen,3065,O
for,3065,O
variants,3065,O
in,3065,O
this,3065,O
region,3065,O
of,3065,O
the,3065,O
gene,3065,O
in,3065,O
a,3065,O
total,3065,O
of,3065,O
45,3065,O
affected,3065,O
but,3065,O
unrelated,3065,O
individuals,3065,O
.,3065,O
Eighteen,3066,O
patients,3066,O
had,3066,O
no,3066,O
family,3066,O
history,3066,O
of,3066,O
the,3066,O
disease,3066,O
;,3066,O
of,3066,O
these,3066,O
11,3066,O
were,3066,O
classified,3066,O
as,3066,O
having,3066,O
a,3066,O
severe,3066,O
phenotype,3066,O
",",3066,O
based,3066,O
on,3066,O
an,3066,O
early,3066,O
age,3066,O
at,3066,O
presentation,3066,O
or,3066,O
cancer,3066,B-Modifier
development,3066,O
.,3066,O
This,3067,O
compared,3067,O
with,3067,O
6,3067,O
of,3067,O
27,3067,O
familial,3067,O
cases,3067,O
.,3067,O
A,3068,O
5,3068,O
bp,3068,O
deletion,3068,O
at,3068,O
codon,3068,O
1309,3068,O
reported,3068,O
to,3068,O
occur,3068,O
in,3068,O
10-15,3068,O
%,3068,O
of,3068,O
unselected,3068,O
APC,3068,B-Modifier
patients,3068,O
worldwide,3068,O
",",3068,O
was,3068,O
found,3068,O
in,3068,O
5,3068,O
of,3068,O
the,3068,O
18,3068,O
new,3068,O
mutation,3068,O
cases,3068,O
and,3068,O
4,3068,O
of,3068,O
the,3068,O
27,3068,O
familial,3068,O
cases,3068,O
all,3068,O
nine,3068,O
were,3068,O
classed,3068,O
as,3068,O
severe,3068,O
.,3068,O
A,3069,O
further,3069,O
3,3069,O
new,3069,O
mutations,3069,O
and,3069,O
1,3069,O
familial,3069,O
mutation,3069,O
were,3069,O
located,3069,O
downstream,3069,O
from,3069,O
codon,3069,O
1309,3069,O
",",3069,O
these,3069,O
individuals,3069,O
similarly,3069,O
being,3069,O
classed,3069,O
as,3069,O
phenotypically,3069,O
severe,3069,O
.,3069,O
In,3070,O
contrast,3070,O
all,3070,O
of,3070,O
the,3070,O
APC,3070,B-Modifier
mutations,3070,O
detected,3070,O
in,3070,O
affected,3070,O
individuals,3070,O
with,3070,O
an,3070,O
average,3070,O
phenotype,3070,O
were,3070,O
located,3070,O
prior,3070,O
to,3070,O
codon,3070,O
1309,3070,O
.,3070,O
The,3071,O
frequent,3071,O
association,3071,O
of,3071,O
a,3071,O
severe,3071,O
phenotype,3071,O
with,3071,O
fresh,3071,O
mutation,3071,O
may,3071,O
explain,3071,O
the,3071,O
apparent,3071,O
conflict,3071,O
of,3071,O
a,3071,O
high,3071,O
mutation,3071,O
rate,3071,O
(,3071,O
20-30,3071,O
%,3071,O
),3071,O
in,3071,O
a,3071,O
condition,3071,O
",",3071,O
which,3071,O
on,3071,O
average,3071,O
",",3071,O
is,3071,O
lethal,3071,O
at,3071,O
a,3071,O
post-reproductive,3071,O
age,3071,O
..,3071,O
Mutations,3072,O
at,3072,O
the,3072,O
PAX6,3072,O
locus,3072,O
are,3072,O
found,3072,O
in,3072,O
heterogeneous,3072,O
anterior,3072,B-DiseaseClass
segment,3072,I-DiseaseClass
malformations,3072,I-DiseaseClass
including,3072,O
Peters,3072,B-SpecificDisease
',3072,I-SpecificDisease
anomaly,3072,I-SpecificDisease
.,3072,O
Mutation,3073,O
or,3073,O
deletion,3073,O
of,3073,O
the,3073,O
PAX6,3073,O
gene,3073,O
underlies,3073,O
many,3073,O
cases,3073,O
of,3073,O
aniridia,3073,B-SpecificDisease
.,3073,O
Three,3074,O
lines,3074,O
of,3074,O
evidence,3074,O
now,3074,O
converge,3074,O
to,3074,O
implicate,3074,O
PAX6,3074,O
more,3074,O
widely,3074,O
in,3074,O
anterior,3074,B-DiseaseClass
segment,3074,I-DiseaseClass
malformations,3074,I-DiseaseClass
including,3074,O
Peters,3074,B-SpecificDisease
anomaly,3074,I-SpecificDisease
.,3074,O
First,3075,O
",",3075,O
a,3075,O
child,3075,O
with,3075,O
Peters,3075,B-SpecificDisease
anomaly,3075,I-SpecificDisease
is,3075,O
deleted,3075,O
for,3075,O
one,3075,O
copy,3075,O
of,3075,O
PAX6,3075,O
.,3075,O
Second,3076,O
",",3076,O
affected,3076,O
members,3076,O
of,3076,O
a,3076,O
family,3076,O
with,3076,O
dominantly,3076,O
inherited,3076,O
anterior,3076,B-DiseaseClass
segment,3076,I-DiseaseClass
malformations,3076,I-DiseaseClass
",",3076,O
including,3076,O
Peters,3076,B-SpecificDisease
anomaly,3076,I-SpecificDisease
are,3076,O
heterozygous,3076,O
for,3076,O
an,3076,O
R26G,3076,O
mutation,3076,O
in,3076,O
the,3076,O
PAX6,3076,O
paired,3076,O
box,3076,O
.,3076,O
Third,3077,O
",",3077,O
a,3077,O
proportion,3077,O
of,3077,O
Sey/+,3077,O
Smalleye,3077,O
mice,3077,O
",",3077,O
heterozygous,3077,O
for,3077,O
a,3077,O
nonsense,3077,O
mutation,3077,O
in,3077,O
murine,3077,O
Pax-6,3077,O
",",3077,O
have,3077,O
an,3077,O
ocular,3077,O
phenotype,3077,O
resembling,3077,O
Peters,3077,B-SpecificDisease
anomaly,3077,I-SpecificDisease
.,3077,O
We,3078,O
therefore,3078,O
propose,3078,O
that,3078,O
a,3078,O
variety,3078,O
of,3078,O
anterior,3078,B-DiseaseClass
segment,3078,I-DiseaseClass
anomalies,3078,I-DiseaseClass
may,3078,O
be,3078,O
associated,3078,O
with,3078,O
PAX6,3078,O
mutations,3078,O
..,3078,O
Huntington,3079,B-SpecificDisease
disease,3079,I-SpecificDisease
without,3079,O
CAG,3079,O
expansion,3079,O
:,3079,O
phenocopies,3079,O
or,3079,O
errors,3079,O
in,3079,O
assignment,3079,O
?,3079,O
Huntington,3080,B-SpecificDisease
disease,3080,I-SpecificDisease
(,3080,O
HD,3080,B-SpecificDisease
),3080,O
has,3080,O
been,3080,O
shown,3080,O
to,3080,O
be,3080,O
associated,3080,O
with,3080,O
an,3080,O
expanded,3080,O
CAG,3080,O
repeat,3080,O
within,3080,O
a,3080,O
novel,3080,O
gene,3080,O
on,3080,O
4p16,3080,O
.,3080,O
3,3081,O
(,3081,O
IT15,3081,O
),3081,O
.,3081,O
A,3082,O
total,3082,O
of,3082,O
30,3082,O
of,3082,O
1,3082,O
",",3082,O
022,3082,O
affected,3082,O
persons,3082,O
(,3082,O
2,3082,O
.,3082,O
9,3083,O
%,3083,O
of,3083,O
our,3083,O
cohort,3083,O
),3083,O
did,3083,O
not,3083,O
have,3083,O
an,3083,O
expanded,3083,O
CAG,3083,O
in,3083,O
the,3083,O
disease,3083,O
range,3083,O
.,3083,O
The,3084,O
reasons,3084,O
for,3084,O
not,3084,O
observing,3084,O
expansion,3084,O
in,3084,O
affected,3084,O
individuals,3084,O
are,3084,O
important,3084,O
for,3084,O
determining,3084,O
the,3084,O
sensitivity,3084,O
of,3084,O
using,3084,O
repeat,3084,O
length,3084,O
both,3084,O
for,3084,O
diagnosis,3084,O
of,3084,O
affected,3084,O
patients,3084,O
and,3084,O
for,3084,O
predictive,3084,O
testing,3084,O
programs,3084,O
and,3084,O
may,3084,O
have,3084,O
biological,3084,O
relevance,3084,O
for,3084,O
the,3084,O
understanding,3084,O
of,3084,O
the,3084,O
molecular,3084,O
mechanism,3084,O
underlying,3084,O
HD,3084,B-SpecificDisease
.,3084,O
Here,3085,O
we,3085,O
show,3085,O
that,3085,O
the,3085,O
majority,3085,O
(,3085,O
18,3085,O
),3085,O
of,3085,O
the,3085,O
individuals,3085,O
with,3085,O
normal,3085,O
sized,3085,O
alleles,3085,O
represent,3085,O
misdiagnosis,3085,O
",",3085,O
sample,3085,O
mix-up,3085,O
",",3085,O
or,3085,O
clerical,3085,O
error,3085,O
.,3085,O
The,3086,O
remaining,3086,O
12,3086,O
patients,3086,O
represent,3086,O
possible,3086,O
phenocopies,3086,O
for,3086,O
HD,3086,B-SpecificDisease
.,3086,O
In,3087,O
at,3087,O
least,3087,O
four,3087,O
cases,3087,O
",",3087,O
family,3087,O
studies,3087,O
of,3087,O
these,3087,O
phenocopies,3087,O
excluded,3087,O
4p16,3087,O
.,3087,O
3,3088,O
as,3088,O
the,3088,O
region,3088,O
responsible,3088,O
for,3088,O
the,3088,O
phenotype,3088,O
.,3088,O
Mutations,3089,O
in,3089,O
the,3089,O
HD,3089,B-Modifier
gene,3089,O
that,3089,O
are,3089,O
other,3089,O
than,3089,O
CAG,3089,O
expansion,3089,O
have,3089,O
not,3089,O
been,3089,O
excluded,3089,O
for,3089,O
the,3089,O
remaining,3089,O
eight,3089,O
cases,3089,O
;,3089,O
however,3089,O
",",3089,O
in,3089,O
as,3089,O
many,3089,O
as,3089,O
seven,3089,O
of,3089,O
these,3089,O
persons,3089,O
",",3089,O
retrospective,3089,O
review,3089,O
of,3089,O
these,3089,O
patients,3089,O
clinical,3089,O
features,3089,O
identified,3089,O
characteristics,3089,O
not,3089,O
typical,3089,O
for,3089,O
HD,3089,B-SpecificDisease
.,3089,O
This,3090,O
study,3090,O
shows,3090,O
that,3090,O
on,3090,O
rare,3090,O
occasions,3090,O
mutations,3090,O
in,3090,O
other,3090,O
",",3090,O
as-yet-undefined,3090,O
genes,3090,O
can,3090,O
present,3090,O
with,3090,O
a,3090,O
clinical,3090,O
phenotype,3090,O
very,3090,O
similar,3090,O
to,3090,O
that,3090,O
of,3090,O
HD,3090,B-SpecificDisease
Frequent,3091,O
detection,3091,O
of,3091,O
codon,3091,O
877,3091,O
mutation,3091,O
in,3091,O
the,3091,O
androgen,3091,O
receptor,3091,O
gene,3091,O
in,3091,O
advanced,3091,B-SpecificDisease
prostate,3091,I-SpecificDisease
cancers,3091,I-SpecificDisease
.,3091,O
Prostatic,3092,O
tissue,3092,O
specimens,3092,O
derived,3092,O
from,3092,O
transurethral,3092,O
resections,3092,O
of,3092,O
patients,3092,O
with,3092,O
metastatic,3092,B-SpecificDisease
prostate,3092,I-SpecificDisease
cancer,3092,I-SpecificDisease
were,3092,O
analyzed,3092,O
for,3092,O
genetic,3092,O
alterations,3092,O
in,3092,O
the,3092,O
hormone-binding,3092,O
domain,3092,O
of,3092,O
the,3092,O
androgen,3092,O
receptor,3092,O
(,3092,O
AR,3092,O
),3092,O
gene,3092,O
.,3092,O
Direct,3093,O
sequencing,3093,O
of,3093,O
the,3093,O
polymerase,3093,O
chain,3093,O
reaction-derived,3093,O
DNAs,3093,O
of,3093,O
6,3093,O
of,3093,O
24,3093,O
specimens,3093,O
revealed,3093,O
a,3093,O
codon,3093,O
877,3093,O
mutation,3093,O
(,3093,O
ACT,3093,O
--,3093,O
>,3093,O
GCT,3093,O
",",3093,O
Thr,3093,O
--,3093,O
>,3093,O
Ala,3093,O
),3093,O
in,3093,O
the,3093,O
hormone-binding,3093,O
domain,3093,O
of,3093,O
the,3093,O
AR,3093,O
gene,3093,O
.,3093,O
This,3094,O
same,3094,O
AR,3094,O
mutation,3094,O
has,3094,O
been,3094,O
reported,3094,O
previously,3094,O
in,3094,O
a,3094,O
metastatic,3094,B-Modifier
prostate,3094,I-Modifier
cancer,3094,I-Modifier
cell,3094,O
line,3094,O
",",3094,O
LNCaP,3094,O
",",3094,O
where,3094,O
this,3094,O
mutation,3094,O
confers,3094,O
upon,3094,O
the,3094,O
AR,3094,O
an,3094,O
altered,3094,O
ligand-binding,3094,O
specificity,3094,O
which,3094,O
is,3094,O
stimulated,3094,O
by,3094,O
estrogens,3094,O
",",3094,O
progestagens,3094,O
",",3094,O
and,3094,O
antiandrogens,3094,O
.,3094,O
It,3095,O
is,3095,O
possible,3095,O
that,3095,O
analogous,3095,O
to,3095,O
an,3095,O
activated/altered,3095,O
growth,3095,O
factor,3095,O
receptor,3095,O
oncogene,3095,O
",",3095,O
codon,3095,O
877,3095,O
mutant,3095,O
AR,3095,O
with,3095,O
altered,3095,O
ligand,3095,O
binding,3095,O
may,3095,O
provide,3095,O
a,3095,O
selective,3095,O
growth,3095,O
advantage,3095,O
in,3095,O
the,3095,O
genesis,3095,O
of,3095,O
a,3095,O
subset,3095,O
of,3095,O
advanced,3095,B-SpecificDisease
prostate,3095,I-SpecificDisease
cancer,3095,I-SpecificDisease
.,3095,O
Although,3096,O
estrogens,3096,O
are,3096,O
used,3096,O
infrequently,3096,O
",",3096,O
antiandrogens,3096,O
are,3096,O
used,3096,O
increasingly,3096,O
in,3096,O
hormonal,3096,O
therapy,3096,O
for,3096,O
patients,3096,O
with,3096,O
advanced,3096,B-SpecificDisease
prostate,3096,I-SpecificDisease
cancer,3096,I-SpecificDisease
.,3096,O
The,3097,O
stimulatory,3097,O
effect,3097,O
of,3097,O
these,3097,O
therapeutic,3097,O
agents,3097,O
on,3097,O
the,3097,O
codon,3097,O
877,3097,O
mutant,3097,O
AR,3097,O
further,3097,O
suggests,3097,O
that,3097,O
this,3097,O
frequently,3097,O
observed,3097,O
AR,3097,O
mutation,3097,O
may,3097,O
contribute,3097,O
to,3097,O
the,3097,O
treatment,3097,O
refractory,3097,O
disease,3097,O
..,3097,O
The,3098,O
human,3098,O
gene,3098,O
for,3098,O
alkaptonuria,3098,B-SpecificDisease
(,3098,O
AKU,3098,B-SpecificDisease
),3098,O
maps,3098,O
to,3098,O
chromosome,3098,O
3q,3098,O
.,3098,O
Alkaptonuria,3099,B-SpecificDisease
(,3099,O
AKU,3099,B-SpecificDisease
;,3099,O
McKusick,3099,O
no,3099,O
.,3099,O
203500,3100,O
),3100,O
is,3100,O
a,3100,O
rare,3100,O
autosomal,3100,B-DiseaseClass
recessive,3100,I-DiseaseClass
disorder,3100,I-DiseaseClass
caused,3100,O
by,3100,O
the,3100,O
lack,3100,O
of,3100,O
homogentisic,3100,O
acid,3100,O
oxidase,3100,O
activity,3100,O
.,3100,O
Patients,3101,O
excrete,3101,O
large,3101,O
amounts,3101,O
of,3101,O
homogentisic,3101,O
acid,3101,O
in,3101,O
their,3101,O
urine,3101,O
and,3101,O
a,3101,O
black,3101,O
ochronotic,3101,O
pigment,3101,O
is,3101,O
deposited,3101,O
in,3101,O
their,3101,O
cartilage,3101,O
and,3101,O
collagenous,3101,O
tissues,3101,O
.,3101,O
Ochronosis,3102,B-SpecificDisease
is,3102,O
the,3102,O
predominant,3102,O
clinical,3102,O
complication,3102,O
of,3102,O
the,3102,O
disease,3102,O
leading,3102,O
to,3102,O
ochronotic,3102,B-SpecificDisease
arthropathy,3102,I-SpecificDisease
",",3102,O
dark,3102,O
urine,3102,O
",",3102,O
pigment,3102,O
changes,3102,O
of,3102,O
the,3102,O
skin,3102,O
",",3102,O
and,3102,O
other,3102,O
clinical,3102,O
features,3102,O
.,3102,O
A,3103,O
mutation,3103,O
causing,3103,O
alkaptonuria,3103,B-SpecificDisease
in,3103,O
the,3103,O
mouse,3103,O
has,3103,O
mapped,3103,O
to,3103,O
chromosome,3103,O
16,3103,O
.,3103,O
Considering,3104,O
conserved,3104,O
synteny,3104,O
",",3104,O
we,3104,O
were,3104,O
able,3104,O
to,3104,O
map,3104,O
the,3104,O
human,3104,O
gene,3104,O
to,3104,O
chromosome,3104,O
3q,3104,O
in,3104,O
six,3104,O
alkaptonuria,3104,B-Modifier
pedigrees,3104,O
of,3104,O
Slovak,3104,O
origin,3104,O
..,3104,O
Structure,3105,O
of,3105,O
the,3105,O
human,3105,O
Na+/glucose,3105,O
cotransporter,3105,O
gene,3105,O
SGLT1,3105,O
.,3105,O
Intestinal,3106,O
uptake,3106,O
of,3106,O
dietary,3106,O
glucose,3106,O
and,3106,O
galactose,3106,O
is,3106,O
mediated,3106,O
by,3106,O
the,3106,O
SGLT1,3106,O
Na,3106,O
+/glucose,3106,O
cotransporter,3106,O
of,3106,O
the,3106,O
brush,3106,O
border,3106,O
.,3106,O
An,3107,O
SGLT1,3107,O
missense,3107,O
mutation,3107,O
underlies,3107,O
hereditary,3107,B-SpecificDisease
glucose/galactose,3107,I-SpecificDisease
malabsorption,3107,I-SpecificDisease
",",3107,O
characterized,3107,O
by,3107,O
potentially,3107,O
fatal,3107,O
diarrhea,3107,B-SpecificDisease
;,3107,O
conversely,3107,O
",",3107,O
oral,3107,O
rehydration,3107,O
therapy,3107,O
exploits,3107,O
normal,3107,O
transport,3107,O
to,3107,O
alleviate,3107,O
life-threatening,3107,O
diarrhea,3107,B-SpecificDisease
of,3107,O
infectious,3107,O
origin,3107,O
.,3107,O
We,3108,O
have,3108,O
mapped,3108,O
the,3108,O
entire,3108,O
human,3108,O
SGLT1,3108,O
Na,3108,O
+/glucose,3108,O
cotransporter,3108,O
gene,3108,O
from,3108,O
cosmid,3108,O
and,3108,O
lambda,3108,O
phage,3108,O
clones,3108,O
representing,3108,O
a,3108,O
genomic,3108,O
region,3108,O
of,3108,O
112,3108,O
kilobases,3108,O
.,3108,O
Transcription,3109,O
initiation,3109,O
occurred,3109,O
from,3109,O
a,3109,O
site,3109,O
27,3109,O
base,3109,O
pairs,3109,O
3,3109,O
of,3109,O
a,3109,O
TATAA,3109,O
sequence,3109,O
.,3109,O
All,3110,O
exon-flanking,3110,O
regions,3110,O
were,3110,O
sequenced,3110,O
",",3110,O
and,3110,O
the,3110,O
entire,3110,O
112-kilobase,3110,O
region,3110,O
mapped,3110,O
with,3110,O
four,3110,O
restriction,3110,O
enzymes,3110,O
.,3110,O
SGLT1,3111,O
is,3111,O
comprised,3111,O
of,3111,O
15,3111,O
exons,3111,O
(,3111,O
spanning,3111,O
72,3111,O
kilobases,3111,O
),3111,O
;,3111,O
a,3111,O
possible,3111,O
evolutionary,3111,O
origin,3111,O
from,3111,O
a,3111,O
six-membrane-span,3111,O
ancestral,3111,O
precursor,3111,O
via,3111,O
a,3111,O
gene,3111,O
duplication,3111,O
event,3111,O
is,3111,O
suggested,3111,O
from,3111,O
comparison,3111,O
of,3111,O
exons,3111,O
against,3111,O
protein,3111,O
secondary,3111,O
structure,3111,O
and,3111,O
from,3111,O
sequence,3111,O
considerations,3111,O
.,3111,O
A,3112,O
new,3112,O
missense,3112,O
mutation,3112,O
in,3112,O
exon,3112,O
1,3112,O
causing,3112,O
glucose/galactose,3112,B-SpecificDisease
malabsorption,3112,I-SpecificDisease
is,3112,O
also,3112,O
described,3112,O
.,3112,O
This,3113,O
is,3113,O
the,3113,O
first,3113,O
Na,3113,O
(,3113,O
+,3113,O
),3113,O
-dependent,3113,O
cotransporter,3113,O
gene,3113,O
structure,3113,O
reported,3113,O
.,3113,O
These,3114,O
data,3114,O
facilitate,3114,O
the,3114,O
search,3114,O
for,3114,O
new,3114,O
glucose/galactose,3114,B-Modifier
malabsorption-related,3114,O
mutations,3114,O
in,3114,O
this,3114,O
important,3114,O
gene,3114,O
and,3114,O
provide,3114,O
a,3114,O
basis,3114,O
for,3114,O
future,3114,O
evolutionary,3114,O
comparisons,3114,O
with,3114,O
other,3114,O
Na,3114,O
(,3114,O
+,3114,O
),3114,O
-dependent,3114,O
cotransporters,3114,O
..,3114,O
Four,3115,O
novel,3115,O
PEPD,3115,O
alleles,3115,O
causing,3115,O
prolidase,3115,B-SpecificDisease
deficiency,3115,I-SpecificDisease
.,3115,O
Mutations,3116,O
at,3116,O
the,3116,O
PEPD,3116,O
locus,3116,O
cause,3116,O
prolidase,3116,B-SpecificDisease
deficiency,3116,I-SpecificDisease
(,3116,O
McKusick,3116,O
170100,3116,O
),3116,O
",",3116,O
a,3116,O
rare,3116,O
autosomal,3116,B-DiseaseClass
recessive,3116,I-DiseaseClass
disorder,3116,I-DiseaseClass
characterized,3116,O
by,3116,O
iminodipeptiduria,3116,B-SpecificDisease
",",3116,O
skin,3116,B-SpecificDisease
ulcers,3116,I-SpecificDisease
",",3116,O
mental,3116,B-DiseaseClass
retardation,3116,I-DiseaseClass
",",3116,O
and,3116,O
recurrent,3116,O
infections,3116,O
.,3116,O
Four,3117,O
PEPD,3117,O
mutations,3117,O
from,3117,O
five,3117,O
severely,3117,O
affected,3117,O
individuals,3117,O
were,3117,O
characterized,3117,O
by,3117,O
analysis,3117,O
of,3117,O
reverse-transcribed,3117,O
",",3117,O
PCR-amplified,3117,O
(,3117,O
RT-PCR,3117,O
),3117,O
cDNA,3117,O
.,3117,O
We,3118,O
used,3118,O
SSCP,3118,O
analysis,3118,O
on,3118,O
four,3118,O
overlapping,3118,O
cDNA,3118,O
fragments,3118,O
covering,3118,O
the,3118,O
entire,3118,O
coding,3118,O
region,3118,O
of,3118,O
the,3118,O
PEPD,3118,O
gene,3118,O
and,3118,O
detected,3118,O
abnormal,3118,O
SSCP,3118,O
bands,3118,O
for,3118,O
the,3118,O
fragment,3118,O
spanning,3118,O
all,3118,O
or,3118,O
part,3118,O
of,3118,O
exons,3118,O
13-15,3118,O
in,3118,O
three,3118,O
of,3118,O
the,3118,O
probands,3118,O
.,3118,O
Direct,3119,O
sequencing,3119,O
of,3119,O
the,3119,O
mutant,3119,O
cDNAs,3119,O
showed,3119,O
a,3119,O
G,3119,O
--,3119,O
>,3119,O
A,3119,O
",",3119,O
1342,3119,O
substitution,3119,O
(,3119,O
G448R,3119,O
),3119,O
in,3119,O
two,3119,O
patients,3119,O
and,3119,O
a,3119,O
3-bp,3119,O
deletion,3119,O
(,3119,O
delta,3119,O
E452,3119,O
or,3119,O
delta,3119,O
E453,3119,O
),3119,O
in,3119,O
another,3119,O
.,3119,O
In,3120,O
the,3120,O
other,3120,O
two,3120,O
probands,3120,O
the,3120,O
amplified,3120,O
products,3120,O
were,3120,O
of,3120,O
reduced,3120,O
size,3120,O
.,3120,O
Direct,3121,O
sequencing,3121,O
of,3121,O
these,3121,O
mutant,3121,O
cDNAs,3121,O
revealed,3121,O
a,3121,O
deletion,3121,O
of,3121,O
exon,3121,O
5,3121,O
in,3121,O
one,3121,O
patient,3121,O
and,3121,O
of,3121,O
exon,3121,O
7,3121,O
in,3121,O
the,3121,O
other,3121,O
.,3121,O
Intronic,3122,O
sequences,3122,O
flanking,3122,O
exons,3122,O
5,3122,O
and,3122,O
7,3122,O
were,3122,O
identified,3122,O
using,3122,O
inverse,3122,O
PCR,3122,O
followed,3122,O
by,3122,O
direct,3122,O
sequencing,3122,O
.,3122,O
Conventional,3123,O
PCR,3123,O
and,3123,O
direct,3123,O
sequencing,3123,O
then,3123,O
established,3123,O
the,3123,O
intron-exon,3123,O
borders,3123,O
of,3123,O
the,3123,O
mutant,3123,O
genomic,3123,O
DNA,3123,O
revealing,3123,O
two,3123,O
splice,3123,O
acceptor,3123,O
mutations,3123,O
a,3123,O
G,3123,O
--,3123,O
>,3123,O
C,3123,O
substitution,3123,O
at,3123,O
position,3123,O
-1,3123,O
of,3123,O
intron,3123,O
4,3123,O
and,3123,O
an,3123,O
A,3123,O
--,3123,O
>,3123,O
G,3123,O
substitution,3123,O
at,3123,O
position,3123,O
-2,3123,O
of,3123,O
intron,3123,O
6,3123,O
.,3123,O
Our,3124,O
results,3124,O
indicate,3124,O
that,3124,O
the,3124,O
severe,3124,O
form,3124,O
of,3124,O
prolidase,3124,B-SpecificDisease
deficiency,3124,I-SpecificDisease
is,3124,O
caused,3124,O
by,3124,O
multiple,3124,O
PEPD,3124,O
alleles,3124,O
.,3124,O
In,3125,O
this,3125,O
report,3125,O
we,3125,O
attempt,3125,O
to,3125,O
begin,3125,O
the,3125,O
process,3125,O
of,3125,O
describing,3125,O
these,3125,O
alleles,3125,O
and,3125,O
cataloging,3125,O
their,3125,O
phenotypic,3125,O
expression,3125,O
..,3125,O
Recombinations,3126,O
in,3126,O
individuals,3126,O
homozygous,3126,O
by,3126,O
descent,3126,O
localize,3126,O
the,3126,O
Friedreich,3126,B-SpecificDisease
ataxia,3126,I-SpecificDisease
locus,3126,O
in,3126,O
a,3126,O
cloned,3126,O
450-kb,3126,O
interval,3126,O
.,3126,O
The,3127,O
locus,3127,O
for,3127,O
Friedreich,3127,B-SpecificDisease
ataxia,3127,I-SpecificDisease
(,3127,O
FRDA,3127,B-SpecificDisease
),3127,O
",",3127,O
a,3127,O
severe,3127,O
neurodegenerative,3127,B-DiseaseClass
disease,3127,I-DiseaseClass
",",3127,O
is,3127,O
tightly,3127,O
linked,3127,O
to,3127,O
markers,3127,O
D9S5,3127,O
and,3127,O
D9S15,3127,O
",",3127,O
and,3127,O
analysis,3127,O
of,3127,O
rare,3127,O
recombination,3127,O
events,3127,O
has,3127,O
suggested,3127,O
the,3127,O
order,3127,O
cen-FRDA-D9S5-D9S15-qter,3127,O
.,3127,O
We,3128,O
report,3128,O
here,3128,O
the,3128,O
construction,3128,O
of,3128,O
a,3128,O
YAC,3128,O
contig,3128,O
extending,3128,O
800,3128,O
kb,3128,O
centromeric,3128,O
to,3128,O
D9S5,3128,O
and,3128,O
the,3128,O
isolation,3128,O
of,3128,O
five,3128,O
new,3128,O
microsatellite,3128,O
markers,3128,O
from,3128,O
this,3128,O
region,3128,O
.,3128,O
In,3129,O
order,3129,O
to,3129,O
map,3129,O
these,3129,O
markers,3129,O
with,3129,O
respect,3129,O
to,3129,O
the,3129,O
FRDA,3129,B-Modifier
locus,3129,O
",",3129,O
all,3129,O
within,3129,O
a,3129,O
1-cM,3129,O
confidence,3129,O
interval,3129,O
",",3129,O
we,3129,O
sought,3129,O
to,3129,O
increase,3129,O
the,3129,O
genetic,3129,O
information,3129,O
of,3129,O
available,3129,O
FRDA,3129,B-Modifier
families,3129,O
by,3129,O
considering,3129,O
homozygosity,3129,O
by,3129,O
descent,3129,O
and,3129,O
association,3129,O
with,3129,O
founder,3129,O
haplotypes,3129,O
in,3129,O
isolated,3129,O
populations,3129,O
.,3129,O
This,3130,O
approach,3130,O
allowed,3130,O
us,3130,O
to,3130,O
identify,3130,O
one,3130,O
phase-known,3130,O
recombination,3130,O
and,3130,O
one,3130,O
probable,3130,O
historic,3130,O
recombination,3130,O
on,3130,O
haplotypes,3130,O
from,3130,O
Reunion,3130,O
Island,3130,O
patients,3130,O
",",3130,O
both,3130,O
of,3130,O
which,3130,O
place,3130,O
three,3130,O
of,3130,O
the,3130,O
five,3130,O
markers,3130,O
proximal,3130,O
to,3130,O
FRDA,3130,B-SpecificDisease
.,3130,O
This,3131,O
represents,3131,O
the,3131,O
first,3131,O
identification,3131,O
of,3131,O
close,3131,O
FRDA,3131,B-Modifier
flanking,3131,O
markers,3131,O
on,3131,O
the,3131,O
centromeric,3131,O
side,3131,O
.,3131,O
The,3132,O
two,3132,O
other,3132,O
markers,3132,O
allowed,3132,O
us,3132,O
to,3132,O
narrow,3132,O
the,3132,O
breakpoint,3132,O
of,3132,O
a,3132,O
previously,3132,O
identified,3132,O
distal,3132,O
recombination,3132,O
that,3132,O
is,3132,O
>,3132,O
180,3132,O
kb,3132,O
from,3132,O
D9S5,3132,O
(,3132,O
26P,3132,O
),3132,O
.,3132,O
Taken,3133,O
together,3133,O
",",3133,O
the,3133,O
results,3133,O
place,3133,O
the,3133,O
FRDA,3133,B-Modifier
locus,3133,O
in,3133,O
a,3133,O
450-kb,3133,O
interval,3133,O
",",3133,O
which,3133,O
is,3133,O
small,3133,O
enough,3133,O
for,3133,O
direct,3133,O
search,3133,O
of,3133,O
candidate,3133,O
genes,3133,O
.,3133,O
A,3134,O
detailed,3134,O
rare,3134,O
cutter,3134,O
restriction,3134,O
map,3134,O
and,3134,O
a,3134,O
cosmid,3134,O
contig,3134,O
covering,3134,O
this,3134,O
interval,3134,O
were,3134,O
constructed,3134,O
and,3134,O
should,3134,O
facilitate,3134,O
the,3134,O
search,3134,O
of,3134,O
genes,3134,O
in,3134,O
this,3134,O
region,3134,O
..,3134,O
Investigation,3135,O
of,3135,O
thermoregulatory,3135,O
characteristics,3135,O
in,3135,O
patients,3135,O
with,3135,O
Prader-Willi,3135,B-SpecificDisease
syndrome,3135,I-SpecificDisease
.,3135,O
A,3136,O
survey,3136,O
instrument,3136,O
is,3136,O
used,3136,O
to,3136,O
assess,3136,O
temperature,3136,O
regulation,3136,O
characteristics,3136,O
in,3136,O
children,3136,O
with,3136,O
Prader-Willi,3136,B-SpecificDisease
syndrome,3136,I-SpecificDisease
(,3136,O
PWS,3136,B-SpecificDisease
),3136,O
compared,3136,O
to,3136,O
3,3136,O
control,3136,O
groups,3136,O
sibs,3136,O
of,3136,O
PWS,3136,B-Modifier
patients,3136,O
(,3136,O
SIB,3136,O
),3136,O
",",3136,O
neurodevelopmentally,3136,B-Modifier
handicapped,3136,I-Modifier
children,3136,O
(,3136,O
ND,3136,O
),3136,O
",",3136,O
and,3136,O
age,3136,O
and,3136,O
gender,3136,O
matched,3136,O
well,3136,O
children,3136,O
(,3136,O
WC,3136,O
),3136,O
.,3136,O
Significant,3137,O
differences,3137,O
were,3137,O
found,3137,O
between,3137,O
PWS,3137,B-Modifier
patients,3137,O
",",3137,O
SIB,3137,O
controls,3137,O
",",3137,O
and,3137,O
WC,3137,O
controls,3137,O
in,3137,O
the,3137,O
prevalence,3137,O
of,3137,O
febrile,3137,O
convulsions,3137,O
",",3137,O
fever-associated,3137,O
symptoms,3137,O
",",3137,O
and,3137,O
temperature,3137,O
less,3137,O
than,3137,O
94,3137,O
degrees,3137,O
F.,3137,O
No,3137,O
differences,3137,O
were,3137,O
noted,3137,O
in,3137,O
any,3137,O
variable,3137,O
between,3137,O
the,3137,O
PWS,3137,B-Modifier
patients,3137,O
and,3137,O
the,3137,O
ND,3137,O
controls,3137,O
",",3137,O
suggesting,3137,O
that,3137,O
these,3137,O
abnormalities,3137,O
are,3137,O
not,3137,O
unique,3137,O
to,3137,O
PWS,3137,B-SpecificDisease
",",3137,O
but,3137,O
can,3137,O
occur,3137,O
in,3137,O
any,3137,O
neurodevelopmentally,3137,B-Modifier
handicapped,3137,I-Modifier
individual,3137,O
",",3137,O
further,3137,O
suggesting,3137,O
these,3137,O
do,3137,O
not,3137,O
necessarily,3137,O
reflect,3137,O
syndrome-specific,3137,O
hypothalamic,3137,B-DiseaseClass
abnormalities,3137,I-DiseaseClass
..,3137,O
Phenotypic,3138,O
variation,3138,O
including,3138,O
retinitis,3138,B-SpecificDisease
pigmentosa,3138,I-SpecificDisease
",",3138,O
pattern,3138,B-SpecificDisease
dystrophy,3138,I-SpecificDisease
",",3138,O
and,3138,O
fundus,3138,B-SpecificDisease
flavimaculatus,3138,I-SpecificDisease
in,3138,O
a,3138,O
single,3138,O
family,3138,O
with,3138,O
a,3138,O
deletion,3138,O
of,3138,O
codon,3138,O
153,3138,O
or,3138,O
154,3138,O
of,3138,O
the,3138,O
peripherin/RDS,3138,O
gene,3138,O
.,3138,O
BACKGROUND,3139,O
AND,3139,O
OBJECTIVES,3139,O
Mutations,3139,O
of,3139,O
the,3139,O
peripherin/RDS,3139,O
gene,3139,O
have,3139,O
been,3139,O
reported,3139,O
in,3139,O
autosomal,3139,B-SpecificDisease
dominant,3139,I-SpecificDisease
retinitis,3139,I-SpecificDisease
pigmentosa,3139,I-SpecificDisease
",",3139,O
pattern,3139,O
macular,3139,B-SpecificDisease
dystrophy,3139,I-SpecificDisease
",",3139,O
and,3139,O
retinitis,3139,B-SpecificDisease
punctata,3139,I-SpecificDisease
albescens,3139,I-SpecificDisease
.,3139,O
We,3140,O
report,3140,O
herein,3140,O
the,3140,O
occurrence,3140,O
of,3140,O
three,3140,O
separate,3140,O
phenotypes,3140,O
within,3140,O
a,3140,O
single,3140,O
family,3140,O
with,3140,O
a,3140,O
novel,3140,O
3-base,3140,O
pair,3140,O
deletion,3140,O
of,3140,O
codon,3140,O
153,3140,O
or,3140,O
154,3140,O
of,3140,O
the,3140,O
peripherin/RDS,3140,O
gene,3140,O
.,3140,O
DESIGN,3141,O
Case,3141,O
reports,3141,O
with,3141,O
clinical,3141,O
features,3141,O
",",3141,O
fluorescein,3141,O
angiography,3141,O
",",3141,O
kinetic,3141,O
perimetry,3141,O
",",3141,O
electrophysiological,3141,O
studies,3141,O
",",3141,O
and,3141,O
molecular,3141,O
genetics,3141,O
.,3141,O
SETTING,3142,O
University,3142,O
medical,3142,O
centers,3142,O
.,3142,O
PATIENTS,3143,O
A,3143,O
75-year-old,3143,O
woman,3143,O
",",3143,O
her,3143,O
two,3143,O
daughters,3143,O
(,3143,O
aged,3143,O
44,3143,O
and,3143,O
50,3143,O
years,3143,O
),3143,O
",",3143,O
and,3143,O
her,3143,O
49-year-old,3143,O
son,3143,O
were,3143,O
screened,3143,O
for,3143,O
peripherin/RDS,3143,O
mutations,3143,O
because,3143,O
of,3143,O
the,3143,O
presence,3143,O
of,3143,O
multiple,3143,O
phenotypes,3143,O
within,3143,O
the,3143,O
same,3143,O
family,3143,O
.,3143,O
RESULTS,3144,O
The,3144,O
mother,3144,O
presented,3144,O
at,3144,O
age,3144,O
63,3144,O
years,3144,O
with,3144,O
a,3144,O
profoundly,3144,O
abnormal,3144,O
electroretinogram,3144,O
(,3144,O
ERG,3144,O
),3144,O
and,3144,O
adult-onset,3144,O
retinitis,3144,B-SpecificDisease
pigmentosa,3144,I-SpecificDisease
that,3144,O
progressed,3144,O
dramatically,3144,O
over,3144,O
12,3144,O
years,3144,O
",",3144,O
with,3144,O
marked,3144,O
loss,3144,O
of,3144,O
peripheral,3144,O
visual,3144,O
field,3144,O
.,3144,O
One,3145,O
daughter,3145,O
developed,3145,O
pattern,3145,B-SpecificDisease
macular,3145,I-SpecificDisease
dystrophy,3145,I-SpecificDisease
at,3145,O
age,3145,O
31,3145,O
years,3145,O
.,3145,O
At,3146,O
age,3146,O
44,3146,O
years,3146,O
",",3146,O
her,3146,O
ERG,3146,O
was,3146,O
moderately,3146,O
abnormal,3146,O
but,3146,O
her,3146,O
clinical,3146,O
disease,3146,O
was,3146,O
limited,3146,O
to,3146,O
the,3146,O
macula,3146,O
.,3146,O
Another,3147,O
daughter,3147,O
presented,3147,O
at,3147,O
age,3147,O
42,3147,O
years,3147,O
with,3147,O
macular,3147,B-SpecificDisease
degeneration,3147,I-SpecificDisease
and,3147,O
over,3147,O
10,3147,O
years,3147,O
developed,3147,O
the,3147,O
clinical,3147,O
picture,3147,O
of,3147,O
fundus,3147,B-SpecificDisease
flavimaculatus,3147,I-SpecificDisease
.,3147,O
Her,3148,O
peripheral,3148,O
visual,3148,O
field,3148,O
was,3148,O
preserved,3148,O
but,3148,O
her,3148,O
ERG,3148,O
was,3148,O
moderately,3148,O
abnormal,3148,O
.,3148,O
The,3149,O
son,3149,O
had,3149,O
onset,3149,O
of,3149,O
macular,3149,B-SpecificDisease
degeneration,3149,I-SpecificDisease
at,3149,O
age,3149,O
44,3149,O
years,3149,O
.,3149,O
Pericentral,3150,B-SpecificDisease
scotomas,3150,I-SpecificDisease
were,3150,O
present,3150,O
and,3150,O
the,3150,O
ERG,3150,O
was,3150,O
markedly,3150,O
abnormal,3150,O
.,3150,O
Fluorescein,3151,O
angiography,3151,O
revealed,3151,O
punctate,3151,O
pigment,3151,O
epithelial,3151,O
transmission,3151,O
defects,3151,O
.,3151,O
CONCLUSIONS,3152,O
A,3152,O
3-base,3152,O
pair,3152,O
deletion,3152,O
of,3152,O
codon,3152,O
153,3152,O
or,3152,O
154,3152,O
of,3152,O
the,3152,O
peripherin/RDS,3152,O
gene,3152,O
can,3152,O
produce,3152,O
clinically,3152,O
disparate,3152,O
phenotypes,3152,O
even,3152,O
within,3152,O
the,3152,O
same,3152,O
family,3152,O
..,3152,O
Assignment,3153,O
of,3153,O
the,3153,O
human,3153,O
Na+/glucose,3153,O
cotransporter,3153,O
gene,3153,O
SGLT1,3153,O
to,3153,O
chromosome,3153,O
22q13.1,3153,O
.,3153,O
The,3154,O
Na,3154,O
+/glucose,3154,O
cotransporter,3154,O
gene,3154,O
SGLT1,3154,O
encodes,3154,O
the,3154,O
primary,3154,O
carrier,3154,O
protein,3154,O
responsible,3154,O
for,3154,O
the,3154,O
uptake,3154,O
of,3154,O
the,3154,O
dietary,3154,O
sugars,3154,O
glucose,3154,O
and,3154,O
galactose,3154,O
from,3154,O
the,3154,O
intestinal,3154,O
lumen,3154,O
.,3154,O
SGLT1,3155,O
transport,3155,O
activity,3155,O
is,3155,O
currently,3155,O
exploited,3155,O
in,3155,O
oral,3155,O
rehydration,3155,O
therapy,3155,O
.,3155,O
The,3156,O
75-kDa,3156,O
glycoprotein,3156,O
is,3156,O
localized,3156,O
in,3156,O
the,3156,O
brush,3156,O
border,3156,O
of,3156,O
the,3156,O
intestinal,3156,O
epithelium,3156,O
and,3156,O
is,3156,O
predicted,3156,O
to,3156,O
comprise,3156,O
12,3156,O
membrane,3156,O
spans,3156,O
.,3156,O
In,3157,O
two,3157,O
patients,3157,O
with,3157,O
the,3157,O
autosomal,3157,B-SpecificDisease
recessive,3157,I-SpecificDisease
disease,3157,I-SpecificDisease
glucose/galactose,3157,I-SpecificDisease
malabsorption,3157,I-SpecificDisease
",",3157,O
the,3157,O
underlying,3157,O
cause,3157,O
was,3157,O
found,3157,O
to,3157,O
be,3157,O
a,3157,O
missense,3157,O
mutation,3157,O
in,3157,O
SGLT1,3157,O
",",3157,O
and,3157,O
the,3157,O
Asp28,3157,O
--,3157,O
>,3157,O
Asn,3157,O
change,3157,O
was,3157,O
demonstrated,3157,O
in,3157,O
vitro,3157,O
to,3157,O
eliminate,3157,O
SGLT1,3157,O
transport,3157,O
activity,3157,O
.,3157,O
The,3158,O
SGLT1,3158,O
gene,3158,O
was,3158,O
previously,3158,O
shown,3158,O
to,3158,O
reside,3158,O
on,3158,O
the,3158,O
distal,3158,O
q,3158,O
arm,3158,O
of,3158,O
chromosome,3158,O
22,3158,O
(,3158,O
11,3158,O
.,3158,O
2,3159,O
--,3159,O
>,3159,O
qter,3159,O
),3159,O
.,3159,O
We,3160,O
have,3160,O
used,3160,O
a,3160,O
cosmid,3160,O
probe,3160,O
for,3160,O
fluorescence,3160,O
in,3160,O
situ,3160,O
hybridization,3160,O
",",3160,O
which,3160,O
refines,3160,O
the,3160,O
localization,3160,O
to,3160,O
22q13,3160,O
.,3160,O
1,3161,O
",",3161,O
and,3161,O
provide,3161,O
an,3161,O
example,3161,O
of,3161,O
the,3161,O
utility,3161,O
of,3161,O
the,3161,O
SGLT1,3161,O
probe,3161,O
as,3161,O
a,3161,O
diagnostic,3161,O
for,3161,O
genetic,3161,B-DiseaseClass
diseases,3161,I-DiseaseClass
associated,3161,O
with,3161,O
translocations,3161,O
of,3161,O
chromosome,3161,O
22,3161,O
.,3161,O
Restriction,3162,O
of,3162,O
ocular,3162,O
fundus,3162,O
lesions,3162,O
to,3162,O
a,3162,O
specific,3162,O
subgroup,3162,O
of,3162,O
APC,3162,B-Modifier
mutations,3162,O
in,3162,O
adenomatous,3162,B-Modifier
polyposis,3162,I-Modifier
coli,3162,I-Modifier
patients,3162,O
.,3162,O
In,3163,O
humans,3163,O
",",3163,O
alteration,3163,O
of,3163,O
the,3163,O
tumor,3163,B-Modifier
suppressor,3163,O
gene,3163,O
",",3163,O
APC,3163,B-Modifier
",",3163,O
causes,3163,O
adenomatous,3163,B-SpecificDisease
polyposis,3163,I-SpecificDisease
coli,3163,I-SpecificDisease
",",3163,O
a,3163,O
condition,3163,O
causing,3163,O
predisposition,3163,O
to,3163,O
colorectal,3163,B-SpecificDisease
cancer,3163,I-SpecificDisease
.,3163,O
The,3164,O
syndrome,3164,O
inconsistently,3164,O
associates,3164,O
characteristic,3164,O
patches,3164,O
of,3164,O
congenital,3164,B-SpecificDisease
hypertrophy,3164,I-SpecificDisease
of,3164,I-SpecificDisease
the,3164,I-SpecificDisease
retinal,3164,I-SpecificDisease
pigment,3164,I-SpecificDisease
epithelium,3164,I-SpecificDisease
(,3164,O
CHRPE,3164,B-SpecificDisease
),3164,O
.,3164,O
Ocular,3165,O
examination,3165,O
revealed,3165,O
that,3165,O
patients,3165,O
expressing,3165,O
CHRPE,3165,B-SpecificDisease
tend,3165,O
to,3165,O
cluster,3165,O
within,3165,O
specific,3165,O
families,3165,O
.,3165,O
The,3166,O
exact,3166,O
APC,3166,B-Modifier
mutation,3166,O
was,3166,O
identified,3166,O
in,3166,O
42,3166,O
unrelated,3166,O
patients,3166,O
.,3166,O
In,3167,O
all,3167,O
cases,3167,O
these,3167,O
mutations,3167,O
were,3167,O
predicted,3167,O
to,3167,O
lead,3167,O
to,3167,O
the,3167,O
synthesis,3167,O
of,3167,O
a,3167,O
truncated,3167,O
protein,3167,O
.,3167,O
The,3168,O
extent,3168,O
of,3168,O
CHRPE,3168,B-SpecificDisease
was,3168,O
found,3168,O
to,3168,O
be,3168,O
dependent,3168,O
on,3168,O
the,3168,O
position,3168,O
of,3168,O
the,3168,O
mutation,3168,O
along,3168,O
the,3168,O
coding,3168,O
sequence,3168,O
.,3168,O
CHRPE,3169,B-Modifier
lesions,3169,O
are,3169,O
almost,3169,O
always,3169,O
absent,3169,O
if,3169,O
the,3169,O
mutation,3169,O
occurs,3169,O
before,3169,O
exon,3169,O
9,3169,O
",",3169,O
but,3169,O
are,3169,O
systematically,3169,O
present,3169,O
if,3169,O
it,3169,O
occurs,3169,O
after,3169,O
this,3169,O
exon,3169,O
.,3169,O
Thus,3170,O
",",3170,O
the,3170,O
range,3170,O
of,3170,O
phenotypic,3170,O
expression,3170,O
observed,3170,O
among,3170,O
affected,3170,O
patients,3170,O
may,3170,O
result,3170,O
in,3170,O
part,3170,O
from,3170,O
different,3170,O
allelic,3170,O
manifestations,3170,O
of,3170,O
APC,3170,B-Modifier
mutations,3170,O
..,3170,O
The,3171,O
effects,3171,O
of,3171,O
dystrophin,3171,O
gene,3171,O
mutations,3171,O
on,3171,O
the,3171,O
ERG,3171,O
in,3171,O
mice,3171,O
and,3171,O
humans,3171,O
.,3171,O
PURPOSE,3172,O
.,3172,O
The,3173,O
authors,3173,O
earlier,3173,O
findings,3173,O
of,3173,O
a,3173,O
negative,3173,O
electroretinogram,3173,O
(,3173,O
ERG,3173,O
),3173,O
in,3173,O
a,3173,O
boy,3173,O
with,3173,O
Duchenne,3173,B-SpecificDisease
muscular,3173,I-SpecificDisease
dystrophy,3173,I-SpecificDisease
(,3173,O
DMD,3173,B-SpecificDisease
),3173,O
led,3173,O
them,3173,O
to,3173,O
investigate,3173,O
dystrophin,3173,O
gene,3173,O
deletions,3173,O
and,3173,O
ERGs,3173,O
in,3173,O
five,3173,O
boys,3173,O
with,3173,O
DMD,3173,B-SpecificDisease
.,3173,O
The,3174,O
authors,3174,O
wanted,3174,O
to,3174,O
determined,3174,O
whether,3174,O
there,3174,O
were,3174,O
similar,3174,O
ERG,3174,O
findings,3174,O
in,3174,O
an,3174,O
animal,3174,O
model,3174,O
for,3174,O
DMD,3174,B-SpecificDisease
",",3174,O
the,3174,O
mdx,3174,O
mouse,3174,O
.,3174,O
METHODS,3175,O
.,3175,O
Ganzfeld,3176,O
ERGs,3176,O
were,3176,O
recorded,3176,O
in,3176,O
five,3176,O
boys,3176,O
with,3176,O
DMD,3176,B-SpecificDisease
after,3176,O
a,3176,O
complete,3176,O
ophthalmic,3176,O
examination,3176,O
.,3176,O
The,3177,O
dystrophin,3177,O
gene,3177,O
was,3177,O
analyzed,3177,O
by,3177,O
Southern,3177,O
blot,3177,O
hybridization,3177,O
.,3177,O
ERGs,3178,O
were,3178,O
recorded,3178,O
in,3178,O
anesthetized,3178,O
mdx,3178,O
and,3178,O
control,3178,O
mice,3178,O
with,3178,O
a,3178,O
modified,3178,O
Grass,3178,O
photostimulator,3178,O
(,3178,O
Grass,3178,O
Instrument,3178,O
Company,3178,O
",",3178,O
Quincy,3178,O
",",3178,O
MA,3178,O
),3178,O
.,3178,O
RESULTS,3179,O
.,3179,O
Ophthalmic,3180,O
examinations,3180,O
in,3180,O
all,3180,O
five,3180,O
boys,3180,O
had,3180,O
normal,3180,O
findings,3180,O
",",3180,O
yet,3180,O
an,3180,O
abnormal,3180,O
negative,3180,O
ERG,3180,O
was,3180,O
recorded,3180,O
for,3180,O
each,3180,O
subject,3180,O
.,3180,O
The,3181,O
subjects,3181,O
gene,3181,O
deletions,3181,O
were,3181,O
variable,3181,O
",",3181,O
ranging,3181,O
from,3181,O
large,3181,O
deletions,3181,O
to,3181,O
no,3181,O
detectable,3181,O
deletions,3181,O
.,3181,O
The,3182,O
ERGs,3182,O
of,3182,O
the,3182,O
mdx,3182,O
mice,3182,O
were,3182,O
normal,3182,O
and,3182,O
did,3182,O
not,3182,O
differ,3182,O
significantly,3182,O
from,3182,O
those,3182,O
of,3182,O
the,3182,O
control,3182,O
mice,3182,O
.,3182,O
CONCLUSIONS,3183,O
.,3183,O
The,3184,O
authors,3184,O
believe,3184,O
the,3184,O
unique,3184,O
ERG,3184,O
recorded,3184,O
for,3184,O
the,3184,O
human,3184,O
subjects,3184,O
is,3184,O
a,3184,O
manifestation,3184,O
of,3184,O
DMD,3184,B-SpecificDisease
associated,3184,O
with,3184,O
defects,3184,O
at,3184,O
the,3184,O
dystrophin,3184,O
gene,3184,O
locus,3184,O
and,3184,O
represents,3184,O
a,3184,O
new,3184,O
clinical,3184,O
entity,3184,O
.,3184,O
The,3185,O
ERG,3185,O
of,3185,O
the,3185,O
mdx,3185,O
mouse,3185,O
may,3185,O
be,3185,O
spared,3185,O
for,3185,O
several,3185,O
reasons,3185,O
",",3185,O
including,3185,O
milder,3185,O
effects,3185,O
of,3185,O
the,3185,O
mouse,3185,O
gene,3185,O
defect,3185,O
",",3185,O
differences,3185,O
in,3185,O
muscle,3185,O
and,3185,O
retinal,3185,O
gene,3185,O
product,3185,O
",",3185,O
or,3185,O
species,3185,O
differences,3185,O
in,3185,O
the,3185,O
biochemical,3185,O
role,3185,O
of,3185,O
dystrophin,3185,O
.,3185,O
The,3186,O
ERG,3186,O
shows,3186,O
promise,3186,O
of,3186,O
becoming,3186,O
a,3186,O
noninvasive,3186,O
diagnostic,3186,O
tool,3186,O
for,3186,O
DMD,3186,B-SpecificDisease
and,3186,O
its,3186,O
milder,3186,O
allelic,3186,O
forms,3186,O
..,3186,O
Association,3187,O
of,3187,O
the,3187,O
APC,3187,B-Modifier
tumor,3187,I-Modifier
suppressor,3187,O
protein,3187,O
with,3187,O
catenins,3187,O
.,3187,O
Mutations,3188,O
of,3188,O
APC,3188,O
appear,3188,O
to,3188,O
initiate,3188,O
sporadic,3188,O
and,3188,O
inherited,3188,O
forms,3188,O
of,3188,O
human,3188,O
colorectal,3188,B-SpecificDisease
cancer,3188,I-SpecificDisease
.,3188,O
Although,3189,O
these,3189,O
mutations,3189,O
have,3189,O
been,3189,O
well,3189,O
characterized,3189,O
",",3189,O
little,3189,O
is,3189,O
known,3189,O
about,3189,O
the,3189,O
function,3189,O
of,3189,O
the,3189,O
APC,3189,B-Modifier
gene,3189,O
product,3189,O
.,3189,O
Two,3190,O
cellular,3190,O
proteins,3190,O
that,3190,O
associate,3190,O
with,3190,O
APC,3190,B-SpecificDisease
were,3190,O
identified,3190,O
by,3190,O
nucleotide,3190,O
sequence,3190,O
analysis,3190,O
and,3190,O
peptide,3190,O
mapping,3190,O
as,3190,O
the,3190,O
E-cadherin-associated,3190,O
proteins,3190,O
alpha-,3190,O
and,3190,O
beta-catenin,3190,O
.,3190,O
A,3191,O
27-residue,3191,O
fragment,3191,O
of,3191,O
APC,3191,O
containing,3191,O
a,3191,O
15-amino,3191,O
acid,3191,O
repeat,3191,O
was,3191,O
sufficient,3191,O
for,3191,O
the,3191,O
interaction,3191,O
with,3191,O
the,3191,O
catenins,3191,O
.,3191,O
These,3192,O
results,3192,O
suggest,3192,O
an,3192,O
important,3192,O
link,3192,O
between,3192,O
tumor,3192,B-Modifier
initiation,3192,O
and,3192,O
cell,3192,O
adhesion,3192,O
..,3192,O
Difference,3193,O
in,3193,O
methylation,3193,O
patterns,3193,O
within,3193,O
the,3193,O
D15S9,3193,O
region,3193,O
of,3193,O
chromosome,3193,O
15q11-13,3193,O
in,3193,O
first,3193,O
cousins,3193,O
with,3193,O
Angelman,3193,B-SpecificDisease
syndrome,3193,I-SpecificDisease
and,3193,O
Prader-Willi,3193,B-SpecificDisease
syndrome,3193,I-SpecificDisease
.,3193,O
Abnormalities,3194,O
of,3194,O
chromosome,3194,O
region,3194,O
15q11-13,3194,O
are,3194,O
associated,3194,O
with,3194,O
Angelman,3194,B-SpecificDisease
syndrome,3194,I-SpecificDisease
(,3194,O
AS,3194,B-SpecificDisease
),3194,O
and,3194,O
Prader-Willi,3194,B-SpecificDisease
syndrome,3194,I-SpecificDisease
(,3194,O
PWS,3194,B-SpecificDisease
),3194,O
.,3194,O
Differences,3195,O
between,3195,O
the,3195,O
methylation,3195,O
patterns,3195,O
of,3195,O
the,3195,O
region,3195,O
of,3195,O
chromosome,3195,O
15q11-13,3195,O
which,3195,O
hybridizes,3195,O
to,3195,O
the,3195,O
highly,3195,O
conserved,3195,O
DNA,3195,O
",",3195,O
DN34,3195,O
",",3195,O
in,3195,O
normal,3195,O
individuals,3195,O
and,3195,O
in,3195,O
patients,3195,O
with,3195,O
AS,3195,B-SpecificDisease
and,3195,O
PWS,3195,B-SpecificDisease
have,3195,O
been,3195,O
described,3195,O
.,3195,O
We,3196,O
report,3196,O
on,3196,O
a,3196,O
family,3196,O
in,3196,O
which,3196,O
first,3196,O
cousins,3196,O
are,3196,O
affected,3196,O
by,3196,O
AS,3196,B-SpecificDisease
and,3196,O
PWS,3196,B-SpecificDisease
as,3196,O
a,3196,O
result,3196,O
of,3196,O
a,3196,O
familial,3196,O
paracentric,3196,O
inversion,3196,O
of,3196,O
15q11-q13,3196,O
.,3196,O
The,3197,O
results,3197,O
of,3197,O
the,3197,O
studies,3197,O
on,3197,O
this,3197,O
family,3197,O
demonstrate,3197,O
the,3197,O
differences,3197,O
in,3197,O
the,3197,O
methylation,3197,O
patterns,3197,O
in,3197,O
the,3197,O
2,3197,O
conditions,3197,O
and,3197,O
the,3197,O
phenomenon,3197,O
of,3197,O
genomic,3197,O
imprinting,3197,O
",",3197,O
whereby,3197,O
genetic,3197,O
information,3197,O
is,3197,O
expressed,3197,O
differently,3197,O
dependent,3197,O
on,3197,O
the,3197,O
parent,3197,O
of,3197,O
origin,3197,O
..,3197,O
Haplotype,3198,O
studies,3198,O
in,3198,O
Wilson,3198,B-SpecificDisease
disease,3198,I-SpecificDisease
.,3198,O
In,3199,O
51,3199,O
families,3199,O
with,3199,O
Wilson,3199,B-SpecificDisease
disease,3199,I-SpecificDisease
",",3199,O
we,3199,O
have,3199,O
studied,3199,O
DNA,3199,O
haplotypes,3199,O
of,3199,O
dinucleotide,3199,O
repeat,3199,O
polymorphisms,3199,O
(,3199,O
CA,3199,O
repeats,3199,O
),3199,O
in,3199,O
the,3199,O
13q14,3199,O
.,3199,O
3,3200,O
region,3200,O
",",3200,O
to,3200,O
examine,3200,O
these,3200,O
markers,3200,O
for,3200,O
association,3200,O
with,3200,O
the,3200,O
Wilson,3200,B-Modifier
disease,3200,I-Modifier
gene,3200,O
(,3200,O
WND,3200,B-SpecificDisease
),3200,O
.,3200,O
In,3201,O
addition,3201,O
to,3201,O
a,3201,O
marker,3201,O
(,3201,O
D13S133,3201,O
),3201,O
described,3201,O
elsewhere,3201,O
",",3201,O
we,3201,O
have,3201,O
developed,3201,O
three,3201,O
new,3201,O
highly,3201,O
polymorphic,3201,O
markers,3201,O
(,3201,O
D13S314,3201,O
",",3201,O
D13S315,3201,O
",",3201,O
and,3201,O
D13S316,3201,O
),3201,O
close,3201,O
to,3201,O
the,3201,O
WND,3201,B-SpecificDisease
locus,3201,O
.,3201,O
We,3202,O
have,3202,O
examined,3202,O
the,3202,O
distribution,3202,O
of,3202,O
marker,3202,O
alleles,3202,O
at,3202,O
the,3202,O
loci,3202,O
studied,3202,O
and,3202,O
have,3202,O
found,3202,O
that,3202,O
D13S314,3202,O
",",3202,O
D13S133,3202,O
",",3202,O
and,3202,O
D13S316,3202,O
each,3202,O
show,3202,O
nonrandom,3202,O
distribution,3202,O
on,3202,O
chromosomes,3202,O
carrying,3202,O
the,3202,O
WND,3202,B-SpecificDisease
mutation,3202,O
.,3202,O
We,3203,O
have,3203,O
studied,3203,O
haplotypes,3203,O
of,3203,O
these,3203,O
three,3203,O
markers,3203,O
and,3203,O
have,3203,O
found,3203,O
that,3203,O
there,3203,O
are,3203,O
highly,3203,O
significant,3203,O
differences,3203,O
between,3203,O
WND,3203,B-SpecificDisease
and,3203,O
normal,3203,O
haplotypes,3203,O
in,3203,O
northern,3203,O
European,3203,O
families,3203,O
.,3203,O
These,3204,O
findings,3204,O
have,3204,O
important,3204,O
implications,3204,O
for,3204,O
mutation,3204,O
detection,3204,O
and,3204,O
molecular,3204,O
diagnosis,3204,O
in,3204,O
families,3204,O
with,3204,O
Wilson,3204,B-SpecificDisease
disease,3204,I-SpecificDisease
.,3204,O
Genetic,3205,O
analysis,3205,O
of,3205,O
the,3205,O
BRCA1,3205,O
region,3205,O
in,3205,O
a,3205,O
large,3205,O
breast/ovarian,3205,O
family,3205,O
:,3205,O
refinement,3205,O
of,3205,O
the,3205,O
minimal,3205,O
region,3205,O
containing,3205,O
BRCA1,3205,O
.,3205,O
We,3206,O
have,3206,O
analyzed,3206,O
a,3206,O
single,3206,O
multi-affected,3206,O
breast/ovarian,3206,B-Modifier
cancer,3206,I-Modifier
pedigree,3206,O
(,3206,O
BOV3,3206,O
),3206,O
and,3206,O
have,3206,O
shown,3206,O
consistent,3206,O
inheritance,3206,O
of,3206,O
markers,3206,O
on,3206,O
chromosome,3206,O
17q,3206,O
with,3206,O
the,3206,O
disease,3206,O
confirming,3206,O
that,3206,O
this,3206,O
family,3206,O
is,3206,O
due,3206,O
to,3206,O
the,3206,O
BRCA1,3206,O
gene,3206,O
.,3206,O
Analysis,3207,O
of,3207,O
17q,3207,O
haplotypes,3207,O
shows,3207,O
a,3207,O
recombination,3207,O
event,3207,O
in,3207,O
a,3207,O
bilateral,3207,O
breast,3207,B-Modifier
cancer,3207,I-Modifier
case,3207,O
which,3207,O
suggests,3207,O
that,3207,O
the,3207,O
BRCA1,3207,O
gene,3207,O
lies,3207,O
distal,3207,O
to,3207,O
D17S857,3207,O
;,3207,O
D17S857,3207,O
is,3207,O
thus,3207,O
the,3207,O
new,3207,O
proximal,3207,O
boundary,3207,O
for,3207,O
the,3207,O
region,3207,O
containing,3207,O
BRCA1,3207,O
.,3207,O
Combining,3208,O
this,3208,O
information,3208,O
with,3208,O
previously,3208,O
published,3208,O
mapping,3208,O
information,3208,O
suggests,3208,O
that,3208,O
BRCA1,3208,O
is,3208,O
contained,3208,O
in,3208,O
a,3208,O
region,3208,O
estimated,3208,O
at,3208,O
1-1,3208,O
.,3208,O
5,3209,O
Mb,3209,O
in,3209,O
length,3209,O
.,3209,O
All,3210,O
seven,3210,O
breast,3210,B-Modifier
tumour/blood,3210,O
pairs,3210,O
examined,3210,O
from,3210,O
this,3210,O
family,3210,O
show,3210,O
loss,3210,O
of,3210,O
heterozygosity,3210,O
in,3210,O
the,3210,O
tumours,3210,B-DiseaseClass
.,3210,O
The,3211,O
allel,3211,O
retained,3211,O
in,3211,O
each,3211,O
tumour,3211,B-DiseaseClass
was,3211,O
from,3211,O
the,3211,O
disease-bearing,3211,O
chromosome,3211,O
implicating,3211,O
BRCA1,3211,O
as,3211,O
a,3211,O
tumour,3211,B-Modifier
suppressor,3211,O
gene,3211,O
.,3211,O
We,3212,O
have,3212,O
sequenced,3212,O
the,3212,O
17,3212,O
beta-oestradiol,3212,O
dehydrogenase,3212,O
genes,3212,O
(,3212,O
EDH17B1,3212,O
and,3212,O
EDH17B2,3212,O
),3212,O
which,3212,O
have,3212,O
been,3212,O
suggested,3212,O
as,3212,O
candidate,3212,O
genes,3212,O
for,3212,O
BRCA1,3212,O
in,3212,O
four,3212,O
members,3212,O
of,3212,O
this,3212,O
family,3212,O
.,3212,O
No,3213,O
germline,3213,O
mutations,3213,O
were,3213,O
detected,3213,O
.,3213,O
Myotonic,3214,B-Modifier
dystrophy,3214,I-Modifier
kinase,3214,O
is,3214,O
a,3214,O
component,3214,O
of,3214,O
neuromuscular,3214,O
junctions,3214,O
.,3214,O
The,3215,O
clinical,3215,O
manifestation,3215,O
of,3215,O
myotonic,3215,B-SpecificDisease
dystrophy,3215,I-SpecificDisease
(,3215,O
DM,3215,B-SpecificDisease
),3215,O
is,3215,O
correlated,3215,O
to,3215,O
the,3215,O
extent,3215,O
of,3215,O
expansion,3215,O
of,3215,O
an,3215,O
unstable,3215,O
[,3215,O
CTG,3215,O
],3215,O
n,3215,O
DNA,3215,O
motif,3215,O
.,3215,O
Recent,3216,O
studies,3216,O
have,3216,O
demonstrated,3216,O
that,3216,O
this,3216,O
trinucleotide,3216,O
motif,3216,O
forms,3216,O
part,3216,O
of,3216,O
the,3216,O
last,3216,O
",",3216,O
3,3216,O
untranslated,3216,O
exon,3216,O
of,3216,O
a,3216,O
gene,3216,O
which,3216,O
potentially,3216,O
encodes,3216,O
multiple,3216,O
protein,3216,O
isoforms,3216,O
of,3216,O
a,3216,O
serine/threonine,3216,O
protein,3216,O
kinase,3216,O
(,3216,O
myotonic,3216,B-Modifier
dystrophy,3216,I-Modifier
protein,3216,O
kinase,3216,O
",",3216,O
DM-PK,3216,O
),3216,O
.,3216,O
We,3217,O
report,3217,O
here,3217,O
on,3217,O
the,3217,O
development,3217,O
of,3217,O
antisera,3217,O
against,3217,O
synthetic,3217,O
DM-PK,3217,O
peptide,3217,O
antigens,3217,O
and,3217,O
their,3217,O
use,3217,O
in,3217,O
biochemical,3217,O
and,3217,O
histochemical,3217,O
studies,3217,O
.,3217,O
Immunoreactive,3218,O
DM-kinase,3218,O
protein,3218,O
of,3218,O
53,3218,O
kD,3218,O
is,3218,O
present,3218,O
at,3218,O
low,3218,O
levels,3218,O
in,3218,O
skeletal,3218,O
and,3218,O
cardiac,3218,O
muscle,3218,O
extracts,3218,O
of,3218,O
DM,3218,B-Modifier
patients,3218,O
and,3218,O
normal,3218,O
controls,3218,O
.,3218,O
Immunohistochemical,3219,O
staining,3219,O
revealed,3219,O
that,3219,O
DM-PK,3219,O
is,3219,O
localised,3219,O
prominently,3219,O
at,3219,O
sites,3219,O
of,3219,O
neuromuscular,3219,O
and,3219,O
myotendinous,3219,O
junctions,3219,O
(,3219,O
NMJs,3219,O
and,3219,O
MTJs,3219,O
),3219,O
of,3219,O
human,3219,O
and,3219,O
rodent,3219,O
skeletal,3219,O
muscles,3219,O
.,3219,O
Furthermore,3220,O
",",3220,O
very,3220,O
low,3220,O
levels,3220,O
of,3220,O
immunoreactive,3220,O
DM-PK,3220,O
protein,3220,O
are,3220,O
present,3220,O
in,3220,O
the,3220,O
sarcoplasm,3220,O
of,3220,O
predominantly,3220,O
type,3220,O
I,3220,O
fibres,3220,O
in,3220,O
various,3220,O
muscles,3220,O
.,3220,O
Strikingly,3221,O
",",3221,O
presence,3221,O
of,3221,O
the,3221,O
protein,3221,O
can,3221,O
also,3221,O
be,3221,O
demonstrated,3221,O
for,3221,O
NMJs,3221,O
of,3221,O
muscular,3221,O
tissues,3221,O
of,3221,O
adult,3221,O
and,3221,O
congenital,3221,O
cases,3221,O
of,3221,O
DM,3221,B-SpecificDisease
",",3221,O
with,3221,O
no,3221,O
gross,3221,O
changes,3221,O
in,3221,O
structural,3221,O
organisation,3221,O
.,3221,O
Our,3222,O
findings,3222,O
provide,3222,O
a,3222,O
basis,3222,O
for,3222,O
further,3222,O
characterisation,3222,O
of,3222,O
the,3222,O
role,3222,O
of,3222,O
the,3222,O
kinase,3222,O
in,3222,O
protein,3222,O
assembly,3222,O
processes,3222,O
or,3222,O
signal,3222,O
mediation,3222,O
at,3222,O
synaptic,3222,O
sites,3222,O
and,3222,O
ultimately,3222,O
for,3222,O
the,3222,O
understanding,3222,O
of,3222,O
the,3222,O
complex,3222,O
pathophysiology,3222,O
of,3222,O
DM,3222,B-SpecificDisease
..,3222,O
Markedly,3223,O
accelerated,3223,O
catabolism,3223,O
of,3223,O
apolipoprotein,3223,O
A-II,3223,O
(,3223,O
ApoA-II,3223,O
),3223,O
and,3223,O
high,3223,O
density,3223,O
lipoproteins,3223,O
containing,3223,O
ApoA-II,3223,O
in,3223,O
classic,3223,O
lecithin,3223,O
:,3223,O
cholesterol,3223,B-SpecificDisease
acyltransferase,3223,I-SpecificDisease
deficiency,3223,I-SpecificDisease
and,3223,O
fish-eye,3223,B-SpecificDisease
disease,3223,I-SpecificDisease
.,3223,O
Classic,3224,B-CompositeMention
(,3224,I-CompositeMention
complete,3224,I-CompositeMention
),3224,I-CompositeMention
lecithin,3224,I-CompositeMention
cholesterol,3224,I-CompositeMention
acyltransferase,3224,I-CompositeMention
(,3224,I-CompositeMention
LCAT,3224,I-CompositeMention
),3224,I-CompositeMention
deficiency,3224,I-CompositeMention
and,3224,O
Fish-eye,3224,B-SpecificDisease
disease,3224,I-SpecificDisease
(,3224,O
partial,3224,B-SpecificDisease
LCAT,3224,I-SpecificDisease
deficiency,3224,I-SpecificDisease
),3224,O
are,3224,O
genetic,3224,O
syndromes,3224,O
associated,3224,O
with,3224,O
markedly,3224,O
decreased,3224,O
plasma,3224,O
levels,3224,O
of,3224,O
high,3224,O
density,3224,O
lipoprotein,3224,O
(,3224,O
HDL,3224,O
),3224,O
cholesterol,3224,O
but,3224,O
not,3224,O
with,3224,O
an,3224,O
increased,3224,O
risk,3224,O
of,3224,O
atherosclerotic,3224,B-SpecificDisease
cardiovascular,3224,I-SpecificDisease
disease,3224,I-SpecificDisease
.,3224,O
We,3225,O
investigated,3225,O
the,3225,O
metabolism,3225,O
of,3225,O
the,3225,O
HDL,3225,O
apolipoproteins,3225,O
(,3225,O
apo,3225,O
),3225,O
apoA-I,3225,O
and,3225,O
apoA-II,3225,O
in,3225,O
a,3225,O
total,3225,O
of,3225,O
five,3225,O
patients,3225,O
with,3225,O
LCAT,3225,B-SpecificDisease
deficiency,3225,I-SpecificDisease
",",3225,O
one,3225,O
with,3225,O
classic,3225,B-SpecificDisease
LCAT,3225,I-SpecificDisease
deficiency,3225,I-SpecificDisease
and,3225,O
four,3225,O
with,3225,O
Fish-eye,3225,B-SpecificDisease
disease,3225,I-SpecificDisease
.,3225,O
Plasma,3226,O
levels,3226,O
of,3226,O
apoA-II,3226,O
were,3226,O
decreased,3226,O
to,3226,O
a,3226,O
proportionately,3226,O
greater,3226,O
extent,3226,O
(,3226,O
23,3226,O
%,3226,O
of,3226,O
normal,3226,O
),3226,O
than,3226,O
apoA-I,3226,O
(,3226,O
30,3226,O
%,3226,O
of,3226,O
normal,3226,O
),3226,O
.,3226,O
In,3227,O
addition,3227,O
",",3227,O
plasma,3227,O
concentrations,3227,O
of,3227,O
HDL,3227,O
particles,3227,O
containing,3227,O
both,3227,O
apoA-I,3227,O
and,3227,O
apoA-II,3227,O
(,3227,O
LpA-I,3227,O
A-II,3227,O
),3227,O
were,3227,O
much,3227,O
lower,3227,O
(,3227,O
18,3227,O
%,3227,O
of,3227,O
normal,3227,O
),3227,O
than,3227,O
those,3227,O
of,3227,O
particles,3227,O
containing,3227,O
only,3227,O
apoA-I,3227,O
(,3227,O
LpA-I,3227,O
),3227,O
(,3227,O
51,3227,O
%,3227,O
of,3227,O
normal,3227,O
),3227,O
.,3227,O
The,3228,O
metabolic,3228,O
basis,3228,O
for,3228,O
the,3228,O
low,3228,O
levels,3228,O
of,3228,O
apoA-II,3228,O
and,3228,O
LpA-I,3228,O
A-II,3228,O
was,3228,O
investigated,3228,O
in,3228,O
all,3228,O
five,3228,O
patients,3228,O
using,3228,O
both,3228,O
exogenous,3228,O
radiotracer,3228,O
and,3228,O
endogenous,3228,O
stable,3228,O
isotope,3228,O
labeling,3228,O
techniques,3228,O
.,3228,O
The,3229,O
mean,3229,O
plasma,3229,O
residence,3229,O
time,3229,O
of,3229,O
apoA-I,3229,O
was,3229,O
decreased,3229,O
at,3229,O
2,3229,O
.,3229,O
08,3230,O
+/-,3230,O
0,3230,O
.,3230,O
27,3231,O
d,3231,O
(,3231,O
controls,3231,O
4,3231,O
.,3231,O
74,3232,O
+/-,3232,O
0,3232,O
.,3232,O
65,3233,O
days,3233,O
),3233,O
;,3233,O
however,3233,O
",",3233,O
the,3233,O
residence,3233,O
time,3233,O
of,3233,O
apoA-II,3233,O
was,3233,O
even,3233,O
shorter,3233,O
at,3233,O
1,3233,O
.,3233,O
66,3234,O
+/-,3234,O
0,3234,O
.,3234,O
24,3235,O
d,3235,O
(,3235,O
controls,3235,O
5,3235,O
.,3235,O
25,3236,O
+/-,3236,O
0,3236,O
.,3236,O
61,3237,O
d,3237,O
),3237,O
.,3237,O
In,3238,O
addition,3238,O
",",3238,O
the,3238,O
catabolism,3238,O
of,3238,O
apoA-I,3238,O
in,3238,O
LpA-I,3238,O
A-II,3238,O
was,3238,O
substantially,3238,O
faster,3238,O
than,3238,O
that,3238,O
of,3238,O
apoA-I,3238,O
in,3238,O
LpA-I,3238,O
.,3238,O
In,3239,O
summary,3239,O
",",3239,O
genetic,3239,O
syndromes,3239,O
of,3239,O
either,3239,O
complete,3239,B-CompositeMention
or,3239,I-CompositeMention
partial,3239,I-CompositeMention
LCAT,3239,I-CompositeMention
deficiency,3239,I-CompositeMention
result,3239,O
in,3239,O
low,3239,O
levels,3239,O
of,3239,O
HDL,3239,O
through,3239,O
preferential,3239,O
hypercatabolism,3239,O
of,3239,O
apoA-II,3239,O
and,3239,O
HDL,3239,O
particles,3239,O
containing,3239,O
apoA-II,3239,O
.,3239,O
Because,3240,O
LpA-I,3240,O
has,3240,O
been,3240,O
proposed,3240,O
to,3240,O
be,3240,O
more,3240,O
protective,3240,O
than,3240,O
LpA-I,3240,O
A-II,3240,O
against,3240,O
atherosclerosis,3240,B-SpecificDisease
",",3240,O
this,3240,O
selective,3240,O
effect,3240,O
on,3240,O
the,3240,O
metabolism,3240,O
of,3240,O
LpA-I,3240,O
A-II,3240,O
may,3240,O
provide,3240,O
a,3240,O
potential,3240,O
explanation,3240,O
why,3240,O
patients,3240,O
with,3240,O
classic,3240,B-SpecificDisease
LCAT,3240,I-SpecificDisease
deficiency,3240,I-SpecificDisease
and,3240,O
Fish-eye,3240,B-SpecificDisease
disease,3240,I-SpecificDisease
are,3240,O
not,3240,O
at,3240,O
increased,3240,O
risk,3240,O
for,3240,O
premature,3240,O
atherosclerosis,3240,B-SpecificDisease
despite,3240,O
markedly,3240,O
decreased,3240,O
levels,3240,O
of,3240,O
HDL,3240,O
cholesterol,3240,O
and,3240,O
apoA-I,3240,O
X,3241,B-SpecificDisease
linked,3241,I-SpecificDisease
recessive,3241,I-SpecificDisease
thrombocytopenia,3241,I-SpecificDisease
.,3241,O
A,3242,O
Saudi,3242,O
Arab,3242,O
boy,3242,O
presented,3242,O
in,3242,O
early,3242,O
childhood,3242,O
with,3242,O
thrombocytopenia,3242,B-SpecificDisease
",",3242,O
morphologically,3242,O
large,3242,O
and,3242,O
normal,3242,O
sized,3242,O
platelets,3242,O
",",3242,O
increased,3242,O
mean,3242,O
platelet,3242,O
volume,3242,O
",",3242,O
and,3242,O
a,3242,O
hypermegakaryocytic,3242,O
bone,3242,O
marrow,3242,O
.,3242,O
There,3243,O
was,3243,O
no,3243,O
clinical,3243,O
and,3243,O
laboratory,3243,O
evidence,3243,O
of,3243,O
any,3243,O
significant,3243,O
immunological,3243,B-DiseaseClass
abnormalities,3243,I-DiseaseClass
.,3243,O
Similar,3244,O
findings,3244,O
in,3244,O
two,3244,O
other,3244,O
brothers,3244,O
suggested,3244,O
strongly,3244,O
that,3244,O
they,3244,O
were,3244,O
all,3244,O
suffering,3244,O
from,3244,O
an,3244,O
X,3244,B-SpecificDisease
linked,3244,I-SpecificDisease
recessive,3244,I-SpecificDisease
thrombocytopenic,3244,I-SpecificDisease
disorder,3244,I-SpecificDisease
.,3244,O
Results,3245,O
of,3245,O
DNA,3245,O
analysis,3245,O
with,3245,O
the,3245,O
probe,3245,O
M27,3245,O
beta,3245,O
are,3245,O
consistent,3245,O
with,3245,O
X,3245,O
linkage,3245,O
and,3245,O
indicate,3245,O
also,3245,O
that,3245,O
the,3245,O
locus,3245,O
of,3245,O
the,3245,O
relevant,3245,O
gene,3245,O
lies,3245,O
close,3245,O
to,3245,O
or,3245,O
is,3245,O
identical,3245,O
to,3245,O
the,3245,O
locus,3245,O
of,3245,O
the,3245,O
gene,3245,O
for,3245,O
the,3245,O
Wiskott-Aldrich,3245,B-SpecificDisease
syndrome,3245,I-SpecificDisease
(,3245,O
WAS,3245,B-SpecificDisease
),3245,O
.,3245,O
Because,3246,O
of,3246,O
various,3246,O
features,3246,O
which,3246,O
include,3246,O
the,3246,O
presence,3246,O
of,3246,O
large,3246,O
and,3246,O
normal,3246,O
sized,3246,O
platelets,3246,O
(,3246,O
rather,3246,O
than,3246,O
small,3246,O
platelets,3246,O
),3246,O
and,3246,O
freedom,3246,O
from,3246,O
significant,3246,O
immune,3246,B-DiseaseClass
deficiencies,3246,I-DiseaseClass
",",3246,O
it,3246,O
is,3246,O
likely,3246,O
that,3246,O
the,3246,O
X,3246,B-SpecificDisease
linked,3246,I-SpecificDisease
recessive,3246,I-SpecificDisease
thrombocytopenia,3246,I-SpecificDisease
in,3246,O
this,3246,O
family,3246,O
is,3246,O
an,3246,O
isolated,3246,O
entity,3246,O
quite,3246,O
distinct,3246,O
from,3246,O
the,3246,O
classical,3246,O
WAS,3246,B-Modifier
phenotype,3246,O
.,3246,O
However,3247,O
",",3247,O
a,3247,O
modified,3247,O
expression,3247,O
of,3247,O
the,3247,O
WAS,3247,B-Modifier
gene,3247,O
producing,3247,O
a,3247,O
mild,3247,O
phenotypic,3247,O
variant,3247,O
can,3247,O
not,3247,O
be,3247,O
excluded,3247,O
entirely,3247,O
..,3247,O
Macular,3248,B-SpecificDisease
dystrophy,3248,I-SpecificDisease
associated,3248,O
with,3248,O
mutations,3248,O
at,3248,O
codon,3248,O
172,3248,O
in,3248,O
the,3248,O
human,3248,O
retinal,3248,B-Modifier
degeneration,3248,I-Modifier
slow,3248,O
gene,3248,O
.,3248,O
BACKGROUND,3249,O
Recently,3249,O
",",3249,O
mutations,3249,O
in,3249,O
the,3249,O
retinal,3249,B-Modifier
degeneration,3249,I-Modifier
slow,3249,O
(,3249,O
rds,3249,O
),3249,O
gene,3249,O
which,3249,O
codes,3249,O
for,3249,O
peripherin-rds,3249,O
have,3249,O
been,3249,O
implicated,3249,O
as,3249,O
a,3249,O
cause,3249,O
of,3249,O
autosomal,3249,B-SpecificDisease
dominant,3249,I-SpecificDisease
retinitis,3249,I-SpecificDisease
pigmentosa,3249,I-SpecificDisease
.,3249,O
Because,3250,O
this,3250,O
gene,3250,O
is,3250,O
expressed,3250,O
in,3250,O
both,3250,O
rods,3250,O
and,3250,O
cones,3250,O
",",3250,O
mutations,3250,O
in,3250,O
the,3250,O
rds,3250,O
gene,3250,O
might,3250,O
be,3250,O
expected,3250,O
to,3250,O
cause,3250,O
degeneration,3250,O
affecting,3250,O
either,3250,O
the,3250,O
scotopic,3250,O
or,3250,O
photopic,3250,O
systems,3250,O
.,3250,O
Mutations,3251,O
at,3251,O
codon,3251,O
172,3251,O
of,3251,O
the,3251,O
rds,3251,O
gene,3251,O
have,3251,O
been,3251,O
identified,3251,O
in,3251,O
three,3251,O
families,3251,O
with,3251,O
autosomal,3251,O
dominantly,3251,O
inherited,3251,O
",",3251,O
progressive,3251,O
macular,3251,B-SpecificDisease
dystrophy,3251,I-SpecificDisease
.,3251,O
METHODS,3252,O
Affected,3252,O
individuals,3252,O
underwent,3252,O
ophthalmic,3252,O
examination,3252,O
",",3252,O
scotopic,3252,O
perimetry,3252,O
",",3252,O
dark,3252,O
adaptometry,3252,O
",",3252,O
measurement,3252,O
of,3252,O
color-contrast,3252,O
sensitivity,3252,O
",",3252,O
and,3252,O
electroretinography,3252,O
to,3252,O
characterize,3252,O
the,3252,O
photoreceptor,3252,O
dysfunction,3252,O
.,3252,O
RESULTS,3253,O
In,3253,O
all,3253,O
but,3253,O
one,3253,O
affected,3253,O
member,3253,O
",",3253,O
symptoms,3253,O
of,3253,O
progressive,3253,O
central,3253,O
visual,3253,B-SpecificDisease
loss,3253,I-SpecificDisease
developed,3253,O
in,3253,O
the,3253,O
third,3253,O
or,3253,O
fourth,3253,O
decade,3253,O
of,3253,O
life,3253,O
accompanied,3253,O
by,3253,O
central,3253,B-SpecificDisease
scotoma,3253,I-SpecificDisease
and,3253,O
well-demarcated,3253,O
atrophy,3253,B-SpecificDisease
of,3253,I-SpecificDisease
the,3253,I-SpecificDisease
retinal,3253,I-SpecificDisease
pigment,3253,I-SpecificDisease
epithelium,3253,I-SpecificDisease
and,3253,O
choriocapillaris,3253,B-SpecificDisease
of,3253,I-SpecificDisease
the,3253,I-SpecificDisease
macula,3253,I-SpecificDisease
.,3253,O
In,3254,O
general,3254,O
",",3254,O
cone,3254,O
and,3254,O
rod,3254,O
thresholds,3254,O
were,3254,O
elevated,3254,O
",",3254,O
and,3254,O
color-contrast,3254,O
sensitivity,3254,O
was,3254,O
absent,3254,O
in,3254,O
the,3254,O
central,3254,O
visual,3254,O
field,3254,O
.,3254,O
Peripherally,3255,O
",",3255,O
the,3255,O
scotopic,3255,O
sensitivities,3255,O
were,3255,O
normal,3255,O
",",3255,O
as,3255,O
was,3255,O
the,3255,O
recovery,3255,O
from,3255,O
bleach,3255,O
.,3255,O
Cone,3256,O
electroretinograms,3256,O
were,3256,O
diminished,3256,O
in,3256,O
amplitude,3256,O
",",3256,O
and,3256,O
delayed,3256,O
in,3256,O
all,3256,O
affected,3256,O
adults,3256,O
except,3256,O
one,3256,O
.,3256,O
Rod,3257,O
electroretinograms,3257,O
were,3257,O
normal,3257,O
or,3257,O
near,3257,O
normal,3257,O
in,3257,O
amplitude,3257,O
",",3257,O
and,3257,O
had,3257,O
normal,3257,O
implicit,3257,O
times,3257,O
.,3257,O
Affected,3258,O
asymptomatic,3258,O
children,3258,O
had,3258,O
macular,3258,O
changes,3258,O
",",3258,O
abnormal,3258,O
color-contrast,3258,O
sensitivity,3258,O
",",3258,O
and,3258,O
reduced,3258,O
pattern,3258,O
and,3258,O
cone,3258,O
electroretinograms,3258,O
.,3258,O
CONCLUSION,3259,O
These,3259,O
results,3259,O
indicate,3259,O
that,3259,O
mutations,3259,O
in,3259,O
the,3259,O
rds,3259,O
gene,3259,O
can,3259,O
be,3259,O
expressed,3259,O
as,3259,O
a,3259,O
macular,3259,B-SpecificDisease
dystrophy,3259,I-SpecificDisease
",",3259,O
with,3259,O
evidence,3259,O
of,3259,O
primary,3259,O
cone,3259,B-DiseaseClass
dysfunction,3259,I-DiseaseClass
and,3259,O
preservation,3259,O
of,3259,O
peripheral,3259,O
rod,3259,O
function,3259,O
..,3259,O
Anonymous,3260,O
marker,3260,O
loci,3260,O
within,3260,O
400,3260,O
kb,3260,O
of,3260,O
HLA-A,3260,O
generate,3260,O
haplotypes,3260,O
in,3260,O
linkage,3260,O
disequilibrium,3260,O
with,3260,O
the,3260,O
hemochromatosis,3260,B-Modifier
gene,3260,O
(,3260,O
HFE,3260,O
),3260,O
The,3260,O
hemochromatosis,3260,B-Modifier
gene,3260,O
(,3260,O
HFE,3260,O
),3260,O
maps,3260,O
to,3260,O
6p21,3260,O
.,3260,O
3,3261,O
and,3261,O
is,3261,O
less,3261,O
than,3261,O
1,3261,O
cM,3261,O
from,3261,O
the,3261,O
HLA,3261,O
class,3261,O
I,3261,O
genes,3261,O
;,3261,O
however,3261,O
",",3261,O
the,3261,O
precise,3261,O
physical,3261,O
location,3261,O
of,3261,O
the,3261,O
gene,3261,O
has,3261,O
remained,3261,O
elusive,3261,O
and,3261,O
controversial,3261,O
.,3261,O
The,3262,O
unambiguous,3262,O
identification,3262,O
of,3262,O
a,3262,O
crossover,3262,O
event,3262,O
within,3262,O
hemochromatosis,3262,B-Modifier
families,3262,O
is,3262,O
very,3262,O
difficult,3262,O
;,3262,O
it,3262,O
is,3262,O
particularly,3262,O
hampered,3262,O
by,3262,O
the,3262,O
variability,3262,O
of,3262,O
the,3262,O
phenotypic,3262,O
expression,3262,O
as,3262,O
well,3262,O
as,3262,O
by,3262,O
the,3262,O
sex-,3262,O
and,3262,O
age-related,3262,O
penetrance,3262,O
of,3262,O
the,3262,O
disease,3262,O
.,3262,O
For,3263,O
these,3263,O
practical,3263,O
considerations,3263,O
",",3263,O
traditional,3263,O
linkage,3263,O
analysis,3263,O
could,3263,O
prove,3263,O
of,3263,O
limited,3263,O
value,3263,O
in,3263,O
further,3263,O
refining,3263,O
the,3263,O
extrapolated,3263,O
physical,3263,O
position,3263,O
of,3263,O
HFE,3263,O
.,3263,O
We,3264,O
therefore,3264,O
embarked,3264,O
upon,3264,O
a,3264,O
linkage-disequilibrium,3264,O
analysis,3264,O
of,3264,O
HFE,3264,O
and,3264,O
normal,3264,O
chromosomes,3264,O
from,3264,O
the,3264,O
Brittany,3264,O
population,3264,O
.,3264,O
In,3265,O
the,3265,O
present,3265,O
report,3265,O
",",3265,O
66,3265,O
hemochromatosis,3265,B-Modifier
families,3265,O
yielding,3265,O
151,3265,O
hemochromatosis,3265,B-Modifier
chromosomes,3265,O
and,3265,O
182,3265,O
normal,3265,O
chromosomes,3265,O
were,3265,O
RFLP-typed,3265,O
with,3265,O
a,3265,O
battery,3265,O
of,3265,O
probes,3265,O
",",3265,O
including,3265,O
two,3265,O
newly,3265,O
derived,3265,O
polymorphic,3265,O
markers,3265,O
from,3265,O
the,3265,O
6,3265,O
.,3265,O
7,3266,O
and,3266,O
HLA-F,3266,O
loci,3266,O
located,3266,O
150,3266,O
and,3266,O
250,3266,O
kb,3266,O
telomeric,3266,O
to,3266,O
HLA-A,3266,O
",",3266,O
respectively,3266,O
.,3266,O
The,3267,O
results,3267,O
suggest,3267,O
a,3267,O
strong,3267,O
peak,3267,O
of,3267,O
existing,3267,O
linkage,3267,O
disequilibrium,3267,O
focused,3267,O
within,3267,O
the,3267,O
i82-to-6,3267,O
.,3267,O
7,3268,O
interval,3268,O
(,3268,O
approximately,3268,O
250,3268,O
kb,3268,O
),3268,O
.,3268,O
The,3269,O
zone,3269,O
of,3269,O
linkage,3269,O
disequilibrium,3269,O
is,3269,O
flanked,3269,O
by,3269,O
the,3269,O
i97,3269,O
locus,3269,O
",",3269,O
positioned,3269,O
30,3269,O
kb,3269,O
proximal,3269,O
to,3269,O
i82,3269,O
",",3269,O
and,3269,O
the,3269,O
HLA-F,3269,O
gene,3269,O
",",3269,O
found,3269,O
250,3269,O
kb,3269,O
distal,3269,O
to,3269,O
HLA-A,3269,O
",",3269,O
markers,3269,O
of,3269,O
which,3269,O
display,3269,O
no,3269,O
significant,3269,O
association,3269,O
with,3269,O
HFE,3269,O
.,3269,O
These,3270,O
data,3270,O
support,3270,O
the,3270,O
possibility,3270,O
that,3270,O
HFE,3270,O
resides,3270,O
within,3270,O
the,3270,O
400-kb,3270,O
expanse,3270,O
of,3270,O
DNA,3270,O
between,3270,O
i97,3270,O
and,3270,O
HLA-F.,3270,O
Alternatively,3270,O
",",3270,O
the,3270,O
very,3270,O
tight,3270,O
association,3270,O
of,3270,O
HLA-A3,3270,O
and,3270,O
allele,3270,O
1,3270,O
of,3270,O
the,3270,O
6,3270,O
.,3270,O
7,3271,O
locus,3271,O
",",3271,O
both,3271,O
of,3271,O
which,3271,O
are,3271,O
comprised,3271,O
by,3271,O
the,3271,O
major,3271,O
ancestral,3271,O
or,3271,O
founder,3271,O
HFE,3271,O
haplotype,3271,O
in,3271,O
Brittany,3271,O
",",3271,O
supports,3271,O
the,3271,O
possibility,3271,O
that,3271,O
the,3271,O
disease,3271,O
gene,3271,O
may,3271,O
reside,3271,O
immediately,3271,O
telomeric,3271,O
to,3271,O
the,3271,O
6,3271,O
.,3271,O
7,3272,O
locus,3272,O
within,3272,O
the,3272,O
linkage-disequilibrium,3272,O
zone,3272,O
.,3272,O
Additionally,3273,O
",",3273,O
hemochromatosis,3273,B-Modifier
haplotypes,3273,O
possessing,3273,O
HLA-A11,3273,O
and,3273,O
the,3273,O
low-frequency,3273,O
HLA-F,3273,O
polymorphism,3273,O
(,3273,O
allele,3273,O
2,3273,O
),3273,O
are,3273,O
supportive,3273,O
of,3273,O
a,3273,O
separate,3273,O
founder,3273,O
chromosome,3273,O
containing,3273,O
a,3273,O
second,3273,O
",",3273,O
independently,3273,O
arising,3273,O
mutant,3273,O
allele,3273,O
.,3273,O
Overall,3274,O
",",3274,O
the,3274,O
establishment,3274,O
of,3274,O
a,3274,O
likely,3274,O
``,3274,O
hemochromatosis,3274,B-Modifier
critical,3274,O
region,3274,O
``,3274,O
centromeric,3274,O
boundary,3274,O
and,3274,O
the,3274,O
identification,3274,O
of,3274,O
a,3274,O
linkage-disequilibrium,3274,O
zone,3274,O
both,3274,O
significantly,3274,O
contribute,3274,O
to,3274,O
a,3274,O
reduction,3274,O
in,3274,O
the,3274,O
amount,3274,O
of,3274,O
DNA,3274,O
required,3274,O
to,3274,O
be,3274,O
searched,3274,O
for,3274,O
novel,3274,O
coding,3274,O
sequences,3274,O
constituting,3274,O
the,3274,O
HFE,3274,B-SpecificDisease
defect,3274,I-SpecificDisease
Genomic,3275,O
structure,3275,O
of,3275,O
the,3275,O
EWS,3275,O
gene,3275,O
and,3275,O
its,3275,O
relationship,3275,O
to,3275,O
EWSR1,3275,O
",",3275,O
a,3275,O
site,3275,O
of,3275,O
tumor-associated,3275,B-Modifier
chromosome,3275,O
translocation,3275,O
.,3275,O
The,3276,O
EWS,3276,O
gene,3276,O
has,3276,O
been,3276,O
identified,3276,O
based,3276,O
on,3276,O
its,3276,O
location,3276,O
at,3276,O
the,3276,O
chromosome,3276,O
22,3276,O
breakpoint,3276,O
of,3276,O
the,3276,O
t,3276,O
(,3276,O
11,3276,O
;,3276,O
22,3276,O
),3276,O
(,3276,O
q24,3276,O
;,3276,O
q12,3276,O
),3276,O
translocation,3276,O
that,3276,O
characterizes,3276,O
Ewing,3276,B-SpecificDisease
sarcoma,3276,I-SpecificDisease
and,3276,O
related,3276,O
neuroectodermal,3276,B-SpecificDisease
tumors,3276,I-SpecificDisease
.,3276,O
The,3277,O
EWS,3277,O
gene,3277,O
spans,3277,O
about,3277,O
40,3277,O
kb,3277,O
of,3277,O
DNA,3277,O
and,3277,O
is,3277,O
encoded,3277,O
by,3277,O
17,3277,O
exons,3277,O
.,3277,O
The,3278,O
nucleotide,3278,O
sequence,3278,O
of,3278,O
the,3278,O
exons,3278,O
is,3278,O
identical,3278,O
to,3278,O
that,3278,O
of,3278,O
the,3278,O
previously,3278,O
described,3278,O
cDNA,3278,O
.,3278,O
The,3279,O
first,3279,O
7,3279,O
exons,3279,O
encode,3279,O
the,3279,O
N-terminal,3279,O
domain,3279,O
of,3279,O
EWS,3279,O
",",3279,O
which,3279,O
consists,3279,O
of,3279,O
a,3279,O
repeated,3279,O
degenerated,3279,O
polypeptide,3279,O
of,3279,O
7,3279,O
to,3279,O
12,3279,O
residues,3279,O
rich,3279,O
in,3279,O
tyrosine,3279,O
",",3279,O
serine,3279,O
",",3279,O
threonine,3279,O
",",3279,O
glycine,3279,O
",",3279,O
and,3279,O
glutamine,3279,O
.,3279,O
Exons,3280,O
11,3280,O
",",3280,O
12,3280,O
",",3280,O
and,3280,O
13,3280,O
encode,3280,O
the,3280,O
putative,3280,O
RNA,3280,O
binding,3280,O
domain,3280,O
.,3280,O
The,3281,O
three,3281,O
glycine-,3281,O
and,3281,O
arginine-rich,3281,O
motifs,3281,O
of,3281,O
the,3281,O
gene,3281,O
are,3281,O
mainly,3281,O
encoded,3281,O
by,3281,O
exons,3281,O
8-9,3281,O
",",3281,O
14,3281,O
",",3281,O
and,3281,O
16,3281,O
.,3281,O
The,3282,O
DNA,3282,O
sequence,3282,O
in,3282,O
the,3282,O
5,3282,O
region,3282,O
of,3282,O
the,3282,O
gene,3282,O
has,3282,O
features,3282,O
of,3282,O
a,3282,O
CpG-rich,3282,O
island,3282,O
and,3282,O
lacks,3282,O
canonical,3282,O
promoter,3282,O
elements,3282,O
",",3282,O
such,3282,O
as,3282,O
TATA,3282,O
and,3282,O
CCAAT,3282,O
consensus,3282,O
sequences,3282,O
.,3282,O
Positions,3283,O
of,3283,O
the,3283,O
chromosome,3283,O
22,3283,O
breakpoints,3283,O
were,3283,O
determined,3283,O
for,3283,O
19,3283,O
Ewing,3283,B-DiseaseClass
tumors,3283,I-DiseaseClass
.,3283,O
They,3284,O
were,3284,O
localized,3284,O
in,3284,O
introns,3284,O
7,3284,O
or,3284,O
8,3284,O
in,3284,O
18,3284,O
cases,3284,O
and,3284,O
in,3284,O
intron,3284,O
10,3284,O
in,3284,O
1,3284,O
case,3284,O
..,3284,O
Norrie,3285,B-Modifier
disease,3285,I-Modifier
gene,3285,O
:,3285,O
characterization,3285,O
of,3285,O
deletions,3285,O
and,3285,O
possible,3285,O
function,3285,O
.,3285,O
Positional,3286,O
cloning,3286,O
experiments,3286,O
have,3286,O
resulted,3286,O
recently,3286,O
in,3286,O
the,3286,O
isolation,3286,O
of,3286,O
a,3286,O
candidate,3286,O
gene,3286,O
for,3286,O
Norrie,3286,B-SpecificDisease
disease,3286,I-SpecificDisease
(,3286,O
pseudoglioma,3286,B-SpecificDisease
;,3286,O
NDP,3286,B-SpecificDisease
),3286,O
",",3286,O
a,3286,O
severe,3286,O
X-linked,3286,B-DiseaseClass
neurodevelopmental,3286,I-DiseaseClass
disorder,3286,I-DiseaseClass
.,3286,O
Here,3287,O
we,3287,O
report,3287,O
the,3287,O
isolation,3287,O
and,3287,O
analysis,3287,O
of,3287,O
human,3287,O
genomic,3287,O
DNA,3287,O
clones,3287,O
encompassing,3287,O
the,3287,O
NDP,3287,B-Modifier
gene,3287,O
.,3287,O
The,3288,O
gene,3288,O
spans,3288,O
28,3288,O
kb,3288,O
and,3288,O
consists,3288,O
of,3288,O
3,3288,O
exons,3288,O
",",3288,O
the,3288,O
first,3288,O
of,3288,O
which,3288,O
is,3288,O
entirely,3288,O
contained,3288,O
within,3288,O
the,3288,O
5,3288,O
untranslated,3288,O
region,3288,O
.,3288,O
Detailed,3289,O
analysis,3289,O
of,3289,O
genomic,3289,O
deletions,3289,O
in,3289,O
Norrie,3289,B-Modifier
patients,3289,O
shows,3289,O
that,3289,O
they,3289,O
are,3289,O
heterogeneous,3289,O
",",3289,O
both,3289,O
in,3289,O
size,3289,O
and,3289,O
in,3289,O
position,3289,O
.,3289,O
By,3290,O
PCR,3290,O
analysis,3290,O
",",3290,O
we,3290,O
found,3290,O
that,3290,O
expression,3290,O
of,3290,O
the,3290,O
NDP,3290,B-Modifier
gene,3290,O
was,3290,O
not,3290,O
confined,3290,O
to,3290,O
the,3290,O
eye,3290,O
or,3290,O
to,3290,O
the,3290,O
brain,3290,O
.,3290,O
An,3291,O
extensive,3291,O
DNA,3291,O
and,3291,O
protein,3291,O
sequence,3291,O
comparison,3291,O
between,3291,O
the,3291,O
human,3291,O
NDP,3291,B-Modifier
gene,3291,O
and,3291,O
related,3291,O
genes,3291,O
from,3291,O
the,3291,O
database,3291,O
revealed,3291,O
homology,3291,O
with,3291,O
cysteine-rich,3291,O
protein-binding,3291,O
domains,3291,O
of,3291,O
immediate,3291,O
--,3291,O
early,3291,O
genes,3291,O
implicated,3291,O
in,3291,O
the,3291,O
regulation,3291,O
of,3291,O
cell,3291,O
proliferation,3291,O
.,3291,O
We,3292,O
propose,3292,O
that,3292,O
NDP,3292,O
is,3292,O
a,3292,O
molecule,3292,O
related,3292,O
in,3292,O
function,3292,O
to,3292,O
these,3292,O
genes,3292,O
and,3292,O
may,3292,O
be,3292,O
involved,3292,O
in,3292,O
a,3292,O
pathway,3292,O
that,3292,O
regulates,3292,O
neural,3292,O
cell,3292,O
differentiation,3292,O
and,3292,O
proliferation,3292,O
..,3292,O
The,3293,O
normal,3293,O
Huntington,3293,B-Modifier
disease,3293,I-Modifier
(,3293,O
HD,3293,B-Modifier
),3293,O
allele,3293,O
",",3293,O
or,3293,O
a,3293,O
closely,3293,O
linked,3293,O
gene,3293,O
",",3293,O
influences,3293,O
age,3293,O
at,3293,O
onset,3293,O
of,3293,O
HD,3293,B-SpecificDisease
.,3293,O
We,3294,O
evaluated,3294,O
the,3294,O
hypothesis,3294,O
that,3294,O
Huntington,3294,B-SpecificDisease
disease,3294,I-SpecificDisease
(,3294,O
HD,3294,B-SpecificDisease
),3294,O
is,3294,O
influenced,3294,O
by,3294,O
the,3294,O
normal,3294,O
HD,3294,B-Modifier
allele,3294,O
by,3294,O
comparing,3294,O
transmission,3294,O
patterns,3294,O
of,3294,O
genetically,3294,O
linked,3294,O
markers,3294,O
at,3294,O
the,3294,O
D4S10,3294,O
locus,3294,O
in,3294,O
the,3294,O
normal,3294,O
parent,3294,O
against,3294,O
age,3294,O
at,3294,O
onset,3294,O
in,3294,O
the,3294,O
affected,3294,O
offspring,3294,O
.,3294,O
Analysis,3295,O
of,3295,O
information,3295,O
from,3295,O
21,3295,O
sibships,3295,O
in,3295,O
14,3295,O
kindreds,3295,O
showed,3295,O
a,3295,O
significant,3295,O
tendency,3295,O
for,3295,O
sibs,3295,O
who,3295,O
have,3295,O
similar,3295,O
onset,3295,O
ages,3295,O
to,3295,O
share,3295,O
the,3295,O
same,3295,O
D4S10,3295,O
allele,3295,O
from,3295,O
the,3295,O
normal,3295,O
parent,3295,O
.,3295,O
Affected,3296,O
sibs,3296,O
who,3296,O
inherited,3296,O
different,3296,O
D4S10,3296,O
alleles,3296,O
from,3296,O
the,3296,O
normal,3296,O
parent,3296,O
tended,3296,O
to,3296,O
have,3296,O
more,3296,O
variable,3296,O
ages,3296,O
at,3296,O
onset,3296,O
.,3296,O
These,3297,O
findings,3297,O
suggest,3297,O
that,3297,O
the,3297,O
expression,3297,O
of,3297,O
HD,3297,B-SpecificDisease
is,3297,O
modulated,3297,O
by,3297,O
the,3297,O
normal,3297,O
HD,3297,B-Modifier
allele,3297,O
or,3297,O
by,3297,O
a,3297,O
closely,3297,O
linked,3297,O
locus,3297,O
..,3297,O
Further,3298,O
investigation,3298,O
of,3298,O
the,3298,O
HEXA,3298,O
gene,3298,O
intron,3298,O
9,3298,O
donor,3298,O
splice,3298,O
site,3298,O
mutation,3298,O
frequently,3298,O
found,3298,O
in,3298,O
non-Jewish,3298,O
Tay-Sachs,3298,B-Modifier
disease,3298,I-Modifier
patients,3298,O
from,3298,O
the,3298,O
British,3298,O
Isles,3298,O
.,3298,O
In,3299,O
a,3299,O
previous,3299,O
study,3299,O
we,3299,O
found,3299,O
that,3299,O
a,3299,O
Tay-Sachs,3299,B-SpecificDisease
disease,3299,I-SpecificDisease
(,3299,O
TSD,3299,B-SpecificDisease
),3299,O
causing,3299,O
mutation,3299,O
in,3299,O
the,3299,O
intron,3299,O
9,3299,O
donor,3299,O
splice,3299,O
site,3299,O
of,3299,O
the,3299,O
HEXA,3299,O
gene,3299,O
occurs,3299,O
at,3299,O
high,3299,O
frequency,3299,O
in,3299,O
non-Jewish,3299,O
patients,3299,O
and,3299,O
carriers,3299,O
from,3299,O
the,3299,O
British,3299,O
Isles,3299,O
.,3299,O
It,3300,O
was,3300,O
found,3300,O
more,3300,O
frequently,3300,O
in,3300,O
subjects,3300,O
of,3300,O
Irish,3300,O
",",3300,O
Scottish,3300,O
",",3300,O
and,3300,O
Welsh,3300,O
origin,3300,O
compared,3300,O
with,3300,O
English,3300,O
origin,3300,O
(,3300,O
63,3300,O
%,3300,O
and,3300,O
31,3300,O
%,3300,O
respectively,3300,O
),3300,O
.,3300,O
We,3301,O
have,3301,O
now,3301,O
tested,3301,O
",",3301,O
in,3301,O
a,3301,O
blind,3301,O
study,3301,O
",",3301,O
26,3301,O
American,3301,O
TSD,3301,B-Modifier
carriers,3301,O
and,3301,O
28,3301,O
non-carriers,3301,O
who,3301,O
have,3301,O
British,3301,O
ancestry,3301,O
for,3301,O
the,3301,O
intron,3301,O
9,3301,O
splice,3301,O
site,3301,O
mutation,3301,O
.,3301,O
Six,3302,O
of,3302,O
the,3302,O
carriers,3302,O
and,3302,O
none,3302,O
of,3302,O
the,3302,O
controls,3302,O
were,3302,O
positive,3302,O
for,3302,O
the,3302,O
mutation,3302,O
.,3302,O
All,3303,O
six,3303,O
had,3303,O
Irish,3303,O
ancestry,3303,O
",",3303,O
compared,3303,O
with,3303,O
nine,3303,O
of,3303,O
the,3303,O
20,3303,O
other,3303,O
(,3303,O
intron,3303,O
9,3303,O
mutation,3303,O
negative,3303,O
),3303,O
TSD,3303,B-Modifier
carriers,3303,O
(,3303,O
p,3303,O
<,3303,O
0,3303,O
.,3303,O
05,3304,O
),3304,O
.,3304,O
These,3305,O
results,3305,O
confirm,3305,O
the,3305,O
previously,3305,O
found,3305,O
high,3305,O
frequency,3305,O
of,3305,O
the,3305,O
intron,3305,O
9,3305,O
mutation,3305,O
in,3305,O
non-Jewish,3305,O
TSD,3305,B-Modifier
families,3305,O
of,3305,O
British,3305,O
Isles,3305,O
",",3305,O
particularly,3305,O
Irish,3305,O
",",3305,O
origin,3305,O
",",3305,O
and,3305,O
reinforce,3305,O
the,3305,O
need,3305,O
to,3305,O
screen,3305,O
such,3305,O
families,3305,O
for,3305,O
this,3305,O
mutation,3305,O
.,3305,O
Molecular,3306,O
mechanisms,3306,O
of,3306,O
oncogenic,3306,O
mutations,3306,O
in,3306,O
tumors,3306,B-DiseaseClass
from,3306,O
patients,3306,O
with,3306,O
bilateral,3306,B-CompositeMention
and,3306,I-CompositeMention
unilateral,3306,I-CompositeMention
retinoblastoma,3306,I-CompositeMention
.,3306,O
The,3307,O
RB1,3307,O
gene,3307,O
from,3307,O
12,3307,O
human,3307,O
retinoblastoma,3307,B-SpecificDisease
tumors,3307,I-SpecificDisease
has,3307,O
been,3307,O
analyzed,3307,O
exon-by-exon,3307,O
with,3307,O
the,3307,O
single-strand,3307,O
conformation,3307,O
polymorphism,3307,O
technique,3307,O
.,3307,O
Mutations,3308,O
were,3308,O
found,3308,O
in,3308,O
all,3308,O
tumors,3308,B-DiseaseClass
",",3308,O
and,3308,O
one-third,3308,O
of,3308,O
the,3308,O
tumors,3308,B-DiseaseClass
had,3308,O
independent,3308,O
mutations,3308,O
in,3308,O
both,3308,O
alleles,3308,O
neither,3308,O
of,3308,O
which,3308,O
were,3308,O
found,3308,O
in,3308,O
the,3308,O
germ,3308,O
line,3308,O
",",3308,O
confirming,3308,O
their,3308,O
true,3308,O
sporadic,3308,O
nature,3308,O
.,3308,O
In,3309,O
the,3309,O
remaining,3309,O
two-thirds,3309,O
of,3309,O
the,3309,O
tumors,3309,B-DiseaseClass
only,3309,O
one,3309,O
mutation,3309,O
was,3309,O
found,3309,O
",",3309,O
consistent,3309,O
with,3309,O
the,3309,O
loss-of-heterozygosity,3309,O
theory,3309,O
of,3309,O
tumorigenesis,3309,O
.,3309,O
Point,3310,O
mutations,3310,O
",",3310,O
the,3310,O
majority,3310,O
of,3310,O
which,3310,O
were,3310,O
C,3310,O
--,3310,O
>,3310,O
T,3310,O
transitions,3310,O
",",3310,O
were,3310,O
the,3310,O
most,3310,O
common,3310,O
abnormality,3310,O
and,3310,O
usually,3310,O
resulted,3310,O
in,3310,O
the,3310,O
conversion,3310,O
of,3310,O
an,3310,O
arginine,3310,O
codon,3310,O
to,3310,O
a,3310,O
stop,3310,O
codon,3310,O
.,3310,O
Small,3311,O
deletions,3311,O
were,3311,O
the,3311,O
second,3311,O
most,3311,O
common,3311,O
abnormality,3311,O
and,3311,O
most,3311,O
often,3311,O
created,3311,O
a,3311,O
downstream,3311,O
stop,3311,O
codon,3311,O
as,3311,O
the,3311,O
result,3311,O
of,3311,O
a,3311,O
reading,3311,O
frameshift,3311,O
.,3311,O
Deletions,3312,O
and,3312,O
point,3312,O
mutations,3312,O
also,3312,O
affected,3312,O
splice,3312,O
junctions,3312,O
.,3312,O
Direct,3313,O
repeats,3313,O
were,3313,O
present,3313,O
at,3313,O
the,3313,O
breakpoint,3313,O
junctions,3313,O
in,3313,O
the,3313,O
majority,3313,O
of,3313,O
deletions,3313,O
",",3313,O
supporting,3313,O
a,3313,O
slipped-mispairing,3313,O
mechanism,3313,O
.,3313,O
Point,3314,O
mutations,3314,O
generally,3314,O
produced,3314,O
DNA,3314,O
sequences,3314,O
which,3314,O
resulted,3314,O
in,3314,O
perfect,3314,O
homology,3314,O
with,3314,O
endogenous,3314,O
sequences,3314,O
which,3314,O
lay,3314,O
within,3314,O
14,3314,O
bp,3314,O
..,3314,O
PAX6,3315,O
mutations,3315,O
in,3315,O
aniridia,3315,B-SpecificDisease
.,3315,O
Aniridia,3316,B-SpecificDisease
is,3316,O
a,3316,O
congenital,3316,B-DiseaseClass
malformation,3316,I-DiseaseClass
of,3316,I-DiseaseClass
the,3316,I-DiseaseClass
eye,3316,I-DiseaseClass
",",3316,O
chiefly,3316,O
characterised,3316,O
by,3316,O
iris,3316,B-SpecificDisease
hypoplasia,3316,I-SpecificDisease
",",3316,O
which,3316,O
can,3316,O
cause,3316,O
blindness,3316,B-SpecificDisease
.,3316,O
The,3317,O
PAX6,3317,O
gene,3317,O
was,3317,O
isolated,3317,O
as,3317,O
a,3317,O
candidate,3317,O
aniridia,3317,B-Modifier
gene,3317,O
by,3317,O
positional,3317,O
cloning,3317,O
from,3317,O
the,3317,O
smallest,3317,O
region,3317,O
of,3317,O
overlap,3317,O
of,3317,O
aniridia-associated,3317,B-Modifier
deletions,3317,O
.,3317,O
Subsequently,3318,O
PAX6,3318,O
intragenic,3318,O
mutations,3318,O
were,3318,O
demonstrated,3318,O
in,3318,O
Smalleye,3318,O
",",3318,O
a,3318,O
mouse,3318,O
mutant,3318,O
which,3318,O
is,3318,O
an,3318,O
animal,3318,O
model,3318,O
for,3318,O
aniridia,3318,B-SpecificDisease
",",3318,O
and,3318,O
six,3318,O
human,3318,O
aniridia,3318,B-Modifier
patients,3318,O
.,3318,O
In,3319,O
this,3319,O
paper,3319,O
we,3319,O
describe,3319,O
four,3319,O
additional,3319,O
PAX6,3319,O
point,3319,O
mutations,3319,O
in,3319,O
aniridia,3319,B-Modifier
patients,3319,O
",",3319,O
both,3319,O
sporadic,3319,O
and,3319,O
familial,3319,O
.,3319,O
These,3320,O
mutations,3320,O
highlight,3320,O
regions,3320,O
of,3320,O
the,3320,O
gene,3320,O
which,3320,O
are,3320,O
essential,3320,O
for,3320,O
normal,3320,O
PAX6,3320,O
function,3320,O
.,3320,O
In,3321,O
addition,3321,O
",",3321,O
the,3321,O
frequency,3321,O
at,3321,O
which,3321,O
we,3321,O
have,3321,O
found,3321,O
PAX6,3321,O
mutations,3321,O
suggests,3321,O
that,3321,O
lesions,3321,O
in,3321,O
PAX6,3321,O
will,3321,O
account,3321,O
for,3321,O
most,3321,O
cases,3321,O
of,3321,O
aniridia,3321,B-SpecificDisease
..,3321,O
Detection,3322,O
of,3322,O
a,3322,O
novel,3322,O
arginine,3322,O
vasopressin,3322,O
defect,3322,O
by,3322,O
dideoxy,3322,O
fingerprinting,3322,O
.,3322,O
Autosomal,3323,B-SpecificDisease
dominant,3323,I-SpecificDisease
neurohypophyseal,3323,I-SpecificDisease
diabetes,3323,I-SpecificDisease
insipidus,3323,I-SpecificDisease
is,3323,O
a,3323,O
familial,3323,O
form,3323,O
of,3323,O
diabetes,3323,B-DiseaseClass
insipidus,3323,I-DiseaseClass
.,3323,O
This,3324,O
disorder,3324,O
is,3324,O
associated,3324,O
with,3324,O
variable,3324,O
levels,3324,O
of,3324,O
arginine,3324,O
vasopressin,3324,O
(,3324,O
AVP,3324,O
),3324,O
and,3324,O
diabetes,3324,B-DiseaseClass
insipidus,3324,I-DiseaseClass
of,3324,O
varying,3324,O
severity,3324,O
",",3324,O
which,3324,O
responds,3324,O
to,3324,O
exogenous,3324,O
AVP,3324,O
.,3324,O
To,3325,O
determine,3325,O
the,3325,O
molecular,3325,O
basis,3325,O
of,3325,O
autosomal,3325,B-SpecificDisease
dominant,3325,I-SpecificDisease
neurohypophyseal,3325,I-SpecificDisease
diabetes,3325,I-SpecificDisease
insipidus,3325,I-SpecificDisease
",",3325,O
the,3325,O
AVP,3325,O
genes,3325,O
of,3325,O
members,3325,O
of,3325,O
a,3325,O
large,3325,O
kindred,3325,O
were,3325,O
analyzed,3325,O
.,3325,O
A,3326,O
new,3326,O
method,3326,O
",",3326,O
called,3326,O
dideoxy,3326,O
fingerprinting,3326,O
",",3326,O
was,3326,O
used,3326,O
to,3326,O
detect,3326,O
an,3326,O
AVP,3326,O
mutation,3326,O
that,3326,O
was,3326,O
characterized,3326,O
by,3326,O
DNA,3326,O
sequencing,3326,O
.,3326,O
The,3327,O
novel,3327,O
defect,3327,O
found,3327,O
changes,3327,O
the,3327,O
last,3327,O
codon,3327,O
of,3327,O
the,3327,O
AVP,3327,O
signal,3327,O
peptide,3327,O
from,3327,O
alanine,3327,O
to,3327,O
threonine,3327,O
",",3327,O
which,3327,O
should,3327,O
perturb,3327,O
cleavage,3327,O
of,3327,O
mature,3327,O
AVP,3327,O
from,3327,O
its,3327,O
precursor,3327,O
protein,3327,O
and,3327,O
inhibit,3327,O
its,3327,O
secretion,3327,O
or,3327,O
action,3327,O
..,3327,O
Germinal,3328,O
mosaicism,3328,O
in,3328,O
a,3328,O
Duchenne,3328,B-Modifier
muscular,3328,I-Modifier
dystrophy,3328,I-Modifier
family,3328,O
:,3328,O
implications,3328,O
for,3328,O
genetic,3328,O
counselling,3328,O
.,3328,O
In,3329,O
this,3329,O
study,3329,O
we,3329,O
describe,3329,O
a,3329,O
three-generation,3329,O
family,3329,O
in,3329,O
which,3329,O
two,3329,O
siblings,3329,O
were,3329,O
affected,3329,O
by,3329,O
Duchenne,3329,B-SpecificDisease
muscular,3329,I-SpecificDisease
dystrophy,3329,I-SpecificDisease
(,3329,O
DMD,3329,B-SpecificDisease
),3329,O
.,3329,O
Immunohistochemical,3330,O
analysis,3330,O
of,3330,O
muscle,3330,O
dystrophin,3330,O
and,3330,O
haplotype,3330,O
analysis,3330,O
of,3330,O
the,3330,O
DMD,3330,B-Modifier
locus,3330,O
revealed,3330,O
that,3330,O
the,3330,O
X,3330,O
chromosome,3330,O
carrying,3330,O
the,3330,O
DMD,3330,B-Modifier
gene,3330,O
was,3330,O
transmitted,3330,O
from,3330,O
the,3330,O
healthy,3330,O
maternal,3330,O
grandfather,3330,O
to,3330,O
his,3330,O
three,3330,O
daughters,3330,O
",",3330,O
including,3330,O
the,3330,O
probands,3330,O
mother,3330,O
.,3330,O
These,3331,O
findings,3331,O
indicate,3331,O
that,3331,O
the,3331,O
grandfather,3331,O
was,3331,O
a,3331,O
germinal,3331,O
mosaic,3331,O
for,3331,O
the,3331,O
DMD,3331,B-Modifier
gene,3331,O
.,3331,O
The,3332,O
definition,3332,O
of,3332,O
the,3332,O
carrier,3332,O
status,3332,O
in,3332,O
two,3332,O
possible,3332,O
carriers,3332,O
led,3332,O
us,3332,O
to,3332,O
give,3332,O
accurate,3332,O
genetic,3332,O
counselling,3332,O
and,3332,O
to,3332,O
prevent,3332,O
the,3332,O
birth,3332,O
of,3332,O
an,3332,O
affected,3332,O
boy,3332,O
.,3332,O
The,3333,O
results,3333,O
of,3333,O
this,3333,O
study,3333,O
demonstrate,3333,O
the,3333,O
usefulness,3333,O
of,3333,O
haplotype,3333,O
analysis,3333,O
and,3333,O
immunohistochemical,3333,O
muscle,3333,O
dystrophin,3333,O
studies,3333,O
to,3333,O
detect,3333,O
hidden,3333,O
germinal,3333,O
mosaicism,3333,O
and,3333,O
to,3333,O
improve,3333,O
genetic,3333,O
counselling,3333,O
..,3333,O
Genetic,3334,O
mapping,3334,O
of,3334,O
the,3334,O
breast-ovarian,3334,B-DiseaseClass
cancer,3334,I-DiseaseClass
syndrome,3334,I-DiseaseClass
to,3334,O
a,3334,O
small,3334,O
interval,3334,O
on,3334,O
chromosome,3334,O
17q12-21,3334,O
:,3334,O
exclusion,3334,O
of,3334,O
candidate,3334,O
genes,3334,O
EDH17B2,3334,O
and,3334,O
RARA,3334,O
.,3334,O
A,3335,O
susceptibility,3335,O
gene,3335,O
for,3335,O
hereditary,3335,B-DiseaseClass
breast-ovarian,3335,I-DiseaseClass
cancer,3335,I-DiseaseClass
",",3335,O
BRCA1,3335,O
",",3335,O
has,3335,O
been,3335,O
assigned,3335,O
by,3335,O
linkage,3335,O
analysis,3335,O
to,3335,O
chromosome,3335,O
17q21,3335,O
.,3335,O
Candidate,3336,O
genes,3336,O
in,3336,O
this,3336,O
region,3336,O
include,3336,O
EDH17B2,3336,O
",",3336,O
which,3336,O
encodes,3336,O
estradiol,3336,O
17,3336,O
beta-hydroxysteroid,3336,O
dehydrogenase,3336,O
II,3336,O
(,3336,O
17,3336,O
beta-HSD,3336,O
II,3336,O
),3336,O
",",3336,O
and,3336,O
RARA,3336,O
",",3336,O
the,3336,O
gene,3336,O
for,3336,O
retinoic,3336,O
acid,3336,O
receptor,3336,O
alpha,3336,O
.,3336,O
We,3337,O
have,3337,O
typed,3337,O
22,3337,O
breast,3337,O
and,3337,O
breast-ovarian,3337,O
cancer,3337,O
families,3337,O
with,3337,O
eight,3337,O
polymorphisms,3337,O
from,3337,O
the,3337,O
chromosome,3337,O
17q12-21,3337,O
region,3337,O
",",3337,O
including,3337,O
two,3337,O
in,3337,O
the,3337,O
EDH17B2,3337,O
gene,3337,O
.,3337,O
Genetic,3338,O
recombination,3338,O
with,3338,O
the,3338,O
breast,3338,B-Modifier
cancer,3338,I-Modifier
trait,3338,O
excludes,3338,O
RARA,3338,O
from,3338,O
further,3338,O
consideration,3338,O
as,3338,O
a,3338,O
candidate,3338,O
gene,3338,O
for,3338,O
BRCA1,3338,O
.,3338,O
Both,3339,O
BRCA1,3339,O
and,3339,O
EDH17B2,3339,O
map,3339,O
to,3339,O
a,3339,O
6,3339,O
cM,3339,O
interval,3339,O
(,3339,O
between,3339,O
THRA1,3339,O
and,3339,O
D17S579,3339,O
),3339,O
and,3339,O
no,3339,O
recombination,3339,O
was,3339,O
observed,3339,O
between,3339,O
the,3339,O
two,3339,O
genes,3339,O
.,3339,O
However,3340,O
",",3340,O
direct,3340,O
sequencing,3340,O
of,3340,O
overlapping,3340,O
PCR,3340,O
products,3340,O
containing,3340,O
the,3340,O
entire,3340,O
EDH17B2,3340,O
gene,3340,O
in,3340,O
four,3340,O
unrelated,3340,O
affected,3340,O
women,3340,O
did,3340,O
not,3340,O
uncover,3340,O
any,3340,O
sequence,3340,O
variation,3340,O
",",3340,O
other,3340,O
than,3340,O
previously,3340,O
described,3340,O
polymorphisms,3340,O
.,3340,O
Mutations,3341,O
in,3341,O
the,3341,O
EDH17B2,3341,O
gene,3341,O
",",3341,O
therefore,3341,O
do,3341,O
not,3341,O
appear,3341,O
to,3341,O
be,3341,O
responsible,3341,O
for,3341,O
the,3341,O
hereditary,3341,B-DiseaseClass
breast-ovarian,3341,I-DiseaseClass
cancer,3341,I-DiseaseClass
syndrome,3341,I-DiseaseClass
.,3341,O
Single,3342,O
meiotic,3342,O
crossovers,3342,O
in,3342,O
affected,3342,O
women,3342,O
suggest,3342,O
that,3342,O
BRCA1,3342,O
is,3342,O
flanked,3342,O
by,3342,O
the,3342,O
loci,3342,O
RARA,3342,O
and,3342,O
D17S78,3342,O
..,3342,O
A,3343,O
missense,3343,O
mutation,3343,O
in,3343,O
the,3343,O
cholesteryl,3343,O
ester,3343,O
transfer,3343,O
protein,3343,O
gene,3343,O
with,3343,O
possible,3343,O
dominant,3343,O
effects,3343,O
on,3343,O
plasma,3343,O
high,3343,O
density,3343,O
lipoproteins,3343,O
.,3343,O
Plasma,3344,O
HDL,3344,O
are,3344,O
a,3344,O
negative,3344,O
risk,3344,O
factor,3344,O
for,3344,O
atherosclerosis,3344,B-SpecificDisease
.,3344,O
Cholesteryl,3345,O
ester,3345,O
transfer,3345,O
protein,3345,O
(,3345,O
CETP,3345,O
;,3345,O
476,3345,O
amino,3345,O
acids,3345,O
),3345,O
transfers,3345,O
cholesteryl,3345,O
ester,3345,O
from,3345,O
HDL,3345,O
to,3345,O
other,3345,O
lipoproteins,3345,O
.,3345,O
Subjects,3346,O
with,3346,O
homozygous,3346,O
CETP,3346,B-SpecificDisease
deficiency,3346,I-SpecificDisease
caused,3346,O
by,3346,O
a,3346,O
gene,3346,O
splicing,3346,O
defect,3346,O
have,3346,O
markedly,3346,O
elevated,3346,O
HDL,3346,O
;,3346,O
however,3346,O
",",3346,O
heterozygotes,3346,O
have,3346,O
only,3346,O
mild,3346,O
increases,3346,O
in,3346,O
HDL,3346,O
.,3346,O
We,3347,O
describe,3347,O
two,3347,O
probands,3347,O
with,3347,O
a,3347,O
CETP,3347,O
missense,3347,O
mutation,3347,O
(,3347,O
442,3347,O
D,3347,O
G,3347,O
),3347,O
.,3347,O
Although,3348,O
heterozygous,3348,O
",",3348,O
they,3348,O
have,3348,O
threefold,3348,O
increases,3348,O
in,3348,O
HDL,3348,O
concentration,3348,O
and,3348,O
markedly,3348,O
decreased,3348,O
plasma,3348,O
CETP,3348,O
mass,3348,O
and,3348,O
activity,3348,O
",",3348,O
suggesting,3348,O
that,3348,O
the,3348,O
mutation,3348,O
has,3348,O
dominant,3348,O
effects,3348,O
on,3348,O
CETP,3348,O
and,3348,O
HDL,3348,O
in,3348,O
vivo,3348,O
.,3348,O
Cellular,3349,O
expression,3349,O
of,3349,O
mutant,3349,O
cDNA,3349,O
results,3349,O
in,3349,O
secretion,3349,O
of,3349,O
only,3349,O
30,3349,O
%,3349,O
of,3349,O
wild,3349,O
type,3349,O
CETP,3349,O
activity,3349,O
.,3349,O
Moreover,3350,O
",",3350,O
coexpression,3350,O
of,3350,O
wild,3350,O
type,3350,O
and,3350,O
mutant,3350,O
cDNAs,3350,O
leads,3350,O
to,3350,O
inhibition,3350,O
of,3350,O
wild,3350,O
type,3350,O
secretion,3350,O
and,3350,O
activity,3350,O
.,3350,O
The,3351,O
dominant,3351,O
effects,3351,O
of,3351,O
the,3351,O
CETP,3351,O
missense,3351,O
mutation,3351,O
during,3351,O
cellular,3351,O
expression,3351,O
probably,3351,O
explains,3351,O
why,3351,O
the,3351,O
probands,3351,O
have,3351,O
markedly,3351,O
increased,3351,O
HDL,3351,O
in,3351,O
the,3351,O
heterozygous,3351,O
state,3351,O
",",3351,O
and,3351,O
suggests,3351,O
that,3351,O
the,3351,O
active,3351,O
molecular,3351,O
species,3351,O
of,3351,O
CETP,3351,O
may,3351,O
be,3351,O
multimeric,3351,O
..,3351,O
Familial,3352,B-SpecificDisease
Mediterranean,3352,I-SpecificDisease
fever,3352,I-SpecificDisease
in,3352,O
the,3352,O
colchicine,3352,O
era,3352,O
:,3352,O
the,3352,O
fate,3352,O
of,3352,O
one,3352,O
family,3352,O
.,3352,O
In,3353,O
order,3353,O
to,3353,O
demonstrate,3353,O
the,3353,O
effect,3353,O
of,3353,O
prophylactic,3353,O
colchicine,3353,O
treatment,3353,O
on,3353,O
the,3353,O
natural,3353,O
history,3353,O
of,3353,O
familial,3353,B-SpecificDisease
Mediterranean,3353,I-SpecificDisease
fever,3353,I-SpecificDisease
(,3353,O
FMF,3353,B-SpecificDisease
),3353,O
",",3353,O
a,3353,O
family,3353,O
is,3353,O
presented,3353,O
with,3353,O
6,3353,O
out,3353,O
of,3353,O
9,3353,O
siblings,3353,O
affected,3353,O
by,3353,O
FMF,3353,B-SpecificDisease
.,3353,O
Each,3354,O
patient,3354,O
represents,3354,O
a,3354,O
different,3354,O
stage,3354,O
of,3354,O
the,3354,O
amyloidotic,3354,B-SpecificDisease
kidney,3354,I-SpecificDisease
disease,3354,I-SpecificDisease
of,3354,O
FMF,3354,B-SpecificDisease
and,3354,O
the,3354,O
effect,3354,O
of,3354,O
continuous,3354,O
colchicine,3354,O
treatment,3354,O
on,3354,O
its,3354,O
course,3354,O
.,3354,O
Considered,3355,O
together,3355,O
",",3355,O
the,3355,O
members,3355,O
of,3355,O
this,3355,O
family,3355,O
present,3355,O
an,3355,O
almost,3355,O
complete,3355,O
clinical,3355,O
",",3355,O
genetic,3355,O
",",3355,O
and,3355,O
behavioral,3355,O
picture,3355,O
of,3355,O
the,3355,O
disease,3355,O
..,3355,O
Detection,3356,O
of,3356,O
a,3356,O
new,3356,O
submicroscopic,3356,O
Norrie,3356,B-Modifier
disease,3356,I-Modifier
deletion,3356,O
interval,3356,O
with,3356,O
a,3356,O
novel,3356,O
DNA,3356,O
probe,3356,O
isolated,3356,O
by,3356,O
differential,3356,O
Alu,3356,O
PCR,3356,O
fingerprint,3356,O
cloning,3356,O
.,3356,O
Differential,3357,O
Alu,3357,O
PCR,3357,O
fingerprint,3357,O
cloning,3357,O
was,3357,O
used,3357,O
to,3357,O
isolate,3357,O
a,3357,O
DNA,3357,O
probe,3357,O
from,3357,O
the,3357,O
Xp11,3357,O
.,3357,O
4,3358,O
--,3358,O
>,3358,O
p11,3358,O
.,3358,O
21,3359,O
region,3359,O
of,3359,O
the,3359,O
human,3359,O
X,3359,O
chromosome,3359,O
.,3359,O
This,3360,O
novel,3360,O
sequence,3360,O
",",3360,O
cpXr318,3360,O
(,3360,O
DXS742,3360,O
),3360,O
",",3360,O
detects,3360,O
a,3360,O
new,3360,O
submicroscopic,3360,O
deletion,3360,O
interval,3360,O
at,3360,O
the,3360,O
Norrie,3360,B-Modifier
disease,3360,I-Modifier
locus,3360,O
(,3360,O
NDP,3360,O
),3360,O
.,3360,O
Combining,3361,O
our,3361,O
data,3361,O
with,3361,O
the,3361,O
consensus,3361,O
genetic,3361,O
map,3361,O
of,3361,O
the,3361,O
proximal,3361,O
short,3361,O
arm,3361,O
of,3361,O
the,3361,O
X,3361,O
chromosome,3361,O
",",3361,O
we,3361,O
propose,3361,O
the,3361,O
physical,3361,O
order,3361,O
Xcen-DXS14-DXS255-,3361,O
(,3361,O
DXS426,3361,O
",",3361,O
TIMP,3361,O
),3361,O
-,3361,O
(,3361,O
DXS742-,3361,O
(,3361,O
[,3361,O
MAOB-MAOA-DXS7,3361,O
],3361,O
",",3361,O
NDP,3361,O
),3361,O
-DXS77-DXS228,3361,O
),3361,O
-DXS209-DXS148-DXS196-,3361,O
+,3361,O
+,3361,O
+,3361,O
Xpter,3361,O
.,3361,O
The,3362,O
cpXr318,3362,O
probe,3362,O
and,3362,O
a,3362,O
subclone,3362,O
from,3362,O
a,3362,O
cosmid,3362,O
corresponding,3362,O
to,3362,O
the,3362,O
DXS7,3362,O
locus,3362,O
were,3362,O
converted,3362,O
into,3362,O
sequence-tagged,3362,O
sites,3362,O
.,3362,O
Finally,3363,O
",",3363,O
DXS742,3363,O
",",3363,O
DSX7,3363,O
",",3363,O
DXS77,3363,O
",",3363,O
and,3363,O
MAOA,3363,O
were,3363,O
integrated,3363,O
into,3363,O
a,3363,O
physical,3363,O
map,3363,O
spanning,3363,O
the,3363,O
Norrie,3363,B-Modifier
disease,3363,I-Modifier
locus,3363,O
Putative,3364,O
X-linked,3364,B-Modifier
adrenoleukodystrophy,3364,I-Modifier
gene,3364,O
shares,3364,O
unexpected,3364,O
homology,3364,O
with,3364,O
ABC,3364,O
transporters,3364,O
.,3364,O
Adrenoleukodystrophy,3365,B-SpecificDisease
(,3365,O
ALD,3365,B-SpecificDisease
),3365,O
is,3365,O
an,3365,O
X-linked,3365,B-DiseaseClass
disease,3365,I-DiseaseClass
affecting,3365,O
1/20,3365,O
",",3365,O
000,3365,O
males,3365,O
either,3365,O
as,3365,O
cerebral,3365,B-SpecificDisease
ALD,3365,I-SpecificDisease
in,3365,O
childhood,3365,O
or,3365,O
as,3365,O
adrenomyeloneuropathy,3365,B-SpecificDisease
(,3365,O
AMN,3365,B-SpecificDisease
),3365,O
in,3365,O
adults,3365,O
.,3365,O
Childhood,3366,O
ALD,3366,B-SpecificDisease
is,3366,O
the,3366,O
more,3366,O
severe,3366,O
form,3366,O
",",3366,O
with,3366,O
onset,3366,O
of,3366,O
neurological,3366,O
symptoms,3366,O
between,3366,O
5-12,3366,O
years,3366,O
of,3366,O
age,3366,O
.,3366,O
Central,3367,B-DiseaseClass
nervous,3367,I-DiseaseClass
system,3367,I-DiseaseClass
demyelination,3367,I-DiseaseClass
progresses,3367,O
rapidly,3367,O
and,3367,O
death,3367,O
occurs,3367,O
within,3367,O
a,3367,O
few,3367,O
years,3367,O
.,3367,O
AMN,3368,B-SpecificDisease
is,3368,O
a,3368,O
milder,3368,O
form,3368,O
of,3368,O
the,3368,O
disease,3368,O
with,3368,O
onset,3368,O
at,3368,O
15-30,3368,O
years,3368,O
of,3368,O
age,3368,O
and,3368,O
a,3368,O
more,3368,O
progressive,3368,O
course,3368,O
.,3368,O
Adrenal,3369,B-DiseaseClass
insufficiency,3369,I-DiseaseClass
(,3369,O
Addisons,3369,B-SpecificDisease
disease,3369,I-SpecificDisease
),3369,O
may,3369,O
remain,3369,O
the,3369,O
only,3369,O
clinical,3369,O
manifestation,3369,O
of,3369,O
ALD,3369,B-SpecificDisease
.,3369,O
The,3370,O
principal,3370,O
biochemical,3370,O
abnormality,3370,O
of,3370,O
ALD,3370,B-SpecificDisease
is,3370,O
the,3370,O
accumulation,3370,O
of,3370,O
very-long-chain,3370,O
fatty,3370,O
acids,3370,O
(,3370,O
VLCFA,3370,O
),3370,O
because,3370,O
of,3370,O
impaired,3370,O
beta-oxidation,3370,O
in,3370,O
peroxisomes,3370,O
.,3370,O
The,3371,O
normal,3371,O
oxidation,3371,O
of,3371,O
VLCFA-CoA,3371,O
in,3371,O
patients,3371,O
fibroblasts,3371,O
suggested,3371,O
that,3371,O
the,3371,O
gene,3371,O
coding,3371,O
for,3371,O
the,3371,O
VLCFA-CoA,3371,O
synthetase,3371,O
could,3371,O
be,3371,O
a,3371,O
candidate,3371,O
gene,3371,O
for,3371,O
ALD,3371,B-SpecificDisease
.,3371,O
Here,3372,O
we,3372,O
use,3372,O
positional,3372,O
cloning,3372,O
to,3372,O
identify,3372,O
a,3372,O
gene,3372,O
partially,3372,O
deleted,3372,O
in,3372,O
6,3372,O
of,3372,O
85,3372,O
independent,3372,O
patients,3372,O
with,3372,O
ALD,3372,B-SpecificDisease
.,3372,O
In,3373,O
familial,3373,O
cases,3373,O
",",3373,O
the,3373,O
deletions,3373,O
segregated,3373,O
with,3373,O
the,3373,O
disease,3373,O
.,3373,O
An,3374,O
identical,3374,O
deletion,3374,O
was,3374,O
detected,3374,O
in,3374,O
two,3374,O
brothers,3374,O
presenting,3374,O
with,3374,O
different,3374,O
clinical,3374,O
ALD,3374,B-Modifier
phenotypes,3374,O
.,3374,O
Candidate,3375,O
exons,3375,O
were,3375,O
identified,3375,O
by,3375,O
computer,3375,O
analysis,3375,O
of,3375,O
genomic,3375,O
sequences,3375,O
and,3375,O
used,3375,O
to,3375,O
isolate,3375,O
complementary,3375,O
DNAs,3375,O
by,3375,O
exon,3375,O
connection,3375,O
and,3375,O
screening,3375,O
of,3375,O
cDNA,3375,O
libraries,3375,O
.,3375,O
The,3376,O
deduced,3376,O
protein,3376,O
sequence,3376,O
shows,3376,O
significant,3376,O
sequence,3376,O
identity,3376,O
to,3376,O
a,3376,O
peroxisomal,3376,O
membrane,3376,O
protein,3376,O
of,3376,O
M,3376,O
(,3376,O
r,3376,O
),3376,O
70K,3376,O
that,3376,O
is,3376,O
involved,3376,O
in,3376,O
peroxisome,3376,O
biogenesis,3376,O
and,3376,O
belongs,3376,O
to,3376,O
the,3376,O
ATP-binding,3376,O
cassette,3376,O
superfamily,3376,O
of,3376,O
transporters,3376,O
..,3376,O
Targeted,3377,O
modification,3377,O
of,3377,O
the,3377,O
apolipoprotein,3377,O
B,3377,O
gene,3377,O
results,3377,O
in,3377,O
hypobetalipoproteinemia,3377,B-SpecificDisease
and,3377,O
developmental,3377,B-DiseaseClass
abnormalities,3377,I-DiseaseClass
in,3377,O
mice,3377,O
.,3377,O
Familial,3378,B-SpecificDisease
hypobetalipoproteinemia,3378,I-SpecificDisease
is,3378,O
an,3378,O
autosomal,3378,B-DiseaseClass
codominant,3378,I-DiseaseClass
disorder,3378,I-DiseaseClass
resulting,3378,O
in,3378,O
a,3378,O
dramatic,3378,O
reduction,3378,O
in,3378,O
plasma,3378,O
concentrations,3378,O
of,3378,O
apolipoprotein,3378,O
(,3378,O
apo,3378,O
),3378,O
B,3378,O
",",3378,O
cholesterol,3378,O
",",3378,O
and,3378,O
beta-migrating,3378,O
lipoproteins,3378,O
.,3378,O
A,3379,O
benefit,3379,O
of,3379,O
hypobetalipoproteinemia,3379,B-SpecificDisease
is,3379,O
that,3379,O
mildly,3379,O
affected,3379,O
individuals,3379,O
may,3379,O
be,3379,O
protected,3379,O
from,3379,O
coronary,3379,B-DiseaseClass
vascular,3379,I-DiseaseClass
disease,3379,I-DiseaseClass
.,3379,O
We,3380,O
have,3380,O
used,3380,O
gene,3380,O
targeting,3380,O
to,3380,O
generate,3380,O
mice,3380,O
with,3380,O
a,3380,O
modified,3380,O
Apob,3380,O
allele,3380,O
.,3380,O
Mice,3381,O
containing,3381,O
this,3381,O
allele,3381,O
display,3381,O
all,3381,O
of,3381,O
the,3381,O
hallmarks,3381,O
of,3381,O
human,3381,O
hypobetalipoproteinemia,3381,B-SpecificDisease
they,3381,O
produce,3381,O
a,3381,O
truncated,3381,O
apoB,3381,O
protein,3381,O
",",3381,O
apoB70,3381,O
",",3381,O
and,3381,O
have,3381,O
markedly,3381,O
decreased,3381,O
plasma,3381,O
concentrations,3381,O
of,3381,O
apoB,3381,O
",",3381,O
beta-lipoproteins,3381,O
",",3381,O
and,3381,O
total,3381,O
cholesterol,3381,O
.,3381,O
In,3382,O
addition,3382,O
",",3382,O
the,3382,O
mice,3382,O
manifest,3382,O
several,3382,O
characteristics,3382,O
that,3382,O
are,3382,O
occasionally,3382,O
observed,3382,O
in,3382,O
human,3382,O
hypobetalipoproteinemia,3382,B-SpecificDisease
",",3382,O
including,3382,O
reduced,3382,O
plasma,3382,O
triglyceride,3382,O
concentrations,3382,O
",",3382,O
fasting,3382,O
chylomicronemia,3382,B-SpecificDisease
",",3382,O
and,3382,O
reduced,3382,O
high,3382,O
density,3382,O
lipoprotein,3382,O
cholesterol,3382,O
.,3382,O
An,3383,O
unexpected,3383,O
finding,3383,O
is,3383,O
that,3383,O
the,3383,O
modified,3383,O
Apob,3383,O
allele,3383,O
is,3383,O
strongly,3383,O
associated,3383,O
with,3383,O
exencephalus,3383,B-SpecificDisease
and,3383,O
hydrocephalus,3383,B-SpecificDisease
.,3383,O
These,3384,O
mice,3384,O
should,3384,O
help,3384,O
increase,3384,O
our,3384,O
understanding,3384,O
of,3384,O
hypobetalipoproteinemia,3384,B-SpecificDisease
",",3384,O
atherogenesis,3384,B-DiseaseClass
",",3384,O
and,3384,O
the,3384,O
etiology,3384,O
of,3384,O
exencephalus,3384,B-SpecificDisease
and,3384,O
hydrocephalus,3384,B-SpecificDisease
..,3384,O
A,3385,O
novel,3385,O
disease,3385,O
with,3385,O
deficiency,3385,B-SpecificDisease
of,3385,I-SpecificDisease
mitochondrial,3385,I-SpecificDisease
very-long-chain,3385,I-SpecificDisease
acyl-CoA,3385,I-SpecificDisease
dehydrogenase,3385,I-SpecificDisease
.,3385,O
Palmitoyl-CoA,3386,O
dehydrogenase,3386,O
activity,3386,O
in,3386,O
skin,3386,O
fibroblasts,3386,O
from,3386,O
seven,3386,O
patients,3386,O
with,3386,O
unidentified,3386,O
defects,3386,O
of,3386,O
fatty,3386,O
acid,3386,O
oxidation,3386,O
was,3386,O
measured,3386,O
in,3386,O
the,3386,O
presence,3386,O
and,3386,O
absence,3386,O
of,3386,O
antibodies,3386,O
against,3386,O
medium-chain,3386,O
",",3386,O
long-chain,3386,O
",",3386,O
and,3386,O
very-long-chain,3386,O
acyl-CoA,3386,O
dehydrogenases,3386,O
(,3386,O
VLCAD,3386,O
),3386,O
.,3386,O
Two,3387,O
of,3387,O
the,3387,O
patients,3387,O
",",3387,O
4-5,3387,O
month,3387,O
old,3387,O
boys,3387,O
",",3387,O
were,3387,O
found,3387,O
to,3387,O
have,3387,O
a,3387,O
novel,3387,O
disease,3387,O
",",3387,O
VLCAD,3387,B-SpecificDisease
deficiency,3387,I-SpecificDisease
",",3387,O
as,3387,O
judged,3387,O
from,3387,O
the,3387,O
results,3387,O
of,3387,O
very,3387,O
low,3387,O
palmitoyl-CoA,3387,O
dehydrogenase,3387,O
activity,3387,O
and,3387,O
the,3387,O
lack,3387,O
of,3387,O
immunoreactivity,3387,O
toward,3387,O
antibody,3387,O
raised,3387,O
to,3387,O
purified,3387,O
VLCAD,3387,O
..,3387,O
Molecular,3388,O
characterization,3388,O
of,3388,O
glucose-6-phosphate,3388,B-SpecificDisease
dehydrogenase,3388,I-SpecificDisease
(,3388,I-SpecificDisease
G6PD,3388,I-SpecificDisease
),3388,I-SpecificDisease
deficiency,3388,I-SpecificDisease
in,3388,O
patients,3388,O
of,3388,O
Chinese,3388,O
descent,3388,O
and,3388,O
identification,3388,O
of,3388,O
new,3388,O
base,3388,O
substitutions,3388,O
in,3388,O
the,3388,O
human,3388,O
G6PD,3388,O
gene,3388,O
.,3388,O
The,3389,O
underlying,3389,O
DNA,3389,O
changes,3389,O
associated,3389,O
with,3389,O
glucose-6-phosphate,3389,B-Modifier
dehydrogenase,3389,I-Modifier
(,3389,I-Modifier
G6PD,3389,I-Modifier
),3389,I-Modifier
-deficient,3389,I-Modifier
Asians,3389,O
have,3389,O
not,3389,O
been,3389,O
extensively,3389,O
investigated,3389,O
.,3389,O
To,3390,O
fill,3390,O
this,3390,O
gap,3390,O
",",3390,O
we,3390,O
sequenced,3390,O
the,3390,O
G6PD,3390,O
gene,3390,O
of,3390,O
43,3390,O
G6PD-deficient,3390,B-Modifier
Chinese,3390,O
whose,3390,O
G6PD,3390,O
was,3390,O
well,3390,O
characterized,3390,O
biochemically,3390,O
.,3390,O
DNA,3391,O
samples,3391,O
were,3391,O
obtained,3391,O
from,3391,O
peripheral,3391,O
blood,3391,O
of,3391,O
these,3391,O
individuals,3391,O
for,3391,O
sequencing,3391,O
using,3391,O
a,3391,O
direct,3391,O
polymerase,3391,O
chain,3391,O
reaction,3391,O
(,3391,O
PCR,3391,O
),3391,O
sequencing,3391,O
procedure,3391,O
.,3391,O
From,3392,O
these,3392,O
43,3392,O
samples,3392,O
",",3392,O
we,3392,O
have,3392,O
identified,3392,O
five,3392,O
different,3392,O
types,3392,O
of,3392,O
nucleotide,3392,O
substitutions,3392,O
in,3392,O
the,3392,O
G6PD,3392,O
gene,3392,O
at,3392,O
cDNA,3392,O
1388,3392,O
from,3392,O
G,3392,O
to,3392,O
A,3392,O
(,3392,O
Arg,3392,O
to,3392,O
His,3392,O
),3392,O
;,3392,O
at,3392,O
cDNA,3392,O
1376,3392,O
from,3392,O
G,3392,O
to,3392,O
T,3392,O
(,3392,O
Arg,3392,O
to,3392,O
Leu,3392,O
),3392,O
;,3392,O
at,3392,O
cDNA,3392,O
1024,3392,O
from,3392,O
C,3392,O
to,3392,O
T,3392,O
(,3392,O
Leu,3392,O
to,3392,O
Phe,3392,O
),3392,O
;,3392,O
at,3392,O
cDNA,3392,O
392,3392,O
from,3392,O
G,3392,O
to,3392,O
T,3392,O
(,3392,O
Gly,3392,O
to,3392,O
Val,3392,O
),3392,O
;,3392,O
at,3392,O
cDNA,3392,O
95,3392,O
from,3392,O
A,3392,O
to,3392,O
G,3392,O
(,3392,O
His,3392,O
to,3392,O
Arg,3392,O
),3392,O
.,3392,O
These,3393,O
five,3393,O
nucleotide,3393,O
substitutions,3393,O
account,3393,O
for,3393,O
over,3393,O
83,3393,O
%,3393,O
of,3393,O
our,3393,O
43,3393,O
G6PD-deficient,3393,B-Modifier
samples,3393,O
and,3393,O
these,3393,O
substitutions,3393,O
have,3393,O
not,3393,O
been,3393,O
reported,3393,O
in,3393,O
non-Asians,3393,O
.,3393,O
The,3394,O
substitutions,3394,O
found,3394,O
at,3394,O
cDNA,3394,O
392,3394,O
and,3394,O
cDNA,3394,O
1024,3394,O
are,3394,O
new,3394,O
findings,3394,O
.,3394,O
The,3395,O
substitutions,3395,O
at,3395,O
cDNA,3395,O
1376,3395,O
and,3395,O
1388,3395,O
account,3395,O
for,3395,O
over,3395,O
50,3395,O
%,3395,O
of,3395,O
the,3395,O
43,3395,O
samples,3395,O
examined,3395,O
indicating,3395,O
a,3395,O
high,3395,O
prevalence,3395,O
of,3395,O
these,3395,O
two,3395,O
alleles,3395,O
among,3395,O
G6PD-deficient,3395,B-Modifier
Chinese,3395,O
.,3395,O
Our,3396,O
findings,3396,O
add,3396,O
support,3396,O
to,3396,O
the,3396,O
notion,3396,O
that,3396,O
diverse,3396,O
point,3396,O
mutations,3396,O
may,3396,O
account,3396,O
largely,3396,O
for,3396,O
much,3396,O
of,3396,O
the,3396,O
phenotypic,3396,O
heterogeneity,3396,O
of,3396,O
G6PD,3396,B-SpecificDisease
deficiency,3396,I-SpecificDisease
..,3396,O
Identification,3397,O
of,3397,O
mutations,3397,O
in,3397,O
Danish,3397,O
choroideremia,3397,B-Modifier
families,3397,O
.,3397,O
We,3398,O
have,3398,O
searched,3398,O
for,3398,O
mutations,3398,O
in,3398,O
the,3398,O
choroideremia,3398,B-Modifier
gene,3398,O
(,3398,O
CHM,3398,B-Modifier
),3398,O
in,3398,O
patients,3398,O
from,3398,O
12,3398,O
Danish,3398,O
families,3398,O
in,3398,O
which,3398,O
CHM,3398,B-SpecificDisease
is,3398,O
segregating,3398,O
.,3398,O
Employing,3399,O
polymerase,3399,O
chain,3399,O
reaction,3399,O
(,3399,O
PCR,3399,O
),3399,O
",",3399,O
single,3399,O
strand,3399,O
conformation,3399,O
polymorphism,3399,O
(,3399,O
SSCP,3399,O
),3399,O
analysis,3399,O
",",3399,O
and,3399,O
direct,3399,O
DNA,3399,O
sequencing,3399,O
",",3399,O
different,3399,O
mutations,3399,O
have,3399,O
been,3399,O
identified,3399,O
in,3399,O
6,3399,O
patients,3399,O
.,3399,O
All,3400,O
the,3400,O
mutations,3400,O
will,3400,O
interfere,3400,O
with,3400,O
the,3400,O
correct,3400,O
translation,3400,O
of,3400,O
the,3400,O
mRNA,3400,O
predicting,3400,O
a,3400,O
truncated,3400,O
protein,3400,O
or,3400,O
no,3400,O
gene,3400,O
product,3400,O
at,3400,O
all,3400,O
..,3400,O
Structure,3401,O
and,3401,O
genomic,3401,O
sequence,3401,O
of,3401,O
the,3401,O
myotonic,3401,B-Modifier
dystrophy,3401,I-Modifier
(,3401,O
DM,3401,B-Modifier
kinase,3401,O
),3401,O
gene,3401,O
.,3401,O
The,3402,O
mutation,3402,O
causing,3402,O
myotonic,3402,B-SpecificDisease
dystrophy,3402,I-SpecificDisease
(,3402,O
DM,3402,B-SpecificDisease
),3402,O
has,3402,O
recently,3402,O
been,3402,O
identified,3402,O
as,3402,O
an,3402,O
unstable,3402,O
CTG,3402,O
trinucleotide,3402,O
repeat,3402,O
located,3402,O
in,3402,O
the,3402,O
3,3402,O
untranslated,3402,O
region,3402,O
of,3402,O
a,3402,O
gene,3402,O
encoding,3402,O
for,3402,O
a,3402,O
protein,3402,O
with,3402,O
putative,3402,O
serine-threonine,3402,O
protein,3402,O
kinase,3402,O
activity,3402,O
.,3402,O
In,3403,O
this,3403,O
report,3403,O
we,3403,O
present,3403,O
the,3403,O
genomic,3403,O
sequences,3403,O
of,3403,O
the,3403,O
human,3403,O
and,3403,O
murine,3403,O
DM,3403,B-Modifier
kinase,3403,O
gene,3403,O
.,3403,O
A,3404,O
comparison,3404,O
of,3404,O
these,3404,O
sequences,3404,O
with,3404,O
each,3404,O
other,3404,O
and,3404,O
with,3404,O
known,3404,O
cDNA,3404,O
sequences,3404,O
from,3404,O
both,3404,O
species,3404,O
",",3404,O
led,3404,O
us,3404,O
to,3404,O
predict,3404,O
a,3404,O
translation,3404,O
initiation,3404,O
codon,3404,O
",",3404,O
as,3404,O
well,3404,O
as,3404,O
determine,3404,O
the,3404,O
organization,3404,O
of,3404,O
the,3404,O
DM,3404,B-Modifier
kinase,3404,O
gene,3404,O
.,3404,O
Several,3405,O
polymorphisms,3405,O
within,3405,O
the,3405,O
human,3405,O
DM,3405,B-Modifier
kinase,3405,O
gene,3405,O
have,3405,O
been,3405,O
identified,3405,O
",",3405,O
and,3405,O
PCR,3405,O
assays,3405,O
to,3405,O
detect,3405,O
two,3405,O
of,3405,O
these,3405,O
are,3405,O
described,3405,O
.,3405,O
The,3406,O
complete,3406,O
sequence,3406,O
and,3406,O
characterization,3406,O
of,3406,O
the,3406,O
structure,3406,O
of,3406,O
the,3406,O
DM,3406,B-Modifier
kinase,3406,O
gene,3406,O
",",3406,O
as,3406,O
well,3406,O
as,3406,O
the,3406,O
identification,3406,O
of,3406,O
novel,3406,O
polymorphisms,3406,O
within,3406,O
the,3406,O
gene,3406,O
",",3406,O
represent,3406,O
an,3406,O
important,3406,O
step,3406,O
in,3406,O
a,3406,O
further,3406,O
understanding,3406,O
of,3406,O
the,3406,O
genetics,3406,O
of,3406,O
myotonic,3406,B-SpecificDisease
dystrophy,3406,I-SpecificDisease
and,3406,O
the,3406,O
molecular,3406,O
biology,3406,O
of,3406,O
the,3406,O
gene,3406,O
..,3406,O
Autosomal,3407,O
recessive,3407,O
transmission,3407,O
of,3407,O
hemophilia,3407,B-SpecificDisease
A,3407,I-SpecificDisease
due,3407,O
to,3407,O
a,3407,O
von,3407,B-Modifier
Willebrand,3407,I-Modifier
factor,3407,O
mutation,3407,O
.,3407,O
The,3408,O
differential,3408,O
diagnosis,3408,O
of,3408,O
the,3408,O
genetic,3408,B-DiseaseClass
bleeding,3408,I-DiseaseClass
disorders,3408,I-DiseaseClass
",",3408,O
hemophilia,3408,B-SpecificDisease
A,3408,I-SpecificDisease
and,3408,O
von,3408,B-SpecificDisease
Willebrand,3408,I-SpecificDisease
disease,3408,I-SpecificDisease
",",3408,O
is,3408,O
occasionally,3408,O
confounded,3408,O
by,3408,O
the,3408,O
close,3408,O
molecular,3408,O
relationship,3408,O
of,3408,O
coagulation,3408,O
factor,3408,O
VIII,3408,O
and,3408,O
von,3408,B-Modifier
Willebrand,3408,I-Modifier
factor,3408,O
(,3408,O
vWF,3408,O
),3408,O
.,3408,O
This,3409,O
report,3409,O
describes,3409,O
the,3409,O
autosomal,3409,O
inheritance,3409,O
of,3409,O
a,3409,O
hemophilia,3409,B-Modifier
A,3409,I-Modifier
phenotype,3409,O
due,3409,O
to,3409,O
a,3409,O
mutation,3409,O
of,3409,O
vWF,3409,O
that,3409,O
results,3409,O
in,3409,O
defective,3409,O
factor,3409,O
VIII,3409,O
binding,3409,O
.,3409,O
The,3410,O
proband,3410,O
was,3410,O
a,3410,O
female,3410,O
patient,3410,O
with,3410,O
low,3410,O
levels,3410,O
of,3410,O
factor,3410,O
VIII,3410,O
activity,3410,O
.,3410,O
Polymerase,3411,O
chain,3411,O
reaction,3411,O
(,3411,O
PCR,3411,O
),3411,O
amplification,3411,O
and,3411,O
DNA,3411,O
sequencing,3411,O
were,3411,O
employed,3411,O
to,3411,O
examine,3411,O
exons,3411,O
encoding,3411,O
the,3411,O
putative,3411,O
factor,3411,O
VIII,3411,O
binding,3411,O
domain,3411,O
of,3411,O
vWF,3411,O
.,3411,O
The,3412,O
patient,3412,O
was,3412,O
found,3412,O
to,3412,O
be,3412,O
homozygous,3412,O
for,3412,O
a,3412,O
single,3412,O
point,3412,O
mutation,3412,O
causing,3412,O
a,3412,O
Thr,3412,O
--,3412,O
>,3412,O
Met,3412,O
substitution,3412,O
at,3412,O
amino,3412,O
acid,3412,O
position,3412,O
28,3412,O
in,3412,O
the,3412,O
mature,3412,O
vWF,3412,O
subunit,3412,O
.,3412,O
The,3413,O
phenotypic,3413,O
expression,3413,O
of,3413,O
the,3413,O
mutation,3413,O
was,3413,O
determined,3413,O
to,3413,O
be,3413,O
recessive,3413,O
because,3413,O
heterozygous,3413,O
family,3413,O
members,3413,O
were,3413,O
clinically,3413,O
unaffected,3413,O
.,3413,O
Recombinant,3414,O
vWF,3414,O
containing,3414,O
the,3414,O
observed,3414,O
amino,3414,O
acid,3414,O
substitution,3414,O
was,3414,O
expressed,3414,O
in,3414,O
COS-1,3414,O
cells,3414,O
.,3414,O
The,3415,O
mutant,3415,O
vWF,3415,O
was,3415,O
processed,3415,O
and,3415,O
secreted,3415,O
normally,3415,O
",",3415,O
and,3415,O
was,3415,O
functionally,3415,O
equivalent,3415,O
to,3415,O
wild-type,3415,O
vWF,3415,O
in,3415,O
its,3415,O
ability,3415,O
to,3415,O
bind,3415,O
to,3415,O
platelets,3415,O
.,3415,O
However,3416,O
",",3416,O
the,3416,O
mutant,3416,O
failed,3416,O
to,3416,O
bind,3416,O
factor,3416,O
VIII,3416,O
",",3416,O
demonstrating,3416,O
that,3416,O
the,3416,O
mutation,3416,O
was,3416,O
functionally,3416,O
related,3416,O
to,3416,O
the,3416,O
observed,3416,O
hemophilia,3416,O
phenotype,3416,O
.,3416,O
The,3417,O
family,3417,O
we,3417,O
describe,3417,O
demonstrates,3417,O
the,3417,O
recessive,3417,O
inheritance,3417,O
of,3417,O
a,3417,O
recently,3417,O
recognized,3417,O
class,3417,O
of,3417,O
genetic,3417,O
bleeding,3417,O
disorders,3417,O
",",3417,O
we,3417,O
call,3417,O
``,3417,O
autosomal,3417,O
hemophilia.,3417,O
``,3417,O
We,3418,O
conclude,3418,O
that,3418,O
vWF,3418,O
mutation,3418,O
may,3418,O
be,3418,O
an,3418,O
under,3418,O
recognized,3418,O
cause,3418,O
of,3418,O
hemophilia,3418,O
",",3418,O
especially,3418,O
in,3418,O
cases,3418,O
where,3418,O
the,3418,O
inheritance,3418,O
pattern,3418,O
is,3418,O
not,3418,O
consistent,3418,O
with,3418,O
X-linked,3418,O
transmission,3418,O
.,3418,O
Somatic,3419,O
von,3419,B-Modifier
Hippel-Lindau,3419,I-Modifier
mutation,3419,O
in,3419,O
clear,3419,O
cell,3419,O
papillary,3419,B-SpecificDisease
cystadenoma,3419,I-SpecificDisease
of,3419,I-SpecificDisease
the,3419,I-SpecificDisease
epididymis,3419,I-SpecificDisease
.,3419,O
Papillary,3420,B-SpecificDisease
cystadenoma,3420,I-SpecificDisease
of,3420,I-SpecificDisease
the,3420,I-SpecificDisease
epididymis,3420,I-SpecificDisease
is,3420,O
an,3420,O
uncommon,3420,O
benign,3420,O
lesion,3420,O
that,3420,O
may,3420,O
occur,3420,O
sporadically,3420,O
or,3420,O
as,3420,O
a,3420,O
manifestation,3420,O
of,3420,O
von,3420,B-SpecificDisease
Hippel-Lindau,3420,I-SpecificDisease
(,3420,I-SpecificDisease
VHL,3420,I-SpecificDisease
),3420,I-SpecificDisease
disease,3420,I-SpecificDisease
.,3420,O
Neither,3421,O
immunohistochemical,3421,O
studies,3421,O
nor,3421,O
molecular,3421,O
genetic,3421,O
analyses,3421,O
of,3421,O
the,3421,O
VHL,3421,B-Modifier
gene,3421,O
have,3421,O
been,3421,O
reported,3421,O
previously,3421,O
for,3421,O
this,3421,O
lesion,3421,O
.,3421,O
The,3422,O
authors,3422,O
describe,3422,O
two,3422,O
cases,3422,O
of,3422,O
clear,3422,O
cell,3422,O
papillary,3422,B-SpecificDisease
cystadenoma,3422,I-SpecificDisease
of,3422,I-SpecificDisease
the,3422,I-SpecificDisease
epididymis,3422,I-SpecificDisease
",",3422,O
both,3422,O
of,3422,O
which,3422,O
were,3422,O
initially,3422,O
confused,3422,O
with,3422,O
metastatic,3422,B-SpecificDisease
renal,3422,I-SpecificDisease
cell,3422,I-SpecificDisease
carcinoma,3422,I-SpecificDisease
.,3422,O
Both,3423,O
lesions,3423,O
showed,3423,O
positive,3423,O
immunohistochemical,3423,O
staining,3423,O
for,3423,O
low,3423,O
and,3423,O
intermediate,3423,O
molecular,3423,O
weight,3423,O
keratins,3423,O
(,3423,O
Cam,3423,O
5,3423,O
.,3423,O
2,3424,O
and,3424,O
AE1/AE3,3424,O
),3424,O
",",3424,O
EMA,3424,O
",",3424,O
vimentin,3424,O
",",3424,O
alpha,3424,O
1-antitrypsin,3424,O
",",3424,O
and,3424,O
alpha,3424,O
1-antichymotrypsin,3424,O
.,3424,O
Each,3425,O
was,3425,O
negative,3425,O
for,3425,O
CEA,3425,O
.,3425,O
Because,3426,O
clear,3426,O
cell,3426,O
papillary,3426,B-SpecificDisease
cystadenoma,3426,I-SpecificDisease
is,3426,O
similar,3426,O
to,3426,O
renal,3426,B-SpecificDisease
cell,3426,I-SpecificDisease
carcinoma,3426,I-SpecificDisease
histologically,3426,O
",",3426,O
and,3426,O
because,3426,O
both,3426,O
occur,3426,O
as,3426,O
components,3426,O
of,3426,O
the,3426,O
von,3426,B-Modifier
Hippel-Lindau,3426,I-Modifier
disease,3426,I-Modifier
complex,3426,O
",",3426,O
the,3426,O
authors,3426,O
analyzed,3426,O
both,3426,O
cases,3426,O
for,3426,O
the,3426,O
presence,3426,O
of,3426,O
mutations,3426,O
in,3426,O
the,3426,O
VHL,3426,B-Modifier
gene,3426,O
.,3426,O
A,3427,O
somatic,3427,O
VHL,3427,B-Modifier
gene,3427,O
mutation,3427,O
was,3427,O
detected,3427,O
in,3427,O
one,3427,O
of,3427,O
the,3427,O
two,3427,O
tumors,3427,B-DiseaseClass
by,3427,O
polymerase,3427,O
chain,3427,O
reaction,3427,O
followed,3427,O
by,3427,O
single-strand,3427,O
conformation,3427,O
polymorphism,3427,O
analysis,3427,O
.,3427,O
Direct,3428,O
sequencing,3428,O
revealed,3428,O
a,3428,O
cytosine,3428,O
to,3428,O
thymine,3428,O
transition,3428,O
at,3428,O
nucleotide,3428,O
694,3428,O
",",3428,O
resulting,3428,O
in,3428,O
the,3428,O
replacement,3428,O
of,3428,O
an,3428,O
arginine,3428,O
with,3428,O
a,3428,O
stop,3428,O
codon,3428,O
after,3428,O
the,3428,O
sixth,3428,O
amino,3428,O
acid,3428,O
of,3428,O
exon,3428,O
3,3428,O
.,3428,O
As,3429,O
the,3429,O
VHL,3429,B-Modifier
gene,3429,O
is,3429,O
believed,3429,O
to,3429,O
function,3429,O
as,3429,O
a,3429,O
tumor,3429,B-Modifier
suppressor,3429,O
gene,3429,O
",",3429,O
VHL,3429,B-Modifier
gene,3429,O
mutations,3429,O
may,3429,O
play,3429,O
a,3429,O
role,3429,O
in,3429,O
the,3429,O
initiation,3429,O
of,3429,O
tumorigenesis,3429,O
in,3429,O
sporadic,3429,O
cystadenomas,3429,B-SpecificDisease
of,3429,I-SpecificDisease
the,3429,I-SpecificDisease
epididymis,3429,I-SpecificDisease
.,3429,O
Identification,3430,O
of,3430,O
WASP,3430,O
mutations,3430,O
in,3430,O
patients,3430,O
with,3430,O
Wiskott-Aldrich,3430,B-SpecificDisease
syndrome,3430,I-SpecificDisease
and,3430,O
isolated,3430,B-SpecificDisease
thrombocytopenia,3430,I-SpecificDisease
reveals,3430,O
allelic,3430,O
heterogeneity,3430,O
at,3430,O
the,3430,O
WAS,3430,B-Modifier
locus,3430,O
.,3430,O
Mutation,3431,O
in,3431,O
the,3431,O
gene,3431,O
encoding,3431,O
the,3431,O
recently,3431,O
isolated,3431,O
WASP,3431,O
protein,3431,O
has,3431,O
now,3431,O
been,3431,O
identified,3431,O
as,3431,O
the,3431,O
genetic,3431,B-DiseaseClass
defect,3431,I-DiseaseClass
responsible,3431,O
for,3431,O
the,3431,O
X-linked,3431,B-SpecificDisease
Wiskott-Aldrich,3431,I-SpecificDisease
syndrome,3431,I-SpecificDisease
(,3431,O
WAS,3431,B-SpecificDisease
),3431,O
",",3431,O
a,3431,O
primary,3431,O
immunodeficiency,3431,B-DiseaseClass
disease,3431,I-DiseaseClass
associated,3431,O
with,3431,O
extensive,3431,O
phenotypic,3431,O
variability,3431,O
.,3431,O
To,3432,O
elucidate,3432,O
the,3432,O
range,3432,O
of,3432,O
WASP,3432,O
mutations,3432,O
responsible,3432,O
for,3432,O
WAS,3432,B-SpecificDisease
",",3432,O
we,3432,O
used,3432,O
PCR-SSCP,3432,O
analysis,3432,O
to,3432,O
screen,3432,O
for,3432,O
WASP,3432,O
gene,3432,O
mutation,3432,O
in,3432,O
19,3432,O
unrelated,3432,O
boys,3432,O
with,3432,O
the,3432,O
diagnosis,3432,O
of,3432,O
classical,3432,O
or,3432,O
attenuated,3432,O
WAS,3432,B-SpecificDisease
or,3432,O
isolated,3432,B-SpecificDisease
thrombocytopenia,3432,I-SpecificDisease
.,3432,O
All,3433,O
19,3433,O
patients,3433,O
had,3433,O
WASP,3433,O
mutations,3433,O
",",3433,O
each,3433,O
of,3433,O
which,3433,O
localized,3433,O
to,3433,O
the,3433,O
initial,3433,O
three,3433,O
or,3433,O
terminal,3433,O
three,3433,O
exons,3433,O
of,3433,O
the,3433,O
gene,3433,O
",",3433,O
and,3433,O
the,3433,O
majority,3433,O
of,3433,O
which,3433,O
were,3433,O
unique,3433,O
in,3433,O
each,3433,O
case,3433,O
.,3433,O
However,3434,O
",",3434,O
a,3434,O
missense,3434,O
mutation,3434,O
which,3434,O
results,3434,O
in,3434,O
substitution,3434,O
of,3434,O
the,3434,O
arginine,3434,O
at,3434,O
WAS,3434,B-Modifier
codon,3434,O
86,3434,O
was,3434,O
identified,3434,O
in,3434,O
three,3434,O
boys,3434,O
with,3434,O
severe,3434,O
WAS,3434,B-SpecificDisease
as,3434,O
well,3434,O
as,3434,O
in,3434,O
one,3434,O
boy,3434,O
presenting,3434,O
with,3434,O
thrombocytopenia,3434,B-SpecificDisease
alone,3434,O
.,3434,O
While,3435,O
the,3435,O
three,3435,O
mutations,3435,O
found,3435,O
in,3435,O
the,3435,O
isolated,3435,B-Modifier
thrombocytopenia,3435,I-Modifier
patients,3435,O
leave,3435,O
the,3435,O
reading,3435,O
frame,3435,O
intact,3435,O
",",3435,O
about,3435,O
one-half,3435,O
of,3435,O
the,3435,O
gene,3435,O
alterations,3435,O
detected,3435,O
in,3435,O
both,3435,O
severe,3435,O
and,3435,O
attenuated,3435,O
WAS,3435,B-SpecificDisease
patients,3435,O
result,3435,O
in,3435,O
frameshifted,3435,O
transcript,3435,O
and,3435,O
premature,3435,O
translation,3435,O
termination,3435,O
.,3435,O
These,3436,O
findings,3436,O
therefore,3436,O
confirm,3436,O
the,3436,O
association,3436,O
of,3436,O
WAS,3436,B-SpecificDisease
with,3436,O
WASP,3436,O
mutation,3436,O
and,3436,O
identify,3436,O
WASP,3436,O
mutation,3436,O
as,3436,O
a,3436,O
cause,3436,O
for,3436,O
isolated,3436,O
congenital,3436,B-SpecificDisease
thrombocytopenia,3436,I-SpecificDisease
in,3436,O
males,3436,O
.,3436,O
While,3437,O
the,3437,O
WASP,3437,O
gene,3437,O
defects,3437,O
responsible,3437,O
for,3437,O
isolated,3437,B-SpecificDisease
thrombocytopenia,3437,I-SpecificDisease
and,3437,O
other,3437,O
mild,3437,O
presentations,3437,O
of,3437,O
WAS,3437,B-SpecificDisease
do,3437,O
not,3437,O
appear,3437,O
distinct,3437,O
from,3437,O
those,3437,O
resulting,3437,O
in,3437,O
severe,3437,O
WAS,3437,B-SpecificDisease
",",3437,O
these,3437,O
data,3437,O
indicate,3437,O
that,3437,O
analysis,3437,O
of,3437,O
WASP,3437,O
gene,3437,O
mutation,3437,O
provides,3437,O
a,3437,O
valuable,3437,O
tool,3437,O
for,3437,O
distinguishing,3437,O
the,3437,O
spectrum,3437,O
of,3437,O
WAS,3437,B-Modifier
patients,3437,O
and,3437,O
the,3437,O
subset,3437,O
of,3437,O
males,3437,O
with,3437,O
isolated,3437,B-SpecificDisease
thrombocytopenia,3437,I-SpecificDisease
who,3437,O
represent,3437,O
mild,3437,O
cases,3437,O
of,3437,O
WAS,3437,B-SpecificDisease
..,3437,O
WASP,3438,O
gene,3438,O
mutations,3438,O
in,3438,O
Wiskott-Aldrich,3438,B-SpecificDisease
syndrome,3438,I-SpecificDisease
and,3438,O
X-linked,3438,B-SpecificDisease
thrombocytopenia,3438,I-SpecificDisease
.,3438,O
The,3439,O
WASP,3439,O
gene,3439,O
has,3439,O
been,3439,O
recently,3439,O
cloned,3439,O
from,3439,O
Xp11,3439,O
.,3439,O
23,3440,O
and,3440,O
shown,3440,O
to,3440,O
be,3440,O
mutated,3440,O
in,3440,O
three,3440,O
patients,3440,O
with,3440,O
the,3440,O
Wiskott-Aldrich,3440,B-SpecificDisease
syndrome,3440,I-SpecificDisease
(,3440,O
WAS,3440,B-SpecificDisease
),3440,O
.,3440,O
We,3441,O
have,3441,O
developed,3441,O
a,3441,O
screening,3441,O
protocol,3441,O
for,3441,O
identifying,3441,O
WASP,3441,O
gene,3441,O
alterations,3441,O
in,3441,O
genomic,3441,O
DNA,3441,O
and,3441,O
have,3441,O
identified,3441,O
a,3441,O
spectrum,3441,O
of,3441,O
novel,3441,O
mutations,3441,O
in,3441,O
12,3441,O
additional,3441,O
unrelated,3441,O
families,3441,O
.,3441,O
These,3442,O
missense,3442,O
",",3442,O
nonsense,3442,O
and,3442,O
frameshift,3442,O
mutations,3442,O
involve,3442,O
eight,3442,O
of,3442,O
the,3442,O
12,3442,O
exons,3442,O
of,3442,O
the,3442,O
gene,3442,O
.,3442,O
Two,3443,O
mutations,3443,O
creating,3443,O
premature,3443,O
termination,3443,O
codons,3443,O
were,3443,O
associated,3443,O
with,3443,O
lack,3443,O
of,3443,O
detectable,3443,O
mRNA,3443,O
on,3443,O
Northern,3443,O
blots,3443,O
.,3443,O
Four,3444,O
amino,3444,O
acid,3444,O
substitutions,3444,O
",",3444,O
Leu27Phe,3444,O
",",3444,O
Thr48Ile,3444,O
",",3444,O
Val75Met,3444,O
and,3444,O
Arg477Lys,3444,O
",",3444,O
were,3444,O
found,3444,O
in,3444,O
patients,3444,O
with,3444,O
congenital,3444,B-SpecificDisease
thrombocytopenia,3444,I-SpecificDisease
and,3444,O
no,3444,O
clinically,3444,O
evident,3444,O
immune,3444,O
defect,3444,O
indicating,3444,O
that,3444,O
the,3444,O
WASP,3444,O
gene,3444,O
is,3444,O
the,3444,O
site,3444,O
for,3444,O
mutations,3444,O
in,3444,O
X-linked,3444,B-SpecificDisease
thrombocytopenia,3444,I-SpecificDisease
as,3444,O
well,3444,O
as,3444,O
in,3444,O
WAS,3444,B-SpecificDisease
.,3444,O
A,3445,O
T-cell,3445,O
line,3445,O
from,3445,O
a,3445,O
WAS,3445,B-Modifier
patient,3445,O
contained,3445,O
two,3445,O
independent,3445,O
DNA,3445,O
alterations,3445,O
",",3445,O
a,3445,O
constitutional,3445,O
frameshift,3445,O
mutation,3445,O
",",3445,O
also,3445,O
present,3445,O
in,3445,O
peripheral,3445,O
blood,3445,O
leukocytes,3445,O
from,3445,O
the,3445,O
patient,3445,O
",",3445,O
and,3445,O
compensatory,3445,O
splice,3445,O
site,3445,O
mutation,3445,O
unique,3445,O
to,3445,O
the,3445,O
cell,3445,O
line,3445,O
.,3445,O
The,3446,O
distribution,3446,O
of,3446,O
eight,3446,O
missense,3446,O
mutations,3446,O
provides,3446,O
valuable,3446,O
information,3446,O
on,3446,O
amino,3446,O
acids,3446,O
which,3446,O
are,3446,O
essential,3446,O
for,3446,O
normal,3446,O
protein,3446,O
function,3446,O
",",3446,O
and,3446,O
suggests,3446,O
that,3446,O
sites,3446,O
in,3446,O
the,3446,O
first,3446,O
two,3446,O
exons,3446,O
are,3446,O
hot-spots,3446,O
for,3446,O
mutation,3446,O
.,3446,O
Evidence,3447,O
for,3447,O
inter-generational,3447,O
instability,3447,O
in,3447,O
the,3447,O
CAG,3447,O
repeat,3447,O
in,3447,O
the,3447,O
MJD1,3447,O
gene,3447,O
and,3447,O
for,3447,O
conserved,3447,O
haplotypes,3447,O
at,3447,O
flanking,3447,O
markers,3447,O
amongst,3447,O
Japanese,3447,O
and,3447,O
Caucasian,3447,O
subjects,3447,O
with,3447,O
Machado-Joseph,3447,B-SpecificDisease
disease,3447,I-SpecificDisease
.,3447,O
The,3448,O
size,3448,O
of,3448,O
the,3448,O
(,3448,O
CAG,3448,O
),3448,O
n,3448,O
repeat,3448,O
array,3448,O
in,3448,O
the,3448,O
3,3448,O
',3448,O
end,3448,O
of,3448,O
the,3448,O
MJD1,3448,O
gene,3448,O
and,3448,O
the,3448,O
haplotype,3448,O
at,3448,O
a,3448,O
series,3448,O
of,3448,O
microsatellite,3448,O
markers,3448,O
surrounding,3448,O
the,3448,O
MJD1,3448,O
gene,3448,O
were,3448,O
examined,3448,O
in,3448,O
a,3448,O
large,3448,O
cohort,3448,O
of,3448,O
Japanese,3448,O
and,3448,O
Caucasian,3448,O
subjects,3448,O
affected,3448,O
with,3448,O
Machado-Joseph,3448,B-SpecificDisease
disease,3448,I-SpecificDisease
(,3448,O
MJD,3448,B-SpecificDisease
),3448,O
.,3448,O
Our,3449,O
data,3449,O
provide,3449,O
five,3449,O
novel,3449,O
observations,3449,O
.,3449,O
First,3450,O
",",3450,O
MJD,3450,B-SpecificDisease
is,3450,O
associated,3450,O
with,3450,O
expansion,3450,O
fo,3450,O
the,3450,O
array,3450,O
from,3450,O
the,3450,O
normal,3450,O
range,3450,O
of,3450,O
14-37,3450,O
repeats,3450,O
to,3450,O
68-84,3450,O
repeats,3450,O
in,3450,O
most,3450,O
Japanese,3450,O
and,3450,O
Caucasian,3450,O
subjects,3450,O
",",3450,O
but,3450,O
no,3450,O
subjects,3450,O
were,3450,O
observed,3450,O
with,3450,O
expansions,3450,O
intermediate,3450,O
in,3450,O
size,3450,O
between,3450,O
those,3450,O
of,3450,O
the,3450,O
normal,3450,O
and,3450,O
MJD,3450,B-Modifier
affected,3450,O
groups,3450,O
.,3450,O
Second,3451,O
",",3451,O
the,3451,O
expanded,3451,O
allele,3451,O
associated,3451,O
with,3451,O
MJD,3451,B-SpecificDisease
displays,3451,O
inter-generational,3451,O
instability,3451,O
",",3451,O
particularly,3451,O
in,3451,O
male,3451,O
meioses,3451,O
",",3451,O
and,3451,O
this,3451,O
instability,3451,O
was,3451,O
associated,3451,O
with,3451,O
the,3451,O
clinical,3451,O
phenomenon,3451,O
of,3451,O
anticipation,3451,O
.,3451,O
Third,3452,O
",",3452,O
the,3452,O
size,3452,O
of,3452,O
the,3452,O
expanded,3452,O
allele,3452,O
is,3452,O
not,3452,O
only,3452,O
inversely,3452,O
correlated,3452,O
with,3452,O
the,3452,O
age-of-onset,3452,O
of,3452,O
MJD,3452,B-SpecificDisease
(,3452,O
r,3452,O
=,3452,O
-0.738,3452,O
",",3452,O
p,3452,O
<,3452,O
0.001,3452,O
),3452,O
",",3452,O
but,3452,O
is,3452,O
also,3452,O
correlated,3452,O
with,3452,O
the,3452,O
frequency,3452,O
of,3452,O
other,3452,O
clinical,3452,O
features,3452,O
[,3452,O
e.g,3452,O
.,3452,O
pseudoexophthalmos,3453,O
and,3453,O
pyramidal,3453,O
signs,3453,O
were,3453,O
more,3453,O
frequent,3453,O
in,3453,O
subjects,3453,O
with,3453,O
large,3453,O
repeats,3453,O
(,3453,O
p,3453,O
<,3453,O
0.001,3453,O
and,3453,O
p,3453,O
<,3453,O
0.05,3453,O
respectively,3453,O
),3453,O
],3453,O
.,3453,O
Fourth,3454,O
",",3454,O
the,3454,O
disease,3454,O
phenotype,3454,O
is,3454,O
significantly,3454,O
more,3454,O
severe,3454,O
and,3454,O
had,3454,O
an,3454,O
early,3454,O
age,3454,O
of,3454,O
onset,3454,O
(,3454,O
16,3454,O
years,3454,O
),3454,O
in,3454,O
a,3454,O
subject,3454,O
homozygous,3454,O
for,3454,O
the,3454,O
expanded,3454,O
allele,3454,O
",",3454,O
which,3454,O
contrasts,3454,O
with,3454,O
Huntington,3454,B-SpecificDisease
disease,3454,I-SpecificDisease
and,3454,O
suggests,3454,O
that,3454,O
the,3454,O
expanded,3454,O
allele,3454,O
in,3454,O
the,3454,O
MJD1,3454,O
gene,3454,O
could,3454,O
exert,3454,O
its,3454,O
effect,3454,O
either,3454,O
by,3454,O
a,3454,O
dominant,3454,O
negative,3454,O
effect,3454,O
(,3454,O
putatively,3454,O
excluded,3454,O
in,3454,O
HD,3454,B-SpecificDisease
),3454,O
or,3454,O
by,3454,O
a,3454,O
gain,3454,O
of,3454,O
function,3454,O
effect,3454,O
as,3454,O
proposed,3454,O
for,3454,O
HD,3454,B-SpecificDisease
.,3454,O
Finally,3455,O
",",3455,O
Japanese,3455,O
and,3455,O
Caucasian,3455,O
subjects,3455,O
affected,3455,O
with,3455,O
MJD,3455,B-SpecificDisease
share,3455,O
haplotypes,3455,O
at,3455,O
several,3455,O
markers,3455,O
surrounding,3455,O
the,3455,O
MJD1,3455,O
gene,3455,O
",",3455,O
which,3455,O
are,3455,O
uncommon,3455,O
in,3455,O
the,3455,O
normal,3455,O
Japanese,3455,O
and,3455,O
Caucasian,3455,O
population,3455,O
",",3455,O
and,3455,O
which,3455,O
suggests,3455,O
the,3455,O
existence,3455,O
either,3455,O
of,3455,O
common,3455,O
founders,3455,O
in,3455,O
these,3455,O
populations,3455,O
or,3455,O
of,3455,O
chromosomes,3455,O
susceptible,3455,O
to,3455,O
pathologic,3455,O
expansion,3455,O
of,3455,O
the,3455,O
CAG,3455,O
repeat,3455,O
in,3455,O
the,3455,O
MJD1,3455,O
gene,3455,O
.,3455,O
Evidence,3456,O
for,3456,O
inter-generational,3456,O
instability,3456,O
in,3456,O
the,3456,O
CAG,3456,O
repeat,3456,O
in,3456,O
the,3456,O
MJD1,3456,O
gene,3456,O
and,3456,O
for,3456,O
conserved,3456,O
haplotypes,3456,O
at,3456,O
flanking,3456,O
markers,3456,O
amongst,3456,O
Japanese,3456,O
and,3456,O
Caucasian,3456,O
subjects,3456,O
with,3456,O
Machado-Joseph,3456,O
disease,3456,O
.,3456,O
The,3457,O
size,3457,O
of,3457,O
the,3457,O
(,3457,O
CAG,3457,O
),3457,O
n,3457,O
repeat,3457,O
array,3457,O
in,3457,O
the,3457,O
3,3457,O
',3457,O
end,3457,O
of,3457,O
the,3457,O
MJD1,3457,O
gene,3457,O
and,3457,O
the,3457,O
haplotype,3457,O
at,3457,O
a,3457,O
series,3457,O
of,3457,O
microsatellite,3457,O
markers,3457,O
surrounding,3457,O
the,3457,O
MJD1,3457,O
gene,3457,O
were,3457,O
examined,3457,O
in,3457,O
a,3457,O
large,3457,O
cohort,3457,O
of,3457,O
Japanese,3457,O
and,3457,O
Caucasian,3457,O
subjects,3457,O
affected,3457,O
with,3457,O
Machado-Joseph,3457,O
disease,3457,O
(,3457,O
MJD,3457,O
),3457,O
.,3457,O
Our,3458,O
data,3458,O
provide,3458,O
five,3458,O
novel,3458,O
observations,3458,O
.,3458,O
First,3459,O
",",3459,O
MJD,3459,O
is,3459,O
associated,3459,O
with,3459,O
expansion,3459,O
fo,3459,O
the,3459,O
array,3459,O
from,3459,O
the,3459,O
normal,3459,O
range,3459,O
of,3459,O
14-37,3459,O
repeats,3459,O
to,3459,O
68-84,3459,O
repeats,3459,O
in,3459,O
most,3459,O
Japanese,3459,O
and,3459,O
Caucasian,3459,O
subjects,3459,O
",",3459,O
but,3459,O
no,3459,O
subjects,3459,O
were,3459,O
observed,3459,O
with,3459,O
expansions,3459,O
intermediate,3459,O
in,3459,O
size,3459,O
between,3459,O
those,3459,O
of,3459,O
the,3459,O
normal,3459,O
and,3459,O
MJD,3459,O
affected,3459,O
groups,3459,O
.,3459,O
Second,3460,O
",",3460,O
the,3460,O
expanded,3460,O
allele,3460,O
associated,3460,O
with,3460,O
MJD,3460,O
displays,3460,O
inter-generational,3460,O
instability,3460,O
",",3460,O
particularly,3460,O
in,3460,O
male,3460,O
meioses,3460,O
",",3460,O
and,3460,O
this,3460,O
instability,3460,O
was,3460,O
associated,3460,O
with,3460,O
the,3460,O
clinical,3460,O
phenomenon,3460,O
of,3460,O
anticipation,3460,O
.,3460,O
Third,3461,O
",",3461,O
the,3461,O
size,3461,O
of,3461,O
the,3461,O
expanded,3461,O
allele,3461,O
is,3461,O
not,3461,O
only,3461,O
inversely,3461,O
correlated,3461,O
with,3461,O
the,3461,O
age-of-onset,3461,O
of,3461,O
MJD,3461,O
(,3461,O
r,3461,O
=,3461,O
-0.738,3461,O
",",3461,O
p,3461,O
<,3461,O
0.001,3461,O
),3461,O
",",3461,O
but,3461,O
is,3461,O
also,3461,O
correlated,3461,O
with,3461,O
the,3461,O
frequency,3461,O
of,3461,O
other,3461,O
clinical,3461,O
features,3461,O
[,3461,O
e.g,3461,O
.,3461,O
pseudoexophthalmos,3462,O
and,3462,O
pyramidal,3462,O
signs,3462,O
were,3462,O
more,3462,O
frequent,3462,O
in,3462,O
subjects,3462,O
with,3462,O
large,3462,O
repeats,3462,O
(,3462,O
p,3462,O
<,3462,O
0.001,3462,O
and,3462,O
p,3462,O
<,3462,O
0.05,3462,O
respectively,3462,O
),3462,O
],3462,O
.,3462,O
Fourth,3463,O
",",3463,O
the,3463,O
disease,3463,O
phenotype,3463,O
is,3463,O
significantly,3463,O
more,3463,O
severe,3463,O
and,3463,O
had,3463,O
an,3463,O
early,3463,O
age,3463,O
of,3463,O
onset,3463,O
(,3463,O
16,3463,O
years,3463,O
),3463,O
in,3463,O
a,3463,O
subject,3463,O
homozygous,3463,O
for,3463,O
the,3463,O
expanded,3463,O
allele,3463,O
",",3463,O
which,3463,O
contrasts,3463,O
with,3463,O
Huntington,3463,O
disease,3463,O
and,3463,O
suggests,3463,O
that,3463,O
the,3463,O
expanded,3463,O
allele,3463,O
in,3463,O
the,3463,O
MJD1,3463,O
gene,3463,O
could,3463,O
exert,3463,O
its,3463,O
effect,3463,O
either,3463,O
by,3463,O
a,3463,O
dominant,3463,O
negative,3463,O
effect,3463,O
(,3463,O
putatively,3463,O
excluded,3463,O
in,3463,O
HD,3463,O
),3463,O
or,3463,O
by,3463,O
a,3463,O
gain,3463,O
of,3463,O
function,3463,O
effect,3463,O
as,3463,O
proposed,3463,O
for,3463,O
HD,3463,O
.,3463,O
Finally,3464,O
",",3464,O
Japanese,3464,O
and,3464,O
Caucasian,3464,O
subjects,3464,O
affected,3464,O
with,3464,O
MJD,3464,O
share,3464,O
haplotypes,3464,O
at,3464,O
several,3464,O
markers,3464,O
surrounding,3464,O
the,3464,O
MJD1,3464,O
gene,3464,O
",",3464,O
which,3464,O
are,3464,O
uncommon,3464,O
in,3464,O
the,3464,O
normal,3464,O
Japanese,3464,O
and,3464,O
Caucasian,3464,O
population,3464,O
",",3464,O
and,3464,O
which,3464,O
suggests,3464,O
the,3464,O
existence,3464,O
either,3464,O
of,3464,O
common,3464,O
founders,3464,O
in,3464,O
these,3464,O
populations,3464,O
or,3464,O
of,3464,O
chromosomes,3464,O
susceptible,3464,O
to,3464,O
pathologic,3464,O
expansion,3464,O
of,3464,O
the,3464,O
CAG,3464,O
repeat,3464,O
in,3464,O
the,3464,O
MJD1,3464,O
gene,3464,O
.,3464,O
A,3465,O
4-megabase,3465,O
YAC,3465,O
contig,3465,O
that,3465,O
spans,3465,O
the,3465,O
Langer-Giedion,3465,B-Modifier
syndrome,3465,I-Modifier
region,3465,O
on,3465,O
human,3465,O
chromosome,3465,O
8q24.1,3465,O
:,3465,O
use,3465,O
in,3465,O
refining,3465,O
the,3465,O
location,3465,O
of,3465,O
the,3465,O
trichorhinophalangeal,3465,B-SpecificDisease
syndrome,3465,I-SpecificDisease
and,3465,O
multiple,3465,O
exostoses,3465,O
genes,3465,O
(,3465,O
TRPS1,3465,O
and,3465,O
EXT1,3465,O
),3465,O
.,3465,O
We,3466,O
have,3466,O
constructed,3466,O
a,3466,O
physical,3466,O
map,3466,O
covering,3466,O
over,3466,O
4,3466,O
Mb,3466,O
of,3466,O
human,3466,O
chromosome,3466,O
8q24,3466,O
.,3466,O
1,3467,O
and,3467,O
used,3467,O
this,3467,O
map,3467,O
to,3467,O
refine,3467,O
the,3467,O
locations,3467,O
of,3467,O
the,3467,O
genes,3467,O
responsible,3467,O
for,3467,O
Langer-Giedion,3467,B-SpecificDisease
syndrome,3467,I-SpecificDisease
.,3467,O
The,3468,O
map,3468,O
is,3468,O
composed,3468,O
of,3468,O
overlapping,3468,O
YAC,3468,O
clones,3468,O
that,3468,O
were,3468,O
identified,3468,O
and,3468,O
ordered,3468,O
in,3468,O
relation,3468,O
to,3468,O
sequence,3468,O
tagged,3468,O
sites,3468,O
mapped,3468,O
to,3468,O
the,3468,O
Langer-Giedion,3468,O
chromosomal,3468,O
region,3468,O
on,3468,O
somatic,3468,O
cell,3468,O
hybrids,3468,O
.,3468,O
The,3469,O
minimal,3469,O
region,3469,O
of,3469,O
overlap,3469,O
of,3469,O
Langer-Giedion,3469,B-Modifier
syndrome,3469,I-Modifier
deletions,3469,O
",",3469,O
previously,3469,O
identified,3469,O
by,3469,O
analysis,3469,O
of,3469,O
15,3469,O
patients,3469,O
",",3469,O
was,3469,O
placed,3469,O
on,3469,O
the,3469,O
map,3469,O
by,3469,O
analysis,3469,O
of,3469,O
2,3469,O
patients,3469,O
whose,3469,O
deletions,3469,O
define,3469,O
the,3469,O
endpoints,3469,O
.,3469,O
The,3470,O
chromosome,3470,O
8,3470,O
breakpoint,3470,O
of,3470,O
a,3470,O
balanced,3470,O
t,3470,O
(,3470,O
8,3470,O
;,3470,O
9,3470,O
),3470,O
(,3470,O
q24,3470,O
.,3470,O
11,3471,O
;,3471,O
q33,3471,O
.,3471,O
3,3472,O
),3472,O
translocation,3472,O
from,3472,O
a,3472,O
patient,3472,O
with,3472,O
trichorhinophalangeal,3472,B-SpecificDisease
syndrome,3472,I-SpecificDisease
(,3472,O
TRPS,3472,B-SpecificDisease
I,3472,O
),3472,O
was,3472,O
found,3472,O
to,3472,O
be,3472,O
located,3472,O
just,3472,O
within,3472,O
the,3472,O
proximal,3472,O
end,3472,O
of,3472,O
the,3472,O
minimal,3472,O
deletion,3472,O
region,3472,O
.,3472,O
A,3473,O
deletion,3473,O
of,3473,O
8q24,3473,O
.,3473,O
11-q24,3474,O
.,3474,O
3,3475,O
in,3475,O
a,3475,O
patient,3475,O
with,3475,O
multiple,3475,O
exostoses,3475,O
was,3475,O
found,3475,O
to,3475,O
overlap,3475,O
the,3475,O
distal,3475,O
end,3475,O
of,3475,O
the,3475,O
LGS,3475,B-Modifier
deletion,3475,O
region,3475,O
",",3475,O
indicating,3475,O
that,3475,O
the,3475,O
EXT1,3475,O
gene,3475,O
is,3475,O
distal,3475,O
to,3475,O
the,3475,O
TRPS1,3475,O
gene,3475,O
and,3475,O
supporting,3475,O
the,3475,O
hypothesis,3475,O
that,3475,O
Langer-Giedion,3475,B-SpecificDisease
syndrome,3475,I-SpecificDisease
is,3475,O
due,3475,O
to,3475,O
loss,3475,O
of,3475,O
functional,3475,O
copies,3475,O
of,3475,O
both,3475,O
the,3475,O
TRPS1,3475,O
and,3475,O
the,3475,O
EXT1,3475,O
genes,3475,O
BRCA1,3476,O
mutations,3476,O
in,3476,O
a,3476,O
population-based,3476,O
sample,3476,O
of,3476,O
young,3476,O
women,3476,O
with,3476,O
breast,3476,B-SpecificDisease
cancer,3476,I-SpecificDisease
.,3476,O
BACKGROUND,3477,O
.,3477,O
Inherited,3478,O
mutations,3478,O
in,3478,O
the,3478,O
BRCA1,3478,O
gene,3478,O
are,3478,O
associated,3478,O
with,3478,O
a,3478,O
high,3478,O
risk,3478,O
of,3478,O
breast,3478,O
and,3478,O
ovarian,3478,O
cancer,3478,O
in,3478,O
some,3478,O
families,3478,O
.,3478,O
However,3479,O
",",3479,O
little,3479,O
is,3479,O
known,3479,O
about,3479,O
the,3479,O
contribution,3479,O
of,3479,O
BRCA1,3479,O
mutations,3479,O
to,3479,O
breast,3479,B-SpecificDisease
cancer,3479,I-SpecificDisease
in,3479,O
the,3479,O
general,3479,O
population,3479,O
.,3479,O
We,3480,O
analyzed,3480,O
DNA,3480,O
samples,3480,O
from,3480,O
women,3480,O
enrolled,3480,O
in,3480,O
a,3480,O
population-based,3480,O
study,3480,O
of,3480,O
early-onset,3480,O
breast,3480,B-SpecificDisease
cancer,3480,I-SpecificDisease
to,3480,O
assess,3480,O
the,3480,O
spectrum,3480,O
and,3480,O
frequency,3480,O
of,3480,O
germ-line,3480,O
BRCA1,3480,O
mutations,3480,O
in,3480,O
young,3480,O
women,3480,O
with,3480,O
breast,3480,B-SpecificDisease
cancer,3480,I-SpecificDisease
.,3480,O
METHODS,3481,O
.,3481,O
We,3482,O
studied,3482,O
80,3482,O
women,3482,O
in,3482,O
whom,3482,O
breast,3482,B-SpecificDisease
cancer,3482,I-SpecificDisease
was,3482,O
diagnosed,3482,O
before,3482,O
the,3482,O
age,3482,O
of,3482,O
35,3482,O
",",3482,O
and,3482,O
who,3482,O
were,3482,O
not,3482,O
selected,3482,O
on,3482,O
the,3482,O
basis,3482,O
of,3482,O
family,3482,O
history,3482,O
.,3482,O
Genomic,3483,O
DNA,3483,O
was,3483,O
studied,3483,O
for,3483,O
BRCA1,3483,O
mutations,3483,O
by,3483,O
analysis,3483,O
involving,3483,O
single-strand,3483,O
conformation,3483,O
polymorphisms,3483,O
and,3483,O
with,3483,O
allele-specific,3483,O
assays,3483,O
.,3483,O
Alterations,3484,O
were,3484,O
defined,3484,O
by,3484,O
DNA,3484,O
sequencing,3484,O
.,3484,O
RESULTS,3485,O
.,3485,O
Germ-line,3486,O
BRCA1,3486,O
mutations,3486,O
were,3486,O
identified,3486,O
in,3486,O
6,3486,O
of,3486,O
the,3486,O
80,3486,O
women,3486,O
.,3486,O
Four,3487,O
additional,3487,O
rare,3487,O
sequence,3487,O
variants,3487,O
of,3487,O
unknown,3487,O
functional,3487,O
importance,3487,O
were,3487,O
also,3487,O
identified,3487,O
.,3487,O
Two,3488,O
of,3488,O
the,3488,O
mutations,3488,O
and,3488,O
three,3488,O
of,3488,O
the,3488,O
rare,3488,O
sequence,3488,O
variants,3488,O
were,3488,O
found,3488,O
among,3488,O
the,3488,O
39,3488,O
women,3488,O
who,3488,O
reported,3488,O
no,3488,O
family,3488,O
history,3488,O
of,3488,O
breast,3488,O
or,3488,O
ovarian,3488,O
cancer,3488,O
.,3488,O
None,3489,O
of,3489,O
the,3489,O
mutations,3489,O
and,3489,O
only,3489,O
one,3489,O
of,3489,O
the,3489,O
rare,3489,O
variants,3489,O
was,3489,O
identified,3489,O
in,3489,O
a,3489,O
reference,3489,O
population,3489,O
of,3489,O
73,3489,O
unrelated,3489,O
subjects,3489,O
.,3489,O
CONCLUSIONS,3490,O
.,3490,O
Alterations,3491,O
in,3491,O
BRCA1,3491,O
were,3491,O
identified,3491,O
in,3491,O
approximately,3491,O
10,3491,O
percent,3491,O
of,3491,O
this,3491,O
cohort,3491,O
of,3491,O
young,3491,O
women,3491,O
with,3491,O
breast,3491,B-SpecificDisease
cancer,3491,I-SpecificDisease
.,3491,O
The,3492,O
risk,3492,O
of,3492,O
harboring,3492,O
a,3492,O
mutation,3492,O
was,3492,O
not,3492,O
limited,3492,O
to,3492,O
women,3492,O
with,3492,O
family,3492,O
histories,3492,O
of,3492,O
breast,3492,O
or,3492,O
ovarian,3492,O
cancer,3492,O
.,3492,O
These,3493,O
results,3493,O
represent,3493,O
a,3493,O
minimal,3493,O
estimate,3493,O
of,3493,O
the,3493,O
frequency,3493,O
of,3493,O
BRCA1,3493,O
mutations,3493,O
in,3493,O
this,3493,O
population,3493,O
.,3493,O
Comprehensive,3494,O
methods,3494,O
of,3494,O
identifying,3494,O
BRCA1,3494,O
mutations,3494,O
and,3494,O
understanding,3494,O
their,3494,O
importance,3494,O
will,3494,O
be,3494,O
needed,3494,O
before,3494,O
testing,3494,O
of,3494,O
women,3494,O
in,3494,O
the,3494,O
general,3494,O
population,3494,O
can,3494,O
be,3494,O
undertaken,3494,O
..,3494,O
Novel,3495,O
inherited,3495,O
mutations,3495,O
and,3495,O
variable,3495,O
expressivity,3495,O
of,3495,O
BRCA1,3495,O
alleles,3495,O
",",3495,O
including,3495,O
the,3495,O
founder,3495,O
mutation,3495,O
185delAG,3495,O
in,3495,O
Ashkenazi,3495,O
Jewish,3495,O
families,3495,O
.,3495,O
Thirty-seven,3496,O
families,3496,O
with,3496,O
four,3496,O
or,3496,O
more,3496,O
cases,3496,O
of,3496,O
breast,3496,B-SpecificDisease
cancer,3496,I-SpecificDisease
or,3496,O
breast,3496,B-CompositeMention
and,3496,I-CompositeMention
ovarian,3496,I-CompositeMention
cancer,3496,I-CompositeMention
were,3496,O
analyzed,3496,O
for,3496,O
mutations,3496,O
in,3496,O
BRCA1,3496,O
.,3496,O
Twelve,3497,O
different,3497,O
germ-line,3497,O
mutations,3497,O
",",3497,O
four,3497,O
novel,3497,O
and,3497,O
eight,3497,O
previously,3497,O
observed,3497,O
",",3497,O
were,3497,O
detected,3497,O
in,3497,O
16,3497,O
families,3497,O
.,3497,O
Five,3498,O
families,3498,O
of,3498,O
Ashkenazi,3498,O
Jewish,3498,O
descent,3498,O
carried,3498,O
the,3498,O
185delAG,3498,O
mutation,3498,O
and,3498,O
shared,3498,O
the,3498,O
same,3498,O
haplotype,3498,O
at,3498,O
eight,3498,O
polymorphic,3498,O
markers,3498,O
spanning,3498,O
approximately,3498,O
850,3498,O
kb,3498,O
at,3498,O
BRCA1,3498,O
.,3498,O
Expressivity,3499,O
of,3499,O
185delAG,3499,O
in,3499,O
these,3499,O
families,3499,O
varied,3499,O
",",3499,O
from,3499,O
early-onset,3499,O
breast,3499,B-SpecificDisease
cancer,3499,I-SpecificDisease
without,3499,O
ovarian,3499,B-SpecificDisease
cancer,3499,I-SpecificDisease
.,3499,O
Mutation,3500,O
4184delTCAA,3500,O
occurred,3500,O
independently,3500,O
in,3500,O
two,3500,O
families,3500,O
.,3500,O
In,3501,O
one,3501,O
family,3501,O
",",3501,O
penetrance,3501,O
was,3501,O
complete,3501,O
",",3501,O
with,3501,O
females,3501,O
developing,3501,O
early-onset,3501,O
breast,3501,B-SpecificDisease
cancer,3501,I-SpecificDisease
or,3501,O
ovarian,3501,B-SpecificDisease
cancer,3501,I-SpecificDisease
and,3501,O
the,3501,O
male,3501,O
carrier,3501,O
developing,3501,O
prostatic,3501,B-SpecificDisease
cancer,3501,I-SpecificDisease
",",3501,O
whereas,3501,O
",",3501,O
in,3501,O
the,3501,O
other,3501,O
family,3501,O
",",3501,O
penetrance,3501,O
was,3501,O
incomplete,3501,O
and,3501,O
only,3501,O
breast,3501,B-SpecificDisease
cancer,3501,I-SpecificDisease
occurred,3501,O
",",3501,O
diagnosed,3501,O
at,3501,O
ages,3501,O
38-81,3501,O
years,3501,O
.,3501,O
Two,3502,O
novel,3502,O
nonsense,3502,O
mutations,3502,O
led,3502,O
to,3502,O
the,3502,O
loss,3502,O
of,3502,O
mutant,3502,O
BRCA1,3502,O
transcript,3502,O
in,3502,O
families,3502,O
with,3502,O
10,3502,O
and,3502,O
6,3502,O
cases,3502,O
of,3502,O
early-onset,3502,O
breast,3502,B-SpecificDisease
cancer,3502,I-SpecificDisease
and,3502,O
ovarian,3502,B-SpecificDisease
cancer,3502,I-SpecificDisease
.,3502,O
A,3503,O
665-nt,3503,O
segment,3503,O
of,3503,O
the,3503,O
BRCA1,3503,O
3-UTR,3503,O
and,3503,O
1,3503,O
.,3503,O
3,3504,O
kb,3504,O
of,3504,O
genomic,3504,O
sequence,3504,O
including,3504,O
the,3504,O
putative,3504,O
promoter,3504,O
region,3504,O
were,3504,O
invariant,3504,O
by,3504,O
single-strand,3504,O
conformation,3504,O
analysis,3504,O
in,3504,O
13,3504,O
families,3504,O
without,3504,O
coding-sequence,3504,O
mutations,3504,O
.,3504,O
Overall,3505,O
in,3505,O
our,3505,O
series,3505,O
",",3505,O
BRCA1,3505,O
mutations,3505,O
have,3505,O
been,3505,O
detected,3505,O
in,3505,O
26,3505,O
families,3505,O
16,3505,O
with,3505,O
positive,3505,O
BRCA1,3505,O
lod,3505,O
scores,3505,O
",",3505,O
7,3505,O
with,3505,O
negative,3505,O
lod,3505,O
scores,3505,O
(,3505,O
reflecting,3505,O
multiple,3505,O
sporadic,3505,O
breast,3505,B-SpecificDisease
cancers,3505,I-SpecificDisease
),3505,O
",",3505,O
and,3505,O
3,3505,O
not,3505,O
tested,3505,O
for,3505,O
linkage,3505,O
.,3505,O
Three,3506,O
other,3506,O
families,3506,O
have,3506,O
positive,3506,O
lod,3506,O
scores,3506,O
for,3506,O
linkage,3506,O
to,3506,O
BRCA2,3506,O
",",3506,O
but,3506,O
13,3506,O
families,3506,O
without,3506,O
detected,3506,O
BRCA1,3506,O
mutations,3506,O
have,3506,O
negative,3506,O
lod,3506,O
scores,3506,O
for,3506,O
both,3506,O
BRCA1,3506,O
and,3506,O
BRCA2,3506,O
.,3506,O
A,3507,O
new,3507,O
glucose-6-phosphate,3507,O
dehydrogenase,3507,O
variant,3507,O
",",3507,O
G6PD,3507,O
Orissa,3507,O
(,3507,O
44,3507,O
Ala,3507,O
--,3507,O
>,3507,O
Gly,3507,O
),3507,O
",",3507,O
is,3507,O
the,3507,O
major,3507,O
polymorphic,3507,O
variant,3507,O
in,3507,O
tribal,3507,O
populations,3507,O
in,3507,O
India,3507,O
.,3507,O
Deficiency,3508,B-SpecificDisease
of,3508,I-SpecificDisease
glucose-6-phosphate,3508,I-SpecificDisease
dehydrogenase,3508,I-SpecificDisease
(,3508,O
G6PD,3508,O
),3508,O
is,3508,O
usually,3508,O
found,3508,O
at,3508,O
high,3508,O
frequencies,3508,O
in,3508,O
areas,3508,O
of,3508,O
the,3508,O
world,3508,O
where,3508,O
malaria,3508,B-SpecificDisease
has,3508,O
been,3508,O
endemic,3508,O
.,3508,O
The,3509,O
frequency,3509,O
and,3509,O
genetic,3509,O
basis,3509,O
of,3509,O
G6PD,3509,B-SpecificDisease
deficiency,3509,I-SpecificDisease
have,3509,O
been,3509,O
studied,3509,O
in,3509,O
Africa,3509,O
",",3509,O
around,3509,O
the,3509,O
Mediterranean,3509,O
",",3509,O
and,3509,O
in,3509,O
the,3509,O
Far,3509,O
East,3509,O
",",3509,O
but,3509,O
little,3509,O
such,3509,O
information,3509,O
is,3509,O
available,3509,O
about,3509,O
the,3509,O
situation,3509,O
in,3509,O
India,3509,O
.,3509,O
To,3510,O
determine,3510,O
the,3510,O
extent,3510,O
of,3510,O
heterogeneity,3510,O
of,3510,O
G6PD,3510,O
",",3510,O
we,3510,O
have,3510,O
studied,3510,O
several,3510,O
different,3510,O
Indian,3510,O
populations,3510,O
by,3510,O
screening,3510,O
for,3510,O
G6PD,3510,B-SpecificDisease
deficiency,3510,I-SpecificDisease
",",3510,O
followed,3510,O
by,3510,O
molecular,3510,O
analysis,3510,O
of,3510,O
deficient,3510,O
alleles,3510,O
.,3510,O
The,3511,O
frequency,3511,O
of,3511,O
G6PD,3511,B-SpecificDisease
deficiency,3511,I-SpecificDisease
varies,3511,O
between,3511,O
3,3511,O
%,3511,O
and,3511,O
15,3511,O
%,3511,O
in,3511,O
different,3511,O
tribal,3511,O
and,3511,O
urban,3511,O
groups,3511,O
.,3511,O
Remarkably,3512,O
",",3512,O
a,3512,O
previously,3512,O
unreported,3512,O
deficient,3512,O
variant,3512,O
",",3512,O
G6PD,3512,O
Orissa,3512,O
(,3512,O
44,3512,O
Ala,3512,O
--,3512,O
>,3512,O
Gly,3512,O
),3512,O
",",3512,O
is,3512,O
responsible,3512,O
for,3512,O
most,3512,O
of,3512,O
the,3512,O
G6PD,3512,B-SpecificDisease
deficiency,3512,I-SpecificDisease
in,3512,O
tribal,3512,O
Indian,3512,O
populations,3512,O
but,3512,O
is,3512,O
not,3512,O
found,3512,O
in,3512,O
urban,3512,O
populations,3512,O
",",3512,O
where,3512,O
most,3512,O
of,3512,O
the,3512,O
G6PD,3512,B-SpecificDisease
deficiency,3512,I-SpecificDisease
is,3512,O
due,3512,O
to,3512,O
the,3512,O
G6PD,3512,O
Mediterranean,3512,O
(,3512,O
188,3512,O
Ser,3512,O
--,3512,O
>,3512,O
Phe,3512,O
),3512,O
variant,3512,O
.,3512,O
The,3513,O
KmNADP,3513,O
of,3513,O
G6PD,3513,O
Orissa,3513,O
is,3513,O
fivefold,3513,O
higher,3513,O
than,3513,O
that,3513,O
of,3513,O
the,3513,O
normal,3513,O
enzyme,3513,O
.,3513,O
This,3514,O
may,3514,O
be,3514,O
due,3514,O
to,3514,O
the,3514,O
fact,3514,O
that,3514,O
the,3514,O
alanine,3514,O
residue,3514,O
that,3514,O
is,3514,O
replaced,3514,O
by,3514,O
glycine,3514,O
is,3514,O
part,3514,O
of,3514,O
a,3514,O
putative,3514,O
coenzyme-binding,3514,O
site,3514,O
..,3514,O
Evidence,3515,O
for,3515,O
linkage,3515,O
of,3515,O
bipolar,3515,B-SpecificDisease
disorder,3515,I-SpecificDisease
to,3515,O
chromosome,3515,O
18,3515,O
with,3515,O
a,3515,O
parent-of-origin,3515,O
effect,3515,O
.,3515,O
A,3516,O
susceptibility,3516,O
gene,3516,O
on,3516,O
chromosome,3516,O
18,3516,O
and,3516,O
a,3516,O
parent-of-origin,3516,O
effect,3516,O
have,3516,O
been,3516,O
suggested,3516,O
for,3516,O
bipolar,3516,B-SpecificDisease
affective,3516,I-SpecificDisease
disorder,3516,I-SpecificDisease
(,3516,O
BPAD,3516,B-SpecificDisease
),3516,O
.,3516,O
We,3517,O
have,3517,O
studied,3517,O
28,3517,O
nuclear,3517,O
families,3517,O
selected,3517,O
for,3517,O
apparent,3517,O
unilineal,3517,O
transmission,3517,O
of,3517,O
the,3517,O
BPAD,3517,B-Modifier
phenotype,3517,O
",",3517,O
by,3517,O
using,3517,O
31,3517,O
polymorphic,3517,O
markers,3517,O
spanning,3517,O
chromosome,3517,O
18,3517,O
.,3517,O
Evidence,3518,O
for,3518,O
linkage,3518,O
was,3518,O
tested,3518,O
with,3518,O
affected-sib-pair,3518,O
and,3518,O
LOD,3518,O
score,3518,O
methods,3518,O
under,3518,O
two,3518,O
definitions,3518,O
of,3518,O
the,3518,O
affected,3518,O
phenotype,3518,O
.,3518,O
The,3519,O
affected-sibpair,3519,O
analyses,3519,O
indicated,3519,O
excess,3519,O
allele,3519,O
sharing,3519,O
for,3519,O
markers,3519,O
on,3519,O
18p,3519,O
within,3519,O
the,3519,O
region,3519,O
reported,3519,O
previously,3519,O
.,3519,O
The,3520,O
greatest,3520,O
sharing,3520,O
was,3520,O
at,3520,O
D18S37,3520,O
64,3520,O
%,3520,O
in,3520,O
bipolar,3520,O
and,3520,O
recurrent,3520,O
unipolar,3520,O
(,3520,O
RUP,3520,O
),3520,O
sib,3520,O
pairs,3520,O
(,3520,O
P,3520,O
=,3520,O
.,3520,O
0006,3521,O
),3521,O
.,3521,O
In,3522,O
addition,3522,O
",",3522,O
excess,3522,O
sharing,3522,O
of,3522,O
the,3522,O
paternally,3522,O
",",3522,O
but,3522,O
not,3522,O
maternally,3522,O
",",3522,O
transmitted,3522,O
alleles,3522,O
was,3522,O
observed,3522,O
at,3522,O
three,3522,O
markers,3522,O
on,3522,O
18q,3522,O
at,3522,O
D18S41,3522,O
",",3522,O
51,3522,O
bipolar,3522,O
and,3522,O
RUP,3522,O
sib,3522,O
pairs,3522,O
were,3522,O
concordant,3522,O
for,3522,O
paternally,3522,O
transmitted,3522,O
alleles,3522,O
",",3522,O
and,3522,O
21,3522,O
pairs,3522,O
were,3522,O
discordant,3522,O
(,3522,O
P,3522,O
=,3522,O
0004,3522,O
),3522,O
.,3522,O
The,3523,O
evidence,3523,O
for,3523,O
linkage,3523,O
to,3523,O
loci,3523,O
on,3523,O
both,3523,O
18p,3523,O
and,3523,O
18q,3523,O
was,3523,O
strongest,3523,O
in,3523,O
the,3523,O
11,3523,O
paternal,3523,O
pedigrees,3523,O
",",3523,O
i.,3523,O
e,3523,O
e.,3523,O
",",3523,O
those,3523,O
in,3523,O
which,3523,O
the,3523,O
father,3523,O
or,3523,O
one,3523,O
of,3523,O
the,3523,O
fathers,3523,O
sibs,3523,O
is,3523,O
affected,3523,O
.,3523,O
In,3524,O
these,3524,O
pedigrees,3524,O
",",3524,O
the,3524,O
greatest,3524,O
allele,3524,O
sharing,3524,O
(,3524,O
81,3524,O
%,3524,O
;,3524,O
P,3524,O
=,3524,O
.,3524,O
00002,3525,O
),3525,O
and,3525,O
the,3525,O
highest,3525,O
LOD,3525,O
score,3525,O
(,3525,O
3,3525,O
.,3525,O
51,3526,O
;,3526,O
phi,3526,O
=,3526,O
0,3526,O
.,3526,O
0,3527,O
),3527,O
were,3527,O
observed,3527,O
at,3527,O
D18S41,3527,O
.,3527,O
Our,3528,O
results,3528,O
provide,3528,O
further,3528,O
support,3528,O
for,3528,O
linkage,3528,O
of,3528,O
BPAD,3528,B-SpecificDisease
to,3528,O
chromosome,3528,O
18,3528,O
and,3528,O
the,3528,O
first,3528,O
molecular,3528,O
evidence,3528,O
for,3528,O
a,3528,O
parent-of-origin,3528,O
effect,3528,O
operating,3528,O
in,3528,O
this,3528,O
disorder,3528,O
.,3528,O
The,3529,O
number,3529,O
of,3529,O
loci,3529,O
involved,3529,O
",",3529,O
and,3529,O
their,3529,O
precise,3529,O
location,3529,O
",",3529,O
require,3529,O
further,3529,O
study,3529,O
A,3530,O
prevalent,3530,O
mutation,3530,O
for,3530,O
galactosemia,3530,B-SpecificDisease
among,3530,O
black,3530,O
Americans,3530,O
.,3530,O
OBJECTIVE,3531,O
To,3531,O
define,3531,O
the,3531,O
mutation,3531,O
causing,3531,O
galactosemia,3531,B-SpecificDisease
in,3531,O
patients,3531,O
of,3531,O
black,3531,O
American,3531,O
origin,3531,O
who,3531,O
have,3531,O
no,3531,O
galactose-1-phosphate,3531,O
uridyltransferase,3531,O
(,3531,O
GALT,3531,O
),3531,O
activity,3531,O
in,3531,O
erythrocytes,3531,O
but,3531,O
good,3531,O
clinical,3531,O
outcome,3531,O
.,3531,O
METHODS,3532,O
We,3532,O
discovered,3532,O
a,3532,O
mutation,3532,O
caused,3532,O
by,3532,O
a,3532,O
C,3532,O
--,3532,O
>,3532,O
T,3532,O
transition,3532,O
at,3532,O
base-pair,3532,O
1158,3532,O
of,3532,O
the,3532,O
GALT,3532,O
gene,3532,O
that,3532,O
results,3532,O
in,3532,O
a,3532,O
serine-to-leucine,3532,O
substitution,3532,O
at,3532,O
codon,3532,O
135,3532,O
(,3532,O
S135L,3532,O
),3532,O
.,3532,O
We,3533,O
developed,3533,O
a,3533,O
method,3533,O
with,3533,O
which,3533,O
to,3533,O
screen,3533,O
populations,3533,O
for,3533,O
its,3533,O
prevalence,3533,O
.,3533,O
We,3534,O
compared,3534,O
galactose-1-phosphate,3534,O
uridyltransferase,3534,O
among,3534,O
erythrocytes,3534,O
",",3534,O
leukocytes,3534,O
",",3534,O
and,3534,O
transformed,3534,O
lymphoblasts,3534,O
",",3534,O
as,3534,O
well,3534,O
as,3534,O
total,3534,O
body,3534,O
oxidation,3534,O
of,3534,O
D-,3534,O
(,3534,O
13C,3534,O
),3534,O
-galactose,3534,O
to,3534,O
13CO2,3534,O
among,3534,O
three,3534,O
genotypes,3534,O
for,3534,O
GALT,3534,O
(,3534,O
S135L/S135L,3534,O
",",3534,O
Q188R/Q188R,3534,O
",",3534,O
and,3534,O
Normal/Normal,3534,O
),3534,O
.,3534,O
RESULTS,3535,O
We,3535,O
found,3535,O
a,3535,O
48,3535,O
%,3535,O
prevalence,3535,O
of,3535,O
the,3535,O
S135L,3535,O
mutation,3535,O
among,3535,O
17,3535,O
black,3535,O
American,3535,O
patients,3535,O
with,3535,O
classic,3535,B-SpecificDisease
galactosemia,3535,I-SpecificDisease
and,3535,O
a,3535,O
1,3535,O
%,3535,O
prevalence,3535,O
in,3535,O
a,3535,O
population,3535,O
of,3535,O
50,3535,O
black,3535,O
Americans,3535,O
without,3535,O
galactosemia,3535,B-SpecificDisease
.,3535,O
The,3536,O
S135L,3536,O
mutation,3536,O
was,3536,O
not,3536,O
found,3536,O
in,3536,O
84,3536,O
white,3536,O
patients,3536,O
with,3536,O
G/G,3536,O
galactosemia,3536,B-SpecificDisease
nor,3536,O
in,3536,O
87,3536,O
white,3536,O
control,3536,O
subjects,3536,O
without,3536,O
galactosemia,3536,B-SpecificDisease
.,3536,O
We,3537,O
found,3537,O
normal,3537,O
whole,3537,O
body,3537,O
oxidation,3537,O
of,3537,O
D-,3537,O
(,3537,O
13C,3537,O
),3537,O
-galactose,3537,O
by,3537,O
the,3537,O
patient,3537,O
homozygous,3537,O
for,3537,O
S135L,3537,O
and,3537,O
various,3537,O
degrees,3537,O
of,3537,O
enzyme,3537,O
impairment,3537,O
among,3537,O
different,3537,O
tissues,3537,O
.,3537,O
CONCLUSIONS,3538,O
The,3538,O
S135L,3538,O
mutation,3538,O
in,3538,O
the,3538,O
GALT,3538,O
gene,3538,O
is,3538,O
a,3538,O
prevalent,3538,O
cause,3538,O
of,3538,O
galactosemia,3538,B-SpecificDisease
among,3538,O
black,3538,O
patients,3538,O
.,3538,O
Because,3539,O
GALT,3539,O
activity,3539,O
varies,3539,O
in,3539,O
different,3539,O
tissues,3539,O
of,3539,O
patients,3539,O
homozygous,3539,O
for,3539,O
S135L,3539,O
",",3539,O
they,3539,O
may,3539,O
have,3539,O
a,3539,O
better,3539,O
clinical,3539,O
outcome,3539,O
than,3539,O
patients,3539,O
who,3539,O
are,3539,O
homozygous,3539,O
for,3539,O
Q188R,3539,O
when,3539,O
both,3539,O
are,3539,O
treated,3539,O
from,3539,O
infancy,3539,O
..,3539,O
A,3540,O
high,3540,O
incidence,3540,O
of,3540,O
BRCA1,3540,O
mutations,3540,O
in,3540,O
20,3540,O
breast-ovarian,3540,B-Modifier
cancer,3540,I-Modifier
families,3540,O
.,3540,O
We,3541,O
have,3541,O
analyzed,3541,O
20,3541,O
breast-ovarian,3541,B-Modifier
cancer,3541,I-Modifier
families,3541,O
",",3541,O
the,3541,O
majority,3541,O
of,3541,O
which,3541,O
show,3541,O
positive,3541,O
evidence,3541,O
of,3541,O
linkage,3541,O
to,3541,O
chromosome,3541,O
17q12,3541,O
for,3541,O
germ-line,3541,O
mutations,3541,O
in,3541,O
the,3541,O
BRCA1,3541,O
gene,3541,O
.,3541,O
BRCA1,3542,O
mutations,3542,O
cosegregating,3542,O
with,3542,O
breast,3542,B-Modifier
and,3542,I-Modifier
ovarian,3542,I-Modifier
cancer,3542,I-Modifier
susceptibility,3542,O
were,3542,O
identified,3542,O
in,3542,O
16,3542,O
families,3542,O
",",3542,O
including,3542,O
1,3542,O
family,3542,O
with,3542,O
a,3542,O
case,3542,O
of,3542,O
male,3542,B-SpecificDisease
breast,3542,I-SpecificDisease
cancer,3542,I-SpecificDisease
.,3542,O
Nine,3543,O
of,3543,O
these,3543,O
mutations,3543,O
have,3543,O
not,3543,O
been,3543,O
reported,3543,O
previously,3543,O
.,3543,O
The,3544,O
majority,3544,O
of,3544,O
mutations,3544,O
were,3544,O
found,3544,O
to,3544,O
generate,3544,O
a,3544,O
premature,3544,O
stop,3544,O
codon,3544,O
leading,3544,O
to,3544,O
the,3544,O
formation,3544,O
of,3544,O
a,3544,O
truncated,3544,O
BRCA1,3544,O
protein,3544,O
of,3544,O
2,3544,O
%,3544,O
-88,3544,O
%,3544,O
of,3544,O
the,3544,O
expected,3544,O
normal,3544,O
length,3544,O
.,3544,O
Two,3545,O
mutations,3545,O
altered,3545,O
the,3545,O
RING,3545,O
finger,3545,O
domain,3545,O
.,3545,O
Sequencing,3546,O
of,3546,O
genomic,3546,O
DNA,3546,O
led,3546,O
to,3546,O
the,3546,O
identification,3546,O
of,3546,O
a,3546,O
mutation,3546,O
in,3546,O
the,3546,O
coding,3546,O
region,3546,O
of,3546,O
BRCA1,3546,O
in,3546,O
12,3546,O
families,3546,O
",",3546,O
and,3546,O
cDNA,3546,O
analysis,3546,O
revealed,3546,O
an,3546,O
abnormal,3546,O
or,3546,O
missing,3546,O
BRCA1,3546,O
transcript,3546,O
in,3546,O
4,3546,O
of,3546,O
the,3546,O
8,3546,O
remaining,3546,O
families,3546,O
.,3546,O
A,3547,O
total,3547,O
of,3547,O
eight,3547,O
mutations,3547,O
were,3547,O
associated,3547,O
with,3547,O
a,3547,O
reduced,3547,O
quantity,3547,O
of,3547,O
BRCA1,3547,O
transcript,3547,O
.,3547,O
We,3548,O
were,3548,O
unable,3548,O
to,3548,O
detect,3548,O
BRCA1,3548,O
mutations,3548,O
in,3548,O
4,3548,O
of,3548,O
the,3548,O
20,3548,O
families,3548,O
",",3548,O
but,3548,O
only,3548,O
1,3548,O
of,3548,O
these,3548,O
was,3548,O
clearly,3548,O
linked,3548,O
to,3548,O
BRCA1,3548,O
.,3548,O
It,3549,O
is,3549,O
expected,3549,O
that,3549,O
the,3549,O
majority,3549,O
of,3549,O
clear,3549,O
examples,3549,O
of,3549,O
the,3549,O
breast-ovarian,3549,B-SpecificDisease
syndrome,3549,I-SpecificDisease
will,3549,O
be,3549,O
associated,3549,O
with,3549,O
germ-line,3549,O
mutations,3549,O
in,3549,O
the,3549,O
coding,3549,O
region,3549,O
of,3549,O
BRCA1,3549,O
..,3549,O
Brca1,3550,B-SpecificDisease
deficiency,3550,I-SpecificDisease
results,3550,O
in,3550,O
early,3550,O
embryonic,3550,B-DiseaseClass
lethality,3550,I-DiseaseClass
characterized,3550,O
by,3550,O
neuroepithelial,3550,B-DiseaseClass
abnormalities,3550,I-DiseaseClass
.,3550,O
The,3551,O
breast,3551,B-Modifier
and,3551,I-Modifier
ovarian,3551,I-Modifier
cancer,3551,I-Modifier
susceptibility,3551,O
gene,3551,O
",",3551,O
BRCA1,3551,O
",",3551,O
has,3551,O
been,3551,O
cloned,3551,O
and,3551,O
shown,3551,O
to,3551,O
encode,3551,O
a,3551,O
zinc-finger,3551,O
protein,3551,O
of,3551,O
unknown,3551,O
function,3551,O
.,3551,O
Mutations,3552,O
in,3552,O
BRCA1,3552,O
account,3552,O
for,3552,O
at,3552,O
least,3552,O
80,3552,O
%,3552,O
of,3552,O
families,3552,O
with,3552,O
both,3552,O
breast,3552,B-CompositeMention
and,3552,I-CompositeMention
ovarian,3552,I-CompositeMention
cancer,3552,I-CompositeMention
",",3552,O
as,3552,O
well,3552,O
as,3552,O
some,3552,O
non-familial,3552,O
sporadic,3552,O
ovarian,3552,B-SpecificDisease
cancers,3552,I-SpecificDisease
.,3552,O
The,3553,O
loss,3553,O
of,3553,O
wild-type,3553,O
BRCA1,3553,O
in,3553,O
tumours,3553,B-DiseaseClass
of,3553,O
individuals,3553,O
carrying,3553,O
one,3553,O
nonfunctional,3553,O
BRCA1,3553,O
allele,3553,O
suggests,3553,O
that,3553,O
BRCA1,3553,O
encodes,3553,O
a,3553,O
tumour,3553,B-Modifier
suppressor,3553,O
that,3553,O
may,3553,O
inhibit,3553,O
the,3553,O
proliferation,3553,O
of,3553,O
mammary,3553,O
epithelial,3553,O
cells,3553,O
.,3553,O
To,3554,O
examine,3554,O
the,3554,O
role,3554,O
of,3554,O
BRCA1,3554,O
in,3554,O
normal,3554,O
tissue,3554,O
growth,3554,O
and,3554,O
differentiation,3554,O
",",3554,O
and,3554,O
to,3554,O
generate,3554,O
a,3554,O
potential,3554,O
model,3554,O
for,3554,O
the,3554,O
cancer,3554,B-Modifier
susceptibility,3554,O
associated,3554,O
with,3554,O
loss,3554,O
of,3554,O
BRCA1,3554,O
function,3554,O
",",3554,O
we,3554,O
have,3554,O
created,3554,O
a,3554,O
mouse,3554,O
line,3554,O
carrying,3554,O
a,3554,O
mutation,3554,O
in,3554,O
one,3554,O
Brca1,3554,O
allele,3554,O
.,3554,O
Analysis,3555,O
of,3555,O
mice,3555,O
homozygous,3555,O
for,3555,O
the,3555,O
mutant,3555,O
allele,3555,O
indicate,3555,O
that,3555,O
Brca1,3555,O
is,3555,O
critical,3555,O
for,3555,O
normal,3555,O
development,3555,O
",",3555,O
as,3555,O
these,3555,O
mice,3555,O
died,3555,O
in,3555,O
utero,3555,O
between,3555,O
10,3555,O
and,3555,O
13,3555,O
days,3555,O
of,3555,O
gestation,3555,O
(,3555,O
E10-E13,3555,O
),3555,O
.,3555,O
Abnormalities,3556,O
in,3556,O
Brca1-deficient,3556,B-Modifier
embryos,3556,O
were,3556,O
most,3556,O
evident,3556,O
in,3556,O
the,3556,O
neural,3556,O
tube,3556,O
",",3556,O
with,3556,O
40,3556,O
%,3556,O
of,3556,O
the,3556,O
embryos,3556,O
presenting,3556,O
with,3556,O
varying,3556,O
degrees,3556,O
of,3556,O
spina,3556,B-SpecificDisease
bifida,3556,I-SpecificDisease
and,3556,O
anencephaly,3556,B-SpecificDisease
.,3556,O
In,3557,O
addition,3557,O
",",3557,O
the,3557,O
neuroepithelium,3557,O
in,3557,O
Brca1-deficient,3557,B-Modifier
embryos,3557,O
appeared,3557,O
disorganized,3557,O
",",3557,O
with,3557,O
signs,3557,O
of,3557,O
both,3557,O
rapid,3557,O
proliferation,3557,O
and,3557,O
excessive,3557,O
cell,3557,O
death,3557,O
..,3557,O
Identification,3558,O
of,3558,O
mutations,3558,O
in,3558,O
the,3558,O
ALD-gene,3558,O
of,3558,O
20,3558,O
families,3558,O
with,3558,O
adrenoleukodystrophy/adrenomyeloneuropathy,3558,B-SpecificDisease
.,3558,O
Adrenoleukodystrophy,3559,B-SpecificDisease
(,3559,O
ALD,3559,B-SpecificDisease
),3559,O
",",3559,O
an,3559,O
X-linked,3559,B-DiseaseClass
inherited,3559,I-DiseaseClass
metabolic,3559,I-DiseaseClass
disorder,3559,I-DiseaseClass
",",3559,O
is,3559,O
the,3559,O
most,3559,O
frequent,3559,O
inborn,3559,B-DiseaseClass
peroxisomal,3559,I-DiseaseClass
disease,3559,I-DiseaseClass
.,3559,O
It,3560,O
leads,3560,O
to,3560,O
demyelination,3560,B-DiseaseClass
in,3560,I-DiseaseClass
the,3560,I-DiseaseClass
central,3560,I-DiseaseClass
and,3560,I-DiseaseClass
peripheral,3560,I-DiseaseClass
nervous,3560,I-DiseaseClass
system,3560,I-DiseaseClass
.,3560,O
Defective,3561,O
beta-oxidation,3561,O
of,3561,O
saturated,3561,O
very,3561,O
long,3561,O
chain,3561,O
fatty,3561,O
acids,3561,O
(,3561,O
VLCFAs,3561,O
;,3561,O
C22,3561,O
0-C26,3561,O
0,3561,O
),3561,O
in,3561,O
peroxisomes,3561,O
has,3561,O
been,3561,O
shown,3561,O
to,3561,O
lead,3561,O
to,3561,O
an,3561,O
accumulation,3561,O
of,3561,O
VLCFAs,3561,O
in,3561,O
leukoid,3561,O
areas,3561,O
of,3561,O
the,3561,O
central,3561,O
nervous,3561,O
system,3561,O
",",3561,O
peripheral,3561,O
nerves,3561,O
",",3561,O
adrenal,3561,O
gland,3561,O
",",3561,O
and,3561,O
blood,3561,O
.,3561,O
The,3562,O
ALD,3562,B-Modifier
gene,3562,O
has,3562,O
been,3562,O
recently,3562,O
identified,3562,O
and,3562,O
encodes,3562,O
a,3562,O
745-amino-acid,3562,O
protein,3562,O
.,3562,O
We,3563,O
screened,3563,O
patients,3563,O
with,3563,O
adrenoleukodystrophy/adrenomyeloneuropathy,3563,B-SpecificDisease
(,3563,O
ALD/AMN,3563,B-SpecificDisease
),3563,O
from,3563,O
20,3563,O
kindreds,3563,O
for,3563,O
mutations,3563,O
in,3563,O
the,3563,O
ALD,3563,B-Modifier
gene,3563,O
.,3563,O
Eleven,3564,O
missense,3564,O
and,3564,O
two,3564,O
nonsense,3564,O
mutations,3564,O
",",3564,O
five,3564,O
deletions,3564,O
",",3564,O
and,3564,O
one,3564,O
insertion,3564,O
were,3564,O
detected,3564,O
by,3564,O
direct,3564,O
sequencing,3564,O
of,3564,O
eight,3564,O
reverse,3564,O
transcribed,3564,O
fragments,3564,O
of,3564,O
the,3564,O
ALD-gene,3564,B-Modifier
mRNA,3564,O
.,3564,O
Four,3565,O
mutations,3565,O
could,3565,O
be,3565,O
shown,3565,O
to,3565,O
be,3565,O
de,3565,O
novo,3565,O
.,3565,O
All,3566,O
mutations,3566,O
could,3566,O
be,3566,O
confirmed,3566,O
in,3566,O
carriers,3566,O
by,3566,O
sequencing,3566,O
genomic,3566,O
DNA,3566,O
.,3566,O
No,3567,O
correlation,3567,O
between,3567,O
the,3567,O
type,3567,O
of,3567,O
mutation,3567,O
and,3567,O
the,3567,O
severity,3567,O
of,3567,O
the,3567,O
phenotype,3567,O
could,3567,O
be,3567,O
observed,3567,O
.,3567,O
The,3568,O
mutations,3568,O
were,3568,O
not,3568,O
detected,3568,O
in,3568,O
the,3568,O
ALD,3568,B-Modifier
gene,3568,O
of,3568,O
30,3568,O
healthy,3568,O
persons,3568,O
..,3568,O
The,3569,O
murine,3569,O
homolog,3569,O
of,3569,O
the,3569,O
human,3569,O
breast,3569,B-Modifier
and,3569,I-Modifier
ovarian,3569,I-Modifier
cancer,3569,I-Modifier
susceptibility,3569,O
gene,3569,O
Brca1,3569,O
maps,3569,O
to,3569,O
mouse,3569,O
chromosome,3569,O
11D,3569,O
.,3569,O
The,3570,O
recently,3570,O
cloned,3570,O
human,3570,O
breast,3570,B-Modifier
and,3570,I-Modifier
ovarian,3570,I-Modifier
cancer,3570,I-Modifier
susceptibility,3570,O
gene,3570,O
",",3570,O
BRCA1,3570,O
",",3570,O
is,3570,O
located,3570,O
on,3570,O
human,3570,O
chromosome,3570,O
17q21,3570,O
.,3570,O
We,3571,O
have,3571,O
isolated,3571,O
murine,3571,O
genomic,3571,O
clones,3571,O
containing,3571,O
Brca1,3571,O
as,3571,O
a,3571,O
first,3571,O
step,3571,O
in,3571,O
generating,3571,O
a,3571,O
mouse,3571,O
model,3571,O
for,3571,O
the,3571,O
loss,3571,O
of,3571,O
BRCA1,3571,O
function,3571,O
.,3571,O
A,3572,O
mouse,3572,O
genomic,3572,O
library,3572,O
was,3572,O
screened,3572,O
using,3572,O
probes,3572,O
corresponding,3572,O
to,3572,O
exon,3572,O
11,3572,O
of,3572,O
the,3572,O
human,3572,O
BRCA1,3572,O
gene,3572,O
.,3572,O
Two,3573,O
overlapping,3573,O
mouse,3573,O
clones,3573,O
were,3573,O
identified,3573,O
that,3573,O
hybridized,3573,O
to,3573,O
human,3573,O
BRCA1,3573,O
exons,3573,O
9-12,3573,O
.,3573,O
Sequence,3574,O
analysis,3574,O
of,3574,O
1,3574,O
.,3574,O
4,3575,O
kb,3575,O
of,3575,O
the,3575,O
region,3575,O
of,3575,O
these,3575,O
clones,3575,O
corresponding,3575,O
to,3575,O
part,3575,O
of,3575,O
human,3575,O
exon,3575,O
11,3575,O
revealed,3575,O
72,3575,O
%,3575,O
nucleic,3575,O
acid,3575,O
identity,3575,O
but,3575,O
only,3575,O
50,3575,O
%,3575,O
amino,3575,O
acid,3575,O
identity,3575,O
with,3575,O
the,3575,O
human,3575,O
gene,3575,O
.,3575,O
The,3576,O
longest,3576,O
of,3576,O
the,3576,O
mouse,3576,O
Brca1,3576,O
genomic,3576,O
clones,3576,O
maps,3576,O
to,3576,O
chromosome,3576,O
11D,3576,O
",",3576,O
as,3576,O
determined,3576,O
by,3576,O
two-color,3576,O
fluorescence,3576,O
in,3576,O
situ,3576,O
hybridization,3576,O
.,3576,O
The,3577,O
synteny,3577,O
to,3577,O
human,3577,O
chromosome,3577,O
17,3577,O
was,3577,O
confirmed,3577,O
by,3577,O
cohybridization,3577,O
with,3577,O
the,3577,O
mouse,3577,O
probe,3577,O
for,3577,O
the,3577,O
NF1-gene,3577,O
.,3577,O
This,3578,O
comparative,3578,O
study,3578,O
confirms,3578,O
that,3578,O
the,3578,O
relative,3578,O
location,3578,O
of,3578,O
the,3578,O
BRCA1,3578,O
gene,3578,O
has,3578,O
been,3578,O
conserved,3578,O
between,3578,O
mice,3578,O
and,3578,O
humans,3578,O
.,3578,O
Atelosteogenesis,3579,B-SpecificDisease
type,3579,I-SpecificDisease
II,3579,I-SpecificDisease
is,3579,O
caused,3579,O
by,3579,O
mutations,3579,O
in,3579,O
the,3579,O
diastrophic,3579,B-Modifier
dysplasia,3579,I-Modifier
sulfate-transporter,3579,O
gene,3579,O
(,3579,O
DTDST,3579,O
),3579,O
:,3579,O
evidence,3579,O
for,3579,O
a,3579,O
phenotypic,3579,O
series,3579,O
involving,3579,O
three,3579,O
chondrodysplasias,3579,B-DiseaseClass
.,3579,O
Atelosteogenesis,3580,B-SpecificDisease
type,3580,I-SpecificDisease
II,3580,I-SpecificDisease
(,3580,O
AO,3580,B-SpecificDisease
II,3580,I-SpecificDisease
),3580,O
is,3580,O
a,3580,O
neonatally,3580,O
lethal,3580,O
chondrodysplasia,3580,B-DiseaseClass
whose,3580,O
clinical,3580,O
and,3580,O
histological,3580,O
characteristics,3580,O
resemble,3580,O
those,3580,O
of,3580,O
another,3580,O
chondrodysplasia,3580,B-DiseaseClass
",",3580,O
the,3580,O
much,3580,O
less,3580,O
severe,3580,O
diastrophic,3580,B-SpecificDisease
dysplasia,3580,I-SpecificDisease
(,3580,O
DTD,3580,B-SpecificDisease
),3580,O
.,3580,O
The,3581,O
similarity,3581,O
suggests,3581,O
a,3581,O
shared,3581,O
pathogenesis,3581,O
involving,3581,O
lesions,3581,O
in,3581,O
the,3581,O
same,3581,O
biochemical,3581,O
pathway,3581,O
and,3581,O
perhaps,3581,O
the,3581,O
same,3581,O
gene,3581,O
.,3581,O
DTD,3582,B-SpecificDisease
is,3582,O
caused,3582,O
by,3582,O
mutations,3582,O
in,3582,O
the,3582,O
recently,3582,O
identified,3582,O
diastrophic,3582,B-Modifier
dysplasia,3582,I-Modifier
sulfate-transporter,3582,O
gene,3582,O
(,3582,O
DTDST,3582,O
),3582,O
.,3582,O
Here,3583,O
",",3583,O
we,3583,O
report,3583,O
that,3583,O
AOII,3583,B-Modifier
patients,3583,O
also,3583,O
have,3583,O
DTDST,3583,O
mutations,3583,O
",",3583,O
which,3583,O
lead,3583,O
to,3583,O
defective,3583,O
uptake,3583,O
of,3583,O
inorganic,3583,O
sulfate,3583,O
and,3583,O
insufficient,3583,O
sulfation,3583,O
of,3583,O
macromolecules,3583,O
by,3583,O
patient,3583,O
mesenchymal,3583,O
cells,3583,O
in,3583,O
vitro,3583,O
.,3583,O
Together,3584,O
with,3584,O
our,3584,O
recent,3584,O
observation,3584,O
that,3584,O
a,3584,O
third,3584,O
even,3584,O
more,3584,O
severe,3584,O
chondrodysplasia,3584,B-DiseaseClass
",",3584,O
achondrogenesis,3584,O
type,3584,O
IB,3584,O
",",3584,O
is,3584,O
also,3584,O
caused,3584,O
by,3584,O
mutations,3584,O
in,3584,O
DTDST,3584,O
",",3584,O
these,3584,O
results,3584,O
demonstrate,3584,O
a,3584,O
phenotypic,3584,O
series,3584,O
of,3584,O
three,3584,O
chondrodysplasias,3584,B-DiseaseClass
of,3584,O
increasing,3584,O
severity,3584,O
caused,3584,O
by,3584,O
lesions,3584,O
in,3584,O
a,3584,O
single,3584,O
sulfate-transporter,3584,O
gene,3584,O
.,3584,O
The,3585,O
severity,3585,O
of,3585,O
the,3585,O
phenotype,3585,O
appears,3585,O
to,3585,O
be,3585,O
correlated,3585,O
with,3585,O
the,3585,O
predicted,3585,O
effect,3585,O
of,3585,O
the,3585,O
mutations,3585,O
on,3585,O
the,3585,O
residual,3585,O
activity,3585,O
of,3585,O
the,3585,O
DTDST,3585,O
protein,3585,O
..,3585,O
Haplotype,3586,O
and,3586,O
phenotype,3586,O
analysis,3586,O
of,3586,O
six,3586,O
recurrent,3586,O
BRCA1,3586,O
mutations,3586,O
in,3586,O
61,3586,O
families,3586,O
:,3586,O
results,3586,O
of,3586,O
an,3586,O
international,3586,O
study,3586,O
.,3586,O
Several,3587,O
BRCA1,3587,O
mutations,3587,O
have,3587,O
now,3587,O
been,3587,O
found,3587,O
to,3587,O
occur,3587,O
in,3587,O
geographically,3587,O
diverse,3587,O
breast,3587,B-Modifier
and,3587,I-Modifier
ovarian,3587,I-Modifier
cancer,3587,I-Modifier
families,3587,O
.,3587,O
To,3588,O
investigate,3588,O
mutation,3588,O
origin,3588,O
and,3588,O
mutation-specific,3588,O
phenotypes,3588,O
due,3588,O
to,3588,O
BRCA1,3588,O
",",3588,O
we,3588,O
constructed,3588,O
a,3588,O
haplotype,3588,O
of,3588,O
nine,3588,O
polymorphic,3588,O
markers,3588,O
within,3588,O
or,3588,O
immediately,3588,O
flanking,3588,O
the,3588,O
BRCA1,3588,O
locus,3588,O
in,3588,O
a,3588,O
set,3588,O
of,3588,O
61,3588,O
breast/ovarian,3588,B-Modifier
cancer,3588,I-Modifier
families,3588,O
selected,3588,O
for,3588,O
having,3588,O
one,3588,O
of,3588,O
six,3588,O
recurrent,3588,O
BRCA1,3588,O
mutations,3588,O
.,3588,O
Tests,3589,O
of,3589,O
both,3589,O
mutations,3589,O
and,3589,O
family-specific,3589,O
differences,3589,O
in,3589,O
age,3589,O
at,3589,O
diagnosis,3589,O
were,3589,O
not,3589,O
significant,3589,O
.,3589,O
A,3590,O
comparison,3590,O
of,3590,O
the,3590,O
six,3590,O
mutations,3590,O
in,3590,O
the,3590,O
relative,3590,O
proportions,3590,O
of,3590,O
cases,3590,O
of,3590,O
breast,3590,B-CompositeMention
and,3590,I-CompositeMention
ovarian,3590,I-CompositeMention
cancer,3590,I-CompositeMention
was,3590,O
suggestive,3590,O
of,3590,O
an,3590,O
effect,3590,O
(,3590,O
P,3590,O
=,3590,O
.,3590,O
069,3591,O
),3591,O
",",3591,O
with,3591,O
57,3591,O
%,3591,O
of,3591,O
women,3591,O
presumed,3591,O
affected,3591,O
because,3591,O
of,3591,O
the,3591,O
1294,3591,O
del,3591,O
40,3591,O
BRCA1,3591,O
mutation,3591,O
having,3591,O
ovarian,3591,B-SpecificDisease
cancer,3591,I-SpecificDisease
",",3591,O
compared,3591,O
with,3591,O
14,3591,O
%,3591,O
of,3591,O
affected,3591,O
women,3591,O
with,3591,O
the,3591,O
splice-site,3591,O
mutation,3591,O
in,3591,O
intron,3591,O
5,3591,O
of,3591,O
BRCA1,3591,O
.,3591,O
For,3592,O
the,3592,O
BRCA1,3592,O
mutations,3592,O
studied,3592,O
here,3592,O
",",3592,O
the,3592,O
individual,3592,O
mutations,3592,O
are,3592,O
estimated,3592,O
to,3592,O
have,3592,O
arisen,3592,O
9-170,3592,O
generations,3592,O
ago,3592,O
.,3592,O
In,3593,O
general,3593,O
",",3593,O
a,3593,O
high,3593,O
degree,3593,O
of,3593,O
haplotype,3593,O
conservation,3593,O
across,3593,O
the,3593,O
region,3593,O
was,3593,O
observed,3593,O
",",3593,O
with,3593,O
haplotype,3593,O
differences,3593,O
most,3593,O
often,3593,O
due,3593,O
to,3593,O
mutations,3593,O
in,3593,O
the,3593,O
short-tandem-repeat,3593,O
markers,3593,O
",",3593,O
although,3593,O
some,3593,O
likely,3593,O
instances,3593,O
of,3593,O
recombination,3593,O
also,3593,O
were,3593,O
observed,3593,O
.,3593,O
For,3594,O
several,3594,O
of,3594,O
the,3594,O
instances,3594,O
",",3594,O
there,3594,O
was,3594,O
evidence,3594,O
for,3594,O
multiple,3594,O
",",3594,O
independent,3594,O
",",3594,O
BRCA1,3594,O
mutational,3594,O
events,3594,O
.,3594,O
Isolation,3595,O
of,3595,O
the,3595,O
mouse,3595,O
homologue,3595,O
of,3595,O
BRCA1,3595,O
and,3595,O
genetic,3595,O
mapping,3595,O
to,3595,O
mouse,3595,O
chromosome,3595,O
11,3595,O
.,3595,O
The,3596,O
BRCA1,3596,O
gene,3596,O
is,3596,O
in,3596,O
large,3596,O
part,3596,O
responsible,3596,O
for,3596,O
hereditary,3596,B-CompositeMention
human,3596,I-CompositeMention
breast,3596,I-CompositeMention
and,3596,I-CompositeMention
ovarian,3596,I-CompositeMention
cancer,3596,I-CompositeMention
.,3596,O
Here,3597,O
we,3597,O
report,3597,O
the,3597,O
isolation,3597,O
of,3597,O
the,3597,O
murine,3597,O
Brca1,3597,O
homologue,3597,O
cDNA,3597,O
clones,3597,O
.,3597,O
In,3598,O
addition,3598,O
",",3598,O
we,3598,O
identified,3598,O
genomic,3598,O
P1,3598,O
clones,3598,O
that,3598,O
contain,3598,O
most,3598,O
",",3598,O
if,3598,O
not,3598,O
all,3598,O
",",3598,O
of,3598,O
the,3598,O
mouse,3598,O
Brca1,3598,O
locus,3598,O
.,3598,O
DNA,3599,O
sequence,3599,O
analysis,3599,O
revealed,3599,O
that,3599,O
the,3599,O
mouse,3599,O
and,3599,O
human,3599,O
coding,3599,O
regions,3599,O
are,3599,O
75,3599,O
%,3599,O
identical,3599,O
at,3599,O
the,3599,O
nucleotide,3599,O
level,3599,O
while,3599,O
the,3599,O
predicted,3599,O
amino,3599,O
acid,3599,O
identity,3599,O
is,3599,O
only,3599,O
58,3599,O
%,3599,O
.,3599,O
A,3600,O
DNA,3600,O
sequence,3600,O
variant,3600,O
in,3600,O
the,3600,O
Brca1,3600,O
locus,3600,O
was,3600,O
identified,3600,O
and,3600,O
used,3600,O
to,3600,O
map,3600,O
this,3600,O
gene,3600,O
on,3600,O
a,3600,O
(,3600,O
Mus,3600,O
m.,3600,O
musculus,3600,O
Czech,3600,O
II,3600,O
x,3600,O
C57BL/KsJ,3600,O
),3600,O
F1,3600,O
x,3600,O
C57BL/KsJ,3600,O
intersubspecific,3600,O
backcross,3600,O
to,3600,O
distal,3600,O
mouse,3600,O
chromosome,3600,O
11,3600,O
.,3600,O
The,3601,O
mapping,3601,O
of,3601,O
this,3601,O
gene,3601,O
to,3601,O
a,3601,O
region,3601,O
highly,3601,O
syntenic,3601,O
with,3601,O
human,3601,O
chromosome,3601,O
17,3601,O
",",3601,O
coupled,3601,O
with,3601,O
Southern,3601,O
and,3601,O
Northern,3601,O
analyses,3601,O
",",3601,O
confirms,3601,O
that,3601,O
we,3601,O
isolated,3601,O
the,3601,O
murine,3601,O
Brca1,3601,O
homologue,3601,O
rather,3601,O
than,3601,O
a,3601,O
related,3601,O
RING,3601,O
finger,3601,O
gene,3601,O
.,3601,O
The,3602,O
isolation,3602,O
of,3602,O
the,3602,O
mouse,3602,O
Brca1,3602,O
homologue,3602,O
will,3602,O
facilitate,3602,O
the,3602,O
creation,3602,O
of,3602,O
mouse,3602,O
models,3602,O
for,3602,O
germline,3602,O
BRCA1,3602,B-SpecificDisease
defects,3602,I-SpecificDisease
..,3602,O
Emerin,3603,B-SpecificDisease
deficiency,3603,I-SpecificDisease
at,3603,O
the,3603,O
nuclear,3603,O
membrane,3603,O
in,3603,O
patients,3603,O
with,3603,O
Emery-Dreifuss,3603,B-SpecificDisease
muscular,3603,I-SpecificDisease
dystrophy,3603,I-SpecificDisease
.,3603,O
Mutations,3604,O
in,3604,O
the,3604,O
STA,3604,O
gene,3604,O
at,3604,O
the,3604,O
Xq28,3604,O
locus,3604,O
have,3604,O
been,3604,O
found,3604,O
in,3604,O
patients,3604,O
with,3604,O
X-linked,3604,B-SpecificDisease
Emery-Dreifuss,3604,I-SpecificDisease
muscular,3604,I-SpecificDisease
dystrophy,3604,I-SpecificDisease
(,3604,O
EDMD,3604,B-SpecificDisease
),3604,O
.,3604,O
This,3605,O
gene,3605,O
encodes,3605,O
a,3605,O
hitherto,3605,O
unknown,3605,O
protein,3605,O
named,3605,O
emerin,3605,O
.,3605,O
To,3606,O
elucidate,3606,O
the,3606,O
subcellular,3606,O
localization,3606,O
of,3606,O
emerin,3606,O
",",3606,O
we,3606,O
raised,3606,O
two,3606,O
antisera,3606,O
against,3606,O
synthetic,3606,O
peptide,3606,O
fragments,3606,O
predicted,3606,O
from,3606,O
emerin,3606,O
cDNA,3606,O
.,3606,O
Using,3607,O
both,3607,O
antisera,3607,O
",",3607,O
we,3607,O
found,3607,O
positive,3607,O
nuclear,3607,O
membrane,3607,O
staining,3607,O
in,3607,O
skeletal,3607,O
",",3607,O
cardiac,3607,O
and,3607,O
smooth,3607,O
muscles,3607,O
in,3607,O
the,3607,O
normal,3607,O
controls,3607,O
and,3607,O
in,3607,O
patients,3607,O
with,3607,O
neuromuscular,3607,B-DiseaseClass
diseases,3607,I-DiseaseClass
other,3607,O
than,3607,O
EDMD,3607,B-SpecificDisease
.,3607,O
In,3608,O
contrast,3608,O
",",3608,O
a,3608,O
deficiency,3608,O
in,3608,O
immunofluorescent,3608,O
staining,3608,O
of,3608,O
skeletal,3608,O
and,3608,O
cardiac,3608,O
muscle,3608,O
from,3608,O
EDMD,3608,B-Modifier
patients,3608,O
was,3608,O
observed,3608,O
.,3608,O
A,3609,O
34,3609,O
kD,3609,O
protein,3609,O
is,3609,O
immunoreactive,3609,O
with,3609,O
the,3609,O
antisera,3609,O
--,3609,O
the,3609,O
protein,3609,O
is,3609,O
equivalent,3609,O
to,3609,O
that,3609,O
predicted,3609,O
for,3609,O
emerin,3609,O
.,3609,O
Together,3610,O
",",3610,O
our,3610,O
findings,3610,O
suggest,3610,O
the,3610,O
specific,3610,O
deficiency,3610,B-SpecificDisease
of,3610,I-SpecificDisease
emerin,3610,I-SpecificDisease
in,3610,O
the,3610,O
nuclear,3610,O
membrane,3610,O
of,3610,O
muscle,3610,O
cells,3610,O
in,3610,O
patients,3610,O
with,3610,O
EDMD,3610,B-SpecificDisease
..,3610,O
Growth,3611,B-DiseaseClass
retardation,3611,I-DiseaseClass
and,3611,O
tumour,3611,B-Modifier
inhibition,3611,O
by,3611,O
BRCA1,3611,O
.,3611,O
Inherited,3612,O
mutations,3612,O
in,3612,O
BRCA1,3612,O
predispose,3612,O
to,3612,O
breast,3612,B-CompositeMention
and,3612,I-CompositeMention
ovarian,3612,I-CompositeMention
cancer,3612,I-CompositeMention
",",3612,O
but,3612,O
the,3612,O
role,3612,O
of,3612,O
BRCA1,3612,O
in,3612,O
sporadic,3612,O
breast,3612,O
and,3612,O
ovarian,3612,O
cancer,3612,O
has,3612,O
previously,3612,O
been,3612,O
elusive,3612,O
.,3612,O
Here,3613,O
",",3613,O
we,3613,O
show,3613,O
that,3613,O
retroviral,3613,O
transfer,3613,O
of,3613,O
the,3613,O
wild-type,3613,O
BRCA1,3613,O
gene,3613,O
inhibits,3613,O
growth,3613,O
in,3613,O
vitro,3613,O
of,3613,O
all,3613,O
breast,3613,O
and,3613,O
ovarian,3613,O
cancer,3613,O
cell,3613,O
lines,3613,O
tested,3613,O
",",3613,O
but,3613,O
not,3613,O
colon,3613,O
or,3613,O
lung,3613,O
cancer,3613,O
cells,3613,O
or,3613,O
fibroblasts,3613,O
.,3613,O
Mutant,3614,O
BRCA1,3614,O
has,3614,O
no,3614,O
effect,3614,O
on,3614,O
growth,3614,O
of,3614,O
breast,3614,B-Modifier
cancer,3614,I-Modifier
cells,3614,O
;,3614,O
ovarian,3614,B-Modifier
cancer,3614,I-Modifier
cell,3614,O
growth,3614,O
is,3614,O
not,3614,O
affected,3614,O
by,3614,O
BRCA1,3614,O
mutations,3614,O
in,3614,O
the,3614,O
5,3614,O
portion,3614,O
of,3614,O
the,3614,O
gene,3614,O
",",3614,O
but,3614,O
is,3614,O
inhibited,3614,O
by,3614,O
3,3614,O
BRCA1,3614,O
mutations,3614,O
.,3614,O
Development,3615,O
of,3615,O
MCF-7,3615,B-DiseaseClass
tumours,3615,I-DiseaseClass
in,3615,O
nude,3615,O
mice,3615,O
is,3615,O
inhibited,3615,O
when,3615,O
MCF-7,3615,O
cells,3615,O
are,3615,O
transfected,3615,O
with,3615,O
wild-type,3615,O
",",3615,O
but,3615,O
not,3615,O
mutant,3615,O
",",3615,O
BRCA1,3615,O
.,3615,O
Most,3616,O
importantly,3616,O
",",3616,O
among,3616,O
mice,3616,O
with,3616,O
established,3616,O
MCF-7,3616,B-DiseaseClass
tumours,3616,I-DiseaseClass
",",3616,O
peritoneal,3616,O
treatment,3616,O
with,3616,O
a,3616,O
retroviral,3616,O
vector,3616,O
expressing,3616,O
wild-type,3616,O
BRCA1,3616,O
significantly,3616,O
inhibits,3616,O
tumour,3616,B-Modifier
growth,3616,O
and,3616,O
increased,3616,O
survival,3616,O
..,3616,O
Identification,3617,O
of,3617,O
APC2,3617,O
",",3617,O
a,3617,O
homologue,3617,O
of,3617,O
the,3617,O
adenomatous,3617,B-Modifier
polyposis,3617,I-Modifier
coli,3617,I-Modifier
tumour,3617,I-Modifier
suppressor,3617,O
.,3617,O
The,3618,O
adenomatous,3618,B-Modifier
polyposis,3618,I-Modifier
coli,3618,I-Modifier
(,3618,I-Modifier
APC,3618,I-Modifier
),3618,I-Modifier
tumour-suppressor,3618,O
protein,3618,O
controls,3618,O
the,3618,O
Wnt,3618,O
signalling,3618,O
pathway,3618,O
by,3618,O
forming,3618,O
a,3618,O
complex,3618,O
with,3618,O
glycogen,3618,O
synthase,3618,O
kinase,3618,O
3beta,3618,O
(,3618,O
GSK-3beta,3618,O
),3618,O
",",3618,O
axin/conductin,3618,O
and,3618,O
betacatenin,3618,O
.,3618,O
Complex,3619,O
formation,3619,O
induces,3619,O
the,3619,O
rapid,3619,O
degradation,3619,O
of,3619,O
betacatenin,3619,O
.,3619,O
In,3620,O
colon,3620,B-Modifier
carcinoma,3620,I-Modifier
cells,3620,O
",",3620,O
loss,3620,O
of,3620,O
APC,3620,O
leads,3620,O
to,3620,O
the,3620,O
accumulation,3620,O
of,3620,O
betacatenin,3620,O
in,3620,O
the,3620,O
nucleus,3620,O
",",3620,O
where,3620,O
it,3620,O
binds,3620,O
to,3620,O
and,3620,O
activates,3620,O
the,3620,O
Tcf-4,3620,O
transcription,3620,O
factor,3620,O
(,3620,O
reviewed,3620,O
in,3620,O
[,3620,O
1,3620,O
],3620,O
[,3620,O
2,3620,O
],3620,O
),3620,O
.,3620,O
Here,3621,O
",",3621,O
we,3621,O
report,3621,O
the,3621,O
identification,3621,O
and,3621,O
genomic,3621,O
structure,3621,O
of,3621,O
APC,3621,O
homologues,3621,O
.,3621,O
Mammalian,3622,O
APC2,3622,O
",",3622,O
which,3622,O
closely,3622,O
resembles,3622,O
APC,3622,O
in,3622,O
overall,3622,O
domain,3622,O
structure,3622,O
",",3622,O
was,3622,O
functionally,3622,O
analyzed,3622,O
and,3622,O
shown,3622,O
to,3622,O
contain,3622,O
two,3622,O
SAMP,3622,O
domains,3622,O
",",3622,O
both,3622,O
of,3622,O
which,3622,O
are,3622,O
required,3622,O
for,3622,O
binding,3622,O
to,3622,O
conductin,3622,O
.,3622,O
Like,3623,O
APC,3623,O
",",3623,O
APC2,3623,O
regulates,3623,O
the,3623,O
formation,3623,O
of,3623,O
active,3623,O
betacatenin-Tcf,3623,O
complexes,3623,O
",",3623,O
as,3623,O
demonstrated,3623,O
using,3623,O
transient,3623,O
transcriptional,3623,O
activation,3623,O
assays,3623,O
in,3623,O
APC,3623,O
-/-,3623,O
colon,3623,B-Modifier
carcinoma,3623,I-Modifier
cells,3623,O
.,3623,O
Human,3624,O
APC2,3624,O
maps,3624,O
to,3624,O
chromosome,3624,O
19p13,3624,O
.,3624,O
3,3625,O
.,3625,O
APC,3626,O
and,3626,O
APC2,3626,O
may,3626,O
therefore,3626,O
have,3626,O
comparable,3626,O
functions,3626,O
in,3626,O
development,3626,O
and,3626,O
cancer,3626,B-SpecificDisease
.,3626,O
A,3627,O
common,3627,O
MSH2,3627,O
mutation,3627,O
in,3627,O
English,3627,O
and,3627,O
North,3627,O
American,3627,O
HNPCC,3627,B-Modifier
families,3627,O
:,3627,O
origin,3627,O
",",3627,O
phenotypic,3627,O
expression,3627,O
",",3627,O
and,3627,O
sex,3627,O
specific,3627,O
differences,3627,O
in,3627,O
colorectal,3627,B-SpecificDisease
cancer,3627,I-SpecificDisease
.,3627,O
The,3628,O
frequency,3628,O
",",3628,O
origin,3628,O
",",3628,O
and,3628,O
phenotypic,3628,O
expression,3628,O
of,3628,O
a,3628,O
germline,3628,O
MSH2,3628,O
gene,3628,O
mutation,3628,O
previously,3628,O
identified,3628,O
in,3628,O
seven,3628,O
kindreds,3628,O
with,3628,O
hereditary,3628,B-SpecificDisease
non-polyposis,3628,I-SpecificDisease
cancer,3628,I-SpecificDisease
syndrome,3628,I-SpecificDisease
(,3628,O
HNPCC,3628,B-SpecificDisease
),3628,O
was,3628,O
investigated,3628,O
.,3628,O
The,3629,O
mutation,3629,O
(,3629,O
A,3629,O
--,3629,O
>,3629,O
T,3629,O
at,3629,O
nt943,3629,O
+,3629,O
3,3629,O
),3629,O
disrupts,3629,O
the,3629,O
3,3629,O
splice,3629,O
site,3629,O
of,3629,O
exon,3629,O
5,3629,O
leading,3629,O
to,3629,O
the,3629,O
deletion,3629,O
of,3629,O
this,3629,O
exon,3629,O
from,3629,O
MSH2,3629,O
mRNA,3629,O
and,3629,O
represents,3629,O
the,3629,O
only,3629,O
frequent,3629,O
MSH2,3629,O
mutation,3629,O
so,3629,O
far,3629,O
reported,3629,O
.,3629,O
Although,3630,O
this,3630,O
mutation,3630,O
was,3630,O
initially,3630,O
detected,3630,O
in,3630,O
four,3630,O
of,3630,O
33,3630,O
colorectal,3630,B-Modifier
cancer,3630,I-Modifier
families,3630,O
analysed,3630,O
from,3630,O
eastern,3630,O
England,3630,O
",",3630,O
more,3630,O
extensive,3630,O
analysis,3630,O
has,3630,O
reduced,3630,O
the,3630,O
frequency,3630,O
to,3630,O
four,3630,O
of,3630,O
52,3630,O
(,3630,O
8,3630,O
%,3630,O
),3630,O
English,3630,O
HNPCC,3630,B-Modifier
kindreds,3630,O
analysed,3630,O
.,3630,O
In,3631,O
contrast,3631,O
",",3631,O
the,3631,O
MSH2,3631,O
mutation,3631,O
was,3631,O
identified,3631,O
in,3631,O
10,3631,O
of,3631,O
20,3631,O
(,3631,O
50,3631,O
%,3631,O
),3631,O
separately,3631,O
identified,3631,O
colorectal,3631,B-Modifier
families,3631,O
from,3631,O
Newfoundland,3631,O
.,3631,O
To,3632,O
investigate,3632,O
the,3632,O
origin,3632,O
of,3632,O
this,3632,O
mutation,3632,O
in,3632,O
colorectal,3632,B-Modifier
cancer,3632,I-Modifier
families,3632,O
from,3632,O
England,3632,O
(,3632,O
n,3632,O
=,3632,O
4,3632,O
),3632,O
",",3632,O
Newfoundland,3632,O
(,3632,O
n,3632,O
=,3632,O
10,3632,O
),3632,O
",",3632,O
and,3632,O
the,3632,O
United,3632,O
States,3632,O
(,3632,O
n,3632,O
=,3632,O
3,3632,O
),3632,O
",",3632,O
haplotype,3632,O
analysis,3632,O
using,3632,O
microsatellite,3632,O
markers,3632,O
linked,3632,O
to,3632,O
MSH2,3632,O
was,3632,O
performed,3632,O
.,3632,O
Within,3633,O
the,3633,O
English,3633,O
and,3633,O
US,3633,O
families,3633,O
there,3633,O
was,3633,O
little,3633,O
evidence,3633,O
for,3633,O
a,3633,O
recent,3633,O
common,3633,O
origin,3633,O
of,3633,O
the,3633,O
MSH2,3633,O
splice,3633,O
site,3633,O
mutation,3633,O
in,3633,O
most,3633,O
families,3633,O
.,3633,O
In,3634,O
contrast,3634,O
",",3634,O
a,3634,O
common,3634,O
haplotype,3634,O
was,3634,O
identified,3634,O
at,3634,O
the,3634,O
two,3634,O
flanking,3634,O
markers,3634,O
(,3634,O
CA5,3634,O
and,3634,O
D2S288,3634,O
),3634,O
in,3634,O
eight,3634,O
of,3634,O
the,3634,O
Newfoundland,3634,O
families,3634,O
.,3634,O
These,3635,O
findings,3635,O
suggested,3635,O
a,3635,O
founder,3635,O
effect,3635,O
within,3635,O
Newfoundland,3635,O
similar,3635,O
to,3635,O
that,3635,O
reported,3635,O
by,3635,O
others,3635,O
for,3635,O
two,3635,O
MLH1,3635,O
mutations,3635,O
in,3635,O
Finnish,3635,O
HNPCC,3635,B-Modifier
families,3635,O
.,3635,O
We,3636,O
calculated,3636,O
age,3636,O
related,3636,O
risks,3636,O
of,3636,O
all,3636,O
",",3636,O
colorectal,3636,O
",",3636,O
endometrial,3636,O
",",3636,O
and,3636,O
ovarian,3636,O
cancers,3636,O
in,3636,O
nt943,3636,O
+,3636,O
3,3636,O
A,3636,O
--,3636,O
>,3636,O
T,3636,O
MSH2,3636,O
mutation,3636,O
carriers,3636,O
(,3636,O
n,3636,O
=,3636,O
76,3636,O
),3636,O
for,3636,O
all,3636,O
patients,3636,O
and,3636,O
for,3636,O
men,3636,O
and,3636,O
women,3636,O
separately,3636,O
.,3636,O
For,3637,O
both,3637,O
sexes,3637,O
combined,3637,O
",",3637,O
the,3637,O
penetrances,3637,O
at,3637,O
age,3637,O
60,3637,O
years,3637,O
for,3637,O
all,3637,O
cancers,3637,B-DiseaseClass
and,3637,O
for,3637,O
colorectal,3637,B-SpecificDisease
cancer,3637,I-SpecificDisease
were,3637,O
0,3637,O
.,3637,O
86,3638,O
and,3638,O
0,3638,O
.,3638,O
57,3639,O
",",3639,O
respectively,3639,O
.,3639,O
The,3640,O
risk,3640,O
of,3640,O
colorectal,3640,B-SpecificDisease
cancer,3640,I-SpecificDisease
was,3640,O
significantly,3640,O
higher,3640,O
(,3640,O
p,3640,O
<,3640,O
0,3640,O
.,3640,O
01,3641,O
),3641,O
in,3641,O
males,3641,O
than,3641,O
females,3641,O
(,3641,O
0,3641,O
.,3641,O
63,3642,O
v,3642,O
0,3642,O
.,3642,O
30,3643,O
and,3643,O
0,3643,O
.,3643,O
84,3644,O
v,3644,O
0,3644,O
.,3644,O
44,3645,O
at,3645,O
ages,3645,O
50,3645,O
and,3645,O
60,3645,O
years,3645,O
",",3645,O
respectively,3645,O
),3645,O
.,3645,O
For,3646,O
females,3646,O
there,3646,O
was,3646,O
a,3646,O
high,3646,O
risk,3646,O
of,3646,O
endometrial,3646,B-SpecificDisease
cancer,3646,I-SpecificDisease
(,3646,O
0,3646,O
.,3646,O
5,3647,O
at,3647,O
age,3647,O
60,3647,O
years,3647,O
),3647,O
and,3647,O
premenopausal,3647,B-SpecificDisease
ovarian,3647,I-SpecificDisease
cancer,3647,I-SpecificDisease
(,3647,O
0,3647,O
.,3647,O
2,3648,O
at,3648,O
50,3648,O
years,3648,O
),3648,O
.,3648,O
These,3649,O
intersex,3649,O
differences,3649,O
in,3649,O
colorectal,3649,B-Modifier
cancer,3649,I-Modifier
risks,3649,O
have,3649,O
implications,3649,O
for,3649,O
screening,3649,O
programmes,3649,O
and,3649,O
for,3649,O
attempts,3649,O
to,3649,O
identify,3649,O
colorectal,3649,B-Modifier
cancer,3649,I-Modifier
susceptibility,3649,O
modifiers,3649,O
.,3649,O
Age,3650,O
of,3650,O
onset,3650,O
in,3650,O
Huntington,3650,B-SpecificDisease
disease,3650,I-SpecificDisease
:,3650,O
sex,3650,O
specific,3650,O
influence,3650,O
of,3650,O
apolipoprotein,3650,O
E,3650,O
genotype,3650,O
and,3650,O
normal,3650,O
CAG,3650,O
repeat,3650,O
length,3650,O
.,3650,O
Age,3651,O
of,3651,O
onset,3651,O
(,3651,O
AO,3651,O
),3651,O
of,3651,O
Huntington,3651,B-SpecificDisease
disease,3651,I-SpecificDisease
(,3651,O
HD,3651,B-SpecificDisease
),3651,O
is,3651,O
known,3651,O
to,3651,O
be,3651,O
correlated,3651,O
with,3651,O
the,3651,O
length,3651,O
of,3651,O
an,3651,O
expanded,3651,O
CAG,3651,O
repeat,3651,O
in,3651,O
the,3651,O
HD,3651,B-Modifier
gene,3651,O
.,3651,O
Apolipoprotein,3652,O
E,3652,O
(,3652,O
APOE,3652,O
),3652,O
genotype,3652,O
",",3652,O
in,3652,O
turn,3652,O
",",3652,O
is,3652,O
known,3652,O
to,3652,O
influence,3652,O
AO,3652,O
in,3652,O
Alzheimer,3652,B-SpecificDisease
disease,3652,I-SpecificDisease
",",3652,O
rendering,3652,O
the,3652,O
APOE,3652,O
gene,3652,O
a,3652,O
likely,3652,O
candidate,3652,O
to,3652,O
affect,3652,O
AO,3652,O
in,3652,O
other,3652,O
neurological,3652,B-DiseaseClass
diseases,3652,I-DiseaseClass
too,3652,O
.,3652,O
We,3653,O
therefore,3653,O
determined,3653,O
APOE,3653,O
genotype,3653,O
and,3653,O
normal,3653,O
CAG,3653,O
repeat,3653,O
length,3653,O
in,3653,O
the,3653,O
HD,3653,B-Modifier
gene,3653,O
for,3653,O
138,3653,O
HD,3653,B-Modifier
patients,3653,O
who,3653,O
were,3653,O
previously,3653,O
analysed,3653,O
with,3653,O
respect,3653,O
to,3653,O
CAG,3653,O
repeat,3653,O
length,3653,O
.,3653,O
Genotyping,3654,O
for,3654,O
APOE,3654,O
was,3654,O
performed,3654,O
blind,3654,O
to,3654,O
clinical,3654,O
information,3654,O
.,3654,O
In,3655,O
addition,3655,O
to,3655,O
highlighting,3655,O
the,3655,O
effect,3655,O
of,3655,O
the,3655,O
normal,3655,O
repeat,3655,O
length,3655,O
upon,3655,O
AO,3655,O
in,3655,O
maternally,3655,O
inherited,3655,O
HD,3655,B-SpecificDisease
and,3655,O
in,3655,O
male,3655,O
patients,3655,O
",",3655,O
we,3655,O
show,3655,O
that,3655,O
the,3655,O
APOE,3655,O
epsilon2epsilon3,3655,O
genotype,3655,O
is,3655,O
associated,3655,O
with,3655,O
significantly,3655,O
earlier,3655,O
AO,3655,O
in,3655,O
males,3655,O
than,3655,O
in,3655,O
females,3655,O
.,3655,O
Such,3656,O
a,3656,O
sex,3656,O
difference,3656,O
in,3656,O
AO,3656,O
was,3656,O
not,3656,O
apparent,3656,O
for,3656,O
any,3656,O
of,3656,O
the,3656,O
other,3656,O
APOE,3656,O
genotypes,3656,O
.,3656,O
Our,3657,O
findings,3657,O
suggest,3657,O
that,3657,O
subtle,3657,O
differences,3657,O
in,3657,O
the,3657,O
course,3657,O
of,3657,O
the,3657,O
neurodegeneration,3657,B-DiseaseClass
in,3657,O
HD,3657,B-SpecificDisease
may,3657,O
allow,3657,O
interacting,3657,O
genes,3657,O
to,3657,O
exert,3657,O
gender,3657,O
specific,3657,O
effects,3657,O
upon,3657,O
AO,3657,O
.,3657,O
Increased,3658,O
incidence,3658,O
of,3658,O
cancer,3658,B-DiseaseClass
in,3658,O
patients,3658,O
with,3658,O
cartilage-hair,3658,B-SpecificDisease
hypoplasia,3658,I-SpecificDisease
.,3658,O
OBJECTIVE,3659,O
Previous,3659,O
reports,3659,O
have,3659,O
suggested,3659,O
an,3659,O
increased,3659,O
risk,3659,O
of,3659,O
cancer,3659,B-DiseaseClass
among,3659,O
patients,3659,O
with,3659,O
cartilage-hair,3659,B-SpecificDisease
hypoplasia,3659,I-SpecificDisease
(,3659,O
CHH,3659,B-SpecificDisease
),3659,O
.,3659,O
This,3660,O
study,3660,O
was,3660,O
carried,3660,O
out,3660,O
to,3660,O
further,3660,O
evaluate,3660,O
this,3660,O
risk,3660,O
among,3660,O
patients,3660,O
with,3660,O
CHH,3660,B-SpecificDisease
and,3660,O
their,3660,O
first-degree,3660,O
relatives,3660,O
.,3660,O
STUDY,3661,O
DESIGN,3661,O
One,3661,O
hundred,3661,O
twenty-two,3661,O
patients,3661,O
with,3661,O
CHH,3661,B-SpecificDisease
were,3661,O
identified,3661,O
through,3661,O
2,3661,O
countrywide,3661,O
epidemiologic,3661,O
surveys,3661,O
in,3661,O
1974,3661,O
and,3661,O
in,3661,O
1986,3661,O
.,3661,O
Their,3662,O
parents,3662,O
and,3662,O
nonaffected,3662,O
siblings,3662,O
were,3662,O
identified,3662,O
through,3662,O
the,3662,O
Population,3662,O
Register,3662,O
Center,3662,O
.,3662,O
This,3663,O
cohort,3663,O
underwent,3663,O
follow-up,3663,O
for,3663,O
cancer,3663,B-Modifier
incidence,3663,O
through,3663,O
the,3663,O
Finnish,3663,O
Cancer,3663,O
Registry,3663,O
to,3663,O
the,3663,O
end,3663,O
of,3663,O
1995,3663,O
.,3663,O
RESULTS,3664,O
A,3664,O
statistically,3664,O
significant,3664,O
excess,3664,O
risk,3664,O
of,3664,O
cancer,3664,B-DiseaseClass
was,3664,O
seen,3664,O
among,3664,O
the,3664,O
patients,3664,O
with,3664,O
CHH,3664,B-SpecificDisease
(,3664,O
standardized,3664,O
incidence,3664,O
ratio,3664,O
6,3664,O
.,3664,O
9,3665,O
",",3665,O
95,3665,O
%,3665,O
confidence,3665,O
interval,3665,O
2,3665,O
.,3665,O
3,3666,O
to,3666,O
16,3666,O
),3666,O
",",3666,O
which,3666,O
was,3666,O
mainly,3666,O
attributable,3666,O
to,3666,O
non-Hodgkins,3666,B-SpecificDisease
lymphoma,3666,I-SpecificDisease
(,3666,O
standardized,3666,O
incidence,3666,O
ratio,3666,O
90,3666,O
",",3666,O
95,3666,O
%,3666,O
confidence,3666,O
interval,3666,O
18,3666,O
to,3666,O
264,3666,O
),3666,O
.,3666,O
In,3667,O
addition,3667,O
",",3667,O
a,3667,O
significant,3667,O
excess,3667,O
risk,3667,O
of,3667,O
basal,3667,B-SpecificDisease
cell,3667,I-SpecificDisease
carcinoma,3667,I-SpecificDisease
was,3667,O
seen,3667,O
(,3667,O
standardized,3667,O
incidence,3667,O
ratio,3667,O
35,3667,O
",",3667,O
95,3667,O
%,3667,O
confidence,3667,O
interval,3667,O
7,3667,O
.,3667,O
2,3668,O
to,3668,O
102,3668,O
),3668,O
.,3668,O
The,3669,O
cancer,3669,B-Modifier
incidence,3669,O
among,3669,O
the,3669,O
siblings,3669,O
or,3669,O
the,3669,O
parents,3669,O
did,3669,O
not,3669,O
differ,3669,O
from,3669,O
the,3669,O
average,3669,O
cancer,3669,B-Modifier
incidence,3669,O
in,3669,O
the,3669,O
Finnish,3669,O
population,3669,O
.,3669,O
CONCLUSIONS,3670,O
This,3670,O
study,3670,O
confirms,3670,O
an,3670,O
increased,3670,O
risk,3670,O
of,3670,O
cancer,3670,B-DiseaseClass
",",3670,O
especially,3670,O
non-Hodgkins,3670,B-SpecificDisease
lymphoma,3670,I-SpecificDisease
",",3670,O
probably,3670,O
attributable,3670,O
to,3670,O
defective,3670,O
immunity,3670,O
",",3670,O
among,3670,O
patients,3670,O
with,3670,O
CHH,3670,B-SpecificDisease
.,3670,O
Genotype,3671,O
and,3671,O
phenotype,3671,O
in,3671,O
patients,3671,O
with,3671,O
dihydropyrimidine,3671,B-SpecificDisease
dehydrogenase,3671,I-SpecificDisease
deficiency,3671,I-SpecificDisease
.,3671,O
Dihydropyrimidine,3672,B-SpecificDisease
dehydrogenase,3672,I-SpecificDisease
(,3672,I-SpecificDisease
DPD,3672,I-SpecificDisease
),3672,I-SpecificDisease
deficiency,3672,I-SpecificDisease
is,3672,O
an,3672,O
autosomal,3672,B-DiseaseClass
recessive,3672,I-DiseaseClass
disease,3672,I-DiseaseClass
characterised,3672,O
by,3672,O
thymine-uraciluria,3672,O
in,3672,O
homozygous,3672,O
deficient,3672,O
patients,3672,O
and,3672,O
has,3672,O
been,3672,O
associated,3672,O
with,3672,O
a,3672,O
variable,3672,O
clinical,3672,O
phenotype,3672,O
.,3672,O
In,3673,O
order,3673,O
to,3673,O
understand,3673,O
the,3673,O
genetic,3673,O
and,3673,O
phenotypic,3673,O
basis,3673,O
for,3673,O
DPD,3673,B-SpecificDisease
deficiency,3673,I-SpecificDisease
",",3673,O
we,3673,O
have,3673,O
reviewed,3673,O
17,3673,O
families,3673,O
presenting,3673,O
22,3673,O
patients,3673,O
with,3673,O
complete,3673,O
deficiency,3673,B-SpecificDisease
of,3673,I-SpecificDisease
DPD,3673,I-SpecificDisease
.,3673,O
In,3674,O
this,3674,O
group,3674,O
of,3674,O
patients,3674,O
",",3674,O
7,3674,O
different,3674,O
mutations,3674,O
have,3674,O
been,3674,O
identified,3674,O
",",3674,O
including,3674,O
2,3674,O
deletions,3674,O
[,3674,O
295-298delTCAT,3674,O
",",3674,O
1897delC,3674,O
],3674,O
",",3674,O
1,3674,O
splice-site,3674,O
mutation,3674,O
[,3674,O
IVS14,3674,O
+,3674,O
1G,3674,O
>,3674,O
A,3674,O
),3674,O
],3674,O
and,3674,O
4,3674,O
missense,3674,O
mutations,3674,O
(,3674,O
85T,3674,O
>,3674,O
C,3674,O
",",3674,O
703C,3674,O
>,3674,O
T,3674,O
",",3674,O
2658G,3674,O
>,3674,O
A,3674,O
",",3674,O
2983G,3674,O
>,3674,O
T,3674,O
),3674,O
.,3674,O
Analysis,3675,O
of,3675,O
the,3675,O
prevalence,3675,O
of,3675,O
the,3675,O
various,3675,O
mutations,3675,O
among,3675,O
DPD,3675,B-Modifier
patients,3675,O
has,3675,O
shown,3675,O
that,3675,O
the,3675,O
G,3675,O
--,3675,O
>,3675,O
A,3675,O
point,3675,O
mutation,3675,O
in,3675,O
the,3675,O
invariant,3675,O
splice,3675,O
donor,3675,O
site,3675,O
is,3675,O
by,3675,O
far,3675,O
the,3675,O
most,3675,O
common,3675,O
(,3675,O
52,3675,O
%,3675,O
),3675,O
",",3675,O
whereas,3675,O
the,3675,O
other,3675,O
six,3675,O
mutations,3675,O
are,3675,O
less,3675,O
frequently,3675,O
observed,3675,O
.,3675,O
A,3676,O
large,3676,O
phenotypic,3676,O
variability,3676,O
has,3676,O
been,3676,O
observed,3676,O
",",3676,O
with,3676,O
convulsive,3676,B-DiseaseClass
disorders,3676,I-DiseaseClass
",",3676,O
motor,3676,B-DiseaseClass
retardation,3676,I-DiseaseClass
and,3676,O
mental,3676,B-DiseaseClass
retardation,3676,I-DiseaseClass
being,3676,O
the,3676,O
most,3676,O
abundant,3676,O
manifestations,3676,O
.,3676,O
A,3677,O
clear,3677,O
correlation,3677,O
between,3677,O
the,3677,O
genotype,3677,O
and,3677,O
phenotype,3677,O
has,3677,O
not,3677,O
been,3677,O
established,3677,O
.,3677,O
An,3678,O
altered,3678,O
beta-alanine,3678,O
",",3678,O
uracil,3678,O
and,3678,O
thymine,3678,O
homeostasis,3678,O
might,3678,O
underlie,3678,O
the,3678,O
various,3678,O
clinical,3678,B-DiseaseClass
abnormalities,3678,I-DiseaseClass
encountered,3678,O
in,3678,O
patients,3678,O
with,3678,O
DPD,3678,B-SpecificDisease
deficiency,3678,I-SpecificDisease
.,3678,O
Fibroblast,3679,O
growth,3679,O
factor,3679,O
homologous,3679,O
factor,3679,O
2,3679,O
(,3679,O
FHF2,3679,O
),3679,O
:,3679,O
gene,3679,O
structure,3679,O
",",3679,O
expression,3679,O
and,3679,O
mapping,3679,O
to,3679,O
the,3679,O
Borjeson-Forssman-Lehmann,3679,B-Modifier
syndrome,3679,I-Modifier
region,3679,O
in,3679,O
Xq26,3679,O
delineated,3679,O
by,3679,O
a,3679,O
duplication,3679,O
breakpoint,3679,O
in,3679,O
a,3679,O
BFLS-like,3679,B-Modifier
patient,3679,O
.,3679,O
Borjeson-Forssman-Lehmann,3680,B-SpecificDisease
syndrome,3680,I-SpecificDisease
(,3680,O
BFLS,3680,B-SpecificDisease
),3680,O
is,3680,O
a,3680,O
syndromal,3680,O
X-linked,3680,B-DiseaseClass
mental,3680,I-DiseaseClass
retardation,3680,I-DiseaseClass
",",3680,O
which,3680,O
maps,3680,O
by,3680,O
linkage,3680,O
to,3680,O
the,3680,O
q26,3680,O
region,3680,O
of,3680,O
the,3680,O
human,3680,O
X,3680,O
chromosome,3680,O
.,3680,O
We,3681,O
have,3681,O
identified,3681,O
a,3681,O
male,3681,O
patient,3681,O
with,3681,O
BFLS-like,3681,B-Modifier
features,3681,O
and,3681,O
a,3681,O
duplication,3681,O
",",3681,O
46,3681,O
",",3681,O
Y,3681,O
",",3681,O
dup,3681,O
(,3681,O
X,3681,O
),3681,O
(,3681,O
q26q28,3681,O
),3681,O
",",3681,O
inherited,3681,O
from,3681,O
his,3681,O
phenotypically,3681,O
normal,3681,O
mother,3681,O
.,3681,O
Fluorescence,3682,O
in,3682,O
situ,3682,O
hybridisation,3682,O
using,3682,O
yeast,3682,O
artificial,3682,O
chromosome,3682,O
clones,3682,O
from,3682,O
Xq26,3682,O
localised,3682,O
the,3682,O
duplication,3682,O
breakpoint,3682,O
to,3682,O
an,3682,O
approximately,3682,O
400-kb,3682,O
interval,3682,O
in,3682,O
the,3682,O
Xq26,3682,O
.,3682,O
3,3683,O
region,3683,O
between,3683,O
DXS155,3683,O
and,3683,O
DXS294/DXS730,3683,O
.,3683,O
Database,3684,O
searches,3684,O
and,3684,O
analysis,3684,O
of,3684,O
available,3684,O
genomic,3684,O
DNA,3684,O
sequence,3684,O
from,3684,O
the,3684,O
region,3684,O
revealed,3684,O
the,3684,O
presence,3684,O
of,3684,O
the,3684,O
fibroblast,3684,O
growth,3684,O
factor,3684,O
homologous,3684,O
factor,3684,O
gene,3684,O
",",3684,O
FHF2,3684,O
",",3684,O
within,3684,O
the,3684,O
duplication,3684,O
breakpoint,3684,O
interval,3684,O
.,3684,O
The,3685,O
gene,3685,O
structure,3685,O
of,3685,O
FHF2,3685,O
was,3685,O
determined,3685,O
and,3685,O
two,3685,O
new,3685,O
exons,3685,O
were,3685,O
identified,3685,O
",",3685,O
including,3685,O
a,3685,O
new,3685,O
5,3685,O
end,3685,O
exon,3685,O
",",3685,O
1B,3685,O
.,3685,O
FHF2,3686,O
is,3686,O
a,3686,O
large,3686,O
gene,3686,O
extending,3686,O
over,3686,O
approximately,3686,O
200,3686,O
kb,3686,O
in,3686,O
Xq26,3686,O
.,3686,O
3,3687,O
and,3687,O
is,3687,O
composed,3687,O
of,3687,O
at,3687,O
least,3687,O
seven,3687,O
exons,3687,O
.,3687,O
It,3688,O
shows,3688,O
tissue-specific,3688,O
alternative,3688,O
splicing,3688,O
and,3688,O
alternative,3688,O
transcription,3688,O
starts,3688,O
.,3688,O
Northern,3689,O
blot,3689,O
hybridisation,3689,O
showed,3689,O
highest,3689,O
expression,3689,O
in,3689,O
brain,3689,O
and,3689,O
skeletal,3689,O
muscle,3689,O
.,3689,O
The,3690,O
FHF2,3690,O
gene,3690,O
localisation,3690,O
and,3690,O
tissue-specific,3690,O
expression,3690,O
pattern,3690,O
suggest,3690,O
it,3690,O
to,3690,O
be,3690,O
a,3690,O
candidate,3690,O
gene,3690,O
for,3690,O
familial,3690,O
cases,3690,O
of,3690,O
the,3690,O
BFLS,3690,B-SpecificDisease
syndrome,3690,I-SpecificDisease
and,3690,O
other,3690,O
syndromal,3690,O
and,3690,O
non-specific,3690,O
forms,3690,O
of,3690,O
X-linked,3690,B-DiseaseClass
mental,3690,I-DiseaseClass
retardation,3690,I-DiseaseClass
mapping,3690,O
to,3690,O
the,3690,O
region,3690,O
.,3690,O
Germline,3691,O
E-cadherin,3691,O
gene,3691,O
(,3691,O
CDH1,3691,O
),3691,O
mutations,3691,O
predispose,3691,O
to,3691,O
familial,3691,B-SpecificDisease
gastric,3691,I-SpecificDisease
cancer,3691,I-SpecificDisease
and,3691,O
colorectal,3691,B-SpecificDisease
cancer,3691,I-SpecificDisease
.,3691,O
Inherited,3692,O
mutations,3692,O
in,3692,O
the,3692,O
E-cadherin,3692,O
gene,3692,O
(,3692,O
CDH1,3692,O
),3692,O
were,3692,O
described,3692,O
recently,3692,O
in,3692,O
three,3692,O
Maori,3692,O
kindreds,3692,O
with,3692,O
familial,3692,B-SpecificDisease
gastric,3692,I-SpecificDisease
cancer,3692,I-SpecificDisease
.,3692,O
Familial,3693,B-SpecificDisease
gastric,3693,I-SpecificDisease
cancer,3693,I-SpecificDisease
is,3693,O
genetically,3693,O
heterogeneous,3693,O
and,3693,O
it,3693,O
is,3693,O
not,3693,O
clear,3693,O
what,3693,O
proportion,3693,O
of,3693,O
gastric,3693,B-Modifier
cancer,3693,I-Modifier
susceptibility,3693,O
in,3693,O
non-Maori,3693,O
populations,3693,O
is,3693,O
due,3693,O
to,3693,O
germline,3693,O
CDH1,3693,O
mutations,3693,O
.,3693,O
Therefore,3694,O
",",3694,O
we,3694,O
screened,3694,O
eight,3694,O
familial,3694,B-Modifier
gastric,3694,I-Modifier
cancer,3694,I-Modifier
kindreds,3694,O
of,3694,O
British,3694,O
and,3694,O
Irish,3694,O
origin,3694,O
for,3694,O
germline,3694,O
CDH1,3694,O
mutations,3694,O
",",3694,O
by,3694,O
SSCP,3694,O
analysis,3694,O
of,3694,O
all,3694,O
16,3694,O
exons,3694,O
and,3694,O
flanking,3694,O
sequences,3694,O
.,3694,O
Each,3695,O
family,3695,O
contained,3695,O
(,3695,O
i,3695,O
),3695,O
two,3695,O
cases,3695,O
of,3695,O
gastric,3695,B-SpecificDisease
cancer,3695,I-SpecificDisease
in,3695,O
first,3695,O
degree,3695,O
relatives,3695,O
with,3695,O
one,3695,O
affected,3695,O
before,3695,O
age,3695,O
50,3695,O
years,3695,O
;,3695,O
or,3695,O
(,3695,O
ii,3695,O
),3695,O
three,3695,O
or,3695,O
more,3695,O
cases,3695,O
of,3695,O
gastric,3695,B-SpecificDisease
cancer,3695,I-SpecificDisease
.,3695,O
Novel,3696,O
germline,3696,O
CDH1,3696,O
mutations,3696,O
(,3696,O
a,3696,O
nonsense,3696,O
and,3696,O
a,3696,O
splice,3696,O
site,3696,O
),3696,O
were,3696,O
detected,3696,O
in,3696,O
two,3696,O
families,3696,O
(,3696,O
25,3696,O
%,3696,O
),3696,O
.,3696,O
Both,3697,O
mutations,3697,O
were,3697,O
predicted,3697,O
to,3697,O
truncate,3697,O
the,3697,O
E-cadherin,3697,O
protein,3697,O
in,3697,O
the,3697,O
signal,3697,O
peptide,3697,O
domain,3697,O
.,3697,O
In,3698,O
one,3698,O
family,3698,O
there,3698,O
was,3698,O
evidence,3698,O
of,3698,O
non-penetrance,3698,O
and,3698,O
susceptibility,3698,O
to,3698,O
both,3698,O
gastric,3698,O
and,3698,O
colorectal,3698,O
cancer,3698,O
;,3698,O
thus,3698,O
",",3698,O
in,3698,O
addition,3698,O
to,3698,O
six,3698,O
cases,3698,O
of,3698,O
gastric,3698,B-SpecificDisease
cancer,3698,I-SpecificDisease
",",3698,O
a,3698,O
CDH1,3698,O
mutation,3698,O
carrier,3698,O
developed,3698,O
colorectal,3698,B-SpecificDisease
cancer,3698,I-SpecificDisease
at,3698,O
age,3698,O
30,3698,O
years,3698,O
.,3698,O
We,3699,O
have,3699,O
confirmed,3699,O
that,3699,O
germline,3699,O
mutations,3699,O
in,3699,O
the,3699,O
CDH1,3699,O
gene,3699,O
cause,3699,O
familial,3699,B-SpecificDisease
gastric,3699,I-SpecificDisease
cancer,3699,I-SpecificDisease
in,3699,O
non-Maori,3699,O
populations,3699,O
.,3699,O
However,3700,O
",",3700,O
only,3700,O
a,3700,O
minority,3700,O
of,3700,O
familial,3700,O
gastric,3700,B-SpecificDisease
cancers,3700,I-SpecificDisease
can,3700,O
be,3700,O
accounted,3700,O
for,3700,O
by,3700,O
CDH1,3700,O
mutations,3700,O
.,3700,O
Loss,3701,O
of,3701,O
E-cadherin,3701,O
function,3701,O
has,3701,O
been,3701,O
implicated,3701,O
in,3701,O
the,3701,O
pathogenesis,3701,O
of,3701,O
sporadic,3701,O
colorectal,3701,O
and,3701,O
other,3701,O
cancers,3701,O
",",3701,O
and,3701,O
our,3701,O
findings,3701,O
provide,3701,O
evidence,3701,O
that,3701,O
germline,3701,O
CDH1,3701,O
mutations,3701,O
predispose,3701,O
to,3701,O
early,3701,O
onset,3701,O
colorectal,3701,B-SpecificDisease
cancer,3701,I-SpecificDisease
.,3701,O
Thus,3702,O
",",3702,O
CDH1,3702,O
should,3702,O
be,3702,O
investigated,3702,O
as,3702,O
a,3702,O
cause,3702,O
of,3702,O
inherited,3702,O
susceptibility,3702,O
to,3702,O
both,3702,O
gastric,3702,O
and,3702,O
colorectal,3702,O
cancers,3702,O
.,3702,O
A,3703,O
zinc,3703,O
finger,3703,O
truncation,3703,O
of,3703,O
murine,3703,O
WT1,3703,O
results,3703,O
in,3703,O
the,3703,O
characteristic,3703,O
urogenital,3703,B-DiseaseClass
abnormalities,3703,I-DiseaseClass
of,3703,O
Denys-Drash,3703,B-SpecificDisease
syndrome,3703,I-SpecificDisease
.,3703,O
The,3704,O
Wilms,3704,B-Modifier
tumor,3704,I-Modifier
-suppressor,3704,O
gene,3704,O
",",3704,O
WT1,3704,O
",",3704,O
plays,3704,O
a,3704,O
key,3704,O
role,3704,O
in,3704,O
urogenital,3704,O
development,3704,O
",",3704,O
and,3704,O
WT1,3704,B-SpecificDisease
dysfunction,3704,I-SpecificDisease
is,3704,O
implicated,3704,O
in,3704,O
both,3704,O
neoplastic,3704,B-Modifier
(,3704,O
Wilms,3704,B-SpecificDisease
tumor,3704,I-SpecificDisease
",",3704,O
mesothelioma,3704,B-SpecificDisease
",",3704,O
leukemias,3704,B-SpecificDisease
",",3704,O
and,3704,O
breast,3704,B-SpecificDisease
cancer,3704,I-SpecificDisease
),3704,O
and,3704,O
nonneoplastic,3704,B-Modifier
(,3704,O
glomerulosclerosis,3704,B-SpecificDisease
),3704,O
disease,3704,O
.,3704,O
The,3705,O
analysis,3705,O
of,3705,O
diseases,3705,O
linked,3705,O
specifically,3705,O
with,3705,O
WT1,3705,O
mutations,3705,O
",",3705,O
such,3705,O
as,3705,O
Denys-Drash,3705,B-SpecificDisease
syndrome,3705,I-SpecificDisease
(,3705,O
DDS,3705,B-SpecificDisease
),3705,O
",",3705,O
can,3705,O
provide,3705,O
valuable,3705,O
insight,3705,O
concerning,3705,O
the,3705,O
role,3705,O
of,3705,O
WT1,3705,O
in,3705,O
development,3705,O
and,3705,O
disease,3705,O
.,3705,O
DDS,3706,B-SpecificDisease
is,3706,O
a,3706,O
rare,3706,O
childhood,3706,O
disease,3706,O
characterized,3706,O
by,3706,O
a,3706,O
nephropathy,3706,B-SpecificDisease
involving,3706,O
mesangial,3706,B-SpecificDisease
sclerosis,3706,I-SpecificDisease
",",3706,O
XY,3706,O
pseudohermaphroditism,3706,B-SpecificDisease
",",3706,O
and/or,3706,O
Wilms,3706,B-SpecificDisease
tumor,3706,I-SpecificDisease
(,3706,O
WT,3706,B-SpecificDisease
),3706,O
.,3706,O
DDS,3707,B-Modifier
patients,3707,O
are,3707,O
constitutionally,3707,O
heterozygous,3707,O
for,3707,O
exonic,3707,O
point,3707,O
mutations,3707,O
in,3707,O
WT1,3707,O
",",3707,O
which,3707,O
include,3707,O
mutations,3707,O
predicted,3707,O
to,3707,O
truncate,3707,O
the,3707,O
protein,3707,O
within,3707,O
the,3707,O
C-terminal,3707,O
zinc,3707,O
finger,3707,O
(,3707,O
ZF,3707,O
),3707,O
region,3707,O
.,3707,O
We,3708,O
report,3708,O
that,3708,O
heterozygosity,3708,O
for,3708,O
a,3708,O
targeted,3708,O
murine,3708,O
Wt1,3708,O
allele,3708,O
",",3708,O
Wt1,3708,O
(,3708,O
tmT396,3708,O
),3708,O
",",3708,O
which,3708,O
truncates,3708,O
ZF3,3708,O
at,3708,O
codon,3708,O
396,3708,O
",",3708,O
induces,3708,O
mesangial,3708,B-SpecificDisease
sclerosis,3708,I-SpecificDisease
characteristic,3708,O
of,3708,O
DDS,3708,B-SpecificDisease
in,3708,O
adult,3708,O
heterozygous,3708,O
and,3708,O
chimeric,3708,O
mice,3708,O
.,3708,O
Male,3709,B-DiseaseClass
genital,3709,I-DiseaseClass
defects,3709,I-DiseaseClass
also,3709,O
were,3709,O
evident,3709,O
and,3709,O
there,3709,O
was,3709,O
a,3709,O
single,3709,O
case,3709,O
of,3709,O
Wilms,3709,B-SpecificDisease
tumor,3709,I-SpecificDisease
in,3709,O
which,3709,O
the,3709,O
transcript,3709,O
of,3709,O
the,3709,O
nontargeted,3709,O
allele,3709,O
showed,3709,O
an,3709,O
exon,3709,O
9,3709,O
skipping,3709,O
event,3709,O
",",3709,O
implying,3709,O
a,3709,O
causal,3709,O
link,3709,O
between,3709,O
Wt1,3709,B-SpecificDisease
dysfunction,3709,I-SpecificDisease
and,3709,O
Wilms,3709,B-SpecificDisease
tumorigenesis,3709,I-SpecificDisease
in,3709,O
mice,3709,O
.,3709,O
However,3710,O
",",3710,O
the,3710,O
mutant,3710,O
WT1,3710,O
(,3710,O
tmT396,3710,O
),3710,O
protein,3710,O
accounted,3710,O
for,3710,O
only,3710,O
5,3710,O
%,3710,O
of,3710,O
WT1,3710,O
in,3710,O
both,3710,O
heterozygous,3710,O
embryonic,3710,O
stem,3710,O
cells,3710,O
and,3710,O
the,3710,O
WT,3710,B-SpecificDisease
.,3710,O
This,3711,O
has,3711,O
implications,3711,O
regarding,3711,O
the,3711,O
mechanism,3711,O
by,3711,O
which,3711,O
the,3711,O
mutant,3711,O
allele,3711,O
exerts,3711,O
its,3711,O
effect,3711,O
.,3711,O
Mechanism,3712,O
of,3712,O
increased,3712,O
iron,3712,O
absorption,3712,O
in,3712,O
murine,3712,O
model,3712,O
of,3712,O
hereditary,3712,B-SpecificDisease
hemochromatosis,3712,I-SpecificDisease
:,3712,O
increased,3712,O
duodenal,3712,O
expression,3712,O
of,3712,O
the,3712,O
iron,3712,O
transporter,3712,O
DMT1,3712,O
.,3712,O
Hereditary,3713,B-SpecificDisease
hemochromatosis,3713,I-SpecificDisease
(,3713,O
HH,3713,B-SpecificDisease
),3713,O
is,3713,O
a,3713,O
common,3713,O
autosomal,3713,B-DiseaseClass
recessive,3713,I-DiseaseClass
disorder,3713,I-DiseaseClass
characterized,3713,O
by,3713,O
tissue,3713,O
iron,3713,O
deposition,3713,O
secondary,3713,O
to,3713,O
excessive,3713,O
dietary,3713,O
iron,3713,O
absorption,3713,O
.,3713,O
We,3714,O
recently,3714,O
reported,3714,O
that,3714,O
HFE,3714,O
",",3714,O
the,3714,O
protein,3714,O
defective,3714,O
in,3714,O
HH,3714,B-SpecificDisease
",",3714,O
was,3714,O
physically,3714,O
associated,3714,O
with,3714,O
the,3714,O
transferrin,3714,O
receptor,3714,O
(,3714,O
TfR,3714,O
),3714,O
in,3714,O
duodenal,3714,O
crypt,3714,O
cells,3714,O
and,3714,O
proposed,3714,O
that,3714,O
mutations,3714,O
in,3714,O
HFE,3714,O
attenuate,3714,O
the,3714,O
uptake,3714,O
of,3714,O
transferrin-bound,3714,O
iron,3714,O
from,3714,O
plasma,3714,O
by,3714,O
duodenal,3714,O
crypt,3714,O
cells,3714,O
",",3714,O
leading,3714,O
to,3714,O
up-regulation,3714,O
of,3714,O
transporters,3714,O
for,3714,O
dietary,3714,O
iron,3714,O
.,3714,O
Here,3715,O
",",3715,O
we,3715,O
tested,3715,O
the,3715,O
hypothesis,3715,O
that,3715,O
HFE-/-,3715,O
mice,3715,O
have,3715,O
increased,3715,O
duodenal,3715,O
expression,3715,O
of,3715,O
the,3715,O
divalent,3715,O
metal,3715,O
transporter,3715,O
(,3715,O
DMT1,3715,O
),3715,O
.,3715,O
By,3716,O
4,3716,O
weeks,3716,O
of,3716,O
age,3716,O
",",3716,O
the,3716,O
HFE-/-,3716,O
mice,3716,O
demonstrated,3716,O
iron,3716,O
loading,3716,O
when,3716,O
compared,3716,O
with,3716,O
HFE,3716,O
+/+,3716,O
littermates,3716,O
",",3716,O
with,3716,O
elevated,3716,O
transferrin,3716,O
saturations,3716,O
(,3716,O
68,3716,O
.,3716,O
4,3717,O
%,3717,O
vs.,3717,O
49,3717,O
.,3717,O
8,3718,O
%,3718,O
),3718,O
and,3718,O
elevated,3718,O
liver,3718,O
iron,3718,O
concentrations,3718,O
(,3718,O
985,3718,O
micrograms,3718,O
vs.,3718,O
381,3718,O
micrograms,3718,O
),3718,O
.,3718,O
By,3719,O
using,3719,O
Northern,3719,O
blot,3719,O
analyses,3719,O
",",3719,O
we,3719,O
quantitated,3719,O
duodenal,3719,O
expression,3719,O
of,3719,O
both,3719,O
classes,3719,O
of,3719,O
DMT1,3719,O
transcripts,3719,O
one,3719,O
containing,3719,O
an,3719,O
iron,3719,O
responsive,3719,O
element,3719,O
(,3719,O
IRE,3719,O
),3719,O
",",3719,O
called,3719,O
DMT1,3719,O
(,3719,O
IRE,3719,O
),3719,O
",",3719,O
and,3719,O
one,3719,O
containing,3719,O
no,3719,O
IRE,3719,O
",",3719,O
called,3719,O
DMT1,3719,O
(,3719,O
non-IRE,3719,O
),3719,O
.,3719,O
The,3720,O
positive,3720,O
control,3720,O
for,3720,O
DMT1,3720,O
up-regulation,3720,O
was,3720,O
a,3720,O
murine,3720,O
model,3720,O
of,3720,O
dietary,3720,B-SpecificDisease
iron,3720,I-SpecificDisease
deficiency,3720,I-SpecificDisease
that,3720,O
demonstrated,3720,O
greatly,3720,O
increased,3720,O
levels,3720,O
of,3720,O
duodenal,3720,O
DMT1,3720,O
(,3720,O
IRE,3720,O
),3720,O
mRNA,3720,O
.,3720,O
HFE-/-,3721,O
mice,3721,O
also,3721,O
demonstrated,3721,O
an,3721,O
increase,3721,O
in,3721,O
duodenal,3721,O
DMT1,3721,O
(,3721,O
IRE,3721,O
),3721,O
mRNA,3721,O
(,3721,O
average,3721,O
7,3721,O
.,3721,O
7-fold,3722,O
),3722,O
",",3722,O
despite,3722,O
their,3722,O
elevated,3722,O
transferrin,3722,O
saturation,3722,O
and,3722,O
hepatic,3722,O
iron,3722,O
content,3722,O
.,3722,O
Duodenal,3723,O
expression,3723,O
of,3723,O
DMT1,3723,O
(,3723,O
non-IRE,3723,O
),3723,O
was,3723,O
not,3723,O
increased,3723,O
",",3723,O
nor,3723,O
was,3723,O
hepatic,3723,O
expression,3723,O
of,3723,O
DMT1,3723,O
increased,3723,O
.,3723,O
These,3724,O
data,3724,O
support,3724,O
the,3724,O
model,3724,O
for,3724,O
HH,3724,O
in,3724,O
which,3724,O
HFE,3724,O
mutations,3724,O
lead,3724,O
to,3724,O
inappropriately,3724,O
low,3724,O
crypt,3724,O
cell,3724,O
iron,3724,O
",",3724,O
with,3724,O
resultant,3724,O
stabilization,3724,O
of,3724,O
DMT1,3724,O
(,3724,O
IRE,3724,O
),3724,O
mRNA,3724,O
",",3724,O
up-regulation,3724,O
of,3724,O
DMT1,3724,O
",",3724,O
and,3724,O
increased,3724,O
absorption,3724,O
of,3724,O
dietary,3724,O
iron,3724,O
.,3724,O
Neurophysiologic,3725,O
follow-up,3725,O
of,3725,O
long-term,3725,O
dietary,3725,O
treatment,3725,O
in,3725,O
adult-onset,3725,O
adrenoleukodystrophy,3725,B-SpecificDisease
.,3725,O
OBJECTIVE,3726,O
To,3726,O
monitor,3726,O
the,3726,O
effects,3726,O
of,3726,O
dietary,3726,O
treatment,3726,O
in,3726,O
adult-onset,3726,O
adrenoleukodystrophy,3726,B-SpecificDisease
(,3726,O
ALD,3726,B-SpecificDisease
),3726,O
by,3726,O
means,3726,O
of,3726,O
somatosensory,3726,O
evoked,3726,O
potentials,3726,O
(,3726,O
SEPs,3726,O
),3726,O
and,3726,O
motor,3726,O
evoked,3726,O
potentials,3726,O
(,3726,O
MEPs,3726,O
),3726,O
.,3726,O
BACKGROUND,3727,O
SEPs,3727,O
and,3727,O
MEPs,3727,O
have,3727,O
proved,3727,O
useful,3727,O
in,3727,O
revealing,3727,O
signs,3727,O
of,3727,O
progressively,3727,O
severe,3727,O
",",3727,O
central,3727,O
dying-back,3727,B-SpecificDisease
axonopathy,3727,I-SpecificDisease
in,3727,O
early,3727,O
stages,3727,O
of,3727,O
adult-onset,3727,O
ALD,3727,B-SpecificDisease
.,3727,O
METHODS,3728,O
Eight,3728,O
patients,3728,O
with,3728,O
adult-onset,3728,O
ALD,3728,B-SpecificDisease
underwent,3728,O
clinical,3728,O
examination,3728,O
",",3728,O
brain,3728,O
and,3728,O
spine,3728,O
MRI,3728,O
",",3728,O
and,3728,O
SEP,3728,O
and,3728,O
MEP,3728,O
studies,3728,O
before,3728,O
and,3728,O
after,3728,O
3,3728,O
years,3728,O
of,3728,O
Lorenzos,3728,O
oil,3728,O
dietary,3728,O
therapy,3728,O
.,3728,O
RESULTS,3729,O
Before,3729,O
treatment,3729,O
",",3729,O
brain,3729,O
MRI,3729,O
was,3729,O
normal,3729,O
in,3729,O
five,3729,O
patients,3729,O
.,3729,O
Three,3730,O
of,3730,O
these,3730,O
patients,3730,O
had,3730,O
pure,3730,O
spinal,3730,B-DiseaseClass
SEP,3730,I-DiseaseClass
abnormalities,3730,I-DiseaseClass
and,3730,O
in,3730,O
the,3730,O
remaining,3730,O
two,3730,O
patients,3730,O
SEPs,3730,O
showed,3730,O
signs,3730,O
of,3730,O
involvement,3730,O
of,3730,O
both,3730,O
the,3730,O
spinal,3730,O
and,3730,O
cerebral,3730,O
somatosensory,3730,O
tracts,3730,O
.,3730,O
After,3731,O
treatment,3731,O
",",3731,O
the,3731,O
three,3731,O
patients,3731,O
with,3731,O
pure,3731,O
spinal,3731,B-DiseaseClass
abnormalities,3731,I-DiseaseClass
showed,3731,O
clinical,3731,O
and,3731,O
neurophysiologic,3731,O
worsening,3731,O
",",3731,O
whereas,3731,O
the,3731,O
two,3731,O
patients,3731,O
with,3731,O
a,3731,O
more,3731,O
advanced,3731,O
stage,3731,O
of,3731,O
disease,3731,O
(,3731,O
exhibited,3731,O
by,3731,O
SEPs,3731,O
),3731,O
showed,3731,O
substantially,3731,O
unchanged,3731,O
clinical,3731,O
and,3731,O
neurophysiologic,3731,O
features,3731,O
.,3731,O
The,3732,O
patients,3732,O
with,3732,O
abnormal,3732,O
brain,3732,O
MRI,3732,O
at,3732,O
the,3732,O
onset,3732,O
of,3732,O
treatment,3732,O
showed,3732,O
clinical,3732,O
and,3732,O
neurophysiologic,3732,O
worsening,3732,O
.,3732,O
CONCLUSIONS,3733,O
Lorenzos,3733,O
oil,3733,O
therapy,3733,O
had,3733,O
no,3733,O
effect,3733,O
on,3733,O
patients,3733,O
with,3733,O
evidence,3733,O
of,3733,O
inflammatory,3733,B-DiseaseClass
brain,3733,I-DiseaseClass
lesions,3733,I-DiseaseClass
.,3733,O
Moreover,3734,O
",",3734,O
in,3734,O
patients,3734,O
without,3734,O
clear,3734,O
signs,3734,O
of,3734,O
inflammatory,3734,O
damage,3734,O
",",3734,O
this,3734,O
treatment,3734,O
does,3734,O
not,3734,O
modify,3734,O
significantly,3734,O
the,3734,O
natural,3734,O
course,3734,O
of,3734,O
the,3734,O
disease,3734,O
.,3734,O
However,3735,O
",",3735,O
because,3735,O
effective,3735,O
treatments,3735,O
should,3735,O
begin,3735,O
before,3735,O
the,3735,O
onset,3735,O
of,3735,O
severe,3735,O
neurologic,3735,O
symptoms,3735,O
",",3735,O
SEPs,3735,O
and,3735,O
MEPs,3735,O
should,3735,O
be,3735,O
considered,3735,O
to,3735,O
evaluate,3735,O
the,3735,O
effectiveness,3735,O
of,3735,O
other,3735,O
experimental,3735,O
treatments,3735,O
in,3735,O
the,3735,O
patient,3735,O
with,3735,O
a,3735,O
negative,3735,O
brain,3735,O
MRI,3735,O
.,3735,O
GCH1,3736,O
mutation,3736,O
in,3736,O
a,3736,O
patient,3736,O
with,3736,O
adult-onset,3736,O
oromandibular,3736,B-SpecificDisease
dystonia,3736,I-SpecificDisease
.,3736,O
The,3737,O
authors,3737,O
report,3737,O
a,3737,O
mutation,3737,O
in,3737,O
exon,3737,O
5,3737,O
of,3737,O
GCH1,3737,O
in,3737,O
a,3737,O
patient,3737,O
with,3737,O
adult-onset,3737,O
oromandibular,3737,B-SpecificDisease
dystonia,3737,I-SpecificDisease
and,3737,O
no,3737,O
obvious,3737,O
family,3737,O
history,3737,O
of,3737,O
dystonia,3737,B-DiseaseClass
.,3737,O
The,3738,O
patient,3738,O
responded,3738,O
positively,3738,O
to,3738,O
treatment,3738,O
with,3738,O
L-dopa,3738,O
.,3738,O
These,3739,O
findings,3739,O
demonstrate,3739,O
that,3739,O
GCH1,3739,O
mutations,3739,O
must,3739,O
be,3739,O
considered,3739,O
even,3739,O
in,3739,O
patients,3739,O
with,3739,O
dystonic,3739,B-Modifier
symptoms,3739,O
not,3739,O
typical,3739,O
of,3739,O
dopa-responsive,3739,B-SpecificDisease
dystonia,3739,I-SpecificDisease
.,3739,O
Germline,3740,O
mutations,3740,O
of,3740,O
the,3740,O
APC,3740,B-Modifier
gene,3740,O
in,3740,O
Korean,3740,O
familial,3740,B-Modifier
adenomatous,3740,I-Modifier
polyposis,3740,I-Modifier
patients,3740,O
.,3740,O
We,3741,O
extensively,3741,O
analyzed,3741,O
genomic,3741,O
DNA,3741,O
and,3741,O
messenger,3741,O
RNA,3741,O
(,3741,O
mRNA,3741,O
),3741,O
from,3741,O
62,3741,O
unrelated,3741,O
Korean,3741,O
patients,3741,O
with,3741,O
familial,3741,B-SpecificDisease
adenomatous,3741,I-SpecificDisease
polyposis,3741,I-SpecificDisease
(,3741,O
FAP,3741,B-SpecificDisease
),3741,O
for,3741,O
identification,3741,O
of,3741,O
germline,3741,O
adenomatous,3741,B-Modifier
polyposis,3741,I-Modifier
coli,3741,I-Modifier
(,3741,O
APC,3741,B-Modifier
),3741,O
gene,3741,O
mutations,3741,O
.,3741,O
We,3742,O
adopted,3742,O
both,3742,O
single-strand,3742,O
conformation,3742,O
polymorphism,3742,O
(,3742,O
SSCP,3742,O
),3742,O
analysis,3742,O
and,3742,O
a,3742,O
method,3742,O
of,3742,O
analysis,3742,O
involving,3742,O
the,3742,O
reverse,3742,O
transcription-polymerase,3742,O
chain,3742,O
reaction,3742,O
(,3742,O
RT-PCR,3742,O
),3742,O
followed,3742,O
by,3742,O
a,3742,O
protein,3742,O
truncation,3742,O
test,3742,O
(,3742,O
PTT,3742,O
),3742,O
.,3742,O
DNA,3743,O
sequencing,3743,O
confirmed,3743,O
all,3743,O
alterations,3743,O
represented,3743,O
by,3743,O
aberrant,3743,O
bands,3743,O
.,3743,O
Germline,3744,O
mutations,3744,O
were,3744,O
identified,3744,O
in,3744,O
38,3744,O
patients,3744,O
(,3744,O
61,3744,O
%,3744,O
),3744,O
.,3744,O
Nineteen,3745,O
of,3745,O
the,3745,O
detected,3745,O
mutations,3745,O
were,3745,O
presumed,3745,O
to,3745,O
be,3745,O
novel,3745,O
",",3745,O
thus,3745,O
emphasizing,3745,O
the,3745,O
heterogeneity,3745,O
of,3745,O
the,3745,O
mutational,3745,O
spectrum,3745,O
in,3745,O
Korean,3745,O
FAP,3745,B-Modifier
patients,3745,O
.,3745,O
In,3746,O
the,3746,O
initial,3746,O
48,3746,O
patients,3746,O
",",3746,O
SSCP,3746,O
analysis,3746,O
was,3746,O
followed,3746,O
by,3746,O
PTT,3746,O
for,3746,O
those,3746,O
patients,3746,O
for,3746,O
whom,3746,O
no,3746,O
detectable,3746,O
mutations,3746,O
were,3746,O
found,3746,O
by,3746,O
SSCP,3746,O
.,3746,O
Using,3747,O
this,3747,O
combined,3747,O
approach,3747,O
",",3747,O
we,3747,O
identified,3747,O
germline,3747,O
APC,3747,B-Modifier
gene,3747,O
mutations,3747,O
in,3747,O
29,3747,O
of,3747,O
the,3747,O
48,3747,O
FAP,3747,B-Modifier
patients,3747,O
(,3747,O
60,3747,O
%,3747,O
),3747,O
",",3747,O
including,3747,O
6,3747,O
patients,3747,O
in,3747,O
whom,3747,O
SSCP,3747,O
analysis,3747,O
failed,3747,O
to,3747,O
distinguish,3747,O
the,3747,O
mutant,3747,O
allele,3747,O
.,3747,O
In,3748,O
the,3748,O
14,3748,O
later,3748,O
patients,3748,O
",",3748,O
we,3748,O
identified,3748,O
truncating,3748,O
mutations,3748,O
in,3748,O
9,3748,O
patients,3748,O
(,3748,O
64,3748,O
%,3748,O
),3748,O
using,3748,O
PTT,3748,O
only,3748,O
.,3748,O
Our,3749,O
results,3749,O
confirm,3749,O
that,3749,O
the,3749,O
mutation,3749,O
detection,3749,O
rate,3749,O
with,3749,O
PTT,3749,O
was,3749,O
superior,3749,O
to,3749,O
that,3749,O
with,3749,O
SSCP,3749,O
",",3749,O
and,3749,O
suggest,3749,O
that,3749,O
PTT,3749,O
would,3749,O
be,3749,O
a,3749,O
more,3749,O
practical,3749,O
screening,3749,O
method,3749,O
to,3749,O
detect,3749,O
germline,3749,O
mutations,3749,O
of,3749,O
the,3749,O
APC,3749,B-Modifier
gene,3749,O
in,3749,O
FAP,3749,B-Modifier
patients,3749,O
.,3749,O
Molecular,3750,O
epidemiology,3750,O
of,3750,O
C9,3750,B-Modifier
deficiency,3750,I-Modifier
heterozygotes,3750,O
with,3750,O
an,3750,O
Arg95Stop,3750,O
mutation,3750,O
of,3750,O
the,3750,O
C9,3750,O
gene,3750,O
in,3750,O
Japan,3750,O
.,3750,O
Deficiency,3751,B-SpecificDisease
of,3751,I-SpecificDisease
the,3751,I-SpecificDisease
ninth,3751,I-SpecificDisease
component,3751,I-SpecificDisease
of,3751,I-SpecificDisease
human,3751,I-SpecificDisease
complement,3751,I-SpecificDisease
(,3751,O
C9,3751,O
),3751,O
is,3751,O
the,3751,O
most,3751,O
common,3751,O
complement,3751,B-DiseaseClass
deficiency,3751,I-DiseaseClass
in,3751,O
Japan,3751,O
",",3751,O
with,3751,O
an,3751,O
incidence,3751,O
of,3751,O
approximately,3751,O
one,3751,O
homozygote,3751,O
in,3751,O
1000,3751,O
",",3751,O
but,3751,O
is,3751,O
very,3751,O
rare,3751,O
in,3751,O
other,3751,O
countries,3751,O
.,3751,O
Genetic,3752,O
analyses,3752,O
of,3752,O
Japanese,3752,O
C9,3752,B-SpecificDisease
deficiency,3752,I-SpecificDisease
have,3752,O
shown,3752,O
that,3752,O
a,3752,O
C-to-T,3752,O
transition,3752,O
leading,3752,O
to,3752,O
TGA,3752,O
stop,3752,O
codon,3752,O
for,3752,O
Arg95,3752,O
in,3752,O
exon,3752,O
4,3752,O
of,3752,O
the,3752,O
C9,3752,O
gene,3752,O
(,3752,O
Arg95Stop,3752,O
),3752,O
is,3752,O
common,3752,O
in,3752,O
Japanese,3752,O
C9,3752,B-SpecificDisease
deficiency,3752,I-SpecificDisease
.,3752,O
To,3753,O
determine,3753,O
the,3753,O
prevalence,3753,O
of,3753,O
heterozygous,3753,O
carriers,3753,O
of,3753,O
the,3753,O
Arg95Stop,3753,O
mutation,3753,O
in,3753,O
a,3753,O
Japanese,3753,O
population,3753,O
",",3753,O
we,3753,O
collected,3753,O
DNA,3753,O
samples,3753,O
from,3753,O
300,3753,O
individuals,3753,O
in,3753,O
two,3753,O
of,3753,O
the,3753,O
four,3753,O
main,3753,O
islands,3753,O
of,3753,O
Japan,3753,O
.,3753,O
Heterozygote,3754,O
detection,3754,O
was,3754,O
performed,3754,O
with,3754,O
an,3754,O
allele-specific,3754,O
polymerase,3754,O
chain,3754,O
reaction,3754,O
(,3754,O
PCR,3754,O
),3754,O
system,3754,O
designed,3754,O
to,3754,O
detect,3754,O
exclusively,3754,O
only,3754,O
one,3754,O
of,3754,O
the,3754,O
normal,3754,O
and,3754,O
mutant,3754,O
alleles,3754,O
",",3754,O
followed,3754,O
by,3754,O
confirmation,3754,O
with,3754,O
PCR/single-strand,3754,O
conformation,3754,O
polymorphism,3754,O
(,3754,O
SSCP,3754,O
),3754,O
analysis,3754,O
and,3754,O
direct,3754,O
sequencing,3754,O
.,3754,O
Twenty,3755,O
individuals,3755,O
were,3755,O
heterozygous,3755,O
for,3755,O
the,3755,O
Arg95Stop,3755,O
mutation,3755,O
.,3755,O
None,3756,O
was,3756,O
homozygous,3756,O
.,3756,O
The,3757,O
prevalence,3757,O
of,3757,O
carriers,3757,O
of,3757,O
the,3757,O
Arg95Stop,3757,O
mutation,3757,O
was,3757,O
6,3757,O
.,3757,O
7,3758,O
%,3758,O
(,3758,O
20/300,3758,O
),3758,O
.,3758,O
An,3759,O
estimated,3759,O
frequency,3759,O
(,3759,O
0,3759,O
.,3759,O
12,3760,O
%,3760,O
),3760,O
of,3760,O
complete,3760,O
C9,3760,B-SpecificDisease
deficiency,3760,I-SpecificDisease
due,3760,O
to,3760,O
homozygous,3760,O
Arg95Stop,3760,O
mutation,3760,O
was,3760,O
consistent,3760,O
with,3760,O
frequencies,3760,O
determined,3760,O
by,3760,O
serological,3760,O
studies,3760,O
The,3761,O
hereditary,3761,B-Modifier
hemochromatosis,3761,I-Modifier
protein,3761,O
",",3761,O
HFE,3761,O
",",3761,O
specifically,3761,O
regulates,3761,O
transferrin-mediated,3761,O
iron,3761,O
uptake,3761,O
in,3761,O
HeLa,3761,O
cells,3761,O
.,3761,O
HFE,3762,O
is,3762,O
the,3762,O
protein,3762,O
product,3762,O
of,3762,O
the,3762,O
gene,3762,O
mutated,3762,O
in,3762,O
the,3762,O
autosomal,3762,B-DiseaseClass
recessive,3762,I-DiseaseClass
disease,3762,I-DiseaseClass
hereditary,3762,B-SpecificDisease
hemochromatosis,3762,I-SpecificDisease
(,3762,O
Feder,3762,O
",",3762,O
J.,3762,O
N.,3762,O
",",3762,O
Gnirke,3762,O
",",3762,O
A.,3762,O
",",3762,O
Thomas,3762,O
",",3762,O
W.,3762,O
",",3762,O
Tsuchihashi,3762,O
",",3762,O
Z.,3762,O
",",3762,O
Ruddy,3762,O
",",3762,O
D.,3762,O
A.,3762,O
",",3762,O
Basava,3762,O
",",3762,O
A.,3762,O
",",3762,O
Dormishian,3762,O
",",3762,O
F.,3762,O
",",3762,O
Domingo,3762,O
",",3762,O
R.,3762,O
J.,3762,O
",",3762,O
Ellis,3762,O
",",3762,O
M.,3762,O
C.,3762,O
",",3762,O
Fullan,3762,O
",",3762,O
A.,3762,O
",",3762,O
Hinton,3762,O
",",3762,O
L.,3762,O
M.,3762,O
",",3762,O
Jones,3762,O
",",3762,O
N.,3762,O
L.,3762,O
",",3762,O
Kimmel,3762,O
",",3762,O
B.,3762,O
E.,3762,O
",",3762,O
Kronmal,3762,O
",",3762,O
G.,3762,O
S.,3762,O
",",3762,O
Lauer,3762,O
",",3762,O
P.,3762,O
",",3762,O
Lee,3762,O
",",3762,O
V.,3762,O
K.,3762,O
",",3762,O
Loeb,3762,O
",",3762,O
D.,3762,O
B.,3762,O
",",3762,O
Mapa,3762,O
",",3762,O
F.,3762,O
A.,3762,O
",",3762,O
McClelland,3762,O
",",3762,O
E.,3762,O
",",3762,O
Meyer,3762,O
",",3762,O
N.,3762,O
C.,3762,O
",",3762,O
Mintier,3762,O
",",3762,O
G.,3762,O
A.,3762,O
",",3762,O
Moeller,3762,O
",",3762,O
N.,3762,O
",",3762,O
Moore,3762,O
",",3762,O
T.,3762,O
",",3762,O
Morikang,3762,O
",",3762,O
E.,3762,O
",",3762,O
Prasss,3762,O
",",3762,O
C.,3762,O
E,3762,O
.,3762,O
",",3762,O
Quintana,3762,O
",",3762,O
L.,3762,O
",",3762,O
Starnes,3762,O
",",3762,O
S.,3762,O
M,3762,O
.,3762,O
",",3762,O
Schatzman,3762,O
",",3762,O
R.,3762,O
C,3762,O
.,3762,O
",",3762,O
Brunke,3762,O
",",3762,O
K.,3762,O
J,3762,O
.,3762,O
",",3762,O
Drayna,3762,O
",",3762,O
D.,3762,O
T.,3762,O
",",3762,O
Risch,3762,O
",",3762,O
N.,3762,O
J,3762,O
.,3762,O
",",3762,O
Bacon,3762,O
",",3762,O
B.,3762,O
R,3762,O
.,3762,O
",",3762,O
and,3762,O
Wolff,3762,O
",",3762,O
R.,3762,O
R,3762,O
.,3762,O
(,3763,O
1996,3763,O
),3763,O
Nat,3763,O
.,3763,O
Genet,3764,O
.,3764,O
13,3765,O
",",3765,O
399-408,3765,O
),3765,O
.,3765,O
At,3766,O
the,3766,O
cell,3766,O
surface,3766,O
",",3766,O
HFE,3766,O
complexes,3766,O
with,3766,O
transferrin,3766,O
receptor,3766,O
(,3766,O
TfR,3766,O
),3766,O
",",3766,O
increasing,3766,O
the,3766,O
dissociation,3766,O
constant,3766,O
of,3766,O
transferrin,3766,O
(,3766,O
Tf,3766,O
),3766,O
for,3766,O
its,3766,O
receptor,3766,O
10-fold,3766,O
(,3766,O
Gross,3766,O
",",3766,O
C.,3766,O
N,3766,O
.,3766,O
",",3766,O
Irrinki,3766,O
",",3766,O
A.,3766,O
",",3766,O
Feder,3766,O
",",3766,O
J.,3766,O
N,3766,O
.,3766,O
",",3766,O
and,3766,O
Enns,3766,O
",",3766,O
C.,3766,O
A,3766,O
.,3766,O
(,3767,O
1998,3767,O
),3767,O
J.,3767,O
Biol,3767,O
.,3767,O
Chem,3768,O
.,3768,O
273,3769,O
",",3769,O
22068-22074,3769,O
;,3769,O
Feder,3769,O
",",3769,O
J.,3769,O
N.,3769,O
",",3769,O
Penny,3769,O
",",3769,O
D.,3769,O
M.,3769,O
",",3769,O
Irrinki,3769,O
",",3769,O
A.,3769,O
",",3769,O
Lee,3769,O
",",3769,O
V.,3769,O
K.,3769,O
",",3769,O
Lebron,3769,O
",",3769,O
J,3769,O
.,3769,O
A.,3770,O
",",3770,O
Watson,3770,O
",",3770,O
N.,3770,O
",",3770,O
Tsuchihashi,3770,O
",",3770,O
Z.,3770,O
",",3770,O
Sigal,3770,O
",",3770,O
E.,3770,O
",",3770,O
Bjorkman,3770,O
",",3770,O
P.,3770,O
J.,3770,O
",",3770,O
and,3770,O
Schatzman,3770,O
",",3770,O
R.,3770,O
C.,3770,O
(,3770,O
1998,3770,O
),3770,O
Proc,3770,O
.,3770,O
Natl,3771,O
.,3771,O
Acad,3772,O
.,3772,O
Sci,3773,O
.,3773,O
U,3774,O
S,3774,O
A,3774,O
95,3774,O
",",3774,O
1472-1477,3774,O
),3774,O
.,3774,O
HFE,3775,O
does,3775,O
not,3775,O
remain,3775,O
at,3775,O
the,3775,O
cell,3775,O
surface,3775,O
",",3775,O
but,3775,O
traffics,3775,O
with,3775,O
TfR,3775,O
to,3775,O
Tf-positive,3775,O
internal,3775,O
compartments,3775,O
(,3775,O
Gross,3775,O
et,3775,O
al.,3775,O
",",3775,O
1998,3775,O
),3775,O
.,3775,O
Using,3776,O
a,3776,O
HeLa,3776,O
cell,3776,O
line,3776,O
in,3776,O
which,3776,O
the,3776,O
expression,3776,O
of,3776,O
HFE,3776,O
is,3776,O
controlled,3776,O
by,3776,O
tetracycline,3776,O
",",3776,O
we,3776,O
show,3776,O
that,3776,O
the,3776,O
expression,3776,O
of,3776,O
HFE,3776,O
reduces,3776,O
55Fe,3776,O
uptake,3776,O
from,3776,O
Tf,3776,O
by,3776,O
33,3776,O
%,3776,O
but,3776,O
does,3776,O
not,3776,O
affect,3776,O
the,3776,O
endocytic,3776,O
or,3776,O
exocytic,3776,O
rates,3776,O
of,3776,O
TfR,3776,O
cycling,3776,O
.,3776,O
Therefore,3777,O
",",3777,O
HFE,3777,O
appears,3777,O
to,3777,O
reduce,3777,O
cellular,3777,O
acquisition,3777,O
of,3777,O
iron,3777,O
from,3777,O
Tf,3777,O
within,3777,O
endocytic,3777,O
compartments,3777,O
.,3777,O
HFE,3778,O
specifically,3778,O
reduces,3778,O
iron,3778,O
uptake,3778,O
from,3778,O
Tf,3778,O
",",3778,O
as,3778,O
non-Tf-mediated,3778,O
iron,3778,O
uptake,3778,O
from,3778,O
Fe-nitrilotriacetic,3778,O
acid,3778,O
is,3778,O
not,3778,O
altered,3778,O
.,3778,O
These,3779,O
results,3779,O
explain,3779,O
the,3779,O
decreased,3779,O
ferritin,3779,O
levels,3779,O
seen,3779,O
in,3779,O
our,3779,O
HeLa,3779,O
cell,3779,O
system,3779,O
and,3779,O
demonstrate,3779,O
the,3779,O
specific,3779,O
control,3779,O
of,3779,O
HFE,3779,O
over,3779,O
the,3779,O
Tf-mediated,3779,O
pathway,3779,O
of,3779,O
iron,3779,O
uptake,3779,O
.,3779,O
These,3780,O
results,3780,O
also,3780,O
have,3780,O
implications,3780,O
for,3780,O
the,3780,O
understanding,3780,O
of,3780,O
cellular,3780,O
iron,3780,O
homeostasis,3780,O
in,3780,O
organs,3780,O
such,3780,O
as,3780,O
the,3780,O
liver,3780,O
",",3780,O
pancreas,3780,O
",",3780,O
heart,3780,O
",",3780,O
and,3780,O
spleen,3780,O
that,3780,O
are,3780,O
iron,3780,O
loaded,3780,O
in,3780,O
hereditary,3780,B-Modifier
hemochromatotic,3780,I-Modifier
individuals,3780,O
lacking,3780,O
functional,3780,O
HFE,3780,O
.,3780,O
Mutation,3781,O
and,3781,O
haplotype,3781,O
studies,3781,O
of,3781,O
familial,3781,B-SpecificDisease
Mediterranean,3781,I-SpecificDisease
fever,3781,I-SpecificDisease
reveal,3781,O
new,3781,O
ancestral,3781,O
relationships,3781,O
and,3781,O
evidence,3781,O
for,3781,O
a,3781,O
high,3781,O
carrier,3781,O
frequency,3781,O
with,3781,O
reduced,3781,O
penetrance,3781,O
in,3781,O
the,3781,O
Ashkenazi,3781,O
Jewish,3781,O
population,3781,O
.,3781,O
Familial,3782,B-SpecificDisease
Mediterranean,3782,I-SpecificDisease
fever,3782,I-SpecificDisease
(,3782,O
FMF,3782,B-SpecificDisease
),3782,O
is,3782,O
a,3782,O
recessive,3782,B-DiseaseClass
disorder,3782,I-DiseaseClass
characterized,3782,O
by,3782,O
episodes,3782,O
of,3782,O
fever,3782,O
with,3782,O
serositis,3782,B-DiseaseClass
or,3782,O
synovitis,3782,B-DiseaseClass
.,3782,O
The,3783,O
FMF,3783,B-Modifier
gene,3783,O
(,3783,O
MEFV,3783,O
),3783,O
was,3783,O
cloned,3783,O
recently,3783,O
",",3783,O
and,3783,O
four,3783,O
missense,3783,O
mutations,3783,O
were,3783,O
identified,3783,O
.,3783,O
Here,3784,O
we,3784,O
present,3784,O
data,3784,O
from,3784,O
non-Ashkenazi,3784,O
Jewish,3784,O
and,3784,O
Arab,3784,O
patients,3784,O
in,3784,O
whom,3784,O
we,3784,O
had,3784,O
not,3784,O
originally,3784,O
found,3784,O
mutations,3784,O
and,3784,O
from,3784,O
a,3784,O
new,3784,O
",",3784,O
more,3784,O
ethnically,3784,O
diverse,3784,O
panel,3784,O
.,3784,O
Among,3785,O
90,3785,O
symptomatic,3785,O
mutation-positive,3785,O
individuals,3785,O
",",3785,O
11,3785,O
mutations,3785,O
accounted,3785,O
for,3785,O
79,3785,O
%,3785,O
of,3785,O
carrier,3785,O
chromosomes,3785,O
.,3785,O
Of,3786,O
the,3786,O
two,3786,O
mutations,3786,O
that,3786,O
are,3786,O
novel,3786,O
",",3786,O
one,3786,O
alters,3786,O
the,3786,O
same,3786,O
residue,3786,O
(,3786,O
680,3786,O
),3786,O
as,3786,O
a,3786,O
previously,3786,O
known,3786,O
mutation,3786,O
",",3786,O
and,3786,O
the,3786,O
other,3786,O
(,3786,O
P369S,3786,O
),3786,O
is,3786,O
located,3786,O
in,3786,O
exon,3786,O
3,3786,O
.,3786,O
Consistent,3787,O
with,3787,O
another,3787,O
recent,3787,O
report,3787,O
",",3787,O
the,3787,O
E148Q,3787,O
mutation,3787,O
was,3787,O
observed,3787,O
in,3787,O
patients,3787,O
of,3787,O
several,3787,O
ethnicities,3787,O
and,3787,O
on,3787,O
multiple,3787,O
microsatellite,3787,O
haplotypes,3787,O
",",3787,O
but,3787,O
haplotype,3787,O
data,3787,O
indicate,3787,O
an,3787,O
ancestral,3787,O
relationships,3787,O
between,3787,O
non-Jewish,3787,O
Italian,3787,O
and,3787,O
Ashkenazi,3787,O
Jewish,3787,O
patients,3787,O
with,3787,O
FMF,3787,B-SpecificDisease
and,3787,O
other,3787,O
affected,3787,O
populations,3787,O
.,3787,O
Among,3788,O
approximately,3788,O
200,3788,O
anonymous,3788,O
Ashkenazi,3788,O
Jewish,3788,O
DNA,3788,O
samples,3788,O
",",3788,O
the,3788,O
MEFV,3788,O
carrier,3788,O
frequency,3788,O
was,3788,O
21,3788,O
%,3788,O
",",3788,O
with,3788,O
E148Q,3788,O
the,3788,O
most,3788,O
common,3788,O
mutation,3788,O
.,3788,O
Several,3789,O
lines,3789,O
of,3789,O
evidence,3789,O
indicate,3789,O
reduced,3789,O
penetrance,3789,O
among,3789,O
Ashkenazi,3789,O
Jews,3789,O
",",3789,O
especially,3789,O
for,3789,O
E148Q,3789,O
",",3789,O
P369S,3789,O
",",3789,O
and,3789,O
K695R,3789,O
.,3789,O
Nevertheless,3790,O
",",3790,O
E148Q,3790,O
helps,3790,O
account,3790,O
for,3790,O
recessive,3790,O
inheritance,3790,O
in,3790,O
an,3790,O
Ashkenazi,3790,O
family,3790,O
previously,3790,O
reported,3790,O
as,3790,O
an,3790,O
unusual,3790,O
case,3790,O
of,3790,O
dominantly,3790,O
inherited,3790,O
FMF,3790,B-SpecificDisease
.,3790,O
The,3791,O
presence,3791,O
of,3791,O
three,3791,O
frequent,3791,O
MEFV,3791,O
mutations,3791,O
in,3791,O
multiple,3791,O
Mediterranean,3791,O
populations,3791,O
strongly,3791,O
suggests,3791,O
a,3791,O
heterozygote,3791,O
advantage,3791,O
in,3791,O
this,3791,O
geographic,3791,O
region,3791,O
.,3791,O
Autoimmune,3792,B-SpecificDisease
lymphoproliferative,3792,I-SpecificDisease
syndrome,3792,I-SpecificDisease
with,3792,O
defective,3792,O
Fas,3792,O
:,3792,O
genotype,3792,O
influences,3792,O
penetrance,3792,O
.,3792,O
Autoimmune,3793,B-SpecificDisease
lymphoproliferative,3793,I-SpecificDisease
syndrome,3793,I-SpecificDisease
(,3793,O
ALPS,3793,B-SpecificDisease
),3793,O
is,3793,O
a,3793,O
disorder,3793,O
of,3793,O
lymphocyte,3793,O
homeostasis,3793,O
and,3793,O
immunological,3793,O
tolerance,3793,O
.,3793,O
Most,3794,O
patients,3794,O
have,3794,O
a,3794,O
heterozygous,3794,O
mutation,3794,O
in,3794,O
the,3794,O
APT1,3794,O
gene,3794,O
",",3794,O
which,3794,O
encodes,3794,O
Fas,3794,O
(,3794,O
CD95,3794,O
",",3794,O
APO-1,3794,O
),3794,O
",",3794,O
mediator,3794,O
of,3794,O
an,3794,O
apoptotic,3794,O
pathway,3794,O
crucial,3794,O
to,3794,O
lymphocyte,3794,O
homeostasis,3794,O
.,3794,O
Of,3795,O
17,3795,O
unique,3795,O
APT1,3795,O
mutations,3795,O
in,3795,O
unrelated,3795,O
ALPS,3795,B-Modifier
probands,3795,O
",",3795,O
12,3795,O
(,3795,O
71,3795,O
%,3795,O
),3795,O
occurred,3795,O
in,3795,O
exons,3795,O
7-9,3795,O
",",3795,O
which,3795,O
encode,3795,O
the,3795,O
intracellular,3795,O
portion,3795,O
of,3795,O
Fas,3795,O
.,3795,O
In,3796,O
vitro,3796,O
",",3796,O
activated,3796,O
lymphocytes,3796,O
from,3796,O
all,3796,O
17,3796,O
patients,3796,O
showed,3796,O
apoptotic,3796,O
defects,3796,O
when,3796,O
exposed,3796,O
to,3796,O
an,3796,O
anti-Fas,3796,O
agonist,3796,O
monoclonal,3796,O
antibody,3796,O
.,3796,O
Similar,3797,O
defects,3797,O
were,3797,O
found,3797,O
in,3797,O
a,3797,O
Fas-negative,3797,O
cell,3797,O
line,3797,O
transfected,3797,O
with,3797,O
cDNAs,3797,O
bearing,3797,O
each,3797,O
of,3797,O
the,3797,O
mutations,3797,O
.,3797,O
In,3798,O
cotransfection,3798,O
experiments,3798,O
",",3798,O
Fas,3798,O
constructs,3798,O
with,3798,O
either,3798,O
intra-,3798,O
or,3798,O
extracellular,3798,O
mutations,3798,O
caused,3798,O
dominant,3798,O
inhibition,3798,O
of,3798,O
apoptosis,3798,O
mediated,3798,O
by,3798,O
wild-type,3798,O
Fas,3798,O
.,3798,O
Two,3799,O
missense,3799,O
Fas,3799,O
variants,3799,O
",",3799,O
not,3799,O
restricted,3799,O
to,3799,O
patients,3799,O
with,3799,O
ALPS,3799,B-SpecificDisease
",",3799,O
were,3799,O
identified,3799,O
.,3799,O
Variant,3800,O
A,3800,O
(,3800,O
-1,3800,O
),3800,O
T,3800,O
at,3800,O
the,3800,O
Fas,3800,O
signal-sequence,3800,O
cleavage,3800,O
site,3800,O
",",3800,O
which,3800,O
mediates,3800,O
apoptosis,3800,O
less,3800,O
well,3800,O
than,3800,O
wild-type,3800,O
Fas,3800,O
and,3800,O
is,3800,O
partially,3800,O
inhibitory,3800,O
",",3800,O
was,3800,O
present,3800,O
in,3800,O
13,3800,O
%,3800,O
of,3800,O
African,3800,O
American,3800,O
alleles,3800,O
.,3800,O
Among,3801,O
the,3801,O
ALPS-associated,3801,B-Modifier
Fas,3801,O
mutants,3801,O
",",3801,O
dominant,3801,O
inhibition,3801,O
of,3801,O
apoptosis,3801,O
was,3801,O
much,3801,O
more,3801,O
pronounced,3801,O
in,3801,O
mutants,3801,O
affecting,3801,O
the,3801,O
intracellular,3801,O
",",3801,O
versus,3801,O
extracellular,3801,O
",",3801,O
portion,3801,O
of,3801,O
the,3801,O
Fas,3801,O
receptor,3801,O
.,3801,O
Mutations,3802,O
causing,3802,O
disruption,3802,O
of,3802,O
the,3802,O
intracellular,3802,O
Fas,3802,O
death,3802,O
domain,3802,O
also,3802,O
showed,3802,O
a,3802,O
higher,3802,O
penetrance,3802,O
of,3802,O
ALPS,3802,B-Modifier
phenotype,3802,O
features,3802,O
in,3802,O
mutation-bearing,3802,O
relatives,3802,O
.,3802,O
Significant,3803,O
ALPS-related,3803,B-Modifier
morbidity,3803,O
occurred,3803,O
in,3803,O
44,3803,O
%,3803,O
of,3803,O
relatives,3803,O
with,3803,O
intracellular,3803,O
mutations,3803,O
",",3803,O
versus,3803,O
0,3803,O
%,3803,O
of,3803,O
relatives,3803,O
with,3803,O
extracellular,3803,O
mutations,3803,O
.,3803,O
Thus,3804,O
",",3804,O
the,3804,O
location,3804,O
of,3804,O
mutations,3804,O
within,3804,O
APT1,3804,O
strongly,3804,O
influences,3804,O
the,3804,O
development,3804,O
and,3804,O
the,3804,O
severity,3804,O
of,3804,O
ALPS,3804,B-SpecificDisease
.,3804,O
Multicentric,3805,O
origin,3805,O
of,3805,O
hemochromatosis,3805,B-Modifier
gene,3805,O
(,3805,O
HFE,3805,O
),3805,O
mutations,3805,O
.,3805,O
Genetic,3806,B-SpecificDisease
hemochromatosis,3806,I-SpecificDisease
(,3806,O
GH,3806,B-SpecificDisease
),3806,O
is,3806,O
believed,3806,O
to,3806,O
be,3806,O
a,3806,O
disease,3806,O
restricted,3806,O
to,3806,O
those,3806,O
of,3806,O
European,3806,O
ancestry,3806,O
.,3806,O
In,3807,O
northwestern,3807,O
Europe,3807,O
",",3807,O
>,3807,O
80,3807,O
%,3807,O
of,3807,O
GH,3807,B-Modifier
patients,3807,O
are,3807,O
homozygous,3807,O
for,3807,O
one,3807,O
mutation,3807,O
",",3807,O
the,3807,O
substitution,3807,O
of,3807,O
tyrosine,3807,O
for,3807,O
cysteine,3807,O
at,3807,O
position,3807,O
282,3807,O
(,3807,O
C282Y,3807,O
),3807,O
in,3807,O
the,3807,O
unprocessed,3807,O
protein,3807,O
.,3807,O
In,3808,O
a,3808,O
proportion,3808,O
of,3808,O
GH,3808,B-Modifier
patients,3808,O
",",3808,O
two,3808,O
mutations,3808,O
are,3808,O
present,3808,O
",",3808,O
C282Y,3808,O
and,3808,O
H63D,3808,O
.,3808,O
The,3809,O
clinical,3809,O
significance,3809,O
of,3809,O
this,3809,O
second,3809,O
mutation,3809,O
is,3809,O
such,3809,O
that,3809,O
it,3809,O
appears,3809,O
to,3809,O
predispose,3809,O
1,3809,O
%,3809,O
-2,3809,O
%,3809,O
of,3809,O
compound,3809,O
heterozygotes,3809,O
to,3809,O
expression,3809,O
of,3809,O
the,3809,O
disease,3809,O
.,3809,O
The,3810,O
distribution,3810,O
of,3810,O
the,3810,O
two,3810,O
mutations,3810,O
differ,3810,O
",",3810,O
C282Y,3810,O
being,3810,O
limited,3810,O
to,3810,O
those,3810,O
of,3810,O
northwestern,3810,O
European,3810,O
ancestry,3810,O
and,3810,O
H63D,3810,O
being,3810,O
found,3810,O
at,3810,O
allele,3810,O
frequencies,3810,O
>,3810,O
5,3810,O
%,3810,O
",",3810,O
in,3810,O
Europe,3810,O
",",3810,O
in,3810,O
countries,3810,O
bordering,3810,O
the,3810,O
Mediterranean,3810,O
",",3810,O
in,3810,O
the,3810,O
Middle,3810,O
East,3810,O
",",3810,O
and,3810,O
in,3810,O
the,3810,O
Indian,3810,O
subcontinent,3810,O
.,3810,O
The,3811,O
C282Y,3811,O
mutation,3811,O
occurs,3811,O
on,3811,O
a,3811,O
haplotype,3811,O
that,3811,O
extends,3811,O
<,3811,O
/=,3811,O
6,3811,O
Mb,3811,O
",",3811,O
suggesting,3811,O
that,3811,O
this,3811,O
mutation,3811,O
has,3811,O
arisen,3811,O
during,3811,O
the,3811,O
past,3811,O
2,3811,O
",",3811,O
000,3811,O
years,3811,O
.,3811,O
The,3812,O
H63D,3812,O
mutation,3812,O
is,3812,O
older,3812,O
and,3812,O
does,3812,O
not,3812,O
occur,3812,O
on,3812,O
such,3812,O
a,3812,O
large,3812,O
extended,3812,O
haplotype,3812,O
",",3812,O
the,3812,O
haplotype,3812,O
in,3812,O
this,3812,O
case,3812,O
extending,3812,O
<,3812,O
/=,3812,O
700,3812,O
kb,3812,O
.,3812,O
Here,3813,O
we,3813,O
report,3813,O
the,3813,O
finding,3813,O
of,3813,O
the,3813,O
H63D,3813,O
and,3813,O
C282Y,3813,O
mutations,3813,O
on,3813,O
new,3813,O
haplotypes,3813,O
.,3813,O
In,3814,O
Sri,3814,O
Lanka,3814,O
we,3814,O
have,3814,O
found,3814,O
H63D,3814,O
on,3814,O
three,3814,O
new,3814,O
haplotypes,3814,O
and,3814,O
have,3814,O
found,3814,O
C282Y,3814,O
on,3814,O
one,3814,O
new,3814,O
haplotype,3814,O
",",3814,O
demonstrating,3814,O
that,3814,O
these,3814,O
mutations,3814,O
have,3814,O
arisen,3814,O
independently,3814,O
on,3814,O
this,3814,O
island,3814,O
.,3814,O
These,3815,O
results,3815,O
suggest,3815,O
that,3815,O
the,3815,O
HFE,3815,O
gene,3815,O
has,3815,O
been,3815,O
the,3815,O
subject,3815,O
of,3815,O
selection,3815,O
pressure,3815,O
.,3815,O
These,3816,O
selection,3816,O
pressures,3816,O
could,3816,O
be,3816,O
due,3816,O
to,3816,O
infectious,3816,B-DiseaseClass
diseases,3816,I-DiseaseClass
",",3816,O
environmental,3816,O
conditions,3816,O
",",3816,O
or,3816,O
other,3816,O
genetic,3816,B-DiseaseClass
disorders,3816,I-DiseaseClass
such,3816,O
as,3816,O
anemia,3816,B-DiseaseClass
.,3816,O
A,3817,O
retrospective,3817,O
anonymous,3817,O
pilot,3817,O
study,3817,O
in,3817,O
screening,3817,O
newborns,3817,O
for,3817,O
HFE,3817,O
mutations,3817,O
in,3817,O
Scandinavian,3817,O
populations,3817,O
.,3817,O
We,3818,O
have,3818,O
retrospectively,3818,O
analyzed,3818,O
837,3818,O
random,3818,O
anonymized,3818,O
dried,3818,O
blood,3818,O
spot,3818,O
(,3818,O
DBS,3818,O
),3818,O
samples,3818,O
from,3818,O
neonatal,3818,O
screening,3818,O
programs,3818,O
in,3818,O
Scandinavia,3818,O
for,3818,O
mutations,3818,O
in,3818,O
HFE,3818,O
",",3818,O
the,3818,O
candidate,3818,O
gene,3818,O
for,3818,O
hemochromatosis,3818,B-SpecificDisease
.,3818,O
We,3819,O
have,3819,O
found,3819,O
C282Y,3819,O
allele,3819,O
frequencies,3819,O
of,3819,O
2,3819,O
.,3819,O
3,3820,O
%,3820,O
(,3820,O
+,3820,O
2,3820,O
.,3820,O
0,3821,O
%,3821,O
),3821,O
(,3821,O
-1,3821,O
.,3821,O
3,3822,O
%,3822,O
),3822,O
in,3822,O
Greenland,3822,O
",",3822,O
4,3822,O
.,3822,O
5,3823,O
%,3823,O
+/-1,3823,O
.,3823,O
9,3824,O
%,3824,O
in,3824,O
Iceland,3824,O
",",3824,O
5,3824,O
.,3824,O
1,3825,O
%,3825,O
+/-2,3825,O
.,3825,O
3,3826,O
%,3826,O
in,3826,O
the,3826,O
Faeroe,3826,O
Islands,3826,O
",",3826,O
and,3826,O
8,3826,O
.,3826,O
2,3827,O
%,3827,O
+/-2,3827,O
.,3827,O
7,3828,O
%,3828,O
in,3828,O
Denmark,3828,O
.,3828,O
The,3829,O
high,3829,O
prevalence,3829,O
of,3829,O
HFE,3829,O
mutations,3829,O
in,3829,O
Denmark,3829,O
suggests,3829,O
that,3829,O
population,3829,O
screening,3829,O
for,3829,O
the,3829,O
C282Y,3829,O
mutation,3829,O
could,3829,O
be,3829,O
highly,3829,O
advantageous,3829,O
in,3829,O
terms,3829,O
of,3829,O
preventive,3829,O
health,3829,O
care,3829,O
.,3829,O
Long-term,3830,O
follow-up,3830,O
evaluation,3830,O
of,3830,O
C282Y,3830,O
homozygotes,3830,O
and,3830,O
H63D/C282Y,3830,O
compound,3830,O
heterozygotes,3830,O
will,3830,O
give,3830,O
an,3830,O
indication,3830,O
of,3830,O
the,3830,O
penetrance,3830,O
of,3830,O
the,3830,O
mutations,3830,O
.,3830,O
Identification,3831,O
of,3831,O
the,3831,O
mutation,3831,O
in,3831,O
the,3831,O
alkaptonuria,3831,B-Modifier
mouse,3831,O
model,3831,O
.,3831,O
Alkaptonuria,3832,B-SpecificDisease
(,3832,O
aku,3832,B-SpecificDisease
),3832,O
",",3832,O
an,3832,O
inborn,3832,B-DiseaseClass
error,3832,I-DiseaseClass
of,3832,I-DiseaseClass
metabolism,3832,I-DiseaseClass
caused,3832,O
by,3832,O
the,3832,O
loss,3832,O
of,3832,O
homogentisate,3832,O
1,3832,O
",",3832,O
2-dioxygenase,3832,O
(,3832,O
HGD,3832,O
),3832,O
",",3832,O
has,3832,O
been,3832,O
described,3832,O
in,3832,O
a,3832,O
mouse,3832,O
model,3832,O
created,3832,O
by,3832,O
ethylnitrosourea,3832,O
mutagenesis,3832,O
but,3832,O
the,3832,O
mutation,3832,O
in,3832,O
these,3832,O
mice,3832,O
has,3832,O
not,3832,O
previously,3832,O
been,3832,O
identified,3832,O
.,3832,O
We,3833,O
used,3833,O
RT-PCR,3833,O
to,3833,O
amplify,3833,O
the,3833,O
Hgd,3833,O
cDNA,3833,O
from,3833,O
Hgd,3833,O
(,3833,O
aku,3833,O
),3833,O
/Hgd,3833,O
(,3833,O
aku,3833,O
),3833,O
mice,3833,O
.,3833,O
Two,3834,O
products,3834,O
shorter,3834,O
than,3834,O
the,3834,O
wild-type,3834,O
product,3834,O
were,3834,O
amplified,3834,O
.,3834,O
Restriction,3835,O
mapping,3835,O
and,3835,O
DNA,3835,O
sequencing,3835,O
were,3835,O
then,3835,O
used,3835,O
to,3835,O
identify,3835,O
the,3835,O
Hgd,3835,O
(,3835,O
aku,3835,O
),3835,O
mouse,3835,O
mutation,3835,O
",",3835,O
found,3835,O
to,3835,O
be,3835,O
a,3835,O
single,3835,O
base,3835,O
change,3835,O
in,3835,O
a,3835,O
splice,3835,O
donor,3835,O
consensus,3835,O
sequence,3835,O
",",3835,O
causing,3835,O
exon,3835,O
skipping,3835,O
and,3835,O
frame-shifted,3835,O
products,3835,O
.,3835,O
This,3836,O
base,3836,O
change,3836,O
allowed,3836,O
us,3836,O
to,3836,O
create,3836,O
a,3836,O
non-radioactive,3836,O
genotyping,3836,O
assay,3836,O
for,3836,O
this,3836,O
allele,3836,O
.,3836,O
Non-syndromic,3837,B-SpecificDisease
hearing,3837,I-SpecificDisease
loss,3837,I-SpecificDisease
associated,3837,O
with,3837,O
enlarged,3837,B-SpecificDisease
vestibular,3837,I-SpecificDisease
aqueduct,3837,I-SpecificDisease
is,3837,O
caused,3837,O
by,3837,O
PDS,3837,B-Modifier
mutations,3837,O
.,3837,O
Enlarged,3838,B-SpecificDisease
vestibular,3838,I-SpecificDisease
aqueduct,3838,I-SpecificDisease
(,3838,O
EVA,3838,B-SpecificDisease
),3838,O
",",3838,O
known,3838,O
as,3838,O
the,3838,O
most,3838,O
common,3838,O
form,3838,O
of,3838,O
inner,3838,B-DiseaseClass
ear,3838,I-DiseaseClass
abnormality,3838,I-DiseaseClass
",",3838,O
has,3838,O
recently,3838,O
been,3838,O
of,3838,O
particular,3838,O
genetic,3838,O
interest,3838,O
because,3838,O
this,3838,O
anomaly,3838,O
is,3838,O
inherited,3838,O
in,3838,O
a,3838,O
recessive,3838,O
manner,3838,O
.,3838,O
The,3839,O
locus,3839,O
for,3839,O
non-syndromic,3839,B-SpecificDisease
sensorineural,3839,I-SpecificDisease
hearing,3839,I-SpecificDisease
loss,3839,I-SpecificDisease
with,3839,O
EVA,3839,B-SpecificDisease
has,3839,O
been,3839,O
mapped,3839,O
to,3839,O
the,3839,O
same,3839,O
chromosomal,3839,O
region,3839,O
",",3839,O
7q31,3839,O
",",3839,O
as,3839,O
the,3839,O
Pendred,3839,B-Modifier
syndrome,3839,I-Modifier
locus,3839,O
.,3839,O
In,3840,O
the,3840,O
present,3840,O
study,3840,O
",",3840,O
seven,3840,O
mutations,3840,O
in,3840,O
the,3840,O
PDS,3840,B-Modifier
gene,3840,O
(,3840,O
PDS,3840,O
),3840,O
",",3840,O
the,3840,O
gene,3840,O
responsible,3840,O
for,3840,O
Pendred,3840,B-SpecificDisease
syndrome,3840,I-SpecificDisease
",",3840,O
have,3840,O
been,3840,O
found,3840,O
in,3840,O
families,3840,O
of,3840,O
non-syndromic,3840,B-SpecificDisease
sensorineural,3840,I-SpecificDisease
hearing,3840,I-SpecificDisease
loss,3840,I-SpecificDisease
with,3840,O
EVA,3840,B-SpecificDisease
.,3840,O
One,3841,O
family,3841,O
is,3841,O
homozygous,3841,O
",",3841,O
three,3841,O
families,3841,O
are,3841,O
compound,3841,O
heterozygotes,3841,O
",",3841,O
and,3841,O
two,3841,O
families,3841,O
are,3841,O
heterozygous,3841,O
but,3841,O
with,3841,O
no,3841,O
other,3841,O
mutation,3841,O
detected,3841,O
.,3841,O
The,3842,O
present,3842,O
results,3842,O
provide,3842,O
evidence,3842,O
that,3842,O
mutations,3842,O
in,3842,O
PDS,3842,O
cause,3842,O
both,3842,O
syndromic,3842,O
and,3842,O
non-syndromic,3842,O
hearing,3842,O
loss,3842,O
..,3842,O
Mutational,3843,O
analysis,3843,O
and,3843,O
genotype-phenotype,3843,O
correlation,3843,O
of,3843,O
29,3843,O
unrelated,3843,O
Japanese,3843,O
patients,3843,O
with,3843,O
X-linked,3843,B-SpecificDisease
adrenoleukodystrophy,3843,I-SpecificDisease
.,3843,O
BACKGROUND,3844,O
X-linked,3844,B-SpecificDisease
adrenoleukodystrophy,3844,I-SpecificDisease
(,3844,O
ALD,3844,B-SpecificDisease
),3844,O
is,3844,O
an,3844,O
inherited,3844,B-DiseaseClass
disease,3844,I-DiseaseClass
characterized,3844,O
by,3844,O
progressive,3844,O
neurologic,3844,B-SpecificDisease
dysfunction,3844,I-SpecificDisease
",",3844,O
occasionally,3844,O
associated,3844,O
with,3844,O
adrenal,3844,B-DiseaseClass
insufficiency,3844,I-DiseaseClass
.,3844,O
The,3845,O
classic,3845,O
form,3845,O
of,3845,O
ALD,3845,B-SpecificDisease
usually,3845,O
has,3845,O
onset,3845,O
in,3845,O
childhood,3845,O
(,3845,O
childhood,3845,B-SpecificDisease
cerebral,3845,I-SpecificDisease
ALD,3845,I-SpecificDisease
),3845,O
",",3845,O
with,3845,O
rapid,3845,O
neurologic,3845,B-DiseaseClass
deterioration,3845,I-DiseaseClass
leading,3845,O
to,3845,O
a,3845,O
vegetative,3845,O
state,3845,O
.,3845,O
Adult-onset,3846,O
cerebral,3846,B-SpecificDisease
ALD,3846,I-SpecificDisease
also,3846,O
presents,3846,O
with,3846,O
rapidly,3846,O
progressive,3846,O
neurologic,3846,B-DiseaseClass
dysfunction,3846,I-DiseaseClass
.,3846,O
Milder,3847,O
phenotypes,3847,O
such,3847,O
as,3847,O
adrenomyeloneuropathy,3847,B-SpecificDisease
and,3847,O
Addison,3847,B-SpecificDisease
disease,3847,I-SpecificDisease
only,3847,O
also,3847,O
have,3847,O
been,3847,O
recognized,3847,O
.,3847,O
Despite,3848,O
discovery,3848,O
of,3848,O
the,3848,O
causative,3848,O
gene,3848,O
",",3848,O
a,3848,O
molecular,3848,O
basis,3848,O
for,3848,O
the,3848,O
diverse,3848,O
clinical,3848,O
presentations,3848,O
remains,3848,O
to,3848,O
be,3848,O
elucidated,3848,O
.,3848,O
OBJECTIVES,3849,O
To,3849,O
conduct,3849,O
mutational,3849,O
analyses,3849,O
in,3849,O
29,3849,O
Japanese,3849,O
patients,3849,O
with,3849,O
ALD,3849,B-SpecificDisease
from,3849,O
29,3849,O
unrelated,3849,O
families,3849,O
",",3849,O
to,3849,O
obtain,3849,O
knowledge,3849,O
of,3849,O
the,3849,O
spectrum,3849,O
of,3849,O
mutations,3849,O
in,3849,O
this,3849,O
gene,3849,O
",",3849,O
and,3849,O
to,3849,O
study,3849,O
genotype-phenotype,3849,O
correlations,3849,O
in,3849,O
Japanese,3849,O
patients,3849,O
.,3849,O
METHODS,3850,O
The,3850,O
29,3850,O
patients,3850,O
comprised,3850,O
13,3850,O
patients,3850,O
with,3850,O
childhood,3850,B-SpecificDisease
cerebral,3850,I-SpecificDisease
ALD,3850,I-SpecificDisease
",",3850,O
11,3850,O
patients,3850,O
with,3850,O
adult-onset,3850,O
cerebral,3850,B-SpecificDisease
ALD,3850,I-SpecificDisease
",",3850,O
and,3850,O
5,3850,O
patients,3850,O
with,3850,O
adrenomyeloneuropathy,3850,B-SpecificDisease
.,3850,O
We,3851,O
conducted,3851,O
detailed,3851,O
mutational,3851,O
analyses,3851,O
of,3851,O
29,3851,O
unrelated,3851,O
Japanese,3851,O
patients,3851,O
with,3851,O
ALD,3851,B-SpecificDisease
by,3851,O
genomic,3851,O
Southern,3851,O
blot,3851,O
analysis,3851,O
and,3851,O
direct,3851,O
nucleotide,3851,O
sequence,3851,O
analysis,3851,O
of,3851,O
reverse,3851,O
transcriptase-polymerase,3851,O
chain,3851,O
reaction,3851,O
products,3851,O
derived,3851,O
from,3851,O
total,3851,O
RNA,3851,O
that,3851,O
was,3851,O
extracted,3851,O
from,3851,O
cultured,3851,O
skin,3851,O
fibroblasts,3851,O
",",3851,O
lymphoblastoid,3851,O
cells,3851,O
",",3851,O
or,3851,O
peripheral,3851,O
blood,3851,O
leukocytes,3851,O
.,3851,O
RESULTS,3852,O
Three,3852,O
patients,3852,O
with,3852,O
adult-onset,3852,O
cerebral,3852,B-SpecificDisease
ALD,3852,I-SpecificDisease
were,3852,O
identified,3852,O
as,3852,O
having,3852,O
large,3852,O
genomic,3852,O
rearrangements,3852,O
.,3852,O
The,3853,O
remaining,3853,O
26,3853,O
patients,3853,O
were,3853,O
identified,3853,O
as,3853,O
having,3853,O
21,3853,O
independent,3853,O
mutations,3853,O
",",3853,O
including,3853,O
12,3853,O
novel,3853,O
mutations,3853,O
resulting,3853,O
in,3853,O
small,3853,O
nucleotide,3853,O
alterations,3853,O
in,3853,O
the,3853,O
ALD,3853,B-Modifier
gene,3853,O
.,3853,O
Eighteen,3854,O
(,3854,O
69,3854,O
%,3854,O
),3854,O
of,3854,O
26,3854,O
mutations,3854,O
were,3854,O
missense,3854,O
mutations,3854,O
.,3854,O
Most,3855,O
missense,3855,O
mutations,3855,O
involved,3855,O
amino,3855,O
acids,3855,O
conserved,3855,O
in,3855,O
homologous,3855,O
gene,3855,O
products,3855,O
",",3855,O
including,3855,O
PMP70,3855,O
",",3855,O
mALDRP,3855,O
",",3855,O
and,3855,O
Pxa1p,3855,O
.,3855,O
The,3856,O
AG,3856,O
dinucleotide,3856,O
deletion,3856,O
at,3856,O
position,3856,O
1081-1082,3856,O
",",3856,O
which,3856,O
has,3856,O
been,3856,O
reported,3856,O
previously,3856,O
to,3856,O
be,3856,O
the,3856,O
most,3856,O
common,3856,O
mutation,3856,O
in,3856,O
white,3856,O
patients,3856,O
(,3856,O
12,3856,O
%,3856,O
-17,3856,O
%,3856,O
),3856,O
",",3856,O
was,3856,O
also,3856,O
identified,3856,O
as,3856,O
the,3856,O
most,3856,O
common,3856,O
mutation,3856,O
in,3856,O
Japanese,3856,O
patients,3856,O
(,3856,O
12,3856,O
%,3856,O
),3856,O
.,3856,O
All,3857,O
phenotypes,3857,O
were,3857,O
associated,3857,O
with,3857,O
mutations,3857,O
resulting,3857,O
in,3857,O
protein,3857,O
truncation,3857,O
or,3857,O
subtle,3857,O
amino,3857,O
acid,3857,O
changes,3857,O
.,3857,O
There,3858,O
were,3858,O
no,3858,O
differences,3858,O
in,3858,O
phenotypic,3858,O
expressions,3858,O
between,3858,O
missense,3858,O
mutations,3858,O
involving,3858,O
conserved,3858,O
amino,3858,O
acids,3858,O
and,3858,O
those,3858,O
involving,3858,O
nonconserved,3858,O
amino,3858,O
acids,3858,O
.,3858,O
CONCLUSIONS,3859,O
There,3859,O
are,3859,O
no,3859,O
obvious,3859,O
correlations,3859,O
between,3859,O
the,3859,O
phenotypes,3859,O
of,3859,O
patients,3859,O
with,3859,O
ALD,3859,B-SpecificDisease
and,3859,O
their,3859,O
genotypes,3859,O
",",3859,O
suggesting,3859,O
that,3859,O
other,3859,O
genetic,3859,O
or,3859,O
environmental,3859,O
factors,3859,O
modify,3859,O
the,3859,O
phenotypic,3859,O
expressions,3859,O
of,3859,O
ALD,3859,B-SpecificDisease
..,3859,O
A,3860,O
common,3860,O
human,3860,O
skin,3860,B-DiseaseClass
tumour,3860,I-DiseaseClass
is,3860,O
caused,3860,O
by,3860,O
activating,3860,O
mutations,3860,O
in,3860,O
beta-catenin,3860,O
.,3860,O
WNT,3861,O
signalling,3861,O
orchestrates,3861,O
a,3861,O
number,3861,O
of,3861,O
developmental,3861,O
programs,3861,O
.,3861,O
In,3862,O
response,3862,O
to,3862,O
this,3862,O
stimulus,3862,O
",",3862,O
cytoplasmic,3862,O
beta-catenin,3862,O
(,3862,O
encoded,3862,O
by,3862,O
CTNNB1,3862,O
),3862,O
is,3862,O
stabilized,3862,O
",",3862,O
enabling,3862,O
downstream,3862,O
transcriptional,3862,O
activation,3862,O
by,3862,O
members,3862,O
of,3862,O
the,3862,O
LEF/TCF,3862,O
family,3862,O
.,3862,O
One,3863,O
of,3863,O
the,3863,O
target,3863,O
genes,3863,O
for,3863,O
beta-catenin/TCF,3863,O
encodes,3863,O
c-MYC,3863,O
",",3863,O
explaining,3863,O
why,3863,O
constitutive,3863,O
activation,3863,O
of,3863,O
the,3863,O
WNT,3863,O
pathway,3863,O
can,3863,O
lead,3863,O
to,3863,O
cancer,3863,B-DiseaseClass
",",3863,O
particularly,3863,O
in,3863,O
the,3863,O
colon,3863,O
.,3863,O
Most,3864,O
colon,3864,B-DiseaseClass
cancers,3864,I-DiseaseClass
arise,3864,O
from,3864,O
mutations,3864,O
in,3864,O
the,3864,O
gene,3864,O
encoding,3864,O
adenomatous,3864,B-SpecificDisease
polyposis,3864,I-SpecificDisease
coli,3864,I-SpecificDisease
(,3864,O
APC,3864,B-SpecificDisease
),3864,O
",",3864,O
a,3864,O
protein,3864,O
required,3864,O
for,3864,O
ubiquitin-mediated,3864,O
degradation,3864,O
of,3864,O
beta-catenin,3864,O
",",3864,O
but,3864,O
a,3864,O
small,3864,O
percentage,3864,O
of,3864,O
colon,3864,O
and,3864,O
some,3864,O
other,3864,O
cancers,3864,O
harbour,3864,O
beta-catenin-stabilizing,3864,O
mutations,3864,O
.,3864,O
Recently,3865,O
",",3865,O
we,3865,O
discovered,3865,O
that,3865,O
transgenic,3865,O
mice,3865,O
expressing,3865,O
an,3865,O
activated,3865,O
beta-catenin,3865,O
are,3865,O
predisposed,3865,O
to,3865,O
developing,3865,O
skin,3865,B-DiseaseClass
tumours,3865,I-DiseaseClass
resembling,3865,O
pilomatricomas,3865,B-SpecificDisease
.,3865,O
Given,3866,O
that,3866,O
the,3866,O
skin,3866,O
of,3866,O
these,3866,O
adult,3866,O
mice,3866,O
also,3866,O
exhibits,3866,O
signs,3866,O
of,3866,O
de,3866,O
novo,3866,O
hair-follicle,3866,O
morphogenesis,3866,O
",",3866,O
we,3866,O
wondered,3866,O
whether,3866,O
human,3866,O
pilomatricomas,3866,B-SpecificDisease
might,3866,O
originate,3866,O
from,3866,O
hair,3866,O
matrix,3866,O
cells,3866,O
and,3866,O
whether,3866,O
they,3866,O
might,3866,O
possess,3866,O
beta-catenin-stabilizing,3866,O
mutations,3866,O
.,3866,O
Here,3867,O
",",3867,O
we,3867,O
explore,3867,O
the,3867,O
cell,3867,O
origin,3867,O
and,3867,O
aetiology,3867,O
of,3867,O
this,3867,O
common,3867,O
human,3867,O
skin,3867,B-DiseaseClass
tumour,3867,I-DiseaseClass
.,3867,O
We,3868,O
found,3868,O
nuclear,3868,O
LEF-1,3868,O
in,3868,O
the,3868,O
dividing,3868,O
tumour,3868,B-Modifier
cells,3868,O
",",3868,O
providing,3868,O
biochemical,3868,O
evidence,3868,O
that,3868,O
pilomatricomas,3868,B-SpecificDisease
are,3868,O
derived,3868,O
from,3868,O
hair,3868,O
matrix,3868,O
cells,3868,O
.,3868,O
At,3869,O
least,3869,O
75,3869,O
%,3869,O
of,3869,O
these,3869,O
tumours,3869,B-DiseaseClass
possess,3869,O
mutations,3869,O
affecting,3869,O
the,3869,O
amino-terminal,3869,O
segment,3869,O
",",3869,O
normally,3869,O
involved,3869,O
in,3869,O
phosphorylation-dependent,3869,O
",",3869,O
ubiquitin-mediated,3869,O
degradation,3869,O
of,3869,O
the,3869,O
protein,3869,O
.,3869,O
This,3870,O
percentage,3870,O
of,3870,O
CTNNB1,3870,O
mutations,3870,O
is,3870,O
greater,3870,O
than,3870,O
in,3870,O
all,3870,O
other,3870,O
human,3870,O
tumours,3870,B-DiseaseClass
examined,3870,O
thus,3870,O
far,3870,O
",",3870,O
and,3870,O
directly,3870,O
implicates,3870,O
beta-catenin/LEF,3870,O
misregulation,3870,O
as,3870,O
the,3870,O
major,3870,O
cause,3870,O
of,3870,O
hair,3870,O
matrix,3870,O
cell,3870,O
tumorigenesis,3870,O
in,3870,O
humans,3870,O
..,3870,O
The,3871,O
Pendred,3871,B-Modifier
syndrome,3871,I-Modifier
gene,3871,O
encodes,3871,O
a,3871,O
chloride-iodide,3871,O
transport,3871,O
protein,3871,O
.,3871,O
Pendred,3872,B-SpecificDisease
syndrome,3872,I-SpecificDisease
is,3872,O
the,3872,O
most,3872,O
common,3872,O
form,3872,O
of,3872,O
syndromic,3872,B-DiseaseClass
deafness,3872,I-DiseaseClass
and,3872,O
characterized,3872,O
by,3872,O
congenital,3872,O
sensorineural,3872,B-SpecificDisease
hearing,3872,I-SpecificDisease
loss,3872,I-SpecificDisease
and,3872,O
goitre,3872,B-SpecificDisease
.,3872,O
This,3873,O
disorder,3873,O
was,3873,O
mapped,3873,O
to,3873,O
chromosome,3873,O
7,3873,O
and,3873,O
the,3873,O
gene,3873,O
causing,3873,O
Pendred,3873,B-SpecificDisease
syndrome,3873,I-SpecificDisease
(,3873,O
PDS,3873,B-SpecificDisease
),3873,O
was,3873,O
subsequently,3873,O
identified,3873,O
by,3873,O
positional,3873,O
cloning,3873,O
.,3873,O
PDS,3874,O
encodes,3874,O
a,3874,O
putative,3874,O
transmembrane,3874,O
protein,3874,O
designated,3874,O
pendrin,3874,O
.,3874,O
Pendrin,3875,O
is,3875,O
closely,3875,O
related,3875,O
to,3875,O
a,3875,O
family,3875,O
of,3875,O
sulfate,3875,O
transport,3875,O
proteins,3875,O
that,3875,O
includes,3875,O
the,3875,O
rat,3875,O
sulfate-anion,3875,O
transporter,3875,O
(,3875,O
encoded,3875,O
by,3875,O
Sat-1,3875,O
;,3875,O
29,3875,O
%,3875,O
amino,3875,O
acid,3875,O
sequence,3875,O
identity,3875,O
),3875,O
",",3875,O
the,3875,O
human,3875,O
diastrophic,3875,B-Modifier
dysplasia,3875,I-Modifier
sulfate,3875,O
transporter,3875,O
(,3875,O
encoded,3875,O
by,3875,O
DTD,3875,O
;,3875,O
32,3875,O
%,3875,O
),3875,O
and,3875,O
the,3875,O
human,3875,O
sulfate,3875,O
transporter,3875,O
downregulated,3875,O
in,3875,O
adenoma,3875,B-DiseaseClass
(,3875,O
encoded,3875,O
by,3875,O
DRA,3875,O
;,3875,O
45,3875,O
%,3875,O
),3875,O
.,3875,O
On,3876,O
the,3876,O
basis,3876,O
of,3876,O
this,3876,O
homology,3876,O
and,3876,O
the,3876,O
presence,3876,O
of,3876,O
a,3876,O
slightly,3876,O
modified,3876,O
sulfate-transporter,3876,O
signature,3876,O
sequence,3876,O
comprising,3876,O
its,3876,O
putative,3876,O
second,3876,O
transmembrane,3876,O
domain,3876,O
",",3876,O
pendrin,3876,O
has,3876,O
been,3876,O
proposed,3876,O
to,3876,O
function,3876,O
as,3876,O
a,3876,O
sulfate,3876,O
transporter,3876,O
.,3876,O
We,3877,O
were,3877,O
unable,3877,O
to,3877,O
detect,3877,O
evidence,3877,O
of,3877,O
sulfate,3877,O
transport,3877,O
following,3877,O
the,3877,O
expression,3877,O
of,3877,O
pendrin,3877,O
in,3877,O
Xenopus,3877,O
laevis,3877,O
oocytes,3877,O
by,3877,O
microinjection,3877,O
of,3877,O
PDS,3877,O
cRNA,3877,O
or,3877,O
in,3877,O
Sf9,3877,O
cells,3877,O
following,3877,O
infection,3877,O
with,3877,O
PDS-recombinant,3877,O
baculovirus,3877,O
.,3877,O
The,3878,O
rates,3878,O
of,3878,O
transport,3878,O
for,3878,O
iodide,3878,O
and,3878,O
chloride,3878,O
were,3878,O
significantly,3878,O
increased,3878,O
following,3878,O
the,3878,O
expression,3878,O
of,3878,O
pendrin,3878,O
in,3878,O
both,3878,O
cell,3878,O
systems,3878,O
.,3878,O
Our,3879,O
results,3879,O
demonstrate,3879,O
that,3879,O
pendrin,3879,O
functions,3879,O
as,3879,O
a,3879,O
transporter,3879,O
of,3879,O
chloride,3879,O
and,3879,O
iodide,3879,O
",",3879,O
but,3879,O
not,3879,O
sulfate,3879,O
",",3879,O
and,3879,O
may,3879,O
provide,3879,O
insight,3879,O
into,3879,O
thyroid,3879,O
physiology,3879,O
and,3879,O
the,3879,O
pathophysiology,3879,O
of,3879,O
Pendred,3879,B-SpecificDisease
syndrome,3879,I-SpecificDisease
..,3879,O
HFE,3880,O
mutations,3880,O
analysis,3880,O
in,3880,O
711,3880,O
hemochromatosis,3880,B-Modifier
probands,3880,O
:,3880,O
evidence,3880,O
for,3880,O
S65C,3880,O
implication,3880,O
in,3880,O
mild,3880,O
form,3880,O
of,3880,O
hemochromatosis,3880,B-SpecificDisease
.,3880,O
Hereditary,3881,B-SpecificDisease
hemochromatosis,3881,I-SpecificDisease
(,3881,O
HH,3881,B-SpecificDisease
),3881,O
is,3881,O
a,3881,O
common,3881,O
autosomal,3881,B-DiseaseClass
recessive,3881,I-DiseaseClass
genetic,3881,I-DiseaseClass
disorder,3881,I-DiseaseClass
of,3881,O
iron,3881,O
metabolism,3881,O
.,3881,O
The,3882,O
HFE,3882,O
candidate,3882,O
gene,3882,O
encoding,3882,O
an,3882,O
HLA,3882,O
class,3882,O
I-like,3882,O
protein,3882,O
involved,3882,O
in,3882,O
HH,3882,B-SpecificDisease
was,3882,O
identified,3882,O
in,3882,O
1996,3882,O
.,3882,O
Two,3883,O
missense,3883,O
mutations,3883,O
have,3883,O
been,3883,O
described,3883,O
C282Y,3883,O
",",3883,O
accounting,3883,O
for,3883,O
80,3883,O
%,3883,O
to,3883,O
90,3883,O
%,3883,O
of,3883,O
HH,3883,B-Modifier
chromosomes,3883,O
",",3883,O
and,3883,O
H63D,3883,O
",",3883,O
which,3883,O
is,3883,O
associated,3883,O
with,3883,O
a,3883,O
milder,3883,O
form,3883,O
of,3883,O
the,3883,O
disease,3883,O
representing,3883,O
40,3883,O
%,3883,O
to,3883,O
70,3883,O
%,3883,O
of,3883,O
non-C282Y,3883,O
HH,3883,B-Modifier
chromosomes,3883,O
.,3883,O
We,3884,O
report,3884,O
here,3884,O
on,3884,O
the,3884,O
analysis,3884,O
of,3884,O
C282Y,3884,O
",",3884,O
H63D,3884,O
",",3884,O
and,3884,O
the,3884,O
193A,3884,O
--,3884,O
>,3884,O
T,3884,O
substitution,3884,O
leading,3884,O
to,3884,O
the,3884,O
S65C,3884,O
missense,3884,O
substitution,3884,O
in,3884,O
a,3884,O
large,3884,O
series,3884,O
of,3884,O
probands,3884,O
and,3884,O
controls,3884,O
.,3884,O
The,3885,O
results,3885,O
confirm,3885,O
that,3885,O
the,3885,O
C282Y,3885,O
substitution,3885,O
was,3885,O
the,3885,O
main,3885,O
mutation,3885,O
involved,3885,O
in,3885,O
hemochromatosis,3885,B-SpecificDisease
",",3885,O
accounting,3885,O
for,3885,O
85,3885,O
%,3885,O
of,3885,O
carrier,3885,O
chromosomes,3885,O
",",3885,O
whereas,3885,O
the,3885,O
H63D,3885,O
substitution,3885,O
represented,3885,O
39,3885,O
%,3885,O
of,3885,O
the,3885,O
HH,3885,B-Modifier
chromosomes,3885,O
that,3885,O
did,3885,O
not,3885,O
carry,3885,O
the,3885,O
C282Y,3885,O
mutation,3885,O
.,3885,O
In,3886,O
addition,3886,O
",",3886,O
our,3886,O
screening,3886,O
showed,3886,O
that,3886,O
the,3886,O
S65C,3886,O
substitution,3886,O
was,3886,O
significantly,3886,O
enriched,3886,O
in,3886,O
probands,3886,O
with,3886,O
at,3886,O
least,3886,O
one,3886,O
chromosome,3886,O
without,3886,O
an,3886,O
assigned,3886,O
mutation,3886,O
.,3886,O
This,3887,O
substitution,3887,O
accounted,3887,O
for,3887,O
7,3887,O
.,3887,O
8,3888,O
%,3888,O
of,3888,O
HH,3888,B-Modifier
chromosomes,3888,O
that,3888,O
were,3888,O
neither,3888,O
C282Y,3888,O
nor,3888,O
H63D,3888,O
.,3888,O
This,3889,O
enrichment,3889,O
of,3889,O
S65C,3889,O
among,3889,O
HH,3889,B-Modifier
chromosomes,3889,O
suggests,3889,O
that,3889,O
the,3889,O
S65C,3889,O
substitution,3889,O
is,3889,O
associated,3889,O
with,3889,O
the,3889,O
mild,3889,O
form,3889,O
of,3889,O
hemochromatosis,3889,B-SpecificDisease
.,3889,O
Germline,3890,O
BRCA1,3890,O
alterations,3890,O
in,3890,O
a,3890,O
population-based,3890,O
series,3890,O
of,3890,O
ovarian,3890,B-Modifier
cancer,3890,I-Modifier
cases,3890,O
.,3890,O
The,3891,O
objective,3891,O
of,3891,O
this,3891,O
study,3891,O
was,3891,O
to,3891,O
provide,3891,O
more,3891,O
accurate,3891,O
frequency,3891,O
estimates,3891,O
of,3891,O
breast,3891,B-Modifier
cancer,3891,I-Modifier
susceptibility,3891,O
gene,3891,O
1,3891,O
(,3891,O
BRCA1,3891,O
),3891,O
germline,3891,O
alterations,3891,O
in,3891,O
the,3891,O
ovarian,3891,B-Modifier
cancer,3891,I-Modifier
population,3891,O
.,3891,O
To,3892,O
achieve,3892,O
this,3892,O
",",3892,O
we,3892,O
determined,3892,O
the,3892,O
prevalence,3892,O
of,3892,O
BRCA1,3892,O
alterations,3892,O
in,3892,O
a,3892,O
population-based,3892,O
series,3892,O
of,3892,O
consecutive,3892,O
ovarian,3892,B-Modifier
cancer,3892,I-Modifier
cases,3892,O
.,3892,O
This,3893,O
is,3893,O
the,3893,O
first,3893,O
population-based,3893,O
ovarian,3893,B-Modifier
cancer,3893,I-Modifier
study,3893,O
reporting,3893,O
BRCA1,3893,O
alterations,3893,O
derived,3893,O
from,3893,O
a,3893,O
comprehensive,3893,O
screen,3893,O
of,3893,O
the,3893,O
entire,3893,O
coding,3893,O
region,3893,O
.,3893,O
One,3894,O
hundred,3894,O
and,3894,O
seven,3894,O
ovarian,3894,B-Modifier
cancer,3894,I-Modifier
cases,3894,O
were,3894,O
analyzed,3894,O
for,3894,O
BRCA1,3894,O
alterations,3894,O
using,3894,O
the,3894,O
RNase,3894,O
mismatch,3894,O
cleavage,3894,O
assay,3894,O
followed,3894,O
by,3894,O
direct,3894,O
sequencing,3894,O
.,3894,O
Two,3895,O
truncating,3895,O
mutations,3895,O
",",3895,O
962del4,3895,O
and,3895,O
3600del11,3895,O
",",3895,O
were,3895,O
identified,3895,O
.,3895,O
Both,3896,O
patients,3896,O
had,3896,O
a,3896,O
family,3896,O
history,3896,O
of,3896,O
breast,3896,O
or,3896,O
ovarian,3896,O
cancer,3896,O
.,3896,O
Several,3897,O
novel,3897,O
as,3897,O
well,3897,O
as,3897,O
previously,3897,O
reported,3897,O
uncharacterized,3897,O
variants,3897,O
were,3897,O
also,3897,O
identified,3897,O
",",3897,O
some,3897,O
of,3897,O
which,3897,O
were,3897,O
associated,3897,O
with,3897,O
a,3897,O
family,3897,O
history,3897,O
of,3897,O
cancer,3897,B-DiseaseClass
.,3897,O
The,3898,O
frequency,3898,O
distribution,3898,O
of,3898,O
common,3898,O
polymorphisms,3898,O
was,3898,O
determined,3898,O
in,3898,O
the,3898,O
91,3898,O
Caucasian,3898,O
cancer,3898,B-Modifier
cases,3898,O
in,3898,O
this,3898,O
series,3898,O
and,3898,O
24,3898,O
sister,3898,O
controls,3898,O
using,3898,O
allele-specific,3898,O
amplification,3898,O
.,3898,O
The,3899,O
rare,3899,O
form,3899,O
of,3899,O
the,3899,O
Q356R,3899,O
polymorphism,3899,O
was,3899,O
significantly,3899,O
(,3899,O
P,3899,O
=,3899,O
0,3899,O
.,3899,O
03,3900,O
),3900,O
associated,3900,O
with,3900,O
a,3900,O
family,3900,O
history,3900,O
of,3900,O
ovarian,3900,B-SpecificDisease
cancer,3900,I-SpecificDisease
",",3900,O
suggesting,3900,O
that,3900,O
this,3900,O
polymorphism,3900,O
may,3900,O
influence,3900,O
ovarian,3900,B-Modifier
cancer,3900,I-Modifier
risk,3900,O
.,3900,O
In,3901,O
summary,3901,O
",",3901,O
our,3901,O
data,3901,O
suggest,3901,O
a,3901,O
role,3901,O
for,3901,O
some,3901,O
uncharacterized,3901,O
variants,3901,O
and,3901,O
rare,3901,O
forms,3901,O
of,3901,O
polymorphisms,3901,O
in,3901,O
determining,3901,O
ovarian,3901,B-Modifier
cancer,3901,I-Modifier
risk,3901,O
",",3901,O
and,3901,O
highlight,3901,O
the,3901,O
necessity,3901,O
to,3901,O
screen,3901,O
for,3901,O
missense,3901,O
alterations,3901,O
as,3901,O
well,3901,O
as,3901,O
truncating,3901,O
mutations,3901,O
in,3901,O
this,3901,O
population,3901,O
.,3901,O
Adrenoleukodystrophy-related,3902,O
protein,3902,O
can,3902,O
compensate,3902,O
functionally,3902,O
for,3902,O
adrenoleukodystrophy,3902,B-SpecificDisease
protein,3902,I-SpecificDisease
deficiency,3902,I-SpecificDisease
(,3902,O
X-ALD,3902,B-SpecificDisease
),3902,O
:,3902,O
implications,3902,O
for,3902,O
therapy,3902,O
.,3902,O
Inherited,3903,B-DiseaseClass
defects,3903,I-DiseaseClass
in,3903,O
the,3903,O
peroxisomal,3903,O
ATP-binding,3903,O
cassette,3903,O
(,3903,O
ABC,3903,O
),3903,O
transporter,3903,O
adrenoleukodystrophy,3903,B-Modifier
protein,3903,O
(,3903,O
ALDP,3903,O
),3903,O
lead,3903,O
to,3903,O
the,3903,O
lethal,3903,O
peroxisomal,3903,B-DiseaseClass
disorder,3903,I-DiseaseClass
X-linked,3903,B-SpecificDisease
adrenoleukodystrophy,3903,I-SpecificDisease
(,3903,O
X-ALD,3903,B-SpecificDisease
),3903,O
",",3903,O
for,3903,O
which,3903,O
no,3903,O
efficient,3903,O
treatment,3903,O
has,3903,O
been,3903,O
established,3903,O
so,3903,O
far,3903,O
.,3903,O
Three,3904,O
other,3904,O
peroxisomal,3904,O
ABC,3904,O
transporters,3904,O
currently,3904,O
are,3904,O
known,3904,O
adrenoleukodystrophy-related,3904,O
protein,3904,O
(,3904,O
ALDRP,3904,O
),3904,O
",",3904,O
70,3904,O
kDa,3904,O
peroxisomal,3904,O
membrane,3904,O
protein,3904,O
(,3904,O
PMP70,3904,O
),3904,O
and,3904,O
PMP70-,3904,O
related,3904,O
protein,3904,O
.,3904,O
By,3905,O
using,3905,O
transient,3905,O
and,3905,O
stable,3905,O
overexpression,3905,O
of,3905,O
human,3905,O
cDNAs,3905,O
encoding,3905,O
ALDP,3905,O
and,3905,O
its,3905,O
closest,3905,O
relative,3905,O
ALDRP,3905,O
",",3905,O
we,3905,O
could,3905,O
restore,3905,O
the,3905,O
impaired,3905,O
peroxisomal,3905,O
beta-oxidation,3905,O
in,3905,O
fibroblasts,3905,O
of,3905,O
X-ALD,3905,B-Modifier
patients,3905,O
.,3905,O
The,3906,O
pathognomonic,3906,O
accumulation,3906,O
of,3906,O
very,3906,O
long,3906,O
chain,3906,O
fatty,3906,O
acids,3906,O
could,3906,O
also,3906,O
be,3906,O
prevented,3906,O
by,3906,O
overexpression,3906,O
of,3906,O
ALDRP,3906,O
in,3906,O
immortalized,3906,O
X-ALD,3906,O
cells,3906,O
.,3906,O
Immunofluorescence,3907,O
analysis,3907,O
demonstrated,3907,O
that,3907,O
the,3907,O
functional,3907,O
replacement,3907,O
of,3907,O
ALDP,3907,O
by,3907,O
ALDRP,3907,O
was,3907,O
not,3907,O
due,3907,O
to,3907,O
stabilization,3907,O
of,3907,O
the,3907,O
mutated,3907,O
ALDP,3907,O
itself,3907,O
.,3907,O
Moreover,3908,O
",",3908,O
we,3908,O
were,3908,O
able,3908,O
to,3908,O
restore,3908,O
the,3908,O
peroxisomal,3908,O
beta-oxidation,3908,O
defect,3908,O
in,3908,O
the,3908,O
liver,3908,O
of,3908,O
ALDP-deficient,3908,O
mice,3908,O
by,3908,O
stimulation,3908,O
of,3908,O
ALDRP,3908,O
and,3908,O
PMP70,3908,O
gene,3908,O
expression,3908,O
through,3908,O
a,3908,O
dietary,3908,O
treatment,3908,O
with,3908,O
the,3908,O
peroxisome,3908,O
proliferator,3908,O
fenofibrate,3908,O
.,3908,O
These,3909,O
results,3909,O
suggest,3909,O
that,3909,O
a,3909,O
correction,3909,O
of,3909,O
the,3909,O
biochemical,3909,O
defect,3909,O
in,3909,O
X-ALD,3909,B-SpecificDisease
could,3909,O
be,3909,O
possible,3909,O
by,3909,O
drug-induced,3909,O
overexpression,3909,O
or,3909,O
ectopic,3909,O
expression,3909,O
of,3909,O
ALDRP,3909,O
..,3909,O
Centrosome,3910,O
amplification,3910,O
and,3910,O
a,3910,O
defective,3910,O
G2-M,3910,O
cell,3910,O
cycle,3910,O
checkpoint,3910,O
induce,3910,O
genetic,3910,O
instability,3910,O
in,3910,O
BRCA1,3910,O
exon,3910,O
11,3910,O
isoform-deficient,3910,O
cells,3910,O
.,3910,O
Germline,3911,O
mutations,3911,O
of,3911,O
the,3911,O
Brca1,3911,O
tumor,3911,B-Modifier
suppressor,3911,O
gene,3911,O
predispose,3911,O
women,3911,O
to,3911,O
breast,3911,B-CompositeMention
and,3911,I-CompositeMention
ovarian,3911,I-CompositeMention
cancers,3911,I-CompositeMention
.,3911,O
To,3912,O
study,3912,O
mechanisms,3912,O
underlying,3912,O
BRCA1-related,3912,O
tumorigenesis,3912,O
",",3912,O
we,3912,O
derived,3912,O
mouse,3912,O
embryonic,3912,O
fibroblast,3912,O
cells,3912,O
carrying,3912,O
a,3912,O
targeted,3912,O
deletion,3912,O
of,3912,O
exon,3912,O
11,3912,O
of,3912,O
the,3912,O
Brca1,3912,O
gene,3912,O
.,3912,O
We,3913,O
show,3913,O
that,3913,O
the,3913,O
mutant,3913,O
cells,3913,O
maintain,3913,O
an,3913,O
intact,3913,O
G1-S,3913,O
cell,3913,O
cycle,3913,O
checkpoint,3913,O
and,3913,O
proliferate,3913,O
poorly,3913,O
.,3913,O
However,3914,O
",",3914,O
a,3914,O
defective,3914,O
G2-M,3914,O
checkpoint,3914,O
in,3914,O
these,3914,O
cells,3914,O
is,3914,O
accompanied,3914,O
by,3914,O
extensive,3914,O
chromosomal,3914,B-DiseaseClass
abnormalities,3914,I-DiseaseClass
.,3914,O
Mutant,3915,O
fibroblasts,3915,O
contain,3915,O
multiple,3915,O
",",3915,O
functional,3915,O
centrosomes,3915,O
",",3915,O
which,3915,O
lead,3915,O
to,3915,O
unequal,3915,O
chromosome,3915,O
segregation,3915,O
",",3915,O
abnormal,3915,O
nuclear,3915,O
division,3915,O
",",3915,O
and,3915,O
aneuploidy,3915,B-SpecificDisease
.,3915,O
These,3916,O
data,3916,O
uncover,3916,O
an,3916,O
essential,3916,O
role,3916,O
of,3916,O
BRCA1,3916,O
in,3916,O
maintaining,3916,O
genetic,3916,O
stability,3916,O
through,3916,O
the,3916,O
regulation,3916,O
of,3916,O
centrosome,3916,O
duplication,3916,O
and,3916,O
the,3916,O
G2-M,3916,O
checkpoint,3916,O
and,3916,O
provide,3916,O
a,3916,O
molecular,3916,O
basis,3916,O
for,3916,O
the,3916,O
role,3916,O
of,3916,O
BRCA1,3916,O
in,3916,O
tumorigenesis,3916,O
..,3916,O
Defective,3917,O
CD95/APO-1/Fas,3917,O
signal,3917,O
complex,3917,O
formation,3917,O
in,3917,O
the,3917,O
human,3917,O
autoimmune,3917,B-SpecificDisease
lymphoproliferative,3917,I-SpecificDisease
syndrome,3917,I-SpecificDisease
",",3917,I-SpecificDisease
type,3917,I-SpecificDisease
Ia,3917,I-SpecificDisease
.,3917,O
Heterozygous,3918,O
mutations,3918,O
in,3918,O
the,3918,O
CD95,3918,O
(,3918,O
APO-1/Fas,3918,O
),3918,O
receptor,3918,O
occur,3918,O
in,3918,O
most,3918,O
individuals,3918,O
with,3918,O
autoimmune,3918,B-SpecificDisease
lymphoproliferative,3918,I-SpecificDisease
syndrome,3918,I-SpecificDisease
(,3918,O
ALPS,3918,B-SpecificDisease
),3918,O
and,3918,O
dominantly,3918,O
interfere,3918,O
with,3918,O
apoptosis,3918,O
by,3918,O
an,3918,O
unknown,3918,O
mechanism,3918,O
.,3918,O
We,3919,O
show,3919,O
that,3919,O
local,3919,O
or,3919,O
global,3919,O
alterations,3919,O
in,3919,O
the,3919,O
structure,3919,O
of,3919,O
the,3919,O
cytoplasmic,3919,O
death,3919,O
domain,3919,O
from,3919,O
nine,3919,O
independent,3919,O
ALPS,3919,B-Modifier
CD95,3919,O
death-domain,3919,O
mutations,3919,O
result,3919,O
in,3919,O
a,3919,O
failure,3919,O
to,3919,O
bind,3919,O
the,3919,O
FADD/MORT1,3919,O
signaling,3919,O
protein,3919,O
.,3919,O
Despite,3920,O
heterozygosity,3920,O
for,3920,O
the,3920,O
abnormal,3920,O
allele,3920,O
",",3920,O
lymphocytes,3920,O
from,3920,O
ALPS,3920,B-Modifier
patients,3920,O
showed,3920,O
markedly,3920,O
decreased,3920,O
FADD,3920,O
association,3920,O
and,3920,O
a,3920,O
loss,3920,O
of,3920,O
caspase,3920,O
recruitment,3920,O
and,3920,O
activation,3920,O
after,3920,O
CD95,3920,O
crosslinking,3920,O
.,3920,O
These,3921,O
data,3921,O
suggest,3921,O
that,3921,O
intracytoplasmic,3921,O
CD95,3921,O
mutations,3921,O
in,3921,O
ALPS,3921,B-SpecificDisease
impair,3921,O
apoptosis,3921,O
chiefly,3921,O
by,3921,O
disrupting,3921,O
death-domain,3921,O
interactions,3921,O
with,3921,O
the,3921,O
signaling,3921,O
protein,3921,O
FADD/MORT1,3921,O
..,3921,O
Analysis,3922,O
of,3922,O
alkaptonuria,3922,B-Modifier
(,3922,O
AKU,3922,B-Modifier
),3922,O
mutations,3922,O
and,3922,O
polymorphisms,3922,O
reveals,3922,O
that,3922,O
the,3922,O
CCC,3922,O
sequence,3922,O
motif,3922,O
is,3922,O
a,3922,O
mutational,3922,O
hot,3922,O
spot,3922,O
in,3922,O
the,3922,O
homogentisate,3922,O
"1,2",3922,O
dioxygenase,3922,O
gene,3922,O
(,3922,O
HGO,3922,O
),3922,O
.,3922,O
We,3923,O
recently,3923,O
showed,3923,O
that,3923,O
alkaptonuria,3923,B-SpecificDisease
(,3923,O
AKU,3923,B-SpecificDisease
),3923,O
is,3923,O
caused,3923,O
by,3923,O
loss-of-function,3923,O
mutations,3923,O
in,3923,O
the,3923,O
homogentisate,3923,O
1,3923,O
",",3923,O
2,3923,O
dioxygenase,3923,O
gene,3923,O
(,3923,O
HGO,3923,O
),3923,O
.,3923,O
Herein,3924,O
we,3924,O
describe,3924,O
haplotype,3924,O
and,3924,O
mutational,3924,O
analyses,3924,O
of,3924,O
HGO,3924,O
in,3924,O
seven,3924,O
new,3924,O
AKU,3924,B-Modifier
pedigrees,3924,O
.,3924,O
These,3925,O
analyses,3925,O
identified,3925,O
two,3925,O
novel,3925,O
single-nucleotide,3925,O
polymorphisms,3925,O
(,3925,O
INV4,3925,O
+,3925,O
31A,3925,O
--,3925,O
>,3925,O
G,3925,O
and,3925,O
INV11,3925,O
+,3925,O
18A,3925,O
--,3925,O
>,3925,O
G,3925,O
),3925,O
and,3925,O
six,3925,O
novel,3925,O
AKU,3925,B-Modifier
mutations,3925,O
(,3925,O
INV1-1G,3925,O
--,3925,O
>,3925,O
A,3925,O
",",3925,O
W60G,3925,O
",",3925,O
Y62C,3925,O
",",3925,O
A122D,3925,O
",",3925,O
P230T,3925,O
",",3925,O
and,3925,O
D291E,3925,O
),3925,O
",",3925,O
which,3925,O
further,3925,O
illustrates,3925,O
the,3925,O
remarkable,3925,O
allelic,3925,O
heterogeneity,3925,O
found,3925,O
in,3925,O
AKU,3925,B-SpecificDisease
.,3925,O
Reexamination,3926,O
of,3926,O
all,3926,O
29,3926,O
mutations,3926,O
and,3926,O
polymorphisms,3926,O
thus,3926,O
far,3926,O
described,3926,O
in,3926,O
HGO,3926,O
shows,3926,O
that,3926,O
these,3926,O
nucleotide,3926,O
changes,3926,O
are,3926,O
not,3926,O
randomly,3926,O
distributed,3926,O
;,3926,O
the,3926,O
CCC,3926,O
sequence,3926,O
motif,3926,O
and,3926,O
its,3926,O
inverted,3926,O
complement,3926,O
",",3926,O
GGG,3926,O
",",3926,O
are,3926,O
preferentially,3926,O
mutated,3926,O
.,3926,O
These,3927,O
analyses,3927,O
also,3927,O
demonstrated,3927,O
that,3927,O
the,3927,O
nucleotide,3927,O
substitutions,3927,O
in,3927,O
HGO,3927,O
do,3927,O
not,3927,O
involve,3927,O
CpG,3927,O
dinucleotides,3927,O
",",3927,O
which,3927,O
illustrates,3927,O
important,3927,O
differences,3927,O
between,3927,O
HGO,3927,O
and,3927,O
other,3927,O
genes,3927,O
for,3927,O
the,3927,O
occurrence,3927,O
of,3927,O
mutation,3927,O
at,3927,O
specific,3927,O
short-sequence,3927,O
motifs,3927,O
.,3927,O
Because,3928,O
the,3928,O
CCC,3928,O
sequence,3928,O
motifs,3928,O
comprise,3928,O
a,3928,O
significant,3928,O
proportion,3928,O
(,3928,O
34,3928,O
.,3928,O
5,3929,O
%,3929,O
),3929,O
of,3929,O
all,3929,O
mutated,3929,O
bases,3929,O
that,3929,O
have,3929,O
been,3929,O
observed,3929,O
in,3929,O
HGO,3929,O
",",3929,O
we,3929,O
conclude,3929,O
that,3929,O
the,3929,O
CCC,3929,O
triplet,3929,O
is,3929,O
a,3929,O
mutational,3929,O
hot,3929,O
spot,3929,O
in,3929,O
HGO,3929,O
.,3929,O
Fabry,3930,B-SpecificDisease
disease,3930,I-SpecificDisease
:,3930,O
identification,3930,O
of,3930,O
novel,3930,O
alpha-galactosidase,3930,O
A,3930,O
mutations,3930,O
and,3930,O
molecular,3930,O
carrier,3930,O
detection,3930,O
by,3930,O
use,3930,O
of,3930,O
fluorescent,3930,O
chemical,3930,O
cleavage,3930,O
of,3930,O
mismatches,3930,O
.,3930,O
Fabry,3931,B-SpecificDisease
disease,3931,I-SpecificDisease
(,3931,O
FD,3931,B-SpecificDisease
),3931,O
(,3931,O
angiokeratoma,3931,B-SpecificDisease
corporis,3931,I-SpecificDisease
diffusum,3931,I-SpecificDisease
),3931,O
is,3931,O
an,3931,O
X-linked,3931,B-DiseaseClass
inborn,3931,I-DiseaseClass
error,3931,I-DiseaseClass
of,3931,I-DiseaseClass
glycosphingolipid,3931,I-DiseaseClass
metabolism,3931,I-DiseaseClass
caused,3931,O
by,3931,O
defects,3931,O
in,3931,O
the,3931,O
lysosomal,3931,O
alpha-galactosidase,3931,O
A,3931,O
gene,3931,O
(,3931,O
GLA,3931,O
),3931,O
.,3931,O
The,3932,O
enzymatic,3932,O
defect,3932,O
leads,3932,O
to,3932,O
the,3932,O
systemic,3932,O
accumulation,3932,O
of,3932,O
neutral,3932,O
glycosphingolipids,3932,O
with,3932,O
terminal,3932,O
alpha-galactosyl,3932,O
moieties,3932,O
.,3932,O
Clinically,3933,O
",",3933,O
affected,3933,O
hemizygous,3933,O
males,3933,O
have,3933,O
angiokeratoma,3933,B-SpecificDisease
",",3933,O
severe,3933,B-SpecificDisease
acroparesthesia,3933,I-SpecificDisease
",",3933,O
renal,3933,B-SpecificDisease
failure,3933,I-SpecificDisease
",",3933,O
and,3933,O
vasculopathy,3933,B-CompositeMention
of,3933,I-CompositeMention
the,3933,I-CompositeMention
heart,3933,I-CompositeMention
and,3933,I-CompositeMention
brain,3933,I-CompositeMention
.,3933,O
While,3934,O
demonstration,3934,O
of,3934,O
alpha-galactosidase,3934,B-SpecificDisease
deficiency,3934,I-SpecificDisease
in,3934,O
leukocytes,3934,O
is,3934,O
diagnostic,3934,O
in,3934,O
affected,3934,O
males,3934,O
",",3934,O
enzymatic,3934,O
detection,3934,O
of,3934,O
female,3934,O
carriers,3934,O
is,3934,O
often,3934,O
inconclusive,3934,O
",",3934,O
due,3934,O
to,3934,O
random,3934,O
X-chromosomal,3934,O
inactivation,3934,O
",",3934,O
underlining,3934,O
the,3934,O
need,3934,O
of,3934,O
molecular,3934,O
investigations,3934,O
for,3934,O
accurate,3934,O
genetic,3934,O
counseling,3934,O
.,3934,O
By,3935,O
use,3935,O
of,3935,O
chemical,3935,O
cleavage,3935,O
of,3935,O
mismatches,3935,O
adapted,3935,O
to,3935,O
fluorescence-based,3935,O
detection,3935,O
systems,3935,O
",",3935,O
we,3935,O
have,3935,O
characterized,3935,O
the,3935,O
mutations,3935,O
underlying,3935,O
alpha-Gal,3935,B-SpecificDisease
A,3935,I-SpecificDisease
deficiency,3935,I-SpecificDisease
in,3935,O
16,3935,O
individuals,3935,O
from,3935,O
six,3935,O
unrelated,3935,O
families,3935,O
with,3935,O
FD,3935,B-SpecificDisease
.,3935,O
The,3936,O
mutational,3936,O
spectrum,3936,O
included,3936,O
five,3936,O
missense,3936,O
mutations,3936,O
(,3936,O
C202W,3936,O
",",3936,O
C223G,3936,O
",",3936,O
N224D,3936,O
",",3936,O
R301Q,3936,O
",",3936,O
and,3936,O
Q327K,3936,O
),3936,O
and,3936,O
one,3936,O
splice-site,3936,O
mutation,3936,O
[,3936,O
IVS3,3936,O
G,3936,O
(,3936,O
-1,3936,O
),3936,O
--,3936,O
>,3936,O
C,3936,O
],3936,O
.,3936,O
Studies,3937,O
at,3937,O
the,3937,O
mRNA,3937,O
level,3937,O
showed,3937,O
that,3937,O
the,3937,O
latter,3937,O
led,3937,O
to,3937,O
altered,3937,O
pre-mRNA,3937,O
splicing,3937,O
with,3937,O
consequent,3937,O
alteration,3937,O
of,3937,O
the,3937,O
mRNA,3937,O
translational,3937,O
reading,3937,O
frame,3937,O
and,3937,O
generation,3937,O
of,3937,O
a,3937,O
premature,3937,O
termination,3937,O
codon,3937,O
of,3937,O
translation,3937,O
.,3937,O
By,3938,O
use,3938,O
of,3938,O
this,3938,O
strategy,3938,O
",",3938,O
carrier,3938,O
status,3938,O
was,3938,O
accurately,3938,O
assessed,3938,O
in,3938,O
all,3938,O
seven,3938,O
at-risk,3938,O
females,3938,O
tested,3938,O
",",3938,O
whereas,3938,O
enzymatic,3938,O
dosages,3938,O
failed,3938,O
to,3938,O
diagnose,3938,O
or,3938,O
exclude,3938,O
heterozygosity,3938,O
..,3938,O
Prenatal,3939,O
diagnosis,3939,O
by,3939,O
FISH,3939,O
in,3939,O
a,3939,O
family,3939,O
with,3939,O
Pelizaeus-Merzbacher,3939,B-SpecificDisease
disease,3939,I-SpecificDisease
caused,3939,O
by,3939,O
duplication,3939,O
of,3939,O
PLP,3939,O
gene,3939,O
.,3939,O
A,3940,O
diagnosis,3940,O
of,3940,O
Pelizaeus-Merzbacher,3940,B-SpecificDisease
disease,3940,I-SpecificDisease
(,3940,O
MIM,3940,O
312080,3940,O
),3940,O
was,3940,O
made,3940,O
in,3940,O
a,3940,O
young,3940,O
boy,3940,O
.,3940,O
No,3941,O
mutation,3941,O
in,3941,O
the,3941,O
coding,3941,O
region,3941,O
of,3941,O
the,3941,O
proteolipid,3941,O
protein,3941,O
(,3941,O
PLP,3941,O
),3941,O
gene,3941,O
had,3941,O
been,3941,O
found,3941,O
.,3941,O
The,3942,O
boys,3942,O
maternal,3942,O
aunt,3942,O
came,3942,O
for,3942,O
prenatal,3942,O
diagnosis,3942,O
when,3942,O
16,3942,O
+,3942,O
weeks,3942,O
pregnant,3942,O
and,3942,O
carrying,3942,O
a,3942,O
male,3942,O
fetus,3942,O
.,3942,O
Samples,3943,O
were,3943,O
tested,3943,O
for,3943,O
duplication,3943,O
of,3943,O
the,3943,O
PLP,3943,O
gene,3943,O
",",3943,O
by,3943,O
interphase,3943,O
FISH,3943,O
",",3943,O
in,3943,O
lymphocyte,3943,O
preparations,3943,O
from,3943,O
the,3943,O
proband,3943,O
",",3943,O
his,3943,O
aunt,3943,O
and,3943,O
an,3943,O
amniotic,3943,O
fluid,3943,O
cell,3943,O
preparation,3943,O
from,3943,O
the,3943,O
fetus,3943,O
.,3943,O
The,3944,O
proband,3944,O
was,3944,O
found,3944,O
to,3944,O
carry,3944,O
the,3944,O
duplication,3944,O
",",3944,O
thus,3944,O
confirming,3944,O
the,3944,O
diagnosis,3944,O
of,3944,O
Pelizaeus,3944,B-SpecificDisease
Merzbacher,3944,I-SpecificDisease
disease,3944,I-SpecificDisease
",",3944,O
but,3944,O
neither,3944,O
the,3944,O
aunt,3944,O
nor,3944,O
the,3944,O
fetus,3944,O
carried,3944,O
a,3944,O
duplication,3944,O
..,3944,O
Dominant,3945,O
negative,3945,O
effect,3945,O
of,3945,O
the,3945,O
APC1309,3945,O
mutation,3945,O
:,3945,O
a,3945,O
possible,3945,O
explanation,3945,O
for,3945,O
genotype-phenotype,3945,O
correlations,3945,O
in,3945,O
familial,3945,B-SpecificDisease
adenomatous,3945,I-SpecificDisease
polyposis,3945,I-SpecificDisease
.,3945,O
Inactivation,3946,O
of,3946,O
the,3946,O
adenomatous,3946,B-Modifier
polyposis,3946,I-Modifier
coli,3946,I-Modifier
(,3946,O
APC,3946,B-Modifier
),3946,O
gene,3946,O
product,3946,O
initiates,3946,O
colorectal,3946,O
tumorigenesis,3946,O
.,3946,O
Patients,3947,O
with,3947,O
familial,3947,B-SpecificDisease
APC,3947,I-SpecificDisease
(,3947,O
FAP,3947,B-SpecificDisease
),3947,O
carry,3947,O
germ-line,3947,O
mutations,3947,O
in,3947,O
the,3947,O
APC,3947,B-Modifier
gene,3947,O
and,3947,O
develop,3947,O
multiple,3947,O
colorectal,3947,B-SpecificDisease
adenomas,3947,I-SpecificDisease
and,3947,O
subsequent,3947,O
carcinomas,3947,B-DiseaseClass
early,3947,O
in,3947,O
life,3947,O
.,3947,O
The,3948,O
severity,3948,O
of,3948,O
the,3948,O
disease,3948,O
correlates,3948,O
with,3948,O
the,3948,O
position,3948,O
of,3948,O
the,3948,O
inherited,3948,O
APC,3948,B-Modifier
mutation,3948,O
(,3948,O
genotype-phenotype,3948,O
correlation,3948,O
),3948,O
.,3948,O
Together,3949,O
with,3949,O
the,3949,O
fact,3949,O
that,3949,O
both,3949,O
germ-line,3949,O
and,3949,O
sporadic,3949,O
APC,3949,B-Modifier
mutations,3949,O
cluster,3949,O
in,3949,O
the,3949,O
central,3949,O
region,3949,O
of,3949,O
the,3949,O
APC,3949,B-Modifier
gene,3949,O
",",3949,O
this,3949,O
points,3949,O
to,3949,O
a,3949,O
dominant,3949,O
negative,3949,O
effect,3949,O
of,3949,O
certain,3949,O
APC,3949,B-Modifier
mutants,3949,O
.,3949,O
Loss,3950,O
of,3950,O
APC,3950,B-Modifier
function,3950,O
was,3950,O
recently,3950,O
shown,3950,O
to,3950,O
result,3950,O
in,3950,O
enhanced,3950,O
beta-catenin-/Tcf-mediated,3950,O
transcription,3950,O
in,3950,O
colon,3950,O
epithelial,3950,O
cells,3950,O
.,3950,O
Here,3951,O
",",3951,O
we,3951,O
provide,3951,O
experimental,3951,O
evidence,3951,O
for,3951,O
a,3951,O
dominant,3951,O
negative,3951,O
effect,3951,O
of,3951,O
APC,3951,B-Modifier
gene,3951,O
products,3951,O
associated,3951,O
with,3951,O
severe,3951,O
polyposis,3951,B-SpecificDisease
.,3951,O
Wild-type,3952,O
APC,3952,B-Modifier
activity,3952,O
in,3952,O
beta-catenin-/Tcf-mediated,3952,O
transcription,3952,O
was,3952,O
strongly,3952,O
inhibited,3952,O
by,3952,O
a,3952,O
mutant,3952,O
APC,3952,B-Modifier
that,3952,O
is,3952,O
truncated,3952,O
at,3952,O
codon,3952,O
1309,3952,O
.,3952,O
In,3953,O
contrast,3953,O
",",3953,O
mutant,3953,O
APC,3953,B-Modifier
gene,3953,O
products,3953,O
that,3953,O
are,3953,O
associated,3953,O
with,3953,O
attenuated,3953,B-SpecificDisease
polyposis,3953,I-SpecificDisease
(,3953,O
codon,3953,O
386,3953,O
or,3953,O
1465,3953,O
),3953,O
interfered,3953,O
only,3953,O
weakly,3953,O
with,3953,O
wild-type,3953,O
APC,3953,B-Modifier
activity,3953,O
.,3953,O
These,3954,O
results,3954,O
suggest,3954,O
a,3954,O
molecular,3954,O
explanation,3954,O
for,3954,O
the,3954,O
genotype-phenotype,3954,O
correlation,3954,O
in,3954,O
FAP,3954,B-Modifier
patients,3954,O
and,3954,O
support,3954,O
the,3954,O
idea,3954,O
that,3954,O
colorectal,3954,B-Modifier
tumor,3954,I-Modifier
growth,3954,O
might,3954,O
be,3954,O
",",3954,O
in,3954,O
part,3954,O
",",3954,O
driven,3954,O
by,3954,O
selection,3954,O
for,3954,O
a,3954,O
mutation,3954,O
in,3954,O
the,3954,O
mutation,3954,O
cluster,3954,O
region,3954,O
..,3954,O
BRCA1,3955,O
interacts,3955,O
with,3955,O
components,3955,O
of,3955,O
the,3955,O
histone,3955,O
deacetylase,3955,O
complex,3955,O
.,3955,O
Germ-line,3956,O
mutations,3956,O
in,3956,O
the,3956,O
BRCA1,3956,O
tumor-suppressor,3956,O
gene,3956,O
are,3956,O
associated,3956,O
with,3956,O
an,3956,O
increased,3956,O
susceptibility,3956,O
to,3956,O
breast,3956,B-CompositeMention
and,3956,I-CompositeMention
ovarian,3956,I-CompositeMention
cancer,3956,I-CompositeMention
.,3956,O
BRCA1,3957,O
contains,3957,O
a,3957,O
carboxyl-terminal,3957,O
domain,3957,O
(,3957,O
BRCT,3957,O
),3957,O
that,3957,O
is,3957,O
shared,3957,O
with,3957,O
several,3957,O
other,3957,O
proteins,3957,O
involved,3957,O
in,3957,O
maintaining,3957,O
genome,3957,O
integrity,3957,O
.,3957,O
In,3958,O
an,3958,O
effort,3958,O
to,3958,O
understand,3958,O
the,3958,O
function,3958,O
of,3958,O
BRCA1,3958,O
",",3958,O
we,3958,O
sought,3958,O
to,3958,O
isolate,3958,O
proteins,3958,O
that,3958,O
interact,3958,O
with,3958,O
the,3958,O
BRCT,3958,O
domain,3958,O
.,3958,O
Purified,3959,O
BRCT,3959,O
polypeptide,3959,O
was,3959,O
used,3959,O
as,3959,O
a,3959,O
probe,3959,O
to,3959,O
screen,3959,O
a,3959,O
human,3959,O
placenta,3959,O
cDNA,3959,O
expression,3959,O
library,3959,O
by,3959,O
Far,3959,O
Western,3959,O
analysis,3959,O
.,3959,O
Here,3960,O
we,3960,O
report,3960,O
that,3960,O
BRCA1,3960,O
interacts,3960,O
in,3960,O
vivo,3960,O
and,3960,O
in,3960,O
vitro,3960,O
with,3960,O
the,3960,O
Rb-binding,3960,O
proteins,3960,O
",",3960,O
RbAp46,3960,O
and,3960,O
RbAp48,3960,O
",",3960,O
as,3960,O
well,3960,O
as,3960,O
with,3960,O
Rb,3960,O
.,3960,O
Moreover,3961,O
",",3961,O
the,3961,O
BRCT,3961,O
domain,3961,O
associates,3961,O
with,3961,O
the,3961,O
histone,3961,O
deacetylases,3961,O
HDAC1,3961,O
and,3961,O
HDAC2,3961,O
.,3961,O
These,3962,O
results,3962,O
demonstrate,3962,O
that,3962,O
BRCA1,3962,O
interacts,3962,O
with,3962,O
components,3962,O
of,3962,O
the,3962,O
histone,3962,O
deacetylase,3962,O
complex,3962,O
",",3962,O
and,3962,O
therefore,3962,O
may,3962,O
explain,3962,O
the,3962,O
involvement,3962,O
of,3962,O
BRCA1,3962,O
in,3962,O
multiple,3962,O
processes,3962,O
such,3962,O
as,3962,O
transcription,3962,O
",",3962,O
DNA,3962,O
repair,3962,O
",",3962,O
and,3962,O
recombination,3962,O
..,3962,O
Changes,3963,O
at,3963,O
P183,3963,O
of,3963,O
emerin,3963,O
weaken,3963,O
its,3963,O
protein-protein,3963,O
interactions,3963,O
resulting,3963,O
in,3963,O
X-linked,3963,B-SpecificDisease
Emery-Dreifuss,3963,I-SpecificDisease
muscular,3963,I-SpecificDisease
dystrophy,3963,I-SpecificDisease
.,3963,O
Emery-Dreifuss,3964,B-SpecificDisease
muscular,3964,I-SpecificDisease
dystrophy,3964,I-SpecificDisease
(,3964,O
EDMD,3964,B-SpecificDisease
),3964,O
is,3964,O
an,3964,O
X-linked,3964,B-DiseaseClass
recessive,3964,I-DiseaseClass
muscular,3964,I-DiseaseClass
dystrophy,3964,I-DiseaseClass
characterized,3964,O
by,3964,O
early,3964,O
contractures,3964,B-CompositeMention
of,3964,I-CompositeMention
the,3964,I-CompositeMention
elbows,3964,I-CompositeMention
",",3964,I-CompositeMention
Achilles,3964,I-CompositeMention
tendons,3964,I-CompositeMention
and,3964,I-CompositeMention
spine,3964,I-CompositeMention
",",3964,O
slowly,3964,O
progressive,3964,O
muscle,3964,B-DiseaseClass
wasting,3964,I-DiseaseClass
and,3964,O
weakness,3964,B-DiseaseClass
",",3964,O
and,3964,O
cardiomyopathy,3964,B-SpecificDisease
associated,3964,O
with,3964,O
cardiac,3964,B-SpecificDisease
conduction,3964,I-SpecificDisease
defects,3964,I-SpecificDisease
.,3964,O
The,3965,O
emerin,3965,O
gene,3965,O
has,3965,O
been,3965,O
mapped,3965,O
to,3965,O
Xq28,3965,O
and,3965,O
encodes,3965,O
a,3965,O
34-kDa,3965,O
serine-rich,3965,O
protein,3965,O
",",3965,O
emerin,3965,O
",",3965,O
which,3965,O
has,3965,O
been,3965,O
localized,3965,O
to,3965,O
the,3965,O
nuclear,3965,O
envelope,3965,O
in,3965,O
a,3965,O
wide,3965,O
variety,3965,O
of,3965,O
tissues,3965,O
",",3965,O
including,3965,O
skeletal,3965,O
and,3965,O
cardiac,3965,O
muscle,3965,O
.,3965,O
Mutations,3966,O
spanning,3966,O
the,3966,O
emerin,3966,O
gene,3966,O
have,3966,O
been,3966,O
identified,3966,O
in,3966,O
patients,3966,O
with,3966,O
EDMD,3966,B-SpecificDisease
.,3966,O
We,3967,O
present,3967,O
here,3967,O
the,3967,O
effect,3967,O
",",3967,O
on,3967,O
emerin,3967,O
protein,3967,O
expression,3967,O
",",3967,O
of,3967,O
two,3967,O
missense,3967,O
mutations,3967,O
identified,3967,O
in,3967,O
unrelated,3967,O
EDMD,3967,B-Modifier
patients,3967,O
.,3967,O
These,3968,O
alterations,3968,O
predict,3968,O
the,3968,O
replacement,3968,O
of,3968,O
a,3968,O
proline,3968,O
residue,3968,O
at,3968,O
position,3968,O
183,3968,O
with,3968,O
either,3968,O
a,3968,O
histidine,3968,O
or,3968,O
a,3968,O
threonine,3968,O
.,3968,O
Biochemical,3969,O
analysis,3969,O
has,3969,O
demonstrated,3969,O
that,3969,O
the,3969,O
mobility,3969,O
and,3969,O
expression,3969,O
levels,3969,O
of,3969,O
the,3969,O
mutant,3969,O
forms,3969,O
of,3969,O
emerin,3969,O
are,3969,O
indistinguishable,3969,O
from,3969,O
that,3969,O
of,3969,O
wild-type,3969,O
emerin,3969,O
",",3969,O
but,3969,O
that,3969,O
they,3969,O
have,3969,O
weakened,3969,O
interactions,3969,O
with,3969,O
nuclear,3969,O
lamina,3969,O
components,3969,O
.,3969,O
In,3970,O
comparison,3970,O
with,3970,O
the,3970,O
usual,3970,O
EDMD,3970,B-Modifier
phenotype,3970,O
",",3970,O
patients,3970,O
with,3970,O
P183,3970,O
missense,3970,O
mutations,3970,O
have,3970,O
a,3970,O
later,3970,O
age,3970,O
at,3970,O
onset,3970,O
of,3970,O
first,3970,O
symptoms,3970,O
",",3970,O
elbow,3970,B-SpecificDisease
contractures,3970,I-SpecificDisease
",",3970,O
ankle,3970,B-SpecificDisease
contractures,3970,I-SpecificDisease
",",3970,O
upper,3970,B-SpecificDisease
limb,3970,I-SpecificDisease
weakness,3970,I-SpecificDisease
and,3970,O
lower,3970,B-SpecificDisease
limb,3970,I-SpecificDisease
weakness,3970,I-SpecificDisease
",",3970,O
but,3970,O
there,3970,O
is,3970,O
no,3970,O
difference,3970,O
for,3970,O
the,3970,O
age,3970,O
at,3970,O
onset,3970,O
of,3970,O
cardiac,3970,B-DiseaseClass
involvement,3970,I-DiseaseClass
.,3970,O
This,3971,O
is,3971,O
the,3971,O
first,3971,O
report,3971,O
of,3971,O
protein,3971,O
studies,3971,O
on,3971,O
patients,3971,O
with,3971,O
missense,3971,O
mutations,3971,O
resulting,3971,O
in,3971,O
the,3971,O
clinical,3971,O
features,3971,O
of,3971,O
EDMD,3971,B-SpecificDisease
.,3971,O
These,3972,O
studies,3972,O
demonstrate,3972,O
the,3972,O
importance,3972,O
of,3972,O
proline,3972,O
183,3972,O
for,3972,O
the,3972,O
proper,3972,O
structure/function,3972,O
of,3972,O
emerin,3972,O
..,3972,O
Microdeletions,3973,O
at,3973,O
chromosome,3973,O
bands,3973,O
1q32-q41,3973,O
as,3973,O
a,3973,O
cause,3973,O
of,3973,O
Van,3973,B-SpecificDisease
der,3973,I-SpecificDisease
Woude,3973,I-SpecificDisease
syndrome,3973,I-SpecificDisease
.,3973,O
Van,3974,B-SpecificDisease
der,3974,I-SpecificDisease
Woude,3974,I-SpecificDisease
syndrome,3974,I-SpecificDisease
(,3974,O
VWS,3974,B-SpecificDisease
),3974,O
is,3974,O
an,3974,O
autosomal,3974,B-DiseaseClass
dominant,3974,I-DiseaseClass
disorder,3974,I-DiseaseClass
comprising,3974,O
cleft,3974,B-SpecificDisease
lip,3974,I-SpecificDisease
and/or,3974,O
cleft,3974,B-SpecificDisease
palate,3974,I-SpecificDisease
and,3974,O
lip,3974,B-SpecificDisease
pits,3974,I-SpecificDisease
.,3974,O
We,3975,O
reported,3975,O
previously,3975,O
a,3975,O
family,3975,O
whose,3975,O
underlying,3975,O
mutation,3975,O
is,3975,O
a,3975,O
500-800,3975,O
kb,3975,O
deletion,3975,O
localized,3975,O
to,3975,O
chromosome,3975,O
bands,3975,O
1q32-q41,3975,O
[,3975,O
Sander,3975,O
et,3975,O
al.,3975,O
",",3975,O
1994,3975,O
Hum,3975,O
Mol,3975,O
Genet,3975,O
3,3975,O
576-578,3975,O
],3975,O
.,3975,O
Along,3976,O
with,3976,O
cleft,3976,O
lip/palate,3976,O
and,3976,O
lip,3976,B-SpecificDisease
pits,3976,I-SpecificDisease
",",3976,O
affected,3976,O
relatives,3976,O
exhibit,3976,O
developmental,3976,B-DiseaseClass
delays,3976,I-DiseaseClass
",",3976,O
suggesting,3976,O
that,3976,O
the,3976,O
function,3976,O
of,3976,O
a,3976,O
gene,3976,O
nearby,3976,O
may,3976,O
also,3976,O
be,3976,O
disrupted,3976,O
.,3976,O
To,3977,O
further,3977,O
localize,3977,O
the,3977,O
VWS,3977,B-Modifier
gene,3977,O
we,3977,O
searched,3977,O
for,3977,O
other,3977,O
deletions,3977,O
that,3977,O
cause,3977,O
VWS,3977,B-SpecificDisease
.,3977,O
An,3978,O
allele,3978,O
loss,3978,O
assay,3978,O
was,3978,O
performed,3978,O
using,3978,O
a,3978,O
novel,3978,O
highly,3978,O
polymorphic,3978,O
marker,3978,O
",",3978,O
D1S3753,3978,O
.,3978,O
From,3979,O
a,3979,O
panel,3979,O
of,3979,O
37,3979,O
unrelated,3979,O
individuals,3979,O
",",3979,O
we,3979,O
detected,3979,O
an,3979,O
allele,3979,O
loss,3979,O
in,3979,O
one,3979,O
family,3979,O
",",3979,O
indicating,3979,O
the,3979,O
presence,3979,O
of,3979,O
a,3979,O
deletion,3979,O
.,3979,O
In,3980,O
this,3980,O
family,3980,O
",",3980,O
the,3980,O
phenotype,3980,O
in,3980,O
three,3980,O
generations,3980,O
of,3980,O
affected,3980,O
individuals,3980,O
was,3980,O
confined,3980,O
to,3980,O
the,3980,O
cardinal,3980,O
signs,3980,O
of,3980,O
VWS,3980,B-SpecificDisease
.,3980,O
Surprisingly,3981,O
",",3981,O
mapping,3981,O
of,3981,O
the,3981,O
new,3981,O
deletion,3981,O
showed,3981,O
that,3981,O
it,3981,O
extended,3981,O
0,3981,O
.,3981,O
2-1,3982,O
Mb,3982,O
beyond,3982,O
the,3982,O
proximal,3982,O
breakpoint,3982,O
for,3982,O
the,3982,O
deletion,3982,O
described,3982,O
previously,3982,O
.,3982,O
No,3983,O
deletions,3983,O
were,3983,O
detected,3983,O
in,3983,O
seven,3983,O
cases,3983,O
of,3983,O
popliteal,3983,B-SpecificDisease
pterygia,3983,I-SpecificDisease
syndrome,3983,I-SpecificDisease
",",3983,O
76,3983,O
cases,3983,O
of,3983,O
mixed,3983,O
syndromic,3983,O
forms,3983,O
of,3983,O
cleft,3983,O
lip,3983,O
and,3983,O
palate,3983,O
",",3983,O
and,3983,O
178,3983,O
cases,3983,O
of,3983,O
nonsyndromic,3983,B-CompositeMention
cleft,3983,I-CompositeMention
lip,3983,I-CompositeMention
and,3983,I-CompositeMention
palate,3983,I-CompositeMention
.,3983,O
Splicing,3984,O
defects,3984,O
in,3984,O
the,3984,O
ataxia-telangiectasia,3984,B-Modifier
gene,3984,O
",",3984,O
ATM,3984,O
:,3984,O
underlying,3984,O
mutations,3984,O
and,3984,O
consequences,3984,O
.,3984,O
Mutations,3985,O
resulting,3985,O
in,3985,O
defective,3985,O
splicing,3985,O
constitute,3985,O
a,3985,O
significant,3985,O
proportion,3985,O
(,3985,O
30/62,3985,O
[,3985,O
48,3985,O
%,3985,O
],3985,O
),3985,O
of,3985,O
a,3985,O
new,3985,O
series,3985,O
of,3985,O
mutations,3985,O
in,3985,O
the,3985,O
ATM,3985,O
gene,3985,O
in,3985,O
patients,3985,O
with,3985,O
ataxia-telangiectasia,3985,B-SpecificDisease
(,3985,O
AT,3985,B-SpecificDisease
),3985,O
that,3985,O
were,3985,O
detected,3985,O
by,3985,O
the,3985,O
protein-truncation,3985,O
assay,3985,O
followed,3985,O
by,3985,O
sequence,3985,O
analysis,3985,O
of,3985,O
genomic,3985,O
DNA,3985,O
.,3985,O
Fewer,3986,O
than,3986,O
half,3986,O
of,3986,O
the,3986,O
splicing,3986,O
mutations,3986,O
involved,3986,O
the,3986,O
canonical,3986,O
AG,3986,O
splice-acceptor,3986,O
site,3986,O
or,3986,O
GT,3986,O
splice-donor,3986,O
site,3986,O
.,3986,O
A,3987,O
higher,3987,O
percentage,3987,O
of,3987,O
mutations,3987,O
occurred,3987,O
at,3987,O
less,3987,O
stringently,3987,O
conserved,3987,O
sites,3987,O
",",3987,O
including,3987,O
silent,3987,O
mutations,3987,O
of,3987,O
the,3987,O
last,3987,O
nucleotide,3987,O
of,3987,O
exons,3987,O
",",3987,O
mutations,3987,O
in,3987,O
nucleotides,3987,O
other,3987,O
than,3987,O
the,3987,O
conserved,3987,O
AG,3987,O
and,3987,O
GT,3987,O
in,3987,O
the,3987,O
consensus,3987,O
splice,3987,O
sites,3987,O
",",3987,O
and,3987,O
creation,3987,O
of,3987,O
splice-acceptor,3987,O
or,3987,O
splice-donor,3987,O
sites,3987,O
in,3987,O
either,3987,O
introns,3987,O
or,3987,O
exons,3987,O
.,3987,O
These,3988,O
splicing,3988,O
mutations,3988,O
led,3988,O
to,3988,O
a,3988,O
variety,3988,O
of,3988,O
consequences,3988,O
",",3988,O
including,3988,O
exon,3988,O
skipping,3988,O
and,3988,O
",",3988,O
to,3988,O
a,3988,O
lesser,3988,O
degree,3988,O
",",3988,O
intron,3988,O
retention,3988,O
",",3988,O
activation,3988,O
of,3988,O
cryptic,3988,O
splice,3988,O
sites,3988,O
",",3988,O
or,3988,O
creation,3988,O
of,3988,O
new,3988,O
splice,3988,O
sites,3988,O
.,3988,O
In,3989,O
addition,3989,O
",",3989,O
5,3989,O
of,3989,O
12,3989,O
nonsense,3989,O
mutations,3989,O
and,3989,O
1,3989,O
missense,3989,O
mutation,3989,O
were,3989,O
associated,3989,O
with,3989,O
deletion,3989,O
in,3989,O
the,3989,O
cDNA,3989,O
of,3989,O
the,3989,O
exons,3989,O
in,3989,O
which,3989,O
the,3989,O
mutations,3989,O
occurred,3989,O
.,3989,O
No,3990,O
ATM,3990,O
protein,3990,O
was,3990,O
detected,3990,O
by,3990,O
western,3990,O
blotting,3990,O
in,3990,O
any,3990,O
AT,3990,B-Modifier
cell,3990,O
line,3990,O
in,3990,O
which,3990,O
splicing,3990,O
mutations,3990,O
were,3990,O
identified,3990,O
.,3990,O
Several,3991,O
cases,3991,O
of,3991,O
exon,3991,O
skipping,3991,O
in,3991,O
both,3991,O
normal,3991,O
controls,3991,O
and,3991,O
patients,3991,O
for,3991,O
whom,3991,O
no,3991,O
underlying,3991,O
defect,3991,O
could,3991,O
be,3991,O
found,3991,O
in,3991,O
genomic,3991,O
DNA,3991,O
were,3991,O
also,3991,O
observed,3991,O
",",3991,O
suggesting,3991,O
caution,3991,O
in,3991,O
the,3991,O
interpretation,3991,O
of,3991,O
exon,3991,O
deletions,3991,O
observed,3991,O
in,3991,O
ATM,3991,O
cDNA,3991,O
when,3991,O
there,3991,O
is,3991,O
no,3991,O
accompanying,3991,O
identification,3991,O
of,3991,O
genomic,3991,O
mutations,3991,O
..,3991,O
Alpha-cardiac,3992,O
actin,3992,O
is,3992,O
a,3992,O
novel,3992,O
disease,3992,O
gene,3992,O
in,3992,O
familial,3992,B-SpecificDisease
hypertrophic,3992,I-SpecificDisease
cardiomyopathy,3992,I-SpecificDisease
.,3992,O
We,3993,O
identified,3993,O
the,3993,O
alpha-cardiac,3993,O
actin,3993,O
gene,3993,O
(,3993,O
ACTC,3993,O
),3993,O
as,3993,O
a,3993,O
novel,3993,O
disease,3993,O
gene,3993,O
in,3993,O
a,3993,O
pedigree,3993,O
suffering,3993,O
from,3993,O
familial,3993,B-SpecificDisease
hypertrophic,3993,I-SpecificDisease
cardiomyopathy,3993,I-SpecificDisease
(,3993,O
FHC,3993,B-SpecificDisease
),3993,O
.,3993,O
Linkage,3994,O
analyses,3994,O
excluded,3994,O
all,3994,O
the,3994,O
previously,3994,O
reported,3994,O
FHC,3994,B-Modifier
loci,3994,O
as,3994,O
possible,3994,O
disease,3994,O
loci,3994,O
in,3994,O
the,3994,O
family,3994,O
studied,3994,O
",",3994,O
with,3994,O
lod,3994,O
scores,3994,O
varying,3994,O
between,3994,O
-2,3994,O
.,3994,O
5,3995,O
and,3995,O
-6,3995,O
.,3995,O
0,3996,O
0,3996,O
.,3996,O
Further,3997,O
linkage,3997,O
analyses,3997,O
of,3997,O
plausible,3997,O
candidate,3997,O
genes,3997,O
highly,3997,O
expressed,3997,O
in,3997,O
the,3997,O
adult,3997,O
human,3997,O
heart,3997,O
identified,3997,O
ACTC,3997,O
as,3997,O
the,3997,O
most,3997,O
likely,3997,O
disease,3997,O
gene,3997,O
",",3997,O
showing,3997,O
a,3997,O
maximal,3997,O
lod,3997,O
score,3997,O
of,3997,O
3,3997,O
.,3997,O
6,3998,O
6,3998,O
.,3998,O
Mutation,3999,O
analysis,3999,O
of,3999,O
ACTC,3999,O
revealed,3999,O
an,3999,O
Ala295Ser,3999,O
mutation,3999,O
in,3999,O
exon,3999,O
5,3999,O
close,3999,O
to,3999,O
2,3999,O
missense,3999,O
mutations,3999,O
recently,3999,O
described,3999,O
to,3999,O
cause,3999,O
the,3999,O
inherited,3999,O
form,3999,O
of,3999,O
idiopathic,3999,B-SpecificDisease
dilated,3999,I-SpecificDisease
cardiomyopathy,3999,I-SpecificDisease
(,3999,O
IDC,3999,B-SpecificDisease
),3999,O
.,3999,O
Overgrowth,4000,B-CompositeMention
of,4000,I-CompositeMention
oral,4000,I-CompositeMention
mucosa,4000,I-CompositeMention
and,4000,I-CompositeMention
facial,4000,I-CompositeMention
skin,4000,I-CompositeMention
",",4000,O
a,4000,O
novel,4000,O
feature,4000,O
of,4000,O
aspartylglucosaminuria,4000,B-SpecificDisease
.,4000,O
Aspartylglucosaminuria,4001,B-SpecificDisease
(,4001,O
AGU,4001,B-SpecificDisease
),4001,O
is,4001,O
a,4001,O
lysosomal,4001,B-DiseaseClass
storage,4001,I-DiseaseClass
disorder,4001,I-DiseaseClass
caused,4001,O
by,4001,O
deficiency,4001,B-SpecificDisease
of,4001,I-SpecificDisease
aspartylglucosaminidase,4001,I-SpecificDisease
(,4001,O
AGA,4001,O
),4001,O
.,4001,O
The,4002,O
main,4002,O
symptom,4002,O
is,4002,O
progressive,4002,O
mental,4002,B-DiseaseClass
retardation,4002,I-DiseaseClass
.,4002,O
A,4003,O
spectrum,4003,O
of,4003,O
different,4003,O
mutations,4003,O
has,4003,O
been,4003,O
reported,4003,O
in,4003,O
this,4003,O
disease,4003,O
",",4003,O
one,4003,O
missense,4003,O
mutation,4003,O
(,4003,O
Cys163Ser,4003,O
),4003,O
being,4003,O
responsible,4003,O
for,4003,O
the,4003,O
majority,4003,O
of,4003,O
Finnish,4003,O
cases,4003,O
.,4003,O
We,4004,O
were,4004,O
able,4004,O
to,4004,O
examine,4004,O
66,4004,O
Finnish,4004,O
AGU,4004,B-Modifier
patients,4004,O
for,4004,O
changes,4004,O
in,4004,O
the,4004,O
oral,4004,O
mucosa,4004,O
and,4004,O
44,4004,O
of,4004,O
these,4004,O
for,4004,O
changes,4004,O
in,4004,O
facial,4004,O
skin,4004,O
.,4004,O
Biopsy,4005,O
specimens,4005,O
of,4005,O
16,4005,O
oral,4005,O
lesions,4005,O
",",4005,O
12,4005,O
of,4005,O
them,4005,O
associated,4005,O
with,4005,O
the,4005,O
teeth,4005,O
",",4005,O
plus,4005,O
two,4005,O
facial,4005,B-DiseaseClass
lesions,4005,I-DiseaseClass
were,4005,O
studied,4005,O
histologically,4005,O
.,4005,O
Immunohistochemical,4006,O
staining,4006,O
for,4006,O
AGA,4006,O
was,4006,O
performed,4006,O
on,4006,O
15,4006,O
oral,4006,O
specimens,4006,O
.,4006,O
Skin,4007,O
was,4007,O
seborrhoeic,4007,O
in,4007,O
adolescent,4007,O
and,4007,O
adult,4007,O
patients,4007,O
",",4007,O
with,4007,O
erythema,4007,B-SpecificDisease
of,4007,I-SpecificDisease
the,4007,I-SpecificDisease
facial,4007,I-SpecificDisease
skin,4007,I-SpecificDisease
already,4007,O
common,4007,O
in,4007,O
childhood,4007,O
.,4007,O
Of,4008,O
44,4008,O
patients,4008,O
",",4008,O
nine,4008,O
(,4008,O
20,4008,O
%,4008,O
),4008,O
had,4008,O
facial,4008,B-SpecificDisease
angiofibromas,4008,I-SpecificDisease
",",4008,O
tumours,4008,B-DiseaseClass
primarily,4008,O
occurring,4008,O
in,4008,O
association,4008,O
with,4008,O
tuberous,4008,B-SpecificDisease
sclerosis,4008,I-SpecificDisease
.,4008,O
Oedemic,4009,B-SpecificDisease
buccal,4009,I-SpecificDisease
mucosa,4009,I-SpecificDisease
(,4009,O
leucoedema,4009,B-SpecificDisease
),4009,O
and,4009,O
gingival,4009,B-SpecificDisease
overgrowths,4009,I-SpecificDisease
were,4009,O
more,4009,O
frequent,4009,O
in,4009,O
AGU,4009,B-Modifier
patients,4009,O
than,4009,O
in,4009,O
controls,4009,O
(,4009,O
p,4009,O
<,4009,O
0,4009,O
.,4009,O
001,4010,O
),4010,O
.,4010,O
Of,4011,O
16,4011,O
oral,4011,B-SpecificDisease
mucosal,4011,I-SpecificDisease
lesions,4011,I-SpecificDisease
studied,4011,O
histologically,4011,O
",",4011,O
15,4011,O
represented,4011,O
fibroepithelial,4011,B-CompositeMention
or,4011,I-CompositeMention
epithelial,4011,I-CompositeMention
hyperplasias,4011,I-CompositeMention
and,4011,O
were,4011,O
reactive,4011,O
in,4011,O
nature,4011,O
.,4011,O
Cytoplasmic,4012,O
vacuolisation,4012,O
was,4012,O
evident,4012,O
in,4012,O
four,4012,O
.,4012,O
Immunohistochemically,4013,O
",",4013,O
expression,4013,O
of,4013,O
AGA,4013,O
in,4013,O
AGU,4013,B-Modifier
patients,4013,O
mucosal,4013,B-SpecificDisease
lesions,4013,I-SpecificDisease
did,4013,O
not,4013,O
differ,4013,O
from,4013,O
that,4013,O
seen,4013,O
in,4013,O
corresponding,4013,O
lesions,4013,O
of,4013,O
normal,4013,O
subjects,4013,O
.,4013,O
Thus,4014,O
",",4014,O
the,4014,O
high,4014,O
frequency,4014,O
of,4014,O
mucosal,4014,B-SpecificDisease
overgrowth,4014,I-SpecificDisease
in,4014,O
AGU,4014,B-Modifier
patients,4014,O
does,4014,O
not,4014,O
appear,4014,O
to,4014,O
be,4014,O
directly,4014,O
associated,4014,O
with,4014,O
lysosomal,4014,O
storage,4014,O
or,4014,O
with,4014,O
alterations,4014,O
in,4014,O
the,4014,O
level,4014,O
of,4014,O
AGA,4014,O
expression,4014,O
.,4014,O
Characterization,4015,O
of,4015,O
a,4015,O
germline,4015,O
mosaicism,4015,O
in,4015,O
families,4015,O
with,4015,O
Lowe,4015,B-SpecificDisease
syndrome,4015,I-SpecificDisease
",",4015,O
and,4015,O
identification,4015,O
of,4015,O
seven,4015,O
novel,4015,O
mutations,4015,O
in,4015,O
the,4015,O
OCRL1,4015,O
gene,4015,O
.,4015,O
The,4016,O
oculocerebrorenal,4016,B-SpecificDisease
syndrome,4016,I-SpecificDisease
of,4016,I-SpecificDisease
Lowe,4016,I-SpecificDisease
(,4016,O
OCRL,4016,B-SpecificDisease
),4016,O
is,4016,O
an,4016,O
X-linked,4016,B-DiseaseClass
disorder,4016,I-DiseaseClass
characterized,4016,O
by,4016,O
major,4016,O
abnormalities,4016,B-CompositeMention
of,4016,I-CompositeMention
eyes,4016,I-CompositeMention
",",4016,I-CompositeMention
nervous,4016,I-CompositeMention
system,4016,I-CompositeMention
",",4016,I-CompositeMention
and,4016,I-CompositeMention
kidneys,4016,I-CompositeMention
.,4016,O
Mutations,4017,O
in,4017,O
the,4017,O
OCRL1,4017,O
gene,4017,O
have,4017,O
been,4017,O
associated,4017,O
with,4017,O
the,4017,O
disease,4017,O
.,4017,O
OCRL1,4018,O
encodes,4018,O
a,4018,O
phosphatidylinositol,4018,O
4,4018,O
",",4018,O
5-biphosphate,4018,O
(,4018,O
PtdIns,4018,O
[,4018,O
4,4018,O
",",4018,O
5,4018,O
],4018,O
P2,4018,O
),4018,O
5-phosphatase,4018,O
.,4018,O
We,4019,O
have,4019,O
examined,4019,O
the,4019,O
OCRL1,4019,O
gene,4019,O
in,4019,O
eight,4019,O
unrelated,4019,O
patients,4019,O
with,4019,O
OCRL,4019,B-SpecificDisease
and,4019,O
have,4019,O
found,4019,O
seven,4019,O
new,4019,O
mutations,4019,O
and,4019,O
one,4019,O
recurrent,4019,O
in-frame,4019,O
deletion,4019,O
.,4019,O
Among,4020,O
the,4020,O
new,4020,O
mutations,4020,O
",",4020,O
two,4020,O
nonsense,4020,O
mutations,4020,O
(,4020,O
R317X,4020,O
and,4020,O
E558X,4020,O
),4020,O
and,4020,O
three,4020,O
other,4020,O
frameshift,4020,O
mutations,4020,O
caused,4020,O
premature,4020,O
termination,4020,O
of,4020,O
the,4020,O
protein,4020,O
.,4020,O
A,4021,O
missense,4021,O
mutation,4021,O
",",4021,O
R483G,4021,O
",",4021,O
was,4021,O
located,4021,O
in,4021,O
the,4021,O
highly,4021,O
conserved,4021,O
PtdIns,4021,O
(,4021,O
4,4021,O
",",4021,O
5,4021,O
),4021,O
P2,4021,O
5-phosphatase,4021,O
domain,4021,O
.,4021,O
Finally,4022,O
",",4022,O
one,4022,O
frameshift,4022,O
mutation,4022,O
",",4022,O
2799delC,4022,O
",",4022,O
modifies,4022,O
the,4022,O
C-terminal,4022,O
part,4022,O
of,4022,O
OCRL1,4022,O
",",4022,O
with,4022,O
an,4022,O
extension,4022,O
of,4022,O
six,4022,O
amino,4022,O
acids,4022,O
.,4022,O
Altogether,4023,O
",",4023,O
70,4023,O
%,4023,O
of,4023,O
missense,4023,O
mutations,4023,O
are,4023,O
located,4023,O
in,4023,O
exon,4023,O
15,4023,O
",",4023,O
and,4023,O
52,4023,O
%,4023,O
of,4023,O
all,4023,O
mutations,4023,O
cluster,4023,O
in,4023,O
exons,4023,O
11-15,4023,O
.,4023,O
We,4024,O
also,4024,O
identified,4024,O
two,4024,O
new,4024,O
microsatellite,4024,O
markers,4024,O
for,4024,O
the,4024,O
OCRL1,4024,O
locus,4024,O
",",4024,O
and,4024,O
we,4024,O
detected,4024,O
a,4024,O
germline,4024,O
mosaicism,4024,O
in,4024,O
one,4024,O
family,4024,O
.,4024,O
This,4025,O
observation,4025,O
has,4025,O
direct,4025,O
implications,4025,O
for,4025,O
genetic,4025,O
counseling,4025,O
of,4025,O
Lowe,4025,B-Modifier
syndrome,4025,I-Modifier
families,4025,O
..,4025,O
MEFV-Gene,4026,O
analysis,4026,O
in,4026,O
armenian,4026,O
patients,4026,O
with,4026,O
Familial,4026,B-SpecificDisease
Mediterranean,4026,I-SpecificDisease
fever,4026,I-SpecificDisease
:,4026,O
diagnostic,4026,O
value,4026,O
and,4026,O
unfavorable,4026,O
renal,4026,O
prognosis,4026,O
of,4026,O
the,4026,O
M694V,4026,O
homozygous,4026,O
genotype-genetic,4026,O
and,4026,O
therapeutic,4026,O
implications,4026,O
.,4026,O
Familial,4027,B-SpecificDisease
Mediterranean,4027,I-SpecificDisease
fever,4027,I-SpecificDisease
(,4027,O
FMF,4027,B-SpecificDisease
),4027,O
is,4027,O
a,4027,O
recessively,4027,B-DiseaseClass
inherited,4027,I-DiseaseClass
disorder,4027,I-DiseaseClass
that,4027,O
is,4027,O
common,4027,O
in,4027,O
patients,4027,O
of,4027,O
Armenian,4027,O
ancestry,4027,O
.,4027,O
To,4028,O
date,4028,O
",",4028,O
its,4028,O
diagnosis,4028,O
",",4028,O
which,4028,O
can,4028,O
be,4028,O
made,4028,O
only,4028,O
retrospectively,4028,O
",",4028,O
is,4028,O
one,4028,O
of,4028,O
exclusion,4028,O
",",4028,O
based,4028,O
entirely,4028,O
on,4028,O
nonspecific,4028,O
clinical,4028,O
signs,4028,O
that,4028,O
result,4028,O
from,4028,O
serosal,4028,B-SpecificDisease
inflammation,4028,I-SpecificDisease
and,4028,O
that,4028,O
may,4028,O
lead,4028,O
to,4028,O
unnecessary,4028,O
surgery,4028,O
.,4028,O
Renal,4029,B-SpecificDisease
amyloidosis,4029,I-SpecificDisease
",",4029,O
prevented,4029,O
by,4029,O
colchicine,4029,O
",",4029,O
is,4029,O
the,4029,O
most,4029,O
severe,4029,O
complication,4029,O
of,4029,O
FMF,4029,B-SpecificDisease
",",4029,O
a,4029,O
disorder,4029,O
associated,4029,O
with,4029,O
mutations,4029,O
in,4029,O
the,4029,O
MEFV,4029,O
gene,4029,O
.,4029,O
To,4030,O
evaluate,4030,O
the,4030,O
diagnostic,4030,O
and,4030,O
prognostic,4030,O
value,4030,O
of,4030,O
MEFV-gene,4030,O
analysis,4030,O
",",4030,O
we,4030,O
investigated,4030,O
90,4030,O
Armenian,4030,O
FMF,4030,B-Modifier
patients,4030,O
from,4030,O
77,4030,O
unrelated,4030,O
families,4030,O
that,4030,O
were,4030,O
not,4030,O
selected,4030,O
through,4030,O
genetic-linkage,4030,O
analysis,4030,O
.,4030,O
Eight,4031,O
mutations,4031,O
",",4031,O
one,4031,O
of,4031,O
which,4031,O
(,4031,O
R408Q,4031,O
),4031,O
is,4031,O
new,4031,O
",",4031,O
were,4031,O
found,4031,O
to,4031,O
account,4031,O
for,4031,O
93,4031,O
%,4031,O
of,4031,O
the,4031,O
163,4031,O
independent,4031,O
FMF,4031,B-Modifier
alleles,4031,O
",",4031,O
with,4031,O
both,4031,O
FMF,4031,B-Modifier
alleles,4031,O
identified,4031,O
in,4031,O
89,4031,O
%,4031,O
of,4031,O
the,4031,O
patients,4031,O
.,4031,O
In,4032,O
several,4032,O
instances,4032,O
",",4032,O
family,4032,O
studies,4032,O
provided,4032,O
molecular,4032,O
evidence,4032,O
for,4032,O
pseudodominant,4032,O
transmission,4032,O
and,4032,O
incomplete,4032,O
penetrance,4032,O
of,4032,O
the,4032,O
disease,4032,O
phenotype,4032,O
.,4032,O
The,4033,O
M694V,4033,O
homozygous,4033,O
genotype,4033,O
was,4033,O
found,4033,O
to,4033,O
be,4033,O
associated,4033,O
with,4033,O
a,4033,O
higher,4033,O
prevalence,4033,O
of,4033,O
renal,4033,B-SpecificDisease
amyloidosis,4033,I-SpecificDisease
and,4033,O
arthritis,4033,B-SpecificDisease
",",4033,O
compared,4033,O
with,4033,O
other,4033,O
genotypes,4033,O
(,4033,O
P,4033,O
=,4033,O
.,4033,O
0002,4034,O
and,4034,O
P,4034,O
=,4034,O
.,4034,O
006,4035,O
",",4035,O
respectively,4035,O
),4035,O
.,4035,O
The,4036,O
demonstration,4036,O
of,4036,O
both,4036,O
the,4036,O
diagnostic,4036,O
and,4036,O
prognostic,4036,O
value,4036,O
of,4036,O
MEFV,4036,O
analysis,4036,O
and,4036,O
particular,4036,O
modes,4036,O
of,4036,O
inheritance,4036,O
should,4036,O
lead,4036,O
to,4036,O
new,4036,O
ways,4036,O
for,4036,O
management,4036,O
of,4036,O
FMF-including,4036,O
genetic,4036,O
counseling,4036,O
and,4036,O
therapeutic,4036,O
decisions,4036,O
in,4036,O
affected,4036,O
families,4036,O
.,4036,O
Noninvasive,4037,O
test,4037,O
for,4037,O
fragile,4037,B-SpecificDisease
X,4037,I-SpecificDisease
syndrome,4037,I-SpecificDisease
",",4037,O
using,4037,O
hair,4037,O
root,4037,O
analysis,4037,O
.,4037,O
Identification,4038,O
of,4038,O
the,4038,O
FMR1,4038,O
gene,4038,O
and,4038,O
the,4038,O
repeat-amplification,4038,O
mechanism,4038,O
causing,4038,O
fragile,4038,B-SpecificDisease
X,4038,I-SpecificDisease
syndrome,4038,I-SpecificDisease
led,4038,O
to,4038,O
development,4038,O
of,4038,O
reliable,4038,O
DNA-based,4038,O
diagnostic,4038,O
methods,4038,O
",",4038,O
including,4038,O
Southern,4038,O
blot,4038,O
hybridization,4038,O
and,4038,O
PCR,4038,O
.,4038,O
Both,4039,O
methods,4039,O
are,4039,O
performed,4039,O
on,4039,O
DNA,4039,O
isolated,4039,O
from,4039,O
peripheral,4039,O
blood,4039,O
cells,4039,O
and,4039,O
measure,4039,O
the,4039,O
repeat,4039,O
size,4039,O
in,4039,O
FMR1,4039,O
.,4039,O
Using,4040,O
an,4040,O
immunocytochemical,4040,O
technique,4040,O
on,4040,O
blood,4040,O
smears,4040,O
",",4040,O
we,4040,O
recently,4040,O
developed,4040,O
a,4040,O
novel,4040,O
test,4040,O
for,4040,O
identification,4040,O
of,4040,O
patients,4040,O
with,4040,O
fragile,4040,B-SpecificDisease
X,4040,I-SpecificDisease
syndrome,4040,I-SpecificDisease
.,4040,O
This,4041,O
method,4041,O
",",4041,O
also,4041,O
called,4041,O
``,4041,O
antibody,4041,O
test,4041,O
",",4041,O
``,4041,O
uses,4041,O
monoclonal,4041,O
antibodies,4041,O
against,4041,O
the,4041,O
FMR1,4041,O
gene,4041,O
product,4041,O
(,4041,O
FMRP,4041,O
),4041,O
and,4041,O
is,4041,O
based,4041,O
on,4041,O
absence,4041,O
of,4041,O
FMRP,4041,O
in,4041,O
patients,4041,O
cells,4041,O
.,4041,O
Here,4042,O
we,4042,O
describe,4042,O
a,4042,O
new,4042,O
diagnostic,4042,O
test,4042,O
to,4042,O
identify,4042,O
male,4042,O
patients,4042,O
with,4042,O
fragile,4042,B-SpecificDisease
X,4042,I-SpecificDisease
syndrome,4042,I-SpecificDisease
",",4042,O
on,4042,O
the,4042,O
basis,4042,O
of,4042,O
lack,4042,O
of,4042,O
FMRP,4042,O
in,4042,O
their,4042,O
hair,4042,O
roots,4042,O
.,4042,O
Expression,4043,O
of,4043,O
FMRP,4043,O
in,4043,O
hair,4043,O
roots,4043,O
was,4043,O
studied,4043,O
by,4043,O
use,4043,O
of,4043,O
an,4043,O
FMRP-specific,4043,O
antibody,4043,O
test,4043,O
",",4043,O
and,4043,O
the,4043,O
percentage,4043,O
of,4043,O
FMRP-expressing,4043,O
hair,4043,O
roots,4043,O
in,4043,O
controls,4043,O
and,4043,O
in,4043,O
male,4043,O
fragile,4043,B-Modifier
X,4043,I-Modifier
patients,4043,O
was,4043,O
determined,4043,O
.,4043,O
Control,4044,O
individuals,4044,O
showed,4044,O
clear,4044,O
expression,4044,O
of,4044,O
FMRP,4044,O
in,4044,O
nearly,4044,O
every,4044,O
hair,4044,O
root,4044,O
",",4044,O
whereas,4044,O
male,4044,O
fragile,4044,B-Modifier
X,4044,I-Modifier
patients,4044,O
lacked,4044,O
expression,4044,O
of,4044,O
FMRP,4044,O
in,4044,O
almost,4044,O
all,4044,O
their,4044,O
hair,4044,O
roots,4044,O
.,4044,O
Mentally,4045,B-Modifier
retarded,4045,I-Modifier
female,4045,O
patients,4045,O
with,4045,O
a,4045,O
full,4045,O
mutation,4045,O
showed,4045,O
FMRP,4045,O
expression,4045,O
in,4045,O
only,4045,O
some,4045,O
of,4045,O
their,4045,O
hair,4045,O
roots,4045,O
(,4045,O
<,4045,O
55,4045,O
%,4045,O
),4045,O
",",4045,O
and,4045,O
no,4045,O
overlap,4045,O
with,4045,O
normal,4045,O
female,4045,O
controls,4045,O
was,4045,O
observed,4045,O
.,4045,O
The,4046,O
advantages,4046,O
of,4046,O
this,4046,O
test,4046,O
are,4046,O
(,4046,O
1,4046,O
),4046,O
plucking,4046,O
of,4046,O
hair,4046,O
follicles,4046,O
does,4046,O
no,4046,O
appreciable,4046,O
harm,4046,O
to,4046,O
the,4046,O
mentally,4046,B-Modifier
retarded,4046,I-Modifier
patient,4046,O
",",4046,O
(,4046,O
2,4046,O
),4046,O
hairs,4046,O
can,4046,O
be,4046,O
sent,4046,O
in,4046,O
a,4046,O
simple,4046,O
envelope,4046,O
to,4046,O
a,4046,O
diagnostic,4046,O
center,4046,O
",",4046,O
and,4046,O
(,4046,O
3,4046,O
),4046,O
the,4046,O
result,4046,O
of,4046,O
the,4046,O
test,4046,O
is,4046,O
available,4046,O
within,4046,O
5,4046,O
h,4046,O
of,4046,O
plucking,4046,O
.,4046,O
In,4047,O
addition,4047,O
",",4047,O
this,4047,O
test,4047,O
enabled,4047,O
us,4047,O
to,4047,O
identify,4047,O
two,4047,O
fragile,4047,B-Modifier
X,4047,I-Modifier
patients,4047,O
who,4047,O
did,4047,O
not,4047,O
show,4047,O
the,4047,O
full,4047,O
mutation,4047,O
by,4047,O
analysis,4047,O
of,4047,O
DNA,4047,O
isolated,4047,O
from,4047,O
blood,4047,O
cells,4047,O
..,4047,O
In,4048,O
Swedish,4048,O
families,4048,O
with,4048,O
hereditary,4048,B-SpecificDisease
prostate,4048,I-SpecificDisease
cancer,4048,I-SpecificDisease
",",4048,O
linkage,4048,O
to,4048,O
the,4048,O
HPC1,4048,O
locus,4048,O
on,4048,O
chromosome,4048,O
1q24-25,4048,O
is,4048,O
restricted,4048,O
to,4048,O
families,4048,O
with,4048,O
early-onset,4048,O
prostate,4048,B-SpecificDisease
cancer,4048,I-SpecificDisease
.,4048,O
Prostate,4049,B-SpecificDisease
cancer,4049,I-SpecificDisease
clusters,4049,O
in,4049,O
some,4049,O
families,4049,O
",",4049,O
and,4049,O
an,4049,O
estimated,4049,O
5,4049,O
%,4049,O
-10,4049,O
%,4049,O
of,4049,O
all,4049,O
cases,4049,O
are,4049,O
estimated,4049,O
to,4049,O
result,4049,O
from,4049,O
inheritance,4049,O
of,4049,O
prostate,4049,O
cancer-susceptibility,4049,O
genes,4049,O
.,4049,O
We,4050,O
previously,4050,O
reported,4050,O
evidence,4050,O
of,4050,O
linkage,4050,O
to,4050,O
the,4050,O
1q24-25,4050,O
region,4050,O
(,4050,O
HPC1,4050,O
),4050,O
in,4050,O
91,4050,O
North,4050,O
American,4050,O
and,4050,O
Swedish,4050,O
families,4050,O
each,4050,O
with,4050,O
multiple,4050,O
cases,4050,O
of,4050,O
prostate,4050,B-SpecificDisease
cancer,4050,I-SpecificDisease
(,4050,O
Smith,4050,O
et,4050,O
al,4050,O
.,4050,O
1996,4051,O
),4051,O
.,4051,O
In,4052,O
the,4052,O
present,4052,O
report,4052,O
we,4052,O
analyze,4052,O
40,4052,O
(,4052,O
12,4052,O
original,4052,O
and,4052,O
28,4052,O
newly,4052,O
identified,4052,O
),4052,O
Swedish,4052,O
families,4052,O
with,4052,O
hereditary,4052,B-SpecificDisease
prostate,4052,I-SpecificDisease
cancer,4052,I-SpecificDisease
(,4052,O
HPC,4052,B-SpecificDisease
),4052,O
that,4052,O
",",4052,O
on,4052,O
the,4052,O
basis,4052,O
of,4052,O
40,4052,O
markers,4052,O
spanning,4052,O
a,4052,O
25-cM,4052,O
interval,4052,O
within,4052,O
1q24-25,4052,O
",",4052,O
have,4052,O
evidence,4052,O
of,4052,O
linkage,4052,O
.,4052,O
In,4053,O
the,4053,O
complete,4053,O
set,4053,O
of,4053,O
families,4053,O
",",4053,O
a,4053,O
maximum,4053,O
two-point,4053,O
LOD,4053,O
score,4053,O
of,4053,O
1,4053,O
.,4053,O
10,4054,O
was,4054,O
observed,4054,O
at,4054,O
D1S413,4054,O
(,4054,O
at,4054,O
a,4054,O
recombination,4054,O
fraction,4054,O
[,4054,O
theta,4054,O
],4054,O
of,4054,O
.,4054,O
1,4055,O
),4055,O
",",4055,O
with,4055,O
a,4055,O
maximum,4055,O
NPL,4055,O
(,4055,O
nonparametric,4055,O
linkage,4055,O
),4055,O
Z,4055,O
score,4055,O
of,4055,O
1,4055,O
.,4055,O
64,4056,O
at,4056,O
D1S202,4056,O
(,4056,O
P,4056,O
=,4056,O
.,4056,O
05,4057,O
),4057,O
.,4057,O
The,4058,O
evidence,4058,O
of,4058,O
linkage,4058,O
to,4058,O
this,4058,O
region,4058,O
originated,4058,O
almost,4058,O
exclusively,4058,O
from,4058,O
the,4058,O
subset,4058,O
of,4058,O
12,4058,O
early-onset,4058,O
(,4058,O
age,4058,O
<,4058,O
65,4058,O
years,4058,O
),4058,O
families,4058,O
",",4058,O
which,4058,O
yielded,4058,O
a,4058,O
maximum,4058,O
LOD,4058,O
score,4058,O
of,4058,O
2,4058,O
.,4058,O
38,4059,O
at,4059,O
D1S413,4059,O
(,4059,O
straight,4059,O
theta,4059,O
=,4059,O
0,4059,O
),4059,O
and,4059,O
an,4059,O
NPL,4059,O
Z,4059,O
score,4059,O
of,4059,O
1,4059,O
.,4059,O
95,4060,O
at,4060,O
D1S422,4060,O
(,4060,O
P,4060,O
=,4060,O
.,4060,O
03,4061,O
),4061,O
.,4061,O
Estimates,4062,O
from,4062,O
heterogeneity,4062,O
tests,4062,O
suggest,4062,O
that,4062,O
",",4062,O
within,4062,O
Sweden,4062,O
",",4062,O
as,4062,O
many,4062,O
as,4062,O
50,4062,O
%,4062,O
of,4062,O
early-onset,4062,O
families,4062,O
had,4062,O
evidence,4062,O
of,4062,O
linkage,4062,O
to,4062,O
the,4062,O
HPC1,4062,O
region,4062,O
.,4062,O
These,4063,O
results,4063,O
are,4063,O
consistent,4063,O
with,4063,O
the,4063,O
hypothesis,4063,O
of,4063,O
linkage,4063,O
to,4063,O
HPC1,4063,O
in,4063,O
a,4063,O
subset,4063,O
of,4063,O
families,4063,O
with,4063,O
prostate,4063,B-SpecificDisease
cancer,4063,I-SpecificDisease
",",4063,O
particularly,4063,O
those,4063,O
with,4063,O
an,4063,O
early,4063,O
age,4063,O
at,4063,O
diagnosis,4063,O
.,4063,O
Molecular,4064,O
basis,4064,O
of,4064,O
feline,4064,O
beta-glucuronidase,4064,B-SpecificDisease
deficiency,4064,I-SpecificDisease
:,4064,O
an,4064,O
animal,4064,O
model,4064,O
of,4064,O
mucopolysaccharidosis,4064,B-SpecificDisease
VII,4064,I-SpecificDisease
.,4064,O
A,4065,O
family,4065,O
of,4065,O
domestic,4065,O
cats,4065,O
was,4065,O
found,4065,O
that,4065,O
exhibited,4065,O
clinical,4065,O
and,4065,O
biochemical,4065,O
abnormalities,4065,O
consistent,4065,O
with,4065,O
mucopolysaccharidosis,4065,B-SpecificDisease
VII,4065,I-SpecificDisease
",",4065,O
an,4065,O
autosomal,4065,B-DiseaseClass
recessive,4065,I-DiseaseClass
lysosomal,4065,I-DiseaseClass
storage,4065,I-DiseaseClass
disorder,4065,I-DiseaseClass
caused,4065,O
by,4065,O
beta-glucuronidase,4065,B-SpecificDisease
deficiency,4065,I-SpecificDisease
.,4065,O
beta-Glucuronidase,4066,O
activity,4066,O
was,4066,O
undetectable,4066,O
in,4066,O
affected,4066,O
cat,4066,O
fibroblasts,4066,O
and,4066,O
restored,4066,O
by,4066,O
retroviral,4066,O
gene,4066,O
transfer,4066,O
of,4066,O
rat,4066,O
beta-glucuronidase,4066,O
cDNA,4066,O
.,4066,O
beta-Glucuronidase,4067,O
mRNA,4067,O
was,4067,O
normal,4067,O
in,4067,O
affected,4067,O
cat,4067,O
testis,4067,O
by,4067,O
Northern,4067,O
blot,4067,O
analysis,4067,O
.,4067,O
Normal,4068,O
feline,4068,O
beta-glucuronidase,4068,O
cDNA,4068,O
was,4068,O
cloned,4068,O
and,4068,O
characterized,4068,O
",",4068,O
and,4068,O
amplified,4068,O
from,4068,O
affected,4068,O
cat,4068,O
fibroblasts,4068,O
by,4068,O
reverse,4068,O
transcription,4068,O
coupled,4068,O
polymerase,4068,O
chain,4068,O
reaction,4068,O
.,4068,O
There,4069,O
was,4069,O
a,4069,O
G-to-A,4069,O
transition,4069,O
in,4069,O
the,4069,O
affected,4069,O
cat,4069,O
cDNA,4069,O
that,4069,O
predicted,4069,O
an,4069,O
E351K,4069,O
substitution,4069,O
",",4069,O
destroyed,4069,O
a,4069,O
BssSI,4069,O
site,4069,O
",",4069,O
and,4069,O
eliminated,4069,O
GUSB,4069,O
enzymatic,4069,O
activity,4069,O
in,4069,O
expression,4069,O
studies,4069,O
.,4069,O
Multiple,4070,O
species,4070,O
comparison,4070,O
and,4070,O
the,4070,O
crystal,4070,O
structure,4070,O
of,4070,O
human,4070,O
beta-glucuronidase,4070,O
indicated,4070,O
that,4070,O
E351,4070,O
is,4070,O
a,4070,O
highly,4070,O
conserved,4070,O
residue,4070,O
most,4070,O
likely,4070,O
essential,4070,O
in,4070,O
maintenance,4070,O
of,4070,O
the,4070,O
enzymes,4070,O
conformation,4070,O
.,4070,O
BssSI,4071,O
digestion,4071,O
of,4071,O
polymerase,4071,O
chain,4071,O
reaction,4071,O
products,4071,O
amplified,4071,O
from,4071,O
genomic,4071,O
DNA,4071,O
indicated,4071,O
that,4071,O
affected,4071,O
cats,4071,O
were,4071,O
homozygous,4071,O
and,4071,O
cats,4071,O
with,4071,O
half-normal,4071,O
beta-glucuronidase,4071,O
activity,4071,O
were,4071,O
heterozygous,4071,O
for,4071,O
the,4071,O
missense,4071,O
mutation,4071,O
.,4071,O
Carriers,4072,O
identified,4072,O
in,4072,O
this,4072,O
manner,4072,O
produced,4072,O
affected,4072,O
kittens,4072,O
in,4072,O
prospective,4072,O
breedings,4072,O
",",4072,O
and,4072,O
a,4072,O
feline,4072,O
MPS,4072,B-Modifier
VII,4072,I-Modifier
breeding,4072,O
colony,4072,O
has,4072,O
been,4072,O
established,4072,O
..,4072,O
A,4073,O
common,4073,O
molecular,4073,O
basis,4073,O
for,4073,O
rearrangement,4073,B-DiseaseClass
disorders,4073,I-DiseaseClass
on,4073,O
chromosome,4073,O
22q11,4073,O
.,4073,O
The,4074,O
chromosome,4074,O
22q11,4074,O
region,4074,O
is,4074,O
susceptible,4074,O
to,4074,O
rearrangements,4074,O
that,4074,O
are,4074,O
associated,4074,O
with,4074,O
congenital,4074,B-DiseaseClass
anomaly,4074,I-DiseaseClass
disorders,4074,I-DiseaseClass
and,4074,O
malignant,4074,B-DiseaseClass
tumors,4074,I-DiseaseClass
.,4074,O
Three,4075,O
congenital,4075,B-DiseaseClass
anomaly,4075,I-DiseaseClass
disorders,4075,I-DiseaseClass
",",4075,O
cat-eye,4075,O
syndrome,4075,O
",",4075,O
der,4075,B-SpecificDisease
(,4075,I-SpecificDisease
),4075,I-SpecificDisease
syndrome,4075,I-SpecificDisease
and,4075,O
velo-cardio-facial,4075,B-SpecificDisease
syndrome/DiGeorge,4075,O
syndrome,4075,I-SpecificDisease
(,4075,O
VCFS/DGS,4075,B-SpecificDisease
),4075,O
are,4075,O
associated,4075,O
with,4075,O
tetrasomy,4075,O
",",4075,O
trisomy,4075,O
or,4075,O
monosomy,4075,O
",",4075,O
respectively,4075,O
",",4075,O
for,4075,O
part,4075,O
of,4075,O
chromosome,4075,O
22q11,4075,O
.,4075,O
VCFS/DGS,4076,B-SpecificDisease
is,4076,O
the,4076,O
most,4076,O
common,4076,O
syndrome,4076,O
associated,4076,O
with,4076,O
22q11,4076,O
rearrangements,4076,O
.,4076,O
In,4077,O
order,4077,O
to,4077,O
determine,4077,O
whether,4077,O
there,4077,O
are,4077,O
particular,4077,O
regions,4077,O
on,4077,O
22q11,4077,O
that,4077,O
are,4077,O
prone,4077,O
to,4077,O
rearrangements,4077,O
",",4077,O
the,4077,O
deletion,4077,O
end-points,4077,O
in,4077,O
a,4077,O
large,4077,O
number,4077,O
of,4077,O
VCFS/DGS,4077,B-Modifier
patients,4077,O
were,4077,O
defined,4077,O
by,4077,O
haplotype,4077,O
analysis,4077,O
.,4077,O
Most,4078,O
VCFS/DGS,4078,B-Modifier
patients,4078,O
have,4078,O
a,4078,O
similar,4078,O
3,4078,O
Mb,4078,O
deletion,4078,O
",",4078,O
some,4078,O
have,4078,O
a,4078,O
nested,4078,O
distal,4078,O
deletion,4078,O
breakpoint,4078,O
resulting,4078,O
in,4078,O
a,4078,O
1,4078,O
.,4078,O
5,4079,O
Mb,4079,O
deletion,4079,O
and,4079,O
a,4079,O
few,4079,O
rare,4079,O
patients,4079,O
have,4079,O
unique,4079,O
deletions,4079,O
or,4079,O
translocations,4079,O
.,4079,O
The,4080,O
high,4080,O
prevalence,4080,O
of,4080,O
the,4080,O
disorder,4080,O
in,4080,O
the,4080,O
population,4080,O
and,4080,O
the,4080,O
fact,4080,O
that,4080,O
most,4080,O
cases,4080,O
occur,4080,O
sporadically,4080,O
suggest,4080,O
that,4080,O
sequences,4080,O
at,4080,O
or,4080,O
near,4080,O
the,4080,O
breakpoints,4080,O
confer,4080,O
susceptibility,4080,O
to,4080,O
chromosome,4080,O
rearrangements,4080,O
.,4080,O
To,4081,O
investigate,4081,O
this,4081,O
hypothesis,4081,O
",",4081,O
we,4081,O
developed,4081,O
hamster-human,4081,O
somatic,4081,O
hybrid,4081,O
cell,4081,O
lines,4081,O
from,4081,O
VCFS/DGS,4081,B-Modifier
patients,4081,O
with,4081,O
all,4081,O
three,4081,O
classes,4081,O
of,4081,O
deletions,4081,O
and,4081,O
we,4081,O
now,4081,O
show,4081,O
that,4081,O
the,4081,O
breakpoints,4081,O
occur,4081,O
within,4081,O
similar,4081,O
low,4081,O
copy,4081,O
repeats,4081,O
",",4081,O
termed,4081,O
LCR22s,4081,O
.,4081,O
To,4082,O
support,4082,O
this,4082,O
idea,4082,O
further,4082,O
",",4082,O
we,4082,O
identified,4082,O
a,4082,O
family,4082,O
that,4082,O
carries,4082,O
an,4082,O
interstitial,4082,O
duplication,4082,O
of,4082,O
the,4082,O
same,4082,O
3,4082,O
Mb,4082,O
region,4082,O
that,4082,O
is,4082,O
deleted,4082,O
in,4082,O
VCFS/DGS,4082,B-Modifier
patients,4082,O
.,4082,O
We,4083,O
present,4083,O
models,4083,O
to,4083,O
explain,4083,O
how,4083,O
the,4083,O
LCR22s,4083,O
can,4083,O
mediate,4083,O
different,4083,O
homologous,4083,O
recombination,4083,O
events,4083,O
",",4083,O
thereby,4083,O
generating,4083,O
a,4083,O
number,4083,O
of,4083,O
rearrangements,4083,O
that,4083,O
are,4083,O
associated,4083,O
with,4083,O
congenital,4083,B-DiseaseClass
anomaly,4083,I-DiseaseClass
disorders,4083,I-DiseaseClass
.,4083,O
We,4084,O
identified,4084,O
five,4084,O
additional,4084,O
copies,4084,O
of,4084,O
the,4084,O
LCR22,4084,O
on,4084,O
22q11,4084,O
that,4084,O
may,4084,O
mediate,4084,O
other,4084,O
rearrangements,4084,O
leading,4084,O
to,4084,O
disease,4084,O
.,4084,O
Functional,4085,O
consequences,4085,O
of,4085,O
mutations,4085,O
in,4085,O
the,4085,O
early,4085,O
growth,4085,O
response,4085,O
2,4085,O
gene,4085,O
(,4085,O
EGR2,4085,O
),4085,O
correlate,4085,O
with,4085,O
severity,4085,O
of,4085,O
human,4085,O
myelinopathies,4085,B-DiseaseClass
.,4085,O
The,4086,O
early,4086,O
growth,4086,O
response,4086,O
2,4086,O
gene,4086,O
(,4086,O
EGR2,4086,O
),4086,O
is,4086,O
a,4086,O
Cys2His2zinc,4086,O
finger,4086,O
transcription,4086,O
factor,4086,O
which,4086,O
is,4086,O
thought,4086,O
to,4086,O
play,4086,O
a,4086,O
role,4086,O
in,4086,O
the,4086,O
regulation,4086,O
of,4086,O
peripheral,4086,O
nervous,4086,O
system,4086,O
myelination,4086,O
.,4086,O
This,4087,O
idea,4087,O
is,4087,O
based,4087,O
partly,4087,O
on,4087,O
the,4087,O
phenotype,4087,O
of,4087,O
homozygous,4087,O
Krox20,4087,O
(,4087,O
Egr2,4087,O
),4087,O
knockout,4087,O
mice,4087,O
",",4087,O
which,4087,O
display,4087,O
hypomyelination,4087,B-DiseaseClass
of,4087,I-DiseaseClass
the,4087,I-DiseaseClass
PNS,4087,I-DiseaseClass
and,4087,O
a,4087,O
block,4087,O
of,4087,O
Schwann,4087,O
cells,4087,O
at,4087,O
an,4087,O
early,4087,O
stage,4087,O
of,4087,O
differentiation,4087,O
.,4087,O
Mutations,4088,O
in,4088,O
the,4088,O
human,4088,O
EGR2,4088,O
gene,4088,O
have,4088,O
recently,4088,O
been,4088,O
associated,4088,O
with,4088,O
the,4088,O
inherited,4088,B-DiseaseClass
peripheral,4088,I-DiseaseClass
neuropathies,4088,I-DiseaseClass
Charcot-Marie-Tooth,4088,B-SpecificDisease
type,4088,I-SpecificDisease
1,4088,I-SpecificDisease
",",4088,O
Dejerine-Sottas,4088,B-SpecificDisease
syndrome,4088,I-SpecificDisease
and,4088,O
congenital,4088,B-SpecificDisease
hypomyelinating,4088,I-SpecificDisease
neuropathy,4088,I-SpecificDisease
.,4088,O
Three,4089,O
of,4089,O
the,4089,O
four,4089,O
EGR2,4089,O
mutations,4089,O
are,4089,O
dominant,4089,O
and,4089,O
occur,4089,O
within,4089,O
the,4089,O
zinc,4089,O
finger,4089,O
DNA-binding,4089,O
domain,4089,O
.,4089,O
The,4090,O
fourth,4090,O
mutation,4090,O
is,4090,O
recessive,4090,O
and,4090,O
affects,4090,O
the,4090,O
inhibitory,4090,O
domain,4090,O
(,4090,O
R1,4090,O
),4090,O
that,4090,O
binds,4090,O
the,4090,O
NAB,4090,O
transcriptional,4090,O
co-repressors,4090,O
.,4090,O
A,4091,O
combination,4091,O
of,4091,O
DNA-binding,4091,O
assays,4091,O
and,4091,O
transcriptional,4091,O
analysis,4091,O
was,4091,O
used,4091,O
to,4091,O
determine,4091,O
the,4091,O
functional,4091,O
consequences,4091,O
of,4091,O
these,4091,O
mutations,4091,O
.,4091,O
The,4092,O
zinc,4092,O
finger,4092,O
mutations,4092,O
affect,4092,O
DNA,4092,O
binding,4092,O
and,4092,O
the,4092,O
amount,4092,O
of,4092,O
residual,4092,O
binding,4092,O
directly,4092,O
correlates,4092,O
with,4092,O
disease,4092,O
severity,4092,O
.,4092,O
The,4093,O
R1,4093,O
domain,4093,O
mutation,4093,O
prevents,4093,O
interaction,4093,O
of,4093,O
EGR2,4093,O
with,4093,O
the,4093,O
NAB,4093,O
co-repressors,4093,O
and,4093,O
thereby,4093,O
increases,4093,O
transcriptional,4093,O
activity,4093,O
.,4093,O
These,4094,O
data,4094,O
provide,4094,O
insight,4094,O
into,4094,O
the,4094,O
possible,4094,O
disease,4094,O
mechanisms,4094,O
underlying,4094,O
EGR2,4094,O
mutations,4094,O
and,4094,O
the,4094,O
reason,4094,O
for,4094,O
varying,4094,O
severity,4094,O
and,4094,O
differences,4094,O
in,4094,O
inheritance,4094,O
patterns,4094,O
..,4094,O
Autosomal,4095,B-SpecificDisease
recessive,4095,I-SpecificDisease
familial,4095,I-SpecificDisease
neurohypophyseal,4095,I-SpecificDisease
diabetes,4095,I-SpecificDisease
insipidus,4095,I-SpecificDisease
with,4095,O
continued,4095,O
secretion,4095,O
of,4095,O
mutant,4095,O
weakly,4095,O
active,4095,O
vasopressin,4095,O
.,4095,O
Familial,4096,B-SpecificDisease
neurohypophyseal,4096,I-SpecificDisease
diabetes,4096,I-SpecificDisease
insipidus,4096,I-SpecificDisease
is,4096,O
an,4096,O
autosomal,4096,B-DiseaseClass
dominant,4096,I-DiseaseClass
disorder,4096,I-DiseaseClass
characterized,4096,O
by,4096,O
post-natal,4096,O
development,4096,O
of,4096,O
arginine,4096,B-SpecificDisease
vasopressin,4096,I-SpecificDisease
(,4096,I-SpecificDisease
AVP,4096,I-SpecificDisease
),4096,I-SpecificDisease
deficiency,4096,I-SpecificDisease
due,4096,O
to,4096,O
mutations,4096,O
in,4096,O
the,4096,O
AVP,4096,O
gene,4096,O
.,4096,O
All,4097,O
published,4097,O
mutations,4097,O
affect,4097,O
the,4097,O
signal,4097,O
peptide,4097,O
or,4097,O
the,4097,O
neurophysin-II,4097,O
carrier,4097,O
protein,4097,O
and,4097,O
are,4097,O
presumed,4097,O
to,4097,O
interfere,4097,O
with,4097,O
processing,4097,O
of,4097,O
the,4097,O
preprohormone,4097,O
",",4097,O
leading,4097,O
to,4097,O
neuronal,4097,B-DiseaseClass
damage,4097,I-DiseaseClass
.,4097,O
We,4098,O
studied,4098,O
an,4098,O
unusual,4098,O
Palestinian,4098,O
family,4098,O
consisting,4098,O
of,4098,O
asymptomatic,4098,O
first,4098,O
cousin,4098,O
parents,4098,O
and,4098,O
three,4098,O
children,4098,O
affected,4098,O
with,4098,O
neurohypophyseal,4098,B-SpecificDisease
diabetes,4098,I-SpecificDisease
insipidus,4098,I-SpecificDisease
",",4098,O
suggesting,4098,O
autosomal,4098,O
recessive,4098,O
inheritance,4098,O
.,4098,O
All,4099,O
three,4099,O
affected,4099,O
children,4099,O
were,4099,O
homozygous,4099,O
and,4099,O
the,4099,O
parents,4099,O
heterozygous,4099,O
for,4099,O
a,4099,O
single,4099,O
novel,4099,O
mutation,4099,O
(,4099,O
C301-,4099,O
>,4099,O
T,4099,O
),4099,O
in,4099,O
exon,4099,O
1,4099,O
",",4099,O
replacing,4099,O
Pro7,4099,O
of,4099,O
mature,4099,O
AVP,4099,O
with,4099,O
Leu,4099,O
(,4099,O
Leu-AVP,4099,O
),4099,O
.,4099,O
Leu-AVP,4100,O
was,4100,O
a,4100,O
weak,4100,O
agonist,4100,O
with,4100,O
approximately,4100,O
30-fold,4100,O
reduced,4100,O
binding,4100,O
to,4100,O
the,4100,O
human,4100,O
V2,4100,O
receptor,4100,O
.,4100,O
Measured,4101,O
by,4101,O
radioimmunoassay,4101,O
with,4101,O
a,4101,O
synthetic,4101,O
Leu-AVP,4101,O
standard,4101,O
",",4101,O
serum,4101,O
Leu-AVP,4101,O
levels,4101,O
were,4101,O
elevated,4101,O
in,4101,O
all,4101,O
three,4101,O
children,4101,O
and,4101,O
further,4101,O
increased,4101,O
during,4101,O
water,4101,O
deprivation,4101,O
to,4101,O
as,4101,O
high,4101,O
as,4101,O
30,4101,O
times,4101,O
normal,4101,O
.,4101,O
The,4102,O
youngest,4102,O
child,4102,O
(,4102,O
2,4102,O
years,4102,O
old,4102,O
),4102,O
was,4102,O
only,4102,O
mildly,4102,O
affected,4102,O
but,4102,O
had,4102,O
Leu-AVP,4102,O
levels,4102,O
similar,4102,O
to,4102,O
her,4102,O
severely,4102,O
affected,4102,O
8-year-old,4102,O
brother,4102,O
",",4102,O
suggesting,4102,O
that,4102,O
unknown,4102,O
mechanisms,4102,O
may,4102,O
partially,4102,O
compensate,4102,O
for,4102,O
a,4102,O
deficiency,4102,B-DiseaseClass
of,4102,I-DiseaseClass
active,4102,I-DiseaseClass
AVP,4102,I-DiseaseClass
in,4102,O
very,4102,O
young,4102,O
children,4102,O
..,4102,O
X,4103,O
inactivation,4103,O
and,4103,O
somatic,4103,O
cell,4103,O
selection,4103,O
rescue,4103,O
female,4103,O
mice,4103,O
carrying,4103,O
a,4103,O
Piga-null,4103,O
mutation,4103,O
.,4103,O
A,4104,O
somatic,4104,O
mutation,4104,O
in,4104,O
the,4104,O
X,4104,O
linked,4104,O
PIGA,4104,O
gene,4104,O
is,4104,O
responsible,4104,O
for,4104,O
the,4104,O
deficiency,4104,B-DiseaseClass
of,4104,I-DiseaseClass
glycosyl,4104,I-DiseaseClass
phosphatidylinositol,4104,I-DiseaseClass
(,4104,I-DiseaseClass
GPI,4104,I-DiseaseClass
),4104,I-DiseaseClass
-anchored,4104,I-DiseaseClass
proteins,4104,I-DiseaseClass
on,4104,O
blood,4104,O
cells,4104,O
from,4104,O
patients,4104,O
with,4104,O
paroxysmal,4104,B-SpecificDisease
nocturnal,4104,I-SpecificDisease
hemoglobinuria,4104,I-SpecificDisease
.,4104,O
No,4105,O
inherited,4105,O
form,4105,O
of,4105,O
GPI-anchor,4105,B-SpecificDisease
deficiency,4105,I-SpecificDisease
has,4105,O
been,4105,O
described,4105,O
.,4105,O
Because,4106,O
conventional,4106,O
Piga,4106,O
gene,4106,O
knockout,4106,O
is,4106,O
associated,4106,O
with,4106,O
high,4106,O
embryonic,4106,B-SpecificDisease
lethality,4106,I-SpecificDisease
in,4106,O
chimeric,4106,O
mice,4106,O
",",4106,O
we,4106,O
used,4106,O
the,4106,O
Cre/loxP,4106,O
system,4106,O
.,4106,O
We,4107,O
generated,4107,O
mice,4107,O
in,4107,O
which,4107,O
two,4107,O
loxP,4107,O
sites,4107,O
flank,4107,O
part,4107,O
of,4107,O
Piga,4107,O
exon,4107,O
2,4107,O
.,4107,O
After,4108,O
crossbreeding,4108,O
with,4108,O
female,4108,O
mice,4108,O
of,4108,O
the,4108,O
EIIa-cre,4108,O
strain,4108,O
",",4108,O
the,4108,O
floxed,4108,O
allele,4108,O
undergoes,4108,O
Cre-mediated,4108,O
recombination,4108,O
with,4108,O
high,4108,O
efficiency,4108,O
during,4108,O
early,4108,O
embryonic,4108,O
development,4108,O
.,4108,O
Because,4109,O
of,4109,O
X,4109,O
chromosome,4109,O
inactivation,4109,O
",",4109,O
female,4109,O
offspring,4109,O
are,4109,O
mosaic,4109,O
for,4109,O
cells,4109,O
that,4109,O
express,4109,O
or,4109,O
lack,4109,O
GPI-linked,4109,O
proteins,4109,O
.,4109,O
Analysis,4110,O
of,4110,O
mosaic,4110,O
mice,4110,O
showed,4110,O
that,4110,O
in,4110,O
heart,4110,O
",",4110,O
lung,4110,O
",",4110,O
kidney,4110,O
",",4110,O
brain,4110,O
",",4110,O
and,4110,O
liver,4110,O
",",4110,O
mainly,4110,O
wild-type,4110,O
Piga,4110,O
is,4110,O
active,4110,O
",",4110,O
suggesting,4110,O
that,4110,O
these,4110,O
tissues,4110,O
require,4110,O
GPI-linked,4110,O
proteins,4110,O
.,4110,O
The,4111,O
salient,4111,O
exceptions,4111,O
were,4111,O
spleen,4111,O
",",4111,O
thymus,4111,O
",",4111,O
and,4111,O
red,4111,O
blood,4111,O
cells,4111,O
",",4111,O
which,4111,O
had,4111,O
almost,4111,O
equal,4111,O
numbers,4111,O
of,4111,O
cells,4111,O
expressing,4111,O
the,4111,O
wild-type,4111,O
or,4111,O
the,4111,O
recombined,4111,O
allele,4111,O
",",4111,O
implying,4111,O
that,4111,O
GPI-linked,4111,O
proteins,4111,O
are,4111,O
not,4111,O
essential,4111,O
for,4111,O
the,4111,O
derivation,4111,O
of,4111,O
these,4111,O
tissues,4111,O
.,4111,O
PIGA,4112,O
(,4112,O
-,4112,O
),4112,O
cells,4112,O
had,4112,O
no,4112,O
growth,4112,O
advantage,4112,O
",",4112,O
suggesting,4112,O
that,4112,O
other,4112,O
factors,4112,O
are,4112,O
needed,4112,O
for,4112,O
their,4112,O
clonal,4112,O
dominance,4112,O
in,4112,O
patients,4112,O
with,4112,O
paroxysmal,4112,B-SpecificDisease
nocturnal,4112,I-SpecificDisease
hemoglobinuria,4112,I-SpecificDisease
..,4112,O
The,4113,O
C282Y,4113,O
mutation,4113,O
causing,4113,O
hereditary,4113,B-SpecificDisease
hemochromatosis,4113,I-SpecificDisease
does,4113,O
not,4113,O
produce,4113,O
a,4113,O
null,4113,O
allele,4113,O
.,4113,O
Targeted,4114,O
mutagenesis,4114,O
was,4114,O
used,4114,O
to,4114,O
produce,4114,O
two,4114,O
mutations,4114,O
in,4114,O
the,4114,O
murine,4114,O
hemochromatosis,4114,B-Modifier
gene,4114,O
(,4114,O
Hfe,4114,O
),4114,O
locus,4114,O
.,4114,O
The,4115,O
first,4115,O
mutation,4115,O
deletes,4115,O
a,4115,O
large,4115,O
portion,4115,O
of,4115,O
the,4115,O
coding,4115,O
sequence,4115,O
",",4115,O
generating,4115,O
a,4115,O
null,4115,O
allele,4115,O
.,4115,O
The,4116,O
second,4116,O
mutation,4116,O
introduces,4116,O
a,4116,O
missense,4116,O
mutation,4116,O
(,4116,O
C282Y,4116,O
),4116,O
into,4116,O
the,4116,O
Hfe,4116,O
locus,4116,O
",",4116,O
but,4116,O
otherwise,4116,O
leaves,4116,O
the,4116,O
gene,4116,O
intact,4116,O
.,4116,O
This,4117,O
mutation,4117,O
is,4117,O
identical,4117,O
to,4117,O
the,4117,O
disease-causing,4117,O
mutation,4117,O
in,4117,O
patients,4117,O
with,4117,O
hereditary,4117,B-SpecificDisease
hemochromatosis,4117,I-SpecificDisease
.,4117,O
Mice,4118,O
carrying,4118,O
each,4118,O
of,4118,O
the,4118,O
two,4118,O
mutations,4118,O
were,4118,O
bred,4118,O
and,4118,O
analyzed,4118,O
.,4118,O
Homozygosity,4119,O
for,4119,O
either,4119,O
mutation,4119,O
results,4119,O
in,4119,O
postnatal,4119,O
iron,4119,O
loading,4119,O
.,4119,O
The,4120,O
effects,4120,O
of,4120,O
the,4120,O
null,4120,O
mutation,4120,O
are,4120,O
more,4120,O
severe,4120,O
than,4120,O
the,4120,O
effects,4120,O
of,4120,O
the,4120,O
C282Y,4120,O
mutation,4120,O
.,4120,O
Mice,4121,O
heterozygous,4121,O
for,4121,O
either,4121,O
mutation,4121,O
accumulate,4121,O
more,4121,O
iron,4121,O
than,4121,O
normal,4121,O
controls,4121,O
.,4121,O
Interestingly,4122,O
",",4122,O
although,4122,O
liver,4122,O
iron,4122,O
stores,4122,O
are,4122,O
greatly,4122,O
increased,4122,O
",",4122,O
splenic,4122,O
iron,4122,O
is,4122,O
decreased,4122,O
.,4122,O
We,4123,O
conclude,4123,O
that,4123,O
the,4123,O
C282Y,4123,O
mutation,4123,O
does,4123,O
not,4123,O
result,4123,O
in,4123,O
a,4123,O
null,4123,O
allele,4123,O
..,4123,O
Genotype-phenotype,4124,O
analysis,4124,O
in,4124,O
X-linked,4124,B-SpecificDisease
Emery-Dreifuss,4124,I-SpecificDisease
muscular,4124,I-SpecificDisease
dystrophy,4124,I-SpecificDisease
and,4124,O
identification,4124,O
of,4124,O
a,4124,O
missense,4124,O
mutation,4124,O
associated,4124,O
with,4124,O
a,4124,O
milder,4124,O
phenotype,4124,O
.,4124,O
Direct,4125,O
sequencing,4125,O
of,4125,O
the,4125,O
emerin,4125,O
gene,4125,O
in,4125,O
22,4125,O
families,4125,O
with,4125,O
Emery-Dreifuss,4125,B-SpecificDisease
muscular,4125,I-SpecificDisease
dystrophy,4125,I-SpecificDisease
(,4125,O
EMD,4125,B-SpecificDisease
),4125,O
revealed,4125,O
mutations,4125,O
in,4125,O
21,4125,O
(,4125,O
95,4125,O
%,4125,O
),4125,O
",",4125,O
confirming,4125,O
that,4125,O
emerin,4125,O
mutations,4125,O
can,4125,O
be,4125,O
identified,4125,O
in,4125,O
the,4125,O
majority,4125,O
of,4125,O
families,4125,O
with,4125,O
X-linked,4125,B-SpecificDisease
EMD,4125,I-SpecificDisease
.,4125,O
Most,4126,O
emerin,4126,O
mutations,4126,O
result,4126,O
in,4126,O
absence,4126,O
of,4126,O
the,4126,O
protein,4126,O
.,4126,O
In,4127,O
this,4127,O
study,4127,O
three,4127,O
mutations,4127,O
(,4127,O
a,4127,O
missense,4127,O
mutation,4127,O
Pro183Thr,4127,O
and,4127,O
two,4127,O
in-frame,4127,O
deletions,4127,O
removing,4127,O
residues,4127,O
95-99,4127,O
and,4127,O
236-241,4127,O
",",4127,O
respectively,4127,O
),4127,O
were,4127,O
unusual,4127,O
in,4127,O
being,4127,O
associated,4127,O
with,4127,O
expression,4127,O
of,4127,O
mutant,4127,O
protein,4127,O
.,4127,O
The,4128,O
phenotype,4128,O
in,4128,O
these,4128,O
families,4128,O
was,4128,O
compared,4128,O
in,4128,O
detail,4128,O
with,4128,O
the,4128,O
clinical,4128,O
features,4128,O
in,4128,O
cases,4128,O
with,4128,O
typical,4128,O
null,4128,O
mutations,4128,O
.,4128,O
For,4129,O
the,4129,O
in-frame,4129,O
deletions,4129,O
there,4129,O
were,4129,O
no,4129,O
significant,4129,O
differences,4129,O
.,4129,O
In,4130,O
the,4130,O
family,4130,O
with,4130,O
the,4130,O
missense,4130,O
mutation,4130,O
the,4130,O
phenotype,4130,O
was,4130,O
milder,4130,O
.,4130,O
Age,4131,O
at,4131,O
onset,4131,O
was,4131,O
later,4131,O
for,4131,O
first,4131,O
symptoms,4131,O
and,4131,O
for,4131,O
development,4131,O
of,4131,O
ankle,4131,B-DiseaseClass
contractures,4131,I-DiseaseClass
and,4131,O
muscle,4131,B-DiseaseClass
weakness,4131,I-DiseaseClass
.,4131,O
These,4132,O
findings,4132,O
have,4132,O
diagnostic,4132,O
implications,4132,O
as,4132,O
well,4132,O
as,4132,O
pointing,4132,O
to,4132,O
functionally,4132,O
important,4132,O
regions,4132,O
of,4132,O
the,4132,O
emerin,4132,O
protein,4132,O
..,4132,O
Severe,4133,O
clinical,4133,O
expression,4133,O
in,4133,O
X-linked,4133,B-SpecificDisease
Emery-Dreifuss,4133,I-SpecificDisease
muscular,4133,I-SpecificDisease
dystrophy,4133,I-SpecificDisease
.,4133,O
X-linked,4134,B-SpecificDisease
Emery-Dreifuss,4134,I-SpecificDisease
muscular,4134,I-SpecificDisease
dystrophy,4134,I-SpecificDisease
(,4134,O
EDMD,4134,B-SpecificDisease
),4134,O
is,4134,O
a,4134,O
relatively,4134,O
rare,4134,O
benign,4134,B-DiseaseClass
neuromuscular,4134,I-DiseaseClass
disorder,4134,I-DiseaseClass
which,4134,O
can,4134,O
vary,4134,O
remarkably,4134,O
in,4134,O
onset,4134,O
",",4134,O
course,4134,O
and,4134,O
severity,4134,O
.,4134,O
In,4135,O
the,4135,O
present,4135,O
study,4135,O
",",4135,O
a,4135,O
TCTAC,4135,O
deletion,4135,O
spanning,4135,O
the,4135,O
nucleotides,4135,O
631-635,4135,O
of,4135,O
the,4135,O
emerin,4135,O
gene,4135,O
caused,4135,O
an,4135,O
unusually,4135,O
severe,4135,O
disease,4135,O
phenotype,4135,O
including,4135,O
loss,4135,B-DiseaseClass
of,4135,I-DiseaseClass
ambulation,4135,I-DiseaseClass
and,4135,O
severe,4135,O
muscle,4135,B-DiseaseClass
wasting,4135,I-DiseaseClass
in,4135,O
two,4135,O
affected,4135,O
brothers,4135,O
.,4135,O
The,4136,O
same,4136,O
mutation,4136,O
has,4136,O
been,4136,O
reported,4136,O
previously,4136,O
in,4136,O
an,4136,O
unrelated,4136,O
family,4136,O
showing,4136,O
a,4136,O
significantly,4136,O
milder,4136,O
phenotype,4136,O
.,4136,O
The,4137,O
interfamilial,4137,O
heterogeneity,4137,O
in,4137,O
distribution,4137,O
and,4137,O
in,4137,O
severity,4137,O
of,4137,O
the,4137,O
features,4137,O
in,4137,O
the,4137,O
two,4137,O
families,4137,O
point,4137,O
to,4137,O
environmental,4137,O
or,4137,O
genetic,4137,O
modification,4137,O
as,4137,O
the,4137,O
cause,4137,O
of,4137,O
clinical,4137,O
variability,4137,O
in,4137,O
Emery-Dreifuss,4137,B-SpecificDisease
muscular,4137,I-SpecificDisease
dystrophy,4137,I-SpecificDisease
..,4137,O
Common,4138,O
mutations,4138,O
in,4138,O
BRCA1,4138,O
and,4138,O
BRCA2,4138,O
do,4138,O
not,4138,O
contribute,4138,O
to,4138,O
early,4138,O
prostate,4138,B-SpecificDisease
cancer,4138,I-SpecificDisease
in,4138,O
Jewish,4138,O
men,4138,O
.,4138,O
BACKGROUND,4139,O
Families,4139,O
with,4139,O
a,4139,O
high,4139,O
incidence,4139,O
of,4139,O
hereditary,4139,B-SpecificDisease
breast,4139,I-SpecificDisease
cancer,4139,I-SpecificDisease
",",4139,O
and,4139,O
subsequently,4139,O
shown,4139,O
to,4139,O
have,4139,O
terminating,4139,O
mutations,4139,O
in,4139,O
BRCA1,4139,O
or,4139,O
BRCA2,4139,O
",",4139,O
appear,4139,O
to,4139,O
have,4139,O
a,4139,O
higher,4139,O
incidence,4139,O
of,4139,O
prostate,4139,B-SpecificDisease
cancer,4139,I-SpecificDisease
among,4139,O
male,4139,O
relatives,4139,O
.,4139,O
We,4140,O
aimed,4140,O
to,4140,O
determine,4140,O
whether,4140,O
the,4140,O
common,4140,O
germline,4140,O
mutations,4140,O
of,4140,O
BRCA1,4140,O
or,4140,O
BRCA2,4140,O
in,4140,O
Ashkenazi,4140,O
Jewish,4140,O
men,4140,O
predisposed,4140,O
them,4140,O
to,4140,O
prostate,4140,B-SpecificDisease
cancer,4140,I-SpecificDisease
.,4140,O
METHODS,4141,O
We,4141,O
examined,4141,O
genomic,4141,O
DNA,4141,O
from,4141,O
83,4141,O
(,4141,O
for,4141,O
BRCA1,4141,O
185delAG,4141,O
),4141,O
or,4141,O
82,4141,O
(,4141,O
for,4141,O
BRCA2,4141,O
6174delT,4141,O
),4141,O
Ashkenazi,4141,O
Jewish,4141,O
prostate,4141,B-Modifier
cancer,4141,I-Modifier
patients,4141,O
",",4141,O
most,4141,O
of,4141,O
whom,4141,O
were,4141,O
treated,4141,O
at,4141,O
a,4141,O
relatively,4141,O
young,4141,O
age,4141,O
",",4141,O
for,4141,O
the,4141,O
most,4141,O
common,4141,O
germline,4141,O
mutation,4141,O
in,4141,O
each,4141,O
gene,4141,O
seen,4141,O
in,4141,O
the,4141,O
Ashkenazi,4141,O
population,4141,O
.,4141,O
RESULTS,4142,O
Our,4142,O
study,4142,O
should,4142,O
have,4142,O
been,4142,O
able,4142,O
to,4142,O
detect,4142,O
a,4142,O
4-5-fold,4142,O
increase,4142,O
in,4142,O
the,4142,O
risk,4142,O
of,4142,O
prostate,4142,B-SpecificDisease
cancer,4142,I-SpecificDisease
due,4142,O
to,4142,O
mutation,4142,O
of,4142,O
BRCA1,4142,O
or,4142,O
BRCA2,4142,O
.,4142,O
However,4143,O
",",4143,O
only,4143,O
one,4143,O
(,4143,O
1,4143,O
.,4143,O
15,4144,O
%,4144,O
;,4144,O
95,4144,O
%,4144,O
confidence,4144,O
interval,4144,O
",",4144,O
0-3,4144,O
.,4144,O
6,4145,O
%,4145,O
),4145,O
of,4145,O
the,4145,O
patients,4145,O
was,4145,O
heterozygous,4145,O
for,4145,O
the,4145,O
BRCA1,4145,O
mutant,4145,O
allele,4145,O
",",4145,O
and,4145,O
only,4145,O
two,4145,O
were,4145,O
heterozygous,4145,O
for,4145,O
the,4145,O
BRCA2,4145,O
mutation,4145,O
(,4145,O
2,4145,O
.,4145,O
4,4146,O
%,4146,O
;,4146,O
95,4146,O
%,4146,O
confidence,4146,O
interval,4146,O
",",4146,O
0-6,4146,O
.,4146,O
2,4147,O
%,4147,O
),4147,O
.,4147,O
CONCLUSIONS,4148,O
The,4148,O
incidence,4148,O
of,4148,O
each,4148,O
of,4148,O
the,4148,O
germline,4148,O
mutations,4148,O
in,4148,O
these,4148,O
prostate,4148,B-Modifier
cancer,4148,I-Modifier
patients,4148,O
closely,4148,O
matched,4148,O
their,4148,O
incidence,4148,O
(,4148,O
about,4148,O
1,4148,O
%,4148,O
),4148,O
in,4148,O
the,4148,O
general,4148,O
Ashkenazi,4148,O
Jewish,4148,O
population,4148,O
.,4148,O
This,4149,O
suggests,4149,O
that,4149,O
unlike,4149,O
cases,4149,O
of,4149,O
breast,4149,O
and,4149,O
ovarian,4149,O
cancers,4149,O
",",4149,O
mutations,4149,O
in,4149,O
BRCA1,4149,O
or,4149,O
BRCA2,4149,O
do,4149,O
not,4149,O
significantly,4149,O
predispose,4149,O
men,4149,O
to,4149,O
prostate,4149,B-SpecificDisease
cancer,4149,I-SpecificDisease
Beta-catenin,4150,O
accumulation,4150,O
and,4150,O
mutation,4150,O
of,4150,O
the,4150,O
CTNNB1,4150,O
gene,4150,O
in,4150,O
hepatoblastoma,4150,B-SpecificDisease
.,4150,O
Hepatoblastoma,4151,B-SpecificDisease
is,4151,O
a,4151,O
rare,4151,O
malignant,4151,B-DiseaseClass
tumor,4151,I-DiseaseClass
of,4151,I-DiseaseClass
the,4151,I-DiseaseClass
liver,4151,I-DiseaseClass
that,4151,O
occurs,4151,O
in,4151,O
children,4151,O
at,4151,O
an,4151,O
average,4151,O
age,4151,O
of,4151,O
2,4151,O
to,4151,O
3,4151,O
years,4151,O
.,4151,O
Epidemiologic,4152,O
studies,4152,O
have,4152,O
shown,4152,O
an,4152,O
increased,4152,O
frequency,4152,O
of,4152,O
this,4152,O
tumor,4152,B-Modifier
type,4152,O
in,4152,O
families,4152,O
affected,4152,O
by,4152,O
adenomatous,4152,B-SpecificDisease
polyposis,4152,I-SpecificDisease
coli,4152,I-SpecificDisease
.,4152,O
In,4153,O
addition,4153,O
to,4153,O
the,4153,O
epidemiologic,4153,O
data,4153,O
",",4153,O
molecular,4153,O
genetic,4153,O
studies,4153,O
suggest,4153,O
that,4153,O
inactivation,4153,O
of,4153,O
the,4153,O
APC,4153,B-Modifier
tumor,4153,I-Modifier
suppressor,4153,O
may,4153,O
be,4153,O
involved,4153,O
in,4153,O
hepatoblastoma,4153,B-Modifier
tumorigenesis,4153,O
.,4153,O
A,4154,O
major,4154,O
function,4154,O
of,4154,O
APC,4154,O
is,4154,O
the,4154,O
downregulation,4154,O
of,4154,O
beta-catenin,4154,O
",",4154,O
a,4154,O
transcription-activating,4154,O
protein,4154,O
with,4154,O
oncogenic,4154,O
potential,4154,O
.,4154,O
In,4155,O
an,4155,O
ongoing,4155,O
immunohistochemical,4155,O
study,4155,O
of,4155,O
beta-catenin,4155,O
expression,4155,O
in,4155,O
sporadic,4155,O
cases,4155,O
of,4155,O
tumor,4155,B-Modifier
types,4155,O
that,4155,O
are,4155,O
associated,4155,O
with,4155,O
adenomatous,4155,B-SpecificDisease
polyposis,4155,I-SpecificDisease
coli,4155,I-SpecificDisease
",",4155,O
we,4155,O
observed,4155,O
increased,4155,O
beta-catenin,4155,O
levels,4155,O
in,4155,O
the,4155,O
cytoplasm,4155,O
and,4155,O
in,4155,O
the,4155,O
nuclei,4155,O
of,4155,O
three,4155,O
investigated,4155,O
hepatoblastomas,4155,B-SpecificDisease
.,4155,O
Sequencing,4156,O
of,4156,O
exon,4156,O
3,4156,O
of,4156,O
the,4156,O
beta-catenin,4156,O
gene,4156,O
(,4156,O
CTNNB1,4156,O
),4156,O
revealed,4156,O
an,4156,O
activating,4156,O
mutation,4156,O
in,4156,O
one,4156,O
of,4156,O
the,4156,O
tumor,4156,B-Modifier
samples,4156,O
.,4156,O
Our,4157,O
data,4157,O
indicate,4157,O
for,4157,O
the,4157,O
first,4157,O
time,4157,O
that,4157,O
beta-catenin,4157,O
accumulation,4157,O
may,4157,O
play,4157,O
a,4157,O
role,4157,O
in,4157,O
the,4157,O
development,4157,O
of,4157,O
hepatoblastoma,4157,B-SpecificDisease
and,4157,O
that,4157,O
activating,4157,O
mutations,4157,O
of,4157,O
the,4157,O
beta-catenin,4157,O
gene,4157,O
may,4157,O
substitute,4157,O
biallelic,4157,O
APC,4157,O
inactivation,4157,O
in,4157,O
this,4157,O
tumor,4157,B-Modifier
type,4157,O
.,4157,O
Genes,4158,O
Chromosomes,4158,O
Cancer,4158,O
25,4158,O
399-402,4158,O
",",4158,O
1999,4158,O
..,4158,O
Decrease,4159,O
in,4159,O
GTP,4159,O
cyclohydrolase,4159,O
I,4159,O
gene,4159,O
expression,4159,O
caused,4159,O
by,4159,O
inactivation,4159,O
of,4159,O
one,4159,O
allele,4159,O
in,4159,O
hereditary,4159,B-SpecificDisease
progressive,4159,I-SpecificDisease
dystonia,4159,I-SpecificDisease
with,4159,O
marked,4159,O
diurnal,4159,O
fluctuation,4159,O
.,4159,O
Hereditary,4160,B-SpecificDisease
progressive,4160,I-SpecificDisease
dystonia,4160,I-SpecificDisease
with,4160,O
marked,4160,O
diurnal,4160,O
fluctuation,4160,O
(,4160,O
HPD,4160,B-SpecificDisease
;,4160,O
dopa-responsive,4160,B-SpecificDisease
dystonia,4160,I-SpecificDisease
",",4160,O
DRD,4160,B-SpecificDisease
),4160,O
have,4160,O
been,4160,O
recently,4160,O
found,4160,O
to,4160,O
be,4160,O
caused,4160,O
by,4160,O
a,4160,O
genetic,4160,B-DiseaseClass
defect,4160,I-DiseaseClass
in,4160,O
the,4160,O
GTP,4160,O
cyclohydrolase,4160,O
I,4160,O
(,4160,O
GCH1,4160,O
),4160,O
gene,4160,O
.,4160,O
In,4161,O
this,4161,O
study,4161,O
",",4161,O
we,4161,O
quantified,4161,O
the,4161,O
mRNA,4161,O
level,4161,O
of,4161,O
GCH1,4161,O
in,4161,O
phytohemagglutinin,4161,O
(,4161,O
PHA,4161,O
),4161,O
-stimulated,4161,O
mononuclear,4161,O
blood,4161,O
cells,4161,O
from,4161,O
one,4161,O
Japanese,4161,O
family,4161,O
that,4161,O
do,4161,O
not,4161,O
have,4161,O
a,4161,O
mutation,4161,O
in,4161,O
the,4161,O
coding,4161,O
region,4161,O
or,4161,O
splice,4161,O
junctions,4161,O
of,4161,O
the,4161,O
gene,4161,O
.,4161,O
The,4162,O
results,4162,O
showed,4162,O
that,4162,O
the,4162,O
amounts,4162,O
of,4162,O
the,4162,O
GCH1,4162,O
mRNA,4162,O
were,4162,O
decreased,4162,O
to,4162,O
about,4162,O
40,4162,O
%,4162,O
of,4162,O
the,4162,O
normal,4162,O
level,4162,O
in,4162,O
both,4162,O
patients,4162,O
and,4162,O
carriers,4162,O
.,4162,O
In,4163,O
addition,4163,O
",",4163,O
we,4163,O
found,4163,O
that,4163,O
the,4163,O
GCH1,4163,O
mRNA,4163,O
was,4163,O
transcribed,4163,O
from,4163,O
only,4163,O
one,4163,O
allele,4163,O
",",4163,O
indicating,4163,O
that,4163,O
the,4163,O
other,4163,O
allele,4163,O
was,4163,O
in,4163,O
an,4163,O
inactive,4163,O
state,4163,O
.,4163,O
These,4164,O
results,4164,O
suggest,4164,O
that,4164,O
some,4164,O
novel,4164,O
mutations,4164,O
should,4164,O
exist,4164,O
on,4164,O
one,4164,O
of,4164,O
the,4164,O
alleles,4164,O
in,4164,O
some,4164,O
unknown,4164,O
region,4164,O
of,4164,O
the,4164,O
GCH1,4164,O
gene,4164,O
",",4164,O
and,4164,O
may,4164,O
decrease,4164,O
the,4164,O
GCH1,4164,O
mRNA,4164,O
causing,4164,O
the,4164,O
HPD/DRD,4164,B-Modifier
symptoms,4164,O
..,4164,O
Sulfate,4165,O
transport,4165,O
is,4165,O
not,4165,O
impaired,4165,O
in,4165,O
pendred,4165,B-Modifier
syndrome,4165,I-Modifier
thyrocytes,4165,O
.,4165,O
Pendred,4166,B-SpecificDisease
syndrome,4166,I-SpecificDisease
is,4166,O
the,4166,O
most,4166,O
common,4166,O
form,4166,O
of,4166,O
syndromic,4166,B-DiseaseClass
deafness,4166,I-DiseaseClass
",",4166,O
characterized,4166,O
by,4166,O
dyshormonogenic,4166,B-SpecificDisease
goiter,4166,I-SpecificDisease
associated,4166,O
with,4166,O
sensory-neural,4166,B-DiseaseClass
deafness,4166,I-DiseaseClass
.,4166,O
The,4167,O
gene,4167,O
responsible,4167,O
for,4167,O
the,4167,O
disease,4167,O
(,4167,O
PDS,4167,B-SpecificDisease
),4167,O
has,4167,O
been,4167,O
cloned,4167,O
",",4167,O
but,4167,O
its,4167,O
function,4167,O
is,4167,O
as,4167,O
yet,4167,O
unknown,4167,O
and,4167,O
the,4167,O
connection,4167,O
between,4167,O
thyroid,4167,B-DiseaseClass
goiter,4167,I-DiseaseClass
and,4167,O
sensory-neural,4167,B-DiseaseClass
deafness,4167,I-DiseaseClass
remains,4167,O
an,4167,O
enigma,4167,O
.,4167,O
PDS,4168,O
codes,4168,O
for,4168,O
a,4168,O
novel,4168,O
protein,4168,O
",",4168,O
pendrin,4168,O
",",4168,O
which,4168,O
is,4168,O
closely,4168,O
related,4168,O
to,4168,O
a,4168,O
number,4168,O
of,4168,O
sufate,4168,O
transporters,4168,O
.,4168,O
Mechanisms,4169,O
by,4169,O
which,4169,O
abnormal,4169,O
sulfate,4169,O
transport,4169,O
could,4169,O
deleteriously,4169,O
affect,4169,O
iodide,4169,O
organification,4169,O
have,4169,O
been,4169,O
proposed,4169,O
.,4169,O
We,4170,O
tested,4170,O
sulfate,4170,O
transport,4170,O
in,4170,O
thyrocytes,4170,O
obtained,4170,O
from,4170,O
Pendred,4170,B-Modifier
syndrome,4170,I-Modifier
patients,4170,O
and,4170,O
found,4170,O
that,4170,O
it,4170,O
was,4170,O
not,4170,O
defective,4170,O
.,4170,O
This,4171,O
suggests,4171,O
that,4171,O
pendrin,4171,O
in,4171,O
fact,4171,O
may,4171,O
not,4171,O
be,4171,O
a,4171,O
sulfate,4171,O
transporter,4171,O
",",4171,O
and,4171,O
emphasizes,4171,O
the,4171,O
importance,4171,O
of,4171,O
functional,4171,O
studies,4171,O
on,4171,O
this,4171,O
novel,4171,O
protein,4171,O
..,4171,O
Small,4172,O
deletions,4172,O
in,4172,O
the,4172,O
type,4172,O
II,4172,O
collagen,4172,O
triple,4172,O
helix,4172,O
produce,4172,O
kniest,4172,B-SpecificDisease
dysplasia,4172,I-SpecificDisease
.,4172,O
Kniest,4173,B-SpecificDisease
dysplasia,4173,I-SpecificDisease
is,4173,O
a,4173,O
moderately,4173,O
severe,4173,O
type,4173,B-DiseaseClass
II,4173,I-DiseaseClass
collagenopathy,4173,I-DiseaseClass
",",4173,O
characterized,4173,O
by,4173,O
short,4173,O
trunk,4173,O
and,4173,O
limbs,4173,O
",",4173,O
kyphoscoliosis,4173,B-DiseaseClass
",",4173,O
midface,4173,B-SpecificDisease
hypoplasia,4173,I-SpecificDisease
",",4173,O
severe,4173,O
myopia,4173,B-DiseaseClass
",",4173,O
and,4173,O
hearing,4173,B-DiseaseClass
loss,4173,I-DiseaseClass
.,4173,O
Mutations,4174,O
in,4174,O
the,4174,O
gene,4174,O
that,4174,O
encodes,4174,O
type,4174,O
II,4174,O
collagen,4174,O
(,4174,O
COL2A1,4174,O
),4174,O
",",4174,O
the,4174,O
predominant,4174,O
protein,4174,O
of,4174,O
cartilage,4174,O
",",4174,O
have,4174,O
been,4174,O
identified,4174,O
in,4174,O
a,4174,O
number,4174,O
of,4174,O
individuals,4174,O
with,4174,O
Kniest,4174,B-SpecificDisease
dysplasia,4174,I-SpecificDisease
.,4174,O
All,4175,O
but,4175,O
two,4175,O
of,4175,O
these,4175,O
previously,4175,O
described,4175,O
mutations,4175,O
cause,4175,O
in-frame,4175,O
deletions,4175,O
in,4175,O
type,4175,O
II,4175,O
collagen,4175,O
",",4175,O
either,4175,O
by,4175,O
small,4175,O
deletions,4175,O
in,4175,O
the,4175,O
gene,4175,O
or,4175,O
splice,4175,O
site,4175,O
alterations,4175,O
.,4175,O
Furthermore,4176,O
",",4176,O
all,4176,O
but,4176,O
one,4176,O
of,4176,O
these,4176,O
mutations,4176,O
is,4176,O
located,4176,O
between,4176,O
exons,4176,O
12,4176,O
and,4176,O
24,4176,O
in,4176,O
the,4176,O
COL2A1,4176,O
gene,4176,O
.,4176,O
We,4177,O
used,4177,O
heteroduplex,4177,O
analysis,4177,O
to,4177,O
identify,4177,O
sequence,4177,O
anomalies,4177,O
in,4177,O
five,4177,O
individuals,4177,O
with,4177,O
Kniest,4177,B-SpecificDisease
dysplasia,4177,I-SpecificDisease
.,4177,O
Sequencing,4178,O
of,4178,O
the,4178,O
index,4178,O
patients,4178,O
genomic,4178,O
DNA,4178,O
identified,4178,O
four,4178,O
new,4178,O
dominant,4178,O
mutations,4178,O
in,4178,O
COL2A1,4178,O
that,4178,O
result,4178,O
in,4178,O
Kniest,4178,B-SpecificDisease
dysplasia,4178,I-SpecificDisease
a,4178,O
21-bp,4178,O
deletion,4178,O
in,4178,O
exon,4178,O
16,4178,O
",",4178,O
an,4178,O
18-bp,4178,O
deletion,4178,O
in,4178,O
exon,4178,O
19,4178,O
",",4178,O
and,4178,O
4-bp,4178,O
deletions,4178,O
in,4178,O
the,4178,O
splice,4178,O
donor,4178,O
sites,4178,O
of,4178,O
introns,4178,O
14,4178,O
and,4178,O
20,4178,O
.,4178,O
A,4179,O
previously,4179,O
described,4179,O
28-bp,4179,O
deletion,4179,O
at,4179,O
the,4179,O
COL2A1,4179,O
exon,4179,O
12-intron,4179,O
12,4179,O
junction,4179,O
",",4179,O
deleting,4179,O
the,4179,O
splice,4179,O
donor,4179,O
site,4179,O
",",4179,O
was,4179,O
identified,4179,O
in,4179,O
the,4179,O
fifth,4179,O
case,4179,O
.,4179,O
The,4180,O
latter,4180,O
three,4180,O
mutations,4180,O
are,4180,O
predicted,4180,O
to,4180,O
result,4180,O
in,4180,O
exon,4180,O
skipping,4180,O
in,4180,O
the,4180,O
mRNA,4180,O
encoded,4180,O
from,4180,O
the,4180,O
mutant,4180,O
allele,4180,O
.,4180,O
These,4181,O
data,4181,O
suggest,4181,O
that,4181,O
Kniest,4181,B-SpecificDisease
dysplasia,4181,I-SpecificDisease
results,4181,O
from,4181,O
shorter,4181,O
type,4181,O
II,4181,O
collagen,4181,O
monomers,4181,O
",",4181,O
and,4181,O
support,4181,O
the,4181,O
hypothesis,4181,O
that,4181,O
alteration,4181,O
of,4181,O
a,4181,O
specific,4181,O
COL2A1,4181,O
domain,4181,O
",",4181,O
which,4181,O
may,4181,O
span,4181,O
from,4181,O
exons,4181,O
12,4181,O
to,4181,O
24,4181,O
",",4181,O
leads,4181,O
to,4181,O
the,4181,O
Kniest,4181,B-Modifier
dysplasia,4181,I-Modifier
phenotype,4181,O
..,4181,O
Classical,4182,B-SpecificDisease
galactosemia,4182,I-SpecificDisease
and,4182,O
mutations,4182,O
at,4182,O
the,4182,O
galactose-1-phosphate,4182,O
uridyl,4182,O
transferase,4182,O
(,4182,O
GALT,4182,O
),4182,O
gene,4182,O
.,4182,O
Classical,4183,B-SpecificDisease
galactosemia,4183,I-SpecificDisease
is,4183,O
caused,4183,O
by,4183,O
a,4183,O
deficiency,4183,O
in,4183,O
activity,4183,O
of,4183,O
the,4183,O
enzyme,4183,O
galactose-1-phosphate,4183,O
uridyl,4183,O
transferase,4183,O
(,4183,O
GALT,4183,O
),4183,O
",",4183,O
which,4183,O
",",4183,O
in,4183,O
turn,4183,O
",",4183,O
is,4183,O
caused,4183,O
by,4183,O
mutations,4183,O
at,4183,O
the,4183,O
GALT,4183,O
gene,4183,O
.,4183,O
The,4184,O
disorder,4184,O
exhibits,4184,O
considerable,4184,O
allelic,4184,O
heterogeneity,4184,O
and,4184,O
",",4184,O
at,4184,O
the,4184,O
end,4184,O
of,4184,O
1998,4184,O
",",4184,O
more,4184,O
than,4184,O
150,4184,O
different,4184,O
base,4184,O
changes,4184,O
were,4184,O
recorded,4184,O
in,4184,O
24,4184,O
different,4184,O
populations,4184,O
and,4184,O
ethnic,4184,O
groups,4184,O
in,4184,O
15,4184,O
countries,4184,O
worldwide,4184,O
.,4184,O
The,4185,O
mutations,4185,O
most,4185,O
frequently,4185,O
cited,4185,O
are,4185,O
Q188R,4185,O
",",4185,O
K285N,4185,O
",",4185,O
S135L,4185,O
",",4185,O
and,4185,O
N314D,4185,O
.,4185,O
Q188R,4186,O
is,4186,O
the,4186,O
most,4186,O
common,4186,O
mutation,4186,O
in,4186,O
European,4186,O
populations,4186,O
or,4186,O
in,4186,O
those,4186,O
predominantly,4186,O
of,4186,O
European,4186,O
descent,4186,O
.,4186,O
Overall,4187,O
",",4187,O
it,4187,O
accounts,4187,O
for,4187,O
60-70,4187,O
%,4187,O
of,4187,O
mutant,4187,O
chromosomes,4187,O
",",4187,O
but,4187,O
there,4187,O
are,4187,O
significant,4187,O
differences,4187,O
in,4187,O
its,4187,O
relative,4187,O
frequency,4187,O
in,4187,O
individual,4187,O
populations,4187,O
.,4187,O
Individuals,4188,O
homoallelic,4188,O
for,4188,O
Q188R,4188,O
tend,4188,O
to,4188,O
have,4188,O
a,4188,O
severe,4188,O
phenotype,4188,O
and,4188,O
this,4188,O
is,4188,O
in,4188,O
keeping,4188,O
with,4188,O
the,4188,O
virtually,4188,O
complete,4188,O
loss,4188,O
of,4188,O
enzyme,4188,O
activity,4188,O
observed,4188,O
in,4188,O
in,4188,O
vitro,4188,O
expression,4188,O
systems,4188,O
.,4188,O
Globally,4189,O
",",4189,O
K285N,4189,O
is,4189,O
rarer,4189,O
",",4189,O
but,4189,O
in,4189,O
many,4189,O
European,4189,O
populations,4189,O
it,4189,O
can,4189,O
be,4189,O
found,4189,O
on,4189,O
25-40,4189,O
%,4189,O
of,4189,O
mutant,4189,O
chromosomes,4189,O
.,4189,O
It,4190,O
is,4190,O
invariably,4190,O
associated,4190,O
with,4190,O
a,4190,O
severe,4190,O
phenotype,4190,O
.,4190,O
S135L,4191,O
is,4191,O
found,4191,O
almost,4191,O
exclusively,4191,O
in,4191,O
African,4191,O
Americans,4191,O
.,4191,O
In,4192,O
vitro,4192,O
expression,4192,O
results,4192,O
are,4192,O
discrepant,4192,O
",",4192,O
but,4192,O
some,4192,O
individuals,4192,O
carrying,4192,O
S135L,4192,O
appear,4192,O
to,4192,O
exhibit,4192,O
GALT,4192,O
activity,4192,O
in,4192,O
some,4192,O
tissues,4192,O
.,4192,O
Duarte,4193,O
1,4193,O
(,4193,O
or,4193,O
Los,4193,O
Angeles,4193,O
),4193,O
and,4193,O
Duarte,4193,O
2,4193,O
(,4193,O
or,4193,O
Duarte,4193,O
),4193,O
variants,4193,O
carry,4193,O
the,4193,O
same,4193,O
amino,4193,O
acid,4193,O
substitution,4193,O
",",4193,O
N314D,4193,O
",",4193,O
even,4193,O
though,4193,O
D1,4193,O
is,4193,O
associated,4193,O
with,4193,O
increased,4193,O
erythrocyte,4193,O
GALT,4193,O
activity,4193,O
and,4193,O
D2,4193,O
with,4193,O
reduced,4193,O
activity,4193,O
.,4193,O
N314D,4194,O
is,4194,O
in,4194,O
linkage,4194,O
disequilibrium,4194,O
with,4194,O
other,4194,O
base,4194,O
changes,4194,O
that,4194,O
differ,4194,O
on,4194,O
the,4194,O
D1,4194,O
and,4194,O
D2,4194,O
alleles,4194,O
.,4194,O
N314D,4195,O
does,4195,O
not,4195,O
impair,4195,O
GALT,4195,O
activity,4195,O
in,4195,O
in,4195,O
vitro,4195,O
expression,4195,O
systems,4195,O
.,4195,O
However,4196,O
",",4196,O
there,4196,O
are,4196,O
differences,4196,O
in,4196,O
the,4196,O
abundance,4196,O
of,4196,O
GALT,4196,O
protein,4196,O
in,4196,O
lymphoblastoid,4196,O
cells,4196,O
lines,4196,O
from,4196,O
D2,4196,O
and,4196,O
D1,4196,O
individuals,4196,O
.,4196,O
It,4197,O
is,4197,O
unclear,4197,O
whether,4197,O
the,4197,O
specific,4197,O
molecular,4197,O
changes,4197,O
that,4197,O
distinguish,4197,O
the,4197,O
D1,4197,O
and,4197,O
D2,4197,O
alleles,4197,O
account,4197,O
for,4197,O
the,4197,O
different,4197,O
activities,4197,O
.,4197,O
The,4198,O
considerable,4198,O
genetic,4198,O
heterogeneity,4198,O
documented,4198,O
to,4198,O
date,4198,O
undoubtedly,4198,O
contributes,4198,O
to,4198,O
the,4198,O
phenotypic,4198,O
heterogeneity,4198,O
that,4198,O
is,4198,O
observed,4198,O
in,4198,O
galactosemia,4198,B-SpecificDisease
.,4198,O
The,4199,O
additional,4199,O
effects,4199,O
of,4199,O
nonallelic,4199,O
variation,4199,O
and,4199,O
other,4199,O
constitutional,4199,O
factors,4199,O
on,4199,O
phenotypic,4199,O
variability,4199,O
remain,4199,O
to,4199,O
be,4199,O
elucidated,4199,O
..,4199,O
Mutations,4200,O
of,4200,O
the,4200,O
VHL,4200,B-Modifier
gene,4200,O
in,4200,O
sporadic,4200,B-SpecificDisease
renal,4200,I-SpecificDisease
cell,4200,I-SpecificDisease
carcinoma,4200,I-SpecificDisease
:,4200,O
definition,4200,O
of,4200,O
a,4200,O
risk,4200,O
factor,4200,O
for,4200,O
VHL,4200,B-Modifier
patients,4200,O
to,4200,O
develop,4200,O
an,4200,O
RCC,4200,B-SpecificDisease
.,4200,O
To,4201,O
investigate,4201,O
the,4201,O
nature,4201,O
of,4201,O
somatic,4201,O
von,4201,B-Modifier
Hippel-Lindau,4201,I-Modifier
(,4201,O
VHL,4201,B-Modifier
),4201,O
mutations,4201,O
",",4201,O
we,4201,O
analyzed,4201,O
173,4201,O
primary,4201,O
sporadic,4201,O
human,4201,O
renal,4201,B-SpecificDisease
cell,4201,I-SpecificDisease
carcinomas,4201,I-SpecificDisease
for,4201,O
mutations,4201,O
of,4201,O
the,4201,O
VHL,4201,B-Modifier
tumor,4201,I-Modifier
suppressor,4201,O
gene,4201,O
",",4201,O
using,4201,O
polymerase,4201,O
chain,4201,O
reaction,4201,O
(,4201,O
PCR,4201,O
),4201,O
and,4201,O
single-strand,4201,O
conformational,4201,O
polymorphism,4201,O
analysis,4201,O
(,4201,O
SSCP,4201,O
),4201,O
of,4201,O
DNA,4201,O
.,4201,O
We,4202,O
detected,4202,O
abnormal,4202,O
SSCP,4202,O
pattern,4202,O
in,4202,O
73,4202,O
samples,4202,O
.,4202,O
After,4203,O
sequencing,4203,O
",",4203,O
we,4203,O
identified,4203,O
microdeletions,4203,O
in,4203,O
58,4203,O
%,4203,O
of,4203,O
cases,4203,O
",",4203,O
microinsertions,4203,O
in,4203,O
17,4203,O
%,4203,O
",",4203,O
nonsense,4203,O
mutations,4203,O
in,4203,O
8,4203,O
%,4203,O
",",4203,O
and,4203,O
missense,4203,O
mutations,4203,O
in,4203,O
17,4203,O
%,4203,O
.,4203,O
Among,4204,O
these,4204,O
mutations,4204,O
",",4204,O
50,4204,O
%,4204,O
correspond,4204,O
to,4204,O
new,4204,O
mutations,4204,O
.,4204,O
VHL,4205,B-Modifier
mutations,4205,O
were,4205,O
found,4205,O
only,4205,O
in,4205,O
the,4205,O
nonpapillary,4205,B-Modifier
renal,4205,I-Modifier
cell,4205,I-Modifier
carcinoma,4205,I-Modifier
(,4205,O
RCC,4205,B-Modifier
),4205,O
subtype,4205,O
",",4205,O
as,4205,O
previously,4205,O
reported,4205,O
.,4205,O
To,4206,O
compare,4206,O
somatic,4206,O
and,4206,O
germline,4206,O
mutations,4206,O
",",4206,O
we,4206,O
used,4206,O
the,4206,O
VHL,4206,B-Modifier
database,4206,O
",",4206,O
which,4206,O
includes,4206,O
507,4206,O
mutations,4206,O
.,4206,O
The,4207,O
study,4207,O
of,4207,O
mutational,4207,O
events,4207,O
revealed,4207,O
a,4207,O
significant,4207,O
difference,4207,O
between,4207,O
somatic,4207,O
and,4207,O
germline,4207,O
mutations,4207,O
with,4207,O
mutations,4207,O
leading,4207,O
to,4207,O
truncated,4207,O
proteins,4207,O
observed,4207,O
in,4207,O
78,4207,O
%,4207,O
of,4207,O
somatic,4207,O
mutations,4207,O
vs,4207,O
only,4207,O
37,4207,O
%,4207,O
in,4207,O
germline,4207,O
mutations,4207,O
(,4207,O
P,4207,O
<,4207,O
0,4207,O
.,4207,O
001,4208,O
),4208,O
.,4208,O
We,4209,O
postulated,4209,O
that,4209,O
a,4209,O
specific,4209,O
pattern,4209,O
of,4209,O
VHL,4209,B-Modifier
mutations,4209,O
is,4209,O
associated,4209,O
with,4209,O
sporadic,4209,B-SpecificDisease
RCC,4209,I-SpecificDisease
.,4209,O
This,4210,O
pattern,4210,O
corresponds,4210,O
to,4210,O
mutations,4210,O
leading,4210,O
mainly,4210,O
to,4210,O
truncated,4210,O
proteins,4210,O
with,4210,O
few,4210,O
specific,4210,O
missense,4210,O
mutations,4210,O
.,4210,O
We,4211,O
then,4211,O
analyzed,4211,O
the,4211,O
occurrence,4211,O
of,4211,O
RCC,4211,B-SpecificDisease
in,4211,O
VHL,4211,B-Modifier
families,4211,O
",",4211,O
based,4211,O
on,4211,O
the,4211,O
nature,4211,O
of,4211,O
mutations,4211,O
.,4211,O
We,4212,O
observed,4212,O
RCC,4212,B-SpecificDisease
in,4212,O
at,4212,O
least,4212,O
one,4212,O
member,4212,O
of,4212,O
the,4212,O
VHL,4212,B-Modifier
families,4212,O
in,4212,O
77,4212,O
%,4212,O
of,4212,O
cases,4212,O
with,4212,O
mutations,4212,O
leading,4212,O
to,4212,O
truncated,4212,O
proteins,4212,O
versus,4212,O
55,4212,O
%,4212,O
in,4212,O
cases,4212,O
with,4212,O
missense,4212,O
mutations,4212,O
(,4212,O
P,4212,O
<,4212,O
0,4212,O
.,4212,O
05,4213,O
),4213,O
.,4213,O
Thus,4214,O
",",4214,O
mutations,4214,O
resulting,4214,O
in,4214,O
truncated,4214,O
proteins,4214,O
may,4214,O
lead,4214,O
to,4214,O
a,4214,O
higher,4214,O
risk,4214,O
of,4214,O
RCC,4214,B-SpecificDisease
in,4214,O
VHL,4214,B-Modifier
patients,4214,O
Defective,4215,O
CTLA-4,4215,O
cycling,4215,O
pathway,4215,O
in,4215,O
Chediak-Higashi,4215,B-SpecificDisease
syndrome,4215,I-SpecificDisease
:,4215,O
a,4215,O
possible,4215,O
mechanism,4215,O
for,4215,O
deregulation,4215,O
of,4215,O
T,4215,O
lymphocyte,4215,O
activation,4215,O
.,4215,O
Cytotoxic,4216,O
T,4216,O
lymphocyte-associated,4216,O
antigen,4216,O
4,4216,O
(,4216,O
CTLA-4,4216,O
",",4216,O
also,4216,O
known,4216,O
as,4216,O
CD152,4216,O
),4216,O
has,4216,O
been,4216,O
shown,4216,O
to,4216,O
play,4216,O
a,4216,O
major,4216,O
role,4216,O
in,4216,O
the,4216,O
regulation,4216,O
of,4216,O
T,4216,O
cell,4216,O
activation,4216,O
.,4216,O
Its,4217,O
membrane,4217,O
expression,4217,O
is,4217,O
highly,4217,O
regulated,4217,O
by,4217,O
endocytosis,4217,O
and,4217,O
trafficking,4217,O
through,4217,O
the,4217,O
secretory,4217,O
lysosome,4217,O
pathway,4217,O
.,4217,O
Chediak-Higashi,4218,B-SpecificDisease
syndrome,4218,I-SpecificDisease
(,4218,O
CHS,4218,B-SpecificDisease
),4218,O
is,4218,O
an,4218,O
inherited,4218,B-DiseaseClass
disorder,4218,I-DiseaseClass
caused,4218,O
by,4218,O
mutations,4218,O
in,4218,O
the,4218,O
lysosomal,4218,O
trafficking,4218,O
regulator,4218,O
gene,4218,O
",",4218,O
LYST,4218,O
.,4218,O
It,4219,O
results,4219,O
in,4219,O
defective,4219,O
membrane,4219,O
targeting,4219,O
of,4219,O
the,4219,O
proteins,4219,O
present,4219,O
in,4219,O
secretory,4219,O
lysosomes,4219,O
",",4219,O
and,4219,O
it,4219,O
is,4219,O
associated,4219,O
with,4219,O
a,4219,O
variety,4219,O
of,4219,O
features,4219,O
",",4219,O
including,4219,O
a,4219,O
lymphoproliferative,4219,B-SpecificDisease
syndrome,4219,I-SpecificDisease
with,4219,O
hemophagocytosis,4219,B-DiseaseClass
.,4219,O
The,4220,O
murine,4220,O
equivalent,4220,O
of,4220,O
CHS,4220,B-SpecificDisease
",",4220,O
beige,4220,O
mice,4220,O
",",4220,O
present,4220,O
similar,4220,O
characteristics,4220,O
but,4220,O
do,4220,O
not,4220,O
develop,4220,O
the,4220,O
lymphoproliferative,4220,B-SpecificDisease
syndrome,4220,I-SpecificDisease
.,4220,O
We,4221,O
show,4221,O
herein,4221,O
that,4221,O
CTLA-4,4221,O
is,4221,O
present,4221,O
in,4221,O
enlarged,4221,O
",",4221,O
abnormal,4221,O
vesicles,4221,O
in,4221,O
CHS,4221,B-Modifier
T,4221,O
cells,4221,O
and,4221,O
is,4221,O
not,4221,O
properly,4221,O
expressed,4221,O
at,4221,O
the,4221,O
cell,4221,O
surface,4221,O
after,4221,O
T,4221,O
cell,4221,O
activation,4221,O
",",4221,O
whereas,4221,O
its,4221,O
surface,4221,O
expression,4221,O
is,4221,O
not,4221,O
impaired,4221,O
.,4221,O
It,4222,O
is,4222,O
therefore,4222,O
proposed,4222,O
that,4222,O
the,4222,O
defective,4222,O
surface,4222,O
expression,4222,O
of,4222,O
CTLA-4,4222,O
by,4222,O
CHS,4222,B-Modifier
T,4222,O
cells,4222,O
is,4222,O
involved,4222,O
in,4222,O
the,4222,O
generation,4222,O
of,4222,O
lymphoproliferative,4222,B-SpecificDisease
disease,4222,I-SpecificDisease
.,4222,O
This,4223,O
observation,4223,O
may,4223,O
provide,4223,O
insight,4223,O
into,4223,O
the,4223,O
role,4223,O
of,4223,O
CTLA-4,4223,O
in,4223,O
humans,4223,O
..,4223,O
Proteolipoprotein,4224,O
gene,4224,O
analysis,4224,O
in,4224,O
82,4224,O
patients,4224,O
with,4224,O
sporadic,4224,O
Pelizaeus-Merzbacher,4224,B-SpecificDisease
Disease,4224,I-SpecificDisease
:,4224,O
duplications,4224,O
",",4224,O
the,4224,O
major,4224,O
cause,4224,O
of,4224,O
the,4224,O
disease,4224,O
",",4224,O
originate,4224,O
more,4224,O
frequently,4224,O
in,4224,O
male,4224,O
germ,4224,O
cells,4224,O
",",4224,O
but,4224,O
point,4224,O
mutations,4224,O
do,4224,O
not,4224,O
.,4224,O
The,4225,O
Clinical,4225,O
European,4225,O
Network,4225,O
on,4225,O
Brain,4225,B-DiseaseClass
Dysmyelinating,4225,I-DiseaseClass
Disease,4225,I-DiseaseClass
.,4225,O
Pelizaeus-Merzbacher,4226,B-SpecificDisease
Disease,4226,I-SpecificDisease
(,4226,O
PMD,4226,B-SpecificDisease
),4226,O
is,4226,O
an,4226,O
X-linked,4226,B-DiseaseClass
developmental,4226,I-DiseaseClass
defect,4226,I-DiseaseClass
of,4226,I-DiseaseClass
myelination,4226,I-DiseaseClass
affecting,4226,O
the,4226,O
central,4226,O
nervous,4226,O
system,4226,O
and,4226,O
segregating,4226,O
with,4226,O
the,4226,O
proteolipoprotein,4226,O
(,4226,O
PLP,4226,O
),4226,O
locus,4226,O
.,4226,O
Investigating,4227,O
82,4227,O
strictly,4227,O
selected,4227,O
sporadic,4227,O
cases,4227,O
of,4227,O
PMD,4227,B-SpecificDisease
",",4227,O
we,4227,O
found,4227,O
PLP,4227,O
mutations,4227,O
in,4227,O
77,4227,O
%,4227,O
;,4227,O
complete,4227,O
PLP-gene,4227,O
duplications,4227,O
were,4227,O
the,4227,O
most,4227,O
frequent,4227,O
abnormality,4227,O
(,4227,O
62,4227,O
%,4227,O
),4227,O
",",4227,O
whereas,4227,O
point,4227,O
mutations,4227,O
in,4227,O
coding,4227,O
or,4227,O
splice-site,4227,O
regions,4227,O
of,4227,O
the,4227,O
gene,4227,O
were,4227,O
involved,4227,O
less,4227,O
frequently,4227,O
(,4227,O
38,4227,O
%,4227,O
),4227,O
.,4227,O
We,4228,O
analyzed,4228,O
the,4228,O
maternal,4228,O
status,4228,O
of,4228,O
56,4228,O
cases,4228,O
to,4228,O
determine,4228,O
the,4228,O
origin,4228,O
of,4228,O
both,4228,O
types,4228,O
of,4228,O
PLP,4228,O
mutation,4228,O
",",4228,O
since,4228,O
this,4228,O
is,4228,O
relevant,4228,O
to,4228,O
genetic,4228,O
counseling,4228,O
.,4228,O
In,4229,O
the,4229,O
22,4229,O
point,4229,O
mutations,4229,O
",",4229,O
68,4229,O
%,4229,O
of,4229,O
mothers,4229,O
were,4229,O
heterozygous,4229,O
for,4229,O
the,4229,O
mutation,4229,O
",",4229,O
a,4229,O
value,4229,O
identical,4229,O
to,4229,O
the,4229,O
two-thirds,4229,O
of,4229,O
carrier,4229,O
mothers,4229,O
that,4229,O
would,4229,O
be,4229,O
expected,4229,O
if,4229,O
there,4229,O
were,4229,O
an,4229,O
equal,4229,O
mutation,4229,O
rate,4229,O
in,4229,O
male,4229,O
and,4229,O
female,4229,O
germ,4229,O
cells,4229,O
.,4229,O
In,4230,O
sharp,4230,O
contrast,4230,O
",",4230,O
among,4230,O
the,4230,O
34,4230,O
duplicated,4230,O
cases,4230,O
",",4230,O
91,4230,O
%,4230,O
of,4230,O
mothers,4230,O
were,4230,O
carriers,4230,O
",",4230,O
a,4230,O
value,4230,O
significantly,4230,O
(,4230,O
chi2,4230,O
=,4230,O
9,4230,O
.,4230,O
20,4231,O
",",4231,O
P,4231,O
<,4231,O
.,4231,O
01,4232,O
),4232,O
in,4232,O
favor,4232,O
of,4232,O
a,4232,O
male,4232,O
bias,4232,O
",",4232,O
with,4232,O
an,4232,O
estimation,4232,O
of,4232,O
the,4232,O
male/female,4232,O
mutation,4232,O
frequency,4232,O
(,4232,O
k,4232,O
),4232,O
of,4232,O
9,4232,O
.,4232,O
3,4233,O
3,4233,O
.,4233,O
Moreover,4234,O
",",4234,O
we,4234,O
observed,4234,O
the,4234,O
occurrence,4234,O
of,4234,O
de,4234,O
novo,4234,O
mutations,4234,O
between,4234,O
parental,4234,O
and,4234,O
grandparental,4234,O
generations,4234,O
in,4234,O
17,4234,O
three-generation,4234,O
families,4234,O
",",4234,O
which,4234,O
allowed,4234,O
a,4234,O
direct,4234,O
estimation,4234,O
of,4234,O
the,4234,O
k,4234,O
value,4234,O
(,4234,O
k,4234,O
=,4234,O
11,4234,O
),4234,O
.,4234,O
Again,4235,O
",",4235,O
a,4235,O
significant,4235,O
male,4235,O
mutation,4235,O
imbalance,4235,O
was,4235,O
observed,4235,O
only,4235,O
for,4235,O
the,4235,O
duplications,4235,O
.,4235,O
Chromosome,4236,O
breakage,4236,O
in,4236,O
the,4236,O
Prader-Willi,4236,O
and,4236,O
Angelman,4236,O
syndromes,4236,O
involves,4236,O
recombination,4236,O
between,4236,O
large,4236,O
",",4236,O
transcribed,4236,O
repeats,4236,O
at,4236,O
proximal,4236,O
and,4236,O
distal,4236,O
breakpoints,4236,O
.,4236,O
Prader-Willi,4237,B-SpecificDisease
syndrome,4237,I-SpecificDisease
(,4237,O
PWS,4237,B-SpecificDisease
),4237,O
and,4237,O
Angelman,4237,B-SpecificDisease
syndrome,4237,I-SpecificDisease
(,4237,O
AS,4237,B-SpecificDisease
),4237,O
are,4237,O
distinct,4237,O
neurobehavioral,4237,B-DiseaseClass
disorders,4237,I-DiseaseClass
that,4237,O
most,4237,O
often,4237,O
arise,4237,O
from,4237,O
a,4237,O
4-Mb,4237,O
deletion,4237,O
of,4237,O
chromosome,4237,O
15q11-q13,4237,O
during,4237,O
paternal,4237,O
or,4237,O
maternal,4237,O
gametogenesis,4237,O
",",4237,O
respectively,4237,O
.,4237,O
At,4238,O
a,4238,O
de,4238,O
novo,4238,O
frequency,4238,O
of,4238,O
approximately,4238,O
.,4238,O
67-1/10,4239,O
",",4239,O
000,4239,O
births,4239,O
",",4239,O
these,4239,O
deletions,4239,O
represent,4239,O
a,4239,O
common,4239,O
structural,4239,O
chromosome,4239,O
change,4239,O
in,4239,O
the,4239,O
human,4239,O
genome,4239,O
.,4239,O
To,4240,O
elucidate,4240,O
the,4240,O
mechanism,4240,O
underlying,4240,O
these,4240,O
events,4240,O
",",4240,O
we,4240,O
characterized,4240,O
the,4240,O
regions,4240,O
that,4240,O
contain,4240,O
two,4240,O
proximal,4240,O
breakpoint,4240,O
clusters,4240,O
and,4240,O
a,4240,O
distal,4240,O
cluster,4240,O
.,4240,O
Novel,4241,O
DNA,4241,O
sequences,4241,O
potentially,4241,O
associated,4241,O
with,4241,O
the,4241,O
breakpoints,4241,O
were,4241,O
positionally,4241,O
cloned,4241,O
from,4241,O
YACs,4241,O
within,4241,O
or,4241,O
near,4241,O
these,4241,O
regions,4241,O
.,4241,O
Analyses,4242,O
of,4242,O
rodent-human,4242,O
somatic-cell,4242,O
hybrids,4242,O
",",4242,O
YAC,4242,O
contigs,4242,O
",",4242,O
and,4242,O
FISH,4242,O
of,4242,O
normal,4242,O
or,4242,O
rearranged,4242,O
chromosomes,4242,O
15,4242,O
identified,4242,O
duplicated,4242,O
sequences,4242,O
(,4242,O
the,4242,O
END,4242,O
repeats,4242,O
),4242,O
at,4242,O
or,4242,O
near,4242,O
the,4242,O
breakpoints,4242,O
.,4242,O
The,4243,O
END-repeat,4243,O
units,4243,O
are,4243,O
derived,4243,O
from,4243,O
large,4243,O
genomic,4243,O
duplications,4243,O
of,4243,O
a,4243,O
novel,4243,O
gene,4243,O
(,4243,O
HERC2,4243,O
),4243,O
",",4243,O
many,4243,O
copies,4243,O
of,4243,O
which,4243,O
are,4243,O
transcriptionally,4243,O
active,4243,O
in,4243,O
germline,4243,O
tissues,4243,O
.,4243,O
One,4244,O
of,4244,O
five,4244,O
PWS/AS,4244,B-Modifier
patients,4244,O
analyzed,4244,O
to,4244,O
date,4244,O
has,4244,O
an,4244,O
identifiable,4244,O
",",4244,O
rearranged,4244,O
HERC2,4244,O
transcript,4244,O
derived,4244,O
from,4244,O
the,4244,O
deletion,4244,O
event,4244,O
.,4244,O
We,4245,O
postulate,4245,O
that,4245,O
the,4245,O
END,4245,O
repeats,4245,O
flanking,4245,O
15q11-q13,4245,O
mediate,4245,O
homologous,4245,O
recombination,4245,O
resulting,4245,O
in,4245,O
deletion,4245,O
.,4245,O
Furthermore,4246,O
",",4246,O
we,4246,O
propose,4246,O
that,4246,O
active,4246,O
transcription,4246,O
of,4246,O
these,4246,O
repeats,4246,O
in,4246,O
male,4246,O
and,4246,O
female,4246,O
germ,4246,O
cells,4246,O
may,4246,O
facilitate,4246,O
the,4246,O
homologous,4246,O
recombination,4246,O
process,4246,O
.,4246,O
Linkage,4247,O
analysis,4247,O
in,4247,O
a,4247,O
large,4247,O
Brazilian,4247,O
family,4247,O
with,4247,O
van,4247,B-SpecificDisease
der,4247,I-SpecificDisease
Woude,4247,I-SpecificDisease
syndrome,4247,I-SpecificDisease
suggests,4247,O
the,4247,O
existence,4247,O
of,4247,O
a,4247,O
susceptibility,4247,O
locus,4247,O
for,4247,O
cleft,4247,B-SpecificDisease
palate,4247,I-SpecificDisease
at,4247,O
17p11.2-11.1,4247,O
.,4247,O
van,4248,B-SpecificDisease
der,4248,I-SpecificDisease
Woude,4248,I-SpecificDisease
syndrome,4248,I-SpecificDisease
(,4248,O
VWS,4248,B-SpecificDisease
),4248,O
",",4248,O
which,4248,O
has,4248,O
been,4248,O
mapped,4248,O
to,4248,O
1q32-41,4248,O
",",4248,O
is,4248,O
characterized,4248,O
by,4248,O
pits,4248,B-CompositeMention
and/or,4248,I-CompositeMention
sinuses,4248,I-CompositeMention
of,4248,I-CompositeMention
the,4248,I-CompositeMention
lower,4248,I-CompositeMention
lip,4248,I-CompositeMention
",",4248,O
cleft,4248,O
lip/palate,4248,O
(,4248,O
CL/P,4248,O
),4248,O
",",4248,O
cleft,4248,B-SpecificDisease
palate,4248,I-SpecificDisease
(,4248,O
CP,4248,B-SpecificDisease
),4248,O
",",4248,O
bifid,4248,B-SpecificDisease
uvula,4248,I-SpecificDisease
",",4248,O
and,4248,O
hypodontia,4248,B-SpecificDisease
(,4248,O
H,4248,B-SpecificDisease
),4248,O
.,4248,O
The,4249,O
expression,4249,O
of,4249,O
VWS,4249,B-SpecificDisease
",",4249,O
which,4249,O
has,4249,O
incomplete,4249,O
penetrance,4249,O
",",4249,O
is,4249,O
highly,4249,O
variable,4249,O
.,4249,O
Both,4250,O
the,4250,O
occurrence,4250,O
of,4250,O
CL/P,4250,O
and,4250,O
CP,4250,B-SpecificDisease
within,4250,O
the,4250,O
same,4250,O
genealogy,4250,O
and,4250,O
a,4250,O
recurrence,4250,O
risk,4250,O
<,4250,O
40,4250,O
%,4250,O
for,4250,O
CP,4250,B-SpecificDisease
among,4250,O
descendants,4250,O
with,4250,O
VWS,4250,B-SpecificDisease
have,4250,O
suggested,4250,O
that,4250,O
the,4250,O
development,4250,O
of,4250,O
clefts,4250,O
in,4250,O
this,4250,O
syndrome,4250,O
is,4250,O
influenced,4250,O
by,4250,O
modifying,4250,O
genes,4250,O
at,4250,O
other,4250,O
loci,4250,O
.,4250,O
To,4251,O
test,4251,O
this,4251,O
hypothesis,4251,O
",",4251,O
we,4251,O
have,4251,O
conducted,4251,O
linkage,4251,O
analysis,4251,O
in,4251,O
a,4251,O
large,4251,O
Brazilian,4251,O
kindred,4251,O
with,4251,O
VWS,4251,B-SpecificDisease
",",4251,O
considering,4251,O
as,4251,O
affected,4251,O
the,4251,O
individuals,4251,O
with,4251,O
CP,4251,B-SpecificDisease
",",4251,O
regardless,4251,O
of,4251,O
whether,4251,O
it,4251,O
is,4251,O
associated,4251,O
with,4251,O
other,4251,O
clinical,4251,O
signs,4251,O
of,4251,O
VWS,4251,B-SpecificDisease
.,4251,O
Our,4252,O
results,4252,O
suggest,4252,O
that,4252,O
a,4252,O
gene,4252,O
at,4252,O
17p11,4252,O
.,4252,O
2-11,4253,O
2-11,4253,O
.,4253,O
1,4254,O
",",4254,O
together,4254,O
with,4254,O
the,4254,O
VWS,4254,B-Modifier
gene,4254,O
at,4254,O
1p32-41,4254,O
",",4254,O
enhances,4254,O
the,4254,O
probability,4254,O
of,4254,O
CP,4254,B-SpecificDisease
in,4254,O
an,4254,O
individual,4254,O
carrying,4254,O
the,4254,O
two,4254,O
at-risk,4254,O
genes,4254,O
.,4254,O
If,4255,O
this,4255,O
hypothesis,4255,O
is,4255,O
confirmed,4255,O
in,4255,O
other,4255,O
VWS,4255,B-Modifier
pedigrees,4255,O
",",4255,O
it,4255,O
will,4255,O
represent,4255,O
one,4255,O
of,4255,O
the,4255,O
first,4255,O
examples,4255,O
of,4255,O
a,4255,O
gene,4255,O
",",4255,O
mapped,4255,O
through,4255,O
linkage,4255,O
analysis,4255,O
",",4255,O
which,4255,O
modifies,4255,O
the,4255,O
expression,4255,O
of,4255,O
a,4255,O
major,4255,O
gene,4255,O
.,4255,O
New,4256,O
mutations,4256,O
",",4256,O
polymorphisms,4256,O
",",4256,O
and,4256,O
rare,4256,O
variants,4256,O
in,4256,O
the,4256,O
ATM,4256,O
gene,4256,O
detected,4256,O
by,4256,O
a,4256,O
novel,4256,O
SSCP,4256,O
strategy,4256,O
.,4256,O
The,4257,O
gene,4257,O
for,4257,O
ataxia-telangiectasia,4257,B-SpecificDisease
",",4257,O
ATM,4257,O
",",4257,O
spans,4257,O
about,4257,O
150,4257,O
kb,4257,O
of,4257,O
genomic,4257,O
DNA,4257,O
.,4257,O
ATM,4258,O
mutations,4258,O
are,4258,O
found,4258,O
along,4258,O
the,4258,O
entire,4258,O
gene,4258,O
",",4258,O
with,4258,O
no,4258,O
evidence,4258,O
of,4258,O
a,4258,O
mutational,4258,O
hot,4258,O
spot,4258,O
.,4258,O
Using,4259,O
DNA,4259,O
as,4259,O
the,4259,O
starting,4259,O
material,4259,O
",",4259,O
we,4259,O
screened,4259,O
the,4259,O
ATM,4259,O
gene,4259,O
in,4259,O
92,4259,O
A-T,4259,B-Modifier
patients,4259,O
",",4259,O
using,4259,O
an,4259,O
optimized,4259,O
single-strand,4259,O
conformation,4259,O
polymorphism,4259,O
(,4259,O
SSCP,4259,O
),4259,O
technique,4259,O
that,4259,O
detected,4259,O
all,4259,O
previously,4259,O
known,4259,O
mutations,4259,O
in,4259,O
the,4259,O
polymerase,4259,O
chain,4259,O
reaction,4259,O
(,4259,O
PCR,4259,O
),4259,O
segments,4259,O
being,4259,O
analyzed,4259,O
.,4259,O
To,4260,O
expedite,4260,O
screening,4260,O
",",4260,O
we,4260,O
sequentially,4260,O
loaded,4260,O
the,4260,O
SSCP,4260,O
gels,4260,O
with,4260,O
three,4260,O
different,4260,O
sets,4260,O
of,4260,O
PCR,4260,O
products,4260,O
that,4260,O
were,4260,O
pretested,4260,O
to,4260,O
avoid,4260,O
overlapping,4260,O
patterns,4260,O
.,4260,O
Many,4261,O
of,4261,O
the,4261,O
DNA,4261,O
changes,4261,O
we,4261,O
detected,4261,O
were,4261,O
intragenic,4261,O
polymorphisms,4261,O
.,4261,O
Of,4262,O
an,4262,O
expected,4262,O
177,4262,O
unknown,4262,O
mutations,4262,O
",",4262,O
we,4262,O
detected,4262,O
approximately,4262,O
70,4262,O
%,4262,O
",",4262,O
mostly,4262,O
protein,4262,O
truncating,4262,O
mutations,4262,O
(,4262,O
that,4262,O
would,4262,O
have,4262,O
been,4262,O
detectable,4262,O
by,4262,O
protein,4262,O
truncation,4262,O
testing,4262,O
if,4262,O
RNA,4262,O
starting,4262,O
material,4262,O
had,4262,O
been,4262,O
available,4262,O
),4262,O
.,4262,O
Mutations,4263,O
have,4263,O
now,4263,O
been,4263,O
defined,4263,O
for,4263,O
every,4263,O
exon,4263,O
of,4263,O
the,4263,O
ATM,4263,O
gene,4263,O
.,4263,O
Herein,4264,O
",",4264,O
we,4264,O
present,4264,O
35,4264,O
new,4264,O
mutations,4264,O
and,4264,O
34,4264,O
new,4264,O
intragenic,4264,O
polymorphisms,4264,O
or,4264,O
rare,4264,O
variants,4264,O
within,4264,O
the,4264,O
ATM,4264,O
gene,4264,O
.,4264,O
This,4265,O
is,4265,O
the,4265,O
most,4265,O
comprehensive,4265,O
compilation,4265,O
of,4265,O
ATM,4265,O
polymorphisms,4265,O
assembled,4265,O
to,4265,O
date,4265,O
.,4265,O
Defining,4266,O
polymorphic,4266,O
sites,4266,O
as,4266,O
well,4266,O
as,4266,O
mutations,4266,O
in,4266,O
the,4266,O
ATM,4266,O
gene,4266,O
will,4266,O
be,4266,O
of,4266,O
great,4266,O
importance,4266,O
in,4266,O
designing,4266,O
automated,4266,O
methods,4266,O
for,4266,O
detecting,4266,O
mutations,4266,O
..,4266,O
A,4267,O
novel,4267,O
frameshift,4267,O
mutation,4267,O
in,4267,O
the,4267,O
McLeod,4267,B-Modifier
syndrome,4267,I-Modifier
gene,4267,O
in,4267,O
a,4267,O
Japanese,4267,O
family,4267,O
.,4267,O
We,4268,O
report,4268,O
a,4268,O
novel,4268,O
mutation,4268,O
in,4268,O
the,4268,O
XK,4268,O
gene,4268,O
(,4268,O
XK,4268,O
),4268,O
in,4268,O
a,4268,O
Japanese,4268,O
patient,4268,O
with,4268,O
McLeod,4268,B-SpecificDisease
syndrome,4268,I-SpecificDisease
.,4268,O
A,4269,O
50-year-old,4269,O
man,4269,O
showed,4269,O
progressive,4269,O
muscular,4269,B-DiseaseClass
atrophy,4269,I-DiseaseClass
",",4269,O
choreic,4269,B-DiseaseClass
movement,4269,I-DiseaseClass
",",4269,O
elevated,4269,O
level,4269,O
of,4269,O
serum,4269,O
creatinine,4269,O
kinase,4269,O
",",4269,O
and,4269,O
acanthocytosis,4269,B-SpecificDisease
.,4269,O
The,4270,O
expression,4270,O
level,4270,O
of,4270,O
all,4270,O
the,4270,O
Kell,4270,O
antigens,4270,O
in,4270,O
erythrocyte,4270,O
was,4270,O
decreased,4270,O
and,4270,O
molecular,4270,O
analysis,4270,O
revealed,4270,O
a,4270,O
single-base,4270,O
(,4270,O
T,4270,O
),4270,O
deletion,4270,O
at,4270,O
the,4270,O
nucleotide,4270,O
position,4270,O
1095,4270,O
in,4270,O
XK,4270,O
.,4270,O
This,4271,O
deletion,4271,O
caused,4271,O
a,4271,O
frameshift,4271,O
in,4271,O
translation,4271,O
",",4271,O
leading,4271,O
to,4271,O
a,4271,O
premature,4271,O
stop,4271,O
codon,4271,O
at,4271,O
the,4271,O
amino,4271,O
acid,4271,O
position,4271,O
408,4271,O
.,4271,O
We,4272,O
conclude,4272,O
this,4272,O
single-base,4272,O
deletion,4272,O
causes,4272,O
defective,4272,O
Kx,4272,O
protein,4272,O
",",4272,O
which,4272,O
is,4272,O
responsible,4272,O
for,4272,O
the,4272,O
McLeod,4272,B-Modifier
phenotype,4272,O
in,4272,O
this,4272,O
patient,4272,O
..,4272,O
Association,4273,O
of,4273,O
BRCA1,4273,O
with,4273,O
the,4273,O
hRad50-hMre11-p95,4273,O
complex,4273,O
and,4273,O
the,4273,O
DNA,4273,O
damage,4273,O
response,4273,O
.,4273,O
BRCA1,4274,O
encodes,4274,O
a,4274,O
tumor,4274,B-Modifier
suppressor,4274,O
that,4274,O
is,4274,O
mutated,4274,O
in,4274,O
familial,4274,B-CompositeMention
breast,4274,I-CompositeMention
and,4274,I-CompositeMention
ovarian,4274,I-CompositeMention
cancers,4274,I-CompositeMention
.,4274,O
Here,4275,O
",",4275,O
it,4275,O
is,4275,O
shown,4275,O
that,4275,O
BRCA1,4275,O
interacts,4275,O
in,4275,O
vitro,4275,O
and,4275,O
in,4275,O
vivo,4275,O
with,4275,O
hRad50,4275,O
",",4275,O
which,4275,O
forms,4275,O
a,4275,O
complex,4275,O
with,4275,O
hMre11,4275,O
and,4275,O
p95/nibrin,4275,O
.,4275,O
Upon,4276,O
irradiation,4276,O
",",4276,O
BRCA1,4276,O
was,4276,O
detected,4276,O
in,4276,O
discrete,4276,O
foci,4276,O
in,4276,O
the,4276,O
nucleus,4276,O
",",4276,O
which,4276,O
colocalize,4276,O
with,4276,O
hRad50,4276,O
.,4276,O
Formation,4277,O
of,4277,O
irradiation-induced,4277,O
foci,4277,O
positive,4277,O
for,4277,O
BRCA1,4277,O
",",4277,O
hRad50,4277,O
",",4277,O
hMre11,4277,O
",",4277,O
or,4277,O
p95,4277,O
was,4277,O
dramatically,4277,O
reduced,4277,O
in,4277,O
HCC/1937,4277,O
breast,4277,B-Modifier
cancer,4277,I-Modifier
cells,4277,O
carrying,4277,O
a,4277,O
homozygous,4277,O
mutation,4277,O
in,4277,O
BRCA1,4277,O
but,4277,O
was,4277,O
restored,4277,O
by,4277,O
transfection,4277,O
of,4277,O
wild-type,4277,O
BRCA1,4277,O
.,4277,O
Ectopic,4278,O
expression,4278,O
of,4278,O
wild-type,4278,O
",",4278,O
but,4278,O
not,4278,O
mutated,4278,O
",",4278,O
BRCA1,4278,O
in,4278,O
these,4278,O
cells,4278,O
rendered,4278,O
them,4278,O
less,4278,O
sensitive,4278,O
to,4278,O
the,4278,O
DNA,4278,O
damage,4278,O
agent,4278,O
",",4278,O
methyl,4278,O
methanesulfonate,4278,O
.,4278,O
These,4279,O
data,4279,O
suggest,4279,O
that,4279,O
BRCA1,4279,O
is,4279,O
important,4279,O
for,4279,O
the,4279,O
cellular,4279,O
responses,4279,O
to,4279,O
DNA,4279,O
damage,4279,O
that,4279,O
are,4279,O
mediated,4279,O
by,4279,O
the,4279,O
hRad50-hMre11-p95,4279,O
complex,4279,O
..,4279,O
Relationship,4280,O
among,4280,O
genotype,4280,O
",",4280,O
biochemical,4280,O
phenotype,4280,O
",",4280,O
and,4280,O
cognitive,4280,O
performance,4280,O
in,4280,O
females,4280,O
with,4280,O
phenylalanine,4280,B-SpecificDisease
hydroxylase,4280,I-SpecificDisease
deficiency,4280,I-SpecificDisease
:,4280,O
report,4280,O
from,4280,O
the,4280,O
Maternal,4280,B-Modifier
Phenylketonuria,4280,I-Modifier
Collaborative,4280,O
Study,4280,O
.,4280,O
OBJECTIVE,4281,O
To,4281,O
examine,4281,O
the,4281,O
relationship,4281,O
of,4281,O
phenylalanine,4281,O
hydroxylase,4281,O
(,4281,O
PAH,4281,O
),4281,O
genotypes,4281,O
to,4281,O
biochemical,4281,O
phenotype,4281,O
and,4281,O
cognitive,4281,O
development,4281,O
in,4281,O
maternal,4281,B-SpecificDisease
phenylketonuria,4281,I-SpecificDisease
(,4281,O
PKU,4281,B-SpecificDisease
),4281,O
.,4281,O
METHODOLOGY,4282,O
PAH,4282,O
gene,4282,O
mutations,4282,O
were,4282,O
examined,4282,O
in,4282,O
222,4282,O
hyperphenylalaninemic,4282,B-Modifier
females,4282,O
enrolled,4282,O
in,4282,O
the,4282,O
Maternal,4282,B-Modifier
PKU,4282,I-Modifier
Collaborative,4282,O
Study,4282,O
(,4282,O
MPKUCS,4282,O
),4282,O
.,4282,O
A,4283,O
total,4283,O
of,4283,O
84,4283,O
different,4283,O
mutations,4283,O
were,4283,O
detected,4283,O
",",4283,O
and,4283,O
complete,4283,O
genotype,4283,O
was,4283,O
obtained,4283,O
in,4283,O
199,4283,O
individuals,4283,O
.,4283,O
Based,4284,O
on,4284,O
previous,4284,O
knowledge,4284,O
about,4284,O
mutation-phenotype,4284,O
associations,4284,O
",",4284,O
78,4284,O
of,4284,O
the,4284,O
mutations,4284,O
could,4284,O
be,4284,O
assigned,4284,O
to,4284,O
one,4284,O
of,4284,O
four,4284,O
classes,4284,O
of,4284,O
severity,4284,O
(,4284,O
severe,4284,O
PKU,4284,B-SpecificDisease
",",4284,O
moderate,4284,O
PKU,4284,B-SpecificDisease
",",4284,O
mild,4284,O
PKU,4284,B-SpecificDisease
",",4284,O
and,4284,O
mild,4284,B-SpecificDisease
hyperphenylalaninemia,4284,I-SpecificDisease
[,4284,O
MHP,4284,B-SpecificDisease
],4284,O
),4284,O
.,4284,O
Then,4285,O
",",4285,O
189,4285,O
MPKUCS,4285,O
subjects,4285,O
were,4285,O
grouped,4285,O
according,4285,O
to,4285,O
the,4285,O
various,4285,O
combinations,4285,O
of,4285,O
mutation,4285,O
classifications,4285,O
.,4285,O
The,4286,O
sample,4286,O
sizes,4286,O
were,4286,O
large,4286,O
enough,4286,O
for,4286,O
statistical,4286,O
testing,4286,O
in,4286,O
four,4286,O
groups,4286,O
with,4286,O
at,4286,O
least,4286,O
one,4286,O
mutation,4286,O
that,4286,O
completely,4286,O
abolishes,4286,O
enzyme,4286,O
activity,4286,O
.,4286,O
These,4287,O
patients,4287,O
are,4287,O
considered,4287,O
functionally,4287,O
hemizygous,4287,O
.,4287,O
RESULTS,4288,O
The,4288,O
biochemical,4288,O
phenotype,4288,O
predicted,4288,O
from,4288,O
the,4288,O
genotype,4288,O
in,4288,O
functionally,4288,O
hemizygous,4288,O
patients,4288,O
was,4288,O
related,4288,O
significantly,4288,O
to,4288,O
the,4288,O
assigned,4288,O
phenylalanine,4288,O
level,4288,O
.,4288,O
Cognitive,4289,O
performance,4289,O
(,4289,O
IQ,4289,O
),4289,O
was,4289,O
also,4289,O
significantly,4289,O
related,4289,O
to,4289,O
genotype,4289,O
.,4289,O
The,4290,O
IQ,4290,O
of,4290,O
PAH-deficient,4290,B-Modifier
mothers,4290,O
with,4290,O
a,4290,O
severe,4290,O
PKU,4290,B-Modifier
mutation,4290,O
in,4290,O
combination,4290,O
with,4290,O
a,4290,O
MHP,4290,B-Modifier
mutation,4290,O
or,4290,O
a,4290,O
mild,4290,O
PKU,4290,B-Modifier
mutation,4290,O
was,4290,O
99,4290,O
and,4290,O
96,4290,O
",",4290,O
respectively,4290,O
",",4290,O
whereas,4290,O
the,4290,O
IQ,4290,O
of,4290,O
PKU,4290,B-Modifier
mothers,4290,O
with,4290,O
two,4290,O
severe,4290,O
PKU,4290,B-Modifier
mutations,4290,O
or,4290,O
with,4290,O
one,4290,O
severe,4290,O
and,4290,O
one,4290,O
moderate,4290,O
PKU,4290,B-Modifier
mutation,4290,O
was,4290,O
83,4290,O
and,4290,O
84,4290,O
",",4290,O
respectively,4290,O
.,4290,O
Of,4291,O
the,4291,O
patients,4291,O
with,4291,O
PKU,4291,B-SpecificDisease
",",4291,O
92,4291,O
%,4291,O
had,4291,O
been,4291,O
treated,4291,O
during,4291,O
childhood,4291,O
.,4291,O
Those,4292,O
who,4292,O
were,4292,O
untreated,4292,O
or,4292,O
treated,4292,O
late,4292,O
had,4292,O
lower,4292,O
than,4292,O
average,4292,O
IQ,4292,O
scores,4292,O
for,4292,O
their,4292,O
group,4292,O
of,4292,O
mutation,4292,O
combinations,4292,O
.,4292,O
Females,4293,O
with,4293,O
moderate,4293,O
or,4293,O
mild,4293,O
PKU,4293,B-SpecificDisease
who,4293,O
were,4293,O
treated,4293,O
early,4293,O
and,4293,O
treated,4293,O
for,4293,O
>,4293,O
6,4293,O
years,4293,O
showed,4293,O
IQ,4293,O
scores,4293,O
10,4293,O
points,4293,O
above,4293,O
average,4293,O
for,4293,O
their,4293,O
group,4293,O
.,4293,O
CONCLUSIONS,4294,O
The,4294,O
reproductive,4294,O
outcome,4294,O
in,4294,O
maternal,4294,B-SpecificDisease
phenylketonuria,4294,I-SpecificDisease
is,4294,O
dependent,4294,O
on,4294,O
prenatal,4294,O
metabolic,4294,O
control,4294,O
and,4294,O
postnatal,4294,O
environmental,4294,O
circumstances,4294,O
.,4294,O
Both,4295,O
factors,4295,O
depend,4295,O
on,4295,O
the,4295,O
intellectual,4295,O
resources,4295,O
of,4295,O
the,4295,O
mother,4295,O
with,4295,O
PKU,4295,B-SpecificDisease
.,4295,O
The,4296,O
significant,4296,O
relationship,4296,O
among,4296,O
genotype,4296,O
",",4296,O
biochemical,4296,O
phenotype,4296,O
",",4296,O
and,4296,O
cognitive,4296,O
performance,4296,O
observed,4296,O
in,4296,O
the,4296,O
present,4296,O
study,4296,O
is,4296,O
of,4296,O
importance,4296,O
for,4296,O
the,4296,O
development,4296,O
of,4296,O
an,4296,O
optimal,4296,O
strategy,4296,O
for,4296,O
future,4296,O
treatment,4296,O
of,4296,O
females,4296,O
with,4296,O
PKU,4296,B-SpecificDisease
who,4296,O
plan,4296,O
pregnancy,4296,O
..,4296,O
Spinal,4297,B-SpecificDisease
xanthomatosis,4297,I-SpecificDisease
:,4297,O
a,4297,O
variant,4297,O
of,4297,O
cerebrotendinous,4297,B-DiseaseClass
xanthomatosis,4297,I-DiseaseClass
.,4297,O
We,4298,O
describe,4298,O
seven,4298,O
Dutch,4298,O
patients,4298,O
from,4298,O
six,4298,O
families,4298,O
with,4298,O
a,4298,O
slowly,4298,O
progressive,4298,O
",",4298,O
mainly,4298,O
spinal,4298,B-SpecificDisease
cord,4298,I-SpecificDisease
syndrome,4298,I-SpecificDisease
that,4298,O
remained,4298,O
for,4298,O
many,4298,O
years,4298,O
the,4298,O
sole,4298,O
expression,4298,O
of,4298,O
cerebrotendinous,4298,B-SpecificDisease
xanthomatosis,4298,I-SpecificDisease
(,4298,O
CTX,4298,B-SpecificDisease
),4298,O
.,4298,O
MRI,4299,O
demonstrated,4299,O
white,4299,B-DiseaseClass
matter,4299,I-DiseaseClass
abnormalities,4299,I-DiseaseClass
in,4299,O
the,4299,O
lateral,4299,O
and,4299,O
dorsal,4299,O
columns,4299,O
of,4299,O
the,4299,O
spinal,4299,O
cord,4299,O
.,4299,O
Post-mortem,4300,O
examination,4300,O
of,4300,O
one,4300,O
of,4300,O
the,4300,O
patients,4300,O
showed,4300,O
extensive,4300,O
myelin,4300,O
loss,4300,O
in,4300,O
these,4300,O
columns,4300,O
.,4300,O
An,4301,O
array,4301,O
of,4301,O
genotypes,4301,O
was,4301,O
found,4301,O
in,4301,O
these,4301,O
patients,4301,O
.,4301,O
We,4302,O
conclude,4302,O
that,4302,O
spinal,4302,B-SpecificDisease
xanthomatosis,4302,I-SpecificDisease
is,4302,O
a,4302,O
clinical,4302,O
and,4302,O
radiological,4302,O
separate,4302,O
entity,4302,O
of,4302,O
CTX,4302,B-SpecificDisease
that,4302,O
should,4302,O
be,4302,O
included,4302,O
in,4302,O
the,4302,O
differential,4302,O
diagnosis,4302,O
of,4302,O
chronic,4302,B-DiseaseClass
myelopathy,4302,I-DiseaseClass
..,4302,O
A,4303,O
transgene,4303,O
insertion,4303,O
creating,4303,O
a,4303,O
heritable,4303,O
chromosome,4303,O
deletion,4303,O
mouse,4303,O
model,4303,O
of,4303,O
Prader-Willi,4303,O
and,4303,O
angelman,4303,O
syndromes,4303,O
.,4303,O
Prader-Willi,4304,B-SpecificDisease
syndrome,4304,I-SpecificDisease
(,4304,O
PWS,4304,B-SpecificDisease
),4304,O
and,4304,O
Angelman,4304,B-SpecificDisease
syndrome,4304,I-SpecificDisease
(,4304,O
AS,4304,B-SpecificDisease
),4304,O
result,4304,O
from,4304,O
the,4304,O
loss,4304,O
of,4304,O
function,4304,O
of,4304,O
imprinted,4304,O
genes,4304,O
in,4304,O
human,4304,O
chromosome,4304,O
15q11-q13,4304,O
.,4304,O
The,4305,O
central,4305,O
part,4305,O
of,4305,O
mouse,4305,O
chromosome,4305,O
7,4305,O
is,4305,O
homologous,4305,O
to,4305,O
human,4305,O
15q11-q13,4305,O
",",4305,O
with,4305,O
conservation,4305,O
of,4305,O
both,4305,O
gene,4305,O
order,4305,O
and,4305,O
imprinted,4305,O
features,4305,O
.,4305,O
We,4306,O
report,4306,O
here,4306,O
the,4306,O
characterization,4306,O
of,4306,O
a,4306,O
transgene,4306,O
insertion,4306,O
(,4306,O
Epstein-Barr,4306,O
virus,4306,O
Latent,4306,O
Membrane,4306,O
Protein,4306,O
2A,4306,O
",",4306,O
LMP2A,4306,O
),4306,O
into,4306,O
mouse,4306,O
chromosome,4306,O
7C,4306,O
",",4306,O
which,4306,O
has,4306,O
resulted,4306,O
in,4306,O
mouse,4306,O
models,4306,O
for,4306,O
PWS,4306,B-SpecificDisease
and,4306,O
AS,4306,B-SpecificDisease
dependent,4306,O
on,4306,O
the,4306,O
sex,4306,O
of,4306,O
the,4306,O
transmitting,4306,O
parent,4306,O
.,4306,O
Epigenotype,4307,O
(,4307,O
allelic,4307,O
expression,4307,O
and,4307,O
DNA,4307,O
methylation,4307,O
),4307,O
and,4307,O
fluorescence,4307,O
in,4307,O
situ,4307,O
hybridization,4307,O
analyses,4307,O
indicate,4307,O
that,4307,O
the,4307,O
transgene-induced,4307,O
mutation,4307,O
has,4307,O
generated,4307,O
a,4307,O
complete,4307,O
deletion,4307,O
of,4307,O
the,4307,O
PWS/AS-homologous,4307,B-Modifier
region,4307,O
but,4307,O
has,4307,O
not,4307,O
deleted,4307,O
flanking,4307,O
loci,4307,O
.,4307,O
Because,4308,O
the,4308,O
intact,4308,O
chromosome,4308,O
7,4308,O
",",4308,O
opposite,4308,O
the,4308,O
deleted,4308,O
homolog,4308,O
",",4308,O
maintains,4308,O
the,4308,O
correct,4308,O
imprint,4308,O
in,4308,O
somatic,4308,O
cells,4308,O
of,4308,O
PWS,4308,B-Modifier
and,4308,O
AS,4308,B-Modifier
mice,4308,O
and,4308,O
establishes,4308,O
the,4308,O
correct,4308,O
imprint,4308,O
in,4308,O
male,4308,O
and,4308,O
female,4308,O
germ,4308,O
cells,4308,O
of,4308,O
AS,4308,B-Modifier
mice,4308,O
",",4308,O
homologous,4308,O
association,4308,O
and,4308,O
replication,4308,O
asynchrony,4308,O
are,4308,O
not,4308,O
part,4308,O
of,4308,O
the,4308,O
imprinting,4308,O
mechanism,4308,O
.,4308,O
This,4309,O
heritable-deletion,4309,O
mouse,4309,O
model,4309,O
will,4309,O
be,4309,O
particularly,4309,O
useful,4309,O
for,4309,O
the,4309,O
identification,4309,O
of,4309,O
the,4309,O
etiological,4309,O
genes,4309,O
and,4309,O
mechanisms,4309,O
",",4309,O
phenotypic,4309,O
basis,4309,O
",",4309,O
and,4309,O
investigation,4309,O
of,4309,O
therapeutic,4309,O
approaches,4309,O
for,4309,O
PWS,4309,B-SpecificDisease
..,4309,O
Linkage,4310,O
analysis,4310,O
of,4310,O
5,4310,O
novel,4310,O
van,4310,B-Modifier
der,4310,I-Modifier
Woude,4310,I-Modifier
syndrome,4310,I-Modifier
kindreds,4310,O
to,4310,O
1q32-q41,4310,O
markers,4310,O
further,4310,O
supports,4310,O
locus,4310,O
homogeneity,4310,O
of,4310,O
the,4310,O
disease,4310,O
trait,4310,O
.,4310,O
van,4311,B-SpecificDisease
der,4311,I-SpecificDisease
Woude,4311,I-SpecificDisease
syndrome,4311,I-SpecificDisease
(,4311,O
vWS,4311,B-SpecificDisease
",",4311,O
MIM,4311,O
119300,4311,O
),4311,O
is,4311,O
a,4311,O
rare,4311,O
autosomal,4311,B-DiseaseClass
dominant,4311,I-DiseaseClass
clefting,4311,I-DiseaseClass
condition,4311,I-DiseaseClass
with,4311,O
cardinal,4311,O
features,4311,O
of,4311,O
mucous,4311,B-SpecificDisease
cysts,4311,I-SpecificDisease
(,4311,O
lower-lip,4311,B-SpecificDisease
pits,4311,I-SpecificDisease
),4311,O
and,4311,O
clefts,4311,O
to,4311,O
the,4311,O
lip,4311,O
and/or,4311,O
palate,4311,O
.,4311,O
The,4312,O
vWS,4312,B-Modifier
gene,4312,O
has,4312,O
been,4312,O
assigned,4312,O
to,4312,O
a,4312,O
locus,4312,O
in,4312,O
1q32-q41,4312,O
by,4312,O
linkage,4312,O
analysis,4312,O
and,4312,O
physical,4312,O
mapping,4312,O
.,4312,O
We,4313,O
have,4313,O
investigated,4313,O
5,4313,O
novel,4313,O
vWS,4313,B-Modifier
families,4313,O
through,4313,O
probands,4313,O
attended,4313,O
for,4313,O
cleft,4313,O
lip,4313,O
and/or,4313,O
palate,4313,O
repair,4313,O
at,4313,O
the,4313,O
Department,4313,O
of,4313,O
Maxillofacial,4313,O
Surgery,4313,O
of,4313,O
Hopital,4313,O
Trousseau,4313,O
",",4313,O
Paris,4313,O
",",4313,O
in,4313,O
order,4313,O
to,4313,O
tentatively,4313,O
refine,4313,O
the,4313,O
genetic,4313,O
map,4313,O
of,4313,O
the,4313,O
vWS,4313,B-Modifier
region,4313,O
in,4313,O
1q32-q41,4313,O
and,4313,O
possibly,4313,O
identify,4313,O
unlinked,4313,O
pedigrees,4313,O
.,4313,O
Linkage,4314,O
analysis,4314,O
was,4314,O
carried,4314,O
out,4314,O
to,4314,O
6,4314,O
microsatellite,4314,O
markers,4314,O
(,4314,O
D1S249,4314,O
",",4314,O
D1S425,4314,O
",",4314,O
D1S491,4314,O
",",4314,O
D1S205,4314,O
",",4314,O
D1S414,4314,O
",",4314,O
D1S425,4314,O
),4314,O
",",4314,O
yielding,4314,O
a,4314,O
maximum,4314,O
cumulative,4314,O
LOD,4314,O
score,4314,O
of,4314,O
Z,4314,O
=,4314,O
3,4314,O
.,4314,O
27,4315,O
at,4315,O
theta,4315,O
=,4315,O
0,4315,O
.,4315,O
00,4316,O
for,4316,O
D1S245,4316,O
.,4316,O
The,4317,O
innermost,4317,O
four,4317,O
markers,4317,O
were,4317,O
found,4317,O
to,4317,O
be,4317,O
tightly,4317,O
linked,4317,O
to,4317,O
one,4317,O
another,4317,O
",",4317,O
with,4317,O
no,4317,O
evidence,4317,O
for,4317,O
recombination,4317,O
.,4317,O
Our,4318,O
results,4318,O
support,4318,O
linkage,4318,O
of,4318,O
vWS,4318,B-SpecificDisease
within,4318,O
a,4318,O
region,4318,O
of,4318,O
tightly,4318,O
linked,4318,O
markers,4318,O
and,4318,O
do,4318,O
not,4318,O
favour,4318,O
locus,4318,O
heterogeneity,4318,O
of,4318,O
the,4318,O
disease,4318,O
trait,4318,O
.,4318,O
Null,4319,O
mutation,4319,O
of,4319,O
the,4319,O
murine,4319,O
ATP7B,4319,O
(,4319,O
Wilson,4319,B-SpecificDisease
disease,4319,I-SpecificDisease
),4319,O
gene,4319,O
results,4319,O
in,4319,O
intracellular,4319,B-DiseaseClass
copper,4319,I-DiseaseClass
accumulation,4319,I-DiseaseClass
and,4319,O
late-onset,4319,B-DiseaseClass
hepatic,4319,I-DiseaseClass
nodular,4319,I-DiseaseClass
transformation,4319,I-DiseaseClass
.,4319,O
The,4320,O
Atp7b,4320,O
protein,4320,O
is,4320,O
a,4320,O
copper-transporting,4320,O
ATPase,4320,O
expressed,4320,O
predominantly,4320,O
in,4320,O
the,4320,O
liver,4320,O
and,4320,O
to,4320,O
a,4320,O
lesser,4320,O
extent,4320,O
in,4320,O
most,4320,O
other,4320,O
tissues,4320,O
.,4320,O
Mutations,4321,O
in,4321,O
the,4321,O
ATP7B,4321,O
gene,4321,O
lead,4321,O
to,4321,O
Wilson,4321,B-SpecificDisease
disease,4321,I-SpecificDisease
",",4321,O
a,4321,O
copper,4321,B-DiseaseClass
toxicity,4321,I-DiseaseClass
disorder,4321,I-DiseaseClass
characterized,4321,O
by,4321,O
dramatic,4321,O
build-up,4321,O
of,4321,O
intracellular,4321,O
hepatic,4321,O
copper,4321,O
with,4321,O
subsequent,4321,O
hepatic,4321,O
and,4321,O
neuro-logical,4321,O
abnormalities,4321,O
.,4321,O
Using,4322,O
homologous,4322,O
recombination,4322,O
to,4322,O
disrupt,4322,O
the,4322,O
normal,4322,O
translation,4322,O
of,4322,O
ATP7B,4322,O
",",4322,O
we,4322,O
have,4322,O
generated,4322,O
a,4322,O
strain,4322,O
of,4322,O
mice,4322,O
that,4322,O
are,4322,O
homozygous,4322,O
mutants,4322,O
(,4322,O
null,4322,O
),4322,O
for,4322,O
the,4322,O
Wilson,4322,B-Modifier
disease,4322,I-Modifier
gene,4322,O
.,4322,O
The,4323,O
ATP7B,4323,O
null,4323,O
mice,4323,O
display,4323,O
a,4323,O
gradual,4323,O
accumulation,4323,O
of,4323,O
hepatic,4323,O
copper,4323,O
that,4323,O
increases,4323,O
to,4323,O
a,4323,O
level,4323,O
60-fold,4323,O
greater,4323,O
than,4323,O
normal,4323,O
by,4323,O
5,4323,O
months,4323,O
of,4323,O
age,4323,O
.,4323,O
An,4324,O
increase,4324,O
in,4324,O
copper,4324,O
concentration,4324,O
was,4324,O
also,4324,O
observed,4324,O
in,4324,O
the,4324,O
kidney,4324,O
",",4324,O
brain,4324,O
",",4324,O
placenta,4324,O
and,4324,O
lactating,4324,O
mammary,4324,O
glands,4324,O
of,4324,O
homo-zygous,4324,O
mutants,4324,O
",",4324,O
although,4324,O
milk,4324,O
from,4324,O
the,4324,O
mutant,4324,O
glands,4324,O
was,4324,O
copper,4324,B-DiseaseClass
deficient,4324,I-DiseaseClass
.,4324,O
Morphological,4325,B-DiseaseClass
abnormalities,4325,I-DiseaseClass
resembling,4325,O
cirrhosis,4325,B-SpecificDisease
developed,4325,O
in,4325,O
the,4325,O
majority,4325,O
of,4325,O
the,4325,O
livers,4325,O
from,4325,O
homozygous,4325,O
mutants,4325,O
older,4325,O
than,4325,O
7,4325,O
months,4325,O
of,4325,O
age,4325,O
.,4325,O
Progeny,4326,O
of,4326,O
the,4326,O
homozygous,4326,O
mutant,4326,O
females,4326,O
demonstrated,4326,O
neurological,4326,B-DiseaseClass
abnormalities,4326,I-DiseaseClass
and,4326,O
growth,4326,B-DiseaseClass
retardation,4326,I-DiseaseClass
characteristic,4326,O
of,4326,O
copper,4326,B-SpecificDisease
deficiency,4326,I-SpecificDisease
.,4326,O
Copper,4327,O
concentration,4327,O
in,4327,O
the,4327,O
livers,4327,O
of,4327,O
the,4327,O
newborn,4327,O
homozygous,4327,O
null,4327,O
mutants,4327,O
was,4327,O
decreased,4327,O
dramatically,4327,O
.,4327,O
In,4328,O
summary,4328,O
",",4328,O
inactivation,4328,O
of,4328,O
the,4328,O
murine,4328,O
ATP7B,4328,O
gene,4328,O
produces,4328,O
a,4328,O
form,4328,O
of,4328,O
cirrhotic,4328,B-DiseaseClass
liver,4328,I-DiseaseClass
disease,4328,I-DiseaseClass
that,4328,O
resembles,4328,O
Wilson,4328,B-SpecificDisease
disease,4328,I-SpecificDisease
in,4328,O
humans,4328,O
and,4328,O
the,4328,O
toxic,4328,O
milk,4328,O
phenotype,4328,O
in,4328,O
the,4328,O
mouse,4328,O
..,4328,O
French,4329,O
Machado-Joseph,4329,B-Modifier
disease,4329,I-Modifier
patients,4329,O
do,4329,O
not,4329,O
exhibit,4329,O
gametic,4329,O
segregation,4329,O
distortion,4329,O
:,4329,O
a,4329,O
sperm,4329,O
typing,4329,O
analysis,4329,O
.,4329,O
Segregation,4330,O
distortion,4330,O
has,4330,O
been,4330,O
reported,4330,O
to,4330,O
occur,4330,O
in,4330,O
a,4330,O
number,4330,O
of,4330,O
the,4330,O
trinucleotide,4330,B-DiseaseClass
repeat,4330,I-DiseaseClass
disorders,4330,I-DiseaseClass
.,4330,O
On,4331,O
the,4331,O
basis,4331,O
of,4331,O
a,4331,O
sperm,4331,O
typing,4331,O
study,4331,O
performed,4331,O
in,4331,O
patients,4331,O
of,4331,O
Japanese,4331,O
descent,4331,O
with,4331,O
Machado-Joseph,4331,B-SpecificDisease
disease,4331,I-SpecificDisease
(,4331,O
MJD,4331,B-SpecificDisease
),4331,O
",",4331,O
it,4331,O
was,4331,O
reported,4331,O
that,4331,O
disease,4331,O
alleles,4331,O
are,4331,O
preferentially,4331,O
transmitted,4331,O
during,4331,O
meiosis,4331,O
.,4331,O
We,4332,O
performed,4332,O
a,4332,O
sperm,4332,O
typing,4332,O
study,4332,O
of,4332,O
five,4332,O
MJD,4332,B-Modifier
patients,4332,O
of,4332,O
French,4332,O
descent,4332,O
and,4332,O
analysis,4332,O
of,4332,O
the,4332,O
pooled,4332,O
data,4332,O
shows,4332,O
a,4332,O
ratio,4332,O
of,4332,O
mutant,4332,O
to,4332,O
normal,4332,O
alleles,4332,O
of,4332,O
379,4332,O
436,4332,O
(,4332,O
46,4332,O
.,4332,O
5,4333,O
53,4333,O
.,4333,O
5,4334,O
%,4334,O
),4334,O
",",4334,O
which,4334,O
does,4334,O
not,4334,O
support,4334,O
meiotic,4334,O
segregation,4334,O
distortion,4334,O
.,4334,O
To,4335,O
confirm,4335,O
these,4335,O
results,4335,O
",",4335,O
sperm,4335,O
typing,4335,O
analysis,4335,O
was,4335,O
also,4335,O
performed,4335,O
using,4335,O
a,4335,O
polymorphic,4335,O
marker,4335,O
",",4335,O
D14S1050,4335,O
",",4335,O
closely,4335,O
linked,4335,O
to,4335,O
the,4335,O
MJD1,4335,O
gene,4335,O
.,4335,O
Among,4336,O
910,4336,O
sperm,4336,O
analyzed,4336,O
",",4336,O
the,4336,O
allele,4336,O
linked,4336,O
to,4336,O
the,4336,O
disease,4336,O
chromosome,4336,O
was,4336,O
detected,4336,O
in,4336,O
50,4336,O
.,4336,O
3,4337,O
%,4337,O
of,4337,O
the,4337,O
samples,4337,O
and,4337,O
the,4337,O
allele,4337,O
linked,4337,O
to,4337,O
the,4337,O
normal,4337,O
chromosome,4337,O
was,4337,O
found,4337,O
in,4337,O
49,4337,O
.,4337,O
6,4338,O
%,4338,O
of,4338,O
the,4338,O
sperm,4338,O
.,4338,O
The,4339,O
difference,4339,O
in,4339,O
frequency,4339,O
of,4339,O
these,4339,O
two,4339,O
alleles,4339,O
is,4339,O
not,4339,O
significant,4339,O
(,4339,O
P,4339,O
=,4339,O
0,4339,O
.,4339,O
8423,4340,O
),4340,O
.,4340,O
Likelihood-based,4341,O
analysis,4341,O
of,4341,O
segregation,4341,O
distortion,4341,O
in,4341,O
the,4341,O
single,4341,O
sperm,4341,O
data,4341,O
using,4341,O
the,4341,O
SPERMSEG,4341,O
program,4341,O
also,4341,O
showed,4341,O
no,4341,O
support,4341,O
for,4341,O
segregation,4341,O
distortion,4341,O
at,4341,O
the,4341,O
gamete,4341,O
level,4341,O
in,4341,O
this,4341,O
patient,4341,O
population,4341,O
.,4341,O
The,4342,O
previous,4342,O
report,4342,O
on,4342,O
the,4342,O
Japanese,4342,O
patients,4342,O
also,4342,O
suggested,4342,O
that,4342,O
disease,4342,O
allele,4342,O
stability,4342,O
may,4342,O
be,4342,O
influenced,4342,O
by,4342,O
a,4342,O
trans,4342,O
effect,4342,O
of,4342,O
an,4342,O
intragenic,4342,O
polymorphism,4342,O
(,4342,O
987,4342,O
G/C,4342,O
),4342,O
in,4342,O
the,4342,O
wild-type,4342,O
allele,4342,O
.,4342,O
All,4343,O
of,4343,O
the,4343,O
French,4343,O
patients,4343,O
were,4343,O
heterozygous,4343,O
for,4343,O
this,4343,O
polymorphism,4343,O
.,4343,O
However,4344,O
",",4344,O
analysis,4344,O
of,4344,O
the,4344,O
variance,4344,O
in,4344,O
repeat,4344,O
number,4344,O
in,4344,O
sperm,4344,O
from,4344,O
the,4344,O
French,4344,O
MJD,4344,B-Modifier
patients,4344,O
overlapped,4344,O
significantly,4344,O
with,4344,O
the,4344,O
variance,4344,O
in,4344,O
repeat,4344,O
number,4344,O
observed,4344,O
in,4344,O
the,4344,O
C/C,4344,O
homozygous,4344,O
Japanese,4344,O
patients,4344,O
.,4344,O
Missense,4345,O
mutation,4345,O
in,4345,O
the,4345,O
alternative,4345,O
splice,4345,O
region,4345,O
of,4345,O
the,4345,O
PAX6,4345,O
gene,4345,O
in,4345,O
eye,4345,B-DiseaseClass
anomalies,4345,I-DiseaseClass
.,4345,O
The,4346,O
PAX6,4346,O
gene,4346,O
is,4346,O
involved,4346,O
in,4346,O
ocular,4346,O
morphogenesis,4346,O
",",4346,O
and,4346,O
PAX6,4346,O
mutations,4346,O
have,4346,O
been,4346,O
detected,4346,O
in,4346,O
various,4346,O
types,4346,O
of,4346,O
ocular,4346,B-DiseaseClass
anomalies,4346,I-DiseaseClass
",",4346,O
including,4346,O
aniridia,4346,B-SpecificDisease
",",4346,O
Peters,4346,B-SpecificDisease
anomaly,4346,I-SpecificDisease
",",4346,O
corneal,4346,B-SpecificDisease
dystrophy,4346,I-SpecificDisease
",",4346,O
congenital,4346,B-SpecificDisease
cataract,4346,I-SpecificDisease
",",4346,O
and,4346,O
foveal,4346,B-SpecificDisease
hypoplasia,4346,I-SpecificDisease
.,4346,O
The,4347,O
gene,4347,O
encodes,4347,O
a,4347,O
transcriptional,4347,O
regulator,4347,O
that,4347,O
recognizes,4347,O
target,4347,O
genes,4347,O
through,4347,O
its,4347,O
paired-type,4347,O
DNA-binding,4347,O
domain,4347,O
.,4347,O
The,4348,O
paired,4348,O
domain,4348,O
is,4348,O
composed,4348,O
of,4348,O
two,4348,O
distinct,4348,O
DNA-binding,4348,O
subdomains,4348,O
",",4348,O
the,4348,O
N-terminal,4348,O
subdomain,4348,O
(,4348,O
NTS,4348,O
),4348,O
and,4348,O
the,4348,O
C-terminal,4348,O
subdomain,4348,O
(,4348,O
CTS,4348,O
),4348,O
",",4348,O
which,4348,O
bind,4348,O
respective,4348,O
consensus,4348,O
DNA,4348,O
sequences,4348,O
.,4348,O
The,4349,O
human,4349,O
PAX6,4349,O
gene,4349,O
produces,4349,O
two,4349,O
alternative,4349,O
splice,4349,O
isoforms,4349,O
that,4349,O
have,4349,O
the,4349,O
distinct,4349,O
structure,4349,O
of,4349,O
the,4349,O
paired,4349,O
domain,4349,O
.,4349,O
The,4350,O
insertion,4350,O
",",4350,O
into,4350,O
the,4350,O
NTS,4350,O
",",4350,O
of,4350,O
14,4350,O
additional,4350,O
amino,4350,O
acids,4350,O
encoded,4350,O
by,4350,O
exon,4350,O
5a,4350,O
abolishes,4350,O
the,4350,O
DNA-binding,4350,O
activity,4350,O
of,4350,O
the,4350,O
NTS,4350,O
and,4350,O
unmasks,4350,O
the,4350,O
DNA-binding,4350,O
ability,4350,O
of,4350,O
the,4350,O
CTS,4350,O
.,4350,O
Thus,4351,O
",",4351,O
exon,4351,O
5a,4351,O
appears,4351,O
to,4351,O
function,4351,O
as,4351,O
a,4351,O
molecular,4351,O
switch,4351,O
that,4351,O
specifies,4351,O
target,4351,O
genes,4351,O
.,4351,O
We,4352,O
ascertained,4352,O
a,4352,O
novel,4352,O
missense,4352,O
mutation,4352,O
in,4352,O
four,4352,O
pedigrees,4352,O
with,4352,O
Peters,4352,B-SpecificDisease
anomaly,4352,I-SpecificDisease
",",4352,O
congenital,4352,B-SpecificDisease
cataract,4352,I-SpecificDisease
",",4352,O
Axenfeldt,4352,B-SpecificDisease
anomaly,4352,I-SpecificDisease
",",4352,O
and/or,4352,O
foveal,4352,B-SpecificDisease
hypoplasia,4352,I-SpecificDisease
",",4352,O
which,4352,O
",",4352,O
to,4352,O
our,4352,O
knowledge,4352,O
",",4352,O
is,4352,O
the,4352,O
first,4352,O
mutation,4352,O
identified,4352,O
in,4352,O
the,4352,O
splice-variant,4352,O
region,4352,O
.,4352,O
A,4353,O
T,4353,O
--,4353,O
>,4353,O
A,4353,O
transition,4353,O
at,4353,O
the,4353,O
20th,4353,O
nucleotide,4353,O
position,4353,O
of,4353,O
exon,4353,O
5a,4353,O
results,4353,O
in,4353,O
a,4353,O
Val,4353,O
--,4353,O
>,4353,O
Asp,4353,O
(,4353,O
GTC,4353,O
--,4353,O
>,4353,O
GAC,4353,O
),4353,O
substitution,4353,O
at,4353,O
the,4353,O
7th,4353,O
codon,4353,O
of,4353,O
the,4353,O
alternative,4353,O
splice,4353,O
region,4353,O
.,4353,O
Functional,4354,O
analyses,4354,O
demonstrated,4354,O
that,4354,O
the,4354,O
V54D,4354,O
mutation,4354,O
slightly,4354,O
increased,4354,O
NTS,4354,O
binding,4354,O
and,4354,O
decreased,4354,O
CTS,4354,O
transactivation,4354,O
activity,4354,O
to,4354,O
almost,4354,O
half,4354,O
..,4354,O
Penetrances,4355,O
of,4355,O
BRCA1,4355,O
1675delA,4355,O
and,4355,O
1135insA,4355,O
with,4355,O
respect,4355,O
to,4355,O
breast,4355,B-SpecificDisease
cancer,4355,I-SpecificDisease
and,4355,O
ovarian,4355,B-SpecificDisease
cancer,4355,I-SpecificDisease
.,4355,O
For,4356,O
genetic,4356,O
counseling,4356,O
and,4356,O
predictive,4356,O
testing,4356,O
in,4356,O
families,4356,O
with,4356,O
inherited,4356,B-CompositeMention
breast-ovarian,4356,I-CompositeMention
cancer,4356,I-CompositeMention
",",4356,O
penetrances,4356,O
and,4356,O
expressions,4356,O
of,4356,O
the,4356,O
underlying,4356,O
mutations,4356,O
should,4356,O
be,4356,O
known,4356,O
.,4356,O
We,4357,O
have,4357,O
previously,4357,O
reported,4357,O
two,4357,O
BRCA1,4357,O
founder,4357,O
mutations,4357,O
in,4357,O
the,4357,O
Norwegian,4357,O
population,4357,O
.,4357,O
Index,4358,O
cases,4358,O
for,4358,O
the,4358,O
present,4358,O
study,4358,O
were,4358,O
found,4358,O
two,4358,O
different,4358,O
ways,4358,O
through,4358,O
a,4358,O
series,4358,O
of,4358,O
consecutive,4358,O
ovarian,4358,B-SpecificDisease
cancers,4358,I-SpecificDisease
(,4358,O
n,4358,O
=,4358,O
16,4358,O
),4358,O
and,4358,O
through,4358,O
our,4358,O
family,4358,O
cancer,4358,B-Modifier
clinic,4358,O
(,4358,O
n,4358,O
=,4358,O
14,4358,O
),4358,O
.,4358,O
Altogether,4359,O
",",4359,O
20,4359,O
of,4359,O
the,4359,O
patients,4359,O
had,4359,O
BRCA1,4359,O
1675delA,4359,O
",",4359,O
and,4359,O
10,4359,O
had,4359,O
1135insA,4359,O
.,4359,O
Their,4360,O
relatives,4360,O
were,4360,O
described,4360,O
with,4360,O
respect,4360,O
to,4360,O
absence/presence,4360,O
of,4360,O
breast,4360,O
and/or,4360,O
ovarian,4360,O
cancer,4360,O
.,4360,O
Of,4361,O
133,4361,O
living,4361,O
female,4361,O
relatives,4361,O
",",4361,O
83,4361,O
(,4361,O
62,4361,O
%,4361,O
),4361,O
were,4361,O
tested,4361,O
for,4361,O
the,4361,O
presence,4361,O
of,4361,O
a,4361,O
mutation,4361,O
.,4361,O
No,4362,O
difference,4362,O
",",4362,O
in,4362,O
penetrance,4362,O
and,4362,O
expression,4362,O
",",4362,O
between,4362,O
the,4362,O
two,4362,O
mutations,4362,O
were,4362,O
found,4362,O
",",4362,O
whereas,4362,O
differences,4362,O
according,4362,O
to,4362,O
method,4362,O
of,4362,O
ascertainment,4362,O
were,4362,O
seen,4362,O
.,4362,O
The,4363,O
overall,4363,O
findings,4363,O
were,4363,O
that,4363,O
disease,4363,O
started,4363,O
to,4363,O
occur,4363,O
at,4363,O
age,4363,O
30,4363,O
years,4363,O
and,4363,O
that,4363,O
by,4363,O
age,4363,O
50,4363,O
years,4363,O
48,4363,O
%,4363,O
of,4363,O
the,4363,O
mutation-carrying,4363,O
women,4363,O
had,4363,O
experienced,4363,O
breast,4363,O
and/or,4363,O
ovarian,4363,O
cancer,4363,O
.,4363,O
More,4364,O
ovarian,4364,B-SpecificDisease
cancers,4364,I-SpecificDisease
than,4364,O
breast,4364,B-SpecificDisease
cancers,4364,I-SpecificDisease
were,4364,O
recorded,4364,O
.,4364,O
Both,4365,O
penetrance,4365,O
and,4365,O
expression,4365,O
(,4365,O
breast,4365,B-SpecificDisease
cancer,4365,I-SpecificDisease
vs.,4365,O
ovarian,4365,B-SpecificDisease
cancer,4365,I-SpecificDisease
),4365,O
were,4365,O
different,4365,O
from,4365,O
those,4365,O
in,4365,O
reports,4365,O
of,4365,O
the,4365,O
Ashkenazi,4365,O
founder,4365,O
mutations,4365,O
.,4365,O
Whether,4366,O
the,4366,O
reported,4366,O
differences,4366,O
reflect,4366,O
true,4366,O
differences,4366,O
and/or,4366,O
methodological,4366,O
problems,4366,O
is,4366,O
discussed,4366,O
.,4366,O
An,4367,O
observed,4367,O
excess,4367,O
of,4367,O
mutation,4367,O
carriers,4367,O
could,4367,O
not,4367,O
be,4367,O
accounted,4367,O
for,4367,O
by,4367,O
methodological,4367,O
problems,4367,O
;,4367,O
possible,4367,O
explanations,4367,O
were,4367,O
a,4367,O
``,4367,O
true,4367,O
``,4367,O
low,4367,O
penetrance,4367,O
or,4367,O
preferential,4367,O
segregation,4367,O
..,4367,O
The,4368,O
dermatofibrosarcoma,4368,B-Modifier
protuberans-associated,4368,O
collagen,4368,O
type,4368,O
Ialpha1/platelet-derived,4368,O
growth,4368,O
factor,4368,O
(,4368,O
PDGF,4368,O
),4368,O
B-chain,4368,O
fusion,4368,O
gene,4368,O
generates,4368,O
a,4368,O
transforming,4368,O
protein,4368,O
that,4368,O
is,4368,O
processed,4368,O
to,4368,O
functional,4368,O
PDGF-BB,4368,O
.,4368,O
Dermatofibrosarcoma,4369,B-SpecificDisease
protuberans,4369,I-SpecificDisease
(,4369,O
DFSP,4369,B-SpecificDisease
),4369,O
displays,4369,O
chromosomal,4369,O
rearrangements,4369,O
involving,4369,O
chromosome,4369,O
17,4369,O
and,4369,O
22,4369,O
",",4369,O
which,4369,O
fuse,4369,O
the,4369,O
collagen,4369,O
type,4369,O
Ialpha1,4369,O
(,4369,O
COLIA1,4369,O
),4369,O
gene,4369,O
to,4369,O
the,4369,O
platelet-derived,4369,O
growth,4369,O
factor,4369,O
(,4369,O
PDGF,4369,O
),4369,O
B-chain,4369,O
(,4369,O
PDGFB,4369,O
),4369,O
gene,4369,O
.,4369,O
To,4370,O
characterize,4370,O
the,4370,O
functional,4370,O
and,4370,O
structural,4370,O
properties,4370,O
of,4370,O
the,4370,O
COLIA1/PDGFB,4370,O
fusion,4370,O
protein,4370,O
",",4370,O
we,4370,O
generated,4370,O
a,4370,O
stable,4370,O
NIH3T3,4370,O
cell,4370,O
line,4370,O
that,4370,O
contained,4370,O
a,4370,O
tumor-derived,4370,O
chimeric,4370,O
gene,4370,O
resulting,4370,O
from,4370,O
a,4370,O
COIA1,4370,O
intron,4370,O
7-PDGFB,4370,O
intron,4370,O
1,4370,O
fusion,4370,O
.,4370,O
Expression,4371,O
of,4371,O
the,4371,O
fusion,4371,O
protein,4371,O
led,4371,O
to,4371,O
morphological,4371,O
transformation,4371,O
and,4371,O
increased,4371,O
growth,4371,O
rate,4371,O
of,4371,O
these,4371,O
cells,4371,O
.,4371,O
The,4372,O
PDGF,4372,O
receptor,4372,O
kinase,4372,O
inhibitor,4372,O
CGP57148B,4372,O
reversed,4372,O
the,4372,O
transformed,4372,O
phenotype,4372,O
and,4372,O
reduced,4372,O
the,4372,O
growth,4372,O
rate,4372,O
of,4372,O
COLIA1/PDGFB-expressing,4372,O
cells,4372,O
but,4372,O
had,4372,O
no,4372,O
effects,4372,O
on,4372,O
control,4372,O
cells,4372,O
.,4372,O
The,4373,O
presence,4373,O
of,4373,O
dimeric,4373,O
COLIA1/PDGFB,4373,O
precursors,4373,O
was,4373,O
demonstrated,4373,O
through,4373,O
PDGFB,4373,O
immunoprecipitations,4373,O
of,4373,O
metabolically,4373,O
labeled,4373,O
cells,4373,O
and,4373,O
also,4373,O
by,4373,O
PDGFB,4373,O
immunoprecipitations,4373,O
followed,4373,O
by,4373,O
immunoblotting,4373,O
with,4373,O
COLIA1,4373,O
antibodies,4373,O
.,4373,O
Pulse-chase,4374,O
studies,4374,O
demonstrated,4374,O
that,4374,O
the,4374,O
COLIA1/PDGFB,4374,O
precursor,4374,O
was,4374,O
processed,4374,O
to,4374,O
an,4374,O
end,4374,O
product,4374,O
that,4374,O
was,4374,O
indistinguishable,4374,O
from,4374,O
wild-type,4374,O
PDGF-BB,4374,O
.,4374,O
Finally,4375,O
",",4375,O
COLIA1/PDGFB-expressing,4375,O
cells,4375,O
generated,4375,O
tumors,4375,B-DiseaseClass
after,4375,O
s.,4375,O
c,4375,O
c.,4375,O
injection,4375,O
into,4375,O
nude,4375,O
mice,4375,O
",",4375,O
and,4375,O
tumor,4375,B-Modifier
growth,4375,O
was,4375,O
reduced,4375,O
by,4375,O
treatment,4375,O
with,4375,O
CGP57148B,4375,O
.,4375,O
We,4376,O
conclude,4376,O
that,4376,O
the,4376,O
COLIA1/PDGFB,4376,O
fusion,4376,O
associated,4376,O
with,4376,O
DFSP,4376,B-SpecificDisease
contributes,4376,O
to,4376,O
tumor,4376,B-Modifier
development,4376,O
through,4376,O
ectopic,4376,O
production,4376,O
of,4376,O
PDGF-BB,4376,O
and,4376,O
the,4376,O
formation,4376,O
of,4376,O
an,4376,O
autocrine,4376,O
loop,4376,O
.,4376,O
Our,4377,O
findings,4377,O
",",4377,O
thus,4377,O
",",4377,O
suggest,4377,O
that,4377,O
PDGF,4377,O
receptors,4377,O
could,4377,O
be,4377,O
a,4377,O
target,4377,O
for,4377,O
pharmacological,4377,O
treatment,4377,O
of,4377,O
DFSP,4377,B-SpecificDisease
and,4377,O
giant,4377,B-SpecificDisease
cell,4377,I-SpecificDisease
fibroblastoma,4377,I-SpecificDisease
",",4377,O
e.,4377,O
g.,4377,O
",",4377,O
through,4377,O
the,4377,O
use,4377,O
of,4377,O
PDGF,4377,O
receptor,4377,O
kinase,4377,O
inhibitors,4377,O
such,4377,O
as,4377,O
CGP57148B,4377,O
.,4377,O
Identification,4378,O
of,4378,O
a,4378,O
common,4378,O
PEX1,4378,O
mutation,4378,O
in,4378,O
Zellweger,4378,B-SpecificDisease
syndrome,4378,I-SpecificDisease
.,4378,O
The,4379,O
Zellweger,4379,B-DiseaseClass
spectrum,4379,I-DiseaseClass
of,4379,I-DiseaseClass
disease,4379,I-DiseaseClass
",",4379,O
encompassing,4379,O
Zellweger,4379,B-SpecificDisease
syndrome,4379,I-SpecificDisease
and,4379,O
the,4379,O
progressively,4379,O
milder,4379,O
phenotypes,4379,O
of,4379,O
neonatal,4379,B-SpecificDisease
adrenoleukodystrophy,4379,I-SpecificDisease
and,4379,O
infantile,4379,B-SpecificDisease
Refsum,4379,I-SpecificDisease
disease,4379,I-SpecificDisease
",",4379,O
is,4379,O
due,4379,O
to,4379,O
a,4379,O
failure,4379,O
to,4379,O
form,4379,O
functional,4379,O
peroxisomes,4379,O
.,4379,O
Cell,4380,O
fusion,4380,O
complementation,4380,O
studies,4380,O
demonstrated,4380,O
that,4380,O
these,4380,O
diseases,4380,O
are,4380,O
genetically,4380,O
heterogeneous,4380,O
",",4380,O
with,4380,O
two-thirds,4380,O
of,4380,O
all,4380,O
patients,4380,O
lying,4380,O
within,4380,O
a,4380,O
single,4380,O
complementation,4380,O
group,4380,O
",",4380,O
CG1,4380,O
.,4380,O
Molecular,4381,O
genetic,4381,O
and,4381,O
cell,4381,O
biology,4381,O
studies,4381,O
have,4381,O
shown,4381,O
that,4381,O
PEX1,4381,O
is,4381,O
deficient,4381,O
in,4381,O
many,4381,O
CG1,4381,O
patients,4381,O
.,4381,O
However,4382,O
",",4382,O
previous,4382,O
studies,4382,O
have,4382,O
focused,4382,O
on,4382,O
mildly,4382,O
affected,4382,O
patients,4382,O
and,4382,O
there,4382,O
is,4382,O
still,4382,O
no,4382,O
report,4382,O
of,4382,O
two,4382,O
mutant,4382,O
PEX1,4382,O
alleles,4382,O
in,4382,O
any,4382,O
Zellweger,4382,B-Modifier
syndrome,4382,I-Modifier
patient,4382,O
.,4382,O
Furthermore,4383,O
",",4383,O
mutations,4383,O
in,4383,O
the,4383,O
PMP70,4383,O
gene,4383,O
have,4383,O
also,4383,O
been,4383,O
identified,4383,O
in,4383,O
two,4383,O
Zellweger,4383,B-Modifier
syndrome,4383,I-Modifier
patients,4383,O
from,4383,O
CG1,4383,O
",",4383,O
raising,4383,O
the,4383,O
possibility,4383,O
that,4383,O
CG1,4383,O
patients,4383,O
may,4383,O
represent,4383,O
a,4383,O
mixture,4383,O
of,4383,O
PEX1-deficient,4383,O
and,4383,O
PMP70-deficient,4383,O
individuals,4383,O
.,4383,O
To,4384,O
address,4384,O
the,4384,O
molecular,4384,O
basis,4384,O
of,4384,O
disease,4384,O
in,4384,O
Zellweger,4384,B-Modifier
syndrome,4384,I-Modifier
patients,4384,O
from,4384,O
CG1,4384,O
",",4384,O
we,4384,O
examined,4384,O
all,4384,O
24,4384,O
PEX1,4384,O
exons,4384,O
in,4384,O
four,4384,O
patients,4384,O
",",4384,O
including,4384,O
both,4384,O
patients,4384,O
that,4384,O
have,4384,O
mutations,4384,O
in,4384,O
PMP70,4384,O
.,4384,O
PEX1,4385,O
mutations,4385,O
were,4385,O
detected,4385,O
in,4385,O
all,4385,O
four,4385,O
patients,4385,O
",",4385,O
including,4385,O
a,4385,O
1-bp,4385,O
insertion,4385,O
(,4385,O
c.,4385,O
2097insT,4385,O
),4385,O
in,4385,O
exon,4385,O
13,4385,O
that,4385,O
was,4385,O
present,4385,O
in,4385,O
three,4385,O
of,4385,O
the,4385,O
four,4385,O
patients,4385,O
.,4385,O
Subsequent,4386,O
studies,4386,O
demonstrated,4386,O
that,4386,O
this,4386,O
mutation,4386,O
is,4386,O
present,4386,O
in,4386,O
one-half,4386,O
of,4386,O
all,4386,O
CG1,4386,O
patients,4386,O
and,4386,O
correlates,4386,O
with,4386,O
the,4386,O
Zellweger,4386,B-Modifier
syndrome,4386,I-Modifier
phenotype,4386,O
.,4386,O
As,4387,O
this,4387,O
mutation,4387,O
leads,4387,O
to,4387,O
a,4387,O
loss,4387,O
of,4387,O
protein,4387,O
function,4387,O
its,4387,O
frequency,4387,O
makes,4387,O
it,4387,O
the,4387,O
most,4387,O
common,4387,O
cause,4387,O
of,4387,O
Zellweger,4387,B-SpecificDisease
syndrome,4387,I-SpecificDisease
",",4387,O
helping,4387,O
to,4387,O
explain,4387,O
the,4387,O
high,4387,O
percentage,4387,O
of,4387,O
patients,4387,O
that,4387,O
belong,4387,O
to,4387,O
CG1,4387,O
.,4387,O
Novel,4388,O
mutations,4388,O
in,4388,O
the,4388,O
Wiskott-Aldrich,4388,B-Modifier
syndrome,4388,I-Modifier
protein,4388,O
gene,4388,O
and,4388,O
their,4388,O
effects,4388,O
on,4388,O
transcriptional,4388,O
",",4388,O
translational,4388,O
",",4388,O
and,4388,O
clinical,4388,O
phenotypes,4388,O
.,4388,O
Wiskott-Aldrich,4389,B-SpecificDisease
syndrome,4389,I-SpecificDisease
(,4389,O
WAS,4389,B-SpecificDisease
),4389,O
is,4389,O
an,4389,O
X-linked,4389,B-DiseaseClass
recessive,4389,I-DiseaseClass
immunodeficiency,4389,I-DiseaseClass
characterized,4389,O
by,4389,O
thrombocytopenia,4389,B-DiseaseClass
",",4389,O
eczema,4389,B-DiseaseClass
",",4389,O
and,4389,O
recurrent,4389,O
infections,4389,O
",",4389,O
and,4389,O
caused,4389,O
by,4389,O
mutations,4389,O
in,4389,O
the,4389,O
WAS,4389,B-Modifier
protein,4389,O
(,4389,O
WASP,4389,O
),4389,O
gene,4389,O
.,4389,O
WASP,4390,O
contains,4390,O
several,4390,O
functional,4390,O
domains,4390,O
through,4390,O
which,4390,O
it,4390,O
interacts,4390,O
with,4390,O
proteins,4390,O
involved,4390,O
in,4390,O
intracellular,4390,O
signaling,4390,O
and,4390,O
regulation,4390,O
of,4390,O
the,4390,O
actin,4390,O
cytoskeleton,4390,O
.,4390,O
In,4391,O
this,4391,O
report,4391,O
",",4391,O
17,4391,O
WASP,4391,O
gene,4391,O
mutations,4391,O
were,4391,O
identified,4391,O
",",4391,O
12,4391,O
of,4391,O
which,4391,O
are,4391,O
novel,4391,O
.,4391,O
DNA,4392,O
of,4392,O
affected,4392,O
males,4392,O
and,4392,O
obligate,4392,O
carriers,4392,O
was,4392,O
PCR,4392,O
amplified,4392,O
and,4392,O
analyzed,4392,O
by,4392,O
SSCA,4392,O
",",4392,O
heteroduplex,4392,O
analysis,4392,O
",",4392,O
and,4392,O
direct,4392,O
sequencing,4392,O
.,4392,O
The,4393,O
effects,4393,O
of,4393,O
the,4393,O
mutations,4393,O
at,4393,O
the,4393,O
mRNA,4393,O
and,4393,O
protein,4393,O
level,4393,O
were,4393,O
ascertained,4393,O
by,4393,O
RT-PCR,4393,O
and,4393,O
Western,4393,O
blot,4393,O
analyses,4393,O
.,4393,O
All,4394,O
missense,4394,O
mutations,4394,O
were,4394,O
located,4394,O
in,4394,O
exons,4394,O
1-4,4394,O
.,4394,O
Most,4395,O
of,4395,O
the,4395,O
nonsense,4395,O
",",4395,O
frameshift,4395,O
and,4395,O
splice,4395,O
site,4395,O
mutations,4395,O
were,4395,O
found,4395,O
in,4395,O
exons,4395,O
6-11,4395,O
.,4395,O
Mutations,4396,O
that,4396,O
alter,4396,O
splice,4396,O
sites,4396,O
led,4396,O
to,4396,O
the,4396,O
synthesis,4396,O
of,4396,O
several,4396,O
types,4396,O
of,4396,O
mRNAs,4396,O
",",4396,O
a,4396,O
fraction,4396,O
of,4396,O
which,4396,O
represented,4396,O
the,4396,O
normally,4396,O
spliced,4396,O
product,4396,O
.,4396,O
The,4397,O
presence,4397,O
of,4397,O
normally,4397,O
spliced,4397,O
transcripts,4397,O
was,4397,O
correlated,4397,O
with,4397,O
a,4397,O
milder,4397,O
phenotype,4397,O
.,4397,O
When,4398,O
one,4398,O
such,4398,O
case,4398,O
was,4398,O
studied,4398,O
by,4398,O
Western,4398,O
blotting,4398,O
",",4398,O
reduced,4398,O
amounts,4398,O
of,4398,O
normal-size,4398,O
WASP,4398,O
were,4398,O
present,4398,O
.,4398,O
In,4399,O
other,4399,O
cases,4399,O
as,4399,O
well,4399,O
",",4399,O
a,4399,O
correlation,4399,O
was,4399,O
found,4399,O
between,4399,O
the,4399,O
amount,4399,O
of,4399,O
normal,4399,O
or,4399,O
mutant,4399,O
WASP,4399,O
present,4399,O
and,4399,O
the,4399,O
phenotypes,4399,O
of,4399,O
the,4399,O
affected,4399,O
individuals,4399,O
.,4399,O
No,4400,O
protein,4400,O
was,4400,O
detected,4400,O
in,4400,O
two,4400,O
individuals,4400,O
with,4400,O
severe,4400,O
WAS,4400,B-SpecificDisease
.,4400,O
Reduced,4401,O
levels,4401,O
of,4401,O
a,4401,O
normal-size,4401,O
WASP,4401,O
with,4401,O
a,4401,O
missense,4401,O
mutation,4401,O
were,4401,O
seen,4401,O
in,4401,O
two,4401,O
individuals,4401,O
with,4401,O
XLT,4401,B-SpecificDisease
.,4401,O
It,4402,O
is,4402,O
concluded,4402,O
that,4402,O
mutation,4402,O
analysis,4402,O
at,4402,O
the,4402,O
DNA,4402,O
level,4402,O
is,4402,O
not,4402,O
sufficient,4402,O
for,4402,O
predicting,4402,O
clinical,4402,O
course,4402,O
.,4402,O
Studies,4403,O
at,4403,O
the,4403,O
transcript,4403,O
and,4403,O
protein,4403,O
level,4403,O
are,4403,O
needed,4403,O
for,4403,O
a,4403,O
better,4403,O
assessment,4403,O
..,4403,O
Aminoglycoside,4404,O
antibiotics,4404,O
restore,4404,O
dystrophin,4404,O
function,4404,O
to,4404,O
skeletal,4404,O
muscles,4404,O
of,4404,O
mdx,4404,O
mice,4404,O
.,4404,O
Duchenne,4405,B-SpecificDisease
muscular,4405,I-SpecificDisease
dystrophy,4405,I-SpecificDisease
(,4405,O
DMD,4405,B-SpecificDisease
),4405,O
is,4405,O
caused,4405,O
by,4405,O
mutations,4405,O
in,4405,O
the,4405,O
dystrophin,4405,O
gene,4405,O
",",4405,O
leading,4405,O
to,4405,O
the,4405,O
absence,4405,O
of,4405,O
the,4405,O
dystrophin,4405,O
protein,4405,O
in,4405,O
striated,4405,O
muscle,4405,O
.,4405,O
A,4406,O
significant,4406,O
number,4406,O
of,4406,O
these,4406,O
mutations,4406,O
are,4406,O
premature,4406,O
stop,4406,O
codons,4406,O
.,4406,O
On,4407,O
the,4407,O
basis,4407,O
of,4407,O
the,4407,O
observation,4407,O
that,4407,O
aminoglycoside,4407,O
treatment,4407,O
can,4407,O
suppress,4407,O
stop,4407,O
codons,4407,O
in,4407,O
cultured,4407,O
cells,4407,O
",",4407,O
we,4407,O
tested,4407,O
the,4407,O
effect,4407,O
of,4407,O
gentamicin,4407,O
on,4407,O
cultured,4407,O
muscle,4407,O
cells,4407,O
from,4407,O
the,4407,O
mdx,4407,O
mouse,4407,O
-,4407,O
an,4407,O
animal,4407,O
model,4407,O
for,4407,O
DMD,4407,B-SpecificDisease
that,4407,O
possesses,4407,O
a,4407,O
premature,4407,O
stop,4407,O
codon,4407,O
in,4407,O
the,4407,O
dystrophin,4407,O
gene,4407,O
.,4407,O
Exposure,4408,O
of,4408,O
mdx,4408,O
myotubes,4408,O
to,4408,O
gentamicin,4408,O
led,4408,O
to,4408,O
the,4408,O
expression,4408,O
and,4408,O
localization,4408,O
of,4408,O
dystrophin,4408,O
to,4408,O
the,4408,O
cell,4408,O
membrane,4408,O
.,4408,O
We,4409,O
then,4409,O
evaluated,4409,O
the,4409,O
effects,4409,O
of,4409,O
differing,4409,O
dosages,4409,O
of,4409,O
gentamicin,4409,O
on,4409,O
expression,4409,O
and,4409,O
functional,4409,O
protection,4409,O
of,4409,O
the,4409,O
muscles,4409,O
of,4409,O
mdx,4409,O
mice,4409,O
.,4409,O
We,4410,O
identified,4410,O
a,4410,O
treatment,4410,O
regimen,4410,O
that,4410,O
resulted,4410,O
in,4410,O
the,4410,O
presence,4410,O
of,4410,O
dystrophin,4410,O
in,4410,O
the,4410,O
cell,4410,O
membrane,4410,O
in,4410,O
all,4410,O
striated,4410,O
muscles,4410,O
examined,4410,O
and,4410,O
that,4410,O
provided,4410,O
functional,4410,O
protection,4410,O
against,4410,O
muscular,4410,B-DiseaseClass
injury,4410,I-DiseaseClass
.,4410,O
To,4411,O
our,4411,O
knowledge,4411,O
",",4411,O
our,4411,O
results,4411,O
are,4411,O
the,4411,O
first,4411,O
to,4411,O
demonstrate,4411,O
that,4411,O
aminoglycosides,4411,O
can,4411,O
suppress,4411,O
stop,4411,O
codons,4411,O
not,4411,O
only,4411,O
in,4411,O
vitro,4411,O
but,4411,O
also,4411,O
in,4411,O
vivo,4411,O
.,4411,O
Furthermore,4412,O
",",4412,O
these,4412,O
results,4412,O
raise,4412,O
the,4412,O
possibility,4412,O
of,4412,O
a,4412,O
novel,4412,O
treatment,4412,O
regimen,4412,O
for,4412,O
muscular,4412,B-SpecificDisease
dystrophy,4412,I-SpecificDisease
and,4412,O
other,4412,O
diseases,4412,O
caused,4412,O
by,4412,O
premature,4412,O
stop,4412,O
codon,4412,O
mutations,4412,O
.,4412,O
This,4413,O
treatment,4413,O
could,4413,O
prove,4413,O
effective,4413,O
in,4413,O
up,4413,O
to,4413,O
15,4413,O
%,4413,O
of,4413,O
patients,4413,O
with,4413,O
DMD,4413,B-SpecificDisease
..,4413,O
Loss,4414,O
of,4414,O
the,4414,O
ataxia-telangiectasia,4414,B-Modifier
gene,4414,O
product,4414,O
causes,4414,O
oxidative,4414,O
damage,4414,O
in,4414,O
target,4414,O
organs,4414,O
.,4414,O
Ataxia-telangiectasia,4415,B-SpecificDisease
(,4415,O
A-T,4415,B-SpecificDisease
),4415,O
is,4415,O
characterized,4415,O
by,4415,O
a,4415,O
markedly,4415,O
increased,4415,O
sensitivity,4415,O
to,4415,O
ionizing,4415,O
radiation,4415,O
",",4415,O
increased,4415,O
incidence,4415,O
of,4415,O
cancer,4415,B-DiseaseClass
",",4415,O
and,4415,O
neurodegeneration,4415,B-DiseaseClass
",",4415,O
especially,4415,O
of,4415,O
the,4415,O
cerebellar,4415,O
Purkinje,4415,O
cells,4415,O
.,4415,O
Ionizing,4416,O
radiation,4416,O
oxidizes,4416,O
macromolecules,4416,O
and,4416,O
causes,4416,O
tissue,4416,O
damage,4416,O
through,4416,O
the,4416,O
generation,4416,O
of,4416,O
reactive,4416,O
oxygen,4416,O
species,4416,O
(,4416,O
ROS,4416,O
),4416,O
.,4416,O
We,4417,O
therefore,4417,O
hypothesized,4417,O
that,4417,O
A-T,4417,B-SpecificDisease
is,4417,O
due,4417,O
to,4417,O
oxidative,4417,O
damage,4417,O
resulting,4417,O
from,4417,O
loss,4417,O
of,4417,O
function,4417,O
of,4417,O
the,4417,O
A-T,4417,B-Modifier
gene,4417,O
product,4417,O
.,4417,O
To,4418,O
assess,4418,O
this,4418,O
hypothesis,4418,O
",",4418,O
we,4418,O
employed,4418,O
an,4418,O
animal,4418,O
model,4418,O
of,4418,O
A-T,4418,B-SpecificDisease
",",4418,O
the,4418,O
mouse,4418,O
with,4418,O
a,4418,O
disrupted,4418,O
Atm,4418,O
gene,4418,O
.,4418,O
We,4419,O
show,4419,O
that,4419,O
organs,4419,O
which,4419,O
develop,4419,O
pathologic,4419,O
changes,4419,O
in,4419,O
the,4419,O
Atm-deficient,4419,O
mice,4419,O
are,4419,O
targets,4419,O
of,4419,O
oxidative,4419,O
damage,4419,O
",",4419,O
and,4419,O
that,4419,O
cerebellar,4419,O
Purkinje,4419,O
cells,4419,O
are,4419,O
particularly,4419,O
affected,4419,O
.,4419,O
These,4420,O
observations,4420,O
provide,4420,O
a,4420,O
mechanistic,4420,O
basis,4420,O
for,4420,O
the,4420,O
A-T,4420,B-Modifier
phenotype,4420,O
and,4420,O
lay,4420,O
a,4420,O
rational,4420,O
foundation,4420,O
for,4420,O
therapeutic,4420,O
intervention,4420,O
..,4420,O
Recessively,4421,O
inherited,4421,O
multiple,4421,B-SpecificDisease
epiphyseal,4421,I-SpecificDisease
dysplasia,4421,I-SpecificDisease
with,4421,O
normal,4421,O
stature,4421,O
",",4421,O
club,4421,B-SpecificDisease
foot,4421,I-SpecificDisease
",",4421,O
and,4421,O
double,4421,B-DiseaseClass
layered,4421,I-DiseaseClass
patella,4421,I-DiseaseClass
caused,4421,O
by,4421,O
a,4421,O
DTDST,4421,O
mutation,4421,O
.,4421,O
We,4422,O
have,4422,O
observed,4422,O
over,4422,O
25,4422,O
different,4422,O
mutations,4422,O
in,4422,O
the,4422,O
diastrophic,4422,B-Modifier
dysplasia,4422,I-Modifier
sulphate,4422,O
transporter,4422,O
gene,4422,O
(,4422,O
DTDST,4422,O
),4422,O
in,4422,O
association,4422,O
with,4422,O
the,4422,O
recessive,4422,B-DiseaseClass
disorders,4422,I-DiseaseClass
achondrogenesis,4422,B-SpecificDisease
1B,4422,I-SpecificDisease
",",4422,O
atelosteogenesis,4422,B-SpecificDisease
2,4422,I-SpecificDisease
",",4422,O
and,4422,O
diastrophic,4422,B-SpecificDisease
dysplasia,4422,I-SpecificDisease
.,4422,O
The,4423,O
c862t,4423,O
(,4423,O
R279W,4423,O
),4423,O
transition,4423,O
is,4423,O
the,4423,O
most,4423,O
common,4423,O
mutation,4423,O
in,4423,O
non-Finnish,4423,O
patients,4423,O
",",4423,O
but,4423,O
in,4423,O
these,4423,O
disorders,4423,O
it,4423,O
is,4423,O
usually,4423,O
combined,4423,O
with,4423,O
other,4423,O
DTDST,4423,O
mutations,4423,O
.,4423,O
We,4424,O
had,4424,O
not,4424,O
seen,4424,O
a,4424,O
case,4424,O
of,4424,O
homozygosity,4424,O
for,4424,O
c862t,4424,O
(,4424,O
R279W,4424,O
),4424,O
until,4424,O
we,4424,O
analysed,4424,O
DNA,4424,O
from,4424,O
a,4424,O
36,4424,O
year,4424,O
old,4424,O
male,4424,O
with,4424,O
tall-normal,4424,O
stature,4424,O
(,4424,O
180,4424,O
cm,4424,O
),4424,O
who,4424,O
asked,4424,O
for,4424,O
genetic,4424,O
counselling,4424,O
for,4424,O
suspected,4424,O
multiple,4424,B-SpecificDisease
epiphyseal,4424,I-SpecificDisease
dysplasia,4424,I-SpecificDisease
.,4424,O
He,4425,O
was,4425,O
treated,4425,O
for,4425,O
club,4425,B-SpecificDisease
foot,4425,I-SpecificDisease
and,4425,O
hip,4425,B-SpecificDisease
dysplasia,4425,I-SpecificDisease
at,4425,O
birth,4425,O
.,4425,O
Skeletal,4426,O
changes,4426,O
consistent,4426,O
with,4426,O
multiple,4426,B-SpecificDisease
epiphyseal,4426,I-SpecificDisease
dysplasia,4426,I-SpecificDisease
",",4426,O
with,4426,O
the,4426,O
peculiar,4426,O
finding,4426,O
of,4426,O
a,4426,O
double,4426,B-DiseaseClass
layered,4426,I-DiseaseClass
patella,4426,I-DiseaseClass
",",4426,O
were,4426,O
recognised,4426,O
during,4426,O
childhood,4426,O
.,4426,O
Cleft,4427,B-SpecificDisease
palate,4427,I-SpecificDisease
",",4427,O
swelling,4427,B-DiseaseClass
of,4427,I-DiseaseClass
the,4427,I-DiseaseClass
ear,4427,I-DiseaseClass
pinna,4427,I-DiseaseClass
",",4427,O
and,4427,O
hitch,4427,B-DiseaseClass
hiker,4427,I-DiseaseClass
thumb,4427,I-DiseaseClass
were,4427,O
absent,4427,O
.,4427,O
He,4428,O
was,4428,O
found,4428,O
to,4428,O
be,4428,O
homozygous,4428,O
",",4428,O
and,4428,O
both,4428,O
healthy,4428,O
parents,4428,O
heterozygous,4428,O
",",4428,O
for,4428,O
the,4428,O
R279W,4428,O
mutation,4428,O
in,4428,O
DTDST,4428,O
",",4428,O
and,4428,O
his,4428,O
fibroblasts,4428,O
showed,4428,O
a,4428,O
sulphate,4428,O
incorporation,4428,O
defect,4428,O
typical,4428,O
of,4428,O
DTDST,4428,B-SpecificDisease
disorders,4428,I-SpecificDisease
.,4428,O
Counselling,4429,O
was,4429,O
given,4429,O
for,4429,O
a,4429,O
recessive,4429,B-DiseaseClass
disorder,4429,I-DiseaseClass
",",4429,O
thereby,4429,O
considerably,4429,O
reducing,4429,O
the,4429,O
probability,4429,O
of,4429,O
affected,4429,O
offspring,4429,O
.,4429,O
Multiple,4430,B-SpecificDisease
epiphyseal,4430,I-SpecificDisease
dysplasia,4430,I-SpecificDisease
is,4430,O
more,4430,O
frequently,4430,O
caused,4430,O
by,4430,O
dominant,4430,O
mutations,4430,O
in,4430,O
the,4430,O
COMP,4430,O
(,4430,O
EDM1,4430,B-SpecificDisease
",",4430,O
McKusick,4430,O
132400,4430,O
),4430,O
and,4430,O
COL9A2,4430,O
genes,4430,O
(,4430,O
EDM2,4430,B-SpecificDisease
",",4430,O
McKusick,4430,O
600204,4430,O
),4430,O
.,4430,O
A,4431,O
few,4431,O
other,4431,O
patients,4431,O
and,4431,O
families,4431,O
with,4431,O
features,4431,O
similar,4431,O
to,4431,O
our,4431,O
proband,4431,O
have,4431,O
been,4431,O
described,4431,O
previously,4431,O
and,4431,O
considered,4431,O
to,4431,O
have,4431,O
autosomal,4431,O
recessive,4431,O
MED,4431,B-SpecificDisease
(,4431,O
EDM4,4431,B-SpecificDisease
",",4431,O
McKusick,4431,O
226900,4431,O
),4431,O
.,4431,O
This,4432,O
observation,4432,O
confirms,4432,O
the,4432,O
existence,4432,O
of,4432,O
this,4432,O
entity,4432,O
and,4432,O
assigns,4432,O
it,4432,O
to,4432,O
the,4432,O
phenotypic,4432,O
spectrum,4432,O
associated,4432,O
with,4432,O
mutations,4432,O
at,4432,O
the,4432,O
DTDST,4432,O
locus,4432,O
..,4432,O
Homozygosity,4433,O
for,4433,O
a,4433,O
novel,4433,O
DTDST,4433,O
mutation,4433,O
in,4433,O
a,4433,O
child,4433,O
with,4433,O
a,4433,O
'broad,4433,O
bone-platyspondylic,4433,O
',4433,O
variant,4433,O
of,4433,O
diastrophic,4433,B-SpecificDisease
dysplasia,4433,I-SpecificDisease
.,4433,O
Atypical,4434,O
or,4434,O
variant,4434,O
forms,4434,O
of,4434,O
well-known,4434,O
chondrodysplasias,4434,B-DiseaseClass
may,4434,O
pose,4434,O
diagnostic,4434,O
problems,4434,O
.,4434,O
We,4435,O
report,4435,O
on,4435,O
a,4435,O
girl,4435,O
with,4435,O
clinical,4435,O
features,4435,O
suggesting,4435,O
diastrophic,4435,B-SpecificDisease
dysplasia,4435,I-SpecificDisease
but,4435,O
with,4435,O
unusual,4435,O
radiographic,4435,O
features,4435,O
including,4435,O
severe,4435,O
platyspondyly,4435,B-DiseaseClass
",",4435,O
wide,4435,O
metaphyses,4435,O
",",4435,O
and,4435,O
fibular,4435,O
overgrowth,4435,O
",",4435,O
which,4435,O
are,4435,O
partially,4435,O
reminiscent,4435,O
of,4435,O
metatropic,4435,B-SpecificDisease
dysplasia,4435,I-SpecificDisease
.,4435,O
The,4436,O
diagnosis,4436,O
was,4436,O
clarified,4436,O
by,4436,O
molecular,4436,O
analysis,4436,O
of,4436,O
the,4436,O
DTDST,4436,O
gene,4436,O
",",4436,O
which,4436,O
revealed,4436,O
homozygosity,4436,O
for,4436,O
a,4436,O
previously,4436,O
undescribed,4436,O
mutation,4436,O
leading,4436,O
to,4436,O
a,4436,O
Q454P,4436,O
substitution,4436,O
in,4436,O
the,4436,O
10th,4436,O
transmembrane,4436,O
domain,4436,O
of,4436,O
the,4436,O
DTDST,4436,O
sulfate,4436,O
transporter,4436,O
.,4436,O
Molecular,4437,O
analysis,4437,O
may,4437,O
be,4437,O
of,4437,O
particular,4437,O
value,4437,O
in,4437,O
such,4437,O
atypical,4437,O
cases,4437,O
..,4437,O
The,4438,O
type,4438,O
of,4438,O
somatic,4438,O
mutation,4438,O
at,4438,O
APC,4438,O
in,4438,O
familial,4438,B-SpecificDisease
adenomatous,4438,I-SpecificDisease
polyposis,4438,I-SpecificDisease
is,4438,O
determined,4438,O
by,4438,O
the,4438,O
site,4438,O
of,4438,O
the,4438,O
germline,4438,O
mutation,4438,O
:,4438,O
a,4438,O
new,4438,O
facet,4438,O
to,4438,O
Knudson,4438,O
's,4438,O
'two-hit,4438,O
',4438,O
hypothesis,4438,O
.,4438,O
APC,4439,O
is,4439,O
often,4439,O
cited,4439,O
as,4439,O
a,4439,O
prime,4439,O
example,4439,O
of,4439,O
a,4439,O
tumor,4439,B-Modifier
suppressor,4439,O
gene,4439,O
.,4439,O
Truncating,4440,O
germline,4440,O
and,4440,O
somatic,4440,O
mutations,4440,O
(,4440,O
or,4440,O
",",4440,O
infrequently,4440,O
",",4440,O
allelic,4440,O
loss,4440,O
),4440,O
occur,4440,O
in,4440,O
tumors,4440,B-DiseaseClass
in,4440,O
FAP,4440,B-SpecificDisease
(,4440,O
familial,4440,B-SpecificDisease
adenomatous,4440,I-SpecificDisease
polyposis,4440,I-SpecificDisease
),4440,O
.,4440,O
Most,4441,O
sporadic,4441,B-SpecificDisease
colorectal,4441,I-SpecificDisease
cancers,4441,I-SpecificDisease
also,4441,O
have,4441,O
two,4441,O
APC,4441,B-Modifier
mutations,4441,O
.,4441,O
Clues,4442,O
from,4442,O
attenuated,4442,B-Modifier
polyposis,4442,I-Modifier
",",4442,O
missense,4442,O
germline,4442,O
variants,4442,O
with,4442,O
mild,4442,O
disease,4442,O
and,4442,O
the,4442,O
somatic,4442,O
mutation,4442,O
cluster,4442,O
region,4442,O
(,4442,O
codons,4442,O
1,4442,O
",",4442,O
250-1,4442,O
",",4442,O
450,4442,O
),4442,O
indicate,4442,O
",",4442,O
however,4442,O
",",4442,O
that,4442,O
APC,4442,B-Modifier
mutations,4442,O
might,4442,O
not,4442,O
result,4442,O
in,4442,O
simple,4442,O
loss,4442,O
of,4442,O
protein,4442,O
function,4442,O
.,4442,O
We,4443,O
have,4443,O
found,4443,O
that,4443,O
FAP,4443,B-Modifier
patients,4443,O
with,4443,O
germline,4443,O
APC,4443,B-Modifier
mutations,4443,O
within,4443,O
a,4443,O
small,4443,O
region,4443,O
(,4443,O
codons,4443,O
1,4443,O
",",4443,O
194-1,4443,O
",",4443,O
392,4443,O
at,4443,O
most,4443,O
),4443,O
mainly,4443,O
show,4443,O
allelic,4443,O
loss,4443,O
in,4443,O
their,4443,O
colorectal,4443,B-SpecificDisease
adenomas,4443,I-SpecificDisease
",",4443,O
in,4443,O
contrast,4443,O
to,4443,O
other,4443,O
FAP,4443,B-Modifier
patients,4443,O
",",4443,O
whose,4443,O
second,4443,O
hits,4443,O
tend,4443,O
to,4443,O
occur,4443,O
by,4443,O
truncating,4443,O
mutations,4443,O
in,4443,O
the,4443,O
mutation,4443,O
cluster,4443,O
region,4443,O
.,4443,O
Our,4444,O
results,4444,O
indicate,4444,O
that,4444,O
different,4444,O
APC,4444,B-Modifier
mutations,4444,O
provide,4444,O
cells,4444,O
with,4444,O
different,4444,O
selective,4444,O
advantages,4444,O
",",4444,O
with,4444,O
mutations,4444,O
close,4444,O
to,4444,O
codon,4444,O
1,4444,O
",",4444,O
300,4444,O
providing,4444,O
the,4444,O
greatest,4444,O
advantage,4444,O
.,4444,O
Allelic,4445,O
loss,4445,O
is,4445,O
selected,4445,O
strongly,4445,O
in,4445,O
cells,4445,O
with,4445,O
one,4445,O
mutation,4445,O
near,4445,O
codon,4445,O
1,4445,O
",",4445,O
300,4445,O
.,4445,O
A,4446,O
different,4446,O
germline-somatic,4446,O
APC,4446,B-Modifier
mutation,4446,O
association,4446,O
exists,4446,O
in,4446,O
FAP,4446,B-SpecificDisease
desmoids,4446,I-SpecificDisease
.,4446,O
APC,4447,O
is,4447,O
not,4447,O
",",4447,O
therefore,4447,O
",",4447,O
a,4447,O
classical,4447,O
tumor,4447,B-Modifier
suppressor,4447,O
.,4447,O
Our,4448,O
findings,4448,O
also,4448,O
indicate,4448,O
a,4448,O
new,4448,O
mechanism,4448,O
for,4448,O
disease,4448,O
severity,4448,O
if,4448,O
a,4448,O
broader,4448,O
spectrum,4448,O
of,4448,O
mutations,4448,O
is,4448,O
selected,4448,O
in,4448,O
tumors,4448,B-DiseaseClass
",",4448,O
the,4448,O
somatic,4448,O
mutation,4448,O
rate,4448,O
is,4448,O
effectively,4448,O
higher,4448,O
and,4448,O
more,4448,O
tumors,4448,B-DiseaseClass
grow,4448,O
..,4448,O
Mxi1,4449,O
mutations,4449,O
in,4449,O
human,4449,O
neurofibrosarcomas,4449,B-SpecificDisease
.,4449,O
Mxi1,4450,O
is,4450,O
thought,4450,O
to,4450,O
negatively,4450,O
regulate,4450,O
Myc,4450,O
function,4450,O
and,4450,O
may,4450,O
therefore,4450,O
be,4450,O
a,4450,O
potential,4450,O
tumor,4450,B-Modifier
suppressor,4450,O
gene,4450,O
.,4450,O
Little,4451,O
effort,4451,O
has,4451,O
yet,4451,O
been,4451,O
made,4451,O
to,4451,O
find,4451,O
alterations,4451,O
involving,4451,O
this,4451,O
gene,4451,O
in,4451,O
human,4451,O
solid,4451,B-DiseaseClass
tumors,4451,I-DiseaseClass
.,4451,O
We,4452,O
screened,4452,O
31,4452,O
human,4452,O
gastric,4452,B-SpecificDisease
cancers,4452,I-SpecificDisease
",",4452,O
7,4452,O
esophageal,4452,B-SpecificDisease
cancers,4452,I-SpecificDisease
",",4452,O
85,4452,O
bone,4452,O
and,4452,O
soft,4452,O
tissue,4452,O
tumors,4452,O
of,4452,O
various,4452,O
types,4452,O
",",4452,O
including,4452,O
4,4452,O
neurofibrosarcomas,4452,B-SpecificDisease
.,4452,O
We,4453,O
also,4453,O
examined,4453,O
29,4453,O
human,4453,O
tumor,4453,B-Modifier
cell,4453,O
lines,4453,O
consisting,4453,O
of,4453,O
12,4453,O
esophageal,4453,B-SpecificDisease
cancers,4453,I-SpecificDisease
",",4453,O
7,4453,O
glioma/glioblastomas,4453,B-SpecificDisease
and,4453,O
10,4453,O
others,4453,O
for,4453,O
Mxi1,4453,O
mutations,4453,O
in,4453,O
exons,4453,O
1,4453,O
",",4453,O
2,4453,O
",",4453,O
4,4453,O
(,4453,O
HLH,4453,O
domain,4453,O
),4453,O
",",4453,O
5,4453,O
and,4453,O
6,4453,O
.,4453,O
Polymerase,4454,O
chain,4454,O
reaction-single-strand,4454,O
conformation,4454,O
polymorphism,4454,O
(,4454,O
PCR-SSCP,4454,O
),4454,O
and,4454,O
subsequent,4454,O
sequencing,4454,O
revealed,4454,O
three,4454,O
distinct,4454,O
polymorphisms,4454,O
in,4454,O
the,4454,O
intron-exon,4454,O
boundary,4454,O
upstream,4454,O
from,4454,O
exon,4454,O
6,4454,O
.,4454,O
We,4455,O
discovered,4455,O
a,4455,O
missense,4455,O
mutation,4455,O
",",4455,O
GCA,4455,O
to,4455,O
GTA,4455,O
(,4455,O
Ala,4455,O
54,4455,O
Val,4455,O
),4455,O
",",4455,O
in,4455,O
exon,4455,O
2,4455,O
in,4455,O
a,4455,O
neurofibrosarcoma,4455,B-Modifier
patient,4455,O
(,4455,O
case,4455,O
1,4455,O
),4455,O
",",4455,O
two,4455,O
missense,4455,O
mutations,4455,O
",",4455,O
AAA,4455,O
to,4455,O
CAA,4455,O
(,4455,O
Lys,4455,O
118,4455,O
Gln,4455,O
),4455,O
and,4455,O
GAA,4455,O
to,4455,O
GGA,4455,O
(,4455,O
Glu,4455,O
154,4455,O
Gly,4455,O
),4455,O
in,4455,O
exon,4455,O
5,4455,O
of,4455,O
another,4455,O
neurofibrosarcoma,4455,B-Modifier
patient,4455,O
(,4455,O
case,4455,O
2,4455,O
),4455,O
",",4455,O
and,4455,O
3,4455,O
amino,4455,O
acid,4455,O
substitutions,4455,O
",",4455,O
GTG,4455,O
to,4455,O
GCG,4455,O
(,4455,O
Val,4455,O
179,4455,O
Ala,4455,O
),4455,O
",",4455,O
GTT,4455,O
to,4455,O
GCT,4455,O
(,4455,O
Val,4455,O
181,4455,O
Ala,4455,O
),4455,O
and,4455,O
TTC,4455,O
to,4455,O
CTC,4455,O
(,4455,O
Phe,4455,O
186,4455,O
Leu,4455,O
),4455,O
",",4455,O
in,4455,O
a,4455,O
third,4455,O
neurofibrosarcoma,4455,B-Modifier
patient,4455,O
(,4455,O
case,4455,O
3,4455,O
),4455,O
.,4455,O
In,4456,O
case,4456,O
3,4456,O
",",4456,O
loss,4456,O
of,4456,O
heterozygosity,4456,O
was,4456,O
also,4456,O
demonstrated,4456,O
by,4456,O
informative,4456,O
(,4456,O
TTC,4456,O
),4456,O
3/,4456,O
(,4456,O
TTC,4456,O
),4456,O
2,4456,O
polymorphism,4456,O
.,4456,O
Our,4457,O
data,4457,O
demonstrate,4457,O
that,4457,O
mutations,4457,O
occur,4457,O
in,4457,O
the,4457,O
Mxi1,4457,O
gene,4457,O
in,4457,O
neurofibrosarcoma,4457,B-SpecificDisease
.,4457,O
Missense,4458,O
mutations,4458,O
in,4458,O
the,4458,O
functional,4458,O
domain,4458,O
of,4458,O
Mxi1,4458,O
in,4458,O
these,4458,O
cases,4458,O
may,4458,O
be,4458,O
involved,4458,O
in,4458,O
the,4458,O
pathogenesis,4458,O
of,4458,O
neurofibrosarcoma,4458,B-SpecificDisease
..,4458,O
A,4459,O
population-based,4459,O
study,4459,O
of,4459,O
the,4459,O
clinical,4459,O
expression,4459,O
of,4459,O
the,4459,O
hemochromatosis,4459,B-Modifier
gene,4459,O
.,4459,O
BACKGROUND,4460,O
AND,4460,O
METHODS,4460,O
Hereditary,4460,B-SpecificDisease
hemochromatosis,4460,I-SpecificDisease
is,4460,O
associated,4460,O
with,4460,O
homozygosity,4460,O
for,4460,O
the,4460,O
C282Y,4460,O
mutation,4460,O
in,4460,O
the,4460,O
hemochromatosis,4460,B-Modifier
(,4460,O
HFE,4460,O
),4460,O
gene,4460,O
on,4460,O
chromosome,4460,O
6,4460,O
",",4460,O
elevated,4460,O
serum,4460,O
transferrin,4460,O
saturation,4460,O
",",4460,O
and,4460,O
excess,4460,B-DiseaseClass
iron,4460,I-DiseaseClass
deposits,4460,I-DiseaseClass
throughout,4460,O
the,4460,O
body,4460,O
.,4460,O
To,4461,O
assess,4461,O
the,4461,O
prevalence,4461,O
and,4461,O
clinical,4461,O
expression,4461,O
of,4461,O
the,4461,O
HFE,4461,O
gene,4461,O
",",4461,O
we,4461,O
conducted,4461,O
a,4461,O
population-based,4461,O
study,4461,O
in,4461,O
Busselton,4461,O
",",4461,O
Australia,4461,O
.,4461,O
In,4462,O
1994,4462,O
",",4462,O
we,4462,O
obtained,4462,O
blood,4462,O
samples,4462,O
for,4462,O
the,4462,O
determination,4462,O
of,4462,O
serum,4462,O
transferrin,4462,O
saturation,4462,O
and,4462,O
ferritin,4462,O
levels,4462,O
and,4462,O
the,4462,O
presence,4462,O
or,4462,O
absence,4462,O
of,4462,O
the,4462,O
C282Y,4462,O
mutation,4462,O
and,4462,O
the,4462,O
H63D,4462,O
mutation,4462,O
(,4462,O
which,4462,O
may,4462,O
contribute,4462,O
to,4462,O
increased,4462,O
hepatic,4462,O
iron,4462,O
levels,4462,O
),4462,O
in,4462,O
3011,4462,O
unrelated,4462,O
white,4462,O
adults,4462,O
.,4462,O
We,4463,O
evaluated,4463,O
all,4463,O
subjects,4463,O
who,4463,O
had,4463,O
persistently,4463,O
elevated,4463,O
transferrin-saturation,4463,O
values,4463,O
(,4463,O
45,4463,O
percent,4463,O
or,4463,O
higher,4463,O
),4463,O
or,4463,O
were,4463,O
homozygous,4463,O
for,4463,O
the,4463,O
C282Y,4463,O
mutation,4463,O
.,4463,O
We,4464,O
recommended,4464,O
liver,4464,O
biopsy,4464,O
for,4464,O
subjects,4464,O
with,4464,O
serum,4464,O
ferritin,4464,O
levels,4464,O
of,4464,O
300,4464,O
ng,4464,O
per,4464,O
milliliter,4464,O
or,4464,O
higher,4464,O
.,4464,O
The,4465,O
subjects,4465,O
were,4465,O
followed,4465,O
for,4465,O
up,4465,O
to,4465,O
four,4465,O
years,4465,O
.,4465,O
RESULTS,4466,O
Sixteen,4466,O
of,4466,O
the,4466,O
subjects,4466,O
(,4466,O
0,4466,O
.,4466,O
5,4467,O
percent,4467,O
),4467,O
were,4467,O
homozygous,4467,O
for,4467,O
the,4467,O
C282Y,4467,O
mutation,4467,O
",",4467,O
and,4467,O
424,4467,O
(,4467,O
14,4467,O
.,4467,O
1,4468,O
percent,4468,O
),4468,O
were,4468,O
heterozygous,4468,O
.,4468,O
The,4469,O
serum,4469,O
transferrin,4469,O
saturation,4469,O
was,4469,O
45,4469,O
percent,4469,O
or,4469,O
higher,4469,O
in,4469,O
15,4469,O
of,4469,O
the,4469,O
16,4469,O
who,4469,O
were,4469,O
homozygous,4469,O
;,4469,O
in,4469,O
1,4469,O
subject,4469,O
it,4469,O
was,4469,O
43,4469,O
percent,4469,O
.,4469,O
Four,4470,O
of,4470,O
the,4470,O
homozygous,4470,O
subjects,4470,O
had,4470,O
previously,4470,O
been,4470,O
given,4470,O
a,4470,O
diagnosis,4470,O
of,4470,O
hemochromatosis,4470,B-SpecificDisease
",",4470,O
and,4470,O
12,4470,O
had,4470,O
not,4470,O
.,4470,O
Seven,4471,O
of,4471,O
these,4471,O
12,4471,O
patients,4471,O
had,4471,O
elevated,4471,O
serum,4471,O
ferritin,4471,O
levels,4471,O
in,4471,O
1994,4471,O
;,4471,O
6,4471,O
of,4471,O
the,4471,O
7,4471,O
had,4471,O
further,4471,O
increases,4471,O
in,4471,O
1998,4471,O
",",4471,O
and,4471,O
1,4471,O
had,4471,O
a,4471,O
decrease,4471,O
",",4471,O
although,4471,O
the,4471,O
value,4471,O
remained,4471,O
elevated,4471,O
.,4471,O
The,4472,O
serum,4472,O
ferritin,4472,O
levels,4472,O
in,4472,O
the,4472,O
four,4472,O
other,4472,O
homozygous,4472,O
patients,4472,O
remained,4472,O
in,4472,O
the,4472,O
normal,4472,O
range,4472,O
.,4472,O
Eleven,4473,O
of,4473,O
the,4473,O
16,4473,O
homozygous,4473,O
subjects,4473,O
underwent,4473,O
liver,4473,O
biopsy,4473,O
;,4473,O
3,4473,O
had,4473,O
hepatic,4473,B-DiseaseClass
fibrosis,4473,I-DiseaseClass
",",4473,O
and,4473,O
1,4473,O
",",4473,O
who,4473,O
had,4473,O
a,4473,O
history,4473,O
of,4473,O
excessive,4473,B-SpecificDisease
alcohol,4473,I-SpecificDisease
consumption,4473,I-SpecificDisease
",",4473,O
had,4473,O
cirrhosis,4473,B-DiseaseClass
and,4473,O
mild,4473,O
microvesicular,4473,B-SpecificDisease
steatosis,4473,I-SpecificDisease
.,4473,O
Eight,4474,O
of,4474,O
the,4474,O
16,4474,O
homozygous,4474,O
subjects,4474,O
had,4474,O
clinical,4474,O
findings,4474,O
that,4474,O
were,4474,O
consistent,4474,O
with,4474,O
the,4474,O
presence,4474,O
of,4474,O
hereditary,4474,B-SpecificDisease
hemochromatosis,4474,I-SpecificDisease
",",4474,O
such,4474,O
as,4474,O
hepatomegaly,4474,B-DiseaseClass
",",4474,O
skin,4474,B-DiseaseClass
pigmentation,4474,I-DiseaseClass
",",4474,O
and,4474,O
arthritis,4474,B-DiseaseClass
.,4474,O
CONCLUSIONS,4475,O
In,4475,O
a,4475,O
population,4475,O
of,4475,O
white,4475,O
adults,4475,O
of,4475,O
northern,4475,O
European,4475,O
ancestry,4475,O
",",4475,O
0,4475,O
.,4475,O
5,4476,O
percent,4476,O
were,4476,O
homozygous,4476,O
for,4476,O
the,4476,O
C282Y,4476,O
mutation,4476,O
in,4476,O
the,4476,O
HFE,4476,O
gene,4476,O
.,4476,O
However,4477,O
",",4477,O
only,4477,O
half,4477,O
of,4477,O
those,4477,O
who,4477,O
were,4477,O
homozygous,4477,O
had,4477,O
clinical,4477,O
features,4477,O
of,4477,O
hemochromatosis,4477,B-SpecificDisease
",",4477,O
and,4477,O
one,4477,O
quarter,4477,O
had,4477,O
serum,4477,O
ferritin,4477,O
levels,4477,O
that,4477,O
remained,4477,O
normal,4477,O
over,4477,O
a,4477,O
four-year,4477,O
period,4477,O
.,4477,O
Large,4478,O
heterozygous,4478,O
deletion,4478,O
masquerading,4478,O
as,4478,O
homozygous,4478,O
missense,4478,O
mutation,4478,O
:,4478,O
a,4478,O
pitfall,4478,O
in,4478,O
diagnostic,4478,O
mutation,4478,O
analysis,4478,O
.,4478,O
The,4479,O
clinical,4479,O
use,4479,O
of,4479,O
molecular,4479,O
analyses,4479,O
in,4479,O
recessive,4479,B-DiseaseClass
disorders,4479,I-DiseaseClass
relies,4479,O
on,4479,O
the,4479,O
exact,4479,O
characterization,4479,O
of,4479,O
both,4479,O
mutant,4479,O
alleles,4479,O
in,4479,O
the,4479,O
affected,4479,O
patient,4479,O
.,4479,O
This,4480,O
can,4480,O
be,4480,O
problematic,4480,O
when,4480,O
only,4480,O
part,4480,O
of,4480,O
the,4480,O
gene,4480,O
is,4480,O
examined,4480,O
or,4480,O
when,4480,O
relevant,4480,O
DNA,4480,O
alterations,4480,O
are,4480,O
not,4480,O
recognized,4480,O
by,4480,O
standard,4480,O
methods,4480,O
.,4480,O
We,4481,O
present,4481,O
a,4481,O
child,4481,O
in,4481,O
whom,4481,O
phenylketonuria,4481,B-SpecificDisease
was,4481,O
apparently,4481,O
caused,4481,O
by,4481,O
homozygosity,4481,O
for,4481,O
the,4481,O
mutation,4481,O
E390G,4481,O
in,4481,O
exon,4481,O
11,4481,O
of,4481,O
the,4481,O
phenylalanine,4481,O
hydroxylase,4481,O
(,4481,O
PAH,4481,O
),4481,O
gene,4481,O
.,4481,O
However,4482,O
",",4482,O
the,4482,O
clinical,4482,O
severity,4482,O
of,4482,O
the,4482,O
disease,4482,O
was,4482,O
not,4482,O
quite,4482,O
as,4482,O
mild,4482,O
as,4482,O
expected,4482,O
",",4482,O
the,4482,O
mutation,4482,O
was,4482,O
not,4482,O
identified,4482,O
in,4482,O
the,4482,O
father,4482,O
despite,4482,O
confirmed,4482,O
paternity,4482,O
",",4482,O
and,4482,O
the,4482,O
paternal,4482,O
allele,4482,O
showed,4482,O
a,4482,O
highly,4482,O
unusual,4482,O
pattern,4482,O
of,4482,O
polymorphic,4482,O
markers,4482,O
in,4482,O
the,4482,O
PAH,4482,O
gene,4482,O
.,4482,O
Presence,4483,O
of,4483,O
a,4483,O
large,4483,O
deletion,4483,O
involving,4483,O
exons,4483,O
9,4483,O
",",4483,O
10,4483,O
and,4483,O
11,4483,O
of,4483,O
the,4483,O
phenylalanine,4483,O
hydroxylase,4483,O
gene,4483,O
was,4483,O
confirmed,4483,O
by,4483,O
long-range,4483,O
PCR,4483,O
.,4483,O
Diagnostic,4484,O
DNA,4484,O
analyses,4484,O
should,4484,O
include,4484,O
a,4484,O
comprehensive,4484,O
examination,4484,O
of,4484,O
the,4484,O
whole,4484,O
relevant,4484,O
gene,4484,O
in,4484,O
the,4484,O
patient,4484,O
and,4484,O
confirmation,4484,O
of,4484,O
carrier,4484,O
status,4484,O
in,4484,O
both,4484,O
parents,4484,O
..,4484,O
Early,4485,O
onset,4485,O
of,4485,O
X-linked,4485,B-SpecificDisease
Emery-Dreifuss,4485,I-SpecificDisease
muscular,4485,I-SpecificDisease
dystrophy,4485,I-SpecificDisease
in,4485,O
a,4485,O
boy,4485,O
with,4485,O
emerin,4485,O
gene,4485,O
deletion,4485,O
.,4485,O
A,4486,O
boy,4486,O
developed,4486,O
contractures,4486,B-DiseaseClass
of,4486,I-DiseaseClass
the,4486,I-DiseaseClass
Achilles,4486,I-DiseaseClass
tendons,4486,I-DiseaseClass
at,4486,O
3,4486,O
years,4486,O
and,4486,O
of,4486,O
the,4486,O
postcervical,4486,O
muscles,4486,O
at,4486,O
7,4486,O
years,4486,O
",",4486,O
although,4486,O
neither,4486,O
contractures,4486,B-DiseaseClass
of,4486,I-DiseaseClass
the,4486,I-DiseaseClass
elbows,4486,I-DiseaseClass
nor,4486,O
cardiac,4486,B-DiseaseClass
abnormality,4486,I-DiseaseClass
were,4486,O
recognized,4486,O
by,4486,O
the,4486,O
age,4486,O
of,4486,O
9,4486,O
years,4486,O
.,4486,O
Muscle,4487,O
computed,4487,O
tomography,4487,O
scanning,4487,O
revealed,4487,O
changes,4487,O
characteristic,4487,O
of,4487,O
muscle,4487,O
involvement,4487,O
.,4487,O
Emerin,4488,O
was,4488,O
not,4488,O
detected,4488,O
in,4488,O
the,4488,O
biopsied,4488,O
muscle,4488,O
",",4488,O
and,4488,O
RT-PCR,4488,O
and,4488,O
PCR-based,4488,O
genomic,4488,O
DNA,4488,O
analyses,4488,O
of,4488,O
the,4488,O
emerin,4488,O
gene,4488,O
demonstrated,4488,O
no,4488,O
amplification,4488,O
product,4488,O
in,4488,O
the,4488,O
patient,4488,O
.,4488,O
These,4489,O
results,4489,O
confirmed,4489,O
the,4489,O
diagnosis,4489,O
of,4489,O
X-linked,4489,B-SpecificDisease
Emery-Dreifuss,4489,I-SpecificDisease
muscular,4489,I-SpecificDisease
dystrophy,4489,I-SpecificDisease
(,4489,O
EDMD,4489,B-SpecificDisease
),4489,O
",",4489,O
and,4489,O
reinforce,4489,O
the,4489,O
necessity,4489,O
of,4489,O
molecular,4489,O
genetic,4489,O
diagnosis,4489,O
of,4489,O
the,4489,O
membrane,4489,O
protein,4489,O
emerin,4489,O
in,4489,O
younger,4489,O
patients,4489,O
with,4489,O
possible,4489,O
EDMD,4489,B-SpecificDisease
before,4489,O
appearance,4489,O
of,4489,O
the,4489,O
typical,4489,O
symptoms,4489,O
",",4489,O
to,4489,O
avoid,4489,O
sudden,4489,B-SpecificDisease
cardiac,4489,I-SpecificDisease
death,4489,I-SpecificDisease
..,4489,O
Duchenne/Becker,4490,O
muscular,4490,O
dystrophy,4490,O
:,4490,O
correlation,4490,O
of,4490,O
phenotype,4490,O
by,4490,O
electroretinography,4490,O
with,4490,O
sites,4490,O
of,4490,O
dystrophin,4490,O
mutations,4490,O
.,4490,O
The,4491,O
dark-adapted,4491,O
electroretinogram,4491,O
(,4491,O
ERG,4491,O
),4491,O
of,4491,O
patients,4491,O
with,4491,O
Duchenne,4491,O
and,4491,O
Becker,4491,O
muscular,4491,O
dystrophy,4491,O
(,4491,O
DMD/BMD,4491,B-SpecificDisease
),4491,O
shows,4491,O
a,4491,O
marked,4491,O
reduction,4491,O
in,4491,O
b-wave,4491,O
amplitude,4491,O
.,4491,O
Genotype-phenotype,4492,O
studies,4492,O
of,4492,O
mouse,4492,O
models,4492,O
for,4492,O
DMD,4492,B-SpecificDisease
show,4492,O
position-specific,4492,O
effects,4492,O
of,4492,O
the,4492,O
mutations,4492,O
upon,4492,O
the,4492,O
phenotype,4492,O
mice,4492,O
with,4492,O
5,4492,O
defects,4492,O
of,4492,O
dystrophin,4492,O
have,4492,O
normal,4492,O
ERGs,4492,O
",",4492,O
those,4492,O
with,4492,O
defects,4492,O
in,4492,O
the,4492,O
central,4492,O
region,4492,O
have,4492,O
a,4492,O
normal,4492,O
b-wave,4492,O
amplitude,4492,O
associated,4492,O
with,4492,O
prolonged,4492,O
implicit,4492,O
times,4492,O
for,4492,O
both,4492,O
the,4492,O
b-wave,4492,O
and,4492,O
oscillatory,4492,O
potentials,4492,O
",",4492,O
and,4492,O
mice,4492,O
with,4492,O
3,4492,O
defects,4492,O
have,4492,O
a,4492,O
phenotype,4492,O
similar,4492,O
to,4492,O
that,4492,O
seen,4492,O
in,4492,O
DMD/BMD,4492,B-Modifier
patients,4492,O
.,4492,O
The,4493,O
mouse,4493,O
studies,4493,O
suggest,4493,O
a,4493,O
key,4493,O
role,4493,O
for,4493,O
the,4493,O
carboxyl,4493,O
terminal,4493,O
dystrophin,4493,O
isoform,4493,O
",",4493,O
Dp260,4493,O
",",4493,O
in,4493,O
retinal,4493,O
electrophysiology,4493,O
.,4493,O
We,4494,O
have,4494,O
undertaken,4494,O
a,4494,O
systematic,4494,O
evaluation,4494,O
of,4494,O
DMD/BMD,4494,B-Modifier
patients,4494,O
through,4494,O
clinical,4494,O
examination,4494,O
and,4494,O
review,4494,O
of,4494,O
the,4494,O
literature,4494,O
in,4494,O
order,4494,O
to,4494,O
determine,4494,O
whether,4494,O
the,4494,O
position-specific,4494,O
effects,4494,O
of,4494,O
mutations,4494,O
noted,4494,O
in,4494,O
the,4494,O
mouse,4494,O
are,4494,O
present,4494,O
in,4494,O
man,4494,O
.,4494,O
We,4495,O
have,4495,O
found,4495,O
that,4495,O
",",4495,O
in,4495,O
man,4495,O
",",4495,O
a,4495,O
wider,4495,O
variation,4495,O
of,4495,O
DMD,4495,B-DiseaseClass
defects,4495,I-DiseaseClass
correlate,4495,O
with,4495,O
reductions,4495,O
in,4495,O
the,4495,O
b-wave,4495,O
amplitude,4495,O
.,4495,O
Individuals,4496,O
with,4496,O
normal,4496,O
ERGs,4496,O
have,4496,O
mutations,4496,O
predominantly,4496,O
located,4496,O
5,4496,O
of,4496,O
the,4496,O
transcript,4496,O
initiation,4496,O
site,4496,O
of,4496,O
Dp260,4496,O
.,4496,O
Our,4497,O
results,4497,O
suggest,4497,O
that,4497,O
the,4497,O
most,4497,O
important,4497,O
determinant,4497,O
in,4497,O
the,4497,O
ERG,4497,O
b-wave,4497,O
phenotype,4497,O
is,4497,O
the,4497,O
mutation,4497,O
position,4497,O
",",4497,O
rather,4497,O
than,4497,O
muscle,4497,B-Modifier
disease,4497,I-Modifier
severity,4497,O
.,4497,O
Forty-six,4498,O
per,4498,O
cent,4498,O
of,4498,O
patients,4498,O
with,4498,O
mutations,4498,O
5,4498,O
of,4498,O
the,4498,O
Dp260,4498,O
transcript,4498,O
start,4498,O
site,4498,O
have,4498,O
abnormal,4498,O
ERGs,4498,O
",",4498,O
as,4498,O
opposed,4498,O
to,4498,O
94,4498,O
%,4498,O
with,4498,O
more,4498,O
distal,4498,O
mutations,4498,O
.,4498,O
The,4499,O
human,4499,O
genotype-phenotype,4499,O
correlations,4499,O
are,4499,O
consistent,4499,O
with,4499,O
a,4499,O
role,4499,O
for,4499,O
Dp260,4499,O
in,4499,O
normal,4499,O
retinal,4499,O
electrophysiology,4499,O
and,4499,O
may,4499,O
also,4499,O
reflect,4499,O
the,4499,O
expression,4499,O
of,4499,O
other,4499,O
C-terminal,4499,O
dystrophin,4499,O
isoforms,4499,O
and,4499,O
their,4499,O
contributions,4499,O
to,4499,O
retinal,4499,O
signal,4499,O
transmission,4499,O
..,4499,O
Cis,4500,O
and,4500,O
trans,4500,O
effects,4500,O
of,4500,O
the,4500,O
myotonic,4500,B-Modifier
dystrophy,4500,I-Modifier
(,4500,O
DM,4500,B-Modifier
),4500,O
mutation,4500,O
in,4500,O
a,4500,O
cell,4500,O
culture,4500,O
model,4500,O
.,4500,O
The,4501,O
mutation,4501,O
causing,4501,O
myotonic,4501,B-SpecificDisease
dystrophy,4501,I-SpecificDisease
(,4501,O
DM,4501,B-SpecificDisease
),4501,O
has,4501,O
been,4501,O
identified,4501,O
as,4501,O
a,4501,O
CTG,4501,O
expansion,4501,O
in,4501,O
the,4501,O
3-untranslated,4501,O
region,4501,O
(,4501,O
3-UTR,4501,O
),4501,O
of,4501,O
the,4501,O
DM,4501,B-Modifier
protein,4501,O
kinase,4501,O
gene,4501,O
(,4501,O
DMPK,4501,O
),4501,O
",",4501,O
but,4501,O
the,4501,O
mechanism,4501,O
(,4501,O
s,4501,O
),4501,O
of,4501,O
pathogenesis,4501,O
remain,4501,O
unknown,4501,O
.,4501,O
Studies,4502,O
using,4502,O
DM,4502,B-Modifier
patient,4502,O
materials,4502,O
have,4502,O
often,4502,O
produced,4502,O
confusing,4502,O
results,4502,O
.,4502,O
Therefore,4503,O
",",4503,O
to,4503,O
study,4503,O
the,4503,O
effects,4503,O
of,4503,O
the,4503,O
DM,4503,B-Modifier
mutation,4503,O
in,4503,O
a,4503,O
controlled,4503,O
environment,4503,O
",",4503,O
we,4503,O
have,4503,O
established,4503,O
a,4503,O
cell,4503,O
culture,4503,O
model,4503,O
system,4503,O
using,4503,O
C2C12,4503,O
mouse,4503,O
myoblasts,4503,O
.,4503,O
By,4504,O
expressing,4504,O
chimeric,4504,O
reporter,4504,O
constructs,4504,O
containing,4504,O
a,4504,O
reporter,4504,O
gene,4504,O
fused,4504,O
to,4504,O
a,4504,O
human,4504,O
DMPK,4504,O
3-UTR,4504,O
",",4504,O
we,4504,O
identified,4504,O
both,4504,O
cis,4504,O
and,4504,O
trans,4504,O
effects,4504,O
that,4504,O
are,4504,O
mediated,4504,O
by,4504,O
the,4504,O
DM,4504,B-Modifier
mutation,4504,O
.,4504,O
Our,4505,O
data,4505,O
show,4505,O
that,4505,O
a,4505,O
mutant,4505,O
DMPK,4505,O
3-UTR,4505,O
",",4505,O
with,4505,O
as,4505,O
few,4505,O
as,4505,O
57,4505,O
CTGs,4505,O
",",4505,O
had,4505,O
a,4505,O
negative,4505,O
cis,4505,O
effect,4505,O
on,4505,O
protein,4505,O
expression,4505,O
and,4505,O
resulted,4505,O
in,4505,O
the,4505,O
aggregation,4505,O
of,4505,O
reporter,4505,O
transcripts,4505,O
into,4505,O
discrete,4505,O
nuclear,4505,O
foci,4505,O
.,4505,O
We,4506,O
determined,4506,O
by,4506,O
deletion,4506,O
analysis,4506,O
that,4506,O
an,4506,O
expanded,4506,O
(,4506,O
CTG,4506,O
),4506,O
(,4506,O
n,4506,O
),4506,O
tract,4506,O
alone,4506,O
was,4506,O
sufficient,4506,O
to,4506,O
mediate,4506,O
these,4506,O
cis,4506,O
effects,4506,O
.,4506,O
Furthermore,4507,O
",",4507,O
in,4507,O
contrast,4507,O
to,4507,O
the,4507,O
normal,4507,O
DMPK,4507,O
3-UTR,4507,O
mRNA,4507,O
",",4507,O
a,4507,O
mutant,4507,O
DMPK,4507,O
3-UTR,4507,O
mRNA,4507,O
with,4507,O
(,4507,O
CUG,4507,O
),4507,O
(,4507,O
200,4507,O
),4507,O
selectively,4507,O
inhibited,4507,O
myogenic,4507,O
differentiation,4507,O
of,4507,O
C2C12,4507,O
myoblasts,4507,O
.,4507,O
Genetic,4508,O
analysis,4508,O
and,4508,O
the,4508,O
Cre-,4508,O
loxP,4508,O
system,4508,O
were,4508,O
used,4508,O
to,4508,O
clearly,4508,O
demonstrate,4508,O
that,4508,O
the,4508,O
myoblast,4508,O
fusion,4508,O
defect,4508,O
could,4508,O
be,4508,O
rescued,4508,O
by,4508,O
eliminating,4508,O
the,4508,O
expression,4508,O
of,4508,O
the,4508,O
mutant,4508,O
DMPK,4508,O
3-UTR,4508,O
transcript,4508,O
.,4508,O
Characterization,4509,O
of,4509,O
spontaneous,4509,O
deletion,4509,O
events,4509,O
mapped,4509,O
the,4509,O
inhibitory,4509,O
effect,4509,O
to,4509,O
the,4509,O
(,4509,O
CTG,4509,O
),4509,O
(,4509,O
n,4509,O
),4509,O
expansion,4509,O
and/or,4509,O
the,4509,O
3,4509,O
end,4509,O
of,4509,O
the,4509,O
DMPK,4509,O
3-UTR,4509,O
.,4509,O
These,4510,O
results,4510,O
provide,4510,O
evidence,4510,O
that,4510,O
the,4510,O
DM,4510,B-Modifier
mutation,4510,O
acts,4510,O
in,4510,O
cis,4510,O
to,4510,O
reduce,4510,O
protein,4510,O
production,4510,O
(,4510,O
consistent,4510,O
with,4510,O
DMPK,4510,B-SpecificDisease
haploinsufficiency,4510,I-SpecificDisease
),4510,O
and,4510,O
in,4510,O
trans,4510,O
as,4510,O
a,4510,O
riboregulator,4510,O
to,4510,O
inhibit,4510,O
myogenesis,4510,O
..,4510,O
Coats,4511,B-SpecificDisease
',4511,I-SpecificDisease
disease,4511,I-SpecificDisease
of,4511,O
the,4511,O
retina,4511,O
(,4511,O
unilateral,4511,B-SpecificDisease
retinal,4511,I-SpecificDisease
telangiectasis,4511,I-SpecificDisease
),4511,O
caused,4511,O
by,4511,O
somatic,4511,O
mutation,4511,O
in,4511,O
the,4511,O
NDP,4511,O
gene,4511,O
:,4511,O
a,4511,O
role,4511,O
for,4511,O
norrin,4511,O
in,4511,O
retinal,4511,O
angiogenesis,4511,O
.,4511,O
Coats,4512,B-SpecificDisease
disease,4512,I-SpecificDisease
is,4512,O
characterized,4512,O
by,4512,O
abnormal,4512,B-DiseaseClass
retinal,4512,I-DiseaseClass
vascular,4512,I-DiseaseClass
development,4512,I-DiseaseClass
(,4512,O
so-called,4512,O
retinal,4512,B-SpecificDisease
telangiectasis,4512,I-SpecificDisease
),4512,O
which,4512,O
results,4512,O
in,4512,O
massive,4512,O
intraretinal,4512,B-CompositeMention
and,4512,I-CompositeMention
subretinal,4512,I-CompositeMention
lipid,4512,I-CompositeMention
accumulation,4512,I-CompositeMention
(,4512,O
exudative,4512,B-DiseaseClass
retinal,4512,I-DiseaseClass
detachment,4512,I-DiseaseClass
),4512,O
.,4512,O
The,4513,O
classical,4513,O
form,4513,O
of,4513,O
Coats,4513,B-SpecificDisease
disease,4513,I-SpecificDisease
is,4513,O
almost,4513,O
invariably,4513,O
isolated,4513,O
",",4513,O
unilateral,4513,O
and,4513,O
seen,4513,O
in,4513,O
males,4513,O
.,4513,O
A,4514,O
female,4514,O
with,4514,O
a,4514,O
unilateral,4514,O
variant,4514,O
of,4514,O
Coats,4514,B-SpecificDisease
disease,4514,I-SpecificDisease
gave,4514,O
birth,4514,O
to,4514,O
a,4514,O
son,4514,O
affected,4514,O
by,4514,O
Norrie,4514,B-SpecificDisease
disease,4514,I-SpecificDisease
.,4514,O
Both,4515,O
carried,4515,O
a,4515,O
missense,4515,O
mutation,4515,O
within,4515,O
the,4515,O
NDP,4515,O
gene,4515,O
on,4515,O
chromosome,4515,O
Xp11,4515,O
.,4515,O
2,4516,O
2,4516,O
.,4516,O
Subsequently,4517,O
analysis,4517,O
of,4517,O
the,4517,O
retinas,4517,O
of,4517,O
nine,4517,O
enucleated,4517,O
eyes,4517,O
from,4517,O
males,4517,O
with,4517,O
Coats,4517,B-SpecificDisease
disease,4517,I-SpecificDisease
demonstrated,4517,O
in,4517,O
one,4517,O
a,4517,O
somatic,4517,O
mutation,4517,O
in,4517,O
the,4517,O
NDP,4517,O
gene,4517,O
which,4517,O
was,4517,O
not,4517,O
present,4517,O
within,4517,O
non-retinal,4517,O
tissue,4517,O
.,4517,O
We,4518,O
suggest,4518,O
that,4518,O
Coats,4518,B-SpecificDisease
telangiectasis,4518,I-SpecificDisease
is,4518,O
secondary,4518,O
to,4518,O
somatic,4518,O
mutation,4518,O
in,4518,O
the,4518,O
NDP,4518,O
gene,4518,O
which,4518,O
results,4518,O
in,4518,O
a,4518,O
deficiency,4518,B-DiseaseClass
of,4518,I-DiseaseClass
norrin,4518,I-DiseaseClass
(,4518,O
the,4518,O
protein,4518,O
product,4518,O
of,4518,O
the,4518,O
NDP,4518,O
gene,4518,O
),4518,O
within,4518,O
the,4518,O
developing,4518,O
retina,4518,O
.,4518,O
This,4519,O
supports,4519,O
recent,4519,O
observations,4519,O
that,4519,O
the,4519,O
protein,4519,O
is,4519,O
critical,4519,O
for,4519,O
normal,4519,O
retinal,4519,O
vasculogenesis,4519,O
.,4519,O
Hereditary,4520,O
TP53,4520,O
codon,4520,O
292,4520,O
and,4520,O
somatic,4520,O
P16INK4A,4520,O
codon,4520,O
94,4520,O
mutations,4520,O
in,4520,O
a,4520,O
Li-Fraumeni,4520,B-Modifier
syndrome,4520,I-Modifier
family,4520,O
.,4520,O
Li-Fraumeni,4521,B-SpecificDisease
syndrome,4521,I-SpecificDisease
is,4521,O
an,4521,O
autosomal,4521,B-DiseaseClass
dominant,4521,I-DiseaseClass
disorder,4521,I-DiseaseClass
that,4521,O
is,4521,O
characterized,4521,O
by,4521,O
various,4521,O
types,4521,O
of,4521,O
cancer,4521,B-DiseaseClass
in,4521,O
childhood,4521,O
and,4521,O
adult,4521,O
cases,4521,O
.,4521,O
Although,4522,O
hereditary,4522,O
TP53,4522,O
mutation,4522,O
is,4522,O
very,4522,O
rare,4522,O
in,4522,O
different,4522,O
human,4522,O
cancers,4522,B-DiseaseClass
",",4522,O
it,4522,O
has,4522,O
been,4522,O
frequently,4522,O
reported,4522,O
in,4522,O
Li-Fraumeni,4522,B-SpecificDisease
syndrome,4522,I-SpecificDisease
.,4522,O
On,4523,O
the,4523,O
other,4523,O
hand,4523,O
",",4523,O
hereditary,4523,O
mutations,4523,O
of,4523,O
TP57KIP2,4523,O
",",4523,O
P15INK4B,4523,O
",",4523,O
and,4523,O
P16INK4A,4523,O
",",4523,O
which,4523,O
affect,4523,O
the,4523,O
cell,4523,O
cycle,4523,O
similar,4523,O
to,4523,O
TP53,4523,O
",",4523,O
were,4523,O
observed,4523,O
in,4523,O
some,4523,O
types,4523,O
of,4523,O
cancer,4523,B-DiseaseClass
.,4523,O
In,4524,O
a,4524,O
Turkish,4524,O
family,4524,O
with,4524,O
the,4524,O
diagnosis,4524,O
of,4524,O
Li-Fraumeni,4524,B-SpecificDisease
syndrome,4524,I-SpecificDisease
",",4524,O
we,4524,O
analyzed,4524,O
the,4524,O
mutation,4524,O
pattern,4524,O
of,4524,O
TP53,4524,O
",",4524,O
P57KIP2,4524,O
",",4524,O
P15INK4B,4524,O
",",4524,O
and,4524,O
P16INK4A,4524,O
in,4524,O
the,4524,O
peripheral,4524,O
blood,4524,O
",",4524,O
and,4524,O
loss,4524,O
of,4524,O
heterozygosity,4524,O
(,4524,O
homo/hemizygous,4524,O
deletion,4524,O
),4524,O
pattern,4524,O
of,4524,O
TP53,4524,O
and,4524,O
P15INK4B/P16INK4A,4524,O
in,4524,O
two,4524,O
tumor,4524,B-Modifier
tissues,4524,O
.,4524,O
The,4525,O
propositus,4525,O
had,4525,O
a,4525,O
seminoma,4525,B-SpecificDisease
",",4525,O
his,4525,O
daughter,4525,O
a,4525,O
medulloblastoma,4525,B-SpecificDisease
",",4525,O
and,4525,O
one,4525,O
of,4525,O
his,4525,O
healthy,4525,O
cousins,4525,O
",",4525,O
a,4525,O
TP53,4525,O
codon,4525,O
292,4525,O
missense,4525,O
point,4525,O
mutation,4525,O
(,4525,O
AAA,4525,O
--,4525,O
>,4525,O
ATA,4525,O
;,4525,O
Lys,4525,O
--,4525,O
>,4525,O
Ile,4525,O
),4525,O
in,4525,O
the,4525,O
peripheral,4525,O
blood,4525,O
cells,4525,O
.,4525,O
Tumor,4526,O
tissue,4526,O
obtained,4526,O
from,4526,O
the,4526,O
propositus,4526,O
with,4526,O
the,4526,O
seminoma,4526,B-SpecificDisease
revealed,4526,O
loss,4526,O
of,4526,O
heterozygosity,4526,O
in,4526,O
the,4526,O
TP53,4526,O
gene,4526,O
.,4526,O
In,4527,O
the,4527,O
analyses,4527,O
of,4527,O
tumor,4527,B-Modifier
tissues,4527,O
from,4527,O
the,4527,O
propositus,4527,O
and,4527,O
his,4527,O
daughter,4527,O
",",4527,O
a,4527,O
P16INK4A,4527,O
codon,4527,O
94,4527,O
missense,4527,O
point,4527,O
mutation,4527,O
(,4527,O
GCG,4527,O
--,4527,O
>,4527,O
GAG,4527,O
;,4527,O
Ala,4527,O
--,4527,O
>,4527,O
Glu,4527,O
),4527,O
was,4527,O
observed,4527,O
with,4527,O
the,4527,O
hereditary,4527,O
TP53,4527,O
mutation,4527,O
.,4527,O
P16INK4A,4528,O
codon,4528,O
94,4528,O
mutation,4528,O
observed,4528,O
in,4528,O
our,4528,O
family,4528,O
is,4528,O
a,4528,O
novel,4528,O
mutation,4528,O
in,4528,O
Li-Fraumeni,4528,B-SpecificDisease
syndrome,4528,I-SpecificDisease
.,4528,O
No,4529,O
other,4529,O
gene,4529,O
alteration,4529,O
in,4529,O
TP53,4529,O
",",4529,O
P57KIP2,4529,O
",",4529,O
P15INK4B,4529,O
",",4529,O
and,4529,O
P16INK4A,4529,O
was,4529,O
observed,4529,O
.,4529,O
Existence,4530,O
of,4530,O
the,4530,O
P16INK4A,4530,O
mutation,4530,O
and,4530,O
the,4530,O
hereditary,4530,O
TP53,4530,O
mutation,4530,O
with,4530,O
or,4530,O
without,4530,O
loss,4530,O
of,4530,O
heterozygosity,4530,O
in,4530,O
the,4530,O
TP53,4530,O
gene,4530,O
(,4530,O
seminoma/medulloblastoma,4530,B-SpecificDisease
),4530,O
may,4530,O
be,4530,O
evidence,4530,O
for,4530,O
a,4530,O
common,4530,O
mechanism,4530,O
involved,4530,O
in,4530,O
tumorogenesis,4530,B-DiseaseClass
.,4530,O
The,4531,O
gene,4531,O
alterations,4531,O
in,4531,O
TP53,4531,O
and,4531,O
P16INK4A,4531,O
genes,4531,O
may,4531,O
be,4531,O
used,4531,O
as,4531,O
tumor,4531,B-Modifier
markers,4531,O
in,4531,O
our,4531,O
family,4531,O
..,4531,O
A,4532,O
novel,4532,O
mutation,4532,O
in,4532,O
the,4532,O
sodium/iodide,4532,O
symporter,4532,O
gene,4532,O
in,4532,O
the,4532,O
largest,4532,O
family,4532,O
with,4532,O
iodide,4532,B-DiseaseClass
transport,4532,I-DiseaseClass
defect,4532,I-DiseaseClass
.,4532,O
We,4533,O
previously,4533,O
reported,4533,O
nine,4533,O
children,4533,O
with,4533,O
an,4533,O
autosomally,4533,O
recessive,4533,O
form,4533,O
of,4533,O
congenital,4533,B-SpecificDisease
hypothyroidism,4533,I-SpecificDisease
due,4533,O
to,4533,O
an,4533,O
iodide,4533,B-DiseaseClass
transport,4533,I-DiseaseClass
defect,4533,I-DiseaseClass
in,4533,O
a,4533,O
large,4533,O
Hutterite,4533,O
family,4533,O
with,4533,O
extensive,4533,O
consanguinity,4533,O
living,4533,O
in,4533,O
central,4533,O
Canada,4533,O
.,4533,O
Since,4534,O
the,4534,O
original,4534,O
report,4534,O
",",4534,O
we,4534,O
have,4534,O
diagnosed,4534,O
congenital,4534,B-SpecificDisease
hypothyroidism,4534,I-SpecificDisease
by,4534,O
newborn,4534,O
TSH,4534,O
screening,4534,O
in,4534,O
9,4534,O
additional,4534,O
children,4534,O
from,4534,O
the,4534,O
family,4534,O
.,4534,O
We,4535,O
performed,4535,O
direct,4535,O
sequencing,4535,O
of,4535,O
the,4535,O
PCR,4535,O
products,4535,O
of,4535,O
each,4535,O
NIS,4535,O
(,4535,O
sodium/iodide,4535,O
symporter,4535,O
),4535,O
gene,4535,O
exon,4535,O
with,4535,O
flanking,4535,O
introns,4535,O
amplified,4535,O
from,4535,O
genomic,4535,O
DNA,4535,O
extracted,4535,O
from,4535,O
peripheral,4535,O
blood,4535,O
cells,4535,O
of,4535,O
the,4535,O
patients,4535,O
.,4535,O
We,4536,O
identified,4536,O
a,4536,O
novel,4536,O
NIS,4536,O
gene,4536,O
mutation,4536,O
",",4536,O
G395R,4536,O
(,4536,O
Gly395,4536,O
--,4536,O
>,4536,O
Arg,4536,O
;,4536,O
GGA,4536,O
--,4536,O
>,4536,O
AGA,4536,O
),4536,O
",",4536,O
in,4536,O
10,4536,O
patients,4536,O
examined,4536,O
in,4536,O
the,4536,O
present,4536,O
study,4536,O
.,4536,O
All,4537,O
of,4537,O
the,4537,O
parents,4537,O
tested,4537,O
were,4537,O
heterozygous,4537,O
for,4537,O
the,4537,O
mutation,4537,O
",",4537,O
suggesting,4537,O
that,4537,O
the,4537,O
patients,4537,O
were,4537,O
homozygous,4537,O
.,4537,O
The,4538,O
mutation,4538,O
was,4538,O
located,4538,O
in,4538,O
the,4538,O
10th,4538,O
transmembrane,4538,O
helix,4538,O
.,4538,O
Expression,4539,O
experiments,4539,O
by,4539,O
transfection,4539,O
of,4539,O
the,4539,O
mutant,4539,O
NIS,4539,O
complimentary,4539,O
DNA,4539,O
into,4539,O
COS-7,4539,O
cells,4539,O
showed,4539,O
no,4539,O
perchlorate-sensitive,4539,O
iodide,4539,O
uptake,4539,O
",",4539,O
confirming,4539,O
that,4539,O
the,4539,O
mutation,4539,O
is,4539,O
the,4539,O
direct,4539,O
cause,4539,O
of,4539,O
the,4539,O
iodide,4539,B-DiseaseClass
transport,4539,I-DiseaseClass
defect,4539,I-DiseaseClass
in,4539,O
these,4539,O
patients,4539,O
.,4539,O
A,4540,O
patient,4540,O
who,4540,O
showed,4540,O
an,4540,O
intermediate,4540,O
saliva/serum,4540,O
technetium,4540,O
ratio,4540,O
(,4540,O
14,4540,O
.,4540,O
0,4541,O
;,4541,O
normal,4541,O
",",4541,O
>,4541,O
or,4541,O
=,4541,O
20,4541,O
),4541,O
and,4541,O
was,4541,O
considered,4541,O
to,4541,O
have,4541,O
a,4541,O
partial,4541,O
or,4541,O
less,4541,O
severe,4541,O
defect,4541,O
in,4541,O
the,4541,O
previous,4541,O
report,4541,O
(,4541,O
IX-24,4541,O
),4541,O
did,4541,O
not,4541,O
have,4541,O
a,4541,O
NIS,4541,O
gene,4541,O
mutation,4541,O
.,4541,O
It,4542,O
is,4542,O
now,4542,O
possible,4542,O
to,4542,O
use,4542,O
gene,4542,O
diagnostics,4542,O
of,4542,O
this,4542,O
unique,4542,O
NIS,4542,O
mutation,4542,O
to,4542,O
identify,4542,O
patients,4542,O
with,4542,O
congenital,4542,B-SpecificDisease
hypothyroidism,4542,I-SpecificDisease
due,4542,O
to,4542,O
an,4542,O
iodide,4542,B-DiseaseClass
transport,4542,I-DiseaseClass
defect,4542,I-DiseaseClass
in,4542,O
this,4542,O
family,4542,O
and,4542,O
to,4542,O
determine,4542,O
the,4542,O
carrier,4542,O
state,4542,O
of,4542,O
potential,4542,O
parents,4542,O
for,4542,O
genetic,4542,O
counseling,4542,O
and,4542,O
arranging,4542,O
rapid,4542,O
and,4542,O
early,4542,O
diagnosis,4542,O
of,4542,O
their,4542,O
infants,4542,O
.,4542,O
Molecular,4543,O
analysis,4543,O
in,4543,O
familial,4543,B-SpecificDisease
neurohypophyseal,4543,I-SpecificDisease
diabetes,4543,I-SpecificDisease
insipidus,4543,I-SpecificDisease
:,4543,O
early,4543,O
diagnosis,4543,O
of,4543,O
an,4543,O
asymptomatic,4543,O
carrier,4543,O
.,4543,O
Familial,4544,B-SpecificDisease
neurohypophyseal,4544,I-SpecificDisease
diabetes,4544,I-SpecificDisease
insipidus,4544,I-SpecificDisease
(,4544,O
FNDI,4544,B-SpecificDisease
),4544,O
is,4544,O
an,4544,O
inherited,4544,O
deficiency,4544,B-DiseaseClass
of,4544,I-DiseaseClass
the,4544,I-DiseaseClass
hormone,4544,I-DiseaseClass
arginine,4544,I-DiseaseClass
vasopressin,4544,I-DiseaseClass
(,4544,O
AVP,4544,O
),4544,O
and,4544,O
is,4544,O
transmitted,4544,O
as,4544,O
an,4544,O
autosomal,4544,O
dominant,4544,O
trait,4544,O
.,4544,O
In,4545,O
the,4545,O
present,4545,O
study,4545,O
we,4545,O
have,4545,O
analyzed,4545,O
the,4545,O
AVP-neurophysin,4545,O
II,4545,O
(,4545,O
AVP-NPII,4545,O
),4545,O
gene,4545,O
in,4545,O
a,4545,O
Spanish,4545,O
kindred,4545,O
.,4545,O
Studies,4546,O
were,4546,O
performed,4546,O
on,4546,O
seven,4546,O
members,4546,O
(,4546,O
four,4546,O
clinically,4546,O
affected,4546,O
),4546,O
of,4546,O
the,4546,O
family,4546,O
.,4546,O
Patients,4547,O
were,4547,O
diagnosed,4547,O
at,4547,O
the,4547,O
Hospital,4547,O
Universitario,4547,O
Gregorio,4547,O
Maranon,4547,O
(,4547,O
Madrid,4547,O
",",4547,O
Spain,4547,O
),4547,O
.,4547,O
The,4548,O
entire,4548,O
coding,4548,O
region,4548,O
of,4548,O
the,4548,O
AVP-NPII,4548,O
gene,4548,O
of,4548,O
all,4548,O
family,4548,O
members,4548,O
was,4548,O
amplified,4548,O
by,4548,O
PCR,4548,O
and,4548,O
sequenced,4548,O
.,4548,O
All,4549,O
affected,4549,O
individuals,4549,O
presented,4549,O
a,4549,O
missense,4549,O
mutation,4549,O
(,4549,O
G1757,4549,O
--,4549,O
>,4549,O
A,4549,O
),4549,O
that,4549,O
replaces,4549,O
glycine,4549,O
at,4549,O
position,4549,O
23,4549,O
with,4549,O
arginine,4549,O
within,4549,O
the,4549,O
NPII,4549,O
domain,4549,O
.,4549,O
The,4550,O
substitution,4550,O
was,4550,O
confirmed,4550,O
by,4550,O
restriction,4550,O
endonuclease,4550,O
analysis,4550,O
and,4550,O
was,4550,O
present,4550,O
in,4550,O
heterozygosis,4550,O
.,4550,O
Additionally,4551,O
",",4551,O
one,4551,O
of,4551,O
the,4551,O
asymptomatic,4551,O
relatives,4551,O
(,4551,O
a,4551,O
girl,4551,O
8,4551,O
months,4551,O
old,4551,O
at,4551,O
the,4551,O
time,4551,O
of,4551,O
study,4551,O
),4551,O
was,4551,O
identified,4551,O
as,4551,O
carrier,4551,O
of,4551,O
the,4551,O
same,4551,O
mutation,4551,O
and,4551,O
developed,4551,O
the,4551,O
disease,4551,O
3,4551,O
months,4551,O
later,4551,O
.,4551,O
The,4552,O
alteration,4552,O
found,4552,O
in,4552,O
the,4552,O
second,4552,O
exon,4552,O
of,4552,O
the,4552,O
gene,4552,O
in,4552,O
this,4552,O
family,4552,O
seems,4552,O
to,4552,O
be,4552,O
responsible,4552,O
for,4552,O
the,4552,O
disease,4552,O
",",4552,O
as,4552,O
all,4552,O
individuals,4552,O
harboring,4552,O
the,4552,O
mutation,4552,O
had,4552,O
been,4552,O
previously,4552,O
diagnosed,4552,O
or,4552,O
have,4552,O
eventually,4552,O
developed,4552,O
FNDI,4552,B-SpecificDisease
.,4552,O
Identification,4553,O
of,4553,O
the,4553,O
molecular,4553,O
defect,4553,O
underlying,4553,O
FNDI,4553,B-SpecificDisease
in,4553,O
affected,4553,O
families,4553,O
is,4553,O
a,4553,O
powerful,4553,O
tool,4553,O
for,4553,O
early,4553,O
asymptomatic,4553,O
diagnosis,4553,O
in,4553,O
infants,4553,O
..,4553,O
Deficit,4554,O
of,4554,O
in,4554,O
vivo,4554,O
mitochondrial,4554,O
ATP,4554,O
production,4554,O
in,4554,O
patients,4554,O
with,4554,O
Friedreich,4554,B-SpecificDisease
ataxia,4554,I-SpecificDisease
.,4554,O
Friedreich,4555,B-SpecificDisease
ataxia,4555,I-SpecificDisease
(,4555,O
FRDA,4555,B-SpecificDisease
),4555,O
",",4555,O
the,4555,O
most,4555,O
common,4555,O
of,4555,O
the,4555,O
inherited,4555,B-DiseaseClass
ataxias,4555,I-DiseaseClass
",",4555,O
is,4555,O
an,4555,O
autosomal,4555,B-DiseaseClass
recessive,4555,I-DiseaseClass
degenerative,4555,I-DiseaseClass
disorder,4555,I-DiseaseClass
",",4555,O
characterized,4555,O
clinically,4555,O
by,4555,O
onset,4555,O
before,4555,O
the,4555,O
age,4555,O
of,4555,O
25,4555,O
of,4555,O
progressive,4555,O
gait,4555,O
and,4555,O
limb,4555,O
ataxia,4555,O
",",4555,O
absence,4555,B-DiseaseClass
of,4555,I-DiseaseClass
deep,4555,I-DiseaseClass
tendon,4555,I-DiseaseClass
reflexes,4555,I-DiseaseClass
",",4555,O
extensor,4555,B-DiseaseClass
plantar,4555,I-DiseaseClass
responses,4555,I-DiseaseClass
",",4555,O
and,4555,O
loss,4555,B-CompositeMention
of,4555,I-CompositeMention
position,4555,I-CompositeMention
and,4555,I-CompositeMention
vibration,4555,I-CompositeMention
sense,4555,I-CompositeMention
in,4555,O
the,4555,O
lower,4555,O
limbs,4555,O
.,4555,O
FRDA,4556,B-SpecificDisease
is,4556,O
caused,4556,O
by,4556,O
a,4556,O
GAA,4556,O
triplet,4556,O
expansion,4556,O
in,4556,O
the,4556,O
first,4556,O
intron,4556,O
of,4556,O
the,4556,O
FRDA,4556,B-Modifier
gene,4556,O
on,4556,O
chromosome,4556,O
9q13,4556,O
in,4556,O
97,4556,O
%,4556,O
of,4556,O
patients,4556,O
.,4556,O
The,4557,O
FRDA,4557,B-Modifier
gene,4557,O
encodes,4557,O
a,4557,O
widely,4557,O
expressed,4557,O
210-aa,4557,O
protein,4557,O
",",4557,O
frataxin,4557,O
",",4557,O
which,4557,O
is,4557,O
located,4557,O
in,4557,O
mitochondria,4557,O
and,4557,O
is,4557,O
severely,4557,O
reduced,4557,O
in,4557,O
FRDA,4557,B-Modifier
patients,4557,O
.,4557,O
Frataxin,4558,O
function,4558,O
is,4558,O
still,4558,O
unknown,4558,O
but,4558,O
the,4558,O
knockout,4558,O
of,4558,O
the,4558,O
yeast,4558,O
frataxin,4558,O
homologue,4558,O
gene,4558,O
(,4558,O
YFH1,4558,O
),4558,O
showed,4558,O
a,4558,O
severe,4558,O
defect,4558,O
of,4558,O
mitochondrial,4558,O
respiration,4558,O
and,4558,O
loss,4558,O
of,4558,O
mtDNA,4558,O
associated,4558,O
with,4558,O
elevated,4558,O
intramitochondrial,4558,O
iron,4558,O
.,4558,O
Here,4559,O
we,4559,O
report,4559,O
in,4559,O
vivo,4559,O
evidence,4559,O
of,4559,O
impaired,4559,O
mitochondrial,4559,O
respiration,4559,O
in,4559,O
skeletal,4559,O
muscle,4559,O
of,4559,O
FRDA,4559,B-Modifier
patients,4559,O
.,4559,O
Using,4560,O
phosphorus,4560,O
magnetic,4560,O
resonance,4560,O
spectroscopy,4560,O
we,4560,O
demonstrated,4560,O
a,4560,O
maximum,4560,O
rate,4560,O
of,4560,O
muscle,4560,O
mitochondrial,4560,O
ATP,4560,O
production,4560,O
(,4560,O
V,4560,O
(,4560,O
max,4560,O
),4560,O
),4560,O
below,4560,O
the,4560,O
normal,4560,O
range,4560,O
in,4560,O
all,4560,O
12,4560,O
FRDA,4560,B-Modifier
patients,4560,O
and,4560,O
a,4560,O
strong,4560,O
negative,4560,O
correlation,4560,O
between,4560,O
mitochondrial,4560,O
V,4560,O
(,4560,O
max,4560,O
),4560,O
and,4560,O
the,4560,O
number,4560,O
of,4560,O
GAA,4560,O
repeats,4560,O
in,4560,O
the,4560,O
smaller,4560,O
allele,4560,O
.,4560,O
Our,4561,O
results,4561,O
show,4561,O
that,4561,O
FRDA,4561,B-SpecificDisease
is,4561,O
a,4561,O
nuclear-encoded,4561,O
mitochondrial,4561,B-DiseaseClass
disorder,4561,I-DiseaseClass
affecting,4561,O
oxidative,4561,O
phosphorylation,4561,O
and,4561,O
give,4561,O
a,4561,O
rationale,4561,O
for,4561,O
treatments,4561,O
aimed,4561,O
to,4561,O
improve,4561,O
mitochondrial,4561,O
function,4561,O
in,4561,O
this,4561,O
condition,4561,O
..,4561,O
Identification,4562,O
of,4562,O
a,4562,O
novel,4562,O
R21X,4562,O
mutation,4562,O
in,4562,O
the,4562,O
liver-type,4562,O
arginase,4562,O
gene,4562,O
(,4562,O
ARG1,4562,O
),4562,O
in,4562,O
four,4562,O
Portuguese,4562,O
patients,4562,O
with,4562,O
argininemia,4562,B-SpecificDisease
.,4562,O
Argininemia,4563,B-SpecificDisease
is,4563,O
a,4563,O
rare,4563,O
autossomal,4563,B-DiseaseClass
recessive,4563,I-DiseaseClass
disorder,4563,I-DiseaseClass
caused,4563,O
by,4563,O
deficiency,4563,B-DiseaseClass
in,4563,I-DiseaseClass
the,4563,I-DiseaseClass
cytosolic,4563,I-DiseaseClass
liver-type,4563,I-DiseaseClass
arginase,4563,I-DiseaseClass
enzyme,4563,I-DiseaseClass
(,4563,O
L-arginine,4563,O
urea-hydrolase,4563,O
;,4563,O
E.,4563,O
C.,4563,O
3,4563,O
.,4563,O
5,4564,O
.,4564,O
3,4565,O
.,4565,O
1,4566,O
),4566,O
.,4566,O
In,4567,O
order,4567,O
to,4567,O
investigate,4567,O
the,4567,O
molecular,4567,O
basis,4567,O
for,4567,O
argininemia,4567,B-SpecificDisease
in,4567,O
four,4567,O
unrelated,4567,O
Portuguese,4567,O
patients,4567,O
(,4567,O
two,4567,O
from,4567,O
northern,4567,O
Portugal,4567,O
and,4567,O
two,4567,O
from,4567,O
Madeira,4567,O
Island,4567,O
),4567,O
we,4567,O
performed,4567,O
a,4567,O
DNA,4567,O
sequence,4567,O
analysis,4567,O
of,4567,O
all,4567,O
the,4567,O
exons,4567,O
and,4567,O
exon/intron,4567,O
boundaries,4567,O
of,4567,O
the,4567,O
liver-type,4567,O
arginase,4567,O
gene,4567,O
(,4567,O
ARG1,4567,O
),4567,O
.,4567,O
All,4568,O
patients,4568,O
were,4568,O
found,4568,O
to,4568,O
be,4568,O
homozygous,4568,O
for,4568,O
a,4568,O
newly,4568,O
identified,4568,O
C,4568,O
-,4568,O
>,4568,O
T,4568,O
transition,4568,O
in,4568,O
codon,4568,O
21,4568,O
(,4568,O
exon,4568,O
2,4568,O
),4568,O
substituting,4568,O
arginine,4568,O
for,4568,O
a,4568,O
premature,4568,O
stop,4568,O
codon,4568,O
(,4568,O
R21X,4568,O
CGA,4568,O
to,4568,O
TGA,4568,O
),4568,O
and,4568,O
generating,4568,O
a,4568,O
NlaIII,4568,O
restriction,4568,O
site,4568,O
.,4568,O
Restriction,4569,O
digestion,4569,O
following,4569,O
PCR,4569,O
amplification,4569,O
of,4569,O
ARG1,4569,O
exon,4569,O
2,4569,O
confirmed,4569,O
the,4569,O
presence,4569,O
of,4569,O
the,4569,O
mutation,4569,O
.,4569,O
Mutation,4570,O
of,4570,O
the,4570,O
sterol,4570,O
27-hydroxylase,4570,O
gene,4570,O
(,4570,O
CYP27,4570,O
),4570,O
results,4570,O
in,4570,O
truncation,4570,O
of,4570,O
mRNA,4570,O
expressed,4570,O
in,4570,O
leucocytes,4570,O
in,4570,O
a,4570,O
Japanese,4570,O
family,4570,O
with,4570,O
cerebrotendinous,4570,B-SpecificDisease
xanthomatosis,4570,I-SpecificDisease
.,4570,O
OBJECTIVES,4571,O
A,4571,O
Japanese,4571,O
family,4571,O
with,4571,O
cerebrotendinous,4571,B-SpecificDisease
xanthomatosis,4571,I-SpecificDisease
(,4571,O
CTX,4571,B-SpecificDisease
),4571,O
was,4571,O
investigated,4571,O
for,4571,O
a,4571,O
sequence,4571,O
alteration,4571,O
in,4571,O
the,4571,O
sterol,4571,O
27-hydroxylase,4571,O
gene,4571,O
(,4571,O
CYP27,4571,O
),4571,O
.,4571,O
The,4572,O
expression,4572,O
of,4572,O
CYP27,4572,O
has,4572,O
been,4572,O
mostly,4572,O
explored,4572,O
using,4572,O
cultured,4572,O
fibroblasts,4572,O
",",4572,O
prompting,4572,O
the,4572,O
examination,4572,O
of,4572,O
the,4572,O
transcripts,4572,O
from,4572,O
blood,4572,O
leucocytes,4572,O
as,4572,O
a,4572,O
simple,4572,O
and,4572,O
rapid,4572,O
technique,4572,O
.,4572,O
METHODS,4573,O
An,4573,O
alteration,4573,O
in,4573,O
CYP27,4573,O
of,4573,O
the,4573,O
proband,4573,O
was,4573,O
searched,4573,O
for,4573,O
by,4573,O
polymerase,4573,O
chain,4573,O
reaction-single,4573,O
strand,4573,O
conformation,4573,O
polymorphism,4573,O
(,4573,O
PCR-SSCP,4573,O
),4573,O
analysis,4573,O
and,4573,O
subsequent,4573,O
sequencing,4573,O
.,4573,O
Samples,4574,O
of,4574,O
RNA,4574,O
were,4574,O
subjected,4574,O
to,4574,O
reverse,4574,O
transcription,4574,O
PCR,4574,O
(,4574,O
RT-PCR,4574,O
),4574,O
and,4574,O
the,4574,O
product,4574,O
of,4574,O
the,4574,O
proband,4574,O
was,4574,O
amplified,4574,O
with,4574,O
nested,4574,O
primers,4574,O
and,4574,O
sequenced,4574,O
.,4574,O
RESULTS,4575,O
A,4575,O
homozygous,4575,O
G,4575,O
to,4575,O
A,4575,O
transition,4575,O
at,4575,O
the,4575,O
5,4575,O
end,4575,O
of,4575,O
intron,4575,O
7,4575,O
was,4575,O
detected,4575,O
in,4575,O
the,4575,O
patient,4575,O
.,4575,O
In,4576,O
RT-PCR,4576,O
analysis,4576,O
",",4576,O
only,4576,O
a,4576,O
truncated,4576,O
transcript,4576,O
was,4576,O
detected,4576,O
in,4576,O
the,4576,O
patient,4576,O
",",4576,O
whereas,4576,O
both,4576,O
normal,4576,O
and,4576,O
truncated,4576,O
transcripts,4576,O
were,4576,O
detected,4576,O
in,4576,O
the,4576,O
siblings,4576,O
.,4576,O
The,4577,O
sequencing,4577,O
of,4577,O
the,4577,O
patients,4577,O
cDNA,4577,O
fragment,4577,O
disclosed,4577,O
a,4577,O
direct,4577,O
conjuction,4577,O
of,4577,O
exon,4577,O
6,4577,O
and,4577,O
exon,4577,O
8,4577,O
.,4577,O
CONCLUSION,4578,O
The,4578,O
mutation,4578,O
at,4578,O
splice,4578,O
donor,4578,O
site,4578,O
and,4578,O
the,4578,O
truncation,4578,O
of,4578,O
mRNA,4578,O
were,4578,O
identical,4578,O
with,4578,O
those,4578,O
of,4578,O
a,4578,O
recently,4578,O
reported,4578,O
Italian,4578,O
patient,4578,O
",",4578,O
although,4578,O
different,4578,O
in,4578,O
symptomatology,4578,O
.,4578,O
The,4579,O
application,4579,O
of,4579,O
blood,4579,O
leucocytes,4579,O
can,4579,O
be,4579,O
a,4579,O
simple,4579,O
technique,4579,O
on,4579,O
analysing,4579,O
a,4579,O
constructive,4579,O
abnormality,4579,B-SpecificDisease
of,4579,I-SpecificDisease
CYP27,4579,I-SpecificDisease
mRNA,4579,O
..,4579,O
Clinical,4580,O
and,4580,O
molecular,4580,O
genetic,4580,O
analysis,4580,O
of,4580,O
19,4580,O
Wolfram,4580,B-Modifier
syndrome,4580,I-Modifier
kindreds,4580,O
demonstrating,4580,O
a,4580,O
wide,4580,O
spectrum,4580,O
of,4580,O
mutations,4580,O
in,4580,O
WFS1,4580,O
.,4580,O
Wolfram,4581,B-SpecificDisease
syndrome,4581,I-SpecificDisease
is,4581,O
an,4581,O
autosomal,4581,B-DiseaseClass
recessive,4581,I-DiseaseClass
neurodegenerative,4581,I-DiseaseClass
disorder,4581,I-DiseaseClass
characterized,4581,O
by,4581,O
juvenile-onset,4581,B-SpecificDisease
diabetes,4581,I-SpecificDisease
mellitus,4581,I-SpecificDisease
and,4581,O
progressive,4581,O
optic,4581,B-SpecificDisease
atrophy,4581,I-SpecificDisease
.,4581,O
mtDNA,4582,O
deletions,4582,O
have,4582,O
been,4582,O
described,4582,O
",",4582,O
and,4582,O
a,4582,O
gene,4582,O
(,4582,O
WFS1,4582,O
),4582,O
recently,4582,O
has,4582,O
been,4582,O
identified,4582,O
",",4582,O
on,4582,O
chromosome,4582,O
4p16,4582,O
",",4582,O
encoding,4582,O
a,4582,O
predicted,4582,O
890,4582,O
amino,4582,O
acid,4582,O
transmembrane,4582,O
protein,4582,O
.,4582,O
Direct,4583,O
DNA,4583,O
sequencing,4583,O
was,4583,O
done,4583,O
to,4583,O
screen,4583,O
the,4583,O
entire,4583,O
coding,4583,O
region,4583,O
of,4583,O
the,4583,O
WFS1,4583,O
gene,4583,O
in,4583,O
30,4583,O
patients,4583,O
from,4583,O
19,4583,O
British,4583,O
kindreds,4583,O
with,4583,O
Wolfram,4583,B-SpecificDisease
syndrome,4583,I-SpecificDisease
.,4583,O
DNA,4584,O
was,4584,O
also,4584,O
screened,4584,O
for,4584,O
structural,4584,O
rearrangements,4584,O
(,4584,O
deletions,4584,O
and,4584,O
duplications,4584,O
),4584,O
and,4584,O
point,4584,O
mutations,4584,O
in,4584,O
mtDNA,4584,O
.,4584,O
No,4585,O
pathogenic,4585,O
mtDNA,4585,O
mutations,4585,O
were,4585,O
found,4585,O
in,4585,O
our,4585,O
cohort,4585,O
.,4585,O
We,4586,O
identified,4586,O
24,4586,O
mutations,4586,O
in,4586,O
the,4586,O
WFS1,4586,O
gene,4586,O
8,4586,O
nonsense,4586,O
mutations,4586,O
",",4586,O
8,4586,O
missense,4586,O
mutations,4586,O
",",4586,O
3,4586,O
in-frame,4586,O
deletions,4586,O
",",4586,O
1,4586,O
in-frame,4586,O
insertion,4586,O
",",4586,O
and,4586,O
4,4586,O
frameshift,4586,O
mutations,4586,O
.,4586,O
Of,4587,O
these,4587,O
",",4587,O
23,4587,O
were,4587,O
novel,4587,O
mutations,4587,O
",",4587,O
and,4587,O
most,4587,O
occurred,4587,O
in,4587,O
exon,4587,O
8,4587,O
.,4587,O
The,4588,O
majority,4588,O
of,4588,O
patients,4588,O
were,4588,O
compound,4588,O
heterozygotes,4588,O
for,4588,O
two,4588,O
mutations,4588,O
",",4588,O
and,4588,O
there,4588,O
was,4588,O
no,4588,O
common,4588,O
founder,4588,O
mutation,4588,O
.,4588,O
The,4589,O
data,4589,O
were,4589,O
also,4589,O
analyzed,4589,O
for,4589,O
genotype-phenotype,4589,O
relationships,4589,O
.,4589,O
Although,4590,O
some,4590,O
interesting,4590,O
cases,4590,O
were,4590,O
noted,4590,O
",",4590,O
consideration,4590,O
of,4590,O
the,4590,O
small,4590,O
sample,4590,O
size,4590,O
and,4590,O
frequency,4590,O
of,4590,O
each,4590,O
mutation,4590,O
indicated,4590,O
no,4590,O
clear-cut,4590,O
correlations,4590,O
between,4590,O
any,4590,O
of,4590,O
the,4590,O
observed,4590,O
mutations,4590,O
and,4590,O
disease,4590,O
severity,4590,O
.,4590,O
There,4591,O
were,4591,O
no,4591,O
obvious,4591,O
mutation,4591,O
hot,4591,O
spots,4591,O
or,4591,O
clusters,4591,O
.,4591,O
Hence,4592,O
",",4592,O
molecular,4592,O
screening,4592,O
for,4592,O
Wolfram,4592,B-SpecificDisease
syndrome,4592,I-SpecificDisease
in,4592,O
affected,4592,O
families,4592,O
and,4592,O
for,4592,O
Wolfram,4592,B-Modifier
syndrome-carrier,4592,O
status,4592,O
in,4592,O
subjects,4592,O
with,4592,O
psychiatric,4592,B-DiseaseClass
disorders,4592,I-DiseaseClass
or,4592,O
diabetes,4592,B-SpecificDisease
mellitus,4592,I-SpecificDisease
will,4592,O
require,4592,O
complete,4592,O
analysis,4592,O
of,4592,O
exon,4592,O
8,4592,O
and,4592,O
upstream,4592,O
exons,4592,O
..,4592,O
Late-onset,4593,O
familial,4593,B-SpecificDisease
Mediterranean,4593,I-SpecificDisease
fever,4593,I-SpecificDisease
(,4593,O
FMF,4593,B-SpecificDisease
),4593,O
:,4593,O
a,4593,O
subset,4593,O
with,4593,O
distinct,4593,O
clinical,4593,O
",",4593,O
demographic,4593,O
",",4593,O
and,4593,O
molecular,4593,O
genetic,4593,O
characteristics,4593,O
.,4593,O
To,4594,O
determine,4594,O
the,4594,O
prevalence,4594,O
and,4594,O
characterize,4594,O
demographic,4594,O
",",4594,O
clinical,4594,O
",",4594,O
and,4594,O
genetic,4594,O
features,4594,O
of,4594,O
familial,4594,B-SpecificDisease
Mediterranean,4594,I-SpecificDisease
fever,4594,I-SpecificDisease
(,4594,O
FMF,4594,B-SpecificDisease
),4594,O
of,4594,O
late,4594,O
onset,4594,O
",",4594,O
all,4594,O
patients,4594,O
experiencing,4594,O
their,4594,O
first,4594,O
FMF,4594,B-Modifier
attack,4594,O
at,4594,O
age,4594,O
40,4594,O
years,4594,O
or,4594,O
more,4594,O
were,4594,O
identified,4594,O
using,4594,O
the,4594,O
computerized,4594,O
registry,4594,O
of,4594,O
our,4594,O
FMF,4594,B-Modifier
clinic,4594,O
",",4594,O
and,4594,O
then,4594,O
thoroughly,4594,O
interviewed,4594,O
and,4594,O
examined,4594,O
.,4594,O
The,4595,O
control,4595,O
group,4595,O
consisted,4595,O
of,4595,O
40,4595,O
consecutive,4595,O
FMF,4595,B-Modifier
patients,4595,O
",",4595,O
who,4595,O
arrived,4595,O
at,4595,O
the,4595,O
FMF,4595,B-Modifier
clinic,4595,O
for,4595,O
their,4595,O
regular,4595,O
follow-up,4595,O
visit,4595,O
and,4595,O
were,4595,O
40,4595,O
years,4595,O
of,4595,O
age,4595,O
or,4595,O
older,4595,O
at,4595,O
the,4595,O
time,4595,O
of,4595,O
the,4595,O
examination,4595,O
.,4595,O
The,4596,O
severity,4596,O
of,4596,O
the,4596,O
disease,4596,O
in,4596,O
patients,4596,O
and,4596,O
controls,4596,O
was,4596,O
determined,4596,O
using,4596,O
a,4596,O
modified,4596,O
score,4596,O
",",4596,O
developed,4596,O
previously,4596,O
.,4596,O
Mutational,4597,O
analysis,4597,O
in,4597,O
the,4597,O
FMF,4597,B-Modifier
gene,4597,O
was,4597,O
performed,4597,O
using,4597,O
a,4597,O
commercial,4597,O
kit,4597,O
.,4597,O
Only,4598,O
20,4598,O
of,4598,O
4000,4598,O
(,4598,O
0,4598,O
.,4598,O
5,4599,O
%,4599,O
),4599,O
patients,4599,O
had,4599,O
late-onset,4599,O
FMF,4599,B-SpecificDisease
.,4599,O
These,4600,O
patients,4600,O
were,4600,O
mostly,4600,O
men,4600,O
",",4600,O
of,4600,O
non-North,4600,O
African,4600,O
origin,4600,O
",",4600,O
P,4600,O
<,4600,O
0,4600,O
.,4600,O
05,4601,O
compared,4601,O
to,4601,O
controls,4601,O
.,4601,O
All,4602,O
had,4602,O
abdominal,4602,O
attacks,4602,O
and,4602,O
in,4602,O
most,4602,O
these,4602,O
were,4602,O
the,4602,O
only,4602,O
manifestation,4602,O
of,4602,O
their,4602,O
disease,4602,O
",",4602,O
P,4602,O
<,4602,O
0,4602,O
.,4602,O
001,4603,O
001,4603,O
.,4603,O
None,4604,O
had,4604,O
chronic,4604,O
or,4604,O
prolonged,4604,O
manifestations,4604,O
of,4604,O
FMF,4604,B-SpecificDisease
",",4604,O
for,4604,O
example,4604,O
",",4604,O
amyloidosis,4604,B-SpecificDisease
",",4604,O
chronic,4604,B-SpecificDisease
arthritis,4604,I-SpecificDisease
",",4604,O
or,4604,O
protracted,4604,O
myalgia,4604,B-SpecificDisease
",",4604,O
P,4604,O
<,4604,O
0,4604,O
.,4604,O
001,4605,O
.,4605,O
The,4606,O
response,4606,O
to,4606,O
treatment,4606,O
was,4606,O
good,4606,O
despite,4606,O
using,4606,O
low,4606,O
colchicine,4606,O
dose,4606,O
",",4606,O
P,4606,O
<,4606,O
0,4606,O
.,4606,O
05,4607,O
.,4607,O
The,4608,O
overall,4608,O
severity,4608,O
score,4608,O
indicated,4608,O
a,4608,O
mild,4608,O
disease,4608,O
",",4608,O
P,4608,O
<,4608,O
0,4608,O
.,4608,O
001,4609,O
.,4609,O
Mutational,4610,O
analysis,4610,O
revealed,4610,O
absence,4610,O
of,4610,O
M694V,4610,O
homozygosity,4610,O
",",4610,O
P,4610,O
<,4610,O
0,4610,O
.,4610,O
01,4611,O
",",4611,O
compared,4611,O
to,4611,O
our,4611,O
regular,4611,O
FMF,4611,B-Modifier
population,4611,O
.,4611,O
We,4612,O
conclude,4612,O
that,4612,O
the,4612,O
onset,4612,O
of,4612,O
FMF,4612,B-SpecificDisease
in,4612,O
a,4612,O
late,4612,O
age,4612,O
defines,4612,O
a,4612,O
milder,4612,O
form,4612,O
of,4612,O
disease,4612,O
with,4612,O
typical,4612,O
clinical,4612,O
",",4612,O
demographic,4612,O
",",4612,O
and,4612,O
molecular,4612,O
genetic,4612,O
characteristics,4612,O
A,4613,O
highly,4613,O
accurate,4613,O
",",4613,O
low,4613,O
cost,4613,O
test,4613,O
for,4613,O
BRCA1,4613,O
mutations,4613,O
.,4613,O
The,4614,O
hereditary,4614,B-CompositeMention
breast,4614,I-CompositeMention
and,4614,I-CompositeMention
ovarian,4614,I-CompositeMention
cancer,4614,I-CompositeMention
syndrome,4614,I-CompositeMention
is,4614,O
associated,4614,O
with,4614,O
a,4614,O
high,4614,O
frequency,4614,O
of,4614,O
BRCA1,4614,O
mutations,4614,O
.,4614,O
However,4615,O
",",4615,O
the,4615,O
widespread,4615,O
use,4615,O
of,4615,O
BRCA1,4615,O
testing,4615,O
has,4615,O
been,4615,O
limited,4615,O
to,4615,O
date,4615,O
by,4615,O
three,4615,O
principal,4615,O
concerns,4615,O
the,4615,O
fear,4615,O
of,4615,O
loss,4615,O
of,4615,O
health,4615,O
and,4615,O
life,4615,O
insurance,4615,O
",",4615,O
the,4615,O
uncertain,4615,O
clinical,4615,O
value,4615,O
of,4615,O
a,4615,O
positive,4615,O
test,4615,O
result,4615,O
",",4615,O
and,4615,O
the,4615,O
current,4615,O
lack,4615,O
of,4615,O
an,4615,O
inexpensive,4615,O
and,4615,O
sensitive,4615,O
screening,4615,O
test,4615,O
for,4615,O
BRCA1,4615,O
mutations,4615,O
.,4615,O
We,4616,O
have,4616,O
developed,4616,O
an,4616,O
inexpensive,4616,O
system,4616,O
for,4616,O
gene,4616,O
mutational,4616,O
scanning,4616,O
",",4616,O
based,4616,O
on,4616,O
a,4616,O
combination,4616,O
of,4616,O
extensive,4616,O
multiplex,4616,O
PCR,4616,O
amplification,4616,O
and,4616,O
two,4616,O
dimensional,4616,O
electrophoresis,4616,O
.,4616,O
The,4617,O
efficiency,4617,O
of,4617,O
this,4617,O
system,4617,O
",",4617,O
as,4617,O
a,4617,O
screening,4617,O
test,4617,O
for,4617,O
BRCA1,4617,O
mutations,4617,O
",",4617,O
was,4617,O
evaluated,4617,O
in,4617,O
a,4617,O
panel,4617,O
of,4617,O
60,4617,O
samples,4617,O
from,4617,O
high,4617,O
risk,4617,O
women,4617,O
",",4617,O
14,4617,O
of,4617,O
which,4617,O
contained,4617,O
a,4617,O
previously,4617,O
identified,4617,O
mutation,4617,O
in,4617,O
BRCA1,4617,O
.,4617,O
All,4618,O
14,4618,O
mutations,4618,O
were,4618,O
identified,4618,O
",",4618,O
as,4618,O
well,4618,O
as,4618,O
an,4618,O
additional,4618,O
five,4618,O
that,4618,O
had,4618,O
previously,4618,O
escaped,4618,O
detection,4618,O
.,4618,O
In,4619,O
addition,4619,O
to,4619,O
the,4619,O
19,4619,O
mutations,4619,O
",",4619,O
a,4619,O
total,4619,O
of,4619,O
15,4619,O
different,4619,O
polymorphic,4619,O
variants,4619,O
were,4619,O
scored,4619,O
",",4619,O
most,4619,O
of,4619,O
which,4619,O
were,4619,O
recurring,4619,O
.,4619,O
All,4620,O
were,4620,O
confirmed,4620,O
by,4620,O
nucleotide,4620,O
sequencing,4620,O
.,4620,O
The,4621,O
cost,4621,O
of,4621,O
screening,4621,O
per,4621,O
sample,4621,O
was,4621,O
calculated,4621,O
to,4621,O
be,4621,O
approximately,4621,O
US,4621,O
$,4621,O
70,4621,O
for,4621,O
the,4621,O
manual,4621,O
technique,4621,O
used,4621,O
in,4621,O
this,4621,O
study,4621,O
",",4621,O
and,4621,O
may,4621,O
be,4621,O
reduced,4621,O
to,4621,O
approximately,4621,O
US,4621,O
$,4621,O
10,4621,O
with,4621,O
the,4621,O
introduction,4621,O
of,4621,O
commercially,4621,O
available,4621,O
PCR,4621,O
robotics,4621,O
and,4621,O
fluorescent,4621,O
imaging,4621,O
.,4621,O
Implementation,4622,O
of,4622,O
this,4622,O
method,4622,O
of,4622,O
mutation,4622,O
screening,4622,O
in,4622,O
the,4622,O
research,4622,O
and,4622,O
clinical,4622,O
setting,4622,O
should,4622,O
permit,4622,O
rapid,4622,O
accrual,4622,O
of,4622,O
quantitative,4622,O
data,4622,O
on,4622,O
genotype-phenotype,4622,O
associations,4622,O
for,4622,O
the,4622,O
evaluation,4622,O
of,4622,O
diagnostic,4622,O
testing,4622,O
..,4622,O
Maternal,4623,B-SpecificDisease
uniparental,4623,I-SpecificDisease
disomy,4623,I-SpecificDisease
for,4623,I-SpecificDisease
chromosome,4623,I-SpecificDisease
14,4623,I-SpecificDisease
in,4623,O
a,4623,O
boy,4623,O
with,4623,O
a,4623,O
normal,4623,O
karyotype,4623,O
.,4623,O
We,4624,O
report,4624,O
on,4624,O
a,4624,O
boy,4624,O
with,4624,O
a,4624,O
maternal,4624,B-SpecificDisease
uniparental,4624,I-SpecificDisease
disomy,4624,I-SpecificDisease
for,4624,I-SpecificDisease
chromosome,4624,I-SpecificDisease
14,4624,I-SpecificDisease
(,4624,O
UPD,4624,B-SpecificDisease
(,4624,O
14,4624,O
),4624,O
),4624,O
.,4624,O
At,4625,O
7,4625,O
years,4625,O
of,4625,O
age,4625,O
he,4625,O
was,4625,O
referred,4625,O
to,4625,O
us,4625,O
by,4625,O
the,4625,O
paediatrician,4625,O
because,4625,O
of,4625,O
symptoms,4625,O
of,4625,O
Prader-Willi,4625,B-SpecificDisease
syndrome,4625,I-SpecificDisease
(,4625,O
PWS,4625,B-SpecificDisease
),4625,O
.,4625,O
He,4626,O
showed,4626,O
short,4626,B-DiseaseClass
stature,4626,I-DiseaseClass
",",4626,O
obesity,4626,B-SpecificDisease
",",4626,O
mild,4626,O
developmental,4626,B-DiseaseClass
delay,4626,I-DiseaseClass
",",4626,O
cryptorchidism,4626,B-SpecificDisease
",",4626,O
and,4626,O
some,4626,O
mild,4626,O
dysmorphic,4626,B-DiseaseClass
features,4626,I-DiseaseClass
.,4626,O
The,4627,O
history,4627,O
further,4627,O
indicated,4627,O
intrauterine,4627,B-DiseaseClass
growth,4627,I-DiseaseClass
retardation,4627,I-DiseaseClass
at,4627,O
the,4627,O
end,4627,O
of,4627,O
the,4627,O
pregnancy,4627,O
.,4627,O
His,4628,O
mother,4628,O
was,4628,O
44,4628,O
years,4628,O
of,4628,O
age,4628,O
at,4628,O
the,4628,O
time,4628,O
of,4628,O
his,4628,O
birth,4628,O
.,4628,O
After,4629,O
birth,4629,O
he,4629,O
showed,4629,O
hypotonia,4629,B-DiseaseClass
with,4629,O
poor,4629,O
sucking,4629,O
",",4629,O
for,4629,O
which,4629,O
gavage,4629,O
feeding,4629,O
was,4629,O
needed,4629,O
.,4629,O
Motor,4630,O
development,4630,O
was,4630,O
delayed,4630,O
.,4630,O
After,4631,O
1,4631,O
year,4631,O
he,4631,O
became,4631,O
obese,4631,B-Modifier
despite,4631,O
a,4631,O
normal,4631,O
appetite,4631,O
.,4631,O
Recurrent,4632,O
middle,4632,B-SpecificDisease
ear,4632,I-SpecificDisease
infections,4632,I-SpecificDisease
",",4632,O
a,4632,O
high,4632,O
pain,4632,O
threshold,4632,O
",",4632,O
and,4632,O
a,4632,O
great,4632,O
skill,4632,O
with,4632,O
jigsaw,4632,O
puzzles,4632,O
were,4632,O
reported,4632,O
.,4632,O
There,4633,O
were,4633,O
no,4633,O
behavioural,4633,O
problems,4633,O
or,4633,O
sleep,4633,O
disturbance,4633,O
.,4633,O
Chromosomal,4634,O
analysis,4634,O
was,4634,O
normal,4634,O
(,4634,O
46,4634,O
",",4634,O
XY,4634,O
),4634,O
.,4634,O
DNA,4635,O
analysis,4635,O
for,4635,O
Prader-Willi,4635,B-SpecificDisease
syndrome,4635,I-SpecificDisease
showed,4635,O
no,4635,O
abnormalities,4635,O
.,4635,O
Two,4636,O
years,4636,O
later,4636,O
he,4636,O
was,4636,O
re-examined,4636,O
because,4636,O
we,4636,O
thought,4636,O
his,4636,O
features,4636,O
fitted,4636,O
the,4636,O
PWS-like,4636,B-Modifier
phenotype,4636,O
associated,4636,O
with,4636,O
maternal,4636,O
UPD,4636,B-SpecificDisease
(,4636,O
14,4636,O
),4636,O
.,4636,O
At,4637,O
that,4637,O
time,4637,O
precocious,4637,O
puberty,4637,O
was,4637,O
evident,4637,O
.,4637,O
DNA,4638,O
analysis,4638,O
showed,4638,O
maternal,4638,B-DiseaseClass
heterodisomy,4638,I-DiseaseClass
for,4638,O
chromosome,4638,O
14,4638,O
.,4638,O
In,4639,O
all,4639,O
the,4639,O
previously,4639,O
described,4639,O
11,4639,O
cases,4639,O
with,4639,O
maternal,4639,O
UPD,4639,B-SpecificDisease
(,4639,O
14,4639,O
),4639,O
",",4639,O
a,4639,O
Robertsonian,4639,O
translocation,4639,O
involving,4639,O
chromosome,4639,O
14,4639,O
was,4639,O
detected,4639,O
cytogenetically,4639,O
before,4639,O
DNA,4639,O
analysis,4639,O
.,4639,O
This,4640,O
is,4640,O
the,4640,O
first,4640,O
report,4640,O
of,4640,O
diagnosis,4640,O
of,4640,O
maternal,4640,O
UPD,4640,B-SpecificDisease
(,4640,O
14,4640,O
),4640,O
based,4640,O
on,4640,O
clinical,4640,O
features,4640,O
.,4640,O
This,4641,O
finding,4641,O
underlines,4641,O
the,4641,O
importance,4641,O
of,4641,O
DNA,4641,O
analysis,4641,O
for,4641,O
maternal,4641,O
UPD,4641,O
(,4641,O
14,4641,O
),4641,O
in,4641,O
patients,4641,O
with,4641,O
a,4641,O
similar,4641,O
PWS-like,4641,B-Modifier
phenotype,4641,O
even,4641,O
without,4641,O
previous,4641,O
identification,4641,O
of,4641,O
a,4641,O
Robertsonian,4641,O
translocation,4641,O
involving,4641,O
chromosome,4641,O
14,4641,O
..,4641,O
Clinical,4642,O
and,4642,O
genetic,4642,O
study,4642,O
of,4642,O
Friedreich,4642,B-SpecificDisease
ataxia,4642,I-SpecificDisease
in,4642,O
an,4642,O
Australian,4642,O
population,4642,O
.,4642,O
Friedreich,4643,B-SpecificDisease
ataxia,4643,I-SpecificDisease
is,4643,O
an,4643,O
autosomal,4643,B-DiseaseClass
recessive,4643,I-DiseaseClass
disorder,4643,I-DiseaseClass
caused,4643,O
by,4643,O
mutations,4643,O
in,4643,O
the,4643,O
FRDA,4643,B-Modifier
gene,4643,O
that,4643,O
encodes,4643,O
a,4643,O
210-amino,4643,O
acid,4643,O
protein,4643,O
called,4643,O
frataxin,4643,O
.,4643,O
An,4644,O
expansion,4644,O
of,4644,O
a,4644,O
GAA,4644,O
trinucleotide,4644,O
repeat,4644,O
in,4644,O
intron,4644,O
1,4644,O
of,4644,O
the,4644,O
gene,4644,O
is,4644,O
present,4644,O
in,4644,O
more,4644,O
than,4644,O
95,4644,O
%,4644,O
of,4644,O
mutant,4644,O
alleles,4644,O
.,4644,O
Of,4645,O
the,4645,O
83,4645,O
people,4645,O
we,4645,O
studied,4645,O
who,4645,O
have,4645,O
mutations,4645,O
in,4645,O
FRDA,4645,O
",",4645,O
78,4645,O
are,4645,O
homozygous,4645,O
for,4645,O
an,4645,O
expanded,4645,O
GAA,4645,O
repeat,4645,O
;,4645,O
the,4645,O
other,4645,O
five,4645,O
patients,4645,O
have,4645,O
an,4645,O
expansion,4645,O
in,4645,O
one,4645,O
allele,4645,O
and,4645,O
a,4645,O
point,4645,O
mutation,4645,O
in,4645,O
the,4645,O
other,4645,O
.,4645,O
Here,4646,O
we,4646,O
present,4646,O
a,4646,O
detailed,4646,O
clinical,4646,O
and,4646,O
genetic,4646,O
study,4646,O
of,4646,O
a,4646,O
subset,4646,O
of,4646,O
51,4646,O
patients,4646,O
homozygous,4646,O
for,4646,O
an,4646,O
expansion,4646,O
of,4646,O
the,4646,O
GAA,4646,O
repeat,4646,O
.,4646,O
We,4647,O
found,4647,O
a,4647,O
correlation,4647,O
between,4647,O
the,4647,O
size,4647,O
of,4647,O
the,4647,O
smaller,4647,O
of,4647,O
the,4647,O
two,4647,O
expanded,4647,O
alleles,4647,O
and,4647,O
age,4647,O
at,4647,O
onset,4647,O
",",4647,O
age,4647,O
into,4647,O
wheelchair,4647,O
",",4647,O
scoliosis,4647,B-DiseaseClass
",",4647,O
impaired,4647,O
vibration,4647,O
sense,4647,O
",",4647,O
and,4647,O
the,4647,O
presence,4647,O
of,4647,O
foot,4647,B-DiseaseClass
deformity,4647,I-DiseaseClass
.,4647,O
There,4648,O
was,4648,O
no,4648,O
significant,4648,O
correlation,4648,O
between,4648,O
the,4648,O
size,4648,O
of,4648,O
the,4648,O
smaller,4648,O
allele,4648,O
and,4648,O
cardiomyopathy,4648,B-SpecificDisease
",",4648,O
diabetes,4648,B-SpecificDisease
mellitus,4648,I-SpecificDisease
",",4648,O
loss,4648,B-DiseaseClass
of,4648,I-DiseaseClass
proprioception,4648,I-DiseaseClass
",",4648,O
or,4648,O
bladder,4648,B-DiseaseClass
symptoms,4648,I-DiseaseClass
.,4648,O
The,4649,O
larger,4649,O
allele,4649,O
size,4649,O
correlated,4649,O
with,4649,O
bladder,4649,B-DiseaseClass
symptoms,4649,I-DiseaseClass
and,4649,O
the,4649,O
presence,4649,O
of,4649,O
foot,4649,B-DiseaseClass
deformity,4649,I-DiseaseClass
.,4649,O
The,4650,O
duration,4650,O
of,4650,O
disease,4650,O
is,4650,O
correlated,4650,O
with,4650,O
wheelchair,4650,O
use,4650,O
and,4650,O
the,4650,O
presence,4650,O
of,4650,O
diabetes,4650,B-DiseaseClass
",",4650,O
scoliosis,4650,B-DiseaseClass
",",4650,O
bladder,4650,B-DiseaseClass
symptoms,4650,I-DiseaseClass
and,4650,O
impaired,4650,B-DiseaseClass
proprioception,4650,I-DiseaseClass
",",4650,O
and,4650,O
vibration,4650,O
sense,4650,O
but,4650,O
no,4650,O
other,4650,O
complications,4650,O
studied,4650,O
..,4650,O
Novel,4651,O
mutations,4651,O
in,4651,O
XLRS1,4651,O
causing,4651,O
retinoschisis,4651,B-SpecificDisease
",",4651,O
including,4651,O
first,4651,O
evidence,4651,O
of,4651,O
putative,4651,O
leader,4651,O
sequence,4651,O
change,4651,O
.,4651,O
Juvenile,4652,B-SpecificDisease
retinoschisis,4652,I-SpecificDisease
is,4652,O
an,4652,O
X-linked,4652,B-DiseaseClass
recessive,4652,I-DiseaseClass
disease,4652,I-DiseaseClass
caused,4652,O
by,4652,O
mutations,4652,O
in,4652,O
the,4652,O
XLRS1,4652,O
gene,4652,O
.,4652,O
We,4653,O
screened,4653,O
31,4653,O
new,4653,O
unrelated,4653,O
patients,4653,O
and,4653,O
families,4653,O
for,4653,O
XLRS1,4653,O
mutations,4653,O
in,4653,O
addition,4653,O
to,4653,O
previously,4653,O
reported,4653,O
mutations,4653,O
for,4653,O
60,4653,O
of,4653,O
our,4653,O
families,4653,O
(,4653,O
Retinoschisis,4653,B-Modifier
Consortium,4653,O
",",4653,O
Hum,4653,O
Mol,4653,O
Genet,4653,O
1998,4653,O
;,4653,O
7,4653,O
1185-1192,4653,O
),4653,O
.,4653,O
Twenty-three,4654,O
different,4654,O
mutations,4654,O
including,4654,O
12,4654,O
novel,4654,O
ones,4654,O
were,4654,O
identified,4654,O
in,4654,O
28,4654,O
patients,4654,O
.,4654,O
Mutations,4655,O
identified,4655,O
in,4655,O
this,4655,O
study,4655,O
include,4655,O
19,4655,O
missense,4655,O
mutations,4655,O
",",4655,O
two,4655,O
nonsense,4655,O
mutations,4655,O
",",4655,O
one,4655,O
intragenic,4655,O
deletion,4655,O
",",4655,O
four,4655,O
microdeletions,4655,O
",",4655,O
one,4655,O
insertion,4655,O
",",4655,O
and,4655,O
one,4655,O
intronic,4655,O
sequence,4655,O
substitution,4655,O
that,4655,O
is,4655,O
likely,4655,O
to,4655,O
result,4655,O
in,4655,O
a,4655,O
splice,4655,O
site,4655,O
defect,4655,O
.,4655,O
Two,4656,O
novel,4656,O
mutations,4656,O
",",4656,O
c.,4656,O
38T,4656,O
--,4656,O
>,4656,O
C,4656,O
(,4656,O
L13P,4656,O
),4656,O
and,4656,O
c.,4656,O
667T,4656,O
--,4656,O
>,4656,O
C,4656,O
(,4656,O
C223R,4656,O
),4656,O
",",4656,O
respectively,4656,O
",",4656,O
present,4656,O
the,4656,O
first,4656,O
genetic,4656,O
evidence,4656,O
for,4656,O
the,4656,O
functional,4656,O
significance,4656,O
of,4656,O
the,4656,O
putative,4656,O
leader,4656,O
peptide,4656,O
sequence,4656,O
and,4656,O
for,4656,O
the,4656,O
functional,4656,O
significance,4656,O
at,4656,O
the,4656,O
carboxyl,4656,O
terminal,4656,O
of,4656,O
the,4656,O
XLRS1,4656,O
protein,4656,O
beyond,4656,O
the,4656,O
discoidin,4656,O
domain,4656,O
.,4656,O
Mutations,4657,O
in,4657,O
25,4657,O
of,4657,O
the,4657,O
families,4657,O
were,4657,O
localized,4657,O
to,4657,O
exons,4657,O
4-6,4657,O
",",4657,O
emphasizing,4657,O
the,4657,O
critical,4657,O
functional,4657,O
significance,4657,O
of,4657,O
the,4657,O
discoidin,4657,O
domain,4657,O
of,4657,O
the,4657,O
XLRS1,4657,O
protein,4657,O
Growth,4658,O
hormone,4658,O
treatment,4658,O
increases,4658,O
CO,4658,O
(,4658,O
2,4658,O
),4658,O
response,4658,O
",",4658,O
ventilation,4658,O
and,4658,O
central,4658,O
inspiratory,4658,O
drive,4658,O
in,4658,O
children,4658,O
with,4658,O
Prader-Willi,4658,B-SpecificDisease
syndrome,4658,I-SpecificDisease
.,4658,O
We,4659,O
studied,4659,O
whether,4659,O
the,4659,O
beneficial,4659,O
effects,4659,O
of,4659,O
growth,4659,O
hormone,4659,O
(,4659,O
GH,4659,O
),4659,O
treatment,4659,O
on,4659,O
growth,4659,O
and,4659,O
body,4659,O
composition,4659,O
in,4659,O
PWS,4659,B-SpecificDisease
are,4659,O
accompanied,4659,O
by,4659,O
an,4659,O
improvement,4659,O
in,4659,O
respiratory,4659,O
function,4659,O
.,4659,O
We,4660,O
measured,4660,O
resting,4660,O
ventilation,4660,O
",",4660,O
airway,4660,O
occlusion,4660,O
pressure,4660,O
(,4660,O
P,4660,O
(,4660,O
0,4660,O
.,4660,O
1,4661,O
),4661,O
),4661,O
and,4661,O
ventilatory,4661,O
response,4661,O
to,4661,O
CO,4661,O
(,4661,O
2,4661,O
),4661,O
in,4661,O
nine,4661,O
children,4661,O
",",4661,O
aged,4661,O
7-14,4661,O
years,4661,O
",",4661,O
before,4661,O
and,4661,O
6-9,4661,O
months,4661,O
after,4661,O
the,4661,O
start,4661,O
of,4661,O
GH,4661,O
treatment,4661,O
.,4661,O
During,4662,O
GH,4662,O
treatment,4662,O
",",4662,O
resting,4662,O
ventilation,4662,O
increased,4662,O
by,4662,O
26,4662,O
%,4662,O
",",4662,O
P,4662,O
(,4662,O
0,4662,O
.,4662,O
1,4663,O
),4663,O
by,4663,O
72,4663,O
%,4663,O
and,4663,O
the,4663,O
response,4663,O
to,4663,O
CO,4663,O
(,4663,O
2,4663,O
),4663,O
by,4663,O
65,4663,O
%,4663,O
(,4663,O
P,4663,O
<,4663,O
0,4663,O
.,4663,O
002,4664,O
",",4664,O
<,4664,O
0,4664,O
.,4664,O
04,4665,O
and,4665,O
<,4665,O
0,4665,O
.,4665,O
02,4666,O
",",4666,O
respectively,4666,O
),4666,O
.,4666,O
This,4667,O
observed,4667,O
increase,4667,O
in,4667,O
ventilatory,4667,O
output,4667,O
was,4667,O
not,4667,O
correlated,4667,O
to,4667,O
changes,4667,O
in,4667,O
body,4667,O
mass,4667,O
index,4667,O
.,4667,O
CONCLUSION,4668,O
Treatment,4668,O
of,4668,O
children,4668,O
with,4668,O
Prader-Willi,4668,B-SpecificDisease
syndrome,4668,I-SpecificDisease
(,4668,O
PWS,4668,B-SpecificDisease
),4668,O
seems,4668,O
to,4668,O
have,4668,O
a,4668,O
stimulatory,4668,O
effect,4668,O
on,4668,O
central,4668,O
respiratory,4668,O
structures,4668,O
.,4668,O
The,4669,O
observed,4669,O
increase,4669,O
in,4669,O
ventilation,4669,O
and,4669,O
inspiratory,4669,O
drive,4669,O
may,4669,O
contribute,4669,O
to,4669,O
the,4669,O
improved,4669,O
activity,4669,O
level,4669,O
reported,4669,O
by,4669,O
parents,4669,O
of,4669,O
PWS,4669,B-Modifier
children,4669,O
during,4669,O
growth,4669,O
hormone,4669,O
therapy,4669,O
G130V,4670,O
",",4670,O
a,4670,O
common,4670,O
FRDA,4670,B-Modifier
point,4670,O
mutation,4670,O
",",4670,O
appears,4670,O
to,4670,O
have,4670,O
arisen,4670,O
from,4670,O
a,4670,O
common,4670,O
founder,4670,O
.,4670,O
Friedreich,4671,B-SpecificDisease
ataxia,4671,I-SpecificDisease
(,4671,O
FRDA,4671,B-SpecificDisease
),4671,O
is,4671,O
the,4671,O
most,4671,O
common,4671,O
inherited,4671,B-DiseaseClass
ataxia,4671,I-DiseaseClass
.,4671,O
About,4672,O
98,4672,O
%,4672,O
of,4672,O
mutant,4672,O
alleles,4672,O
have,4672,O
an,4672,O
expansion,4672,O
of,4672,O
a,4672,O
GAA,4672,O
trinucleotide,4672,O
repeat,4672,O
in,4672,O
intron,4672,O
1,4672,O
of,4672,O
the,4672,O
affected,4672,O
gene,4672,O
",",4672,O
FRDA,4672,O
.,4672,O
The,4673,O
other,4673,O
2,4673,O
%,4673,O
are,4673,O
point,4673,O
mutations,4673,O
.,4673,O
Of,4674,O
the,4674,O
17,4674,O
point,4674,O
mutations,4674,O
so,4674,O
far,4674,O
described,4674,O
",",4674,O
three,4674,O
appear,4674,O
to,4674,O
be,4674,O
more,4674,O
common,4674,O
.,4674,O
One,4675,O
of,4675,O
these,4675,O
is,4675,O
the,4675,O
G130V,4675,O
mutation,4675,O
in,4675,O
exon,4675,O
4,4675,O
of,4675,O
FRDA,4675,O
.,4675,O
G130V,4676,O
",",4676,O
when,4676,O
present,4676,O
with,4676,O
an,4676,O
expanded,4676,O
GAA,4676,O
repeat,4676,O
on,4676,O
the,4676,O
other,4676,O
allele,4676,O
",",4676,O
is,4676,O
associated,4676,O
with,4676,O
an,4676,O
atypical,4676,O
FRDA,4676,B-Modifier
phenotype,4676,O
.,4676,O
Haplotype,4677,O
analysis,4677,O
was,4677,O
undertaken,4677,O
on,4677,O
the,4677,O
four,4677,O
families,4677,O
who,4677,O
have,4677,O
been,4677,O
described,4677,O
with,4677,O
this,4677,O
mutation,4677,O
.,4677,O
The,4678,O
results,4678,O
suggest,4678,O
a,4678,O
common,4678,O
founder,4678,O
for,4678,O
this,4678,O
mutation,4678,O
.,4678,O
Although,4679,O
marked,4679,O
differences,4679,O
in,4679,O
extragenic,4679,O
marker,4679,O
haplotypes,4679,O
were,4679,O
seen,4679,O
in,4679,O
one,4679,O
family,4679,O
",",4679,O
similar,4679,O
intragenic,4679,O
haplotyping,4679,O
suggests,4679,O
the,4679,O
same,4679,O
mutation,4679,O
founder,4679,O
for,4679,O
this,4679,O
family,4679,O
with,4679,O
the,4679,O
differences,4679,O
explicable,4679,O
by,4679,O
two,4679,O
recombination,4679,O
events,4679,O
..,4679,O
Synergistic,4680,O
effect,4680,O
of,4680,O
histone,4680,O
hyperacetylation,4680,O
and,4680,O
DNA,4680,O
demethylation,4680,O
in,4680,O
the,4680,O
reactivation,4680,O
of,4680,O
the,4680,O
FMR1,4680,O
gene,4680,O
.,4680,O
Most,4681,O
fragile,4681,B-Modifier
X,4681,I-Modifier
syndrome,4681,I-Modifier
patients,4681,O
have,4681,O
expansion,4681,O
of,4681,O
a,4681,O
(,4681,O
CGG,4681,O
),4681,O
(,4681,O
n,4681,O
),4681,O
sequence,4681,O
with,4681,O
>,4681,O
200,4681,O
repeats,4681,O
(,4681,O
full,4681,O
mutation,4681,O
),4681,O
in,4681,O
the,4681,O
FMR1,4681,O
gene,4681,O
responsible,4681,O
for,4681,O
this,4681,O
condition,4681,O
.,4681,O
Hypermethylation,4682,O
of,4682,O
the,4682,O
expanded,4682,O
repeat,4682,O
and,4682,O
of,4682,O
the,4682,O
FMR1,4682,O
promoter,4682,O
is,4682,O
almost,4682,O
always,4682,O
present,4682,O
and,4682,O
apparently,4682,O
suppresses,4682,O
transcription,4682,O
",",4682,O
resulting,4682,O
in,4682,O
absence,4682,O
of,4682,O
the,4682,O
FMR1,4682,O
protein,4682,O
.,4682,O
We,4683,O
recently,4683,O
showed,4683,O
that,4683,O
transcriptional,4683,O
reactivation,4683,O
of,4683,O
FMR1,4683,O
full,4683,O
mutations,4683,O
can,4683,O
be,4683,O
achieved,4683,O
by,4683,O
inducing,4683,O
DNA,4683,O
demethylation,4683,O
with,4683,O
5-azadeoxycytidine,4683,O
(,4683,O
5-azadC,4683,O
),4683,O
.,4683,O
The,4684,O
level,4684,O
of,4684,O
histone,4684,O
acetylation,4684,O
is,4684,O
another,4684,O
important,4684,O
factor,4684,O
in,4684,O
regulating,4684,O
gene,4684,O
expression,4684,O
;,4684,O
therefore,4684,O
",",4684,O
we,4684,O
treated,4684,O
lymphoblastoid,4684,O
cell,4684,O
lines,4684,O
of,4684,O
non-mosaic,4684,O
full,4684,O
mutation,4684,O
patients,4684,O
with,4684,O
three,4684,O
drugs,4684,O
capable,4684,O
of,4684,O
inducing,4684,O
histone,4684,O
hyperacetylation,4684,O
.,4684,O
We,4685,O
observed,4685,O
a,4685,O
consistent,4685,O
",",4685,O
although,4685,O
modest,4685,O
",",4685,O
reactivation,4685,O
of,4685,O
the,4685,O
FMR1,4685,O
gene,4685,O
with,4685,O
4-phenylbutyrate,4685,O
",",4685,O
sodium,4685,O
butyrate,4685,O
and,4685,O
trichostatin,4685,O
A,4685,O
",",4685,O
as,4685,O
shown,4685,O
by,4685,O
RT-PCR,4685,O
.,4685,O
However,4686,O
",",4686,O
we,4686,O
report,4686,O
that,4686,O
combining,4686,O
these,4686,O
drugs,4686,O
with,4686,O
5-azadC,4686,O
results,4686,O
in,4686,O
a,4686,O
2-,4686,O
to,4686,O
5-fold,4686,O
increase,4686,O
in,4686,O
FMR1,4686,O
mRNA,4686,O
levels,4686,O
obtained,4686,O
with,4686,O
5-azadC,4686,O
alone,4686,O
",",4686,O
thus,4686,O
showing,4686,O
a,4686,O
marked,4686,O
synergistic,4686,O
effect,4686,O
of,4686,O
histone,4686,O
hyperacetylation,4686,O
and,4686,O
DNA,4686,O
demethylation,4686,O
in,4686,O
the,4686,O
reactivation,4686,O
of,4686,O
FMR1,4686,O
full,4686,O
mutations,4686,O
..,4686,O
Constitutional,4687,O
von,4687,B-Modifier
Hippel-Lindau,4687,I-Modifier
(,4687,O
VHL,4687,B-Modifier
),4687,O
gene,4687,O
deletions,4687,O
detected,4687,O
in,4687,O
VHL,4687,B-Modifier
families,4687,O
by,4687,O
fluorescence,4687,O
in,4687,O
situ,4687,O
hybridization,4687,O
.,4687,O
von,4688,B-SpecificDisease
Hippel-Lindau,4688,I-SpecificDisease
(,4688,I-SpecificDisease
VHL,4688,I-SpecificDisease
),4688,I-SpecificDisease
disease,4688,I-SpecificDisease
is,4688,O
an,4688,O
autosomal,4688,B-DiseaseClass
dominantly,4688,I-DiseaseClass
inherited,4688,I-DiseaseClass
cancer,4688,I-DiseaseClass
syndrome,4688,I-DiseaseClass
predisposing,4688,O
to,4688,O
a,4688,O
variety,4688,O
of,4688,O
tumor,4688,B-Modifier
types,4688,O
that,4688,O
include,4688,O
retinal,4688,O
hemangioblastomas,4688,B-DiseaseClass
",",4688,O
hemangioblastomas,4688,B-DiseaseClass
of,4688,O
the,4688,O
central,4688,O
nervous,4688,O
system,4688,O
",",4688,O
renal,4688,B-SpecificDisease
cell,4688,I-SpecificDisease
carcinomas,4688,I-SpecificDisease
",",4688,O
pancreatic,4688,O
cysts,4688,O
and,4688,O
tumors,4688,O
",",4688,O
pheochromocytomas,4688,B-DiseaseClass
",",4688,O
endolymphatic,4688,B-DiseaseClass
sac,4688,I-DiseaseClass
tumors,4688,I-DiseaseClass
",",4688,O
and,4688,O
epididymal,4688,B-DiseaseClass
cystadenomas,4688,I-DiseaseClass
[,4688,O
W.,4688,O
M.,4688,O
Linehan,4688,O
et,4688,O
al.,4688,O
",",4688,O
J,4688,O
.,4688,O
Am,4689,O
.,4689,O
Med,4690,O
.,4690,O
Assoc.,4691,O
",",4691,O
273,4691,O
564-570,4691,O
",",4691,O
1995,4691,O
;,4691,O
E.,4691,O
A.,4691,O
Maher,4691,O
and,4691,O
W.,4691,O
G.,4691,O
Kaelin,4691,O
",",4691,O
Jr.,4691,O
",",4691,O
Medicine,4691,O
(,4691,O
Baltimore,4691,O
),4691,O
",",4691,O
76,4691,O
381-391,4691,O
",",4691,O
1997,4691,O
;,4691,O
W.,4691,O
M.,4691,O
Linehan,4691,O
and,4691,O
R.,4691,O
D.,4691,O
Klausner,4691,O
",",4691,O
In,4691,O
B.,4691,O
Vogelstein,4691,O
and,4691,O
K.,4691,O
Kinzler,4691,O
(,4691,O
eds,4691,O
.,4691,O
),4692,O
",",4692,O
The,4692,O
Genetic,4692,O
Basis,4692,O
of,4692,O
Human,4692,O
Cancer,4692,O
",",4692,O
pp,4692,O
.,4692,O
455-473,4693,O
",",4693,O
McGraw-Hill,4693,O
",",4693,O
1998,4693,O
],4693,O
.,4693,O
The,4694,O
VHL,4694,O
gene,4694,O
was,4694,O
localized,4694,O
to,4694,O
chromosome,4694,O
3p25-26,4694,O
and,4694,O
cloned,4694,O
[,4694,O
F.,4694,O
Latif,4694,O
et,4694,O
al.,4694,O
",",4694,O
Science,4694,O
(,4694,O
Washington,4694,O
DC,4694,O
),4694,O
",",4694,O
260,4694,O
1317-1320,4694,O
",",4694,O
1993,4694,O
],4694,O
.,4694,O
Germline,4695,O
mutations,4695,O
in,4695,O
the,4695,O
VHL,4695,O
gene,4695,O
have,4695,O
been,4695,O
detected,4695,O
in,4695,O
the,4695,O
majority,4695,O
of,4695,O
VHL,4695,O
kindreds,4695,O
.,4695,O
The,4696,O
reported,4696,O
frequency,4696,O
of,4696,O
detection,4696,O
of,4696,O
VHL,4696,O
germline,4696,O
mutations,4696,O
has,4696,O
varied,4696,O
from,4696,O
39,4696,O
to,4696,O
80,4696,O
%,4696,O
(,4696,O
J.,4696,O
M.,4696,O
Whaley,4696,O
et,4696,O
al.,4696,O
",",4696,O
Am,4696,O
.,4696,O
J.,4697,O
Hum,4697,O
.,4697,O
Genet.,4698,O
",",4698,O
55,4698,O
1092-1102,4698,O
",",4698,O
1994,4698,O
;,4698,O
Clinical,4698,O
Research,4698,O
Group,4698,O
for,4698,O
Japan,4698,O
",",4698,O
Hum,4698,O
.,4698,O
Mol,4699,O
.,4699,O
Genet.,4700,O
",",4700,O
4,4700,O
2233-2237,4700,O
",",4700,O
1995,4700,O
;,4700,O
F.,4700,O
Chen,4700,O
et,4700,O
al.,4700,O
",",4700,O
Hum,4700,O
.,4700,O
Mutat.,4701,O
",",4701,O
5,4701,O
66-75,4701,O
",",4701,O
1995,4701,O
;,4701,O
E.,4701,O
R.,4701,O
Maher,4701,O
et,4701,O
al.,4701,O
",",4701,O
J.,4701,O
Med,4701,O
.,4701,O
Genet.,4702,O
",",4702,O
33,4702,O
328-332,4702,O
",",4702,O
1996,4702,O
;,4702,O
B.,4702,O
Zbar,4702,O
",",4702,O
Cancer,4702,O
Surv.,4702,O
",",4702,O
25,4702,O
219-232,4702,O
",",4702,O
1995,4702,O
),4702,O
.,4702,O
Recently,4703,O
a,4703,O
quantitative,4703,O
Southern,4703,O
blotting,4703,O
procedure,4703,O
was,4703,O
found,4703,O
to,4703,O
improve,4703,O
this,4703,O
frequency,4703,O
(,4703,O
C.,4703,O
Stolle,4703,O
et,4703,O
al.,4703,O
",",4703,O
Hum,4703,O
.,4703,O
Mutat.,4704,O
",",4704,O
12,4704,O
417-423,4704,O
",",4704,O
1998,4704,O
),4704,O
.,4704,O
In,4705,O
the,4705,O
present,4705,O
study,4705,O
",",4705,O
we,4705,O
report,4705,O
the,4705,O
use,4705,O
of,4705,O
fluorescence,4705,O
in,4705,O
situ,4705,O
hybridization,4705,O
(,4705,O
FISH,4705,O
),4705,O
as,4705,O
a,4705,O
method,4705,O
to,4705,O
detect,4705,O
and,4705,O
characterize,4705,O
VHL,4705,O
germline,4705,O
deletions,4705,O
.,4705,O
We,4706,O
reexamined,4706,O
a,4706,O
group,4706,O
of,4706,O
VHL,4706,O
patients,4706,O
shown,4706,O
previously,4706,O
by,4706,O
single-strand,4706,O
conformation,4706,O
and,4706,O
sequencing,4706,O
analysis,4706,O
not,4706,O
to,4706,O
harbor,4706,O
point,4706,O
mutations,4706,O
in,4706,O
the,4706,O
VHL,4706,O
locus,4706,O
.,4706,O
We,4707,O
found,4707,O
constitutional,4707,O
deletions,4707,O
in,4707,O
29,4707,O
of,4707,O
30,4707,O
VHL,4707,O
patients,4707,O
in,4707,O
this,4707,O
group,4707,O
using,4707,O
cosmid,4707,O
and,4707,O
P1,4707,O
probes,4707,O
that,4707,O
cover,4707,O
the,4707,O
VHL,4707,O
locus,4707,O
.,4707,O
We,4708,O
then,4708,O
tested,4708,O
six,4708,O
phenotypically,4708,O
normal,4708,O
offspring,4708,O
from,4708,O
four,4708,O
of,4708,O
these,4708,O
VHL,4708,O
families,4708,O
two,4708,O
were,4708,O
found,4708,O
to,4708,O
carry,4708,O
the,4708,O
deletion,4708,O
and,4708,O
the,4708,O
other,4708,O
four,4708,O
were,4708,O
deletion-free,4708,O
.,4708,O
In,4709,O
addition,4709,O
",",4709,O
germline,4709,O
mosaicism,4709,O
of,4709,O
the,4709,O
VHL,4709,O
gene,4709,O
was,4709,O
identified,4709,O
in,4709,O
one,4709,O
family,4709,O
.,4709,O
In,4710,O
sum,4710,O
",",4710,O
FISH,4710,O
was,4710,O
found,4710,O
to,4710,O
be,4710,O
a,4710,O
simple,4710,O
and,4710,O
reliable,4710,O
method,4710,O
to,4710,O
detect,4710,O
VHL,4710,O
germline,4710,O
deletions,4710,O
and,4710,O
practically,4710,O
useful,4710,O
in,4710,O
cases,4710,O
where,4710,O
other,4710,O
methods,4710,O
of,4710,O
screening,4710,O
have,4710,O
failed,4710,O
to,4710,O
detect,4710,O
a,4710,O
VHL,4710,I-SpecificDisease
gene,4710,I-SpecificDisease
abnormality,4710,O
Spectrum,4711,O
of,4711,O
hSNF5/INI1,4711,O
somatic,4711,O
mutations,4711,O
in,4711,O
human,4711,O
cancer,4711,B-DiseaseClass
and,4711,O
genotype-phenotype,4711,O
correlations,4711,O
.,4711,O
The,4712,O
hSNF5/INI1,4712,O
gene,4712,O
which,4712,O
encodes,4712,O
a,4712,O
member,4712,O
of,4712,O
the,4712,O
SWI/SNF,4712,O
chromatin,4712,O
ATP-dependent,4712,O
remodeling,4712,O
complex,4712,O
",",4712,O
is,4712,O
a,4712,O
new,4712,O
tumor,4712,B-Modifier
suppressor,4712,O
gene,4712,O
localized,4712,O
on,4712,O
chromosome,4712,O
22q11,4712,O
.,4712,O
2,4713,O
and,4713,O
recently,4713,O
shown,4713,O
to,4713,O
be,4713,O
mutated,4713,O
in,4713,O
malignant,4713,B-DiseaseClass
rhabdoid,4713,I-DiseaseClass
tumors,4713,I-DiseaseClass
.,4713,O
We,4714,O
have,4714,O
searched,4714,O
for,4714,O
hSNF5/INI1,4714,O
mutations,4714,O
in,4714,O
229,4714,O
tumors,4714,B-DiseaseClass
of,4714,O
various,4714,O
origins,4714,O
using,4714,O
a,4714,O
screening,4714,O
method,4714,O
based,4714,O
on,4714,O
denaturing,4714,O
high-performance,4714,O
liquid,4714,O
chromatography,4714,O
.,4714,O
A,4715,O
total,4715,O
of,4715,O
31,4715,O
homozygous,4715,O
deletions,4715,O
and,4715,O
36,4715,O
point,4715,O
alterations,4715,O
were,4715,O
identified,4715,O
.,4715,O
Point,4716,O
mutations,4716,O
were,4716,O
scattered,4716,O
along,4716,O
the,4716,O
coding,4716,O
sequence,4716,O
and,4716,O
included,4716,O
15,4716,O
nonsense,4716,O
",",4716,O
15,4716,O
frameshift,4716,O
",",4716,O
three,4716,O
splice,4716,O
site,4716,O
",",4716,O
two,4716,O
missense,4716,O
and,4716,O
one,4716,O
editing,4716,O
mutations,4716,O
.,4716,O
Mutations,4717,O
were,4717,O
retrieved,4717,O
in,4717,O
most,4717,O
rhabdoid,4717,B-DiseaseClass
tumors,4717,I-DiseaseClass
",",4717,O
whatever,4717,O
their,4717,O
sites,4717,O
of,4717,O
occurrence,4717,O
",",4717,O
indicating,4717,O
the,4717,O
common,4717,O
pathogenetic,4717,O
origin,4717,O
of,4717,O
these,4717,O
tumors,4717,B-DiseaseClass
.,4717,O
Recurrent,4718,O
hSNF5/INI1,4718,O
alterations,4718,O
were,4718,O
also,4718,O
observed,4718,O
in,4718,O
choroid,4718,B-SpecificDisease
plexus,4718,I-SpecificDisease
carcinomas,4718,I-SpecificDisease
and,4718,O
in,4718,O
a,4718,O
subset,4718,O
of,4718,O
central,4718,O
primitive,4718,O
neuroectodermal,4718,B-DiseaseClass
tumors,4718,I-DiseaseClass
(,4718,O
cPNETs,4718,O
),4718,O
and,4718,O
medulloblastomas,4718,B-SpecificDisease
.,4718,O
In,4719,O
contrast,4719,O
",",4719,O
hSNF5/INI1,4719,O
point,4719,O
mutations,4719,O
were,4719,O
not,4719,O
detected,4719,O
in,4719,O
breast,4719,B-SpecificDisease
cancers,4719,I-SpecificDisease
",",4719,O
Wilms,4719,B-SpecificDisease
tumors,4719,I-SpecificDisease
",",4719,O
gliomas,4719,B-SpecificDisease
",",4719,O
ependymomas,4719,B-SpecificDisease
",",4719,O
sarcomas,4719,B-DiseaseClass
and,4719,O
other,4719,O
tumor,4719,B-Modifier
types,4719,O
",",4719,O
even,4719,O
though,4719,O
most,4719,O
analyzed,4719,O
cases,4719,O
harbored,4719,O
loss,4719,O
of,4719,O
heterozygosity,4719,O
at,4719,O
22q11,4719,O
.,4719,O
2,4720,O
loci,4720,O
.,4720,O
These,4721,O
results,4721,O
suggest,4721,O
that,4721,O
rhabdoid,4721,B-DiseaseClass
tumors,4721,I-DiseaseClass
",",4721,O
choroid,4721,B-SpecificDisease
plexus,4721,I-SpecificDisease
carcinomas,4721,I-SpecificDisease
and,4721,O
a,4721,O
subset,4721,O
of,4721,O
medulloblastomas,4721,B-SpecificDisease
and,4721,O
cPNETs,4721,O
share,4721,O
common,4721,O
pathways,4721,O
of,4721,O
oncogenesis,4721,O
related,4721,O
to,4721,O
hSNF5/INI1,4721,O
alteration,4721,O
and,4721,O
that,4721,O
hSNF5/INI1,4721,O
mutations,4721,O
define,4721,O
a,4721,O
genetically,4721,O
homogeneous,4721,O
family,4721,O
of,4721,O
highly,4721,O
aggressive,4721,O
cancers,4721,B-DiseaseClass
mainly,4721,O
occurring,4721,O
in,4721,O
young,4721,O
children,4721,O
and,4721,O
frequently,4721,O
",",4721,O
but,4721,O
not,4721,O
always,4721,O
",",4721,O
exhibiting,4721,O
a,4721,O
rhabdoid,4721,B-Modifier
phenotype,4721,O
Ataxin-3,4722,O
with,4722,O
an,4722,O
altered,4722,O
conformation,4722,O
that,4722,O
exposes,4722,O
the,4722,O
polyglutamine,4722,O
domain,4722,O
is,4722,O
associated,4722,O
with,4722,O
the,4722,O
nuclear,4722,O
matrix,4722,O
.,4722,O
Spinocerebellar,4723,B-SpecificDisease
ataxia,4723,I-SpecificDisease
type-3,4723,I-SpecificDisease
or,4723,O
Machado-Joseph,4723,B-SpecificDisease
disease,4723,I-SpecificDisease
(,4723,O
SCA3/MJD,4723,B-SpecificDisease
),4723,O
is,4723,O
a,4723,O
member,4723,O
of,4723,O
the,4723,O
CAG/polyglutamine,4723,B-DiseaseClass
repeat,4723,I-DiseaseClass
disease,4723,I-DiseaseClass
family,4723,O
.,4723,O
In,4724,O
this,4724,O
family,4724,O
of,4724,O
disorders,4724,O
",",4724,O
a,4724,O
normally,4724,O
polymorphic,4724,O
CAG,4724,O
repeat,4724,O
becomes,4724,O
expanded,4724,O
",",4724,O
resulting,4724,O
in,4724,O
expression,4724,O
of,4724,O
an,4724,O
expanded,4724,O
polyglutamine,4724,O
domain,4724,O
in,4724,O
the,4724,O
disease,4724,O
gene,4724,O
product,4724,O
.,4724,O
Experimental,4725,O
models,4725,O
of,4725,O
polyglutamine,4725,B-DiseaseClass
disease,4725,I-DiseaseClass
implicate,4725,O
the,4725,O
nucleus,4725,O
in,4725,O
pathogenesis,4725,O
;,4725,O
however,4725,O
",",4725,O
the,4725,O
link,4725,O
between,4725,O
intranuclear,4725,O
expression,4725,O
of,4725,O
expanded,4725,O
polyglutamine,4725,O
and,4725,O
neuronal,4725,B-DiseaseClass
dysfunction,4725,I-DiseaseClass
remains,4725,O
unclear,4725,O
.,4725,O
Here,4726,O
we,4726,O
demonstrate,4726,O
that,4726,O
ataxin-3,4726,O
",",4726,O
the,4726,O
disease,4726,O
protein,4726,O
in,4726,O
SCA3/MJD,4726,B-SpecificDisease
",",4726,O
adopts,4726,O
a,4726,O
unique,4726,O
conformation,4726,O
when,4726,O
expressed,4726,O
within,4726,O
the,4726,O
nucleus,4726,O
of,4726,O
transfected,4726,O
cells,4726,O
.,4726,O
The,4727,O
monoclonal,4727,O
antibody,4727,O
1C2,4727,O
is,4727,O
known,4727,O
preferentially,4727,O
to,4727,O
bind,4727,O
expanded,4727,O
polyglutamine,4727,O
",",4727,O
but,4727,O
we,4727,O
find,4727,O
that,4727,O
it,4727,O
also,4727,O
binds,4727,O
a,4727,O
fragment,4727,O
of,4727,O
ataxin-3,4727,O
containing,4727,O
a,4727,O
normal,4727,O
glutamine,4727,O
repeat,4727,O
.,4727,O
In,4728,O
addition,4728,O
",",4728,O
expression,4728,O
of,4728,O
ataxin-3,4728,O
within,4728,O
the,4728,O
nucleus,4728,O
exposes,4728,O
the,4728,O
glutamine,4728,O
domain,4728,O
of,4728,O
the,4728,O
full-length,4728,O
non-pathological,4728,O
protein,4728,O
",",4728,O
allowing,4728,O
it,4728,O
to,4728,O
bind,4728,O
the,4728,O
monoclonal,4728,O
antibody,4728,O
1C2,4728,O
.,4728,O
Fractionation,4729,O
and,4729,O
immunochemical,4729,O
experiments,4729,O
indicate,4729,O
that,4729,O
this,4729,O
novel,4729,O
conformation,4729,O
of,4729,O
intranuclear,4729,O
ataxin-3,4729,O
is,4729,O
not,4729,O
due,4729,O
to,4729,O
proteolysis,4729,O
",",4729,O
suggesting,4729,O
instead,4729,O
that,4729,O
association,4729,O
with,4729,O
nuclear,4729,O
protein,4729,O
(,4729,O
s,4729,O
),4729,O
alters,4729,O
the,4729,O
structure,4729,O
of,4729,O
full-length,4729,O
ataxin-3,4729,O
which,4729,O
exposes,4729,O
the,4729,O
polyglutamine,4729,O
domain,4729,O
.,4729,O
This,4730,O
conformationally,4730,O
altered,4730,O
ataxin-3,4730,O
is,4730,O
bound,4730,O
to,4730,O
the,4730,O
nuclear,4730,O
matrix,4730,O
.,4730,O
The,4731,O
pathological,4731,O
form,4731,O
of,4731,O
ataxin-3,4731,O
with,4731,O
an,4731,O
expanded,4731,O
polyglutamine,4731,O
domain,4731,O
also,4731,O
associates,4731,O
with,4731,O
the,4731,O
nuclear,4731,O
matrix,4731,O
.,4731,O
These,4732,O
data,4732,O
suggest,4732,O
that,4732,O
an,4732,O
early,4732,O
event,4732,O
in,4732,O
the,4732,O
pathogenesis,4732,O
of,4732,O
SCA3/MJD,4732,B-SpecificDisease
may,4732,O
be,4732,O
an,4732,O
altered,4732,O
conformation,4732,O
of,4732,O
ataxin-3,4732,O
within,4732,O
the,4732,O
nucleus,4732,O
that,4732,O
exposes,4732,O
the,4732,O
polyglutamine,4732,O
domain,4732,O
..,4732,O
The,4733,O
human,4733,O
MAGEL2,4733,O
gene,4733,O
and,4733,O
its,4733,O
mouse,4733,O
homologue,4733,O
are,4733,O
paternally,4733,O
expressed,4733,O
and,4733,O
mapped,4733,O
to,4733,O
the,4733,O
Prader-Willi,4733,B-Modifier
region,4733,O
.,4733,O
Prader-Willi,4734,B-SpecificDisease
syndrome,4734,I-SpecificDisease
(,4734,O
PWS,4734,B-SpecificDisease
),4734,O
is,4734,O
a,4734,O
complex,4734,O
neurogenetic,4734,B-DiseaseClass
disorder,4734,I-DiseaseClass
.,4734,O
The,4735,O
phenotype,4735,O
is,4735,O
likely,4735,O
to,4735,O
be,4735,O
a,4735,O
contiguous,4735,B-DiseaseClass
gene,4735,I-DiseaseClass
syndrome,4735,I-DiseaseClass
involving,4735,O
genes,4735,O
which,4735,O
are,4735,O
paternally,4735,O
expressed,4735,O
only,4735,O
",",4735,O
located,4735,O
in,4735,O
the,4735,O
human,4735,O
15q11-q13,4735,O
region,4735,O
.,4735,O
Four,4736,O
mouse,4736,O
models,4736,O
of,4736,O
PWS,4736,B-SpecificDisease
have,4736,O
been,4736,O
reported,4736,O
but,4736,O
these,4736,O
do,4736,O
not,4736,O
definitively,4736,O
allow,4736,O
the,4736,O
delineation,4736,O
of,4736,O
the,4736,O
critical,4736,O
region,4736,O
and,4736,O
the,4736,O
associated,4736,O
genes,4736,O
involved,4736,O
in,4736,O
the,4736,O
aetiology,4736,O
of,4736,O
PWS,4736,B-SpecificDisease
.,4736,O
Moreover,4737,O
",",4737,O
targeted,4737,O
mutagenesis,4737,O
of,4737,O
mouse,4737,O
homologues,4737,O
of,4737,O
the,4737,O
human,4737,O
candidate,4737,O
PWS,4737,B-Modifier
genes,4737,O
does,4737,O
not,4737,O
appear,4737,O
to,4737,O
result,4737,O
in,4737,O
any,4737,O
of,4737,O
the,4737,O
features,4737,O
of,4737,O
PWS,4737,B-SpecificDisease
.,4737,O
Therefore,4738,O
",",4738,O
the,4738,O
isolation,4738,O
of,4738,O
new,4738,O
genes,4738,O
in,4738,O
this,4738,O
region,4738,O
remains,4738,O
crucial,4738,O
for,4738,O
a,4738,O
better,4738,O
understanding,4738,O
of,4738,O
the,4738,O
molecular,4738,O
basis,4738,O
of,4738,O
PWS,4738,B-SpecificDisease
.,4738,O
In,4739,O
this,4739,O
manuscript,4739,O
",",4739,O
we,4739,O
report,4739,O
the,4739,O
characterization,4739,O
of,4739,O
MAGEL2,4739,O
and,4739,O
its,4739,O
mouse,4739,O
homologue,4739,O
Magel2,4739,O
.,4739,O
These,4740,O
are,4740,O
located,4740,O
in,4740,O
the,4740,O
human,4740,O
15q11-q13,4740,O
and,4740,O
mouse,4740,O
7C,4740,O
regions,4740,O
",",4740,O
in,4740,O
close,4740,O
proximity,4740,O
to,4740,O
NDN/Ndn,4740,O
.,4740,O
By,4741,O
northern,4741,O
blot,4741,O
analysis,4741,O
we,4741,O
did,4741,O
not,4741,O
detect,4741,O
any,4741,O
expression,4741,O
of,4741,O
MAGEL2/Magel2,4741,O
but,4741,O
by,4741,O
RT-PCR,4741,O
analysis,4741,O
",",4741,O
specific,4741,O
expression,4741,O
was,4741,O
detected,4741,O
in,4741,O
fetal,4741,O
and,4741,O
adult,4741,O
brain,4741,O
and,4741,O
in,4741,O
placenta,4741,O
.,4741,O
Both,4742,O
genes,4742,O
are,4742,O
intronless,4742,O
with,4742,O
tandem,4742,O
direct,4742,O
repeat,4742,O
sequences,4742,O
contained,4742,O
within,4742,O
a,4742,O
CpG,4742,O
island,4742,O
in,4742,O
the,4742,O
5-untranscribed,4742,O
region,4742,O
.,4742,O
The,4743,O
transcripts,4743,O
encode,4743,O
putative,4743,O
proteins,4743,O
that,4743,O
are,4743,O
homologous,4743,O
to,4743,O
the,4743,O
MAGE,4743,O
proteins,4743,O
and,4743,O
NDN,4743,O
.,4743,O
Moreover,4744,O
",",4744,O
MAGEL2/Magel2,4744,O
are,4744,O
expressed,4744,O
only,4744,O
from,4744,O
the,4744,O
paternal,4744,O
allele,4744,O
in,4744,O
brain,4744,O
",",4744,O
suggesting,4744,O
a,4744,O
potential,4744,O
role,4744,O
in,4744,O
the,4744,O
aetiology,4744,O
of,4744,O
PWS,4744,B-SpecificDisease
and,4744,O
its,4744,O
mouse,4744,O
model,4744,O
",",4744,O
respectively,4744,O
..,4744,O
cDNA,4745,O
microarrays,4745,O
detect,4745,O
activation,4745,O
of,4745,O
a,4745,O
myogenic,4745,O
transcription,4745,O
program,4745,O
by,4745,O
the,4745,O
PAX3-FKHR,4745,O
fusion,4745,O
oncogene,4745,O
.,4745,O
Alveolar,4746,B-SpecificDisease
rhabdomyosarcoma,4746,I-SpecificDisease
is,4746,O
an,4746,O
aggressive,4746,O
pediatric,4746,B-SpecificDisease
cancer,4746,I-SpecificDisease
of,4746,I-SpecificDisease
striated,4746,I-SpecificDisease
muscle,4746,I-SpecificDisease
characterized,4746,O
in,4746,O
60,4746,O
%,4746,O
of,4746,O
cases,4746,O
by,4746,O
a,4746,O
t,4746,O
(,4746,O
2,4746,O
;,4746,O
13,4746,O
),4746,O
(,4746,O
q35,4746,O
;,4746,O
q14,4746,O
),4746,O
.,4746,O
This,4747,O
results,4747,O
in,4747,O
the,4747,O
fusion,4747,O
of,4747,O
PAX3,4747,O
",",4747,O
a,4747,O
developmental,4747,O
transcription,4747,O
factor,4747,O
required,4747,O
for,4747,O
limb,4747,O
myogenesis,4747,O
",",4747,O
with,4747,O
FKHR,4747,O
",",4747,O
a,4747,O
member,4747,O
of,4747,O
the,4747,O
forkhead,4747,O
family,4747,O
of,4747,O
transcription,4747,O
factors,4747,O
.,4747,O
The,4748,O
resultant,4748,O
PAX3-FKHR,4748,O
gene,4748,O
possesses,4748,O
transforming,4748,O
properties,4748,O
;,4748,O
however,4748,O
",",4748,O
the,4748,O
effects,4748,O
of,4748,O
this,4748,O
chimeric,4748,O
oncogene,4748,O
on,4748,O
gene,4748,O
expression,4748,O
are,4748,O
largely,4748,O
unknown,4748,O
.,4748,O
To,4749,O
investigate,4749,O
the,4749,O
actions,4749,O
of,4749,O
these,4749,O
transcription,4749,O
factors,4749,O
",",4749,O
both,4749,O
Pax3,4749,O
and,4749,O
PAX3-FKHR,4749,O
were,4749,O
introduced,4749,O
into,4749,O
NIH,4749,O
3T3,4749,O
cells,4749,O
",",4749,O
and,4749,O
the,4749,O
resultant,4749,O
gene,4749,O
expression,4749,O
changes,4749,O
were,4749,O
analyzed,4749,O
with,4749,O
a,4749,O
murine,4749,O
cDNA,4749,O
microarray,4749,O
containing,4749,O
2,4749,O
",",4749,O
225,4749,O
elements,4749,O
.,4749,O
We,4750,O
found,4750,O
that,4750,O
PAX3-FKHR,4750,O
but,4750,O
not,4750,O
PAX3,4750,O
activated,4750,O
a,4750,O
myogenic,4750,O
transcription,4750,O
program,4750,O
including,4750,O
the,4750,O
induction,4750,O
of,4750,O
transcription,4750,O
factors,4750,O
MyoD,4750,O
",",4750,O
Myogenin,4750,O
",",4750,O
Six1,4750,O
",",4750,O
and,4750,O
Slug,4750,O
as,4750,O
well,4750,O
as,4750,O
a,4750,O
battery,4750,O
of,4750,O
genes,4750,O
involved,4750,O
in,4750,O
several,4750,O
aspects,4750,O
of,4750,O
muscle,4750,O
function,4750,O
.,4750,O
Notable,4751,O
among,4751,O
this,4751,O
group,4751,O
were,4751,O
the,4751,O
growth,4751,O
factor,4751,O
gene,4751,O
Igf2,4751,O
and,4751,O
its,4751,O
binding,4751,O
protein,4751,O
Igfbp5,4751,O
.,4751,O
Relevance,4752,O
of,4752,O
this,4752,O
model,4752,O
was,4752,O
suggested,4752,O
by,4752,O
verification,4752,O
that,4752,O
three,4752,O
of,4752,O
these,4752,O
genes,4752,O
(,4752,O
IGFBP5,4752,O
",",4752,O
HSIX1,4752,O
",",4752,O
and,4752,O
Slug,4752,O
),4752,O
were,4752,O
also,4752,O
expressed,4752,O
in,4752,O
alveolar,4752,B-Modifier
rhabdomyosarcoma,4752,I-Modifier
cell,4752,O
lines,4752,O
.,4752,O
This,4753,O
study,4753,O
utilizes,4753,O
cDNA,4753,O
microarrays,4753,O
to,4753,O
elucidate,4753,O
the,4753,O
pattern,4753,O
of,4753,O
gene,4753,O
expression,4753,O
induced,4753,O
by,4753,O
an,4753,O
oncogenic,4753,O
transcription,4753,O
factor,4753,O
and,4753,O
demonstrates,4753,O
the,4753,O
profound,4753,O
myogenic,4753,O
properties,4753,O
of,4753,O
PAX3-FKHR,4753,O
in,4753,O
NIH,4753,O
3T3,4753,O
cells,4753,O
..,4753,O
Experimental,4754,O
hemochromatosis,4754,B-SpecificDisease
due,4754,O
to,4754,O
MHC,4754,O
class,4754,O
I,4754,O
HFE,4754,B-SpecificDisease
deficiency,4754,I-SpecificDisease
:,4754,O
immune,4754,O
status,4754,O
and,4754,O
iron,4754,O
metabolism,4754,O
.,4754,O
The,4755,O
puzzling,4755,O
linkage,4755,O
between,4755,O
genetic,4755,O
hemochromatosis,4755,B-SpecificDisease
and,4755,O
histocompatibility,4755,O
loci,4755,O
became,4755,O
even,4755,O
more,4755,O
so,4755,O
when,4755,O
the,4755,O
gene,4755,O
involved,4755,O
",",4755,O
HFE,4755,O
",",4755,O
was,4755,O
identified,4755,O
.,4755,O
Indeed,4756,O
",",4756,O
within,4756,O
the,4756,O
well,4756,O
defined,4756,O
",",4756,O
mainly,4756,O
peptide-binding,4756,O
",",4756,O
MHC,4756,O
class,4756,O
I,4756,O
family,4756,O
of,4756,O
molecules,4756,O
",",4756,O
HFE,4756,O
seems,4756,O
to,4756,O
perform,4756,O
an,4756,O
unusual,4756,O
yet,4756,O
essential,4756,O
function,4756,O
.,4756,O
As,4757,O
yet,4757,O
",",4757,O
our,4757,O
understanding,4757,O
of,4757,O
HFE,4757,O
function,4757,O
in,4757,O
iron,4757,O
homeostasis,4757,O
is,4757,O
only,4757,O
partial,4757,O
;,4757,O
an,4757,O
even,4757,O
more,4757,O
open,4757,O
question,4757,O
is,4757,O
its,4757,O
possible,4757,O
role,4757,O
in,4757,O
the,4757,O
immune,4757,O
system,4757,O
.,4757,O
To,4758,O
advance,4758,O
on,4758,O
both,4758,O
of,4758,O
these,4758,O
avenues,4758,O
",",4758,O
we,4758,O
report,4758,O
the,4758,O
deletion,4758,O
of,4758,O
HFE,4758,O
alpha1,4758,O
and,4758,O
alpha2,4758,O
putative,4758,O
ligand,4758,O
binding,4758,O
domains,4758,O
in,4758,O
vivo,4758,O
.,4758,O
HFE-deficient,4759,B-Modifier
animals,4759,O
were,4759,O
analyzed,4759,O
for,4759,O
a,4759,O
comprehensive,4759,O
set,4759,O
of,4759,O
metabolic,4759,O
and,4759,O
immune,4759,O
parameters,4759,O
.,4759,O
Faithfully,4760,O
mimicking,4760,O
human,4760,O
hemochromatosis,4760,B-SpecificDisease
",",4760,O
mice,4760,O
homozygous,4760,O
for,4760,O
this,4760,O
deletion,4760,O
develop,4760,O
iron,4760,O
overload,4760,O
",",4760,O
characterized,4760,O
by,4760,O
a,4760,O
higher,4760,O
plasma,4760,O
iron,4760,O
content,4760,O
and,4760,O
a,4760,O
raised,4760,O
transferrin,4760,O
saturation,4760,O
as,4760,O
well,4760,O
as,4760,O
an,4760,O
elevated,4760,O
hepatic,4760,O
iron,4760,O
load,4760,O
.,4760,O
The,4761,O
primary,4761,O
defect,4761,O
could,4761,O
",",4761,O
indeed,4761,O
",",4761,O
be,4761,O
traced,4761,O
to,4761,O
an,4761,O
augmented,4761,O
duodenal,4761,O
iron,4761,O
absorption,4761,O
.,4761,O
In,4762,O
parallel,4762,O
",",4762,O
measurement,4762,O
of,4762,O
the,4762,O
gut,4762,O
mucosal,4762,O
iron,4762,O
content,4762,O
as,4762,O
well,4762,O
as,4762,O
iron,4762,O
regulatory,4762,O
proteins,4762,O
allows,4762,O
a,4762,O
more,4762,O
informed,4762,O
evaluation,4762,O
of,4762,O
various,4762,O
hypotheses,4762,O
regarding,4762,O
the,4762,O
precise,4762,O
role,4762,O
of,4762,O
HFE,4762,O
in,4762,O
iron,4762,O
homeostasis,4762,O
.,4762,O
Finally,4763,O
",",4763,O
an,4763,O
extensive,4763,O
phenotyping,4763,O
of,4763,O
primary,4763,O
and,4763,O
secondary,4763,O
lymphoid,4763,O
organs,4763,O
including,4763,O
the,4763,O
gut,4763,O
provides,4763,O
no,4763,O
compelling,4763,O
evidence,4763,O
for,4763,O
an,4763,O
obvious,4763,O
immune-linked,4763,O
function,4763,O
for,4763,O
HFE,4763,O
..,4763,O
Exon,4764,O
9,4764,O
mutations,4764,O
in,4764,O
the,4764,O
WT1,4764,O
gene,4764,O
",",4764,O
without,4764,O
influencing,4764,O
KTS,4764,O
splice,4764,O
isoforms,4764,O
",",4764,O
are,4764,O
also,4764,O
responsible,4764,O
for,4764,O
Frasier,4764,B-SpecificDisease
syndrome,4764,I-SpecificDisease
.,4764,O
We,4765,O
report,4765,O
new,4765,O
mutations,4765,O
in,4765,O
exon,4765,O
9,4765,O
of,4765,O
the,4765,O
WT1,4765,O
gene,4765,O
that,4765,O
did,4765,O
not,4765,O
alter,4765,O
the,4765,O
ratio,4765,O
of,4765,O
+/-,4765,O
KTS,4765,O
splice,4765,O
isoforms,4765,O
in,4765,O
two,4765,O
unrelated,4765,O
patients,4765,O
with,4765,O
Frasier,4765,B-SpecificDisease
syndrome,4765,I-SpecificDisease
(,4765,O
FS,4765,B-SpecificDisease
),4765,O
.,4765,O
The,4766,O
mutation,4766,O
of,4766,O
intron,4766,O
9,4766,O
inducing,4766,O
defective,4766,O
alternative,4766,O
splicing,4766,O
was,4766,O
reported,4766,O
to,4766,O
be,4766,O
responsible,4766,O
for,4766,O
this,4766,O
syndrome,4766,O
.,4766,O
The,4767,O
mutations,4767,O
found,4767,O
in,4767,O
our,4767,O
cases,4767,O
occurred,4767,O
in,4767,O
the,4767,O
same,4767,O
exon,4767,O
of,4767,O
the,4767,O
WT1,4767,O
gene,4767,O
as,4767,O
detected,4767,O
in,4767,O
Denys-Drash,4767,B-SpecificDisease
syndrome,4767,I-SpecificDisease
(,4767,O
DDS,4767,B-SpecificDisease
),4767,O
and,4767,O
could,4767,O
not,4767,O
be,4767,O
explained,4767,O
by,4767,O
the,4767,O
previously,4767,O
proposed,4767,O
mechanism,4767,O
.,4767,O
The,4768,O
results,4768,O
suggest,4768,O
that,4768,O
the,4768,O
two,4768,O
syndromes,4768,O
originate,4768,O
from,4768,O
the,4768,O
same,4768,O
WT1,4768,B-SpecificDisease
gene,4768,I-SpecificDisease
abnormality,4768,I-SpecificDisease
.,4768,O
From,4769,O
a,4769,O
molecular,4769,O
biological,4769,O
point,4769,O
of,4769,O
view,4769,O
",",4769,O
we,4769,O
concluded,4769,O
that,4769,O
the,4769,O
two,4769,O
diseases,4769,O
were,4769,O
not,4769,O
separable,4769,O
",",4769,O
and,4769,O
that,4769,O
FS,4769,B-SpecificDisease
should,4769,O
be,4769,O
included,4769,O
as,4769,O
an,4769,O
atypical,4769,O
form,4769,O
of,4769,O
DDS,4769,B-SpecificDisease
..,4769,O
Splice-site,4770,O
mutation,4770,O
in,4770,O
the,4770,O
PDS,4770,B-Modifier
gene,4770,O
may,4770,O
result,4770,O
in,4770,O
intrafamilial,4770,O
variability,4770,O
for,4770,O
deafness,4770,B-SpecificDisease
in,4770,O
Pendred,4770,B-SpecificDisease
syndrome,4770,I-SpecificDisease
.,4770,O
Pendred,4771,B-SpecificDisease
syndrome,4771,I-SpecificDisease
is,4771,O
a,4771,O
recessive,4771,B-DiseaseClass
inherited,4771,I-DiseaseClass
disorder,4771,I-DiseaseClass
that,4771,O
consists,4771,O
of,4771,O
developmental,4771,B-DiseaseClass
abnormalities,4771,I-DiseaseClass
of,4771,I-DiseaseClass
the,4771,I-DiseaseClass
cochlea,4771,I-DiseaseClass
",",4771,O
sensorineural,4771,B-SpecificDisease
hearing,4771,I-SpecificDisease
loss,4771,I-SpecificDisease
",",4771,O
and,4771,O
diffuse,4771,B-SpecificDisease
thyroid,4771,I-SpecificDisease
enlargement,4771,I-SpecificDisease
(,4771,O
goiter,4771,B-SpecificDisease
),4771,O
.,4771,O
This,4772,O
disorder,4772,O
may,4772,O
account,4772,O
for,4772,O
up,4772,O
to,4772,O
10,4772,O
%,4772,O
of,4772,O
cases,4772,O
of,4772,O
hereditary,4772,B-SpecificDisease
deafness,4772,I-SpecificDisease
.,4772,O
The,4773,O
disease,4773,O
gene,4773,O
(,4773,O
PDS,4773,B-SpecificDisease
),4773,O
has,4773,O
been,4773,O
mapped,4773,O
to,4773,O
chromosome,4773,O
7q22-q31,4773,O
",",4773,O
and,4773,O
encodes,4773,O
a,4773,O
chloride-iodide,4773,O
transport,4773,O
protein,4773,O
.,4773,O
We,4774,O
performed,4774,O
mutation,4774,O
analysis,4774,O
of,4774,O
individual,4774,O
exons,4774,O
of,4774,O
the,4774,O
PDS,4774,B-Modifier
gene,4774,O
in,4774,O
one,4774,O
Spanish,4774,O
family,4774,O
that,4774,O
shows,4774,O
intrafamilial,4774,O
variability,4774,O
of,4774,O
the,4774,O
deafness,4774,B-Modifier
phenotype,4774,O
(,4774,O
two,4774,O
patients,4774,O
with,4774,O
profound,4774,O
and,4774,O
one,4774,O
with,4774,O
moderate-severe,4774,O
deafness,4774,B-SpecificDisease
),4774,O
.,4774,O
We,4775,O
identified,4775,O
a,4775,O
new,4775,O
splice-site,4775,O
mutation,4775,O
affecting,4775,O
intron,4775,O
4,4775,O
of,4775,O
the,4775,O
PDS,4775,B-Modifier
gene,4775,O
",",4775,O
at,4775,O
nucleotide,4775,O
position,4775,O
639,4775,O
+,4775,O
7,4775,O
.,4775,O
RNA,4776,O
analysis,4776,O
from,4776,O
lymphocytes,4776,O
of,4776,O
the,4776,O
affected,4776,O
patients,4776,O
showed,4776,O
that,4776,O
mutation,4776,O
639,4776,O
+,4776,O
7A,4776,O
--,4776,O
>,4776,O
G,4776,O
generates,4776,O
a,4776,O
new,4776,O
donor,4776,O
splice,4776,O
site,4776,O
",",4776,O
leading,4776,O
to,4776,O
an,4776,O
mRNA,4776,O
with,4776,O
an,4776,O
insertion,4776,O
of,4776,O
six,4776,O
nucleotides,4776,O
from,4776,O
intron,4776,O
4,4776,O
of,4776,O
PDS,4776,O
.,4776,O
Since,4777,O
the,4777,O
newly,4777,O
created,4777,O
donor,4777,O
splice,4777,O
site,4777,O
is,4777,O
likely,4777,O
to,4777,O
compete,4777,O
with,4777,O
the,4777,O
normal,4777,O
one,4777,O
",",4777,O
variations,4777,O
of,4777,O
the,4777,O
levels,4777,O
of,4777,O
normal,4777,O
and,4777,O
aberrant,4777,O
transcripts,4777,O
of,4777,O
the,4777,O
PDS,4777,B-Modifier
gene,4777,O
in,4777,O
the,4777,O
cochlea,4777,O
may,4777,O
explain,4777,O
the,4777,O
variability,4777,O
in,4777,O
the,4777,O
deafness,4777,B-Modifier
presentation,4777,O
..,4777,O
The,4778,O
molecular,4778,O
basis,4778,O
of,4778,O
Sjogren-Larsson,4778,B-SpecificDisease
syndrome,4778,I-SpecificDisease
:,4778,O
mutation,4778,O
analysis,4778,O
of,4778,O
the,4778,O
fatty,4778,O
aldehyde,4778,O
dehydrogenase,4778,O
gene,4778,O
.,4778,O
Sjogren-Larsson,4779,B-SpecificDisease
syndrome,4779,I-SpecificDisease
(,4779,O
SLS,4779,B-SpecificDisease
),4779,O
is,4779,O
an,4779,O
autosomal,4779,B-DiseaseClass
recessive,4779,I-DiseaseClass
disorder,4779,I-DiseaseClass
characterized,4779,O
by,4779,O
ichthyosis,4779,B-DiseaseClass
",",4779,O
mental,4779,B-DiseaseClass
retardation,4779,I-DiseaseClass
",",4779,O
spasticity,4779,B-DiseaseClass
",",4779,O
and,4779,O
deficient,4779,B-SpecificDisease
activity,4779,I-SpecificDisease
of,4779,I-SpecificDisease
fatty,4779,I-SpecificDisease
aldehyde,4779,I-SpecificDisease
dehydrogenase,4779,I-SpecificDisease
(,4779,O
FALDH,4779,O
),4779,O
.,4779,O
To,4780,O
define,4780,O
the,4780,O
molecular,4780,O
defects,4780,O
causing,4780,O
SLS,4780,B-SpecificDisease
",",4780,O
we,4780,O
performed,4780,O
mutation,4780,O
analysis,4780,O
of,4780,O
the,4780,O
FALDH,4780,O
gene,4780,O
in,4780,O
probands,4780,O
from,4780,O
63,4780,O
kindreds,4780,O
with,4780,O
SLS,4780,B-SpecificDisease
.,4780,O
Among,4781,O
these,4781,O
patients,4781,O
",",4781,O
49,4781,O
different,4781,O
mutations-including,4781,O
10,4781,O
deletions,4781,O
",",4781,O
2,4781,O
insertions,4781,O
",",4781,O
22,4781,O
amino,4781,O
acid,4781,O
substitutions,4781,O
",",4781,O
3,4781,O
nonsense,4781,O
mutations,4781,O
",",4781,O
9,4781,O
splice-site,4781,O
defects,4781,O
",",4781,O
and,4781,O
3,4781,O
complex,4781,O
mutations-were,4781,O
found,4781,O
.,4781,O
All,4782,O
of,4782,O
the,4782,O
patients,4782,O
with,4782,O
SLS,4782,B-SpecificDisease
were,4782,O
found,4782,O
to,4782,O
carry,4782,O
mutations,4782,O
.,4782,O
Nineteen,4783,O
of,4783,O
the,4783,O
missense,4783,O
mutations,4783,O
resulted,4783,O
in,4783,O
a,4783,O
severe,4783,O
reduction,4783,O
of,4783,O
FALDH,4783,O
enzyme,4783,O
catalytic,4783,O
activity,4783,O
when,4783,O
expressed,4783,O
in,4783,O
mammalian,4783,O
cells,4783,O
",",4783,O
but,4783,O
one,4783,O
mutation,4783,O
(,4783,O
798G,4783,O
--,4783,O
>,4783,O
C,4783,O
[,4783,O
K266N,4783,O
],4783,O
),4783,O
seemed,4783,O
to,4783,O
have,4783,O
a,4783,O
greater,4783,O
effect,4783,O
on,4783,O
mRNA,4783,O
stability,4783,O
.,4783,O
The,4784,O
splice-site,4784,O
mutations,4784,O
led,4784,O
to,4784,O
exon,4784,O
skipping,4784,O
or,4784,O
utilization,4784,O
of,4784,O
cryptic,4784,O
acceptor-splice,4784,O
sites,4784,O
.,4784,O
Thirty-seven,4785,O
mutations,4785,O
were,4785,O
private,4785,O
",",4785,O
and,4785,O
12,4785,O
mutations,4785,O
were,4785,O
seen,4785,O
in,4785,O
two,4785,O
or,4785,O
more,4785,O
probands,4785,O
of,4785,O
European,4785,O
or,4785,O
Middle,4785,O
Eastern,4785,O
descent,4785,O
.,4785,O
Four,4786,O
single-nucleotide,4786,O
polymorphisms,4786,O
(,4786,O
SNPs,4786,O
),4786,O
were,4786,O
found,4786,O
in,4786,O
the,4786,O
FALDH,4786,O
gene,4786,O
.,4786,O
At,4787,O
least,4787,O
four,4787,O
of,4787,O
the,4787,O
common,4787,O
mutations,4787,O
(,4787,O
551C,4787,O
--,4787,O
>,4787,O
T,4787,O
",",4787,O
682C,4787,O
--,4787,O
>,4787,O
T,4787,O
",",4787,O
733G,4787,O
--,4787,O
>,4787,O
A,4787,O
",",4787,O
and,4787,O
798,4787,O
+,4787,O
1delG,4787,O
),4787,O
were,4787,O
associated,4787,O
with,4787,O
multiple,4787,O
SNP,4787,O
haplotypes,4787,O
",",4787,O
suggesting,4787,O
that,4787,O
these,4787,O
mutations,4787,O
originated,4787,O
independently,4787,O
on,4787,O
more,4787,O
than,4787,O
one,4787,O
occasion,4787,O
or,4787,O
were,4787,O
ancient,4787,O
SLS,4787,B-Modifier
genes,4787,O
that,4787,O
had,4787,O
undergone,4787,O
intragenic,4787,O
recombination,4787,O
.,4787,O
Our,4788,O
results,4788,O
demonstrate,4788,O
that,4788,O
SLS,4788,B-SpecificDisease
is,4788,O
caused,4788,O
by,4788,O
a,4788,O
strikingly,4788,O
heterogeneous,4788,O
group,4788,O
of,4788,O
mutations,4788,O
in,4788,O
the,4788,O
FALDH,4788,O
gene,4788,O
and,4788,O
provide,4788,O
a,4788,O
framework,4788,O
for,4788,O
understanding,4788,O
the,4788,O
genetic,4788,O
basis,4788,O
of,4788,O
SLS,4788,B-SpecificDisease
and,4788,O
the,4788,O
development,4788,O
of,4788,O
DNA-based,4788,O
diagnostic,4788,O
tests,4788,O
..,4788,O
Loss-of-function,4789,O
mutations,4789,O
in,4789,O
the,4789,O
cathepsin,4789,O
C,4789,O
gene,4789,O
result,4789,O
in,4789,O
periodontal,4789,B-SpecificDisease
disease,4789,I-SpecificDisease
and,4789,O
palmoplantar,4789,B-DiseaseClass
keratosis,4789,I-DiseaseClass
.,4789,O
Papillon-Lefevre,4790,B-SpecificDisease
syndrome,4790,I-SpecificDisease
",",4790,O
or,4790,O
keratosis,4790,B-DiseaseClass
palmoplantaris,4790,I-DiseaseClass
with,4790,O
periodontopathia,4790,B-SpecificDisease
(,4790,O
PLS,4790,B-SpecificDisease
",",4790,O
MIM,4790,O
245000,4790,O
),4790,O
",",4790,O
is,4790,O
an,4790,O
autosomal,4790,B-DiseaseClass
recessive,4790,I-DiseaseClass
disorder,4790,I-DiseaseClass
that,4790,O
is,4790,O
mainly,4790,O
ascertained,4790,O
by,4790,O
dentists,4790,O
because,4790,O
of,4790,O
the,4790,O
severe,4790,O
periodontitis,4790,B-SpecificDisease
that,4790,O
afflicts,4790,O
patients,4790,O
.,4790,O
Both,4791,O
the,4791,O
deciduous,4791,O
and,4791,O
permanent,4791,O
dentitions,4791,O
are,4791,O
affected,4791,O
",",4791,O
resulting,4791,O
in,4791,O
premature,4791,O
tooth,4791,B-SpecificDisease
loss,4791,I-SpecificDisease
.,4791,O
Palmoplantar,4792,B-DiseaseClass
keratosis,4792,I-DiseaseClass
",",4792,O
varying,4792,O
from,4792,O
mild,4792,O
psoriasiform,4792,O
scaly,4792,O
skin,4792,O
to,4792,O
overt,4792,O
hyperkeratosis,4792,B-SpecificDisease
",",4792,O
typically,4792,O
develops,4792,O
within,4792,O
the,4792,O
first,4792,O
three,4792,O
years,4792,O
of,4792,O
life,4792,O
.,4792,O
Keratosis,4793,B-SpecificDisease
also,4793,O
affects,4793,O
other,4793,O
sites,4793,O
such,4793,O
as,4793,O
elbows,4793,O
and,4793,O
knees,4793,O
.,4793,O
Most,4794,O
PLS,4794,B-Modifier
patients,4794,O
display,4794,O
both,4794,O
periodontitis,4794,B-SpecificDisease
and,4794,O
hyperkeratosis,4794,B-SpecificDisease
.,4794,O
Some,4795,O
patients,4795,O
have,4795,O
only,4795,O
palmoplantar,4795,B-DiseaseClass
keratosis,4795,I-DiseaseClass
or,4795,O
periodontitis,4795,B-SpecificDisease
",",4795,O
and,4795,O
in,4795,O
rare,4795,O
individuals,4795,O
the,4795,O
periodontitis,4795,B-SpecificDisease
is,4795,O
mild,4795,O
and,4795,O
of,4795,O
late,4795,O
onset,4795,O
.,4795,O
The,4796,O
PLS,4796,O
locus,4796,O
has,4796,O
been,4796,O
mapped,4796,O
to,4796,O
chromosome,4796,O
11q14-q21,4796,O
(,4796,O
refs,4796,O
7,4796,O
",",4796,O
8,4796,O
",",4796,O
9,4796,O
),4796,O
.,4796,O
Using,4797,O
homozygosity,4797,O
mapping,4797,O
in,4797,O
eight,4797,O
small,4797,O
consanguineous,4797,O
families,4797,O
",",4797,O
we,4797,O
have,4797,O
narrowed,4797,O
the,4797,O
candidate,4797,O
region,4797,O
to,4797,O
a,4797,O
1,4797,O
.,4797,O
2-cM,4798,O
interval,4798,O
between,4798,O
D11S4082,4798,O
and,4798,O
D11S931,4798,O
.,4798,O
The,4799,O
gene,4799,O
(,4799,O
CTSC,4799,O
),4799,O
encoding,4799,O
the,4799,O
lysosomal,4799,O
protease,4799,O
cathepsin,4799,O
C,4799,O
(,4799,O
or,4799,O
dipeptidyl,4799,O
aminopeptidase,4799,O
I,4799,O
),4799,O
lies,4799,O
within,4799,O
this,4799,O
interval,4799,O
.,4799,O
We,4800,O
defined,4800,O
the,4800,O
genomic,4800,O
structure,4800,O
of,4800,O
CTSC,4800,O
and,4800,O
found,4800,O
mutations,4800,O
in,4800,O
all,4800,O
eight,4800,O
families,4800,O
.,4800,O
In,4801,O
two,4801,O
of,4801,O
these,4801,O
families,4801,O
we,4801,O
used,4801,O
a,4801,O
functional,4801,O
assay,4801,O
to,4801,O
demonstrate,4801,O
an,4801,O
almost,4801,O
total,4801,O
loss,4801,O
of,4801,O
cathepsin,4801,O
C,4801,O
activity,4801,O
in,4801,O
PLS,4801,B-Modifier
patients,4801,O
and,4801,O
reduced,4801,O
activity,4801,O
in,4801,O
obligate,4801,O
carriers,4801,O
.,4801,O
Confirmation,4802,O
of,4802,O
linkage,4802,O
of,4802,O
Van,4802,B-SpecificDisease
der,4802,I-SpecificDisease
Woude,4802,I-SpecificDisease
syndrome,4802,I-SpecificDisease
to,4802,O
chromosome,4802,O
1q32,4802,O
:,4802,O
evidence,4802,O
of,4802,O
association,4802,O
with,4802,O
STR,4802,O
alleles,4802,O
suggests,4802,O
possible,4802,O
unique,4802,O
origin,4802,O
of,4802,O
the,4802,O
disease,4802,O
mutation,4802,O
.,4802,O
Van,4803,B-SpecificDisease
der,4803,I-SpecificDisease
Woude,4803,I-SpecificDisease
syndrome,4803,I-SpecificDisease
(,4803,O
VWS,4803,B-SpecificDisease
),4803,O
is,4803,O
an,4803,O
autosomal,4803,B-DiseaseClass
dominant,4803,I-DiseaseClass
craniofacial,4803,I-DiseaseClass
disorder,4803,I-DiseaseClass
with,4803,O
high,4803,O
penetrance,4803,O
and,4803,O
variable,4803,O
expression,4803,O
.,4803,O
Its,4804,O
clinical,4804,O
features,4804,O
are,4804,O
variably,4804,O
expressed,4804,O
",",4804,O
but,4804,O
include,4804,O
cleft,4804,B-SpecificDisease
lip,4804,I-SpecificDisease
and/or,4804,O
cleft,4804,B-SpecificDisease
palate,4804,I-SpecificDisease
",",4804,O
lip,4804,B-SpecificDisease
pits,4804,I-SpecificDisease
and,4804,O
hypodontia,4804,B-SpecificDisease
.,4804,O
All,4805,O
VWS,4805,B-Modifier
families,4805,O
studied,4805,O
to,4805,O
date,4805,O
map,4805,O
the,4805,O
disease,4805,O
gene,4805,O
to,4805,O
a,4805,O
<,4805,O
2,4805,O
cM,4805,O
region,4805,O
of,4805,O
chromosome,4805,O
1q32,4805,O
",",4805,O
with,4805,O
no,4805,O
evidence,4805,O
of,4805,O
locus,4805,O
heterogeneity,4805,O
.,4805,O
The,4806,O
aim,4806,O
of,4806,O
this,4806,O
study,4806,O
is,4806,O
to,4806,O
refine,4806,O
the,4806,O
localization,4806,O
of,4806,O
the,4806,O
VWS,4806,B-Modifier
gene,4806,O
and,4806,O
to,4806,O
further,4806,O
assess,4806,O
possible,4806,O
heterogeneity,4806,O
.,4806,O
We,4807,O
analyzed,4807,O
four,4807,O
multiplex,4807,O
VWS,4807,B-Modifier
families,4807,O
.,4807,O
All,4808,O
available,4808,O
members,4808,O
were,4808,O
clinically,4808,O
assessed,4808,O
and,4808,O
genotyped,4808,O
for,4808,O
19,4808,O
short,4808,O
tandem,4808,O
repeat,4808,O
markers,4808,O
on,4808,O
chromosome,4808,O
1,4808,O
in,4808,O
the,4808,O
VWS,4808,B-Modifier
candidate,4808,O
gene,4808,O
region,4808,O
.,4808,O
We,4809,O
performed,4809,O
two-point,4809,O
and,4809,O
multipoint,4809,O
limit,4809,O
of,4809,O
detection,4809,O
(,4809,O
LOD,4809,O
),4809,O
score,4809,O
analyses,4809,O
using,4809,O
a,4809,O
high,4809,O
penetrance,4809,O
autosomal,4809,O
dominant,4809,O
model,4809,O
.,4809,O
All,4810,O
families,4810,O
showed,4810,O
positive,4810,O
LOD,4810,O
scores,4810,O
without,4810,O
any,4810,O
recombination,4810,O
in,4810,O
the,4810,O
candidate,4810,O
region,4810,O
.,4810,O
The,4811,O
largest,4811,O
two-point,4811,O
LOD,4811,O
score,4811,O
was,4811,O
5,4811,O
.,4811,O
87,4812,O
87,4812,O
.,4812,O
Our,4813,O
assay,4813,O
method,4813,O
for,4813,O
short,4813,O
tandem,4813,O
repeat,4813,O
(,4813,O
STR,4813,O
),4813,O
markers,4813,O
provided,4813,O
highly,4813,O
accurate,4813,O
size,4813,O
estimation,4813,O
of,4813,O
marker,4813,O
allele,4813,O
fragment,4813,O
sizes,4813,O
",",4813,O
and,4813,O
therefore,4813,O
enabled,4813,O
us,4813,O
to,4813,O
determine,4813,O
the,4813,O
specific,4813,O
alleles,4813,O
segregating,4813,O
with,4813,O
the,4813,O
VWS,4813,B-Modifier
gene,4813,O
in,4813,O
each,4813,O
of,4813,O
our,4813,O
four,4813,O
families,4813,O
.,4813,O
We,4814,O
observed,4814,O
a,4814,O
striking,4814,O
pattern,4814,O
of,4814,O
STR,4814,O
allele,4814,O
sharing,4814,O
at,4814,O
several,4814,O
closely,4814,O
linked,4814,O
loci,4814,O
among,4814,O
our,4814,O
four,4814,O
Caucasian,4814,O
VWS,4814,B-Modifier
families,4814,O
recruited,4814,O
at,4814,O
three,4814,O
different,4814,O
locations,4814,O
in,4814,O
the,4814,O
US,4814,O
.,4814,O
These,4815,O
results,4815,O
suggest,4815,O
the,4815,O
possibility,4815,O
of,4815,O
a,4815,O
unique,4815,O
origin,4815,O
for,4815,O
a,4815,O
mutation,4815,O
responsible,4815,O
for,4815,O
many,4815,O
or,4815,O
most,4815,O
cases,4815,O
of,4815,O
VWS,4815,B-SpecificDisease
.,4815,O
A,4816,O
point,4816,O
mutation,4816,O
Thr,4816,O
(,4816,O
799,4816,O
),4816,O
Met,4816,O
on,4816,O
the,4816,O
alpha,4816,O
(,4816,O
2,4816,O
),4816,O
integrin,4816,O
leads,4816,O
to,4816,O
the,4816,O
formation,4816,O
of,4816,O
new,4816,O
human,4816,O
platelet,4816,O
alloantigen,4816,O
Sit,4816,O
(,4816,O
a,4816,O
),4816,O
and,4816,O
affects,4816,O
collagen-induced,4816,O
aggregation,4816,O
.,4816,O
A,4817,O
new,4817,O
platelet-specific,4817,O
alloantigen,4817,O
",",4817,O
termed,4817,O
Sit,4817,O
(,4817,O
a,4817,O
),4817,O
",",4817,O
was,4817,O
identified,4817,O
in,4817,O
a,4817,O
severe,4817,O
case,4817,O
of,4817,O
neonatal,4817,B-SpecificDisease
alloimmune,4817,I-SpecificDisease
thrombocytopenia,4817,I-SpecificDisease
.,4817,O
The,4818,O
Sit,4818,O
(,4818,O
a,4818,O
),4818,O
alloantigen,4818,O
is,4818,O
of,4818,O
low,4818,O
frequency,4818,O
(,4818,O
1/400,4818,O
),4818,O
in,4818,O
the,4818,O
German,4818,O
population,4818,O
.,4818,O
Immunochemical,4819,O
studies,4819,O
demonstrated,4819,O
that,4819,O
the,4819,O
Sit,4819,O
(,4819,O
a,4819,O
),4819,O
epitopes,4819,O
reside,4819,O
on,4819,O
platelet,4819,O
glycoprotein,4819,O
(,4819,O
GP,4819,O
),4819,O
Ia,4819,O
.,4819,O
Nucleotide,4820,O
sequence,4820,O
analysis,4820,O
of,4820,O
GPIa,4820,O
cDNA,4820,O
derived,4820,O
from,4820,O
Sit,4820,O
(,4820,O
a,4820,O
),4820,O
-positive,4820,O
platelets,4820,O
showed,4820,O
C,4820,O
(,4820,O
2531,4820,O
),4820,O
--,4820,O
>,4820,O
T,4820,O
(,4820,O
2531,4820,O
),4820,O
point,4820,O
mutation,4820,O
",",4820,O
resulting,4820,O
in,4820,O
Thr,4820,O
(,4820,O
799,4820,O
),4820,O
Met,4820,O
dimorphism,4820,O
.,4820,O
Analysis,4821,O
of,4821,O
genomic,4821,O
DNA,4821,O
from,4821,O
22,4821,O
Sit,4821,O
(,4821,O
a,4821,O
),4821,O
-negative,4821,O
normal,4821,O
individuals,4821,O
showed,4821,O
that,4821,O
the,4821,O
Thr,4821,O
(,4821,O
799,4821,O
),4821,O
is,4821,O
encoded,4821,O
by,4821,O
ACG,4821,O
(,4821,O
2532,4821,O
),4821,O
(,4821,O
90,4821,O
.,4821,O
9,4822,O
%,4822,O
),4822,O
or,4822,O
ACA,4822,O
(,4822,O
2532,4822,O
),4822,O
(,4822,O
9,4822,O
.,4822,O
1,4823,O
%,4823,O
),4823,O
.,4823,O
To,4824,O
establish,4824,O
a,4824,O
DNA,4824,O
typing,4824,O
technique,4824,O
",",4824,O
we,4824,O
elucidated,4824,O
the,4824,O
organization,4824,O
of,4824,O
the,4824,O
GPIa,4824,O
gene,4824,O
adjacent,4824,O
to,4824,O
the,4824,O
polymorphic,4824,O
bases,4824,O
.,4824,O
The,4825,O
introns,4825,O
(,4825,O
421,4825,O
bp,4825,O
and,4825,O
1,4825,O
.,4825,O
2,4826,O
kb,4826,O
),4826,O
encompass,4826,O
a,4826,O
142-bp,4826,O
exon,4826,O
with,4826,O
the,4826,O
2,4826,O
polymorphic,4826,O
bases,4826,O
2531,4826,O
and,4826,O
2532,4826,O
.,4826,O
Polymerase,4827,O
chain,4827,O
reaction-restriction,4827,O
fragment,4827,O
length,4827,O
polymorphism,4827,O
analysis,4827,O
on,4827,O
DNA,4827,O
derived,4827,O
from,4827,O
100,4827,O
donors,4827,O
using,4827,O
the,4827,O
restriction,4827,O
enzyme,4827,O
Mae,4827,O
III,4827,O
showed,4827,O
that,4827,O
the,4827,O
Met,4827,O
(,4827,O
799,4827,O
),4827,O
form,4827,O
of,4827,O
GPIa,4827,O
is,4827,O
restricted,4827,O
to,4827,O
Sit,4827,O
(,4827,O
a,4827,O
),4827,O
(,4827,O
+,4827,O
),4827,O
phenotype,4827,O
.,4827,O
Analysis,4828,O
of,4828,O
stable,4828,O
Chinese,4828,O
hamster,4828,O
ovary,4828,O
transfectants,4828,O
expressing,4828,O
allele-specific,4828,O
recombinant,4828,O
forms,4828,O
of,4828,O
GPIa,4828,O
showed,4828,O
that,4828,O
anti-Sit,4828,O
(,4828,O
a,4828,O
),4828,O
exclusively,4828,O
reacted,4828,O
with,4828,O
the,4828,O
Glu,4828,O
(,4828,O
505,4828,O
),4828,O
Met,4828,O
(,4828,O
799,4828,O
),4828,O
",",4828,O
but,4828,O
not,4828,O
with,4828,O
the,4828,O
Glu,4828,O
(,4828,O
505,4828,O
),4828,O
Thr,4828,O
(,4828,O
799,4828,O
),4828,O
and,4828,O
the,4828,O
Lys,4828,O
(,4828,O
505,4828,O
),4828,O
Thr,4828,O
(,4828,O
799,4828,O
),4828,O
isoforms,4828,O
.,4828,O
In,4829,O
contrast,4829,O
",",4829,O
anti-Br,4829,O
(,4829,O
a,4829,O
),4829,O
(,4829,O
HPA-5b,4829,O
),4829,O
only,4829,O
recognized,4829,O
the,4829,O
Lys,4829,O
(,4829,O
505,4829,O
),4829,O
Thr,4829,O
(,4829,O
799,4829,O
),4829,O
form,4829,O
",",4829,O
whereas,4829,O
anti-Br,4829,O
(,4829,O
b,4829,O
),4829,O
(,4829,O
HPA-5a,4829,O
),4829,O
reacted,4829,O
with,4829,O
both,4829,O
Glu,4829,O
(,4829,O
505,4829,O
),4829,O
Thr,4829,O
(,4829,O
799,4829,O
),4829,O
and,4829,O
Glu,4829,O
(,4829,O
505,4829,O
),4829,O
Met,4829,O
(,4829,O
799,4829,O
),4829,O
isoforms,4829,O
.,4829,O
These,4830,O
results,4830,O
demonstrated,4830,O
that,4830,O
the,4830,O
Met,4830,O
(,4830,O
799,4830,O
),4830,O
is,4830,O
responsible,4830,O
for,4830,O
formation,4830,O
of,4830,O
the,4830,O
Sit,4830,O
(,4830,O
a,4830,O
),4830,O
alloantigenic,4830,O
determinants,4830,O
",",4830,O
whereas,4830,O
amino,4830,O
acid,4830,O
505,4830,O
(,4830,O
Lys,4830,O
or,4830,O
Glu,4830,O
),4830,O
specifically,4830,O
controls,4830,O
the,4830,O
expression,4830,O
of,4830,O
Br,4830,O
(,4830,O
a,4830,O
),4830,O
and,4830,O
Br,4830,O
(,4830,O
b,4830,O
),4830,O
epitopes,4830,O
",",4830,O
respectively,4830,O
.,4830,O
Platelet,4831,O
aggregation,4831,O
responses,4831,O
of,4831,O
Sit,4831,O
(,4831,O
a,4831,O
),4831,O
(,4831,O
+,4831,O
),4831,O
individuals,4831,O
were,4831,O
diminished,4831,O
in,4831,O
response,4831,O
to,4831,O
collagen,4831,O
",",4831,O
indicating,4831,O
that,4831,O
the,4831,O
Thr,4831,O
(,4831,O
799,4831,O
),4831,O
Met,4831,O
mutation,4831,O
affects,4831,O
the,4831,O
function,4831,O
of,4831,O
the,4831,O
GPIa/IIa,4831,O
complex,4831,O
Mutations,4832,O
of,4832,O
the,4832,O
cathepsin,4832,O
C,4832,O
gene,4832,O
are,4832,O
responsible,4832,O
for,4832,O
Papillon-Lefevre,4832,B-SpecificDisease
syndrome,4832,I-SpecificDisease
.,4832,O
Papillon-Lefevre,4833,B-SpecificDisease
syndrome,4833,I-SpecificDisease
(,4833,O
PLS,4833,B-SpecificDisease
),4833,O
is,4833,O
an,4833,O
autosomal,4833,B-DiseaseClass
recessive,4833,I-DiseaseClass
disorder,4833,I-DiseaseClass
characterised,4833,O
by,4833,O
palmoplantar,4833,B-SpecificDisease
hyperkeratosis,4833,I-SpecificDisease
and,4833,O
severe,4833,O
early,4833,O
onset,4833,O
periodontitis,4833,B-SpecificDisease
that,4833,O
results,4833,O
in,4833,O
the,4833,O
premature,4833,O
loss,4833,O
of,4833,O
the,4833,O
primary,4833,O
and,4833,O
secondary,4833,O
dentitions,4833,O
.,4833,O
A,4834,O
major,4834,O
gene,4834,O
locus,4834,O
for,4834,O
PLS,4834,B-SpecificDisease
has,4834,O
been,4834,O
mapped,4834,O
to,4834,O
a,4834,O
2,4834,O
.,4834,O
8,4835,O
cM,4835,O
interval,4835,O
on,4835,O
chromosome,4835,O
11q14,4835,O
.,4835,O
Correlation,4836,O
of,4836,O
physical,4836,O
and,4836,O
genetic,4836,O
maps,4836,O
of,4836,O
this,4836,O
interval,4836,O
indicate,4836,O
it,4836,O
includes,4836,O
at,4836,O
least,4836,O
40,4836,O
ESTs,4836,O
and,4836,O
six,4836,O
known,4836,O
genes,4836,O
including,4836,O
the,4836,O
lysosomal,4836,O
protease,4836,O
cathepsin,4836,O
C,4836,O
gene,4836,O
(,4836,O
CTSC,4836,O
),4836,O
.,4836,O
The,4837,O
CTSC,4837,O
message,4837,O
is,4837,O
expressed,4837,O
at,4837,O
high,4837,O
levels,4837,O
in,4837,O
a,4837,O
variety,4837,O
of,4837,O
immune,4837,O
cells,4837,O
including,4837,O
polymorphonuclear,4837,O
leucocytes,4837,O
",",4837,O
macrophages,4837,O
",",4837,O
and,4837,O
their,4837,O
precursors,4837,O
.,4837,O
By,4838,O
RT-PCR,4838,O
",",4838,O
we,4838,O
found,4838,O
CTSC,4838,O
is,4838,O
also,4838,O
expressed,4838,O
in,4838,O
epithelial,4838,O
regions,4838,O
commonly,4838,O
affected,4838,O
by,4838,O
PLS,4838,B-SpecificDisease
",",4838,O
including,4838,O
the,4838,O
palms,4838,O
",",4838,O
soles,4838,O
",",4838,O
knees,4838,O
",",4838,O
and,4838,O
oral,4838,O
keratinised,4838,O
gingiva,4838,O
.,4838,O
The,4839,O
4,4839,O
.,4839,O
7,4840,O
kb,4840,O
CTSC,4840,O
gene,4840,O
consists,4840,O
of,4840,O
two,4840,O
exons,4840,O
.,4840,O
Sequence,4841,O
analysis,4841,O
of,4841,O
CTSC,4841,O
from,4841,O
subjects,4841,O
affected,4841,O
with,4841,O
PLS,4841,B-SpecificDisease
from,4841,O
five,4841,O
consanguineous,4841,O
Turkish,4841,O
families,4841,O
identified,4841,O
four,4841,O
different,4841,O
mutations,4841,O
.,4841,O
An,4842,O
exon,4842,O
1,4842,O
nonsense,4842,O
mutation,4842,O
(,4842,O
856C,4842,O
--,4842,O
>,4842,O
T,4842,O
),4842,O
introduces,4842,O
a,4842,O
premature,4842,O
stop,4842,O
codon,4842,O
at,4842,O
amino,4842,O
acid,4842,O
286,4842,O
.,4842,O
Three,4843,O
exon,4843,O
2,4843,O
mutations,4843,O
were,4843,O
identified,4843,O
",",4843,O
including,4843,O
a,4843,O
single,4843,O
nucleotide,4843,O
deletion,4843,O
(,4843,O
2692delA,4843,O
),4843,O
of,4843,O
codon,4843,O
349,4843,O
introducing,4843,O
a,4843,O
frameshift,4843,O
and,4843,O
premature,4843,O
termination,4843,O
codon,4843,O
",",4843,O
a,4843,O
2,4843,O
bp,4843,O
deletion,4843,O
(,4843,O
2673-2674delCT,4843,O
),4843,O
that,4843,O
results,4843,O
in,4843,O
introduction,4843,O
of,4843,O
a,4843,O
stop,4843,O
codon,4843,O
at,4843,O
amino,4843,O
acid,4843,O
343,4843,O
",",4843,O
and,4843,O
a,4843,O
G,4843,O
--,4843,O
>,4843,O
A,4843,O
substitution,4843,O
in,4843,O
codon,4843,O
429,4843,O
(,4843,O
2931G,4843,O
--,4843,O
>,4843,O
A,4843,O
),4843,O
introducing,4843,O
a,4843,O
premature,4843,O
termination,4843,O
codon,4843,O
.,4843,O
All,4844,O
PLS,4844,B-Modifier
patients,4844,O
were,4844,O
homozygous,4844,O
for,4844,O
cathepsin,4844,O
C,4844,O
mutations,4844,O
inherited,4844,O
from,4844,O
a,4844,O
common,4844,O
ancestor,4844,O
.,4844,O
Parents,4845,O
and,4845,O
sibs,4845,O
heterozygous,4845,O
for,4845,O
cathepsin,4845,O
C,4845,O
mutations,4845,O
do,4845,O
not,4845,O
show,4845,O
either,4845,O
the,4845,O
palmoplantar,4845,B-SpecificDisease
hyperkeratosis,4845,I-SpecificDisease
or,4845,O
severe,4845,O
early,4845,O
onset,4845,O
periodontitis,4845,B-SpecificDisease
characteristic,4845,O
of,4845,O
PLS,4845,B-SpecificDisease
.,4845,O
A,4846,O
more,4846,O
complete,4846,O
understanding,4846,O
of,4846,O
the,4846,O
functional,4846,O
physiology,4846,O
of,4846,O
cathepsin,4846,O
C,4846,O
carries,4846,O
significant,4846,O
implications,4846,O
for,4846,O
understanding,4846,O
normal,4846,O
and,4846,O
abnormal,4846,O
skin,4846,O
development,4846,O
and,4846,O
periodontal,4846,B-Modifier
disease,4846,I-Modifier
susceptibility,4846,O
Mutational,4847,O
analysis,4847,O
of,4847,O
the,4847,O
HGO,4847,O
gene,4847,O
in,4847,O
Finnish,4847,O
alkaptonuria,4847,B-Modifier
patients,4847,O
.,4847,O
Alkaptonuria,4848,B-SpecificDisease
(,4848,O
AKU,4848,B-SpecificDisease
),4848,O
",",4848,O
the,4848,O
prototypic,4848,O
inborn,4848,B-DiseaseClass
error,4848,I-DiseaseClass
of,4848,I-DiseaseClass
metabolism,4848,I-DiseaseClass
",",4848,O
has,4848,O
recently,4848,O
been,4848,O
shown,4848,O
to,4848,O
be,4848,O
caused,4848,O
by,4848,O
loss,4848,O
of,4848,O
function,4848,O
mutations,4848,O
in,4848,O
the,4848,O
homogentisate-1,4848,O
",",4848,O
2-dioxygenase,4848,O
gene,4848,O
(,4848,O
HGO,4848,O
),4848,O
.,4848,O
So,4849,O
far,4849,O
17,4849,O
mutations,4849,O
have,4849,O
been,4849,O
characterised,4849,O
in,4849,O
AKU,4849,B-Modifier
patients,4849,O
of,4849,O
different,4849,O
ethnic,4849,O
origin,4849,O
.,4849,O
We,4850,O
describe,4850,O
three,4850,O
novel,4850,O
mutations,4850,O
(,4850,O
R58fs,4850,O
",",4850,O
R330S,4850,O
",",4850,O
and,4850,O
H371R,4850,O
),4850,O
and,4850,O
one,4850,O
common,4850,O
AKU,4850,B-Modifier
mutation,4850,O
(,4850,O
M368V,4850,O
),4850,O
",",4850,O
detected,4850,O
by,4850,O
mutational,4850,O
and,4850,O
polymorphism,4850,O
analysis,4850,O
of,4850,O
the,4850,O
HGO,4850,O
gene,4850,O
in,4850,O
five,4850,O
Finnish,4850,O
AKU,4850,B-Modifier
pedigrees,4850,O
.,4850,O
The,4851,O
three,4851,O
novel,4851,O
AKU,4851,B-Modifier
mutations,4851,O
are,4851,O
most,4851,O
likely,4851,O
specific,4851,O
for,4851,O
the,4851,O
Finnish,4851,O
population,4851,O
and,4851,O
have,4851,O
originated,4851,O
recently,4851,O
..,4851,O
The,4852,O
identical,4852,O
5,4852,O
',4852,O
splice-site,4852,O
acceptor,4852,O
mutation,4852,O
in,4852,O
five,4852,O
attenuated,4852,B-Modifier
APC,4852,I-Modifier
families,4852,O
from,4852,O
Newfoundland,4852,O
demonstrates,4852,O
a,4852,O
founder,4852,O
effect,4852,O
.,4852,O
Inherited,4853,O
mutations,4853,O
of,4853,O
the,4853,O
APC,4853,B-Modifier
gene,4853,O
predispose,4853,O
carriers,4853,O
to,4853,O
multiple,4853,O
adenomatous,4853,B-CompositeMention
polyps,4853,I-CompositeMention
of,4853,I-CompositeMention
the,4853,I-CompositeMention
colon,4853,I-CompositeMention
and,4853,I-CompositeMention
rectum,4853,I-CompositeMention
and,4853,O
to,4853,O
colorectal,4853,B-SpecificDisease
cancer,4853,I-SpecificDisease
.,4853,O
Mutations,4854,O
located,4854,O
at,4854,O
the,4854,O
extreme,4854,O
5,4854,O
end,4854,O
of,4854,O
the,4854,O
APC,4854,B-Modifier
gene,4854,O
",",4854,O
however,4854,O
",",4854,O
are,4854,O
associated,4854,O
with,4854,O
a,4854,O
less,4854,O
severe,4854,O
disease,4854,O
known,4854,O
as,4854,O
attenuated,4854,B-SpecificDisease
adenomatous,4854,I-SpecificDisease
polyposis,4854,I-SpecificDisease
coli,4854,I-SpecificDisease
(,4854,O
AAPC,4854,B-SpecificDisease
),4854,O
.,4854,O
Many,4855,O
individuals,4855,O
with,4855,O
AAPC,4855,B-SpecificDisease
develop,4855,O
relatively,4855,O
few,4855,O
colorectal,4855,B-SpecificDisease
polyps,4855,I-SpecificDisease
but,4855,O
are,4855,O
still,4855,O
at,4855,O
high,4855,O
risk,4855,O
for,4855,O
colorectal,4855,B-SpecificDisease
cancer,4855,I-SpecificDisease
.,4855,O
We,4856,O
report,4856,O
here,4856,O
the,4856,O
identification,4856,O
of,4856,O
a,4856,O
5,4856,O
APC,4856,B-Modifier
germline,4856,O
mutation,4856,O
in,4856,O
five,4856,O
separately,4856,O
ascertained,4856,O
AAPC,4856,B-Modifier
families,4856,O
from,4856,O
Newfoundland,4856,O
",",4856,O
Canada,4856,O
.,4856,O
This,4857,O
disease-causing,4857,O
mutation,4857,O
is,4857,O
a,4857,O
single,4857,O
basepair,4857,O
change,4857,O
(,4857,O
G,4857,O
to,4857,O
A,4857,O
),4857,O
in,4857,O
the,4857,O
splice-acceptor,4857,O
region,4857,O
of,4857,O
APC,4857,B-Modifier
intron,4857,O
3,4857,O
that,4857,O
creates,4857,O
a,4857,O
mutant,4857,O
RNA,4857,O
without,4857,O
exon,4857,O
4,4857,O
of,4857,O
APC,4857,O
.,4857,O
The,4858,O
observation,4858,O
of,4858,O
the,4858,O
same,4858,O
APC,4858,B-Modifier
mutation,4858,O
in,4858,O
five,4858,O
families,4858,O
from,4858,O
the,4858,O
same,4858,O
geographic,4858,O
area,4858,O
demonstrates,4858,O
a,4858,O
founder,4858,O
effect,4858,O
.,4858,O
Furthermore,4859,O
",",4859,O
the,4859,O
identification,4859,O
of,4859,O
this,4859,O
germline,4859,O
mutation,4859,O
strengthens,4859,O
the,4859,O
correlation,4859,O
between,4859,O
the,4859,O
5,4859,O
location,4859,O
of,4859,O
an,4859,O
APC,4859,B-Modifier
disease-causing,4859,O
mutation,4859,O
and,4859,O
the,4859,O
attenuated,4859,B-Modifier
polyposis,4859,I-Modifier
phenotype,4859,O
..,4859,O
Alstrom,4860,B-SpecificDisease
syndrome,4860,I-SpecificDisease
:,4860,O
further,4860,O
evidence,4860,O
for,4860,O
linkage,4860,O
to,4860,O
human,4860,O
chromosome,4860,O
2p13,4860,O
.,4860,O
Alstrom,4861,B-SpecificDisease
syndrome,4861,I-SpecificDisease
is,4861,O
a,4861,O
rare,4861,O
autosomal,4861,B-DiseaseClass
recessive,4861,I-DiseaseClass
disorder,4861,I-DiseaseClass
characterized,4861,O
by,4861,O
retinal,4861,B-SpecificDisease
degeneration,4861,I-SpecificDisease
",",4861,O
sensorineural,4861,B-SpecificDisease
hearing,4861,I-SpecificDisease
loss,4861,I-SpecificDisease
",",4861,O
early-onset,4861,O
obesity,4861,B-SpecificDisease
",",4861,O
and,4861,O
non-insulin-dependent,4861,B-SpecificDisease
diabetes,4861,I-SpecificDisease
mellitus,4861,I-SpecificDisease
.,4861,O
The,4862,O
gene,4862,O
for,4862,O
Alstrom,4862,B-SpecificDisease
syndrome,4862,I-SpecificDisease
(,4862,O
ALMS1,4862,O
),4862,O
has,4862,O
been,4862,O
previously,4862,O
localized,4862,O
to,4862,O
human,4862,O
chromosome,4862,O
2p13,4862,O
by,4862,O
homozygosity,4862,O
mapping,4862,O
in,4862,O
two,4862,O
distinct,4862,O
isolated,4862,O
populations,4862,O
-,4862,O
French,4862,O
Acadian,4862,O
and,4862,O
North,4862,O
African,4862,O
.,4862,O
Pair-wise,4863,O
analyses,4863,O
resulted,4863,O
in,4863,O
maximum,4863,O
lod,4863,O
(,4863,O
logarithm,4863,O
of,4863,O
the,4863,O
odds,4863,O
ratio,4863,O
),4863,O
scores,4863,O
of,4863,O
3,4863,O
.,4863,O
84,4864,O
and,4864,O
2,4864,O
.,4864,O
9,4865,O
",",4865,O
respectively,4865,O
.,4865,O
To,4866,O
confirm,4866,O
these,4866,O
findings,4866,O
",",4866,O
a,4866,O
large,4866,O
linkage,4866,O
study,4866,O
was,4866,O
performed,4866,O
in,4866,O
twelve,4866,O
additional,4866,O
families,4866,O
segregating,4866,O
for,4866,O
Alstrom,4866,B-SpecificDisease
syndrome,4866,I-SpecificDisease
.,4866,O
A,4867,O
maximum,4867,O
two-point,4867,O
lod,4867,O
score,4867,O
of,4867,O
7,4867,O
.,4867,O
13,4868,O
(,4868,O
theta,4868,O
=,4868,O
0,4868,O
.,4868,O
00,4869,O
),4869,O
for,4869,O
marker,4869,O
D2S2110,4869,O
and,4869,O
a,4869,O
maximum,4869,O
cumulative,4869,O
multipoint,4869,O
lod,4869,O
score,4869,O
of,4869,O
9,4869,O
.,4869,O
16,4870,O
for,4870,O
marker,4870,O
D2S2110,4870,O
were,4870,O
observed,4870,O
",",4870,O
further,4870,O
supporting,4870,O
linkage,4870,O
to,4870,O
chromosome,4870,O
2p13,4870,O
.,4870,O
No,4871,O
evidence,4871,O
of,4871,O
genetic,4871,O
heterogeneity,4871,O
was,4871,O
observed,4871,O
in,4871,O
these,4871,O
families,4871,O
.,4871,O
Meiotic,4872,O
recombination,4872,O
events,4872,O
have,4872,O
localized,4872,O
the,4872,O
critical,4872,O
region,4872,O
containing,4872,O
ALMS1,4872,O
to,4872,O
a,4872,O
6,4872,O
.,4872,O
1-cM,4873,O
interval,4873,O
flanked,4873,O
by,4873,O
markers,4873,O
D2S327,4873,O
and,4873,O
D2S286,4873,O
.,4873,O
A,4874,O
fine,4874,O
resolution,4874,O
radiation,4874,O
hybrid,4874,O
map,4874,O
of,4874,O
31,4874,O
genes,4874,O
and,4874,O
markers,4874,O
has,4874,O
been,4874,O
constructed,4874,O
.,4874,O
Pendred,4875,B-SpecificDisease
syndrome,4875,I-SpecificDisease
:,4875,O
phenotypic,4875,O
variability,4875,O
in,4875,O
two,4875,O
families,4875,O
carrying,4875,O
the,4875,O
same,4875,O
PDS,4875,B-Modifier
missense,4875,O
mutation,4875,O
.,4875,O
Pendred,4876,B-SpecificDisease
syndrome,4876,I-SpecificDisease
comprises,4876,O
congenital,4876,B-SpecificDisease
sensorineural,4876,I-SpecificDisease
hearing,4876,I-SpecificDisease
loss,4876,I-SpecificDisease
",",4876,O
thyroid,4876,B-SpecificDisease
goiter,4876,I-SpecificDisease
",",4876,O
and,4876,O
positive,4876,O
perchlorate,4876,O
discharge,4876,O
test,4876,O
.,4876,O
Recently,4877,O
",",4877,O
this,4877,O
autosomal,4877,B-DiseaseClass
recessive,4877,I-DiseaseClass
disorder,4877,I-DiseaseClass
was,4877,O
shown,4877,O
to,4877,O
be,4877,O
caused,4877,O
by,4877,O
mutations,4877,O
in,4877,O
the,4877,O
PDS,4877,B-Modifier
gene,4877,O
",",4877,O
which,4877,O
encodes,4877,O
an,4877,O
anion,4877,O
transporter,4877,O
called,4877,O
pendrin,4877,O
.,4877,O
Molecular,4878,O
analysis,4878,O
of,4878,O
the,4878,O
PDS,4878,B-Modifier
gene,4878,O
was,4878,O
performed,4878,O
in,4878,O
two,4878,O
consanguineous,4878,O
large,4878,O
families,4878,O
from,4878,O
Southern,4878,O
Tunisia,4878,O
comprising,4878,O
a,4878,O
total,4878,O
of,4878,O
23,4878,O
individuals,4878,O
affected,4878,O
with,4878,O
profound,4878,O
congenital,4878,B-SpecificDisease
deafness,4878,I-SpecificDisease
;,4878,O
the,4878,O
same,4878,O
missense,4878,O
mutation,4878,O
",",4878,O
L445W,4878,O
",",4878,O
was,4878,O
identified,4878,O
in,4878,O
all,4878,O
affected,4878,O
individuals,4878,O
.,4878,O
A,4879,O
widened,4879,B-SpecificDisease
vestibular,4879,I-SpecificDisease
aqueduct,4879,I-SpecificDisease
was,4879,O
found,4879,O
in,4879,O
all,4879,O
patients,4879,O
who,4879,O
underwent,4879,O
computed,4879,O
tomography,4879,O
(,4879,O
CT,4879,O
),4879,O
scan,4879,O
exploration,4879,O
of,4879,O
the,4879,O
inner,4879,O
ear,4879,O
.,4879,O
In,4880,O
contrast,4880,O
",",4880,O
goiter,4880,B-SpecificDisease
was,4880,O
present,4880,O
in,4880,O
only,4880,O
11,4880,O
affected,4880,O
individuals,4880,O
",",4880,O
who,4880,O
interestingly,4880,O
had,4880,O
a,4880,O
normal,4880,O
result,4880,O
of,4880,O
the,4880,O
perchlorate,4880,O
discharge,4880,O
test,4880,O
whenever,4880,O
performed,4880,O
.,4880,O
The,4881,O
present,4881,O
results,4881,O
question,4881,O
the,4881,O
sensitivity,4881,O
of,4881,O
the,4881,O
perchlorate,4881,O
test,4881,O
for,4881,O
the,4881,O
diagnosis,4881,O
of,4881,O
Pendred,4881,B-SpecificDisease
syndrome,4881,I-SpecificDisease
and,4881,O
support,4881,O
the,4881,O
use,4881,O
of,4881,O
a,4881,O
molecular,4881,O
analysis,4881,O
of,4881,O
the,4881,O
PDS,4881,B-Modifier
gene,4881,O
in,4881,O
the,4881,O
assessment,4881,O
of,4881,O
individuals,4881,O
with,4881,O
severe,4881,O
to,4881,O
profound,4881,O
congenital,4881,B-SpecificDisease
hearing,4881,I-SpecificDisease
loss,4881,I-SpecificDisease
associated,4881,O
with,4881,O
inner,4881,B-SpecificDisease
ear,4881,I-SpecificDisease
morphological,4881,I-SpecificDisease
anomaly,4881,I-SpecificDisease
even,4881,O
in,4881,O
the,4881,O
absence,4881,O
of,4881,O
a,4881,O
thyroid,4881,B-SpecificDisease
goiter,4881,I-SpecificDisease
..,4881,O
Knobloch,4882,B-SpecificDisease
syndrome,4882,I-SpecificDisease
involving,4882,O
midline,4882,B-DiseaseClass
scalp,4882,I-DiseaseClass
defect,4882,I-DiseaseClass
of,4882,I-DiseaseClass
the,4882,I-DiseaseClass
frontal,4882,I-DiseaseClass
region,4882,I-DiseaseClass
.,4882,O
We,4883,O
report,4883,O
on,4883,O
a,4883,O
4-year-old,4883,O
boy,4883,O
with,4883,O
Knobloch,4883,B-SpecificDisease
syndrome,4883,I-SpecificDisease
.,4883,O
He,4884,O
has,4884,O
vitreoretinal,4884,B-SpecificDisease
degeneration,4884,I-SpecificDisease
",",4884,O
high,4884,B-SpecificDisease
myopia,4884,I-SpecificDisease
",",4884,O
cataract,4884,B-SpecificDisease
",",4884,O
telecanthus,4884,B-SpecificDisease
",",4884,O
hypertelorism,4884,B-SpecificDisease
",",4884,O
and,4884,O
a,4884,O
high-arched,4884,B-SpecificDisease
palate,4884,I-SpecificDisease
.,4884,O
He,4885,O
also,4885,O
has,4885,O
a,4885,O
defect,4885,B-DiseaseClass
of,4885,I-DiseaseClass
the,4885,I-DiseaseClass
anterior,4885,I-DiseaseClass
midline,4885,I-DiseaseClass
scalp,4885,I-DiseaseClass
with,4885,O
involvement,4885,O
of,4885,O
the,4885,O
frontal,4885,O
bone,4885,O
as,4885,O
documented,4885,O
by,4885,O
a,4885,O
computed,4885,O
tomography,4885,O
(,4885,O
CT,4885,O
),4885,O
scan,4885,O
.,4885,O
The,4886,O
brain,4886,O
was,4886,O
normal,4886,O
on,4886,O
CT,4886,O
scan,4886,O
and,4886,O
magnetic,4886,O
resonance,4886,O
imaging,4886,O
.,4886,O
We,4887,O
present,4887,O
a,4887,O
review,4887,O
of,4887,O
the,4887,O
23,4887,O
published,4887,O
cases,4887,O
with,4887,O
this,4887,O
syndrome,4887,O
.,4887,O
Our,4888,O
patient,4888,O
illustrates,4888,O
the,4888,O
importance,4888,O
of,4888,O
investigating,4888,O
for,4888,O
underlying,4888,O
ocular,4888,O
and,4888,O
central,4888,O
nervous,4888,O
system,4888,O
pathology,4888,O
whenever,4888,O
midline,4888,B-DiseaseClass
scalp,4888,I-DiseaseClass
defects,4888,I-DiseaseClass
are,4888,O
present,4888,O
..,4888,O
The,4889,O
DNA,4889,O
double-strand,4889,O
break,4889,O
repair,4889,O
gene,4889,O
hMRE11,4889,O
is,4889,O
mutated,4889,O
in,4889,O
individuals,4889,O
with,4889,O
an,4889,O
ataxia-telangiectasia-like,4889,B-SpecificDisease
disorder,4889,I-SpecificDisease
.,4889,O
We,4890,O
show,4890,O
that,4890,O
hypomorphic,4890,O
mutations,4890,O
in,4890,O
hMRE11,4890,O
",",4890,O
but,4890,O
not,4890,O
in,4890,O
ATM,4890,O
",",4890,O
are,4890,O
present,4890,O
in,4890,O
certain,4890,O
individuals,4890,O
with,4890,O
an,4890,O
ataxia-telangiectasia-like,4890,B-SpecificDisease
disorder,4890,I-SpecificDisease
(,4890,O
ATLD,4890,B-SpecificDisease
),4890,O
.,4890,O
The,4891,O
cellular,4891,O
features,4891,O
resulting,4891,O
from,4891,O
these,4891,O
hMRE11,4891,O
mutations,4891,O
are,4891,O
similar,4891,O
to,4891,O
those,4891,O
seen,4891,O
in,4891,O
A-T,4891,B-SpecificDisease
as,4891,O
well,4891,O
as,4891,O
NBS,4891,B-SpecificDisease
and,4891,O
include,4891,O
hypersensitivity,4891,B-SpecificDisease
to,4891,I-SpecificDisease
ionizing,4891,I-SpecificDisease
radiation,4891,I-SpecificDisease
",",4891,O
radioresistant,4891,O
DNA,4891,O
synthesis,4891,O
",",4891,O
and,4891,O
abrogation,4891,O
of,4891,O
ATM-dependent,4891,O
events,4891,O
",",4891,O
such,4891,O
as,4891,O
the,4891,O
activation,4891,O
of,4891,O
Jun,4891,O
kinase,4891,O
following,4891,O
exposure,4891,O
to,4891,O
gamma,4891,O
irradiation,4891,O
.,4891,O
Although,4892,O
the,4892,O
mutant,4892,O
hMre11,4892,O
proteins,4892,O
retain,4892,O
some,4892,O
ability,4892,O
to,4892,O
interact,4892,O
with,4892,O
hRad50,4892,O
and,4892,O
Nbs1,4892,O
",",4892,O
formation,4892,O
of,4892,O
ionizing,4892,O
radiation-induced,4892,O
hMre11,4892,O
and,4892,O
Nbs1,4892,O
foci,4892,O
was,4892,O
absent,4892,O
in,4892,O
hMRE11,4892,O
mutant,4892,O
cells,4892,O
.,4892,O
These,4893,O
data,4893,O
demonstrate,4893,O
that,4893,O
ATM,4893,O
and,4893,O
the,4893,O
hMre11/hRad50/Nbs1,4893,O
protein,4893,O
complex,4893,O
act,4893,O
in,4893,O
the,4893,O
same,4893,O
DNA,4893,O
damage,4893,O
response,4893,O
pathway,4893,O
and,4893,O
link,4893,O
hMre11,4893,O
to,4893,O
the,4893,O
complex,4893,O
pathology,4893,O
of,4893,O
A-T,4893,B-SpecificDisease
..,4893,O
Mutations,4894,O
in,4894,O
TNFRSF11A,4894,O
",",4894,O
affecting,4894,O
the,4894,O
signal,4894,O
peptide,4894,O
of,4894,O
RANK,4894,O
",",4894,O
cause,4894,O
familial,4894,B-SpecificDisease
expansile,4894,I-SpecificDisease
osteolysis,4894,I-SpecificDisease
.,4894,O
Familial,4895,B-SpecificDisease
expansile,4895,I-SpecificDisease
osteolysis,4895,I-SpecificDisease
(,4895,O
FEO,4895,B-SpecificDisease
",",4895,O
MIM,4895,O
174810,4895,O
),4895,O
is,4895,O
a,4895,O
rare,4895,O
",",4895,O
autosomal,4895,B-DiseaseClass
dominant,4895,I-DiseaseClass
bone,4895,I-DiseaseClass
disorder,4895,I-DiseaseClass
characterized,4895,O
by,4895,O
focal,4895,O
areas,4895,O
of,4895,O
increased,4895,B-SpecificDisease
bone,4895,I-SpecificDisease
remodelling,4895,I-SpecificDisease
.,4895,O
The,4896,O
osteolytic,4896,B-SpecificDisease
lesions,4896,I-SpecificDisease
",",4896,O
which,4896,O
develop,4896,O
usually,4896,O
in,4896,O
the,4896,O
long,4896,O
bones,4896,O
during,4896,O
early,4896,O
adulthood,4896,O
",",4896,O
show,4896,O
increased,4896,O
osteoblast,4896,O
and,4896,O
osteoclast,4896,O
activity,4896,O
.,4896,O
Our,4897,O
previous,4897,O
linkage,4897,O
studies,4897,O
mapped,4897,O
the,4897,O
gene,4897,O
responsible,4897,O
for,4897,O
FEO,4897,B-SpecificDisease
to,4897,O
an,4897,O
interval,4897,O
of,4897,O
less,4897,O
than,4897,O
5,4897,O
cM,4897,O
between,4897,O
D18S64,4897,O
and,4897,O
D18S51,4897,O
on,4897,O
chromosome,4897,O
18q21,4897,O
.,4897,O
2-21,4898,O
2-21,4898,O
.,4898,O
3,4899,O
in,4899,O
a,4899,O
large,4899,O
Northern,4899,O
Irish,4899,O
family,4899,O
.,4899,O
The,4900,O
gene,4900,O
encoding,4900,O
receptor,4900,O
activator,4900,O
of,4900,O
nuclear,4900,O
factor-kappa,4900,O
B,4900,O
(,4900,O
RANK,4900,O
;,4900,O
ref,4900,O
.,4900,O
5,4901,O
),4901,O
",",4901,O
TNFRSF11A,4901,O
",",4901,O
maps,4901,O
to,4901,O
this,4901,O
region,4901,O
.,4901,O
RANK,4902,O
is,4902,O
essential,4902,O
in,4902,O
osteoclast,4902,O
formation,4902,O
.,4902,O
We,4903,O
identified,4903,O
two,4903,O
heterozygous,4903,O
insertion,4903,O
mutations,4903,O
in,4903,O
exon,4903,O
1,4903,O
of,4903,O
TNFRSF11A,4903,O
in,4903,O
affected,4903,O
members,4903,O
of,4903,O
four,4903,O
families,4903,O
with,4903,O
FEO,4903,B-SpecificDisease
or,4903,O
familial,4903,B-SpecificDisease
Paget,4903,I-SpecificDisease
disease,4903,I-SpecificDisease
of,4903,I-SpecificDisease
bone,4903,I-SpecificDisease
(,4903,O
PDB,4903,B-SpecificDisease
),4903,O
.,4903,O
One,4904,O
was,4904,O
a,4904,O
duplication,4904,O
of,4904,O
18,4904,O
bases,4904,O
and,4904,O
the,4904,O
other,4904,O
a,4904,O
duplication,4904,O
of,4904,O
27,4904,O
bases,4904,O
",",4904,O
both,4904,O
of,4904,O
which,4904,O
affected,4904,O
the,4904,O
signal,4904,O
peptide,4904,O
region,4904,O
of,4904,O
the,4904,O
RANK,4904,O
molecule,4904,O
.,4904,O
Expression,4905,O
of,4905,O
recombinant,4905,O
forms,4905,O
of,4905,O
the,4905,O
mutant,4905,O
RANK,4905,O
proteins,4905,O
revealed,4905,O
perturbations,4905,O
in,4905,O
expression,4905,O
levels,4905,O
and,4905,O
lack,4905,O
of,4905,O
normal,4905,O
cleavage,4905,O
of,4905,O
the,4905,O
signal,4905,O
peptide,4905,O
.,4905,O
Both,4906,O
mutations,4906,O
caused,4906,O
an,4906,O
increase,4906,O
in,4906,O
RANK-mediated,4906,O
nuclear,4906,O
factor-kappaB,4906,O
(,4906,O
NF-kappaB,4906,O
),4906,O
signalling,4906,O
in,4906,O
vitro,4906,O
",",4906,O
consistent,4906,O
with,4906,O
the,4906,O
presence,4906,O
of,4906,O
an,4906,O
activating,4906,O
mutation,4906,O
.,4906,O
Cardiac,4907,O
Na,4907,O
(,4907,O
+,4907,O
),4907,O
channel,4907,O
dysfunction,4907,O
in,4907,O
Brugada,4907,B-SpecificDisease
syndrome,4907,I-SpecificDisease
is,4907,O
aggravated,4907,O
by,4907,O
beta,4907,O
(,4907,O
1,4907,O
),4907,O
-subunit,4907,O
.,4907,O
BACKGROUND,4908,O
Mutations,4908,O
in,4908,O
the,4908,O
gene,4908,O
encoding,4908,O
the,4908,O
human,4908,O
cardiac,4908,O
Na,4908,O
(,4908,O
+,4908,O
),4908,O
channel,4908,O
alpha-subunit,4908,O
(,4908,O
hH1,4908,O
),4908,O
are,4908,O
responsible,4908,O
for,4908,O
chromosome,4908,O
3-linked,4908,O
congenital,4908,B-SpecificDisease
long-QT,4908,I-SpecificDisease
syndrome,4908,I-SpecificDisease
(,4908,O
LQT3,4908,B-SpecificDisease
),4908,O
and,4908,O
idiopathic,4908,B-SpecificDisease
ventricular,4908,I-SpecificDisease
fibrillation,4908,I-SpecificDisease
(,4908,O
IVF,4908,B-SpecificDisease
),4908,O
.,4908,O
An,4909,O
auxiliary,4909,O
beta,4909,O
(,4909,O
1,4909,O
),4909,O
-subunit,4909,O
",",4909,O
widely,4909,O
expressed,4909,O
in,4909,O
excitable,4909,O
tissues,4909,O
",",4909,O
shifts,4909,O
the,4909,O
voltage,4909,O
dependence,4909,O
of,4909,O
steady-state,4909,O
inactivation,4909,O
toward,4909,O
more,4909,O
negative,4909,O
potentials,4909,O
and,4909,O
restores,4909,O
normal,4909,O
gating,4909,O
kinetics,4909,O
of,4909,O
brain,4909,O
and,4909,O
skeletal,4909,O
muscle,4909,O
Na,4909,O
(,4909,O
+,4909,O
),4909,O
channels,4909,O
expressed,4909,O
in,4909,O
Xenopus,4909,O
oocytes,4909,O
but,4909,O
has,4909,O
little,4909,O
if,4909,O
any,4909,O
functional,4909,O
effect,4909,O
on,4909,O
the,4909,O
cardiac,4909,O
isoform,4909,O
.,4909,O
Here,4910,O
",",4910,O
we,4910,O
characterize,4910,O
the,4910,O
altered,4910,O
effects,4910,O
of,4910,O
a,4910,O
human,4910,O
beta,4910,O
(,4910,O
1,4910,O
),4910,O
-subunit,4910,O
(,4910,O
hbeta,4910,O
(,4910,O
1,4910,O
),4910,O
),4910,O
on,4910,O
the,4910,O
heterologously,4910,O
expressed,4910,O
hH1,4910,O
mutation,4910,O
(,4910,O
T1620M,4910,O
),4910,O
previously,4910,O
associated,4910,O
with,4910,O
IVF,4910,B-SpecificDisease
.,4910,O
METHODS,4911,O
AND,4911,O
RESULTS,4911,O
When,4911,O
expressed,4911,O
alone,4911,O
in,4911,O
Xenopus,4911,O
oocytes,4911,O
",",4911,O
T1620M,4911,O
exhibited,4911,O
no,4911,O
persistent,4911,O
currents,4911,O
",",4911,O
in,4911,O
contrast,4911,O
to,4911,O
the,4911,O
LQT3,4911,B-Modifier
mutant,4911,O
channels,4911,O
",",4911,O
but,4911,O
the,4911,O
midpoint,4911,O
of,4911,O
steady-state,4911,O
inactivation,4911,O
(,4911,O
V,4911,O
(,4911,O
1/2,4911,O
),4911,O
),4911,O
was,4911,O
significantly,4911,O
shifted,4911,O
toward,4911,O
more,4911,O
positive,4911,O
potentials,4911,O
than,4911,O
for,4911,O
wild-type,4911,O
hH1,4911,O
.,4911,O
Coexpression,4912,O
of,4912,O
hbeta,4912,O
(,4912,O
1,4912,O
),4912,O
did,4912,O
not,4912,O
significantly,4912,O
alter,4912,O
current,4912,O
decay,4912,O
or,4912,O
recovery,4912,O
from,4912,O
inactivation,4912,O
of,4912,O
wild-type,4912,O
hH1,4912,O
;,4912,O
however,4912,O
",",4912,O
it,4912,O
further,4912,O
shifted,4912,O
the,4912,O
V,4912,O
(,4912,O
1/2,4912,O
),4912,O
and,4912,O
accelerated,4912,O
the,4912,O
recovery,4912,O
from,4912,O
inactivation,4912,O
of,4912,O
T1620M,4912,O
.,4912,O
Oocyte,4913,O
macropatch,4913,O
analysis,4913,O
revealed,4913,O
that,4913,O
the,4913,O
activation,4913,O
kinetics,4913,O
of,4913,O
T1620M,4913,O
were,4913,O
normal,4913,O
.,4913,O
CONCLUSIONS,4914,O
It,4914,O
is,4914,O
suggested,4914,O
that,4914,O
coexpression,4914,O
of,4914,O
hbeta,4914,O
(,4914,O
1,4914,O
),4914,O
exposes,4914,O
a,4914,O
more,4914,O
severe,4914,O
functional,4914,O
defect,4914,O
that,4914,O
results,4914,O
in,4914,O
a,4914,O
greater,4914,O
overlap,4914,O
in,4914,O
the,4914,O
relationship,4914,O
between,4914,O
channel,4914,O
inactivation,4914,O
and,4914,O
activation,4914,O
(,4914,O
window,4914,O
current,4914,O
),4914,O
in,4914,O
T1620M,4914,O
",",4914,O
which,4914,O
is,4914,O
proposed,4914,O
to,4914,O
be,4914,O
a,4914,O
potential,4914,O
pathophysiological,4914,O
mechanism,4914,O
of,4914,O
IVF,4914,B-SpecificDisease
in,4914,O
vivo,4914,O
.,4914,O
One,4915,O
possible,4915,O
explanation,4915,O
for,4915,O
our,4915,O
finding,4915,O
is,4915,O
an,4915,O
altered,4915,O
alpha-/beta,4915,O
(,4915,O
1,4915,O
),4915,O
-subunit,4915,O
association,4915,O
in,4915,O
the,4915,O
mutant,4915,O
..,4915,O
Meiotic,4916,O
segregation,4916,O
analysis,4916,O
of,4916,O
RB1,4916,O
alleles,4916,O
in,4916,O
retinoblastoma,4916,B-Modifier
pedigrees,4916,O
by,4916,O
use,4916,O
of,4916,O
single-sperm,4916,O
typing,4916,O
.,4916,O
In,4917,O
hereditary,4917,B-SpecificDisease
retinoblastoma,4917,I-SpecificDisease
",",4917,O
different,4917,O
epidemiological,4917,O
studies,4917,O
have,4917,O
indicated,4917,O
a,4917,O
preferential,4917,O
paternal,4917,O
transmission,4917,O
of,4917,O
mutant,4917,O
retinoblastoma,4917,B-Modifier
alleles,4917,O
to,4917,O
offspring,4917,O
",",4917,O
suggesting,4917,O
the,4917,O
occurrence,4917,O
of,4917,O
a,4917,O
meiotic,4917,O
drive,4917,O
.,4917,O
To,4918,O
investigate,4918,O
this,4918,O
mechanism,4918,O
",",4918,O
we,4918,O
analyzed,4918,O
sperm,4918,O
samples,4918,O
from,4918,O
six,4918,O
individuals,4918,O
from,4918,O
five,4918,O
unrelated,4918,O
families,4918,O
affected,4918,O
with,4918,O
hereditary,4918,B-SpecificDisease
retinoblastoma,4918,I-SpecificDisease
.,4918,O
Single-sperm,4919,O
typing,4919,O
techniques,4919,O
were,4919,O
performed,4919,O
for,4919,O
each,4919,O
sample,4919,O
by,4919,O
study,4919,O
of,4919,O
two,4919,O
informative,4919,O
short,4919,O
tandem,4919,O
repeats,4919,O
located,4919,O
either,4919,O
in,4919,O
or,4919,O
close,4919,O
to,4919,O
the,4919,O
retinoblastoma,4919,B-Modifier
gene,4919,O
(,4919,O
RB1,4919,O
),4919,O
.,4919,O
The,4920,O
segregation,4920,O
probability,4920,O
of,4920,O
mutant,4920,O
RB1,4920,O
alleles,4920,O
in,4920,O
sperm,4920,O
samples,4920,O
was,4920,O
assessed,4920,O
by,4920,O
use,4920,O
of,4920,O
the,4920,O
SPERMSEG,4920,O
program,4920,O
",",4920,O
which,4920,O
includes,4920,O
experimental,4920,O
parameters,4920,O
",",4920,O
recombination,4920,O
fractions,4920,O
between,4920,O
the,4920,O
markers,4920,O
",",4920,O
and,4920,O
segregation,4920,O
parameters,4920,O
.,4920,O
A,4921,O
total,4921,O
of,4921,O
2,4921,O
",",4921,O
952,4921,O
single,4921,O
sperm,4921,O
from,4921,O
the,4921,O
six,4921,O
donors,4921,O
were,4921,O
analyzed,4921,O
.,4921,O
We,4922,O
detected,4922,O
a,4922,O
significant,4922,O
segregation,4922,O
distortion,4922,O
in,4922,O
the,4922,O
data,4922,O
as,4922,O
a,4922,O
whole,4922,O
(,4922,O
P,4922,O
=,4922,O
.,4922,O
0099,4923,O
),4923,O
and,4923,O
a,4923,O
significant,4923,O
heterogeneity,4923,O
in,4923,O
the,4923,O
segregation,4923,O
rate,4923,O
across,4923,O
donors,4923,O
(,4923,O
.,4923,O
0092,4924,O
),4924,O
.,4924,O
Further,4925,O
analysis,4925,O
shows,4925,O
that,4925,O
this,4925,O
result,4925,O
can,4925,O
be,4925,O
explained,4925,O
by,4925,O
segregation,4925,O
distortion,4925,O
in,4925,O
favor,4925,O
of,4925,O
the,4925,O
normal,4925,O
allele,4925,O
in,4925,O
one,4925,O
donor,4925,O
only,4925,O
and,4925,O
that,4925,O
it,4925,O
does,4925,O
not,4925,O
provide,4925,O
evidence,4925,O
of,4925,O
a,4925,O
significant,4925,O
segregation,4925,O
distortion,4925,O
in,4925,O
the,4925,O
other,4925,O
donors,4925,O
.,4925,O
The,4926,O
segregation,4926,O
distortion,4926,O
favoring,4926,O
the,4926,O
mutant,4926,O
RB1,4926,O
allele,4926,O
does,4926,O
not,4926,O
seem,4926,O
to,4926,O
occur,4926,O
during,4926,O
spermatogenesis,4926,O
",",4926,O
and,4926,O
",",4926,O
thus,4926,O
",",4926,O
meiotic,4926,O
drive,4926,O
may,4926,O
result,4926,O
either,4926,O
from,4926,O
various,4926,O
mechanisms,4926,O
",",4926,O
including,4926,O
a,4926,O
fertilization,4926,O
advantage,4926,O
or,4926,O
a,4926,O
better,4926,O
mobility,4926,O
in,4926,O
sperm,4926,O
bearing,4926,O
a,4926,O
mutant,4926,O
RB1,4926,O
gene,4926,O
",",4926,O
or,4926,O
from,4926,O
the,4926,O
existence,4926,O
of,4926,O
a,4926,O
defectively,4926,O
imprinted,4926,O
gene,4926,O
located,4926,O
on,4926,O
the,4926,O
human,4926,O
X,4926,O
chromosome,4926,O
.,4926,O
Friedreich,4927,B-SpecificDisease
ataxia,4927,I-SpecificDisease
:,4927,O
an,4927,O
overview,4927,O
.,4927,O
Friedreich,4928,B-SpecificDisease
ataxia,4928,I-SpecificDisease
",",4928,O
an,4928,O
autosomal,4928,B-DiseaseClass
recessive,4928,I-DiseaseClass
neurodegenerative,4928,I-DiseaseClass
disease,4928,I-DiseaseClass
",",4928,O
is,4928,O
the,4928,O
most,4928,O
common,4928,O
of,4928,O
the,4928,O
inherited,4928,B-SpecificDisease
ataxias,4928,I-SpecificDisease
.,4928,O
The,4929,O
recent,4929,O
discovery,4929,O
of,4929,O
the,4929,O
gene,4929,O
that,4929,O
is,4929,O
mutated,4929,O
in,4929,O
this,4929,O
condition,4929,O
",",4929,O
FRDA,4929,O
",",4929,O
has,4929,O
led,4929,O
to,4929,O
rapid,4929,O
advances,4929,O
in,4929,O
the,4929,O
understanding,4929,O
of,4929,O
the,4929,O
pathogenesis,4929,O
of,4929,O
Friedreich,4929,B-SpecificDisease
ataxia,4929,I-SpecificDisease
.,4929,O
About,4930,O
98,4930,O
%,4930,O
of,4930,O
mutant,4930,O
alleles,4930,O
have,4930,O
an,4930,O
expansion,4930,O
of,4930,O
a,4930,O
GAA,4930,O
trinucleotide,4930,O
repeat,4930,O
in,4930,O
intron,4930,O
1,4930,O
of,4930,O
the,4930,O
gene,4930,O
.,4930,O
This,4931,O
leads,4931,O
to,4931,O
reduced,4931,O
levels,4931,O
of,4931,O
the,4931,O
protein,4931,O
",",4931,O
frataxin,4931,O
.,4931,O
There,4932,O
is,4932,O
mounting,4932,O
evidence,4932,O
to,4932,O
suggest,4932,O
that,4932,O
Friedreich,4932,B-SpecificDisease
ataxia,4932,I-SpecificDisease
is,4932,O
the,4932,O
result,4932,O
of,4932,O
accumulation,4932,O
of,4932,O
iron,4932,O
in,4932,O
mitochondria,4932,O
leading,4932,O
to,4932,O
excess,4932,O
production,4932,O
of,4932,O
free,4932,O
radicals,4932,O
",",4932,O
which,4932,O
then,4932,O
results,4932,O
in,4932,O
cellular,4932,O
damage,4932,O
and,4932,O
death,4932,O
.,4932,O
Currently,4933,O
there,4933,O
is,4933,O
no,4933,O
known,4933,O
treatment,4933,O
that,4933,O
alters,4933,O
the,4933,O
natural,4933,O
course,4933,O
of,4933,O
the,4933,O
disease,4933,O
.,4933,O
The,4934,O
discovery,4934,O
of,4934,O
the,4934,O
FRDA,4934,B-Modifier
gene,4934,O
and,4934,O
its,4934,O
possible,4934,O
function,4934,O
has,4934,O
raised,4934,O
hope,4934,O
that,4934,O
rational,4934,O
therapeutic,4934,O
strategies,4934,O
will,4934,O
be,4934,O
developed,4934,O
..,4934,O
X-linked,4935,B-SpecificDisease
retinoschisis,4935,I-SpecificDisease
with,4935,O
point,4935,O
mutations,4935,O
in,4935,O
the,4935,O
XLRS1,4935,O
gene,4935,O
.,4935,O
BACKGROUND,4936,O
X-linked,4936,B-SpecificDisease
retinoschisis,4936,I-SpecificDisease
(,4936,O
XLRS,4936,B-SpecificDisease
),4936,O
is,4936,O
a,4936,O
relatively,4936,O
rare,4936,O
vitreoretinal,4936,B-DiseaseClass
dystrophy,4936,I-DiseaseClass
that,4936,O
causes,4936,O
visual,4936,B-SpecificDisease
loss,4936,I-SpecificDisease
in,4936,O
young,4936,O
men,4936,O
.,4936,O
Recently,4937,O
",",4937,O
a,4937,O
gene,4937,O
responsible,4937,O
for,4937,O
this,4937,O
disease,4937,O
",",4937,O
designated,4937,O
XLRS1,4937,O
",",4937,O
was,4937,O
identified,4937,O
",",4937,O
and,4937,O
several,4937,O
deleterious,4937,O
gene,4937,O
mutations,4937,O
were,4937,O
reported,4937,O
.,4937,O
OBJECTIVE,4938,O
To,4938,O
analyze,4938,O
Japanese,4938,O
patients,4938,O
clinically,4938,O
diagnosed,4938,O
as,4938,O
having,4938,O
XLRS,4938,B-Modifier
formutational,4938,O
changes,4938,O
in,4938,O
the,4938,O
XLRS1,4938,O
gene,4938,O
.,4938,O
METHODS,4939,O
Ten,4939,O
patients,4939,O
with,4939,O
XLRS,4939,B-SpecificDisease
underwent,4939,O
full,4939,O
ophthalmologic,4939,O
examination,4939,O
",",4939,O
including,4939,O
slitlamp,4939,O
biomicroscopy,4939,O
and,4939,O
dilated,4939,O
funduscopy,4939,O
.,4939,O
Genomic,4940,O
DNA,4940,O
was,4940,O
isolated,4940,O
from,4940,O
leukocytes,4940,O
",",4940,O
and,4940,O
all,4940,O
exons,4940,O
of,4940,O
the,4940,O
XLRS1,4940,O
gene,4940,O
were,4940,O
amplified,4940,O
by,4940,O
polymerase,4940,O
chain,4940,O
reaction,4940,O
and,4940,O
analyzed,4940,O
using,4940,O
a,4940,O
direct,4940,O
sequencing,4940,O
method,4940,O
.,4940,O
RESULTS,4941,O
Point,4941,O
mutations,4941,O
in,4941,O
the,4941,O
XLRS1,4941,O
gene,4941,O
were,4941,O
identified,4941,O
in,4941,O
all,4941,O
10,4941,O
patients,4941,O
.,4941,O
The,4942,O
mutations,4942,O
were,4942,O
identical,4942,O
in,4942,O
each,4942,O
of,4942,O
2,4942,O
pairs,4942,O
of,4942,O
brothers,4942,O
.,4942,O
Six,4943,O
of,4943,O
the,4943,O
point,4943,O
mutations,4943,O
represented,4943,O
missense,4943,O
mutations,4943,O
",",4943,O
1,4943,O
was,4943,O
a,4943,O
nonsense,4943,O
mutation,4943,O
",",4943,O
and,4943,O
1,4943,O
was,4943,O
a,4943,O
frameshift,4943,O
mutation,4943,O
.,4943,O
Five,4944,O
of,4944,O
the,4944,O
mutations,4944,O
are,4944,O
newly,4944,O
reported,4944,O
herein,4944,O
.,4944,O
CONCLUSIONS,4945,O
The,4945,O
discovery,4945,O
of,4945,O
new,4945,O
point,4945,O
mutations,4945,O
in,4945,O
this,4945,O
study,4945,O
increases,4945,O
the,4945,O
available,4945,O
information,4945,O
regarding,4945,O
the,4945,O
spectrum,4945,O
of,4945,O
genetic,4945,B-DiseaseClass
abnormalities,4945,I-DiseaseClass
and,4945,O
clinical,4945,O
manifestations,4945,O
of,4945,O
XLRS,4945,B-SpecificDisease
.,4945,O
However,4946,O
",",4946,O
the,4946,O
limited,4946,O
data,4946,O
failed,4946,O
to,4946,O
reveal,4946,O
a,4946,O
correlation,4946,O
between,4946,O
mutation,4946,O
and,4946,O
disease,4946,O
phenotype,4946,O
.,4946,O
CLINICAL,4947,O
RELEVANCE,4947,O
Identification,4947,O
of,4947,O
mutations,4947,O
in,4947,O
the,4947,O
XLRS1,4947,O
gene,4947,O
and,4947,O
expanded,4947,O
information,4947,O
on,4947,O
clinical,4947,O
manifestations,4947,O
will,4947,O
facilitate,4947,O
early,4947,O
diagnosis,4947,O
",",4947,O
appropriate,4947,O
early,4947,O
therapy,4947,O
",",4947,O
and,4947,O
genetic,4947,O
counseling,4947,O
regarding,4947,O
the,4947,O
prognosis,4947,O
of,4947,O
XLRS,4947,B-SpecificDisease
..,4947,O
Atm,4948,O
and,4948,O
Bax,4948,O
cooperate,4948,O
in,4948,O
ionizing,4948,O
radiation-induced,4948,O
apoptosis,4948,O
in,4948,O
the,4948,O
central,4948,O
nervous,4948,O
system,4948,O
.,4948,O
Ataxia-telangiectasia,4949,B-SpecificDisease
is,4949,O
a,4949,O
hereditary,4949,B-DiseaseClass
multisystemic,4949,I-DiseaseClass
disease,4949,I-DiseaseClass
resulting,4949,O
from,4949,O
mutations,4949,O
of,4949,O
ataxia,4949,B-SpecificDisease
telangiectasia,4949,I-SpecificDisease
",",4949,O
mutated,4949,O
(,4949,O
ATM,4949,O
),4949,O
and,4949,O
is,4949,O
characterized,4949,O
by,4949,O
neurodegeneration,4949,B-DiseaseClass
",",4949,O
cancer,4949,B-DiseaseClass
",",4949,O
immune,4949,B-DiseaseClass
defects,4949,I-DiseaseClass
",",4949,O
and,4949,O
hypersensitivity,4949,B-DiseaseClass
to,4949,I-DiseaseClass
ionizing,4949,I-DiseaseClass
radiation,4949,I-DiseaseClass
.,4949,O
The,4950,O
molecular,4950,O
details,4950,O
of,4950,O
ATM,4950,O
function,4950,O
in,4950,O
the,4950,O
nervous,4950,O
system,4950,O
are,4950,O
unclear,4950,O
",",4950,O
although,4950,O
the,4950,O
neurological,4950,B-DiseaseClass
lesion,4950,I-DiseaseClass
in,4950,O
ataxia-telangiectasia,4950,B-SpecificDisease
becomes,4950,O
apparent,4950,O
early,4950,O
in,4950,O
life,4950,O
",",4950,O
suggesting,4950,O
a,4950,O
developmental,4950,O
origin,4950,O
.,4950,O
The,4951,O
central,4951,O
nervous,4951,O
system,4951,O
(,4951,O
CNS,4951,O
),4951,O
of,4951,O
Atm-null,4951,O
mice,4951,O
shows,4951,O
a,4951,O
pronounced,4951,O
defect,4951,O
in,4951,O
apoptosis,4951,O
induced,4951,O
by,4951,O
genotoxic,4951,O
stress,4951,O
",",4951,O
suggesting,4951,O
ATM,4951,O
functions,4951,O
to,4951,O
eliminate,4951,O
neurons,4951,O
with,4951,O
excessive,4951,O
genomic,4951,O
damage,4951,O
.,4951,O
Here,4952,O
",",4952,O
we,4952,O
report,4952,O
that,4952,O
the,4952,O
death,4952,O
effector,4952,O
Bax,4952,O
is,4952,O
required,4952,O
for,4952,O
a,4952,O
large,4952,O
proportion,4952,O
of,4952,O
Atm-dependent,4952,O
apoptosis,4952,O
in,4952,O
the,4952,O
developing,4952,O
CNS,4952,O
after,4952,O
ionizing,4952,O
radiation,4952,O
(,4952,O
IR,4952,O
),4952,O
.,4952,O
Although,4953,O
many,4953,O
of,4953,O
the,4953,O
same,4953,O
regions,4953,O
of,4953,O
the,4953,O
CNS,4953,O
in,4953,O
both,4953,O
Bax-/-,4953,O
and,4953,O
Atm-/-,4953,O
mice,4953,O
were,4953,O
radioresistant,4953,O
",",4953,O
mice,4953,O
nullizygous,4953,O
for,4953,O
both,4953,O
Bax,4953,O
and,4953,O
Atm,4953,O
showed,4953,O
additional,4953,O
reduction,4953,O
in,4953,O
IR-induced,4953,O
apoptosis,4953,O
in,4953,O
the,4953,O
CNS,4953,O
.,4953,O
Therefore,4954,O
",",4954,O
although,4954,O
the,4954,O
major,4954,O
IR-induced,4954,O
apoptotic,4954,O
pathway,4954,O
in,4954,O
the,4954,O
CNS,4954,O
requires,4954,O
Atm,4954,O
and,4954,O
Bax,4954,O
",",4954,O
a,4954,O
p53-dependent,4954,O
collateral,4954,O
pathway,4954,O
exists,4954,O
that,4954,O
has,4954,O
both,4954,O
Atm-,4954,O
and,4954,O
Bax-independent,4954,O
branches,4954,O
.,4954,O
Further,4955,O
",",4955,O
Atm-,4955,O
and,4955,O
Bax-dependent,4955,O
apoptosis,4955,O
in,4955,O
the,4955,O
CNS,4955,O
also,4955,O
required,4955,O
caspase-3,4955,O
activation,4955,O
.,4955,O
These,4956,O
data,4956,O
implicate,4956,O
Bax,4956,O
and,4956,O
caspase-3,4956,O
as,4956,O
death,4956,O
effectors,4956,O
in,4956,O
neurodegenerative,4956,O
pathways,4956,O
..,4956,O
Haim-Munk,4957,B-SpecificDisease
syndrome,4957,I-SpecificDisease
and,4957,O
Papillon-Lefevre,4957,B-SpecificDisease
syndrome,4957,I-SpecificDisease
are,4957,O
allelic,4957,O
mutations,4957,O
in,4957,O
cathepsin,4957,O
C.,4957,O
Of,4957,O
the,4957,O
many,4957,O
palmoplantar,4957,B-DiseaseClass
keratoderma,4957,I-DiseaseClass
(,4957,I-DiseaseClass
PPK,4957,I-DiseaseClass
),4957,I-DiseaseClass
conditions,4957,I-DiseaseClass
",",4957,O
only,4957,O
Papillon-Lefevre,4957,B-SpecificDisease
syndrome,4957,I-SpecificDisease
(,4957,O
PLS,4957,B-SpecificDisease
),4957,O
and,4957,O
Haim-Munk,4957,B-SpecificDisease
syndrome,4957,I-SpecificDisease
(,4957,O
HMS,4957,B-SpecificDisease
),4957,O
are,4957,O
associated,4957,O
with,4957,O
premature,4957,O
periodontal,4957,O
destruction,4957,O
.,4957,O
Although,4958,O
both,4958,O
PLS,4958,B-SpecificDisease
and,4958,O
HMS,4958,B-SpecificDisease
share,4958,O
the,4958,O
cardinal,4958,O
features,4958,O
of,4958,O
PPK,4958,B-DiseaseClass
and,4958,O
severe,4958,O
periodontitis,4958,B-SpecificDisease
",",4958,O
a,4958,O
number,4958,O
of,4958,O
additional,4958,O
findings,4958,O
are,4958,O
reported,4958,O
in,4958,O
HMS,4958,B-SpecificDisease
including,4958,O
arachnodactyly,4958,B-SpecificDisease
",",4958,O
acro-osteolysis,4958,B-SpecificDisease
",",4958,O
atrophic,4958,B-SpecificDisease
changes,4958,I-SpecificDisease
of,4958,I-SpecificDisease
the,4958,I-SpecificDisease
nails,4958,I-SpecificDisease
",",4958,O
and,4958,O
a,4958,O
radiographic,4958,B-SpecificDisease
deformity,4958,I-SpecificDisease
of,4958,I-SpecificDisease
the,4958,I-SpecificDisease
fingers,4958,I-SpecificDisease
.,4958,O
While,4959,O
PLS,4959,B-Modifier
cases,4959,O
have,4959,O
been,4959,O
identified,4959,O
throughout,4959,O
the,4959,O
world,4959,O
",",4959,O
HMS,4959,B-SpecificDisease
has,4959,O
only,4959,O
been,4959,O
described,4959,O
among,4959,O
descendants,4959,O
of,4959,O
a,4959,O
religious,4959,O
isolate,4959,O
originally,4959,O
from,4959,O
Cochin,4959,O
",",4959,O
India,4959,O
.,4959,O
Parental,4960,O
consanguinity,4960,O
is,4960,O
a,4960,O
characteristic,4960,O
of,4960,O
many,4960,O
cases,4960,O
of,4960,O
both,4960,O
conditions,4960,O
.,4960,O
Although,4961,O
autosomal,4961,O
recessive,4961,O
transmission,4961,O
of,4961,O
PLS,4961,B-SpecificDisease
is,4961,O
evident,4961,O
",",4961,O
a,4961,O
more,4961,O
``,4961,O
complex,4961,O
``,4961,O
autosomal,4961,O
recessive,4961,O
pattern,4961,O
of,4961,O
inheritance,4961,O
with,4961,O
phenotypic,4961,O
influences,4961,O
from,4961,O
a,4961,O
closely,4961,O
linked,4961,O
modifying,4961,O
locus,4961,O
has,4961,O
been,4961,O
hypothesised,4961,O
for,4961,O
HMS,4961,B-SpecificDisease
.,4961,O
Recently,4962,O
",",4962,O
mutations,4962,O
of,4962,O
the,4962,O
cathepsin,4962,O
C,4962,O
gene,4962,O
have,4962,O
been,4962,O
identified,4962,O
as,4962,O
the,4962,O
underlying,4962,O
genetic,4962,B-DiseaseClass
defect,4962,I-DiseaseClass
in,4962,O
PLS,4962,B-SpecificDisease
.,4962,O
To,4963,O
determine,4963,O
if,4963,O
a,4963,O
cathepsin,4963,O
C,4963,O
mutation,4963,O
is,4963,O
also,4963,O
responsible,4963,O
for,4963,O
HMS,4963,B-SpecificDisease
",",4963,O
we,4963,O
sequenced,4963,O
the,4963,O
gene,4963,O
in,4963,O
affected,4963,O
and,4963,O
unaffected,4963,O
subjects,4963,O
from,4963,O
the,4963,O
Cochin,4963,O
isolate,4963,O
in,4963,O
which,4963,O
both,4963,O
the,4963,O
PLS,4963,B-Modifier
and,4963,O
HMS,4963,B-Modifier
phenotypes,4963,O
appear,4963,O
.,4963,O
Here,4964,O
we,4964,O
report,4964,O
identification,4964,O
of,4964,O
a,4964,O
mutation,4964,O
of,4964,O
cathepsin,4964,O
C,4964,O
(,4964,O
exon,4964,O
6,4964,O
",",4964,O
2127A,4964,O
--,4964,O
>,4964,O
G,4964,O
),4964,O
that,4964,O
changes,4964,O
a,4964,O
highly,4964,O
conserved,4964,O
amino,4964,O
acid,4964,O
in,4964,O
the,4964,O
cathepsin,4964,O
C,4964,O
peptide,4964,O
.,4964,O
This,4965,O
mutation,4965,O
segregates,4965,O
with,4965,O
HMS,4965,B-SpecificDisease
in,4965,O
four,4965,O
nuclear,4965,O
families,4965,O
.,4965,O
Additionally,4966,O
",",4966,O
the,4966,O
existence,4966,O
of,4966,O
a,4966,O
shared,4966,O
common,4966,O
haplotype,4966,O
for,4966,O
genetic,4966,O
loci,4966,O
flanking,4966,O
the,4966,O
cathepsin,4966,O
C,4966,O
gene,4966,O
suggests,4966,O
that,4966,O
affected,4966,O
subjects,4966,O
descended,4966,O
from,4966,O
the,4966,O
Cochin,4966,O
isolate,4966,O
are,4966,O
homozygous,4966,O
for,4966,O
a,4966,O
mutation,4966,O
inherited,4966,O
``,4966,O
identical,4966,O
by,4966,O
descent,4966,O
``,4966,O
from,4966,O
a,4966,O
common,4966,O
ancestor,4966,O
.,4966,O
This,4967,O
finding,4967,O
supports,4967,O
simple,4967,O
autosomal,4967,O
recessive,4967,O
inheritance,4967,O
for,4967,O
HMS,4967,B-SpecificDisease
in,4967,O
these,4967,O
families,4967,O
.,4967,O
We,4968,O
also,4968,O
report,4968,O
a,4968,O
mutation,4968,O
of,4968,O
the,4968,O
same,4968,O
exon,4968,O
6,4968,O
CTSC,4968,O
codon,4968,O
(,4968,O
2126C,4968,O
--,4968,O
>,4968,O
T,4968,O
),4968,O
in,4968,O
a,4968,O
Turkish,4968,O
family,4968,O
with,4968,O
classical,4968,O
PLS,4968,B-SpecificDisease
.,4968,O
These,4969,O
findings,4969,O
provide,4969,O
evidence,4969,O
that,4969,O
PLS,4969,B-SpecificDisease
and,4969,O
HMS,4969,B-SpecificDisease
are,4969,O
allelic,4969,O
variants,4969,O
of,4969,O
cathepsin,4969,O
C,4969,O
gene,4969,O
mutations,4969,O
..,4969,O
ATM-heterozygous,4970,O
germline,4970,O
mutations,4970,O
contribute,4970,O
to,4970,O
breast,4970,B-Modifier
cancer-susceptibility,4970,O
.,4970,O
Approximately,4971,O
0,4971,O
.,4971,O
5,4972,O
%,4972,O
-1,4972,O
%,4972,O
of,4972,O
the,4972,O
general,4972,O
population,4972,O
has,4972,O
been,4972,O
estimated,4972,O
to,4972,O
be,4972,O
heterozygous,4972,O
for,4972,O
a,4972,O
germline,4972,O
mutation,4972,O
in,4972,O
the,4972,O
ATM,4972,O
gene,4972,O
.,4972,O
Mutations,4973,O
in,4973,O
the,4973,O
ATM,4973,O
gene,4973,O
are,4973,O
responsible,4973,O
for,4973,O
the,4973,O
autosomal,4973,B-DiseaseClass
recessive,4973,I-DiseaseClass
disorder,4973,I-DiseaseClass
ataxia-telangiectasia,4973,B-SpecificDisease
(,4973,O
A-T,4973,B-SpecificDisease
),4973,O
(,4973,O
MIM,4973,O
208900,4973,O
),4973,O
.,4973,O
The,4974,O
finding,4974,O
that,4974,O
ATM-heterozygotes,4974,O
have,4974,O
an,4974,O
increased,4974,O
relative,4974,O
risk,4974,O
for,4974,O
breast,4974,B-SpecificDisease
cancer,4974,I-SpecificDisease
was,4974,O
supported,4974,O
by,4974,O
some,4974,O
studies,4974,O
but,4974,O
not,4974,O
confirmed,4974,O
by,4974,O
others,4974,O
.,4974,O
In,4975,O
view,4975,O
of,4975,O
this,4975,O
discrepancy,4975,O
",",4975,O
we,4975,O
examined,4975,O
the,4975,O
frequency,4975,O
of,4975,O
ATM,4975,O
germline,4975,O
mutations,4975,O
in,4975,O
a,4975,O
selected,4975,O
group,4975,O
of,4975,O
Dutch,4975,O
patients,4975,O
with,4975,O
breast,4975,B-SpecificDisease
cancer,4975,I-SpecificDisease
.,4975,O
We,4976,O
have,4976,O
analyzed,4976,O
ATM,4976,O
germline,4976,O
mutations,4976,O
in,4976,O
normal,4976,O
blood,4976,O
lymphocytes,4976,O
",",4976,O
using,4976,O
the,4976,O
protein-truncation,4976,O
test,4976,O
followed,4976,O
by,4976,O
genomic-sequence,4976,O
analysis,4976,O
.,4976,O
A,4977,O
high,4977,O
percentage,4977,O
of,4977,O
ATM,4977,O
germline,4977,O
mutations,4977,O
was,4977,O
demonstrated,4977,O
among,4977,O
patients,4977,O
with,4977,O
sporadic,4977,B-SpecificDisease
breast,4977,I-SpecificDisease
cancer,4977,I-SpecificDisease
.,4977,O
The,4978,O
82,4978,O
patients,4978,O
included,4978,O
in,4978,O
this,4978,O
study,4978,O
had,4978,O
developed,4978,O
breast,4978,B-SpecificDisease
cancer,4978,I-SpecificDisease
at,4978,O
age,4978,O
<,4978,O
45,4978,O
and,4978,O
had,4978,O
survived,4978,O
>,4978,O
/=,4978,O
5,4978,O
years,4978,O
(,4978,O
mean,4978,O
15,4978,O
years,4978,O
),4978,O
",",4978,O
and,4978,O
in,4978,O
33,4978,O
(,4978,O
40,4978,O
%,4978,O
),4978,O
of,4978,O
the,4978,O
patients,4978,O
a,4978,O
contralateral,4978,O
breast,4978,O
tumor,4978,O
had,4978,O
been,4978,O
diagnosed,4978,O
.,4978,O
Among,4979,O
these,4979,O
patients,4979,O
we,4979,O
identified,4979,O
seven,4979,O
(,4979,O
8,4979,O
.,4979,O
5,4980,O
%,4980,O
),4980,O
ATM,4980,O
germline,4980,O
mutations,4980,O
",",4980,O
of,4980,O
which,4980,O
five,4980,O
are,4980,O
distinct,4980,O
.,4980,O
One,4981,O
splice-site,4981,O
mutation,4981,O
(,4981,O
IVS10-6T,4981,O
--,4981,O
>,4981,O
G,4981,O
),4981,O
was,4981,O
detected,4981,O
three,4981,O
times,4981,O
in,4981,O
our,4981,O
series,4981,O
.,4981,O
Four,4982,O
heterozygous,4982,O
carriers,4982,O
were,4982,O
patients,4982,O
with,4982,O
bilateral,4982,O
breast,4982,O
cancer,4982,O
.,4982,O
Our,4983,O
results,4983,O
indicate,4983,O
that,4983,O
the,4983,O
mutations,4983,O
identified,4983,O
in,4983,O
this,4983,O
study,4983,O
are,4983,O
``,4983,O
A-T,4983,O
disease-causing,4983,O
``,4983,O
mutations,4983,O
that,4983,O
might,4983,O
be,4983,O
associated,4983,O
with,4983,O
an,4983,O
increased,4983,O
risk,4983,O
of,4983,O
breast,4983,O
cancer,4983,O
in,4983,O
heterozygotes,4983,O
.,4983,O
We,4984,O
conclude,4984,O
that,4984,O
ATM,4984,O
heterozygotes,4984,O
have,4984,O
an,4984,O
approximately,4984,O
ninefold-increased,4984,O
risk,4984,O
of,4984,O
developing,4984,O
a,4984,O
type,4984,O
of,4984,O
breast,4984,O
cancer,4984,O
characterized,4984,O
by,4984,O
frequent,4984,O
bilateral,4984,O
occurrence,4984,O
",",4984,O
early,4984,O
age,4984,O
at,4984,O
onset,4984,O
",",4984,O
and,4984,O
long-term,4984,O
survival,4984,O
.,4984,O
The,4985,O
specific,4985,O
characteristics,4985,O
of,4985,O
our,4985,O
population,4985,O
of,4985,O
patients,4985,O
may,4985,O
explain,4985,O
why,4985,O
such,4985,O
a,4985,O
high,4985,O
frequency,4985,O
was,4985,O
not,4985,O
found,4985,O
in,4985,O
other,4985,O
series,4985,O
.,4985,O
Human,4986,O
mutations,4986,O
in,4986,O
glucose,4986,O
6-phosphate,4986,O
dehydrogenase,4986,O
reflect,4986,O
evolutionary,4986,O
history,4986,O
.,4986,O
Glucose,4987,O
6-phosphate,4987,O
dehydrogenase,4987,O
(,4987,O
G6PD,4987,O
),4987,O
is,4987,O
a,4987,O
cytosolic,4987,O
enzyme,4987,O
encoded,4987,O
by,4987,O
a,4987,O
housekeeping,4987,O
X-linked,4987,O
gene,4987,O
whose,4987,O
main,4987,O
function,4987,O
is,4987,O
to,4987,O
produce,4987,O
NADPH,4987,O
",",4987,O
a,4987,O
key,4987,O
electron,4987,O
donor,4987,O
in,4987,O
the,4987,O
defense,4987,O
against,4987,O
oxidizing,4987,O
agents,4987,O
and,4987,O
in,4987,O
reductive,4987,O
biosynthetic,4987,O
reactions,4987,O
.,4987,O
Inherited,4988,O
G6PD,4988,B-SpecificDisease
deficiency,4988,I-SpecificDisease
is,4988,O
associated,4988,O
with,4988,O
either,4988,O
episodic,4988,B-SpecificDisease
hemolytic,4988,I-SpecificDisease
anemia,4988,I-SpecificDisease
(,4988,O
triggered,4988,O
by,4988,O
fava,4988,O
beans,4988,O
or,4988,O
other,4988,O
agents,4988,O
),4988,O
or,4988,O
life-long,4988,B-SpecificDisease
hemolytic,4988,I-SpecificDisease
anemia,4988,I-SpecificDisease
.,4988,O
We,4989,O
show,4989,O
here,4989,O
that,4989,O
an,4989,O
evolutionary,4989,O
analysis,4989,O
is,4989,O
a,4989,O
key,4989,O
to,4989,O
understanding,4989,O
the,4989,O
biology,4989,O
of,4989,O
a,4989,O
housekeeping,4989,O
gene,4989,O
.,4989,O
From,4990,O
the,4990,O
alignment,4990,O
of,4990,O
the,4990,O
amino,4990,O
acid,4990,O
(,4990,O
aa,4990,O
),4990,O
sequence,4990,O
of,4990,O
52,4990,O
glucose,4990,O
6-phosphate,4990,O
dehydrogenase,4990,O
(,4990,O
G6PD,4990,O
),4990,O
species,4990,O
from,4990,O
42,4990,O
different,4990,O
organisms,4990,O
",",4990,O
we,4990,O
found,4990,O
a,4990,O
striking,4990,O
correlation,4990,O
between,4990,O
the,4990,O
aa,4990,O
replacements,4990,O
that,4990,O
cause,4990,O
G6PD,4990,B-SpecificDisease
deficiency,4990,I-SpecificDisease
in,4990,O
humans,4990,O
and,4990,O
the,4990,O
sequence,4990,O
conservation,4990,O
of,4990,O
G6PD,4990,O
two-thirds,4990,O
of,4990,O
such,4990,O
replacements,4990,O
are,4990,O
in,4990,O
highly,4990,O
and,4990,O
moderately,4990,O
conserved,4990,O
(,4990,O
50-99,4990,O
%,4990,O
),4990,O
aa,4990,O
;,4990,O
relatively,4990,O
few,4990,O
are,4990,O
in,4990,O
fully,4990,O
conserved,4990,O
aa,4990,O
(,4990,O
where,4990,O
they,4990,O
might,4990,O
be,4990,O
lethal,4990,O
),4990,O
or,4990,O
in,4990,O
poorly,4990,O
conserved,4990,O
aa,4990,O
",",4990,O
where,4990,O
presumably,4990,O
they,4990,O
simply,4990,O
would,4990,O
not,4990,O
cause,4990,O
G6PD,4990,B-SpecificDisease
deficiency,4990,I-SpecificDisease
.,4990,O
This,4991,O
is,4991,O
consistent,4991,O
with,4991,O
the,4991,O
notion,4991,O
that,4991,O
all,4991,O
human,4991,O
mutants,4991,O
have,4991,O
residual,4991,O
enzyme,4991,O
activity,4991,O
and,4991,O
that,4991,O
null,4991,O
mutations,4991,O
are,4991,O
lethal,4991,O
at,4991,O
some,4991,O
stage,4991,O
of,4991,O
development,4991,O
.,4991,O
Comparing,4992,O
the,4992,O
distribution,4992,O
of,4992,O
mutations,4992,O
in,4992,O
a,4992,O
human,4992,O
housekeeping,4992,O
gene,4992,O
with,4992,O
evolutionary,4992,O
conservation,4992,O
is,4992,O
a,4992,O
useful,4992,O
tool,4992,O
for,4992,O
pinpointing,4992,O
amino,4992,O
acid,4992,O
residues,4992,O
important,4992,O
for,4992,O
the,4992,O
stability,4992,O
or,4992,O
the,4992,O
function,4992,O
of,4992,O
the,4992,O
corresponding,4992,O
protein,4992,O
.,4992,O
In,4993,O
view,4993,O
of,4993,O
the,4993,O
current,4993,O
explosive,4993,O
increase,4993,O
in,4993,O
full,4993,O
genome,4993,O
sequencing,4993,O
projects,4993,O
",",4993,O
this,4993,O
tool,4993,O
will,4993,O
become,4993,O
rapidly,4993,O
available,4993,O
for,4993,O
numerous,4993,O
other,4993,O
genes,4993,O
..,4993,O
Constitutive,4994,O
and,4994,O
regulated,4994,O
modes,4994,O
of,4994,O
splicing,4994,O
produce,4994,O
six,4994,O
major,4994,O
myotonic,4994,B-Modifier
dystrophy,4994,I-Modifier
protein,4994,O
kinase,4994,O
(,4994,O
DMPK,4994,O
),4994,O
isoforms,4994,O
with,4994,O
distinct,4994,O
properties,4994,O
.,4994,O
Myotonic,4995,B-SpecificDisease
dystrophy,4995,I-SpecificDisease
(,4995,O
DM,4995,B-SpecificDisease
),4995,O
is,4995,O
the,4995,O
most,4995,O
prevalent,4995,O
inherited,4995,B-DiseaseClass
neuromuscular,4995,I-DiseaseClass
disease,4995,I-DiseaseClass
in,4995,O
adults,4995,O
.,4995,O
The,4996,O
genetic,4996,B-DiseaseClass
defect,4996,I-DiseaseClass
is,4996,O
a,4996,O
CTG,4996,O
triplet,4996,O
repeat,4996,O
expansion,4996,O
in,4996,O
the,4996,O
3-untranslated,4996,O
region,4996,O
of,4996,O
the,4996,O
myotonic,4996,B-Modifier
dystrophy,4996,I-Modifier
protein,4996,O
kinase,4996,O
(,4996,O
DMPK,4996,O
),4996,O
gene,4996,O
",",4996,O
consisting,4996,O
of,4996,O
15,4996,O
exons,4996,O
.,4996,O
Using,4997,O
a,4997,O
transgenic,4997,O
DMPK-overexpressor,4997,O
mouse,4997,O
model,4997,O
",",4997,O
we,4997,O
demonstrate,4997,O
here,4997,O
that,4997,O
the,4997,O
endogenous,4997,O
mouse,4997,O
DMPK,4997,O
gene,4997,O
and,4997,O
the,4997,O
human,4997,O
DMPK,4997,O
transgene,4997,O
produce,4997,O
six,4997,O
major,4997,O
alternatively,4997,O
spliced,4997,O
mRNAs,4997,O
which,4997,O
have,4997,O
almost,4997,O
identical,4997,O
cell,4997,O
type-dependent,4997,O
distribution,4997,O
frequencies,4997,O
and,4997,O
expression,4997,O
patterns,4997,O
.,4997,O
Use,4998,O
of,4998,O
a,4998,O
cryptic,4998,O
5,4998,O
splice,4998,O
site,4998,O
in,4998,O
exon,4998,O
8,4998,O
",",4998,O
which,4998,O
results,4998,O
in,4998,O
absence,4998,O
or,4998,O
presence,4998,O
of,4998,O
15,4998,O
nucleotides,4998,O
specifying,4998,O
a,4998,O
VSGGG,4998,O
peptide,4998,O
motif,4998,O
",",4998,O
and/or,4998,O
use,4998,O
of,4998,O
a,4998,O
cryptic,4998,O
3,4998,O
splice,4998,O
site,4998,O
in,4998,O
exon,4998,O
14,4998,O
",",4998,O
which,4998,O
leads,4998,O
to,4998,O
a,4998,O
frameshift,4998,O
in,4998,O
the,4998,O
mRNA,4998,O
reading,4998,O
frame,4998,O
",",4998,O
occur,4998,O
as,4998,O
independent,4998,O
stochastic,4998,O
events,4998,O
in,4998,O
all,4998,O
tissues,4998,O
examined,4998,O
.,4998,O
In,4999,O
contrast,4999,O
",",4999,O
the,4999,O
excision,4999,O
of,4999,O
exons,4999,O
13/14,4999,O
that,4999,O
causes,4999,O
a,4999,O
frameshift,4999,O
and,4999,O
creates,4999,O
a,4999,O
C-terminally,4999,O
truncated,4999,O
protein,4999,O
is,4999,O
clearly,4999,O
cell,4999,O
type,4999,O
dependent,4999,O
and,4999,O
occurs,4999,O
predominantly,4999,O
in,4999,O
smooth,4999,O
muscle,4999,O
.,4999,O
We,5000,O
generated,5000,O
all,5000,O
six,5000,O
full-length,5000,O
mouse,5000,O
cDNAs,5000,O
that,5000,O
result,5000,O
from,5000,O
combinations,5000,O
of,5000,O
these,5000,O
three,5000,O
major,5000,O
splicing,5000,O
events,5000,O
and,5000,O
show,5000,O
that,5000,O
their,5000,O
transfection,5000,O
into,5000,O
cells,5000,O
in,5000,O
culture,5000,O
leads,5000,O
to,5000,O
production,5000,O
of,5000,O
four,5000,O
different,5000,O
approximately,5000,O
74,5000,O
kDa,5000,O
full-length,5000,O
(,5000,O
heart-,5000,O
",",5000,O
skeletal,5000,O
muscle-,5000,O
or,5000,O
brain-specific,5000,O
),5000,O
and,5000,O
two,5000,O
C-terminally,5000,O
truncated,5000,O
approximately,5000,O
68,5000,O
kDa,5000,O
(,5000,O
smooth,5000,O
muscle-specific,5000,O
),5000,O
isoforms,5000,O
.,5000,O
Information,5001,O
on,5001,O
DMPK,5001,O
mRNA,5001,O
and,5001,O
protein,5001,O
isoform,5001,O
expression,5001,O
patterns,5001,O
will,5001,O
be,5001,O
useful,5001,O
for,5001,O
recognizing,5001,O
differential,5001,O
effects,5001,O
of,5001,O
(,5001,O
CTG,5001,O
),5001,O
(,5001,O
n,5001,O
),5001,O
expansion,5001,O
in,5001,O
DM,5001,B-Modifier
manifestation,5001,O
..,5001,O
Genetic,5002,O
analysis,5002,O
",",5002,O
phenotypic,5002,O
diagnosis,5002,O
",",5002,O
and,5002,O
risk,5002,O
of,5002,O
venous,5002,B-SpecificDisease
thrombosis,5002,I-SpecificDisease
in,5002,O
families,5002,O
with,5002,O
inherited,5002,O
deficiencies,5002,B-SpecificDisease
of,5002,I-SpecificDisease
protein,5002,I-SpecificDisease
S.,5002,O
Protein,5002,B-SpecificDisease
S,5002,I-SpecificDisease
deficiency,5002,I-SpecificDisease
is,5002,O
a,5002,O
recognized,5002,O
risk,5002,O
factor,5002,O
for,5002,O
venous,5002,B-SpecificDisease
thrombosis,5002,I-SpecificDisease
.,5002,O
Of,5003,O
all,5003,O
the,5003,O
inherited,5003,O
thrombophilic,5003,B-DiseaseClass
conditions,5003,I-DiseaseClass
",",5003,O
it,5003,O
remains,5003,O
the,5003,O
most,5003,O
difficult,5003,O
to,5003,O
diagnose,5003,O
because,5003,O
of,5003,O
phenotypic,5003,O
variability,5003,O
",",5003,O
which,5003,O
can,5003,O
lead,5003,O
to,5003,O
inconclusive,5003,O
results,5003,O
.,5003,O
We,5004,O
have,5004,O
overcome,5004,O
this,5004,O
problem,5004,O
by,5004,O
studying,5004,O
a,5004,O
cohort,5004,O
of,5004,O
patients,5004,O
from,5004,O
a,5004,O
single,5004,O
center,5004,O
where,5004,O
the,5004,O
diagnosis,5004,O
was,5004,O
confirmed,5004,O
at,5004,O
the,5004,O
genetic,5004,O
level,5004,O
.,5004,O
Twenty-eight,5005,O
index,5005,O
patients,5005,O
with,5005,O
protein,5005,B-SpecificDisease
S,5005,I-SpecificDisease
deficiency,5005,I-SpecificDisease
and,5005,O
a,5005,O
PROS1,5005,B-SpecificDisease
gene,5005,I-SpecificDisease
defect,5005,I-SpecificDisease
were,5005,O
studied,5005,O
",",5005,O
together,5005,O
with,5005,O
109,5005,O
first-degree,5005,O
relatives,5005,O
.,5005,O
To,5006,O
avoid,5006,O
selection,5006,O
bias,5006,O
",",5006,O
we,5006,O
confined,5006,O
analysis,5006,O
of,5006,O
total,5006,O
and,5006,O
free,5006,O
protein,5006,O
S,5006,O
levels,5006,O
and,5006,O
thrombotic,5006,O
risk,5006,O
to,5006,O
the,5006,O
patients,5006,O
relatives,5006,O
.,5006,O
In,5007,O
this,5007,O
group,5007,O
of,5007,O
relatives,5007,O
",",5007,O
a,5007,O
low,5007,O
free,5007,O
protein,5007,O
S,5007,O
level,5007,O
was,5007,O
the,5007,O
most,5007,O
reliable,5007,O
predictor,5007,O
of,5007,O
a,5007,O
PROS1,5007,B-SpecificDisease
gene,5007,I-SpecificDisease
defect,5007,I-SpecificDisease
(,5007,O
sensitivity,5007,O
97,5007,O
.,5007,O
7,5008,O
%,5008,O
",",5008,O
specificity,5008,O
100,5008,O
%,5008,O
),5008,O
.,5008,O
First-degree,5009,O
relatives,5009,O
with,5009,O
a,5009,O
PROS1,5009,B-SpecificDisease
gene,5009,I-SpecificDisease
defect,5009,I-SpecificDisease
had,5009,O
a,5009,O
5,5009,O
.,5009,O
0-fold,5010,O
higher,5010,O
risk,5010,O
of,5010,O
thrombosis,5010,B-SpecificDisease
(,5010,O
95,5010,O
%,5010,O
confidence,5010,O
interval,5010,O
",",5010,O
1,5010,O
.,5010,O
5-16,5011,O
.,5011,O
8,5012,O
),5012,O
than,5012,O
those,5012,O
with,5012,O
a,5012,O
normal,5012,O
PROS1,5012,O
gene,5012,O
and,5012,O
no,5012,O
other,5012,O
recognized,5012,O
thrombophilic,5012,B-SpecificDisease
defect,5012,I-SpecificDisease
.,5012,O
Although,5013,O
pregnancy/puerperium,5013,O
and,5013,O
immobility/trauma,5013,O
were,5013,O
important,5013,O
precipitating,5013,O
factors,5013,O
for,5013,O
thrombosis,5013,B-SpecificDisease
",",5013,O
almost,5013,O
half,5013,O
of,5013,O
the,5013,O
events,5013,O
were,5013,O
spontaneous,5013,O
.,5013,O
Relatives,5014,O
with,5014,O
splice-site,5014,O
or,5014,O
major,5014,O
structural,5014,O
defects,5014,B-SpecificDisease
in,5014,I-SpecificDisease
the,5014,I-SpecificDisease
PROS1,5014,I-SpecificDisease
gene,5014,I-SpecificDisease
were,5014,O
more,5014,O
likely,5014,O
to,5014,O
have,5014,O
had,5014,O
a,5014,O
thrombotic,5014,O
event,5014,O
and,5014,O
had,5014,O
significantly,5014,O
lower,5014,O
total,5014,O
and,5014,O
free,5014,O
protein,5014,O
S,5014,O
levels,5014,O
than,5014,O
those,5014,O
relatives,5014,O
having,5014,O
missense,5014,O
mutations,5014,O
.,5014,O
We,5015,O
conclude,5015,O
that,5015,O
persons,5015,O
with,5015,O
PROS1,5015,B-SpecificDisease
gene,5015,I-SpecificDisease
defects,5015,I-SpecificDisease
and,5015,O
protein,5015,B-SpecificDisease
S,5015,I-SpecificDisease
deficiency,5015,I-SpecificDisease
are,5015,O
at,5015,O
increased,5015,O
risk,5015,O
of,5015,O
thrombosis,5015,B-SpecificDisease
and,5015,O
that,5015,O
free,5015,O
protein,5015,O
S,5015,O
estimation,5015,O
offers,5015,O
the,5015,O
most,5015,O
reliable,5015,O
way,5015,O
of,5015,O
diagnosing,5015,O
the,5015,O
deficiency,5015,O
.,5015,O
(,5016,O
Blood,5016,O
.,5016,O
2000,5017,O
;,5017,O
95,5017,O
1935-1941,5017,O
),5017,O
.,5017,O
Autoimmune,5018,B-SpecificDisease
lymphoproliferative,5018,I-SpecificDisease
syndrome,5018,I-SpecificDisease
(,5018,O
ALPS,5018,B-SpecificDisease
),5018,O
in,5018,O
a,5018,O
child,5018,O
from,5018,O
consanguineous,5018,O
parents,5018,O
:,5018,O
a,5018,O
dominant,5018,O
or,5018,O
recessive,5018,O
disease,5018,O
?,5018,O
Autoimmune,5019,B-SpecificDisease
lymphoproliferative,5019,I-SpecificDisease
syndrome,5019,I-SpecificDisease
(,5019,O
ALPS,5019,B-SpecificDisease
),5019,O
is,5019,O
characterized,5019,O
by,5019,O
autoimmune,5019,O
features,5019,O
and,5019,O
lymphoproliferations,5019,O
and,5019,O
is,5019,O
generally,5019,O
caused,5019,O
by,5019,O
defective,5019,O
Fas-mediated,5019,O
apoptosis,5019,O
.,5019,O
This,5020,O
report,5020,O
describes,5020,O
a,5020,O
child,5020,O
with,5020,O
clinical,5020,O
features,5020,O
of,5020,O
ALPS,5020,B-SpecificDisease
without,5020,O
detectable,5020,O
Fas,5020,O
expression,5020,O
on,5020,O
freshly,5020,O
isolated,5020,O
blood,5020,O
leukocytes,5020,O
.,5020,O
Detection,5021,O
of,5021,O
FAS,5021,O
transcripts,5021,O
via,5021,O
real-time,5021,O
quantitative,5021,O
PCR,5021,O
made,5021,O
a,5021,O
severe,5021,O
transcriptional,5021,O
defect,5021,O
unlikely,5021,O
.,5021,O
Sequencing,5022,O
of,5022,O
the,5022,O
FAS,5022,O
gene,5022,O
revealed,5022,O
a,5022,O
20-nucleotide,5022,O
duplication,5022,O
in,5022,O
the,5022,O
last,5022,O
exon,5022,O
affecting,5022,O
the,5022,O
cytoplasmic,5022,O
signaling,5022,O
domain,5022,O
.,5022,O
The,5023,O
patient,5023,O
was,5023,O
homozygous,5023,O
for,5023,O
this,5023,O
mutation,5023,O
",",5023,O
whereas,5023,O
the,5023,O
consanguineous,5023,O
parents,5023,O
and,5023,O
the,5023,O
siblings,5023,O
were,5023,O
heterozygous,5023,O
.,5023,O
The,5024,O
patient,5024,O
reported,5024,O
here,5024,O
is,5024,O
a,5024,O
human,5024,O
homologue,5024,O
of,5024,O
the,5024,O
Fas-null,5024,O
mouse,5024,O
",",5024,O
inasmuch,5024,O
as,5024,O
she,5024,O
carries,5024,O
an,5024,O
autosomal,5024,O
homozygous,5024,O
mutation,5024,O
in,5024,O
the,5024,O
FAS,5024,O
gene,5024,O
and,5024,O
she,5024,O
shows,5024,O
the,5024,O
severe,5024,O
and,5024,O
accelerated,5024,O
ALPS,5024,B-Modifier
phenotype,5024,O
.,5024,O
The,5025,O
heterozygous,5025,O
family,5025,O
members,5025,O
did,5025,O
not,5025,O
have,5025,O
the,5025,O
ALPS,5025,B-Modifier
phenotype,5025,O
",",5025,O
indicating,5025,O
that,5025,O
the,5025,O
disease-causing,5025,O
FAS,5025,O
mutation,5025,O
in,5025,O
this,5025,O
family,5025,O
is,5025,O
autosomal,5025,O
recessive,5025,O
..,5025,O
Identification,5026,O
of,5026,O
novel,5026,O
imprinted,5026,O
transcripts,5026,O
in,5026,O
the,5026,O
Prader-Willi,5026,B-Modifier
syndrome,5026,I-Modifier
and,5026,O
Angelman,5026,B-Modifier
syndrome,5026,I-Modifier
deletion,5026,O
region,5026,O
:,5026,O
further,5026,O
evidence,5026,O
for,5026,O
regional,5026,O
imprinting,5026,O
control,5026,O
.,5026,O
Deletions,5027,O
and,5027,O
other,5027,O
abnormalities,5027,O
of,5027,O
human,5027,O
chromosome,5027,O
15q11-q13,5027,O
are,5027,O
associated,5027,O
with,5027,O
two,5027,O
developmental,5027,O
disorders,5027,O
",",5027,O
Prader-Willi,5027,B-SpecificDisease
syndrome,5027,I-SpecificDisease
(,5027,O
PWS,5027,B-SpecificDisease
),5027,O
and,5027,O
Angelman,5027,B-SpecificDisease
syndrome,5027,I-SpecificDisease
(,5027,O
AS,5027,B-SpecificDisease
),5027,O
.,5027,O
Loss,5028,O
of,5028,O
expression,5028,O
of,5028,O
imprinted,5028,O
",",5028,O
paternally,5028,O
expressed,5028,O
genes,5028,O
has,5028,O
been,5028,O
implicated,5028,O
in,5028,O
PWS,5028,B-SpecificDisease
.,5028,O
However,5029,O
",",5029,O
the,5029,O
number,5029,O
of,5029,O
imprinted,5029,O
genes,5029,O
that,5029,O
contribute,5029,O
to,5029,O
PWS,5029,B-SpecificDisease
",",5029,O
and,5029,O
the,5029,O
range,5029,O
over,5029,O
which,5029,O
the,5029,O
imprinting,5029,O
signal,5029,O
acts,5029,O
to,5029,O
silence,5029,O
one,5029,O
copy,5029,O
of,5029,O
the,5029,O
gene,5029,O
in,5029,O
a,5029,O
parent-of-origin-specific,5029,O
manner,5029,O
",",5029,O
are,5029,O
unknown,5029,O
.,5029,O
To,5030,O
identify,5030,O
additional,5030,O
imprinted,5030,O
genes,5030,O
that,5030,O
could,5030,O
contribute,5030,O
to,5030,O
the,5030,O
PWS,5030,B-Modifier
phenotype,5030,O
and,5030,O
to,5030,O
understand,5030,O
the,5030,O
regional,5030,O
control,5030,O
of,5030,O
imprinting,5030,O
in,5030,O
15q11-q13,5030,O
",",5030,O
we,5030,O
have,5030,O
constructed,5030,O
an,5030,O
imprinted,5030,O
transcript,5030,O
map,5030,O
of,5030,O
the,5030,O
PWS-AS,5030,O
deletion,5030,O
interval,5030,O
.,5030,O
The,5031,O
imprinting,5031,O
status,5031,O
of,5031,O
22,5031,O
expressed,5031,O
sequence,5031,O
tags,5031,O
derived,5031,O
from,5031,O
the,5031,O
radiation-hybrid,5031,O
human,5031,O
transcript,5031,O
maps,5031,O
or,5031,O
physical,5031,O
maps,5031,O
was,5031,O
determined,5031,O
in,5031,O
a,5031,O
reverse,5031,O
transcriptase-PCR,5031,O
assay,5031,O
and,5031,O
correlated,5031,O
with,5031,O
the,5031,O
position,5031,O
of,5031,O
the,5031,O
transcripts,5031,O
on,5031,O
the,5031,O
physical,5031,O
map,5031,O
.,5031,O
Seven,5032,O
new,5032,O
paternally,5032,O
expressed,5032,O
transcripts,5032,O
localize,5032,O
to,5032,O
an,5032,O
approximately,5032,O
1,5032,O
.,5032,O
5-Mb,5033,O
domain,5033,O
surrounding,5033,O
the,5033,O
SNRPN-associated,5033,O
imprinting,5033,O
center,5033,O
",",5033,O
which,5033,O
already,5033,O
includes,5033,O
four,5033,O
imprinted,5033,O
",",5033,O
paternally,5033,O
expressed,5033,O
genes,5033,O
.,5033,O
All,5034,O
other,5034,O
tested,5034,O
new,5034,O
transcripts,5034,O
in,5034,O
the,5034,O
deletion,5034,O
region,5034,O
were,5034,O
expressed,5034,O
from,5034,O
both,5034,O
alleles,5034,O
.,5034,O
A,5035,O
domain,5035,O
of,5035,O
exclusive,5035,O
paternal,5035,O
expression,5035,O
surrounding,5035,O
the,5035,O
imprinting,5035,O
center,5035,O
suggests,5035,O
strong,5035,O
regional,5035,O
control,5035,O
of,5035,O
the,5035,O
imprinting,5035,O
process,5035,O
.,5035,O
This,5036,O
study,5036,O
provides,5036,O
the,5036,O
means,5036,O
for,5036,O
further,5036,O
investigation,5036,O
of,5036,O
additional,5036,O
genes,5036,O
that,5036,O
cause,5036,O
or,5036,O
modify,5036,O
the,5036,O
phenotypes,5036,O
associated,5036,O
with,5036,O
rearrangements,5036,O
of,5036,O
15q11-q13,5036,O
.,5036,O
Combined,5037,O
analysis,5037,O
of,5037,O
hereditary,5037,B-Modifier
prostate,5037,I-Modifier
cancer,5037,I-Modifier
linkage,5037,O
to,5037,O
1q24-25,5037,O
:,5037,O
results,5037,O
from,5037,O
772,5037,O
hereditary,5037,B-Modifier
prostate,5037,I-Modifier
cancer,5037,I-Modifier
families,5037,O
from,5037,O
the,5037,O
International,5037,O
Consortium,5037,O
for,5037,O
Prostate,5037,B-Modifier
Cancer,5037,I-Modifier
Genetics,5037,O
.,5037,O
A,5038,O
previous,5038,O
linkage,5038,O
study,5038,O
provided,5038,O
evidence,5038,O
for,5038,O
a,5038,O
prostate,5038,B-Modifier
cancer-susceptibility,5038,O
locus,5038,O
at,5038,O
1q24-25,5038,O
.,5038,O
Subsequent,5039,O
reports,5039,O
in,5039,O
additional,5039,O
collections,5039,O
of,5039,O
families,5039,O
have,5039,O
yielded,5039,O
conflicting,5039,O
results,5039,O
.,5039,O
In,5040,O
addition,5040,O
",",5040,O
evidence,5040,O
for,5040,O
locus,5040,O
heterogeneity,5040,O
has,5040,O
been,5040,O
provided,5040,O
by,5040,O
the,5040,O
identification,5040,O
of,5040,O
other,5040,O
putative,5040,O
hereditary,5040,B-Modifier
prostate,5040,I-Modifier
cancer,5040,I-Modifier
loci,5040,O
on,5040,O
Xq27-28,5040,O
",",5040,O
1q42-43,5040,O
",",5040,O
and,5040,O
1p36,5040,O
.,5040,O
The,5041,O
present,5041,O
study,5041,O
describes,5041,O
a,5041,O
combined,5041,O
analysis,5041,O
for,5041,O
six,5041,O
markers,5041,O
in,5041,O
the,5041,O
1q24-25,5041,O
region,5041,O
in,5041,O
772,5041,O
families,5041,O
affected,5041,O
by,5041,O
hereditary,5041,B-SpecificDisease
prostate,5041,I-SpecificDisease
cancer,5041,I-SpecificDisease
and,5041,O
ascertained,5041,O
by,5041,O
the,5041,O
members,5041,O
of,5041,O
the,5041,O
International,5041,O
Consortium,5041,O
for,5041,O
Prostate,5041,B-Modifier
Cancer,5041,I-Modifier
Genetics,5041,O
(,5041,O
ICPCG,5041,O
),5041,O
from,5041,O
North,5041,O
America,5041,O
",",5041,O
Australia,5041,O
",",5041,O
Finland,5041,O
",",5041,O
Norway,5041,O
",",5041,O
Sweden,5041,O
",",5041,O
and,5041,O
the,5041,O
United,5041,O
Kingdom,5041,O
.,5041,O
Overall,5042,O
",",5042,O
there,5042,O
was,5042,O
some,5042,O
evidence,5042,O
for,5042,O
linkage,5042,O
",",5042,O
with,5042,O
a,5042,O
peak,5042,O
parametric,5042,O
multipoint,5042,O
LOD,5042,O
score,5042,O
assuming,5042,O
heterogeneity,5042,O
(,5042,O
HLOD,5042,O
),5042,O
of,5042,O
1,5042,O
.,5042,O
40,5043,O
(,5043,O
P,5043,O
=,5043,O
.,5043,O
01,5044,O
),5044,O
at,5044,O
D1S212,5044,O
.,5044,O
The,5045,O
estimated,5045,O
proportion,5045,O
of,5045,O
families,5045,O
(,5045,O
alpha,5045,O
),5045,O
linked,5045,O
to,5045,O
the,5045,O
locus,5045,O
was,5045,O
.,5045,O
06,5046,O
(,5046,O
1-LOD,5046,O
support,5046,O
interval,5046,O
.,5046,O
01-,5047,O
.,5047,O
12,5048,O
),5048,O
.,5048,O
This,5049,O
evidence,5049,O
was,5049,O
not,5049,O
observed,5049,O
by,5049,O
a,5049,O
nonparametric,5049,O
approach,5049,O
",",5049,O
presumably,5049,O
because,5049,O
of,5049,O
the,5049,O
extensive,5049,O
heterogeneity,5049,O
.,5049,O
Further,5050,O
parametric,5050,O
analysis,5050,O
revealed,5050,O
a,5050,O
significant,5050,O
effect,5050,O
of,5050,O
the,5050,O
presence,5050,O
of,5050,O
male-to-male,5050,O
disease,5050,O
transmission,5050,O
within,5050,O
the,5050,O
families,5050,O
.,5050,O
In,5051,O
the,5051,O
subset,5051,O
of,5051,O
491,5051,O
such,5051,O
families,5051,O
",",5051,O
the,5051,O
peak,5051,O
HLOD,5051,O
was,5051,O
2,5051,O
.,5051,O
In,5052,O
the,5052,O
subset,5052,O
of,5052,O
491,5052,O
such,5052,O
families,5052,O
",",5052,O
the,5052,O
peak,5052,O
HLOD,5052,O
was,5052,O
2,5052,O
.,5052,O
56,5053,O
(,5053,O
P,5053,O
=,5053,O
.,5053,O
0006,5054,O
),5054,O
and,5054,O
alpha,5054,O
=,5054,O
.,5054,O
11,5055,O
(,5055,O
1-LOD,5055,O
support,5055,O
interval,5055,O
.,5055,O
04-,5056,O
.,5056,O
19,5057,O
),5057,O
",",5057,O
compared,5057,O
with,5057,O
HLODs,5057,O
of,5057,O
0,5057,O
in,5057,O
the,5057,O
remaining,5057,O
281,5057,O
families,5057,O
.,5057,O
Within,5058,O
the,5058,O
families,5058,O
with,5058,O
male-to-male,5058,O
disease,5058,O
transmission,5058,O
",",5058,O
alpha,5058,O
increased,5058,O
with,5058,O
the,5058,O
early,5058,O
mean,5058,O
age,5058,O
at,5058,O
diagnosis,5058,O
(,5058,O
<,5058,O
65,5058,O
years,5058,O
",",5058,O
alpha,5058,O
=,5058,O
.,5058,O
19,5059,O
",",5059,O
with,5059,O
1-LOD,5059,O
support,5059,O
interval,5059,O
.,5059,O
06-,5060,O
.,5060,O
34,5061,O
),5061,O
and,5061,O
the,5061,O
number,5061,O
of,5061,O
affected,5061,O
family,5061,O
members,5061,O
(,5061,O
five,5061,O
or,5061,O
more,5061,O
family,5061,O
members,5061,O
",",5061,O
alpha,5061,O
=,5061,O
.,5061,O
15,5062,O
",",5062,O
with,5062,O
1-LOD,5062,O
support,5062,O
interval,5062,O
.,5062,O
04-,5063,O
.,5063,O
28,5064,O
),5064,O
.,5064,O
The,5065,O
highest,5065,O
value,5065,O
of,5065,O
alpha,5065,O
was,5065,O
observed,5065,O
for,5065,O
the,5065,O
48,5065,O
families,5065,O
that,5065,O
met,5065,O
all,5065,O
three,5065,O
criteria,5065,O
(,5065,O
peak,5065,O
HLOD,5065,O
=,5065,O
2,5065,O
.,5065,O
25,5066,O
",",5066,O
P,5066,O
=,5066,O
.,5066,O
001,5067,O
",",5067,O
alpha,5067,O
=,5067,O
.,5067,O
29,5068,O
",",5068,O
with,5068,O
1-LOD,5068,O
support,5068,O
interval,5068,O
.,5068,O
08-,5069,O
.,5069,O
53,5070,O
),5070,O
.,5070,O
These,5071,O
results,5071,O
support,5071,O
the,5071,O
finding,5071,O
of,5071,O
a,5071,O
prostate,5071,B-Modifier
cancer-susceptibility,5071,O
gene,5071,O
linked,5071,O
to,5071,O
1q24-25,5071,O
",",5071,O
albeit,5071,O
in,5071,O
a,5071,O
defined,5071,O
subset,5071,O
of,5071,O
prostate,5071,B-Modifier
cancer,5071,I-Modifier
families,5071,O
.,5071,O
Although,5072,O
HPC1,5072,O
accounts,5072,O
for,5072,O
only,5072,O
a,5072,O
small,5072,O
proportion,5072,O
of,5072,O
all,5072,O
families,5072,O
affected,5072,O
by,5072,O
hereditary,5072,B-SpecificDisease
prostate,5072,I-SpecificDisease
cancer,5072,I-SpecificDisease
",",5072,O
it,5072,O
appears,5072,O
to,5072,O
play,5072,O
a,5072,O
more,5072,O
prominent,5072,O
role,5072,O
in,5072,O
the,5072,O
subset,5072,O
of,5072,O
families,5072,O
with,5072,O
several,5072,O
members,5072,O
affected,5072,O
at,5072,O
an,5072,O
early,5072,O
age,5072,O
and,5072,O
with,5072,O
male-to-male,5072,O
disease,5072,O
transmission,5072,O
.,5072,O
A,5073,O
recurrent,5073,O
expansion,5073,O
of,5073,O
a,5073,O
maternal,5073,O
allele,5073,O
with,5073,O
36,5073,O
CAG,5073,O
repeats,5073,O
causes,5073,O
Huntington,5073,B-SpecificDisease
disease,5073,I-SpecificDisease
in,5073,O
two,5073,O
sisters,5073,O
.,5073,O
Large,5074,O
intergenerational,5074,O
repeat,5074,O
expansions,5074,O
of,5074,O
the,5074,O
CAG,5074,O
trinucleotide,5074,O
repeat,5074,O
in,5074,O
the,5074,O
HD,5074,B-Modifier
gene,5074,O
have,5074,O
been,5074,O
well,5074,O
documented,5074,O
for,5074,O
the,5074,O
male,5074,O
germline,5074,O
.,5074,O
We,5075,O
describe,5075,O
a,5075,O
recurrent,5075,O
large,5075,O
expansion,5075,O
of,5075,O
a,5075,O
maternal,5075,O
allele,5075,O
with,5075,O
36,5075,O
CAG,5075,O
repeats,5075,O
(,5075,O
to,5075,O
66,5075,O
and,5075,O
57,5075,O
repeats,5075,O
",",5075,O
respectively,5075,O
",",5075,O
in,5075,O
two,5075,O
daughters,5075,O
),5075,O
associated,5075,O
with,5075,O
onset,5075,O
of,5075,O
Huntington,5075,B-SpecificDisease
disease,5075,I-SpecificDisease
(,5075,O
HD,5075,B-SpecificDisease
),5075,O
in,5075,O
the,5075,O
second,5075,O
and,5075,O
third,5075,O
decade,5075,O
in,5075,O
a,5075,O
family,5075,O
without,5075,O
history,5075,O
of,5075,O
HD,5075,B-SpecificDisease
.,5075,O
Our,5076,O
findings,5076,O
give,5076,O
evidence,5076,O
of,5076,O
a,5076,O
gonadal,5076,O
mosaicism,5076,O
in,5076,O
the,5076,O
unaffected,5076,O
mother,5076,O
.,5076,O
We,5077,O
hypothesize,5077,O
that,5077,O
large,5077,O
expansions,5077,O
also,5077,O
occur,5077,O
in,5077,O
the,5077,O
female,5077,O
germline,5077,O
and,5077,O
that,5077,O
a,5077,O
negative,5077,O
selection,5077,O
of,5077,O
oocytes,5077,O
with,5077,O
long,5077,O
repeats,5077,O
might,5077,O
explain,5077,O
the,5077,O
different,5077,O
instability,5077,O
behavior,5077,O
of,5077,O
the,5077,O
male,5077,O
and,5077,O
the,5077,O
female,5077,O
germlines,5077,O
..,5077,O
Abnormal,5078,O
development,5078,O
of,5078,O
Purkinje,5078,O
cells,5078,O
and,5078,O
lymphocytes,5078,O
in,5078,O
Atm,5078,O
mutant,5078,O
mice,5078,O
.,5078,O
Motor,5079,B-DiseaseClass
incoordination,5079,I-DiseaseClass
",",5079,O
immune,5079,B-DiseaseClass
deficiencies,5079,I-DiseaseClass
",",5079,O
and,5079,O
an,5079,O
increased,5079,O
risk,5079,O
of,5079,O
cancer,5079,B-DiseaseClass
are,5079,O
the,5079,O
characteristic,5079,O
features,5079,O
of,5079,O
the,5079,O
hereditary,5079,B-DiseaseClass
disease,5079,I-DiseaseClass
ataxia-telangiectasia,5079,B-SpecificDisease
(,5079,O
A-T,5079,B-SpecificDisease
),5079,O
",",5079,O
which,5079,O
is,5079,O
caused,5079,O
by,5079,O
mutations,5079,O
in,5079,O
the,5079,O
ATM,5079,O
gene,5079,O
.,5079,O
Through,5080,O
gene,5080,O
targeting,5080,O
",",5080,O
we,5080,O
have,5080,O
generated,5080,O
a,5080,O
line,5080,O
of,5080,O
Atm,5080,O
mutant,5080,O
mice,5080,O
",",5080,O
Atm,5080,O
(,5080,O
y/y,5080,O
),5080,O
mice,5080,O
.,5080,O
In,5081,O
contrast,5081,O
to,5081,O
other,5081,O
Atm,5081,O
mutant,5081,O
mice,5081,O
",",5081,O
Atm,5081,O
(,5081,O
y/y,5081,O
),5081,O
mice,5081,O
show,5081,O
a,5081,O
lower,5081,O
incidence,5081,O
of,5081,O
thymic,5081,B-SpecificDisease
lymphoma,5081,I-SpecificDisease
and,5081,O
survive,5081,O
beyond,5081,O
a,5081,O
few,5081,O
months,5081,O
of,5081,O
age,5081,O
.,5081,O
Atm,5082,O
(,5082,O
y/y,5082,O
),5082,O
mice,5082,O
exhibit,5082,O
deficits,5082,O
in,5082,O
motor,5082,O
learning,5082,O
indicative,5082,O
of,5082,O
cerebellar,5082,B-DiseaseClass
dysfunction,5082,I-DiseaseClass
.,5082,O
Even,5083,O
though,5083,O
we,5083,O
found,5083,O
no,5083,O
gross,5083,O
cerebellar,5083,B-DiseaseClass
degeneration,5083,I-DiseaseClass
in,5083,O
older,5083,O
Atm,5083,O
(,5083,O
y/y,5083,O
),5083,O
animals,5083,O
",",5083,O
ectopic,5083,O
and,5083,O
abnormally,5083,O
differentiated,5083,O
Purkinje,5083,O
cells,5083,O
were,5083,O
apparent,5083,O
in,5083,O
mutant,5083,O
mice,5083,O
of,5083,O
all,5083,O
ages,5083,O
.,5083,O
These,5084,O
findings,5084,O
establish,5084,O
that,5084,O
some,5084,O
neuropathological,5084,B-DiseaseClass
abnormalities,5084,I-DiseaseClass
seen,5084,O
in,5084,O
A-T,5084,B-Modifier
patients,5084,O
also,5084,O
are,5084,O
present,5084,O
in,5084,O
Atm,5084,O
mutant,5084,O
mice,5084,O
.,5084,O
In,5085,O
addition,5085,O
",",5085,O
we,5085,O
report,5085,O
a,5085,O
previously,5085,O
unrecognized,5085,O
effect,5085,O
of,5085,O
Atm,5085,B-SpecificDisease
deficiency,5085,I-SpecificDisease
on,5085,O
development,5085,O
or,5085,O
maintenance,5085,O
of,5085,O
CD4,5085,O
(,5085,O
+,5085,O
),5085,O
8,5085,O
(,5085,O
+,5085,O
),5085,O
thymocytes,5085,O
.,5085,O
We,5086,O
discuss,5086,O
these,5086,O
findings,5086,O
in,5086,O
the,5086,O
context,5086,O
of,5086,O
the,5086,O
hypothesis,5086,O
that,5086,O
abnormal,5086,O
development,5086,O
of,5086,O
Purkinje,5086,O
cells,5086,O
and,5086,O
lymphocytes,5086,O
contributes,5086,O
to,5086,O
the,5086,O
pathogenesis,5086,O
of,5086,O
A-T,5086,B-SpecificDisease
..,5086,O
Novel,5087,O
mutations,5087,O
of,5087,O
the,5087,O
ATP7B,5087,O
gene,5087,O
in,5087,O
Japanese,5087,O
patients,5087,O
with,5087,O
Wilson,5087,B-SpecificDisease
disease,5087,I-SpecificDisease
.,5087,O
Wilson,5088,B-SpecificDisease
disease,5088,I-SpecificDisease
(,5088,O
WD,5088,B-SpecificDisease
),5088,O
is,5088,O
an,5088,O
autosomal,5088,B-DiseaseClass
recessive,5088,I-DiseaseClass
disorder,5088,I-DiseaseClass
characterized,5088,O
by,5088,O
copper,5088,O
accumulation,5088,O
in,5088,O
the,5088,O
liver,5088,O
",",5088,O
brain,5088,O
",",5088,O
kidneys,5088,O
",",5088,O
and,5088,O
corneas,5088,O
",",5088,O
and,5088,O
culminating,5088,O
in,5088,O
copper,5088,O
toxication,5088,O
in,5088,O
these,5088,O
organs,5088,O
.,5088,O
In,5089,O
this,5089,O
study,5089,O
",",5089,O
we,5089,O
analyzed,5089,O
mutations,5089,O
of,5089,O
the,5089,O
responsible,5089,O
gene,5089,O
",",5089,O
ATP7B,5089,O
",",5089,O
in,5089,O
four,5089,O
Japanese,5089,O
patients,5089,O
with,5089,O
WD,5089,B-SpecificDisease
.,5089,O
By,5090,O
direct,5090,O
sequencing,5090,O
",",5090,O
we,5090,O
identified,5090,O
five,5090,O
mutations,5090,O
",",5090,O
of,5090,O
which,5090,O
two,5090,O
were,5090,O
novel,5090,O
",",5090,O
and,5090,O
16,5090,O
polymorphisms,5090,O
",",5090,O
of,5090,O
which,5090,O
6,5090,O
were,5090,O
novel,5090,O
.,5090,O
The,5091,O
mutations,5091,O
2871delC,5091,O
and,5091,O
2513delA,5091,O
shift,5091,O
the,5091,O
reading,5091,O
frame,5091,O
so,5091,O
that,5091,O
truncated,5091,O
abnormal,5091,O
protein,5091,O
is,5091,O
expected,5091,O
.,5091,O
In,5092,O
contrast,5092,O
to,5092,O
these,5092,O
mutations,5092,O
found,5092,O
in,5092,O
patients,5092,O
with,5092,O
hepatic-type,5092,O
of,5092,O
early,5092,O
onset,5092,O
",",5092,O
the,5092,O
mutations,5092,O
A874V,5092,O
",",5092,O
R778L,5092,O
",",5092,O
and,5092,O
3892delGTC,5092,O
were,5092,O
either,5092,O
missense,5092,O
mutations,5092,O
or,5092,O
in,5092,O
frame,5092,O
1-amino,5092,O
acid,5092,O
deletion,5092,O
",",5092,O
and,5092,O
occurred,5092,O
in,5092,O
the,5092,O
patients,5092,O
with,5092,O
hepato-neurologic,5092,O
type,5092,O
of,5092,O
late,5092,O
onset,5092,O
.,5092,O
The,5093,O
mutations,5093,O
2871delC,5093,O
and,5093,O
R778L,5093,O
have,5093,O
been,5093,O
previously,5093,O
reported,5093,O
in,5093,O
a,5093,O
relatively,5093,O
large,5093,O
number,5093,O
of,5093,O
Japanese,5093,O
patients,5093,O
.,5093,O
In,5094,O
particular,5094,O
",",5094,O
R778L,5094,O
is,5094,O
known,5094,O
to,5094,O
be,5094,O
more,5094,O
prevalent,5094,O
in,5094,O
Asian,5094,O
countries,5094,O
than,5094,O
in,5094,O
other,5094,O
countries,5094,O
of,5094,O
the,5094,O
world,5094,O
.,5094,O
Our,5095,O
data,5095,O
are,5095,O
compatible,5095,O
with,5095,O
the,5095,O
hypothesis,5095,O
that,5095,O
the,5095,O
mutations,5095,O
tend,5095,O
to,5095,O
occur,5095,O
in,5095,O
a,5095,O
population-specific,5095,O
manner,5095,O
.,5095,O
Therefore,5096,O
",",5096,O
the,5096,O
accumulation,5096,O
of,5096,O
the,5096,O
types,5096,O
of,5096,O
mutations,5096,O
in,5096,O
Japanese,5096,O
patients,5096,O
with,5096,O
WD,5096,B-SpecificDisease
will,5096,O
facilitate,5096,O
the,5096,O
fast,5096,O
and,5096,O
effective,5096,O
genetic,5096,O
diagnosis,5096,O
of,5096,O
WD,5096,B-SpecificDisease
in,5096,O
Japanese,5096,O
patients,5096,O
..,5096,O
Autoinhibition,5097,O
and,5097,O
activation,5097,O
mechanisms,5097,O
of,5097,O
the,5097,O
Wiskott-Aldrich,5097,B-Modifier
syndrome,5097,I-Modifier
protein,5097,O
.,5097,O
The,5098,O
Rho-family,5098,O
GTPase,5098,O
",",5098,O
Cdc42,5098,O
",",5098,O
can,5098,O
regulate,5098,O
the,5098,O
actin,5098,O
cytoskeleton,5098,O
through,5098,O
activation,5098,O
of,5098,O
Wiskott-Aldrich,5098,B-Modifier
syndrome,5098,I-Modifier
protein,5098,O
(,5098,O
WASP,5098,O
),5098,O
family,5098,O
members,5098,O
.,5098,O
Activation,5099,O
relieves,5099,O
an,5099,O
autoinhibitory,5099,O
contact,5099,O
between,5099,O
the,5099,O
GTPase-binding,5099,O
domain,5099,O
and,5099,O
the,5099,O
carboxy-terminal,5099,O
region,5099,O
of,5099,O
WASP,5099,O
proteins,5099,O
.,5099,O
Here,5100,O
we,5100,O
report,5100,O
the,5100,O
autoinhibited,5100,O
structure,5100,O
of,5100,O
the,5100,O
GTPase-binding,5100,O
domain,5100,O
of,5100,O
WASP,5100,O
",",5100,O
which,5100,O
can,5100,O
be,5100,O
induced,5100,O
by,5100,O
the,5100,O
C-terminal,5100,O
region,5100,O
or,5100,O
by,5100,O
organic,5100,O
co-solvents,5100,O
.,5100,O
In,5101,O
the,5101,O
autoinhibited,5101,O
complex,5101,O
",",5101,O
intramolecular,5101,O
interactions,5101,O
with,5101,O
the,5101,O
GTPase-binding,5101,O
domain,5101,O
occlude,5101,O
residues,5101,O
of,5101,O
the,5101,O
C,5101,O
terminus,5101,O
that,5101,O
regulate,5101,O
the,5101,O
Arp2/3,5101,O
actin-nucleating,5101,O
complex,5101,O
.,5101,O
Binding,5102,O
of,5102,O
Cdc42,5102,O
to,5102,O
the,5102,O
GTPase-binding,5102,O
domain,5102,O
causes,5102,O
a,5102,O
dramatic,5102,O
conformational,5102,O
change,5102,O
",",5102,O
resulting,5102,O
in,5102,O
disruption,5102,O
of,5102,O
the,5102,O
hydrophobic,5102,O
core,5102,O
and,5102,O
release,5102,O
of,5102,O
the,5102,O
C,5102,O
terminus,5102,O
",",5102,O
enabling,5102,O
its,5102,O
interaction,5102,O
with,5102,O
the,5102,O
actin,5102,O
regulatory,5102,O
machinery,5102,O
.,5102,O
These,5103,O
data,5103,O
show,5103,O
that,5103,O
intrinsically,5103,O
unstructured,5103,O
peptides,5103,O
such,5103,O
as,5103,O
the,5103,O
GTPase-binding,5103,O
domain,5103,O
of,5103,O
WASP,5103,O
can,5103,O
be,5103,O
induced,5103,O
into,5103,O
distinct,5103,O
structural,5103,O
and,5103,O
functional,5103,O
states,5103,O
depending,5103,O
on,5103,O
context,5103,O
..,5103,O
hCds1-mediated,5104,O
phosphorylation,5104,O
of,5104,O
BRCA1,5104,O
regulates,5104,O
the,5104,O
DNA,5104,O
damage,5104,O
response,5104,O
.,5104,O
Mutations,5105,O
in,5105,O
the,5105,O
BRCA1,5105,O
(,5105,O
ref,5105,O
.,5105,O
1,5106,O
),5106,O
tumour,5106,B-Modifier
suppressor,5106,O
gene,5106,O
are,5106,O
found,5106,O
in,5106,O
almost,5106,O
all,5106,O
of,5106,O
the,5106,O
families,5106,O
with,5106,O
inherited,5106,B-CompositeMention
breast,5106,I-CompositeMention
and,5106,I-CompositeMention
ovarian,5106,I-CompositeMention
cancers,5106,I-CompositeMention
and,5106,O
about,5106,O
half,5106,O
of,5106,O
the,5106,O
families,5106,O
with,5106,O
only,5106,O
breast,5106,B-SpecificDisease
cancer,5106,I-SpecificDisease
.,5106,O
Although,5107,O
the,5107,O
biochemical,5107,O
function,5107,O
of,5107,O
BRCA1,5107,O
is,5107,O
not,5107,O
well,5107,O
understood,5107,O
",",5107,O
it,5107,O
is,5107,O
important,5107,O
for,5107,O
DNA,5107,O
damage,5107,O
repair,5107,O
and,5107,O
cell-cycle,5107,O
checkpoint,5107,O
.,5107,O
BRCA1,5108,O
exists,5108,O
in,5108,O
nuclear,5108,O
foci,5108,O
but,5108,O
is,5108,O
hyperphosphorylated,5108,O
and,5108,O
disperses,5108,O
after,5108,O
DNA,5108,O
damage,5108,O
.,5108,O
It,5109,O
is,5109,O
not,5109,O
known,5109,O
whether,5109,O
BRCA1,5109,O
phosphorylation,5109,O
and,5109,O
dispersion,5109,O
and,5109,O
its,5109,O
function,5109,O
in,5109,O
DNA,5109,O
damage,5109,O
response,5109,O
are,5109,O
related,5109,O
.,5109,O
In,5110,O
yeast,5110,O
the,5110,O
DNA,5110,O
damage,5110,O
response,5110,O
and,5110,O
the,5110,O
replication-block,5110,O
checkpoint,5110,O
are,5110,O
mediated,5110,O
partly,5110,O
through,5110,O
the,5110,O
Cds1,5110,O
kinase,5110,O
family,5110,O
.,5110,O
Here,5111,O
we,5111,O
report,5111,O
that,5111,O
the,5111,O
human,5111,O
Cds1,5111,O
kinase,5111,O
(,5111,O
hCds1/Chk2,5111,O
),5111,O
regulates,5111,O
BRCA1,5111,O
function,5111,O
after,5111,O
DNA,5111,O
damage,5111,O
by,5111,O
phosphorylating,5111,O
serine,5111,O
988,5111,O
of,5111,O
BRCA1,5111,O
.,5111,O
We,5112,O
show,5112,O
that,5112,O
hCds1,5112,O
and,5112,O
BRCA1,5112,O
interact,5112,O
and,5112,O
co-localize,5112,O
within,5112,O
discrete,5112,O
nuclear,5112,O
foci,5112,O
but,5112,O
separate,5112,O
after,5112,O
gamma,5112,O
irradiation,5112,O
.,5112,O
Phosphorylation,5113,O
of,5113,O
BRCA1,5113,O
at,5113,O
serine,5113,O
988,5113,O
is,5113,O
required,5113,O
for,5113,O
the,5113,O
release,5113,O
of,5113,O
BRCA1,5113,O
from,5113,O
hCds1,5113,O
.,5113,O
This,5114,O
phosphorylation,5114,O
is,5114,O
also,5114,O
important,5114,O
for,5114,O
the,5114,O
ability,5114,O
of,5114,O
BRCA1,5114,O
to,5114,O
restore,5114,O
survival,5114,O
after,5114,O
DNA,5114,O
damage,5114,O
in,5114,O
the,5114,O
BRCA1-mutated,5114,O
cell,5114,O
line,5114,O
HCC1937,5114,O
..,5114,O
Characterization,5115,O
of,5115,O
the,5115,O
rat,5115,O
spinocerebellar,5115,O
ataxia,5115,O
type,5115,O
3,5115,O
gene,5115,O
.,5115,O
Machado-Joseph,5116,B-SpecificDisease
disease,5116,I-SpecificDisease
(,5116,O
MJD,5116,B-SpecificDisease
),5116,O
belongs,5116,O
to,5116,O
a,5116,O
group,5116,O
of,5116,O
clinically,5116,O
and,5116,O
genetically,5116,O
heterogeneous,5116,O
neurodegenerative,5116,B-DiseaseClass
disorders,5116,I-DiseaseClass
characterized,5116,O
by,5116,O
progressive,5116,B-SpecificDisease
cerebellar,5116,I-SpecificDisease
ataxia,5116,I-SpecificDisease
.,5116,O
The,5117,O
disease-causing,5117,O
mutation,5117,O
has,5117,O
recently,5117,O
been,5117,O
identified,5117,O
as,5117,O
an,5117,O
unstable,5117,O
and,5117,O
expanded,5117,O
(,5117,O
CAG,5117,O
),5117,O
n,5117,O
trinucleotide,5117,O
repeat,5117,O
in,5117,O
a,5117,O
novel,5117,O
gene,5117,O
of,5117,O
unknown,5117,O
function,5117,O
.,5117,O
In,5118,O
Caucasians,5118,O
",",5118,O
repeat,5118,O
expansions,5118,O
in,5118,O
the,5118,O
MJD1,5118,O
gene,5118,O
have,5118,O
also,5118,O
been,5118,O
found,5118,O
in,5118,O
patients,5118,O
with,5118,O
the,5118,O
clinically,5118,O
distinct,5118,O
autosomal,5118,O
dominant,5118,O
spinocerebellar,5118,B-SpecificDisease
ataxia,5118,I-SpecificDisease
type,5118,I-SpecificDisease
3,5118,I-SpecificDisease
(,5118,O
SCA3,5118,B-SpecificDisease
),5118,O
.,5118,O
In,5119,O
order,5119,O
to,5119,O
gain,5119,O
insight,5119,O
into,5119,O
the,5119,O
biology,5119,O
of,5119,O
the,5119,O
MJD1/SCA3,5119,O
gene,5119,O
we,5119,O
cloned,5119,O
the,5119,O
rat,5119,O
homologue,5119,O
and,5119,O
studied,5119,O
its,5119,O
expression,5119,O
.,5119,O
The,5120,O
rat,5120,O
and,5120,O
human,5120,O
ataxin-3,5120,O
genes,5120,O
are,5120,O
highly,5120,O
homologous,5120,O
with,5120,O
an,5120,O
overall,5120,O
sequence,5120,O
identity,5120,O
of,5120,O
approximately,5120,O
88,5120,O
%,5120,O
.,5120,O
However,5121,O
",",5121,O
the,5121,O
C-terminal,5121,O
end,5121,O
of,5121,O
the,5121,O
putative,5121,O
protein,5121,O
differs,5121,O
strongly,5121,O
from,5121,O
the,5121,O
published,5121,O
human,5121,O
sequence,5121,O
.,5121,O
The,5122,O
(,5122,O
CAG,5122,O
),5122,O
n,5122,O
block,5122,O
in,5122,O
the,5122,O
rat,5122,O
cDNA,5122,O
consists,5122,O
of,5122,O
just,5122,O
three,5122,O
interrupted,5122,O
units,5122,O
suggesting,5122,O
that,5122,O
a,5122,O
long,5122,O
polyglutamine,5122,O
stretch,5122,O
is,5122,O
not,5122,O
essential,5122,O
for,5122,O
the,5122,O
normal,5122,O
function,5122,O
of,5122,O
the,5122,O
ataxin-3,5122,O
protein,5122,O
in,5122,O
rodents,5122,O
.,5122,O
The,5123,O
expression,5123,O
pattern,5123,O
of,5123,O
the,5123,O
SCA3,5123,O
gene,5123,O
in,5123,O
various,5123,O
rat,5123,O
and,5123,O
human,5123,O
tissues,5123,O
was,5123,O
investigated,5123,O
by,5123,O
Northern,5123,O
blot,5123,O
analyses,5123,O
.,5123,O
The,5124,O
mature,5124,O
transcript,5124,O
is,5124,O
approximately,5124,O
6,5124,O
kb,5124,O
in,5124,O
length,5124,O
.,5124,O
In,5125,O
rat,5125,O
testis,5125,O
",",5125,O
a,5125,O
smaller,5125,O
transcript,5125,O
of,5125,O
1,5125,O
.,5125,O
3,5126,O
kb,5126,O
was,5126,O
identified,5126,O
.,5126,O
Transcription,5127,O
of,5127,O
rsca3,5127,O
was,5127,O
detected,5127,O
in,5127,O
most,5127,O
rat,5127,O
tissues,5127,O
including,5127,O
brain,5127,O
.,5127,O
Analyzing,5128,O
the,5128,O
expression,5128,O
level,5128,O
of,5128,O
the,5128,O
SCA3,5128,O
gene,5128,O
in,5128,O
several,5128,O
human,5128,O
brain,5128,O
sections,5128,O
revealed,5128,O
no,5128,O
significant,5128,O
higher,5128,O
mRNA,5128,O
level,5128,O
in,5128,O
regions,5128,O
predominantly,5128,O
affected,5128,O
in,5128,O
MJD,5128,B-SpecificDisease
.,5128,O
Thus,5129,O
additional,5129,O
molecules,5129,O
and/or,5129,O
regulatory,5129,O
events,5129,O
are,5129,O
necessary,5129,O
to,5129,O
explain,5129,O
the,5129,O
exclusive,5129,O
degeneration,5129,B-DiseaseClass
of,5129,I-DiseaseClass
certain,5129,I-DiseaseClass
brain,5129,I-DiseaseClass
areas,5129,I-DiseaseClass
.,5129,O
Emerin,5130,B-SpecificDisease
",",5130,I-SpecificDisease
deficiency,5130,I-SpecificDisease
of,5130,O
which,5130,O
causes,5130,O
Emery-Dreifuss,5130,B-SpecificDisease
muscular,5130,I-SpecificDisease
dystrophy,5130,I-SpecificDisease
",",5130,O
is,5130,O
localized,5130,O
at,5130,O
the,5130,O
inner,5130,O
nuclear,5130,O
membrane,5130,O
.,5130,O
X-linked,5131,B-SpecificDisease
recessive,5131,I-SpecificDisease
Emery-Dreifuss,5131,I-SpecificDisease
muscular,5131,I-SpecificDisease
dystrophy,5131,I-SpecificDisease
(,5131,O
EDMD,5131,B-SpecificDisease
),5131,O
is,5131,O
an,5131,O
inherited,5131,B-DiseaseClass
muscle,5131,I-DiseaseClass
disorder,5131,I-DiseaseClass
characterized,5131,O
by,5131,O
the,5131,O
clinical,5131,O
triad,5131,O
of,5131,O
progressive,5131,O
wasting,5131,B-SpecificDisease
of,5131,I-SpecificDisease
humero-peroneal,5131,I-SpecificDisease
muscles,5131,I-SpecificDisease
",",5131,O
early,5131,O
contractures,5131,B-CompositeMention
of,5131,I-CompositeMention
the,5131,I-CompositeMention
elbows,5131,I-CompositeMention
",",5131,I-CompositeMention
Achilles,5131,I-CompositeMention
tendons,5131,I-CompositeMention
and,5131,I-CompositeMention
postcervical,5131,I-CompositeMention
muscles,5131,I-CompositeMention
",",5131,O
and,5131,O
cardiac,5131,B-SpecificDisease
conduction,5131,I-SpecificDisease
block,5131,I-SpecificDisease
with,5131,O
a,5131,O
high,5131,O
risk,5131,O
of,5131,O
sudden,5131,B-SpecificDisease
death,5131,I-SpecificDisease
.,5131,O
The,5132,O
gene,5132,O
for,5132,O
EDMD,5132,B-SpecificDisease
on,5132,O
Xq28,5132,O
encodes,5132,O
a,5132,O
novel,5132,O
protein,5132,O
named,5132,O
emerin,5132,O
that,5132,O
localizes,5132,O
at,5132,O
the,5132,O
nuclear,5132,O
membrane,5132,O
of,5132,O
skeletal,5132,O
",",5132,O
cardiac,5132,O
and,5132,O
smooth,5132,O
muscles,5132,O
and,5132,O
some,5132,O
other,5132,O
non-muscle,5132,O
tissues,5132,O
.,5132,O
To,5133,O
investigate,5133,O
a,5133,O
possible,5133,O
physiological,5133,O
role,5133,O
for,5133,O
emerin,5133,O
",",5133,O
we,5133,O
examined,5133,O
the,5133,O
ultrastructural,5133,O
localization,5133,O
of,5133,O
the,5133,O
protein,5133,O
in,5133,O
human,5133,O
skeletal,5133,O
muscle,5133,O
and,5133,O
HeLa,5133,O
cells,5133,O
",",5133,O
using,5133,O
ultrathin,5133,O
cryosections,5133,O
.,5133,O
We,5134,O
found,5134,O
that,5134,O
the,5134,O
immune-labeled,5134,O
colloidal,5134,O
gold,5134,O
particles,5134,O
were,5134,O
localized,5134,O
on,5134,O
the,5134,O
nucleoplasmic,5134,O
surface,5134,O
of,5134,O
the,5134,O
inner,5134,O
nuclear,5134,O
membrane,5134,O
",",5134,O
but,5134,O
not,5134,O
on,5134,O
the,5134,O
nuclear,5134,O
pore,5134,O
.,5134,O
Emerin,5135,O
stayed,5135,O
on,5135,O
the,5135,O
cytoplasmic,5135,O
surface,5135,O
of,5135,O
the,5135,O
nuclear,5135,O
lamina,5135,O
",",5135,O
even,5135,O
after,5135,O
detergent,5135,O
treatment,5135,O
that,5135,O
solubilizes,5135,O
membrane,5135,O
lipids,5135,O
and,5135,O
washes,5135,O
out,5135,O
membrane,5135,O
proteins,5135,O
.,5135,O
These,5136,O
results,5136,O
suggest,5136,O
that,5136,O
emerin,5136,O
anchors,5136,O
at,5136,O
the,5136,O
inner,5136,O
nuclear,5136,O
membrane,5136,O
through,5136,O
the,5136,O
hydrophobic,5136,O
stretch,5136,O
",",5136,O
and,5136,O
protrudes,5136,O
from,5136,O
the,5136,O
hydrophilic,5136,O
region,5136,O
to,5136,O
the,5136,O
nucleoplasm,5136,O
where,5136,O
it,5136,O
interacts,5136,O
with,5136,O
the,5136,O
nuclear,5136,O
lamina,5136,O
.,5136,O
We,5137,O
speculate,5137,O
that,5137,O
emerin,5137,O
contributes,5137,O
to,5137,O
maintain,5137,O
the,5137,O
nuclear,5137,O
structure,5137,O
and,5137,O
stability,5137,O
",",5137,O
as,5137,O
well,5137,O
as,5137,O
nuclear,5137,O
functions,5137,O
",",5137,O
particularly,5137,O
in,5137,O
muscle,5137,O
tissues,5137,O
that,5137,O
have,5137,O
severe,5137,O
stress,5137,O
with,5137,O
rigorous,5137,O
contraction-relaxation,5137,O
movements,5137,O
and,5137,O
calcium,5137,O
flux,5137,O
..,5137,O
Locus,5138,O
heterogeneity,5138,O
in,5138,O
Friedreich,5138,B-SpecificDisease
ataxia,5138,I-SpecificDisease
.,5138,O
Friedreich,5139,B-SpecificDisease
ataxia,5139,I-SpecificDisease
(,5139,O
FRDA,5139,B-SpecificDisease
),5139,O
is,5139,O
the,5139,O
most,5139,O
common,5139,O
form,5139,O
of,5139,O
autosomal,5139,B-DiseaseClass
recessive,5139,I-DiseaseClass
ataxia,5139,I-DiseaseClass
.,5139,O
The,5140,O
disease,5140,O
locus,5140,O
was,5140,O
assigned,5140,O
to,5140,O
chromosome,5140,O
9,5140,O
and,5140,O
the,5140,O
disease,5140,O
gene,5140,O
",",5140,O
STM7/X25,5140,O
",",5140,O
has,5140,O
been,5140,O
isolated,5140,O
.,5140,O
To,5141,O
date,5141,O
most,5141,O
data,5141,O
suggest,5141,O
locus,5141,O
homogeneity,5141,O
in,5141,O
FRDA,5141,B-SpecificDisease
.,5141,O
We,5142,O
now,5142,O
provide,5142,O
strong,5142,O
evidence,5142,O
of,5142,O
a,5142,O
second,5142,O
FRDA,5142,B-Modifier
locus,5142,O
.,5142,O
Studying,5143,O
two,5143,O
siblings,5143,O
with,5143,O
FRDA,5143,B-SpecificDisease
from,5143,O
two,5143,O
families,5143,O
we,5143,O
did,5143,O
not,5143,O
detect,5143,O
a,5143,O
mutation,5143,O
in,5143,O
STM7/X25,5143,O
.,5143,O
Haplotype,5144,O
analysis,5144,O
of,5144,O
the,5144,O
STM7/X25,5144,O
region,5144,O
of,5144,O
chromosome,5144,O
9,5144,O
demonstrated,5144,O
that,5144,O
the,5144,O
relevant,5144,O
portion,5144,O
of,5144,O
chromosome,5144,O
9,5144,O
differs,5144,O
in,5144,O
the,5144,O
patients,5144,O
.,5144,O
Although,5145,O
the,5145,O
patients,5145,O
studied,5145,O
had,5145,O
typical,5145,O
FRDA,5145,B-SpecificDisease
",",5145,O
one,5145,O
sibpair,5145,O
had,5145,O
the,5145,O
uncommon,5145,O
symptom,5145,O
of,5145,O
retained,5145,O
tendon,5145,O
reflexes,5145,O
.,5145,O
In,5146,O
order,5146,O
to,5146,O
investigate,5146,O
whether,5146,O
retained,5146,O
tendon,5146,O
reflexes,5146,O
are,5146,O
characteristic,5146,O
of,5146,O
FRDA,5146,B-SpecificDisease
caused,5146,O
by,5146,O
the,5146,O
second,5146,O
locus,5146,O
",",5146,O
FRDA2,5146,O
",",5146,O
we,5146,O
studied,5146,O
an,5146,O
unrelated,5146,O
FRDA,5146,B-Modifier
patient,5146,O
with,5146,O
retained,5146,O
tendon,5146,O
reflexes,5146,O
.,5146,O
The,5147,O
observation,5147,O
of,5147,O
typical,5147,O
mutations,5147,O
in,5147,O
STM7/X25,5147,O
(,5147,O
GAA,5147,O
expansions,5147,O
),5147,O
in,5147,O
this,5147,O
patient,5147,O
demonstrates,5147,O
that,5147,O
the,5147,O
two,5147,O
genetically,5147,O
different,5147,O
forms,5147,O
of,5147,O
FRDA,5147,B-SpecificDisease
can,5147,O
not,5147,O
be,5147,O
distinguished,5147,O
clinically,5147,O
..,5147,O
Glycerol,5148,O
as,5148,O
a,5148,O
correlate,5148,O
of,5148,O
impaired,5148,B-SpecificDisease
glucose,5148,I-SpecificDisease
tolerance,5148,I-SpecificDisease
:,5148,O
dissection,5148,O
of,5148,O
a,5148,O
complex,5148,O
system,5148,O
by,5148,O
use,5148,O
of,5148,O
a,5148,O
simple,5148,O
genetic,5148,O
trait,5148,O
.,5148,O
Glycerol,5149,O
kinase,5149,O
(,5149,O
GK,5149,O
),5149,O
represents,5149,O
the,5149,O
primary,5149,O
entry,5149,O
of,5149,O
glycerol,5149,O
into,5149,O
glucose,5149,O
and,5149,O
triglyceride,5149,O
metabolism,5149,O
.,5149,O
Impaired,5150,B-SpecificDisease
glucose,5150,I-SpecificDisease
tolerance,5150,I-SpecificDisease
(,5150,O
IGT,5150,B-SpecificDisease
),5150,O
and,5150,O
hypertriglyceridemia,5150,B-SpecificDisease
are,5150,O
associated,5150,O
with,5150,O
an,5150,O
increased,5150,O
risk,5150,O
of,5150,O
diabetes,5150,B-SpecificDisease
mellitus,5150,I-SpecificDisease
and,5150,O
cardiovascular,5150,B-SpecificDisease
disease,5150,I-SpecificDisease
.,5150,O
The,5151,O
relationship,5151,O
between,5151,O
glycerol,5151,O
and,5151,O
the,5151,O
risk,5151,O
of,5151,O
IGT,5151,B-SpecificDisease
",",5151,O
however,5151,O
",",5151,O
is,5151,O
poorly,5151,O
understood,5151,O
.,5151,O
We,5152,O
therefore,5152,O
undertook,5152,O
the,5152,O
study,5152,O
of,5152,O
fasting,5152,O
plasma,5152,O
glycerol,5152,O
levels,5152,O
in,5152,O
a,5152,O
cohort,5152,O
of,5152,O
1,5152,O
",",5152,O
056,5152,O
unrelated,5152,O
men,5152,O
and,5152,O
women,5152,O
of,5152,O
French-Canadian,5152,O
descent,5152,O
.,5152,O
Family,5153,O
screening,5153,O
in,5153,O
the,5153,O
initial,5153,O
cohort,5153,O
identified,5153,O
18,5153,O
men,5153,O
from,5153,O
five,5153,O
families,5153,O
with,5153,O
severe,5153,O
hyperglycerolemia,5153,B-SpecificDisease
(,5153,O
values,5153,O
above,5153,O
2,5153,O
.,5153,O
0,5154,O
mmol/liter,5154,O
),5154,O
and,5154,O
demonstrated,5154,O
an,5154,O
X-linked,5154,O
pattern,5154,O
of,5154,O
inheritance,5154,O
.,5154,O
Linkage,5155,O
analysis,5155,O
of,5155,O
the,5155,O
data,5155,O
from,5155,O
12,5155,O
microsatellite,5155,O
markers,5155,O
surrounding,5155,O
the,5155,O
Xp21,5155,O
.,5155,O
3,5156,O
GK,5156,O
gene,5156,O
resulted,5156,O
in,5156,O
a,5156,O
peak,5156,O
LOD,5156,O
score,5156,O
of,5156,O
3,5156,O
.,5156,O
46,5157,O
",",5157,O
centered,5157,O
around,5157,O
marker,5157,O
DXS8039,5157,O
.,5157,O
In,5158,O
addition,5158,O
",",5158,O
since,5158,O
all,5158,O
of,5158,O
the,5158,O
families,5158,O
originated,5158,O
in,5158,O
a,5158,O
population,5158,O
with,5158,O
a,5158,O
proven,5158,O
founder,5158,O
effect-the,5158,O
Saguenay,5158,O
Lac-St.,5158,O
-Jean,5158,O
region,5158,O
of,5158,O
Quebec-a,5158,O
common,5158,O
disease,5158,O
haplotype,5158,O
was,5158,O
sought,5158,O
.,5158,O
Indeed,5159,O
",",5159,O
a,5159,O
six-marker,5159,O
haplotype,5159,O
extending,5159,O
over,5159,O
a,5159,O
region,5159,O
of,5159,O
5,5159,O
.,5159,O
5,5160,O
cM,5160,O
was,5160,O
observed,5160,O
in,5160,O
all,5160,O
families,5160,O
.,5160,O
Resequencing,5161,O
of,5161,O
the,5161,O
GK,5161,O
gene,5161,O
in,5161,O
family,5161,O
members,5161,O
led,5161,O
to,5161,O
the,5161,O
discovery,5161,O
of,5161,O
a,5161,O
N288D,5161,O
missense,5161,O
mutation,5161,O
in,5161,O
exon,5161,O
10,5161,O
",",5161,O
which,5161,O
resulted,5161,O
in,5161,O
the,5161,O
substitution,5161,O
of,5161,O
a,5161,O
highly,5161,O
conserved,5161,O
asparagine,5161,O
residue,5161,O
by,5161,O
a,5161,O
negatively,5161,O
charged,5161,O
aspartic,5161,O
acid,5161,O
.,5161,O
Clinical,5162,O
and,5162,O
molecular,5162,O
genetics,5162,O
of,5162,O
primary,5162,B-DiseaseClass
dystonias,5162,I-DiseaseClass
.,5162,O
Primary,5163,B-DiseaseClass
dystonias,5163,I-DiseaseClass
are,5163,O
movement,5163,B-DiseaseClass
disorders,5163,I-DiseaseClass
with,5163,O
dystonia,5163,B-DiseaseClass
as,5163,O
a,5163,O
major,5163,O
symptom,5163,O
.,5163,O
They,5164,O
are,5164,O
frequently,5164,O
inherited,5164,O
as,5164,O
Mendelian,5164,O
traits,5164,O
.,5164,O
There,5165,O
are,5165,O
at,5165,O
least,5165,O
eight,5165,O
clinically,5165,O
distinct,5165,O
autosomal,5165,O
dominant,5165,O
and,5165,O
two,5165,O
X-linked,5165,O
recessive,5165,O
forms,5165,O
.,5165,O
In,5166,O
addition,5166,O
",",5166,O
pedigree,5166,O
analyses,5166,O
suggest,5166,O
the,5166,O
occurrence,5166,O
of,5166,O
an,5166,O
autosomal,5166,O
recessive,5166,O
variant,5166,O
.,5166,O
The,5167,O
clinical,5167,O
classification,5167,O
is,5167,O
increasingly,5167,O
being,5167,O
replaced,5167,O
by,5167,O
a,5167,O
genetic,5167,O
one,5167,O
.,5167,O
To,5168,O
date,5168,O
gene,5168,O
loci,5168,O
have,5168,O
been,5168,O
identified,5168,O
in,5168,O
at,5168,O
least,5168,O
six,5168,O
autosomal,5168,O
dominant,5168,O
forms,5168,O
",",5168,O
i.,5168,O
e.,5168,O
",",5168,O
in,5168,O
idiopathic,5168,B-SpecificDisease
torsion,5168,I-SpecificDisease
dystonia,5168,I-SpecificDisease
(,5168,O
9q34,5168,O
),5168,O
",",5168,O
focal,5168,B-SpecificDisease
dystonia,5168,I-SpecificDisease
(,5168,O
18p,5168,O
),5168,O
",",5168,O
adult-onset,5168,O
idiopathic,5168,B-SpecificDisease
torsion,5168,I-SpecificDisease
dystonia,5168,I-SpecificDisease
of,5168,O
mixed,5168,O
type,5168,O
(,5168,O
8p21-q22,5168,O
),5168,O
",",5168,O
dopa-responsive,5168,B-SpecificDisease
dystonia,5168,I-SpecificDisease
(,5168,O
14q22,5168,O
.,5168,O
1-q22,5169,O
.,5169,O
2,5170,O
),5170,O
",",5170,O
and,5170,O
paroxysmal,5170,B-SpecificDisease
dystonic,5170,I-SpecificDisease
choreoathetosis,5170,I-SpecificDisease
(,5170,O
2q25-q33,5170,O
;,5170,O
1p21-p13,5170,O
.,5170,O
3,5171,O
),5171,O
.,5171,O
Gene,5172,O
loci,5172,O
in,5172,O
the,5172,O
X-linked,5172,O
recessive,5172,O
forms,5172,O
have,5172,O
been,5172,O
assigned,5172,O
to,5172,O
Xq13,5172,O
.,5172,O
1,5173,O
in,5173,O
the,5173,O
X-linked,5173,B-SpecificDisease
dystonia,5173,I-SpecificDisease
parkinsonism,5173,I-SpecificDisease
syndrome,5173,I-SpecificDisease
and,5173,O
to,5173,O
Xq22,5173,O
in,5173,O
X-linked,5173,B-DiseaseClass
sensorineural,5173,I-DiseaseClass
deafness,5173,I-DiseaseClass
",",5173,O
dystonia,5173,B-DiseaseClass
",",5173,O
and,5173,O
mental,5173,B-DiseaseClass
retardation,5173,I-DiseaseClass
.,5173,O
The,5174,O
disease,5174,O
genes,5174,O
have,5174,O
been,5174,O
identified,5174,O
in,5174,O
two,5174,O
autosomal,5174,O
dominant,5174,O
forms,5174,O
and,5174,O
in,5174,O
one,5174,O
X-linked,5174,O
recessive,5174,O
form,5174,O
.,5174,O
Mutations,5175,O
in,5175,O
a,5175,O
gene,5175,O
coding,5175,O
for,5175,O
an,5175,O
ATP-binding,5175,O
protein,5175,O
were,5175,O
detected,5175,O
in,5175,O
idiopathic,5175,B-SpecificDisease
torsion,5175,I-SpecificDisease
dystonia,5175,I-SpecificDisease
(,5175,O
DYT1,5175,O
),5175,O
",",5175,O
and,5175,O
the,5175,O
GTP,5175,O
cyclohydrolase,5175,O
1,5175,O
gene,5175,O
is,5175,O
mutated,5175,O
in,5175,O
dopa-responsive,5175,B-SpecificDisease
dystonia,5175,I-SpecificDisease
(,5175,O
DYT5,5175,O
),5175,O
.,5175,O
In,5176,O
sensorineural,5176,B-DiseaseClass
deafness,5176,I-DiseaseClass
",",5176,O
dystonia,5176,B-DiseaseClass
",",5176,O
and,5176,O
mental,5176,B-DiseaseClass
retardation,5176,I-DiseaseClass
",",5176,O
mutations,5176,O
were,5176,O
found,5176,O
in,5176,O
the,5176,O
gene,5176,O
DDP,5176,O
coding,5176,O
for,5176,O
a,5176,O
polypeptide,5176,O
of,5176,O
unknown,5176,O
function,5176,O
.,5176,O
This,5177,O
article,5177,O
reviews,5177,O
the,5177,O
clinical,5177,O
and,5177,O
molecular,5177,O
genetics,5177,O
of,5177,O
primary,5177,B-DiseaseClass
dystonias,5177,I-DiseaseClass
",",5177,O
critically,5177,O
discusses,5177,O
present,5177,O
findings,5177,O
",",5177,O
and,5177,O
proposes,5177,O
referring,5177,O
to,5177,O
the,5177,O
known,5177,O
forms,5177,O
",",5177,O
most,5177,O
of,5177,O
which,5177,O
can,5177,O
be,5177,O
distinguished,5177,O
by,5177,O
genetic,5177,O
criteria,5177,O
",",5177,O
as,5177,O
dystonias,5177,B-CompositeMention
1-12,5177,I-CompositeMention
.,5177,O
Determination,5178,O
of,5178,O
30,5178,O
X-linked,5178,B-Modifier
adrenoleukodystrophy,5178,I-Modifier
mutations,5178,O
",",5178,O
including,5178,O
15,5178,O
not,5178,O
previously,5178,O
described,5178,O
.,5178,O
X-linked,5179,B-SpecificDisease
Adrenoleukodystrophy,5179,I-SpecificDisease
(,5179,O
X-ALD,5179,B-SpecificDisease
),5179,O
is,5179,O
the,5179,O
most,5179,O
frequent,5179,O
peroxisomal,5179,B-DiseaseClass
disease,5179,I-DiseaseClass
.,5179,O
It,5180,O
mainly,5180,O
involves,5180,O
the,5180,O
nervous,5180,O
system,5180,O
white,5180,O
matter,5180,O
",",5180,O
adrenal,5180,O
cortex,5180,O
and,5180,O
testes,5180,O
.,5180,O
Several,5181,O
distinct,5181,O
clinical,5181,O
phenotypes,5181,O
are,5181,O
known,5181,O
.,5181,O
The,5182,O
principal,5182,O
biochemical,5182,O
abnormality,5182,O
is,5182,O
the,5182,O
accumulation,5182,O
of,5182,O
saturated,5182,O
very-long-chain,5182,O
fatty,5182,O
acids,5182,O
(,5182,O
VLCFAs,5182,O
>,5182,O
C22,5182,O
0,5182,O
",",5182,O
mainly,5182,O
C26,5182,O
0,5182,O
),5182,O
",",5182,O
which,5182,O
is,5182,O
due,5182,O
to,5182,O
impaired,5182,O
capacity,5182,O
for,5182,O
beta-oxidation,5182,O
in,5182,O
peroxisomes,5182,O
.,5182,O
Diagnosis,5183,O
is,5183,O
usually,5183,O
based,5183,O
on,5183,O
the,5183,O
VLCFA,5183,O
levels,5183,O
in,5183,O
plasma,5183,O
or,5183,O
cultured,5183,O
skin,5183,O
fibroblasts,5183,O
in,5183,O
both,5183,O
patients,5183,O
and,5183,O
carriers,5183,O
.,5183,O
In,5184,O
0,5184,O
.,5184,O
1,5185,O
%,5185,O
of,5185,O
affected,5185,O
males,5185,O
",",5185,O
however,5185,O
",",5185,O
the,5185,O
plasma,5185,O
C26,5185,O
0,5185,O
level,5185,O
is,5185,O
borderline,5185,O
normal,5185,O
",",5185,O
and,5185,O
15,5185,O
%,5185,O
of,5185,O
obligate,5185,O
female,5185,O
carriers,5185,O
have,5185,O
normal,5185,O
results,5185,O
.,5185,O
Effective,5186,O
mutation,5186,O
detection,5186,O
in,5186,O
these,5186,O
families,5186,O
is,5186,O
therefore,5186,O
fundamental,5186,O
to,5186,O
unambiguously,5186,O
determine,5186,O
the,5186,O
genetic,5186,O
status,5186,O
of,5186,O
each,5186,O
individual,5186,O
at,5186,O
risk,5186,O
.,5186,O
Of,5187,O
particular,5187,O
concern,5187,O
are,5187,O
female,5187,O
members,5187,O
of,5187,O
kindreds,5187,O
segregating,5187,O
X-ALD,5187,B-Modifier
mutations,5187,O
",",5187,O
because,5187,O
normal,5187,O
VLCFA,5187,O
levels,5187,O
do,5187,O
not,5187,O
guarantee,5187,O
lack,5187,O
of,5187,O
carrier,5187,O
status,5187,O
.,5187,O
We,5188,O
describe,5188,O
a,5188,O
fast,5188,O
method,5188,O
for,5188,O
detection,5188,O
of,5188,O
X-ALD,5188,B-Modifier
mutations,5188,O
.,5188,O
The,5189,O
method,5189,O
is,5189,O
based,5189,O
on,5189,O
SSCP,5189,O
analysis,5189,O
of,5189,O
nested,5189,O
PCR,5189,O
fragments,5189,O
followed,5189,O
by,5189,O
sequence-determination,5189,O
reactions,5189,O
.,5189,O
Using,5190,O
this,5190,O
methodology,5190,O
we,5190,O
have,5190,O
found,5190,O
X-ALD,5190,B-Modifier
mutations,5190,O
in,5190,O
30,5190,O
kindreds,5190,O
",",5190,O
including,5190,O
15,5190,O
not,5190,O
previously,5190,O
reported,5190,O
.,5190,O
beta-galactosidase,5191,O
gene,5191,O
mutations,5191,O
affecting,5191,O
the,5191,O
lysosomal,5191,O
enzyme,5191,O
and,5191,O
the,5191,O
elastin-binding,5191,O
protein,5191,O
in,5191,O
GM1-gangliosidosis,5191,B-Modifier
patients,5191,O
with,5191,O
cardiac,5191,B-SpecificDisease
involvement,5191,I-SpecificDisease
.,5191,O
GM1-gangliosidosis,5192,B-SpecificDisease
is,5192,O
a,5192,O
lysosomal,5192,B-DiseaseClass
storage,5192,I-DiseaseClass
disorder,5192,I-DiseaseClass
caused,5192,O
by,5192,O
deficiency,5192,B-SpecificDisease
of,5192,I-SpecificDisease
acid,5192,I-SpecificDisease
beta-galactosidase,5192,I-SpecificDisease
(,5192,O
GLB1,5192,O
),5192,O
.,5192,O
We,5193,O
report,5193,O
five,5193,O
new,5193,O
beta-galactosidase,5193,O
gene,5193,O
mutations,5193,O
in,5193,O
nine,5193,O
Italian,5193,O
patients,5193,O
and,5193,O
one,5193,O
fetus,5193,O
",",5193,O
segregating,5193,O
in,5193,O
seven,5193,O
unrelated,5193,O
families,5193,O
.,5193,O
Six,5194,O
of,5194,O
the,5194,O
eight,5194,O
patients,5194,O
with,5194,O
the,5194,O
infantile,5194,O
",",5194,O
severe,5194,O
form,5194,O
of,5194,O
the,5194,O
disease,5194,O
presented,5194,O
cardiac,5194,B-DiseaseClass
involvement,5194,I-DiseaseClass
",",5194,O
a,5194,O
feature,5194,O
rarely,5194,O
associated,5194,O
with,5194,O
GM1-gangliosidosis,5194,B-SpecificDisease
.,5194,O
Molecular,5195,O
analysis,5195,O
of,5195,O
the,5195,O
patients,5195,O
RNA,5195,O
and,5195,O
DNA,5195,O
identified,5195,O
two,5195,O
new,5195,O
RNA,5195,O
splicing,5195,O
defects,5195,O
",",5195,O
three,5195,O
new,5195,O
and,5195,O
three,5195,O
previously,5195,O
described,5195,O
amino,5195,O
acid,5195,O
substitutions,5195,O
.,5195,O
Interestingly,5196,O
",",5196,O
all,5196,O
patients,5196,O
with,5196,O
cardiac,5196,B-DiseaseClass
involvement,5196,I-DiseaseClass
were,5196,O
homozygous,5196,O
for,5196,O
one,5196,O
of,5196,O
these,5196,O
mutations,5196,O
R59H,5196,O
",",5196,O
Y591C,5196,O
",",5196,O
Y591N,5196,O
",",5196,O
or,5196,O
IVS14-2A,5196,O
>,5196,O
G.,5196,O
In,5196,O
contrast,5196,O
",",5196,O
all,5196,O
other,5196,O
patients,5196,O
were,5196,O
compound,5196,O
heterozygous,5196,O
for,5196,O
one,5196,O
of,5196,O
the,5196,O
following,5196,O
mutations,5196,O
R201H,5196,O
",",5196,O
R482H,5196,O
",",5196,O
G579D,5196,O
",",5196,O
IVS8,5196,O
+,5196,O
2T,5196,O
>,5196,O
C.,5196,O
Although,5196,O
we,5196,O
could,5196,O
not,5196,O
directly,5196,O
correlate,5196,O
the,5196,O
presence,5196,O
of,5196,O
cardiac,5196,B-DiseaseClass
abnormalities,5196,I-DiseaseClass
with,5196,O
specific,5196,O
genetic,5196,B-DiseaseClass
lesions,5196,I-DiseaseClass
",",5196,O
the,5196,O
mutations,5196,O
identified,5196,O
in,5196,O
patients,5196,O
with,5196,O
cardiomyopathy,5196,B-DiseaseClass
fell,5196,O
in,5196,O
the,5196,O
GLB1,5196,O
cDNA,5196,O
region,5196,O
common,5196,O
to,5196,O
the,5196,O
lysosomal,5196,O
enzyme,5196,O
and,5196,O
the,5196,O
Hbeta-Gal-related,5196,O
protein,5196,O
",",5196,O
also,5196,O
known,5196,O
as,5196,O
the,5196,O
elastin,5196,O
binding,5196,O
protein,5196,O
(,5196,O
EBP,5196,O
),5196,O
.,5196,O
Consequently,5197,O
",",5197,O
both,5197,O
molecules,5197,O
are,5197,O
affected,5197,O
by,5197,O
the,5197,O
mutations,5197,O
",",5197,O
and,5197,O
they,5197,O
may,5197,O
contribute,5197,O
differently,5197,O
to,5197,O
the,5197,O
occurrence,5197,O
of,5197,O
specific,5197,O
clinical,5197,O
manifestations,5197,O
..,5197,O
In,5198,O
vivo,5198,O
modulation,5198,O
of,5198,O
Hmgic,5198,O
reduces,5198,O
obesity,5198,B-SpecificDisease
.,5198,O
The,5199,O
HMGI,5199,O
family,5199,O
of,5199,O
proteins,5199,O
consists,5199,O
of,5199,O
three,5199,O
members,5199,O
",",5199,O
HMGIC,5199,O
",",5199,O
HMGI,5199,O
and,5199,O
HMGI,5199,O
(,5199,O
Y,5199,O
),5199,O
",",5199,O
that,5199,O
function,5199,O
as,5199,O
architectural,5199,O
factors,5199,O
and,5199,O
are,5199,O
essential,5199,O
components,5199,O
of,5199,O
the,5199,O
enhancesome,5199,O
.,5199,O
HMGIC,5200,O
is,5200,O
predominantly,5200,O
expressed,5200,O
in,5200,O
proliferating,5200,O
",",5200,O
undifferentiated,5200,O
mesenchymal,5200,O
cells,5200,O
and,5200,O
is,5200,O
not,5200,O
detected,5200,O
in,5200,O
adult,5200,O
tissues,5200,O
.,5200,O
It,5201,O
is,5201,O
disrupted,5201,O
and,5201,O
misexpressed,5201,O
in,5201,O
a,5201,O
number,5201,O
of,5201,O
mesenchymal,5201,B-Modifier
tumour,5201,I-Modifier
cell,5201,O
types,5201,O
",",5201,O
including,5201,O
fat-cell,5201,B-DiseaseClass
tumours,5201,I-DiseaseClass
(,5201,O
lipomas,5201,B-DiseaseClass
),5201,O
.,5201,O
In,5202,O
addition,5202,O
Hmgic-/-,5202,O
mice,5202,O
have,5202,O
a,5202,O
deficiency,5202,O
in,5202,O
fat,5202,O
tissue,5202,O
.,5202,O
To,5203,O
study,5203,O
its,5203,O
role,5203,O
in,5203,O
adipogenesis,5203,O
and,5203,O
obesity,5203,B-SpecificDisease
",",5203,O
we,5203,O
examined,5203,O
Hmgic,5203,O
expression,5203,O
in,5203,O
the,5203,O
adipose,5203,O
tissue,5203,O
of,5203,O
adult,5203,O
",",5203,O
obese,5203,B-Modifier
mice,5203,O
.,5203,O
Mice,5204,O
with,5204,O
a,5204,O
partial,5204,B-CompositeMention
or,5204,I-CompositeMention
complete,5204,I-CompositeMention
deficiency,5204,I-CompositeMention
of,5204,I-CompositeMention
Hmgic,5204,I-CompositeMention
resisted,5204,O
diet-induced,5204,O
obesity,5204,B-SpecificDisease
.,5204,O
Disruption,5205,O
of,5205,O
Hmgic,5205,O
caused,5205,O
a,5205,O
reduction,5205,O
in,5205,O
the,5205,O
obesity,5205,B-SpecificDisease
induced,5205,O
by,5205,O
leptin,5205,B-SpecificDisease
deficiency,5205,I-SpecificDisease
(,5205,O
Lepob/Lepob,5205,O
),5205,O
in,5205,O
a,5205,O
gene-dose-dependent,5205,O
manner,5205,O
.,5205,O
Our,5206,O
studies,5206,O
implicate,5206,O
a,5206,O
role,5206,O
for,5206,O
HMGIC,5206,O
in,5206,O
fat-cell,5206,O
proliferation,5206,O
",",5206,O
indicating,5206,O
that,5206,O
it,5206,O
may,5206,O
be,5206,O
an,5206,O
adipose-specific,5206,O
target,5206,O
for,5206,O
the,5206,O
treatment,5206,O
of,5206,O
obesity,5206,B-SpecificDisease
..,5206,O
Molecular,5207,O
analysis,5207,O
of,5207,O
the,5207,O
genotype-phenotype,5207,O
relationship,5207,O
in,5207,O
factor,5207,B-SpecificDisease
X,5207,I-SpecificDisease
deficiency,5207,I-SpecificDisease
.,5207,O
Factor,5208,B-SpecificDisease
X,5208,I-SpecificDisease
deficiency,5208,I-SpecificDisease
is,5208,O
a,5208,O
rare,5208,O
haemorrhagic,5208,B-DiseaseClass
condition,5208,I-DiseaseClass
",",5208,O
normally,5208,O
inherited,5208,O
as,5208,O
an,5208,O
autosomal,5208,O
recessive,5208,O
trait,5208,O
",",5208,O
in,5208,O
which,5208,O
a,5208,O
variable,5208,O
clinical,5208,O
presentation,5208,O
correlates,5208,O
poorly,5208,O
with,5208,O
laboratory,5208,O
phenotype,5208,O
.,5208,O
The,5209,O
factor,5209,O
X,5209,O
(,5209,O
F10,5209,O
),5209,O
genes,5209,O
of,5209,O
14,5209,O
unrelated,5209,O
individuals,5209,O
with,5209,O
factor,5209,B-SpecificDisease
X,5209,I-SpecificDisease
deficiency,5209,I-SpecificDisease
(,5209,O
12,5209,O
familial,5209,O
and,5209,O
two,5209,O
sporadic,5209,O
cases,5209,O
),5209,O
were,5209,O
sequenced,5209,O
yielding,5209,O
a,5209,O
total,5209,O
of,5209,O
13,5209,O
novel,5209,O
mutations,5209,O
.,5209,O
Family,5210,O
studies,5210,O
were,5210,O
performed,5210,O
in,5210,O
order,5210,O
to,5210,O
distinguish,5210,O
the,5210,O
contributions,5210,O
of,5210,O
individual,5210,O
mutant,5210,O
F10,5210,O
alleles,5210,O
to,5210,O
the,5210,O
clinical,5210,O
and,5210,O
laboratory,5210,O
phenotypes,5210,O
.,5210,O
Missense,5211,O
mutations,5211,O
were,5211,O
studied,5211,O
by,5211,O
means,5211,O
of,5211,O
molecular,5211,O
modelling,5211,O
",",5211,O
whereas,5211,O
single,5211,O
basepair,5211,O
substitutions,5211,O
in,5211,O
splice,5211,O
sites,5211,O
and,5211,O
the,5211,O
5,5211,O
flanking,5211,O
region,5211,O
were,5211,O
examined,5211,O
by,5211,O
in,5211,O
vitro,5211,O
splicing,5211,O
assay,5211,O
and,5211,O
luciferase,5211,O
reporter,5211,O
gene,5211,O
assay,5211,O
respectively,5211,O
.,5211,O
The,5212,O
deletion,5212,O
allele,5212,O
of,5212,O
a,5212,O
novel,5212,O
hexanucleotide,5212,O
insertion/deletion,5212,O
polymorphism,5212,O
in,5212,O
the,5212,O
F10,5212,O
gene,5212,O
promoter,5212,O
region,5212,O
was,5212,O
shown,5212,O
by,5212,O
reporter,5212,O
gene,5212,O
assay,5212,O
",",5212,O
to,5212,O
reduce,5212,O
promoter,5212,O
activity,5212,O
by,5212,O
approximately,5212,O
20,5212,O
%,5212,O
.,5212,O
One,5213,O
family,5213,O
manifesting,5213,O
an,5213,O
autosomal,5213,O
dominant,5213,O
pattern,5213,O
of,5213,O
inheritance,5213,O
possessed,5213,O
three,5213,O
clinically,5213,O
affected,5213,O
members,5213,O
who,5213,O
were,5213,O
heterozygous,5213,O
for,5213,O
a,5213,O
splice-site,5213,O
mutation,5213,O
that,5213,O
was,5213,O
predicted,5213,O
to,5213,O
lead,5213,O
to,5213,O
the,5213,O
production,5213,O
of,5213,O
a,5213,O
truncated,5213,O
protein,5213,O
product,5213,O
.,5213,O
A,5214,O
model,5214,O
which,5214,O
accounts,5214,O
for,5214,O
the,5214,O
dominant,5214,O
negative,5214,O
effect,5214,O
of,5214,O
this,5214,O
lesion,5214,O
is,5214,O
presented,5214,O
.,5214,O
Variation,5215,O
in,5215,O
the,5215,O
antigen,5215,O
level,5215,O
of,5215,O
heterozygous,5215,O
relatives,5215,O
of,5215,O
probands,5215,O
was,5215,O
found,5215,O
to,5215,O
be,5215,O
significantly,5215,O
higher,5215,O
between,5215,O
families,5215,O
than,5215,O
within,5215,O
families,5215,O
",",5215,O
consistent,5215,O
with,5215,O
the,5215,O
view,5215,O
that,5215,O
the,5215,O
nature,5215,O
of,5215,O
the,5215,O
F10,5215,O
lesion,5215,O
(,5215,O
s,5215,O
),5215,O
segregating,5215,O
in,5215,O
a,5215,O
given,5215,O
family,5215,O
is,5215,O
a,5215,O
prime,5215,O
determinant,5215,O
of,5215,O
the,5215,O
laboratory,5215,O
phenotype,5215,O
.,5215,O
By,5216,O
contrast,5216,O
",",5216,O
no,5216,O
such,5216,O
relationship,5216,O
could,5216,O
be,5216,O
discerned,5216,O
between,5216,O
laboratory,5216,O
phenotype,5216,O
and,5216,O
polymorphism,5216,O
genotype,5216,O
..,5216,O
Transgenic,5217,O
mice,5217,O
expressing,5217,O
a,5217,O
truncated,5217,O
form,5217,O
of,5217,O
the,5217,O
high,5217,O
mobility,5217,O
group,5217,O
I-C,5217,O
protein,5217,O
develop,5217,O
adiposity,5217,O
and,5217,O
an,5217,O
abnormally,5217,O
high,5217,O
prevalence,5217,O
of,5217,O
lipomas,5217,B-DiseaseClass
.,5217,O
Chromosomal,5218,O
translocations,5218,O
in,5218,O
human,5218,O
lipomas,5218,B-DiseaseClass
frequently,5218,O
create,5218,O
fusion,5218,O
transcripts,5218,O
encoding,5218,O
high,5218,O
mobility,5218,O
group,5218,O
(,5218,O
HMG,5218,O
),5218,O
I-C,5218,O
DNA-binding,5218,O
domains,5218,O
and,5218,O
C-terminal,5218,O
sequences,5218,O
from,5218,O
different,5218,O
presumed,5218,O
transcription,5218,O
factors,5218,O
",",5218,O
suggesting,5218,O
a,5218,O
potential,5218,O
role,5218,O
for,5218,O
HMG,5218,O
I-C,5218,O
in,5218,O
the,5218,O
development,5218,O
of,5218,O
lipomas,5218,B-DiseaseClass
.,5218,O
To,5219,O
evaluate,5219,O
the,5219,O
role,5219,O
of,5219,O
the,5219,O
HMG,5219,O
I-C,5219,O
component,5219,O
",",5219,O
the,5219,O
three,5219,O
DNA-binding,5219,O
domains,5219,O
of,5219,O
HMG,5219,O
I-C,5219,O
have,5219,O
now,5219,O
been,5219,O
expressed,5219,O
in,5219,O
transgenic,5219,O
mice,5219,O
.,5219,O
Despite,5220,O
the,5220,O
ubiquitous,5220,O
expression,5220,O
of,5220,O
the,5220,O
truncated,5220,O
HMG,5220,O
I-C,5220,O
protein,5220,O
",",5220,O
the,5220,O
transgenic,5220,O
mice,5220,O
develop,5220,O
a,5220,O
selective,5220,O
abundance,5220,O
of,5220,O
fat,5220,O
tissue,5220,O
early,5220,O
in,5220,O
life,5220,O
",",5220,O
show,5220,O
marked,5220,O
adipose,5220,B-SpecificDisease
tissue,5220,I-SpecificDisease
inflammation,5220,I-SpecificDisease
",",5220,O
and,5220,O
have,5220,O
an,5220,O
abnormally,5220,O
high,5220,O
incidence,5220,O
of,5220,O
lipomas,5220,B-DiseaseClass
.,5220,O
These,5221,O
findings,5221,O
demonstrate,5221,O
that,5221,O
the,5221,O
DNA-binding,5221,O
domains,5221,O
of,5221,O
HMG,5221,O
I-C,5221,O
",",5221,O
in,5221,O
the,5221,O
absence,5221,O
of,5221,O
a,5221,O
C-terminal,5221,O
fusion,5221,O
partner,5221,O
",",5221,O
are,5221,O
sufficient,5221,O
to,5221,O
perturb,5221,O
adipogenesis,5221,O
and,5221,O
predispose,5221,O
to,5221,O
lipomas,5221,B-DiseaseClass
.,5221,O
We,5222,O
provide,5222,O
data,5222,O
supporting,5222,O
the,5222,O
central,5222,O
utility,5222,O
of,5222,O
this,5222,O
animal,5222,O
model,5222,O
as,5222,O
a,5222,O
tool,5222,O
to,5222,O
understand,5222,O
the,5222,O
molecular,5222,O
mechanisms,5222,O
underlying,5222,O
the,5222,O
development,5222,O
of,5222,O
one,5222,O
of,5222,O
the,5222,O
most,5222,O
common,5222,O
kind,5222,O
of,5222,O
human,5222,O
benign,5222,B-DiseaseClass
tumors,5222,I-DiseaseClass
..,5222,O
ATM,5223,O
phosphorylates,5223,O
p95/nbs1,5223,O
in,5223,O
an,5223,O
S-phase,5223,O
checkpoint,5223,O
pathway,5223,O
.,5223,O
The,5224,O
rare,5224,B-DiseaseClass
diseases,5224,I-DiseaseClass
ataxia-telangiectasia,5224,B-SpecificDisease
(,5224,O
AT,5224,B-SpecificDisease
),5224,O
",",5224,O
caused,5224,O
by,5224,O
mutations,5224,O
in,5224,O
the,5224,O
ATM,5224,O
gene,5224,O
",",5224,O
and,5224,O
Nijmegen,5224,B-SpecificDisease
breakage,5224,I-SpecificDisease
syndrome,5224,I-SpecificDisease
(,5224,O
NBS,5224,B-SpecificDisease
),5224,O
",",5224,O
with,5224,O
mutations,5224,O
in,5224,O
the,5224,O
p95/nbs1,5224,O
gene,5224,O
",",5224,O
share,5224,O
a,5224,O
variety,5224,O
of,5224,O
phenotypic,5224,B-DiseaseClass
abnormalities,5224,I-DiseaseClass
such,5224,O
as,5224,O
chromosomal,5224,B-DiseaseClass
instability,5224,I-DiseaseClass
",",5224,O
radiation,5224,O
sensitivity,5224,O
and,5224,O
defects,5224,O
in,5224,O
cell-cycle,5224,O
checkpoints,5224,O
in,5224,O
response,5224,O
to,5224,O
ionizing,5224,O
radiation,5224,O
.,5224,O
The,5225,O
ATM,5225,O
gene,5225,O
encodes,5225,O
a,5225,O
protein,5225,O
kinase,5225,O
that,5225,O
is,5225,O
activated,5225,O
by,5225,O
ionizing,5225,O
radiation,5225,O
or,5225,O
radiomimetic,5225,O
drugs,5225,O
",",5225,O
whereas,5225,O
p95/nbs1,5225,O
is,5225,O
part,5225,O
of,5225,O
a,5225,O
protein,5225,O
complex,5225,O
that,5225,O
is,5225,O
involved,5225,O
in,5225,O
responses,5225,O
to,5225,O
DNA,5225,O
double-strand,5225,O
breaks,5225,O
.,5225,O
Here,5226,O
",",5226,O
because,5226,O
of,5226,O
the,5226,O
similarities,5226,O
between,5226,O
AT,5226,B-SpecificDisease
and,5226,O
NBS,5226,B-SpecificDisease
",",5226,O
we,5226,O
evaluated,5226,O
the,5226,O
functional,5226,O
interactions,5226,O
between,5226,O
ATM,5226,O
and,5226,O
p95/nbs1,5226,O
.,5226,O
Activation,5227,O
of,5227,O
the,5227,O
ATM,5227,O
kinase,5227,O
by,5227,O
ionizing,5227,O
radiation,5227,O
and,5227,O
induction,5227,O
of,5227,O
ATM-dependent,5227,O
responses,5227,O
in,5227,O
NBS,5227,B-Modifier
cells,5227,O
indicated,5227,O
that,5227,O
p95/nbs1,5227,O
may,5227,O
not,5227,O
be,5227,O
required,5227,O
for,5227,O
signalling,5227,O
to,5227,O
ATM,5227,O
after,5227,O
ionizing,5227,O
radiation,5227,O
.,5227,O
However,5228,O
",",5228,O
p95/nbs1,5228,O
was,5228,O
phosphorylated,5228,O
on,5228,O
serine,5228,O
343,5228,O
in,5228,O
an,5228,O
ATM-dependent,5228,O
manner,5228,O
in,5228,O
vitro,5228,O
and,5228,O
in,5228,O
vivo,5228,O
after,5228,O
ionizing,5228,O
radiation,5228,O
.,5228,O
A,5229,O
p95/nbs1,5229,O
construct,5229,O
mutated,5229,O
at,5229,O
the,5229,O
ATM,5229,O
phosphorylation,5229,O
site,5229,O
abrogated,5229,O
an,5229,O
S-phase,5229,O
checkpoint,5229,O
induced,5229,O
by,5229,O
ionizing,5229,O
radiation,5229,O
in,5229,O
normal,5229,O
cells,5229,O
and,5229,O
failed,5229,O
to,5229,O
compensate,5229,O
for,5229,O
this,5229,O
functional,5229,O
deficiency,5229,O
in,5229,O
NBS,5229,B-Modifier
cells,5229,O
.,5229,O
These,5230,O
observations,5230,O
link,5230,O
ATM,5230,O
and,5230,O
p95/nbs1,5230,O
in,5230,O
a,5230,O
common,5230,O
signalling,5230,O
pathway,5230,O
and,5230,O
provide,5230,O
an,5230,O
explanation,5230,O
for,5230,O
phenotypic,5230,O
similarities,5230,O
in,5230,O
these,5230,O
two,5230,O
diseases,5230,O
..,5230,O
Understanding,5231,O
the,5231,O
molecular,5231,O
basis,5231,O
of,5231,O
fragile,5231,B-SpecificDisease
X,5231,I-SpecificDisease
syndrome,5231,I-SpecificDisease
.,5231,O
Fragile,5232,B-SpecificDisease
X,5232,I-SpecificDisease
syndrome,5232,I-SpecificDisease
",",5232,O
a,5232,O
common,5232,O
form,5232,O
of,5232,O
inherited,5232,B-DiseaseClass
mental,5232,I-DiseaseClass
retardation,5232,I-DiseaseClass
",",5232,O
is,5232,O
mainly,5232,O
caused,5232,O
by,5232,O
massive,5232,O
expansion,5232,O
of,5232,O
CGG,5232,O
triplet,5232,O
repeats,5232,O
located,5232,O
in,5232,O
the,5232,O
5-untranslated,5232,O
region,5232,O
of,5232,O
the,5232,O
fragile,5232,B-Modifier
X,5232,I-Modifier
mental,5232,I-Modifier
retardation-1,5232,O
(,5232,O
FMR1,5232,O
),5232,O
gene,5232,O
.,5232,O
In,5233,O
patients,5233,O
with,5233,O
fragile,5233,B-SpecificDisease
X,5233,I-SpecificDisease
syndrome,5233,I-SpecificDisease
",",5233,O
the,5233,O
expanded,5233,O
CGG,5233,O
triplet,5233,O
repeats,5233,O
are,5233,O
hypermethylated,5233,O
and,5233,O
the,5233,O
expression,5233,O
of,5233,O
the,5233,O
FMR1,5233,O
gene,5233,O
is,5233,O
repressed,5233,O
",",5233,O
which,5233,O
leads,5233,O
to,5233,O
the,5233,O
absence,5233,O
of,5233,O
FMR1,5233,O
protein,5233,O
(,5233,O
FMRP,5233,O
),5233,O
and,5233,O
subsequent,5233,O
mental,5233,B-DiseaseClass
retardation,5233,I-DiseaseClass
.,5233,O
FMRP,5234,O
is,5234,O
an,5234,O
RNA-binding,5234,O
protein,5234,O
that,5234,O
shuttles,5234,O
between,5234,O
the,5234,O
nucleus,5234,O
and,5234,O
cytoplasm,5234,O
.,5234,O
This,5235,O
protein,5235,O
has,5235,O
been,5235,O
implicated,5235,O
in,5235,O
protein,5235,O
translation,5235,O
as,5235,O
it,5235,O
is,5235,O
found,5235,O
associated,5235,O
with,5235,O
polyribosomes,5235,O
and,5235,O
the,5235,O
rough,5235,O
endoplasmic,5235,O
reticulum,5235,O
.,5235,O
We,5236,O
discuss,5236,O
here,5236,O
the,5236,O
recent,5236,O
progress,5236,O
made,5236,O
towards,5236,O
understanding,5236,O
the,5236,O
molecular,5236,O
mechanism,5236,O
of,5236,O
CGG,5236,O
repeat,5236,O
expansion,5236,O
and,5236,O
physiological,5236,O
function,5236,O
(,5236,O
s,5236,O
),5236,O
of,5236,O
FMRP,5236,O
.,5236,O
These,5237,O
studies,5237,O
will,5237,O
not,5237,O
only,5237,O
help,5237,O
to,5237,O
illuminate,5237,O
the,5237,O
molecular,5237,O
basis,5237,O
of,5237,O
the,5237,O
general,5237,O
class,5237,O
of,5237,O
human,5237,O
diseases,5237,O
with,5237,O
trinucleotide,5237,O
repeat,5237,O
expansion,5237,O
but,5237,O
also,5237,O
provide,5237,O
an,5237,O
avenue,5237,O
to,5237,O
understand,5237,O
aspects,5237,O
of,5237,O
human,5237,O
cognition,5237,O
and,5237,O
intelligence,5237,O
..,5237,O
Haploinsufficiency,5238,O
of,5238,O
the,5238,O
transcription,5238,O
factors,5238,O
FOXC1,5238,O
and,5238,O
FOXC2,5238,O
results,5238,O
in,5238,O
aberrant,5238,O
ocular,5238,O
development,5238,O
.,5238,O
Anterior,5239,B-DiseaseClass
segment,5239,I-DiseaseClass
developmental,5239,I-DiseaseClass
disorders,5239,I-DiseaseClass
",",5239,O
including,5239,O
Axenfeld-Rieger,5239,B-SpecificDisease
anomaly,5239,I-SpecificDisease
(,5239,O
ARA,5239,B-SpecificDisease
),5239,O
",",5239,O
variably,5239,O
associate,5239,O
with,5239,O
harmfully,5239,O
elevated,5239,O
intraocular,5239,O
pressure,5239,O
(,5239,O
IOP,5239,O
),5239,O
",",5239,O
which,5239,O
causes,5239,O
glaucoma,5239,B-SpecificDisease
.,5239,O
Clinically,5240,O
observed,5240,O
dysgenesis,5240,O
does,5240,O
not,5240,O
correlate,5240,O
with,5240,O
IOP,5240,O
",",5240,O
however,5240,O
",",5240,O
and,5240,O
the,5240,O
etiology,5240,O
of,5240,O
glaucoma,5240,B-Modifier
development,5240,O
is,5240,O
not,5240,O
understood,5240,O
.,5240,O
The,5241,O
forkhead,5241,O
transcription,5241,O
factor,5241,O
genes,5241,O
Foxc1,5241,O
(,5241,O
formerly,5241,O
Mf1,5241,O
),5241,O
and,5241,O
Foxc2,5241,O
(,5241,O
formerly,5241,O
Mfh1,5241,O
),5241,O
are,5241,O
expressed,5241,O
in,5241,O
the,5241,O
mesenchyme,5241,O
from,5241,O
which,5241,O
the,5241,O
ocular,5241,O
drainage,5241,O
structures,5241,O
derive,5241,O
.,5241,O
Mutations,5242,O
in,5242,O
the,5242,O
human,5242,O
homolog,5242,O
of,5242,O
Foxc1,5242,O
",",5242,O
FKHL7,5242,O
",",5242,O
cause,5242,O
dominant,5242,O
anterior,5242,B-DiseaseClass
segment,5242,I-DiseaseClass
defects,5242,I-DiseaseClass
and,5242,O
glaucoma,5242,B-SpecificDisease
in,5242,O
various,5242,O
families,5242,O
.,5242,O
We,5243,O
show,5243,O
that,5243,O
Foxc1,5243,O
(,5243,O
+/-,5243,O
),5243,O
mice,5243,O
have,5243,O
anterior,5243,B-DiseaseClass
segment,5243,I-DiseaseClass
abnormalities,5243,I-DiseaseClass
similar,5243,O
to,5243,O
those,5243,O
reported,5243,O
in,5243,O
human,5243,O
patients,5243,O
.,5243,O
These,5244,O
abnormalities,5244,O
include,5244,O
small,5244,O
or,5244,O
absent,5244,O
Schlemms,5244,O
canal,5244,O
",",5244,O
aberrantly,5244,O
developed,5244,O
trabecular,5244,O
meshwork,5244,O
",",5244,O
iris,5244,B-SpecificDisease
hypoplasia,5244,I-SpecificDisease
",",5244,O
severely,5244,O
eccentric,5244,O
pupils,5244,O
and,5244,O
displaced,5244,O
Schwalbes,5244,O
line,5244,O
.,5244,O
The,5245,O
penetrance,5245,O
of,5245,O
clinically,5245,O
obvious,5245,O
abnormalities,5245,O
varies,5245,O
with,5245,O
genetic,5245,O
background,5245,O
.,5245,O
In,5246,O
some,5246,O
affected,5246,O
eyes,5246,O
",",5246,O
collagen,5246,O
bundles,5246,O
were,5246,O
half,5246,O
normal,5246,O
diameter,5246,O
",",5246,O
or,5246,O
collagen,5246,O
and,5246,O
elastic,5246,O
tissue,5246,O
were,5246,O
very,5246,O
sparse,5246,O
.,5246,O
Thus,5247,O
",",5247,O
abnormalities,5247,O
in,5247,O
extracellular,5247,O
matrix,5247,O
synthesis,5247,O
or,5247,O
organization,5247,O
may,5247,O
contribute,5247,O
to,5247,O
development,5247,O
of,5247,O
the,5247,O
ocular,5247,O
phenotypes,5247,O
.,5247,O
Despite,5248,O
the,5248,O
abnormalities,5248,O
in,5248,O
ocular,5248,O
drainage,5248,O
structures,5248,O
in,5248,O
Foxc1,5248,O
(,5248,O
+/-,5248,O
),5248,O
mice,5248,O
",",5248,O
IOP,5248,O
was,5248,O
normal,5248,O
in,5248,O
almost,5248,O
all,5248,O
mice,5248,O
analyzed,5248,O
",",5248,O
on,5248,O
all,5248,O
genetic,5248,O
backgrounds,5248,O
and,5248,O
at,5248,O
all,5248,O
ages,5248,O
.,5248,O
Similar,5249,O
abnormalities,5249,O
were,5249,O
found,5249,O
in,5249,O
Foxc2,5249,O
(,5249,O
+/-,5249,O
),5249,O
mice,5249,O
",",5249,O
but,5249,O
no,5249,O
disease-associated,5249,O
mutations,5249,O
were,5249,O
identified,5249,O
in,5249,O
the,5249,O
human,5249,O
homolog,5249,O
FKHL14,5249,O
in,5249,O
32,5249,O
ARA,5249,B-Modifier
patients,5249,O
.,5249,O
Foxc1,5250,O
(,5250,O
+/-,5250,O
),5250,O
and,5250,O
Foxc2,5250,O
(,5250,O
+/-,5250,O
),5250,O
mice,5250,O
are,5250,O
useful,5250,O
models,5250,O
for,5250,O
studying,5250,O
anterior,5250,O
segment,5250,O
development,5250,O
and,5250,O
its,5250,O
anomalies,5250,O
",",5250,O
and,5250,O
may,5250,O
allow,5250,O
identification,5250,O
of,5250,O
genes,5250,O
that,5250,O
interact,5250,O
with,5250,O
Foxc1,5250,O
and,5250,O
Foxc2,5250,O
(,5250,O
or,5250,O
FKHL7,5250,O
and,5250,O
FKHL14,5250,O
),5250,O
to,5250,O
produce,5250,O
a,5250,O
phenotype,5250,O
with,5250,O
elevated,5250,O
IOP,5250,O
and,5250,O
glaucoma,5250,B-SpecificDisease
..,5250,O
(,5251,O
Over,5251,O
),5251,O
correction,5251,O
of,5251,O
FMR1,5251,B-SpecificDisease
deficiency,5251,I-SpecificDisease
with,5251,O
YAC,5251,O
transgenics,5251,O
:,5251,O
behavioral,5251,O
and,5251,O
physical,5251,O
features,5251,O
.,5251,O
Fragile,5252,B-SpecificDisease
X,5252,I-SpecificDisease
syndrome,5252,I-SpecificDisease
is,5252,O
a,5252,O
common,5252,O
cause,5252,O
of,5252,O
mental,5252,B-DiseaseClass
retardation,5252,I-DiseaseClass
involving,5252,O
loss,5252,O
of,5252,O
expression,5252,O
of,5252,O
the,5252,O
FMR1,5252,O
gene,5252,O
.,5252,O
The,5253,O
role,5253,O
of,5253,O
FMR1,5253,O
remains,5253,O
undetermined,5253,O
but,5253,O
the,5253,O
protein,5253,O
appears,5253,O
to,5253,O
be,5253,O
involved,5253,O
in,5253,O
RNA,5253,O
metabolism,5253,O
.,5253,O
Fmr1,5254,O
knockout,5254,O
mice,5254,O
exhibit,5254,O
a,5254,O
phenotype,5254,O
with,5254,O
some,5254,O
similarities,5254,O
to,5254,O
humans,5254,O
",",5254,O
such,5254,O
as,5254,O
macroorchidism,5254,B-SpecificDisease
and,5254,O
behavioral,5254,O
abnormalities,5254,O
.,5254,O
As,5255,O
a,5255,O
step,5255,O
toward,5255,O
understanding,5255,O
the,5255,O
function,5255,O
of,5255,O
FMR1,5255,O
and,5255,O
the,5255,O
determination,5255,O
of,5255,O
the,5255,O
potential,5255,O
for,5255,O
therapeutic,5255,O
approaches,5255,O
to,5255,O
fragile,5255,B-SpecificDisease
X,5255,I-SpecificDisease
syndrome,5255,I-SpecificDisease
",",5255,O
yeast,5255,O
artificial,5255,O
chromosome,5255,O
(,5255,O
YAC,5255,O
),5255,O
transgenic,5255,O
mice,5255,O
were,5255,O
generated,5255,O
in,5255,O
order,5255,O
to,5255,O
determine,5255,O
whether,5255,O
the,5255,O
Fmr1,5255,O
knockout,5255,O
mouse,5255,O
phenotype,5255,O
could,5255,O
be,5255,O
rescued,5255,O
.,5255,O
Several,5256,O
transgenic,5256,O
lines,5256,O
were,5256,O
generated,5256,O
that,5256,O
carried,5256,O
the,5256,O
entire,5256,O
FMR1,5256,O
locus,5256,O
with,5256,O
extensive,5256,O
amounts,5256,O
of,5256,O
flanking,5256,O
sequence,5256,O
.,5256,O
We,5257,O
observed,5257,O
that,5257,O
the,5257,O
YAC,5257,O
transgene,5257,O
supported,5257,O
production,5257,O
of,5257,O
the,5257,O
human,5257,O
protein,5257,O
(,5257,O
FMRP,5257,O
),5257,O
which,5257,O
was,5257,O
present,5257,O
at,5257,O
levels,5257,O
10,5257,O
to,5257,O
15,5257,O
times,5257,O
that,5257,O
of,5257,O
endogenous,5257,O
protein,5257,O
and,5257,O
was,5257,O
expressed,5257,O
in,5257,O
a,5257,O
cell-,5257,O
and,5257,O
tissue-specific,5257,O
manner,5257,O
.,5257,O
Macro-orchidism,5258,O
was,5258,O
absent,5258,O
in,5258,O
knockout,5258,O
mice,5258,O
carrying,5258,O
the,5258,O
YAC,5258,O
transgene,5258,O
indicating,5258,O
functional,5258,O
rescue,5258,O
by,5258,O
the,5258,O
human,5258,O
protein,5258,O
.,5258,O
Given,5259,O
the,5259,O
complex,5259,O
behavioral,5259,O
phenotype,5259,O
in,5259,O
fragile,5259,B-Modifier
X,5259,I-Modifier
patients,5259,O
and,5259,O
the,5259,O
mild,5259,O
phenotype,5259,O
previously,5259,O
reported,5259,O
for,5259,O
the,5259,O
Fmr1,5259,O
knockout,5259,O
mouse,5259,O
",",5259,O
we,5259,O
performed,5259,O
a,5259,O
more,5259,O
thorough,5259,O
evaluation,5259,O
of,5259,O
the,5259,O
Fmr1,5259,O
knockout,5259,O
phenotype,5259,O
using,5259,O
additional,5259,O
behavioral,5259,O
assays,5259,O
that,5259,O
had,5259,O
not,5259,O
previously,5259,O
been,5259,O
reported,5259,O
for,5259,O
this,5259,O
animal,5259,O
model,5259,O
.,5259,O
The,5260,O
mouse,5260,O
displayed,5260,O
reduced,5260,O
anxiety-related,5260,B-Modifier
responses,5260,O
with,5260,O
increased,5260,O
exploratory,5260,O
behavior,5260,O
.,5260,O
FMR1,5261,O
YAC,5261,O
transgenic,5261,O
mice,5261,O
overexpressing,5261,O
the,5261,O
human,5261,O
protein,5261,O
did,5261,O
produce,5261,O
opposing,5261,O
behavioral,5261,O
responses,5261,O
and,5261,O
additional,5261,O
abnormal,5261,O
behaviors,5261,O
were,5261,O
also,5261,O
observed,5261,O
.,5261,O
These,5262,O
findings,5262,O
have,5262,O
significant,5262,O
implications,5262,O
for,5262,O
gene,5262,O
therapy,5262,O
for,5262,O
fragile,5262,B-SpecificDisease
X,5262,I-SpecificDisease
syndrome,5262,I-SpecificDisease
since,5262,O
overexpression,5262,O
of,5262,O
the,5262,O
gene,5262,O
may,5262,O
harbor,5262,O
its,5262,O
own,5262,O
phenotype,5262,O
..,5262,O
Transgenic,5263,O
mice,5263,O
carrying,5263,O
large,5263,O
human,5263,O
genomic,5263,O
sequences,5263,O
with,5263,O
expanded,5263,O
CTG,5263,O
repeat,5263,O
mimic,5263,O
closely,5263,O
the,5263,O
DM,5263,B-Modifier
CTG,5263,O
repeat,5263,O
intergenerational,5263,O
and,5263,O
somatic,5263,O
instability,5263,O
.,5263,O
Myotonic,5264,B-SpecificDisease
dystrophy,5264,I-SpecificDisease
(,5264,O
DM,5264,B-SpecificDisease
),5264,O
is,5264,O
caused,5264,O
by,5264,O
a,5264,O
CTG,5264,O
repeat,5264,O
expansion,5264,O
in,5264,O
the,5264,O
3UTR,5264,O
of,5264,O
the,5264,O
DM,5264,B-Modifier
protein,5264,O
kinase,5264,O
(,5264,O
DMPK,5264,O
),5264,O
gene,5264,O
.,5264,O
A,5265,O
very,5265,O
high,5265,O
level,5265,O
of,5265,O
instability,5265,O
is,5265,O
observed,5265,O
through,5265,O
successive,5265,O
generations,5265,O
and,5265,O
the,5265,O
size,5265,O
of,5265,O
the,5265,O
repeat,5265,O
is,5265,O
generally,5265,O
correlated,5265,O
with,5265,O
the,5265,O
severity,5265,O
of,5265,O
the,5265,O
disease,5265,O
and,5265,O
with,5265,O
age,5265,O
at,5265,O
onset,5265,O
.,5265,O
Furthermore,5266,O
",",5266,O
tissues,5266,O
from,5266,O
DM,5266,B-Modifier
patients,5266,O
exhibit,5266,O
somatic,5266,O
mosaicism,5266,O
that,5266,O
increases,5266,O
with,5266,O
age,5266,O
.,5266,O
We,5267,O
generated,5267,O
transgenic,5267,O
mice,5267,O
carrying,5267,O
large,5267,O
human,5267,O
genomic,5267,O
sequences,5267,O
with,5267,O
20,5267,O
",",5267,O
55,5267,O
or,5267,O
>,5267,O
300,5267,O
CTG,5267,O
",",5267,O
cloned,5267,O
from,5267,O
patients,5267,O
from,5267,O
the,5267,O
same,5267,O
affected,5267,O
DM,5267,B-Modifier
family,5267,O
.,5267,O
Using,5268,O
large,5268,O
human,5268,O
flanking,5268,O
sequences,5268,O
and,5268,O
a,5268,O
large,5268,O
amplification,5268,O
",",5268,O
we,5268,O
demonstrate,5268,O
that,5268,O
the,5268,O
intergenerational,5268,O
CTG,5268,O
repeat,5268,O
instability,5268,O
is,5268,O
reproduced,5268,O
in,5268,O
mice,5268,O
",",5268,O
with,5268,O
a,5268,O
strong,5268,O
bias,5268,O
towards,5268,O
expansions,5268,O
and,5268,O
with,5268,O
the,5268,O
same,5268,O
sex-,5268,O
and,5268,O
size-dependent,5268,O
characteristics,5268,O
as,5268,O
in,5268,O
humans,5268,O
.,5268,O
Moreover,5269,O
",",5269,O
a,5269,O
high,5269,O
level,5269,O
of,5269,O
instability,5269,O
",",5269,O
increasing,5269,O
with,5269,O
age,5269,O
",",5269,O
can,5269,O
be,5269,O
observed,5269,O
in,5269,O
tissues,5269,O
and,5269,O
in,5269,O
sperm,5269,O
.,5269,O
Although,5270,O
we,5270,O
did,5270,O
not,5270,O
observe,5270,O
dramatic,5270,O
expansions,5270,O
(,5270,O
or,5270,O
big,5270,O
jumps,5270,O
over,5270,O
several,5270,O
hundred,5270,O
CTG,5270,O
repeats,5270,O
),5270,O
as,5270,O
in,5270,O
congenital,5270,O
forms,5270,O
of,5270,O
DM,5270,B-SpecificDisease
",",5270,O
our,5270,O
model,5270,O
carrying,5270,O
>,5270,O
300,5270,O
CTG,5270,O
is,5270,O
the,5270,O
first,5270,O
to,5270,O
show,5270,O
instability,5270,O
so,5270,O
close,5270,O
to,5270,O
the,5270,O
human,5270,O
DM,5270,B-Modifier
situation,5270,O
.,5270,O
Our,5271,O
three,5271,O
models,5271,O
carrying,5271,O
different,5271,O
sizes,5271,O
of,5271,O
CTG,5271,O
repeat,5271,O
provide,5271,O
insight,5271,O
on,5271,O
the,5271,O
different,5271,O
factors,5271,O
modulating,5271,O
the,5271,O
CTG,5271,O
repeat,5271,O
instability,5271,O
..,5271,O
Inactivation,5272,O
of,5272,O
the,5272,O
Friedreich,5272,B-Modifier
ataxia,5272,I-Modifier
mouse,5272,O
gene,5272,O
leads,5272,O
to,5272,O
early,5272,O
embryonic,5272,B-SpecificDisease
lethality,5272,I-SpecificDisease
without,5272,O
iron,5272,O
accumulation,5272,O
.,5272,O
Friedreich,5273,B-SpecificDisease
ataxia,5273,I-SpecificDisease
(,5273,O
FRDA,5273,B-SpecificDisease
),5273,O
",",5273,O
the,5273,O
most,5273,O
common,5273,O
autosomal,5273,B-DiseaseClass
recessive,5273,I-DiseaseClass
ataxia,5273,I-DiseaseClass
",",5273,O
is,5273,O
caused,5273,O
in,5273,O
almost,5273,O
all,5273,O
cases,5273,O
by,5273,O
homozygous,5273,O
intronic,5273,O
expansions,5273,O
resulting,5273,O
in,5273,O
the,5273,O
loss,5273,O
of,5273,O
frataxin,5273,O
",",5273,O
a,5273,O
mitochondrial,5273,O
protein,5273,O
conserved,5273,O
through,5273,O
evolution,5273,O
",",5273,O
and,5273,O
involved,5273,O
in,5273,O
mitochondrial,5273,O
iron,5273,O
homeostasis,5273,O
.,5273,O
Yeast,5274,O
knockout,5274,O
models,5274,O
",",5274,O
and,5274,O
histological,5274,O
and,5274,O
biochemical,5274,O
data,5274,O
from,5274,O
patient,5274,O
heart,5274,O
biopsies,5274,O
or,5274,O
autopsies,5274,O
indicate,5274,O
that,5274,O
the,5274,O
frataxin,5274,O
defect,5274,O
causes,5274,O
a,5274,O
specific,5274,O
iron-sulfur,5274,B-SpecificDisease
protein,5274,I-SpecificDisease
deficiency,5274,I-SpecificDisease
and,5274,O
mitochondrial,5274,O
iron,5274,O
accumulation,5274,O
leading,5274,O
to,5274,O
the,5274,O
pathological,5274,O
changes,5274,O
.,5274,O
Affected,5275,O
human,5275,O
tissues,5275,O
are,5275,O
rarely,5275,O
available,5275,O
to,5275,O
further,5275,O
examine,5275,O
this,5275,O
hypothesis,5275,O
.,5275,O
To,5276,O
study,5276,O
the,5276,O
mechanism,5276,O
of,5276,O
the,5276,O
disease,5276,O
",",5276,O
we,5276,O
generated,5276,O
a,5276,O
mouse,5276,O
model,5276,O
by,5276,O
deletion,5276,O
of,5276,O
exon,5276,O
4,5276,O
leading,5276,O
to,5276,O
inactivation,5276,O
of,5276,O
the,5276,O
Frda,5276,B-Modifier
gene,5276,O
product,5276,O
.,5276,O
We,5277,O
show,5277,O
that,5277,O
homozygous,5277,O
deletions,5277,O
cause,5277,O
embryonic,5277,B-SpecificDisease
lethality,5277,I-SpecificDisease
a,5277,O
few,5277,O
days,5277,O
after,5277,O
implantation,5277,O
",",5277,O
demonstrating,5277,O
an,5277,O
important,5277,O
role,5277,O
for,5277,O
frataxin,5277,O
during,5277,O
early,5277,O
development,5277,O
.,5277,O
These,5278,O
results,5278,O
suggest,5278,O
that,5278,O
the,5278,O
milder,5278,O
phenotype,5278,O
in,5278,O
humans,5278,O
is,5278,O
due,5278,O
to,5278,O
residual,5278,O
frataxin,5278,O
expression,5278,O
associated,5278,O
with,5278,O
the,5278,O
expansion,5278,O
mutations,5278,O
.,5278,O
Surprisingly,5279,O
",",5279,O
in,5279,O
the,5279,O
frataxin,5279,O
knockout,5279,O
mouse,5279,O
",",5279,O
no,5279,O
iron,5279,O
accumulation,5279,O
was,5279,O
observed,5279,O
during,5279,O
embryonic,5279,O
resorption,5279,O
",",5279,O
suggesting,5279,O
that,5279,O
cell,5279,O
death,5279,O
could,5279,O
be,5279,O
due,5279,O
to,5279,O
a,5279,O
mechanism,5279,O
independent,5279,O
of,5279,O
iron,5279,O
accumulation,5279,O
..,5279,O
Gaucher,5280,B-SpecificDisease
disease,5280,I-SpecificDisease
:,5280,O
the,5280,O
origins,5280,O
of,5280,O
the,5280,O
Ashkenazi,5280,O
Jewish,5280,O
N370S,5280,O
and,5280,O
84GG,5280,O
acid,5280,O
beta-glucosidase,5280,O
mutations,5280,O
.,5280,O
Type,5281,O
1,5281,O
Gaucher,5281,B-SpecificDisease
disease,5281,I-SpecificDisease
(,5281,O
GD,5281,B-SpecificDisease
),5281,O
",",5281,O
a,5281,O
non-neuronopathic,5281,O
lysosomal,5281,B-DiseaseClass
storage,5281,I-DiseaseClass
disorder,5281,I-DiseaseClass
",",5281,O
results,5281,O
from,5281,O
the,5281,O
deficient,5281,O
activity,5281,O
of,5281,O
acid,5281,O
beta-glucosidase,5281,O
(,5281,O
GBA,5281,O
),5281,O
.,5281,O
Type,5282,O
1,5282,O
disease,5282,O
is,5282,O
panethnic,5282,O
but,5282,O
is,5282,O
more,5282,O
prevalent,5282,O
in,5282,O
individuals,5282,O
of,5282,O
Ashkenazi,5282,O
Jewish,5282,O
(,5282,O
AJ,5282,O
),5282,O
descent,5282,O
.,5282,O
Of,5283,O
the,5283,O
causative,5283,O
GBA,5283,O
mutations,5283,O
",",5283,O
N370S,5283,O
is,5283,O
particularly,5283,O
frequent,5283,O
in,5283,O
the,5283,O
AJ,5283,O
population,5283,O
",",5283,O
(,5283,O
q,5283,O
approximately,5283,O
.,5283,O
03,5284,O
),5284,O
",",5284,O
whereas,5284,O
the,5284,O
84GG,5284,O
insertion,5284,O
(,5284,O
q,5284,O
approximately,5284,O
.,5284,O
003,5285,O
),5285,O
occurs,5285,O
exclusively,5285,O
in,5285,O
the,5285,O
Ashkenazim,5285,O
.,5285,O
To,5286,O
investigate,5286,O
the,5286,O
genetic,5286,O
history,5286,O
of,5286,O
these,5286,O
mutations,5286,O
in,5286,O
the,5286,O
AJ,5286,O
population,5286,O
",",5286,O
short,5286,O
tandem,5286,O
repeat,5286,O
(,5286,O
STR,5286,O
),5286,O
markers,5286,O
were,5286,O
used,5286,O
to,5286,O
map,5286,O
a,5286,O
9,5286,O
.,5286,O
3-cM,5287,O
region,5287,O
containing,5287,O
the,5287,O
GBA,5287,O
locus,5287,O
and,5287,O
to,5287,O
genotype,5287,O
261,5287,O
AJ,5287,O
N370S,5287,O
chromosomes,5287,O
",",5287,O
60,5287,O
European,5287,O
non-Jewish,5287,O
N370S,5287,O
chromosomes,5287,O
",",5287,O
and,5287,O
62,5287,O
AJ,5287,O
84GG,5287,O
chromosomes,5287,O
.,5287,O
A,5288,O
highly,5288,O
conserved,5288,O
haplotype,5288,O
at,5288,O
four,5288,O
markers,5288,O
flanking,5288,O
GBA,5288,O
(,5288,O
PKLR,5288,O
",",5288,O
D1S1595,5288,O
",",5288,O
D1S2721,5288,O
",",5288,O
and,5288,O
D1S2777,5288,O
),5288,O
was,5288,O
observed,5288,O
on,5288,O
both,5288,O
the,5288,O
AJ,5288,O
chromosomes,5288,O
and,5288,O
the,5288,O
non-Jewish,5288,O
N370S,5288,O
chromosomes,5288,O
",",5288,O
suggesting,5288,O
the,5288,O
occurrence,5288,O
of,5288,O
a,5288,O
founder,5288,O
common,5288,O
to,5288,O
both,5288,O
populations,5288,O
.,5288,O
Of,5289,O
note,5289,O
",",5289,O
the,5289,O
presence,5289,O
of,5289,O
different,5289,O
divergent,5289,O
haplotypes,5289,O
suggested,5289,O
the,5289,O
occurrence,5289,O
of,5289,O
de,5289,O
novo,5289,O
",",5289,O
recurrent,5289,O
N370S,5289,O
mutations,5289,O
.,5289,O
In,5290,O
contrast,5290,O
",",5290,O
a,5290,O
different,5290,O
conserved,5290,O
haplotype,5290,O
at,5290,O
these,5290,O
markers,5290,O
was,5290,O
identified,5290,O
on,5290,O
the,5290,O
84GG,5290,O
chromosomes,5290,O
",",5290,O
which,5290,O
was,5290,O
unique,5290,O
to,5290,O
the,5290,O
AJ,5290,O
population,5290,O
.,5290,O
On,5291,O
the,5291,O
basis,5291,O
of,5291,O
the,5291,O
linkage,5291,O
disequilibrium,5291,O
(,5291,O
LD,5291,O
),5291,O
delta,5291,O
values,5291,O
",",5291,O
the,5291,O
non-Jewish,5291,O
European,5291,O
N370S,5291,O
chromosomes,5291,O
had,5291,O
greater,5291,O
haplotype,5291,O
diversity,5291,O
and,5291,O
less,5291,O
LD,5291,O
at,5291,O
the,5291,O
markers,5291,O
flanking,5291,O
the,5291,O
conserved,5291,O
haplotype,5291,O
than,5291,O
did,5291,O
the,5291,O
AJ,5291,O
N370S,5291,O
chromosomes,5291,O
.,5291,O
This,5292,O
finding,5292,O
is,5292,O
consistent,5292,O
with,5292,O
the,5292,O
presence,5292,O
of,5292,O
the,5292,O
N370S,5292,O
mutation,5292,O
in,5292,O
the,5292,O
non-Jewish,5292,O
European,5292,O
population,5292,O
prior,5292,O
to,5292,O
the,5292,O
founding,5292,O
of,5292,O
the,5292,O
AJ,5292,O
population,5292,O
.,5292,O
Coalescence,5293,O
analyses,5293,O
for,5293,O
the,5293,O
N370S,5293,O
and,5293,O
84GG,5293,O
mutations,5293,O
estimated,5293,O
similar,5293,O
coalescence,5293,O
times,5293,O
",",5293,O
of,5293,O
48,5293,O
and,5293,O
55.5,5293,O
generations,5293,O
ago,5293,O
",",5293,O
respectively,5293,O
.,5293,O
The,5294,O
results,5294,O
of,5294,O
these,5294,O
studies,5294,O
are,5294,O
consistent,5294,O
with,5294,O
a,5294,O
significant,5294,O
bottleneck,5294,O
occurring,5294,O
in,5294,O
the,5294,O
AJ,5294,O
population,5294,O
during,5294,O
the,5294,O
first,5294,O
millennium,5294,O
",",5294,O
when,5294,O
the,5294,O
population,5294,O
became,5294,O
established,5294,O
in,5294,O
Europe,5294,O
.,5294,O
Founder,5295,O
mutations,5295,O
in,5295,O
the,5295,O
BRCA1,5295,O
gene,5295,O
in,5295,O
Polish,5295,O
families,5295,O
with,5295,O
breast-ovarian,5295,B-CompositeMention
cancer,5295,I-CompositeMention
.,5295,O
We,5296,O
have,5296,O
undertaken,5296,O
a,5296,O
hospital-based,5296,O
study,5296,O
",",5296,O
to,5296,O
identify,5296,O
possible,5296,O
BRCA1,5296,O
and,5296,O
BRCA2,5296,O
founder,5296,O
mutations,5296,O
in,5296,O
the,5296,O
Polish,5296,O
population,5296,O
.,5296,O
The,5297,O
study,5297,O
group,5297,O
consisted,5297,O
of,5297,O
66,5297,O
Polish,5297,O
families,5297,O
with,5297,O
cancer,5297,B-DiseaseClass
who,5297,O
have,5297,O
at,5297,O
least,5297,O
three,5297,O
related,5297,O
females,5297,O
affected,5297,O
with,5297,O
breast,5297,O
or,5297,O
ovarian,5297,O
cancer,5297,O
and,5297,O
who,5297,O
had,5297,O
cancer,5297,B-DiseaseClass
diagnosed,5297,O
",",5297,O
in,5297,O
at,5297,O
least,5297,O
one,5297,O
of,5297,O
the,5297,O
three,5297,O
affected,5297,O
females,5297,O
",",5297,O
at,5297,O
age,5297,O
<,5297,O
50,5297,O
years,5297,O
.,5297,O
A,5298,O
total,5298,O
of,5298,O
26,5298,O
families,5298,O
had,5298,O
both,5298,O
breast,5298,O
and,5298,O
ovarian,5298,O
cancers,5298,O
",",5298,O
4,5298,O
families,5298,O
had,5298,O
ovarian,5298,B-SpecificDisease
cancers,5298,I-SpecificDisease
only,5298,O
",",5298,O
and,5298,O
36,5298,O
families,5298,O
had,5298,O
breast,5298,B-SpecificDisease
cancers,5298,I-SpecificDisease
only,5298,O
.,5298,O
Genomic,5299,O
DNA,5299,O
was,5299,O
prepared,5299,O
from,5299,O
the,5299,O
peripheral,5299,O
blood,5299,O
leukocytes,5299,O
of,5299,O
at,5299,O
least,5299,O
one,5299,O
affected,5299,O
woman,5299,O
from,5299,O
each,5299,O
family,5299,O
.,5299,O
The,5300,O
entire,5300,O
coding,5300,O
region,5300,O
of,5300,O
BRCA1,5300,O
and,5300,O
BRCA2,5300,O
was,5300,O
screened,5300,O
for,5300,O
the,5300,O
presence,5300,O
of,5300,O
germline,5300,O
mutations,5300,O
",",5300,O
by,5300,O
use,5300,O
of,5300,O
SSCP,5300,O
followed,5300,O
by,5300,O
direct,5300,O
sequencing,5300,O
of,5300,O
observed,5300,O
variants,5300,O
.,5300,O
Mutations,5301,O
were,5301,O
found,5301,O
in,5301,O
35,5301,O
(,5301,O
53,5301,O
%,5301,O
),5301,O
of,5301,O
the,5301,O
66,5301,O
families,5301,O
studied,5301,O
.,5301,O
All,5302,O
but,5302,O
one,5302,O
of,5302,O
the,5302,O
mutations,5302,O
were,5302,O
detected,5302,O
within,5302,O
the,5302,O
BRCA1,5302,O
gene,5302,O
.,5302,O
BRCA1,5303,B-DiseaseClass
abnormalities,5303,I-DiseaseClass
were,5303,O
identified,5303,O
in,5303,O
all,5303,O
four,5303,O
families,5303,O
with,5303,O
ovarian,5303,B-SpecificDisease
cancer,5303,I-SpecificDisease
only,5303,O
",",5303,O
in,5303,O
67,5303,O
%,5303,O
of,5303,O
27,5303,O
families,5303,O
with,5303,O
both,5303,O
breast,5303,O
and,5303,O
ovarian,5303,O
cancer,5303,O
",",5303,O
and,5303,O
in,5303,O
34,5303,O
%,5303,O
of,5303,O
35,5303,O
families,5303,O
with,5303,O
breast,5303,B-SpecificDisease
cancer,5303,I-SpecificDisease
only,5303,O
.,5303,O
The,5304,O
single,5304,O
family,5304,O
with,5304,O
a,5304,O
BRCA2,5304,O
mutation,5304,O
had,5304,O
the,5304,O
breast-ovarian,5304,B-SpecificDisease
cancer,5304,I-SpecificDisease
syndrome,5304,I-SpecificDisease
.,5304,O
Seven,5305,O
distinct,5305,O
mutations,5305,O
were,5305,O
identified,5305,O
;,5305,O
five,5305,O
of,5305,O
these,5305,O
occurred,5305,O
in,5305,O
two,5305,O
or,5305,O
more,5305,O
families,5305,O
.,5305,O
In,5306,O
total,5306,O
",",5306,O
recurrent,5306,O
mutations,5306,O
were,5306,O
found,5306,O
in,5306,O
33,5306,O
(,5306,O
94,5306,O
%,5306,O
),5306,O
of,5306,O
the,5306,O
35,5306,O
families,5306,O
with,5306,O
detected,5306,O
mutations,5306,O
.,5306,O
Three,5307,O
BRCA1,5307,B-DiseaseClass
abnormalities,5307,I-DiseaseClass
-,5307,O
5382insC,5307,O
",",5307,O
C61G,5307,O
",",5307,O
and,5307,O
4153delA,5307,O
-,5307,O
accounted,5307,O
for,5307,O
51,5307,O
%,5307,O
",",5307,O
20,5307,O
%,5307,O
",",5307,O
and,5307,O
11,5307,O
%,5307,O
of,5307,O
the,5307,O
identified,5307,O
mutations,5307,O
",",5307,O
respectively,5307,O
..,5307,O
Molecular,5308,O
basis,5308,O
of,5308,O
very,5308,B-SpecificDisease
long,5308,I-SpecificDisease
chain,5308,I-SpecificDisease
acyl-CoA,5308,I-SpecificDisease
dehydrogenase,5308,I-SpecificDisease
deficiency,5308,I-SpecificDisease
in,5308,O
three,5308,O
Israeli,5308,O
patients,5308,O
:,5308,O
identification,5308,O
of,5308,O
a,5308,O
complex,5308,O
mutant,5308,O
allele,5308,O
with,5308,O
P65L,5308,O
and,5308,O
K247Q,5308,O
mutations,5308,O
",",5308,O
the,5308,O
former,5308,O
being,5308,O
an,5308,O
exonic,5308,O
mutation,5308,O
causing,5308,O
exon,5308,O
3,5308,O
skipping,5308,O
.,5308,O
Very,5309,B-SpecificDisease
long,5309,I-SpecificDisease
chain,5309,I-SpecificDisease
acyl-CoA,5309,I-SpecificDisease
dehydrogenase,5309,I-SpecificDisease
(,5309,I-SpecificDisease
VLCAD,5309,I-SpecificDisease
),5309,I-SpecificDisease
deficiency,5309,I-SpecificDisease
is,5309,O
a,5309,O
life-threatening,5309,O
disorder,5309,O
of,5309,O
mitochondrial,5309,O
fatty,5309,O
acid,5309,O
beta-oxidation,5309,O
.,5309,O
We,5310,O
identified,5310,O
four,5310,O
novel,5310,O
mutations,5310,O
in,5310,O
three,5310,O
unrelated,5310,O
patients,5310,O
.,5310,O
All,5311,O
patients,5311,O
had,5311,O
the,5311,O
severe,5311,O
childhood,5311,O
form,5311,O
of,5311,O
VLCAD,5311,B-SpecificDisease
deficiency,5311,I-SpecificDisease
with,5311,O
early,5311,O
onset,5311,O
and,5311,O
high,5311,O
mortality,5311,O
.,5311,O
Immunoblot,5312,O
analysis,5312,O
revealed,5312,O
that,5312,O
VLCAD,5312,O
protein,5312,O
was,5312,O
undetectable,5312,O
in,5312,O
patients,5312,O
2,5312,O
and,5312,O
3,5312,O
",",5312,O
whereas,5312,O
normal-size,5312,O
VLCAD,5312,O
protein,5312,O
and,5312,O
an,5312,O
aberrant,5312,O
form,5312,O
of,5312,O
VLCAD,5312,O
(,5312,O
4kDa,5312,O
smaller,5312,O
),5312,O
were,5312,O
detected,5312,O
in,5312,O
patient,5312,O
1,5312,O
.,5312,O
As,5313,O
expected,5313,O
",",5313,O
null,5313,O
mutations,5313,O
were,5313,O
found,5313,O
in,5313,O
patients,5313,O
2,5313,O
and,5313,O
3,5313,O
patient,5313,O
2,5313,O
is,5313,O
homozygous,5313,O
for,5313,O
a,5313,O
frameshift,5313,O
mutation,5313,O
",",5313,O
del,5313,O
4,5313,O
bp,5313,O
at,5313,O
798-801,5313,O
",",5313,O
and,5313,O
patient,5313,O
3,5313,O
is,5313,O
homozygous,5313,O
for,5313,O
a,5313,O
nonsense,5313,O
mutation,5313,O
65C,5313,O
>,5313,O
A,5313,O
(,5313,O
S22X,5313,O
),5313,O
.,5313,O
Patient,5314,O
1,5314,O
was,5314,O
homozygous,5314,O
for,5314,O
a,5314,O
complex,5314,O
mutant,5314,O
allele,5314,O
containing,5314,O
two,5314,O
alterations,5314,O
",",5314,O
including,5314,O
a,5314,O
194C,5314,O
>,5314,O
T,5314,O
transition,5314,O
(,5314,O
P65L,5314,O
),5314,O
and,5314,O
739A,5314,O
>,5314,O
C,5314,O
transversion,5314,O
(,5314,O
K247Q,5314,O
),5314,O
;,5314,O
in,5314,O
the,5314,O
case,5314,O
of,5314,O
P65L,5314,O
",",5314,O
the,5314,O
amino,5314,O
acid,5314,O
change,5314,O
does,5314,O
not,5314,O
reduce,5314,O
enzyme,5314,O
activity,5314,O
.,5314,O
However,5315,O
",",5315,O
the,5315,O
nucleotide,5315,O
change,5315,O
resulted,5315,O
in,5315,O
exon,5315,O
3,5315,O
skipping,5315,O
",",5315,O
whereas,5315,O
the,5315,O
latter,5315,O
K247Q,5315,O
mutation,5315,O
had,5315,O
a,5315,O
drastic,5315,O
effect,5315,O
on,5315,O
enzyme,5315,O
activity,5315,O
.,5315,O
We,5316,O
verified,5316,O
these,5316,O
events,5316,O
by,5316,O
in,5316,O
vivo,5316,O
splicing,5316,O
experiments,5316,O
and,5316,O
transient,5316,O
expression,5316,O
analysis,5316,O
of,5316,O
mutant,5316,O
cDNAs,5316,O
.,5316,O
The,5317,O
P65L,5317,O
mutation,5317,O
locates,5317,O
11,5317,O
bases,5317,O
upstream,5317,O
of,5317,O
a,5317,O
splice,5317,O
donor,5317,O
site,5317,O
of,5317,O
intron,5317,O
3,5317,O
.,5317,O
This,5318,O
is,5318,O
an,5318,O
example,5318,O
of,5318,O
an,5318,O
exonic,5318,O
mutation,5318,O
which,5318,O
affects,5318,O
exon-splicing,5318,O
..,5318,O
Submicroscopic,5319,O
deletion,5319,O
in,5319,O
cousins,5319,O
with,5319,O
Prader-Willi,5319,B-SpecificDisease
syndrome,5319,I-SpecificDisease
causes,5319,O
a,5319,O
grandmatrilineal,5319,O
inheritance,5319,O
pattern,5319,O
:,5319,O
effects,5319,O
of,5319,O
imprinting,5319,O
.,5319,O
The,5320,O
Prader-Willi,5320,B-SpecificDisease
syndrome,5320,I-SpecificDisease
(,5320,O
PWS,5320,B-SpecificDisease
),5320,O
critical,5320,O
region,5320,O
on,5320,O
15q11-q13,5320,O
is,5320,O
subject,5320,O
to,5320,O
imprinting,5320,O
.,5320,O
PWS,5321,B-SpecificDisease
becomes,5321,O
apparent,5321,O
when,5321,O
genes,5321,O
on,5321,O
the,5321,O
paternally,5321,O
inherited,5321,O
chromosome,5321,O
are,5321,O
not,5321,O
expressed,5321,O
.,5321,O
Familial,5322,B-SpecificDisease
PWS,5322,I-SpecificDisease
is,5322,O
rare,5322,O
.,5322,O
We,5323,O
report,5323,O
on,5323,O
a,5323,O
family,5323,O
in,5323,O
which,5323,O
a,5323,O
male,5323,O
and,5323,O
a,5323,O
female,5323,O
paternal,5323,O
first,5323,O
cousin,5323,O
both,5323,O
have,5323,O
PWS,5323,B-SpecificDisease
with,5323,O
cytogenetically,5323,O
normal,5323,O
karyotypes,5323,O
.,5323,O
Fluorescence,5324,O
in,5324,O
situ,5324,O
hybridization,5324,O
(,5324,O
FISH,5324,O
),5324,O
analysis,5324,O
shows,5324,O
a,5324,O
submicroscopic,5324,O
deletion,5324,O
of,5324,O
SNRPN,5324,O
",",5324,O
but,5324,O
not,5324,O
the,5324,O
closely,5324,O
associated,5324,O
loci,5324,O
D15S10,5324,O
",",5324,O
D15S11,5324,O
",",5324,O
D15S63,5324,O
",",5324,O
and,5324,O
GABRB3,5324,O
.,5324,O
The,5325,O
cousins,5325,O
fathers,5325,O
and,5325,O
two,5325,O
paternal,5325,O
aunts,5325,O
have,5325,O
the,5325,O
same,5325,O
deletion,5325,O
and,5325,O
are,5325,O
clinically,5325,O
normal,5325,O
.,5325,O
The,5326,O
grandmother,5326,O
of,5326,O
the,5326,O
cousins,5326,O
is,5326,O
deceased,5326,O
and,5326,O
not,5326,O
available,5326,O
for,5326,O
study,5326,O
",",5326,O
and,5326,O
their,5326,O
grandfather,5326,O
is,5326,O
not,5326,O
deleted,5326,O
for,5326,O
SNRPN,5326,O
.,5326,O
DNA,5327,O
methylation,5327,O
analysis,5327,O
of,5327,O
D15S63,5327,O
is,5327,O
consistent,5327,O
with,5327,O
an,5327,O
abnormality,5327,O
of,5327,O
the,5327,O
imprinting,5327,O
center,5327,O
associated,5327,O
with,5327,O
PWS.,5327,B-SpecificDisease
``,5327,O
Grandmatrilineal,5328,O
``,5328,O
inheritance,5328,O
occurs,5328,O
when,5328,O
a,5328,O
woman,5328,O
with,5328,O
deletion,5328,O
of,5328,O
an,5328,O
imprinted,5328,O
",",5328,O
paternally,5328,O
expressed,5328,O
gene,5328,O
is,5328,O
at,5328,O
risk,5328,O
of,5328,O
having,5328,O
affected,5328,O
grandchildren,5328,O
through,5328,O
her,5328,O
sons,5328,O
.,5328,O
In,5329,O
this,5329,O
case,5329,O
",",5329,O
PWS,5329,B-SpecificDisease
does,5329,O
not,5329,O
become,5329,O
evident,5329,O
as,5329,O
long,5329,O
as,5329,O
the,5329,O
deletion,5329,O
is,5329,O
passed,5329,O
through,5329,O
the,5329,O
matrilineal,5329,O
line,5329,O
.,5329,O
This,5330,O
represents,5330,O
a,5330,O
unique,5330,O
inheritance,5330,O
pattern,5330,O
due,5330,O
to,5330,O
imprinting,5330,O
..,5330,O
Human,5331,O
glycine,5331,O
decarboxylase,5331,O
gene,5331,O
(,5331,O
GLDC,5331,O
),5331,O
and,5331,O
its,5331,O
highly,5331,O
conserved,5331,O
processed,5331,O
pseudogene,5331,O
(,5331,O
psiGLDC,5331,O
),5331,O
:,5331,O
their,5331,O
structure,5331,O
and,5331,O
expression,5331,O
",",5331,O
and,5331,O
the,5331,O
identification,5331,O
of,5331,O
a,5331,O
large,5331,O
deletion,5331,O
in,5331,O
a,5331,O
family,5331,O
with,5331,O
nonketotic,5331,B-SpecificDisease
hyperglycinemia,5331,I-SpecificDisease
.,5331,O
Mutations,5332,O
in,5332,O
the,5332,O
glycine,5332,O
decarboxylase,5332,O
gene,5332,O
(,5332,O
GLDC,5332,O
),5332,O
cause,5332,O
nonketotic,5332,B-SpecificDisease
hyperglycinemia,5332,I-SpecificDisease
(,5332,O
NKH,5332,B-SpecificDisease
),5332,O
",",5332,O
an,5332,O
in-born,5332,B-DiseaseClass
error,5332,I-DiseaseClass
of,5332,I-DiseaseClass
metabolism,5332,I-DiseaseClass
characterized,5332,O
by,5332,O
severe,5332,O
neurological,5332,B-DiseaseClass
disturbance,5332,I-DiseaseClass
.,5332,O
We,5333,O
have,5333,O
determined,5333,O
the,5333,O
structure,5333,O
of,5333,O
GLDC,5333,O
and,5333,O
of,5333,O
its,5333,O
pseudogene,5333,O
(,5333,O
psiGLDC,5333,O
),5333,O
and,5333,O
studied,5333,O
their,5333,O
expression,5333,O
for,5333,O
a,5333,O
molecular,5333,O
analysis,5333,O
of,5333,O
NKH,5333,B-SpecificDisease
.,5333,O
The,5334,O
GLDC,5334,O
gene,5334,O
spans,5334,O
at,5334,O
least,5334,O
135,5334,O
kb,5334,O
and,5334,O
consists,5334,O
of,5334,O
25,5334,O
exons,5334,O
.,5334,O
All,5335,O
donor,5335,O
and,5335,O
acceptor,5335,O
sites,5335,O
adhere,5335,O
to,5335,O
the,5335,O
canonical,5335,O
GT-AG,5335,O
rule,5335,O
",",5335,O
except,5335,O
for,5335,O
the,5335,O
donor,5335,O
site,5335,O
of,5335,O
intron,5335,O
21,5335,O
",",5335,O
where,5335,O
a,5335,O
variant,5335,O
form,5335,O
GC,5335,O
is,5335,O
used,5335,O
instead,5335,O
of,5335,O
GT,5335,O
.,5335,O
The,5336,O
transcription,5336,O
initiation,5336,O
site,5336,O
has,5336,O
been,5336,O
assigned,5336,O
to,5336,O
a,5336,O
residue,5336,O
163,5336,O
bp,5336,O
upstream,5336,O
from,5336,O
the,5336,O
translation,5336,O
initiation,5336,O
triplet,5336,O
by,5336,O
primer,5336,O
extension,5336,O
analysis,5336,O
.,5336,O
The,5337,O
psiGLDC,5337,O
gene,5337,O
has,5337,O
no,5337,O
intron,5337,O
and,5337,O
shares,5337,O
97,5337,O
.,5337,O
5,5338,O
%,5338,O
homology,5338,O
with,5338,O
the,5338,O
coding,5338,O
region,5338,O
of,5338,O
functional,5338,O
GLDC,5338,O
",",5338,O
suggesting,5338,O
that,5338,O
psiGLDC,5338,O
is,5338,O
a,5338,O
processed,5338,O
pseudogene,5338,O
that,5338,O
arose,5338,O
from,5338,O
the,5338,O
GLDC,5338,O
transcript,5338,O
about,5338,O
4-8,5338,O
million,5338,O
years,5338,O
ago,5338,O
.,5338,O
RNA,5339,O
blotting,5339,O
analysis,5339,O
has,5339,O
revealed,5339,O
that,5339,O
GLDC,5339,O
is,5339,O
expressed,5339,O
in,5339,O
human,5339,O
liver,5339,O
",",5339,O
kidney,5339,O
",",5339,O
brain,5339,O
",",5339,O
and,5339,O
placenta,5339,O
.,5339,O
We,5340,O
have,5340,O
also,5340,O
examined,5340,O
a,5340,O
patient,5340,O
with,5340,O
NKH,5340,B-SpecificDisease
with,5340,O
no,5340,O
detectable,5340,O
GLDC,5340,O
mRNA,5340,O
in,5340,O
his,5340,O
lymphoblasts,5340,O
.,5340,O
Exons,5341,O
1-3,5341,O
of,5341,O
the,5341,O
functional,5341,O
GLDC,5341,O
gene,5341,O
from,5341,O
this,5341,O
patient,5341,O
are,5341,O
not,5341,O
amplified,5341,O
by,5341,O
polymerase,5341,O
chain,5341,O
reaction,5341,O
(,5341,O
PCR,5341,O
),5341,O
",",5341,O
whereas,5341,O
those,5341,O
from,5341,O
control,5341,O
subjects,5341,O
are,5341,O
.,5341,O
These,5342,O
results,5342,O
suggest,5342,O
a,5342,O
large,5342,O
homozygous,5342,O
deletion,5342,O
(,5342,O
at,5342,O
least,5342,O
30,5342,O
kb,5342,O
),5342,O
in,5342,O
the,5342,O
patient,5342,O
.,5342,O
Furthermore,5343,O
",",5343,O
we,5343,O
have,5343,O
devised,5343,O
a,5343,O
semi-quantitative,5343,O
PCR,5343,O
to,5343,O
estimate,5343,O
the,5343,O
number,5343,O
of,5343,O
GLDC,5343,O
alleles,5343,O
by,5343,O
using,5343,O
psiGLDC,5343,O
as,5343,O
an,5343,O
internal,5343,O
control,5343,O
and,5343,O
have,5343,O
confirmed,5343,O
the,5343,O
homozygosity,5343,O
and,5343,O
heterozygosity,5343,O
of,5343,O
the,5343,O
deletion,5343,O
in,5343,O
the,5343,O
patient,5343,O
and,5343,O
his,5343,O
parents,5343,O
",",5343,O
respectively,5343,O
.,5343,O
Structural,5344,O
information,5344,O
of,5344,O
GLDC,5344,O
and,5344,O
psiGLDC,5344,O
should,5344,O
facilitate,5344,O
the,5344,O
molecular,5344,O
analysis,5344,O
of,5344,O
NKH,5344,B-SpecificDisease
.,5344,O
De,5345,O
novo,5345,O
deletions,5345,O
of,5345,O
SNRPN,5345,O
exon,5345,O
1,5345,O
in,5345,O
early,5345,O
human,5345,O
and,5345,O
mouse,5345,O
embryos,5345,O
result,5345,O
in,5345,O
a,5345,O
paternal,5345,O
to,5345,O
maternal,5345,O
imprint,5345,O
switch,5345,O
.,5345,O
Prader-Willi,5346,B-SpecificDisease
syndrome,5346,I-SpecificDisease
(,5346,O
PWS,5346,B-SpecificDisease
),5346,O
is,5346,O
a,5346,O
neurogenetic,5346,B-DiseaseClass
disease,5346,I-DiseaseClass
characterized,5346,O
by,5346,O
infantile,5346,B-SpecificDisease
hypotonia,5346,I-SpecificDisease
",",5346,O
gonadal,5346,B-SpecificDisease
hypoplasia,5346,I-SpecificDisease
",",5346,O
obsessive,5346,O
behaviour,5346,O
and,5346,O
neonatal,5346,O
feeding,5346,O
difficulties,5346,O
followed,5346,O
by,5346,O
hyperphagia,5346,B-SpecificDisease
",",5346,O
leading,5346,O
to,5346,O
profound,5346,O
obesity,5346,B-SpecificDisease
.,5346,O
PWS,5347,B-SpecificDisease
is,5347,O
due,5347,O
to,5347,O
a,5347,O
lack,5347,O
of,5347,O
paternal,5347,O
genetic,5347,O
information,5347,O
at,5347,O
15q11-q13,5347,O
(,5347,O
ref,5347,O
.,5347,O
2,5348,O
),5348,O
.,5348,O
Five,5349,O
imprinted,5349,O
",",5349,O
paternally,5349,O
expressed,5349,O
genes,5349,O
map,5349,O
to,5349,O
the,5349,O
PWS,5349,B-Modifier
region,5349,O
",",5349,O
MKRN3,5349,O
(,5349,O
ref,5349,O
.,5349,O
3,5350,O
),5350,O
",",5350,O
NDN,5350,O
(,5350,O
ref,5350,O
.,5350,O
4,5351,O
),5351,O
",",5351,O
NDNL1,5351,O
(,5351,O
ref,5351,O
.,5351,O
5,5352,O
),5352,O
",",5352,O
SNRPN,5352,O
(,5352,O
refs,5352,O
6-8,5352,O
),5352,O
and,5352,O
IPW,5352,O
(,5352,O
ref,5352,O
.,5352,O
9,5353,O
),5353,O
",",5353,O
as,5353,O
well,5353,O
as,5353,O
two,5353,O
poorly,5353,O
characterized,5353,O
framents,5353,O
designated,5353,O
PAR-1,5353,O
and,5353,O
PAR-5,5353,O
(,5353,O
ref,5353,O
.,5353,O
10,5354,O
),5354,O
.,5354,O
Imprinting,5355,O
of,5355,O
this,5355,O
region,5355,O
involves,5355,O
a,5355,O
bipartite,5355,O
imprinting,5355,O
centre,5355,O
(,5355,O
IC,5355,O
),5355,O
",",5355,O
which,5355,O
overlaps,5355,O
SNRPN,5355,O
(,5355,O
refs,5355,O
10,5355,O
",",5355,O
11,5355,O
),5355,O
.,5355,O
Deletion,5356,O
of,5356,O
the,5356,O
SNRPN,5356,O
promoter/exon,5356,O
1,5356,O
region,5356,O
(,5356,O
the,5356,O
PWS,5356,B-Modifier
IC,5356,O
element,5356,O
),5356,O
appears,5356,O
to,5356,O
impair,5356,O
the,5356,O
establishment,5356,O
of,5356,O
the,5356,O
paternal,5356,O
imprint,5356,O
in,5356,O
the,5356,O
male,5356,O
germ,5356,O
line,5356,O
and,5356,O
leads,5356,O
to,5356,O
PWS,5356,B-SpecificDisease
.,5356,O
Here,5357,O
we,5357,O
report,5357,O
a,5357,O
PWS,5357,B-Modifier
family,5357,O
in,5357,O
which,5357,O
the,5357,O
father,5357,O
is,5357,O
mosaic,5357,O
for,5357,O
an,5357,O
IC,5357,O
deletion,5357,O
on,5357,O
his,5357,O
paternal,5357,O
chromosome,5357,O
.,5357,O
The,5358,O
deletion,5358,O
chromosome,5358,O
has,5358,O
acquired,5358,O
a,5358,O
maternal,5358,O
methylation,5358,O
imprint,5358,O
in,5358,O
his,5358,O
somatic,5358,O
cells,5358,O
.,5358,O
We,5359,O
have,5359,O
made,5359,O
identical,5359,O
findings,5359,O
in,5359,O
chimaeric,5359,O
mice,5359,O
generated,5359,O
from,5359,O
two,5359,O
independent,5359,O
embryonic,5359,O
stem,5359,O
(,5359,O
ES,5359,O
),5359,O
cell,5359,O
lines,5359,O
harbouring,5359,O
a,5359,O
similar,5359,O
deletion,5359,O
.,5359,O
Our,5360,O
studies,5360,O
demonstrate,5360,O
that,5360,O
the,5360,O
PWS,5360,B-Modifier
IC,5360,O
element,5360,O
is,5360,O
not,5360,O
only,5360,O
required,5360,O
for,5360,O
the,5360,O
establishment,5360,O
of,5360,O
the,5360,O
paternal,5360,O
imprint,5360,O
",",5360,O
but,5360,O
also,5360,O
for,5360,O
its,5360,O
postzygotic,5360,O
maintenance,5360,O
..,5360,O
Mice,5361,O
deficient,5361,B-SpecificDisease
in,5361,I-SpecificDisease
Six5,5361,I-SpecificDisease
develop,5361,O
cataracts,5361,B-SpecificDisease
:,5361,O
implications,5361,O
for,5361,O
myotonic,5361,B-SpecificDisease
dystrophy,5361,I-SpecificDisease
.,5361,O
Expansion,5362,O
of,5362,O
a,5362,O
CTG,5362,O
trinucleotide,5362,O
repeat,5362,O
in,5362,O
the,5362,O
3,5362,O
UTR,5362,O
of,5362,O
the,5362,O
gene,5362,O
DMPK,5362,O
at,5362,O
the,5362,O
DM1,5362,O
locus,5362,O
on,5362,O
chromosome,5362,O
19,5362,O
causes,5362,O
myotonic,5362,B-SpecificDisease
dystrophy,5362,I-SpecificDisease
",",5362,O
a,5362,O
dominantly,5362,B-DiseaseClass
inherited,5362,I-DiseaseClass
disease,5362,I-DiseaseClass
characterized,5362,O
by,5362,O
skeletal,5362,O
muscle,5362,B-SpecificDisease
dystrophy,5362,I-SpecificDisease
and,5362,O
myotonia,5362,B-DiseaseClass
",",5362,O
cataracts,5362,B-SpecificDisease
and,5362,O
cardiac,5362,B-DiseaseClass
conduction,5362,I-DiseaseClass
defects,5362,I-DiseaseClass
.,5362,O
Targeted,5363,O
deletion,5363,O
of,5363,O
Dm15,5363,O
",",5363,O
the,5363,O
mouse,5363,O
orthologue,5363,O
of,5363,O
human,5363,O
DMPK,5363,O
",",5363,O
produced,5363,O
mice,5363,O
with,5363,O
a,5363,O
mild,5363,O
myopathy,5363,B-DiseaseClass
and,5363,O
cardiac,5363,B-DiseaseClass
conduction,5363,I-DiseaseClass
abnormalities,5363,I-DiseaseClass
",",5363,O
but,5363,O
without,5363,O
other,5363,O
features,5363,O
of,5363,O
myotonic,5363,B-SpecificDisease
dystrophy,5363,I-SpecificDisease
",",5363,O
such,5363,O
as,5363,O
myotonia,5363,B-DiseaseClass
and,5363,O
cataracts,5363,B-SpecificDisease
.,5363,O
We,5364,O
",",5364,O
and,5364,O
others,5364,O
",",5364,O
have,5364,O
demonstrated,5364,O
that,5364,O
repeat,5364,O
expansion,5364,O
decreases,5364,O
expression,5364,O
of,5364,O
the,5364,O
adjacent,5364,O
gene,5364,O
SIX5,5364,O
(,5364,O
refs,5364,O
7,5364,O
",",5364,O
8,5364,O
),5364,O
",",5364,O
which,5364,O
encodes,5364,O
a,5364,O
homeodomain,5364,O
transcription,5364,O
factor,5364,O
.,5364,O
To,5365,O
determine,5365,O
whether,5365,O
SIX5,5365,B-SpecificDisease
deficiency,5365,I-SpecificDisease
contributes,5365,O
to,5365,O
the,5365,O
myotonic,5365,B-Modifier
dystrophy,5365,I-Modifier
phenotype,5365,O
",",5365,O
we,5365,O
disrupted,5365,O
mouse,5365,O
Six5,5365,O
by,5365,O
replacing,5365,O
the,5365,O
first,5365,O
exon,5365,O
with,5365,O
a,5365,O
beta-galactosidase,5365,O
reporter,5365,O
.,5365,O
Six5-mutant,5366,O
mice,5366,O
showed,5366,O
reporter,5366,O
expression,5366,O
in,5366,O
multiple,5366,O
tissues,5366,O
",",5366,O
including,5366,O
the,5366,O
developing,5366,O
lens,5366,O
.,5366,O
Homozygous,5367,O
mutant,5367,O
mice,5367,O
had,5367,O
no,5367,O
apparent,5367,O
abnormalities,5367,B-DiseaseClass
of,5367,I-DiseaseClass
skeletal,5367,I-DiseaseClass
muscle,5367,I-DiseaseClass
function,5367,I-DiseaseClass
",",5367,O
but,5367,O
developed,5367,O
lenticular,5367,B-SpecificDisease
opacities,5367,I-SpecificDisease
at,5367,O
a,5367,O
higher,5367,O
rate,5367,O
than,5367,O
controls,5367,O
.,5367,O
Our,5368,O
results,5368,O
suggest,5368,O
that,5368,O
SIX5,5368,B-SpecificDisease
deficiency,5368,I-SpecificDisease
contributes,5368,O
to,5368,O
the,5368,O
cataract,5368,B-Modifier
phenotype,5368,O
in,5368,O
myotonic,5368,B-SpecificDisease
dystrophy,5368,I-SpecificDisease
",",5368,O
and,5368,O
that,5368,O
myotonic,5368,B-SpecificDisease
dystrophy,5368,I-SpecificDisease
represents,5368,O
a,5368,O
multigenic,5368,B-DiseaseClass
disorder,5368,I-DiseaseClass
..,5368,O
Heterozygous,5369,O
loss,5369,O
of,5369,O
Six5,5369,O
in,5369,O
mice,5369,O
is,5369,O
sufficient,5369,O
to,5369,O
cause,5369,O
ocular,5369,O
cataracts,5369,B-SpecificDisease
.,5369,O
Myotonic,5370,B-SpecificDisease
dystrophy,5370,I-SpecificDisease
(,5370,O
DM,5370,B-SpecificDisease
),5370,O
is,5370,O
an,5370,O
autosomal,5370,B-DiseaseClass
dominant,5370,I-DiseaseClass
disorder,5370,O
characterized,5370,O
by,5370,O
skeletal,5370,O
muscle,5370,B-SpecificDisease
wasting,5370,I-SpecificDisease
",",5370,O
myotonia,5370,B-DiseaseClass
",",5370,O
cardiac,5370,B-DiseaseClass
arrhythmia,5370,I-DiseaseClass
",",5370,O
hyperinsulinaemia,5370,B-SpecificDisease
",",5370,O
mental,5370,B-DiseaseClass
retardation,5370,I-DiseaseClass
and,5370,O
ocular,5370,O
cataracts,5370,B-SpecificDisease
.,5370,O
The,5371,O
genetic,5371,B-DiseaseClass
defect,5371,I-DiseaseClass
in,5371,O
DM,5371,B-SpecificDisease
is,5371,O
a,5371,O
CTG,5371,O
repeat,5371,O
expansion,5371,O
located,5371,O
in,5371,O
the,5371,O
3,5371,O
untranslated,5371,O
region,5371,O
of,5371,O
DMPK,5371,O
and,5371,O
5,5371,O
of,5371,O
a,5371,O
homeodomain-encoding,5371,O
gene,5371,O
",",5371,O
SIX5,5371,O
(,5371,O
formerly,5371,O
DMAHP,5371,O
;,5371,O
refs,5371,O
2-5,5371,O
),5371,O
.,5371,O
There,5372,O
are,5372,O
three,5372,O
mechanisms,5372,O
by,5372,O
which,5372,O
CTG,5372,O
expansion,5372,O
can,5372,O
result,5372,O
in,5372,O
DM,5372,B-SpecificDisease
.,5372,O
First,5373,O
",",5373,O
repeat,5373,O
expansion,5373,O
may,5373,O
alter,5373,O
the,5373,O
processing,5373,O
or,5373,O
transport,5373,O
of,5373,O
the,5373,O
mutant,5373,O
DMPK,5373,O
mRNA,5373,O
and,5373,O
consequently,5373,O
reduce,5373,O
DMPK,5373,O
levels,5373,O
.,5373,O
Second,5374,O
",",5374,O
CTG,5374,O
expansion,5374,O
may,5374,O
establish,5374,O
a,5374,O
region,5374,O
of,5374,O
heterochromatin,5374,O
3,5374,O
of,5374,O
the,5374,O
repeat,5374,O
sequence,5374,O
and,5374,O
decrease,5374,O
SIX5,5374,O
transcription,5374,O
.,5374,O
Third,5375,O
",",5375,O
toxic,5375,O
effects,5375,O
of,5375,O
the,5375,O
repeat,5375,O
expansion,5375,O
may,5375,O
be,5375,O
intrinsic,5375,O
to,5375,O
the,5375,O
repeated,5375,O
elements,5375,O
at,5375,O
the,5375,O
level,5375,O
of,5375,O
DNA,5375,O
or,5375,O
RNA,5375,O
(,5375,O
refs,5375,O
10,5375,O
",",5375,O
11,5375,O
),5375,O
.,5375,O
Previous,5376,O
studies,5376,O
have,5376,O
demonstrated,5376,O
that,5376,O
a,5376,O
dose-dependent,5376,O
loss,5376,O
of,5376,O
Dm15,5376,O
(,5376,O
the,5376,O
mouse,5376,O
DMPK,5376,O
homologue,5376,O
),5376,O
in,5376,O
mice,5376,O
produces,5376,O
a,5376,O
partial,5376,O
DM,5376,B-Modifier
phenotype,5376,O
characterized,5376,O
by,5376,O
decreased,5376,O
development,5376,O
of,5376,O
skeletal,5376,O
muscle,5376,O
force,5376,O
and,5376,O
cardiac,5376,B-DiseaseClass
conduction,5376,I-DiseaseClass
disorders,5376,I-DiseaseClass
.,5376,O
To,5377,O
test,5377,O
the,5377,O
role,5377,O
of,5377,O
Six5,5377,O
loss,5377,O
in,5377,O
DM,5377,B-SpecificDisease
",",5377,O
we,5377,O
have,5377,O
analysed,5377,O
a,5377,O
strain,5377,O
of,5377,O
mice,5377,O
in,5377,O
which,5377,O
Six5,5377,O
was,5377,O
deleted,5377,O
.,5377,O
Our,5378,O
results,5378,O
demonstrate,5378,O
that,5378,O
the,5378,O
rate,5378,O
and,5378,O
severity,5378,O
of,5378,O
cataract,5378,B-Modifier
formation,5378,O
is,5378,O
inversely,5378,O
related,5378,O
to,5378,O
Six5,5378,O
dosage,5378,O
and,5378,O
is,5378,O
temporally,5378,O
progressive,5378,O
.,5378,O
Six5,5379,O
+/-,5379,O
and,5379,O
Six5-/-,5379,O
mice,5379,O
show,5379,O
increased,5379,O
steady-state,5379,O
levels,5379,O
of,5379,O
the,5379,O
Na,5379,O
+/K,5379,O
+,5379,O
-ATPase,5379,O
alpha-1,5379,O
subunit,5379,O
and,5379,O
decreased,5379,O
Dm15,5379,O
mRNA,5379,O
levels,5379,O
.,5379,O
Thus,5380,O
",",5380,O
altered,5380,O
ion,5380,O
homeostasis,5380,O
within,5380,O
the,5380,O
lens,5380,O
may,5380,O
contribute,5380,O
to,5380,O
cataract,5380,B-Modifier
formation,5380,O
.,5380,O
As,5381,O
ocular,5381,O
cataracts,5381,B-SpecificDisease
are,5381,O
a,5381,O
characteristic,5381,O
feature,5381,O
of,5381,O
DM,5381,B-SpecificDisease
",",5381,O
these,5381,O
results,5381,O
demonstrate,5381,O
that,5381,O
decreased,5381,O
SIX5,5381,O
transcription,5381,O
is,5381,O
important,5381,O
in,5381,O
the,5381,O
aetiology,5381,O
of,5381,O
DM,5381,B-SpecificDisease
.,5381,O
Our,5382,O
data,5382,O
support,5382,O
the,5382,O
hypothesis,5382,O
that,5382,O
DM,5382,B-SpecificDisease
is,5382,O
a,5382,O
contiguous,5382,O
gene,5382,O
syndrome,5382,O
associated,5382,O
with,5382,O
the,5382,O
partial,5382,O
loss,5382,O
of,5382,O
both,5382,O
DMPK,5382,O
and,5382,O
SIX5,5382,O
..,5382,O
ATM-dependent,5383,O
phosphorylation,5383,O
of,5383,O
nibrin,5383,O
in,5383,O
response,5383,O
to,5383,O
radiation,5383,O
exposure,5383,O
.,5383,O
Mutations,5384,O
in,5384,O
the,5384,O
gene,5384,O
ATM,5384,O
are,5384,O
responsible,5384,O
for,5384,O
the,5384,O
genetic,5384,B-DiseaseClass
disorder,5384,I-DiseaseClass
ataxia-telangiectasia,5384,B-SpecificDisease
(,5384,O
A-T,5384,B-SpecificDisease
),5384,O
",",5384,O
which,5384,O
is,5384,O
characterized,5384,O
by,5384,O
cerebellar,5384,B-DiseaseClass
dysfunction,5384,I-DiseaseClass
",",5384,O
radiosensitivity,5384,O
",",5384,O
chromosomal,5384,O
instability,5384,O
and,5384,O
cancer,5384,B-Modifier
predisposition,5384,O
.,5384,O
Both,5385,O
the,5385,O
A-T,5385,B-Modifier
phenotype,5385,O
and,5385,O
the,5385,O
similarity,5385,O
of,5385,O
the,5385,O
ATM,5385,O
protein,5385,O
to,5385,O
other,5385,O
DNA-damage,5385,O
sensors,5385,O
suggests,5385,O
a,5385,O
role,5385,O
for,5385,O
ATM,5385,O
in,5385,O
biochemical,5385,O
pathways,5385,O
involved,5385,O
in,5385,O
the,5385,O
recognition,5385,O
",",5385,O
signalling,5385,O
and,5385,O
repair,5385,O
of,5385,O
DNA,5385,O
double-strand,5385,O
breaks,5385,O
(,5385,O
DSBs,5385,O
),5385,O
.,5385,O
There,5386,O
are,5386,O
strong,5386,O
parallels,5386,O
between,5386,O
the,5386,O
pattern,5386,O
of,5386,O
radiosensitivity,5386,O
",",5386,O
chromosomal,5386,O
instability,5386,O
and,5386,O
cancer,5386,B-Modifier
predisposition,5386,O
in,5386,O
A-T,5386,B-SpecificDisease
patients,5386,O
and,5386,O
that,5386,O
in,5386,O
patients,5386,O
with,5386,O
Nijmegen,5386,B-SpecificDisease
breakage,5386,I-SpecificDisease
syndrome,5386,I-SpecificDisease
(,5386,O
NBS,5386,B-SpecificDisease
),5386,O
.,5386,O
The,5387,O
protein,5387,O
defective,5387,O
in,5387,O
NBS,5387,B-SpecificDisease
",",5387,O
nibrin,5387,O
(,5387,O
encoded,5387,O
by,5387,O
NBS1,5387,O
),5387,O
",",5387,O
forms,5387,O
a,5387,O
complex,5387,O
with,5387,O
MRE11,5387,O
and,5387,O
RAD50,5387,O
(,5387,O
refs,5387,O
1,5387,O
",",5387,O
2,5387,O
),5387,O
.,5387,O
This,5388,O
complex,5388,O
localizes,5388,O
to,5388,O
DSBs,5388,O
within,5388,O
30,5388,O
minutes,5388,O
after,5388,O
cellular,5388,O
exposure,5388,O
to,5388,O
ionizing,5388,O
radiation,5388,O
(,5388,O
IR,5388,O
),5388,O
and,5388,O
is,5388,O
observed,5388,O
in,5388,O
brightly,5388,O
staining,5388,O
nuclear,5388,O
foci,5388,O
after,5388,O
a,5388,O
longer,5388,O
period,5388,O
of,5388,O
time,5388,O
.,5388,O
The,5389,O
overlap,5389,O
between,5389,O
clinical,5389,O
and,5389,O
cellular,5389,O
phenotypes,5389,O
in,5389,O
A-T,5389,B-SpecificDisease
and,5389,O
NBS,5389,B-SpecificDisease
suggests,5389,O
that,5389,O
ATM,5389,O
and,5389,O
nibrin,5389,O
may,5389,O
function,5389,O
in,5389,O
the,5389,O
same,5389,O
biochemical,5389,O
pathway,5389,O
.,5389,O
Here,5390,O
we,5390,O
demonstrate,5390,O
that,5390,O
nibrin,5390,O
is,5390,O
phosphorylated,5390,O
within,5390,O
one,5390,O
hour,5390,O
of,5390,O
treatment,5390,O
of,5390,O
cells,5390,O
with,5390,O
IR,5390,O
.,5390,O
This,5391,O
response,5391,O
is,5391,O
abrogated,5391,O
in,5391,O
A-T,5391,B-Modifier
cells,5391,O
that,5391,O
either,5391,O
do,5391,O
not,5391,O
express,5391,O
ATM,5391,O
protein,5391,O
or,5391,O
express,5391,O
near,5391,O
full-length,5391,O
mutant,5391,O
protein,5391,O
.,5391,O
We,5392,O
also,5392,O
show,5392,O
that,5392,O
ATM,5392,O
physically,5392,O
interacts,5392,O
with,5392,O
and,5392,O
phosphorylates,5392,O
nibrin,5392,O
on,5392,O
serine,5392,O
343,5392,O
both,5392,O
in,5392,O
vivo,5392,O
and,5392,O
in,5392,O
vitro,5392,O
.,5392,O
Phosphorylation,5393,O
of,5393,O
this,5393,O
site,5393,O
appears,5393,O
to,5393,O
be,5393,O
functionally,5393,O
important,5393,O
because,5393,O
mutated,5393,O
nibrin,5393,O
(,5393,O
S343A,5393,O
),5393,O
does,5393,O
not,5393,O
completely,5393,O
complement,5393,O
radiosensitivity,5393,O
in,5393,O
NBS,5393,B-Modifier
cells,5393,O
.,5393,O
ATM,5394,O
phosphorylation,5394,O
of,5394,O
nibrin,5394,O
does,5394,O
not,5394,O
affect,5394,O
nibrin-MRE11-RAD50,5394,O
association,5394,O
as,5394,O
revealed,5394,O
by,5394,O
radiation-induced,5394,O
foci,5394,O
formation,5394,O
.,5394,O
Our,5395,O
data,5395,O
provide,5395,O
a,5395,O
biochemical,5395,O
explanation,5395,O
for,5395,O
the,5395,O
similarity,5395,O
in,5395,O
phenotype,5395,O
between,5395,O
A-T,5395,B-SpecificDisease
and,5395,O
NBS,5395,B-SpecificDisease
..,5395,O
Clinicopathologic,5396,O
features,5396,O
of,5396,O
BRCA-linked,5396,O
and,5396,O
sporadic,5396,O
ovarian,5396,O
cancer,5396,O
.,5396,O
CONTEXT,5397,O
Most,5397,O
hereditary,5397,B-SpecificDisease
ovarian,5397,I-SpecificDisease
cancers,5397,I-SpecificDisease
are,5397,O
associated,5397,O
with,5397,O
germline,5397,O
mutations,5397,O
in,5397,O
BRCA1,5397,O
or,5397,O
BRCA2,5397,O
.,5397,O
Attempts,5398,O
to,5398,O
define,5398,O
the,5398,O
clinical,5398,O
significance,5398,O
of,5398,O
BRCA,5398,O
mutation,5398,O
status,5398,O
in,5398,O
ovarian,5398,B-SpecificDisease
cancer,5398,I-SpecificDisease
have,5398,O
produced,5398,O
conflicting,5398,O
results,5398,O
",",5398,O
especially,5398,O
regarding,5398,O
survival,5398,O
.,5398,O
OBJECTIVE,5399,O
To,5399,O
determine,5399,O
whether,5399,O
hereditary,5399,B-SpecificDisease
ovarian,5399,I-SpecificDisease
cancers,5399,I-SpecificDisease
have,5399,O
distinct,5399,O
clinical,5399,O
and,5399,O
pathological,5399,O
features,5399,O
compared,5399,O
with,5399,O
sporadic,5399,B-SpecificDisease
(,5399,I-SpecificDisease
nonhereditary,5399,I-SpecificDisease
),5399,I-SpecificDisease
ovarian,5399,I-SpecificDisease
cancers,5399,I-SpecificDisease
.,5399,O
DESIGN,5400,O
AND,5400,O
SETTING,5400,O
Retrospective,5400,O
cohort,5400,O
study,5400,O
of,5400,O
a,5400,O
consecutive,5400,O
series,5400,O
of,5400,O
933,5400,O
ovarian,5400,B-SpecificDisease
cancers,5400,I-SpecificDisease
diagnosed,5400,O
and,5400,O
treated,5400,O
at,5400,O
our,5400,O
institution,5400,O
",",5400,O
which,5400,O
is,5400,O
a,5400,O
comprehensive,5400,O
cancer,5400,B-Modifier
center,5400,O
as,5400,O
designated,5400,O
by,5400,O
the,5400,O
National,5400,O
Cancer,5400,B-Modifier
Institute,5400,O
",",5400,O
over,5400,O
a,5400,O
12-year,5400,O
period,5400,O
(,5400,O
December,5400,O
1986,5400,O
to,5400,O
August,5400,O
1998,5400,O
),5400,O
.,5400,O
PATIENTS,5401,O
The,5401,O
study,5401,O
was,5401,O
restricted,5401,O
to,5401,O
patients,5401,O
of,5401,O
Jewish,5401,O
origin,5401,O
because,5401,O
of,5401,O
the,5401,O
ease,5401,O
of,5401,O
BRCA1,5401,O
and,5401,O
BRCA2,5401,O
genotyping,5401,O
in,5401,O
this,5401,O
ethnic,5401,O
group,5401,O
.,5401,O
From,5402,O
the,5402,O
189,5402,O
patients,5402,O
who,5402,O
identified,5402,O
themselves,5402,O
as,5402,O
Jewish,5402,O
",",5402,O
88,5402,O
hereditary,5402,O
cases,5402,O
were,5402,O
identified,5402,O
with,5402,O
the,5402,O
presence,5402,O
of,5402,O
a,5402,O
germline,5402,O
founder,5402,O
mutation,5402,O
in,5402,O
BRCA1,5402,O
or,5402,O
BRCA2,5402,O
.,5402,O
The,5403,O
remaining,5403,O
101,5403,O
cases,5403,O
from,5403,O
the,5403,O
same,5403,O
series,5403,O
not,5403,O
associated,5403,O
with,5403,O
a,5403,O
BRCA,5403,O
mutation,5403,O
and,5403,O
2,5403,O
additional,5403,O
groups,5403,O
(,5403,O
Gynecologic,5403,O
Oncology,5403,O
Group,5403,O
protocols,5403,O
52,5403,O
and,5403,O
111,5403,O
),5403,O
with,5403,O
ovarian,5403,B-SpecificDisease
cancer,5403,I-SpecificDisease
from,5403,O
clinical,5403,O
trials,5403,O
(,5403,O
for,5403,O
the,5403,O
survival,5403,O
analysis,5403,O
),5403,O
were,5403,O
included,5403,O
for,5403,O
comparison,5403,O
.,5403,O
MAIN,5404,O
OUTCOME,5404,O
MEASURES,5404,O
Age,5404,O
at,5404,O
diagnosis,5404,O
",",5404,O
surgical,5404,O
stage,5404,O
",",5404,O
histologic,5404,O
cell,5404,O
type,5404,O
and,5404,O
grade,5404,O
",",5404,O
and,5404,O
surgical,5404,O
outcome,5404,O
;,5404,O
and,5404,O
response,5404,O
to,5404,O
chemotherapy,5404,O
and,5404,O
survival,5404,O
for,5404,O
advanced-stage,5404,O
(,5404,O
II,5404,O
and,5404,O
IV,5404,O
),5404,O
cases,5404,O
.,5404,O
RESULTS,5405,O
Hereditary,5405,B-DiseaseClass
cancers,5405,I-DiseaseClass
were,5405,O
rarely,5405,O
diagnosed,5405,O
before,5405,O
age,5405,O
40,5405,O
years,5405,O
and,5405,O
were,5405,O
common,5405,O
after,5405,O
age,5405,O
60,5405,O
years,5405,O
",",5405,O
with,5405,O
mean,5405,O
age,5405,O
at,5405,O
diagnosis,5405,O
being,5405,O
significantly,5405,O
younger,5405,O
for,5405,O
BRCA1-,5405,O
vs,5405,O
BRCA2-linked,5405,O
patients,5405,O
(,5405,O
54,5405,O
vs,5405,O
62,5405,O
years,5405,O
;,5405,O
P,5405,O
=,5405,O
.,5405,O
04,5406,O
),5406,O
.,5406,O
Histology,5407,O
",",5407,O
grade,5407,O
",",5407,O
stage,5407,O
",",5407,O
and,5407,O
success,5407,O
of,5407,O
cytoreductive,5407,O
surgery,5407,O
were,5407,O
similar,5407,O
for,5407,O
hereditary,5407,O
and,5407,O
sporadic,5407,O
cases,5407,O
.,5407,O
The,5408,O
hereditary,5408,O
group,5408,O
had,5408,O
a,5408,O
longer,5408,O
disease-free,5408,O
interval,5408,O
following,5408,O
primary,5408,O
chemotherapy,5408,O
in,5408,O
comparison,5408,O
with,5408,O
the,5408,O
nonhereditary,5408,O
group,5408,O
",",5408,O
with,5408,O
a,5408,O
median,5408,O
time,5408,O
to,5408,O
recurrence,5408,O
of,5408,O
14,5408,O
months,5408,O
and,5408,O
7,5408,O
months,5408,O
",",5408,O
respectively,5408,O
(,5408,O
P,5408,O
<,5408,O
.,5408,O
001,5409,O
),5409,O
.,5409,O
Those,5410,O
with,5410,O
hereditary,5410,B-DiseaseClass
cancers,5410,I-DiseaseClass
had,5410,O
improved,5410,O
survival,5410,O
compared,5410,O
with,5410,O
the,5410,O
nonhereditary,5410,O
group,5410,O
(,5410,O
P,5410,O
=,5410,O
.,5410,O
004,5411,O
),5411,O
.,5411,O
For,5412,O
stage,5412,B-DiseaseClass
III,5412,I-DiseaseClass
cancers,5412,I-DiseaseClass
",",5412,O
BRCA,5412,O
mutation,5412,O
status,5412,O
was,5412,O
an,5412,O
independent,5412,O
prognostic,5412,O
variable,5412,O
(,5412,O
P,5412,O
=,5412,O
.,5412,O
03,5413,O
),5413,O
.,5413,O
CONCLUSIONS,5414,O
Although,5414,O
BRCA-associated,5414,O
hereditary,5414,O
ovarian,5414,O
cancers,5414,O
in,5414,O
this,5414,O
population,5414,O
have,5414,O
surgical,5414,O
and,5414,O
pathological,5414,O
characteristics,5414,O
similar,5414,O
to,5414,O
those,5414,O
of,5414,O
sporadic,5414,B-DiseaseClass
cancers,5414,I-DiseaseClass
",",5414,O
advanced-stage,5414,B-Modifier
hereditary,5414,I-Modifier
cancer,5414,I-Modifier
patients,5414,O
survive,5414,O
longer,5414,O
than,5414,O
nonhereditary,5414,B-Modifier
cancer,5414,I-Modifier
patients,5414,O
.,5414,O
Age,5415,O
penetrance,5415,O
is,5415,O
greater,5415,O
for,5415,O
BRCA1-linked,5415,O
than,5415,O
for,5415,O
BRCA2-linked,5415,O
cancers,5415,O
in,5415,O
this,5415,O
population,5415,O
.,5415,O
The,5416,O
gene,5416,O
for,5416,O
familial,5416,B-SpecificDisease
Mediterranean,5416,I-SpecificDisease
fever,5416,I-SpecificDisease
",",5416,O
MEFV,5416,O
",",5416,O
is,5416,O
expressed,5416,O
in,5416,O
early,5416,O
leukocyte,5416,O
development,5416,O
and,5416,O
is,5416,O
regulated,5416,O
in,5416,O
response,5416,O
to,5416,O
inflammatory,5416,O
mediators,5416,O
.,5416,O
Familial,5417,B-SpecificDisease
Mediterranean,5417,I-SpecificDisease
fever,5417,I-SpecificDisease
(,5417,O
FMF,5417,B-SpecificDisease
),5417,O
is,5417,O
a,5417,O
recessive,5417,B-DiseaseClass
disorder,5417,I-DiseaseClass
characterized,5417,O
by,5417,O
episodes,5417,O
of,5417,O
fever,5417,B-DiseaseClass
and,5417,O
neutrophil-mediated,5417,B-SpecificDisease
serosal,5417,I-SpecificDisease
inflammation,5417,I-SpecificDisease
.,5417,O
We,5418,O
recently,5418,O
identified,5418,O
the,5418,O
gene,5418,O
causing,5418,O
FMF,5418,B-SpecificDisease
",",5418,O
designated,5418,O
MEFV,5418,O
",",5418,O
and,5418,O
found,5418,O
it,5418,O
to,5418,O
be,5418,O
expressed,5418,O
in,5418,O
mature,5418,O
neutrophils,5418,O
",",5418,O
suggesting,5418,O
that,5418,O
it,5418,O
functions,5418,O
as,5418,O
an,5418,O
inflammatory,5418,O
regulator,5418,O
.,5418,O
To,5419,O
facilitate,5419,O
our,5419,O
understanding,5419,O
of,5419,O
the,5419,O
normal,5419,O
function,5419,O
of,5419,O
MEFV,5419,O
",",5419,O
we,5419,O
extended,5419,O
our,5419,O
previous,5419,O
studies,5419,O
.,5419,O
MEFV,5420,O
messenger,5420,O
RNA,5420,O
was,5420,O
detected,5420,O
by,5420,O
reverse,5420,O
transcriptase-polymerase,5420,O
chain,5420,O
reaction,5420,O
in,5420,O
bone,5420,O
marrow,5420,O
leukocytes,5420,O
",",5420,O
with,5420,O
differential,5420,O
expression,5420,O
observed,5420,O
among,5420,O
cells,5420,O
by,5420,O
in,5420,O
situ,5420,O
hybridization,5420,O
.,5420,O
CD34,5421,O
hematopoietic,5421,O
stem-cell,5421,O
cultures,5421,O
induced,5421,O
toward,5421,O
the,5421,O
granulocytic,5421,O
lineage,5421,O
expressed,5421,O
MEFV,5421,O
at,5421,O
the,5421,O
myelocyte,5421,O
stage,5421,O
",",5421,O
concurrently,5421,O
with,5421,O
lineage,5421,O
commitment,5421,O
.,5421,O
The,5422,O
prepromyelocytic,5422,O
cell,5422,O
line,5422,O
HL60,5422,O
expressed,5422,O
MEFV,5422,O
only,5422,O
at,5422,O
granulocytic,5422,O
and,5422,O
monocytic,5422,O
differentiation,5422,O
.,5422,O
MEFV,5423,O
was,5423,O
also,5423,O
expressed,5423,O
in,5423,O
the,5423,O
monocytic,5423,O
cell,5423,O
lines,5423,O
U937,5423,O
and,5423,O
THP-1,5423,O
.,5423,O
Among,5424,O
peripheral,5424,O
blood,5424,O
leukocytes,5424,O
",",5424,O
MEFV,5424,O
expression,5424,O
was,5424,O
detected,5424,O
in,5424,O
neutrophils,5424,O
",",5424,O
eosinophils,5424,O
",",5424,O
and,5424,O
to,5424,O
varying,5424,O
degrees,5424,O
",",5424,O
monocytes,5424,O
.,5424,O
Consistent,5425,O
with,5425,O
the,5425,O
tissue,5425,O
specificity,5425,O
of,5425,O
expression,5425,O
",",5425,O
complete,5425,O
sequencing,5425,O
and,5425,O
analysis,5425,O
of,5425,O
upstream,5425,O
regulatory,5425,O
regions,5425,O
of,5425,O
MEFV,5425,O
revealed,5425,O
homology,5425,O
to,5425,O
myeloid-specific,5425,O
promoters,5425,O
and,5425,O
to,5425,O
more,5425,O
broadly,5425,O
expressed,5425,O
inflammatory,5425,O
promoter,5425,O
elements,5425,O
.,5425,O
In,5426,O
vitro,5426,O
stimulation,5426,O
of,5426,O
monocytes,5426,O
with,5426,O
the,5426,O
proinflammatory,5426,O
agents,5426,O
interferon,5426,O
(,5426,O
IFN,5426,O
),5426,O
gamma,5426,O
",",5426,O
tumor,5426,B-Modifier
necrosis,5426,O
factor,5426,O
",",5426,O
and,5426,O
lipopolysaccharide,5426,O
induced,5426,O
MEFV,5426,O
expression,5426,O
",",5426,O
whereas,5426,O
the,5426,O
antiinflammatory,5426,O
cytokines,5426,O
interleukin,5426,O
(,5426,O
IL,5426,O
),5426,O
4,5426,O
",",5426,O
IL-10,5426,O
",",5426,O
and,5426,O
transforming,5426,O
growth,5426,O
factor,5426,O
beta,5426,O
inhibited,5426,O
such,5426,O
expression,5426,O
.,5426,O
Induction,5427,O
by,5427,O
IFN-gamma,5427,O
occurred,5427,O
rapidly,5427,O
and,5427,O
was,5427,O
resistant,5427,O
to,5427,O
cycloheximide,5427,O
.,5427,O
IFN-alpha,5428,O
also,5428,O
induced,5428,O
MEFV,5428,O
expression,5428,O
.,5428,O
In,5429,O
granulocytes,5429,O
",",5429,O
MEFV,5429,O
was,5429,O
up-regulated,5429,O
by,5429,O
IFN-gamma,5429,O
and,5429,O
the,5429,O
combination,5429,O
of,5429,O
IFN-alpha,5429,O
and,5429,O
colchicine,5429,O
.,5429,O
These,5430,O
results,5430,O
refine,5430,O
understanding,5430,O
of,5430,O
MEFV,5430,O
by,5430,O
placing,5430,O
the,5430,O
gene,5430,O
in,5430,O
the,5430,O
myelomonocytic-specific,5430,O
proinflammatory,5430,O
pathway,5430,O
and,5430,O
identifying,5430,O
it,5430,O
as,5430,O
an,5430,O
IFN-gamma,5430,O
immediate,5430,O
early,5430,O
gene,5430,O
..,5430,O
Biochemical,5431,O
and,5431,O
structural,5431,O
analysis,5431,O
of,5431,O
missense,5431,O
mutations,5431,O
in,5431,O
N-acetylgalactosamine-6-sulfate,5431,O
sulfatase,5431,O
causing,5431,O
mucopolysaccharidosis,5431,B-Modifier
IVA,5431,I-Modifier
phenotypes,5431,O
.,5431,O
Mucopolysaccharidosis,5432,B-SpecificDisease
IVA,5432,I-SpecificDisease
(,5432,O
MPS,5432,B-SpecificDisease
IVA,5432,I-SpecificDisease
;,5432,O
OMIM,5432,O
#,5432,O
253000,5432,O
),5432,O
",",5432,O
a,5432,O
lysosomal,5432,B-DiseaseClass
storage,5432,I-DiseaseClass
disorder,5432,I-DiseaseClass
caused,5432,O
by,5432,O
a,5432,O
deficiency,5432,B-SpecificDisease
of,5432,I-SpecificDisease
N,5432,I-SpecificDisease
-acetylgalactosamine-6-sulfate,5432,I-SpecificDisease
sulfatase,5432,I-SpecificDisease
(,5432,O
GALNS,5432,O
),5432,O
",",5432,O
has,5432,O
variable,5432,O
clinical,5432,O
phenotypes,5432,O
.,5432,O
To,5433,O
date,5433,O
we,5433,O
have,5433,O
identified,5433,O
65,5433,O
missense,5433,O
mutations,5433,O
in,5433,O
the,5433,O
GALNS,5433,O
gene,5433,O
from,5433,O
MPS,5433,B-Modifier
IVA,5433,I-Modifier
patients,5433,O
",",5433,O
but,5433,O
the,5433,O
correlation,5433,O
between,5433,O
genotype,5433,O
and,5433,O
phenotype,5433,O
has,5433,O
remained,5433,O
unclear,5433,O
.,5433,O
We,5434,O
studied,5434,O
17,5434,O
missense,5434,O
mutations,5434,O
using,5434,O
biochemical,5434,O
approaches,5434,O
and,5434,O
32,5434,O
missense,5434,O
mutations,5434,O
",",5434,O
using,5434,O
structural,5434,O
analyses,5434,O
.,5434,O
Fifteen,5435,O
missense,5435,O
mutations,5435,O
and,5435,O
two,5435,O
newly,5435,O
engineered,5435,O
active,5435,O
site,5435,O
mutations,5435,O
(,5435,O
C79S,5435,O
",",5435,O
C79T,5435,O
),5435,O
were,5435,O
characterized,5435,O
by,5435,O
transient,5435,O
expression,5435,O
analysis,5435,O
.,5435,O
Mutant,5436,O
proteins,5436,O
",",5436,O
except,5436,O
for,5436,O
C79S,5436,O
and,5436,O
C79T,5436,O
",",5436,O
were,5436,O
destabilized,5436,O
and,5436,O
detected,5436,O
as,5436,O
insoluble,5436,O
precursor,5436,O
forms,5436,O
while,5436,O
the,5436,O
C79S,5436,O
and,5436,O
C79T,5436,O
mutants,5436,O
were,5436,O
of,5436,O
a,5436,O
soluble,5436,O
mature,5436,O
size,5436,O
.,5436,O
Mutants,5437,O
found,5437,O
in,5437,O
the,5437,O
severe,5437,O
phenotype,5437,O
had,5437,O
no,5437,O
activity,5437,O
.,5437,O
Mutants,5438,O
found,5438,O
in,5438,O
the,5438,O
mild,5438,O
phenotype,5438,O
had,5438,O
a,5438,O
considerable,5438,O
residual,5438,O
activity,5438,O
(,5438,O
1,5438,O
.,5438,O
3-13,5439,O
.,5439,O
3,5440,O
%,5440,O
of,5440,O
wild-type,5440,O
GALNS,5440,O
activity,5440,O
),5440,O
.,5440,O
Sulfatases,5441,O
",",5441,O
including,5441,O
GALNS,5441,O
",",5441,O
are,5441,O
members,5441,O
of,5441,O
a,5441,O
highly,5441,O
conserved,5441,O
gene,5441,O
family,5441,O
sharing,5441,O
an,5441,O
extensive,5441,O
sequence,5441,O
homology,5441,O
.,5441,O
Thus,5442,O
",",5442,O
a,5442,O
tertiary,5442,O
structural,5442,O
model,5442,O
of,5442,O
human,5442,O
GALNS,5442,O
was,5442,O
constructed,5442,O
from,5442,O
the,5442,O
X-ray,5442,O
crystal,5442,O
structure,5442,O
of,5442,O
N,5442,O
-acetylgalacto-samine-4-sulfatase,5442,O
and,5442,O
arylsulfatase,5442,O
A,5442,O
",",5442,O
using,5442,O
homology,5442,O
modeling,5442,O
",",5442,O
and,5442,O
32,5442,O
missense,5442,O
mutations,5442,O
were,5442,O
investigated,5442,O
.,5442,O
Consequently,5443,O
",",5443,O
we,5443,O
propose,5443,O
that,5443,O
there,5443,O
are,5443,O
at,5443,O
least,5443,O
three,5443,O
different,5443,O
reasons,5443,O
for,5443,O
the,5443,O
severe,5443,O
phenotype,5443,O
(,5443,O
i,5443,O
),5443,O
destruction,5443,O
of,5443,O
the,5443,O
hydrophobic,5443,O
core,5443,O
or,5443,O
modification,5443,O
of,5443,O
the,5443,O
packing,5443,O
;,5443,O
(,5443,O
ii,5443,O
),5443,O
removal,5443,O
of,5443,O
a,5443,O
salt,5443,O
bridge,5443,O
to,5443,O
destabilize,5443,O
the,5443,O
entire,5443,O
conformation,5443,O
;,5443,O
(,5443,O
iii,5443,O
),5443,O
modification,5443,O
of,5443,O
the,5443,O
active,5443,O
site,5443,O
.,5443,O
In,5444,O
contrast,5444,O
",",5444,O
mild,5444,O
mutations,5444,O
were,5444,O
mostly,5444,O
located,5444,O
on,5444,O
the,5444,O
surface,5444,O
of,5444,O
the,5444,O
GALNS,5444,O
protein,5444,O
.,5444,O
These,5445,O
studies,5445,O
shed,5445,O
further,5445,O
light,5445,O
on,5445,O
the,5445,O
genotype-phenotype,5445,O
correlation,5445,O
of,5445,O
MPS,5445,B-SpecificDisease
IVA,5445,I-SpecificDisease
and,5445,O
structure-function,5445,O
relationship,5445,O
in,5445,O
the,5445,O
sulfatase,5445,O
family,5445,O
.,5445,O
Mutations,5446,O
at,5446,O
the,5446,O
ataxia-telangiectasia,5446,B-Modifier
locus,5446,O
and,5446,O
clinical,5446,O
phenotypes,5446,O
of,5446,O
A-T,5446,B-Modifier
patients,5446,O
.,5446,O
Mutations,5447,O
at,5447,O
the,5447,O
ataxia-telangiectasia,5447,B-Modifier
(,5447,O
A-T,5447,B-Modifier
),5447,O
locus,5447,O
on,5447,O
chromosome,5447,O
band,5447,O
11q22,5447,O
cause,5447,O
a,5447,O
distinctive,5447,O
autosomal,5447,B-DiseaseClass
recessive,5447,I-DiseaseClass
syndrome,5447,I-DiseaseClass
in,5447,O
homozygotes,5447,O
and,5447,O
predispose,5447,O
heterozygotes,5447,O
to,5447,O
cancer,5447,B-DiseaseClass
",",5447,O
ischemic,5447,B-SpecificDisease
heart,5447,I-SpecificDisease
disease,5447,I-SpecificDisease
",",5447,O
and,5447,O
early,5447,O
mortality,5447,O
.,5447,O
PCR,5448,O
amplification,5448,O
from,5448,O
genomic,5448,O
DNA,5448,O
and,5448,O
automated,5448,O
sequencing,5448,O
of,5448,O
the,5448,O
entire,5448,O
coding,5448,O
region,5448,O
(,5448,O
66,5448,O
exons,5448,O
),5448,O
and,5448,O
splice,5448,O
junctions,5448,O
detected,5448,O
77,5448,O
mutations,5448,O
(,5448,O
85,5448,O
%,5448,O
),5448,O
in,5448,O
90,5448,O
A-T,5448,B-Modifier
chromosomes,5448,O
.,5448,O
Heteroduplex,5449,O
analysis,5449,O
detected,5449,O
another,5449,O
42,5449,O
mutations,5449,O
at,5449,O
the,5449,O
A-T,5449,B-Modifier
locus,5449,O
.,5449,O
Out,5450,O
of,5450,O
a,5450,O
total,5450,O
of,5450,O
71,5450,O
unique,5450,O
mutations,5450,O
",",5450,O
50,5450,O
were,5450,O
found,5450,O
only,5450,O
in,5450,O
a,5450,O
single,5450,O
family,5450,O
",",5450,O
and,5450,O
51,5450,O
had,5450,O
not,5450,O
been,5450,O
reported,5450,O
previously,5450,O
.,5450,O
Most,5451,O
(,5451,O
58/71,5451,O
",",5451,O
82,5451,O
%,5451,O
),5451,O
mutations,5451,O
were,5451,O
frameshift,5451,O
and,5451,O
nonsense,5451,O
mutations,5451,O
that,5451,O
are,5451,O
predicted,5451,O
to,5451,O
cause,5451,O
truncation,5451,O
of,5451,O
the,5451,O
A-T,5451,B-Modifier
protein,5451,O
;,5451,O
the,5451,O
less,5451,O
common,5451,O
mutation,5451,O
types,5451,O
were,5451,O
missense,5451,O
(,5451,O
9/71,5451,O
",",5451,O
13,5451,O
%,5451,O
),5451,O
",",5451,O
splicing,5451,O
(,5451,O
3/71,5451,O
",",5451,O
4,5451,O
%,5451,O
),5451,O
and,5451,O
one,5451,O
in-frame,5451,O
deletion,5451,O
",",5451,O
2546,5451,O
3,5451,O
(,5451,O
1/71,5451,O
",",5451,O
1,5451,O
%,5451,O
),5451,O
.,5451,O
The,5452,O
mean,5452,O
survival,5452,O
and,5452,O
height,5452,O
distribution,5452,O
of,5452,O
134,5452,O
A-T,5452,B-Modifier
patients,5452,O
correlated,5452,O
significantly,5452,O
with,5452,O
the,5452,O
specific,5452,O
mutations,5452,O
present,5452,O
in,5452,O
the,5452,O
patients,5452,O
.,5452,O
Patients,5453,O
homozygous,5453,O
for,5453,O
a,5453,O
single,5453,O
truncating,5453,O
mutation,5453,O
",",5453,O
typically,5453,O
near,5453,O
the,5453,O
N-terminal,5453,O
end,5453,O
of,5453,O
the,5453,O
gene,5453,O
",",5453,O
or,5453,O
heterozygous,5453,O
for,5453,O
the,5453,O
in-frame,5453,O
deletion,5453,O
2546,5453,O
3,5453,O
",",5453,O
were,5453,O
shorter,5453,O
and,5453,O
had,5453,O
significantly,5453,O
shorter,5453,O
survival,5453,O
than,5453,O
those,5453,O
heterozygous,5453,O
for,5453,O
a,5453,O
splice,5453,O
site,5453,O
or,5453,O
missense,5453,O
mutation,5453,O
",",5453,O
or,5453,O
heterozygous,5453,O
for,5453,O
two,5453,O
truncating,5453,O
mutations,5453,O
.,5453,O
Alterations,5454,O
of,5454,O
the,5454,O
length,5454,O
or,5454,O
amino,5454,O
acid,5454,O
composition,5454,O
of,5454,O
the,5454,O
A-T,5454,B-Modifier
gene,5454,O
product,5454,O
affect,5454,O
the,5454,O
A-T,5454,B-Modifier
clinical,5454,O
phenotype,5454,O
in,5454,O
different,5454,O
ways,5454,O
.,5454,O
Mutation,5455,O
analysis,5455,O
at,5455,O
the,5455,O
A-T,5455,B-Modifier
locus,5455,O
may,5455,O
help,5455,O
estimate,5455,O
the,5455,O
prognosis,5455,O
of,5455,O
A-T,5455,B-Modifier
patients,5455,O
..,5455,O
Isolation,5456,O
",",5456,O
genomic,5456,O
organization,5456,O
",",5456,O
and,5456,O
expression,5456,O
analysis,5456,O
of,5456,O
the,5456,O
mouse,5456,O
and,5456,O
rat,5456,O
homologs,5456,O
of,5456,O
MEFV,5456,O
",",5456,O
the,5456,O
gene,5456,O
for,5456,O
familial,5456,B-SpecificDisease
mediterranean,5456,I-SpecificDisease
fever,5456,I-SpecificDisease
.,5456,O
Familial,5457,B-SpecificDisease
Mediterranean,5457,I-SpecificDisease
fever,5457,I-SpecificDisease
(,5457,O
FMF,5457,B-SpecificDisease
),5457,O
is,5457,O
a,5457,O
recessive,5457,B-DiseaseClass
disorder,5457,I-DiseaseClass
characterized,5457,O
by,5457,O
episodes,5457,O
of,5457,O
fever,5457,B-DiseaseClass
with,5457,O
serositis,5457,B-SpecificDisease
or,5457,O
synovitis,5457,B-SpecificDisease
.,5457,O
Recently,5458,O
the,5458,O
FMF,5458,B-Modifier
gene,5458,O
(,5458,O
MEFV,5458,O
),5458,O
was,5458,O
cloned,5458,O
;,5458,O
the,5458,O
protein,5458,O
product,5458,O
",",5458,O
pyrin/marenostrin,5458,O
",",5458,O
is,5458,O
thought,5458,O
to,5458,O
regulate,5458,O
inflammation,5458,O
in,5458,O
myeloid,5458,O
cells,5458,O
.,5458,O
In,5459,O
this,5459,O
manuscript,5459,O
we,5459,O
report,5459,O
the,5459,O
mouse,5459,O
and,5459,O
rat,5459,O
homologs,5459,O
of,5459,O
MEFV,5459,O
.,5459,O
The,5460,O
murine,5460,O
gene,5460,O
contains,5460,O
ten,5460,O
exons,5460,O
with,5460,O
a,5460,O
coding,5460,O
sequence,5460,O
of,5460,O
2304,5460,O
bp,5460,O
",",5460,O
while,5460,O
the,5460,O
rat,5460,O
homolog,5460,O
has,5460,O
nine,5460,O
exons,5460,O
with,5460,O
a,5460,O
coding,5460,O
sequence,5460,O
of,5460,O
2253,5460,O
bp,5460,O
.,5460,O
A,5461,O
considerable,5461,O
amino,5461,O
acid,5461,O
sequence,5461,O
homology,5461,O
was,5461,O
observed,5461,O
between,5461,O
the,5461,O
mouse,5461,O
and,5461,O
human,5461,O
(,5461,O
47,5461,O
.,5461,O
6,5462,O
%,5462,O
identity,5462,O
and,5462,O
65,5462,O
.,5462,O
5,5463,O
%,5463,O
similarity,5463,O
),5463,O
and,5463,O
between,5463,O
the,5463,O
mouse,5463,O
and,5463,O
rat,5463,O
genes,5463,O
(,5463,O
73,5463,O
.,5463,O
5,5464,O
%,5464,O
identity,5464,O
and,5464,O
82,5464,O
.,5464,O
1,5465,O
%,5465,O
similarity,5465,O
),5465,O
.,5465,O
The,5466,O
predicted,5466,O
rodent,5466,O
proteins,5466,O
have,5466,O
several,5466,O
important,5466,O
domains,5466,O
and,5466,O
signals,5466,O
found,5466,O
in,5466,O
human,5466,O
pyrin,5466,O
",",5466,O
including,5466,O
a,5466,O
B-box,5466,O
zinc,5466,O
finger,5466,O
domain,5466,O
",",5466,O
Robbins-Dingwall,5466,O
nuclear,5466,O
localization,5466,O
signal,5466,O
",",5466,O
and,5466,O
coiled-coil,5466,O
domain,5466,O
.,5466,O
However,5467,O
",",5467,O
perhaps,5467,O
because,5467,O
of,5467,O
an,5467,O
ancient,5467,O
frame-shift,5467,O
mutation,5467,O
",",5467,O
neither,5467,O
the,5467,O
mouse,5467,O
nor,5467,O
the,5467,O
rat,5467,O
protein,5467,O
has,5467,O
an,5467,O
intact,5467,O
C-terminal,5467,O
B30,5467,O
.,5467,O
2,5468,O
domain,5468,O
",",5468,O
in,5468,O
which,5468,O
most,5468,O
FMF-associated,5468,B-Modifier
mutations,5468,O
have,5468,O
been,5468,O
found,5468,O
in,5468,O
human,5468,O
MEFV,5468,O
.,5468,O
Nevertheless,5469,O
",",5469,O
like,5469,O
the,5469,O
human,5469,O
gene,5469,O
",",5469,O
mouse,5469,O
Mefv,5469,O
is,5469,O
expressed,5469,O
in,5469,O
peripheral,5469,O
blood,5469,O
granulocytes,5469,O
but,5469,O
not,5469,O
lymphocytes,5469,O
.,5469,O
Consistent,5470,O
with,5470,O
its,5470,O
expression,5470,O
in,5470,O
granulocytes,5470,O
",",5470,O
Mefv,5470,O
was,5470,O
detected,5470,O
at,5470,O
high,5470,O
levels,5470,O
in,5470,O
the,5470,O
primary,5470,O
follicles,5470,O
and,5470,O
marginal,5470,O
zones,5470,O
of,5470,O
the,5470,O
splenic,5470,O
white,5470,O
pulp,5470,O
.,5470,O
Mefv,5471,O
is,5471,O
localized,5471,O
on,5471,O
mouse,5471,O
Chromosome,5471,O
(,5471,O
Chr,5471,O
),5471,O
16,5471,O
",",5471,O
region,5471,O
A3-B1,5471,O
",",5471,O
extending,5471,O
a,5471,O
region,5471,O
of,5471,O
synteny,5471,O
with,5471,O
human,5471,O
Chr,5471,O
16p13,5471,O
.,5471,O
3,5472,O
.,5472,O
Development,5473,O
of,5473,O
knockout,5473,O
and,5473,O
knockin,5473,O
mouse,5473,O
models,5473,O
may,5473,O
provide,5473,O
further,5473,O
insights,5473,O
into,5473,O
the,5473,O
functional,5473,O
evolution,5473,O
of,5473,O
this,5473,O
gene,5473,O
.,5473,O
Additional,5474,O
copies,5474,O
of,5474,O
the,5474,O
proteolipid,5474,O
protein,5474,O
gene,5474,O
causing,5474,O
Pelizaeus-Merzbacher,5474,B-SpecificDisease
disease,5474,I-SpecificDisease
arise,5474,O
by,5474,O
separate,5474,O
integration,5474,O
into,5474,O
the,5474,O
X,5474,O
chromosome,5474,O
.,5474,O
The,5475,O
proteolipid,5475,O
protein,5475,O
gene,5475,O
(,5475,O
PLP,5475,O
),5475,O
is,5475,O
normally,5475,O
present,5475,O
at,5475,O
chromosome,5475,O
Xq22,5475,O
.,5475,O
Mutations,5476,O
and,5476,O
duplications,5476,O
of,5476,O
this,5476,O
gene,5476,O
are,5476,O
associated,5476,O
with,5476,O
Pelizaeus-Merzbacher,5476,B-SpecificDisease
disease,5476,I-SpecificDisease
(,5476,O
PMD,5476,B-SpecificDisease
),5476,O
.,5476,O
Here,5477,O
we,5477,O
describe,5477,O
two,5477,O
new,5477,O
families,5477,O
in,5477,O
which,5477,O
males,5477,O
affected,5477,O
with,5477,O
PMD,5477,B-SpecificDisease
were,5477,O
found,5477,O
to,5477,O
have,5477,O
a,5477,O
copy,5477,O
of,5477,O
PLP,5477,O
on,5477,O
the,5477,O
short,5477,O
arm,5477,O
of,5477,O
the,5477,O
X,5477,O
chromosome,5477,O
",",5477,O
in,5477,O
addition,5477,O
to,5477,O
a,5477,O
normal,5477,O
copy,5477,O
on,5477,O
Xq22,5477,O
.,5477,O
In,5478,O
the,5478,O
first,5478,O
family,5478,O
",",5478,O
the,5478,O
extra,5478,O
copy,5478,O
was,5478,O
first,5478,O
detected,5478,O
by,5478,O
the,5478,O
presence,5478,O
of,5478,O
heterozygosity,5478,O
of,5478,O
the,5478,O
AhaII,5478,O
dimorphism,5478,O
within,5478,O
the,5478,O
PLP,5478,O
gene,5478,O
.,5478,O
The,5479,O
results,5479,O
of,5479,O
FISH,5479,O
analysis,5479,O
showed,5479,O
an,5479,O
additional,5479,O
copy,5479,O
of,5479,O
PLP,5479,O
in,5479,O
Xp22,5479,O
.,5479,O
1,5480,O
",",5480,O
although,5480,O
no,5480,O
chromosomal,5480,O
rearrangements,5480,O
could,5480,O
be,5480,O
detected,5480,O
by,5480,O
standard,5480,O
karyotype,5480,O
analysis,5480,O
.,5480,O
Another,5481,O
three,5481,O
affected,5481,O
males,5481,O
from,5481,O
the,5481,O
family,5481,O
had,5481,O
similar,5481,O
findings,5481,O
.,5481,O
In,5482,O
a,5482,O
second,5482,O
unrelated,5482,O
family,5482,O
with,5482,O
signs,5482,O
of,5482,O
PMD,5482,B-SpecificDisease
",",5482,O
cytogenetic,5482,O
analysis,5482,O
showed,5482,O
a,5482,O
pericentric,5482,O
inversion,5482,O
of,5482,O
the,5482,O
X,5482,O
chromosome,5482,O
.,5482,O
In,5483,O
the,5483,O
inv,5483,O
(,5483,O
X,5483,O
),5483,O
carried,5483,O
by,5483,O
several,5483,O
affected,5483,O
family,5483,O
members,5483,O
",",5483,O
FISH,5483,O
showed,5483,O
PLP,5483,O
signals,5483,O
at,5483,O
Xp11,5483,O
.,5483,O
4,5484,O
and,5484,O
Xq22,5484,O
.,5484,O
A,5485,O
third,5485,O
family,5485,O
has,5485,O
previously,5485,O
been,5485,O
reported,5485,O
",",5485,O
in,5485,O
which,5485,O
affected,5485,O
members,5485,O
had,5485,O
an,5485,O
extra,5485,O
copy,5485,O
of,5485,O
the,5485,O
PLP,5485,O
gene,5485,O
detected,5485,O
at,5485,O
Xq26,5485,O
in,5485,O
a,5485,O
chromosome,5485,O
with,5485,O
an,5485,O
otherwise,5485,O
normal,5485,O
banding,5485,O
pattern,5485,O
.,5485,O
The,5486,O
identification,5486,O
of,5486,O
three,5486,O
separate,5486,O
families,5486,O
in,5486,O
which,5486,O
PLP,5486,O
is,5486,O
duplicated,5486,O
at,5486,O
a,5486,O
noncontiguous,5486,O
site,5486,O
suggests,5486,O
that,5486,O
such,5486,O
duplications,5486,O
could,5486,O
be,5486,O
a,5486,O
relatively,5486,O
common,5486,O
but,5486,O
previously,5486,O
undetected,5486,O
cause,5486,O
of,5486,O
genetic,5486,B-DiseaseClass
disorders,5486,I-DiseaseClass
.,5486,O
The,5487,O
exon,5487,O
13,5487,O
duplication,5487,O
in,5487,O
the,5487,O
BRCA1,5487,O
gene,5487,O
is,5487,O
a,5487,O
founder,5487,O
mutation,5487,O
present,5487,O
in,5487,O
geographically,5487,O
diverse,5487,O
populations,5487,O
.,5487,O
The,5488,O
BRCA1,5488,O
Exon,5488,O
13,5488,O
Duplication,5488,O
Screening,5488,O
Group,5488,O
.,5488,O
Recently,5489,O
",",5489,O
a,5489,O
6-kb,5489,O
duplication,5489,O
of,5489,O
exon,5489,O
13,5489,O
",",5489,O
which,5489,O
creates,5489,O
a,5489,O
frameshift,5489,O
in,5489,O
the,5489,O
coding,5489,O
sequence,5489,O
of,5489,O
the,5489,O
BRCA1,5489,O
gene,5489,O
",",5489,O
has,5489,O
been,5489,O
described,5489,O
in,5489,O
three,5489,O
unrelated,5489,O
U,5489,O
.,5489,O
S,5490,O
S.,5490,O
families,5490,O
of,5490,O
European,5490,O
ancestry,5490,O
and,5490,O
in,5490,O
one,5490,O
Portuguese,5490,O
family,5490,O
.,5490,O
Here,5491,O
",",5491,O
our,5491,O
goal,5491,O
was,5491,O
to,5491,O
estimate,5491,O
the,5491,O
frequency,5491,O
and,5491,O
geographic,5491,O
diversity,5491,O
of,5491,O
carriers,5491,O
of,5491,O
this,5491,O
duplication,5491,O
.,5491,O
To,5492,O
do,5492,O
this,5492,O
",",5492,O
a,5492,O
collaborative,5492,O
screening,5492,O
study,5492,O
was,5492,O
set,5492,O
up,5492,O
that,5492,O
involved,5492,O
39,5492,O
institutions,5492,O
from,5492,O
19,5492,O
countries,5492,O
and,5492,O
included,5492,O
3,5492,O
",",5492,O
580,5492,O
unrelated,5492,O
individuals,5492,O
with,5492,O
a,5492,O
family,5492,O
history,5492,O
of,5492,O
the,5492,O
disease,5492,O
and,5492,O
934,5492,O
early-onset,5492,O
breast,5492,B-Modifier
and/or,5492,I-Modifier
ovarian,5492,I-Modifier
cancer,5492,I-Modifier
cases,5492,O
.,5492,O
A,5493,O
total,5493,O
of,5493,O
11,5493,O
additional,5493,O
families,5493,O
carrying,5493,O
this,5493,O
mutation,5493,O
were,5493,O
identified,5493,O
in,5493,O
Australia,5493,O
(,5493,O
1,5493,O
),5493,O
",",5493,O
Belgium,5493,O
(,5493,O
1,5493,O
),5493,O
",",5493,O
Canada,5493,O
(,5493,O
1,5493,O
),5493,O
",",5493,O
Great,5493,O
Britain,5493,O
(,5493,O
6,5493,O
),5493,O
",",5493,O
and,5493,O
the,5493,O
United,5493,O
States,5493,O
(,5493,O
2,5493,O
),5493,O
.,5493,O
Haplotyping,5494,O
showed,5494,O
that,5494,O
they,5494,O
are,5494,O
likely,5494,O
to,5494,O
derive,5494,O
from,5494,O
a,5494,O
common,5494,O
ancestor,5494,O
",",5494,O
possibly,5494,O
of,5494,O
northern,5494,O
British,5494,O
origin,5494,O
.,5494,O
Our,5495,O
results,5495,O
demonstrate,5495,O
that,5495,O
it,5495,O
is,5495,O
strongly,5495,O
advisable,5495,O
",",5495,O
for,5495,O
laboratories,5495,O
carrying,5495,O
out,5495,O
screening,5495,O
either,5495,O
in,5495,O
English-speaking,5495,O
countries,5495,O
or,5495,O
in,5495,O
countries,5495,O
with,5495,O
historical,5495,O
links,5495,O
with,5495,O
Britain,5495,O
",",5495,O
to,5495,O
include,5495,O
within,5495,O
their,5495,O
BRCA1,5495,O
screening,5495,O
protocols,5495,O
the,5495,O
polymerase,5495,O
chain,5495,O
reaction-based,5495,O
assay,5495,O
described,5495,O
in,5495,O
this,5495,O
report,5495,O
.,5495,O
Genotype-phenotype,5496,O
correlations,5496,O
in,5496,O
families,5496,O
with,5496,O
deletions,5496,O
in,5496,O
the,5496,O
von,5496,B-Modifier
Hippel-Lindau,5496,I-Modifier
(,5496,O
VHL,5496,B-Modifier
),5496,O
gene,5496,O
.,5496,O
Von,5497,B-SpecificDisease
Hippel-Lindau,5497,I-SpecificDisease
(,5497,I-SpecificDisease
VHL,5497,I-SpecificDisease
),5497,I-SpecificDisease
disease,5497,I-SpecificDisease
is,5497,O
a,5497,O
hereditary,5497,B-DiseaseClass
tumor,5497,I-DiseaseClass
syndrome,5497,I-DiseaseClass
characterized,5497,O
by,5497,O
predisposition,5497,O
for,5497,O
bilateral,5497,B-CompositeMention
and,5497,I-CompositeMention
multi-centric,5497,I-CompositeMention
hemangioblastoma,5497,I-CompositeMention
in,5497,O
the,5497,O
retina,5497,O
and,5497,O
central,5497,O
nervous,5497,O
system,5497,O
",",5497,O
pheochromocytoma,5497,B-SpecificDisease
",",5497,O
renal,5497,B-SpecificDisease
cell,5497,I-SpecificDisease
carcinoma,5497,I-SpecificDisease
",",5497,O
and,5497,O
cysts,5497,O
in,5497,O
the,5497,O
kidney,5497,O
",",5497,O
pancreas,5497,O
",",5497,O
and,5497,O
epididymis,5497,O
.,5497,O
We,5498,O
describe,5498,O
five,5498,O
families,5498,O
for,5498,O
which,5498,O
direct,5498,O
sequencing,5498,O
of,5498,O
the,5498,O
coding,5498,O
region,5498,O
of,5498,O
the,5498,O
VHL,5498,B-Modifier
gene,5498,O
had,5498,O
failed,5498,O
to,5498,O
identify,5498,O
the,5498,O
family-specific,5498,O
mutation,5498,O
.,5498,O
Further,5499,O
molecular,5499,O
analysis,5499,O
revealed,5499,O
deletions,5499,O
involving,5499,O
the,5499,O
VHL,5499,B-Modifier
gene,5499,O
in,5499,O
each,5499,O
of,5499,O
these,5499,O
families,5499,O
.,5499,O
In,5500,O
four,5500,O
families,5500,O
",",5500,O
partial,5500,O
deletions,5500,O
of,5500,O
one,5500,O
or,5500,O
more,5500,O
exons,5500,O
were,5500,O
detected,5500,O
by,5500,O
Southern,5500,O
blot,5500,O
analysis,5500,O
.,5500,O
In,5501,O
the,5501,O
fifth,5501,O
family,5501,O
",",5501,O
FISH,5501,O
analysis,5501,O
demonstrated,5501,O
the,5501,O
deletion,5501,O
of,5501,O
the,5501,O
entire,5501,O
VHL,5501,B-Modifier
gene,5501,O
.,5501,O
Our,5502,O
results,5502,O
show,5502,O
that,5502,O
(,5502,O
quantitative,5502,O
),5502,O
Southern,5502,O
blot,5502,O
analysis,5502,O
is,5502,O
a,5502,O
sensitive,5502,O
method,5502,O
for,5502,O
detecting,5502,O
germline,5502,O
deletions,5502,O
of,5502,O
the,5502,O
VHL,5502,B-Modifier
gene,5502,O
and,5502,O
should,5502,O
be,5502,O
implemented,5502,O
in,5502,O
routine,5502,O
DNA,5502,O
diagnosis,5502,O
for,5502,O
VHL,5502,B-SpecificDisease
disease,5502,I-SpecificDisease
.,5502,O
Our,5503,O
data,5503,O
support,5503,O
the,5503,O
previously,5503,O
established,5503,O
observation,5503,O
that,5503,O
families,5503,O
with,5503,O
a,5503,O
germline,5503,O
deletion,5503,O
have,5503,O
a,5503,O
low,5503,O
risk,5503,O
for,5503,O
pheochromocytoma,5503,B-SpecificDisease
.,5503,O
Further,5504,O
unraveling,5504,O
of,5504,O
genotype-phenotype,5504,O
correlations,5504,O
in,5504,O
VHL,5504,B-SpecificDisease
disease,5504,I-SpecificDisease
has,5504,O
revealed,5504,O
that,5504,O
families,5504,O
with,5504,O
a,5504,O
full,5504,O
or,5504,O
partial,5504,O
deletion,5504,O
of,5504,O
the,5504,O
VHL,5504,B-Modifier
gene,5504,O
exhibit,5504,O
a,5504,O
phenotype,5504,O
with,5504,O
a,5504,O
preponderance,5504,O
of,5504,O
central,5504,B-SpecificDisease
nervous,5504,I-SpecificDisease
system,5504,I-SpecificDisease
hemangioblastoma,5504,I-SpecificDisease
..,5504,O
Age,5505,O
of,5505,O
the,5505,O
intronic,5505,O
GAA,5505,O
triplet,5505,O
repeat,5505,O
expansion,5505,O
mutation,5505,O
in,5505,O
Friedreich,5505,B-SpecificDisease
ataxia,5505,I-SpecificDisease
.,5505,O
Friedreich,5506,B-SpecificDisease
ataxia,5506,I-SpecificDisease
(,5506,O
FRDA,5506,B-SpecificDisease
),5506,O
",",5506,O
the,5506,O
most,5506,O
frequently,5506,O
inherited,5506,B-DiseaseClass
ataxia,5506,I-DiseaseClass
",",5506,O
is,5506,O
due,5506,O
in,5506,O
the,5506,O
vast,5506,O
majority,5506,O
of,5506,O
cases,5506,O
to,5506,O
a,5506,O
large,5506,O
expansion,5506,O
of,5506,O
an,5506,O
intronic,5506,O
GAA,5506,O
repeat,5506,O
.,5506,O
Using,5507,O
linkage,5507,O
disequilibrium,5507,O
analysis,5507,O
based,5507,O
on,5507,O
haplotype,5507,O
data,5507,O
of,5507,O
seven,5507,O
polymorphic,5507,O
markers,5507,O
close,5507,O
to,5507,O
the,5507,O
frataxin,5507,O
gene,5507,O
",",5507,O
the,5507,O
age,5507,O
of,5507,O
FRDA,5507,B-Modifier
founding,5507,O
mutational,5507,O
event,5507,O
(,5507,O
s,5507,O
),5507,O
is,5507,O
estimated,5507,O
to,5507,O
be,5507,O
at,5507,O
least,5507,O
682,5507,O
+/-203,5507,O
generations,5507,O
(,5507,O
95,5507,O
%,5507,O
confidence,5507,O
interval,5507,O
564-801,5507,O
g,5507,O
),5507,O
",",5507,O
a,5507,O
dating,5507,O
which,5507,O
is,5507,O
consistent,5507,O
with,5507,O
little,5507,O
or,5507,O
no,5507,O
negative,5507,O
selection,5507,O
and,5507,O
provides,5507,O
further,5507,O
evidence,5507,O
for,5507,O
an,5507,O
ancient,5507,O
spread,5507,O
of,5507,O
a,5507,O
pre-mutation,5507,O
(,5507,O
at-risk,5507,O
alleles,5507,O
),5507,O
in,5507,O
western,5507,O
Europe,5507,O
..,5507,O
Functional,5508,O
link,5508,O
between,5508,O
ataxia-telangiectasia,5508,B-Modifier
and,5508,O
Nijmegen,5508,B-Modifier
breakage,5508,I-Modifier
syndrome,5508,I-Modifier
gene,5508,O
products,5508,O
.,5508,O
Ataxia-telangiectasia,5509,B-SpecificDisease
(,5509,O
A-T,5509,B-SpecificDisease
),5509,O
and,5509,O
Nijmegen,5509,B-SpecificDisease
breakage,5509,I-SpecificDisease
syndrome,5509,I-SpecificDisease
(,5509,O
NBS,5509,B-SpecificDisease
),5509,O
are,5509,O
recessive,5509,B-DiseaseClass
genetic,5509,I-DiseaseClass
disorders,5509,I-DiseaseClass
with,5509,O
susceptibility,5509,O
to,5509,O
cancer,5509,B-DiseaseClass
and,5509,O
similar,5509,O
cellular,5509,O
phenotypes,5509,O
.,5509,O
The,5510,O
protein,5510,O
product,5510,O
of,5510,O
the,5510,O
gene,5510,O
responsible,5510,O
for,5510,O
A-T,5510,B-SpecificDisease
",",5510,O
designated,5510,O
ATM,5510,O
",",5510,O
is,5510,O
a,5510,O
member,5510,O
of,5510,O
a,5510,O
family,5510,O
of,5510,O
kinases,5510,O
characterized,5510,O
by,5510,O
a,5510,O
carboxy-terminal,5510,O
phosphatidylinositol,5510,O
3-kinase-like,5510,O
domain,5510,O
.,5510,O
The,5511,O
NBS1,5511,O
protein,5511,O
is,5511,O
specifically,5511,O
mutated,5511,O
in,5511,O
patients,5511,O
with,5511,O
Nijmegen,5511,B-SpecificDisease
breakage,5511,I-SpecificDisease
syndrome,5511,I-SpecificDisease
and,5511,O
forms,5511,O
a,5511,O
complex,5511,O
with,5511,O
the,5511,O
DNA,5511,O
repair,5511,O
proteins,5511,O
Rad50,5511,O
and,5511,O
Mrel1,5511,O
.,5511,O
Here,5512,O
we,5512,O
show,5512,O
that,5512,O
phosphorylation,5512,O
of,5512,O
NBS1,5512,O
",",5512,O
induced,5512,O
by,5512,O
ionizing,5512,O
radiation,5512,O
",",5512,O
requires,5512,O
catalytically,5512,O
active,5512,O
ATM,5512,O
.,5512,O
Complexes,5513,O
containing,5513,O
ATM,5513,O
and,5513,O
NBS1,5513,O
exist,5513,O
in,5513,O
vivo,5513,O
in,5513,O
both,5513,O
untreated,5513,O
cells,5513,O
and,5513,O
cells,5513,O
treated,5513,O
with,5513,O
ionizing,5513,O
radiation,5513,O
.,5513,O
We,5514,O
have,5514,O
identified,5514,O
two,5514,O
residues,5514,O
of,5514,O
NBS1,5514,O
",",5514,O
Ser,5514,O
278,5514,O
and,5514,O
Ser,5514,O
343,5514,O
that,5514,O
are,5514,O
phosphorylated,5514,O
in,5514,O
vitro,5514,O
by,5514,O
ATM,5514,O
and,5514,O
whose,5514,O
modification,5514,O
in,5514,O
vivo,5514,O
is,5514,O
essential,5514,O
for,5514,O
the,5514,O
cellular,5514,O
response,5514,O
to,5514,O
DNA,5514,O
damage,5514,O
.,5514,O
This,5515,O
response,5515,O
includes,5515,O
S-phase,5515,O
checkpoint,5515,O
activation,5515,O
",",5515,O
formation,5515,O
of,5515,O
the,5515,O
NBS1/Mrel1/Rad50,5515,O
nuclear,5515,O
foci,5515,O
and,5515,O
rescue,5515,O
of,5515,O
hypersensitivity,5515,B-DiseaseClass
to,5515,I-DiseaseClass
ionizing,5515,I-DiseaseClass
radiation,5515,I-DiseaseClass
.,5515,O
Together,5516,O
",",5516,O
these,5516,O
results,5516,O
demonstrate,5516,O
a,5516,O
biochemical,5516,O
link,5516,O
between,5516,O
cell-cycle,5516,O
checkpoints,5516,O
activated,5516,O
by,5516,O
DNA,5516,O
damage,5516,O
and,5516,O
DNA,5516,O
repair,5516,O
in,5516,O
two,5516,O
genetic,5516,B-DiseaseClass
diseases,5516,I-DiseaseClass
with,5516,O
overlapping,5516,O
phenotypes,5516,O
..,5516,O
Homozygosity,5517,O
mapping,5517,O
in,5517,O
a,5517,O
family,5517,O
with,5517,O
microcephaly,5517,B-DiseaseClass
",",5517,O
mental,5517,B-DiseaseClass
retardation,5517,I-DiseaseClass
",",5517,O
and,5517,O
short,5517,B-DiseaseClass
stature,5517,I-DiseaseClass
to,5517,O
a,5517,O
Cohen,5517,B-Modifier
syndrome,5517,I-Modifier
region,5517,O
on,5517,O
8q21.3-8q22.1,5517,O
:,5517,O
redefining,5517,O
a,5517,O
clinical,5517,O
entity,5517,O
.,5517,O
A,5518,O
syndrome,5518,O
of,5518,O
microcephaly,5518,B-DiseaseClass
",",5518,O
progressive,5518,O
postnatal,5518,B-DiseaseClass
growth,5518,I-DiseaseClass
deficiency,5518,I-DiseaseClass
",",5518,O
and,5518,O
mental,5518,B-DiseaseClass
retardation,5518,I-DiseaseClass
was,5518,O
observed,5518,O
in,5518,O
two,5518,O
brothers,5518,O
and,5518,O
their,5518,O
cousin,5518,O
from,5518,O
a,5518,O
multiply,5518,O
consanguineous,5518,O
kindred,5518,O
of,5518,O
Lebanese,5518,O
descent,5518,O
.,5518,O
Hypotonia,5519,B-DiseaseClass
",",5519,O
chorioretinal,5519,B-DiseaseClass
dystrophy,5519,I-DiseaseClass
",",5519,O
and,5519,O
myopia,5519,B-DiseaseClass
were,5519,O
also,5519,O
identified,5519,O
.,5519,O
The,5520,O
severity,5520,O
of,5520,O
the,5520,O
condition,5520,O
varied,5520,O
among,5520,O
the,5520,O
closely,5520,O
related,5520,O
patients,5520,O
.,5520,O
Because,5521,O
of,5521,O
absence,5521,O
of,5521,O
a,5521,O
distinctive,5521,O
facial,5521,O
appearance,5521,O
",",5521,O
the,5521,O
degree,5521,O
of,5521,O
mental,5521,B-DiseaseClass
retardation,5521,I-DiseaseClass
",",5521,O
and,5521,O
short,5521,B-DiseaseClass
stature,5521,I-DiseaseClass
",",5521,O
the,5521,O
initially,5521,O
considered,5521,O
clinical,5521,O
diagnosis,5521,O
of,5521,O
Cohen,5521,B-SpecificDisease
syndrome,5521,I-SpecificDisease
was,5521,O
withdrawn,5521,O
and,5521,O
a,5521,O
novel,5521,O
genetic,5521,O
entity,5521,O
was,5521,O
assumed,5521,O
.,5521,O
Homozygosity,5522,O
mapping,5522,O
in,5522,O
this,5522,O
family,5522,O
assigned,5522,O
the,5522,O
gene,5522,O
to,5522,O
a,5522,O
26,5522,O
.,5522,O
8-cM,5523,O
region,5523,O
on,5523,O
the,5523,O
chromosome,5523,O
band,5523,O
8q21,5523,O
.,5523,O
3,5524,O
-22,5524,O
.,5524,O
1,5525,O
",",5525,O
between,5525,O
the,5525,O
microsatellites,5525,O
at,5525,O
D8S270,5525,O
and,5525,O
D8S514,5525,O
.,5525,O
The,5526,O
maximum,5526,O
two-point,5526,O
LOD,5526,O
score,5526,O
was,5526,O
found,5526,O
for,5526,O
marker,5526,O
at,5526,O
D8S267,5526,O
(,5526,O
Zmax,5526,O
=,5526,O
3,5526,O
..,5526,O
237,5526,O
at,5526,O
Omax,5526,O
=,5526,O
0,5526,O
.,5526,O
00,5527,O
),5527,O
.,5527,O
Intriguingly,5528,O
enough,5528,O
",",5528,O
the,5528,O
identified,5528,O
gene,5528,O
region,5528,O
overlaps,5528,O
the,5528,O
refined,5528,O
gene,5528,O
region,5528,O
for,5528,O
Cohen,5528,B-SpecificDisease
syndrome,5528,I-SpecificDisease
(,5528,O
COH1,5528,O
),5528,O
[,5528,O
Kolehmainen,5528,O
et,5528,O
al.,5528,O
",",5528,O
1997,5528,O
Euro,5528,O
J,5528,O
Hum,5528,O
Genet,5528,O
5,5528,O
206-213,5528,O
],5528,O
.,5528,O
This,5529,O
fact,5529,O
encourages,5529,O
the,5529,O
hypothesis,5529,O
that,5529,O
the,5529,O
described,5529,O
kindred,5529,O
segregates,5529,O
for,5529,O
a,5529,O
variant,5529,O
of,5529,O
Cohen,5529,B-SpecificDisease
syndrome,5529,I-SpecificDisease
and,5529,O
suggests,5529,O
a,5529,O
redefinition,5529,O
of,5529,O
its,5529,O
phenotype,5529,O
Polymorphisms,5530,O
of,5530,O
the,5530,O
CYP2D6,5530,O
gene,5530,O
increase,5530,O
susceptibility,5530,O
to,5530,O
ankylosing,5530,B-SpecificDisease
spondylitis,5530,I-SpecificDisease
.,5530,O
Ankylosing,5531,B-SpecificDisease
spondylitis,5531,I-SpecificDisease
(,5531,O
AS,5531,B-SpecificDisease
),5531,O
is,5531,O
a,5531,O
common,5531,O
and,5531,O
highly,5531,O
familial,5531,O
rheumatic,5531,B-DiseaseClass
disorder,5531,I-DiseaseClass
.,5531,O
The,5532,O
sibling,5532,O
recurrence,5532,O
risk,5532,O
ratio,5532,O
for,5532,O
the,5532,O
disease,5532,O
is,5532,O
63,5532,O
and,5532,O
heritability,5532,O
assessed,5532,O
in,5532,O
twins,5532,O
>,5532,O
90,5532,O
%,5532,O
.,5532,O
Although,5533,O
MHC,5533,O
genes,5533,O
",",5533,O
including,5533,O
HLA-B27,5533,O
",",5533,O
contribute,5533,O
only,5533,O
20-50,5533,O
%,5533,O
of,5533,O
the,5533,O
genetic,5533,O
risk,5533,O
for,5533,O
the,5533,O
disease,5533,O
",",5533,O
no,5533,O
non-MHC,5533,O
gene,5533,O
has,5533,O
yet,5533,O
been,5533,O
convincingly,5533,O
demonstrated,5533,O
to,5533,O
influence,5533,O
either,5533,O
susceptibility,5533,O
to,5533,O
the,5533,O
disease,5533,O
or,5533,O
its,5533,O
phenotypic,5533,O
expression,5533,O
.,5533,O
Previous,5534,O
linkage,5534,O
and,5534,O
association,5534,O
studies,5534,O
have,5534,O
suggested,5534,O
the,5534,O
presence,5534,O
of,5534,O
a,5534,O
susceptibility,5534,O
gene,5534,O
for,5534,O
AS,5534,B-SpecificDisease
close,5534,O
to,5534,O
",",5534,O
or,5534,O
within,5534,O
",",5534,O
the,5534,O
cytochrome,5534,O
P450,5534,O
2D6,5534,O
gene,5534,O
(,5534,O
CYP2D6,5534,O
",",5534,O
debrisoquine,5534,O
hydroxylase,5534,O
),5534,O
located,5534,O
at,5534,O
chromosome,5534,O
22q13.1,5534,O
.,5534,O
We,5535,O
performed,5535,O
a,5535,O
linkage,5535,O
study,5535,O
of,5535,O
chromosome,5535,O
22,5535,O
in,5535,O
200,5535,O
families,5535,O
with,5535,O
AS,5535,B-SpecificDisease
affected,5535,O
sibling-pairs,5535,O
.,5535,O
Association,5536,O
of,5536,O
alleles,5536,O
of,5536,O
the,5536,O
CYP2D6,5536,O
gene,5536,O
was,5536,O
examined,5536,O
by,5536,O
both,5536,O
case-control,5536,O
and,5536,O
within-family,5536,O
means,5536,O
.,5536,O
For,5537,O
case-control,5537,O
studies,5537,O
",",5537,O
617,5537,O
unrelated,5537,O
individuals,5537,O
with,5537,O
AS,5537,B-SpecificDisease
(,5537,O
361,5537,O
probands,5537,O
from,5537,O
sibling-pair,5537,O
and,5537,O
parent-case,5537,O
trio,5537,O
families,5537,O
and,5537,O
256,5537,O
unrelated,5537,O
non-familial,5537,O
sporadic,5537,O
cases,5537,O
),5537,O
and,5537,O
402,5537,O
healthy,5537,O
ethnically,5537,O
matched,5537,O
controls,5537,O
were,5537,O
employed,5537,O
.,5537,O
For,5538,O
within-family,5538,O
association,5538,O
studies,5538,O
",",5538,O
361,5538,O
families,5538,O
including,5538,O
161,5538,O
parent-case,5538,O
trios,5538,O
and,5538,O
200,5538,O
affected,5538,O
sibling-pair,5538,O
families,5538,O
were,5538,O
employed,5538,O
.,5538,O
Homozygosity,5539,O
for,5539,O
poor,5539,O
metabolizer,5539,O
alleles,5539,O
was,5539,O
found,5539,O
to,5539,O
be,5539,O
associated,5539,O
with,5539,O
AS,5539,B-SpecificDisease
.,5539,O
Heterozygosity,5540,O
for,5540,O
the,5540,O
most,5540,O
frequent,5540,O
poor,5540,O
metabolizer,5540,O
allele,5540,O
(,5540,O
CYP2D6,5540,O
*,5540,O
4,5540,O
),5540,O
was,5540,O
not,5540,O
associated,5540,O
with,5540,O
increased,5540,O
susceptibility,5540,O
to,5540,O
AS,5540,B-SpecificDisease
.,5540,O
Significant,5541,O
within-family,5541,O
association,5541,O
of,5541,O
CYP2D6,5541,O
*,5541,O
4,5541,O
alleles,5541,O
and,5541,O
AS,5541,B-SpecificDisease
was,5541,O
demonstrated,5541,O
.,5541,O
Weak,5542,O
linkage,5542,O
was,5542,O
also,5542,O
demonstrated,5542,O
between,5542,O
CYP2D6,5542,O
and,5542,O
AS,5542,B-SpecificDisease
.,5542,O
We,5543,O
postulate,5543,O
that,5543,O
altered,5543,O
metabolism,5543,O
of,5543,O
a,5543,O
natural,5543,O
toxin,5543,O
or,5543,O
antigen,5543,O
by,5543,O
the,5543,O
CYP2D6,5543,O
gene,5543,O
may,5543,O
increase,5543,O
susceptibility,5543,O
to,5543,O
AS,5543,B-SpecificDisease
.,5543,O
Functional,5544,O
differences,5544,O
of,5544,O
the,5544,O
PDS,5544,B-Modifier
gene,5544,O
product,5544,O
are,5544,O
associated,5544,O
with,5544,O
phenotypic,5544,O
variation,5544,O
in,5544,O
patients,5544,O
with,5544,O
Pendred,5544,B-SpecificDisease
syndrome,5544,I-SpecificDisease
and,5544,O
non-syndromic,5544,B-SpecificDisease
hearing,5544,I-SpecificDisease
loss,5544,I-SpecificDisease
(,5544,O
DFNB4,5544,B-SpecificDisease
),5544,O
.,5544,O
The,5545,O
PDS,5545,B-Modifier
gene,5545,O
encodes,5545,O
a,5545,O
transmembrane,5545,O
protein,5545,O
",",5545,O
known,5545,O
as,5545,O
pendrin,5545,O
",",5545,O
which,5545,O
functions,5545,O
as,5545,O
a,5545,O
transporter,5545,O
of,5545,O
iodide,5545,O
and,5545,O
chloride,5545,O
.,5545,O
Mutations,5546,O
in,5546,O
this,5546,O
gene,5546,O
are,5546,O
responsible,5546,O
for,5546,O
Pendred,5546,B-SpecificDisease
syndrome,5546,I-SpecificDisease
and,5546,O
autosomal,5546,B-SpecificDisease
recessive,5546,I-SpecificDisease
non-syndromic,5546,I-SpecificDisease
hearing,5546,I-SpecificDisease
loss,5546,I-SpecificDisease
at,5546,O
the,5546,O
DFNB4,5546,B-Modifier
locus,5546,O
on,5546,O
chromosome,5546,O
7q31,5546,O
.,5546,O
A,5547,O
screen,5547,O
of,5547,O
20,5547,O
individuals,5547,O
from,5547,O
the,5547,O
midwestern,5547,O
USA,5547,O
with,5547,O
non-syndromic,5547,B-SpecificDisease
hearing,5547,I-SpecificDisease
loss,5547,I-SpecificDisease
and,5547,O
dilated,5547,O
vestibular,5547,O
aqueducts,5547,O
identified,5547,O
three,5547,O
people,5547,O
(,5547,O
15,5547,O
%,5547,O
),5547,O
with,5547,O
PDS,5547,B-Modifier
mutations,5547,O
.,5547,O
To,5548,O
determine,5548,O
whether,5548,O
PDS,5548,B-Modifier
mutations,5548,O
in,5548,O
individuals,5548,O
with,5548,O
Pendred,5548,B-SpecificDisease
syndrome,5548,I-SpecificDisease
differ,5548,O
functionally,5548,O
from,5548,O
PDS,5548,B-Modifier
mutations,5548,O
in,5548,O
individuals,5548,O
with,5548,O
non-syndromic,5548,B-SpecificDisease
hearing,5548,I-SpecificDisease
loss,5548,I-SpecificDisease
",",5548,O
we,5548,O
compared,5548,O
three,5548,O
common,5548,O
Pendred,5548,B-Modifier
syndrome,5548,I-Modifier
allele,5548,O
variants,5548,O
(,5548,O
L236P,5548,O
",",5548,O
T416P,5548,O
and,5548,O
E384G,5548,O
),5548,O
",",5548,O
with,5548,O
three,5548,O
PDS,5548,B-Modifier
mutations,5548,O
reported,5548,O
only,5548,O
in,5548,O
individuals,5548,O
with,5548,O
non-syndromic,5548,B-SpecificDisease
hearing,5548,I-SpecificDisease
loss,5548,I-SpecificDisease
(,5548,O
V480D,5548,O
",",5548,O
V653A,5548,O
and,5548,O
I490L/G497S,5548,O
),5548,O
.,5548,O
The,5549,O
mutations,5549,O
associated,5549,O
with,5549,O
Pendred,5549,B-SpecificDisease
syndrome,5549,I-SpecificDisease
have,5549,O
complete,5549,O
loss,5549,O
of,5549,O
pendrin-induced,5549,O
chloride,5549,O
and,5549,O
iodide,5549,O
transport,5549,O
",",5549,O
while,5549,O
alleles,5549,O
unique,5549,O
to,5549,O
people,5549,O
with,5549,O
DFNB4,5549,B-SpecificDisease
are,5549,O
able,5549,O
to,5549,O
transport,5549,O
both,5549,O
iodide,5549,O
and,5549,O
chloride,5549,O
",",5549,O
albeit,5549,O
at,5549,O
a,5549,O
much,5549,O
lower,5549,O
level,5549,O
than,5549,O
wild-type,5549,O
pendrin,5549,O
.,5549,O
We,5550,O
hypothesize,5550,O
that,5550,O
this,5550,O
residual,5550,O
level,5550,O
of,5550,O
anion,5550,O
transport,5550,O
is,5550,O
sufficient,5550,O
to,5550,O
eliminate,5550,O
or,5550,O
postpone,5550,O
the,5550,O
onset,5550,O
of,5550,O
goiter,5550,B-DiseaseClass
in,5550,O
individuals,5550,O
with,5550,O
DFNB4,5550,B-SpecificDisease
.,5550,O
We,5551,O
propose,5551,O
a,5551,O
model,5551,O
for,5551,O
pendrin,5551,O
function,5551,O
in,5551,O
the,5551,O
thyroid,5551,O
in,5551,O
which,5551,O
pendrin,5551,O
transports,5551,O
iodide,5551,O
across,5551,O
the,5551,O
apical,5551,O
membrane,5551,O
of,5551,O
the,5551,O
thyrocyte,5551,O
into,5551,O
the,5551,O
colloid,5551,O
space,5551,O
..,5551,O
The,5552,O
human,5552,O
factor,5552,O
IX,5552,O
gene,5552,O
as,5552,O
germline,5552,O
mutagen,5552,O
test,5552,O
:,5552,O
samples,5552,O
from,5552,O
Mainland,5552,O
China,5552,O
have,5552,O
the,5552,O
putatively,5552,O
endogenous,5552,O
pattern,5552,O
of,5552,O
mutation,5552,O
.,5552,O
Germline,5553,O
mutations,5553,O
are,5553,O
the,5553,O
major,5553,O
source,5553,O
of,5553,O
genetic,5553,O
variation,5553,O
that,5553,O
allows,5553,O
a,5553,O
species,5553,O
to,5553,O
evolve,5553,O
over,5553,O
time,5553,O
but,5553,O
at,5553,O
the,5553,O
cost,5553,O
of,5553,O
Mendelian,5553,B-DiseaseClass
disease,5553,I-DiseaseClass
and,5553,O
genetic,5553,O
predisposition,5553,O
to,5553,O
multifactorial,5553,B-DiseaseClass
diseases,5553,I-DiseaseClass
.,5553,O
Previous,5554,O
analyses,5554,O
have,5554,O
revealed,5554,O
that,5554,O
the,5554,O
pattern,5554,O
of,5554,O
germline,5554,O
mutations,5554,O
in,5554,O
the,5554,O
factor,5554,O
IX,5554,O
gene,5554,O
(,5554,O
F9,5554,O
),5554,O
is,5554,O
similar,5554,O
among,5554,O
a,5554,O
variety,5554,O
of,5554,O
ethnically,5554,O
and,5554,O
geographically,5554,O
diverse,5554,O
populations,5554,O
and,5554,O
compatible,5554,O
with,5554,O
the,5554,O
ancient,5554,O
pattern,5554,O
that,5554,O
has,5554,O
shaped,5554,O
the,5554,O
mammalian,5554,O
genome,5554,O
.,5554,O
Here,5555,O
",",5555,O
we,5555,O
compare,5555,O
the,5555,O
pattern,5555,O
of,5555,O
germline,5555,O
mutation,5555,O
in,5555,O
a,5555,O
population,5555,O
of,5555,O
hemophilia,5555,B-Modifier
B,5555,I-Modifier
patients,5555,O
from,5555,O
Mainland,5555,O
China,5555,O
(,5555,O
n,5555,O
=,5555,O
66,5555,O
),5555,O
to,5555,O
that,5555,O
in,5555,O
U.,5555,O
S.,5555,O
Caucasians,5555,O
",",5555,O
Blacks,5555,O
",",5555,O
and,5555,O
Mexican,5555,O
Hispanics,5555,O
and,5555,O
stratify,5555,O
by,5555,O
disease,5555,O
severity,5555,O
and,5555,O
ethnicity,5555,O
.,5555,O
The,5556,O
similar,5556,O
pattern,5556,O
of,5556,O
germline,5556,O
mutation,5556,O
in,5556,O
all,5556,O
ethnic,5556,O
groups,5556,O
studied,5556,O
to,5556,O
date,5556,O
provides,5556,O
additional,5556,O
data,5556,O
compatible,5556,O
with,5556,O
the,5556,O
inference,5556,O
that,5556,O
endogenous,5556,O
processes,5556,O
predominate,5556,O
in,5556,O
germline,5556,O
mutations,5556,O
.,5556,O
Fas,5557,O
preassociation,5557,O
required,5557,O
for,5557,O
apoptosis,5557,O
signaling,5557,O
and,5557,O
dominant,5557,O
inhibition,5557,O
by,5557,O
pathogenic,5557,O
mutations,5557,O
.,5557,O
Heterozygous,5558,O
mutations,5558,O
encoding,5558,O
abnormal,5558,O
forms,5558,O
of,5558,O
the,5558,O
death,5558,O
receptor,5558,O
Fas,5558,O
dominantly,5558,O
interfere,5558,O
with,5558,O
Fas-induced,5558,O
lymphocyte,5558,O
apoptosis,5558,O
in,5558,O
human,5558,O
autoimmune,5558,B-SpecificDisease
lymphoproliferative,5558,I-SpecificDisease
syndrome,5558,I-SpecificDisease
.,5558,O
This,5559,O
effect,5559,O
",",5559,O
rather,5559,O
than,5559,O
depending,5559,O
on,5559,O
ligand-induced,5559,O
receptor,5559,O
oligomerization,5559,O
",",5559,O
was,5559,O
found,5559,O
to,5559,O
stem,5559,O
from,5559,O
ligand-,5559,O
independent,5559,O
interaction,5559,O
of,5559,O
wild-type,5559,O
and,5559,O
mutant,5559,O
Fas,5559,O
receptors,5559,O
through,5559,O
a,5559,O
specific,5559,O
region,5559,O
in,5559,O
the,5559,O
extracellular,5559,O
domain,5559,O
.,5559,O
Preassociated,5560,O
Fas,5560,O
complexes,5560,O
were,5560,O
found,5560,O
in,5560,O
living,5560,O
cells,5560,O
by,5560,O
means,5560,O
of,5560,O
fluorescence,5560,O
resonance,5560,O
energy,5560,O
transfer,5560,O
between,5560,O
variants,5560,O
of,5560,O
green,5560,O
fluorescent,5560,O
protein,5560,O
.,5560,O
These,5561,O
results,5561,O
show,5561,O
that,5561,O
formation,5561,O
of,5561,O
preassociated,5561,O
receptor,5561,O
complexes,5561,O
is,5561,O
necessary,5561,O
for,5561,O
Fas,5561,O
signaling,5561,O
and,5561,O
dominant,5561,O
interference,5561,O
in,5561,O
human,5561,O
disease,5561,O
..,5561,O
Determination,5562,O
of,5562,O
carrier,5562,O
status,5562,O
for,5562,O
the,5562,O
Wiskott-Aldrich,5562,B-SpecificDisease
syndrome,5562,I-SpecificDisease
by,5562,O
flow,5562,O
cytometric,5562,O
analysis,5562,O
of,5562,O
Wiskott-Aldrich,5562,B-Modifier
syndrome,5562,I-Modifier
protein,5562,O
expression,5562,O
in,5562,O
peripheral,5562,O
blood,5562,O
mononuclear,5562,O
cells,5562,O
.,5562,O
The,5563,O
Wiskott-Aldrich,5563,B-SpecificDisease
syndrome,5563,I-SpecificDisease
(,5563,O
WAS,5563,B-SpecificDisease
),5563,O
is,5563,O
caused,5563,O
by,5563,O
defects,5563,O
in,5563,O
the,5563,O
WAS,5563,B-Modifier
protein,5563,O
(,5563,O
WASP,5563,O
),5563,O
gene,5563,O
on,5563,O
the,5563,O
X,5563,O
chromosome,5563,O
.,5563,O
Previous,5564,O
study,5564,O
disclosed,5564,O
that,5564,O
flow,5564,O
cytometric,5564,O
analysis,5564,O
of,5564,O
intracellular,5564,O
WASP,5564,O
expression,5564,O
(,5564,O
FCM-WASP,5564,O
analysis,5564,O
),5564,O
in,5564,O
lymphocytes,5564,O
was,5564,O
useful,5564,O
for,5564,O
the,5564,O
diagnosis,5564,O
of,5564,O
WAS,5564,B-Modifier
patients,5564,O
.,5564,O
Lymphocytes,5565,O
from,5565,O
all,5565,O
WAS,5565,B-Modifier
patients,5565,O
showed,5565,O
WASPdim,5565,O
instead,5565,O
of,5565,O
WASPbright,5565,O
.,5565,O
Here,5566,O
we,5566,O
report,5566,O
that,5566,O
FCM-WASP,5566,O
analysis,5566,O
in,5566,O
monocytes,5566,O
could,5566,O
be,5566,O
a,5566,O
useful,5566,O
tool,5566,O
for,5566,O
the,5566,O
WAS,5566,B-Modifier
carrier,5566,O
diagnosis,5566,O
.,5566,O
Monocytes,5567,O
from,5567,O
all,5567,O
nine,5567,O
WAS,5567,B-Modifier
carriers,5567,O
showed,5567,O
varied,5567,O
population,5567,O
of,5567,O
WASPdim,5567,O
together,5567,O
with,5567,O
WASPbright,5567,O
.,5567,O
None,5568,O
of,5568,O
control,5568,O
individuals,5568,O
possessed,5568,O
the,5568,O
WASPdim,5568,O
population,5568,O
.,5568,O
In,5569,O
contrast,5569,O
",",5569,O
lymphocytes,5569,O
from,5569,O
all,5569,O
the,5569,O
carriers,5569,O
except,5569,O
two,5569,O
lacked,5569,O
the,5569,O
WASPdim,5569,O
population,5569,O
.,5569,O
The,5570,O
difference,5570,O
of,5570,O
the,5570,O
WASPdim,5570,O
population,5570,O
in,5570,O
monocytes,5570,O
and,5570,O
lymphocytes,5570,O
observed,5570,O
in,5570,O
WAS,5570,B-Modifier
carriers,5570,O
suggests,5570,O
that,5570,O
WASP,5570,O
plays,5570,O
a,5570,O
more,5570,O
critical,5570,O
role,5570,O
in,5570,O
the,5570,O
development,5570,O
of,5570,O
lymphocytes,5570,O
than,5570,O
in,5570,O
that,5570,O
of,5570,O
monocytes,5570,O
.,5570,O
The,5571,O
present,5571,O
studies,5571,O
suggest,5571,O
that,5571,O
a,5571,O
skewed,5571,O
X-chromosomal,5571,O
inactivation,5571,O
pattern,5571,O
observed,5571,O
in,5571,O
WAS,5571,B-Modifier
carrier,5571,O
peripheral,5571,O
blood,5571,O
cells,5571,O
is,5571,O
not,5571,O
fixed,5571,O
at,5571,O
the,5571,O
hemopoietic,5571,O
stem,5571,O
cell,5571,O
level,5571,O
but,5571,O
progresses,5571,O
after,5571,O
the,5571,O
lineage,5571,O
commitment,5571,O
..,5571,O
Restoration,5572,O
of,5572,O
photoreceptor,5572,O
ultrastructure,5572,O
and,5572,O
function,5572,O
in,5572,O
retinal,5572,B-Modifier
degeneration,5572,I-Modifier
slow,5572,O
mice,5572,O
by,5572,O
gene,5572,O
therapy,5572,O
.,5572,O
The,5573,O
gene,5573,O
Prph2,5573,O
encodes,5573,O
a,5573,O
photoreceptor-specific,5573,O
membrane,5573,O
glycoprotein,5573,O
",",5573,O
peripherin-2,5573,O
(,5573,O
also,5573,O
known,5573,O
as,5573,O
peripherin/rds,5573,O
),5573,O
",",5573,O
which,5573,O
is,5573,O
inserted,5573,O
into,5573,O
the,5573,O
rims,5573,O
of,5573,O
photoreceptor,5573,O
outer,5573,O
segment,5573,O
discs,5573,O
in,5573,O
a,5573,O
complex,5573,O
with,5573,O
rom-1,5573,O
(,5573,O
ref,5573,O
.,5573,O
2,5574,O
),5574,O
.,5574,O
The,5575,O
complex,5575,O
is,5575,O
necessary,5575,O
for,5575,O
the,5575,O
stabilization,5575,O
of,5575,O
the,5575,O
discs,5575,O
",",5575,O
which,5575,O
are,5575,O
renewed,5575,O
constantly,5575,O
throughout,5575,O
life,5575,O
",",5575,O
and,5575,O
which,5575,O
contain,5575,O
the,5575,O
visual,5575,O
pigments,5575,O
necessary,5575,O
for,5575,O
photon,5575,O
capture,5575,O
.,5575,O
Mutations,5576,O
in,5576,O
Prph2,5576,O
have,5576,O
been,5576,O
shown,5576,O
to,5576,O
result,5576,O
in,5576,O
a,5576,O
variety,5576,O
of,5576,O
photoreceptor,5576,B-DiseaseClass
dystrophies,5576,I-DiseaseClass
",",5576,O
including,5576,O
autosomal,5576,B-SpecificDisease
dominant,5576,I-SpecificDisease
retinitis,5576,I-SpecificDisease
pigmentosa,5576,I-SpecificDisease
and,5576,O
macular,5576,B-SpecificDisease
dystrophy,5576,I-SpecificDisease
.,5576,O
A,5577,O
common,5577,O
feature,5577,O
of,5577,O
these,5577,O
diseases,5577,O
is,5577,O
the,5577,O
loss,5577,O
of,5577,O
photoreceptor,5577,O
function,5577,O
",",5577,O
also,5577,O
seen,5577,O
in,5577,O
the,5577,O
retinal,5577,B-Modifier
degeneration,5577,I-Modifier
slow,5577,O
(,5577,O
rds,5577,O
or,5577,O
Prph2,5577,O
Rd2/Rd2,5577,O
),5577,O
mouse,5577,O
",",5577,O
which,5577,O
is,5577,O
homozygous,5577,O
for,5577,O
a,5577,O
null,5577,O
mutation,5577,O
in,5577,O
Prph2,5577,O
.,5577,O
It,5578,O
is,5578,O
characterized,5578,O
by,5578,O
a,5578,O
complete,5578,O
failure,5578,O
to,5578,O
develop,5578,O
photoreceptor,5578,O
discs,5578,O
and,5578,O
outer,5578,O
segments,5578,O
",",5578,O
downregulation,5578,O
of,5578,O
rhodopsin,5578,O
and,5578,O
apoptotic,5578,O
loss,5578,O
of,5578,O
photoreceptor,5578,O
cells,5578,O
.,5578,O
The,5579,O
electroretinograms,5579,O
(,5579,O
ERGs,5579,O
),5579,O
of,5579,O
Prph2Rd2/Rd2,5579,O
mice,5579,O
have,5579,O
greatly,5579,O
diminished,5579,O
a-wave,5579,O
and,5579,O
b-wave,5579,O
amplitudes,5579,O
",",5579,O
which,5579,O
decline,5579,O
to,5579,O
virtually,5579,O
undetectable,5579,O
concentrations,5579,O
by,5579,O
two,5579,O
months,5579,O
.,5579,O
Subretinal,5580,O
injection,5580,O
of,5580,O
recombinant,5580,O
adeno-associated,5580,O
virus,5580,O
(,5580,O
AAV,5580,O
),5580,O
encoding,5580,O
a,5580,O
Prph2,5580,O
transgene,5580,O
results,5580,O
in,5580,O
stable,5580,O
generation,5580,O
of,5580,O
outer,5580,O
segment,5580,O
structures,5580,O
and,5580,O
formation,5580,O
of,5580,O
new,5580,O
stacks,5580,O
of,5580,O
discs,5580,O
containing,5580,O
both,5580,O
perpherin-2,5580,O
and,5580,O
rhodopsin,5580,O
",",5580,O
which,5580,O
in,5580,O
many,5580,O
cases,5580,O
are,5580,O
morphologically,5580,O
similar,5580,O
to,5580,O
normal,5580,O
outer,5580,O
segments,5580,O
.,5580,O
Moreover,5581,O
",",5581,O
the,5581,O
re-establishment,5581,O
of,5581,O
the,5581,O
structural,5581,O
integrity,5581,O
of,5581,O
the,5581,O
photoreceptor,5581,O
layer,5581,O
also,5581,O
results,5581,O
in,5581,O
electrophysiological,5581,O
correction,5581,O
.,5581,O
These,5582,O
studies,5582,O
demonstrate,5582,O
for,5582,O
the,5582,O
first,5582,O
time,5582,O
that,5582,O
a,5582,O
complex,5582,O
ultrastructural,5582,O
cell,5582,O
defect,5582,O
can,5582,O
be,5582,O
corrected,5582,O
both,5582,O
morphologically,5582,O
and,5582,O
functionally,5582,O
by,5582,O
in,5582,O
vivo,5582,O
gene,5582,O
transfer,5582,O
..,5582,O
Mutations,5583,O
in,5583,O
the,5583,O
fibrinogen,5583,O
aalpha,5583,O
gene,5583,O
account,5583,O
for,5583,O
the,5583,O
majority,5583,O
of,5583,O
cases,5583,O
of,5583,O
congenital,5583,B-SpecificDisease
afibrinogenemia,5583,I-SpecificDisease
.,5583,O
Congenital,5584,B-SpecificDisease
afibrinogenemia,5584,I-SpecificDisease
is,5584,O
a,5584,O
rare,5584,O
",",5584,O
autosomal,5584,B-DiseaseClass
",",5584,I-DiseaseClass
recessive,5584,I-DiseaseClass
disorder,5584,I-DiseaseClass
characterized,5584,O
by,5584,O
the,5584,O
complete,5584,O
absence,5584,O
of,5584,O
detectable,5584,O
fibrinogen,5584,O
.,5584,O
We,5585,O
previously,5585,O
identified,5585,O
the,5585,O
first,5585,O
causative,5585,O
mutations,5585,O
in,5585,O
a,5585,O
nonconsanguineous,5585,O
Swiss,5585,O
family,5585,O
;,5585,O
the,5585,O
4,5585,O
affected,5585,O
persons,5585,O
have,5585,O
homozygous,5585,O
deletions,5585,O
of,5585,O
approximately,5585,O
11,5585,O
kb,5585,O
of,5585,O
the,5585,O
fibrinogen,5585,O
alpha,5585,O
(,5585,O
FGA,5585,O
),5585,O
gene,5585,O
.,5585,O
Haplotype,5586,O
data,5586,O
implied,5586,O
that,5586,O
these,5586,O
deletions,5586,O
occurred,5586,O
on,5586,O
distinct,5586,O
ancestral,5586,O
chromosomes,5586,O
",",5586,O
suggesting,5586,O
that,5586,O
this,5586,O
region,5586,O
may,5586,O
be,5586,O
susceptible,5586,O
to,5586,O
deletion,5586,O
by,5586,O
a,5586,O
common,5586,O
mechanism,5586,O
.,5586,O
We,5587,O
subsequently,5587,O
showed,5587,O
that,5587,O
all,5587,O
the,5587,O
deletions,5587,O
were,5587,O
identical,5587,O
to,5587,O
the,5587,O
base,5587,O
pair,5587,O
and,5587,O
probably,5587,O
resulted,5587,O
from,5587,O
a,5587,O
nonhomologous,5587,O
recombination,5587,O
mediated,5587,O
by,5587,O
7-bp,5587,O
direct,5587,O
repeats,5587,O
.,5587,O
In,5588,O
this,5588,O
study,5588,O
",",5588,O
we,5588,O
have,5588,O
collected,5588,O
data,5588,O
on,5588,O
13,5588,O
additional,5588,O
unrelated,5588,O
patients,5588,O
to,5588,O
identify,5588,O
the,5588,O
causative,5588,O
mutations,5588,O
and,5588,O
to,5588,O
determine,5588,O
the,5588,O
prevalence,5588,O
of,5588,O
the,5588,O
11-kb,5588,O
deletion,5588,O
.,5588,O
A,5589,O
common,5589,O
recurrent,5589,O
mutation,5589,O
",",5589,O
at,5589,O
the,5589,O
donor,5589,O
splice,5589,O
site,5589,O
of,5589,O
FGA,5589,O
intron,5589,O
4,5589,O
(,5589,O
IVS4,5589,O
+,5589,O
1,5589,O
G,5589,O
>,5589,O
T,5589,O
),5589,O
",",5589,O
accounted,5589,O
for,5589,O
14,5589,O
of,5589,O
the,5589,O
26,5589,O
(,5589,O
54,5589,O
%,5589,O
),5589,O
alleles,5589,O
.,5589,O
One,5590,O
patient,5590,O
was,5590,O
heterozygous,5590,O
for,5590,O
the,5590,O
previously,5590,O
identified,5590,O
deletion,5590,O
.,5590,O
Three,5591,O
more,5591,O
frameshift,5591,O
mutations,5591,O
",",5591,O
2,5591,O
nonsense,5591,O
mutations,5591,O
",",5591,O
and,5591,O
a,5591,O
second,5591,O
splice,5591,O
site,5591,O
mutation,5591,O
were,5591,O
also,5591,O
identified,5591,O
.,5591,O
Consequently,5592,O
",",5592,O
86,5592,O
%,5592,O
of,5592,O
afibrinogenemia,5592,B-Modifier
alleles,5592,O
analyzed,5592,O
to,5592,O
date,5592,O
have,5592,O
truncating,5592,O
mutations,5592,O
of,5592,O
FGA,5592,O
",",5592,O
though,5592,O
mutations,5592,O
in,5592,O
all,5592,O
3,5592,O
fibrinogen,5592,O
genes,5592,O
",",5592,O
FGG,5592,O
",",5592,O
FGA,5592,O
",",5592,O
and,5592,O
FGB,5592,O
",",5592,O
might,5592,O
be,5592,O
predicted,5592,O
to,5592,O
cause,5592,O
congenital,5592,B-SpecificDisease
afibrinogenemia,5592,I-SpecificDisease
..,5592,O
Myotonic,5593,B-SpecificDisease
dystrophy,5593,I-SpecificDisease
:,5593,O
the,5593,O
role,5593,O
of,5593,O
the,5593,O
CUG,5593,O
triplet,5593,O
repeats,5593,O
in,5593,O
splicing,5593,O
of,5593,O
a,5593,O
novel,5593,O
DMPK,5593,O
exon,5593,O
and,5593,O
altered,5593,O
cytoplasmic,5593,O
DMPK,5593,O
mRNA,5593,O
isoform,5593,O
ratios,5593,O
.,5593,O
The,5594,O
mechanism,5594,O
by,5594,O
which,5594,O
(,5594,O
CTG,5594,O
),5594,O
n,5594,O
expansion,5594,O
in,5594,O
the,5594,O
3,5594,O
UTR,5594,O
of,5594,O
the,5594,O
DMPK,5594,O
gene,5594,O
causes,5594,O
myotonic,5594,B-SpecificDisease
dystrophy,5594,I-SpecificDisease
(,5594,O
DM,5594,B-SpecificDisease
),5594,O
is,5594,O
unknown,5594,O
.,5594,O
We,5595,O
identified,5595,O
four,5595,O
RNA,5595,O
splicing,5595,O
factors,5595,O
--,5595,O
hnRNP,5595,O
C,5595,O
",",5595,O
U2AF,5595,O
(,5595,O
U2,5595,O
auxiliary,5595,O
factor,5595,O
),5595,O
",",5595,O
PTB,5595,O
(,5595,O
polypyrimidine,5595,O
tract,5595,O
binding,5595,O
protein,5595,O
),5595,O
",",5595,O
and,5595,O
PSF,5595,O
(,5595,O
PTB,5595,O
associated,5595,O
splicing,5595,O
factor,5595,O
),5595,O
--,5595,O
that,5595,O
bind,5595,O
to,5595,O
two,5595,O
short,5595,O
regions,5595,O
3,5595,O
of,5595,O
the,5595,O
(,5595,O
CUG,5595,O
),5595,O
n,5595,O
",",5595,O
and,5595,O
found,5595,O
a,5595,O
novel,5595,O
3,5595,O
DMPK,5595,O
exon,5595,O
resulting,5595,O
in,5595,O
an,5595,O
mRNA,5595,O
lacking,5595,O
the,5595,O
repeats,5595,O
.,5595,O
We,5596,O
propose,5596,O
that,5596,O
the,5596,O
(,5596,O
CUG,5596,O
),5596,O
n,5596,O
is,5596,O
an,5596,O
essential,5596,O
cis,5596,O
acting,5596,O
element,5596,O
for,5596,O
this,5596,O
splicing,5596,O
event,5596,O
.,5596,O
In,5597,O
contrast,5597,O
to,5597,O
(,5597,O
CUG,5597,O
),5597,O
n,5597,O
containing,5597,O
mRNAs,5597,O
",",5597,O
the,5597,O
novel,5597,O
isoform,5597,O
is,5597,O
not,5597,O
retained,5597,O
in,5597,O
the,5597,O
nucleus,5597,O
in,5597,O
DM,5597,B-Modifier
cells,5597,O
",",5597,O
resulting,5597,O
in,5597,O
imbalances,5597,O
in,5597,O
relative,5597,O
levels,5597,O
of,5597,O
cytoplasmic,5597,O
DMPK,5597,O
mRNA,5597,O
isoforms,5597,O
and,5597,O
a,5597,O
new,5597,O
dominant,5597,O
effect,5597,O
of,5597,O
the,5597,O
mutation,5597,O
on,5597,O
DMPK,5597,O
..,5597,O
Expression,5598,O
and,5598,O
imprinting,5598,O
of,5598,O
MAGEL2,5598,O
suggest,5598,O
a,5598,O
role,5598,O
in,5598,O
Prader-willi,5598,B-SpecificDisease
syndrome,5598,I-SpecificDisease
and,5598,O
the,5598,O
homologous,5598,O
murine,5598,O
imprinting,5598,O
phenotype,5598,O
.,5598,O
Prader-Willi,5599,B-SpecificDisease
syndrome,5599,I-SpecificDisease
(,5599,O
PWS,5599,B-SpecificDisease
),5599,O
is,5599,O
caused,5599,O
by,5599,O
the,5599,O
loss,5599,O
of,5599,O
expression,5599,O
of,5599,O
imprinted,5599,O
genes,5599,O
in,5599,O
chromosome,5599,O
15q11-q13,5599,O
.,5599,O
Affected,5600,O
individuals,5600,O
exhibit,5600,O
neonatal,5600,B-SpecificDisease
hypotonia,5600,I-SpecificDisease
",",5600,O
developmental,5600,B-DiseaseClass
delay,5600,I-DiseaseClass
and,5600,O
childhood-onset,5600,B-DiseaseClass
obesity,5600,I-DiseaseClass
.,5600,O
Necdin,5601,O
",",5601,O
a,5601,O
protein,5601,O
implicated,5601,O
in,5601,O
the,5601,O
terminal,5601,O
differentiation,5601,O
of,5601,O
neurons,5601,O
",",5601,O
is,5601,O
the,5601,O
only,5601,O
PWS,5601,B-Modifier
candidate,5601,O
gene,5601,O
to,5601,O
reduce,5601,O
viability,5601,O
when,5601,O
disrupted,5601,O
in,5601,O
a,5601,O
mouse,5601,O
model,5601,O
.,5601,O
In,5602,O
this,5602,O
study,5602,O
",",5602,O
we,5602,O
have,5602,O
characterized,5602,O
MAGEL2,5602,O
(,5602,O
also,5602,O
known,5602,O
as,5602,O
NDNL1,5602,O
),5602,O
",",5602,O
a,5602,O
gene,5602,O
with,5602,O
51,5602,O
%,5602,O
amino,5602,O
acid,5602,O
sequence,5602,O
similarity,5602,O
to,5602,O
necdin,5602,O
and,5602,O
located,5602,O
41,5602,O
kb,5602,O
distal,5602,O
to,5602,O
NDN,5602,O
in,5602,O
the,5602,O
PWS,5602,B-Modifier
deletion,5602,O
region,5602,O
.,5602,O
MAGEL2,5603,O
is,5603,O
expressed,5603,O
predominantly,5603,O
in,5603,O
brain,5603,O
",",5603,O
the,5603,O
primary,5603,O
tissue,5603,O
affected,5603,O
in,5603,O
PWS,5603,B-SpecificDisease
and,5603,O
in,5603,O
several,5603,O
fetal,5603,O
tissues,5603,O
as,5603,O
shown,5603,O
by,5603,O
northern,5603,O
blot,5603,O
analysis,5603,O
.,5603,O
MAGEL2,5604,O
is,5604,O
imprinted,5604,O
with,5604,O
monoallelic,5604,O
expression,5604,O
in,5604,O
control,5604,O
brain,5604,O
",",5604,O
and,5604,O
paternal-only,5604,O
expression,5604,O
in,5604,O
the,5604,O
central,5604,O
nervous,5604,O
system,5604,O
as,5604,O
demonstrated,5604,O
by,5604,O
its,5604,O
lack,5604,O
of,5604,O
expression,5604,O
in,5604,O
brain,5604,O
from,5604,O
a,5604,O
PWS-affected,5604,B-Modifier
individual,5604,O
.,5604,O
The,5605,O
orthologous,5605,O
mouse,5605,O
gene,5605,O
(,5605,O
Magel2,5605,O
),5605,O
is,5605,O
located,5605,O
within,5605,O
150,5605,O
kb,5605,O
of,5605,O
NDN,5605,O
",",5605,O
is,5605,O
imprinted,5605,O
with,5605,O
paternal-only,5605,O
expression,5605,O
and,5605,O
is,5605,O
expressed,5605,O
predominantly,5605,O
in,5605,O
late,5605,O
developmental,5605,O
stages,5605,O
and,5605,O
adult,5605,O
brain,5605,O
as,5605,O
shown,5605,O
by,5605,O
northern,5605,O
blotting,5605,O
",",5605,O
RT-PCR,5605,O
and,5605,O
whole-mount,5605,O
RNA,5605,O
in,5605,O
situ,5605,O
hybridization,5605,O
.,5605,O
Magel2,5606,O
distribution,5606,O
partially,5606,O
overlaps,5606,O
that,5606,O
of,5606,O
NDN,5606,O
",",5606,O
with,5606,O
strong,5606,O
expression,5606,O
being,5606,O
detected,5606,O
in,5606,O
the,5606,O
central,5606,O
nervous,5606,O
system,5606,O
in,5606,O
mid-gestation,5606,O
mouse,5606,O
embryos,5606,O
by,5606,O
in,5606,O
situ,5606,O
hybridization,5606,O
.,5606,O
We,5607,O
hypothesize,5607,O
that,5607,O
",",5607,O
although,5607,O
loss,5607,O
of,5607,O
necdin,5607,O
expression,5607,O
may,5607,O
be,5607,O
important,5607,O
in,5607,O
the,5607,O
neonatal,5607,O
presentation,5607,O
of,5607,O
PWS,5607,B-SpecificDisease
",",5607,O
loss,5607,O
of,5607,O
MAGEL2,5607,O
may,5607,O
be,5607,O
critical,5607,O
to,5607,O
abnormalities,5607,B-DiseaseClass
in,5607,I-DiseaseClass
brain,5607,I-DiseaseClass
development,5607,I-DiseaseClass
and,5607,O
dysmorphic,5607,B-DiseaseClass
features,5607,I-DiseaseClass
in,5607,O
individuals,5607,O
with,5607,O
PWS,5607,B-SpecificDisease
..,5607,O
Retinoschisin,5608,O
",",5608,O
the,5608,O
X-linked,5608,B-Modifier
retinoschisis,5608,I-Modifier
protein,5608,O
",",5608,O
is,5608,O
a,5608,O
secreted,5608,O
photoreceptor,5608,O
protein,5608,O
",",5608,O
and,5608,O
is,5608,O
expressed,5608,O
and,5608,O
released,5608,O
by,5608,O
Weri-Rb1,5608,O
cells,5608,O
.,5608,O
X-linked,5609,B-SpecificDisease
retinoschisis,5609,I-SpecificDisease
is,5609,O
characterized,5609,O
by,5609,O
microcystic-like,5609,O
changes,5609,O
of,5609,O
the,5609,O
macular,5609,O
region,5609,O
and,5609,O
schisis,5609,O
within,5609,O
the,5609,O
inner,5609,O
retinal,5609,O
layers,5609,O
",",5609,O
leading,5609,O
to,5609,O
visual,5609,B-DiseaseClass
deterioration,5609,I-DiseaseClass
in,5609,O
males,5609,O
.,5609,O
Many,5610,O
missense,5610,O
and,5610,O
protein-truncating,5610,O
mutations,5610,O
of,5610,O
the,5610,O
causative,5610,O
gene,5610,O
RS1,5610,O
have,5610,O
now,5610,O
been,5610,O
identified,5610,O
and,5610,O
are,5610,O
thought,5610,O
to,5610,O
be,5610,O
inactivating,5610,O
.,5610,O
RS1,5611,O
encodes,5611,O
a,5611,O
224,5611,O
amino,5611,O
acid,5611,O
protein,5611,O
",",5611,O
retinoschisin,5611,O
",",5611,O
which,5611,O
contains,5611,O
a,5611,O
discoidin,5611,O
domain,5611,O
but,5611,O
is,5611,O
of,5611,O
unknown,5611,O
function,5611,O
.,5611,O
We,5612,O
have,5612,O
generated,5612,O
a,5612,O
polyclonal,5612,O
antibody,5612,O
against,5612,O
a,5612,O
peptide,5612,O
from,5612,O
a,5612,O
unique,5612,O
region,5612,O
within,5612,O
retinoschisin,5612,O
",",5612,O
which,5612,O
detects,5612,O
a,5612,O
protein,5612,O
of,5612,O
approximately,5612,O
28,5612,O
kDa,5612,O
in,5612,O
retinal,5612,O
samples,5612,O
reduced,5612,O
with,5612,O
dithiothreitol,5612,O
",",5612,O
but,5612,O
multimers,5612,O
sized,5612,O
>,5612,O
40,5612,O
kDa,5612,O
under,5612,O
non-reducing,5612,O
conditions,5612,O
.,5612,O
A,5613,O
screen,5613,O
of,5613,O
human,5613,O
tissues,5613,O
with,5613,O
this,5613,O
antibody,5613,O
reveals,5613,O
retinoschisin,5613,O
to,5613,O
be,5613,O
retina,5613,O
specific,5613,O
and,5613,O
the,5613,O
antibody,5613,O
detects,5613,O
a,5613,O
protein,5613,O
of,5613,O
similar,5613,O
size,5613,O
in,5613,O
bovine,5613,O
and,5613,O
murine,5613,O
retinae,5613,O
.,5613,O
We,5614,O
investigated,5614,O
the,5614,O
expression,5614,O
pattern,5614,O
in,5614,O
the,5614,O
retina,5614,O
of,5614,O
both,5614,O
RS1,5614,O
mRNA,5614,O
(,5614,O
using,5614,O
in,5614,O
situ,5614,O
hybridization,5614,O
with,5614,O
riboprobes,5614,O
),5614,O
and,5614,O
retinoschisin,5614,O
(,5614,O
using,5614,O
immunohistochemistry,5614,O
),5614,O
.,5614,O
The,5615,O
antisense,5615,O
riboprobe,5615,O
detected,5615,O
RS1,5615,O
mRNA,5615,O
only,5615,O
in,5615,O
the,5615,O
photoreceptor,5615,O
layer,5615,O
but,5615,O
the,5615,O
protein,5615,O
product,5615,O
of,5615,O
the,5615,O
gene,5615,O
was,5615,O
present,5615,O
both,5615,O
in,5615,O
the,5615,O
photoreceptors,5615,O
and,5615,O
within,5615,O
the,5615,O
inner,5615,O
portions,5615,O
of,5615,O
the,5615,O
retina,5615,O
.,5615,O
Furthermore,5616,O
",",5616,O
differentiated,5616,O
retinoblastoma,5616,B-Modifier
cells,5616,O
(,5616,O
Weri-Rb1,5616,O
cells,5616,O
),5616,O
were,5616,O
found,5616,O
to,5616,O
express,5616,O
RS1,5616,O
mRNA,5616,O
and,5616,O
to,5616,O
release,5616,O
retinoschisin,5616,O
.,5616,O
These,5617,O
results,5617,O
suggest,5617,O
that,5617,O
retinoschisin,5617,O
is,5617,O
released,5617,O
by,5617,O
photo-receptors,5617,O
and,5617,O
has,5617,O
functions,5617,O
within,5617,O
the,5617,O
inner,5617,O
retinal,5617,O
layers,5617,O
.,5617,O
Thus,5618,O
",",5618,O
X-linked,5618,B-SpecificDisease
retinoschisis,5618,I-SpecificDisease
is,5618,O
caused,5618,O
by,5618,O
abnormalities,5618,O
in,5618,O
a,5618,O
putative,5618,O
secreted,5618,O
photoreceptor,5618,O
protein,5618,O
and,5618,O
is,5618,O
the,5618,O
first,5618,O
example,5618,O
of,5618,O
a,5618,O
secreted,5618,O
photo-receptor,5618,O
protein,5618,O
associated,5618,O
with,5618,O
a,5618,O
retinal,5618,B-DiseaseClass
dystrophy,5618,I-DiseaseClass
..,5618,O
Study,5619,O
of,5619,O
the,5619,O
voltage-gated,5619,O
sodium,5619,O
channel,5619,O
beta,5619,O
1,5619,O
subunit,5619,O
gene,5619,O
(,5619,O
SCN1B,5619,O
),5619,O
in,5619,O
the,5619,O
benign,5619,B-SpecificDisease
familial,5619,I-SpecificDisease
infantile,5619,I-SpecificDisease
convulsions,5619,I-SpecificDisease
syndrome,5619,I-SpecificDisease
(,5619,O
BFIC,5619,B-SpecificDisease
),5619,O
.,5619,O
Benign,5620,B-SpecificDisease
familial,5620,I-SpecificDisease
infantile,5620,I-SpecificDisease
convulsions,5620,I-SpecificDisease
(,5620,O
BFIC,5620,B-SpecificDisease
),5620,O
is,5620,O
a,5620,O
rare,5620,O
autosomal,5620,B-DiseaseClass
dominant,5620,I-DiseaseClass
epilepsy,5620,I-DiseaseClass
syndrome,5620,I-DiseaseClass
.,5620,O
This,5621,O
syndrome,5621,O
has,5621,O
been,5621,O
recently,5621,O
described,5621,O
in,5621,O
Italian,5621,O
and,5621,O
French,5621,O
pedigrees,5621,O
.,5621,O
Patients,5622,O
present,5622,O
with,5622,O
partial,5622,O
",",5622,O
then,5622,O
generalized,5622,O
seizures,5622,O
",",5622,O
with,5622,O
onset,5622,O
at,5622,O
age,5622,O
three,5622,O
months,5622,O
.,5622,O
The,5623,O
seizures,5623,O
usually,5623,O
spontaneously,5623,O
cease,5623,O
after,5623,O
one,5623,O
year,5623,O
without,5623,O
treatment,5623,O
",",5623,O
leaving,5623,O
no,5623,O
neurological,5623,B-DiseaseClass
abnormalities,5623,I-DiseaseClass
.,5623,O
We,5624,O
have,5624,O
mapped,5624,O
BFIC,5624,B-SpecificDisease
to,5624,O
chromosome,5624,O
19q,5624,O
in,5624,O
five,5624,O
Italian,5624,O
pedigrees,5624,O
.,5624,O
The,5625,O
sodium,5625,O
channel,5625,O
beta1,5625,O
subunit,5625,O
gene,5625,O
(,5625,O
SCN1B,5625,O
),5625,O
maps,5625,O
to,5625,O
this,5625,O
candidate,5625,O
region,5625,O
and,5625,O
has,5625,O
been,5625,O
shown,5625,O
to,5625,O
be,5625,O
involved,5625,O
in,5625,O
one,5625,O
Australian,5625,O
pedigree,5625,O
with,5625,O
generalized,5625,B-SpecificDisease
epilepsy,5625,I-SpecificDisease
and,5625,I-SpecificDisease
febrile,5625,I-SpecificDisease
seizures,5625,I-SpecificDisease
``,5625,O
plus,5625,I-SpecificDisease
``,5625,O
(,5625,O
GEFS,5625,O
+,5625,O
),5625,O
.,5625,O
In,5626,O
this,5626,O
family,5626,O
",",5626,O
a,5626,O
missense,5626,O
mutation,5626,O
in,5626,O
SCN1B,5626,O
cosegregates,5626,O
with,5626,O
the,5626,O
GEFS,5626,O
+,5626,O
phenotype,5626,O
.,5626,O
BFIC,5627,B-SpecificDisease
and,5627,O
GEFS,5627,O
+,5627,O
have,5627,O
clinical,5627,O
features,5627,O
in,5627,O
common,5627,O
",",5627,O
therefore,5627,O
SCN1B,5627,O
is,5627,O
a,5627,O
candidate,5627,O
gene,5627,O
for,5627,O
BFIC,5627,B-SpecificDisease
.,5627,O
We,5628,O
studied,5628,O
SCN1B,5628,O
exons,5628,O
1,5628,O
",",5628,O
2,5628,O
",",5628,O
3,5628,O
",",5628,O
4,5628,O
",",5628,O
and,5628,O
5,5628,O
",",5628,O
using,5628,O
four,5628,O
SSCP,5628,O
methods,5628,O
in,5628,O
10,5628,O
Caucasian,5628,O
BFIC,5628,B-Modifier
probands,5628,O
of,5628,O
Western,5628,O
Europe,5628,O
.,5628,O
We,5629,O
found,5629,O
no,5629,O
exon,5629,O
variants,5629,O
.,5629,O
One,5630,O
variant,5630,O
was,5630,O
identified,5630,O
in,5630,O
intron,5630,O
5,5630,O
(,5630,O
IVS5-10C,5630,O
>,5630,O
G,5630,O
),5630,O
",",5630,O
which,5630,O
did,5630,O
not,5630,O
segregate,5630,O
with,5630,O
BFIC,5630,B-SpecificDisease
and,5630,O
was,5630,O
observed,5630,O
in,5630,O
9,5630,O
.,5630,O
2,5631,O
%,5631,O
controls,5631,O
.,5631,O
A,5632,O
second,5632,O
variant,5632,O
in,5632,O
intron,5632,O
5,5632,O
was,5632,O
identified,5632,O
(,5632,O
IVS5,5632,O
+,5632,O
30G,5632,O
>,5632,O
A,5632,O
),5632,O
.,5632,O
It,5633,O
was,5633,O
rare,5633,O
",",5633,O
as,5633,O
not,5633,O
observed,5633,O
in,5633,O
controls,5633,O
",",5633,O
but,5633,O
not,5633,O
segregating,5633,O
with,5633,O
the,5633,O
BFIC,5633,B-Modifier
phenotype,5633,O
.,5633,O
Inactivation,5634,O
of,5634,O
germline,5634,O
mutant,5634,O
APC,5634,B-Modifier
alleles,5634,O
by,5634,O
attenuated,5634,O
somatic,5634,O
mutations,5634,O
:,5634,O
a,5634,O
molecular,5634,O
genetic,5634,O
mechanism,5634,O
for,5634,O
attenuated,5634,B-SpecificDisease
familial,5634,I-SpecificDisease
adenomatous,5634,I-SpecificDisease
polyposis,5634,I-SpecificDisease
.,5634,O
Germline,5635,O
mutations,5635,O
of,5635,O
the,5635,O
adenomatous,5635,B-Modifier
polyposis,5635,I-Modifier
coli,5635,I-Modifier
(,5635,I-Modifier
APC,5635,I-Modifier
),5635,I-Modifier
tumor-suppressor,5635,O
gene,5635,O
result,5635,O
in,5635,O
familial,5635,B-SpecificDisease
adenomatous,5635,I-SpecificDisease
polyposis,5635,I-SpecificDisease
(,5635,O
FAP,5635,B-SpecificDisease
),5635,O
.,5635,O
Patients,5636,O
with,5636,O
FAP,5636,B-SpecificDisease
typically,5636,O
develop,5636,O
hundreds,5636,O
to,5636,O
thousands,5636,O
of,5636,O
benign,5636,B-SpecificDisease
colorectal,5636,I-SpecificDisease
tumors,5636,I-SpecificDisease
and,5636,O
early-onset,5636,O
colorectal,5636,B-SpecificDisease
cancer,5636,I-SpecificDisease
.,5636,O
A,5637,O
subset,5637,O
of,5637,O
germline,5637,O
APC,5637,B-Modifier
mutations,5637,O
results,5637,O
in,5637,O
an,5637,O
attenuated,5637,B-Modifier
FAP,5637,I-Modifier
(,5637,O
AFAP,5637,B-Modifier
),5637,O
phenotype,5637,O
",",5637,O
in,5637,O
which,5637,O
patients,5637,O
develop,5637,O
fewer,5637,O
tumors,5637,B-DiseaseClass
and,5637,O
develop,5637,O
them,5637,O
at,5637,O
an,5637,O
older,5637,O
age,5637,O
.,5637,O
Although,5638,O
a,5638,O
genotype-phenotype,5638,O
correlation,5638,O
between,5638,O
the,5638,O
locations,5638,O
of,5638,O
APC,5638,B-Modifier
germline,5638,O
mutations,5638,O
and,5638,O
the,5638,O
development,5638,O
of,5638,O
AFAP,5638,B-SpecificDisease
has,5638,O
been,5638,O
well,5638,O
documented,5638,O
",",5638,O
the,5638,O
mechanism,5638,O
for,5638,O
AFAP,5638,B-SpecificDisease
has,5638,O
not,5638,O
been,5638,O
well,5638,O
defined,5638,O
.,5638,O
We,5639,O
investigated,5639,O
the,5639,O
mechanism,5639,O
for,5639,O
AFAP,5639,B-SpecificDisease
in,5639,O
patients,5639,O
carrying,5639,O
a,5639,O
mutant,5639,O
APC,5639,B-Modifier
allele,5639,O
(,5639,O
APC,5639,O
(,5639,O
AS9,5639,O
),5639,O
),5639,O
that,5639,O
has,5639,O
a,5639,O
mutation,5639,O
in,5639,O
the,5639,O
alternatively,5639,O
spliced,5639,O
region,5639,O
of,5639,O
exon,5639,O
9,5639,O
.,5639,O
APC,5640,O
(,5640,O
AS9,5640,O
),5640,O
was,5640,O
found,5640,O
to,5640,O
down-regulate,5640,O
beta-catenin-regulated,5640,O
transcription,5640,O
",",5640,O
the,5640,O
major,5640,O
tumor-suppressor,5640,B-Modifier
function,5640,O
of,5640,O
APC,5640,O
",",5640,O
as,5640,O
did,5640,O
the,5640,O
wild-type,5640,O
APC,5640,O
.,5640,O
Mutation,5641,O
analysis,5641,O
showed,5641,O
that,5641,O
both,5641,O
APC,5641,O
(,5641,O
AS9,5641,O
),5641,O
and,5641,O
the,5641,O
wild-type,5641,O
APC,5641,B-Modifier
alleles,5641,O
were,5641,O
somatically,5641,O
mutated,5641,O
in,5641,O
most,5641,O
colorectal,5641,B-SpecificDisease
tumors,5641,I-SpecificDisease
from,5641,O
these,5641,O
patients,5641,O
.,5641,O
Functional,5642,O
analysis,5642,O
showed,5642,O
that,5642,O
4666insA,5642,O
",",5642,O
a,5642,O
common,5642,O
somatic,5642,O
mutation,5642,O
in,5642,O
APC,5642,O
(,5642,O
AS9,5642,O
),5642,O
in,5642,O
these,5642,O
tumors,5642,B-DiseaseClass
",",5642,O
did,5642,O
not,5642,O
inactivate,5642,O
the,5642,O
wild-type,5642,O
APC,5642,O
.,5642,O
Our,5643,O
results,5643,O
indicate,5643,O
that,5643,O
carriers,5643,O
of,5643,O
APC,5643,O
(,5643,O
AS9,5643,O
),5643,O
develop,5643,O
fewer,5643,O
colorectal,5643,B-SpecificDisease
tumors,5643,I-SpecificDisease
than,5643,O
do,5643,O
typical,5643,O
patients,5643,O
with,5643,O
FAP,5643,B-SpecificDisease
because,5643,O
somatic,5643,O
inactivation,5643,O
of,5643,O
both,5643,O
APC,5643,B-Modifier
alleles,5643,O
is,5643,O
necessary,5643,O
for,5643,O
colorectal,5643,O
tumorigenesis,5643,O
.,5643,O
However,5644,O
",",5644,O
these,5644,O
patients,5644,O
develop,5644,O
colorectal,5644,B-SpecificDisease
tumors,5644,I-SpecificDisease
more,5644,O
frequently,5644,O
than,5644,O
does,5644,O
the,5644,O
general,5644,O
population,5644,O
because,5644,O
APC,5644,O
(,5644,O
AS9,5644,O
),5644,O
is,5644,O
inactivated,5644,O
by,5644,O
mutations,5644,O
that,5644,O
do,5644,O
not,5644,O
inactivate,5644,O
the,5644,O
wild-type,5644,O
APC,5644,O
..,5644,O
Iron-dependent,5645,O
self-assembly,5645,O
of,5645,O
recombinant,5645,O
yeast,5645,O
frataxin,5645,O
:,5645,O
implications,5645,O
for,5645,O
Friedreich,5645,B-SpecificDisease
ataxia,5645,I-SpecificDisease
.,5645,O
Frataxin,5646,B-SpecificDisease
deficiency,5646,I-SpecificDisease
is,5646,O
the,5646,O
primary,5646,O
cause,5646,O
of,5646,O
Friedreich,5646,B-SpecificDisease
ataxia,5646,I-SpecificDisease
(,5646,O
FRDA,5646,B-SpecificDisease
),5646,O
",",5646,O
an,5646,O
autosomal,5646,B-DiseaseClass
recessive,5646,I-DiseaseClass
cardiodegenerative,5646,I-DiseaseClass
and,5646,I-DiseaseClass
neurodegenerative,5646,I-DiseaseClass
disease,5646,I-DiseaseClass
.,5646,O
Frataxin,5647,O
is,5647,O
a,5647,O
nuclear-encoded,5647,O
mitochondrial,5647,O
protein,5647,O
that,5647,O
is,5647,O
widely,5647,O
conserved,5647,O
among,5647,O
eukaryotes,5647,O
.,5647,O
Genetic,5648,O
inactivation,5648,O
of,5648,O
the,5648,O
yeast,5648,O
frataxin,5648,O
homologue,5648,O
(,5648,O
Yfh1p,5648,O
),5648,O
results,5648,O
in,5648,O
mitochondrial,5648,B-SpecificDisease
iron,5648,I-SpecificDisease
accumulation,5648,I-SpecificDisease
and,5648,O
hypersensitivity,5648,B-SpecificDisease
to,5648,I-SpecificDisease
oxidative,5648,I-SpecificDisease
stress,5648,I-SpecificDisease
.,5648,O
Increased,5649,O
iron,5649,O
deposition,5649,O
and,5649,O
evidence,5649,O
of,5649,O
oxidative,5649,O
damage,5649,O
have,5649,O
also,5649,O
been,5649,O
observed,5649,O
in,5649,O
cardiac,5649,O
tissue,5649,O
and,5649,O
cultured,5649,O
fibroblasts,5649,O
from,5649,O
patients,5649,O
with,5649,O
FRDA,5649,B-SpecificDisease
.,5649,O
These,5650,O
findings,5650,O
indicate,5650,O
that,5650,O
frataxin,5650,O
is,5650,O
essential,5650,O
for,5650,O
mitochondrial,5650,O
iron,5650,O
homeostasis,5650,O
and,5650,O
protection,5650,O
from,5650,O
iron-induced,5650,O
formation,5650,O
of,5650,O
free,5650,O
radicals,5650,O
.,5650,O
The,5651,O
functional,5651,O
mechanism,5651,O
of,5651,O
frataxin,5651,O
",",5651,O
however,5651,O
",",5651,O
is,5651,O
still,5651,O
unknown,5651,O
.,5651,O
We,5652,O
have,5652,O
expressed,5652,O
the,5652,O
mature,5652,O
form,5652,O
of,5652,O
Yfh1p,5652,O
(,5652,O
mYfh1p,5652,O
),5652,O
in,5652,O
Escherichia,5652,O
coli,5652,O
and,5652,O
have,5652,O
analyzed,5652,O
its,5652,O
function,5652,O
in,5652,O
vitro,5652,O
.,5652,O
Isolated,5653,O
mYfh1p,5653,O
is,5653,O
a,5653,O
soluble,5653,O
monomer,5653,O
(,5653,O
13,5653,O
",",5653,O
783,5653,O
Da,5653,O
),5653,O
that,5653,O
contains,5653,O
no,5653,O
iron,5653,O
and,5653,O
shows,5653,O
no,5653,O
significant,5653,O
tendency,5653,O
to,5653,O
self-associate,5653,O
.,5653,O
Aerobic,5654,O
addition,5654,O
of,5654,O
ferrous,5654,O
iron,5654,O
to,5654,O
mYfh1p,5654,O
results,5654,O
in,5654,O
assembly,5654,O
of,5654,O
regular,5654,O
spherical,5654,O
multimers,5654,O
with,5654,O
a,5654,O
molecular,5654,O
mass,5654,O
of,5654,O
approximately,5654,O
1,5654,O
.,5654,O
1,5655,O
MDa,5655,O
(,5655,O
megadaltons,5655,O
),5655,O
and,5655,O
a,5655,O
diameter,5655,O
of,5655,O
13,5655,O
+/-2,5655,O
nm,5655,O
.,5655,O
Each,5656,O
multimer,5656,O
consists,5656,O
of,5656,O
approximately,5656,O
60,5656,O
subunits,5656,O
and,5656,O
can,5656,O
sequester,5656,O
>,5656,O
3,5656,O
",",5656,O
000,5656,O
atoms,5656,O
of,5656,O
iron,5656,O
.,5656,O
Titration,5657,O
of,5657,O
mYfh1p,5657,O
with,5657,O
increasing,5657,O
iron,5657,O
concentrations,5657,O
supports,5657,O
a,5657,O
stepwise,5657,O
mechanism,5657,O
of,5657,O
multimer,5657,O
assembly,5657,O
.,5657,O
Sequential,5658,O
addition,5658,O
of,5658,O
an,5658,O
iron,5658,O
chelator,5658,O
and,5658,O
a,5658,O
reducing,5658,O
agent,5658,O
results,5658,O
in,5658,O
quantitative,5658,O
iron,5658,O
release,5658,O
with,5658,O
concomitant,5658,O
disassembly,5658,O
of,5658,O
the,5658,O
multimer,5658,O
",",5658,O
indicating,5658,O
that,5658,O
mYfh1p,5658,O
sequesters,5658,O
iron,5658,O
in,5658,O
an,5658,O
available,5658,O
form,5658,O
.,5658,O
In,5659,O
yeast,5659,O
mitochondria,5659,O
",",5659,O
native,5659,O
mYfh1p,5659,O
exists,5659,O
as,5659,O
monomer,5659,O
and,5659,O
a,5659,O
higher-order,5659,O
species,5659,O
with,5659,O
a,5659,O
molecular,5659,O
weight,5659,O
>,5659,O
600,5659,O
",",5659,O
000,5659,O
.,5659,O
After,5660,O
addition,5660,O
of,5660,O
(,5660,O
55,5660,O
),5660,O
Fe,5660,O
to,5660,O
the,5660,O
medium,5660,O
",",5660,O
immunoprecipitates,5660,O
of,5660,O
this,5660,O
species,5660,O
contain,5660,O
>,5660,O
16,5660,O
atoms,5660,O
of,5660,O
(,5660,O
55,5660,O
),5660,O
Fe,5660,O
per,5660,O
molecule,5660,O
of,5660,O
mYfh1p,5660,O
.,5660,O
We,5661,O
propose,5661,O
that,5661,O
iron-dependent,5661,O
self-assembly,5661,O
of,5661,O
recombinant,5661,O
mYfh1p,5661,O
reflects,5661,O
a,5661,O
physiological,5661,O
role,5661,O
for,5661,O
frataxin,5661,O
in,5661,O
mitochondrial,5661,O
iron,5661,O
sequestration,5661,O
and,5661,O
bioavailability,5661,O
..,5661,O
A,5662,O
mutation,5662,O
in,5662,O
the,5662,O
pleckstrin,5662,O
homology,5662,O
(,5662,O
PH,5662,O
),5662,O
domain,5662,O
of,5662,O
the,5662,O
FGD1,5662,O
gene,5662,O
in,5662,O
an,5662,O
Italian,5662,O
family,5662,O
with,5662,O
faciogenital,5662,B-SpecificDisease
dysplasia,5662,I-SpecificDisease
(,5662,O
Aarskog-Scott,5662,B-SpecificDisease
syndrome,5662,I-SpecificDisease
),5662,O
.,5662,O
Aarskog-Scott,5663,B-SpecificDisease
Syndrome,5663,I-SpecificDisease
(,5663,O
AAS,5663,B-SpecificDisease
),5663,O
is,5663,O
an,5663,O
X-linked,5663,B-DiseaseClass
disorder,5663,I-DiseaseClass
characterised,5663,O
by,5663,O
short,5663,B-DiseaseClass
stature,5663,I-DiseaseClass
and,5663,O
multiple,5663,O
facial,5663,O
",",5663,O
limb,5663,O
and,5663,O
genital,5663,O
abnormalities,5663,O
.,5663,O
A,5664,O
gene,5664,O
",",5664,O
FGD1,5664,O
",",5664,O
altered,5664,O
in,5664,O
a,5664,O
patient,5664,O
with,5664,O
AAS,5664,B-Modifier
phenotype,5664,O
",",5664,O
has,5664,O
been,5664,O
identified,5664,O
and,5664,O
found,5664,O
to,5664,O
encode,5664,O
a,5664,O
protein,5664,O
with,5664,O
homology,5664,O
to,5664,O
Rho/Rac,5664,O
guanine,5664,O
nucleotide,5664,O
exchange,5664,O
factors,5664,O
(,5664,O
Rho/Rac,5664,O
GEF,5664,O
),5664,O
.,5664,O
However,5665,O
",",5665,O
since,5665,O
this,5665,O
original,5665,O
report,5665,O
on,5665,O
identification,5665,O
of,5665,O
a,5665,O
mutated,5665,O
FGD1,5665,O
gene,5665,O
in,5665,O
an,5665,O
AAS,5665,B-Modifier
patient,5665,O
",",5665,O
no,5665,O
additional,5665,O
mutations,5665,O
in,5665,O
the,5665,O
FGD1,5665,O
gene,5665,O
have,5665,O
been,5665,O
described,5665,O
.,5665,O
We,5666,O
analysed,5666,O
13,5666,O
independent,5666,O
patients,5666,O
with,5666,O
clinical,5666,O
diagnosis,5666,O
of,5666,O
AAS,5666,B-SpecificDisease
.,5666,O
One,5667,O
patient,5667,O
presented,5667,O
a,5667,O
mutation,5667,O
that,5667,O
results,5667,O
in,5667,O
a,5667,O
nucleotide,5667,O
change,5667,O
in,5667,O
exon,5667,O
10,5667,O
of,5667,O
the,5667,O
FGD1,5667,O
gene,5667,O
(,5667,O
G2559,5667,O
>,5667,O
A,5667,O
),5667,O
substituting,5667,O
a,5667,O
Gln,5667,O
for,5667,O
Arg,5667,O
in,5667,O
position,5667,O
610,5667,O
.,5667,O
The,5668,O
mutation,5668,O
was,5668,O
found,5668,O
to,5668,O
segregate,5668,O
with,5668,O
the,5668,O
AAS,5668,B-Modifier
phenotype,5668,O
in,5668,O
affected,5668,O
males,5668,O
and,5668,O
carrier,5668,O
females,5668,O
in,5668,O
the,5668,O
family,5668,O
of,5668,O
this,5668,O
patient,5668,O
.,5668,O
Interestingly,5669,O
",",5669,O
Arg-610,5669,O
is,5669,O
located,5669,O
within,5669,O
one,5669,O
of,5669,O
the,5669,O
two,5669,O
pleckstrin,5669,O
homology,5669,O
(,5669,O
PH,5669,O
),5669,O
domains,5669,O
of,5669,O
the,5669,O
FGD1,5669,O
gene,5669,O
and,5669,O
it,5669,O
corresponds,5669,O
to,5669,O
a,5669,O
highly,5669,O
conserved,5669,O
residue,5669,O
which,5669,O
has,5669,O
been,5669,O
involved,5669,O
in,5669,O
InsP,5669,O
binding,5669,O
in,5669,O
PH,5669,O
domains,5669,O
of,5669,O
other,5669,O
proteins,5669,O
.,5669,O
The,5670,O
same,5670,O
residue,5670,O
is,5670,O
often,5670,O
mutated,5670,O
in,5670,O
the,5670,O
Brutons,5670,O
tyrosine,5670,O
kinase,5670,O
(,5670,O
Btk,5670,O
),5670,O
gene,5670,O
in,5670,O
patients,5670,O
with,5670,O
an,5670,O
X-linked,5670,B-SpecificDisease
agammaglobulinemia,5670,I-SpecificDisease
.,5670,O
The,5671,O
Arg610Gln,5671,O
mutation,5671,O
represents,5671,O
the,5671,O
first,5671,O
case,5671,O
of,5671,O
a,5671,O
mutation,5671,O
in,5671,O
the,5671,O
PH,5671,O
domain,5671,O
of,5671,O
the,5671,O
FGD1,5671,O
gene,5671,O
and,5671,O
additional,5671,O
evidence,5671,O
that,5671,O
mutations,5671,O
in,5671,O
PH,5671,O
domains,5671,O
can,5671,O
be,5671,O
associated,5671,O
to,5671,O
human,5671,O
diseases,5671,O
..,5671,O
Amino-terminal,5672,O
fragments,5672,O
of,5672,O
mutant,5672,O
huntingtin,5672,O
show,5672,O
selective,5672,O
accumulation,5672,O
in,5672,O
striatal,5672,O
neurons,5672,O
and,5672,O
synaptic,5672,O
toxicity,5672,O
.,5672,O
Huntington,5673,B-SpecificDisease
disease,5673,I-SpecificDisease
(,5673,O
HD,5673,B-SpecificDisease
),5673,O
is,5673,O
caused,5673,O
by,5673,O
expansion,5673,O
of,5673,O
a,5673,O
glutamine,5673,O
repeat,5673,O
in,5673,O
the,5673,O
amino-terminal,5673,O
region,5673,O
of,5673,O
huntingtin,5673,O
.,5673,O
Despite,5674,O
its,5674,O
widespread,5674,O
expression,5674,O
",",5674,O
mutant,5674,O
huntingtin,5674,O
induces,5674,O
selective,5674,O
neuronal,5674,O
loss,5674,O
in,5674,O
striatal,5674,O
neurons,5674,O
.,5674,O
Here,5675,O
we,5675,O
report,5675,O
that,5675,O
",",5675,O
in,5675,O
mutant,5675,O
mice,5675,O
expressing,5675,O
HD,5675,B-Modifier
repeats,5675,O
",",5675,O
the,5675,O
production,5675,O
and,5675,O
aggregation,5675,O
of,5675,O
N-terminal,5675,O
huntingtin,5675,O
fragments,5675,O
preferentially,5675,O
occur,5675,O
in,5675,O
HD-affected,5675,B-Modifier
neurons,5675,O
and,5675,O
their,5675,O
processes,5675,O
and,5675,O
axonal,5675,O
terminals,5675,O
.,5675,O
N-terminal,5676,O
fragments,5676,O
of,5676,O
mutant,5676,O
huntingtin,5676,O
form,5676,O
aggregates,5676,O
and,5676,O
induce,5676,O
neuritic,5676,B-DiseaseClass
degeneration,5676,I-DiseaseClass
in,5676,O
cultured,5676,O
striatal,5676,O
neurons,5676,O
.,5676,O
N-terminal,5677,O
mutant,5677,O
huntingtin,5677,O
also,5677,O
binds,5677,O
to,5677,O
synaptic,5677,O
vesicles,5677,O
and,5677,O
inhibits,5677,O
their,5677,O
glutamate,5677,O
uptake,5677,O
in,5677,O
vitro,5677,O
.,5677,O
The,5678,O
specific,5678,O
processing,5678,O
and,5678,O
accumulation,5678,O
of,5678,O
toxic,5678,O
fragments,5678,O
of,5678,O
N-terminal,5678,O
huntingtin,5678,O
in,5678,O
HD-affected,5678,B-Modifier
striatal,5678,O
neurons,5678,O
",",5678,O
especially,5678,O
in,5678,O
their,5678,O
neuronal,5678,O
processes,5678,O
and,5678,O
axonal,5678,O
terminals,5678,O
",",5678,O
may,5678,O
contribute,5678,O
to,5678,O
the,5678,O
selective,5678,O
neuropathology,5678,O
of,5678,O
HD,5678,B-SpecificDisease
..,5678,O
BRCA1,5679,O
is,5679,O
associated,5679,O
with,5679,O
a,5679,O
human,5679,O
SWI/SNF-related,5679,O
complex,5679,O
:,5679,O
linking,5679,O
chromatin,5679,O
remodeling,5679,O
to,5679,O
breast,5679,B-SpecificDisease
cancer,5679,I-SpecificDisease
.,5679,O
Germline,5680,O
mutations,5680,O
in,5680,O
the,5680,O
tumor,5680,B-Modifier
suppressor,5680,O
gene,5680,O
",",5680,O
BRCA1,5680,O
",",5680,O
predispose,5680,O
individuals,5680,O
to,5680,O
breast,5680,O
and,5680,O
ovarian,5680,O
cancers,5680,O
.,5680,O
Using,5681,O
a,5681,O
combination,5681,O
of,5681,O
affinity-,5681,O
and,5681,O
conventional,5681,O
chromatographic,5681,O
techniques,5681,O
",",5681,O
we,5681,O
have,5681,O
isolated,5681,O
a,5681,O
predominant,5681,O
form,5681,O
of,5681,O
a,5681,O
multiprotein,5681,O
BRCA1-containing,5681,O
complex,5681,O
from,5681,O
human,5681,O
cells,5681,O
displaying,5681,O
chromatin-remodeling,5681,O
activity,5681,O
.,5681,O
Mass,5682,O
spectrometric,5682,O
sequencing,5682,O
of,5682,O
components,5682,O
of,5682,O
this,5682,O
complex,5682,O
indicated,5682,O
that,5682,O
BRCA1,5682,O
is,5682,O
associated,5682,O
with,5682,O
a,5682,O
SWI/SNF-related,5682,O
complex,5682,O
.,5682,O
We,5683,O
show,5683,O
that,5683,O
BRCA1,5683,O
can,5683,O
directly,5683,O
interact,5683,O
with,5683,O
the,5683,O
BRG1,5683,O
subunit,5683,O
of,5683,O
the,5683,O
SWI/SNF,5683,O
complex,5683,O
.,5683,O
Moreover,5684,O
",",5684,O
p53-mediated,5684,O
stimulation,5684,O
of,5684,O
transcription,5684,O
by,5684,O
BRCA1,5684,O
was,5684,O
completely,5684,O
abrogated,5684,O
by,5684,O
either,5684,O
a,5684,O
dominant-negative,5684,O
mutant,5684,O
of,5684,O
BRG1,5684,O
or,5684,O
the,5684,O
cancer-causing,5684,B-DiseaseClass
deletion,5684,O
in,5684,O
exon,5684,O
11,5684,O
of,5684,O
BRCA1,5684,O
.,5684,O
These,5685,O
findings,5685,O
reveal,5685,O
a,5685,O
direct,5685,O
function,5685,O
for,5685,O
BRCA1,5685,O
in,5685,O
transcriptional,5685,O
control,5685,O
through,5685,O
modulation,5685,O
of,5685,O
chromatin,5685,O
structure,5685,O
..,5685,O
Asef,5686,O
",",5686,O
a,5686,O
link,5686,O
between,5686,O
the,5686,O
tumor,5686,B-Modifier
suppressor,5686,O
APC,5686,O
and,5686,O
G-protein,5686,O
signaling,5686,O
.,5686,O
The,5687,O
adenomatous,5687,B-Modifier
polyposis,5687,I-Modifier
coli,5687,I-Modifier
gene,5687,O
(,5687,O
APC,5687,O
),5687,O
is,5687,O
mutated,5687,O
in,5687,O
familial,5687,B-SpecificDisease
adenomatous,5687,I-SpecificDisease
polyposis,5687,I-SpecificDisease
and,5687,O
in,5687,O
sporadic,5687,O
colorectal,5687,B-SpecificDisease
tumors,5687,I-SpecificDisease
.,5687,O
Here,5688,O
the,5688,O
APC,5688,B-Modifier
gene,5688,O
product,5688,O
is,5688,O
shown,5688,O
to,5688,O
bind,5688,O
through,5688,O
its,5688,O
armadillo,5688,O
repeat,5688,O
domain,5688,O
to,5688,O
a,5688,O
Rac-specific,5688,O
guanine,5688,O
nucleotide,5688,O
exchange,5688,O
factor,5688,O
(,5688,O
GEF,5688,O
),5688,O
",",5688,O
termed,5688,O
Asef,5688,O
.,5688,O
Endogenous,5689,O
APC,5689,O
colocalized,5689,O
with,5689,O
Asef,5689,O
in,5689,O
mouse,5689,O
colon,5689,O
epithelial,5689,O
cells,5689,O
and,5689,O
neuronal,5689,O
cells,5689,O
.,5689,O
Furthermore,5690,O
",",5690,O
APC,5690,O
enhanced,5690,O
the,5690,O
GEF,5690,O
activity,5690,O
of,5690,O
Asef,5690,O
and,5690,O
stimulated,5690,O
Asef-mediated,5690,O
cell,5690,O
flattening,5690,O
",",5690,O
membrane,5690,O
ruffling,5690,O
",",5690,O
and,5690,O
lamellipodia,5690,O
formation,5690,O
in,5690,O
MDCK,5690,O
cells,5690,O
.,5690,O
These,5691,O
results,5691,O
suggest,5691,O
that,5691,O
the,5691,O
APC-Asef,5691,O
complex,5691,O
may,5691,O
regulate,5691,O
the,5691,O
actin,5691,O
cytoskeletal,5691,O
network,5691,O
",",5691,O
cell,5691,O
morphology,5691,O
and,5691,O
migration,5691,O
",",5691,O
and,5691,O
neuronal,5691,O
function,5691,O
..,5691,O
Function,5692,O
of,5692,O
an,5692,O
axonal,5692,O
chemoattractant,5692,O
modulated,5692,O
by,5692,O
metalloprotease,5692,O
activity,5692,O
.,5692,O
The,5693,O
axonal,5693,O
chemoattractant,5693,O
netrin-1,5693,O
guides,5693,O
spinal,5693,O
commissural,5693,O
axons,5693,O
by,5693,O
activating,5693,O
its,5693,O
receptor,5693,O
DCC,5693,O
(,5693,O
Deleted,5693,O
in,5693,O
Colorectal,5693,B-SpecificDisease
Cancer,5693,I-SpecificDisease
),5693,O
.,5693,O
We,5694,O
have,5694,O
found,5694,O
that,5694,O
chemical,5694,O
inhibitors,5694,O
of,5694,O
metalloproteases,5694,O
potentiate,5694,O
netrin-mediated,5694,O
axon,5694,O
outgrowth,5694,O
in,5694,O
vitro,5694,O
.,5694,O
We,5695,O
have,5695,O
also,5695,O
found,5695,O
that,5695,O
DCC,5695,O
is,5695,O
a,5695,O
substrate,5695,O
for,5695,O
metalloprotease-dependent,5695,O
ectodomain,5695,O
shedding,5695,O
",",5695,O
and,5695,O
that,5695,O
the,5695,O
inhibitors,5695,O
block,5695,O
proteolytic,5695,O
processing,5695,O
of,5695,O
DCC,5695,O
and,5695,O
cause,5695,O
an,5695,O
increase,5695,O
in,5695,O
DCC,5695,O
protein,5695,O
levels,5695,O
on,5695,O
axons,5695,O
within,5695,O
spinal,5695,O
cord,5695,O
explants,5695,O
.,5695,O
Thus,5696,O
",",5696,O
potentiation,5696,O
of,5696,O
netrin,5696,O
activity,5696,O
by,5696,O
inhibitors,5696,O
may,5696,O
result,5696,O
from,5696,O
stabilization,5696,O
of,5696,O
DCC,5696,O
on,5696,O
the,5696,O
axons,5696,O
",",5696,O
and,5696,O
proteolytic,5696,O
activity,5696,O
may,5696,O
regulate,5696,O
axon,5696,O
migration,5696,O
by,5696,O
controlling,5696,O
the,5696,O
number,5696,O
of,5696,O
functional,5696,O
extracellular,5696,O
axon,5696,O
guidance,5696,O
receptors,5696,O
..,5696,O
Myotonic,5697,B-SpecificDisease
dystrophy,5697,I-SpecificDisease
in,5697,O
transgenic,5697,O
mice,5697,O
expressing,5697,O
an,5697,O
expanded,5697,O
CUG,5697,O
repeat,5697,O
.,5697,O
Myotonic,5698,B-SpecificDisease
dystrophy,5698,I-SpecificDisease
(,5698,O
DM,5698,B-SpecificDisease
),5698,O
",",5698,O
the,5698,O
most,5698,O
common,5698,O
form,5698,O
of,5698,O
muscular,5698,B-SpecificDisease
dystrophy,5698,I-SpecificDisease
in,5698,O
adult,5698,O
humans,5698,O
",",5698,O
results,5698,O
from,5698,O
expansion,5698,O
of,5698,O
a,5698,O
CTG,5698,O
repeat,5698,O
in,5698,O
the,5698,O
3,5698,O
untranslated,5698,O
region,5698,O
of,5698,O
the,5698,O
DMPK,5698,O
gene,5698,O
.,5698,O
The,5699,O
mutant,5699,O
DMPK,5699,O
messenger,5699,O
RNA,5699,O
(,5699,O
mRNA,5699,O
),5699,O
contains,5699,O
an,5699,O
expanded,5699,O
CUG,5699,O
repeat,5699,O
and,5699,O
is,5699,O
retained,5699,O
in,5699,O
the,5699,O
nucleus,5699,O
.,5699,O
We,5700,O
have,5700,O
expressed,5700,O
an,5700,O
untranslated,5700,O
CUG,5700,O
repeat,5700,O
in,5700,O
an,5700,O
unrelated,5700,O
mRNA,5700,O
in,5700,O
transgenic,5700,O
mice,5700,O
.,5700,O
Mice,5701,O
that,5701,O
expressed,5701,O
expanded,5701,O
CUG,5701,O
repeats,5701,O
developed,5701,O
myotonia,5701,B-DiseaseClass
and,5701,O
myopathy,5701,B-DiseaseClass
",",5701,O
whereas,5701,O
mice,5701,O
expressing,5701,O
a,5701,O
nonexpanded,5701,O
repeat,5701,O
did,5701,O
not,5701,O
.,5701,O
Thus,5702,O
",",5702,O
transcripts,5702,O
with,5702,O
expanded,5702,O
CUG,5702,O
repeats,5702,O
are,5702,O
sufficient,5702,O
to,5702,O
generate,5702,O
a,5702,O
DM,5702,B-Modifier
phenotype,5702,O
.,5702,O
This,5703,O
result,5703,O
supports,5703,O
a,5703,O
role,5703,O
for,5703,O
RNA,5703,O
gain,5703,O
of,5703,O
function,5703,O
in,5703,O
disease,5703,O
pathogenesis,5703,O
..,5703,O
Genomic,5704,O
rearrangements,5704,O
of,5704,O
the,5704,O
APC,5704,B-Modifier
tumor-suppressor,5704,O
gene,5704,O
in,5704,O
familial,5704,B-SpecificDisease
adenomatous,5704,I-SpecificDisease
polyposis,5704,I-SpecificDisease
.,5704,O
Germline,5705,O
mutations,5705,O
of,5705,O
the,5705,O
adenomatous,5705,B-Modifier
polyposis,5705,I-Modifier
coli,5705,I-Modifier
(,5705,I-Modifier
APC,5705,I-Modifier
),5705,I-Modifier
tumor-suppressor,5705,O
gene,5705,O
result,5705,O
in,5705,O
the,5705,O
hereditary,5705,B-SpecificDisease
colorectal,5705,I-SpecificDisease
cancer,5705,I-SpecificDisease
syndrome,5705,I-SpecificDisease
familial,5705,B-SpecificDisease
adenomatous,5705,I-SpecificDisease
polyposis,5705,I-SpecificDisease
(,5705,O
FAP,5705,B-SpecificDisease
),5705,O
.,5705,O
Almost,5706,O
all,5706,O
APC,5706,B-Modifier
mutations,5706,O
that,5706,O
have,5706,O
been,5706,O
identified,5706,O
are,5706,O
single-nucleotide,5706,O
alterations,5706,O
",",5706,O
small,5706,O
insertions,5706,O
",",5706,O
or,5706,O
small,5706,O
deletions,5706,O
that,5706,O
would,5706,O
truncate,5706,O
the,5706,O
protein,5706,O
product,5706,O
of,5706,O
the,5706,O
gene,5706,O
.,5706,O
No,5707,O
well-characterized,5707,O
intragenic,5707,O
rearrangement,5707,O
of,5707,O
APC,5707,O
has,5707,O
been,5707,O
described,5707,O
",",5707,O
and,5707,O
the,5707,O
prevalence,5707,O
of,5707,O
this,5707,O
type,5707,O
of,5707,O
mutation,5707,O
in,5707,O
FAP,5707,B-Modifier
patients,5707,O
is,5707,O
not,5707,O
clear,5707,O
.,5707,O
We,5708,O
screened,5708,O
49,5708,O
potential,5708,O
FAP,5708,B-Modifier
families,5708,O
and,5708,O
identified,5708,O
26,5708,O
different,5708,O
germline,5708,O
APC,5708,B-Modifier
mutations,5708,O
in,5708,O
30,5708,O
families,5708,O
.,5708,O
Four,5709,O
of,5709,O
these,5709,O
mutations,5709,O
were,5709,O
genomic,5709,O
rearrangements,5709,O
resulting,5709,O
from,5709,O
homologous,5709,O
and,5709,O
nonhomologous,5709,O
recombinations,5709,O
mediated,5709,O
by,5709,O
Alu,5709,O
elements,5709,O
.,5709,O
Two,5710,O
of,5710,O
these,5710,O
four,5710,O
rearrangements,5710,O
were,5710,O
complex,5710,O
",",5710,O
involving,5710,O
deletion,5710,O
and,5710,O
insertion,5710,O
of,5710,O
nucleotides,5710,O
.,5710,O
Of,5711,O
these,5711,O
four,5711,O
rearrangements,5711,O
",",5711,O
one,5711,O
resulted,5711,O
in,5711,O
the,5711,O
deletion,5711,O
of,5711,O
exons,5711,O
11,5711,O
and,5711,O
12,5711,O
and,5711,O
two,5711,O
others,5711,O
resulted,5711,O
in,5711,O
either,5711,O
complete,5711,O
or,5711,O
partial,5711,O
deletion,5711,O
of,5711,O
exon,5711,O
14,5711,O
.,5711,O
The,5712,O
fourth,5712,O
rearrangement,5712,O
grossly,5712,O
altered,5712,O
the,5712,O
sequence,5712,O
within,5712,O
intron,5712,O
14,5712,O
.,5712,O
Although,5713,O
this,5713,O
rearrangement,5713,O
did,5713,O
not,5713,O
affect,5713,O
any,5713,O
coding,5713,O
sequence,5713,O
of,5713,O
APC,5713,O
at,5713,O
the,5713,O
genomic,5713,O
DNA,5713,O
level,5713,O
",",5713,O
it,5713,O
caused,5713,O
inappropriate,5713,O
splicing,5713,O
of,5713,O
exon,5713,O
14,5713,O
.,5713,O
These,5714,O
rearrangements,5714,O
were,5714,O
initially,5714,O
revealed,5714,O
by,5714,O
analyzing,5714,O
cDNAs,5714,O
and,5714,O
could,5714,O
not,5714,O
have,5714,O
been,5714,O
identified,5714,O
by,5714,O
using,5714,O
mutation,5714,O
detection,5714,O
methods,5714,O
that,5714,O
screened,5714,O
each,5714,O
exon,5714,O
individually,5714,O
.,5714,O
The,5715,O
identification,5715,O
of,5715,O
a,5715,O
rearrangement,5715,O
that,5715,O
did,5715,O
not,5715,O
alter,5715,O
any,5715,O
coding,5715,O
exons,5715,O
yet,5715,O
affected,5715,O
the,5715,O
splicing,5715,O
further,5715,O
underscores,5715,O
the,5715,O
importance,5715,O
of,5715,O
using,5715,O
cDNA,5715,O
for,5715,O
mutation,5715,O
analysis,5715,O
.,5715,O
The,5716,O
identification,5716,O
of,5716,O
four,5716,O
genomic,5716,O
rearrangements,5716,O
among,5716,O
30,5716,O
mutations,5716,O
suggests,5716,O
that,5716,O
genomic,5716,O
rearrangements,5716,O
are,5716,O
frequent,5716,O
germline,5716,O
APC,5716,B-Modifier
mutations,5716,O
..,5716,O
Detection,5717,O
of,5717,O
a,5717,O
novel,5717,O
missense,5717,O
mutation,5717,O
and,5717,O
second,5717,O
recurrent,5717,O
mutation,5717,O
in,5717,O
the,5717,O
CACNA1A,5717,O
gene,5717,O
in,5717,O
individuals,5717,O
with,5717,O
EA-2,5717,B-SpecificDisease
and,5717,O
FHM,5717,B-SpecificDisease
.,5717,O
Mutations,5718,O
in,5718,O
the,5718,O
brain,5718,O
specific,5718,O
P/Q,5718,O
type,5718,O
Ca2,5718,O
+,5718,O
channel,5718,O
alpha1,5718,O
subunit,5718,O
gene,5718,O
",",5718,O
CACNA1A,5718,O
",",5718,O
have,5718,O
been,5718,O
identified,5718,O
in,5718,O
three,5718,O
clinically,5718,O
distinct,5718,O
disorders,5718,O
",",5718,O
viz,5718,O
.,5718,O
episodic,5719,B-SpecificDisease
ataxia,5719,I-SpecificDisease
type,5719,I-SpecificDisease
2,5719,I-SpecificDisease
(,5719,O
EA-2,5719,B-SpecificDisease
),5719,O
",",5719,O
familial,5719,B-SpecificDisease
hemiplegic,5719,I-SpecificDisease
migraine,5719,I-SpecificDisease
(,5719,O
FHM,5719,B-SpecificDisease
),5719,O
and,5719,O
spinocerebellar,5719,B-SpecificDisease
ataxia,5719,I-SpecificDisease
6,5719,I-SpecificDisease
(,5719,O
SCA6,5719,B-SpecificDisease
),5719,O
.,5719,O
For,5720,O
individuals,5720,O
with,5720,O
EA-2,5720,B-SpecificDisease
",",5720,O
the,5720,O
mutations,5720,O
described,5720,O
thus,5720,O
far,5720,O
are,5720,O
presumed,5720,O
to,5720,O
result,5720,O
in,5720,O
a,5720,O
truncated,5720,O
protein,5720,O
product,5720,O
.,5720,O
Several,5721,O
different,5721,O
missense,5721,O
mutations,5721,O
have,5721,O
been,5721,O
identified,5721,O
in,5721,O
patients,5721,O
with,5721,O
FHM,5721,B-SpecificDisease
.,5721,O
At,5722,O
least,5722,O
two,5722,O
of,5722,O
these,5722,O
mutations,5722,O
have,5722,O
been,5722,O
identified,5722,O
on,5722,O
two,5722,O
different,5722,O
chromosome,5722,O
19p13,5722,O
haplotypes,5722,O
and,5722,O
thus,5722,O
represent,5722,O
recurrent,5722,O
mutations,5722,O
.,5722,O
In,5723,O
the,5723,O
present,5723,O
study,5723,O
",",5723,O
we,5723,O
have,5723,O
screened,5723,O
several,5723,O
individuals,5723,O
for,5723,O
mutations,5723,O
in,5723,O
all,5723,O
47,5723,O
exons,5723,O
in,5723,O
the,5723,O
CACNA1A,5723,O
gene,5723,O
by,5723,O
single-strand,5723,O
conformation,5723,O
analysis,5723,O
.,5723,O
We,5724,O
have,5724,O
characterised,5724,O
a,5724,O
novel,5724,O
missense,5724,O
mutation,5724,O
",",5724,O
G5260A,5724,O
",",5724,O
in,5724,O
exon,5724,O
32,5724,O
in,5724,O
a,5724,O
family,5724,O
segregating,5724,O
for,5724,O
EA-2,5724,B-SpecificDisease
.,5724,O
The,5725,O
consequence,5725,O
of,5725,O
this,5725,O
mutation,5725,O
is,5725,O
an,5725,O
amino,5725,O
acid,5725,O
substitution,5725,O
at,5725,O
a,5725,O
highly,5725,O
conserved,5725,O
position,5725,O
within,5725,O
the,5725,O
CACNA1A,5725,O
gene,5725,O
.,5725,O
This,5726,O
represents,5726,O
the,5726,O
first,5726,O
point,5726,O
mutation,5726,O
not,5726,O
resulting,5726,O
in,5726,O
a,5726,O
proposed,5726,O
truncated,5726,O
protein,5726,O
.,5726,O
Furthermore,5727,O
",",5727,O
this,5727,O
mutation,5727,O
has,5727,O
been,5727,O
detected,5727,O
in,5727,O
a,5727,O
family,5727,O
member,5727,O
with,5727,O
mild,5727,O
clinical,5727,O
signs,5727,O
including,5727,O
only,5727,O
migraine,5727,B-SpecificDisease
.,5727,O
Additionally,5728,O
",",5728,O
a,5728,O
second,5728,O
previously,5728,O
identified,5728,O
recurrent,5728,O
muta,5728,O
tion,5728,O
",",5728,O
C2272T,5728,O
",",5728,O
in,5728,O
exon,5728,O
16,5728,O
has,5728,O
been,5728,O
discovered,5728,O
in,5728,O
a,5728,O
patient,5728,O
with,5728,O
FHM,5728,B-SpecificDisease
..,5728,O
